<SEC-DOCUMENT>0000950170-22-003499.txt : 20220314
<SEC-HEADER>0000950170-22-003499.hdr.sgml : 20220314
<ACCEPTANCE-DATETIME>20220314070420
ACCESSION NUMBER:		0000950170-22-003499
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		120
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220314
DATE AS OF CHANGE:		20220314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Verve Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001840574
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824800132
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40489
		FILM NUMBER:		22735047

	BUSINESS ADDRESS:	
		STREET 1:		500 TECHNOLOGY SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		(978) 501-3026

	MAIL ADDRESS:	
		STREET 1:		500 TECHNOLOGY SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>verv-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-03-11T19:57:50.9836+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:verv="http://www.vervetx.com/20211231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonFraction id="F_b2d78b98-0d63-4d03-af96-185a21d44c07" name="us-gaap:PreferredStockConvertibleConversionRatio" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" unitRef="U_pure" decimals="-2" scale="2" format="ixt:numdotdecimal">1</ix:nonFraction><ix:nonNumeric id="F_4711663b-eb09-4c14-bccc-f40f8ee10977" name="dei:CurrentFiscalYearEndDate" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" format="ixt:datemonthday">12-31</ix:nonNumeric><ix:nonFraction id="F_7b568b03-6f3e-45ce-a87c-1ec473c7ffe5" name="verv:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_49633ab7-17ec-409d-b405-fd6cdad7c037" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_efbe0182-38f2-4c14-aa56-5eaf21133d27" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_c08a69ad-f5e0-4908-9918-b4f986751489" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_24f0c297-5b40-4261-8880-ccb299caf8c9" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_5d453b81-de24-40a9-aeeb-d32cb8afa2fc" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_99459b3b-1a2c-459f-b816-892c31fc08bc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_69242d4b-64e4-4e88-8436-10a5845fd9c6" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_de72a9fd-4a77-4d2f-ba45-5844e0d16589" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_6343e105-a44a-4f4c-ad0d-c287a92b1cc7" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_d49f3879-e87a-4c1e-a6e0-035761dfab62" name="verv:SettlementOfTrancheRightLliability" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_7ab3c223-66e6-4171-bde7-910ed8108a8e" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_69242d4b-64e4-4e88-8436-10a5845fd9c6" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_4473dfb8-6ba4-4ff4-a96b-2aef947716c9" name="us-gaap:EmployeeStockOwnershipPlanESOPCashContributionsToESOP" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_f3bdee0c-b5f4-4a77-95ee-e42be9f8c8f6" name="us-gaap:EmployeeStockOwnershipPlanESOPCashContributionsToESOP" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_668b85ea-2c1e-4621-b400-bb2f4a0c0f4d" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3">FY</ix:nonNumeric><ix:nonFraction id="F_20d4266c-6aad-4cbb-ab46-faac5900b5d5" name="verv:DeferredTaxLiabilitiesRightOfUseAsset" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_a3f44760-a4cb-49fc-bd74-735d8b6dacf1" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_02e069bd-fd82-4cb6-b6b3-51bdba9b5b35" name="verv:ProceedFromShareholderLoan" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_932e1120-c25b-42f9-8bd9-be59fe4ca8b0" name="us-gaap:CommitmentsAndContingencies" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_13b5ecec-3028-4049-b33c-b897063f625f" name="us-gaap:ProvisionForLeaseLosses" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_91ee41f9-52b7-4c98-a858-be106bcef7e4" name="us-gaap:PreferredStockSharesIssued" contextRef="C_1d25d519-2490-4618-87e0-211daed76d06" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">29,347,825</ix:nonFraction><ix:nonFraction id="F_d1baddea-0268-4ef8-92ff-2fd1d349837d" name="us-gaap:PreferredStockValue" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_d83fbab4-b113-4b4d-a221-03e745689d8d" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_716c6897-a6df-4fdf-9e99-b336dfd3b30f" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="C_d4248d0a-06a2-4040-a853-becbd34bcc18" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_d90eb3d0-a3a5-4e78-a456-79d0199bcd53" name="us-gaap:PreferredStockValue" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_8f855dc4-4041-400d-9c4c-39e7f19cdb67" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_5d453b81-de24-40a9-aeeb-d32cb8afa2fc" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_170610ab-9c1b-4510-8f28-c508389451c8" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="C_d8897390-cbaa-48a9-b558-fd628bd36c53" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_daa77256-f925-4e80-9690-a788d67f31a1" name="us-gaap:ProceedsFromContributedCapital" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_6a658ad5-652c-475a-ae7d-c2c5d9b56b54" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_5d453b81-de24-40a9-aeeb-d32cb8afa2fc" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_d4188ab7-710e-403e-8205-b3322f211365" name="dei:AmendmentFlag" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonFraction id="F_0691f387-dd9a-4985-8c9a-0c01efabf653" name="us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_42dc52cc-b872-424a-896a-7d468cadf04e" name="dei:EntityCentralIndexKey" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3">0001840574</ix:nonNumeric><ix:nonFraction id="F_0b5612a3-b12a-43fc-ba6b-c3bd38e949ff" name="verv:IssuanceOfPreferredStockTrancheLiability" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_290ed904-ef2e-4b0f-8479-82d256b9d6b1" name="us-gaap:CommitmentsAndContingencies" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_a0e3a388-511c-4ae3-a547-38055910ae18" name="verv:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="verv-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_758d254a-8812-49dd-a35c-9b632827b258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6d1a849-b7f6-4b32-8b52-0bd344744eb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d70dec1-7c1e-48b3-b61d-3e6ca572b452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd29659d-951a-45fc-a69a-2e59256ccd54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">verv:FourZeroOneKPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1541fd57-3030-489b-9a4b-89cd76467fe9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">verv:BeamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b6cf2c2-5ffb-41c1-b814-6954698f90f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ccde73cb-e336-419a-a1be-6bc267e8d5ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89a10d74-f017-4e8e-9761-a6d46cf3afb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:OfficeFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d2ce482-3934-425f-b2d1-f6ee23bbabef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47adbab3-b838-4d39-aa2e-17b98510b0b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88ca2b88-300c-48c8-815f-cc259e125c7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46b3a3b3-5e47-4d6e-bbdd-cf18cb6fea59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a01908a-58f3-4cbb-a2c9-d102afa07909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c6e9331-d8d3-43e7-8098-fbde994f4649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:CambridgeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-31</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d04521c5-cb77-4e26-9e7d-c596e315d733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a65eb8e-9c85-4a38-b989-299e4aceb2c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b374bc60-e066-42aa-99b0-3e124c675fda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8128aaac-e7e6-4fa6-bac7-a3ac19d8ff0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_140060dd-8e0c-44a2-9769-d8ce6de4ed4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bae1dfa2-41b7-46c1-9e1e-5fae784a1de3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b218daf-9568-4fb9-ba54-24937e994d44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d971946d-306c-459c-8b3a-e96fc64334f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7dd626b0-6fc1-4783-8c59-97a950918aed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4af95d5-0d99-42f7-b5a7-c6ec697551f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">verv:DeliveryTechnologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_335ebba5-72b4-421b-898b-d3de7d54c1a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d5e8986-339e-4a27-a33a-2ddab2c8cf2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66e16c0c-c5f1-4264-b019-a5f4059f00f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3585e227-4c98-4454-befd-78b3ac98ed4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VerilyLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d25de583-668f-4235-b7a0-421690a06540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ff558da-6b5f-4d32-9a66-1203371d1d23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d6fc6e3-0bd2-4c41-a389-d8c78306592d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:PreferredStockTrancheLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_492a51ac-c738-417e-89a8-b0263437fb8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4248d0a-06a2-4040-a853-becbd34bcc18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30c56851-0530-4749-a9d8-9d1a01a7d426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d44651b4-0a1c-4a0d-ae7f-725d09d63521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fb1ec91-4db7-4fda-877e-5282a568c8a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea995c0d-ad65-44c4-b2b7-9fa84f6854c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6147ead1-a934-40a0-954e-50f7ab4904e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c269b18-dd31-496d-b16c-e1c0dd1e2c99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d0c6332-d1dd-4a36-9324-fb3b21711262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VerilyLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dee7f513-4115-4cdf-b302-37edddf7187e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_456b2896-d611-45e2-8641-7467961b8168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_470eef76-a3e4-47c1-9135-bcd76e05752b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3282e3cf-7f95-478d-ade5-6727746ef749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94dd9299-01a2-4f67-9f44-7bbd116cd6f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7eaf2c5f-f4cf-4ef5-8686-522ecb024096"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c5380ff-43e4-4da6-9d3d-4f142569329f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6318768f-6910-4cea-8012-84a1cded066e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cef2ca29-eb4f-4af7-8d4a-cda3d18e4727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:SeriesA2PreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_556c543d-6999-40a3-9b90-5c280daba957"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02e26f3d-99d2-4166-a4b7-b128f163b312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e66db40-4afb-4ea5-b66c-0674f32df2e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c90a925-ca54-4ef3-abb8-1d5e67ef2449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f78045b2-d23b-4e9d-b193-d192ee9bb611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">verv:FourZeroOneKPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e0553e9-7c8d-4aae-b19e-97a94012299f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc246b1a-e277-4475-a822-7b299288320b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc02f4c1-1fb9-4d8b-93c6-bd1442840b62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29a82fc7-8d8b-4988-8c6b-cb6aaeac3cf1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dae0176e-5286-4cb9-be3e-28858705d8a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea3f7d23-8c4f-4c06-944b-9769311160d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a295b66-ffd1-4f8f-9e1a-8acda5aafa35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db7855c5-c342-42e3-a442-d44d2061ccbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b37319a-0d54-4ccd-83eb-9d11fc5d438b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b587c055-bdab-476a-b3ab-de00dcd68ee5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">verv:SecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc4de63a-1a13-435a-91bf-1d42b2503336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69242d4b-64e4-4e88-8436-10a5845fd9c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5026dda8-28ac-4046-b30f-f4c2af3df266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:CambridgeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1fa28ee7-1e59-47ad-b9b0-95bb75660ed2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_597ac98d-16ac-4d83-be6a-8276c0ed1129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9315a78c-93a9-491d-b78a-acdccb6d99a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">verv:MassachusettsTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0199df91-6706-46b0-a6e5-0c3d2416dcec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e74774f-4077-4438-a31c-22d5b9e9bf39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1afabfe3-8755-45d0-ac91-81a3418d2248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e08bb552-0254-44e1-ada0-095671a76529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f4306bb-8ee0-4a9e-a1ff-c73a4446835b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:OptionLicenseAgreementAndPatentLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:OfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc4c7421-4413-4b48-9fbf-b319860463d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c27b92cd-9d6c-4111-bd60-2b3bb8205544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13793679-16f2-4f46-aa19-c85c5a12a0ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d11db810-1bfc-445d-b0c0-43624d7bd52d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bcc73401-287e-4ac0-a87f-a7584a3ebe73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea8434d0-a39e-4a6a-bb26-7799962446b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b400acd-8cd9-40ff-8255-a68985c37814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">verv:FirstAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:CambridgeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40e00f19-0436-48b3-a978-909a38c95f51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7349e083-8b38-4939-84b9-b52dd9e2c764"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75ebca27-b89c-4f74-8d07-a6fdfe31387c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8020214a-330a-4afc-8e4e-cfbc08b56cfc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:AcuitasAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9ae8471-e3e2-4484-84b2-6eaafd17e730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:PreferredStockTrancheLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ace78012-0407-4c33-9333-78a05d5e4482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c286c886-b8bc-4074-85c6-6c1d797c88f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a988b86-2da6-44fb-8d8b-025bc3040bcb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">verv:HarvardAndBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2da1fcc5-d34b-4f3a-ae28-f14234789060"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f014d533-46a7-4112-9279-b10412cf8bb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b046bc96-323a-433d-9185-6710e68adfba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:AcuitasAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e2eab36f-a537-4eda-9a0f-fecf0f2bddb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79857874-5e87-4b53-b5bf-f51a27d64b5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25716468-76d3-40f2-8351-b9e832a0d2ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1407fd53-32a3-4a0c-83d7-8d75bcc6c92f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ea046e2-86bb-4bd2-985f-27d259b832a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:CambridgeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea754504-c0d8-4221-a285-32e891462575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96a9ec98-0425-4b68-a1ef-a3660007003a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f97bfb71-9b79-4c00-862c-5692b411f52b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:SeriesA2PreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84c106c3-aeb7-42d5-ab70-a059d1961a3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8deec1cb-9d18-458c-80a6-69065b7fd6e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f16c804-a208-4c37-b6c5-31908dac33d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">verv:SecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:CambridgeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0a301cf-8d3e-495c-a4ea-93524f1c444e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1a50b9b-5f34-479b-86a9-1686cbaaf4d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">verv:FourZeroOneKPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38d1bdab-4490-418c-9908-c0fd520a968b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac6b8994-377a-4736-97a7-37eee958602b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e7d3e278-0275-4b6b-8cfb-0c4d84c235a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3965b88b-aada-4b0f-bb79-9e1564c8b01f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_892a0591-a196-401b-abe3-20fff82d78ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9dfcbc2-a577-4626-9277-24561a8feca3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_314775f6-60d3-4cdd-a7e4-d2d47b4bb14b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VerilyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf52cb0e-645b-4c9d-abcc-988c1ab77568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c20382c9-9ff7-450f-8cd6-93193f146b1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef58d5a4-7912-466b-bc19-b009959eba29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">verv:HarvardAndBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_371af29c-852e-4e21-b3b0-7a743ce9c595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cace6097-6c52-4518-b31c-14d8a4a9ede2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_671bfcc0-ebf7-4194-8895-80b3fa98b658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1981d33-fdc8-48c3-99e8-ac5c58411837"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d8591bc-11a9-40ab-b3a4-bc7e3800e026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_20e318f5-772b-42ae-8de4-e92d6afce885"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82be291d-e5c6-4821-b8c8-65d4e399c80f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VerilyLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_900eaaf9-9f36-4773-beee-ac7b0f139194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c8d563c-b4ce-43e3-aa5e-0284d836e33c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24a4dfda-a75a-45db-8bd3-e0d4bcac39a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6111bf12-8023-40ef-949d-f9fc8eb769e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ad41b74-8200-44de-a163-b3c17e30b9e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fec04bb0-37db-4624-a7d4-cd02343359c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86c2f76f-8f40-41c6-a1f0-570a5a905595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1349c1bd-0a8c-4898-8535-2e458967423b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fcb68bae-6468-4eef-9487-908de3c3ac46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d453b81-de24-40a9-aeeb-d32cb8afa2fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45b88831-c3cd-4f43-a393-141647d5c8ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd92968d-2cf3-45c1-b345-bc554cadcd11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwentyTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_55860b8b-baa2-4e63-b435-ce9e60ae5e06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a2a7d48-0ad0-4027-b312-8b11192978ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">verv:BeamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:MaterialsExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9ee4883-4610-4244-845a-4be4346c5921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91c2bb60-3204-485e-91bc-fcd6e061eaf0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25c1a637-7cb1-4291-89c3-54a541318110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1bcde1fb-0fd0-4aef-8c8e-7bc374f704bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5cba4e1e-72af-462f-b037-4423f24b01af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_adefa849-4678-4e94-b863-2d12ecdad8f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9897674-e8be-4c3a-a297-cb53a9538487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:SeriesA2PreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8085576-61b7-454c-a519-9ae96812318a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7230ac96-5876-4bec-b9a0-17578497db18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e544b1d4-8651-4bbd-86e5-229213fc8bef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f64ad974-2e0f-4ca6-b8b0-bd9dc4283255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">verv:ThirdTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b94a23b8-43bb-4383-a20f-d50aa1e8c3b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6306fa6b-7c2e-44e2-9da5-5dfd36995ad7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">verv:ThirdTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f674fccd-11fb-4942-800b-db52e4338c03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7db4cc42-112c-43d0-8092-a99672ba28cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a46f484-c7b1-4249-a6d6-d259c573d801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">verv:AntidilutionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37648f64-a03f-4b57-83e1-dcf5c52767e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_894ba0d1-0497-4bb2-8773-85db59da1dac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01810b2e-60ca-470b-a8e4-f620cad1af9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VerilyLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a01d169a-8516-477d-a424-137cbc7bf6ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e36ace04-7d0f-46f4-a4fc-05e0cddb3357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5758acaf-19d3-46c4-a26d-234bb9c7e3a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5c31764-a8fd-4905-a067-8962ee2846e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4871c68a-70f7-4ee7-b7ae-3986b18102dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56d972ec-31cc-4208-aa1d-caae39e63a9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8bbab493-1d5c-406a-b732-8bf3f0c4c8aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27017e45-4a76-45b0-84c2-5942f0fdfb77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwentyTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70bdd4a9-53a3-4196-bff4-9fe631ab414d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:PreferredStockTrancheLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c672a00b-7f2c-4ee3-878b-42ff6ea68467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_428c5b12-83cd-4341-b4bb-932e3b77cd04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:PreferredStockTrancheLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a692e9d-fc22-429a-866a-28850d71edcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38d37eaf-cd29-452c-8228-ce29419522e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d0f6183-f1e6-4aa0-b41e-2e38deb97369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_577f8c7c-690b-48eb-85f5-78944ac5fb74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae35d2d7-335e-4000-8d8b-98d22cdc0bcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d594e36-72b4-4236-bd90-bc5bab9f7a9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4303f47d-2279-40f2-a160-e7a91300902b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46b68a29-4a56-4a0e-b6e7-327c4a2472e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc8e1463-c758-4dfb-9de6-62be2741f27c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5b793ed-2405-4df6-a73b-f8234a21676c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bc5b84f-e1f5-4d52-92d2-4a44875d520e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9dffce0-4bc6-41d0-9e68-e6fdba07b1d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_676f07bf-c94c-4783-88ad-393a30ab16eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwentyEighteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_368253bb-0ab9-4644-bcce-9c12ebebd714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">verv:BeamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c8ab043-9f70-4b7c-b82d-c140cdb7038c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6bcfa12-5656-4390-89e7-006e60b45be7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7f9ed07-4a59-4247-ad5a-a6b36bcb98c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6fe755bd-39b2-4058-bb31-ac7a1399a7a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:OptionLicenseAgreementAndPatentLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:OfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d25d519-2490-4618-87e0-211daed76d06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">verv:SecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b00ab393-cfc3-45d7-90b3-dfac30d815bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">verv:BeamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:MaterialsExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62daab16-1f95-4011-9dfa-cdc86ccb527d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5f342f9-12eb-4269-ba58-fc8d87544ebf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9bb47951-6b36-400c-bc9e-6e6219af2c06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">verv:ThirdTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8943ede3-21ba-4dd5-a69f-6510b3c9441e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81529f1c-4f4b-492c-a430-5a7eaa203e49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_765b171f-952c-4b00-b1af-1c4809294e61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac0671b9-90e0-41a4-b113-3a0ff36d64e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ce3a7dc-9959-4295-a7ff-97a898ccd354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f357484d-ef7a-4007-9dd8-60b4ae94c728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_07b567cb-3946-416a-a923-420f97322263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5489e665-131f-4276-8480-9cbe40f275d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc3057b9-a834-4bce-9400-bb870b34a39e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VerilyLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a807f8cc-a5fc-49a8-8923-6ff09f00f06a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c4a09a2-209e-467e-bf15-7eedabe54a49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5a60e47-ab5b-41f6-99da-8c71cb8625d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">verv:BeamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5fed7261-bc42-45e4-aa7b-b1860010cd80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8b5087a-c8c5-42b6-b02a-2126a65898d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1a13442-1d67-4846-9344-f2e64eb45cf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d62c74e-40c7-4d44-95f2-9153b525923e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e18a72a-d76f-4344-ab19-24bc729bb1a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25e7d82a-63d5-46e3-ace4-4ed5f2668166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8897390-cbaa-48a9-b558-fd628bd36c53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:PreferredStockTrancheLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d26e837-c809-4998-bfb7-aca676d66949"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a47c1a5e-5ed1-4aff-9633-a0341b906481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwentyTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48f8ab70-75b9-4435-b737-aadd04d499cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd01459a-975e-48f9-9d4f-b18bb361be4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4862c09a-79bf-4f14-8cca-db22dcbb94b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0b06ae8-891a-4456-9a30-d851caa260c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2dcf3819-ab63-4939-86b0-10870a857990"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb1b7494-a0dd-49fc-8914-d1f55848827c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-19</xbrli:startDate><xbrli:endDate>2021-08-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f15881ae-e851-43f0-9443-9c9364fbebc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwentyTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5a771bf-09d6-4a35-b7ac-216b653bc10f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwentyTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a7068fa-0013-401d-b7c4-675485fce3a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac07bf25-eb1b-41db-9a17-637a6b3c0cf0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e665d618-f742-42d3-8066-c2f5fa033034"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_238fca8e-6dc3-4ea3-aa6d-7d316fa8ad10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9143aa7-990d-4ec9-968a-0a9605086b21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ad6efa1-92e1-4627-b9eb-e717d27461ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e418dc0-e214-4a34-8796-62a40cabca50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17fbf683-2a55-4bef-952f-f0d1c18ff75d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b41bdfb-bbc2-43d8-bf32-532fc3b99db4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_249fda00-bd80-4288-a41d-c1199d73ce90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76a2ae17-640c-473b-b6d2-7f1f8e136700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">verv:MassachusettsTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e65181b-d50d-473b-a928-4dbc316e780c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_078a5bfc-2f82-4f5d-a355-1da428971361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5703a3c6-815c-4560-9f18-f134cd85e185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f480ce79-c162-4b52-8c8e-1412a8a69e68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_604919a2-0184-407a-a67d-53f3e9d796d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_256a0140-df8b-4d59-a0a5-3457018ea09f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VerilyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a810db97-eb14-448b-9d1b-137166449fdd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">verv:NewAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a75dc28-f9fd-42c4-8bd8-5f9dfd827ae8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_983ffc57-7b63-4e06-ab2d-e82bf6082b61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53ef7791-90d1-4f91-a9c9-7449eead72a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03a67782-22aa-4a91-8ef4-d8c7202b8a6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3c87878-bc9c-48e0-848d-9e7ea4f29412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_235eb2e2-4747-444d-b7ee-6cc0e5a83ec6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67f0fbbf-3525-49ad-8377-5e53391e7282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb24676f-df61-4c43-a65c-58adb308cd98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">verv:SecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c294a1f-8a23-47e3-aa6b-63b180777613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db73ec29-59ce-4649-9f8f-424cfebeac57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_898d61f8-6a19-4832-b357-ffe134d84eaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7eaf836e-97a5-4b96-901b-fbc846401d37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38e0bdc6-ddc8-4961-80a7-3305ab5afc10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a3189e2-c048-4d31-976f-cb3b47d3233e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec36089a-8e3c-4348-a1b7-6a7b4ec227a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5482ed2-d888-4dd2-a7a7-cb1d249e3b82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa339973-30be-44d3-9b51-80410c37ae10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0e52d02-fa91-4a31-93c5-67e517633a88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59fe6e15-fa1d-432e-b68b-41815233efa2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af6a2a40-edbe-4dd3-98a2-c59fe2070928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VerilyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>verv:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Instalment"><xbrli:measure>verv:Instalment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_247ca409-7f5d-47a8-8c48-39a833c8dcd8" fromRefs="F_9802e87b-b16a-46c7-b5ca-97ffa81f49a2 F_fe0539bc-5d0e-4e16-bca5-d18ebbbf88c5"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_cbfa0a0e-19c5-4a4c-98d4-6e84510cdcd3" fromRefs="F_07bb18eb-0554-426b-b84f-e1ce1d9e124f F_09c816c2-1e12-4899-9ecf-678b1a4962d0 F_24230ffe-ae0b-4bb2-ad26-32083b8b57ec"></ix:relationship></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Arial;">&#160;</span></p>
  <p style="border-top:2.250pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Arial;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Arial;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">FORM </span><span style="font-size:18.0pt;font-family:Arial;"><ix:nonNumeric id="F_285bdbbe-45f7-4aee-88f8-e9d1fa448eb3" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"> (Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_92192fba-312a-4fcb-838e-d3961ddee1f2" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">For the fiscal year ended </span><span style="font-size:9.0pt;font-family:Arial;"><ix:nonNumeric id="F_ce149dbb-8f7b-4b36-a8e9-04d6c83d6025" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">December 31, </span><span style="font-size:9.0pt;font-family:Arial;"><ix:nonNumeric id="F_44d5b546-3627-4775-9f04-2f43ee62ab0c" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">2021</span></ix:nonNumeric></span><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;"></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_19e00e2f-1d2e-459a-b99c-766e00a8ac99" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Commission File Number </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_9ea9bdea-30bf-474c-b6f9-0c2c1bf31e82" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">001-40489</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:20.0pt;font-family:Arial;"><ix:nonNumeric id="F_fdd01a10-9a2e-45a9-af28-00fbdc8b3e53" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:20.0pt;font-family:Arial;">VERVE THERAPEUTICS, INC.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">(Exact name of Registrant as specified in its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Arial;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_3216b3fc-f18f-48c0-92ad-d72cb405dce2" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_cccdc195-2cf0-49a2-b4be-8bd9fbf4145e" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">82-4800132</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_700637c5-ae33-429c-8d7c-d5bf6b6fe62f" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">500 Technology Square, Suite 901</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_c5e7870b-8927-441c-a0d9-708f58282cdc" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Cambridge</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">, </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_42e17c88-9325-41bb-9d81-447e955528f7" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_26d07b84-0302-4a47-9ff5-dbcf68e10f1d" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">02139</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:9.0pt;font-family:Arial;"><ix:nonNumeric id="F_e68143ef-5976-4dc0-8b1d-83da464c8ecc" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">617</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">) </span><span style="font-size:9.0pt;font-family:Arial;"><ix:nonNumeric id="F_00f5d761-5303-41a5-84d9-d0220688f2dc" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">603-0070</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Arial;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_dc569aa9-a03f-49c3-a684-e2a04f5ad7de" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Common stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_c466fd87-d4fa-462e-960f-0affa9b3c4db" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">VERV</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_da81291c-f7a2-4fec-a932-97915d3dc774" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">     </span><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_e2c8cc31-c1b5-48e4-9a4f-acb774f60dbf" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  Yes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">     </span><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_aedb6d95-1571-4cf9-8c30-5bde1d3c5a68" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_efc90f84-d578-4373-b7ee-9045d294a5e0" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">     No </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_6e67d064-7883-403a-9ca9-294e6ac9391b" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">     No </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.296%;"></td>
    <td style="width:0.602%;"></td>
    <td style="width:55.843%;"></td>
    <td style="width:1.056%;"></td>
    <td style="width:20.5%;"></td>
    <td style="width:0.602%;"></td>
    <td style="width:2.102%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_6a5e12db-0697-4c64-8e2c-9960ffa80753" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cde85b49-1d1d-47f2-86b0-78e53c51dd30" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d450487-c31d-4942-9b27-b689e3977fea" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e29f4a85-a50d-4ca9-80b5-0c60027b95b9" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e197b63-3d10-4035-9b55-fcdd6b59a585" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">     No </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f222858-513c-463f-ab41-61af5ba8c488" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">The registrant&#x2019;s common stock began trading on the Nasdaq Global Select Market (&#x201c;Nasdaq&#x201d;) on June 16, 2021. The aggregate market value of the voting and non-voting common stock held by non-affiliates of the Registrant was $</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_3e6c9ee3-1b9e-40cc-8491-cda83012f869" contextRef="C_c9dfcbc2-a577-4626-9277-24561a8feca3" name="dei:EntityPublicFloat" unitRef="U_USD" scale="9" decimals="-6" format="ixt:numdotdecimal">2.185</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> billion based on the closing price of the registrant&#x2019;s common stock on Nasdaq as of June 30, 2021, the last business day of the registrant&#x2019;s most recently completed second quarter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">The number of shares of registrant&#x2019;s common stock outstanding as </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">of March 9, 2022 was </span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_d0102689-ad51-444b-a3b9-37877862b018" contextRef="C_7e66db40-4afb-4ea5-b66c-0674f32df2e3" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,576,595</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_4c9ede53-7831-4416-a5d0-24ba894a28d5" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Portions of the registrant&#x2019;s definitive proxy statement that will be filed for the 2022 Annual Meeting of Stockholders </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">which the registrant intends to file with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year ended December 31, 2021, are incorporated by reference in Part III of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Arial;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.123%;"></td>
    <td style="width:81.74%;"></td>
    <td style="width:7.137%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#forward_looking_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">FORWARD-LOOKING STATEMENTS</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#risk_factor_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">RISK FACTORS SUMMARY</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">PART I</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">70</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">135</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">135</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">135</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">135</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">PART II</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">139</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">152</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">153</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">153</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">153</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">153</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_regarding"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">154</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">PART III</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">155</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">155</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_of_certain"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">155</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">155</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">155</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">PART IV</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">156</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 16.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">157</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="forward_looking_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This Annual Report on Form 10-K includes forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;might,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would,&#x201d; or the negative of these words or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the initiation, timing, progress and results of our research and development programs, preclinical studies and clinical trials, including the timing of our submissions of investigational new drug applications, or INDs, and clinical trial applications to regulatory authorities; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the impact of the COVID-19 pandemic and our response to the pandemic; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our estimates regarding expenses, future revenue, capital requirements, need for additional financing and the period over which we believe our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the timing of and our ability to submit applications for and obtain and maintain regulatory approvals for our current and future product candidates; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the potential therapeutic attributes and advantages of our current and future product candidates; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our expectations about the translatability of non-human primates results into humans; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our plans to develop and, if approved, subsequently commercialize any product candidates we may develop; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the rate and degree of market acceptance and clinical utility of our products, if approved; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our estimates regarding the addressable patient population and potential market opportunity for our current and future product candidates; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our commercialization, marketing and manufacturing capabilities and strategy; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our expectations regarding our ability to obtain and maintain intellectual property protection; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the impact of government laws and regulations; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our competitive position and expectations regarding developments and projections relating to our competitors and any competing therapies that are or become available; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">developments relating to our competitors and our industry; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our ability to establish and maintain collaborations or obtain additional funding; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in the &#x201c;Risk Factors&#x201d; section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments we may make or enter into.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K and have filed as exhibits to our other filings with the SEC completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Annual Report on Form 10-K are made as of the date of this Annual Report on Form 10-K, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Except where the context otherwise requires or where otherwise indicated, the terms &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;our company,&#x201d; &#x201c;the company,&#x201d; and &#x201c;our business&#x201d; in this Annual Report refer to Verve Therapeutics, Inc. and its consolidated subsidiary.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;" id="risk_factor_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">RISK FACTOR SUMMARY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our business is subject to a number of risks of which you should be aware before making an investment decision. Below we summarize what we believe to be the principal risks facing our business, in addition to the risks described more fully in Item 1A, &#x201c;Risk Factors&#x201d; of Part I of this Annual Report on Form 10-K and other information included in this report. The risks and uncertainties described below are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If any of the following risks occurs, our business, financial condition and results of operations and future growth prospects could be materially and adversely affected, and the actual outcomes of matters as to which forward-looking statements are made in this report could be materially different from those anticipated in such forward-looking statements:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are very early in our development efforts, and we have not yet completed IND-enabling studies or initiated clinical development of any product candidate. As a result, we expect it will be many years before we commercialize any product candidate, if ever. If we are unable to advance our current or future product candidates into and through clinical trials, obtain marketing approval and ultimately commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Gene editing, including base editing, is a novel technology in a rapidly evolving field that is not yet clinically validated as being safe and efficacious for human therapeutic use. The approaches we are taking to discover and develop novel therapeutics are unproven and may never lead to marketable products. We are focusing our research and development efforts on gene editing using base editing technology, but other gene editing technologies may be discovered that provide significant advantages over base editing and we may not be able to access or use those technologies, which could materially harm our business; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The outcome of preclinical studies and earlier-stage clinical trials may not be predictive of future results or the success of later preclinical studies and clinical trials;</span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If any of the product candidates we may develop, or the delivery modes we rely on to administer them, cause serious adverse events, undesirable side effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit the commercial potential or result in significant negative consequences following any potential marketing approval; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Adverse public perception of genetic medicines, and gene editing and base editing in particular, may negatively impact regulatory approval of, and/or demand for, our potential products; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Genetic medicines are complex and difficult to manufacture. We could experience delays in satisfying regulatory authorities or production problems that result in delays in our development programs, limit the supply of our product candidates we may develop, or otherwise harm our business; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical testing, and these third parties may not perform satisfactorily; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have entered into collaborations, and may enter into additional collaborations, with third parties for the research, development, manufacture and commercialization of programs or product candidates. If these collaborations are not successful, our business could be adversely affected;</span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we or our licensors are unable to obtain, maintain, defend and enforce patent rights that cover our gene editing technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we fail to comply with our obligations in our intellectual property license arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The intellectual property landscape around genome editing technology, including base editing, is highly dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and may prevent, delay or otherwise interfere with our product discovery, development and commercialization efforts; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We face substantial competition, which may result in others discovering, developing or commercializing products before us or more successfully than we do; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The COVID-19 pandemic may affect our ability to initiate and complete preclinical studies, delay the initiation of future clinical trials, disrupt regulatory activities or have other adverse effects on our business and operations. In addition, this pandemic has adversely impacted economies worldwide, which could result in adverse effects on our business, operations and ability to raise capital.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">PART I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 1. Business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are a genetic medicines company pioneering a new approach to the care of cardiovascular disease, or CVD, transforming treatment from chronic management to single-course gene editing medicines. Despite advances in treatment over the last 50 years, CVD remains the leading cause of death worldwide. The current paradigm of chronic care is fragile&#x2014;requiring rigorous patient adherence, extensive healthcare infrastructure and regular healthcare access&#x2014;and leaves many patients without adequate care. Our goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. Our initial two programs target PCSK9 and ANGPTL3, respectively, genes that have been extensively validated as targets for lowering blood lipids, such as low-density lipoprotein cholesterol, or LDL-C. We believe that editing these genes could potently and durably lower LDL-C throughout the lifetime of patients with or at risk for atherosclerotic cardiovascular disease, or ASCVD, the most common form of CVD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our approach leverages multiple breakthroughs in 21</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.025pt;font-family:Arial;">st</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> century biomedicine&#x2014;human genetic analysis, gene editing, messenger RNA, or mRNA, -based therapies and lipid nanoparticle, or LNP, delivery&#x2014;to target genes that are predominantly expressed in the liver and disrupt the production of proteins that cause CVD. We are advancing a pipeline of single-course </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> gene editing programs, each designed to mimic natural disease resistance mutations and turn off specific genes in order to lower blood lipids, thereby reducing the risk of ASCVD. We intend to initially develop these programs for the treatment of patients with familial hypercholesterolemia, or FH, a genetic disease that causes life-long severely elevated blood LDL-C, leading to increased risk of early-onset ASCVD. If our programs are successful in FH, we believe they could also provide a potential treatment for the broader population of patients with established ASCVD. Ultimately, we believe that these treatments could potentially be developed for administration to people at risk for ASCVD as a preventative measure similar to the way that certain vaccines offer long-term protection against infectious diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">High cumulative life-long exposure to LDL-C drives the development of atherosclerotic plaque that results in the hardening of arteries seen in ASCVD. The relationship between lowering of cumulative LDL-C exposure and reduction in the risk of ASCVD is among the best understood relationships in medicine. Studies have shown that lowering LDL-C by 39 mg/dL for five years in patients with established ASCVD reduces the risk of a further event by 21%, whereas a similar degree of LDL-C difference over a lifetime reduces the risk of a first ASCVD event by 88%. This demonstrates that the challenge is not only to substantially reduce LDL-C but also to sustain such a reduction throughout a patient&#x2019;s lifetime. We believe that the cornerstone of the treatment and prevention of ASCVD must be early and aggressive reduction of LDL-C for as long as possible.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The current standard of care is a chronic care model that often fails to sufficiently control overall LDL-C exposure due to the continuous and life-long nature of its treatment approaches and the inherent adherence issues it presents. As a result, a large proportion of patients with established ASCVD have LDL-C levels above the goal recommended by the American Heart Association, or the AHA, and the American College of Cardiology, or the ACC, leaving them at risk for recurrent ASCVD events and the potential for invasive medical procedures or even death. Furthermore, given the silent nature of the damage done by elevated LDL-C, many patients at risk for ASCVD do not properly appreciate the therapeutic benefits of consistent treatment as well as the substantial risk of foregoing treatment, focusing instead on the heavy, life-long medication burden of daily pills, lifestyle changes and other chronic approaches. We believe that single-course gene editing treatments that potently and durably control cumulative LDL-C exposure could fundamentally disrupt the chronic care model for treating patients with or at risk for ASCVD and relieve the significant burden placed on patients, providers and the healthcare system.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. PCSK9 is a highly validated target that plays a critical role in controlling blood LDL-C through its regulation of the LDL receptor, or LDLR. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In a subsequent and ongoing </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> proof-of-concept study of a precursor formulation of VERVE-101 in NHPs, we observed substantial lowering of LDL-C levels that was sustained over an extended period of time following treatment. In this study, following a single intravenous infusion of a base editor targeting PCSK9, we observed an</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">average reduction of blood PCSK9 protein of 89% accompanied by an average reduction of blood LDL-C levels of 59% at two weeks after treatment. This LDL-C reduction was maintained at an average of 60% for 15 months following treatment. If we are able to achieve similar reductions in PCSK9 protein levels in humans, we believe this could result in marked and sustained LDL-C reductions of approximately 60%, which would potentially offer superior cumulative LDL-C lowering to what has been clinically demonstrated with other PCSK9-targeting treatment modalities. We expect to expand beyond our PCSK9 and ANGPTL3 programs to develop a suite of single-course gene editing medicines that address root causes of disease.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In an ongoing preclinical study with VERVE-101 in NHPs, we observed 70% mean editing following a single administration of 1.5 mg/kg dose at the PCSK9 target gene site in liver biopsies taken at day 15. In this study, we also observed an average reduction in blood PCSK9 protein of 86% accompanied by an average reduction of blood LDL-C levels of 62% at two weeks after treatment, which were maintained to 180 days.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, in our preclinical studies in NHPs, VERVE-101 has been well tolerated following a single administration with only mild elevations in liver function tests that resolved within two weeks. In primary human hepatocytes treated with VERVE-101, we observed on-target editing at the PCSK9 target site and did not observe significant editing at any of approximately 3,000 identified potential off-target sites.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Based on our preclinical data, we are advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia, or HeFH, which is estimated to affect approximately 31 million patients globally. We plan to expand clinical development of VERVE-101 in a stepwise fashion beyond HeFH for the treatment of patients with established ASCVD, which represents hundreds of millions of potential patients globally. Ultimately, we believe that VERVE-101 may be useful to people at risk for ASCVD as a preventative measure in the general population. We have initiated investigational new drug application, or IND, -enabling studies for VERVE-101. We expect to complete our submissions of clinical trial applications, or CTAs, to certain foreign regulatory authorities, and an IND to the United States Food and Drug Administration, or FDA, in the second half of 2022, followed by initiation of clinical development for patients with HeFH.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism. We believe that disrupting ANGPTL3 protein production may lead to reductions in LDL-C and triglyceride levels through a mechanism distinct from that of PCSK9. We plan to develop this program initially for the treatment of homozygous familial hypercholesterolemia, or HoFH, which affects approximately 1,300 patients in the United States. Similar to our approach with VERVE-101, we plan to expand the clinical development of our ANGPTL3 program in a stepwise fashion beyond HoFH to patients with established ASCVD who may need additional LDL-C and/or triglycerides reduction. Ultimately, we believe that our ANGPTL3 program may also be useful to people at risk for ASCVD as a preventative measure in the general population. We plan to select the development candidate for our ANGPTL3 program and to initiate IND-enabling studies in the second half of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We plan to utilize internally developed GalNAc-LNP technology in our ANGPTL3 program to deliver a base editor targeting the ANGPTL3 gene to the liver. In patients with HoFH, delivery of base editors with standard LNPs to the liver is challenging due to the deficiency of LDLR, which is known to mediate LNP uptake. We have developed proprietary LNPs with a GalNAc ligand designed to bind to asialoglycoprotein receptors, or ASGPR, in the liver, which bypass LDLR, thereby enabling uptake into the liver in HoFH patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In our preclinical studies of our ANGPTL3 program using a single treatment of two different formulations of our proprietary GalNAc-LNPs to deliver our ANGPTL3-targeted base editor we observed approximately 94% (n=3) and 97% (n=3) reduction in blood ANGPTL3 protein, and reductions in LDL-C of nearly 100 mg/dL, which was an approximately 35% reduction from baseline. We conducted these studies in an internally developed NHP model of HoFH, which we created by editing the LDLR gene in wild-type NHPs and eliminating LDLR expression in the livers of NHPs using a Cas9 and dual guide RNA strategy encapsulated in standard LNPs, which led to nearly 70% whole liver DNA editing at the LDLR gene and resulted in an approximately 94% reduction in LDLR protein in the liver and a six-fold increase in blood LDL-C.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have also assessed the potential broad utility of our proprietary GalNAc-LNP approach for delivery of our ANGPTL3-targeted base editor, in a preclinical study evaluating delivery efficiency of our ANGPTL3 base editor using both a GalNAc-LNP and a standard LNP without GalNAc in wild-type NHPs with normal livers. In these studies, we observed that wild-type NHPs treated with our ANGPTL3-targeted base editor delivered via our GalNAc-LNP had an approximately 89% reduction in ANGPTL3 protein compared to an approximately 74% reduction in wild-type NHPs treated with a standard LNP. We believe this suggests that GalNAc-LNP delivery may be utilized in indications where LDLR is present. We are conducting additional preclinical studies with our GalNAc-LNP technology.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are focused on building the preeminent company developing gene editing medicines to treat patients with CVD, the world&#x2019;s leading cause of mortality. Ultimately, we intend to leverage the expertise and capabilities of our team to expand our pipeline beyond PCSK9 and ANGPTL3 and apply our single-course gene editing approach to additional </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vivo</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> liver gene editing treatments to develop a suite of single-course gene editing medicines that address the root causes of disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Our team</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We were founded in 2018 by a team of world-renowned researchers in cardiovascular genetics, pioneers of gene editing and proven business leaders, including Sekar Kathiresan, M.D., Kiran Musunuru, M.D., Ph.D., MPH, J. Keith Joung, M.D., Ph.D., Burt Adelman, M.D., Issi Rozen, MBA, and Barry Ticho, M.D., Ph.D. Since our founding, we have built an organization and culture driven by a talented team of individuals who embody the meaning behind our name&#x2014;vigor, spirit and enthusiasm&#x2014;and who are motivated by a common goal of transforming the care of patients with or at risk for CVD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Members of our leadership team have extensive collective experience in human genetics, gene editing, CVD care and drug development and commercialization. Our chief executive officer, Dr. Kathiresan, is a preventive cardiologist who has made groundbreaking discoveries of genetic mutations that confer resistance to CVD. Andrew Ashe, J.D., our president and chief operating officer, is an accomplished biotech executive with over 20 years of experience in operations and legal management. Andrew Bellinger, M.D., Ph.D., our chief scientific officer and chief medical officer, is a cardiologist with proven expertise in drug delivery, drug development and translational medicine. Allison Dorval, our chief financial officer, has more than 20 years of leadership in finance, accounting, financial reporting and investor relations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have attracted a diverse team of experts in discovery, preclinical research and clinical development, as well as gene editing technologies and the manufacturing and delivery of genetic medicines. Our team is built on several core values that drive our day-to-day activities and inspire our long-term vision:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Grit: we work tenaciously to solve problems and advance science with rigor and care. </span></div></div>
  <div style="display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Spirit: we act with integrity and inclusion to earn the trust of colleagues, partners, patients and providers. </span></div></div>
  <div style="display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Drive: we enthusiastically pursue our potential, and we empower those around us to do the same. </span></div></div>
  <div style="display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Passion: we are motivated by our mission to reimagine the approach to the treatment of CVD for patients and their families. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have a Scientific Advisory Board, or SAB, comprising leading experts in the fields of cardiology, human genetics, translational medicine, delivery technologies, business and finance, including Eugene Braunwald, M.D., Daniel J. Rader, M.D., Andrew Geall, Ph.D., Anthony Philippakis, M.D., Ph.D, Kiran Musunuru, M.D., Ph.D., MPH, and Penny M. Heaton, M.D. Dr. Braunwald, a cardiovascular medicine specialist at Brigham and Women&#x2019;s Hospital and Hersey Professor of Medicine at Harvard Medical School, serves as chair of our SAB, has been listed as the most frequently cited author in cardiology, and was the first cardiologist elected to the National Academy of Sciences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have in-licensed technologies and intellectual property covering various elements of gene editing, including base editing and CRISPR nucleases, as well as multiple LNPs, with licenses from Beam Therapeutics Inc., or Beam, The Broad Institute, Inc., or Broad, Editas Medicine, Inc., the President and Fellows of Harvard College, or Harvard, Massachusetts General Hospital and Acuitas Therapeutics Inc., or Acuitas.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Transforming cardiovascular care</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Despite advances in treatment over the last 50 years, CVD remains a global epidemic. The current paradigm of chronic care is fragile&#x2014;requiring rigorous patient adherence, extensive healthcare infrastructure and regular healthcare access&#x2014;and leaves many patients without adequate care. CVD remains the leading cause of death worldwide, responsible for nearly one in three deaths according to the World Health Organization. It is also a leading contributor to reductions in life expectancy and is one of the most expensive health conditions in the United States. According to the United States Centers for Disease Control and Prevention, or CDC, CVD costs the U.S. healthcare system more than $350 billion per year in annual costs and lost productivity. Our goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach focused on addressing the root causes of this highly prevalent and life-threatening disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">CVD collectively refers to diseases of the heart and blood vessels, which are diagnosed as ASCVD, among others, as depicted in the figure below. In ASCVD, a large subset of CVD, cholesterol drives the development of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">atherosclerotic plaque, a mixture of cholesterol, cells and cellular debris in the wall of a blood vessel that results in the hardening of the arteries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_0.jpg" alt="img242628118_0.jpg" style="width:633px;height:329px;" />&#160;</p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">High cumulative life-long exposure to blood cholesterol, which is carried in each of low-density lipoprotein, or LDL, triglyceride-rich lipoprotein, or TRL, or lipoprotein(a), or Lp(a), is a root cause of ASCVD. The graphic below depicts these liver-produced lipoproteins being secreted into the blood and their typical compositions, comprising cholesterol and triglycerides and with apolipoprotein B, or ApoB, on the surface. Each of these three lipoproteins represents an independent pathway of risk for ASCVD, and we believe that concurrently reducing the blood lipids carried in more than one of these pathways should provide additive benefit for the treatment of ASCVD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_1.jpg" alt="img242628118_1.jpg" style="width:335px;height:159px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Current treatment approaches to lower LDL-C utilize continuous, life-long treatment, and due to the limitations of this chronic care model, cumulative exposure to LDL-C for many patients with ASCVD remains insufficiently controlled. The most common treatment for patients with ASCVD is daily statin pills in combination with recommended therapeutic lifestyle changes. There are several non-statin daily pills, including ezetimibe, bile acid sequestrants and bempedoic acid, that may be used alone or added sequentially to statin treatment in order to help patients with ASCVD reach recommended LDL-C goals. There are also two FDA-approved monoclonal antibodies, or mAbs, evolocumab and alirocumab, that target and bind to PCSK9 protein and are typically administered via injection twice per month. In addition, inclisiran, a small interfering RNA, or siRNA, that targets PCSK9 and is subcutaneously administered twice per year, was recently approved by the FDA and the European Medicines Administration, or EMA. Despite these approved treatments, effectively controlling LDL-C levels long-term in patients with or at high risk for ASCVD remains a significant unmet need.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The relationship between lowering of cumulative LDL-C exposure and reduction in the risk of ASCVD is among the best understood relationships in medicine. Human genetic studies have shown that those with FH, a genetic disease, have life-long severely elevated blood LDL-C, which can lead to increased risk of early-onset ASCVD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Conversely, individuals born with resistance mutations that turn off a cholesterol-raising gene expressed in the liver, such as PCSK9, have life-long low levels of LDL-C and rarely suffer from ASCVD. These insights point to the importance of early aggressive treatment to reduce LDL-C exposure over a patient&#x2019;s lifetime. For patients with established ASCVD, such as those who have previously suffered a heart attack, clinical treatment guidelines published by the AHA/ACC recommend lowering blood LDL-C to a goal of less than 70 mg/dL, and the European Society of Cardiology, or ESC, recommends lowering blood LDL-C to a goal of less than 55 mg/dL. If blood LDL-C is maintained low enough for long enough, the risk of a first ASCVD event, including a heart attack, can be dramatically reduced. Studies have shown that lowering LDL-C by 39 mg/dL for five years in patients with established ASCVD reduces the risk of a further event by 21%, whereas a similar degree of LDL-C difference over a lifetime reduces the risk of a first ASCVD event by 88%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Despite the availability of statin and non-statin therapies, cumulative exposure to LDL-C is often insufficiently controlled in many patients with ASCVD. As a result, a large proportion of patients with established ASCVD have LDL-C levels above clinical treatment guidelines. In a national registry of outpatient cardiovascular care in the United States, out of 2.6 million patients who had suffered a clinical ASCVD event, 53% had not received any cholesterol-lowering therapy and 72% remained above the LDL-C levels recommended by the AHA/ACC. Further, data from a clinical trial of approximately 6,000 patients in the year following a heart attack showed that among the approximately 3,000 patients for whom the medication was provided for free, only 39% reported full adherence to their statin therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A large proportion of patients with or at risk for ASCVD opt against starting or remaining on treatment due to the heavy, life-long medication burden associated with daily pills or frequent injections. Given the silent nature of the damage done by elevated LDL-C, many patients at risk for ASCVD do not properly appreciate the therapeutic benefits of consistent treatment as well as the substantial risk of foregoing treatment, focusing instead on the heavy, life-long medication burden of chronic approaches. Numerous prior studies of statins and injectable mAb PCSK9 inhibitors showed that treatment discontinuation is frequent. The graphic below illustrates findings from two of these studies, which showed that 50% of patients or fewer remain on treatment with PCSK9 inhibitor mAbs or statins over four years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_2.jpg" alt="img242628118_2.jpg" style="width:653px;height:319px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Incomplete adherence to treatment may result in significant oscillation in blood LDL-C levels over a patient&#x2019;s lifetime. The illustrative graphic below depicts the journey of a hypothetical patient with FH who began standard-of-care treatment after suffering a heart attack at age 44, at which point the patient was diagnosed with ASCVD, and the potential consequences of incomplete control of LDL-C over several years due to poor adherence and insufficient healthcare access. Incomplete LDL-C control can lead to recurrent clinical ASCVD events and the need for invasive medical procedures, such as intracoronary stenting and coronary artery bypass surgery, and can be fatal. These recurrent events and procedures place a heavy burden on patients, treating providers and the medical system as a whole, with increased cost and use of healthcare services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_3.jpg" alt="img242628118_3.jpg" style="width:540px;height:306px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Advantages of our single-course gene editing treatments for ASCVD</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe that single-course gene editing treatments for patients with ASCVD have the potential to solve many of the challenges of the chronic care model and create a new paradigm for the treatment of this highly prevalent and life-threatening disease. By potently and durably controlling cumulative LDL-C exposure throughout a patient&#x2019;s lifetime, we believe our gene editing medicines could fundamentally disrupt the chronic care model for patients with or at risk for ASCVD and relieve the significant burden placed on patients, providers and the healthcare system. The illustrative graphic below depicts the journey of the same hypothetical patient with FH</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">who, in this case, received a single-course gene editing treatment after suffering a heart attack and avoided recurrent ASCVD events as a result.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_4.jpg" alt="img242628118_4.jpg" style="width:534px;height:299px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To achieve our goal of transforming the treatment of ASCVD, we are developing a pipeline of single-course gene editing treatments that leverage multiple breakthroughs of 21</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.025pt;font-family:Arial;">st</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> century biomedicine&#x2014;human genetic analysis,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">gene editing, mRNA-based therapies and LNP-mediated delivery. We believe our approach benefits from the following potential advantages:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Validated liver targets implicated in ASCVD risk:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">    Our approach specifically targets genes that are predominantly expressed in the liver and have been validated through human genetics research. Naturally occurring mutations in each of these target genes are associated with a reduced risk of ASCVD. Our gene editing programs are designed to mimic these natural resistance mutations to turn off specific genes in the liver implicated in the risks of ASCVD. Such resistance mutations in PCSK9, even in adults with homozygous mutations and complete PCSK9 protein deficiency, do not appear to have any serious adverse health consequences. Furthermore, there is established human pharmacologic proof-of-concept and positive tolerability profiles with other modalities targeting these genes, such as mAbs, siRNA and antisense oligonucleotides. </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Potent, durable and life-long lowering of blood lipids through a single-course treatment:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">    We are leveraging gene editing technologies, including base editing, to make a permanent change in the target gene and disrupt the production of specific proteins that cause ASCVD. The durability of a gene editing approach appears to hold true in tissues with cell turnover, such as the liver, since the edit is passed on as cells divide. With VERVE-101, we are leveraging base editing with the goal of potently and permanently reducing blood lipids in order to create the potential for a life-long therapeutic outcome. In an ongoing preclinical proof-of-concept study in NHPs using a precursor formulation of VERVE-101, we observed a 59% reduction in blood LDL-C at two weeks after treatment, with LDL-C reduction maintained at an average of 60% at 15 months. In another preclinical proof-of-concept study in NHPs, we observed that a single administration of a precursor formulation targeting ANGPTL3 resulted in a 64% reduction in blood triglycerides at two weeks after treatment, with triglyceride reduction maintained at an average of 69% at ten months. We believe that our gene editing approach has the potential to potently and durably lower blood lipids throughout a patient&#x2019;s lifetime, thereby reducing their risk of ASCVD. </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Designed and optimized to reduce or avoid safety risks:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">    To optimize the safety profile of our gene editing programs, we utilize non-viral LNP delivery of a gene editor to the liver due to the potentially superior safety profile of LNPs compared with available viral delivery approaches, specifically the minimization of genome integration risk and immunogenicity. In addition, we use base editing for our initial programs, which enables highly precise editing at the single base pair level and minimizes the risks of unwanted DNA modifications associated with double-stranded breaks from nuclease-based editing approaches. Finally, we extensively screen pairs of gene editors with guide RNA, or gRNA, in human cells, mice and NHPs to maximize the likelihood that our gene editing programs will have limited or no off-target editing effects. For VERVE-101, we have identified a base editor paired with a gRNA targeting PCSK9 and have not observed any significant off-target editing in preclinical studies using primary human hepatocytes. </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">A suite of complementary single-course gene editing treatments to broadly reduce blood lipids and ASCVD risk:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">    We are focused on targeting distinct pathways implicated in elevated blood lipid levels and related ASCVD risk. VERVE-101, our lead program, is designed to target the PCSK9 gene, a validated regulator of blood LDL-C levels. Our second program targets the ANGPTL3 gene, a regulator of both cholesterol and triglycerides that contributes to ASCVD risk independent of the PCSK9 pathway. We believe that patients with established ASCVD who may need additional LDL-C and/or triglyceride reduction may benefit from treatment with an ANGPTL3-lowering therapy.</span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Potential to manufacture our programs in a scalable manner to reach a broad population:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">    We have designed our single-course treatments as LNPs encapsulating mRNA and gRNA, a similar construction to that used in two recent mRNA-based vaccines approved by the FDA for the prevention of COVID-19. We believe we will benefit from the rapid increase in investment, validation and real-world application of these technologies on a global scale as a result of the COVID-19 pandemic, which should enhance our potential to manufacture our gene editing programs for use with a broad patient population.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe that scalable manufacturing is paramount to unlocking the true potential of our single-course gene editing treatments to tackle the worldwide burden of ASCVD. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Our strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are executing a strategy with the following key elements:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Employ a stepwise approach to realize the full potential of VERVE-101, with initial development for the treatment of patients with HeFH followed by expansion to the broader population of patients with or at risk for </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">ASCVD.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">    We are pioneering a new approach with single-course gene editing medicines aimed at transforming the care of patients with or at risk for ASCVD. We are initially developing VERVE-101 for the treatment of HeFH, a genetic cardiovascular disorder that causes life-long elevated LDL-C levels and leads to early-onset ASCVD. If we successfully develop VERVE-101 for the treatment of patients with HeFH, we believe it could also be used to treat the broader population of patients with established ASCVD. Ultimately, we believe these treatments could be potentially developed for administration to people at risk for ASCVD as a preventative measure. We have initiated IND-enabling studies with VERVE-101, and expect to complete our submissions of CTAs to certain foreign regulatory authorities and an IND to the FDA in the second half of 2022, followed by initiation of clinical development for patients with HeFH.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Expand our pipeline of gene editing treatments within ASCVD and beyond to additional CVD indications</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">.    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are currently developing two gene editing programs focused on targeting two independent pathways controlling blood lipids implicated in ASCVD risk&#x2014;PCSK9 and ANGPTL3. We envision expanding beyond our PCSK9 and ANGPTL3 programs to develop a suite of single-course gene editing medicines that comprehensively and robustly address additional independent causes of CVD. We believe our approach may be applicable to additional CVD indications with high unmet need driven by mutations in target genes expressed in the liver. </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Leverage our expertise and access to multiple gene editing technologies to become the leader in gene editing for CVD.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">    We believe that the deep expertise of our team in human genetics, gene editing and off-target analysis combined with multiple in-licensed technologies, including base editing and CRISPR nucleases, positions us to be able to develop single-course gene editing medicines designed to make a precise, predictable and permanent change in a target gene for the treatment of CVD. For each new target, our expertise allows us to systematically evaluate each gene editing technology in primary human hepatocytes, mice and NHPs to identify the optimal approach based on potential efficacy and safety. We believe that our singular focus on developing gene editing medicines to treat CVD enables us to move rapidly and has culminated in the first ever proof-of-concept data in NHPs for base editing. </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Advance LNP delivery technology leveraging both external as well as internal LNP capabilities to target the liver</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On a target-by-target basis, we evaluate the best options for non-viral delivery from our external partnerships or our internal LNP discovery platform. For our lead program, VERVE-101, we have licensed LNP technology from Acuitas, an established company with a track record of partnering and developing LNPs for clinical use. Additionally, our internal team&#x2019;s expertise in biodegradable LNP chemistry, formulation and manufacturing has allowed us to develop and screen potent, liver-directed LNPs, including novel liver-targeting GalNAc-LNPs, which may offer superior delivery in certain CVD patient populations. We plan to utilize our proprietary GalNAc-LNPs to deliver a base editor targeting the ANGPTL3 gene to the liver in our ANGPTL3 program.</span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Prioritize rapid iteration of product candidates in NHP preclinical models as an early development strategy</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.    We believe that studies in NHPs are a powerful predictor of efficacy in humans for gene editing and LNP delivery to the liver. Our preclinical validation approach prioritizes NHP experiments early in the process, enabling us to rapidly optimize drug product development to identify a lead candidate to take into clinical development.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">With VERVE-101, the bulk of our preclinical studies have been performed in NHPs, allowing us to establish the pharmacodynamic relationship between liver editing and resulting reductions in circulating PCSK9 protein and LDL-C that we believe will translate into a similar profile in humans. </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Develop manufacturing capabilities to produce in vivo gene editing medicines at scale.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">    We are currently working with Good Manufacturing Practice, or GMP, vendors to produce all components of our drug candidates for our first clinical trial batches. We have successfully executed batches at near clinical scale through our vendors and are on-track to produce clinical batches for our planned first-in-human trial of VERVE-101. We have also developed proprietary production processes designed to yield high-purity and high-quality mRNA that are crucial for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> liver editing applications. We are continuing to invest in building internal manufacturing capabilities for mRNA and LNP production, in order to fulfill our vision of delivering gene editing medicines to millions of patients with CVD. </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Build the leading cardiovascular gene editing company by maintaining a dynamic culture that attracts and retains a talented and collaborative team.    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have attracted a talented team of scientists, cardiologists, drug developers and business professionals, as well as experts in the fields of human genetics, gene editing technologies, mRNA biology, off-target analysis and genetic medicine delivery modalities. Developing gene editing medicines that transform the care of CVD requires that we solve many new and complex problems as a natural component of the drug discovery and development process. Our vision, values, talent and strategy are </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">essential to maximizing our ability to address these problems and bring forward a new approach to treating the leading cause of the death in the world.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Our approach</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are employing a tailored approach aimed at developing single-course gene editing medicines to transform treatment for patients with CVD. Our gene editing programs target validated genes in the liver that are supported by extensive human genetics and human pharmacology data and are known to be implicated in CVD. We use base editing for our initial programs, a next-generation gene editing approach that enables precise and efficient editing at the single base level in the genome without making a double-stranded break in the DNA. Our gene editing programs consist of LNPs that encapsulate mRNA encoding for a gene or base editor as well as a gRNA targeting the gene of interest expressed in the liver. We believe that the following key elements of our approach will help us achieve our goal of delivering gene editing treatments on a global scale for millions of patients with CVD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Editor selection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We selected gene editing as the core technology to develop our single-course gene editing treatments for CVD because we believe it offers the potential for durability of effect and versatility in the type of genetic modification compared to other genetic medicine approaches, including gene therapy and RNA therapeutics. We have access to multiple gene editing technologies through licenses including base editing and CRISPR nucleases. We believe having the flexibility to apply different gene editing technologies to different single-course treatments for CVD enables us to identify the best potential option for any given therapeutic application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">CRISPR-Cas is a form of nuclease-based gene editing that enables targeting of genomic DNA sequences with high specificity in human cells by assessing for a match between the gRNA sequence and the DNA sequence. The gRNA allows the Cas protein to recognize a complementary part of the DNA sequence. Once RNA-DNA pairing occurs, the Cas enzyme makes a double-stranded DNA break, and the cell&#x2019;s natural DNA repair mechanisms work to make changes or repair the genome. When the repair is faulty, there can be disruption of a target gene, known as a knockout. CRISPR-Cas is effective at knocking out, or silencing, a targeted gene through disruption. However, potential limitations of standard CRISPR-Cas gene editing include lack of predictability in genetic outcomes and potential toxicities associated with double-stranded DNA breaks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Base editing is a next-generation gene editing approach that enables precise and efficient editing at the single base level in the genome without making a double-stranded break in the DNA. If CRISPR-Cas gene editing approaches are akin to &#x201c;scissors&#x201d; for the genome, base editors are akin to &#x201c;pencils,&#x201d; erasing and rewriting one letter in a gene.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Through our license agreement with Beam, we have access to two different types of base editors&#x2014;adenine base editors, or ABEs, and cytosine base editors, or CBEs, each of which has a modified Cas9 protein bound to a gRNA, retaining the ability to target a genomic sequence, yet avoiding double-stranded DNA breaks. The base editors are distinguished by the kind of deaminase, the base editing enzyme that carries out the chemical modification, that is fused to Cas9. The deaminase makes a predictable chemical modification, called deamination, of the amine group on either an adenine, or A, base or a cytosine, or C, base as shown in the figure below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_5.jpg" alt="img242628118_5.jpg" style="width:503px;height:200px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For our lead programs for PCSK9 and ANGPTL3, we are using an ABE to convert an amine group of A to an inosine, or I, base, which is read by DNA polymerase as a guanine, or G, base, leading ultimately to an A-to-G spelling change. Once the initial modification has occurred, the intermediate DNA consists of an edited strand, containing an I at the target site, and an unedited strand with a thymine, or T, base. The I:T base pair is a mismatch, which the cell will normally attempt to repair in a process that can potentially lose the edit. In order to preserve the editing, our base editors cleave the unedited single strand of the DNA, referred to as nicking, rather than creating double-stranded breaks. The presence of the nick on the unedited strand, however, increases the efficiency of editing by inducing the cell to use the newly edited strand, and not the unedited strand, as the template for repair, resulting in an I:C base pair. Upon DNA repair or replication, the I is read as a G, resulting in a G:C base pair, and the permanent conversion of an A:T base pair to a G:C base pair is completed. This single base pair change at the specific site within the PCSK9 or ANGPTL3 gene alters the gene in such a way that no functional PCSK9 or ANGPTL3 protein is made, disrupting its role in maintaining elevated levels of circulating blood lipids.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Target selection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We focus on validated genes in the liver-cardiovascular axis, which are genes predominantly expressed in the liver and where disrupting protein production or introducing a beneficial mutation may effectively treat an underlying cause of CVD. When considering targets for our programs, we evaluate the following criteria:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">human genetic evidence that loss-of-function, or LoF, mutations confer resistance to disease; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">human genetic evidence that LoF mutations do not have adverse effects, and that homozygous LoF, inheriting two mutant alleles, are well tolerated; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">human clinical proof-of-concept data for targeting with other modalities to support the potential safety and efficacy of permanent gene or base editing; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">technical efficiencies, such as liver-predominant expression and known estimates of the pharmacodynamic relationship between target protein and therapeutic effect; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">existence of circulating protein biomarkers for efficacy, clinical biomarkers of disease modulation, and the availability of appropriate preclinical disease models; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">clear unmet medical need and development rationale for the target indications. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Evaluating for off-target editing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Gene editing enables precise alterations at specific locations in the genome but has the potential to make alterations at undesired locations, known as off-target editing. Base editing has inherently fewer risks for off-target editing than CRISPR-Cas nuclease editing given the precision and efficiency of editing at the single base pair level and ability to make the edit without making a double-stranded DNA break.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our approach to minimizing off-target editing involves the use of comprehensive, sensitive and state-of-the-art methods to identify potential off-target sites with our editors. These include computational methods that predict off-target sites based on sequence similarity to the on-target site. We also use biochemical methods in which either DNA extracted from cells or synthetic DNA is treated with a nuclease or base editor </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and edited sites are identified by next-generation DNA sequencing. A key part of our approach includes the use of a new technique called ONE-seq, which was developed by Dr. Keith Joung, one of our founders. ONE-seq is an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> method to screen tens of thousands of potential sites in the genome where editing may occur. We believe that our internal expertise in the application of multiple innovative techniques to evaluate off-target editing gives us a leading position in the field and the ability to rapidly advance future programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Lipid nanoparticle delivery selection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Gene editing treatments require intracellular delivery of mRNA and gRNA molecules into the target cell type&#x2014;in our case, hepatocytes in the liver&#x2014;and all of our programs utilize a non-viral approach, LNPs, for delivery. LNPs are well-established, both by approved products and by clinical trials conducted by others with other agents, to preferentially accumulate in the liver after systemic administration. We have chosen non-viral LNP delivery due to the potentially superior safety profile compared with available viral delivery approaches, as well as the high efficiencies of liver editing achievable with LNPs due to their natural tropism to the liver.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Non-viral delivery to the liver with LNPs confers potential advantages, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">protection of the mRNA and gRNA payloads while in circulation in the blood; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">transient expression of gene editing proteins, allowing more control over the editing process; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">transient expression of the editing protein and rapid completion of the editing process within days, minimizing immunogenicity; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">absence of DNA or viral components, avoiding exogenous DNA capable of inserting into the genome; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">rapid degradation of drug product within one to two weeks, supporting the potential for long-term safety; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">known, manageable infusion-related side effects; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">cost-effective manufacturing with potential to efficiently scale to reach millions of patients. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On a target-by-target basis, we evaluate the optimal LNP delivery options from either external partnerships or our internal LNP discovery platform. For our lead program, VERVE-101, we have licensed LNP technology from Acuitas, an established company with a track record of partnering and developing LNPs for clinical use. Our collaboration with Acuitas included several NHP studies to evaluate various LNP formulations and RNA payloads prior to selecting an Acuitas LNP for VERVE-101.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We view our internal LNP discovery platform as an important source of delivery technology for future therapeutic programs. We are optimizing our internal LNP discovery platform by focusing on:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">strategies to enhance delivery to the liver in certain CVD patient populations, such as patients with HoFH, in whom LNP-mediated delivery may be challenging; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">improved efficiency of delivery to the liver, such that lower doses of RNA payload could be used; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">wider therapeutic indices to optimize the benefit-risk profile of our product candidates; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">improved stability and potential for powder formulation enabling easier storage for commercial application. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To date, our LNP discovery platform has yielded novel proprietary ionizable lipids that we have designed, synthesized and evaluated for their potential to deliver gene editing payloads to the liver in mice. We are further optimizing and scaling up such formulations for evaluation in NHPs. We have also developed novel targeting ligands that when added to LNPs allow for more efficient delivery of RNA payloads to the liver. We believe that our internal LNP discovery platform will yield improvement in our product candidates for current and future programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Single-course therapy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are designing our single-course gene editing treatments to be administered as single-dose regimens through intravenous infusion, which is supported by data generated in our preclinical studies in NHPs. However, an advantage of using LNPs is the potential for split-dosing. In the case of our gene editing programs, we may elect to dose patients using a single, short course consisting of a limited number of split-doses over a short period of time to improve safety, efficacy or both. In patients who may not receive an adequate therapeutic effect with a single course of treatment, our approach may enable the option to re-dose. Patisiran, an approved LNP-encapsulated siRNA, is chronically administered without safety and efficacy concerns for patients with transthyretin amyloidosis, or ATTR. This is in contrast to viral vectors, which face safety and efficacy challenges with re-dosing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The value of a single-course gene editing treatment will be determined by the safety, potency and durability of its desired effect. We believe a single-course treatment with VERVE-101 could durably lower LDL-C throughout the lifetime of patients with or at risk for ASCVD. Our gene editing treatments are designed to make a permanent change in the DNA of liver cells. With VERVE-101, transient expression of ABE protein in hepatocytes is designed to lead to permanent editing of the PCSK9 gene. Since liver cells turn over predominantly through division of hepatocytes that themselves will carry the PCSK9 edit, we believe that the efficacy resulting from the edit will be durable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This stands in contrast to gene therapy, where the therapeutic benefit has been challenged by a lack of durability. Gene therapies are often designed to express exogenous mRNA by viral delivery or viral expression of mRNA. The durability of therapeutic effect can be limited by the loss of mRNA expression from a viral vector that does not integrate into the genome. This leads to either a reliance on viral integration at unpredictable sites in the genome, which can lead to safety challenges, or on repeat dosing that has its own challenges with viral delivery.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe that single-course gene editing treatments could provide durable and transformative outcomes, producing sustained health benefits for patients with CVD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Scalable manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">By designing our gene editing treatments as LNPs encapsulating mRNA and gRNA, we expect to benefit from the potential for scalable and cost-effective manufacturing processes enabling the opportunity to treat millions of patients with CVD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our product candidates are similar to two validated and approved drug classes: LNP-encapsulated siRNAs, such as patisiran, and LNP-encapsulated mRNA-based COVID-19 vaccines, which are LNPs containing a long mRNA molecule for the spike protein of SARS-CoV-2. Significant and ongoing investments are being made by multiple organizations to enhance the supply chain for all components and processes related to mRNA production, LNP production and fill-finish, especially in light of the intense worldwide efforts to manufacture massive quantities of COVID-19 vaccines. We believe we will ultimately benefit from the increased global capacity for LNP-encapsulated mRNA production over the next several years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are currently working with GMP vendors to produce all components of our drug candidates for our first clinical trial batches. These include plasmid DNA preparation, mRNA production via </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> transcription reactions, gRNA synthesis via solid state synthesis, lipid synthesis and LNP formulation and fill finish. Working closely with these vendors, we have successfully executed batches at clinical scale and are on track to produce clinical batches for our planned first-in-human trial of VERVE-101.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are also investing in the buildout of internal process development capabilities in mRNA production and LNP formulation, which we believe will become one of our core competencies in the future. The goals of this internal process development capability are to scale up plasmid DNA, mRNA and LNP production batches, to make improvements in order to enhance quality, consistency and stability, and to reduce costs. Further, we are investing in analytical method development including bioactivity and potency assays that will be critical to further product development, batch comparability assessments and additional manufacturing growth.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Our gene editing programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are advancing a pipeline of single-course </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> gene editing programs intended to durably turn off genes in the liver implicated in CVD. Our gene editing programs consist of LNPs that encapsulate mRNA encoding for a gene editor as well as a gRNA targeting the gene of interest expressed in the liver. Our initial pipeline is focused on two genes, PCSK9 and ANGPTL3, implicated in the control of blood lipids. We are developing these gene editing treatments initially for the treatment of patients with forms of FH, which is an autosomal dominant genetic disorder, leading to life-long severely elevated blood LDL-C and increased risk of early-onset ASCVD. Patients with FH have mutations predominantly in the LDLR gene that affect the ability of liver cells to remove LDL from the circulation. FH manifests clinically in two forms: the more common heterozygous form, known as HeFH, and the rarer homozygous form, known as HoFH.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following graphic summarizes our pipeline of programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_6.jpg" alt="img242628118_6.jpg" style="width:628px;height:205px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our most advanced product candidate, VERVE-101 targeting the PCSK9 gene, is in IND-enabling studies for the treatment of patients with HeFH, which affects approximately 1.3 million people in the United States, 2.1 million in the European Union and the United Kingdom and approximately 31 million worldwide. We expect to complete submissions of CTAs to certain foreign regulatory authorities and an IND to the FDA in the second half of 2022, followed by initiation of clinical development for patients with HeFH. Our approval pathway is subject to discussions with the FDA and other regulatory authorities; however, we note that FDA-approved lipid-lowering</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">therapies, including for FH, have used LDL-C reduction as a primary endpoint in registrational trials. Outcome studies have not been required for initial approval of these other therapies in patients with FH.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are strategically developing VERVE-101 initially in patients with HeFH, recognizing that the unmet need is highest in those patients and the benefit-risk profile may be more favorable. We intend to use a stepwise clinical development plan for VERVE-101 as depicted in the illustration below, evaluating efficacy and safety in higher-risk populations first, and then if successful, expanding into broader population of patients with established ASCVD, and ultimately to those at risk for ASCVD in the general population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_7.jpg" alt="img242628118_7.jpg" style="width:565px;height:214px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We plan to develop our second program targeting the ANGPTL3 gene using a similar stepwise approach. We plan to initially develop this program for the treatment of HoFH, which affects approximately 1,300 patients in the United States. Similar to our approach with VERVE-101, we plan to expand the clinical development of our ANGPTL3 program in a stepwise fashion beyond HoFH to patients with established ASCVD who may need additional LDL-C and/or triglycerides reduction. We plan to select a development candidate for our ANGPTL3 program and to initiate IND-enabling studies for this program in the second half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We intend to develop a broad pipeline of gene editing programs targeting distinct pathways implicated with ASCVD risk. Additionally, we believe our gene editing approach could have broader application for additional indications having both high unmet medical needs and validated gene targets expressed in the liver. With a focus on </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">vivo gene editing treatments, we plan to develop a suite of single-course gene editing medicines that address root causes of disease.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Familial hypercholesterolemia: our initial focus for our single-course gene editing treatments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">FH is a genetic disorder where patients have life-long severely elevated blood LDL-C, which can lead to increased risk of early-onset ASCVD. FH is an autosomal dominant disease often caused by a mutation in the LDLR gene. Individuals with FH may harbor one mutant allele and are thereby heterozygous for the disease, known as HeFH, or two mutated alleles and are therefore homozygous for the disease, known as HoFH. HoFH is typically more severe than HeFH.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Men and women with untreated HeFH typically have LDL-C levels ranging from approximately 200 to 400 mg/dL and develop ASCVD before age 50 and 60, respectively. The estimated prevalence of HeFH is roughly one in 250, which translates to about 1.3 million patients in the United States. Men and women with HoFH have LDL-C levels above 500 mg/dL and typically develop ASCVD before the age of 20 and, without intervention, die before age 30. The estimated prevalence of HoFH is roughly one in 250,000, which translates to about 1,300 patients in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">FH is clinically diagnosed based on a combination of factors, including the concentration of blood LDL-C, physical findings, personal or family history of hypercholesterolemia and early onset of ASCVD. Extensor tendon xanthomas, typically Achilles, subpatellar and hand extensor tendons, with extremely elevated LDL-C levels are considered specific for FH. However, FH is often silent until the development of a heart attack at a young age, at which time a family history of ASCVD and elevated LDL-C levels are often the only findings. In an analysis of the FH phenotype, which typically means LDL-C levels of greater 190 mg/dL, from six prospective cohort studies with 30-year follow-up, the FH phenotype was associated with up to a five-fold elevated 30-year ASCVD risk. ASCVD development was accelerated in those with the FH phenotype by 10 to 20 years in men and 20 to 30 years in women. In HoFH, patients typically develop atherosclerosis in childhood, initially in the aortic root, causing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">supravalvular aortic stenosis, and then extending into the coronary arteries. If the LDL-C level is not effectively reduced, people with HoFH die prematurely of ASCVD. The severity of atherosclerosis in FH is proportional to the extent and duration of elevated blood LDL-C levels.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Although the diagnosis of FH can be made on the basis of clinical features, genetic testing may offer additional insight into cardiac risk and diagnosis. Recent analysis of data from more than 26,000 individuals suggests that at any given LDL-C level, having an identified FH mutation is associated with significantly higher ASCVD risk than having the same LDL-C level but no apparent pathogenic FH mutation. In this analysis, individuals with an LDL-C level greater than or equal to 190 mg/dL and no pathogenic FH mutation had a six-fold higher risk of ASCVD than the reference group with an LDL-C level less than or equal to 130 mg/dL. However, individuals with an LDL-C level greater than or equal to 190 mg/dL and a pathogenic FH mutation were at a 22-fold higher risk of ASCVD than the reference group, possibly reflecting greater atherogenicity of life-long LDL-C elevation in FH compared with LDL-C elevation acquired later in life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">While dietary and lifestyle changes are important for LDL-C lowering in patients with FH, multidrug treatment is often required to achieve recommended LDL-C levels. The recommended LDL-C levels for FH patients are similar to those for non-FH patients with ASCVD. Treatment for FH patients tends to start earlier than those with or at risk for ASCVD without FH, and typically follows a more aggressive course with multidrug treatment given the elevated risk of early-onset ASCVD. While FH patients are treated with medicines similar to those used for non-FH patients, the chronic care for FH patients is typically more burdensome with earlier intervention and more drugs. In addition, for many patients, especially those with HoFH, their LDL-C levels remain inadequately controlled and do not reach goals recommended by clinical treatment guidelines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">VERVE-101: PCSK9 program</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our lead product candidate, VERVE-101, is designed to be a single-course </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">gene editing treatment targeting the PCSK9 gene. We plan to develop VERVE-101 initially for patients with HeFH, and, if successful, to expand development for the broader population of patients who have established ASCVD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In patients with HeFH, a genetic mutation in the LDLR gene down-regulates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">LDLR expression, which limits the ability of liver cells to remove LDL from the bloodstream, resulting in extremely high LDL-C levels in the blood. Over time, high LDL-C builds up in the arteries, leading to formation of atherosclerotic plaque, reduced blood flow or blockage and ultimately heart attack or stroke. We believe that inactivation of the PCSK9 gene will result in lower PCSK9 protein levels, thereby increasing LDLR expression, leading to lower LDL-C levels and reduced risk for ASCVD. Clinical trials conducted by others evaluating PCSK9 inhibitors have suggested that targeting PCSK9 has the potential to work in patients with HeFH regardless of the underlying mutation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">VERVE-101 consists of an LNP encapsulating an mRNA encoding an ABE and a gRNA, as depicted in the image below. Four lipid components assemble along with the RNAs to form a dense, stable LNP that is approximately 60 nanometers in diameter.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_8.jpg" alt="img242628118_8.jpg" style="width:309px;height:169px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">VERVE-101 is designed to be infused intravenously into the patient over approximately one to two hours, and then accumulates in the liver. Prior to administration of VERVE-101, a pre-medication regimen is given that consists of antihistamines and steroids. Once in the liver, VERVE-101 is brought into hepatocytes and escapes into the cytoplasm where the base editor protein is transiently expressed. The gRNA then binds to the base editor protein, and the complex is carried into the nucleus to locate the gene target specified by the 20-nucleotide spacer sequence of the gRNA. The ABE binds to the DNA and makes a single A-to-G spelling change at the target site, thereby turning off the PCSK9 gene. The ABE mRNA construct is codon-optimized and contains chemical modifications to reduce the potential for mRNA-mediated immune responses. The gRNA sequence has several chemical modifications to enhance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> stability to endonucleases and exonucleases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">PCSK9 as a target</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The PCSK9 gene plays a critical role in the regulation of blood LDL-C through its regulation of the LDLR gene. The normal function of PCSK9 is depicted in the figure below on the left. The PCSK9 gene produces a protein in the liver that is released into the blood. LDLR is present on the surface of liver cells and binds to LDL and removes LDL from circulation. The LDL bound to LDLR is taken up by liver cells to enable the breakdown of LDL particles. LDLR is then recycled back to the surface of the cell, enabling the process of LDL uptake to recur. PCSK9 protein in the blood interrupts this LDLR recycling process. Specifically, PCSK9 protein in the blood binds to LDLR and targets LDLR for destruction. In doing so, PCSK9 reduces the number of LDLRs on the liver cell surface, thereby reducing the ability of the liver to clear LDL from the blood. The figure on the right depicts a loss of PCKS9 gene function, which results in less PCSK9 protein and thereby increased LDLR expression and uptake of LDL-C.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_9.jpg" alt="img242628118_9.jpg" style="width:628px;height:255px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As reported in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">The New England Journal of Medicine</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, one study found that adults with naturally occurring LoF mutations in the PCSK9 gene had LDL-C levels that were 38 mg/dL lower than adults without the mutation, and those with the mutation had an 88% lower risk of ASCVD. Human genetic studies also showed that carrying naturally occurring loss-of-function mutations in one or both copies of the PCSK9 gene was not associated with serious adverse health consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition to human genetic studies, human pharmacology studies have provided validation for PCSK9 as a target. The impact of PCSK9 inhibition on cardiovascular outcomes has been established by two large, randomized, double-blind, placebo-controlled studies of two approved mAbs that bind to PCSK9 protein and block its activity, the FOURIER trial and the ODYSSEY OUTCOMES trial. The FOURIER trial demonstrated that treatment with evolocumab in addition to background statin therapy over a median of 2.2 years reduced major cardiovascular events by an additional 15% in patients with established ASCVD. The ODYSSEY OUTCOMES trial demonstrated that treatment with alirocumab in addition to background statin therapy over a median of 2.8 years reduced major cardiovascular events by an additional 15% in patients with established ASCVD. Treatment with these mAbs demonstrated an approximately 60% reduction in LDL-C on average across clinical trials when compared with placebo treatment. Notably, in both trials, with the exception of injection site reactions, overall adverse event rates were similar between patients treated with placebo or drug, with no observed increase of new-onset diabetes, worsening glycemic control or neurocognitive adverse events.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The PCSK9 target has been further validated by inclisiran, which was approved by the EMA in 2020 and by the FDA in December 2021. In the ORION-9 trial, the pivotal Phase 3 trial of inclisiran in patients with HeFH, the percent change in the PCSK9 level after 510 days was a decrease of 60.7% in the inclisiran-treated group compared with baseline, which led to a reduction in LDL-C after 510 days of 39.7% compared to baseline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe the human genetic studies and the human pharmacology with PCSK9 inhibitors provide substantial evidence that targeting PCSK9 is a potentially safe and effective approach to lower LDL-C and reduce ASCVD risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Preclinical studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We discovered VERVE-101 based on extensive screening of a large library of gRNA candidates, evaluation of multiple LNP formulations and optimization of the ABE mRNA construct. We have tested a mouse surrogate of VERVE-101, precursor formulations of VERVE-101, which we refer to as our ABE-PCSK9 precursor formulation, and VERVE-101 itself </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> across multiple animal models. In these studies, we have observed the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">high PCSK9 gene editing activity in the liver by a mouse surrogate of VERVE-101 in both wild type mice and heterozygous LDLR knockout mice, a well-established mouse model of HeFH; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">15-month NHP durability data for blood PCSK9 protein and LDL-C reduction following treatment with our ABE-PCSK9 precursor formulation, with average reductions of 90% of PCSK9 protein and 60% for LDL-C; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">dose-responsive liver PCSK9 gene editing, blood PCSK9 protein reduction, and LDL-C reduction in NHPs, with a 1 mg/kg dose of VERVE-101 achieving approximately 71% editing, approximately 85% reduction in blood PCSK9 protein and approximately 64% reduction in LDL-C; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Six month NHP durability data for blood PCSK9 protein and LDL-C reduction following treatment with VERVE-101, with average reductions of 86% of PCSK9 protein and 62% for LDL-C;</span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">VERVE-101 editing occurred predominantly in the liver and within 24 hours of treatment in NHP studies; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Evidence that VERVE-101 is potent in NHPs at doses as low as 0.5 mg/kg;</span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">No evidence of germline editing in an analysis conducted in sexually mature male NHPs receiving a 1.5 mg/kg dose of VERVE-101;</span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Sustained editing of the PCSK9 gene in regenerated liver lobes at 95 days post-treatment, as demonstrated in a partial hepatectomy mouse model designed to determine durability of PCSK9 base editing in the liver;</span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">administration of VERVE-101 to NHPs caused transient, mild elevations in liver function tests that entirely resolved within two weeks; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no significant off-target editing in primary human hepatocytes after evaluation at any of approximately 3,000 potential off-target sites. </span></div></div>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">In vivo validation with ABE-PCSK9 mouse surrogate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our initial target patient population for VERVE-101 is patients with HeFH who produce reduced levels of functional LDLR, which results in increased levels of LDL-C in the blood. We utilized heterozygous LDLR knockout mice to model the HeFH disease state. A mouse surrogate version of VERVE-101 was developed for use in this model comprising a mouse surrogate gRNA targeting the ortholog of the same PCSK9 site, along with two components identical to VERVE-101&#x2014;the ABE mRNA and LNP. As shown in the figure below, we observed that doses of 0.05, 0.1 and 0.5 mg/kg of the mouse surrogate of VERVE-101 administered once to wild-type and heterozygous LDLR knockout mice resulted in similar and robust amounts of PCSK9 editing in the liver.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_10.jpg" alt="img242628118_10.jpg" style="width:413px;height:353px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">NHP validation with ABE-PCSK9 precursor formulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We then applied this approach in an NHP model to establish preclinical proof-of-concept using an ABE-PCSK9 precursor formulation. In this study, which is ongoing, we administered a single dose to healthy NHPs. In the figures below, each treated NHP is represented by a purple bar and each vehicle treated control is represented by a blue bar. Following a single treatment with our ABE-PCSK9 precursor formulation, we observed an average 67% editing of PCSK9 in whole liver tissue sampled through a liver biopsy two weeks after dosing, as shown in the first graph. This was accompanied by an average 89% reduction of blood PCSK9 protein and an average 59% reduction of blood LDL-C concentrations, as shown in the additional two graphs below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_11.jpg" alt="img242628118_11.jpg" style="width:328px;height:374px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_12.jpg" alt="img242628118_12.jpg" style="width:638px;height:324px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Importantly, in this preclinical study, we observed that the reductions in blood PCSK9 protein and blood LDL-C levels were durably maintained. As shown in the figures below, at 15 months following a single intravenous administration of ABE-PCSK9, we observed that the NHPs continued to exhibit an average 90% reduction in blood PCSK9 protein and an average 60% reduction in blood LDL-C. If we are able to achieve similar reductions in PCSK9 protein levels in humans, we believe this could result in marked and sustained LDL-C reductions of approximately 60%, which would potentially offer superior cumulative LDL-C lowering to what has been clinically demonstrated with other PCSK9-targeting treatment modalities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img242628118_13.jpg" alt="img242628118_13.jpg" style="width:672px;height:276px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Turnover of mature hepatocytes in the liver is estimated to occur on average every 200 to 300 days. The source of new hepatocytes is not certain, but evidence suggests that mature hepatocytes are responsible for production of new hepatocytes during both homeostatic liver turnover and following liver injury. Less likely, a fraction of hepatocytes with greater regenerative capacity may exist in the liver. In either case, the 450-day durability data shown above in our preclinical studies with an ABE-PCSK9 precursor formulation suggest that the liver cells responsible for regeneration are edited at the PCSK9 gene site. In addition, we have not observed evidence of persistent inflammation or liver injury that might suggest more rapid hepatocyte turnover or immune-mediated clearance of edited hepatocytes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have explored the pharmacodynamics of liver editing and consequent effect on blood PCSK9 protein levels across a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">large number of iterative NHP studies. We have identified a linear relationship between editing of the PCSK9 gene in liver cells and blood PCSK9 protein levels. The figure below shows a best-fit line with confidence intervals representing a large number of data points from individual NHPs. In NHPs, we have achieved a reduction of greater than 60% in PCSK9 protein with a whole liver editing rate of approximately 50% to 55%. We believe that this relationship between whole liver editing and PCSK9 reduction should be similar in humans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_14.jpg" alt="img242628118_14.jpg" style="width:420px;height:409px;" />&#160;</p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">VERVE-101 preclinical efficacy data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our preclinical studies of our ABE-PCSK9 precursor formulation led to the development of VERVE-101.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Short-term preclinical study of VERVE-101</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In a preclinical dose-response study of VERVE-101 in the figure below, in NHPs, we administered VERVE-101 at four dose levels with three NHPs per dose level. In the figure below each bar represents a different dose group ranging from 0.5 mg/ kg to 3.0 mg/kg. With a dose of 1 mg/kg, we observed whole liver editing levels of approximately 71%, as shown in the figure below, which we believe represents editing of the majority of hepatocytes. We also observed that the level of editing translated into dose-dependent reductions of both blood PCSK9 protein and blood LDL-C. At the 1 mg/kg dose, we observed a PCSK9 protein reduction of approximately 85% and a robust LDL-C reduction of approximately 64%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_15.jpg" alt="img242628118_15.jpg" style="width:561px;height:330px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We observed that editing occurred quickly following dosing of VERVE-101 in NHPs, with the majority of the editing observed within one to two days of dosing. In the study, NHPs (n=2 per group) were administered the same 1 mg/kg dose, and necropsies were serially performed on day one, day two, day seven, day 14 and day 28. We observed high efficiency editing within 24 hours with minimal additional editing at subsequent time points as shown in the figure below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_16.jpg" alt="img242628118_16.jpg" style="width:396px;height:371px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The effects on blood PCSK9 protein and LDL-C reached their peak outcomes within two weeks of dosing. The major component of the LNP, the ionizable lipid, is designed to be biodegradable and to be eliminated from the blood within two weeks, and we observed that it was largely eliminated from the liver, to less than 10% of peak concentration, within two weeks of dosing. ABE mRNA levels in the liver decreased by 97% within one week of dosing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Long-term preclinical study of VERVE-101</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In an ongoing long-term NHP study in 36 NHPs, we administrated 1.5 mg/kg of VERVE-101 (n=22) and 0.75 mg/kg (n=4) with a control group (n=10). The study was designed to measure whole liver editing, blood PCSK9 protein levels and blood LDL-C levels. This study utilized our final VERVE-101 drug product that was manufactured at our planned clinical manufacturing site. We plan to continue this study in the dosed NHPs for three or more years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">With a dose of 1.5 mg/kg (n=22), we observed an average of 70% whole liver editing at the PCSK9 target site at day 15, as shown in the figure below, which we believe represents editing of the majority of hepatocytes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">At the 1.5 mg/kg dose, we observed a PCSK9 protein reduction of approximately 86% and a robust LDL-C reduction of approximately 62% at two weeks following treatment, which was maintained at 180 days following treatment. At a 0.75 mg/kg dose level (n=4), we observed a PCSK9 protein reduction of approximately 54% and a robust LDL-C reduction of approximately 38% at two weeks following treatment, which improved to 71% and 46%, respectively, at 180 days following treatment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_17.jpg" alt="img242628118_17.jpg" style="width:482px;height:320px;" />&#160;</p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Partial hepatectomy mouse model</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We conducted a durability challenge study in a partial hepatectomy mouse model in order to evaluate whether the level of editing remains following the turnover of liver cells. In this study, a partial hepatectomy that removed two-thirds of the liver or a sham surgery was conducted 11 days after dosing with a mouse surrogate of VERVE-101. In the mice with a partial hepatectomy, the rest of the liver regrows to restore liver weight in approximately nine days. We then performed a necropsy at either 22 days or 95 days post-treatment. We observed sustained editing of PCSK9 in regenerated liver lobes at both 22 days and 95 days post-treatment. We also observed sustained reductions in PCSK9 protein level at both 22 days and 95 days post-treatment. This data supports our belief that as the liver regenerates, the level of editing achieved by VERVE-101 is expected to remain robust and durable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">VERVE-101 biodistribution data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are using an LNP-based approach to deliver VERVE-101 to the liver. An analysis of the biodistribution of VERVE-101 following administration of a single dose of 1 mg/kg in NHPs indicated that the large majority of editing occurred in the liver in a dose-dependent manner, with lesser rates of editing observed in the spleen and adrenal glands, as shown in the figure below. Other tissues examined showed editing of less than about 2%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_18.jpg" alt="img242628118_18.jpg" style="width:636px;height:287px;" />&#160;</p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Tolerability of VERVE-101 in NHPs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">VERVE-101 was generally well tolerated in NHP studies. We compared treatment with VERVE-101 to a control, or DPBS, at doses of 1 mg/kg or less and observed transient elevations of alanine aminotransferase, or ALT, consistent with mild acute liver injury within one to two days after dosing, which then peaked two to three days after dosing, with average values around 300 U/L following a 1 mg/kg dose. ALT is a commonly used blood marker of liver injury. Within one week of dosing, the average ALT value was within the normal range, indicating recovery, as shown in the figure below. These findings are consistent with observations from nonclinical studies performed for an approved LNP-based product that is administered intravenously.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_19.jpg" alt="img242628118_19.jpg" style="width:622px;height:232px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The liver enzyme findings, which can be monitored with standard clinical laboratory testing, were consistently transient and mild in nature and fully normalized by one to two weeks. We believe that these findings compare favorably to viral vector delivery approaches, which can lead to unpredictable and acute liver injury.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In order to assess the long-term liver safety of VERVE-101, we monitored liver enzymes in a long-term durability study of an ABE-PCSK9 precursor formulation. As shown in the figure below, at eight months following administration, we did not observe evidence of any ongoing inflammation in the livers of NHPs that had undergone high levels of PCSK9 editing in the liver. In contrast, viral vector delivery can have subacute and chronic liver injury as a result of autoimmune reactions to the viral vector.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_20.jpg" alt="img242628118_20.jpg" style="width:621px;height:229px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In our ongoing long-term preclinical study of VERVE-101, we have not observed any long-term effects on liver function tests, and have only observed mild, transient increases in ALT levels, similar to the study described above. In this study, we also evaluated whether glucose homeostasis may be impacted by systemic PCSK9 inhibition. We have not observed any impact on glucose homeostasis up to 180 days following administration of VERVE-101.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In a study of 1.5 mg/kg dose of VERVE-101 in six sexually mature male NHPs, we did not observe evidence of germline editing at the PSCK9 site measured in a targeted amplicon assay at 11 weeks following treatment, which is greater than one full cycle of spermatogenesis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As LNPs are known to stimulate the immune system, we also assessed a panel of common cytokines following administration of a single dose of VERVE-101 in NHPs. At doses of 1 mg/kg or less, we observed mild and transient activation of certain cytokines, such as IP-10 or MCP-1, compared to control animals. This activation was apparent within 24 hours of dosing and fully resolved by the next observation point at one week. Other cytokines, including TNF-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, did not exhibit any changes above those seen in control animals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We also assessed complement activation in NHPs that received single administration of VERVE-101. At doses of 1 mg/kg and less, we observed only minimal activation above that in control animals. This minimal activation was detectable approximately two hours after dosing but resolved by 24 hours.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Preclinical off-target editing in NHP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">While the human genome is the relevant genome to assess off-target editing, we believe that evaluations of off-target editing in NHPs can support the ability of off-target analysis in primary hepatocytes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> to predict off-target editing in the liver when dosed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our approach to the identification of potential off-target sites includes a combination of bioinformatic and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> biochemical techniques, including ABE-Digenome-seq and a new, state-of-the-art technique called ONE-seq. ONE-seq is a comprehensive and sensitive </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> method to screen for and identify potential sequences where editing may occur. Using ONE-seq, we evaluated the 25,000 sequences in the NHP genome most closely matching the sequence of our on-target site. We prioritized 45 potential sites where editing may occur, of which the PCSK9 target site was identified as the top site.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We then used next-generation DNA sequencing to assess these sites for editing in primary NHP hepatocytes treated with VERVE-101. As shown in the figure below, besides editing at the PCSK9 target site, we did not observe off-target editing at any of the 44 potential off-target sites evaluated, depicted by the purple dots, except for one site designated C5. The C5 site is not present in the human genome.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We then treated NHPs with VERVE-101, took NHP liver samples and sequenced the same sites that we evaluated in primary NHP hepatocytes. In NHP liver samples, we identified off-target editing only at the C5 site. These data support our belief that we have the ability to accurately predict off-target sites </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> based on off-target analysis in primary hepatocytes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_21.jpg" alt="img242628118_21.jpg" style="width:631px;height:192px;" />&#160;</p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Off-target analysis in primary human hepatocytes</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Having established a methodology to connect off-target analysis in cells to in vivo editing, we turned to evaluation of the human genome for VERVE-101. Using two orthogonal techniques &#x2013; the ONE-seq methodology and ABE-Digenome-seq, we prioritized approximately 3,000 potential sites and assessed editing in primary human hepatocytes using a highly sensitive hybrid capture assay. As shown in the figure below, we did not observe any significant net editing at any of the approximately 3,000 potential off-target sites (black circles) when compared to untreated cells and observed only on-target editing at the PCSK9 target site (purple dot).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img242628118_22.jpg" alt="img242628118_22.jpg" style="width:672px;height:418px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition to the above analyses, we have evaluated for two other theoretical risks: editing of RNA by the base editor and translocations of DNA. In primary human hepatocytes, we did not observe any RNA editing above control or any translocations of DNA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Preclinical study of multiple doses of VERVE-101</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are developing VERVE-101 as a single-course gene editing medicine. However, given the complexities of treating patients with ASCVD, we believe that some patients may benefit from additional lipid lowering after treatment with any single agent. We conducted a 90-day preclinical study of VERVE-101 in four NHPs to explore the potential to re-dose patients. In this study, we dosed 0.5 mg/kg of a VERVE-101 precursor on days 1, 30 and 60. We measured editing of PCSK9 by liver biopsy on days 14, 46 and 75, and by liver necropsy on day 90. As shown in the figure below, we observed an increase in PCSK9 editing over the course of the study, with an average of 29% at day 14, 36% at day 46, 53% at day 75 and 59% at day 90. We believe that these data suggest that repeat low doses of a PCSK9 base editor could achieve a high level of liver editing. We did not observe evidence of liver injury following any of the doses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img242628118_23.jpg" alt="img242628118_23.jpg" style="width:672px;height:288px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe these data highlight one of the potential key advantages of LNPs as a delivery approach for gene editing medicines.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">VERVE-101 next steps</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have had an initial regulatory interaction with the FDA via the INTERACT mechanism and held a pre-IND meeting with the FDA in July 2021 and have had regulatory interactions with comparable foreign regulatory authorities. We have initiated IND-enabling studies for VERVE-101 and expect to complete our submissions of CTAs to certain foreign regulatory agencies and an IND to the FDA in the second half of 2022, followed by initiation of clinical development for patients with HeFH.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Subject to discussion of the trial design with regulatory agencies, we expect that the patient population for the first-in-human, Phase 1 clinical trial of VERVE-101 will be approximately 40 adult patients with HeFH, including patients with an LDLR mutation, ASCVD and LDL that is not at goal on oral therapy. We expect the trial to have an open-label design and include three or four single-ascending dose cohorts with three to six patients per group as well as a dose-expansion cohort of 12 to 20 patients at a selected dose. We also plan to offer a second dose to patients who receive a lower dose in the single-ascending dose cohort than the dose being administered in the dose-expansion cohort. Participants will be evaluated for safety and circulating PCSK9 protein, LDL-C and ApoB levels at three months and at later time points. We expect that all participants will be subsequently enrolled into a long-term follow-up trial for up to 15 years to characterize the long-term safety and efficacy of VERVE-101.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">ANGPTL3 program</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our second gene editing program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism. We plan to develop this program initially for the treatment of HoFH, which affects approximately 1,300 patients in the United States. Similar to our approach with VERVE-101, we plan to expand the clinical development of our ANGPTL3 program in a stepwise fashion beyond HoFH to patients with established ASCVD who may need additional LDL-C and/or triglycerides reduction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Ultimately, we believe that our ANGPTL3 program may also be useful to people at risk for ASCVD as a preventative measure in the general population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our ANGPTL3 program is currently in the lead optimization stage. We expect that this program will utilize a GalNAc-modified LNP encapsulating an mRNA encoding an ABE and a gRNA targeting the ANGPTL3 gene. We have developed proprietary LNPs based on our internally developed GalNAc technology that we believe are well suited to delivery in patients with HoFH as well as patients with established ASCVD who may need additional LDL-C and/or triglycerides reduction. We plan to select a development candidate for this program and initiate IND-enabling studies in the second half of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">ANGPTL3 as a target</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The ANGPTL3 gene has recently emerged as a new and promising target for severe hyperlipidemia. The ANGPTL3 protein is produced almost exclusively in the liver and released into the blood. It was first identified as a regulator of cholesterol and triglyceride metabolism through genetic studies of a naturally occurring strain of mice with low cholesterol, low triglycerides and low circulating fatty acids. The main function of the ANGPTL3 protein is the inhibition of lipoprotein lipase, an enzyme on the surface of blood vessels in the heart, skeletal muscle and fat that is responsible for the breakdown and clearance of circulating triglycerides. ANGPTL3 protein has also been shown to regulate LDL-C by a mechanism that does not depend on LDLR expression, which is in contrast to the mechanism by which PCSK9 regulates LDL-C.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Human genetic studies, conducted by our founders, determined that naturally occurring loss-of-function mutations in the ANGPTL3 gene result in extremely low levels of triglycerides, LDL-C and high-density lipoprotein cholesterol, or HDL-C. Subsequent studies determined that there were no apparent adverse health consequences observed in patients who naturally lack ANGPTL3 function. Furthermore, individuals completely lacking ANGTPL3 gene function were free from coronary atherosclerotic plaques evaluated by coronary computerized tomography, or CT, scan, compared to matched control family members. Two independent population genetic studies of individuals carrying a single mutated copy of ANGPTL3 demonstrated that partial loss of ANGPTL3 function is protective against ASCVD, with a 34% and 41% lower risk, respectively, compared to individuals without any ANGPTL3 mutations. Collectively, these studies provided strong evidence for ANGPTL3 as a potential therapeutic target for hyperlipidemia and ASCVD risk reduction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Multiple therapeutic approaches targeting ANGPTL3 have been developed or are being evaluated in the clinic and provide further validation for ANGPTL3 as a target. Evinacumab is a mAb targeting ANGPTL3 that has been shown to effectively lower LDL-C and triglycerides in patients with HoFH and HeFH. The Phase 3 trial for evinacumab in patients with HoFH demonstrated a 49% reduction of LDL-C and a 50% reduction of triglycerides after 24 weeks compared to placebo. Based on these data, evinacumab was approved by the FDA in 2021 for the treatment of patients with HoFH.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The LDL-C lowering effect of evinacumab has been demonstrated to be additive to that of PCSK9 inhibition. In a late-stage clinical trial of patients with refractory hypercholesterolemia, due to HeFH in the majority of cases, the addition of evinacumab to a PCSK9 inhibitor further reduced LDL-C by 56% compared to placebo. In addition, other investigational agents targeting ANGPTL3 are being evaluated in patients with severe hypertriglyceridemia or CVD, including vupanorsen, an antisense oligonucleotide therapy targeting ANGPTL3 and two different siRNA programs targeting ANGPTL3 from Arrowhead Pharmaceuticals (ARO-ANG3) as well as Eli Lillly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Preclinical studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are evaluating multiple LNP formulations with a view to enabling treatment of patients with all forms of FH, as well as multiple editor and gRNA options. In preclinical data generated to date, and discussed below, we have observed the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">development of a proprietary GalNAc-targeting ligand that when added to an LNP is capable of delivering a base editor to the liver independent of the LDL receptor status in mice, and which may potentially be used to treat patients with HeFH and HoFH; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">proof-of-concept data in NHPs for an ABE-ANGPTL3 precursor formulation demonstrating 60% whole liver editing, 95% reduction in ANGPTL3 and 64% reduction in triglycerides at two weeks after a single treatment; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">durability data in NHPs for an ABE-ANGPTL3 precursor formulation demonstrating an ANGPTL3 reduction of 96% and triglyceride reduction of 69% seen at ten months following a single treatment; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">proof-of-concept data in an internally developed NHP model of HoFH using a single treatment of two different formulations of our proprietary GalNAc-LNPs to deliver our ANGPTL3-targeted base editor demonstrating </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">approximately 94% (n=3) and 97% (n=3) reduction in blood ANGPTL3 protein, respectively, and reductions in LDL-C of nearly 100mg/dL, which was an approximately 35% reduction from baseline.</span></div></div>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Discovery and validation of LNPs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">LNP-mediated delivery to the liver is more challenging in patients with HoFH than in those with HeFH. This is due to the fact that deficiency in the LDLR gene often drives HoFH pathophysiology, and uptake of LNPs into the liver is generally thought to be through a predominantly LDLR-dependent pathway. An approach to bypass the LDLR would be the addition of a targeting ligand to LNPs that works through a receptor other than LDLR.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have screened and developed a proprietary GalNAc-targeting ligand that can be incorporated into LNPs. GalNAc ligands bind to the asialoglycoprotein receptors, or ASGPR, in the liver and have been used to enhance delivery of siRNAs to the liver. ASGPR is highly expressed in the liver with rapid turnover in about 15 minutes and high capacity to mediate uptake into the liver independent of LDLR.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We conducted a preclinical study in mice that were entirely deficient in the LDL receptor, or LDLR -/- mice, in order to evaluate the efficacy of our proprietary GalNAc-targeted LNPs. As shown in the graphic below, the addition of the GalNAc ligand onto the LNP increased editing in the liver of LDLR -/- mice. We observed that GalNAc-targeted LNPs have similar apparent potency in wild-type, LDLR +/- mice and LDLR -/- mice.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_24.jpg" alt="img242628118_24.jpg" style="width:459px;height:376px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are continuing to invest and build out capabilities in the development of novel and optimized GalNAc-targeting ligands, optimal lipid anchors, optimal compositions and ratios of LNP components, and optimal processes of addition and LNP formation with targeting ligands. We believe GalNAc provides a delivery platform for patients with both forms of FH and potentially may be applicable in other applications where liver-directed delivery is advantageous.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">NHP model of HoFH</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In order to create a model of HoFH in NHPs, we edited the LDLR gene in wild-type NHPs and eliminated LDLR expression in the liver using a Cas9 and dual guide RNA strategy encapsulated in standard LNPs, which led to nearly 70% whole liver DNA editing at the LDLR gene and resulted in an approximately 94% reduction in LDLR protein in the liver and a six-fold increase in blood LDL-C.</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Validation in an NHP model of HoFH using internally developed GalNAc-LNPs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Using this novel NHP model of HoFH, we conducted a preclinical study using two different formulations of our proprietary GalNAc-LNPs to deliver ANGPTL3-targeted base editor. In this study, we observed that delivery of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">base editor using standard LNPs did not achieve effective ANGPTL3 editing in the liver of the NHP model of HoFH. As shown in the figures below, in NHPs treated with our ANGPTL3-targeted base editor delivered with a GalNAc-LNP, we observed approximately 94% (n=3) and 97% (n=3) reduction in blood ANGPTL3 protein, and reductions in LDL-C of nearly 100 mg/dL, which was an approximately 35% reduction from baseline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_25.jpg" alt="img242628118_25.jpg" style="width:627px;height:345px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">GalNAc-LNP delivery to normal livers of NHPs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have also assessed the potential broad utility of our proprietary GalNAc-LNP approach for delivery of our ANGPTL3-targeted base editor, in a preclinical study evaluating delivery efficiency of our ANGPTL3 base editor using both a GalNAc-LNP and a standard LNP without GalNAc in wild-type NHPs with normal livers. In these studies, we observed that wild-type NHPs treated with our ANGPTL3-targeted base editor delivered via our GalNAc-LNP had an approximately 89% reduction in ANGPTL3 protein compared to an approximately 74% reduction in wild-type NHPs treated with a standard LNP. We believe this suggests that GalNAc-LNP delivery may be utilized in indications where LDLR is present.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_26.jpg" alt="img242628118_26.jpg" style="width:597px;height:337px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are conducting a large confirmatory dose-response study in wild-type NHPs.</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">NHP validation with ABE-ANGPTL3 precursor formulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We conducted a preclinical proof-of-concept study using an ABE-ANGPTL3 precursor formulation. In this study, which is ongoing, we administered a single dose to healthy NHPs. In the figure below, each treated NHP is represented by a purple bar and each vehicle treated control is represented by a blue bar. Following a single treatment with our ABE-ANGPTL3 precursor formulation, we observed an average 60% editing of ANGPTL3 in whole liver tissue sampled through a liver biopsy two weeks after dosing. This was accompanied by an average 95% reduction of blood ANGPTL3 protein and an average 64% reduction of blood triglycerides concentrations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_27.jpg" alt="img242628118_27.jpg" style="width:336px;height:420px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Importantly, in this preclinical study, we observed that the reductions in blood ANGPTL3 protein and blood triglycerides levels were durably maintained. As shown in the figure below, at ten months following a single intravenous administration of ABE-ANGPTL3, we observed that the NHPs continued to exhibit an average reduction of 96% in blood ANGPTL3 protein and an average reduction of 69% in blood triglycerides.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img242628118_28.jpg" alt="img242628118_28.jpg" style="width:628px;height:204px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">ANGPTL3 program next steps</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are currently conducting additional mouse and NHP preclinical studies as we optimize the gRNA, editor and LNP delivery, including GalNAc modifications, for our ANGPTL3 program. We plan to select a development candidate and to initiate IND-enabling studies in the second half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Sequential dosing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe that patients with very high LDL-C levels or patients with hyperlipidemia that also have high LDL-C levels and high triglyceride levels may benefit from treatment with gene editing medicines that target two lipid pathways, such as PCSK9 and ANGPTL3. We conducted a 90-day preclinical study in four NHPs to assess the potential for sequential dosing of our base editors. In this study, we dosed 1.0 mg/kg of a VERVE-101 precursor on day 1, followed by a 1.0 mg/kg dose of an ANGPTL3 base editor on day 30. As shown in the figure below, we</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">observed a substantial reduction of plasma protein levels of both PCSK9 and ANGPTL3 following sequential dosing. We measured PCSK9 editing by liver biopsy on day 15 and observed an average of 71% editing. We measured ANGPTL3 editing by liver biopsy on day 45 and observed an average of 52% editing. We conducted a liver necropsy on day 90 and observed an average of 69% PCSK9 editing and 63% ANGPTL3 editing. We also monitored plasma PCSK9 and ANGPTL3 protein levels during the study and observed a greater than 90% reduction of plasma PCSK9 protein after the first dose and a greater than 90% reduction of plasma ANGPTL3 protein after the second dose, and observed similar reductions at the end of the study. These data suggest that sequential dosing of a PCSK9 base editor followed by an ANGPTL3 base editor may be able to edit two genes that control two key lipid pathways.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img242628118_29.jpg" alt="img242628118_29.jpg" style="width:672px;height:293px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Future opportunities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are investing in the identification of additional </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vivo</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> liver gene editing treatments and intend to develop a suite of single-course gene editing medicines that address root causes of disease. We plan to continue to focus on programs where the target has biology substantially validated by human genetics and, in many cases, by clinical development programs using other modalities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Manufacturing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We do not currently own or operate manufacturing facilities. We currently rely on third-party contract manufacturing organizations, or CMOs, and suppliers for critical starting materials, drug substances&#x2014;gRNA, mRNA&#x2014;and our drug products. We plan to use third-party CMOs to support our IND-enabling studies and to fully supply our clinical trials and commercial activities. As we scale manufacturing, we intend to continue to expand and strengthen our network of CMOs. We believe there are multiple sources for all of the materials required for the manufacture of our product candidates, as well as multiple CMOs who could assemble the components of our program candidates. For VERVE-101, we have purchased and stockpiled critical raw materials and completed a tech transfer of drug substance and drug product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are continuing to invest in building internal manufacturing capabilities for mRNA production and LNP formulation, including the development of novel and optimized GalNAc-targeting ligands, lipid anchors, optimal compositions and ratios of LNP components, and optimal processes of addition and LNP formation with targeting ligands. We are also investing in analytical method development including bioactivity and potency assays that will be critical to further product development, batch comparability assessments and additional manufacturing growth.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Manufacturing is subject to extensive regulations that impose procedural and documentation requirements. These regulations govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance. Our CMOs are required to comply with these regulations and are assessed by regular monitoring and formal audits. Our third-party manufacturers are required to manufacture any product candidates we develop under current Good Manufacturing Practice, or cGMP, requirements and other applicable laws and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have personnel with extensive technical, manufacturing, analytical and quality experience to oversee our contracted manufacturing and testing activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Competition</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The biotechnology and biopharmaceutical industries generally, and the CVD field specifically, are characterized by rapid evolution of technologies, sharp competition and strong defense of intellectual property. Any product candidates that we successfully develop and commercialize will have to compete with existing therapies and new therapies that may become available in the future. While we believe that our technology, development experience and scientific knowledge in CVD, gene editing and manufacturing provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The key competitive factors affecting the success of all of our product candidates that we develop for the treatment of CVD if approved, are likely to be efficacy, safety, convenience, price, the level of generic competition and the availability of reimbursement from government and other third-party payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium to competitive generic products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There are several approved products for LDL-C lowering or cardiovascular risk reduction, such as statins, ezetimibe, bempedoic acid, lomitapide, mipomersen and icosapent ethyl. There are several approved products that target PCSK9 protein as a mechanism to lower LDL-C and reduce the risk of ASCVD. Evolocumab, which is a mAb marketed as Repatha</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.025pt;font-family:Arial;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> by Amgen Inc., is approved by the FDA for the treatment of patients with HeFH, patients with HoFH and patients with ASCVD. Alirocumab, which is a mAb marketed as PRALUENT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.025pt;font-family:Arial;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> by both Sanofi and Regeneron Pharmaceuticals, Inc., is approved by the FDA for the treatment of patients with ASCVD and for the treatment of patients with primary hyperlipidemia, including HeFH. The approved mAb treatments act through extracellular inhibition of the PCSK9 protein. Inclisiran, which is a siRNA marketed as Leqvio</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.025pt;font-family:Arial;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> by Novartis, is approved in the United States for the treatment of patients with clinical ASCVD or HeFH who require additional lowering of LDL-C and in Europe for the treatment of patients with hypercholesterolemia, including HeFH, or mixed dyslipidemia. Inclisiran acts by inhibiting the synthesis of PCSK9 within liver cells, which is distinct from extracellular protein inhibition. We are also aware of several product candidates in clinical development that target PCSK9 protein as a mechanism to lower LDL-C and reduce the risk of ASCVD, including an oral small molecule PCSK9 inhibitor from Serometrix LLC in-licensed by Esperion Therapeutics, Inc. for which they disclosed plans to submit an IND in 2022, and an oral PCSK9 inhibitor from Merck &amp; Co., Inc, for which they plan to progress to Phase 2 in 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are aware of one other gene editing program targeting the PCSK9 gene in preclinical development. Precision Biosciences, Inc. has published preclinical data showing long-term stable reduction of LDL-C levels in NHPs following </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> gene editing of the PCSK9 gene using its gene editing platform. In September 2021, Precision entered into a collaboration with iECURE under which iECURE plans to advance Precision&#x2019;s PCSK9-directed nuclease product candidate into Phase 1 clinical trials for the treatment of FH in 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Evinacumab, which is a mAb targeting ANGPTL3 protein that is marketed by Regeneron Pharmaceuticals, Inc., is approved by the FDA for the treatment of patients with HoFH and being evaluated in Phase 2 development for</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">severe hypertriglyceridemia. We are aware of several product candidates in clinical development that target ANGPTL3 as a mechanism to lower LDL-C and reduce the risk of ASCVD, including vupanorsen, an antisense oligonucleotide therapy in a Phase 2 clinical trial by Ionis Pharmaceuticals and Pfizer Inc. for the treatment of patients with elevated non-HDL-C and triglycerides. ARO-ANG3, a siRNA targeting ANGPTL3, is being evaluated in a Phase 1/2 clinical trial by Arrowhead Pharmaceuticals. In 2021, Arrowhead initiated a Phase 2b trial of ARO-ANG3 for the treatment of patients with mixed dyslipidemia. In addition, Eli Lilly is evaluating a siRNA targeting ANGPTL3 protein in a Phase 1 study for the treatment of CVD.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Intellectual property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We strive to protect the proprietary technologies that we believe are important to our business, including pursuing and maintaining patent protection intended to cover the composition of matter of our product candidates, their methods of use, related technologies and other inventions that are important to our business. In addition to patent protection, we also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection, including certain aspects of our technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our commercial success depends in part upon our ability to obtain and maintain patent and other proprietary protection for commercially important technologies, inventions and know how related to our business, defend and enforce our intellectual property rights, in particular, our patent rights, preserve the confidentiality of our trade secrets and operate without infringing valid and enforceable intellectual property rights of others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The patent positions for biotechnology and pharmaceutical companies like ours are generally uncertain and can involve complex legal, scientific and factual issues. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our product candidates will be protected or remain protectable by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021, our patent estate covers various aspects of our programs and technology, including our gene editing programs for PCSK9 and ANGPTL3 targets as well as our RNA delivery and other platform technology. Any U.S. or foreign patents issued or pending would be scheduled to expire on various dates from 2041 through 2042, without taking into account any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity and other governmental fees. Further details on certain segments of our patent portfolio are included below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">PCSK9 program</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">With regard to our VERVE-101 program, as of December 31, 2021, our patent estate includes one pending international PCT application and two pending U.S. provisional patent applications that we own or control and cover various aspects of our VERVE-101 program, including guide RNA sequences targeting the PCSK9 gene, mRNAs encoding adenine base editors, and compositions thereof, methods of using such compositions for therapeutic indications, methods for in vivo gene editing, formulations, dosing regimens, and combination therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">ANGPTL3 program</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">With regard to our ANGPTL3 program, as of December 31, 2021, our patent estate includes one pending international PCT application and one pending U.S. provisional patent application that we own or control and cover various aspects of our ANGPTL3 program, including guide RNA sequences targeting the ANGPTL3 gene, mRNAs encoding adenine base editors, and compositions thereof, methods of using such compositions for therapeutic indications, methods for in vivo gene editing, formulations, dosing regimens, and combination therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">License and collaboration agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are a party to a number of license agreements under which we license patents, patent applications and other intellectual property from third parties. The licensed intellectual property covers, in part, CRISPR-related compositions of matter and their use for base editing. These licenses impose various diligence and financial payment obligations on us. We expect to continue to enter into these types of license agreements in the future. We consider the following license agreements to be material to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Collaboration and license agreement with Beam Therapeutics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In April 2019, we entered into a collaboration and license agreement with Beam, or the Beam Agreement, pursuant to which we received an exclusive, worldwide, sublicensable license under certain of Beam&#x2019;s base editing technology, as well as gene editing and delivery technologies to develop, make, use, offer for sale, sell and import base editing products and nuclease products using Beam&#x2019;s CRISPR associated protein 12b, or Cas12b technology, in each case, directed to any of four gene targets, including the PCSK9 and ANGPTL3 genes, that are associated with an increased risk of coronary diseases, or the licensed products. Upon execution of the Beam Agreement and as partial consideration for the rights granted to us thereunder, we issued 276,075 shares of our common stock to Beam.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, we granted Beam a non-exclusive license under know-how and patents controlled by us, and an interest in joint collaboration technology, to allow Beam to conduct activities under agreed upon research and development plans, as applicable, under the Beam Agreement. We further granted Beam an exclusive, worldwide, sublicensable license under certain of our delivery technology relating to our know-how and patent rights solely to the extent such rights claim, embody or incorporate a delivery system or component thereof that can be used for the delivery of base editor product to human genome targets, to allow Beam to develop, make, use, offer for sale, sell, and import product candidates and products, except for base editor products licensed to Verve.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We and Beam each have the right to sublicense our licensed rights, subject to certain restrictions and provided that the sublicense agreement is in compliance and consistent with the terms of the Beam Agreement and any applicable in-licensed agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Following the final dosing of a patient in a Phase 1 clinical trial of a given licensed product, Beam has the right to opt in to share 33% of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share profits and expenses of commercializing such licensed product in the United States on a 50/50 basis. If Beam exercises its opt-in right for a given licensed product, which we refer to following such opt-in as a collaboration product, it will be obligated to pay for a specified percentage of the development and commercialization costs of such collaboration product and will have the right to receive a specified percentage of the profits from any sales of such collaboration product. With respect to each collaboration product, we and Beam will enter into a subsequent co-promotion agreement prior to the anticipated sale of such collaboration product in the United States, pursuant to which we and Beam will each provide 50% of the promotional effort required to promote the collaboration product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Except as described in the foregoing, we are fully responsible for the development of licensed products under the Beam Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For collaboration products, on a product-by-product basis outside of the United States, we are obligated to pay clinical and regulatory milestones of up to an aggregate of $5.6 million and sales-based milestones of up to an aggregate of $7.5 million. For non-collaboration products, on a product-by-product basis worldwide, we are obligated to pay clinical and regulatory milestones of up to an aggregate of $11.3 million and sales-based milestones of up to an aggregate of $15.0 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To the extent there are sales of a collaboration product outside of the United States or a non-collaboration product worldwide, we will be required to pay tiered royalties to Beam at rates ranging from the low-to-mid single digit percentage of net sales, subject to specified reductions. Such royalty payments will terminate on a country-by-country and product-by-product basis upon the later to occur of (i) the expiration of the last to expire valid claim under the patent rights covering such product in such country, (ii) the period of regulatory exclusivity associated with such product in such country or (iii) 10 years after the first commercial sale of such product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In further consideration for the licenses granted under each of our and Beam&#x2019;s respective delivery technologies, we or Beam will pay to the other party development-based milestone payments of up to $6.0 million for each delivery technology product of such paying party to achieve the corresponding milestone event. To the extent there are sales of a delivery technology product, we or Beam will pay the other party low-to-mid single digit royalties based on the annual aggregate worldwide net sales resulting from the sale of each delivery technology product of such paying party on a delivery technology product-by-delivery technology product basis; provided however that such royalty payments will not apply to net sales of the collaboration products or licensed products. Such royalty payments will terminate on a country-by-country and delivery technology product-by-delivery technology product basis upon the later to occur of (i) the expiration of the last to expire valid claim under the patent rights covering such delivery technology product in such country, (ii) the period of regulatory exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">associated with such delivery technology in such country or (iii) 10 years after the first commercial sale of such delivery technology product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Beam retains control of the prosecution of its respective patent rights, at its sole expense. We have the first right, but not the obligation, to file for, and prosecute and enforce, at our sole expense, product-specific patent rights under the Beam Agreement, to the extent permitted by Beam&#x2019;s applicable in-license agreements, and we have the exclusive right to file for, prosecute and maintain the patent rights under our delivery technology and any other patent rights that we licensed to Beam under the Beam Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">With respect to intellectual property rights jointly developed by Beam and Verve arising out of a party&#x2019;s performance of its obligations under the agreement, such intellectual property, depending on its nature, is considered under the agreement as joint collaboration technology and subject to joint ownership by Beam and Verve and we and Beam shall decide in good faith as to who shall bear responsibility for filing for, prosecuting and maintaining the jointly owned patent rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The term of the Beam Agreement continues until the last to expire of any royalty term for any licensed product. We have the right to terminate the Beam Agreement as to any licensed product, but not for any collaboration product, by delivering a 90-day termination notice to Beam, provided that Beam has elected not to exercise its opt-in right or the period to exercise such opt-in right has expired. The Beam Agreement may be terminated by either party upon (i) written notice if the other party is in material breach and fails to cure such breach within the specified cure period or (ii) the other party&#x2019;s bankruptcy or liquidation. Beam may terminate the Beam Agreement, and we may terminate the licenses granted to Beam under the Beam Agreement, immediately if the other party, directly or indirectly, challenges the enforceability, validity or scope of any patent rights underlying the licenses granted under the Beam Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Acuitas agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Development and option agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2019, we entered into a development and option agreement with Acuitas, which agreement we amended and restated in October 2020, or the Acuitas Development Agreement, pursuant to which Acuitas granted us a non-exclusive, worldwide, royalty-free license under its LNP technology. The Acuitas Development Agreement provides us the option to enter into separate non-exclusive license agreements for a specified number of targets under which we can pursue further development and commercialization of licensed products that include the Acuitas LNP technology. Under the Acuitas Development Agreement, we paid Acuitas an upfront technology access fee of $0.5 million and we are obligated to pay annual maintenance fees of $0.3 million for each target and annual target reservation fees of $0.1 million per target to Acuitas. Upon exercising an option to enter into a non-exclusive license agreement for any gene target, we are required to pay Acuitas $2.0 million less any amounts from the target reservation and maintenance fees that are creditable against the option exercise fee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The collaboration is supervised by a joint development committee that oversees, reviews and manages the development plan with respect to LNPs developed and optimized under the collaboration. With respect to the patent rights underlying each license, we and Acuitas separately retain control of the prosecution of our respective in-licensed patent rights. With respect to any intellectual property rights resulting from the collaboration, other than improvements to each parties&#x2019; solely owned intellectual property, we and Acuitas each have a one-half interest in the intellectual property rights and jointly maintain and prosecute such intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Acuitas Development Agreement will terminate in December 2022, provided that we have the option to extend the term for an additional two years upon prior written notice. We may terminate the Acuitas Development Agreement without cause upon prior written notice to Acuitas. Either party may terminate the Acuitas Development Agreement upon (i) written notice if the other party is in material breach and fails to cure such breach within the specified cure period or (ii) immediately upon notice in the event of the other party&#x2019;s bankruptcy or insolvency.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">License agreement for the PCSK9 gene target</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In October 2020, we selected an LNP optimized under the Acuitas Development Agreement to be a component of our VERVE-101 product candidate. In connection with that selection, we exercised an option with respect to the use of the LNP technology and entered into a non-exclusive, worldwide license with Acuitas, or the Acuitas License Agreement, with a right to sub-license through multiple tiers, under the licensed LNP technology to research, develop, have developed, make, have made, keep, use and have used, sell, offer for sale, have sold, import and have imported, export and have exported and otherwise commercialize and exploit licensed products</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">using the LNP technology in connection with the PCSK9 gene target for all human therapeutic or prophylactic uses. Under the Acuitas License Agreement, we are obligated to use diligent efforts to develop and commercialize licensed products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Acuitas retained the right to prosecute and maintain, at its sole expense, patents related to the LNP technology. In the event that Acuitas elects not to file, prosecute or maintain patents related to the LNP technology, it will notify us and we have the right, but not the obligation, to request that Acuitas continue to file, prosecute or maintain such patents, at our expense, and our license to such patents will automatically become irrevocable, perpetual, fully paid-up and royalty free, but such patents will thereafter no longer be part of the licensed technology in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We and Acuitas will enter into a joint patent prosecution and maintenance agreement with respect to the jointly owned patents under the Acuitas License Agreement and as further provided in the Acuitas Development Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We paid Acuitas an upfront license fee of $2.0 million (less previously paid target reservation fees) and are required to pay an annual license maintenance fee of $0.8 million until the achievement of a certain development-based milestone. We are also obligated to reimburse Acuitas quarterly for employee and reasonable external expenses incurred that are related to the transfer of its licensed technology to our CMO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are also obligated to pay Acuitas up to an aggregate of $9.8 million in clinical and regulatory milestones and $9.5 million in sales-based milestones. We will be required to pay royalties at a low single digit percentage based on annual net sales of licensed products sold by us, our affiliates or our sublicensees. Such royalty payments are subject to reduction if we obtain a license from a third party under technology relating to the LNP technology. Any such royalty payments are payable, on a country-by-country and licensed product-by-licensed product basis, until the later of (i) the expiration of the last to expire valid claim in the licensed technology that covers the licensed product in such country, (ii) the expiration of the regulatory exclusivity period in such country and (iii) ten years from the first commercial sale of the licensed product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Acuitas License Agreement will terminate on a licensed product-by-licensed product and country-by-country basis upon the last-to-expire royalty term in such country with respect to such licensed product. We may terminate the Acuitas License Agreement without cause upon prior written notice to Acuitas. Either party may terminate the Acuitas License Agreement upon (i) written notice if the other party is in material breach and fails to cure such breach within the specified cure period or (ii) immediately upon notice in the event of the other party&#x2019;s bankruptcy or insolvency. In lieu of terminating the agreement for Acuitas&#x2019; uncured material breach, we have the alternative option, upon written notice to Acuitas, not to terminate the agreement but instead reduce the applicable milestone and royalty payments by a specified percentage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In March 2019, we entered into a license agreement with Broad and Harvard for specified patent rights and in December 2019, we entered into an amendment to this license agreement, or, as amended, the Cas9 License Agreement. The licenses granted to us under the Cas9 License Agreement include rights to (i) certain patents and patent applications solely owned by Harvard, or the Harvard Cas9-I Patent Rights, certain patents and patent applications co-owned by the Massachusetts Institute of Technology, or MIT, and Broad, certain patents and patent applications co-owned by The Rockefeller University, or Rockefeller, and Broad, and certain patents and patent applications co-owned by MIT, Broad and Harvard, which patents and patent applications licensed under the Cas9 License Agreement we refer to as the Harvard/Broad Cas9-I Patent Rights and (ii) certain patents and patent applications co-owned by MIT, Broad, Harvard and the University of Iowa Research Foundation, or Iowa, which patents and patent applications licensed under the Cas9 License Agreement we refer to as the Harvard/Broad Cas9-II Patent Rights, and together with the Harvard/Broad Cas9-I Patent Rights, the Harvard/Broad Cas9 Patent Rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In February 2017, Broad and Rockefeller entered into an inter-institutional agreement pursuant to which Rockefeller authorized Broad to act as its sole and exclusive agent for the purposes of licensing Rockefeller&#x2019;s rights in such Harvard/Broad Cas9-I Patent Rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2014, as amended in August 2016, MIT, Iowa and Broad entered into a joint invention administration agreement pursuant to which Iowa authorized Broad to act as their sole and exclusive agent for the purposes of licensing their rights in such Harvard/Broad Cas9-II Patent Rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">License rights under Cas9 License Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pursuant to the Cas9 License Agreement, Broad and Harvard granted us a worldwide, royalty-bearing, sublicensable license to the Harvard/Broad Cas9 Patent Rights to make, have made, use, have used, sell, offer for sale, have sold, import and export products directed to PCSK9, ANGPTL3 and two additional targets, in the field of the prevention and treatment of human disease, subject to certain limitations and retained rights. With respect to the Harvard/Broad Cas9-I Patent Rights and certain of the Harvard/Broad Cas9-II Patent Rights, or the Cas 9-II Group A Patent Rights, the license is co-exclusive with Editas Medicine, Inc., or Editas. With respect to certain other of the Harvard/Broad Cas9-II Patent Rights, or the Cas9-II Group B Patent Rights, the license is non-exclusive. The license follows the inclusive innovation strategy developed by Broad, MIT and Harvard.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Broad and Harvard also granted us a non-exclusive, worldwide, royalty-bearing, sublicensable license to the Harvard/Broad Cas9 Patent Rights for internal research purposes; for research, development and commercialization of products for the prevention or treatment of human disease outside the field of Editas&#x2019; exclusive license agreements with Broad and Harvard; and with respect to the targets, to make, have made, use, have used, sell, offer for sale, have sold, import and export products that are not Cas9 licensed products but is a Cas9 enabled products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The licenses granted by Broad and Harvard to us under the Cas9 License Agreement are subject to retained rights of the U.S. government in the Harvard/Broad Cas9 Patent Rights and the rights retained by Broad, Harvard, MIT, Rockefeller and Iowa on behalf of themselves and other academic, government and non-profit entities, to practice the Harvard/Broad Cas9 Patent Rights, as applicable, for research, educational or teaching purposes. In addition, certain rights granted to us under the Cas9 License Agreement for the Harvard/Broad Cas9-I Patent Rights are further subject to a non-exclusive license to the Howard Hughes Medical Institute for research purposes. Our co-exclusive license rights also are subject to rights retained by Broad, Harvard, MIT, Rockefeller and Iowa, for each of them and for any third party (including non-profit and for-profit entities), to research, develop, make, have made, use, offer for sale, sell, have sold, import or otherwise exploit the Harvard/Broad Cas9 Patent Rights and licensed products as research products or research tools, or for research purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have the right to sublicense our licensed rights, subject to certain restrictions and provided that the sublicense agreement must be in compliance and consistent with the terms of the Cas9 License Agreement. Any sublicense agreement cannot include the right to assign sublicenses without the written consent of Broad and Harvard. In addition, any sublicense agreements must contain certain terms, including a provision requiring the sublicensee to indemnify Harvard, Broad, MIT, Rockefeller, Iowa and Howard Hughes Medical Institute according to the same terms as are provided in the Cas9 License Agreement and a statement that Broad, Harvard, MIT, Rockefeller, Iowa and Howard Hughes Medical Institute are intended third-party beneficiaries of the sublicense agreement for certain purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are obligated to use commercially reasonable efforts, or to cause at least one of our affiliates or sublicensees to use commercially reasonable efforts, (i) to research and develop Cas9 licensed products in the licensed field, (ii) to introduce such products in the licensed field into the commercial market, and (iii) to market such products in the licensed field following such introduction into the market and make such products reasonably available to the public. In addition, we, by ourselves or through any of our affiliates or sublicensees, are obligated to achieve certain development milestones within certain time periods. Broad and Harvard have the right to terminate the Cas9 License Agreement if we fail to achieve a development milestone, subject to our right to extend or amend such milestone in accordance with certain procedures. Such termination right will not apply solely with respect to a particular target if, at the time Broad and Harvard elect to terminate the Cas9 License Agreement for failure to achieve a development milestone, we provide evidence reasonably acceptable to Harvard and Broad that we are not in breach of our development milestone diligence obligations with respect to such target and that we are, or one of our affiliates or sublicensees are, (a) researching and developing Cas9 licensed products in the licensed field directed to such target, (b) using commercially reasonable efforts to introduce Cas9 licensed products in the licensed field directed to such target into the commercial market (if applicable), and (c) using commercially reasonable efforts to market Cas9 licensed products in the licensed field directed to such target following such introduction into the market and make such Cas9 licensed products reasonably available to the public (if applicable), and thereafter, for the remainder of the term, we continue, or cause at least one of our affiliates or sublicensees to continue, to develop and commercialize Cas9 licensed products directed to such target in accordance with the foregoing (a)-(c).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the Cas9 License Agreement, Broad and Harvard also retained rights to grant further licenses, through its inclusive innovation strategy, under specified circumstances, to third parties, other than specified entities, that wish to develop and commercialize products that target a particular gene outside of the cardiovascular disease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">field and that otherwise would fall within the scope of our co-exclusive license from Broad and Harvard. If a third party requests a license under the Harvard/Broad Cas9-I Patent Rights for the development and commercialization of a product that would be subject to our co-exclusive license grant from Broad and Harvard under the Cas9 License Agreement, Broad and Harvard may notify us of the request, which we refer to as the Cas9 Third Party Proposed Product Requests. A Cas9 Third Party Proposed Product Request must be accompanied by the third party&#x2019;s bona fide proposal, including the proposed target or category. Broad may not grant a Cas9 Third Party Proposed Product Request (i) if we, directly or indirectly through any of our affiliates or sublicensees, are researching, developing or commercializing a product directed to the same gene target that is the subject of the Cas9 Third Party Proposed Product Request, or the Cas9 Licensee Product, and we can demonstrate such ongoing efforts to Broad&#x2019;s reasonable satisfaction, or (ii) if we, directly or indirectly through any of our affiliates or sublicensees, wish to do so, and we can demonstrate to Broad&#x2019;s reasonable satisfaction that we are interested in researching, developing and commercializing a Cas9 Licensee Product, that we have a commercially reasonable research, development and commercialization plan to do so, and we commence and continue reasonable commercial efforts under such plan. Furthermore, if we, directly or indirectly through any of our affiliates or sublicensees, are not researching, developing or commercializing a Cas9 Licensee Product but wish to grant a sublicense to do so, Broad is obligated to disclose to us the name of the third party and we may enter into a sublicense agreement with the third party. If we, directly or indirectly through any of our affiliates or sublicensees, are not researching, developing or commercializing a Cas9 Licensee Product, are unable to develop and implement a plan reasonably satisfactory to Broad and Harvard, or are unable to enter into a sublicense agreement with the third party, Broad and Harvard have the right to terminate our rights to the specified third-party target or to a specified category and have the right to freely grant to third parties licenses in the licensed field (a) under the patent rights that are exclusively or co-exclusively licensed to us with respect to such specified third party target or (b) under the patent rights that are exclusively or co-exclusively licensed to us within such specified category, provided that such licenses do not grant rights to commercialize products intended for use in the cardiovascular disease field.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Payment terms</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the Cas9 License Agreement, we paid Broad and Harvard an upfront license fee of $0.1 million and issued an aggregate of 138,037 shares of our common stock to Broad and Harvard. Broad and Harvard also have anti-dilution rights, pursuant to which we (i) have issued Broad and Harvard an aggregate of an additional 309,278 shares of our common stock in the aggregate following the completion of preferred stock financings and (ii) have issued Broad and Harvard an aggregate of an additional 878,098 shares of common stock upon the closing of our IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We also must pay an annual license maintenance fee ranging in dollars from the low- to mid-five figures, depending on the calendar year. A portion of this annual license maintenance fee is creditable against royalties owed on licensed or enabled products in the same year as the maintenance fee is paid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Broad and Harvard, collectively, are entitled to receive (i) clinical and regulatory milestone payments of up to an aggregate of $5.7 million per licensed product in the United States, the European Union and Japan for the prevention or treatment of a human disease that afflicts fewer than a certain number of patients in the United States and (ii) clinical and regulatory milestone payments of up to an aggregate of $17.4 million per licensed product in the United States, the European Union and Japan for the prevention or treatment of a human disease that afflicts at least a certain number of patients in the United States. If we undergo a change of control during the term of the Cas9 License Agreement, certain of these clinical and regulatory milestone payments will increase by a certain percentage. We are also obligated to make additional payments to Broad and Harvard, collectively, of up to an aggregate of $54.0 million upon the occurrence of certain sales-based milestones per licensed product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are also obligated to pay to Broad and Harvard tiered success payments in the event our average market capitalization exceeds specified thresholds ascending from a high nine digit dollar amount to $10.0 billion, or the Market Cap Success Payments, or sale of our company for consideration in excess of those thresholds, or the Company Sale Success Payments, which with the Market Cap Success Payments, we refer to as the Success Payments. Market Cap Success Payments are payable by us in cash, in shares of our common stock, with such shares being valued for such purpose at the closing price of our common stock as reported on the Nasdaq Stock Market for the trading day immediately preceding the date of such payment if our common stock was then listed on the Nasdaq Stock Market, or a combination of shares and cash. In the event of a change of control of our company or a sale of our company, we are required to pay the related Company Sale Success Payment in cash within a specified period following such event. The Success Payments are cumulative and more than one Success Payment may be due and payable based on the average market capitalization on any trigger date. The maximum aggregate Success Payments that could be payable by us are $31.3 million. Certain of the Success Payments are only payable if a licensed product is or has been evaluated in clinical trials. To the extent we issue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">shares of our common stock in satisfaction of such Success Payments, we will be obligated to file a registration statement with the SEC to register the resale of such shares by Broad and Harvard.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In September 2021, we notified Harvard and Broad that our average market capitalization exceeded three specified thresholds as of a relevant measurement date and aggregate success payments of approximately $6.3 million became payable under the Cas9 License Agreement, which we settled in cash in November 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Broad and Harvard, collectively, are entitled to receive mid single-digit percentage royalties on net sales of licensed products, and low single-digit percentage royalties on net sales of other products enabled by the license, made by us, our affiliates or our sublicensees. The royalty percentage depends on the aggregate amount of the net sales for the licensed or enabled products. If we are legally required to pay royalties to a third party on net sales of our licensed products because such third party holds patent rights that cover such licensed product, then we can credit, subject to a floor, up to a certain percentage of the amount paid to such third party against the royalties due to Broad and Harvard in the same period. On a target-by-target basis, if Editas initiates a program that uses technology covered by the Harvard/Broad Cas Patent Rights and is directed to one of the targets, then the milestone and royalty payments for that specific target shall be reduced by a certain percentage. Our obligation to pay royalties will expire on a product-by-product and country-by-country basis upon the later of (i) the expiration of the last to expire valid claim of the Harvard/Broad Cas9 Patent Rights that cover the composition, manufacture or use of each covered product in each country or (ii) the tenth anniversary of the date of the first commercial sale of the licensed or enabled product. If we sublicense any of the Harvard/Broad Cas9 Patent Rights to a third party, Broad and Harvard, collectively, have the right to receive between 10% and 20% of the sublicense income, which percentage shall decrease to a high single-digit after we meet certain clinical milestones.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Prosecution and enforcement provisions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Broad and Harvard retain control of the prosecution of their respective patent rights. We are obligated to reimburse Broad and Harvard for certain expenses associated with the prosecution and maintenance of the Harvard/Broad Cas9 Patent Rights, including expenses associated with any interference proceedings in the USPTO, any opposition proceedings in the European Patent Office, or any other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> or other post grant proceedings in these or other jurisdictions where we are seeking patent protection. Broad and Harvard are required to maintain any application or patent within the Harvard/Broad Patents Rights so long as we meet our obligation to reimburse Broad and Harvard for expenses related to prosecution, there is a good faith basis for doing so and doing so is consistent with Broad or Harvard&#x2019;s patent prosecution strategy. If we cease payment for the prosecution of any Harvard/Broad Cas9 Patent Right, then any license granted to us with respect to such Harvard/Broad Cas9 Patent Right will terminate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have the first right, but not the obligation, to enforce the Harvard/Broad Cas9-I Patent Rights with respect to our licensed products so long as certain conditions are met, such as providing Broad and Harvard with evidence demonstrating a good faith basis for bringing suit against a third party and subject to coordination with Editas. We are solely responsible for the costs of any lawsuits we elect to initiate and cannot enter into a settlement without the prior written consent of Broad and Harvard (and MIT, Rockefeller and Iowa, if applicable). Any sums recovered in such lawsuits will be shared among us, Broad and Harvard.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Termination provisions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unless terminated earlier, the term of the Cas9 License Agreement will expire upon the expiration of the last to expire valid claim of the Harvard/Broad Cas9 Patent Rights. However, our royalty and milestone payment obligations, discussed above, may survive expiration or termination. We have the right to terminate the agreement at will upon four months&#x2019; written notice to Broad and Harvard. Either we or Broad and Harvard may terminate the agreement upon a specified period of notice in the event of the other party&#x2019;s uncured material breach, such notice period varying depending on the nature of the breach. Both Broad and Harvard may terminate the Cas9 License Agreement immediately if we, or our affiliates or sublicensee(s), subject to our ability to cure, challenge the enforceability, validity or scope of any Harvard/Broad Patent Right or assist a third party to do so, or in the event of our bankruptcy or insolvency. Neither Broad nor Harvard acting alone has the right to terminate the Cas9 License Agreement. However, Broad and Harvard may separately terminate the licenses granted to us with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">respect to their respective patent rights upon the occurrence of the same events that would give rise to the right of both institutions acting collectively to terminate the Cas9 License Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Government regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Government authorities in the United States, at the federal, state and local level and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting and import and export of pharmaceutical products, including biological products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Licensure and regulation of biologics in the United States</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the United States, any product candidates we may develop would be regulated as biological products, or biologics, under the Public Health Service Act, or PHSA, and the Federal Food, Drug and Cosmetic Act, or FDCA, and its implementing regulations and guidance. The failure to comply with the applicable U.S. requirements at any time during the product development process, including preclinical testing, clinical testing, the approval process, or post-approval process, may subject an applicant to delays in the conduct of the study, regulatory review and approval and/or administrative or judicial sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The FDA must approve a product candidate for a therapeutic indication before it may be marketed in the United States. An applicant seeking approval to market and distribute a new biologic in the United States generally must satisfactorily complete each of the following steps:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the FDA&#x2019;s Good Laboratory Practices, or GLP regulations; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">completion of the manufacture, under cGMP conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">design of a clinical protocol and its submission to the FDA as part of an IND for human clinical testing, which must become effective before human clinical trials may begin; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">performance of adequate and well-controlled human clinical trials to establish the safety, potency and purity of the product candidate for each proposed indication, in accordance with current Good Clinical Practices, or GCP; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">preparation and submission to the FDA of a Biologics License Application, or BLA, for a biologic product requesting marketing for one or more proposed indications, including submission of detailed information on the manufacture and composition of the product in clinical development and proposed labelling; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">review of the product by an FDA advisory committee, where appropriate or if applicable; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#x2019;s identity, strength, quality and purity; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">satisfactory completion of any FDA audits of the preclinical studies and clinical trial sites to assure compliance with GLP, as applicable, and GCP, and the integrity of clinical data in support of the BLA; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">payment of user Prescription Drug User Fee Act, or PDUFA, securing FDA approval of the BLA and licensure of the new biologic product; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and any post-approval studies or other post-marketing commitments required by the FDA. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Preclinical studies and investigational new drug application</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Before testing any biologic product candidate in humans, the product candidate must undergo preclinical testing. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate the potential for efficacy and toxicity in animal studies. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations and standards and the United States Department of Agriculture&#x2019;s Animal Welfare Act, if applicable. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. Such authorization must be secured prior to interstate shipment and administration of any product candidate that is not the subject of an approved new drug application, or NDA. In support of a request for an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trials can begin or recommence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a partial clinical hold might state that a specific protocol or part of a protocol may not proceed, while other parts of a protocol or other protocols may do so. No more than 30 days after the imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following the issuance of a clinical hold or partial clinical hold, a clinical investigation may only resume once the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed or recommence. Occasionally, clinical holds are imposed due to manufacturing issues that may present safety issues for the clinical study subjects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived by the FDA. When a foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for an IND or application for marketing approval. Specifically, the studies must be conducted in accordance with GCP, including undergoing review and receiving approval by an independent ethics committee and seeking and receiving informed consent from subjects. GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#x2019;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well as the quality and integrity of the resulting data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additionally, genetic medicine clinical trials conducted at institutions that receive funding for recombinant DNA research from the U.S. National Institutes of Health, or NIH, also are potentially subject to review by a committee within the NIH&#x2019;s Office of Science Policy called the Novel and Exceptional Technology and Research Advisory Committee, or the NExTRAC. As of 2019, the charter of this review group has evolved to focus public review on clinical trials that cannot be evaluated by standard oversight bodies and pose unusual risks. With certain genetic medicine protocols, FDA review of or clearance to allow the IND to proceed could be delayed if the NExTRAC decides that full public review of the protocol is warranted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Reporting clinical trial results</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the PHSA, sponsors of clinical trials of certain FDA-regulated products, including prescription drugs and biologics, are required to register and disclose certain clinical trial information on a public registry (clinicaltrials.gov) maintained by the NIH. In particular, information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Although sponsors are also obligated to disclose the results of their clinical trials after completion, disclosure of the results can be delayed in some cases for up to two years after the date of completion of the trial. The NIH&#x2019;s final rule on registration and reporting requirements for clinical trials became effective in 2017, and both the NIH and the FDA have recently signaled the government&#x2019;s willingness to begin enforcing those requirements against non-compliant clinical trial sponsors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Specifically, the PHSA grants the Secretary of the U.S. Department of Health and Human Services, or HHS, the authority to issue a notice of noncompliance to a responsible party for failure to submit clinical trial information as required. The responsible party, however, is allowed 30 days to correct the noncompliance and submit the required information. The failure to submit clinical trial information to clinicaltrials.gov, as required, is also a prohibited act under the FDCA with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues. In addition to civil monetary penalties, violations may also result in other regulatory action, such as injunction and/or criminal prosecution or disqualification from federal grants. Although the FDA has historically not enforced these reporting requirements due to the HHS&#x2019;s long delay in issuing final implementing regulations, those regulations have now been issued and the FDA did issue its first notice of noncompliance to a manufacturer in April 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Expanded access to an investigational drug for treatment use</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expanded access, sometimes called &#x201c;compassionate use,&#x201d; is the use of investigational products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational products for patients who may benefit from investigational therapies. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the investigational product under a treatment protocol or treatment IND application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational drug for the requested treatment will not interfere with initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There is no obligation for a sponsor to make its drug products available for expanded access; however, as required by the 21st Century Cures Act, or Cures Act, passed in 2016, if a sponsor has a policy regarding how it responds to expanded access requests, it must make that policy publicly available. Sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3 trial; or 15 days after the investigational drug or biologic receives designation as a breakthrough therapy, Fast Track product, or regenerative medicine advanced therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, on May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a manufacturer to make its investigational products available to eligible patients as a result of the Right to Try Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Human clinical trials in support of a BLA</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease or condition to be treated under the supervision of a qualified principal investigator in accordance with GCP requirements. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical trial is not conducted under an IND, the sponsor must ensure that the trial complies with certain regulatory requirements of the FDA in order to use the trial as support for an IND or application for marketing approval. Specifically, the FDA requires that such trials be conducted in accordance with GCP, including review and approval by an independent ethics committee and informed consent from participants. The GCP requirements encompass both ethical and data integrity standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">for clinical trials. The FDA&#x2019;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical trials, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign trials are conducted in a manner comparable to that required for clinical trials in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Further, each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects, and the possible liability of the institution. An IRB must operate in compliance with FDA regulations. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or that the participants are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP rules and the requirements for informed consent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, or DSMB. This group may recommend continuation of the trial as planned, changes in trial conduct, or cessation of the trial at designated check points based on certain available data from the trial to which only the DSMB has access.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Phase 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics in healthy humans or, on occasion, in patients, such as cancer patients. </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Phase 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials. </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Phase 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical efficacy and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a biologic; such Phase 3 studies are referred to as &#x201c;pivotal.&#x201d; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A clinical trial may combine the elements of more than one phase and the FDA often requires more than one Phase 3 trial to support marketing approval of a product candidate. A company&#x2019;s designation of a clinical trial as being of a particular phase is not necessarily indicative that the study will be sufficient to satisfy the FDA requirements of that phase because this determination cannot be made until the protocol and data have been submitted to and reviewed by the FDA. Moreover, as noted above, a pivotal trial is a clinical trial that is believed to satisfy FDA requirements for the evaluation of a product candidate&#x2019;s safety and efficacy such that it can be used, alone or with other pivotal or non-pivotal trials, to support regulatory approval. Generally, pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in an area of unmet medical need.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In some cases, the FDA may approve a BLA for a product but require the sponsor to conduct additional clinical trials to further assess the product&#x2019;s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement or to request a change in the product labeling. The failure to exercise due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In response to the COVID-19 pandemic, the FDA issued guidance on March 18, 2020, and has updated it periodically since that time to address the conduct of clinical trials during the pandemic. The guidance sets forth a number of considerations for sponsors of clinical trials impacted by the COVID-19 pandemic, including the requirement to include in the clinical study report (or as a separate document) contingency measures</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">implemented to manage the study, and any disruption of the study as a result of the COVID-19 pandemic; a list of all study participants affected by COVID-19-related study disruptions by a unique subject identifier and by investigational site, and a description of how the individual&#x2019;s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the study, among other things. The FDA has indicated that it will continue to provide any necessary guidance to sponsors, clinical investigators, and research institutions as the public health emergency evolves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Interactions with FDA during the clinical development program</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Following the clearance of an IND and the commencement of clinical trials, the sponsor will continue to have interactions with the FDA. Progress reports detailing the results of clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or in vitro testing that suggest a significant risk in humans exposed to the product; and any clinically important increase in the occurrence of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. When clinical data is submitted to support marketing applications, the FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, sponsors are given opportunities to meet with the FDA at certain points in the clinical development program. Specifically, sponsors may meet with the FDA prior to the submission of an IND, or pre-IND application meeting, at the end of a Phase 2 clinical trial, or EOP2 meeting, and before an NDA or BLA is submitted, or pre-NDA or pre-BLA meeting. Meetings at other times may also be requested. There are four types of meetings that occur between sponsors and the FDA. Type A meetings are those that are necessary for an otherwise stalled product development program to proceed or to address an important safety issue. Type B meetings include pre-IND application and pre-NDA/pre-BLA meetings, as well as Type B end of phase meetings, such as EOP2 meetings. A Type C meeting is any meeting other than a Type A or Type B meeting regarding the development and review of a product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">These meetings provide an opportunity for the sponsor to share information about the data gathered to date with the FDA and for the FDA to provide advice on the next phase of development. For example, at an EOP2 meeting, a sponsor may discuss its Phase 2 clinical results and present its plans for the pivotal Phase 3 clinical trial(s) that it believes will support the approval of the new product. Such meetings may be conducted in person, via teleconference/videoconference or written response only with minutes reflecting the questions that the sponsor posed to the FDA and the FDA&#x2019;s responses. The FDA has indicated that its responses, as conveyed in meeting minutes and advice letters, only constitute mere recommendations and/or advice made to a sponsor and, as such, sponsors are not bound by such recommendations and/or advice. Nonetheless, from a practical perspective, a sponsor&#x2019;s failure to follow the FDA&#x2019;s recommendations for design of a clinical program may put the program at significant risk of failure.</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Pediatric studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the Pediatric Research Equity Act of 2003, or PREA, a BLA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor must submit an initial pediatric study plan within 60 days of an end-of-phase 2 meeting or as may be agreed between the sponsor and the FDA. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA, and the FDA&#x2019;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For investigational products intended to treat a serious or life-threatening disease or condition, the FDA must, upon the request of an applicant, meet to discuss preparation of the initial pediatric study plan or to discuss deferral or waiver of pediatric assessments. In addition, the FDA will meet early in the development process to discuss pediatric study plans with sponsors and the FDA must meet with sponsors by no later than the end-of-phase 1 meeting for serious or life-threatening diseases and by no later than 90 days after the FDA&#x2019;s receipt of the study plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although the FDA has recently taken steps to limit what it considers abuse of this statutory exemption in the PREA by announcing that it does not intend to grant any additional orphan drug designations for rare pediatric subpopulations of what is otherwise a common disease. The FDA also maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population.</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Special regulations and guidance governing gene therapy products</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We expect that the procedures and standards applied to gene therapy products will be applied to any product candidates we may develop. The FDA has defined a gene therapy product as one that seeks to modify or manipulate the expression of a gene or to alter the biological properties of living cells for therapeutic use. The products may be used to modify cells in vivo or transferred to cells ex vivo prior to administration to the recipient.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Within the FDA, the Center for Biologics Evaluation and Research, or CBER, regulates gene therapy products. Within CBER, the review of gene therapy and related products is consolidated in the Office of Tissues and Advanced Therapies and the FDA has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its reviews. The NIH, including the NExTRAC, also advises the FDA on gene therapy issues and other issues related to emerging biotechnologies. The FDA and the NIH have published guidance documents with respect to the development and submission of gene therapy protocols.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The FDA has issued various guidance documents regarding gene therapies, including final guidance documents released in January 2020 relating to chemistry, manufacturing and controls information for gene therapy INDs, long-term follow-up after the administration of gene therapy products, gene therapies for rare diseases and gene therapies for retinal disorders, as well as draft guidance in January 2021 for Human Gene Therapy for Neurodegenerative Diseases. Although the FDA has indicated that these and other guidance documents it previously issued are not legally binding, compliance with them is likely necessary to gain approval for any gene therapy product candidate. The guidance documents provide additional factors that the FDA will consider at each of the above stages of development and relate to, among other things: the proper preclinical assessment of gene therapies; the chemistry, manufacturing and control information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA application; and measures to observe for potential delayed adverse effects in participants who have received investigational gene therapies with the duration of follow-up based on the potential for risk of such effects. For AAV vectors specifically, the FDA typically recommends that sponsors continue to monitor participants for potential gene therapy-related adverse events for up to a 5-year period. Other types of gene therapy or gene editing products may require longer follow up, potentially up to a maximum 15-year period.</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Compliance with cGMP requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Concurrent with clinical trials, companies usually complete additional preclinical studies and must also develop additional information about the physical characteristics of the biologic product candidate as well as finalize a process for manufacturing the product candidate in commercial quantities in accordance with cGMP requirements. Before approving a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in full compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. To help reduce the risk of the introduction of adventitious agents or of causing other adverse events with the use of biologic products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other requirements, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biologic product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biologic product candidate does not undergo unacceptable deterioration over its shelf life.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Manufacturers and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not registered, whether foreign or domestic, is deemed misbranded under the FDCA. Establishments may be subject to periodic unannounced</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">inspections by government authorities to ensure compliance with cGMPs and other laws. Inspections must follow a &#x201c;risk&#x2011;based schedule&#x201d; that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Regulatory requirements governing manufacturing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The FDA&#x2019;s regulations require that pharmaceutical products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. Manufacturers and other entities involved in the manufacture and distribution of approved pharmaceuticals are required to register their establishments with the FDA and some state agencies, and are subject to periodic unannounced inspections by the FDA for compliance with cGMPs and other requirements. Inspections must follow a &#x201c;risk-based schedule&#x201d; that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. Changes to the manufacturing process, specifications or container closure system for an approved product are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require, among other things, the investigation and correction of any deviations from cGMP and the imposition of reporting and documentation requirements upon the NDA sponsor and any third-party manufacturers involved in producing the approved product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Acceptance and review of a BLA</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, along with information relating to the product&#x2019;s chemistry, manufacturing, controls, safety updates, patent information, abuse information and proposed labeling, are submitted to the FDA as part of an application requesting approval to market the product candidate for one or more indications. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#x2019;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of a drug product and the safety, potency and purity of the biological product to the satisfaction of the FDA. The fee required for the submission and review of an application under PDUFA is substantial (for example, for fiscal year 2022 this application fee is approximately $3.1 million), and the sponsor of an approved NDA is also subject to an annual program fee, which for fiscal year 2022 is more than $369,000 per eligible prescription product. These fees, of which the application fee may be waived for products with orphan drug designation, are typically adjusted annually, and exemptions and waivers may be available under certain circumstances, such as where a waiver is necessary to protect the public health, where the fee would present a significant barrier to innovation, or where the applicant is a small business submitting its first human therapeutic application for review.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The FDA conducts a preliminary review of all applications within 60 days of receipt and must inform the sponsor by that time whether an application is sufficiently complete to permit substantive review. In pertinent part, the FDA&#x2019;s regulations state that an application &#x201c;shall not be considered as filed until all pertinent information and data have been received&#x201d; by the FDA. In the event that the FDA determines that an application does not satisfy this standard, it will issue a Refuse to File, or RTF, determination to the applicant. Typically, an RTF will be based on administrative incompleteness, such as clear omission of information or sections of required information; scientific incompleteness, such as omission of critical data, information or analyses needed to evaluate safety, purity and efficacy or provide adequate directions for use; or inadequate content, presentation, or organization of information such that substantive and meaningful review is precluded. The FDA may request additional information rather than accept an application for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">After the submission is accepted for filing, the FDA begins an in-depth substantive review of the application. The FDA reviews the application to determine, among other things, whether the proposed product is safe and effective for its intended use, whether it has an acceptable purity profile and whether the product is being manufactured in accordance with cGMP. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months from the filing date in which to complete its initial review of a standard application that is a new molecular entity, and six months from the filing date for an application with &#x201c;priority review.&#x201d; The review process may be extended by the FDA for three additional months to consider new information or in the case of a clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">submission. Despite these review goals, it is not uncommon for FDA review of an application to extend beyond the PDUFA goal date.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In connection with its review of an application, the FDA will typically submit information requests to the applicant and set deadlines for responses thereto. The FDA will also conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether the manufacturing processes and facilities comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications. The FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with IND applications and GCP requirements and the integrity of the clinical data submitted to the FDA. To ensure cGMP and GCP compliance by its employees and third-party contractors, an applicant may incur significant expenditure of time, money and effort in the areas of training, record keeping, production and quality control.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additionally, the FDA may refer an application, including applications for novel product candidates which present difficult questions of safety or efficacy, to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it considers such recommendations when making final decisions on approval. Data from clinical trials are not always conclusive, and the FDA or its advisory committee may interpret data differently than the sponsor interprets the same data. The FDA may also re-analyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The FDA also may require submission of a REMS if it determines that a REMS is necessary to ensure that the benefits of the product outweigh its risks and to assure the safe use of the product. The REMS could include medication guides, physician communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS is needed, the sponsor of the application must submit a proposed REMS and the FDA will not approve the application without a REMS.</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Decisions on BLAs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The FDA reviews an application to determine, among other things, whether the product is safe and whether it is effective for its intended use(s), with the latter determination being made on the basis of substantial evidence. The term &#x201c;substantial evidence&#x201d; is defined under the FDCA as &#x201c;evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the product involved, on the basis of which it could fairly and responsibly be concluded by such experts that the product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling or proposed labeling thereof.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The FDA has interpreted this evidentiary standard to require at least two adequate and well-controlled clinical investigations to establish effectiveness of a new product. Under certain circumstances, however, the FDA has indicated that a single trial with certain characteristics and additional information may satisfy this standard. This approach was subsequently endorsed by Congress in 1998 with legislation providing, in pertinent part, that &#x201c;If [FDA] determines, based on relevant science, that data from one adequate and well-controlled clinical investigation and confirmatory evidence (obtained prior to or after such investigation) are sufficient to establish effectiveness, FDA may consider such data and evidence to constitute substantial evidence.&#x201d; This modification to the law recognized the potential for the FDA to find that one adequate and well controlled clinical investigation with confirmatory evidence, including supportive data outside of a controlled trial, is sufficient to establish effectiveness. In December 2019, the FDA issued draft guidance further explaining the studies that are needed to establish substantial evidence of effectiveness. It has not yet finalized that guidance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">After evaluating the application and all related information, including the advisory committee recommendations, if any, and inspection reports of manufacturing facilities and clinical trial sites, the FDA will issue either a CRL or an approval letter. To reach this determination, the FDA must determine that the drug is effective and that its expected benefits outweigh its potential risks to patients. This &#x201c;benefit-risk&#x201d; assessment is informed by the extensive body of evidence about the product&#x2019;s safety and efficacy in the NDA or BLA. This assessment is also informed by other factors, including: the severity of the underlying condition and how well patients&#x2019; medical needs are addressed by currently available therapies; uncertainty about how the premarket clinical trial evidence will</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">extrapolate to real-world use of the product in the post-market setting; and whether risk management tools are necessary to manage specific risks. In connection with this assessment, the FDA review team will assemble all individual reviews and other documents into an &#x201c;action package,&#x201d; which becomes the record for the FDA&#x2019;s review. The FDA review team then issues a recommendation, and a senior FDA official makes a decision.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time- consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the applicant will have one year to respond to the deficiencies identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the applicant an additional six month extension to respond. The FDA has committed to reviewing such resubmissions in response to an issued CRL in either two or six months depending on the type of information included. Even with the submission of this additional information, however, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. The FDA has taken the position that a CRL is not final agency action making the determination subject to judicial review.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">An approval letter, on the other hand, authorizes commercial marketing of the product with specific prescribing information for specific indications. That is, the approval will be limited to the conditions of use (e.g., patient population and indication) described in the FDA-approved labeling. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings, or precautions be included in the product labeling; post-approval trials, including Phase 4 clinical trials, be conducted to further assess a product&#x2019;s safety after approval; and/or testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the Ensuring Innovation Act, which was signed into law in April 2021, the FDA must publish action packages summarizing its decisions to approve new drugs and biologics within 30 days of approval of such products. To date, CRLs are not publicly available documents.</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Expedited review programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The FDA is authorized to expedite the review of BLAs in several ways. Under the Fast Track program, the sponsor of a product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of the IND. Candidate products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. In addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track application before the application is complete, a process known as rolling review.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any product candidate submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as breakthrough therapy designation, priority review, accelerated approval or regenerative medicine advanced therapy designation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Breakthrough therapy designation.    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that such product candidates may demonstrate substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review. </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Priority review.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">    A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention compared to marketed products. The FDA aims to complete its review of priority review applications within six months as opposed to 10 months for standard review. </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Accelerated approval.    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Drug or biologic products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biologic product candidate receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Regenerative medicine advanced therapy.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">    With passage of the 21st Century Cures Act, or the Cures Act, in December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">None of these expedited programs changes the standards for approval but they may help expedite the development or approval process of product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Post-approval regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-approval regulatory requirements as well as any post-approval requirements that the FDA have imposed as part of the approval process. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#x2019;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity, potency and effectiveness of pharmaceutical products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about a product;</span></div></div>
  <div style="display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">mandated modification of promotional materials and labeling and issuance of corrective information;</span></div></div>
  <div style="display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">fines, warning letters or holds on post-approval clinical trials; </span></div></div>
  <div style="display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </span></div></div>
  <div style="display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">product recall, seizure or detention, or refusal to permit the import or export of products; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">injunctions or the imposition of civil or criminal penalties; and</span></div></div>
  <div style="display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pharmaceutical products may be promoted only for the approved indications and in accordance with the provisions of the approved label. Although healthcare providers may prescribe products for uses not described in the drug&#x2019;s labeling, known as off-label uses, in their professional judgment, drug manufacturers are prohibited from soliciting, encouraging or promoting unapproved uses of a product. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. This regulation includes, among other things, standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional activities involving the Internet and social media. Promotional claims about a drug&#x2019;s safety or effectiveness are prohibited before the drug is approved. After approval, a drug product generally may not be promoted for uses that are not approved by the FDA, as reflected in the product&#x2019;s prescribing information. In September 2021, the FDA published final regulations that describe the types of evidence that the agency will consider in determining the intended use of a drug or biologic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Finally, if there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or a BLA supplement, which may require the applicant to develop additional data or conduct additional preclinical studies and clinical trials. Securing FDA approval for new indications is similar to the process for approval of the original indication and requires, among other things, submitting data from adequate and well-controlled clinical trials to demonstrate the product&#x2019;s safety and efficacy in the new indication. Even if such trials are conducted, the FDA may not approve any expansion of the labeled indications for use in a timely fashion, or at all. There also are continuing, annual user fee requirements that are now assessed as program fees for certain approved drugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Orphan drug designation and exclusivity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for treatment of rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available the biologic for the disease or condition will be recovered from sales of the product in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Orphan drug designation qualifies a company for tax credits and market exclusivity for seven years following the date of the product&#x2019;s marketing approval if granted by the FDA. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. A product becomes an orphan when it receives orphan drug designation from the Office of Orphan Products Development at the FDA based on acceptable confidential requests made under the regulatory provisions. The product must then go through the review and approval process like any other product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first drug. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">approve another sponsor&#x2019;s marketing application for the same product for the same indication for seven years, except in certain limited circumstances. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The period of exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the indication for which the product has been designated. The FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the same use. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if the company with orphan drug exclusivity is not able to meet market demand or the subsequent product with the same drug for the same condition is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care. This is the case despite an earlier court opinion holding that the Orphan Drug Act unambiguously required the FDA to recognize orphan drug exclusivity regardless of a showing of clinical superiority. Under Omnibus legislation signed by President Trump on December 27, 2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of the FDA Reauthorization Act of 2017, but have not yet been approved or licensed by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In September 2021, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of exclusivity, the term &#x201c;same disease or condition&#x201d; in the statute means the designated &#x201c;rare disease or condition&#x201d; and could not be interpreted by the FDA to mean the &#x201c;indication or use.&#x201d; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#x201c;indication or use.&#x201d; It is unclear how this court decision will be implemented by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Pediatric exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#x2019;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of non-patent exclusivity that cover the product are extended by six months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Regulatory exclusivity governing biologics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">When a biological product is licensed for marketing by the FDA with approval of a BLA, the product may be entitled to certain types of market and data exclusivity barring the FDA from approving competing products for certain periods of time. In March 2010, the Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the PPACA, was enacted in the United States and included a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA. The BPCIA amended the PHSA to create an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. To date, the FDA has approved a number of biosimilars and the first interchangeable biosimilar product was approved on July 30, 2021 and a second product previously approved as a biosimilar was designated as interchangeable in October 2021. The FDA has also issued numerous guidance documents outlining its approach to reviewing and licensing biosimilars and interchangeable biosimilars under the PHSA, including a draft guidance issued in November 2020 that seeks to provide additional clarity to manufacturers of interchangeable biosimilars.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the BPCIA, a manufacturer may submit an application for a product that is &#x201c;biosimilar to&#x201d; a previously approved biological product, which the statute refers to as a &#x201c;reference product.&#x201d; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and the proposed biosimilar product in terms of safety, purity and potency. The biosimilar applicant may demonstrate that its product is biosimilar to the reference product on the basis of data from analytical studies, animal studies and one or more clinical studies to demonstrate safety, purity and potency in one or more appropriate conditions of use for which the reference product is approved. In addition, the applicant must show that the biosimilar and reference products have the same mechanism of action for the conditions of use on the label, route of administration, dosage and strength, and the production facility must meet standards designed to assure product safety, purity and potency.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For the FDA to approve a biosimilar product as interchangeable with a reference product, the FDA must find not only that the product is biosimilar to the reference product but also that it can be expected to produce the same clinical results as the reference product such that the two products may be switched without increasing safety</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Upon licensure by the FDA, an interchangeable biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product. Following approval of the interchangeable biosimilar product, the FDA may not grant interchangeability status for any second biosimilar until one year after the first commercial marketing of the first interchangeable biosimilar product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A reference biological product is granted 12 years of exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference product until four years after the date of first licensure of the reference product. Even if a product is considered to be a reference product eligible for exclusivity, however, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of their product. There have been recent government proposals to reduce the 12-year reference product exclusivity period, but none has been enacted to date. At the same time, since the passage of the BPCIA, many states have passed laws or amendments to laws that address pharmacy practices involving biosimilar products.</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Patent term restoration and extension</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the United States, a patent claiming a new biologic product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought, the restoration period for a patent covering a product is typically one-half the time between the effective date of the IND application and the submission date of the BLA, plus the time between the submission date of the BLA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#x2019;s approval date in the United States. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension in consultation with the FDA.</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Federal and state data privacy and security laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There are multiple privacy and data security laws that may impact our business activities, in the United States and other countries where we conduct our trials or where we may do business in the future. These laws are evolving and may increase both our obligations and our regulatory risks in the future. In the health care industry generally, under the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, the HHS has issued regulations to protect the privacy and security of protected health information, or PHI, used or disclosed by covered entities including certain healthcare providers, health plans and healthcare clearinghouses. HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers. HIPAA also imposes certain obligations on the business associates of covered entities that obtain protected health information in providing services to or on behalf of covered entities. HIPAA may apply to us in certain circumstances and may also apply to our business partners in ways that may impact our relationships with them. Our clinical trials will be regulated by HIPAA's Common Rule, which also includes specific privacy-related provisions. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information that may be applicable to our business. In addition to possible federal civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#x2019;s fees and costs associated with pursuing federal civil actions. In addition, state attorneys general (along with private plaintiffs) have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#x2019;s privacy and security rules. State attorneys general also have authority to enforce state privacy and security laws. New laws and regulations governing privacy and security may be adopted in the future as well.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">At the state level, California has enacted legislation that has been dubbed the first &#x201c;GDPR-like&#x201d; law in the United States. Known as the California Consumer Privacy Act, or CCPA, it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA went into effect on January 1, 2020 and requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. Additionally, effective starting on January 1, 2023, the California Privacy Rights Act, or CPRA, will significantly modify the CCPA, including by expanding consumers&#x2019; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">and the CPRA. The CCPA and CPRA could impact our business activities depending on how it is interpreted and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and individually identifiable health information. These provisions may apply to some of our business activities. In addition, other states, including Virginia and Colorado, have already passed state privacy laws and other states will likely be considering similar laws in the near future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our current or future business activities, including certain clinical research, sales and marketing practices and the provision of certain items and services to our customers, could be subject to challenge under one or more of such privacy and data security laws. The heightening compliance environment and the need to build and maintain robust and secure systems to comply with different privacy compliance and/or reporting requirements in multiple jurisdictions could increase the possibility that a healthcare company may fail to comply fully with one or more of these requirements. If our operations are found to be in violation of any of the privacy or data security laws or regulations described above that are applicable to us, or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil and administrative penalties, damages, fines, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a consent decree or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any product candidates we may develop, once approved, are sold in a foreign country, we may be subject to similar foreign laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">FDA approval of companion diagnostics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and in vitro companion diagnostics. According to the guidance, for novel drugs, a companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#x2019;s labeling. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. In July 2016, the FDA issued a draft guidance intended to assist sponsors of the drug therapeutic and in vitro companion diagnostic device on issues related to co-development of the products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The 2014 guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a biologic product candidate generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#x2019;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a product are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In April 2020, the FDA issued additional guidance that describes considerations for the development and labeling of companion diagnostic devices to support the indicated uses of multiple drug or biological oncology products, when appropriate. This guidance builds upon existing policy regarding the labeling of companion diagnostics. In its 2014 guidance, the FDA stated that if evidence is sufficient to conclude that the companion diagnostic is appropriate for use with a specific group of therapeutic products, the companion diagnostic&#x2019;s intended use or indications for use should name the specific group of therapeutic products, rather than specific products. The 2020 guidance expands on the policy statement in the 2014 guidance by recommending that companion diagnostic developers consider a number of factors when determining whether their test could be developed, or the labeling for approved companion diagnostics could be revised through a supplement, to support a broader labeling claim such as use with a specific group of oncology therapeutic products (rather than listing an individual therapeutic product(s)).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the FDCA, in vitro diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import and post-market surveillance. Unless an exemption applies, diagnostic tests require pre-notification marketing clearance or approval from the FDA prior to commercial distribution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The FDA previously has required in vitro companion diagnostics intended to select the patients who will respond to the product candidate to obtain pre-market approval, or PMA, simultaneously with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#x2019;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. For fiscal year 2022, the standard fee is $374,858 and the small business fee is $93,714.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Regulation and procedures governing approval of medicinal products in the European Union</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the European Union generally follows the same lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent authorities of an MAA and granting of a marketing authorization by these authorities before the product can be marketed and sold in the European Union.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Clinical trial approval</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pursuant to the currently applicable Clinical Trials Directive 2001/20/EC and the Directive 2005/28/EC on GCP, a system for the approval of clinical trials in the European Union has been implemented through national legislation of the member states. Under this system, an applicant must obtain approval from the competent national authority of a European Union member state in which the clinical trial is to be conducted, or in multiple member states if the clinical trial is to be conducted in a number of member states. Furthermore, the applicant may only start a clinical trial at a specific site after the competent ethics committee has issued a favorable opinion. The clinical trial application must be accompanied by an investigational medicinal product dossier with supporting information prescribed by Directive 2001/20/EC and Directive 2005/28/EC and corresponding national laws of the member states and further detailed in applicable guidance documents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In April 2014, the European Union adopted a new Clinical Trials Regulation (EU) No 536/2014, but it has not yet become effective. The Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the European Union. The main characteristics of the regulation include a streamlined application procedure via a single entry point, the &#x201c;EU portal&#x201d;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all European Union member states in which an application for authorization of a clinical trial has been submitted (member states concerned). Part II is assessed separately by each member state concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned European Union member states. However, overall related timelines will be defined by the Clinical Trials Regulation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The conduct of all clinical trials performed in the European Union will continue to be bound by currently applicable provisions until the new Clinical Trials Regulation becomes applicable. The extent to which on-going clinical trials will be governed by the Clinical Trials Regulation will depend on when the Clinical Trials Regulation becomes applicable and on the duration of the individual clinical trial. If a clinical trial continues for more than three years from the day on which the Clinical Trials Regulation becomes applicable the Clinical Trials Regulation will at that time begin to apply to the clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On January 1, 2020, the website of the European Commission reported that the implementation of the new Clinical Trials Regulation was dependent on the development of a fully functional clinical trials portal and database, which would be confirmed by an independent audit, and that the new legislation would come into effect six months after the European Commission publishes a notice of this confirmation. In late 2020, the European Medicines Agency, or EMA, indicated that it plans to focus on the findings of a system audit; improving the usability, quality and stability of the clinical trial information system; and knowledge transfer to prepare users and their organizations for the new clinical trial system. The Clinical Trial Information System went live in January 2022 and will be fully implemented under a three-year transition period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Parties conducting certain clinical trials must, as in the United States, post clinical trial information in the European Union at the EudraCT website: https://eudract.ema.europa.eu.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">PRIME designation in the European Union</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated EMA contact and rapporteur from the Committee for Human Medicinal Products, or CHMP, or Committee for Advanced Therapies are appointed early in the PRIME scheme facilitating increased understanding of the product at the EMA&#x2019;s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Marketing authorization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To obtain a marketing authorization for a product under the European Union regulatory system, an applicant must submit an MAA, either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in European Union member states (decentralized procedure, national procedure, or mutual recognition procedure). A marketing authorization may be granted only to an applicant established in the European Union. Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the European Union, an applicant must demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver or a deferral for one or more of the measures included in the PIP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all European Union member states. Pursuant to Regulation (EC) No. 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. Manufacturers must demonstrate the quality, safety and efficacy of their products to the EMA, which provides an opinion regarding the MAA. The European Commission grants or refuses marketing authorization in light of the opinion delivered by the EMA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Specifically, the grant of marketing authorization in the European Union for products containing viable human tissues or cells such as gene therapy medicinal products is governed by Regulation 1394/2007/EC on advanced therapy medicinal products, read in combination with Directive 2001/83/EC of the European Parliament and of the Council, commonly known as the Community code on medicinal products. Regulation 1394/2007/EC lays down specific rules concerning the authorization, supervision and pharmacovigilance of gene therapy medicinal products, somatic cell therapy medicinal products and tissue engineered products. Manufacturers of advanced therapy medicinal products must demonstrate the quality, safety and efficacy of their products to EMA which provides an opinion regarding the application for marketing authorization. The European Commission grants or refuses marketing authorization in light of the opinion delivered by EMA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the centralized procedure, the CHMP established at the EMA is responsible for conducting an initial assessment of a product. Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the time limit of 210 days will be reduced to 150 days, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">National Authorization Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There are also two other possible routes to authorize medicinal products in several European Union member states, which are available for investigational medicinal products that fall outside the scope of the centralized procedure:</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Decentralized procedure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one European Union member state of medicinal products that have not yet been authorized in any European Union member state and that do not fall within the mandatory scope of the centralized procedure. The applicant may choose a European Union member state as the reference member state to lead the scientific evaluation of the application.</span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Mutual recognition procedure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. In the mutual recognition procedure, a medicine is first authorized in one European Union member state (which acts as the reference member state), in accordance with the national procedures of that member state. Following this, further marketing authorizations can be progressively sought from other European Union member states in a procedure whereby the members concerned agree to recognize the validity of the original, national marketing authorization produced by the reference European Union member state.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the above-described procedures, before granting the marketing authorization, the EMA or the competent authorities of the European Union member state of the European Economic Area, or the EEA, make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Conditional Approval</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In specific circumstances, E.U. legislation (Article 14&#x2013;a Regulation (EC) No 726/2004 (as amended by Regulation (EU) 2019/5 and Regulation (EC) No 507/2006 on Conditional Marketing Authorizations for Medicinal Products for Human Use) enables applicants to obtain a conditional marketing authorization prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted for product candidates (including medicines designated as orphan medicinal products) if (1) the product candidate is intended for the treatment, prevention or medical diagnosis of seriously debilitating or life-threatening diseases; (2) the product candidate is intended to meet unmet medical needs of patients; (3)  a marketing authorization may be granted prior to submission of comprehensive clinical data provided that the benefit of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required; (4) the risk-benefit balance of the product candidate is positive, and (5) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization.</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Specialized procedures for gene therapies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The grant of marketing authorization in the European Union for gene therapy products is governed by Regulation 1394/2007/EC on advanced therapy medicinal products, read in combination with Directive 2001/83/EC of the European Parliament and of the Council, commonly known as the Community code on medicinal products. Regulation 1394/2007/EC includes specific rules concerning the authorization, supervision and pharmacovigilance of gene therapy medicinal products. Manufacturers of advanced therapy medicinal products must demonstrate the quality, safety and efficacy of their products to the EMA, which provides an opinion regarding the MAA. The European Commission grants or refuses marketing authorization in light of the opinion delivered by the EMA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Pediatric studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to obtaining a marketing authorization in the European Union, applicants must demonstrate compliance with all measures included in an EMA-approved PIP covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are provided in Regulation (EC) No 1901/2006, the so-called Paediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Paediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine for children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine for children is not needed or is not appropriate, such as for diseases that only affect the elderly population. Before an MAA can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Regulatory data protection in the European Union</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the European Union, new chemical entities approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Regulation (EC) No 726/2004, as amended, and Directive 2001/83/EC, as amended. Data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#x2019;s data to assess a generic (abbreviated) application for a period of eight years. During the additional two-year period of market exclusivity, a generic marketing authorization application can be submitted, and the innovator&#x2019;s data may be referenced, but no generic medicinal product can be marketed until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Patent term extensions in the European Union and other jurisdictions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The European Union also provides for patent term extension through Supplementary Protection Certificates, or SPCs. The rules and requirements for obtaining a SPC are similar to those in the United States. An SPC may extend the term of a patent for up to five years after its originally scheduled expiration date and can provide up to a maximum of fifteen years of marketing exclusivity for a drug. In certain circumstances, these periods may be extended for six additional months if pediatric exclusivity is obtained, which is described in detail below. Although SPCs are available throughout the European Union, sponsors must apply on a country-by-country basis. Similar patent term extension rights exist in certain other foreign jurisdictions outside the European Union.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Periods of authorization and renewals</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A marketing authorization is valid for five years, in principle, and it may be renewed after five years on the basis of a reevaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To that end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal period. Any authorization that is not followed by the placement of the drug on the European Union market (in the case of the centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Regulatory requirements after marketing authorization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include compliance with the European Union&#x2019;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be imposed. In addition, the manufacturing of authorized products, for which a separate manufacturer&#x2019;s license is mandatory, must also be conducted in strict compliance with the EMA&#x2019;s GMP requirements and comparable requirements of other regulatory bodies in the European Union, which mandate the methods, facilities and controls used in manufacturing, processing and packing of drugs to assure their safety and identity. Finally, the marketing and promotion of authorized products, including industry-sponsored continuing medical education and advertising directed toward the prescribers of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">drugs and/or the general public, are strictly regulated in the European Union under Directive 2001/83EC, as amended.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Orphan drug designation and exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Regulation (EC) No 141/2000 and Regulation (EC) No. 847/2000 provide that a product can be designated as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (1) a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the European Union when the application is made, or (2) a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the drug in the European Union would generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the drug will be of significant benefit to those affected by that condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">An orphan drug designation provides a number of benefits, including fee reductions, regulatory assistance and the possibility to apply for a centralized European Union marketing authorization. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. During this market exclusivity period, neither the EMA nor the European Commission or the member states can accept an application or grant a marketing authorization for a &#x201c;similar medicinal product.&#x201d; A &#x201c;similar medicinal product&#x201d; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation because, for example, the product is sufficiently profitable not to justify market exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Pediatric exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If an applicant obtains a marketing authorization in all European Union member states, or a marketing authorization granted in the centralized procedure by the European Commission, and the study results for the pediatric population are included in the product information, even when negative, the medicine is then eligible for an additional six-month period of qualifying patent protection through extension of the term of the Supplementary Protection Certificate, or SPC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Approval of companion diagnostic devices</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the European Union, medical devices such as companion diagnostics must comply with the General Safety and Performance Requirements, or SPRs, detailed in Annex I of the EU Medical Devices Regulation (Regulation (EU) 2017/745), or MDR, which came into force on May 26, 2021 and replaced the previously applicable EU Medical Devices Directive (Council Directive 93/42/EEC). Compliance with SPRs and additional requirements applicable to companion medical devices is a prerequisite to be able to affix the Conformit&#xe8; Europ&#xeb;enne mark of conformity to medical devices, without which they cannot be marketed or sold. To demonstrate compliance with the SPRs, a manufacturer must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. The MDR is meant to establish a uniform, transparent, predictable, and sustainable regulatory framework across the European Union for medical devices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Separately, the regulatory authorities in the European Union also adopted a new In Vitro Diagnostic Regulation (Regulation (EU) 2017/746), which will become effective in May 2022. The new regulation will replace the In Vitro Diagnostics Directive (IVDD) 98/79/EC. Manufacturers wishing to apply to a notified body for a conformity assessment of their in vitro diagnostic medical device have until May 2022 to update their technical documentation to meet the requirements and comply with the new, more stringent regulation. Once applicable, the regulation will, among other things:</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">strengthen the rules on placing devices on the market and reinforce surveillance once they are available; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">establish explicit provisions on manufacturers&#x2019; responsibilities for the follow-up of the quality, performance and safety of devices placed on the market; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the European Union; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">strengthen rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Brexit and the regulatory framework in the United Kingdom</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On June 23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as Brexit. Following protracted negotiations, the United Kingdom left the European Union on January 31, 2020. Pursuant to the formal withdrawal arrangements agreed between the United Kingdom and the European Union, the United Kingdom was subject to a transition period until December 31, 2020, during which European Union rules continued to apply. A trade and cooperation agreement, or the Trade and Cooperation Agreement, which outlines the future trading relationship between the United Kingdom and the European Union was agreed in December 2020. Great Britain is no longer covered by the European Union&#x2019;s procedures for the grant of marketing authorizations (Northern Ireland is covered by the centralized authorization procedure and can be covered under the decentralized or mutual recognition procedures). A separate marketing authorization will be required to market drugs in Great Britain. For two years from 1 January 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, may adopt decisions taken by the European Commission on the approval of new marketing authorizations through the centralized procedure, and the MHRA will have regard to marketing authorizations approved in a country in the EEA (although in both cases a marketing authorization will only be granted if any Great Britain-specific requirements are met). Various national procedures are now available to place a drug on the market in the United Kingdom, Great Britain, or Northern Ireland, with the main national procedure having a maximum timeframe of 150 days (excluding time taken to provide any further information or data required). The data exclusivity periods in the United Kingdom are currently in line with those in the European Union, but the Trade and Cooperation Agreement provides that the periods for both data and market exclusivity are to be determined by domestic law, and so there could be divergence in the future. It is currently unclear whether the MHRA in the United Kingdom is sufficiently prepared to handle the increased volume of marketing authorization applications that it is likely to receive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Also, notwithstanding the United Kingdom&#x2019;s withdrawal from the European Union, by operation of the so-called &#x2018;UK GDPR&#x2019; (i.e., the EU General Data Protection Regulation, or GDPR, as it continues to form part of the law of the United Kingdom by virtue of section 3 of the EU (Withdrawal) Act 2018 and as subsequently amended) the GDPR continues to apply in substantially equivalent form to processing operations carried out in the context of an establishment in the United Kingdom and any processing relating to the offering of goods or services to individuals in the United Kingdom and/or monitoring of their behavior in the United Kingdom.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">However, it is still unclear whether transfers of data from the EEA to the United Kingdom will remain lawful under the GDPR. The Trade and Cooperation Agreement provides for a transitional period during which the UK will be treated like a European Union member state in relation to processing and transfers of personal data for four months from January 1, 2021. This may be extended by two further months. After such period, the United Kingdom will be a &#x201c;third country&#x201d; under the GDPR (and transfers of data from the EEA to the United Kingdom will require a &#x2018;transfer mechanism&#x2019; such as the Standard Contractual Clauses) unless the European Commission adopts an adequacy decision in respect of transfers of personal data to the United Kingdom. While the European Commission has published draft adequacy decisions in respect of the United Kingdom, these are subject to further review and it remains to be seen whether or when any such decisions will be adopted. The UK government has already determined that it considers all European Union and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the European Union and EEA remain unaffected. We may, however, incur liabilities, expenses, costs and other operational losses under GDPR and applicable European Union member states and the United Kingdom privacy laws in connection with any measures we take to comply with them. Furthermore, in general terms, there will now be increasing scope for divergence in application, interpretation and enforcement of the data protection law as between the United Kingdom and EEA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">General Data Protection Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The collection, use, disclosure, transfer or other processing of personal data in the context of the activities of an establishment in the EEA and/or regarding the offering of goods or services to, and/or the monitoring of the behavior of individuals in the EEA, including health data, is subject to the GDPR, which became effective on May 25, 2018. As noted above, by operation of the so-called &#x2018;UK GDPR,&#x2019; the GDPR continues to apply in substantially equivalent form in the context of the UK, UK establishments and UK-focused processing operations&#x2014;so, when we refer to the GDPR in this section, we are also making reference to the UK GDPR in the context of the United Kingdom, unless the context requires otherwise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The GDPR is wide-ranging in scope and imposes numerous, significant and complex requirements on companies that process personal data, such as: requiring the establishment of a legal basis for processing personal data; broadening the definition of personal data (including to capture &#x2018;pseudonymized&#x2019; or key-coded data that is commonly processed in a clinical trial-related context); creating obligations for controllers and processors to appoint data protection officers in certain circumstances; increasing transparency obligations to data subjects; establishing limitations on the retention of personal data; introducing obligations to honor increased rights for data subjects; formalizing a heightened standard of data subject consent; establishing obligations to implement certain technical and organizational safeguards to protect the security and confidentiality of personal data; introducing obligations to agree to certain specific contractual terms and to take certain measures when working with third-party processors or joint controllers; introducing the obligation to provide notice of certain significant personal data breaches to the relevant supervisory authority(ies) and affected individuals; and mandating the appointment of representatives in the United Kingdom and/or European Union in certain circumstances. In particular, the processing of &#x201c;special category personal data&#x201d; (such as personal data related to health and genetic information), which will be relevant to our operations in the context of clinical trials, imposes heightened compliance burdens under the GDPR and is a topic of active interest among relevant regulators. In addition, the GDPR provides that EEA member states may introduce specific requirements related to the processing of special categories of personal data such as health data that we may process in connection with clinical trials or otherwise. In the United Kingdom, the UK Data Protection Act 2018 complements the UK GDPR in this regard. More broadly, European data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which contributes to the complexity of processing personal data in or from the EEA and/or United Kingdom. Guidance on implementation and compliance practices is often updated or otherwise revised. This fact may lead to greater divergence on the law that applies to the processing of personal data across the EEA and/or United Kingdom, which may increase our costs and overall compliance risk. Such country-specific regulations could also limit our ability to process relevant personal data in the context of our EEA and/or United Kingdom operations ultimately having an adverse impact on our business, and harming our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The GDPR also imposes strict rules on the transfer of personal data to countries outside Europe, including to the United States, unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data. Certain previously available safeguards have been invalidated, and reliance on alternative safeguards may be complex or not possible in certain circumstances, following a recent ruling of the Court of Justice of the European Union and subsequent regulatory guidance. If we are unable to implement a valid solution for personal data transfers from the EEA and United Kingdom, including, for example, obtaining individuals&#x2019; explicit consent to transfer their personal data to the United States or other countries, we will face increased exposure to regulatory actions, substantial fines and injunctions against transferring personal data from the EEA and United Kingdom. Inability to export personal data from the EEA and United Kingdom may also restrict our activities outside the EEA and United Kingdom; limit our ability to collaborate with partners as well as other service providers, contractors and other companies outside of the EEA and United Kingdom; and/or require us to increase our processing capabilities within the EEA and/or United Kingdom at significant expense or otherwise cause us to change the geographical location or segregation of our relevant systems and operations&#x2014;any or all of which could adversely affect our operations or financial results. Additionally, other countries outside of the EEA and United Kingdom have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The GDPR also provides for more robust regulatory enforcement and permits supervisory authorities to impose greater penalties for violations than under previous European data protection laws, including potential fines of up to &#x20ac;20 million or 4% of annual global revenues for the preceding financial year, whichever is greater. In addition to administrative fines, a wide variety of other potential enforcement powers are available to supervisory authorities in respect of potential and suspected violations of the GDPR, including extensive audit and inspection rights, and powers to order temporary or permanent bans on all or some processing of personal data carried out by noncompliant actors. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Coverage, pricing and reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may seek regulatory approval by the FDA or other government authorities. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payers to reimburse all or part of the associated healthcare costs. Patients are unlikely to use any product candidates we may develop unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of such product candidates. Even if any product candidates we may develop are approved, sales of such product candidates will depend, in part, on the extent to which third-party payers, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for, such product candidates. The process for determining whether a payer will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payer will pay for the product once coverage is approved. Third-party payers are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payers may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payer not to cover any product candidates we may develop could reduce physician utilization of such product candidates once approved and have a material adverse effect on our sales, results of operations and financial condition. Additionally, a payer&#x2019;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payer&#x2019;s determination to provide coverage for a product does not assure that other payers will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payer to payer. Third-party reimbursement and coverage may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. In addition, any companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to any companion diagnostics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of pharmaceuticals have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#x2019;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we obtain approval in the future to market in the United States any product candidates we may develop, we may be required to provide discounts or rebates under government healthcare programs or to certain government and private purchasers in order to obtain coverage under federal healthcare programs such as Medicaid. Participation in such programs may require us to track and report certain drug prices. We may be subject to fines and other penalties if we fail to report such prices accurately.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Outside the United States, ensuring adequate coverage and payment for any product candidates we may develop will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of any product candidates we may develop to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies (so called health technology assessments) in order to obtain reimbursement or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade (arbitrage between low-priced and high-priced member states), can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Healthcare law and regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Health care providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with providers, consultants, third-party payors and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, patient privacy laws and regulations and other health care laws and regulations that may constrain business and/or financial arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Restrictions under applicable federal and state health care laws and regulations include the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal health care program such as Medicare and Medicaid; the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious or fraudulent or knowingly making, using or causing to made or used a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government; HIPAA, which created additional federal criminal statutes that prohibit, among other things, a person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services; the Foreign Corrupt Practices Act, or FCPA, which prohibits companies and their intermediaries from making, or offering or promising to make, improper payments to non-U.S. officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment; and the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, within HHS, information related to payments and other transfers of value made by that entity to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members, and, beginning in 2022, will require applicable manufacturers to report information regarding payments and other transfers of value provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, and certified nurse midwives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Further, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. Additionally, some state and local laws require the registration of pharmaceutical sales representatives in the jurisdiction. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Healthcare reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In March 2010, the United States Congress enacted the PPACA, which, among other things, includes changes to the coverage and payment for drug products under government health care programs. Other legislative changes have been proposed and adopted since the PPACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#x2019;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to two percent per fiscal year, which went into effect in April 2013 and will remain in effect through 2031. Pursuant to the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, and subsequent legislation, these Medicare sequester reductions have been suspended through the end of, March 2022. From April 2022 through June 2022, a 1% sequester cut will be in effect, with the full 2% cut remaining thereafter. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Since enactment of the PPACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, the Tax Act repealed the &#x201c;individual mandate.&#x201d; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. Further, on December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the PPACA is an essential and inseverable feature of the PPACA, and therefore because the mandate was repealed as part of the Tax Act, the remaining provisions of the PPACA are invalid as well.  The U.S. Supreme Court heard this case on November 10, 2020 and, on June 17, 2021, dismissed this action after finding that the plaintiffs do not have standing to challenge the constitutionality of the PPACA. Litigation and legislation over the PPACA are likely to continue, with unpredictable and uncertain results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Trump administration also took executive actions to undermine or delay implementation of the PPACA, including directing federal agencies with authorities and responsibilities under the PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On January 28, 2021, however, President Biden revoked those orders and issued a new Executive Order which directs federal agencies to reconsider rules and other policies that limit Americans&#x2019; access to health care, and consider actions that will protect and strengthen that access. Under this Order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19; demonstrations and waivers under Medicaid and the PPACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and the PPACA; and policies that reduce affordability of coverage or financial assistance, including for dependents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Pharmaceutical prices</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, presidential executive orders, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the prices of pharmaceuticals under Medicare and Medicaid. In 2020, President Trump issued several executive orders intended to lower the prices of prescription products and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and on December 29, 2021, CMS issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries&#x2019; access to evidence-based care.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> In addition, in October 2020, the HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. The final rule is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for review and approval by the FDA. Further, on November 20, 2020, the HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden Administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed by the Biden Administration until January 1, 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On July 9, 2021, President Biden signed Executive Order 14063, which focuses on, among other things, the price of pharmaceuticals. The order directs the HHS to create a plan within 45 days to combat &#x201c;excessive pricing of prescription pharmaceuticals and enhance domestic pharmaceutical supply chains, to reduce the prices paid by the federal government for such pharmaceuticals, and to address the recurrent problem of price gouging.&#x201d; On September 9, 2021, the HHS released its plan to reduce pharmaceutical prices. The key features of that plan are to make pharmaceutical prices more affordable and equitable for all consumers and throughout the health care system by supporting pharmaceutical price negotiations with manufacturers; improve and promote competition throughout the prescription pharmaceutical industry by supporting market changes that strengthen supply chains, promote biosimilars and generic pharmaceuticals, and increase transparency; and foster scientific innovation to promote better healthcare and improve health by supporting public and private research and making sure that market incentives promote discovery of valuable and accessible new treatments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states, for example, require drug manufacturers and other entities in the drug supply chain, including health carriers, pharmacy benefit managers, wholesale distributors, to disclose information about pricing of pharmaceuticals. In addition, regional health care organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription pharmaceutical and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Employees and human capital resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021, we had 113 full-time employees, including 35 employees with M.D., Pharm.D. or Ph.D. degrees. Of these full-time employees, 87 are engaged in research and development activities and 26 are engaged in general and administrative activities. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. We are committed to diversity, equity and inclusion across all aspects of our organization, including in our recruitment, advancement and development practices. Each year, we review employee demographic information to evaluate our diversity efforts across all functions and levels of the company. We conduct annual performance and development reviews for each of our employees to discuss the individual&#x2019;s strengths and development opportunities, career development goals and performance goals. We also regularly survey employees to assess employee engagement and satisfaction. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees and directors through the granting of stock-based compensation awards. We value our employees and regularly benchmark total rewards we provide, such as short-and long-term compensation, 401(k) contributions, health, welfare and quality of life benefits, paid time off and personal leave, against our industry peers to ensure we remain competitive and attractive to potential new hires.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Our Corporate Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We were incorporated under the laws of the state of Delaware on March 9, 2018 under the name Endcadia, Inc. On January 15, 2019, we changed our name to Verve Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our principal executive offices are located at 500 Technology Square, Suite 901, Cambridge, Massachusetts 02139 and our telephone number is (617) 603-0070. Our website address is http://www.vervetx.com. The information contained on, or accessible through, our website does not constitute part of this Annual Report. We have included our website address in this Annual Report solely as an inactive textual reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Available Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our Internet address is http://www.vervetx.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act are available through the &#x201c;Investors&#x201d; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or SEC. Information on our website is not part of this Annual Report or any of our other securities filings unless specifically incorporated herein by reference. In addition, our filings with the SEC may be accessed through the SEC&#x2019;s Interactive Data Electronic Applications system at http://www.sec.gov. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 1A. Risk Factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Our future operating results could differ materially from the results described in this Annual Report on Form 10-K due to the risks and uncertainties described below. You should consider carefully the following information about risks below in evaluating our business. If any of the following risks actually occur, our business, financial conditions, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline. In addition, we cannot assure investors that our assumptions and expectations will prove to be correct. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> See page 3 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">of this Annual Report on Form 10-K for a discussion of some of the forward-looking statements that are qualified by these risk factors. Factors that could cause or contribute to such differences include those factors discussed below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Risks related to our financial position and need for additional capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We have incurred significant losses since our inception and have no products approved for sale. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Since our inception, we have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies, and have incurred significant operating losses. Our net losses were $120.3 million, $45.7 million and $19.3 million for the years ended December 31, 2021, 2020 and 2019, respectively. As of December 31, 2021, we had an accumulated deficit of $186.9 million. To date, we have generated no revenue and have financed our operations primarily through private placements of our preferred stock and from the sale of common stock in our initial public offering, or IPO. We have devoted all of our efforts to research and development, are still in the early stages of development of our research programs and have not commenced clinical development of any product candidates. We expect to continue to incur significant expenses and operating losses for the foreseeable future. Our operating expenses and net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">continue our current research programs and our preclinical development of product candidates from our current research programs; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">seek to identify additional research programs and additional product candidates; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">advance our existing and future product candidates into clinical development; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">initiate preclinical studies and clinical trials for any additional product candidates we identify and develop or expand development of existing programs into additional patient populations; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">maintain, expand, enforce, defend and protect our intellectual property portfolio and provide reimbursement of third-party expenses related to our patent portfolio; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">seek regulatory and marketing approvals for any of our product candidates that we develop; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">seek to identify, establish and maintain additional collaborations and license agreements, and the success of those collaborations and license agreements; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">make milestone payments to Beam Therapeutics Inc., or Beam, under our collaboration and license agreement with Beam, or the Beam Agreement, milestone payments to Acuitas Therapeutics Inc., or Acuitas, under our non-exclusive license agreement with Acuitas, or the Acuitas Agreement, and milestone payments or success payments to The Broad Institute, Inc., or Broad, and the President and Fellows of Harvard College, or Harvard, under our license agreement with Broad and Harvard (as amended, the Cas9 License Agreement), and under our other collaboration agreements or any additional future collaboration or license agreements that we obtain; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ultimately establish a sales, marketing, and distribution infrastructure to commercialize any drug products for which we may obtain marketing approval, either by ourselves or in collaboration with others; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">generate revenue from commercial sales of product candidates we may develop for which we receive marketing approval; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">further develop our base editing technology; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">hire additional personnel including research and development, clinical and commercial personnel; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">add operational, financial and management information systems and personnel, including personnel to support our product development; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">acquire or in-license products, intellectual property, medicines and technologies; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">satisfy any post-marketing requirements, such as a cardiovascular outcomes trial, or CVOT; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">establish commercial-scale current good manufacturing practices capabilities through a third-party or our own manufacturing facility; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">continue to operate as a public company. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, our expenses will increase if, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we are required by the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or the EMA, or other regulatory authorities to perform trials or studies in addition to, or different than, those expected; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">there are any delays in completing our clinical trials or the development of any of our product candidates; or </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">there are any third-party challenges to our intellectual property or we need to defend against any intellectual property-related claim. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Even if we obtain marketing approval for, and are successful in commercializing, one or more of our product candidates, we expect to incur substantial additional research and development and other expenditures to develop and market additional product candidates and/or to expand the approved indications of any marketed product. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We have never generated revenue from product sales and may never achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have not initiated clinical development of any product candidate and expect that it will be many years, if ever, before we have a product candidate ready for commercialization. To become and remain profitable, we must succeed in developing, obtaining the necessary regulatory approvals for and eventually commercializing a product or products that generate significant revenue. The ability to achieve this success will require us to be effective in a range of challenging activities, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">completing preclinical testing and clinical trials; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">identifying additional product candidates; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">obtaining marketing approval for these product candidates; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">manufacturing, marketing and selling any products for which we may obtain marketing approval; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">achieving market acceptance of products for which we may obtain marketing approval as viable treatment options. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are only in the preliminary stages of these activities and there is no assurance that we will be successful in these activities and, even if we are, may never generate revenues that are significant enough to achieve profitability. We are currently only in the preclinical stage of our research programs. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to generate revenue or achieve profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Even if we are able to generate revenue from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations. Our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement, and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We expect to devote substantial financial resources to our ongoing and planned activities, particularly as we conduct research, development and preclinical testing, initiate clinical trials and potentially seek marketing approval for our current and any additional product candidates we may develop. We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance our preclinical activities and initiate clinical trials. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution. Furthermore, we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. We currently do not have a credit facility or any committed sources of capital. If we are unable to raise capital or obtain adequate funds when needed or on acceptable terms, we may be forced to delay, limit, reduce or terminate our research and development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the costs of acquiring licenses for the delivery modalities that will be used with our product candidates; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the scope, progress, results and costs of discovery, preclinical and clinical development for any product candidates we may develop; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the cost and timing of completion of commercial-scale manufacturing activities; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights, and defending intellectual property-related claims, including claims of infringement, misappropriation or other violation of third-party intellectual property; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the costs, timing and outcome of regulatory review of the product candidates we may develop; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the costs of future commercialization activities, either by ourselves or in collaboration with others, including product sales, marketing, manufacturing, and distribution for any product candidates for which we receive marketing approval; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the costs of satisfying any post-marketing requirements, such as a CVOT; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the revenue, if any, received from commercial sales of product candidates we may develop for which we receive marketing approval; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the success of our license agreements and our collaborations; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our ability to establish and maintain additional collaborations on favorable terms, if at all; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the achievement of milestones or occurrence of other developments that trigger payments under any additional collaboration agreements we obtain; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the extent to which we acquire or in-license products, intellectual property and technologies; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the costs of operational, financial and management information systems and associated personnel; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the costs of operating as a public company. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, even if we successfully identify and develop product candidates and those are approved, we may not achieve commercial success. Our commercial revenues, if any, may not be sufficient to sustain our operations. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021, we had cash, cash equivalents and marketable securities of approximately $360.4 million. We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2024</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. As a result, we could deplete our capital resources sooner than we currently expect and could be forced to seek additional funding sooner than planned.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize any product candidates. We cannot be certain that additional funding will be available on acceptable terms, or at all. For example, while the potential impact and duration of the COVID-19 pandemic on the global economy and our business in particular may be difficult to assess or predict, the pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. We have no committed source of additional capital and, if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. We could be required to seek collaborators for product candidates we may develop at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to product candidates we may develop in markets where we otherwise would seek to pursue development or commercialization ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Until such time, if ever, as we can generate substantial revenues from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not have any source of committed external funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#x2019; interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#x2019; rights as a common stockholder. Any debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures, declaring dividends or encumbering our assets to secure future indebtedness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed or on terms acceptable to us, we would be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our limited operating history may make it difficult for stockholders to evaluate the success of our business to date and to assess our future viability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We commenced operations in 2018 and are an early-stage company. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our technology, identifying potential product candidates, securing intellectual property rights and undertaking preclinical studies. All of our research programs are still in the research or preclinical stage of development, and their risk of failure is high. We have not yet demonstrated our ability to initiate or complete any clinical trials, obtain marketing approvals, manufacture a clinical development or commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. In part because of this lack of experience, we cannot be certain that our ongoing preclinical studies will be completed on time or if the planned preclinical studies and clinical trials will begin or be completed on time, if at all. Consequently, any predictions stockholders make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing gene editing products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our limited operating history, particularly in light of the rapidly evolving genetic medicines field, may make it difficult to evaluate our technology and industry and predict our future performance. Our limited history as an operating company makes any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, as our business grows, we may encounter unforeseen expenses, restrictions, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our ability to use our net operating losses and research and development tax credit carryforwards to offset future taxable income or taxes may be subject to certain limitations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have a history of cumulative losses and anticipate that we will continue to incur significant losses in the foreseeable future; thus, we do not know whether or when we will generate taxable income necessary to utilize our net operating losses, or NOLs, or research and development tax credit carryforwards. As of December 31, 2021, we had federal NOL carryforwards of $124.7 million and state NOL carryforwards of $114.4 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law, a corporation that undergoes an &#x201c;ownership change,&#x201d; generally defin</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ed as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, is subject to limitations on its ability to utilize its pre-change NOLs and research and development tax credit carryforwards to offset post-change taxable income or taxes. We have not conducted a study to assess whether any such ownership changes have occurred. We may have experienced such ownership changes in the past and may experience such ownership changes in the future as a result of subsequent changes in our stock ownership (which may be outside our control). As a result, if, and to the extent that, we earn net taxable income, our ability to use our pre-change NOLs and research and development tax credit carryforwards to offset such taxable income may be subject to limitations. Our NOLs or credits may also be impaired under state law.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise become unavailable to offset future income tax liabilities. As described below in &#x201c;Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition,&#x201d; the Tax Cuts and Jobs Act, or the Tax Act, as amended by the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, included changes to U.S. federal tax rates and the rules governing NOL carryforwards that may significantly impact our ability to utilize our NOLs to offset taxable income in the future. For these reasons, even if we attain profitability, we may be unable to use a material portion of our NOLs and other tax attributes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Risks related to discovery and development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We are very early in our development efforts, and we have not yet completed investigational new drug, or IND-, enabling studies or initiated clinical development of any product candidate. As a result, we expect it will be many years before we commercialize any product candidate, if ever. If we are unable to advance our current or future product candidates into and through clinical trials, obtain marketing approval and ultimately commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are very early in our development efforts and have focused our research and development efforts to date on research efforts and preclinical development. Currently, all of our programs are in preclinical development or in discovery. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development, marketing approval and eventual commercialization of our product candidates, which may never occur. We have not yet generated revenue from product sales or otherwise, and we may never be able to develop or commercialize a marketable product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Commencing clinical trials in the United States is subject to acceptance by the FDA of an IND and finalizing the trial design based on discussions with the FDA and other regulatory authorities. We have had initial discussions with regulatory authorities with respect to our clinical trial design for our planned Phase 1 clinical trial of VERVE-101, but we have not yet made regulatory submissions with respect to the planned trial design and that trial design may change subject to those discussions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The FDA or other regulatory agencies may require us to complete additional preclinical studies or require us to satisfy other FDA requests prior to commencing clinical trials, which may delay the start of our first clinical trials beyond our planned timeline. As a result, we cannot be certain that we will be able to initiate our planned clinical trial of VERVE-101 in the second half of 2022. Even after we receive and incorporate guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence any clinical trial or change their position on the acceptability of our trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials, delay</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the enrollment of our clinical trials or impose stricter approval conditions than we currently expect. There are equivalent processes and risks applicable to clinical trial applications in other countries, including countries in the European Union.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Commercialization of any product candidates we may develop will require preclinical and clinical development; regulatory and marketing approval in multiple jurisdictions, including by the FDA and the EMA; manufacturing supply, capacity and expertise; a commercial organization; and significant marketing efforts. The success of product candidates we may identify and develop will depend on many factors, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies and minimally efficacious dose studies in animals, where applicable; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">effective INDs or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for any product candidates we may develop; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">successful enrollment and completion of clinical trials, including under the FDA&#x2019;s current Good Clinical Practices, or GCPs, current Good Laboratory Practices and any additional regulatory requirements from foreign regulatory authorities; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">positive results from our future clinical trials that support a finding of safety and effectiveness and an acceptable risk-benefit profile in the intended populations; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">receipt of marketing approvals from applicable regulatory authorities; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">establishment of arrangements through our own facilities or with third-party manufacturers for clinical supply and, where applicable, commercial manufacturing capabilities; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">establishment, maintenance, defense and enforcement of patent, trademark, trade secret and other intellectual property protection or regulatory exclusivity for any product candidates we may develop; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">commercial launch of any product candidates we may develop, if approved, whether alone or in collaboration with others; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">acceptance of the benefits and use of our product candidates we may develop, including method of administration, if and when approved, by patients, the medical community and third-party payers; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">effective competition with other therapies; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">maintenance of a continued acceptable safety, tolerability and efficacy profile of any product candidates we may develop following approval; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">establishment and maintenance of healthcare coverage and adequate reimbursement by payers. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we do not succeed in one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize any product candidates we may develop, which would materially harm our business. If we are unable to advance our product candidates to clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Gene editing, including base editing, is a novel technology that is not yet clinically validated as being safe and efficacious for human therapeutic use. The approaches we are taking to discover and develop novel therapeutics are unproven and may never lead to marketable products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are focused on developing medicines utilizing gene editing technology, which is new and largely unproven. The base editing technologies that we have licensed and that we are utilizing with VERVE-101 and in our ANGPTL3 program have not yet been clinically tested, nor are we aware of any clinical trials for safety or efficacy having been completed by third parties using our base editing or similar technologies. The scientific evidence to support the feasibility of developing product candidates based on gene editing technologies is both preliminary and limited. Successful development of our product candidates will require us to safely deliver a gene editor into target cells, optimize the efficiency and specificity of such product candidates and ensure the therapeutic selectivity of such product candidates. There can be no assurance that base editing technology will lead to the development of genetic medicines or that we will be successful in solving any or all of these issues.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our future success is highly dependent on the successful development of gene editing technologies, cellular delivery methods and therapeutic applications of that technology. We may decide to alter or abandon our initial programs as new data become available and we gain experience in developing gene editing therapeutics. We</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">cannot be sure that our technologies will yield satisfactory products that are safe and effective, scalable or profitable in our initial indications or any other indication we pursue. Adverse developments in the clinical development efforts of other gene editing technology companies could adversely affect our efforts or the perception of our product candidates by both investors and regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Similarly, another new gene editing technology that has not been discovered yet may be determined to be more attractive than base editing. Moreover, if we decide to develop gene editing technologies other than those involving base editing, we cannot be certain we will be able to obtain rights to such technologies. Although all of our founders who currently provide consulting and advisory services to us in the area of base editing technologies have assignment of inventions obligations to us with respect to the services they perform for us, these assignment of inventions obligations are subject to limitations and do not extend to their work in other fields or to the intellectual property arising from their employment with their respective academic and research institutions. To obtain intellectual property rights assigned by these founders to such institutions, we would need to enter into license agreements with such institutions, which may not be available on commercially reasonable terms or at all. Any of these factors could reduce or eliminate our commercial opportunity and could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Development activities in the field of gene editing are currently subject to a number of risks related to the ownership and use of certain intellectual property rights that are subject to patent interference proceedings in the United States and opposition proceedings in Europe. For additional information regarding the risks that may apply to our and our licensors&#x2019; intellectual property rights, see the section entitled &#x201c;&#x2014;Risks related to our intellectual property&#x201d; for more information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additionally, public perception and related media coverage relating to the adoption of new therapeutics or novel approaches to treatment, as well as ethical concerns related specifically to gene editing, may adversely influence the willingness of subjects to participate in clinical trials, or, if any therapeutic is approved, of physicians and patients to accept these novel and personalized treatments. Physicians, health care providers and third-party payors often are slow to adopt new products, technologies and treatment practices, particularly those that may also require additional upfront costs and training. Physicians may not be willing to undergo training to adopt these novel and potentially personalized therapies, may decide the particular therapy is too complex or potentially risky to adopt without appropriate training, and may choose not to administer the therapy. Further, due to health conditions, genetic profile or other reasons, certain patients may not be candidates for the therapies. In addition, responses by federal and state agencies, Congressional committees and foreign governments to negative public perception, ethical concerns or financial considerations may result in new legislation, regulations or medical standards that could limit our ability to develop or commercialize any product candidates, obtain or maintain regulatory approval or otherwise achieve profitability. New government requirements may be established that could delay or prevent regulatory approval of our product candidates under development. It is impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be. Based on these and other factors, health care providers and payors may decide that the benefits of these new therapies do not or will not outweigh their costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">The gene editing field is relatively new and is evolving rapidly. We are focusing our research and development efforts on gene editing using base editing technology, but other gene editing technologies may be discovered that provide significant advantages over base editing, which could materially harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To date, we have focused our efforts on gene editing technologies using base editing. Other companies have previously undertaken research and development of gene editing technologies using zinc finger nucleases, engineered meganucleases and transcription activator-like effector nucleases, but to date none have obtained marketing approval for a product candidate. There can be no certainty that base editing technology will lead to the development of genetic medicines or that other gene editing technologies will not be considered better or more attractive for the development of medicines. For example, Feng Zhang&#x2019;s group at the Massachusetts Institute of Technology, or MIT, and Broad, and, separately, Samuel Sternberg&#x2019;s group at Columbia University recently announced the discovery of the use of transposons, or &#x201c;jumping genes.&#x201d; Transposons can insert themselves into different places in the genome and can be programmed to carry specific DNA sequences to specific sites, without the need for making double-stranded breaks in DNA. Beam uses prime editing technology, which utilizes a CRISPR protein to target a mutation site in DNA and to nick a single strand of the target DNA. Guide RNA allows the CRISPR protein to recognize a DNA sequence that is complementary to the guide RNA and also carries a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">primer for reverse transcription and a replacement template. The reverse transcriptase copies the template sequence in the nicked site, installing the edit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A number of alternative approaches are being developed by others, including, for example, Intellia Therapeutics, Inc., which recently reported clinical data from a Phase 1 trial of a CRISPR/Cas9-based gene editing product candidate for the treatment of hereditary transthyretin amyloidosis with polyneuropathy. Similarly, other new gene editing technologies that have not been discovered yet may be more attractive than base editing. Moreover, if we decide to develop gene editing technologies other than those involving base editing, we cannot be certain we will be able to obtain rights to use such technologies. Any of these factors could reduce or eliminate our commercial opportunity, and could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We may not be successful in our efforts to identify and develop potential product candidates. If these efforts are unsuccessful, we may never become a commercial stage company or generate any revenues.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The success of our business depends primarily upon our ability to identify, develop and commercialize product candidates based on our approach to gene editing. All of our product development programs are still in the research or preclinical stage of development and we have not yet completed IND-enabling studies for any product candidate. Our research programs may fail to identify potential product candidates for clinical development for a number of reasons. Our research methodology may be unsuccessful in identifying additional potential product candidates, our potential product candidates may be shown to have harmful side effects in preclinical</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> experiments or animal model studies, they may not show promising signals of therapeutic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable or unlikely to receive marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If any of these events occur, we may be forced to abandon our research or development efforts for a program or programs, which would have a material adverse effect on our business, financial condition, results of operations and prospects. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful, which would be costly and time-consuming.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">The COVID-19 pandemic may affect our ability to initiate and complete preclinical studies, delay the initiation of future clinical trials, disrupt regulatory activities or have other adverse effects on our business and operations. In addition, this pandemic has adversely impacted economies worldwide, which could result in adverse effects on our business, operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The COVID-19 pandemic has caused, and may continue to cause, many governments to implement measures to slow the spread of the pandemic through quarantines, travel restrictions, heightened border scrutiny and other measures. The pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The future progression of the pandemic and its effects on our business and operations are uncertain. We and our contract manufacturing organizations, or CMOs, and contract research organizations, or CROs, have experienced a reduction in the capacity to undertake research-scale production and to execute some preclinical studies, and we have faced and may face disruptions that affect our ability to initiate and complete preclinical studies, and disruptions in procuring items that are essential for our research and development activities, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">raw materials and supplies used in the production and purification of messenger RNA, or mRNA, nucleic acids as well as lipids used in the production of lipid nanoparticles, or LNPs; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">raw materials and supplies used in the manufacture of any product candidates we may develop; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">laboratory supplies used in our preclinical studies; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">animals that are used for preclinical testing for which there are shortages because of ongoing efforts to address components of the pandemic. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We and our CROs and CMOs may also face disruptions related to our future IND-enabling studies and clinical trials arising from delays in preclinical studies, manufacturing disruptions, and the ability to obtain necessary institutional review board, or IRB, institutional biosafety committee, or IBC, or other necessary site approvals, as well as other delays at clinical trial sites.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The response to the COVID-19 pandemic may also redirect resources with respect to regulatory and intellectual property matters in a way that would adversely impact our ability to progress regulatory approvals and protect our intellectual property, for example by causing interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines. We have experienced delays with the FDA as a result of the COVID-19 pandemic. In addition, we may face impediments or delays to regulatory meetings and approvals due to measures intended to limit in-person interactions. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business, although for the reasons described above it has the potential to adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. If we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The risk of failure for each of our product candidates is high. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval. The time required to obtain approval from the FDA, EMA or other comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of regulatory authorities. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. We have not yet begun or completed a clinical trial of any product candidate. Clinical trials may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. Even if initial clinical trials in any of our product candidates we may develop are successful, these product candidates we may develop may fail to show the desired safety and efficacy in later stages of clinical development despite having successfully advanced through preclinical studies and initial clinical trials. There is a high failure rate for drugs and biologics proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later stage clinical trials even after achieving promising results in earlier stage clinical trials. Furthermore, even if the clinical trials are successful, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our planned INDs and other regulatory filings in the United States and abroad. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the outcome of our preclinical testing and studies will ultimately support the further development of our current or future product candidates or whether regulatory authorities will accept our proposed clinical programs. As a result, we may not be able to submit applications to initiate clinical development on the timelines we expect, if at all, and the submission of these applications may not result in regulatory authorities allowing clinical trials to begin. Furthermore, product candidates are subject to continued preclinical safety studies, which may be conducted concurrently with our clinical testing. The outcomes of these safety studies may delay the launch of or enrollment in future clinical trials and could impact our ability to continue to conduct our clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Clinical testing is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome. We cannot guarantee that any of our clinical trials will be conducted as planned or completed on schedule, or at all. A failure of one or more clinical trials can occur at any stage of testing, which may result from a multitude of factors, including, but not limited to, flaws in study design, dose selection issues, placebo effects, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Furthermore, the failure of any of our product candidates to demonstrate safety and efficacy in any clinical trial could negatively impact the perception of our other product candidates and/or cause the FDA, EMA or other regulatory authorities to require additional testing before approving any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our current and future product candidates could fail to receive regulatory approval for many reasons, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the FDA, EMA or other foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we may be unable to demonstrate to the satisfaction of the FDA, EMA or other foreign regulatory authorities that a product candidate is safe, pure and potent or effective for its proposed indication; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the results of clinical trials may not meet the level of statistical significance required by the FDA, EMA or other foreign regulatory authorities for approval; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we may be unable to demonstrate that a product candidate&#x2019;s clinical and other benefits outweigh its safety risks; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the FDA, EMA or other foreign regulatory authorities may disagree with our interpretation of data from clinical trials or preclinical studies; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a Biologics License Application, or BLA, to the FDA, or similar foreign submission to the EMA or other foreign regulatory authority, to obtain approval in the United States, the European Union or elsewhere; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the FDA, EMA or other foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the approval policies or regulations of the FDA, EMA or other foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market any product candidate we develop, which would significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The FDA, EMA and other comparable foreign regulatory authorities have substantial discretion in the approval process and determining when or whether regulatory approval will be obtained for any product candidate that we develop. Even if we believe the data collected from future clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA, EMA or any other comparable foreign regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may grant approval contingent on the performance of costly post-marketing clinical trials or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Additionally, outside of the United States, regulatory authorities may not approve the price we intend to charge for our products. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In response to the COVID-19 pandemic, the FDA issued guidance on March 18, 2020, and subsequently updated it on July 2, 2020, January 27, 2021, and August 30, 2021, to address the conduct of clinical trials during the pandemic. The guidance sets out a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical study report (or as a separate document) contingency measures implemented to manage the study, and any disruption of the study as a result of COVID-19; a list of all study participants affected by COVID-19-related study disruptions by a unique subject identifier and by investigational site, and a description of how the individual&#x2019;s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the study. In its most recent update to this guidance, FDA addresses questions received during the past year from clinical practitioners who are adapting their operations in a pandemic environment. These questions focused on, among other things, when to suspend, continue or initiate a trial and how to submit changes to protocols for INDs and handle remote site monitoring visits. There is no assurance that this guidance governing clinical studies during the pandemic will remain in effect or, even if it does, that it will help address the risks and challenges enumerated above. Accordingly, our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or might require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, slow down or halt our product candidate development and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">approval process and jeopardize our ability to seek and obtain the marketing approval required to commence product sales and generate revenue, which would cause the value of our company to decline and limit our ability to obtain additional financing if needed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accordingly, the COVID-19 pandemic may continue to significantly impact economies and financial markets worldwide, which could result in adverse effects on our business and operations, impact our ability to raise additional funds through public offerings and impact the volatility of our stock price and trading in our stock. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business and it has the potential to adversely affect our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">The outcome of preclinical studies and earlier-stage clinical trials may not be predictive of future results or the success of later preclinical studies and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are in the early stage of research in the development of our programs and have not conducted any clinical trials. As a result, our belief in the potential capabilities of our programs is based on early research and preclinical studies. However, the results of preclinical studies may not be predictive of the results of later preclinical studies or clinical trials, and the results of any early-stage clinical trials may not be predictive of the results of later clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. We have conducted several preclinical studies of our product candidates in NHPs, but we cannot be certain that the results observed in such studies will translate into the similar results in clinical trials of our product candidates in humans. Our future clinical trials may not ultimately be successful or support further clinical development of any product candidates we may develop. There is a high failure rate for product candidates proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving encouraging results in earlier studies. Any such setbacks in our clinical development could materially harm our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">regulators, IRBs, or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">regulators may decide that longer follow-up data are needed before they will consider our marketing application, which would delay our ability to obtain approval; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">regulators may decide the design of our clinical trials is flawed, for example if regulators do not agree with our chosen primary endpoints; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">regulators may decide to slow patient enrollment, resulting in delays to our ability to meet our timelines; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">preclinical testing may produce results based on which we may decide, or regulators may require us, to conduct additional preclinical studies before we proceed with certain clinical trials, limit the scope of our clinical trials, halt ongoing clinical trials or abandon product development programs; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">regulators, IRBs or ethics committees may require us to perform additional or unanticipated clinical trials to obtain approval or we may be subject to additional post-marketing testing requirements to maintain regulatory approval, such as a CVOT; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the cost of clinical trials of our product candidates may be greater than we anticipate; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, IRBs or ethics committees to suspend or terminate the trials; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">regulators may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a risk evaluation and mitigation strategy, or REMS. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are conducted or their ethics committees, by the data review committee or data safety monitoring board for such trial or by the FDA, EMA or other foreign regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, including those relating to the class of products to which our product candidates belong.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">be delayed in obtaining marketing approval for our product candidates; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">not obtain marketing approval at all; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">obtain approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">obtain approval with labeling or a REMS that includes significant use or distribution restrictions or safety warnings; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">be subject to additional post-marketing testing requirements; or </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">have the product removed from the market after obtaining marketing approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our development costs will also increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. We may also determine to change the design or protocol of one or more of our clinical trials, including to add additional patients or arms, which could result in increased costs and expenses and/or delays. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Preclinical drug development is uncertain. Some or all of our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain marketing approvals or commercialize these product candidates on a timely basis or at all, which would have an adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In order to obtain FDA approval to market a new biological product, we must demonstrate product purity (or product quality) as well as proof of safety and potency or efficacy in humans. To satisfy these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support an IND in the United States. We have not yet submitted an IND to the FDA for any of our product candidates. We cannot be certain of the timely completion or outcome of our preclinical testing and studies, and we cannot predict if the FDA will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">support the further development of these product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for any preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity, novelty and intended use of the product candidate, and often can be several years or more per product candidate. Delays associated with product candidates for which we are conducting preclinical testing and studies ourselves may cause us to incur additional operating expenses. Moreover, we may be affected by delays associated with the preclinical testing and studies of certain product candidates conducted by our potential partners over which we have no control. The commencement and rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including, for example:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">inability to generate sufficient preclinical or other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> data to support the initiation of clinical trials; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delays in reaching a consensus with regulatory agencies on study design. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Moreover, even if we do initiate clinical trials for other product candidates, our development efforts may not be successful, and clinical trials that we conduct or that third parties conduct on our behalf may not demonstrate product purity (or quality) as well as proof of safety and potency or efficacy necessary to obtain the requisite marketing approvals for any of our product candidates or product candidates employing our technology. Even if we obtain positive results from preclinical studies or initial clinical trials, we may not achieve the same success in future trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Identifying and qualifying patients to participate in clinical trials for our product candidates is critical to our success. Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients who remain in the trial until its conclusion. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside of the United States. Given the large patient population for atherosclerotic cardiovascular disease, or ASCVD, if we expand clinical development of VERVE-101 for the treatment of patients with established ASCVD, the number of patients that may be required for clinical trials could be high, we may not be able to enroll a sufficient number of patients and we may not be able to initiate or complete clinical trials of VERVE-101 for the treatment of patients with established ASCVD. Because of the small patient population for homozygous familial hypercholesterolemia, or HoFH, we may have difficulty enrolling patients and we may not be able to initiate or complete clinical trials for our ANGPTL3 program for the treatment of HoFH.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Patient enrollment is affected by a variety of other factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the prevalence and severity of the disease under investigation; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the eligibility criteria for the trial in question; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the perceived risks and benefits of the product candidate under trial; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the requirements of the trial protocols, which for products targeting cardiovascular disease, or CVD, could include up to 15 years of long-term patient follow-up; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the availability of existing treatments for the indications for which we are conducting clinical trials; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the efforts to facilitate timely enrollment in clinical trials; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the patient referral practices of physicians; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the ability to monitor patients adequately during and after treatment; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the proximity and availability of clinical trial sites for prospective patients; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">perceived negative public perception of gene editing; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the conduct of clinical trials by competitors for product candidates that treat the same indications or address the same patient populations as our product candidates; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the cost to, or lack of adequate compensation for, prospective patients. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other pharmaceutical and biotechnology companies have reported experiencing delays in enrollment in their ongoing clinical trials as a result of the COVID-19 pandemic, and we could also experience such delays. Our inability to locate and enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary regulatory approvals. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Even if we are able to enroll a sufficient number of patients for our future clinical trials, we may have difficulty maintaining patients in our clinical trials. Many of the patients who end up receiving placebo may perceive that they are not receiving the product candidate being tested, and they may decide to withdraw from our clinical trials to pursue alternative therapies rather than continue the trial. If we have difficulty enrolling or maintaining a sufficient number of patients to conduct our clinical trials, we may need to delay, limit or terminate clinical trials, any of which would harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If any of the product candidates we may develop, or the delivery modes we rely on to administer them, cause serious adverse events, undesirable side effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have not evaluated any product candidates in human clinical trials. Moreover, there have been only a limited number of clinical trials involving the use of gene editing technologies and none involving base editing technology similar to our technology. Furthermore, there has not been any gene editing product candidate that has received regulatory approval for use in humans. It is impossible to predict when or if any product candidates we may develop will prove safe in humans. There can be no assurance that gene editing technologies will not cause undesirable side effects, as improper editing of a patient&#x2019;s DNA could lead to lymphoma, leukemia or other cancers or other aberrantly functioning cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A significant risk in any gene editing product candidate is that &#x201c;off-target&#x201d; edits may occur, which could cause serious adverse events, undesirable side effects or unexpected characteristics. We cannot be certain that off-target editing will not occur in any of our planned or future clinical studies, and the lack of observed side effects in preclinical studies does not guarantee that such side effects will not occur in human clinical studies. There is also the potential risk of delayed or late presentation of adverse events following exposure to gene editors due to the potential permanence of edits to DNA or due to other components of product candidates used to carry the genetic material. Further, because gene editing makes a permanent change, the therapy cannot be withdrawn, even after a side effect is observed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We intend to use LNPs to deliver our gene editors to the liver. LNPs have recently been used to deliver mRNA in humans, including the COVID-19 vaccines developed by Pfizer Inc., or Pfizer, and BioNTech SE and by Moderna, Inc., and LNPs are being used to deliver mRNA for therapeutic use in clinical trials. LNPs have the potential to induce liver injury and/or initiate a systemic inflammatory response, either of which could potentially be fatal. While we aim to continue to optimize our LNPs, there can be no assurance that our LNPs will not have undesired effects. Our LNPs could contribute, in whole or in part, to one or more of the following: liver injury, immune reactions, infusion reactions, complement reactions, opsonization reactions, antibody reactions including IgA, IgM, IgE or IgG or some combination thereof, or reactions to the polyethylene glycol, or PEG, from some lipids or PEG otherwise associated with the LNP. Certain aspects of our investigational medicines may induce immune reactions from either the mRNA or the lipid as well as adverse reactions within liver pathways or degradation of the mRNA or the LNP, any of which could lead to significant adverse events in one or more of our future clinical trials. Some of these types of adverse effects have been observed for other LNPs. There may be uncertainty as to the underlying cause of any such adverse event, which would make it difficult to accurately predict side effects in future clinical trials and would result in significant delays in our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our GalNAc-LNPs are a novel delivery mechanism for delivery of gene editors to the liver and have not yet been used in humans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If any product candidates we develop are associated with serious adverse events, undesirable side effects or unexpected characteristics, we may need to abandon their development or limit development to certain uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, any of which would have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If in the future we are unable to demonstrate that any of the above adverse events were caused by factors other than our product candidate, the FDA, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, any product candidates we are able to develop for any or all targeted indications. They could also revoke a marketing authorization if a serious safety concern is identified in any post-marketing follow up studies. Even if we are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of any product candidate we may develop, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to identify and develop product candidates, and may harm our business, financial condition, result of operations, and prospects significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Adverse public perception of genetic medicines, and gene editing and base editing in particular, may negatively impact regulatory approval of, and/or demand for, our potential products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our programs involve editing the human genome. The clinical and commercial success of our product candidates will depend in part on public understanding and acceptance of the use of gene editing therapy for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that gene editing is unsafe, unethical or immoral, and, consequently, our product candidates may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, gene editing technology is subject to public debate and heightened regulatory scrutiny due to ethical concerns.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair our development and commercialization of product candidates or demand for any product candidates we may develop. Adverse events in our preclinical studies or clinical trials or those of our licensors, partners or competitors or of academic researchers utilizing gene editing technologies, even if not ultimately attributable to product candidates we may identify and develop, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of potential product candidates we may identify and develop, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. Use of gene editing technology by a third party or government to develop biological agents or products that threaten U.S. national security could similarly result in such negative impacts to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Interim and preliminary results from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures, which could result in material changes in the final data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">From time to time, we may publish or report interim or preliminary results from our clinical trials. Interim results from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become available. For example, our planned clinical trial design for our Phase 1 clinical trial of VERVE-101 contemplates an interim analysis of three-month data from the trial and these data could be materially different than the data reported at the end of the study. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. Preliminary or top-line results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could be material and could significantly harm our reputation and business prospects and may cause the trading price of our common stock to fluctuate significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Genetic medicines are complex and difficult to manufacture. We could experience delays in satisfying regulatory authorities or production problems that result in delays in our development programs, limit the supply of our product candidates we may develop, or otherwise harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any product candidates we may develop will likely require processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as the product candidates we intend to develop generally cannot be fully characterized. As a result, assays of the finished product candidate may not be sufficient to ensure that the product candidate will perform in the intended manner. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims or insufficient inventory or potentially delay progression of our potential IND filings. If we successfully develop product candidates, we may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA, EMA or other comparable applicable foreign standards or specifications with consistent and acceptable production yields and costs. In addition, the product candidates we may develop will require complicated delivery modalities, such as LNPs, which will introduce additional complexities in the manufacturing process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, the FDA, the EMA and other regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials or product launches, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to manage our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Given the nature of biologics manufacturing, there is a risk of contamination during manufacturing. Any contamination could materially harm our ability to produce product candidates on schedule and could harm our results of operations and cause reputational damage. Some of the raw materials that we anticipate will be required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of any product candidates we may develop could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially harm our development timelines and our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any problems in our manufacturing process or the facilities with which we contract could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs. Problems in third-party manufacturing process or facilities also could restrict our ability to ensure sufficient clinical material for any clinical trials we may be conducting or are planning to conduct and meet market demand for any product candidates we develop and commercialize.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the drug could be compromised.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Clinical trials of our product candidates are conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If one or more of our product candidates receives regulatory approval, and we, or others, later discover that they are less effective than previously believed, or cause undesirable side effects, a number of potentially significant negative consequences could result, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">withdrawal or limitation by regulatory authorities of approvals of such product; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">seizure of the product by regulatory authorities; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">recall of the product; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">restrictions on the marketing of the product or the manufacturing process for any component thereof; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">requirement by regulatory authorities of additional warnings on the label, such as a &#x201c;black box&#x201d; warning or contraindication; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">requirement that we implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">commitment to expensive post-marketing studies as a prerequisite of approval by regulatory authorities of such product; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the product may become less competitive; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">initiation of regulatory investigations and government enforcement actions; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">initiation of legal action against us to hold us liable for harm caused to patients; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">harm to our reputation and resulting harm to physician or patient acceptance of our products. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any of these events could prevent us from achieving or maintaining market acceptance of a particular product candidate, if approved, and could significantly harm our business, financial condition, and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Because we have limited financial and managerial resources, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Failure to allocate resources or capitalize on strategies in a successful manner will have an adverse impact on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We plan to conduct clinical trials at sites outside the United States. The FDA may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We may conduct one or more of our clinical trials with one or more trial sites that are located outside the United States, including our planned Phase 1 trial of VERVE-101. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and be performed by qualified investigators in accordance with ethical principles. The FDA must be able to validate the data from the trial through an onsite inspection, if necessary. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, whether the FDA accepts the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and could delay or permanently halt our development of the applicable product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, conducting clinical trials outside the United States could have a significant adverse impact on us. Risks inherent in conducting international clinical trials include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">clinical practice patterns and standards of care that vary widely among countries; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">non-U.S. regulatory authority requirements that could restrict or limit our ability to conduct our clinical trials; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">administrative burdens of conducting clinical trials under multiple non-U.S. regulatory authority schema; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">foreign exchange fluctuations; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">diminished protection of intellectual property in some countries. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Risks related to our dependence on third parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical testing, and these third parties may not perform satisfactorily.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We do not expect to independently conduct all aspects of our product manufacturing, research and preclinical and clinical testing. We currently rely, and expect to continue to rely, on third parties with respect to many of these items, including CMOs for the manufacturing of any product candidates we test in preclinical or clinical development, as well as CROs for the conduct of our animal testing and research. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it could delay our product development activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations and study protocols. For example, for product candidates that we develop and commercialize on our own, we will remain responsible for ensuring that each of our IND-enabling studies and clinical trials are conducted in accordance with the study plan and protocols.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Although we intend to design the clinical trials for any product candidates we may develop, CROs will conduct some or all of the clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future preclinical studies and clinical trials will also result in less direct control over the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">have staffing difficulties; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">fail to comply with contractual obligations; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">experience regulatory compliance issues; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">undergo changes in priorities or become financially distressed; or </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">form relationships with other entities, some of which may be our competitors. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">These factors may materially adversely affect the willingness or ability of third parties to conduct our preclinical studies and clinical trials and may subject us to unexpected cost increases that are beyond our control. If the CROs and other third parties do not perform preclinical studies and future clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of any product candidates we may develop may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates or our development programs may be materially and irreversibly harmed. If we are unable to rely on preclinical and clinical data collected by our CROs and other third parties, we could be required to repeat, extend the duration of or increase the size of any preclinical studies or clinical trials we conduct and this could significantly delay commercialization and require greater expenditures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, the preclinical studies and clinical trials required to support future IND submissions and approval of any product candidates we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Manufacturing biologic products is complex and subject to product loss for a variety of reasons. We contract with third parties for the manufacture of our product candidates for preclinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of VERVE-101 and our other product candidates for preclinical and clinical testing, as well as for commercial manufacture if any of our product candidates receive marketing approval. We also rely on these third parties for packaging, labeling, sterilization, storage, distribution and other production logistics. This reliance on third parties increases the risk that we will not have sufficient</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">reliance on the third party for regulatory compliance and quality assurance; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the possible breach of the manufacturing agreement by the third party; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We or our third-party manufacturers may encounter shortages in the raw materials or active pharmaceutical ingredients, or API, necessary to produce our product candidates in the quantities needed for our clinical trials or, if our product candidates are approved, in sufficient quantities for commercialization or to meet an increase in demand, as a result of capacity constraints or delays or disruptions in the market for the raw materials or API, including shortages caused by the purchase of such raw materials or API by our competitors or others. The failure of us or our third-party manufacturers to obtain the raw materials or API necessary to manufacture sufficient quantities of our product candidates may have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with current good manufacturing practices, or cGMP. Our third-party manufacturers are subject to inspection and approval by regulatory authorities before we can commence the manufacture and sale of any of our product candidates, and thereafter subject to ongoing inspection from time to time. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in regulatory actions, such as the issuance of FDA Form 483 notices of observations, warning letters or sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Manufacturing biologic products, such as VERVE-101, is complex, especially in large quantities. Biologic products must be made consistently and in compliance with a clearly defined manufacturing process. Accordingly, it is essential to be able to validate and control the manufacturing process to assure that it is reproducible. The manufacture of biologics is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the product process. We have not yet scaled up the manufacturing process for any of our product candidates for potential commercialization. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could harm our results of operations and cause potential reputational damage. Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply or a source for bulk drug substance nor do we have any agreements with third-party manufacturers for long-term commercial supply. If any of our future contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement or be unable to reach agreement with an alternative manufacturer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If any third-party manufacturer of our product candidates is unable to increase the scale of its production of our product candidates, and/or increase the product yield of its manufacturing, then our costs to manufacture the product candidate may increase and commercialization may be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of any current or future product candidates that we may develop, our third-party manufacturers will be required to increase their production and optimize their manufacturing processes while maintaining the quality of the product. The transition to larger scale production could prove difficult. In addition, if our third-party manufacturers are not able to optimize their manufacturing processes to increase the product yield for our product candidates, or if they are unable to produce increased amounts of our product candidates while maintaining the quality of the product, then we may not be able to meet the demands of clinical trials or market demands, which could decrease our ability to generate profits and have a material adverse impact on our business and results of operation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We have entered into collaborations, and may enter into additional collaborations, with third parties for the research, development, manufacture and commercialization of programs or product candidates. If these collaborations are not successful, our business could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As part of our strategy, we have entered into collaborations and intend to seek to enter into additional collaborations with third parties for one or more of our programs or product candidates. For example, in April 2019, we entered into the Beam Agreement to exclusively license certain of Beam&#x2019;s base editing, gene editing and delivery technology against certain cardiovascular targets for use in our product candidates, and in October 2020, we entered into the Acuitas Agreement to license from Acuitas its LNP delivery technology. Our likely collaborators for any other collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. We have under the Beam Agreement, and we may have under any other arrangements that we may enter into with any third parties, limited control over the amount and timing of resources that collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements may depend on our collaborators&#x2019; abilities to successfully perform the functions assigned to them in these arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Collaborations that we enter into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators. Collaborations pose a number of risks, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators may not perform their obligations as expected; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators may not pursue development of our product candidates or may elect not to continue or renew development programs based on results of clinical trials or other studies, changes in the collaborators&#x2019; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators may not pursue commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew commercialization programs based on results of clinical trials or other studies, changes in the collaborators&#x2019; strategic focus or available funding, or external factors, such as an acquisition, that may divert resources or create competing priorities; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators may delay preclinical studies and clinical trials, provide insufficient funding for a preclinical study or clinical trial program, stop a preclinical study or clinical trial or abandon a product candidate, repeat or conduct new preclinical studies or clinical trials or require a new formulation of a product candidate for preclinical or clinical testing; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such product candidates on a discretionary basis; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a collaborator may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">disagreements with collaborators, including disagreements over intellectual property or proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators may not properly obtain, maintain, enforce, defend or protect our intellectual property or proprietary rights or may use our proprietary information in such a way as to potentially lead to disputes or legal proceedings that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators may infringe, misappropriate or otherwise violate the intellectual property or proprietary rights of third parties, which may expose us to litigation and potential liability; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborations may be terminated for the convenience of the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all. If any current or future collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our product candidates could be delayed and we may need additional resources to develop our product candidates. All of the risks relating to product development, regulatory approval and commercialization described in this &#34;Risk Factors&#34; section also apply to the activities of our collaborators.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Collaboration agreements may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. For example, upon execution of the Beam Agreement, we issued 276,075 shares of our common stock to Beam. In addition, under the Cas9 License Agreement, we issued 138,037 shares of our common stock to Broad and Harvard. Broad and Harvard also had anti-dilution rights, pursuant to which we issued Broad and Harvard an additional 309,278 shares of our common stock in the aggregate following the completion of preferred stock financings. We also issued 878,098 additional shares of common stock to Broad and Harvard upon the closing of our initial public offering pursuant to the Cas9 License Agreement. We are also obligated to pay to Harvard and Broad tiered success payments in the event our average market capitalization exceeds specified thresholds ascending from a high nine-digit dollar amount to $10.0 billion, or sale of our company for consideration in excess of those thresholds. In the event of a change of control of our company or a sale of our company, we are required to pay any related success payment in cash within a specified period following such event. Otherwise, the success payments may be settled at our option in either cash or shares of our common stock, or a combination of cash and shares of our common stock. In September 2021, we notified Harvard and Broad that our average market capitalization exceeded three specified thresholds as of a relevant measurement date and aggregate success payments of approximately $6.3 million became payable under the Cas9 License Agreement, which we settled in cash in the November 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration agreement will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#x2019;s evaluation of several factors. If we license rights to any</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">product candidates we or our collaborators may develop, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additionally, subject to its contractual obligations to us, if a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If we are not able to establish or maintain collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans and our business could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We face significant competition in attracting appropriate collaborators, and a number of more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#x2019;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, EMA or other regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, the terms of any existing collaboration agreements, and industry and market conditions generally. The collaborator may also have the opportunity to collaborate on other product candidates or technologies for similar indications and will have to evaluate whether such a collaboration could be more attractive than the one with us for our product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We may also be restricted under existing or future license agreements from entering into agreements on certain terms with potential collaborators.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Collaborations are complex and time-consuming to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology companies has reduced the number of potential future collaborators.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We depend on single-source suppliers for some of the components and materials used in our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We depend on single-source suppliers for some of the components and materials used in our product candidates. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes and finished goods exposes us to several risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delays or interruptions, which would damage our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we have to switch to a replacement supplier, the manufacture and delivery of any product candidates we may develop could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single source components and materials used in our products, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Risks related to our intellectual property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If we or our licensors are unable to obtain, maintain, defend and enforce patent rights that cover our gene editing technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our success depends in large part on our ability to obtain, maintain, defend, and enforce protection of the intellectual property we may own solely and jointly with others or may license from others, particularly patents, in the United States and other countries with respect to proprietary technology and product candidates we develop. It is difficult and costly to protect our gene editing technologies and product candidates, and we may not be able to ensure their protection. Our ability to stop unauthorized third parties from making, using, selling, offering to sell, importing or otherwise commercializing our product candidates we may develop, or operatively similar products, is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates that are important to our business and by in-licensing intellectual property related to our technologies and product candidates. If we are unable to obtain or maintain patent protection with respect to any proprietary technology or product candidate, our business, financial condition, results of operations and prospects could be materially harmed. Failure to obtain protection including patent protection, may be a result of specific legal and factual circumstances that may preclude the availability of protection for our product candidates in the United States or any given country. For example, inadequate, faulty or erroneous patent prosecution may result in diminution, loss or unavailability of patent rights that adequately cover our products. Patent disclosures and claims that are intended to cover our product candidates that are sufficient or allowable in one country may not be sufficient or allowable in another country. The requirements for filing a patent application in the United States may not be sufficient to support a patent filing in a country or region outside the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, defend or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain, enforce and defend the patents, covering technology that we license from third parties. Therefore, these in-licensed patents and applications may not be prepared, filed, prosecuted, maintained, defended and enforced in a manner consistent with the best interests of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The patent position of pharmaceutical and biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. The field of gene editing especially has been the subject of extensive patenting activity and litigation. In addition, the scope of patent protection outside of the United States is uncertain and laws of foreign countries may not protect our rights to the same extent as the laws of the United States or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Further, no earlier that October 1, 2022, European applications will soon have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (&#x201c;UPC&#34;). This will be a significant</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">change in European patent practice.  As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">With respect to both owned and in-licensed patent rights, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not published at all. Therefore, neither we nor our licensors can know with certainty whether either we or our licensors were the first to make the inventions claimed in the patents and patent applications we own or in-license now or in the future, or that either we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our owned and in-licensed patent rights are highly uncertain. Moreover, our owned and in-licensed pending and future patent applications may not result in patents being issued which protect our technology and product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents and our ability to obtain, protect, maintain, defend and enforce our patent rights, narrow the scope of our patent protection and, more generally, could affect the value or narrow the scope of our patent rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Moreover, we or our licensors may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our owned and in-licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our competitors may be able to circumvent our owned or in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. As a result, our owned and in-licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar or identical to any of our technology and product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our rights to develop and commercialize our gene editing technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We depend on intellectual property licensed from third parties, and our licensors may not always act in our best interest. If we fail to comply with our obligations under our intellectual property licenses, if the licenses are terminated, or if disputes regarding these licenses arise, we could lose significant rights that are important to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have licensed and are dependent on certain patent rights and proprietary technology from third parties that are important or necessary to the development of our gene editing technology and product candidates. For example, we are a party to the Beam Agreement, the Cas9 License Agreement, the Acuitas Agreement and other</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">license agreements, pursuant to which we in-license key patents and patent applications for our gene editing technology, LNP technology and product candidates. These license agreements impose various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, our licensors may have the right to terminate our license, in which event we would not be able to develop or market our gene editing technology or product candidates covered by the intellectual property licensed under these agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our gene editing technology and product candidates in the future. Some licenses granted to us are expressly subject to certain preexisting rights held by the licensor or certain third parties. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in certain territories or fields. If we determine that rights to such excluded fields are necessary to commercialize our product candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to continue developing, manufacturing or marketing our product candidates. We may not be able to obtain such a license on an exclusive basis, on commercially reasonable terms, or at all, which could prevent us from commercializing our product candidates or allow our competitors or others the chance to access technology that is important to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, pursuant to the Cas9 License Agreement, under certain specific circumstances, Harvard and Broad may grant a license to the patents that are the subject of such license agreements to a third party in the same field as such patents are licensed to us. Such third party may then have full rights that are the subject of the Cas9 License Agreement, which could impact our competitive position and enable a third party to commercialize products similar to our potential future product candidates and technology. Any grant of rights to a third party in this scenario would narrow the scope of our exclusive rights to the patents and patent applications we have in-licensed from Harvard and Broad.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We do not have complete control in the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the technology that we license from third parties. It is possible that our licensors&#x2019; enforcement of patents against infringers or defense of such patents against challenges of validity or claims of enforceability may be less vigorous than if we had conducted them ourselves, or may not be conducted in accordance with our best interests. We cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. If our licensors fail to prosecute, maintain, enforce and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, our right to develop and commercialize any of our product candidates we may develop that are the subject of such licensed rights could be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights to our in-licensed patents, the license granted to us in jurisdictions where the consent of a co-owner is necessary to grant such a license may not be valid and such co-owners may be able to license such patents to our competitors, and our competitors could market competing products and technology. In addition, our rights to our in-licensed patents and patent applications are dependent, in part, on inter-institutional or other operating agreements between the joint owners of such in-licensed patents and patent applications. If one or more of such joint owners breaches such inter-institutional or operating agreements, our rights to such in-licensed patents and patent applications may be adversely affected. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Furthermore, inventions contained within some of our in-licensed patents and patent applications were made using U.S. government funding. We rely on our licensors to ensure compliance with applicable obligations arising from such funding, such as timely reporting, an obligation associated with our in-licensed patents and patent applications. The failure of our licensors to meet their obligations may lead to a loss of rights or the unenforceability of relevant patents. For example, the U.S. government could have certain rights in such in-licensed patents, including a non-exclusive license authorizing the U.S. government to use the invention or to have others use the invention on its behalf. If the U.S. government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. The U.S. government&#x2019;s rights may also permit it to disclose the funded inventions and technology to third parties and to exercise march-in rights to use or allow third parties to use the technology we have licensed that was developed using U.S. government funding. The U.S. government may also exercise its march-in rights if it determines that action is necessary because we or our licensors failed to achieve practical application of the U.S. government-funded technology, because action is</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">necessary to alleviate health or safety needs, to meet requirements of federal regulations or to give preference to U.S. industry. In addition, our rights in such in-licensed U.S. government-funded inventions may be subject to certain requirements to manufacture product candidates embodying such inventions in the United States. Any of the foregoing could harm our business, financial condition, results of operations and prospects significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the event any of our third-party licensors determine that, in spite of our efforts, we have materially breached a license agreement or have failed to meet certain obligations thereunder, it may elect to terminate the applicable license agreement or, in some cases, one or more license(s) under the applicable license agreement, and such termination would result in us no longer having the ability to develop and commercialize product candidates and technology covered by that license agreement or license. In the event of such termination of a third-party in-license, or if the underlying patents under a third-party in-license fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our owned patent applications and in-licensed patents and patent applications and other intellectual property may be subject to priority or inventorship disputes, interferences and similar proceedings. If we or our licensors are unsuccessful in any of these proceedings, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, or to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop, which could have a material adverse impact on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Certain of the U.S. patents and one U.S. patent application to which we hold an option are co-owned by Broad and MIT, and in some cases co-owned by Broad, MIT and Harvard, which we refer to together as the Boston Licensing Parties, and were involved in U.S. Interference No. 106,048 with one U.S. patent application co-owned by the University of California, the University of Vienna, and Emmanuelle Charpentier, which we refer to together as CVC. On September 10, 2018, the Court of Appeals for the Federal Circuit, or the CAFC, affirmed the Patent Trial and Appeal Board of the USPTO&#x2019;s, or PTAB&#x2019;s, holding that there was no interference-in-fact. An interference is a proceeding within the USPTO to determine priority of invention of the subject matter of patent claims filed by different parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On June 24, 2019, the PTAB declared an interference (U.S. Interference No. 106,115) between 10 U.S. patent applications that are co-owned by CVC, and 13 U.S. patents and one U.S. patent application (that are co-owned by the Boston Licensing Parties). In the declared interference, CVC has been designated as the junior party and the Boston Licensing Parties have been designated as the senior party. On February 28, 2022, the PTAB held that the Boston Licensing Parties had priority over CVC with respect to Count 1 of the interference: a single RNA CRISPR-Cas9 system that functions in eukaryotic cells. As a result, CVC&#x2019;s patent applications involved in this interference were deemed unpatentable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On December 20, 2020, the PTAB declared an interference (U.S. Interference No. 106,126) between one U.S. patent application owned by Toolgen, Inc. and 14 U.S. patents and two U.S. patent applications that are co-owned by the Boston Licensing Parties. In the declared interference, Boston Licensing Parties have been designated as the junior party and Toolgen, Inc. has been designated as the senior party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On June 21, 2021, the PTAB declared an interference (U.S. Interference No. 106,133) between one U.S. patent application owned by Sigma-Aldrich Co., LLC and 14 U.S. patents and two U.S. patent applications that are co-owned by the Boston Licensing Parties. In the declared interference, Boston Licensing Parties have been designated as the junior party and Sigma-Aldrich Co., LLC has been designated as the senior party.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As a result of the declaration of interference, an adversarial proceeding in the USPTO before the PTAB has been initiated, which is declared to ultimately determine priority, specifically and which party was first to invent the claimed subject matter. An interference is typically divided into two phases. The first phase is referred to as the motions or preliminary motions phase while the second is referred to as the priority phase. In the first phase, each party may raise issues including but not limited to those relating to the patentability of a party&#x2019;s claims based on prior art, written description, and enablement. A party also may seek an earlier priority benefit or may challenge whether the declaration of interference was proper in the first place. Priority, or a determination of who first invented the commonly claimed invention, is determined in the second phase of an interference. Although we cannot predict with any certainty how long each phase will actually take, each phase may take approximately a year or longer before a decision is made by the PTAB. It is possible for motions filed in the preliminary motions phase to be dispositive of the interference proceeding, such that the second priority phase is not reached.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There can be no assurance that these pending U.S. interference proceedings will be resolved in favor of the Boston Licensing Parties. If the 106,126, or 106,133 interference resolves in favor Toolgen, Inc., or Sigma-Aldrich Co., LLC, respectively, or if the Boston Licensing Parties&#x2019; patents and patent application are narrowed, invalidated, or held unenforceable, we will lose the ability to license the optioned patents and patent application and our ability to commercialize our product candidates may be adversely affected if we cannot obtain a license to relevant third-party patents that cover our product candidates. We may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our gene editing technology or product candidates or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We or our licensors may also be subject to claims that former employees, collaborators, or other third parties have an interest in our owned patent applications or in-licensed patents or patent applications or other intellectual property as an inventor or co-inventor. If we are unable to obtain an exclusive license to any such third-party co-owners&#x2019; interest in such patent applications, such co-owners rights may be subject, or in the future subject, to assignment or license to other third parties, including our competitors. In addition, we may need the cooperation of any such co-owners to enforce any patents that issue from such patent applications against third parties, and such cooperation may not be provided to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we or our licensors are unsuccessful in any interference proceedings or other priority, validity (including any patent oppositions) or inventorship disputes to which we or they are subject, we may lose valuable intellectual property rights through the loss of one or more of our owned, licensed or optioned patents, or such patent claims may be narrowed, invalidated or held unenforceable, or through loss of exclusive ownership of or the exclusive right to use our owned or in-licensed patents. In the event of loss of patent rights as a result of any of these disputes, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our patent claims could limit our ability to stop others from using or commercializing similar or identical technology and product candidates. Even if we or our licensors are successful in an interference proceeding, other similar priority disputes, or inventorship or ownership disputes, it could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations or prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If we fail to comply with our obligations in our intellectual property licenses arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are party to agreements, and we may enter into additional arrangements, with third parties that may impose diligence, development and commercialization timelines, milestone payment, royalty, insurance and other obligations on us. We have existing agreements, pursuant to which we are obligated to pay royalties on net product sales of product candidates or related technologies to the extent they are covered by the agreements. If we fail to comply with such obligations under current or future agreements, our counterparties may have the right to terminate these agreements or require us to grant them certain rights. Such an occurrence could materially adversely affect the value of any product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, which would have a material adverse effect on our business, financial condition, results of operations and prospects. While we still face all of the risks described herein with respect to those agreements, we cannot prevent third parties from also accessing those technologies. In addition, our licenses may place restrictions on our future business opportunities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the scope of rights granted under the agreement and other interpretation related issues; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the sublicensing of patent and other rights under our collaborative development relationships; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our diligence obligations under the agreement and what activities satisfy those diligence obligations; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the priority of invention of patented technology. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the intellectual property or intellectual property rights we in-license. If other third parties have ownership rights to intellectual property or intellectual property rights we in-license, they may be able to license such intellectual property or intellectual property rights to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product candidates and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We currently have rights to intellectual property, through licenses from third parties, to identify and develop product candidates, and we expect to seek to expand our product candidate pipeline in part by in-licensing the rights to key technologies. Although we have succeeded in licensing technologies from third-party licensors including Harvard, Broad, Beam, and Acuitas in the past, we cannot assure our stockholders that we will be able to in-license or acquire the rights to any product candidates or technologies from third parties on acceptable terms or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Various third parties practice in competitive technology areas and may have issued patents or patent applications that will issue as patents in the future, which could impede or preclude our ability to commercialize our product candidates. For any third-party patents that could be relevant to our product candidates, we rely in part on the &#x201c;safe harbor&#x201d; or research exemption under 35 U.S.C. &#167; 271(e)(1), which exempts from patent infringement activities related to pursuing FDA approval for a drug product. However, while U.S. patent law provides such a &#x201c;safe harbor&#x201d; to our clinical product candidates under this provision, that exemption expires when an IND or BLA is submitted. Given the uncertainty of clinical trials, we cannot be certain of the timing of their completion and it is possible that we may submit a BLA for one of our product candidates at a time when one or more relevant third-party patents is in force.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">It may therefore be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales or an</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Furthermore, there has been extensive patenting activity in the field of gene editing, and pharmaceutical companies, biotechnology companies, and academic institutions are competing with us or are expected to compete with us in the field of gene editing technology and filing patent applications potentially relevant to our business, and there may be third-party patent applications that, if issued, may allow the third party to circumvent our patent rights. Because of the large number of patents issued and patent applications filed in our field, these and other third parties could allege they have patent rights encompassing our product candidates, technologies or methods. In order to market our product candidates, we may find it necessary or prudent to obtain licenses from such third-party intellectual property holders. However, we may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for product candidates and gene editing technology we may develop. We may also require licenses from third parties for certain gene editing technologies including certain delivery and gene editing compositions and methods that we are evaluating, or may in the future evaluate, for use with product candidates we may develop. In addition, some of our owned patent applications and in-licensed patents and patent applications may be determined to be co-owned with third parties. With respect to any patents co-owned with third parties, we may require licenses to such co-owners&#x2019; interest to such patents. If we are unable to obtain an exclusive license to any such third-party co-owners&#x2019; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additionally, we may collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#x2019;s rights in technology resulting from the collaboration. Even if we hold such an option, we may be unable to negotiate a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, the licensing or acquisition of third-party intellectual property rights is a highly competitive area, and a number of more established companies are also pursuing strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could harm our business, financial condition, results of operations and prospects significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additionally, if we fail to comply with our obligations under license agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology or impede, or delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">The intellectual property landscape around genome editing technology, including base editing, is highly dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and may prevent, delay or otherwise interfere with our product discovery and development efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our commercial success depends upon our ability and the ability of our collaborators to research, develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. The field of genome editing, especially in the area of base editing technology, is still in its infancy, and no such product candidates have reached the market. Due to the intense research and development that is taking place by several companies, including us and our competitors, in this field, the intellectual property landscape is evolving and in flux, and it may remain uncertain for the coming years. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights as well as administrative proceedings for challenging patents, including interference, derivation, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. There may be significant intellectual property related litigation and proceedings relating to our owned and in-licensed, and other third party, intellectual property and proprietary rights in the future. We may be subject to and may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our gene editing platform technology and any product candidates we may develop, including interference proceedings, post-grant review,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the European Patent Office. Numerous U.S. and foreign issued patents and pending patent applications that are owned by third parties exist in the fields in which we are developing our product candidates and they may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our gene editing technology and product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of therapies, products or their methods of use or manufacture. We are aware of certain third-party patent applications that, if issued, may be construed to cover our gene editing technology and product candidates. There may also be third-party patents of which we are currently unaware with claims to technologies, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">It is possible that we have failed to identify relevant third-party patents or applications that our product candidates and programs may infringe. Because patent applications can take many years to issue, may be confidential for 18 months or more after filing and can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use, sale or importation of any product candidates we may develop or our technology, and we may not be aware of such patents. Furthermore, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the United States may remain confidential until a patent issues. Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to any product candidates we may develop and our technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patent applications may issue with claims of relevance to our technology. In addition, we may incorrectly conclude that a third-party patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, any product candidates we may develop or the use of any product candidates we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could adversely affect our ability to commercialize our product candidates or any other of our product candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. Our product candidates make use of CRISPR-based gene editing technology, which is a field that is highly active for patent filings. The extensive patent filings related to CRISPR and Cas make it difficult for us to assess the full extent of relevant patents and pending applications that may cover our gene editing technology and product candidates and their use or manufacture. There may be third-party patents or patent applications, including patents held or controlled by our competitors with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our gene editing technology and product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we are found to infringe, misappropriate or otherwise violate a third party&#x2019;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidates and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees, if we are found to have willfully infringed a patent or other intellectual property right indemnify our customers or collaborators. A finding of infringement could prevent us from manufacturing and commercializing our product candidates or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Patents have a limited lifespan. The terms of individual patents depend upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest non-provisional filing date in the applicable country. However, the actual protection afforded by a patent varies from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our product candidates may face competition from biosimilars approved through an abbreviated regulatory pathway.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the PPACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the other company&#x2019;s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for any product candidates we may develop, our business may be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the United States, the patent term of a patent that covers an FDA-approved drug may be eligible for limited patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under clinical development and regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent applicable to and that covers an approved drug may be extended. Similar provisions are available in Europe, such as supplementary protection certificates, and certain other non-United States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when our product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates, there is no guarantee that the applicable authorities will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. We may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of operations and prospects could be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">It is possible that we will not obtain patent term extension under the Hatch-Waxman Act for a U.S. patent covering any of our product candidates that we may identify even where that patent is eligible for patent term extension, or if we obtain such an extension, it may be for a shorter period than we had sought.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our gene editing platform technology and product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As is the case with other biotech and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of our owned and in-licensed patent applications and the maintenance, enforcement or defense of our owned and in-licensed issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future. For example, in the case, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Assoc. for Molecular Pathology v. Myriad Genetics, Inc.,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> the U.S. Supreme Court held that claims to certain DNA molecules are not patentable. More recently, in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Amgen Inc. v. Sanofi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, the Federal Circuit held that claims with functional language may pose high hurdles in fulfilling the enablement requirement for claims with broad functional language. We cannot predict how this and future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Any similar adverse changes in the patent laws of other jurisdictions could also have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court. We may not be able to protect our trade secrets in court.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we or one of our licensing partners initiates legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. In addition, patent validity challenges may, under certain circumstances, be based upon non-statutory obviousness-type double patenting, which, if successful, could result in a finding that the claims are invalid for obviousness-type double patenting or the loss of patent term, including a patent term adjustment granted by the USPTO, if a terminal disclaimer is filed to obviate a finding of obviousness-type double patenting. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> review and equivalent proceedings in foreign jurisdictions. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which the patent examiner and we or our licensing partners were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect, and some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We cannot guarantee that we have entered into such agreements with each party that may have or have had access</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">to our trade secrets or proprietary technology and processes. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could compromise our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of our owned and in-licensed patents and patent applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we may rely on our licensing partners to pay these fees to, or comply with the procedural and documentary rules of, the relevant patent agency. With respect to our patents, we rely on outside firms and outside counsel to remind us of the due dates and to make payment after we instruct them to do so. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, it would have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We have limited foreign intellectual property rights and may not be able to protect our intellectual property and proprietary rights throughout the world.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have limited intellectual property rights outside the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect to the same extent or at all inventions that constitute new methods of treatment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties, or we have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Many of our employees, consultants and contractors were previously employed at universities or other pharmaceutical or biotechnology companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#x2019;s current or former employer. Litigation may be necessary to defend against these claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition to seeking patents for our some of our technology and product candidates, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants, but we cannot guarantee that we have entered into such</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">agreements with each party that may have or has had access to our trade secrets or proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition to contractual measures, we try to protect the confidential nature of our proprietary information through other appropriate precautions, such as physical and technological security measures. However, trade secrets and know-how can be difficult to protect. These measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and any recourse we might take against this type of misconduct may not provide an adequate remedy to protect our interests fully. In addition, trade secrets may be independently developed by others in a manner that could prevent us from receiving legal recourse. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any of that information was independently developed by a competitor, our competitive position could be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any registered trademarks or trade names may be challenged, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Intellectual property rights do not necessarily address all potential threats.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">any product candidates we may develop will eventually become commercially available in generic or biosimilar product forms; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">others may be able to make gene editing product that are similar to ours but that are not covered by the claims of the patents that we own; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we, or our license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent applications that we license or may own in the future; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">it is possible that our pending owned and in-licensed patent applications or those we may own or in-license in the future will not lead to issued patents; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">it is possible that there are prior public disclosures that could invalidate our owned or in-licensed patents, or parts of our owned or in-licensed patents; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our product candidates or technology similar to ours; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">it is possible that our owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the laws of foreign countries may not protect our proprietary rights or the proprietary rights of license partners or current or future collaborators to the same extent as the laws of the United States; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the inventors of our owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes that design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we have engaged in scientific collaborations in the past and will continue to do so in the future and our collaborators may develop adjacent or competing products that are outside the scope of our patent rights; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates or will provide us with any competitive advantages; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before our relevant patents that we own or license expire; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we may not develop additional proprietary technologies that are patentable; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the patents of others may harm our business; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Risks related to commercialization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Even if any of our current or future product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, and the market opportunity for any of such product candidates, if approved, may be smaller than we estimate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If any of our current or future product candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current CVD treatments such as statins, ezetimibe, bempedoic acid, lomitapide, mipomersen and icosapent ethyl are well-established in the medical community, and physicians may continue to rely on these treatments. Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If our current or future product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">and we may not become profitable. The degree of market acceptance of our current or future product candidates, if approved for commercial sale, will depend on a number of factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the efficacy and potential advantages of such product candidates compared to the advantages and relative risks of alternative treatments; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the effectiveness of sales and marketing efforts; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the cost of treatment in relation to alternative treatments, including any similar biosimilar treatments; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our ability to offer our products, if approved, for sale at competitive prices; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the clinical indications for which the product is approved; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the convenience and ease of administration compared to alternative treatments; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the strength of marketing and distribution support; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the timing of market introduction of competitive products; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the availability of third-party coverage and adequate reimbursement, and patients&#x2019; willingness to pay out of pocket for required co-payments or in the absence of third-party coverage or adequate reimbursement; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the prevalence and severity of any side effects; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">any restrictions on the use of our products, if approved, together with other medications. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our assessment of the potential market opportunity for our current or future product candidates is based on industry and market data that we obtained from industry publications, research, surveys and studies conducted by third parties and our analysis of these data, research, surveys and studies. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. Our estimates of the potential market opportunities for our product candidates include a number of key assumptions based on our industry knowledge, industry publications and third-party research, surveys and studies, which may be based on a small sample size and fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. If any of our assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the actual market for any of our product candidates may be smaller than we expect, and as a result our revenues from product sales may be limited and it may be more difficult for us to achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We face substantial competition, which may result in others discovering, developing or commercializing products before us or more successfully than we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The development and commercialization of new drug or biologic products is highly competitive. It is particularly competitive with respect to new products for CVD, for which the standard of care is well-established. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of many of the disease indications for which we are developing our product candidates. Some of these competitive products and therapies are based on scientific approaches that are similar to our approach, and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There are several approved products for low-density lipoprotein cholesterol, or LDL-C, lowering or cardiovascular risk reduction, such as statins, ezetimibe, bempedoic acid, lomitapide, mipomersen and icosapent ethyl.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There are several approved products that target PCSK9 protein as a mechanism to lower LDL-C and reduce the risk of ASCVD. Evolocumab, a monoclonal antibody, or mAb, marketed as Repatha by Amgen, is approved by</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the FDA for the treatment of patients with heterozygous familial hypercholesterolemia, or HeFH, patients with HoFH and in patients with ASCVD. Alirocumab, a mAb marketed as Praulent by Sanofi and Regeneron Pharmaceuticals, Inc., or Regeneron, is approved by the FDA for the treatment of patients with ASCVD and for the treatment of patients with primary hyperlipidemia, including HeFH. Regeneron has sole U.S. rights to alirocumab and Sanofi has sole ex-U.S. rights to alirocumab. The approved mAb treatments act through extracellular inhibition of PCSK9 protein. Inclisiran, a small interfering RNA, or siRNA, marketed as Leqvio by Novartis AG, is approved in the United States for the treatment of patients with clinical ASCVD or HeFH who require additional lowering of LDL-C and in Europe for the treatment of patients with hypercholesterolemia, including HeFH, or mixed dyslipidemia. Inclisiran acts by inhibiting the synthesis of PCKS9 within liver cells, which is distinct from extracellular protein inhibition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are aware of several product candidates in clinical development that target PCSK9 protein as a mechanism to lower LDL-C and reduce the risk of ASCVD, including peptide-based anti PCSK9 vaccination, small molecule oral PCSK9 inhibitors, small binding proteins, and antisense oligonucleotides. In 2021, Esperion in-licensed an oral small molecule PCSK9 inhibitor from Serometrix LLC for which it disclosed plans to submit an IND in 2022, and an oral PCSK9 inhibitor from Merck &amp; Co., Inc, for which they plan to progress to Phase 2 in 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are aware of one other gene editing program targeting the PCKS9 gene in preclinical development. Precision Biosciences, Inc., or Precision, has published preclinical data showing long-term stable reduction of LDL-C levels in non-human primates following </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">gene editing of the PCSK9 gene using its gene editing platform. In September 2021, Precision entered into a collaboration with iECURE under which iECURE plans to advance Precision&#x2019;s PCSK9-directed nuclease product candidate into Phase 1 clinical trials for the treatment of familial hypercholesterolemia in 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Evinacumab, a mAb targeting ANGPTL3 protein that is marketed by Regeneron, is approved by the FDA for the treatment of patients with HoFH. Evinacumab is also being evaluated by Regeneron in Phase 2 development for severe hypertriglyceridemia.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are aware of several product candidates in clinical development that target ANGPTL3 protein as a mechanism to lower LDL-C and reduce the risk of ASCVD, including vupanorsen, an antisense oligonucleotide therapy being evaluated in a Phase 2 clinical trial by Ionis Pharmaceuticals, Inc. and Pfizer for the treatment of patients with elevated non-high density lipoprotein cholesterol and triglycerides. ARO-ANG3, a siRNA targeting ANGPTL3 protein, is being evaluated in a Phase 1/2 clinical trial by Arrowhead Pharmaceuticals, Inc., or Arrowhead. In 2021, Arrowhead initiated a Phase 2b trial of ARO-ANG3 for the treatment of patients with mixed dyslipidemia. In addi</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">tion, Eli Lilly a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">nd Company, or Eli Lilly, is evaluating a siRNA targeting ANGPTL3 protein in a Phase 1 study for the treatment of CVD.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of biosimilar products. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive biosimilar products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing our current and future product candidates if and when they are approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We do not have a sales or marketing infrastructure and have no experience as a company with the commercialization of products. To achieve commercial success for any product for which we have obtained marketing approval, we will need to establish a sales, marketing and distribution organization, either ourselves or through collaborations or other arrangements with third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the future, we expect to build a sales and marketing infrastructure to market some of our product candidates in the United States, if and when they are approved. There are risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Factors that may inhibit our efforts to commercialize our products on our own include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our inability to recruit, train and retain adequate numbers of effective sales, marketing, coverage or reimbursement, customer service, medical affairs and other support personnel; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the inability of reimbursement professionals to negotiate arrangements for coverage, formulary access, reimbursement and other acceptance by payors; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we are unable to establish our own sales, marketing and distribution capabilities and we enter into arrangements with third parties to perform these services, our product revenues and our profitability, if any, are likely to be lower than if we were to market, sell and distribute any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute our product candidates or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We expect to rely on CMOs to manufacture our product candidates. If we are unable to enter into such arrangements as expected or if such organizations do not meet our supply requirements, development and/or commercialization of our product candidates may be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We expect to rely on third parties to manufacture clinical supplies of our product candidates and commercial supplies of our products, if and when approved for marketing by applicable regulatory authorities, as well as for packaging, sterilization, storage, distribution and other production logistics. If we are unable to enter into such arrangements on the terms or timeline we expect, development and/or commercialization of our product candidates may be delayed. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or manufacture our product candidates in accordance with regulatory requirements, if there are disagreements between us and such parties or if such parties are unable to expand capacities to support commercialization of any of our product candidates for which we obtain marketing approval, we may not be able to fulfill, or may be delayed in producing sufficient product candidates to meet, our supply requirements. These facilities may also be affected by catastrophic events, including pandemics, including the ongoing COVID-19 pandemic, terrorist attacks, wars or other armed conflicts, geopolitical tensions, such as the ongoing conflict</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">between Russia and Ukraine, natural disasters, such as floods or fire, or such facilities could face manufacturing issues, such as contamination or regulatory concerns following a regulatory inspection of such facility. In such instances, we may need to locate an appropriate replacement third-party facility and establish a contractual relationship, which may not be readily available or on acceptable terms, which would cause additional delay and increased expense, including as a result of additional required FDA approvals, and may have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our third-party manufacturers will be subject to inspection and approval by the FDA before we can commence the manufacture and sale of any of our product candidates, and thereafter subject to FDA inspection from time to time. Failure by our third-party manufacturers to pass such inspections and otherwise satisfactorily complete the FDA approval regimen with respect to our product candidates may result in regulatory actions such as the issuance of FDA Form 483 notices of observations, warning letters or injunctions or the loss of operating licenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We or our third-party manufacturers may also encounter shortages in the raw materials or API necessary to produce our product candidates in the quantities needed for our clinical trials or, if our product candidates are approved, in sufficient quantities for commercialization or to meet an increase in demand, as a result of capacity constraints or delays or disruptions in the market for the raw materials or API, including shortages caused by the purchase of such raw materials or API by our competitors or others. The failure of us or our third-party manufacturers to obtain the raw materials or API necessary to manufacture sufficient quantities of our product candidates may have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party coverage or reimbursement practices or healthcare reform initiatives, which could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#x2019;s determination that use of a product is:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a covered benefit under its health plan; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">safe, effective and medically necessary; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">appropriate for the specific patient; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">cost-effective; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">neither experimental nor investigational. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the United States, there is no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our products on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford our product candidates, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for our product</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">candidates, if approved, by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize, our product candidates. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require patient out-of-pocket costs that patients find unacceptably high.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There can be no assurance that our product candidates, even if they are approved for sale in the United States or in other countries, will be considered medically reasonable and necessary for a specific indication or cost-effective by third-party payors, or that coverage and an adequate level of reimbursement will be available or that third-party payors&#x2019; reimbursement policies will not adversely affect our ability to sell our product candidates profitably.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties that, if they materialize, could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our future profitability will depend, in part, on our ability to commercialize our product candidates in markets outside of the United States. If we commercialize our product candidates in foreign markets, we will be subject to additional risks and uncertainties, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">economic weakness, including inflation, or political instability in particular economies and markets; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements, many of which vary between countries; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">different medical practices and customs in foreign countries affecting acceptance in the marketplace; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">tariffs and trade barriers, as well as other governmental controls and trade restrictions; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">other trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or foreign governments; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">longer accounts receivable collection times; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">longer lead times for shipping; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">workforce uncertainty in countries where labor unrest is common; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">language barriers for technical training; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">reduced protection of intellectual property rights in some foreign countries, and related prevalence of biosimilar alternatives to therapeutics; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">foreign currency exchange rate fluctuations and currency controls; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">differing foreign reimbursement landscapes; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">uncertain and potentially inadequate reimbursement of our products; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If risks related to any of these uncertainties materializes, it could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Clinical trial and product liability lawsuits against us could divert our resources and could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We will face an inherent risk of clinical trial and product liability exposure related to the testing of our product candidates in human clinical trials, and we will face an even greater risk if we commercially sell any products that we may develop. While we currently have no products in clinical trials or that have been approved for commercial sale, the future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">decreased demand for any product candidates or products that we may develop; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">termination of clinical trials; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">injury to our reputation and significant negative media attention; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">withdrawal of clinical trial participants; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">significant costs to defend any related litigation; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">loss of revenue; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">reduced resources of our management to pursue our business strategy; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the inability to commercialize any products that we may develop. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We currently do not hold any clinical trial liability insurance coverage. We may need to obtain insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to obtain and maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Risks related to regulatory approval and other legal compliance matters</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Gene editing is novel and the regulatory landscape that will govern any product candidates we may develop is uncertain and may change. As a result, we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The regulatory requirements that will govern any novel gene editing product candidates we develop are not entirely clear and may change. Within the broader genetic medicines field, we are aware of a limited number of gene therapy products that have received marketing authorization from the FDA and the EMA. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. Regulatory requirements governing gene therapy products and cell therapy products have changed frequently and will likely continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">on its review. Gene therapy clinical trials may also be subject to review and oversight by an IBC, a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical trial, even if the FDA has reviewed the trial and approved its initiation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The same applies in the European Union. In the European Union, the development and evaluation of a gene therapy medicinal product must be considered in the context of the relevant EU guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines. Additionally, for advanced therapy medicinal products, a marketing application authorization undergoes review by the EMA&#x2019;s Committee for Advanced Therapies, or CAT, in addition to review by the Committee for Medicinal Products for Human Use, or CHMP. As a result, the procedures and standards applied to gene therapy products and cell therapy products may be applied to any product candidates we may develop, but that remains uncertain at this point.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Adverse developments in post-marketing experience or in clinical trials conducted by others of gene therapy products, cell therapy products, or products developed through the application of a base editing or other gene editing technology may cause the FDA, the EMA, and other regulatory bodies to revise the requirements for development or approval of any product candidates we may develop or limit the use of products utilizing base editing technologies, either of which could materially harm our business. In addition, the clinical trial requirements of the FDA, the EMA, and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty, and intended use and market of the potential products. The regulatory approval process for novel product candidates such as the product candidates we may develop can be more expensive and take longer than for other, better known, or more extensively studied pharmaceutical or other product candidates. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing base editing technology in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays, or other impediments to our research programs or the commercialization of resulting products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The regulatory review committees and advisory groups described above and the new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment candidates, or lead to significant post-approval limitations or restrictions. As we advance our research programs and develop future product candidates, we will be required to consult with these regulatory and advisory groups and to comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of any product candidates we identify and develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Because we are developing product candidates in the field of genetic medicines, a field that includes gene therapy and gene editing, in which there is little clinical experience, there is increased risk that the FDA, the EMA, or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results and that these results may be difficult to analyze.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the regulatory review process, we will need to identify success criteria and endpoints such that the FDA, the EMA, or other regulatory authorities will be able to determine the clinical efficacy and safety profile of any product candidates we may develop. As we are seeking to identify and develop product candidates to treat diseases in which there is no clinical experience using a gene editing approach, there is heightened risk that the FDA, the EMA, or other regulatory authorities may not consider the clinical trial endpoints that we propose to provide clinically meaningful results (reflecting a tangible benefit to patients). In addition, the resulting clinical data and results may be difficult to analyze. Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoints to a degree of statistical significance. Further, even if we do achieve the pre-specified criteria, we may produce results that are unpredictable or inconsistent with the results of the non-primary endpoints or other relevant data. The FDA also weighs the benefits of a product against its risks, and the FDA may view the efficacy results in the context of safety as not being supportive of regulatory approval. Other regulatory authorities in the European Union and other countries may make similar comments with respect to these endpoints and data. Any product candidates we may develop will be based on a novel technology that makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval. No gene editing therapeutic product has been approved in the United States or in Europe.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of any product candidates we develop. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, product candidates we develop, and our ability to generate revenue will be materially impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any product candidates we develop and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States and by comparable authorities in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction. We have no experience as a company in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information, including manufacturing information, to the various regulatory authorities for each therapeutic indication to establish the biologic product candidate&#x2019;s safety, purity and potency. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we develop may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved and the specific disease or condition to be treated. Of the large number of products in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. Even if any product candidates we may develop demonstrate safety and efficacy in clinical trials, the regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we experience delays in obtaining approval or if we fail to obtain approval of any product candidates we develop, the commercial prospects for those product candidates may be harmed and our ability to generate revenues will be materially impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Obtaining and maintaining marketing approval or commercialization of our product candidates in the United States does not mean that we will be successful in obtaining marketing approval of our product candidates in other jurisdictions. Failure to obtain marketing approval in foreign jurisdictions would prevent any product candidates we develop from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In order to market and sell any product candidates we may develop in the European Union and many other foreign jurisdictions, we or our collaborators must obtain separate marketing approvals and comply with numerous and varying local regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our product candidates in any jurisdiction, which would materially impair our ability to generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On June 23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as Brexit. Following protracted negotiations, the United Kingdom left the European Union on January 31, 2020 and a transition period to December 31, 2020 was established to allow the United Kingdom and the European Union to negotiate the United Kingdom&#x2019;s withdrawal. As a result, effective January 1, 2021, the United Kingdom is no longer part of the European Single Market and European Union Customs Union. A cooperation agreement was signed between the United Kingdom and the European Union in December 2020 which has been applied provisionally since January 1, 2021 until it is ratified by all parties to that agreement. The agreement addresses trade, economic arrangements, law enforcement, judicial cooperation and a governance framework including procedures for dispute resolution, among other things. As both parties continue to work on the rules for implementation, significant political and economic uncertainty remains about how the precise terms of the relationship between the parties will differ from the terms before withdrawal.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Since the regulatory framework for pharmaceutical products in the United Kingdom covering the quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from European Union directives and regulations, the consequences of Brexit and the impact the future regulatory regime that applies to products and the approval of product candidates in the United Kingdom remains unclear. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We expect that we will be subject to additional risks in commercializing any of our product candidates that receive</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">currency fluctuations, which could result in increased operating expenses and reduced revenue, and other</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">obligations incident to doing business in another country; and workforce uncertainty in countries where labor</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">unrest is more common than in the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We may seek certain designations for our product candidates, including Fast Track, Breakthrough Therapy, Regenerative Medicine Advanced Therapy and Priority Review designations in the United States, and PRIME Designation in the European Union, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If a product candidate is intended for the treatment of a serious or life-threatening condition and the product candidate demonstrates the potential to address unmet medical need for this condition, the sponsor may apply to the FDA for Fast Track designation. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#x2019;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, an applicant may seek designation of its product as a breakthrough therapy, which is a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs and biologics that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additionally, a product is eligible for Regenerative Medicine Advanced Therapy, or RMAT, designation if it is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of an RMAT designation are similar to a breakthrough therapy designation, and include early interactions with the FDA to expedite development and review, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Further, if the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We may seek these and other designations for our product candidates. The FDA has broad discretion with respect to whether or not to grant these designations to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a Fast Track, breakthrough therapy, or RMAT designation does not necessarily mean a faster regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. As a result, while we may seek and receive these designations for our product candidates, we may not experience a faster development process, review or approval compared to conventional FDA procedures. In addition, the FDA may withdraw these designations if it believes that the designation is no longer supported by data from our clinical development program.<br /><br />In the European Union, we may seek PRIME designation for some of our product candidates in the future. PRIME is a voluntary program aimed at enhancing the EMA&#x2019;s role to reinforce scientific and regulatory support in order to optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet medical needs. The program focuses on medicines that target conditions for which there exists no satisfactory method of treatment in the European Union or even if such a method exists, it may offer a major therapeutic advantage over existing treatments. PRIME is limited to medicines under development and not authorized in the European Union and the applicant intends to apply for an initial marketing authorization application through the centralized procedure. To be accepted for PRIME, a product candidate must meet the eligibility criteria in respect of its major public health interest and therapeutic innovation based on information that is capable of substantiating the claims. The benefits of a PRIME designation include the appointment of a CHMP rapporteur to provide continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME also encourages an applicant to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if we receive PRIME designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of EMA&#x2019;s grant of a marketing authorization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We may not be able to obtain orphan drug exclusivity for any product candidates we may develop, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. A similar regulatory scheme governs approval of orphan products by the EMA in the European Union. Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same product for the same therapeutic indication for that time period. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In order for the FDA to grant orphan drug exclusivity to one of our products, the agency must find that the product is indicated for the treatment of a condition or disease with a patient population of fewer than 200,000 individuals annually in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this standard. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. In particular, the concept of what constitutes the &#x201c;same drug&#x201d; for purposes of orphan drug exclusivity remains in flux in the context of gene therapies, and the FDA has issued recent final guidance suggesting that it would not consider two genetic medicine products to be different drugs solely based on minor differences in the transgenes or vectors. In addition, even after an orphan drug is approved, the FDA can</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">subsequently approve the same product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In 2017, the Congress passed the FDA Reauthorization Act of 2017, or the FDARA. FDARA, among other things, codified the FDA&#x2019;s pre-existing regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. Under Omnibus legislation signed by President Trump on December 27, 2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of FDARA in 2017, but have not yet been approved or licensed by FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the 11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Arial;">th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> Circuit in September 2021 finding that, for the purpose of determining the scope of exclusivity, the term &#x201c;same disease or condition&#x201d; means the designated &#x201c;rare disease or condition&#x201d; and could not be interpreted by the FDA to mean the &#x201c;indication or use.&#x201d; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#x201c;indication or use.&#x201d; We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Negative public opinion of gene editing and increased regulatory scrutiny of gene editing and genetic research may adversely impact public perception of our future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our potential therapeutic products involve introducing genetic material into patients&#x2019; cells. The clinical and commercial success of our potential products will depend in part on public acceptance of the use of gene editing and gene regulation for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that gene editing and gene regulation are unsafe, unethical or immoral, and, consequently, our products may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products once approved. For example, in 2003, trials using early versions of murine gamma-retroviral vectors, which integrate with, and thereby alter, the host cell&#x2019;s DNA, have led to several well-publicized adverse events, including reported cases of leukemia. Adverse events in our clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. The risk of cancer remains a concern for gene editing and we cannot assure that it will not occur in any of our planned or future clinical trials. If any such adverse events occur, commercialization of our product candidates or further advancement of our clinical trials could be halted or delayed, which would have a negative impact on our business and operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Even if we, or any collaborators we may have, obtain marketing approvals for any product candidates we develop, the terms of approvals and ongoing regulation of our products could require the substantial expenditure of resources and may limit how we, or they, manufacture and market our products, which could materially impair our ability to generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising, and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">product to meet the specifications in the BLA. The FDA typically advises that patients treated with genetic medicine undergo follow-up observations for potential adverse events for up to a 15-year period. The holder of an</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">to the approved product, product labeling or manufacturing process. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accordingly, assuming we, or any collaborators we may have, receive marketing approval for one or more product candidates we develop, we, and such collaborators, and our and their contract manufacturers will continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, and quality control. If we and such collaborators are not able to comply with post-approval regulatory requirements, we and such collaborators could have the marketing approvals for our products withdrawn by regulatory authorities and our, or such collaborators&#x2019;, ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our business, operating results, financial condition, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Any product candidate for which we obtain marketing approval could be subject to restrictions or withdrawal from the market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The FDA and other regulatory agencies closely regulate the post-approval marketing and promotion of medicines to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. Although physicians may prescribe products for uses not described in the product&#x2019;s labeling, known as off-label uses, in their professional medical judgment, the FDA and other regulatory agencies impose stringent restrictions on manufacturers&#x2019; communications regarding off-label use, and if we market our products, if approved, in a manner inconsistent with their approved labeling, we may be subject to enforcement action for off-label marketing by the FDA and other federal and state enforcement agencies, including the Department of Justice, or DOJ. Violation of the Federal Food, Product, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may also lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws. In September 2021, the FDA published final regulations that describe the types of evidence that the FDA will consider in determining the intended use of a drug or biologic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, later discovery of previously unknown problems with our product candidates, manufacturers, or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">restrictions on such products, manufacturers, or manufacturing processes; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">restrictions on the labeling or marketing of a medicine; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">restrictions on the distribution or use of a medicine; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">requirements to conduct post-marketing clinical trials; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">receipt of warning or untitled letters; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">withdrawal of the medicines from the market; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">refusal to approve pending applications or supplements to approved applications that we submit; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">recall of medicines; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">fines, restitution, or disgorgement of profits or revenue; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">suspension or withdrawal of marketing approvals; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">suspension of any ongoing clinical trials; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">refusal to permit the import or export of our medicines; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">product seizure; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any product candidates we develop and adversely affect our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these agencies&#x2019; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the Securities and Exchange Commission, or the SEC, and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Separately, in response to the COVID-19 pandemic, since March 2020 when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic inspections. As of May 2021, certain inspections, such as foreign pre-approval, surveillance, and for-cause inspections that are not deemed mission-critical, remain temporarily postponed. In April 2021, the FDA issued guidance formally announcing plans to employ remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates and in May 2021 announced plans to continue progress toward resuming standard operational levels. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the FDA has stated that it generally intends to issue a complete response letter or defer action on the application until an inspection can be completed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In 2020 and 2021, a number of companies announced receipt of complete response letters due to the FDA&#x2019;s inability to complete required inspections for their applications. As of May 26, 2021, the FDA noted it was continuing to ensure timely reviews of applications for medical products during the ongoing COVID-19 pandemic in line with its user fee performance goals and conducting mission-critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. However, the FDA may not be able to continue its current pace and review timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the ongoing COVID-19 pandemic and travel restrictions, the FDA is unable to complete such required inspections during the review period. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Any relationships we may have with customers, healthcare providers and professionals, and third-party payors, among others, will be subject to applicable anti-kickback, fraud and abuse and other healthcare</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">laws and regulations, which could expose us to penalties, including criminal sanctions, civil penalties, contractual damages, reputational harm, fines, disgorgement, exclusion from participation in government healthcare programs, curtailment or restricting of our operations, and diminished profits and future earnings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any products for which we are able to obtain marketing approval. Any arrangements we have with healthcare providers, third-party payors and customers will subject us to broadly applicable fraud and abuse and other healthcare laws and regulations. The laws and regulations may constrain the business or financial arrangements and relationships through which we conduct clinical research, market, sell and distribute any products for which we obtain marketing approval. These include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order, or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the federal civil and criminal false claims laws, including the federal False Claims Act, which can be enforced through civil whistleblower or qui tam actions, and civil monetary penalty laws impose civil and criminal penalties against individuals or entities for knowingly presenting or causing to be presented, to the federal government, claims for payment or approval from Medicare, Medicaid or other government payers that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">HIPAA, as further amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, which imposes certain requirements, including mandatory contractual terms, on covered entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers, as well as their respective business associates and their subcontractors that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security, and transmission of such individually identifiable health information; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the federal transparency requirements under the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report to the Department of Health and Human Services, or HHS, information related to payments and other transfers of value to physicians, as defined by such law, and teaching hospitals and other covered recipients and ownership and investment interests held by healthcare providers and their immediate family members and applicable group purchasing organizations, and, beginning in 2022, will require applicable manufacturers to report information regarding payments and other transfers of value provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, and certified nurse midwives; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">analogous state laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers, including private insurers, and certain state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to drug pricing and payments to physicians and other healthcare providers or marketing expenditures and state and local laws that require the registration of sales representatives; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Efforts to ensure that any business arrangements we have with third parties, and our business generally, will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, individual imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval and commercialize our product candidates and affect the prices we, or they, may obtain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any collaborators, to profitably sell or commercialize any product candidate for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In March 2010, President Obama signed into law the PPACA. In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#x2019;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to two percent per fiscal year, which went into effect in April 2013 and will remain in effect through 2031, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. Pursuant to the CARES Act and subsequent legislation, these Medicare sequester reductions have been suspended through the end of March 2022. From April 2022 through June 2022, a 1% sequester cut will be in effect, with the full 2% cut resuming thereafter. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Since enactment of the PPACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, the Tax Act repealed the &#x201c;individual mandate.&#x201d; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. Further, on December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the PPACA is an essential and inseverable feature of the PPACA, and therefore because the mandate was repealed as part of the Tax Act, the remaining provisions of the PPACA are invalid as well. However, on June 17, 2021, the U.S. Supreme Court dismissed the case and sustained the PPACA. Litigation and legislation over the PPACA are likely to continue, with unpredictable and uncertain results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The former Trump presidential administration also took executive actions to undermine or delay implementation of the PPACA, including directing federal agencies with authorities and responsibilities under the PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On January 28, 2021, however, President Biden revoked those orders and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">issued a new Executive Order which directs federal agencies to reconsider rules and other policies that limit Americans&#x2019; access to health care, and consider actions that will protect and strengthen that access. Under this Executive Order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19; demonstrations and waivers under Medicaid and the PPACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and the PPACA; and policies that reduce affordability of coverage or financial assistance, including for dependents. This Executive Order also directs the HHS to create a special enrollment period for the Health Insurance Marketplace in response to the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We expect that these healthcare reform measures, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates. It is also possible that additional governmental action will be taken in response to the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">The prices of prescription pharmaceuticals in the United States and foreign jurisdictions is subject to considerable legislative and executive actions and could impact the prices we obtain for our products, if and when licensed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, reduce the prices of pharmaceuticals under Medicare and Medicaid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In markets outside of the United States and the European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies, contractual obligations, and the failure to comply with such requirements could subject us to significant</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">122</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the United States, European Union and United Kingdom. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. These obligations may be applicable to some or all of our business activities now or in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we are unable to properly protect the privacy and security of protected health information, we could be found to have breached certain contracts with our business partners. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. HHS enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In 2018, California passed into law the CCPA, which took effect on January 1, 2020 and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#x2019;s requirements are similar to those found in the GDPR, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of &#x201c;sales&#x201d; of their personal information. The CCPA contains significant penalties for companies that violate its requirements. On November 3, 2020, California voters passed the CPRA, which will significantly expand the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. Most CPRA provisions will take effect on January 1, 2023, though the obligations will apply to any personal information collected after January 1, 2022. These provisions may apply to some of our business activities. In addition, other states, including Virginia and Colorado, already have passed state privacy laws. Other states will be considering these laws in the future. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Similar to the laws in the United States, there are significant privacy and data security laws that apply in Europe and other countries. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the EEA, and the processing of personal data that takes place in the EEA, is regulated by the GDPR, which went into effect in May 2018 and imposes obligations on companies that operate in our industry with respect to the processing of personal data and the cross-border transfer of such data. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and policies. If our or our partners&#x2019; or service providers&#x2019; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">123</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">of up to 20 million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The GDPR places restrictions on the cross-border transfer of personal data from the EU to countries that have not been found by the European Commission to offer adequate data protection legislation, such as the United States. There are ongoing concerns about the ability of companies to transfer personal data from the EU to other countries. In July 2020, the Court of Justice of the European Union, or CJEU, invalidated the EU-U.S. Privacy Shield, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the U.S. The CJEU&#x2019;s decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the U.S. While we were not self-certified under the EU-U.S. Privacy Shield, this CJEU decision may lead to increased scrutiny on data transfers from the EEA to the U.S. generally and increase our costs of compliance with data privacy legislation as well as our costs of negotiating appropriate privacy and security agreements with our vendors and business partners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Following the withdrawal of the United Kingdom from the European Union, the United Kingdom&#x2019;s Data Protection Act 2018, which &#x201c;implements&#x201d; and complements the GDPR and achieved Royal Assent on May 23, 2018, applies to the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR. While the Data Protection Act of 2018 is now effective in the United Kingdom, it is still unclear whether transfer of data from the EEA to the United Kingdom will remain lawful under GDPR. The United Kingdom has already determined that it considers all European Union and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the European Union and EEA remain unaffected. In addition, a recent decision from the European Commission appears to deem the United Kingdom as being &#x201c;essentially adequate&#x201d; for purposes of data transfer from the European Union to the United Kingdom, although this decision may be re-evaluated in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow GDPR as a model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and any eventual sale and distribution of commercial products, through increased compliance costs, costs associated with contracting and potential enforcement actions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">While we continue to address the implications of the recent changes to data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges, and our efforts to comply with the evolving data protection rules may be unsuccessful. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. We must devote significant resources to understanding and complying with this changing landscape. Failure to comply with laws regarding data protection would expose us to risk of enforcement actions taken by data protection authorities in the EEA and elsewhere and carries with it the potential for significant penalties if we are found to be non-compliant. Similarly, failure to comply with federal and state laws in the United States regarding privacy and security of personal information could expose us to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business, financial condition, results of operations or prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are exposed to the risk of fraud or other misconduct by our employees, vendors, consultants and partners, and, if we commence clinical trials, our principal investigators and CROs. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions, provide accurate information to the FDA, the European Commission, and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately, or disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">124</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">incentive programs, and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are subject to numerous laws and regulations in each jurisdiction outside the United States in which we operate. The creation, implementation and maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the DOJ. The SEC is involved with enforcement of the books and records provisions of the FCPA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Compliance with the FCPA and other anti-corruption laws potentially applicable to our business is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the compliance with the FCPA and other anti-corruption laws presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are also subject to other laws and regulations governing our international operations, including applicable export control laws, economic sanctions on countries and persons, and customs requirements. In addition, various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Our expansion outside of the United States has required, and will continue to require, us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain drugs and drug candidates outside of the United States, which could limit our growth potential and increase our development costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There is no assurance that we will be completely effective in ensuring our compliance with the FCPA and other applicable anti-corruption, export, sanctions, and customs laws. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violations of these laws, including the FCPA, can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#x2019;s accounting provisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">125</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If we or any third-party manufacturer we engage now or in the future fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs or liabilities that could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We and third-party manufacturers we engage now are, and any third-party manufacturer we may engage in the future will be, subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Although we maintain general liability insurance as well as workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Further, with respect to the operations of our current and any future third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of our product candidates or products. In addition, our supply chain may be adversely impacted if any of our third-party contract manufacturers become subject to injunctions or other sanctions as a result of their non-compliance with environmental, health and safety laws and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Risks related to employee matters and managing growth</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are highly dependent on the research and development, clinical, financial, operational and other business expertise of Sekar Kathiresan, M.D., our chief executive officer, Andrew Ashe, J.D., our president and chief operating officer, Allison Dorval, our chief financial officer, and Andrew Bellinger, M.D., Ph.D., our chief scientific officer and chief medical officer, as well as the other principal members of our management, scientific and clinical teams. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#x201c;key person&#x201d; insurance for any of our executives or other employees. Recruiting and retaining qualified scientific, clinical, manufacturing, accounting, legal and sales and marketing personnel will also be critical to our success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. Our success also depends on implementing and maintaining internal controls and the accuracy and timeliness of our financial reporting. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">126</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As our development progresses, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical, regulatory affairs, manufacturing and quality control and, if any of our product candidates receive marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Future acquisitions or strategic alliances could disrupt our business and harm our financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We may acquire additional businesses, technologies or assets, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products or product candidates resulting from a strategic alliance or acquisition that may delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure our stockholders that, following any such acquisition, we will achieve the expected synergies to justify the transaction. The risks we face in connection with acquisitions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">diversion of management time and focus from operating our business to addressing acquisition integration challenges; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">coordination of research and development efforts; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">retention of key employees from the acquired company; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">changes in relationships with collaborators as a result of product acquisitions or strategic positioning resulting from the acquisition; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">cultural challenges associated with integrating employees from the acquired company into our organization; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the need to implement or improve controls, procedures and policies at a business that prior to the acquisition may have lacked sufficiently effective controls, procedures and policies; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">liability for activities of the acquired company before the acquisition, including intellectual property infringement claims, violation of laws, commercial disputes, tax liabilities and other known liabilities; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">unanticipated write-offs or charges; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">litigation or other claims in connection with the acquired company, including claims from terminated employees, customers, former stockholders or other third parties. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our failure to address these risks or other problems encountered in connection with our past or future acquisitions or strategic alliances could cause us to fail to realize the anticipated benefits of these transactions, cause us to incur unanticipated liabilities and harm the business generally. There is also a risk that future acquisitions will result in the incurrence of debt, contingent liabilities, amortization expenses or incremental operating expenses, any of which could harm our financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our internal information technology systems, or those of our collaborators, vendors or other contractors or consultants, may fail or suffer security breaches, loss of data and other disruptions, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or prevent us from accessing critical information, trigger contractual and legal</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">127</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">obligations, potentially exposing us to liability, reputational harm or otherwise adversely affecting our business and financial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information, including but not limited to intellectual property, proprietary business information and personal information. It is critical that we, our vendors, collaborators or other contractors or consultants, do so in a secure manner to maintain the availability, security, confidentiality, privacy and integrity of such confidential information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Despite the implementation of security measures, our internal information technology systems and those of any collaborators, vendors, contractors or consultants are vulnerable to damage or interruption from computer viruses, computer hackers, malicious code, employee error, theft or misuse, denial-of-service attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, wars or other armed conflict, telecommunication and electrical failures or other compromise. There could be an increase in cybersecurity attacks generally as a result of the ongoing conflict between Russia and Ukraine and the resulting sanctions imposed by the United States and European governments, together with any additional future sanctions or other actions by them.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, unauthorized access to or deletion of files, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cyber-attacks also could include phishing attempts or e-mail fraud to cause payments or information to be transmitted to an unintended recipient. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies. We cannot guarantee that the measures we have taken to date, and actions we may take in the future, will be sufficient to prevent any future breaches.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To the extent we experience a material system failure, accident, cyber-attack or security breach, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary or confidential information or other disruptions. For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. If we do not allocate and effectively manage the resources necessary to build and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption, including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual property or other proprietary information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To the extent that any disruption or security breach were to result in a loss of, or damage to, our or our vendors&#x2019;, collaborators&#x2019; or other contractors&#x2019; or consultants&#x2019; data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, including litigation exposure, penalties and fines, we could become the subject of regulatory action or investigation, our competitive position and reputation could be harmed and the further development and commercialization of our product candidates could be delayed. As a result of such an event, we may be in breach of our contractual obligations. Furthermore, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our customers or employees, could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages. Any of the above could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The financial exposure from the events referenced above could either not be insured against or not be fully covered through any insurance that we maintain and could have a material adverse effect on our business, financial condition, results of operations or prospects. In addition, we cannot be sure that our existing insurance coverage will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages as a result of the events referenced above.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">128</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Risks related to ownership of our common stock and our status as a public company</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our executive officers, directors and their affiliates, if they choose to act together, will have the ability to significantly influence all matters submitted to stockholders for approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our executive officers and directors and their affiliates, in the aggregate, beneficially owned shares representing approxim</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ately 26.2% of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our common stock as of January 31, 2022. As a result, if these stockholders were to choose to act together, they would effectively be able to significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, could significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This concentration of ownership control may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delay, defer or prevent a change in control; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">entrench our management and board of directors; or </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delay or prevent a merger, consolidation, takeover or other business combination involving us that other stockholders may desire. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Provisions in our restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">establish a classified board of directors such that only one of three classes of directors is elected each year; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">allow the authorized number of our directors to be changed only by resolution of our board of directors; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">limit the manner in which stockholders can remove directors from our board of directors; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">limit who may call stockholder meetings; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#x201c;poison pill&#x201d; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our restated certificate of incorporation or amended and restated bylaws. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">An active trading market for our common stock may not continue to develop or be sustained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our common stock began trading on the Nasdaq Global Select Market on June 17, 2021. Given the limited trading history of our common stock, there is a risk that an active trading market for our shares may not continue to develop or be sustained. If an active market for our common stock does not continue to develop or is not</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">129</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">sustained, it may be difficult for our stockholders to sell their shares without depressing the market price for the shares, or at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If securities analysts do not publish or cease publishing research or reports or publish misleading, inaccurate or unfavorable research about our business or if they publish negative evaluations of our stock, the price and trading volume of our stock could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The trading market for our common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business. There can be no assurance that existing analysts will continue to cover us or that new analysts will begin to cover us. There is also no assurance that any covering analysts will provide favorable coverage. Although we have obtained analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock or publish inaccurate or unfavorable research about our business, or provides more favorable relative recommendations about our competitors, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price and trading volume to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">The price of our common stock has been volatile and may fluctuate substantially, which could result in substantial losses for our stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our stock price has been and is likely to continue to be volatile. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, our stockholders may not be able to sell their common stock at or above the price they paid for their shares. The market price for our common stock may be influenced by many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">timing and results of or developments in preclinical studies and clinical trials of our product candidates or those of our competitors or potential collaborators; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adverse regulatory decisions, including failure to receive regulatory approvals for any of our product candidates; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our success in commercializing our product candidates, if and when approved; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">developments with respect to competitive products or technologies; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">regulatory or legal developments in the United States and other countries; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">developments or disputes concerning patent applications, issued patents or other intellectual property or proprietary rights; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the recruitment or departure of key personnel; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the level of expenses related to any of our product candidates or clinical development programs; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the results of our efforts to discover, develop, acquire or in-license products, product candidates, technologies, the costs of commercializing any such products and the costs of development of any such product candidates or technologies; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">variations in our financial results or the financial results of companies that are perceived to be similar to us; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">sales of common stock by us, our executive officers, directors or principal stockholders, or others; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">general economic, industry and market conditions, such as the impact of the COVID-19 pandemic on our industry and market conditions; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the other factors described in this &#x201c;Risk factors&#x201d; section. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the past, following periods of volatility in the market price of a company&#x2019;s securities, securities class-action litigation has often been instituted against that company. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">130</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adverse changes to our offerings or business practices. Such litigation may also cause us to incur other substantial costs to defend such claims and divert management&#x2019;s attention and resources. Furthermore, negative public announcements of the results of hearings, motions or other interim proceedings or developments could have a negative effect on the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We have broad discretion in the use of our cash and cash equivalents and may not use them effectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our management has broad discretion in the application of our cash and cash equivalents and could use such funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest these funds in a manner that does not produce income or that loses value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">A significant portion of our total outstanding shares are eligible to be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Persons who were our stockholders prior to our IPO continue to hold a substantial number of shares of our common stock. If such persons sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, certain of our executive officers, directors and stockholders affiliated with our directors have entered or may enter into Rule 10b5-1 plans providing for sales of shares of our common stock from time to time. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the executive officer, director or affiliated stockholder when entering into the plan, without further direction from the executive officer, director or affiliated stockholder. A Rule 10b5-1 plan may be amended or terminated in some circumstances. Our executive officers, directors and stockholders affiliated with our directors also may buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of material, nonpublic information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Moreover, holders of a substantial number of shares of our common stock have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We have also filed a registration statement on Form S-8 to register all of the shares of common stock that we were able to issue under our equity compensation plans as of June 17, 2021 and we intend to file a registration statement on Form S-8 to register the additional 2,910,704 shares of our common stock that became issuable under our equity compensation plans on January 1, 2022. Shares registered under the registration statement on Form S-8 can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates, vesting arrangements, exercise of options, and the lock-up agreements entered into in connection with our IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We are an &#x201c;emerging growth company&#x201d; and a &#x201c;smaller reporting company,&#x201d; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are an &#x201c;emerging growth company,&#x201d; or EGC, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may remain an EGC until the end of 2026, although if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June 30 before that time or if we have annual gross revenues of $1.07 billion or more in any fiscal year, we would cease to be an EGC as of December 31 of the applicable year. We also would cease to be an EGC if we issue more than $1 billion of non-convertible debt over a three-year period. For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not EGCs. These exemptions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">131</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">reduced disclosure obligations regarding executive compensation; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are also a &#x201c;smaller reporting company,&#x201d; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, although we expect to cease to be a smaller reporting company in connection with the filing of our Quarterly Report on Form 10-Q for the first quarter of 2022. Similar to EGCs, smaller reporting companies have reduced disclosure obligations, such as an exemption from providing selected financial data and an ability to provide simplified executive compensation information and only two years of audited financial statement in an annual report on Form 10-K, with correspondingly reduced &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; disclosure. We cannot predict whether investors will find our common stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, the JOBS Act permits an EGC to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected not to &#x201c;opt out&#x201d; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to &#x201c;opt out&#x201d; of such extended transition period or (ii) no longer qualify as an EGC or a smaller reporting company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management has devoted and will continue to be required to devote substantial time to new compliance initiatives and corporate governance practices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As a public company, we have incurred and particularly after we are no longer an EGC or a smaller reporting company, we will continue to incur significant legal, accounting and other expenses that we did not previously incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote and will need to continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs, particularly as we hire additional financial and accounting employees to meet public company internal control and financial reporting requirements, and will make some activities more time-consuming and costly compared to when we were a private company. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pursuant to Section 404, we will be required to furnish a report by our management on our internal control over financial reporting beginning with our filing of an Annual Report on Form 10-K with the SEC for the year ended December 31, 2022. However, while we remain an EGC or a smaller reporting company with less than $100 million in annual revenue, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, including through hiring additional financial and accounting personnel, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">132</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses in our internal control over financial reporting, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be our stockholders' sole source of gain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be our stockholders' sole source of gain for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our restated certificate of incorporation designates the Court of Chancery of the State of Delaware and the federal district courts of the United States of America as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers and employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">any derivative action or proceeding brought on our behalf; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or stockholders to our company or our stockholders; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; or </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">any action asserting a claim arising pursuant to any provision of our restated certificate of incorporation or amended and restated bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">These choice of forum provisions will not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any claims arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">These exclusive forum provisions may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees. If a court were to find either exclusive forum provision contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could materially adversely affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">General risk factors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">133</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the Exchange Act is accumulated and communicated to management, recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Changes in tax law may adversely affect our business or financial condition. On December 22, 2017, the U.S. government enacted the Tax Act, which significantly reformed the Code. The Tax Act, as amended by the CARES Act, among other things, contains significant changes to corporate taxation, including reducing the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limiting the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), limiting the deduction for NOLs arising in taxable years beginning after December 31, 2017 to 80% of current year taxable income in tax years beginning after December 31, 2020 and eliminating NOL carrybacks for losses arising in taxable years ending after December 31, 2017 (though any such NOLs may be carried forward indefinitely and such NOLs arising in taxable years beginning before January 1, 2021 are generally eligible to be carried back up to five years), imposing a one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, eliminating U.S. tax on foreign earnings (subject to certain important exceptions), allowing immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition to the CARES Act, as part of Congress&#x2019; response to the COVID-19 pandemic, economic relief legislation has been enacted in 2020 and 2021 containing tax provisions. Regulatory guidance under the Tax Act and such additional legislation is and continues to be forthcoming, and such guidance could ultimately increase or lessen their impact on our business and financial condition. Also, as a result of the changes in the U.S. presidential administration and control of the U.S. Senate, additional tax legislation may be enacted; any such additional legislation could have an impact on us. In addition, it is uncertain if and to what extent various states will conform to the Tax Act and additional tax legislation. We urge prospective investors in our common stock to consult with their legal and tax advisors with respect to any recently enacted tax legislation, or proposed changes in law, and the potential tax consequences of investing in or holding our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Unfavorable global economic conditions could adversely affect our business, financial condition, stock price and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets and uncertainty about economic stability. The global economy and financial markets may also be adversely affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the sanctions relating to Russia, may also adversely impact the financial markets and the global economy, and the economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for any product candidates we may develop and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could impair our ability to achieve our growth strategy, could harm our financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that our current or future service providers, manufacturers or other collaborators may not survive such difficult economic times, which could directly</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">134</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">affect our ability to attain our operating goals on schedule and on budget. We cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 1B. Unresolved Staff Comments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 2. Properties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We currently lease 19,823 square feet of office and laboratory space in Cambridge, Massachusetts under a sublease that expires in August 2022 with an option to extend for an additional three months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In August 2021, we entered into a new lease agreement for 104,933 square feet of office and laboratory space in Boston, Massachusetts and plan to move into this space on or before August 2022. The lease has a ten-year term, which lease term will commence on the earlier of (1) the date the landlord delivers the premises to us, which we expect to be on or prior to August 1, 2022, or (2) the date the landlord could have delivered the premises but for any delays attributable to us, and we have an option to extend the term for an additional five years. In January 2022, we amended the lease to include an additional 211 square feet, for a total of 105,144 square feet.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In October 2021, we entered into a sublease agreement with Beam Therapeutics, Inc. for 11,931 square feet of additional office and laboratory space in Cambridge, Massachusetts. The sublease commenced in December 2021 and will expire in December 2022. We have the option to extend the sublease for one extension term of three months by written notice not less than six months prior to the expiration of the sublease term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 3. Legal Proceedings.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are currently not a party to any material legal proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 4. Mine Safety Disclosures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">135</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Market information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our common stock has been publicly traded on the Nasdaq Global Select Market under the symbol &#x201c;VERV&#x201d; since June 16, 2021. Prior to that time, there was no public market for our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Holders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of March 9, 2022, there were approximately 16 h</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">olders of record of our common stock. This number does not include beneficial owners whose shares are held by nominees in street name.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Dividends</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have not declared or paid any cash dividends on our capital stock since our inception. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends to holders of common stock in the foreseeable future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Recent sales of unregistered securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following list sets forth information regarding all unregistered securities sold by us during the year ended December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">From January 1, 2021 through June 30, 2021, we issued and sold an aggregate of 352,219 shares of common stock to our employees, advisors and consultants upon the exercise of stock options under our 2018 Equity Incentive Plan at a weighted-average per share exercise price of $1.49.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The common stock issued upon the exercise of options described above were issued under our 2018 Equity Incentive Plan in reliance on the exemption provided by Rule 701 promulgated under the Securities Act. The recipients of securities in these transactions had adequate access, through employment, business or other relationships, to information about us. The foregoing transactions did not involve any underwriters, underwriting discounts or commissions, or any public offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On January 14, 2021, we issued and sold 77,163,022 shares of our Series B preferred stock to 22 investors at a price per share of $1.2182 in cash, for an aggregate purchase price of $94.0 million. In June 2021, in connection with the closing of our IPO, all of our outstanding shares of preferred stock were converted into an aggregate of 27,720,923 shares of common stock. The conversion of preferred stock into common stock occurred in accordance with the terms of our certificate of incorporation and did not constitute a sale for purposes of the Securities Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">No underwriters were involved in the foregoing issuances of securities. The foregoing securities were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section 4(a)(2) under the Securities Act and, in certain cases, Regulation D thereunder, relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. All purchasers received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration statement or an available exemption from such registration.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On June 21, 2021, in connection with the closing of our initial public offering, or IPO, we issued an aggregate of 878,098 shares of common stock to The Broad Institute, Inc., or Broad, and the President and Fellows of Harvard College, or Harvard, in satisfaction of certain contractual obligations under a license and collaboration agreement, based on the IPO price of $19.00 per share. The shares of common stock issued to Harvard and Broad were exempt from registration pursuant to Section 4(a)(2) of the Securities Act because the issuance did not involve a public offering and was not accompanied by any general advertisement or general solicitation..</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">136</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Use of proceeds from registered securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On June 21, 2021, we completed our IPO of common stock pursuant to a Registration Statement on Form S-1 (File No. 333-256608), which was declared effective by the SEC on June 16, 2021 and Form S-1 (File No. 333-257158), which was filed pursuant to Rule 462(b) of the Securities Act and was declared effective by the SEC on June 16, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The net offering proceeds to us, after deducting underwriting discounts and offering expenses payable by us of $25.1 million, were $281.6 million. As of December 31, 2021, we had not used any of the net proceeds from the IPO. We have invested the net proceeds from the offering in money market funds and short-term investments. There has been no material change in our planned use of the net proceeds from our IPO as described in our final prospectus, dated June 16, 2021, filed with the SEC pursuant to Rule 424(b).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Purchases of equity securities by the issuer or affiliated purchasers</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Neither we nor any affiliated purchaser or anyone acting on our behalf or on behalf of an affiliated purchaser made any purchases of shares of our common stock during the year ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">137</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 6.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[Reserved.]</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">138</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 7. Management&#x2019;s Discussion </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">and Analysis of Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K, or the Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#x201c;Risk factors&#x201d; section of this Annual Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are a genetic medicines company pioneering a new approach to the care of cardiovascular disease, or CVD, transforming treatment from chronic management to single-course gene editing medicines. We believe that single-course treatments could provide substantial health benefits that are sustained throughout the lifetimes of patients with or at risk for atherosclerotic cardiovascular disease, or ASCVD, the most common form of CVD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We were incorporated in March 2018 and commenced operations shortly thereafter. Since our inception, we have devoted substantially all of our resources to building our gene editing and LNP technology and advancing development of our portfolio of programs, establishing and protecting our intellectual property, conducting research and development activities, organizing and staffing our company, business planning, raising capital and providing general and administrative support for these operations. To date, we have financed our operations primarily through the sales of our preferred stock and through the sale of our common stock in our initial public offering, or IPO. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Through December 31, 2021, we had raised an aggregate of $523.2 million in gross proceeds from sales of our preferred stock in private placements and common stock in our IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are a development-stage company, and all of our programs are at a preclinical stage of development. To date, we have not generated any revenue and do not expect to generate revenue from the sale of products for the foreseeable future. Since our inception, we have incurred significant operating losses. Our net losses for the years ended December 31, 2021, 2020 and 2019 were $120.3 million, $45.7 million and $19.3 million, respectively. As of December 31, 2021, we had an accumulated deficit of $186.9 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our total operating expenses were $87.1 million, $40.6 million and $13.6 million for the years ended December 31, 2021, 2020 and 2019, respectively. We expect to continue to incur significant expenses and increasing operating losses in connection with ongoing development activities related to our portfolio of programs as we continue our preclinical development of product candidates; advance these product candidates toward clinical development; further develop our base editing technology and manufacturing capabilities; seek to discover and develop additional product candidates; maintain, expand enforcement, defend, and protect our intellectual property portfolio; hire research and development and clinical personnel; ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain regulatory approval; and add operational, legal, compliance, financial and management information systems and personnel to support our research, product development, future commercialization efforts and operations as a public company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As a result, we will need substantial additional funding to support our continuing operations and pursue our strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings and other sources of capital, which may include collaborations or licensing arrangements with other companies or other strategic transactions. If we are unable to raise capital or obtain adequate funds when needed or on acceptable terms, we may be required to delay, limit, reduce or terminate our research and development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">139</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021, we had cash, cash equivalents and marketable securities of $360.4 million. We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2024</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. To finance our operations beyond that point we will need to raise additional capital, which cannot be assured. See &#x201c;Liquidity and capital resources.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Impact of COVID-19 on our business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In March 2020, COVID-19 was declared a global pandemic by the World Health Organization and to date, the COVID-19 pandemic continues to present a substantial public health and economic challenge around the world. The length of time and full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and difficult to predict. We, our contract manufacturing organizations, or CMOs, and our contract research organizations, or CROs, experienced temporary reductions in the capacity to undertake research-scale production and to execute some preclinical studies. While these operations have since normalized, we, together with our CMOs and CROs, are closely monitoring the impact of the COVID-19 pandemic on these operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We also plan to continue to closely monitor the ongoing impact of the COVID-19 pandemic on our employees and our other business operations. In an effort to provide a safe work environment for our employees, we have, among other things, limited employees in our office and lab facilities to those where on-site presence is needed for their job activities, increased the cadence of sanitization of our office and lab facilities, implemented various social distancing measures in our offices and labs including replacing all in-person meetings with virtual interactions, and are providing personal protective equipment for our employees present in our office and lab facilities. Recently, additional employees have returned to our office and lab facilities in limited capacities. We are continuing to monitor the impact and effects of the COVID-19 pandemic and our response to it, and we expect to continue to take actions as may be required or recommended by government authorities or as we determine are in the best interests of our employees and other business partners in light of the pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">License and collaboration agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have obligations under various license and collaboration agreements to make potentially significant milestone and success payments in the future and to pay royalties on sales of any product candidates covered by those agreements that eventually achieve regulatory approval and commercialization. For information regarding these agreements, see &#x201c;Business&#x2014;License and collaboration agreements&#x201d; included in Part I, Item 1 of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Components of our results of operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To date, we have not generated any revenue. We do not expect to generate any revenue from the sale of products in the near future and unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates. If our development efforts for our product candidates are successful and result in regulatory approval or we successfully enter into license or collaboration agreements with third parties, we may generate revenue in the future from product sales, payments from third-party collaboration or license agreements, or any combination thereof.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Operating expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Research and development expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development expenses consist of costs incurred in performing research and development activities, which include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the cost to obtain and maintain licenses to intellectual property, such as those with the President and Fellows of Harvard College, or Harvard, The Broad Institute, Inc., or Broad, Beam Therapeutics Inc., or Beam, Verily Life Sciences LLC, Acuitas Therapeutics, Inc., or Acuitas, and others, and related future payments should certain development and regulatory milestones be achieved; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">140</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">personnel-related expenses, including salaries, bonuses, benefits and stock-based compensation for employees engaged in research and development functions; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">expenses incurred in connection with the discovery and preclinical development of our research programs, including under agreements with third parties, such as consultants, contractors and CROs; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the cost of developing and validating our manufacturing process for use in our preclinical studies and future clinical trials, including the cost of raw materials used in our research and development activities; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the cost of laboratory supplies and research materials; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We expense research and development costs as incurred. Nonrefundable advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the benefits are consumed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the early phases of development, our research and development costs are often devoted to proof-of-concept studies that are not necessarily allocable to a specific target; therefore, we have not yet begun tracking our expenses on a program-by-program basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase for the foreseeable future as we advance our programs and product candidates into and through clinical development, and as we continue to develop additional product candidates. We also expect our discovery research efforts and our related personnel costs will increase and, as a result, we expect our research and development expenses, including costs associated with stock-based compensation, will increase above historical levels. In addition, we may incur additional expenses related to milestone and royalty payments payable to third parties with whom we may enter into license, acquisition and option agreements to acquire the rights to future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of, and obtain regulatory approval for, any of our product candidates or programs. The successful development of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with product development, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the timing and progress of preclinical and clinical development activities; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the number and scope of preclinical and clinical programs we decide to pursue; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">raising additional funds necessary to complete preclinical and clinical development of our product candidates; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the timing of filing and acceptance of investigational new drug applications, or INDs, or comparable foreign applications that allow commencement of future clinical trials for our product candidates; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the successful initiation, enrollment and completion of clinical trials; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our ability to achieve positive results from our future clinical programs that support a finding of safety and effectiveness and an acceptable risk-benefit profile in the intended patient populations of any product candidates we may develop; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize, our product candidates for the expected indications and patient populations; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our ability to hire and retain key research and development personnel; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the costs associated with the development of any additional product candidates we develop or acquire through collaborations; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our ability to establish and maintain agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidates are approved; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the terms and timing of any existing or future collaboration, license or other arrangement, including the terms and timing of any milestone payments thereunder; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our ability to establish and obtain intellectual property protection and regulatory exclusivity for our product candidates and enforce and defend our intellectual property rights and claims; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">141</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our ability to commercialize products, if and when approved, whether alone or in collaboration with others; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our ability to maintain a continued acceptable safety, tolerability and efficacy profile of our product candidates following approval; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the effects of the COVID-19 pandemic. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A change in any of these variables with respect to any of our current or future product candidates could significantly change the costs, timing and viability associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any product candidate we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">General and administrative expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">General and administrative expenses consist primarily of personnel-related costs, including salaries, benefits and stock-based compensation, for personnel in our executive, intellectual property, business development, and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters, professional fees for accounting, auditing, tax and consulting services, insurance costs, travel, and direct and allocated facility-related expenses and other operating costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We anticipate that our general and administrative expenses will increase in the future to support increased research and development activities. We also expect to continue to incur increased costs associated with being a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq and Securities and Exchange Commission, or SEC, requirements, director and officer insurance costs, and investor and public relations costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Other income (expense)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Change in fair value of preferred stock tranche liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value of preferred stock tranche liability consists primarily of remeasurement gains or losses associated with changes in the fair value of the tranche rights associated with our Series A Preferred Stock. The preferred stock tranche liability was settled as of December 31, 2020, and therefore, there will be no further remeasurement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Change in fair value of antidilution rights liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value of antidilution rights liability consists of remeasurement gains or losses associated with changes in the antidilution rights liability associated with our license agreements with Harvard and Broad, or the Harvard/Broad License Agreement, and Broad, or the Broad License Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The antidilution rights represent the obligation to issue additional shares of common stock to Harvard and Broad following the completion of preferred stock financings and other equity financings, which was fully satisfied upon the closing of our IPO. At the inception of the agreements, the liability for the antidilution rights was recorded at fair value with the cost recorded as research and development expense and will be remeasured at each reporting period with changes recorded in other income (expense) while the instruments are outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The antidilution rights liability was partially satisfied in 2019 and 2020 and was satisfied in full in June 2021 upon the closing of our IPO with the issuance of an additional 878,098 shares of our common stock.</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Change in fair value of success payment liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are also obligated to pay to Harvard and Broad tiered success payments in the event our average market capitalization exceeds specified thresholds ascending from a high nine-digit dollar amount to $10.0 billion, or sale of our company for consideration in excess of those thresholds. In the event of a change of control of our company or a sale of our company, we are required to pay any related success payment in cash within a specified period following such event. Otherwise, the success payments may be settled at our option in either cash or shares of our common stock, or a combination of cash and shares of our common stock. The maximum aggregate success payments that could be payable by us are $31.3 million. At inception of the agreements, the success payment liabilities were recorded at fair value with the cost recorded as research and development expense and will be remeasured at each reporting period with charges recorded in other income (expense) while the instrument is outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Depending on our valuation, the fair value of the antidilution rights and success payment liabilities, and the corresponding changes in fair value that we record in our statements of operations, could fluctuate significantly from period to period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">142</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the year ended December 31, 2021, certain success payment obligations were triggered, and amounts due to Harvard and Broad totaled $6.3 million. These amounts were settled in cash in November 2021. The remaining success payment obligations will continue to be revalued at the end of each reporting period.</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Interest and other income (expense), net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Interest and other income primarily consisted of interest earned on our marketable securities and other miscellaneous income and expenses unrelated to our core operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Income tax</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021, we had federal net operating loss, or NOL, carryforwards of $124.7 million and state NOL carryforwards of $114.4 million. The federal NOL carryforwards have an indefinite life and can be utilized to offset 80% of future taxable income, while the state NOL carryforwards will expire at various dates through 2041</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. We have recorded a full valuation allowance against our net deferred tax assets due to uncertainties as to their ultimate realization. We currently anticipate that there will be no change in our unrecognized tax benefits in the next twelve months. As of December 31, 2021, we had no unrecognized tax benefits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Results of operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Comparison of years ended December 31, 2021 and 2020</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes our results of operations for the years ended December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.586%;"></td>
    <td style="width:1.372%;"></td>
    <td style="width:1.432%;"></td>
    <td style="width:10.826%;"></td>
    <td style="width:0.855%;"></td>
    <td style="width:1.372%;"></td>
    <td style="width:1.432%;"></td>
    <td style="width:10.806%;"></td>
    <td style="width:0.855%;"></td>
    <td style="width:1.372%;"></td>
    <td style="width:1.432%;"></td>
    <td style="width:10.806%;"></td>
    <td style="width:0.855%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended<br />December 31,</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">68,202</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">35,371</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,831</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18,865</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,256</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13,609</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">87,067</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">40,627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">46,440</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value of preferred stock tranche liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,507</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(2,507</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value of antidilution rights liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(25,574</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(5,359</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(20,215</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value of success payment liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(7,815</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(2,387</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(5,428</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Interest and other income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">142</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">162</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(20</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total other expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(33,247</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(5,077</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(28,170</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(120,314</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(45,704</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(74,610</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Research and development expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes our research and development expenses for the years ended December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.385%;"></td>
    <td style="width:1.6%;"></td>
    <td style="width:1.441%;"></td>
    <td style="width:13.05%;"></td>
    <td style="width:0.716%;"></td>
    <td style="width:1.6%;"></td>
    <td style="width:1.441%;"></td>
    <td style="width:13.05%;"></td>
    <td style="width:0.716%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended<br />December 31,</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Employee-related expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19,859</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,294</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Raw material costs and external expenses associated with manufacturing activities, including third-party CMOs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,628</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,684</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">External expenses associated with preclinical studies performed by outside consulting services, including third-party CROs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17,681</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11,907</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Lab supplies used in research and development activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,094</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Facility-related costs (including depreciation)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,583</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,542</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">License and milestone payments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,031</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,938</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other research and development costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,790</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,912</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">68,202</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">35,371</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">143</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development expenses were $68.2 million for the year ended December 31, 2021, compared to $35.4 million for the year ended December 31, 2020. The increase of $32.8 million was primarily due to the advancement of our pipeline and included the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an increase in external expenses associated with preclinical studies (primarily animal-study costs) performed by outside consulting services, including third-party CROs, of $5.8 million; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an increase in raw material costs and expenses associated with developing and validating our manufacturing process for use in our preclinical studies and future clinical trials of $10.9 million;</span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an increase in personnel-related costs, including stock-based compensation, of $12.6 million driven by an increase in headcount of employees involved in research and development activities; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an increase in lab supplies of $2.5 million due to the increased investment in research and development activities in 2021; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an increase in facility-related costs (including depreciation) and other allocated miscellaneous expenses of $1.0 million due to the increased investment in research and development activities in 2021; and</span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an increase in other research and development costs of $1.9 million, primarily due to an increase in professional fees and consulting fees in support of increased investment in research and development activities in 2021; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">partially offset by a decrease in research and development expense attributed to license and milestone payments of $1.9 million, primarily due to fewer licensing transactions in 2021 (and therefore reduced upfront licensing payments). </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We expect that our research and development expenses will continue to increase for the foreseeable future as we advance our programs and product candidates into and through clinical development, and as we continue to develop additional product candidates.</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">General and administrative expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">General and administrative expenses were $18.9 million for the year ended December 31, 2021, compared to $5.3 million for the year ended December 31, 2020. The increase of $13.6 million was primarily attributable to the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an increase of $8.3 million in personnel costs stemming from an increase in headcount to support our growth; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an increase of $2.4 million in legal and professional service fees, primarily due to increased professional fees for audit, tax and consulting services; and</span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an increase in other expenses of approximately $2.9 million, including increased insurance expense of $1.5 million for our directors and officers insurance policy and increases in software, IT and facility costs.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We anticipate that our general and administrative expenses will increase in the future to support increased research and development activities.</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Other income (expense)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Change in fair value of preferred stock tranche liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The decrease of $2.5 million in fair value of the preferred stock tranche liability was due to the modification of the remaining milestones and subsequent settlement of the preferred stock tranche liability in March 2020, resulting in the issuance of Series A Preferred Stock. The preferred stock tranche liability was fully settled as of December 31, 2020.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Change in fair value of antidilution rights liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The increase of $20.2 million in fair value of the antidilution rights liability was primarily due to the settlement of the liability during the year ended December 31, 2021 with the issuance of 878,098 shares of our common stock. The settlement amount was $32.5 million and resulted in a fair value adjustment to the antidilution rights liability of $25.6 million due to an increase in the fair value of the shares being issued upon settlement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">144</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Change in fair value of success payments liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The increase of $5.4 million in fair value of the success payments liability was primarily attributable to the increase in the fair value of our common stock which resulted in a fair value adjustment of $7.8 million to other expense during the year ended December 31, 2021. During the year ended December 31, 2021, certain success payment obligations were triggered, and amounts due to Harvard and Broad totaled $6.3 million. These amounts were settled in cash in November 2021. The remaining success payment obligations will continue to be revalued at the end of each reporting period.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Interest and other income (expense), net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The decrease of less than $0.1 million in 2021 was primarily attributable to losses on foreign currency transactions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Comparison of years ended December 31, 2020 and 2019</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes our results of operations for the years ended December 31, 2020 and 2019:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.589%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:1.431%;"></td>
    <td style="width:10.803%;"></td>
    <td style="width:0.865%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:1.431%;"></td>
    <td style="width:10.803%;"></td>
    <td style="width:0.865%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:1.431%;"></td>
    <td style="width:10.803%;"></td>
    <td style="width:0.865%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended<br />December 31,</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">35,371</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11,144</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">24,227</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,256</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,498</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,758</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">40,627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13,642</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">26,985</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value of preferred stock tranche liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,507</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(4,883</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,390</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value of antidilution rights liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(5,359</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(982</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(4,377</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value of success payment liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(2,387</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(68</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(2,319</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Interest and other income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">162</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">278</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(116</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total other expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(5,077</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(5,655</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">578</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(45,704</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(19,297</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(26,407</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Research and development expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes our research and development expenses for the years ended December 31, 2020 and 2019:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.385%;"></td>
    <td style="width:1.6%;"></td>
    <td style="width:1.441%;"></td>
    <td style="width:13.05%;"></td>
    <td style="width:0.716%;"></td>
    <td style="width:1.6%;"></td>
    <td style="width:1.441%;"></td>
    <td style="width:13.05%;"></td>
    <td style="width:0.716%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended<br />December 31,</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Employee-related expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,294</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,602</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Raw material costs and external expenses associated with manufacturing activities, including third-party CMOs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,684</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">External expenses associated with preclinical studies performed by outside consulting services, including third-party CROs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11,907</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,417</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Lab supplies used in research and development activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,094</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,190</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Facility-related costs (including depreciation)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,542</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">307</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">License and milestone payments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,938</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,613</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other research and development costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,912</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,003</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">35,371</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11,144</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development expenses were $35.4 million for the year ended December 31, 2020, compared to $11.1 million for the year ended December 31, 2019. The increase of $24.2 million was primarily due to the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an increase in external expenses associated with preclinical studies (primarily animal-study costs) performed by outside consulting services, including third-party CROs, of $10.5 million; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an increase in raw material costs and expenses associated with developing and validating our manufacturing process for use in our preclinical studies and future clinical trials of $5.7 million;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">145</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an increase in personnel-related costs of $4.7 million driven by an increase in headcount of employees involved in research and development activities; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an increase in lab supplies of $0.9 million due to the increased investment in research and development activities in 2020; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an increase in facility-related costs (including depreciation) and other allocated miscellaneous expenses of $2.2 million due to the increased investment in research and development activities in 2020; and</span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an increase in other research and development costs of $0.9 million, primarily due to an increase in professional fees and consulting fees in support of increased investment in research and development activities in 2020; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">partially offset by a decrease in research and development expense attributed to license and milestone payments of $0.7 million, primarily due to fewer licensing transactions in 2020 (and therefore reduced upfront licensing payments). </span></div></div>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">General and administrative expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">General and administrative expenses were $5.3 million for the year ended December 31, 2020, compared to $2.5 million for the year ended December 31, 2019. The increase of $2.8 million was primarily attributable to the following: </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an increase of $2.0 million in personnel, facility and other expenses stemming from an increase in headcount to support our growth; and</span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an increase of $0.4 million in legal and professional service fees, primarily due to increased professional fees for audit, tax and consulting services. </span></div></div>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Other income (expense)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Change in fair value of preferred stock tranche liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The change in fair value of the preferred stock tranche liability was primarily due to an increase in 2019 of the probability of the tranche milestones being met, followed by the settlement of the preferred stock tranche liability in March 2020 and issuance of Series A Preferred Stock.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Change in fair value of antidilution rights liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The change in fair value of the antidilution rights liability was primarily attributable to a higher cumulative probability in 2020 of the respective triggering events being met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Change in fair value of success payments liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The change in fair value of the success payments liability was primarily attributable to a higher cumulative probability in 2020 of the respective triggering events being met.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Interest and other income (expense), net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The decrease of $0.1 million in 2020 was attributable to lower interest rates on our investments in 2020 compared to 2019.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Liquidity and capital resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Sources of liquidity and capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Since our inception in 2018, we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and, if successful, clinical development of our programs. To date, we have funded our operations primarily through equity offerings. Through December 31, 2021, we had raised an aggregate of $523.2 million in gross proceeds from sales of our preferred stock in private placements and common stock in our IPO. As of December 31, 2021, we had $360.4 million in cash, cash equivalents and marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2021, we completed our IPO in which we issued 16,141,157 shares of common stock, including 2,105,368 shares of common stock sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a public offering price of $19.00 per share. We received net proceeds from our IPO of $281.6</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">146</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">million, after deducting underwriting discounts and offering expenses payable by us. In June 2021, we issued 878,098 shares of our common stock to Harvard and Broad as final settlement of the antidilution rights liability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Cash flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes our sources and uses of cash for each period presented:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.555%;"></td>
    <td style="width:1.372%;"></td>
    <td style="width:1.431%;"></td>
    <td style="width:10.834%;"></td>
    <td style="width:0.865%;"></td>
    <td style="width:1.372%;"></td>
    <td style="width:1.431%;"></td>
    <td style="width:10.804%;"></td>
    <td style="width:0.865%;"></td>
    <td style="width:1.372%;"></td>
    <td style="width:1.431%;"></td>
    <td style="width:10.804%;"></td>
    <td style="width:0.865%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended<br />December 31,</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(77,880</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(35,265</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(7,442</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cash used in investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(239,098</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(51,127</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(12,758</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">377,089</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">92,627</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17,954</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">60,111</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,235</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(2,246</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Operating activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For the year ended December 31, 2021, net cash used in operating activities was $77.9 million, consisting primarily of our net loss of $120.3 million and a net decr</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ease in our operating assets and liabilities of $2.9 million. These amounts were partially offset by the following non-cash changes: change in fair value of antidilution rights and success payment liabilities of $33.4 million, depreciation expense of $1.5 million, stock-based compensation of $7.1 million, non-cash lease expense of $1.8 million and amortization of premiums on marketable securities of $1.5 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For the year ended December 31, 2020, net cash used in operating activities was $35.3 million, consisting primarily of our net loss of $45.7 million and a </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">decrease attributable to non-cash items of $2.5 million associated with the fair value change in the preferred stock tranche liability. These amounts were partially offset by the following non-cash changes: change in fair value of antidilution rights and success payment liabilities of $7.7 million, depreciation expense of $1.3 million, stock-based compensation of $0.9 million and amortization of premiums on marketable securities of $0.4 million, as well as a net increase in our operating assets and liabilities of $2.6 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For the year ended December 31, 2019, net cash used in operating activities was $7.4 million, consisting primarily of our net loss of $19.3 million, which was partially offset by the following non-cash charges: change in fair value of preferred stock tranche liability of $4.9 million, non-cash research and development license expense of $2.8 million (primarily associated with our Harvard/ Broad License Agreement and Broad License Agreement), change in fair value of antidilution rights and success payment liabilities of $1.1 million, stock-based compensation of $0.4 million and a net increase in our operating assets and liabilities of $2.7 million.</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Investing activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For the year ended December 31, 2021, net cash u</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">sed in investing activities was $239.1 million, consisting of purchases of marketable securities of $371.5 million and purchases of property and equipment of $4.4 million, primarily related to lab equipment, which amounts were offset partially by maturities of marketable securities of $136.8 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For the year ended December 31, 2020, net cash used in investing activities was $51.1 million, consisting of purchases of marketable securities of $98.5 million and purchases of property and equipment of $3.4 million, primarily related to lab equipment, which amounts were offset partially by maturities of marketable securities of $50.8 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For the year ended December 31, 2019, net cash used in investing activities was $12.8 million, consisting of purchases of marketable securities of $22.0 million and purchases of property and equipment of $1.9 million, primarily related to lab equipment, and  which amounts were offset partially by maturities of marketable securities of $11.1 million.</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Financing activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For the year ended December 31, 2021, net cash provided by financing activities was $377.1 million, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">consisting of the net proceeds from the issuance of Series B Preferred Stock of $93.8 million, net proceeds from the sale of our common stock in our IPO of $285.2 million, proceeds from exercises of stock options of $1.0 million and issuance of shares through our employee stock purchase plan of approximately $0.7 million, offset partially by payment of IPO expenses of $3.6 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">147</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For the year ended December 31, 2020, net cash provided by financing activities was $92.6 million consisting of the net proceeds from the issuance of Series A Preferred Stock of $29.7 million and net proceeds from the issuance of Series A-2 Preferred Stock of $62.9 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For the year ended December 31, 2019, net cash provided by financing activities was $18.0 million consisting primarily of net proceeds from the issuance of Series A Preferred Stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Funding requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our operating expenses and future funding requirements are expected to increase substantially as we continue to advance our portfolio of programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Specifically, our expenses will increase if and as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">continue our current research programs and our preclinical development of product candidates from our current research programs; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">seek to identify additional research programs and additional product candidates; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">advance our existing and future product candidates into clinical development; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">initiate preclinical studies and clinical trials for any additional product candidates we identify and develop or expand development of existing programs into additional patient populations; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">maintain, expand, enforce, defend and protect our intellectual property portfolio and provide reimbursement of third-party expenses related to our patent portfolio; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">seek regulatory and marketing approvals for any of our product candidates that we develop; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">seek to identify, establish and maintain additional collaborations and license agreements, and the success of those collaborations and license agreements; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">make milestone payments to Beam under our collaboration and license agreement with Beam, to Acuitas under our non-exclusive license agreement with Acuitas, under the Harvard/ Broad License Agreements, and under any additional future collaboration or license agreements that we obtain; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ultimately establish a sales, marketing, and distribution infrastructure to commercialize any drug products for which we may obtain marketing approval, either by ourselves or in collaboration with others; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">generate revenue from commercial sales of product candidates we may develop for which we receive marketing approval; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">further develop our base editing technology; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">hire additional personnel including research and development, clinical and commercial personnel; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">add operational, financial and management information systems;</span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">add personnel including personnel to support our product development; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">acquire or in-license products, intellectual property, medicines and technologies; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">satisfy any post-marketing requirements, such as a cardiovascular outcomes trial; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">establish commercial-scale current good manufacturing practices, or cGMP, capabilities through a third-party or our own manufacturing facility; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">continue to operate as a public company. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021, we had cash, cash equivalents and marketable securities of $360.4 million. We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2024</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">148</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">products that we do not expect to be commercially available for several years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our expectation with respect to our ability to fund current planned operations is based on estimates that are subject to risks and uncertainties. Our operating plan may change as a result of many factors currently unknown to management and there can be no assurance that the current operating plan will be achieved in the time frame anticipated by us, and we may need to seek additional funds sooner than planned.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Adequate additional funds may not be available to us on acceptable terms, or at all. We do not have any source of committed external funds. Market volatility could also adversely impact our ability to access capital as and when needed. Additional capital raised through the sale of equity or convertible debt securities, may include liquidation or other preferences. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures or declaring dividends and may require the issuance of warrants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed or on terms acceptable to us, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Contractual obligations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We lease certain assets under noncancelable operating leases, which expire through 2032. The leases relate primarily to office space and laboratory space. Our aggregate future minimum commitments under these office and laboratory leases were $108.8 million as of December 31, 2021, excluding any related common area maintenance charges or real estate taxes. For additional information regarding these leases, refer to Note 7, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, to our consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We enter into contracts in the normal course of business with CROs, CMOs and other third parties for preclinical research studies and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable by us upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have also entered into license agreements under which we may be obligated to make certain payments. For example, in November 2021, we paid success payments of approximately $6.3 million to Broad and Harvard that were triggered under the Harvard/Broad License Agreement. If additional success payments are triggered, we would be obligated to pay Broad and Harvard up to an additional $25.0 million under the Harvard/Broad License Agreement. Our agreements to license intellectual property include potential milestone payments that are dependent upon the development of products using the intellectual property licensed under the agreements and contingent upon the achievement of development or regulatory approval milestones, as well as commercial and success payment milestones. Such payment obligations are contingent upon the occurrence of future events and the timing and likelihood of such potential obligations are not known. For additional information about our license agreements and amounts that could become payable in the future under such agreements, see &#x201c;Business&#x2014;License and collaboration agreements&#x201d; and Note 8, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">License agreements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, to our consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Emerging growth company and smaller reporting company status</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As an emerging growth company, or EGC, under the Jumpstart Our Business Startups Act of 2012, or JOBS Act, we may delay the adoption of certain accounting standards until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for EGCs include presentation of only two years of audited financial statements in a registration statement for an initial public offering, or IPO, an exemption from the requirement to provide an auditor&#x2019;s report on internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, the JOBS Act provides that an EGC can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an EGC to delay the adoption of some</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">149</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">accounting standards until those standards would otherwise apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We may remain classified as an EGC until the end of the fiscal year until December 31, 2026, although if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June 30 before that time or if we have annual gross revenues of $1.07 billion or more in any fiscal year, we would cease to be an emerging growth company as of December 31 of the applicable year. We also would cease to be an EGC if we issue more than $1 billion of non-convertible debt over a three-year period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are also a &#x201c;smaller reporting company,&#x201d; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act,, although we will cease to be a smaller reporting company in connection with the filing of our Quarterly Report on Form 10-Q for the first quarter of 2022. Similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations, such as an ability to provide simplified executive compensation information and only two years of audited financial statements in an annual report on Form 10-K, with correspondingly reduced &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; disclosure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Critical accounting policies and significant judgments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This management&#x2019;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements and related disclosures requires us to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">While our significant accounting policies are described in more detail in Note 2, Summary of significant accounting policies, to our consolidated financial statements, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">accrued research and development expenses; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">stock-based compensation and common stock valuation; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">fair value measurements. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Accrued research and development expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As part of the process of preparing our consolidated financial statements, we are required to estimate certain accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include those related to fees paid to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">vendors in connection with discovery and preclinical development activities; </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">CROs in connection with preclinical studies and testing; and </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">CMOs in connection with the process development and scale up activities and the production of materials. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We base the expense recorded related to contract research and manufacturing on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CROs and CMOs that conduct services and supply materials. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">150</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses. While the majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; some require advance payments. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. We record these as prepaid expenses on our consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We measure stock options and other stock-based awards granted to employees, directors, consultants or founders based upon their fair value on the date of the grant and recognize stock-based compensation expense over the requisite service period, which is generally the vesting period of the respective award. We recognize forfeitures as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The stock-based compensation awards are subject to either service or performance-based vesting conditions. We apply the straight-line method of expense recognition to all awards with service-based vesting and recognize stock-based compensation for performance awards based on grant date fair value over the service period using the accelerated attribution method to the extent achievement of the performance condition is probable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We estimate the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model, which uses inputs such as the fair value of our common stock, assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-fee interest rate for a period that approximates the expected term of our stock options and our expected dividend yield. The fair value of our common stock is used to determine the fair value of restricted stock awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to our IPO in June 2021, there was no public market for our common stock. As a result, prior to our IPO, the estimated fair value of our common stock was determined by our board of directors as of the date of each option grant, with input from management, considering our most recently available third-party valuations of common stock and our board of directors' assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of grant. Following our IPO, the fair value of our common stock is determined based on the quoted market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Fair value measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Antidilution rights liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The antidilution rights liability represents the obligation to issue additional shares of common stock to Harvard and Broad following the completion of preferred stock financings and upon the closing of our IPO. These antidilution rights are accounted for under ASC 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, and were initially recorded at fair value with a corresponding charge to research and development expense. Any subsequent changes in fair value are recognized in other income (expense) in the statement of operations at each reporting period. The antidilution rights liability was valued using (i) a probability-weighted present value model that considered the probability of meeting the defined aggregate level of preferred stock financing, as well as the fair value of our common stock and (ii) a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the fair value of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The antidilution rights liability was partially satisfied in 2019 and 2020 and was satisfied in full upon the issuance of an aggregate of an additional 878,098 shares of common stock upon the closing of our IPO in June 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Success payments liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are required to make success payments to Harvard and Broad in the event our average market capitalization, since the filing of our first Quarterly Report on Form 10-Q, exceeds specified thresholds ascending from a high nine digit dollar amount to $10.0 billion, or sale of our company for consideration in excess of those thresholds. In the event of a change of control of our company or a sale of our company, we are required to pay in cash within a specified period following such event. Otherwise, the payments may be settled at our option in either cash or shares of our common stock, or a combination of cash and shares of our common stock. The success payments are accounted for under ASC 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, and were initially recorded at fair value with a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">151</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">corresponding charge to research and development expense. Any subsequent changes in fair value are recognized in other income (expense) in the statement of operations. We will continue to adjust the liability for changes in fair value until the earlier of the achievement or expiration of the success payment obligation. To determine the estimated fair value of the success payments, we used a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the value of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Recently issued accounting pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">See Note 2, &#x201c;Summary of significant accounting policies &#x2013; Recently issued accounting pronouncements&#x201d; in the accompanying notes to our consolidated financial statements included at the end of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 7A. Quantitative and Qualitative Disclosures</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;"> About Market Risk.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Interest rate risk</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are exposed to market risk related to changes in interest rates. As of December 31, 2021, we had cash and equivalents of $64.3 million, which consisted of standard checking accounts and money market account funds that invest primarily in the U.S. government-backed securities and treasuries. In addition, as of December 31, 2021, we had marketable securities of $296.1 million, which consist of U.S. treasury securities and agency securities. Interest income is sensitive to change in the general level of interest rates, however, due to the short-term maturities of our cash equivalents and the low risk profile of our marketable securities, an immediate 10% change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Foreign currency exchange risk</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we do contract with vendors that are located outside of the United States and may be subject to fluctuations in foreign currency rates. We may enter into additional contracts with vendors located outside of the United States in the future, which may increase our foreign currency exchange risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We do not believe that inflation had a material effect on our business, financial condition or results of operations during the year ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">152</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 8. Financial Statements and Supplementary Data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The financial statements required pursuant to Item 8 are incorporated by reference herein from the applicable information included in Item 15 of this Annual Report on Form 10-K and are presented beginning on page F-1.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 9. Changes in and Disagreements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;"> With Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 9A. Controls and Procedures</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this annual report. Based on such evaluation, our principal executive officer and principal financial officer have concluded that as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Management&#x2019;s Annual Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This annual report does not include a report of management&#x2019;s assessment regarding internal control over financial reporting due to a transition period established by the rules of the SEC for newly public companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Attestation Report of the Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This annual report does not include an attestation report of our registered public accounting firm due to an exemption provided by the JOBS Act for &#x201c;emerging growth companies.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2011;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">15(f) under the Exchange Act) during the three months ended December 31, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 9B. Other Information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">153</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_disclosure_regarding"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 9C. Disclosure Re</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">garding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">154</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">PART III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 10. Directors, Executive Officers a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">nd Corporate Governance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The information required by this Item 10 will be included in our definitive proxy statement to be filed with the Securities and Exchange Commission, or SEC, with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have adopted a written code of business conduct and ethics, or Code, that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the Code is available on the investor section of our website at investors.vervetx.com. We intend to disclose on our website any amendments to, or waivers from, our Code that are required to be disclosed pursuant to SEC rules.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 11. Executive Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The information required by this Item 11 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_of_certain"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 12. Security Ownership of Certain</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;"> Beneficial Owners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The information required by this Item 12 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 13. Certain Relationships and Related </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Transactions, and Director Independence.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The information required by this Item 13 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 14. Principal Accounting Fees</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;"> and Services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The information required by this Item 14 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">155</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">PART IV</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 15. Exhibits, Financial Statement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;"> Schedules.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Financial Statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The financial statements of Verve Therapeutics, Inc., together with the report thereon of Ernst &amp; Young LLP, an independent registered public accounting firm (PCAOB ID: </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_cf784487-7054-4eee-b4d3-aeed5800ed03" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">42</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">), are included in this Annual Report on Form 10-K beginning on page F-1.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Financial Statement Schedules.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Exhibits</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.001%;"></td>
    <td style="width:2.004%;"></td>
    <td style="width:86.995%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521195234/d188013dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Restated Certificate of Incorporation of the Registrant, effective as of June 21, 2021 (incorporated by reference to Exhibit 3.1 to the Registrant&#x2019;s Current Report on Form 8-K, File No. 001-40489, filed June 21, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521195234/d188013dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Amended and Restated Bylaws of the Registrant, effective as of June 21, 2021 (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K, File No. 001-40489, filed June 21, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Specimen Stock Certificate evidencing the shares of common stock (incorporated by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-1, File No. 333-256608, filed May 28,2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Second Amended and Restated Investors&#x2019; Rights Agreement, dated as of January 14, 2021, by and among the Registrant and the other parties thereto (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Registration Statement on Form S-1, File No. 333-256608, filed May 28, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.3*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex4_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Description of Securities Registered under Section 12 of the Exchange Act</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;">#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">2018 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant&#x2019;s Registration Statement on Form S-1, File No. 333-256608, filed May 28, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;">#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Form of Stock Option Agreement under the 2018 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant&#x2019;s Registration Statement on Form S-1, File No. 333-256608, filed May 28, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;">#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521189442/d140009dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">2021 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant&#x2019;s Amendment No. 1 to Registration Statement on Form S-1, File No. 333-256608, filed June 14, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.4*</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;">#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex10_4.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Form of Stock Option Agreement under the 2021 Stock Incentive Plan</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.5*</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;">#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex10_5.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Form of Restricted Stock Unit Agreement under the 2021 Stock Incentive Plan</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;">#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521189442/d140009dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Amended and Restated 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.7 to the Registrant&#x2019;s Amendment No. 1 to Registration Statement on Form S-1, File No. 333-256608, filed June 14, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.7*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex10_7.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Summary of Non-Employee Director Compensation Program</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Collaboration and License Agreement, dated as of April 3, 2019, by and between the Registrant and Beam Therapeutics Inc. (incorporated by reference to Exhibit 10.9 to the Registrant&#x2019;s Registration Statement on Form S-1, File No. 333-256608, filed May 28, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Amended and Restated Development and Option Agreement, dated as of October 6, 2020, by and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">between the Registrant and Acuitas Therapeutics, Inc. (incorporated by reference to Exhibit 10.10 to the Registrant&#x2019;s Registration Statement on Form S-1, File No. 333-256608, filed May 28, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex1011.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Non-Exclusive License Agreement, dated as of October 14, 2020, by and between the Registrant and Acuitas Therapeutics, Inc. (incorporated by reference to Exhibit 10.11 to the Registrant&#x2019;s</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Registration Statement on Form S-1, File No. 333-256608, filed May 28, 2021)</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">156</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.001%;"></td>
    <td style="width:2.004%;"></td>
    <td style="width:86.995%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex1012.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Cas9 License Agreement, dated as of March 15, 2019, by and among the Registrant, The President and Fellows of Harvard College and The Broad Institute, Inc., as amended (incorporated by reference to Exhibit 10.12 to the Registrant&#x2019;s Registration Statement on Form S-1, File</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">No. 333-256608, filed May 28, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.12</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex1013.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Sublease, dated as of April 13, 2020, by and between the Registrant and Foghorn Therapeutics Inc., as amended (incorporated by reference to Exhibit 10.13 to the Registrant&#x2019;s Registration Statement on Form S-1, File No. 333-256608, filed May 28, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000095017021003894/verv-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Lease, dated as of August 19, 2021, by and between the Registrant and ARE-MA Region No. 87</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Tenant, LLC (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Quarterly Report on Form 10-Q, filed on November 10, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.14*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex10_14.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">First Amendment to Lease, dated as of January 4, 2022, by and between the Registrant and ARE-MA Region No. 87 Tenant, LLC</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.15#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex1017.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Form of indemnification agreement between the Registrant and each of its executive officers and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">directors (incorporated by reference to Exhibit 10.17 to the Registrant&#x2019;s Registration Statement on Form S-1, File No. 333-256608, filed May 28, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.16#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521189442/d140009dex1018.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Employment Agreement, dated as of June 11, 2021, between the Registrant and Sekar Kathiresan, M.D. (incorporated by reference to Exhibit 10.18 to the Registrant&#x2019;s Amendment No. 1 to Registration Statement on Form S-1, File No. 333-256608, filed June 14, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.17#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521189442/d140009dex1019.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Employment Agreement, dated as of June 11, 2021, between the Registrant and Andrew Ashe, J.D. (incorporated by reference to Exhibit 10.19 to the Registrant&#x2019;s Amendment No. 1 to Registration Statement on Form S-1, File No. 333-256608, filed June 14, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.18#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521189442/d140009dex1020.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Employment Agreement, dated as of June 11, 2021, between the Registrant and Andrew Bellinger, M.D., Ph.D. (incorporated by reference to Exhibit 10.20 to the Registrant&#x2019;s Amendment No. 1 to Registration Statement on Form S-1, File No. 333-256608, filed June 14, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.19*#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex10_19.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Employment Agreement, dated as of November 26, 2021, between the Registrant and Allison Dorval</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex211.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Registrant&#x2019;s</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Registration Statement on Form S-1, File No. 333-256608, filed May 28, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">23.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Consent of Ernst &amp; Young LLP, independent registered public accounting firm</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">31.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">31.2*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32.1**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32.2**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">* Filed herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">** Furnished herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#134; Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"># Indicates management contract or compensatory plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Item 16. Form 10-K Summary</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">157</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.223%;"></td>
    <td style="width:2.823%;"></td>
    <td style="width:5.667%;"></td>
    <td style="width:46.287%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">VERVE THERAPEUTICS, INC.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Date:</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;&#160;March 14, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ Sekar Kathiresan</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Sekar Kathiresan</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Chief Executive Officer</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Principal Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.467%;"></td>
    <td style="width:1.533%;"></td>
    <td style="width:16.686%;"></td>
    <td style="width:1.533%;"></td>
    <td style="width:31.781%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Date</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ Sekar Kathiresan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;Chief Executive Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">March 14, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Sekar Kathiresan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#160;(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ Allison Dorval</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;Chief Financial Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">March 14, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Allison Dorval</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#160;(Principal Financial Officer and Principal Accounting Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ Burt Adelman</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">March 14, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Burt Adelman</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ John Evans</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">March 14, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">John Evans</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ Michael MacLean</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">March 14, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Michael MacLean</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ Sheila Mikhail</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">March 14, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Sheila Mikhail</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ Krishna Yeshwant</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">March 14, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Krishna Yeshwant</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">158</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.321%;"></td>
    <td style="width:7.679%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Arial;">Page</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Audited Financial Statements</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_independent_registered_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Report of independent registered public accounting firm</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Consolidated balance sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_stmts_of_opr_and_comp"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Consolidated statements of operations and comprehensive loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_stmt_of_convertible_prefer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Consolidated statements of convertible preferred stock and stockholders&#x2019; equity (deficit)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_stmt_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Consolidated statements of cash flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_cons_financial_stmt"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Notes to consolidated financial statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="report_of_independent_registered_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Report of Indep</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">endent Registered Public Accounting Firm</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To the Shareholders and the Board of Directors of Verve Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Opinion on the Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have audited the accompanying consolidated balance sheets of Verve Therapeutics, Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#x2019; equity (deficit) and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Adoption of ASU No. 2016-02</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As discussed in Note 2 to the consolidated financial statements, the Company changed its method of accounting for leases in 2021 due to the adoption of Accounting Standards Update (ASU) No. 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> (Topic 842), and the related amendments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Basis for Opinion</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_c797f504-8cf1-4a3a-8004-8264eba8105d" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Ernst &amp; Young LLP</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have served as the Company&#x2019;s auditor since 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_5a49f3af-9a2c-417c-85a0-50232bc6f82b" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Boston, Massachusetts</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">March 14, 2022</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Verve Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Consolidated balance sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.335%;"></td>
    <td style="width:1.6%;"></td>
    <td style="width:1.431%;"></td>
    <td style="width:12.941%;"></td>
    <td style="width:0.865%;"></td>
    <td style="width:1.6%;"></td>
    <td style="width:1.431%;"></td>
    <td style="width:12.931%;"></td>
    <td style="width:0.865%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31,</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands, except share and per share amounts)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Current assets:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a51fae52-5078-49d4-b720-8a47ed05f1f9" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,330</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1ceb684a-e429-4d0b-961b-3fdd1028de54" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,993</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Marketable securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b9091609-e59b-4a03-91c4-c6dafe8fe39e" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">296,112</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2667a7c4-705e-4899-ab7c-13eab4f4508b" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,119</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_88199754-54a6-4b66-a425-bfcfa8a2c1e5" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,686</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_92d1600b-14d6-4960-80b7-b882c7f7fd2d" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,854</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8628350c-7d28-4152-a7fb-448cf7ddf0db" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">367,128</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_672c3d50-4942-47d2-9ed3-941abf945227" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73,966</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c14da6c5-b71e-4e6e-9dfb-519e887ccabc" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,224</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_24637723-830b-4a13-b271-44423d63c753" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,984</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ab9a0b62-574b-4e4a-b5b2-a5b420713e98" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,237</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f2f55cee-3f7b-45de-b858-4249314d33f0" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">463</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_75b27076-f915-41fa-aa36-4839571c1b72" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,839</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_64ac9484-eb3b-4bca-b98e-0135f5b9319b" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other long term assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b1c97340-0b35-4ce6-8952-24173373c03b" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,696</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d98febaa-4eda-4755-a064-a684d3838efe" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6335638c-2e23-4268-8bdd-693a488786b5" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">384,124</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_25bd7310-847a-4fa9-9d26-3c5a0484a4de" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78,413</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Liabilities, convertible preferred stock, and stockholders&#x2019; equity (deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a85f864a-aca5-4528-b009-14c0b6d0ec6c" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a934d6ba-6fdd-40c0-9ed9-0f86f1189f26" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1e477143-f6df-4679-ab01-9a33f3db6218" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,992</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5e792990-8c0b-433f-8b8a-b28e2cad617c" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,189</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease obligations, current portion</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ab6de889-2dfd-4cc5-904d-4964550b06a6" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,955</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b00a4ec0-778a-4d69-8166-eb5fd1c9c29b" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred rent, current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8fc883a9-92db-48a7-a895-7a7a72f401e2" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:DeferredRentCreditCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_911188ef-0b7d-4419-876c-32a4aa3cc611" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:DeferredRentCreditCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">90</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_021e3a73-61cd-4e06-8aea-2c49249dcfce" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,024</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6b32b4b8-c4c1-4434-bfd3-4eb34d07e854" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,315</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred rent, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6a13dff3-0c68-4082-a47a-2b72be08f8be" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:DeferredRentCreditNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_67175970-d0a6-4319-a512-bbd20bead636" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:DeferredRentCreditNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">125</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Success payment liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_58274360-c9d2-42cf-a8d2-ca681fe7250e" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="verv:SuccessPaymentLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,371</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9739dee4-00b4-4064-ac86-a3e32f86ec4c" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="verv:SuccessPaymentLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,806</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Antidilution rights liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b82279ed-e492-4826-b9a1-f0a66a82a843" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="verv:AntidilutionRightsLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_05870e75-b964-4b35-a977-69648b9fc564" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="verv:AntidilutionRightsLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,916</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other long term liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ae9a2c2b-476b-460c-84ed-0f8adf6f7c65" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">377</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8af1377b-859e-447a-b0b3-371d1f26cb84" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ab8a86fc-2653-4362-bb3e-603926413d4c" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,772</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0b5bbf8f-6684-42a9-9186-bfb0ebb0d780" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,162</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_290ed904-ef2e-4b0f-8479-82d256b9d6b1;"><span style="-sec-ix-hidden:F_932e1120-c25b-42f9-8bd9-be59fe4ca8b0;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Commitments and contingencies (See Notes 7 and 8)</span></span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Convertible preferred stock (See Note 10)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_747ebff7-8b2b-4198-a3b4-d8d41165402e" contextRef="C_37648f64-a03f-4b57-83e1-dcf5c52767e2" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_de0ed0df-f492-4697-9669-d22ace666b44" contextRef="C_2c8ab043-9f70-4b7c-b82d-c140cdb7038c" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">125,160</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Stockholders&#x2019; equity (deficit):</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_93f5ba50-4f92-4b4c-b5f3-9b8de738e0d1" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_5c988436-9af9-4118-b6fe-31c181084a6b" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;par value; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_47209971-e492-4e4c-a2bc-23c25d5cff48" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_9a0f7e94-520a-4e38-936c-60420cf15837" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;shares authorized, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_57ba3643-4f7b-49da-8803-de116c0d5116" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2e1126db-a646-4d88-92f2-03fbc55829a8" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d30475fd-a943-48fe-8907-90e0357fd8aa" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_05b15d10-fe88-4488-a7f5-8f913fb161a4" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;shares issued and outstanding</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_d1baddea-0268-4ef8-92ff-2fd1d349837d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_d90eb3d0-a3a5-4e78-a456-79d0199bcd53;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Common stock, $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_088613a8-51b7-4c59-aa11-2ef0b4ceb220" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_b199e1f2-95bd-497c-9787-db3c3997faa6" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;par value; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_81d7b26f-47ee-4b2f-9c8d-4fb970a2afdd" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4cd3867e-130c-40fe-b545-0737cfbf237c" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">255,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;shares authorized at December 31, 2021 and 2020, respectively, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_cc674b35-13dc-4619-a562-13c30ddb9e6b" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,511,735</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6057a13a-4fda-4fc6-8573-7dc75201dafc" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,123,424</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;shares issued at December 31, 2021 and 2020, respectively; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6b3663f2-893c-4038-a01c-439724b08a56" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,511,735</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2d372f37-858a-496f-852e-724c08503745" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,585,789</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;shares outstanding at December 31, 2021 and 2020, respectively</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_86987cf8-ea18-412c-bb54-27c1512248f4" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_23f86597-32d7-4271-8509-7dbefc40a240" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c7c38810-4532-47fd-a298-92a157db5121" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">544,381</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6a3ff5c3-b329-4e81-bc06-84c75e53a8bc" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,616</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accumulated other comprehensive (loss) income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_caf9e20c-6474-41ef-8e8b-dca862afdd11" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">228</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_582c52fa-0edc-4a31-b86f-20ed848eff0f" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_778f7081-4af2-4d17-a272-078468b56894" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">186,850</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_aa44b87a-6c1e-4845-b4ee-10d7d934c8b6" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,536</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total stockholders&#x2019; equity (deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_203d2411-2f98-40f4-870d-e76a11a4ce89" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">357,352</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_be5e39c7-ea1b-4feb-bf88-ed52056251c5" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">63,909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total liabilities, convertible preferred stock, and stockholders&#x2019; equity (deficit)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f0e61c9a-bf65-4afb-b2d3-b39508116738" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">384,124</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_17645dd7-ec01-4f85-a534-93e70738163f" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78,413</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Verve Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="consolidated_stmts_of_opr_and_comp"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Consolidated statements of operations and comprehensive loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.457%;"></td>
    <td style="width:1.372%;"></td>
    <td style="width:1.432%;"></td>
    <td style="width:10.876%;"></td>
    <td style="width:0.855%;"></td>
    <td style="width:1.372%;"></td>
    <td style="width:1.432%;"></td>
    <td style="width:10.846%;"></td>
    <td style="width:0.855%;"></td>
    <td style="width:1.372%;"></td>
    <td style="width:1.432%;"></td>
    <td style="width:10.846%;"></td>
    <td style="width:0.855%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended December 31,</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands, except share and per share amounts)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e17c4a3f-15f4-42f5-b6e6-c81f9931331e" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,202</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_303f04a6-9f4d-46eb-be33-cd6f0e0b2eea" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,371</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e711f529-6af0-47c2-be63-a3b2aa746483" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,144</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_485d0c56-6ae6-4841-9c27-56eafee9a817" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,865</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_08bb3bee-d47c-4e0b-a455-7720469e2345" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,256</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_821e015b-7d97-4169-b428-a0ce51a7d6fc" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,498</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5911d009-aae6-4419-a9d6-24390fea6437" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,067</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f64e2a9f-91fe-4c75-9cdc-76529d5a3508" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,627</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_81e3033b-b828-4e15-8e9c-a00243ddc211" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,642</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1ea0a570-f55a-47a3-9649-1bc1dbfcaa4d" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">87,067</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_844be838-228b-4d9a-9730-c79af6392eca" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">40,627</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d29ec4bf-c4f5-4d24-806f-3c143758c4ad" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">13,642</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value of preferred stock tranche liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a935956f-84a0-429e-92f5-ee7f012afdf7" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:ChangeInFairValueOfPreferredStockTrancheLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ca192b77-9b02-49b5-be83-e0cc9c8cf971" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:ChangeInFairValueOfPreferredStockTrancheLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,507</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bed13db2-1b85-4a65-a2c0-647d726ed54c" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:ChangeInFairValueOfPreferredStockTrancheLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,883</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value of antidilution rights liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6a0e3ae6-4d9a-458d-a7da-f9b59ddf55bf" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:ChangeInFairValueOfAntidilutionRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,574</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a8a84390-d402-4dc0-b28a-a4bcbffbd2d1" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:ChangeInFairValueOfAntidilutionRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,359</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_cf75a017-b407-4ea1-9448-d169d5c20d1b" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:ChangeInFairValueOfAntidilutionRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">982</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value of success payment liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f400d4fc-0a61-4097-b4f8-e1ce2039e6c8" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:ChangeInFairValueOfSuccessPaymentsLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,815</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_52f57b29-8ea7-474c-9724-c0372f96e58b" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:ChangeInFairValueOfSuccessPaymentsLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,387</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_761acd68-42d8-4562-94af-da36048b8ca1" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:ChangeInFairValueOfSuccessPaymentsLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Interest and other income, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_43f21d05-c1c8-4fce-86c2-1b344d6ecb83" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">142</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f6b6265d-7d3b-45bd-a385-c96914399ee9" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">162</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c3525023-b061-48df-ba2a-6d55f8126751" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total other expense, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7050b25a-a5af-40d3-8ac8-e846d292977d" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">33,247</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_61b6a7ee-dab0-4dcc-b097-2eaefb3ba057" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_cd0aa2b9-7bfa-4805-b989-2e236fc27c54" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,655</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3012f02e-33c2-4f9d-b6e8-9a4a7b446900" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b0e32c01-1b26-4224-ac49-073b1dbbbb69" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,704</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_068f75c0-0655-4232-8c1a-6846c6743a5f" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">19,297</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss per common share attributable to common stockholders, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_129f19f7-f831-424f-a8fa-b8409db068ed" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">4.48</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_848431d1-530e-477f-b184-0d80e80daaec" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">20.31</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d5c17042-53f5-4585-ade3-c0cd3b9c650b" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">15.11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted-average common shares used in net loss per share attributable to common stockholders, basic and diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_203d5814-98c8-4579-96d1-13799b8815b4" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">26,872,036</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_20020b40-e83b-4de5-8d46-4dd4f0510dc4" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,250,093</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7b714ba1-37b6-426e-baa3-3af92689e40b" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,277,156</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Comprehensive Loss:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e901f7cd-3579-4134-8c38-b3a9e15abab2" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c5f4c4de-cedb-4808-8b44-6ce0e56109a4" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,704</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5695fa66-c320-4a6c-9f8f-6e7a40c8d95d" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">19,297</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other comprehensive (loss) income:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unrealized (loss) gain on marketable securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b231ab16-4fad-41ed-93fc-cd71e940edcf" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">236</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_222c5736-be92-4bf8-9955-8659758c2e6f" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_21f43725-58f4-48d5-9fd2-2684df391c3c" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8f30ae09-8909-4f5e-87ba-dd7a15ce038d" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,550</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_49d47ab4-c453-4bde-baac-2683698791ed" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,705</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0ca5cfef-c41f-4476-863a-471a6f64efe9" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">19,288</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Verve Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="consolidated_stmt_of_convertible_prefer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Consolidated statements of convertible preferred</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;"> stock and stockholders&#x2019; equity (deficit)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:26.281%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:0.41%;"></td>
    <td style="width:6.901%;"></td>
    <td style="width:0.498%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:0.856%;"></td>
    <td style="width:6.089%;"></td>
    <td style="width:0.498%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:0.41%;"></td>
    <td style="width:6.66%;"></td>
    <td style="width:0.41%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:0.864%;"></td>
    <td style="width:6.177%;"></td>
    <td style="width:0.41%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:0.864%;"></td>
    <td style="width:6.704%;"></td>
    <td style="width:0.41%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:0.864%;"></td>
    <td style="width:8.204%;"></td>
    <td style="width:0.498%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:0.864%;"></td>
    <td style="width:6.631%;"></td>
    <td style="width:0.498%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:0.864%;"></td>
    <td style="width:7.684%;"></td>
    <td style="width:0.498%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Convertible preferred<br />stock</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Common stock</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Additional</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Accumulated<br />other</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Total</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(in thousands, except share <br />amounts)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">paid-in<br />capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">comprehensive <br />income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Accumulated<br />deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">stockholders&#x2019; equity (deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Balance at December 31, 2018</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_3a3f7bbc-2e93-4745-a7d2-465820c0934d" contextRef="C_758d254a-8812-49dd-a35c-9b632827b258" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">19,565,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_4f8b82b7-93bc-499f-a446-ddd5d01ade07" contextRef="C_758d254a-8812-49dd-a35c-9b632827b258" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,905</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_9a3cded9-a893-482a-907f-ef6557517168" contextRef="C_48f8ab70-75b9-4435-b737-aadd04d499cd" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">537,635</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_4dcff5b8-5904-452a-874a-aeb62c3003bd" contextRef="C_48f8ab70-75b9-4435-b737-aadd04d499cd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_1379a97e-e0a0-45b0-9596-2a2928050442" contextRef="C_e1981d33-fdc8-48c3-99e8-ac5c58411837" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_1a01c320-ba7b-417c-a0c3-ecc644fc0ad1" contextRef="C_492a51ac-c738-417e-89a8-b0263437fb8f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_f53c3b4f-41a3-4276-a3ae-8a4d4691cc13" contextRef="C_13793679-16f2-4f46-aa19-c85c5a12a0ab" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,535</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_fd3ea7e6-5a14-40c1-9f7a-aa4b0adce5fc" contextRef="C_ace78012-0407-4c33-9333-78a05d5e4482" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,484</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Issuance of Series A convertible preferred stock, net of issuance costs of $</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_0ac22d1e-08ea-46d4-bc5f-52419c5e25ad" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:IssuanceCostsOfSeriesAConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#160;and tranche right liability of $</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_32a1b76c-2bef-4537-b0c6-a042ff04eee1" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_c2339faf-104d-4cff-aa10-25c6a7bf639c" contextRef="C_62daab16-1f95-4011-9dfa-cdc86ccb527d" name="verv:StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,183,947</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_eb4050f7-44c0-4673-9588-ec8ce4e50af3" contextRef="C_62daab16-1f95-4011-9dfa-cdc86ccb527d" name="verv:StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,956</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Issuance of Series A Preferred Stock in payment of licensing fee</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_9b3fcbbb-bdf4-48f7-b332-f1a8b3d4ec7a" contextRef="C_62daab16-1f95-4011-9dfa-cdc86ccb527d" name="verv:StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,672,240</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_5f31fd36-590f-4599-bdb3-c61a01ae8028" contextRef="C_62daab16-1f95-4011-9dfa-cdc86ccb527d" name="verv:StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">619</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Issuance of common stock to licensor institutions</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_6cb6d6c6-be40-4bc9-8ebb-ba0258cf298d" contextRef="C_3282e3cf-7f95-478d-ade5-6727746ef749" name="verv:StockIssuedDuringPeriodShareLicensorInstitutions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">673,562</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_094e169d-cc9d-4270-862e-346231440bc1" contextRef="C_3282e3cf-7f95-478d-ade5-6727746ef749" name="verv:StockIssuedDuringPeriodValueLicensorInstitutions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_e5d5767c-c13e-43e9-9d44-8eed02d47c4c" contextRef="C_a807f8cc-a5fc-49a8-8923-6ff09f00f06a" name="verv:StockIssuedDuringPeriodValueLicensorInstitutions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">747</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_d48c5fc4-d2d0-42e5-a89e-6eeaf4932ed2" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:StockIssuedDuringPeriodValueLicensorInstitutions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">748</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_b2ae96c4-b090-46c1-b102-f01d817af5db" contextRef="C_3282e3cf-7f95-478d-ade5-6727746ef749" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">643,241</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_7f50ecd4-2d24-42bb-9d68-7b73caf5027e" contextRef="C_3282e3cf-7f95-478d-ade5-6727746ef749" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_b337cd10-7d4f-40ba-89ed-a4c7530557ae" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Repayment of shareholder loan</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_5a525a2a-cce0-41b6-bd61-7eade266a016" contextRef="C_a807f8cc-a5fc-49a8-8923-6ff09f00f06a" name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_57cd3b75-c207-41d1-89be-3c62e169829b" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Unrealized gain on available-for-sale securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_b0d7d634-d5a9-49e9-b3a0-e5e98a56e304" contextRef="C_e2eab36f-a537-4eda-9a0f-fecf0f2bddb9" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_358a9c22-1e3f-4acb-bf60-e1cd780cab5c" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_7d76be0a-4187-4bec-adc7-01d25611a7f7" contextRef="C_a807f8cc-a5fc-49a8-8923-6ff09f00f06a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">446</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_67fa5a65-ca20-49a7-822b-e11534b3be0a" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">446</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_8a69c29f-5ead-4816-a6a6-32e66f4680ec" contextRef="C_2b6cf2c2-5ffb-41c1-b814-6954698f90f6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">19,297</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_0acac921-456b-43ee-b76d-90c6d45006c2" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">19,297</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Balance at December 31, 2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_6d9cb3a6-6917-4b8f-8d05-d00f42aea45d" contextRef="C_e7d3e278-0275-4b6b-8cfb-0c4d84c235a4" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">51,421,404</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_ecc6c0cc-1b22-4b58-98b9-ba712e2b36c1" contextRef="C_e7d3e278-0275-4b6b-8cfb-0c4d84c235a4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,480</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_25c7daef-d095-43bd-89b8-5623b6cb8cd6" contextRef="C_4fb1ec91-4db7-4fda-877e-5282a568c8a6" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,854,438</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_3d1c00f2-be79-48d2-931a-41007f6dd30f" contextRef="C_4fb1ec91-4db7-4fda-877e-5282a568c8a6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_b6add65a-7957-4455-8ca7-eb9d709e5c13" contextRef="C_45b88831-c3cd-4f43-a393-141647d5c8ee" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,268</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_e06926e2-17f8-4b85-bfe0-5a4906f1efcb" contextRef="C_a01d169a-8516-477d-a424-137cbc7bf6ac" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_6dd0256f-3d23-4e92-baed-4a938de24879" contextRef="C_a0a301cf-8d3e-495c-a4ea-93524f1c444e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">20,832</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_8d4dcdb5-8f6b-46a0-853a-c65a7399d3e9" contextRef="C_9d0f6183-f1e6-4aa0-b41e-2e38deb97369" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">19,553</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Issuance of Series A convertible preferred stock and settlement of tranche right liability of $</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_c2f4f7c7-4bee-404e-8eed-fb93f8909f11" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#160;million, net of issuance costs of $</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_c31d047c-7545-47b8-acd9-d72aaea91bda" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:IssuanceCostsOfSeriesAConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_289be1cd-953b-4d4b-b8d0-2ada30bda344" contextRef="C_f480ce79-c162-4b52-8c8e-1412a8a69e68" name="verv:StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">49,749,167</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_308947a1-2d31-41e7-9c62-46e1237e97e3" contextRef="C_f480ce79-c162-4b52-8c8e-1412a8a69e68" name="verv:StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,792</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Issuance of Series A-2 convertible preferred stock, net of issuance costs of $</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_111c0078-af39-41c0-b3b0-a998441b00b0" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:IssuanceCostsOfSeriesA2ConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">112</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_ba159799-06b4-4d16-8562-1374578e12bc" contextRef="C_f480ce79-c162-4b52-8c8e-1412a8a69e68" name="verv:StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">78,348,461</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_f6b27704-0a42-48df-a41f-8538f8c01601" contextRef="C_f480ce79-c162-4b52-8c8e-1412a8a69e68" name="verv:StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,888</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Additional issuances of common stock to<br />&#160;&#160;&#160;licensor institutions</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_bb464bfb-1f30-41db-b1f1-fa70dec0b43c" contextRef="C_d9143aa7-990d-4ec9-968a-0a9605086b21" name="verv:StockIssuedDuringPeriodAdditionalShareLicensorInstitutions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">187,867</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_0f36b1a4-d278-482a-a5e9-bf7fc0e987c2" contextRef="C_66e16c0c-c5f1-4264-b019-a5f4059f00f4" name="verv:StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_bd618cf9-216f-4d94-8d44-9807610465ac" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_9bfe9d1f-3914-4093-ac73-64250684d1b8" contextRef="C_d9143aa7-990d-4ec9-968a-0a9605086b21" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">537,635</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_9b574ad1-7975-4039-bde5-0c318259d4d4" contextRef="C_d9143aa7-990d-4ec9-968a-0a9605086b21" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_f9bfd702-6bcb-4aac-84fe-99bab49c576f" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Unrealized loss on available-for-sale securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_7e9900f3-49f5-4da5-b3b4-049a82109d78" contextRef="C_c6bcfa12-5656-4390-89e7-006e60b45be7" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_5ed58e9b-1f62-4449-bba3-65814ae945af" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_6c373337-26b1-4360-b66e-4059fe1484a3" contextRef="C_66e16c0c-c5f1-4264-b019-a5f4059f00f4" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">850</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_79e4154c-7e8f-4cb3-bd16-dab194d8403f" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">850</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_5dad2389-401b-4a7c-b005-e2ac2f477d2c" contextRef="C_d9143aa7-990d-4ec9-968a-0a9605086b21" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,849</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_74f01467-f981-4810-aae6-ed557eb7bda5" contextRef="C_66e16c0c-c5f1-4264-b019-a5f4059f00f4" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_086f0077-5560-4d18-b5c7-4fa9b76bcd78" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_f20e66c9-d5a4-404a-a5eb-0893778e772e" contextRef="C_ea3f7d23-8c4f-4c06-944b-9769311160d9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,704</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_43342c5e-b38a-41bb-85e5-1db03dc55f11" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,704</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_063123ba-4fed-4063-ab3a-9f080ee961e7" contextRef="C_8bbab493-1d5c-406a-b732-8bf3f0c4c8aa" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">179,519,032</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_8e3fd0ba-2647-4f25-9e51-2e8e80d40a37" contextRef="C_8bbab493-1d5c-406a-b732-8bf3f0c4c8aa" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">125,160</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_ebe2289d-7302-418b-91bf-d3f3f62016a8" contextRef="C_5e0553e9-7c8d-4aae-b19e-97a94012299f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,585,789</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_bfebbc35-8512-4f9f-a60a-59bdd32fc459" contextRef="C_5e0553e9-7c8d-4aae-b19e-97a94012299f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_379095d0-3bb3-4bb6-a2c3-9895e1efa53b" contextRef="C_40e00f19-0436-48b3-a978-909a38c95f51" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,616</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_95f55839-e05d-40b2-b6bf-8ed7708f496d" contextRef="C_e665d618-f742-42d3-8066-c2f5fa033034" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_12db51c9-8243-477c-92ee-d72a8e638c46" contextRef="C_5c294a1f-8a23-47e3-aa6b-63b180777613" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,536</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_5694afe2-bd4a-4b33-8825-9bba3fd78038" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">63,909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Issuance of Series B convertible preferred stock, net of issuance costs of $</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_15d24441-2cfe-4988-9516-6f7e572cb820" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:IssuanceCostsOfSeriesBConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">241</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_df3e87f9-57d5-4239-b754-47549f58e4bd" contextRef="C_0199df91-6706-46b0-a6e5-0c3d2416dcec" name="verv:StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">77,163,022</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_cdd13871-726d-4b7b-9c38-66b2439b3a3c" contextRef="C_0199df91-6706-46b0-a6e5-0c3d2416dcec" name="verv:StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93,759</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Conversion of convertible preferred stock to common stock upon closing of initial public offering</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_017ad52a-bfce-4af0-aade-62735862db1f" contextRef="C_0199df91-6706-46b0-a6e5-0c3d2416dcec" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">256,682,054</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_b2c49252-b190-4ad6-a2af-4ce7c0f05952" contextRef="C_0199df91-6706-46b0-a6e5-0c3d2416dcec" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">218,919</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_432742d6-295f-4f12-9ffb-6cde037bd112" contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,720,923</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_d14f81f8-03cf-473e-afe6-0e1c36f364d8" contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_9be50ca4-105c-4cba-aaf1-26c4a7155687" contextRef="C_0c4a09a2-209e-467e-bf15-7eedabe54a49" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">218,891</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_f2189005-c708-47cb-a9f4-2011f4bbf41b" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">218,919</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Issuance of common stock from initial public offering, net of issuance costs of $</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_53442a00-27bc-4571-8d27-bbc12a0db1e6" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:IssuanceCostsOfCommonStockFromInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_b0106072-3856-4d9b-9091-467200586093" contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,141,157</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_48274c5a-d678-482a-9c22-e334d5675c24" contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_f6caf6fc-63ef-4226-85ab-5e1ba98afc46" contextRef="C_0c4a09a2-209e-467e-bf15-7eedabe54a49" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">281,568</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_7e6058e9-f638-43d0-94d6-3675d56eeb61" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">281,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Issuance of common stock to licensor institutions</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_2681e1e2-dd5b-4ac8-9dc9-f269117d2af4" contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4" name="verv:StockIssuedDuringPeriodShareLicensorInstitutions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">878,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_7f682017-bd83-44bd-9c45-08987d474fa7" contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4" name="verv:StockIssuedDuringPeriodValueLicensorInstitutions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_d01fabcf-e4c1-4ea0-95e6-3587718d12d0" contextRef="C_0c4a09a2-209e-467e-bf15-7eedabe54a49" name="verv:StockIssuedDuringPeriodValueLicensorInstitutions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,489</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_dc1401fd-61f5-4d8c-9c16-cd8393515340" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:StockIssuedDuringPeriodValueLicensorInstitutions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,490</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_3114d981-73eb-49ff-9889-66ed8d678960" contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">537,633</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_43937e9f-20b8-4687-af8e-33a39bb53b75" contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">599,838</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_58839a2b-4c81-4bfd-94c1-8a20f5fa0185" contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_861ace3e-05ee-464b-8962-2328be6f6bbd" contextRef="C_0c4a09a2-209e-467e-bf15-7eedabe54a49" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">965</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_230675dd-3d24-4455-a63a-1027a9fcb5b0" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">966</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Purchase of common stock under ESPP</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_77130e95-3648-4674-bcf9-0e130e30522c" contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,297</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_278e4139-a880-4c8d-9e7e-c94f20f2c2a8" contextRef="C_0c4a09a2-209e-467e-bf15-7eedabe54a49" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">780</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_7ab3c223-66e6-4171-bde7-910ed8108a8e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_6a658ad5-652c-475a-ae7d-c2c5d9b56b54;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_4f3d9e06-cd71-4268-b622-ff2c7d01e1d8" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">780</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Unrealized loss on available-for-sale securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_dc5bda91-5f3e-4302-9f17-ec27a9c68604" contextRef="C_69242d4b-64e4-4e88-8436-10a5845fd9c6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">236</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_24f0c297-5b40-4261-8880-ccb299caf8c9;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_f32b4d9b-4f45-4632-a6a1-8e7108cb8b8f" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">236</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_a5f3df76-dd86-41c5-926e-55eeb3fc649a" contextRef="C_0c4a09a2-209e-467e-bf15-7eedabe54a49" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,072</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_99459b3b-1a2c-459f-b816-892c31fc08bc;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_8f855dc4-4041-400d-9c4c-39e7f19cdb67;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_bf9ceb07-8a49-4c8b-990d-0d891ba02f6e" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,072</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_2d52ea39-20b8-4b9a-bc92-59c1dcac197e" contextRef="C_5d453b81-de24-40a9-aeeb-d32cb8afa2fc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_bca1d83a-284a-4522-8cd1-a11195b34bb9" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:26.281%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:0.41%;"></td>
    <td style="width:6.901%;"></td>
    <td style="width:0.498%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:0.856%;"></td>
    <td style="width:6.089%;"></td>
    <td style="width:0.498%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:0.41%;"></td>
    <td style="width:6.66%;"></td>
    <td style="width:0.41%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:0.864%;"></td>
    <td style="width:6.177%;"></td>
    <td style="width:0.41%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:0.864%;"></td>
    <td style="width:6.704%;"></td>
    <td style="width:0.41%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:0.864%;"></td>
    <td style="width:8.204%;"></td>
    <td style="width:0.498%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:0.864%;"></td>
    <td style="width:6.631%;"></td>
    <td style="width:0.498%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:0.864%;"></td>
    <td style="width:7.684%;"></td>
    <td style="width:0.498%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_8012dc6e-d486-4e32-a895-6ec135f1b027" contextRef="C_cace6097-6c52-4518-b31c-14d8a4a9ede2" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,511,735</ix:nonFraction></span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_e3a401ee-1682-4cef-a9e4-9d2921641a64" contextRef="C_cace6097-6c52-4518-b31c-14d8a4a9ede2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49</ix:nonFraction></span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_9f630540-f071-4063-8703-4a866772f066" contextRef="C_67f0fbbf-3525-49ad-8377-5e53391e7282" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">544,381</ix:nonFraction></span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_8e66921c-d46d-4014-9103-24ab02981c3b" contextRef="C_07b567cb-3946-416a-a923-420f97322263" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">228</ix:nonFraction></span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_cf696ab4-21c3-4b3d-9c78-09bd3222bd51" contextRef="C_3c269b18-dd31-496d-b16c-e1c0dd1e2c99" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">186,850</ix:nonFraction></span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_696eef82-7e56-40c3-b77f-b8736f20248f" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">357,352</ix:nonFraction></span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Verve Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="consolidated_stmt_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">C</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">onsolidated statements of cash flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.484%;"></td>
    <td style="width:1.401%;"></td>
    <td style="width:1.183%;"></td>
    <td style="width:10.883%;"></td>
    <td style="width:0.706%;"></td>
    <td style="width:1.401%;"></td>
    <td style="width:1.183%;"></td>
    <td style="width:10.883%;"></td>
    <td style="width:0.706%;"></td>
    <td style="width:1.401%;"></td>
    <td style="width:1.183%;"></td>
    <td style="width:10.883%;"></td>
    <td style="width:0.706%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year ended<br />December 31,</span></p></td>
    <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Cash flows from operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_72242b1b-caa6-4588-b19c-69bb568f26e1" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_6585c1cc-fa84-402f-a65d-088084adcba6" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,704</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_ddfe237e-b41b-4af2-ac91-26662d81f388" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">19,297</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Depreciation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_e071ffb0-549a-43a6-816b-2f8badd8b0a9" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,535</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_654e956b-c4e1-4287-8542-eca4c79419f1" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,328</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_57500eb6-bb98-4b99-a419-8c9d4ff745be" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Non-cash research and development license expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_3af3057a-aafb-4135-aae8-8b1c1f7495a0" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_4bbd495a-58ad-4896-bcb5-b2dc0aeef6f7" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_9a42ad40-f061-400a-aa0f-1fecc51536a4" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,781</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Non-cash lease expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_494b0cbf-70d7-4f36-ae39-75df83a224ea" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ProvisionForLeaseLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,842</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_13b5ecec-3028-4049-b33c-b897063f625f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_81bf6ad3-ceaa-4b65-95e7-0703067ea43c" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:ProvisionForLeaseLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Amortization of premium on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_a077f254-1ca9-4ce6-bf3e-eca2f24d118c" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:AmortizationOfPremiumOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,508</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_48dc9ae1-71d2-42b3-97dd-3a91f0a0e7b4" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:AmortizationOfPremiumOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">380</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_f349312d-3fc6-42b9-8e29-f989374f3dc9" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:AmortizationOfPremiumOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">72</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_0f4f4228-1221-4457-831f-c5cf8d054489" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,072</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_aecc6746-a067-4431-b531-a59420d4bdc3" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">850</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_da913716-f06d-4cad-876b-15f476383510" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">446</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Change in fair value of preferred stock tranche liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_d285f6bd-1be9-457c-ae20-9c006a88c407" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:ChangeInFairValueOfPreferredStockTrancheLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_8b07fcf0-3610-4dc3-8c80-4040284f0c52" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:ChangeInFairValueOfPreferredStockTrancheLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,507</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_9502d78d-8f67-4478-8e0e-9ddbafcaa784" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:ChangeInFairValueOfPreferredStockTrancheLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,883</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Change in fair value of antidilution rights</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_117952f0-fd37-473a-a12e-85c0903ec992" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:ChangeInFairValueOfAntidilutionRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,574</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_eb0df781-7700-4dad-8de8-542476be8b4c" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:ChangeInFairValueOfAntidilutionRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,359</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_7fa36348-d8b5-4116-8aaf-22a5bf90845f" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:ChangeInFairValueOfAntidilutionRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">982</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Change in fair value of success payments liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_2784cb7d-d315-449f-b25d-83eb83a3e70e" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:ChangeInFairValueOfSuccessPaymentsLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,815</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_2c7ff87e-5c70-4350-a77b-9fc782fc8841" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:ChangeInFairValueOfSuccessPaymentsLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,387</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_a6376081-9c64-4308-919e-7859b46507ef" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:ChangeInFairValueOfSuccessPaymentsLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:42.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_566afad4-f233-4b8a-85c4-511b4c7455a0" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,528</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_ab308196-7e08-4c21-b1e6-06e8f0911ca2" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,582</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_c1bf943b-f0ac-4e19-8452-0bffa0473420" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">182</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:42.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_12967d40-b13a-486b-8a76-8acb952743bb" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,829</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_899d04ff-788f-45f9-b0fc-b2a8cc064e01" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,898</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_fe0a526f-4867-47a5-a92e-3234fbd07192" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,735</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:42.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Accrued expenses and other liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_40c555f6-15a3-45c4-8907-289696f354cb" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,977</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_d09262bc-e2b1-41cf-8cd9-57445f69b753" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,071</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_17c9e9ca-f58a-4d69-966f-033d15e0e61c" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">945</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:42.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Success payment liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_9345770d-f811-4c82-90f7-559225ace066" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:SuccessOfPaymentLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,250</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_df87b555-a8fd-4888-920c-0dbf12e05c6e" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:SuccessOfPaymentLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_c6bb8fa5-8579-45ff-afbe-3c24c92c4107" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:SuccessOfPaymentLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:42.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_77118c09-6cfc-4809-8b1f-224c03891c39" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,940</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_d83fbab4-b113-4b4d-a221-03e745689d8d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_299ac9cc-51c0-4875-835b-31815e27fb07" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:42.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Deferred rent liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_ad8ffba9-2e26-42ab-92c7-75267dc0a44d" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:IncreaseDecreaseInOtherDeferredLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_475831e5-eb3a-4d42-a857-95edff0a6534" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:IncreaseDecreaseInOtherDeferredLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_aa1352be-cda4-4d64-8f55-6bd35f7fc6bb" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:IncreaseDecreaseInOtherDeferredLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">163</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:56.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:56.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_0af904a7-4ccf-4781-b2f2-007fbea0dbb8" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">77,880</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_395342a9-783a-4123-90c4-84cc41e89b0a" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35,265</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_a0f9a615-3576-4140-8dc2-2f95bcced577" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,442</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Cash flows from investing activities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_c1a92001-49c0-4ff2-950b-ee3ea7b8c5e7" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,359</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_543653f2-112e-476c-811e-f010a62b3428" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,424</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_787bbc21-ce5a-4b59-b0ed-fb5e36caf599" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,857</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Purchases of marketable securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_2201ca3d-ab9a-47c6-abba-c0cdc1901b4f" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">371,494</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_dd7596ce-75aa-46f9-956f-68ea9851e71a" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">98,484</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_447c7a42-879d-4bcb-a699-78e096fd2ca0" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,001</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Maturities of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_e0afd937-29dd-411e-a301-acda5e30a67d" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:MaturitiesOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">136,755</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_657dcc2b-65ca-441a-9549-83a3893b75f1" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:MaturitiesOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,781</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_7f57d877-1c64-4673-a5ad-eb315ef64afb" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:MaturitiesOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,100</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:56.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:56.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_dbf986bd-c69c-4f17-af9c-0efa4c671493" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">239,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_518ee430-b462-4c20-819d-b3dec360d98a" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,127</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_54b405c9-4053-430b-bd05-2dec4b359c3c" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,758</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Cash flows from financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Proceeds from issuance of Preferred Stock, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_643bf729-ba6f-4807-a93d-11fafb665cd3" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93,759</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_62fc96b3-e575-4e68-85da-7a82578a6831" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">92,616</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_43df18e4-db89-45e1-af12-454114d2e913" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,040</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Proceeds from initial public offering, net of underwriting discount</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_960c2583-3520-4918-98ce-c6608762037c" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">285,214</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_a3f44760-a4cb-49fc-bd74-735d8b6dacf1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_1cfd9018-0f1f-4ea0-ae7d-4b366161360d" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Shareholder loan given</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_8717d460-6332-416b-ae33-6633ea62d241" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:ProceedFromShareholderLoan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_02e069bd-fd82-4cb6-b6b3-51bdba9b5b35;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_48d3f077-8c1c-4fbe-8e12-5d12e9f57e11" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:ProceedFromShareholderLoan" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Payment of initial public offering costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_2a4d6d67-14d3-43a9-80d3-b266e87ef9b0" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,630</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_de72a9fd-4a77-4d2f-ba45-5844e0d16589;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_efbe0182-38f2-4c14-aa56-5eaf21133d27;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Proceeds from exercise of stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_b2b81c5c-1bac-4e90-b911-5b8d3e4e9eb7" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">966</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_5dc28582-a9e8-48a3-a549-6ca1db167a58" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_c08a69ad-f5e0-4908-9918-b4f986751489;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Payments received on shareholder loan</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_6b1b0f05-bddd-4876-8612-5f672b7cbf15" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ProceedsFromContributedCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_daa77256-f925-4e80-9690-a788d67f31a1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_1f938ed0-4fc4-475f-bdec-c61defde13bd" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:ProceedsFromContributedCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Proceeds from purchase of shares through employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_697cdbe8-83c0-4d01-9377-f2580edc6a33" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:EmployeeStockOwnershipPlanESOPCashContributionsToESOP" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">780</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_f3bdee0c-b5f4-4a77-95ee-e42be9f8c8f6;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_4473dfb8-6ba4-4ff4-a96b-2aef947716c9;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:56.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:56.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_bf394e6b-9baa-4cd1-884c-ee46ea21a0e5" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">377,089</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_2c3b6c59-6255-407c-b0ac-5286d278c314" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">92,627</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_8656330e-da47-433c-8089-35d3ece8363a" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,954</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Increase (decrease) in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_2dfe2bc4-9897-4428-8d11-c6aa90717f86" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,111</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_87bbc9fd-d302-4eb1-bb88-cde0c27bb667" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,235</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_fce92172-f40d-4e97-93a6-a65b4cf78472" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,246</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Cash, cash equivalents and restricted cash&#x2014;beginning of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_f9dfbd10-ff13-4dd3-af8f-9b3704f28b49" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,456</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_1bce4bf2-08aa-4384-99c6-d55d7abc7dfc" contextRef="C_9d0f6183-f1e6-4aa0-b41e-2e38deb97369" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,221</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_438bf6e0-8f77-4ec5-8281-021c97c3246b" contextRef="C_ace78012-0407-4c33-9333-78a05d5e4482" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,467</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Cash, cash equivalents and restricted cash&#x2014;end of period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_51e7f618-a97c-4090-9272-effe13f42159" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,567</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_3a3b89eb-ad6c-4968-8d7c-6c9e286a2503" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,456</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_47043e1d-154b-4471-a323-cdc4148c5543" contextRef="C_9d0f6183-f1e6-4aa0-b41e-2e38deb97369" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,221</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Supplemental disclosure of noncash investing and financing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Property and equipment additions included in accounts payable and accrued expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_6d8ff399-2768-4243-9b5a-850dc2d8caf2" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">503</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_b9ac7ceb-f9e3-4a83-aeab-d7a518bf79c1" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">86</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_731dcab6-aac7-4bb4-a1d1-e58e5364ac99" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">556</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Issuance of preferred stock tranche liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_e3457fdd-4edc-41c0-9176-3120d144815f" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:SettlementOfTrancheRightLliability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_0b5612a3-b12a-43fc-ba6b-c3bd38e949ff;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_0e34cd30-4705-41a8-b30c-6845070e7473" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:IssuanceOfPreferredStockTrancheLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Settlement of tranche right liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_ceb1185c-3a41-499a-9161-a77ef5610672" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:SettlementOfTrancheRightLliability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_9fd6ed98-1fbe-4e0d-9fde-bd3e9e0222c0" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:SettlementOfTrancheRightLliability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,064</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_d49f3879-e87a-4c1e-a6e0-035761dfab62;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Conversion of convertible preferred stock to common stock upon closing of initial public offering</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_56fcdf28-7cf5-4362-89a3-080bde2d8357" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">218,919</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_a0e3a388-511c-4ae3-a547-38055910ae18;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_7b568b03-6f3e-45ce-a87c-1ec473c7ffe5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Settlement of derivative liability by issuing common stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_3ba00fe1-ae58-4b22-ae9b-8e5b9e40abe6" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,490</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_8c6d0ef4-57bb-4873-b94f-6b1821816e2a" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_ab0d91dd-1367-4160-b3ca-9321414e5736" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">135</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Right-of-use assets obtained in exchange for new operating lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_837f4a32-2847-4fad-a035-d0ab69d072c8" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">809</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_49633ab7-17ec-409d-b405-fd6cdad7c037;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_6343e105-a44a-4f4c-ad0d-c287a92b1cc7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Verve Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="notes_to_cons_financial_stmt"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">Notes to consolidated financial statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;"> </span></p>
  <div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_5245fd97-6ac7-49d2-8f6c-dd4d573b7ec4" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:NatureOfOperations" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">1. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Nature of the business and basis of presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Organization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Verve Therapeutics, Inc. (the &#x201c;Company&#x201d; or &#x201c;Verve&#x201d;) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The Company was incorporated on March 9, 2018 as Endcadia, Inc., a Delaware corporation, and began operations shortly thereafter. In January 2019, the Company amended its certificate of incorporation to change its name to Verve Therapeutics, Inc. The Company&#x2019;s principal offices are located in Cambridge, Massachusetts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Liquidity and capital resources</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On June 21, 2021, the Company completed its initial public offering, or IPO, in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fc2e5b00-b68e-4f82-8850-014ee61b0e3b" contextRef="C_1ff558da-6b5f-4d32-9a66-1203371d1d23" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,141,157</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of its common stock, including </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_322be980-a8b2-47bc-bece-b71f258e9730" contextRef="C_3965b88b-aada-4b0f-bb79-9e1564c8b01f" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,105,368</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4c7d2d44-e656-4abf-a968-e0b7e331daa0" contextRef="C_6111bf12-8023-40ef-949d-f9fc8eb769e3" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">19.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_57e28610-3af9-4f8a-808d-24a0e465f9e0" contextRef="C_1ff558da-6b5f-4d32-9a66-1203371d1d23" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">306.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. The Company received approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d542cb88-f34d-4103-b2be-11b0d32369e6" contextRef="C_1ff558da-6b5f-4d32-9a66-1203371d1d23" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">281.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in net proceeds after deducting underwriting discounts and offering expenses payable by the Company. In connection with the IPO, all outstanding shares of convertible preferred stock converted into </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5ccd6123-3ca5-4e80-bbc2-1e6cd745a2c5" contextRef="C_6111bf12-8023-40ef-949d-f9fc8eb769e3" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,720,923</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company&#x2019;s common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In connection with the Company's IPO, the Company effected a </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_8ce1c6e7-ec61-4125-b9c7-679170c396d9" contextRef="C_6318768f-6910-4cea-8012-84a1cded066e" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">one-for-9.2595</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> reverse stock split of the Company&#x2019;s issued and outstanding common stock. Accordingly, all shares of common stock and per share amounts, as well as the conversion ratio of the Company&#x2019;s outstanding convertible preferred stock, for all periods presented in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split, including reclassification of par and additional paid-in capital amounts as a result of the reverse stock split.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Basis of presentation and liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred losses since its inception, including losses of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_37040f59-8db6-43d9-b26f-4a4481824c6d" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">120.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0a0e7447-8e95-4184-8b96-4b29a5ea9a31" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">45.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f9c2b4b1-8fec-4c33-98a5-2c0d0c6cb05e" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">19.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> for the years ended December 31, 2021, 2020 and 2019, respectively. As of December 31, 2021, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_40d45dd1-ee44-4d4b-8fae-9638e53ea890" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">186.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. To date, the Company has funded its operations primarily through equity offerings. Through December 31, 2021, the Company had raised an aggregate $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_41de67f1-71e1-41ac-bdb4-4c79baca1fdb" contextRef="C_6318768f-6910-4cea-8012-84a1cded066e" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">523.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in gross proceeds from the sales of its preferred stock in private placements and common stock in its IPO. The Company expects to generate operating losses and negative operating cash flows for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company expects that its cash, cash equivalents and marketable securities as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> will </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">be sufficient to fund its operations for at least the next twelve months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">strategy. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed could have a negative impact on the Company&#x2019;s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_583ca74f-38d2-43b3-bb08-49e7a5321b97" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_583ca74f-38d2-43b3-bb08-49e7a5321b97_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">2. S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">ummary of significant accounting policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_aed9b359-a27e-4559-913d-ed12255a5f35" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ConsolidationPolicyTextBlock" escape="true" continuedAt="F_aed9b359-a27e-4559-913d-ed12255a5f35_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Principles of consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_aed9b359-a27e-4559-913d-ed12255a5f35_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The accompanying consolidated financial statements include the accounts of Verve and its wholly owned subsidiary, Verve Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_916cba5c-4f50-467b-a62e-c3157bd17aad" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:UseOfEstimates" escape="true" continuedAt="F_916cba5c-4f50-467b-a62e-c3157bd17aad_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_916cba5c-4f50-467b-a62e-c3157bd17aad_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair values of common stock (prior to completion of the IPO), convertible preferred stock, preferred stock tranche liability, stock-based compensation, and the liabilities for antidilution rights and success payments. Actual results could differ from these estimates.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_87f1bbf8-d595-4188-a033-52bc19df12a6" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true" continuedAt="F_87f1bbf8-d595-4188-a033-52bc19df12a6_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Cash and cash equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_87f1bbf8-d595-4188-a033-52bc19df12a6_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cash and cash equivalents consist of standard checking accounts and money market account funds that invest primarily in U.S. government-backed securities and treasuries. The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at cost, which is substantially equivalent to fair value.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div><ix:nonNumeric id="F_7617d36e-b1a0-4d61-a874-12343010908b" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Restricted cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Restricted cash represents collateral provided for a letter of credit issued as a security deposit in connection with the Company&#x2019;s leases of its corporate facilities. </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_1f4622e3-61f2-497f-a7ab-7c1f8cce355f" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" escape="true" continuedAt="F_1f4622e3-61f2-497f-a7ab-7c1f8cce355f_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_1f4622e3-61f2-497f-a7ab-7c1f8cce355f_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.402%;"></td>
          <td style="width:1.6%;"></td>
          <td style="width:1.441%;"></td>
          <td style="width:13.052%;"></td>
          <td style="width:0.716%;"></td>
          <td style="width:1.6%;"></td>
          <td style="width:1.441%;"></td>
          <td style="width:13.032%;"></td>
          <td style="width:0.716%;"></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31,</span></p></td>
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bec5d017-a50a-41bd-9d60-54f0c77ab38d" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,330</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e404bc04-a3ea-435b-acc4-baaed1fe268c" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,993</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_841c9165-e360-4b58-b18f-5f60b355d37c" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,237</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_02fe5c17-91bf-4511-b318-431689661b19" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">463</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d7fa0568-c3a5-4c6e-91b7-d8e0b276c12c" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,567</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ab9ee428-4c6a-4d21-92da-dabd575a8603" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,456</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_0b3f3954-9d7e-4b69-bd5b-122be6e825f1" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:MarketableSecuritiesPolicy" escape="true" continuedAt="F_0b3f3954-9d7e-4b69-bd5b-122be6e825f1_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Marketable securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_0b3f3954-9d7e-4b69-bd5b-122be6e825f1_1" continuedAt="F_0b3f3954-9d7e-4b69-bd5b-122be6e825f1_2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are maintained by the Company&#x2019;s investment managers and consist of U.S. treasury bills and U.S agency securities. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income (loss) as a component of stockholders&#x2019; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense).</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_0b3f3954-9d7e-4b69-bd5b-122be6e825f1_2"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Company reviews marketable securities for other-than-temporary impairment whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security&#x2019;s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if the Company has experienced a credit loss, has the intent to sell the marketable security, or if it is more likely than not that the Company will be required to sell the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">marketable </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">security before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company&#x2019;s investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period. The Company evaluated its securities for other-than-temporary impairment and considered the decline in market value for the securities to be primarily attributable to current economic and market conditions. It is not more likely than not that the Company will be required to sell the securities, and the Company does not intend to do so prior to the recovery of the amortized cost basis. Based on this analysis, these marketable securities were not considered to be other-than-temporarily impaired as of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span></p></ix:continuation></div><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_bc347694-a55d-4383-881d-551a04cc8c46" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" continuedAt="F_bc347694-a55d-4383-881d-551a04cc8c46_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Concentrations of credit risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_bc347694-a55d-4383-881d-551a04cc8c46_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and restricted cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_1ff4b253-5d0b-4f67-ac90-ada5a08700c3" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:DeferredOfferingCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Deferred offering costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company capitalized incremental legal, professional accounting and other third-party fees that were directly associated with the IPO as other non-current assets until the IPO was consummated. After consummation of the IPO, these costs were recorded in stockholders&#x2019; equity (deficit) as a reduction of additional paid-in-capital generated as a result of the offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_af4fc85a-30e2-4e7b-98a7-66d0d85f0089" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:IndemnificationAgreementsPolicyTextBlock" escape="true" continuedAt="F_af4fc85a-30e2-4e7b-98a7-66d0d85f0089_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Indemnification agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_af4fc85a-30e2-4e7b-98a7-66d0d85f0089_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_64f4134f-1198-46a9-ad0c-f1b05182355c" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true" continuedAt="F_64f4134f-1198-46a9-ad0c-f1b05182355c_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Fair value of financial instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ASC Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Fair Value Measurement </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Level 1&#x2014;Quoted market prices in active markets for identical assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Level 2&#x2014;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Level 3&#x2014;Unobservable inputs for the asset or liability (i.e. supported by little or no market activity). Level 3 inputs include management&#x2019;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_64f4134f-1198-46a9-ad0c-f1b05182355c_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There have been no changes to the valuation methods utilized by the Company during the years ended December 31, 2021, 2020 and 2019. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_ea20810d-169b-4e69-a3aa-ebe4e6568c16" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true" continuedAt="F_ea20810d-169b-4e69-a3aa-ebe4e6568c16_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Property and equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment are stated at cost less accumulated depreciation. </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_3f265e3d-d76b-433c-9646-0e1b46b67911" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" escape="true" continuedAt="F_3f265e3d-d76b-433c-9646-0e1b46b67911_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_3f265e3d-d76b-433c-9646-0e1b46b67911_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.968%;"></td>
          <td style="width:2.064%;"></td>
          <td style="width:48.968%;"></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Asset category</span></p></td>
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_bc086466-58f7-468f-b1fb-0b14febc9b25" contextRef="C_47adbab3-b838-4d39-aa2e-17b98510b0b2" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Office furniture</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_7d8fcb95-df90-42f0-bb82-a69c5a5d388d" contextRef="C_89a10d74-f017-4e8e-9761-a6d46cf3afb2" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_a41e78fe-94cf-4a47-a9b3-109fd8cab670" contextRef="C_25e7d82a-63d5-46e3-ace4-4ed5f2668166" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_48cd622b-82c5-40dc-9f3f-2ecdb9a1578e" contextRef="C_bf52cb0e-645b-4c9d-abcc-988c1ab77568" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Shorter of useful life or remaining lease term</span></ix:nonNumeric></span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11</span></p>
         <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_ea20810d-169b-4e69-a3aa-ebe4e6568c16_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_8765d91d-f860-4b16-b2c1-bb8727a01263" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true" continuedAt="F_8765d91d-f860-4b16-b2c1-bb8727a01263_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Impairment of long-lived assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_8765d91d-f860-4b16-b2c1-bb8727a01263_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1f575086-efce-4204-8c38-897e9d401bbb" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_df6852ac-fc37-4177-95b6-060848a9b27e" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_97f25cd1-10d8-4e2f-a588-315cf6916989" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> impairment losses recognized during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021, 2020 and 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_977783b8-9784-465f-a09b-4b6269d58006" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock" escape="true" continuedAt="F_977783b8-9784-465f-a09b-4b6269d58006_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Freestanding financial instruments and derivatives</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has identified the following financial instruments, which are recorded as liabilities in the balance sheet and separately accounted for at fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Preferred Stock Tranche Liabilities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;The Company has determined that its obligation to issue, and the Company&#x2019;s investors&#x2019; right to purchase, additional shares of convertible Series A Preferred Stock (&#x201c;Series A Preferred&#x201d;) pursuant to subsequent closings represent a freestanding financial instrument. The freestanding preferred stock tranche liability (the &#x201c;tranche liability&#x201d;) was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss. The tranche liabilities were remeasured at each reporting period and upon the exercise or expiration of the obligation. As of December 31, 2020, all Series A Preferred closings occurred, and all preferred stock tranche liabilities have been settled. Refer to Note 9, Preferred Stock tranche liability, for additional discussion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pursuant to license agreements with (i) the President and Fellows of Harvard College (&#x201c;Harvard&#x201d;) and The Broad Institute, Inc. (&#x201c;Broad&#x201d;) (&#x201c;Harvard/Broad License Agreement&#x201d;) and (ii) Broad (&#x201c;Broad License Agreement&#x201d;) (see Note 8, License agreements), the following financial instruments were issued by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Antidilution Rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;The antidilution rights represent the obligation to issue additional shares of common stock to Harvard and Broad following the completion of additional financings, including the Company&#x2019;s initial public offering. These antidilution rights were accounted for under ASC 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Derivatives and Hedging (&#34;ASC 815&#34;),</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and were initially recorded at fair value with a corresponding charge to research and development expense. The liability was remeasured at each reporting period, with changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss while this instrument was outstanding. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The obligation was satisfied in full upon the issuance of an aggregate of an additional </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_dfc0dfbe-c007-4308-9b38-2f9888467c2f" contextRef="C_db7855c5-c342-42e3-a442-d44d2061ccbe" name="verv:IssuanceOfAdditionalCommonStock" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">878,098</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock upon the closing of the Company's IPO in June 2021. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Refer to Note 5, Fair value of financial instruments, for additional discussion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_977783b8-9784-465f-a09b-4b6269d58006_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Success Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;The Company is obligated to pay to Harvard and Broad tiered success payments in the event the Company&#x2019;s average market capitalization exceeds specified thresholds ascending from a high nine digit dollar amount to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_00e74a8d-9abd-450e-b5b1-8554944ca6f0" contextRef="C_e8b5087a-c8c5-42b6-b02a-2126a65898d5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control of the Company or a sale of the Company, the Company is required to pay in cash within a specified period following such event. Otherwise, the payments may be settled at the Company&#x2019;s option in either cash or shares of the Company&#x2019;s common stock. The success payments are accounted for under ASC 815 and were initially recorded at fair value with a corresponding charge to research and development expense. The liability is remeasured at each reporting period with all changes in value recognized in other income (expense) in the statement of operations and other comprehensive loss. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the year ended December 31, 2021, certain success payment obligations were triggered, and amounts paid to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5aded431-cd1c-4291-b3da-3f4a88bda714" contextRef="C_30c56851-0530-4749-a9d8-9d1a01a7d426" name="verv:SuccessLiabilityPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> These amounts were settled in cash in November 2021. The Company will continue to adjust the liability for changes in fair value until the earlier of the achievement or expiration of the remaining success payment obligation. Refer to Note 5, Fair value of financial instruments, for additional discussion</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_fcf3f601-a6d6-4909-9e24-a5ddb9d5f50a" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" continuedAt="F_fcf3f601-a6d6-4909-9e24-a5ddb9d5f50a_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Research and development costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, third-party license fees related to technology with no alternative</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_fcf3f601-a6d6-4909-9e24-a5ddb9d5f50a_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">future </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">use, laboratory supplies, depreciation, manufacturing expenses, preclinical expenses, consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_f666bfc5-78c3-4122-a562-60265c68bb10" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true" continuedAt="F_f666bfc5-78c3-4122-a562-60265c68bb10_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#x2019;s stock-based compensation program allows for grants of stock options and restricted stock awards. Grants are awarded to employees and non-employees, including directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Compensation-Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> (&#x2018;&#x2018;ASC 718&#x2019;&#x2019;). ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#x2018;&#x2018;Black-Scholes&#x2019;&#x2019;) for stock option grants to both employees and non-employees. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#x2019;s stock-based compensation awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized over the implied service period when achievement of the performance-based milestones is deemed probable. The Company uses judgement to determine whether and, if so, how many awards are deemed probable of vesting at each reporting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The estimation of fair value for stock-based compensation requires management to make estimates and judgments about, among other things, the estimated life of options and volatility of the Company&#x2019;s common stock. The judgments directly affect the amount of compensation expense that will be recognized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_f666bfc5-78c3-4122-a562-60265c68bb10_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to the Company's IPO in June 2021, there was no public market for its common stock. As a result, prior to the IPO, the estimated fair value of the Company's common stock was determined by its board of directors as of the date of each option grant, with input from management, considering the Company's most recently available third-party valuations of common stock and its board of directors' assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of grant. Following the Company's IPO, the fair value of its common stock is determined based on the closing price of the Company's common stock as reported on the Nasdaq Global Select Market</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_186dd7ed-e017-4813-b895-72996897bab3" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:RentExpensePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Rent expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#x2019;s real estate operating leases provide for scheduled annual rent increases throughout the lease term. The Company recognizes the effects of the scheduled rent increases on a straight-line basis over the full term of the lease. Prior to the adoption of ASU 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, or ASC 842, tenant improvement allowances, if any, provided by the landlord are recorded as deferred rent and amortized as reduction to rent expense over the lease term. Subsequent to the adoption of ASC 842, tenant improvement allowances, if any, provided by a landlord are recorded as a reduction of the right-of-use, or ROU, asset related to that lease.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_17b5eee7-2816-4393-8489-cf31fe2927fb" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_17b5eee7-2816-4393-8489-cf31fe2927fb_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Income taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_17b5eee7-2816-4393-8489-cf31fe2927fb_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fac67e05-e0f5-40fc-9023-eeb56def41e8" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="verv:PercentageOfTaxBenefitRealized" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_44bf6855-6531-4ce8-9d24-da4ce6952b1e" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true" continuedAt="F_44bf6855-6531-4ce8-9d24-da4ce6952b1e_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Comprehensive loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_44bf6855-6531-4ce8-9d24-da4ce6952b1e_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2021, 2020 and 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, the Company&#x2019;s only element of other comprehensive income (loss) was unrealized gains (losses) on marketable securities.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_7a39b202-b8fe-400c-8ef8-6010933a177d" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" continuedAt="F_7a39b202-b8fe-400c-8ef8-6010933a177d_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Net loss per share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_7a39b202-b8fe-400c-8ef8-6010933a177d_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#x2019;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2021, 2020 and 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_44e8e985-6119-4d77-8d4c-5870f84f2fcd" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:SegmentAndGeographicInformationPolicyTextBlock" escape="true" continuedAt="F_44e8e985-6119-4d77-8d4c-5870f84f2fcd_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Segment and geographic information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_44e8e985-6119-4d77-8d4c-5870f84f2fcd_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;), or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#x2019;s Chief Executive Officer. The Company views its operations as and manages its business in </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a1d2bc75-f64f-4af8-b463-0a438cc91ea7" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> operating segment operating exclusively in the United States.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_90d868c1-a716-413d-a0b3-65cae5a28847" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" escape="true" continuedAt="F_90d868c1-a716-413d-a0b3-65cae5a28847_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Subsequent events</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_90d868c1-a716-413d-a0b3-65cae5a28847_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company performs an evaluation of all subsequent events after the balance sheet date through the date of issuance of the consolidated financial statements to ensure appropriate disclosure of events both recognized in the consolidated financial statements and events which occurred subsequently but were not recognized in the consolidated financial statements.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_d8d49096-5159-42ed-91f6-c48a662a04e5" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" continuedAt="F_d8d49096-5159-42ed-91f6-c48a662a04e5_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Recently adopted accounting pronouncements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), as subsequently amended, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors), and replaces the existing guidance in ASC 840. The FASB has issued several updates to the standard which: (i) clarify how to apply certain aspects of the new standard; (ii) provide an additional transition method for adoption of the new standard; (iii) provide a practical expedient for certain lessor accounting; and (iv) amend certain narrow aspects of the guidance. The new standard requires the identification and classification of arrangements that are or contain a lease and requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine the recognition pattern of lease expense over the term of the lease. In addition, a lessee is required to record (i) a right-of-use asset and a lease liability on its balance sheet for all leases with accounting lease terms of more than 12 months regardless of whether it is an operating or finance lease and (ii) lease expense in its consolidated statement of operations for operating leases and amortization and interest expense in its consolidated statement of operations for financing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">14</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">leases. Leases with a term of 12 months or less may be accounted for similar to existing guidance for operating leases under ASC 840. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842), which added an optional transition method that allows companies to adopt the standard as of the beginning of the year of adoption as opposed to the earliest comparative period presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to January 1, 2021, the Company accounted for leases pursuant to ASC 840, Leases. At lease inception, the Company determined if an arrangement was an operating or capital lease. For operating leases, the Company recognized rent expense, inclusive of rent escalations, holidays and lease incentives, on a straight-line basis over the lease term. The difference between rent expense recorded and the amount paid was recorded as deferred rent. The Company presented lease incentives as deferred rent and amortized the incentives as a reduction to rent expense on a straight-line basis over the lease term. The Company classified deferred rent as current and noncurrent liabilities based on the portion of the deferred rent that was scheduled to mature within the next twelve months.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_f5aa6f95-8bea-43f3-a617-fa4df3bf91f3" contextRef="C_88ca2b88-300c-48c8-815f-cc259e125c7f" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adopted </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Topic 842 during the quarter ended September 30, 2021, with an effective adoption date of </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_069ae8d5-049a-4c2b-9d3e-66c62ce24ad2" contextRef="C_88ca2b88-300c-48c8-815f-cc259e125c7f" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">January 1, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, using the modified retrospective transition approach which uses the effective date, or January 1, 2021, as the date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. At contract inception, the Company determines if an arrangement is or contains a lease. A lease conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If an arrangement is determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on which the leased asset is made available for use by the Company, based on the economic characteristics of the lease. The Company has elected to apply the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or the capitalization of initial direct costs for any existing leases. As a result of the adoption of ASC 842, the Company recorded (i) an operating lease liability of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f3f5849f-a7d5-47ed-b9e1-095092b256de" contextRef="C_88ca2b88-300c-48c8-815f-cc259e125c7f" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million determined using an incremental borrowing rate as of the effective adoption date and (ii) an operating lease right-of-use asset of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ec6d73ad-818f-4a34-8505-10cafd092b23" contextRef="C_88ca2b88-300c-48c8-815f-cc259e125c7f" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, net of the unamortized balance of prepaid/accrued rent as of the transition date. There was </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_916b20b7-88e1-48af-8ccf-e6abe50a20b0" contextRef="C_88ca2b88-300c-48c8-815f-cc259e125c7f" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> impact to the Company&#x2019;s results of operations and cash flows from operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has elected the short-term lease exemption, which allows the Company to not recognize lease liabilities and right-of-use assets arising from lease arrangements with lease terms of twelve months or less. For each lease with a term greater than twelve months, the Company records a right-of-use asset and lease liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A right-of-use asset represents the economic benefit conveyed to the Company by the right to use the underlying asset over the lease term. A lease liability represents the Company&#x2019;s obligation to make lease payments under the arrangement. The Company measures its lease liabilities at lease commencement as the present value of the future lease payments in the contract using the rate implicit in the contract, when available. As an implicit rate has not historically been readily determinable, the Company uses an incremental borrowing rate measured as the rate at which the Company could borrow, on a fully collateralized basis, a commensurate loan in the same currency over a period consistent with the lease term at the commencement date. The incremental borrowing rate is determined based on the Company's synthetic secured rating using the ordered logit model as of the measurement date. The Company measures its right-of-use assets as the lease liability plus initial direct costs and prepaid lease payments, less lease incentives granted by the lessor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Components of a lease are split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) are allocated, based on the respective relative fair values, to the lease components and non-lease components. The Company has elected to account for lease and associated non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company remeasures right-of-use assets and lease liabilities when a lease is modified, and the modification is not accounted for as a separate contract. A modification is accounted for as a separate contract if the modification grants the Company an additional right of use not included in the original lease arrangement and the increase in lease payments is commensurate with the additional right of use. The Company assesses its right-of-use assets for impairment in a manner consistent with its assessment for long-lived assets held and used in operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#x2019;s operating leases are presented in the consolidated balance sheet as operating lease right-of-use assets, classified as noncurrent assets, and operating lease liabilities, classified as current and noncurrent liabilities. Operating lease expense is recognized on a straight-line basis over the lease term. Variable costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">15</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">associated with a lease, such as maintenance and utilities, are not included in the measurement of the lease liabilities and right-of-use assets but rather are expensed when the events determining the amount of variable consideration to be paid have occurred.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Recently issued accounting pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company (&#34;EGC&#34;) to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. As an EGC, the Company has elected to take advantage of this extended transition period for certain new accounting standards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_d8d49096-5159-42ed-91f6-c48a662a04e5_1"><span style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_583ca74f-38d2-43b3-bb08-49e7a5321b97_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Financial Instruments&#x2014;Credit Losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The new standard will be effective for the Company on January 1, 2023. The Company is currently evaluating the potential impact that this standard may have on its consolidated financial position and results of operations.</span></ix:continuation></span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"></span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_0b89be4e-4c85-426d-8553-dcfb69a899a8" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">3. Marketable securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_2569f2c8-c555-498e-9657-6fe2fbdf0f5c" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:MarketableSecuritiesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Marketable securities by security type consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.07%;"></td>
        <td style="width:1.183%;"></td>
        <td style="width:1.432%;"></td>
        <td style="width:9.414%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:1.183%;"></td>
        <td style="width:1.441%;"></td>
        <td style="width:9.414%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:1.183%;"></td>
        <td style="width:1.441%;"></td>
        <td style="width:9.285%;"></td>
        <td style="width:0.855%;"></td>
        <td style="width:1.183%;"></td>
        <td style="width:1.432%;"></td>
        <td style="width:9.365%;"></td>
        <td style="width:0.706%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31, 2021</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Amortized<br />cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Gross<br />unrealized<br />gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Gross<br />unrealized<br />losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Fair<br />value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8a827730-32bc-48f0-a2dd-3993a375a2ad" contextRef="C_c0b06ae8-891a-4456-9a30-d851caa260c4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">277,559</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_52623e9f-ca4a-4498-91f5-2649a7ed24b1" contextRef="C_c0b06ae8-891a-4456-9a30-d851caa260c4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">218</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d263ff55-a10b-4577-a162-38c44dcebd15" contextRef="C_c0b06ae8-891a-4456-9a30-d851caa260c4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">277,341</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a9b326d3-9bdd-42e1-a8c3-25ed8a394f74" contextRef="C_dee7f513-4115-4cdf-b302-37edddf7187e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,781</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_54b9eec5-6dfa-4beb-8b5f-c0c734350590" contextRef="C_dee7f513-4115-4cdf-b302-37edddf7187e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9dcbf029-4f0b-49d1-a7b8-52af5ed0231c" contextRef="C_dee7f513-4115-4cdf-b302-37edddf7187e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,771</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6e89a28e-efb0-43cb-90bd-4cbc5e333e0f" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">296,340</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_89d713eb-3082-40ac-84cf-4483a414f05b" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">228</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c02d674e-2e65-4361-a31d-cf027ee04910" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">296,112</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.12%;"></td>
        <td style="width:1.183%;"></td>
        <td style="width:1.432%;"></td>
        <td style="width:9.414%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:1.183%;"></td>
        <td style="width:1.441%;"></td>
        <td style="width:9.414%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:1.183%;"></td>
        <td style="width:1.441%;"></td>
        <td style="width:9.414%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:1.183%;"></td>
        <td style="width:1.432%;"></td>
        <td style="width:9.335%;"></td>
        <td style="width:0.706%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31, 2020</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Amortized<br />cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Gross<br />unrealized<br />gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Gross<br />unrealized<br />losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Fair<br />value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fb18e436-7197-4b69-b1e1-21c46de350ff" contextRef="C_dae0176e-5286-4cb9-be3e-28858705d8a5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,221</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_29a129d1-32e5-459c-a70c-2798f0d2bf5c" contextRef="C_dae0176e-5286-4cb9-be3e-28858705d8a5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ef04fb35-9d8d-4319-813b-f56c3d41fca1" contextRef="C_dae0176e-5286-4cb9-be3e-28858705d8a5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,224</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_85a70808-d14c-4f3d-aff3-a4a5a5128804" contextRef="C_6d2ce482-3934-425f-b2d1-f6ee23bbabef" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,890</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7b33745c-6825-46c3-91a4-7d30932f65f1" contextRef="C_6d2ce482-3934-425f-b2d1-f6ee23bbabef" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_90408028-cc57-41bf-a017-63abf3d15ea0" contextRef="C_6d2ce482-3934-425f-b2d1-f6ee23bbabef" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,895</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_39b90851-086e-455a-a800-c878e28c4434" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,111</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3c25243b-b25f-4289-99c1-6f2de8970323" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ee207300-ab76-4e18-a32c-6e8714d5683b" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,119</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The remaining contractual maturities of all marketable securities were less than </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_1aabd6b6-2385-4bea-ac98-22e15af74ad5" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:RemainingContractualMaturitiesOfMarketableSecuritiesTerm" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_fbfdc4ce-941c-4b43-9e55-09fb75d304f2" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:RemainingContractualMaturitiesOfMarketableSecuritiesTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">one year</span></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_602e56ff-f245-4ee0-bfe3-034021e77526" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true" continuedAt="F_602e56ff-f245-4ee0-bfe3-034021e77526_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">4. P</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">roperty and equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_4d86f1df-32aa-4023-9575-2d874c901033" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment, net, consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.359%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1.441%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:0.865%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1.441%;"></td>
        <td style="width:12.91%;"></td>
        <td style="width:0.865%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Lab equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_268fb89f-e4b5-486f-9f8e-a4447082679b" contextRef="C_0bc5b84f-e1f5-4d52-92d2-4a44875d520e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,567</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0da12667-acd9-4688-b693-d83176b64d34" contextRef="C_ac6b8994-377a-4736-97a7-37eee958602b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,937</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_95003466-6917-40d1-9489-92bb809504ce" contextRef="C_5489e665-131f-4276-8480-9cbe40f275d4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">266</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ac9bb1d7-14cf-4d38-8076-146156075c93" contextRef="C_20e318f5-772b-42ae-8de4-e92d6afce885" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">259</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_177a4538-c33e-4862-9cc6-0500d8b08c71" contextRef="C_078a5bfc-2f82-4f5d-a355-1da428971361" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">566</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_86e3124a-33e5-47b9-a179-6f1374038c00" contextRef="C_597ac98d-16ac-4d83-be6a-8276c0ed1129" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">481</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Computer equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_78bc303f-e6a9-4a56-8bba-5db8f818794c" contextRef="C_b5b793ed-2405-4df6-a73b-f8234a21676c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">158</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a3af4f5a-6915-4625-b934-0ed3407830f7" contextRef="C_f357484d-ef7a-4007-9dd8-60b4ae94c728" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">105</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4f61622d-bb99-4984-a7f5-97e58fe19bd8" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,557</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f40b04bb-9c70-4983-ba0b-a2d4f79112f1" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,782</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5fbb0d1f-ee0d-493b-a0bf-1d1b70a8b9fb" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,333</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fa00dfff-68c2-4045-90f1-4716901fd3b2" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">798</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_764fdc20-3921-4ebe-8a3a-6f04c2889883" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,224</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_08b8facd-47e8-4966-985b-1aeccc9dfb89" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,984</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_602e56ff-f245-4ee0-bfe3-034021e77526_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Depreciation expense for the years ended December 31, 2021, 2020 and 2019 w</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">as $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_acbb6c3c-00dc-4230-814c-83dbbd8177df" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9a39e5cf-332c-48c2-84e0-e31728b62a95" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fd711dfc-adf9-4721-97a4-e4f53d0021d1" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div><ix:nonNumeric id="F_e9424503-4914-4f4b-b0a4-ee75786113b7" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">5. f</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">air value of financial instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#x2019;s financial instruments consist of money market funds, marketable securities, the preferred stock tranche liability, the antidilution right liability, and success payment liability pursuant to the Harvard/ Broad License Agreement and the Broad License Agreement. The preferred stock tranche liability was fully settled in the year ended December 31, 2020, and the antidilution right liability was fully settled in the year ended December 31, 2021. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The liabilities are carried at fair value. </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_bcd9a29d-674c-4f45-8387-045745de323e" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true" continuedAt="F_bcd9a29d-674c-4f45-8387-045745de323e_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following tables set forth the fair value of the Company&#x2019;s financial instruments by level within the fair value hierarchy: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_bcd9a29d-674c-4f45-8387-045745de323e_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.289%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.431%;"></td>
        <td style="width:9.373%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.431%;"></td>
        <td style="width:9.343%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.431%;"></td>
        <td style="width:9.373%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.431%;"></td>
        <td style="width:9.303%;"></td>
        <td style="width:0.706%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">As of December 31, 2021</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Fair<br />value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_59a9ec8d-48b9-4dd8-9750-bd59fbecb6cc" contextRef="C_aa339973-30be-44d3-9b51-80410c37ae10" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,127</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a2537bc9-2b2a-4fab-9fd1-62b05beb72bf" contextRef="C_8ce3a7dc-9959-4295-a7ff-97a898ccd354" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,127</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1aac1561-3e0a-416a-af6d-96c3588208d5" contextRef="C_e1a13442-1d67-4846-9344-f2e64eb45cf4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1d21d31d-202f-45a8-a97e-abcb2975386d" contextRef="C_25716468-76d3-40f2-8351-b9e832a0d2ec" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5ec0dc35-0b16-4387-8719-15917499f296" contextRef="C_894ba0d1-0497-4bb2-8773-85db59da1dac" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">277,341</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_62b41829-65f4-4116-aec1-233a358b121b" contextRef="C_ec36089a-8e3c-4348-a1b7-6a7b4ec227a5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_aeaef4e6-9f99-46a9-9669-95541d024cd5" contextRef="C_7a75dc28-f9fd-42c4-8bd8-5f9dfd827ae8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">277,341</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ad850c03-8049-477a-8fc1-dc34f5a984ef" contextRef="C_765b171f-952c-4b00-b1af-1c4809294e61" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_138a8ded-97dc-48a5-a080-6b6539676d57" contextRef="C_5703a3c6-815c-4560-9f18-f134cd85e185" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,771</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_84b736a4-4527-4787-b2d3-cba01d5536b5" contextRef="C_d44651b4-0a1c-4a0d-ae7f-725d09d63521" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e9c45200-4193-4469-9bfb-9a82321deaec" contextRef="C_1407fd53-32a3-4a0c-83d7-8d75bcc6c92f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,771</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a64882f6-c9b2-4fab-95f0-aa868724e02c" contextRef="C_4862c09a-79bf-4f14-8cca-db22dcbb94b8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0c10cfb2-0a2d-4747-a5a8-fd90d9895160" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">354,239</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0eea3d80-a182-4990-9f9e-eb27ebc7c361" contextRef="C_7230ac96-5876-4bec-b9a0-17578497db18" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,127</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_826f6c7c-3588-4383-8f8f-fe0d70747ff0" contextRef="C_8c90a925-ca54-4ef3-abb8-1d5e67ef2449" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">296,112</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e9136b00-0c65-413e-ae52-e51922290f65" contextRef="C_470eef76-a3e4-47c1-9135-bcd76e05752b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Success payment liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5165db28-f71f-4360-96a0-09c3e8a3e71d" contextRef="C_7349e083-8b38-4939-84b9-b52dd9e2c764" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,371</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_912a226c-9130-48a6-9dc3-a61c9f5d16a8" contextRef="C_75ebca27-b89c-4f74-8d07-a6fdfe31387c" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3a8dc576-86e5-4609-8721-0f18f7bfe6e0" contextRef="C_79857874-5e87-4b53-b5bf-f51a27d64b5e" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_66acce79-31ae-40e6-95dc-38f2b30ebab8" contextRef="C_604919a2-0184-407a-a67d-53f3e9d796d4" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,371</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_71072021-752f-42f8-bcf1-7cb9b7d99e2a" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,371</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_732640ce-d4a9-4c0a-93f8-d5ea2097d987" contextRef="C_7230ac96-5876-4bec-b9a0-17578497db18" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3791ad8f-d84f-42fa-84a0-578380bcacc8" contextRef="C_8c90a925-ca54-4ef3-abb8-1d5e67ef2449" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a025c259-a341-460c-aa4a-0cabff3c6cdb" contextRef="C_470eef76-a3e4-47c1-9135-bcd76e05752b" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,371</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.359%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.432%;"></td>
        <td style="width:9.345%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.432%;"></td>
        <td style="width:9.315%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.432%;"></td>
        <td style="width:9.345%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.432%;"></td>
        <td style="width:9.315%;"></td>
        <td style="width:0.706%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">As of December 31, 2020</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Fair<br />value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8f1cc944-94cf-4f44-bb14-1ea58b870fa4" contextRef="C_55860b8b-baa2-4e63-b435-ce9e60ae5e06" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,724</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f7228270-3c68-4502-b88f-ba56fa8a6ac7" contextRef="C_5d8591bc-11a9-40ab-b3a4-bc7e3800e026" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,724</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9f22e028-db08-441f-b3d6-79146c53a05a" contextRef="C_c20382c9-9ff7-450f-8cd6-93193f146b1d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1040b145-a0b2-44b5-992f-65d883cc8a77" contextRef="C_adefa849-4678-4e94-b863-2d12ecdad8f9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d00614ae-22b1-4f13-8cda-ce846723dc6a" contextRef="C_dd01459a-975e-48f9-9d4f-b18bb361be4f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,224</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4728c1f9-fc3c-4f1b-a5fa-b2353293a4b1" contextRef="C_3d70dec1-7c1e-48b3-b61d-3e6ca572b452" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e1e9248b-35ea-4021-b0d9-e0a9d79c3290" contextRef="C_b3c87878-bc9c-48e0-848d-9e7ea4f29412" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,224</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8a1d0030-7151-46dd-bc57-6382428585ba" contextRef="C_7dd626b0-6fc1-4783-8c59-97a950918aed" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b8cebfad-2551-4a40-8f00-4b2a89a5a278" contextRef="C_235eb2e2-4747-444d-b7ee-6cc0e5a83ec6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,895</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_04079d02-93c1-4305-952d-d42f9a852632" contextRef="C_dc4c7421-4413-4b48-9fbf-b319860463d2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_edaf6119-d57a-4dff-8e60-d5ed2d00d915" contextRef="C_f9dffce0-4bc6-41d0-9e68-e6fdba07b1d5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,895</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_63f8233e-199c-4401-8e11-3e0217d36e1c" contextRef="C_fec04bb0-37db-4624-a7d4-cd02343359c8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_12bd5615-45e0-4b97-a674-3a71be67404a" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,843</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e1af820d-2f66-44f9-a179-bd7a513cdba7" contextRef="C_9b218daf-9568-4fb9-ba54-24937e994d44" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,724</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_aef1854f-9af7-4a18-b92d-51debcfadbe5" contextRef="C_d971946d-306c-459c-8b3a-e96fc64334f7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,119</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_87412c66-0d57-40d5-bee4-7f85abe8c753" contextRef="C_fcb68bae-6468-4eef-9487-908de3c3ac46" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Success payment liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_650bfcaa-5e8c-4c6c-bb92-6078b5863583" contextRef="C_ea8434d0-a39e-4a6a-bb26-7799962446b9" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,806</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_19afaae9-71a0-488a-9214-16ec5e6e868c" contextRef="C_2e418dc0-e214-4a34-8796-62a40cabca50" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0a0a4dc1-788d-4331-9bc6-9f4e32e4b2c0" contextRef="C_c27b92cd-9d6c-4111-bd60-2b3bb8205544" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_de2d689e-8d58-4876-9055-7f301b72a007" contextRef="C_2da1fcc5-d34b-4f3a-ae28-f14234789060" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,806</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Antidilution rights liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2673090f-55ec-463e-82ea-e98ea67d67e8" contextRef="C_0e18a72a-d76f-4344-ab19-24bc729bb1a1" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,916</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_046dda2f-f641-4888-a22d-5316ba99c97e" contextRef="C_bae1dfa2-41b7-46c1-9e1e-5fae784a1de3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4e225368-9ba4-47ab-a01d-4d20d80351c9" contextRef="C_2a3189e2-c048-4d31-976f-cb3b47d3233e" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c0dae9fe-ff81-41c0-841b-3ace6881d4f7" contextRef="C_1a692e9d-fc22-429a-866a-28850d71edcd" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,916</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a716a00a-91d7-45d1-b16d-0588d013e7d6" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,722</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_efcfb617-310e-4677-bc17-426d3011f6fd" contextRef="C_9b218daf-9568-4fb9-ba54-24937e994d44" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0ea0bd6d-642b-48b0-9575-6e39fbbe21e0" contextRef="C_d971946d-306c-459c-8b3a-e96fc64334f7" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4b9f1df4-4978-4740-a9a8-a278c04c9174" contextRef="C_fcb68bae-6468-4eef-9487-908de3c3ac46" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,722</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Cash Equivalents</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;Cash equivalents of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_928addd6-1b7b-450d-a683-6ddeed5cb4f6" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">58.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d57a39df-1c3c-4298-bf08-1f2aff6bf696" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> as of December 31, 2021 and 2020, respectively, consisted of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Marketable Securities&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company measures its marketable securities at fair value on a recurring basis and classifies those instruments within Level 2 of the fair value hierarchy. Marketable securities are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Preferred Stock Tranche Liability</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;The preferred stock tranche liability is stated at fair value and is considered Level 3 within the fair value hierarchy because its fair value measurement is based, in part, on significant inputs not observed in the market. The tranche liability was valued using a probability-adjusted scenario-based method that considered the probability of triggering the tranche rights through achievement of certain non-scientific and scientific milestones as well as the pu</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">rchase price of Series A preferred stock. Subsequent Series A Preferred Stock closings occurred in both 2019 and 2020 and the preferred stock tranche liability was fully settled as of December 31, 2020 (refer to Note 9, Preferred stock tranche liability). Prior to settlement, the Company remeasured the liability with a corresponding increase of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f2baeb7b-5428-424d-b430-f7a21c1a26c4" contextRef="C_70bdd4a9-53a3-4196-bff4-9fe631ab414d" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million to other expense for the year ended December 31, 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Antidilution Rights Liability</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014; The antidilution rights liability represents the obligation to issue additional shares of common stock to Harvard and Broad following the completion of (1) a defined aggregate level of preferred stock financing and (2) either a sale of the Company&#x2019;s preferred stock, an initial public offering, or a company sale meeting a certain value threshold. The antidilution rights liability was stated at fair value and was considered Level 3 in the fair value hierarchy because its fair value measurement was based, in part, on significant inputs not</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">observed in the market. The antidilution rights liability related to meeting a defined aggregate level of preferred stock financing was valued using a probability-weighted present value model that considered the probability of meeting the defined aggregate level of preferred stock financing, as well as the fair value of the Company&#x2019;s common stock. The antidilution rights liability related to the achievement of a specified valuation through either a sale of the Company&#x2019;s preferred stock, an initial public offering, or a company sale was valued using a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the fair value of the Company&#x2019;s common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">At issuance in 2019, the estimated fair value of the antidilution rights liability was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9eba4e63-cf69-417b-8ebb-902716c2c659" contextRef="C_9d0f6183-f1e6-4aa0-b41e-2e38deb97369" name="verv:ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, which was recorded as research and development expense. The Company remeasured the liability at fair value with corresponding charges of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1e142230-07bb-4c69-acac-6577f72c2a43" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9398b980-f4f1-4c9c-8e44-1c661bc81aa6" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million recorded to other expense for the years ended December 31, 2020 and 2019, respectively. The antidilution rights associated with the Company achieving a defined aggregate level of preferred stock financing were partially satisfied in 2019 and fully satisfied in 2020, which settlement amounts totaled $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6698ec8c-9694-4589-8d77-924854a0e302" contextRef="C_0e18a72a-d76f-4344-ab19-24bc729bb1a1" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2e58c0a7-deb1-4595-8bbe-3d745f3d6801" contextRef="C_d11db810-1bfc-445d-b0c0-43624d7bd52d" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively, and which amounts were settled through issuances of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_88a57ce1-322e-41ef-b1e3-71e305818f5b" contextRef="C_d11db810-1bfc-445d-b0c0-43624d7bd52d" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">121,411</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_17e2c68d-c11d-488e-9d14-5418ec2609a0" contextRef="C_0e18a72a-d76f-4344-ab19-24bc729bb1a1" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">187,867</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company common stock, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2021, upon completion of its IPO, the Company settled the antidilution rights liability in full through the issuance of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_99705fed-3d84-43d8-9af2-ccc7aa0d1b1a" contextRef="C_4303f47d-2279-40f2-a160-e7a91300902b" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">878,098</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company's common stock for a settlement amount of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c43d1af5-db55-4b92-86fe-d86f8af274c7" contextRef="C_4303f47d-2279-40f2-a160-e7a91300902b" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">32.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. Prior to settlement, the Company remeasured the liability with a corresponding increase of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_59acd1fc-7b40-447d-a3f0-3f84f97be906" contextRef="C_84c106c3-aeb7-42d5-ab70-a059d1961a3b" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million to other expense for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Success Payment Liability</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014; The Company is obligated to pay to Harvard and Broad tiered success payments in the event its average market capitalization exceeds specified thresholds for a specified period of time ascending from a high nine-digit dollar amount to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_36a20210-e688-43fc-8e4d-17bd636d8101" contextRef="C_e8b5087a-c8c5-42b6-b02a-2126a65898d5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control or a sale of the Company, the Company is required to pay success payments in cash within a specified period following such event. Otherwise, the success payments may be settled at the Company&#x2019;s option in either cash or shares of its common stock, or a combination of cash and shares of its common stock. The maximum aggregate success payments that could be payable by the Company is $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fd60e236-c77d-420c-ae9b-3f07695d31d0" contextRef="C_c286c886-b8bc-4074-85c6-6c1d797c88f0" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">31.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million (after termination of the Broad License Agreement).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The success payments liability is stated at fair value and is considered Level 3 because its fair value measurement is based, in part, on significant inputs not observed in the market. The Company used a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the value of the Company&#x2019;s common stock. The Company also estimated the likelihood that it would maintain both the Harvard/Broad License Agreement and the Broad License Agreement based on its on-going research efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company remeasured the liability at fair value with incre</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ases of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3b2127c3-dbab-4359-b572-fdd069fd7220" contextRef="C_dc4de63a-1a13-435a-91bf-1d42b2503336" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_01d8b8f3-5ad3-40f4-9013-44f68ccceb54" contextRef="C_d04521c5-cb77-4e26-9e7d-c596e315d733" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.4</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ed35125d-387d-4aa8-9f3c-a78c04c820cb" contextRef="C_556c543d-6999-40a3-9b90-5c280daba957" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> recorded to other expense </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">for the years ended December 31, 2021, 2020 and 2019, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In September 2021, multiple success payments were triggered and amounts due to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_dc625304-9ad4-4237-bb91-c688f6b285f8" contextRef="C_ea754504-c0d8-4221-a285-32e891462575" name="verv:SuccessPaymentLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. These amounts were settled in cash in November 2021. The Company will continue to adjust the remaining success payment liability for changes in fair value until the earlier of the achievement or expiration of the obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_4aff1eeb-6402-45b2-921f-00a65231210e" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The primary inputs used in valuing (i) the success payments liability and (ii) the antidilution rights liability associated with the Company&#x2019;s realization of a certain valuation threshold through either a sale of the Company&#x2019;s preferred stock, an initial public offering, or a company sale at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 (only applicable to success payments liability), 2020 and 2019, were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.375%;"></td>
        <td style="width:1.352%;"></td>
        <td style="width:1.432%;"></td>
        <td style="width:12.138%;"></td>
        <td style="width:2.287%;"></td>
        <td style="width:1.352%;"></td>
        <td style="width:1.432%;"></td>
        <td style="width:12.138%;"></td>
        <td style="width:2.287%;"></td>
        <td style="width:1.352%;"></td>
        <td style="width:1.432%;"></td>
        <td style="width:12.138%;"></td>
        <td style="width:2.287%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">At<br />December 31,<br />2021</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">At<br />December 31,<br />2020</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">At<br />December 31,<br />2019</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fair value of common stock (per share)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_961f204a-4515-4b04-84f8-5c0cb2ac5269" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="verv:FairValueOfCommonStockPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">36.87</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_55b30178-001a-4dc0-ae5b-0064632b8cb1" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="verv:FairValueOfCommonStockPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">8.24</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8e3f2d6d-af49-43c0-bff8-4590d89e195b" contextRef="C_9d0f6183-f1e6-4aa0-b41e-2e38deb97369" name="verv:FairValueOfCommonStockPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.59</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Equity volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6c406168-9348-45b8-8e1f-1f3708beaee6" contextRef="C_bc02f4c1-1fb9-4d8b-93c6-bd1442840b62" name="verv:FairValueAssumptionOfEquityVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">77</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9f93ef32-d55c-48c3-8942-c82d50d704ae" contextRef="C_46b68a29-4a56-4a0e-b6e7-327c4a2472e7" name="verv:FairValueAssumptionOfEquityVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">105</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f50a8f18-00ab-4e14-9ba0-0f8bb32d9a40" contextRef="C_0e74774f-4077-4438-a31c-22d5b9e9bf39" name="verv:FairValueAssumptionOfEquityVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cumulative probability of triggering event</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">n/a</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7b4cb2c1-e05f-43c6-b416-59bad49d4761" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:CumulativeProbabilityOfTriggeringEvent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bb8a4160-253d-4ce1-87c5-b8e92442fcc4" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:CumulativeProbabilityOfTriggeringEvent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">n/a</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_45336371-7440-411b-b0c4-b1d32c08bab7" contextRef="C_456b2896-d611-45e2-8641-7467961b8168" name="verv:FairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.50</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_11c69e3d-d6ec-46dd-9ca6-cb6ffab30229" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:FairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.89</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">At </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2020 and 2019, the fair value of the Company's common stock was determined by management with the assistance of an independent third-party valuation specialist using methods consistent with the AICPA Valuation Guide. The computation of equity volatility was estimated using available information about the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">historical </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">volatility of stocks of similar publicly traded companies for a period matching the expected term assumption. In addition, the Company incorporated the timing and probability of future events in the calculation of liabilities. The Company also estimated the likelihood that it would maintain both the Harvard/Broad License Agreement and the Broad License Agreement based on its on-going research efforts. The Company applied a </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_be178b54-aed5-463f-ab18-baaef524fae9" contextRef="C_671bfcc0-ebf7-4194-8895-80b3fa98b658" name="verv:FairValueInputsProbabilityOfTermination" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">90</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% probability of termination of the Broad License Agreement at December 31, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In February 2021, the Company provided written notice to Broad of its election to terminate the Broad License Agreement, which termination became effective in June 2021.</span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_0a19e1c8-a172-4d01-97c9-184e242281bb" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.244%;"></td>
        <td style="width:1.183%;"></td>
        <td style="width:1.431%;"></td>
        <td style="width:10.556%;"></td>
        <td style="width:0.855%;"></td>
        <td style="width:1.183%;"></td>
        <td style="width:1.441%;"></td>
        <td style="width:10.635%;"></td>
        <td style="width:0.855%;"></td>
        <td style="width:1.183%;"></td>
        <td style="width:1.431%;"></td>
        <td style="width:10.536%;"></td>
        <td style="width:0.855%;"></td>
        <td style="width:1.183%;"></td>
        <td style="width:1.431%;"></td>
        <td style="width:9.144%;"></td>
        <td style="width:0.855%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Preferred<br />stock<br />tranche<br />liability</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Antidilution<br />rights<br />liability</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Success<br />payment<br />liability</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Balance at December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_83bdef29-aa3f-4072-816b-c5cf62eb59c8" contextRef="C_7d6fc6e3-0bd2-4c41-a389-d8c78306592d" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,571</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_51537789-acf0-4ffa-aaf2-730bd5e53d4f" contextRef="C_d11db810-1bfc-445d-b0c0-43624d7bd52d" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,044</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_abe51183-9e8d-4fe8-87a1-949cc3a80851" contextRef="C_cc8e1463-c758-4dfb-9de6-62be2741f27c" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">419</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9d0a4f71-155c-4e0f-8d78-a1b731925b92" contextRef="C_9d0f6183-f1e6-4aa0-b41e-2e38deb97369" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,034</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of Series A Preferred</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8cbd6174-acb5-4d49-ad91-36a591df2c81" contextRef="C_70bdd4a9-53a3-4196-bff4-9fe631ab414d" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,064</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_877bab3f-45a2-4a8e-b480-4f257d3e1a91" contextRef="C_a6d1a849-b7f6-4b32-8b52-0bd344744eb9" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_33fdf371-28d1-474c-868f-d9b168a28dfd" contextRef="C_b374bc60-e066-42aa-99b0-3e124c675fda" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ab997002-95b7-4731-9352-bf69cbfe008d" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,064</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_516a9bd8-9e7b-4138-a389-13c0fe042dac" contextRef="C_70bdd4a9-53a3-4196-bff4-9fe631ab414d" name="verv:CommonStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4e68e4b9-fa4b-4c74-8c18-fd723ced7c2d" contextRef="C_a6d1a849-b7f6-4b32-8b52-0bd344744eb9" name="verv:CommonStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">487</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_68e9b49b-355f-4005-8d00-5631883b675c" contextRef="C_b374bc60-e066-42aa-99b0-3e124c675fda" name="verv:CommonStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_550621d4-ca11-4305-8785-086e3854162d" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:CommonStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">487</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a7bc52f8-3857-4a31-8d22-5a27a340b9f8" contextRef="C_70bdd4a9-53a3-4196-bff4-9fe631ab414d" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,507</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_56701c1c-a478-4151-adda-dddac65a7ed3" contextRef="C_a6d1a849-b7f6-4b32-8b52-0bd344744eb9" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,359</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9cfa8121-caaf-40e3-aea8-a1e49852b40d" contextRef="C_b374bc60-e066-42aa-99b0-3e124c675fda" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,387</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_722eb242-52cf-4fdc-88c4-78faf7d2c524" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,239</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b3d88014-9004-46ad-9946-2efb7d361f51" contextRef="C_a9ae8471-e3e2-4484-84b2-6eaafd17e730" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_820a2af1-b709-47cd-a15e-50e27c3b920f" contextRef="C_0e18a72a-d76f-4344-ab19-24bc729bb1a1" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,916</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_53b38a61-90de-4240-8fe9-65c2a45780d5" contextRef="C_ea8434d0-a39e-4a6a-bb26-7799962446b9" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,806</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7399c03b-b50e-4931-8f33-67794d5bc35a" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,722</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of common stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_75e12c86-32ba-4d74-8114-e5c131a78b59" contextRef="C_428c5b12-83cd-4341-b4bb-932e3b77cd04" name="verv:CommonStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a95b2f42-359e-4c0e-bc36-dca1ee8da839" contextRef="C_ccde73cb-e336-419a-a1be-6bc267e8d5ae" name="verv:CommonStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">32,490</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9d6069ea-e067-44cc-80c0-30b0970d42b6" contextRef="C_02e26f3d-99d2-4166-a4b7-b128f163b312" name="verv:CommonStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_224135ad-4d8a-4902-b65b-d14e1268e1fe" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:CommonStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">32,490</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Success payment liability earned and paid</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_170610ab-9c1b-4510-8f28-c508389451c8;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_716c6897-a6df-4fdf-9e99-b336dfd3b30f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9bd5c2af-897e-4f55-a318-751f7d337d0e" contextRef="C_7349e083-8b38-4939-84b9-b52dd9e2c764" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c02a509b-8ce8-4301-8f17-3212655b3a24" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_984f39ca-45a8-4013-bdcf-991b052e9cb2" contextRef="C_428c5b12-83cd-4341-b4bb-932e3b77cd04" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f923abc7-7cf5-45ed-a844-3ff72965540f" contextRef="C_ccde73cb-e336-419a-a1be-6bc267e8d5ae" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,574</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d3c73700-86e5-419b-9f1c-91317f8e7950" contextRef="C_02e26f3d-99d2-4166-a4b7-b128f163b312" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,815</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_696e8fdc-03cb-4f8f-bdac-db102b735ee4" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,389</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_68f6d087-757f-40d2-a77c-b018bb0f253f" contextRef="C_d8897390-cbaa-48a9-b558-fd628bd36c53" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3ce8e30c-5963-4546-9419-cc60bac51309" contextRef="C_d4248d0a-06a2-4040-a853-becbd34bcc18" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fe3630f4-3971-4bc3-89bf-f89b15b5c7e8" contextRef="C_7349e083-8b38-4939-84b9-b52dd9e2c764" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,371</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e2e239f7-26e2-4e3e-9be7-63a97025c916" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,371</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_c9ac1cda-cca0-4872-b187-c0b859e59c84" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">6. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Accrued expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_cdb0d812-ce68-451c-aa7b-9de5beef4b0c" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued expenses consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.395%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1.441%;"></td>
        <td style="width:13.05%;"></td>
        <td style="width:0.716%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1.441%;"></td>
        <td style="width:13.04%;"></td>
        <td style="width:0.716%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Employee compensation and related benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7e99517b-fa90-4918-98a0-a8bf0c86f780" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,050</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1e7bfe61-e769-436d-8483-76b25c60c049" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,636</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued external research and development expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_21036f38-c3ca-463a-9b22-5fa8453732a7" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="verv:AccruedExternalResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,041</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ecf1e015-aec3-4018-bb84-a5be40d8c173" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="verv:AccruedExternalResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,827</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c323b9f4-adb3-4a92-9183-a318346e43f4" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,109</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0c899048-85b9-4e34-a901-7d0e674bf281" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">303</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_726af2b9-7126-4e7b-8c61-dbf3b6b3c133" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">792</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f149f819-e7c2-4287-aaf7-75faab95399c" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">423</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bc8bb8c9-c66e-4515-93ca-42ae2208e583" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,992</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2b5dc6a5-2a70-4f0a-af64-4d7d2e0e436e" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,189</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_ec76d4e7-beb1-4586-b86e-ae1f314d2f1e" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">7. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#x2019;s operating lease activity is comprised of non-cancelable facility leases for office and laboratory space in Cambridge, Massachusetts. In March 2020, the Company entered into an operating lease agreement for </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_dfd8ee05-13ab-4254-8441-95f12a1ff452" contextRef="C_5026dda8-28ac-4046-b30f-f4c2af3df266" name="verv:LesseeOperatingLeaseArea" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">16,843</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> square feet of space located at 500 Technology Square, Cambridge, Massachusetts (the &#x201c;Cambridge Lease&#x201d;), with the Company acting as subtenant. The term of the Cambridge Lease commenced in August 2020 and is scheduled to expire </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_42e9ee53-50e0-4a73-b7e7-11f3408d3bb5" contextRef="C_5026dda8-28ac-4046-b30f-f4c2af3df266" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">two years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> from the commencement date. The lease provides for annual rent escalations. The Company pays for its proportionate share of building operating costs such as maintenance, utilities, and insurance. In June 2020, the Company entered into the First Amendment to the Cambridge Lease adding </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5d5eb654-3df1-4724-81d1-f8c79ddeb9b3" contextRef="C_2b400acd-8cd9-40ff-8255-a68985c37814" name="verv:LesseeOperatingLeaseArea" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">2,980</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> square feet of additional space. In January 2021, the Company entered into the Second Amendment to the Cambridge Lease adding </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d901e511-82d8-4328-a5fc-fd6408a236ac" contextRef="C_1f16c804-a208-4c37-b6c5-31908dac33d8" name="verv:LesseeOperatingLeaseArea" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">2,980</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> square feet of additional space at a commensurate rent increase which was treated as a new contract. In July, 2021, the Company entered into an amendment for its office space at 500 Technology Square and corresponding parking lot to extend the lease term through </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_dc1df3fa-7900-4cee-8404-778a4a582e3e" contextRef="C_0ea046e2-86bb-4bd2-985f-27d259b832a4" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">November 30, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. The renewal operates under the same terms and conditions as the original lease. As a result of the renewal, the right-of-use asset and lease liability were remeasured at the present value of the lease payments not yet paid, discounted by the incremental borrowing rate (IBR) at the remeasurement date. This resulted in a net increase to the lease liability and right-of-use asset of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d49e1867-03d7-4b4b-8bbd-7fb02982bbf7" contextRef="C_3c6e9331-d8d3-43e7-8098-fbde994f4649" name="verv:IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_9d407fff-5153-431a-956c-ced452ab5225" contextRef="C_3c6e9331-d8d3-43e7-8098-fbde994f4649" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. There was no impact on the consolidated statement of operations and comprehensive loss or the consolidated statement of cash flows as a result of the lease renewal.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has also entered into multiple contract research and contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. The embedded leases are</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">considered short term leases, as the contractual terms are twelve months or less. Accordingly, no lease liability or right of use asset has been recorded, and the Company has recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_77b1c8e4-5bf6-4056-ab14-2e93a3cbf0ca" contextRef="C_0d594e36-72b4-4236-bd90-bc5bab9f7a9e" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of short term lease costs associated with the embedded leases during the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_88fce536-a431-4513-8762-d0967b079f69" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The components of operating lease cost were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.863%;"></td>
        <td style="width:1.938%;"></td>
        <td style="width:1.441%;"></td>
        <td style="width:16.032%;"></td>
        <td style="width:0.726%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31, 2021</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5df73ae8-7efa-4ad9-b6c9-ad8f05d5504f" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,923</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Variable lease costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6032bcb4-bd36-4cb8-b5c7-0a761188b440" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">747</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Short term lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_37b6e701-80a5-4795-a0bb-12da16b85cf0" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,278</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a7062af5-80c6-45ab-9db2-1a23966108c5" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,948</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_0c43ad9c-3a38-4ebf-99a8-e0eb14d2a7dd" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Supplemental cash flow information related to operating leases was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.863%;"></td>
        <td style="width:1.938%;"></td>
        <td style="width:1.441%;"></td>
        <td style="width:16.032%;"></td>
        <td style="width:0.726%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31, 2021</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cash paid for amounts included in the measurements of lease liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating cash flows related to operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7d0e1eb1-ada3-450f-a000-2f5e328fd9cf" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,021</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021, the Company&#x2019;s operating leases were measured using a weighted-average incremental borrowing rate </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2a892a8c-f160-4d74-9f8f-5f63f8ad3a00" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="verv:LesseeOperatingLeaseIncrementalBorrowingRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.57</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> over a weighted-average remaining lease ter</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">m of 0</span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_18c751ed-902e-456b-8d93-8ce25e1f9226" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.9 </span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On August 19, 2021, the Company entered into a lease agreement with ARE-MA Region No. 87 Tenant, LLC, a Delaware limited liability company (the &#x201c;Landlord&#x201d;), pursuant to which the Company will lease approximately </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1a9c73c3-c0e2-4753-92d4-a010ffc299c6" contextRef="C_ac0671b9-90e0-41a4-b113-3a0ff36d64e8" name="verv:LesseeOperatingLeaseArea" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">104,933</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> square feet of office and laboratory space located at 201 Brookline Avenue, Boston, Massachusetts (the &#x201c;Boston Lease&#x201d;), further amended in January 2022 to include an additional </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0b456726-6972-4719-a9e5-2cc651b8a176" contextRef="C_a810db97-eb14-448b-9d1b-137166449fdd" name="verv:AdditionalLesseeOperatingLeaseArea" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">211</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> square feet, for a total of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_62f3c73e-bd7f-4a35-98dc-d1c33eebe3d5" contextRef="C_a810db97-eb14-448b-9d1b-137166449fdd" name="verv:LesseeOperatingLeaseArea" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">105,144</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> square feet. The Boston Lease premises have not been made available to the Company as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 and is therefore excluded from the table below, as the Lease has not commenced.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The term of the Lease will commence on the earlier of (1) the date the Landlord </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delivers the premises under the Boston Lease to the Company, which the parties expect to be on or prior to August 1, 2022, or (2) the date the Landlord could have delivered the premises but for any delays attributable to the Company (the &#x201c;Commencement Date&#x201d;). </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_30ee5534-441d-44a5-86cb-334102c93680" contextRef="C_e544b1d4-8651-4bbd-86e5-229213fc8bef" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#x2019;s obligation for the payment of base rent for the Boston Lease begins 90 days after the Commencement Date (the &#x201c;Rent Commencement Date&#x201d;) and will initially be $0.8 million per month, which will increase by approximately 3% per annum.</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> The Boston Lease has a term of </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_9136bb54-a38e-4eeb-ac1a-52d36cb01150" contextRef="C_ac0671b9-90e0-41a4-b113-3a0ff36d64e8" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" format="ixt-sec:duryear"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> years, measured from the Rent Commencement Date. The Company has the </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_a174abc4-deb0-4f6f-a373-38042ddea732" contextRef="C_cb1b7494-a0dd-49fc-8914-d1f55848827c" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">option to extend</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> the term of the Lease for a period of an additional </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_0c6f3856-46ea-4fe4-a594-010cc4b83548" contextRef="C_cb1b7494-a0dd-49fc-8914-d1f55848827c" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Under the terms of the Lease, the Landlord has agreed to make up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a73f030a-9454-4f42-abe9-9f4979200c44" contextRef="C_ac0671b9-90e0-41a4-b113-3a0ff36d64e8" name="verv:TenantImprovementsAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in certain tenant improvements to the premises to suit the Company&#x2019;s use (the &#x201c;Tenant Improvement Allowance&#x201d;), which amount is included in the base rent set forth in the Boston Lease. In addition to the Tenant Improvement Allowance, the Company may receive up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1ec5ff8b-9008-4751-9569-8671c2979eac" contextRef="C_ac0671b9-90e0-41a4-b113-3a0ff36d64e8" name="verv:AdditionalTenantImprovementsAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.2</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for additional improvements to the premises, which amount is subject to an </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d4a3c486-1e05-4b8a-acfd-8d71fd62c306" contextRef="C_cb1b7494-a0dd-49fc-8914-d1f55848827c" name="verv:InterestRateForAdditionalImprovementsAllowance" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% annual interest charge and may be paid in equal monthly installments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In connection with its entry into the Boston Lease and as a security deposit, the Company has provided the Landlord a letter of credit in the amount of approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8a3cb0a6-190c-408e-a980-05db5c2e351f" contextRef="C_96a9ec98-0425-4b68-a1ef-a3660007003a" name="us-gaap:ShortTermBorrowings" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, which may be reduced to approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_557a0b1b-39fa-4607-924e-74836514082d" contextRef="C_96a9ec98-0425-4b68-a1ef-a3660007003a" name="verv:ShortTermBorrowingsReducedValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million on the expiration of the 36-month anniversary of the Rent Commencement Date so long as there are, and have been, no defaults by the Company under the terms of the Boston Lease. The Company also paid a deposit in the amount of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d9810f7a-9c08-4d90-a618-dc33eaef3413" contextRef="C_ac07bf25-eb1b-41db-9a17-637a6b3c0cf0" name="us-gaap:PrepaidRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, which is equal to the first month of base rent.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Landlord has the right to terminate the Boston Lease upon customary events of default. The Company </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_9331ff94-4e22-427d-8ee5-8546fc694267" contextRef="C_cb1b7494-a0dd-49fc-8914-d1f55848827c" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate" format="ixt:booleantrue"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">may also termina</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">te</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> the Boston Lease if the premises are not ready for occupancy within a specified time period after August 1, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Boston Lease requires the Landlord to perform a scope of work to build-out the base building prior to the construction of the premises. The Company concluded the accounting commencement date will occur when the Landlord completes the build-out of the base building and control passes to the Company. The Company will assess the classification of the Boston Lease at the accounting commencement date, measure the right-of-use asset and lease liability. Payments made by the Company prior to commencement will be treated as prepaid rent which will increase the right-of-use asset. As of December 31, 2021, the Company has incurr</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ed $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_05017be7-2dde-46ca-bf0c-08fb0bffa74e" contextRef="C_e544b1d4-8651-4bbd-86e5-229213fc8bef" name="verv:OperatingLeaseRelatedExpensesPriorToCommencement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million re</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">lated to the build out of the lease space prior to the Commencement Date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">20</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In October 2021, the Company entered into a sublease for </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f8faea77-4eea-4fd2-b02f-62734b13181c" contextRef="C_7eaf2c5f-f4cf-4ef5-8686-522ecb024096" name="verv:LesseeOperatingLeaseArea" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">11,931</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> square feet of office and laboratory space in Cambridge, Massachusetts. The sublease commenced in </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_e9576d66-bc51-4319-a155-2735da202c36" contextRef="C_4d5e8986-339e-4a27-a33a-2ddab2c8cf2a" name="verv:LeaseCommencementDate" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and has an initial noncancelable term of </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_d63d3e53-3c3d-4929-9925-fb028b4c8f31" contextRef="C_4d5e8986-339e-4a27-a33a-2ddab2c8cf2a" name="verv:LeaseNoncancelableTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">twelve months</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_df85c665-1298-40a1-85ed-0206d0efaabe" contextRef="C_4d5e8986-339e-4a27-a33a-2ddab2c8cf2a" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has the option to extend the sublease for one extension term of three months by written notice not less than six months prior to the expiration of the sublease term, which the Company is not reasonably certain of exercising.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> Therefore, this sublease is treated as a short term lease. The total fixed lease payments over the sublease term is approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1107bbb2-c9ec-4381-8a28-f3c275f6ce6b" contextRef="C_7d62c74e-40c7-4d44-95f2-9153b525923e" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and the Company is also required to pay its proportional share of operating expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_3bc16061-4f01-428c-925d-3fc5367e040e" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Future minimum commitments under non-cancellable leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.833%;"></td>
        <td style="width:1.938%;"></td>
        <td style="width:1.441%;"></td>
        <td style="width:15.923%;"></td>
        <td style="width:0.865%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Years ending December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Amount</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_985f04be-f325-4c26-86a4-3840501351fb" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,951</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1bb89759-c9a0-4224-a5a7-060a4ef0a067" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,958</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3efad5fc-bceb-4c08-943a-ee193b0c293f" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,257</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_53fa8207-bb87-4957-a179-509f7b344bb6" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,565</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6c878b17-2c59-44c4-adf7-34ffedd938db" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,882</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_90660f4a-cb3e-4579-b4c1-5503ca526b95" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="verv:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54,158</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_87930dee-9edd-4737-a1ce-5d65cc32b410" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,771</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less: interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4b7cc866-6238-4226-adb6-ebce83f76392" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4e7a03cb-a50b-4a39-a154-7df1e7f1c587" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,758</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Accounting under ASC 840</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to the adoption of ASC 842, the Company recorded rent expense on a straight-line basis over the term of the lease, including any rent-free periods. In addition, the Company recorded deferred rent for certain lease incentives received, which were amortized as a reduction of rent expense over the life of the lease. Rent expense was presented as part of continuing operations in the consolidated statement of operations and comprehensive loss; deferred rent was recorded on the consolidated balance sheet.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Rent expense for the years ended December 31, 2020 and 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f7fe94af-f283-4a93-822a-75b9de1acd89" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0035d75a-9517-4e49-ab56-ed1ec884a42c" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_97edbfe1-f1ca-4bd4-bf1c-3a7f56ad76fe" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:LicenseAgreementDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">8.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> License agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Harvard/Broad license agreement and Broad license agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In March 2019, the Company simultaneously entered into the Harvard/Broad License Agreement and Broad License Agreement (the &#x201c;license agreements&#x201d;) for certain base editing technologies pursuant to which the Company received exclusive, worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed products and nonexclusive, worldwide, sublicensable, royalty-bearing licenses under certain patent rights to research and develop licensed products. The Company agreed to use commercially reasonable efforts to develop licensed products in accordance with the development plans, to introduce any licensed products that gain regulatory approval into the commercial market, to market licensed products that have gained regulatory approval following such introduction into the market, and to make licensed products that have gained regulatory approval reasonably available to the public. The term of the agreements will continue until the expiration of the last to expire valid claim. The Company may terminate either of the license agreements without cause upon four months&#x2019; prior written notice to Harvard and Broad, unless terminated earlier. In February 2021, the Company provided written notice to Broad of its intent to terminate the Broad License Agreement, which termination was effective in June 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As partial consideration for the rights granted under the Harvard/ Broad License Agreement and Broad License Agreement, the Company paid $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6795cd6e-54f6-4285-ad52-ea28307cfe32" contextRef="C_e5482ed2-d888-4dd2-a7a7-cb1d249e3b82" name="verv:NonRefundableUpfrontLicenseFeesPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in non-refundable upfront license fees and also issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e9f611f2-cf5b-471a-b81c-3a01812c8182" contextRef="C_6ad6efa1-92e1-4627-b9eb-e717d27461ed" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">276,075</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of its common stock with a fair value of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9c2a0740-31ae-46be-8c4d-b156a5a344cf" contextRef="C_e36ace04-7d0f-46f4-a4fc-05e0cddb3357" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. Additional consideration under the license agreements is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Antidilution Rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;The initial shares of common stock issued to Harvard and Broad are subject to antidilution provisions as further described in Note 5, Fair value of financial instruments. The antidilution rights associated with the Company achieving a defined aggregate level of preferred stock financing were partially satisfied in 2019 and fully satisfied in 2020, which settlement amounts totaled $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2890fa5d-def1-46c4-85e8-2b2f5b013fab" contextRef="C_29a82fc7-8d8b-4988-8c6b-cb6aaeac3cf1" name="verv:PreferredStockFinancingPartiallySatisfied" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_069af261-c399-42e2-8a66-f5ce7321027d" contextRef="C_671bfcc0-ebf7-4194-8895-80b3fa98b658" name="verv:PreferredStockFinancingFullySatisfied" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively, and which amounts were settled through issuances of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_329968ff-e5d7-4706-b7ff-868a5db33b76" contextRef="C_29a82fc7-8d8b-4988-8c6b-cb6aaeac3cf1" name="verv:CommonStockIssuedForPartlySatisfyingPreferredStockFinancing" unitRef="U_USD" decimals="INF" format="ixt:numdotdecimal">121,411</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_605000ec-a24f-4ce5-ab82-14e4ed42e6ed" contextRef="C_671bfcc0-ebf7-4194-8895-80b3fa98b658" name="verv:CommonStockIssuedForFullySatisfyingPreferredStockFinancing" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">187,867</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">of common stock, respectively. The remaining antidilution rights obligation was fully satisfied in June 2021 upon the Company&#x2019;s IPO. The settlement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">amount </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">totaled $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_668ab4ee-e0b1-4955-8296-e726af209b16" contextRef="C_3a46f484-c7b1-4249-a6d6-d259c573d801" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">32.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and was settled through issuance of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1e7ea8da-f256-4b3c-beea-69c4bdbd72b5" contextRef="C_3a46f484-c7b1-4249-a6d6-d259c573d801" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">878,098</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company's common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Success Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;The Company is required to make success payments under the license agreements as further described in Note 5, Fair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">value of financial instruments. For the years ended December 31, 2020 and 2019, no success payments were paid or due. In September 2021, certain success payments were triggered and amounts due to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9a41cd7e-3df4-4740-96c4-373eaf95e7a4" contextRef="C_ea754504-c0d8-4221-a285-32e891462575" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_999288cd-f895-49b2-9c49-ed10963dd03f" contextRef="C_e8b5087a-c8c5-42b6-b02a-2126a65898d5" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.3</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. These amounts were settled in cash in November 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Other Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;The Company agreed to pay an annual license maintenance fee ranging from low-to-mid five figures to low six figures,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">depending on the particular calendar year, for each of the license agreements. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Harvard and Broad related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fb895f56-5710-41f1-8ec7-ebe86aee56eb" contextRef="C_e36ace04-7d0f-46f4-a4fc-05e0cddb3357" name="verv:PaymentOfMilestoneDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">46.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c15d6dd1-55d8-4f35-8438-134b670cf8d6" contextRef="C_e36ace04-7d0f-46f4-a4fc-05e0cddb3357" name="verv:PaymentOfSalesBasedMilestone" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">108</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in development and sales-based milestones, respectively. If the Company undergoes a change of control during the term of the license agreements, then certain of the milestone payments would be increased by a mid-double-digit percentage. The milestones have not been achieved and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0fc1964f-996d-46fa-9152-83aa021a2fa9" contextRef="C_e36ace04-7d0f-46f4-a4fc-05e0cddb3357" name="verv:MilestoneRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> expense has been recorded for these milestones as of December 31, 2021. To the extent there are sales of a licensed product, the Company is required to pay low single digit royalties on net sales, for each of the license agreements. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company concluded that the assets acquired from Harvard and Broad did not meet the accounting definition of a business as inputs, but no processes or outputs were acquired with the licenses. As the inputs that were acquired along with the licenses do not constitute a &#x201c;business,&#x201d; the transaction has been accounted for as an asset acquisition. As of the date of the license agreements, the assets acquired had no alternative future use and the assets had not reached a stage of technological feasibility. As a result, all share-based and cash payment obligations have been recorded as research and development expense in the statement of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">At the inception of the license agreements in March 2019, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3dd87235-77e2-44c5-af6a-c1c0376b6c85" contextRef="C_898d61f8-6a19-4832-b357-ffe134d84eaf" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as research and development expense, which includes the non-refundable upfront license fees payable in cash and the fair value of the common stock issued, along with the initial fair values of the antidilution rights liability and success payment liability. As further disclosed in Note 5, the antidilution rights liability and success payment liability are remeasured at fair value each reporting period with subsequent changes recognized in other income (expense).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Verily agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In March 2019, the Company and Verily Life Sciences LLC (&#x201c;Verily&#x201d;) entered into a collaboration agreement. Pursuant to the agreement, the Company and Verily intend to collaborate to utilize Verily&#x2019;s nanoparticle platform to screen, develop and characterize improved nanoparticles for the delivery of the Company&#x2019;s gene editing tools to enable development and commercialization of nanoparticle-based drug products. As part of the agreement, Verily granted the Company an exclusive, perpetual, worldwide, sublicensable, fully paid right and license to Verily&#x2019;s solely owned and developed intellectual property to research, develop, make, offer for sale, sell and import products targeting the Company&#x2019;s gene targets for the treatment or prevention of atherosclerotic cardiovascular disease. The term of the agreement continues until the earlier of (i) completion of all activities related to the collaboration or (ii) the three-year anniversary of the agreement date, unless terminated earlier. At any time during the term, the Company has the right to terminate the agreement in its entirety for any reason by delivering a 90-day termination notice to Verily.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As partial consideration for the license rights granted by Verily, at inception of the arrangement, the Company paid a one-time, nonrefundable fee through the issuance of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b9751dca-a20b-4456-a030-ba27239f3710" contextRef="C_314775f6-60d3-4cdd-a7e4-d2d47b4bb14b" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,672,240</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred with a fair value of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3704656d-b9c9-49aa-baf3-785349d2c0e8" contextRef="C_3585e227-4c98-4454-befd-78b3ac98ed4a" name="verv:NonRefundableUpfrontLicenseFeesPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. To the extent achieved, the Company was obligated to make one-time payments to Verily of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_85a169e2-ddce-4358-8b69-8afd1580ed8a" contextRef="C_3585e227-4c98-4454-befd-78b3ac98ed4a" name="verv:DevelopedBaseMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in development-based milestones. The Company paid a milestone payment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d2a17364-8630-4204-9950-e2618eba742c" contextRef="C_3585e227-4c98-4454-befd-78b3ac98ed4a" name="verv:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in 2020 related to a study in wild type mice that demonstrated a certain gene editing percentage level. In addition, as consideration for Verily&#x2019;s activities under the agreement, the Company was obligated to pay a $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4636333c-4d1c-49b5-a1cb-d49b2d3af351" contextRef="C_3585e227-4c98-4454-befd-78b3ac98ed4a" name="verv:DevelopedBaseMilestonePaymentsForStatedPeriod" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million quarterly development payment for a period of ten quarters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company concluded the assets acquired from Verily did not meet the accounting definition of a business as inputs, but no processes or outputs were acquired with the licenses. As the inputs that were acquired along with the licenses do not constitute a &#x201c;business,&#x201d; the transaction has been accounted for as an asset acquisition. As of the date of the collaboration agreement, the assets acquired had no alternative future use and the assets had not reached a stage of technological feasibility. As a result, at the inception of the agreement in 2019, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9691044a-1985-4d48-9c11-a2db342192ec" contextRef="C_3d0c6332-d1dd-4a36-9324-fb3b21711262" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">as research and development expense, which includes the one-time, nonrefundable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">22</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">license </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">fee settled through issuing </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_175d8201-412a-4260-8474-ddc6e5210c3b" contextRef="C_af6a2a40-edbe-4dd3-98a2-c59fe2070928" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,672,240</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred. In addition, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_934d5a0d-d421-4ca2-9a6d-d95e3235c79a" contextRef="C_3d0c6332-d1dd-4a36-9324-fb3b21711262" name="verv:DevelopedBaseMilestonePaymentsForStatedPeriod" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in quarterly development payments to Verily as research and development expense in 2019. In 2020, the Company recognized the milestone payment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_936a6a1b-14e5-44c5-81f7-9002dcf81f62" contextRef="C_dc3057b9-a834-4bce-9400-bb870b34a39e" name="verv:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million described above as research and development expense upon achievement of the related development-based milestone. Further, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2d698e39-d654-46fd-929b-620db3b3d161" contextRef="C_dc3057b9-a834-4bce-9400-bb870b34a39e" name="verv:DevelopedBaseMilestonePaymentsForStatedPeriod" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in quarterly development payments to Verily as research and development expense in 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company elected to terminate the agreement with Verily effective June 26, 2020 and has </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1085f00a-b6b3-4bf2-9abd-3123707e9667" contextRef="C_01810b2e-60ca-470b-a8e4-f620cad1af9d" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5d17a45c-b471-4236-a377-bbb3481fda27" contextRef="C_82be291d-e5c6-4821-b8c8-65d4e399c80f" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> outstanding amounts due or payable to Verily as of December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Beam license agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In April 2019, the Company and Beam Therapeutics, Inc. (&#x201c;Beam&#x201d;) entered into a collaboration and license agreement. Pursuant to the agreement, the Company received an exclusive, worldwide, sublicensable license under certain of Beam&#x2019;s base editing technology, gene editing, and delivery technologies to develop, make, use, offer for sale, sell and import base editing products and nuclease products using Beam&#x2019;s CRISPR associated protein 12b, or Cas12b technology, in each case, directed to any of four gene targets, including the PCSK9 and ANGPTL3 genes, that are associated with an increased risk of coronary diseases. In addition, the Company granted Beam an exclusive, worldwide, sublicensable license under certain of its delivery technology to develop, manufacture, sell and import product candidates and products, except for base editor products licensed to Verve.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Both parties may conduct certain activities in accordance with an agreed-upon research and/or development plan. Following the final dosing of a patient in a Phase 1 clinical trial of a given licensed product, Beam has the right to opt in to share </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6f83b1f0-cd77-49e2-b2f9-b732711279ed" contextRef="C_81529f1c-4f4b-492c-a430-5a7eaa203e49" name="verv:PercentageSharesOfDevelopmentExpense" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">33</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share profits and expenses of commercializing such licensed product in the United States on a 50/50 basis. If Beam exercises its opt-in right for a given licensed product, which we refer to following such opt-in as a collaboration product, it will be obligated to pay for a specified percentage of the development and commercialization costs of such collaboration product and will have the right to receive a specified percentage of the profits from any sales of such collaboration product. The term of the agreement continues until the last to expire of any royalty term for any product. The Company has the right to terminate the agreement as to any licensed product, but not for any collaboration product, by delivering a 90-day termination notice to Beam, provided that Beam has elected not to exercise its opt-in right or the period to exercise such opt-in right has expired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company is responsible for all costs and expenses incurred in the conduct of activities under the research plan, any development plan and any costs and expenses for the development of a licensed product for which Beam has not elected to opt-in.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As partial consideration for the license rights granted by Beam, the Company paid a one-time, nonrefundable fee through issuing </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e7d2fcfd-2132-4019-9244-d31241628c2a" contextRef="C_983ffc57-7b63-4e06-ab2d-e82bf6082b61" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">276,075</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of its common stock with a fair value of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bf06edf3-ea61-4dc3-9c83-96b3577990b7" contextRef="C_983ffc57-7b63-4e06-ab2d-e82bf6082b61" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. To the extent achieved, for each licensed product, the Company is also obligated to pay up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_79653bbd-b9c3-489c-a94c-0b747ebf023f" contextRef="C_81529f1c-4f4b-492c-a430-5a7eaa203e49" name="verv:PaymentOfMilestoneDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in development and regulatory-based milestones and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_24b79e9c-1299-40b7-ab4e-251d608e035e" contextRef="C_81529f1c-4f4b-492c-a430-5a7eaa203e49" name="verv:PaymentOfSalesBasedMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in sales-based milestones. To the extent there are sales of a licensed product, the Company is required to pay low-to-mid single digit royalties on net sales. To the extent achieved, for each collaboration product outside of the United States, the Company is obligated to pay up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b7b11378-fa16-46f4-9914-ccc125b86433" contextRef="C_1ad41b74-8200-44de-a163-b3c17e30b9e5" name="verv:PaymentOfMilestoneDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in development and regulatory-based milestones and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_dcdfa498-5f5d-4bb7-bf08-1de333185777" contextRef="C_1ad41b74-8200-44de-a163-b3c17e30b9e5" name="verv:PaymentOfSalesBasedMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in sales-based milestones. To the extent there are ex-U.S. sales of a collaboration product, the Company is required to pay low-to-mid single digit royalties on net sales. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The milestones have not been achieved and no expense has been recorded for these milestones as of December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The parties have also promised that in further consideration for the licenses granted under the parties&#x2019; respective delivery technologies, each party will pay to the other party development-based milestone payments up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_246a66dc-ebad-48d2-bd5f-dabc7839df42" contextRef="C_a4af95d5-0d99-42f7-b5a7-c6ec697551f5" name="verv:PaymentOfMilestoneDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for each delivery technology product of such paying party to achieve the corresponding milestone event. The triggering of these milestone payments was not considered probable as of the transaction date, and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f9a2871b-e430-4628-bd56-3021cdf3a00a" contextRef="C_38e0bdc6-ddc8-4961-80a7-3305ab5afc10" name="verv:MilestoneRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> expense has been recorded for these milestones as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021. To the extent there are sales of a delivery technology product, each party will pay the other party low-to-mid single digit royalties based on the annual aggregate worldwide net sales resulting from the sale of each delivery technology product of such paying party; provided, however, that such royalty payments will not apply to net sales of the collaboration products or licensed products. The Company concluded the receipt of any milestone or royalty payments under the agreement was not probable as of December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Company further concluded the assets acquired from Beam did not meet the accounting definition of a business as inputs, but no processes or outputs were acquired with the licenses. As the inputs that were acquired along with the licenses do not constitute a &#x201c;business,&#x201d; the transaction has been accounted for as an asset</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">23</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">acquisition. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of the date of the license agreement, the assets acquired had no alternative future use and the assets had not reached a stage of technological feasibility. As a result, at the inception of the agreement in 2019, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c28f907e-388a-438f-9be4-90370cc8d1bd" contextRef="C_81529f1c-4f4b-492c-a430-5a7eaa203e49" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as research and development expense, which includes the one-time, nonrefundable license fee settled through the issuance of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d131cf84-7337-4aa6-92c0-21c1e05ab02a" contextRef="C_983ffc57-7b63-4e06-ab2d-e82bf6082b61" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">276,075</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Beam materials exchange letter agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In October 2020, the Company and Beam entered into a materials exchange agreement wherein the parties agreed that Beam would provide certain mRNA, gRNA, and protein to the Company and that the Company would provide certain gRNAs to Beam at an agreed upon price per each material provided.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For the year ended December 31, 2021, the Company did </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9ee0b004-5adc-41b4-9740-f5558f32f9fc" contextRef="C_38e0bdc6-ddc8-4961-80a7-3305ab5afc10" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">t purchase any materials from Beam. For the year ended December 31, 2020, the Company purchased $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fa249b10-0162-4939-a37a-52edec776478" contextRef="C_8943ede3-21ba-4dd5-a69f-6510b3c9441e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as a charge to research and development expense related to materials purchased from Beam.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For the year ended December 31, 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_eaec161c-a9d8-4423-92fd-57cd2d0589b6" contextRef="C_577f8c7c-690b-48eb-85f5-78944ac5fb74" name="verv:PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as a reduction to research and development expense related to reimbursements received for materials sold to Beam. During the year ended December 31, 2020, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e4dd2c0f-ea64-438d-a432-ace9ccce2829" contextRef="C_db73ec29-59ce-4649-9f8f-424cfebeac57" name="verv:PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as a reduction to research and development expense related to reimbursements received for materials sold to Beam.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Acuitas agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Development and option agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2019, the Company and Acuitas Therapeutics, Inc. (&#34;Acuitas&#34;) entered into a development and collaboration agreement, which agreement was amended and restated in October 2020. The Company agreed to reimburse Acuitas on a quarterly basis for its services performed related to the program activities based on an agreed upon number of fulltime employees committed to work on the program at an annual rate per employee, including reimbursement of reasonable external costs. These services commenced during 2020 and the Company recognized research and development expense of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f540a9b6-f95e-41aa-88c8-10562f2453f1" contextRef="C_8020214a-330a-4afc-8e4e-cfbc08b56cfc" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c0895d1e-1002-42e6-bbb0-1423eeed94e1" contextRef="C_b046bc96-323a-433d-9185-6710e68adfba" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for the years ended December 31, 2021 and 2020, respectively, related to the reimbursement of research and development services provided by Acuitas and technology maintenance fees. In 2020 upon the one-year anniversary of the agreement the Company had exercised one of its options to enter into a non-exclusive license agreement, as further described below.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">License agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In October 2020, the Company paid Acuitas a non-refundable, upfront license fee of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_03e65150-7079-4ae5-b055-6c073d065f53" contextRef="C_1bcde1fb-0fd0-4aef-8c8e-7bc374f704bf" name="verv:NonRefundableUpfrontLicenseFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million (less a previously paid target reservation fee) to exercise an option with respect to a licensed product and a licensed genome target and entered into a non-exclusive, worldwide license with Acuitas, with a right to sub-license through multiple tiers, under the licensed LNP technology to research, develop and commercialize the licensed products using the LNP technology in connection with the PCSK9 gene target for all human therapeutic or prophylactic uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To the extent achieved, the Company is also obligated to pay up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7a2102cf-a42e-46e7-9b6e-328295d5ecbc" contextRef="C_ae35d2d7-335e-4000-8d8b-98d22cdc0bcd" name="verv:ClinicalAndRegulatoryMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in clinical and regulatory milestones and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bd6044d9-b393-4b48-9af5-d19d52af4af3" contextRef="C_ae35d2d7-335e-4000-8d8b-98d22cdc0bcd" name="verv:SalesBasedMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in sales-based milestones. The milestones have not been achieved and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7656141a-63e7-486c-ae38-4e64e2d9a8fe" contextRef="C_ae35d2d7-335e-4000-8d8b-98d22cdc0bcd" name="verv:MilestoneRelatedExpenses" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> expense has been recorded for these milestones as of December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Third-party license agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In October 2021, the Company entered into a license agreement with a third party to obtain a non-exclusive license to certain technology the Company is using for research and development. As consideration for the license and rights granted under the agreement, the Company made a one-time, non-refundable, upfront payment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_907fcb1e-6e01-425c-baee-8995104f884a" contextRef="C_1349c1bd-0a8c-4898-8535-2e458967423b" name="verv:NonRefundableUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million during the three months ended December 31, 2021. The license agreement provides for specified development milestones relating to the licensed technology and requires the Company to make payments upon achievement of each milestone up to an aggregate amount of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_50316d06-37cc-4db2-9bf2-7150c9700285" contextRef="C_1349c1bd-0a8c-4898-8535-2e458967423b" name="verv:MilestoneRelatedExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_78489430-1a5a-48dc-93b8-9572d5a2e402" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:PreferredStockTrancheLiabilityTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">9. Preferred stock tranche liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Included in the terms of the Series A Preferred Stock purchase agreement were certain tranche rights whereupon the Company was obligated to issue, and the Series A Preferred investors had the obligation to purchase, additional shares of Series A Preferred Stock, as follows:</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">24</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3ebb689e-5b11-4009-b5bb-5176d5df023c" contextRef="C_bb24676f-df61-4c43-a65c-58adb308cd98" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">29,347,825</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred Stock at $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fba91369-4397-404e-a659-ba927f505087" contextRef="C_bb24676f-df61-4c43-a65c-58adb308cd98" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.598</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share upon the Company achieving certain scientific and non-scientific milestones (&#34;second tranche&#34;); and</span></div></div><div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_294beff0-341f-43a8-97ec-2940923d0a65" contextRef="C_9bb47951-6b36-400c-bc9e-6e6219af2c06" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">49,749,167</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred Stock at $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9ac58b83-429d-4567-a5d9-3066784851ad" contextRef="C_9bb47951-6b36-400c-bc9e-6e6219af2c06" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.598</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share upon the Company achieving additional scientific and non-scientific milestones (&#34;third tranche&#34;).</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The second tranche and third tranche represent freestanding financial instruments accounted for as liabilities under ASC 480, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Distinguishing Liabilities From Equity, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">because these tranche rights (i) embody an obligation to repurchase the Company's equity shares and (ii) may require the Company to settle the obligation by transferring assets. As a result, upon issuance, the respective tranche rights were initially recorded at fair value and subsequently re-measured at fair value in each reporting period (and at settlement, as applicable). Changes in fair value were recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. The second tranche and third tranche were settled in 2019 and 2020, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Second tranche</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In April 2019, the board of directors agreed to amend certain scientific milestones and subsequently determined the second tranche milestones, as modified, were achieved and the Company settled the second tranche by issuing </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_91ee41f9-52b7-4c98-a858-be106bcef7e4;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">29,347,825</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred Stock at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5ae6d810-6f77-409a-b9df-44109acab18f" contextRef="C_1d25d519-2490-4618-87e0-211daed76d06" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.598</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e55318ce-56f0-4e44-8e99-d467be7a34e3" contextRef="C_b587c055-bdab-476a-b3ab-de00dcd68ee5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Third tranche</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In March 2020, the board of directors agreed to waive the final remaining milestones and determined the third tranche milestones, as modified, were achieved. In March 2020, the Company settled the third tranche by issuing </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d6c13514-d2db-4ec1-ab68-124a255fcab1" contextRef="C_f64ad974-2e0f-4ca6-b8b0-bd9dc4283255" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">49,749,167</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred Stock at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_27f24d05-f75f-48fa-be62-7656c5b6c7f7" contextRef="C_f64ad974-2e0f-4ca6-b8b0-bd9dc4283255" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.598</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_089d237f-342c-4c76-8137-205a3254c3c4" contextRef="C_6306fa6b-7c2e-44e2-9da5-5dfd36995ad7" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">29.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_bdca0d67-c220-4b62-9b84-6d044bcbbbdb" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:PreferredAndCommonStockTextBlock" escape="true" continuedAt="F_bdca0d67-c220-4b62-9b84-6d044bcbbbdb_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">10. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Preferred and common stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has issued and sold Series A Preferred, Series A-2 Preferred, Series B Preferred and common stock, as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During 2018, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b783a066-012a-4f6d-a676-064720b76912" contextRef="C_8b41bdfb-bbc2-43d8-bf32-532fc3b99db4" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">19,565,217</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9b150e91-2b78-429f-8492-957bb19f1397" contextRef="C_8b41bdfb-bbc2-43d8-bf32-532fc3b99db4" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.598</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4c710f44-1ea5-4ea0-af90-380d8169862d" contextRef="C_335ebba5-72b4-421b-898b-d3de7d54c1a3" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. The Company incurred issuance costs in connection with these transactions of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_17b05281-3305-40d9-9981-972ac5c20b9a" contextRef="C_335ebba5-72b4-421b-898b-d3de7d54c1a3" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. These issuances included the tranche rights for the second tranche and third tranche, as previously described in Note 9, Preferred Stock tranche liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In March 2019, the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1464bb17-0dd4-4797-bc87-ea9672effa98" contextRef="C_256a0140-df8b-4d59-a0a5-3457018ea09f" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,672,240</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred in exchange for in-licensing certain technologies from Verily. See Note 8, License agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In August 2019, the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a0b18463-e345-432d-96f9-509105315b96" contextRef="C_25c1a637-7cb1-4291-89c3-54a541318110" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">29,347,825</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_13d017c2-9573-47b7-a2a4-c0ecb0336eb4" contextRef="C_25c1a637-7cb1-4291-89c3-54a541318110" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.598</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a95b5160-241b-44e4-9a27-b49228b790a8" contextRef="C_6147ead1-a934-40a0-954e-50f7ab4904e4" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. This issuance represented the settlement of the second tranche. See Note 9, Preferred Stock tranche liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In October 2019, the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ca2de50e-c691-4d97-8801-bd3ac4183664" contextRef="C_03a67782-22aa-4a91-8ef4-d8c7202b8a6a" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">836,122</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7ad6dd3c-e15c-4013-b28f-4c456671b220" contextRef="C_03a67782-22aa-4a91-8ef4-d8c7202b8a6a" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.598</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_79651330-728e-4e66-ad65-e635550fce25" contextRef="C_1fa28ee7-1e59-47ad-b9b0-95bb75660ed2" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. This issuance included tranche rights for the third tranche.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In March 2020, the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_156b3ba1-46e6-4661-b561-e821c56f8653" contextRef="C_4871c68a-70f7-4ee7-b7ae-3986b18102dc" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">49,749,167</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d299181f-2145-47ca-8456-79cf6020eceb" contextRef="C_4871c68a-70f7-4ee7-b7ae-3986b18102dc" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.598</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d652697a-ddaf-432b-a5b9-63ab62affd9e" contextRef="C_8128aaac-e7e6-4fa6-bac7-a3ac19d8ff0f" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">29.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. This issuance represented the settlement of the third tranche.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Between April and June 2020, the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a26ce785-6808-42bf-be8e-856c9b9f09e9" contextRef="C_f97bfb71-9b79-4c00-862c-5692b411f52b" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">78,348,461</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A-2 Preferred at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_87e21bf6-03bc-4593-a46d-fa94c4e1f276" contextRef="C_f97bfb71-9b79-4c00-862c-5692b411f52b" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">0.8041</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6e31882e-aa25-4bb5-b523-c04db9cd011b" contextRef="C_cef2ca29-eb4f-4af7-8d4a-cda3d18e4727" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">63.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. The Company incurred issuance costs in connection with this transaction of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_cbd60be1-f42d-4188-82e6-98c4562487ec" contextRef="C_cef2ca29-eb4f-4af7-8d4a-cda3d18e4727" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In January 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1084915f-21d4-4b6b-8042-6ed9d2d7245a" contextRef="C_7db4cc42-112c-43d0-8092-a99672ba28cd" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">77,163,022</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series B Preferred Stock at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3c956fca-130b-4a59-b69d-9742b6d9b986" contextRef="C_7db4cc42-112c-43d0-8092-a99672ba28cd" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">1.2182</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0ec0db8e-67d3-4591-bf39-23d5a1215f37" contextRef="C_238fca8e-6dc3-4ea3-aa6d-7d316fa8ad10" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">94.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. The Company incurred issuance costs in connection with this transaction of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3dfbc269-1613-46d3-b64d-bea0360a2ec8" contextRef="C_238fca8e-6dc3-4ea3-aa6d-7d316fa8ad10" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2021, the Company amended and restated its certificate of incorporation to authorize </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6ba87b7b-9bf3-4346-8c8d-9faac914bf50" contextRef="C_140060dd-8e0c-44a2-9769-d8ce6de4ed4b" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of preferred stock, which shares of preferred stock are currently undesignated, and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d045bdeb-8ae2-4e91-a81a-0b13aa7a435b" contextRef="C_d25de583-668f-4235-b7a0-421690a06540" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock, $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_57e79717-89fc-42b2-b46d-222c8e483a9a" contextRef="C_d25de583-668f-4235-b7a0-421690a06540" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> par value per share.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2021, the Company completed its IPO, pursuant to which the Company issued and sold </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_99c1bafb-bb91-4781-bee7-cb4a46db6ff3" contextRef="C_892a0591-a196-401b-abe3-20fff82d78ec" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,141,157</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of its common stock, including </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_658222b5-6fea-4e9c-9b75-908029eba4ea" contextRef="C_91c2bb60-3204-485e-91bc-fcd6e061eaf0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,105,368</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2edbaf6f-8bde-47bb-adcc-538189e19496" contextRef="C_94dd9299-01a2-4f67-9f44-7bbd116cd6f9" name="verv:PublicPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">19.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_18bed447-d711-484d-bf1c-8133d30d50d6" contextRef="C_91c2bb60-3204-485e-91bc-fcd6e061eaf0" name="verv:ProceedsFromIssuanceOfCommonStockUnderIPOGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">306.7</ix:nonFraction></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">25</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company received approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_079a43e8-dc12-43f2-a39d-94d29e019016" contextRef="C_6318768f-6910-4cea-8012-84a1cded066e" name="verv:ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">281.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in net proceeds, after deducting underwriting discounts and offering expenses payable by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Upon the closing of the IPO, all outstanding shares of the Company's preferred stock automatically converted into </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f36bd0b2-11b1-4941-9972-1831166690ba" contextRef="C_5758acaf-19d3-46c4-a26d-234bb9c7e3a1" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,720,923</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company's common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d08efe5f-0899-4aa6-91d6-02a91f29906f" contextRef="C_ef58d5a4-7912-466b-bc19-b009959eba29" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">878,098</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of its common stock to Harvard and Broad as final settlement of its antidilution rights obligation.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The holders of common stock are entitled to one vote for each share of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following is a summary of the rights and preferences of the Series A Preferred, Series A-2 Preferred and Series B Preferred, prior to the completion of the Company's IPO:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Conversion</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_5d3d7d34-c7cc-4c96-b25a-f8a25257ef0e" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ConvertiblePreferredStockTermsOfConversion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Each share of Series A Preferred, Series A-2 Preferred and Series B Preferred may be converted at any time, at the option of the holder, into shares of common stock, subject to the applicable conversion rate as determined by dividing the original issue price by the conversion price. The initial conversion price for each of the Series A Preferred, Series A-2 Preferred and Series B Preferred (each as may be adjusted for certain dilutive events) was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_71bcb644-3869-4989-a2f5-0dfe72ee64dd" contextRef="C_249fda00-bd80-4288-a41d-c1199d73ce90" name="us-gaap:PreferredStockConvertibleConversionPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.598</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f2a80fdf-280e-413a-b6c7-ffb216e11bca" contextRef="C_f9897674-e8be-4c3a-a297-cb53a9538487" name="us-gaap:PreferredStockConvertibleConversionPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">0.8041</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_cde30a73-17b2-4602-a89b-17b3e10eff39" contextRef="C_a9ee4883-4610-4244-845a-4be4346c5921" name="us-gaap:PreferredStockConvertibleConversionPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">1.2182</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, respectively. Each series of Series A Preferred, Series A-2 Preferred and Series B Preferred automatically converted into shares of common stock on a </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_b2d78b98-0d63-4d03-af96-185a21d44c07;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1:1</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> conversion ratio (as may be adjusted for certain dilutive events) at the earlier of the closing of an initial public offering of the Company&#x2019;s common stock with gross proceeds to the Company of at least $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_47a81eec-25fc-4db2-8391-06d12f204526" contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and a purchase price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3822b655-c693-424a-a759-694a713de5a2" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">22.34</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, or at the election of the holders of at least two-thirds of the then-outstanding shares of Preferred Stock.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Dividends</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;Holders were entitled to non-cumulative dividends of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5e10f418-cad0-4ad1-86b5-83845c15659f" contextRef="C_249fda00-bd80-4288-a41d-c1199d73ce90" name="us-gaap:DividendsPayableAmountPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.05</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share with respect to Series A Preferred and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bba0b59a-8467-41af-a623-28db8773e736" contextRef="C_f9897674-e8be-4c3a-a297-cb53a9538487" name="us-gaap:DividendsPayableAmountPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.06</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share with respect to the Series A-2 Preferred, and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_85bc7696-3653-479d-b33c-055d159ee8d3" contextRef="C_a9ee4883-4610-4244-845a-4be4346c5921" name="us-gaap:DividendsPayableAmountPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share with respect to Series B Preferred when, as, and if declared by the board of directors. No dividends have been declared through December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Voting Rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;Series A Preferred, Series A-2 Preferred, Series B Preferred and common stock generally voting together as one class on an as-converted basis; however, common stock voting rights on certain matters were subject to the powers, preferences, and rights of the Series A Preferred, Series A-2 Preferred and Series B Preferred. The holders of Series A Preferred, Series A-2 Preferred and Series B Preferred, voting together as a single class, were entitled to elect three directors to the Company&#x2019;s board of directors and the holders of common stock, voting as a single class, were entitled to elect two directors to the Company&#x2019;s board of directors. Certain actions, such as mergers, consolidation, sale of substantially all assets, liquidation, dissolution, wind up of business, or any other deemed liquidation events, must be approved by the holders of at least two-thirds of the then-outstanding shares of Series A Preferred, Series A-2 Preferred and Series B Preferred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Liquidation Preference</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;Upon liquidation, dissolution, or winding up of business, the holders of the Series A Preferred, Series A-2 Preferred and Series B Preferred were entitled to receive a liquidation preference in priority over the holders of common stock, at an amount per share equal to the greater of i) the original Series A Preferred, Series A-2 Preferred and Series B Preferred issue price plus any declared but unpaid dividends, or ii) the amount per share payable had all shares of Series A Preferred, Series A-2 Preferred and Series B Preferred been converted to common stock immediately prior to such liquidation. If assets available for distribution are insufficient to satisfy the liquidation payment to holders in full, assets available for distribution would have been allocated among holders based on their pro rata shareholdings. When holders are satisfied in full, any excess assets available for distribution would have been allocated ratably among the holders of common stock based on their pro rata holdings. Upon a deemed liquidation event, as defined, holders had the option to redeem their outstanding shares at a price equal to the liquidation payment amounts summarized above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_bdca0d67-c220-4b62-9b84-6d044bcbbbdb_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Redemption</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;Aside from upon the occurrence of a deemed liquidation event, the Series A Preferred, Series A-2 Preferred and Series B Preferred were not redeemable.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_f4703c94-e43f-49b9-a8a6-80ba7c39c6c6" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">11. Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2018 Equity Incentive Plan, or the 2018 Plan, adopted by the board of directors in August 2018 provided for the grant of qualified incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock and restricted stock units to the Company&#x2019;s employees, officers, directors, advisors, and outside consultants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">26</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the issuance or purchase of shares of the Company&#x2019;s common stock. The maximum number of shares of common stock that were authorized for issuance under the 2018 Plan was </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ba56e261-27d6-4c16-97e3-5c6306860efb" contextRef="C_676f07bf-c94c-4783-88ad-393a30ab16eb" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,885,653</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2021, the Company's board of directors adopted, and the Company's stockholders approved, the 2021 Stock Incentive Plan, or the 2021 Plan, which became effective on June 16, 2021. The 2021 Plan provides for grant of qualified and nonqualified stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, and other share-based awards to the Company's employees, directors, advisors and outside consultants. Under the 2021 Plan, the number of shares of common stock that was initially reserved for issuance under the 2021 Plan was the sum of: (1) </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3a4ac815-d0c9-4207-a1ad-a293f97880fb" contextRef="C_371af29c-852e-4e21-b3b0-7a743ce9c595" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,466,530</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">; plus (2) the number of shares as is equal to the sum of (x) the number of shares of common stock reserved for issuance under the 2018 Plan that remained available for grant under the 2018 Plan on June 16, 2021 and (y) the number of shares of common stock subject to outstanding awards granted under the 2018 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_b2e7184e-696b-4327-b998-4968ee01cc0d" contextRef="C_0a65eb8e-9c85-4a38-b989-299e4aceb2c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an annual increase, to be added on the first day of each fiscal year, commencing on January 1, 2022 and continuing until, and including, January 1, 2031, equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1ae185e7-d6fb-4948-954d-aa69e90987f4" contextRef="C_46b3a3b3-5e47-4d6e-bbdd-cf18cb6fea59" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the number of shares of common stock outstanding on such date</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and (ii) the number of shares of common stock determined by the Company's board of directors. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 the Company had reserved</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9a7571b3-0496-453b-9638-e47e4148616e" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,632,042</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company's common stock for issuance of stock options and restricted stock, of which </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b2db3e81-3572-4fa8-811a-e149e962c681" contextRef="C_9a295b66-ffd1-4f8f-9e1a-8acda5aafa35" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,489,589</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> remained outstanding for future grant under the 2021 Plan. On January 1, 2022, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_75a96bcb-c0d3-4b16-9891-03f39d618419" contextRef="C_f674fccd-11fb-4942-800b-db52e4338c03" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,425,587</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company's common stock were added to the amount reserved for issuance under the 2021 Plan in accordance with the 2021 Plan described above. Upon effectiveness of the 2021 Plan, the Company ceased granting additional awards under the 2018 Plan.</span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_3ef679e6-9294-4840-a01c-5639b6e38086" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Stock-based compensation expense recorded in the consolidated statements of operations and comprehensive loss is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.764%;"></td>
        <td style="width:1.382%;"></td>
        <td style="width:1.431%;"></td>
        <td style="width:10.903%;"></td>
        <td style="width:0.716%;"></td>
        <td style="width:1.382%;"></td>
        <td style="width:1.431%;"></td>
        <td style="width:10.874%;"></td>
        <td style="width:0.716%;"></td>
        <td style="width:1.382%;"></td>
        <td style="width:1.431%;"></td>
        <td style="width:10.874%;"></td>
        <td style="width:0.716%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended<br />December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_adcbad96-11a4-43f4-8806-f65ba2c646a0" contextRef="C_c672a00b-7f2c-4ee3-878b-42ff6ea68467" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,830</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b5fdb866-2c1f-4b03-b990-a162c704d70c" contextRef="C_b5c31764-a8fd-4905-a067-8962ee2846e9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">494</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1d44e08a-1f35-4b14-b7cc-5fb2551a5c94" contextRef="C_5a7068fa-0013-401d-b7c4-675485fce3a2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">336</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_43ab446d-ebf3-4957-bbba-6d5a41506f66" contextRef="C_9a01908a-58f3-4cbb-a2c9-d102afa07909" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,242</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ac3c5e6d-635a-4143-a5cf-40b794799753" contextRef="C_5fed7261-bc42-45e4-aa7b-b1860010cd80" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">356</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fd0be8aa-3b32-42cc-9309-ffea10d8c579" contextRef="C_0c8d563c-b4ce-43e3-aa5e-0284d836e33c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b86ac30c-a7e0-493e-9bff-41f6edc50e22" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,072</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a32f90eb-489e-4070-b36f-00f8edc46c5d" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">850</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a9228411-d465-4136-beb0-12af45951877" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">446</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Stock options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_e8bb2a2c-fbde-4b33-a534-01d405e7bfd0" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The assumptions used in Black-Scholes for stock options granted were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.355%;"></td>
        <td style="width:1.371%;"></td>
        <td style="width:0.715%;"></td>
        <td style="width:10.166%;"></td>
        <td style="width:2.296%;"></td>
        <td style="width:1.371%;"></td>
        <td style="width:0.715%;"></td>
        <td style="width:10.166%;"></td>
        <td style="width:2.296%;"></td>
        <td style="width:1.371%;"></td>
        <td style="width:0.715%;"></td>
        <td style="width:10.166%;"></td>
        <td style="width:2.296%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended<br />December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a10c39a6-c39a-4ce6-8ef4-0bb8d954988b" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">77.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ebf164b6-35b6-4392-8ab9-1d11532bee4e" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">84.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9b3caba3-9966-4b6a-9b5f-5878ddc9406f" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">76.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted-average risk-free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a3e0c520-401f-4c0f-89fa-9a2ac8dae0a7" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_84126fe0-6eac-419a-839b-3988eade2d00" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6a16f510-8b91-4310-a833-d69e5aaeb8a8" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_239d6154-5337-467d-8a84-993b7de8d071" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_b358f697-4f34-4f90-a294-d045fc51169c" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_dc98141a-6906-44e0-852c-c3b1b71f8799" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_8c7bed02-c541-4897-8ce2-dc403a873684" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.9</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_bc6910a5-0098-49fc-bf8c-2266e58b7440" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table provides a summary of stock option activity during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.065%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:9.89%;"></td>
        <td style="width:0.855%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.431%;"></td>
        <td style="width:10.764%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:0.726%;"></td>
        <td style="width:11.42%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.431%;"></td>
        <td style="width:10.824%;"></td>
        <td style="width:0.706%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Number of<br />options</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Weighted<br />average<br />exercise<br />price per<br />share</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Weighted<br />average<br />remaining<br />contractual<br />life (in years)</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Aggregate<br />intrinsic<br />value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Arial;position:relative;">(2)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"><br />(in thousands)</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_36c52a92-fe3f-4e31-a7f4-eaf8aadd3c6b" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,888,823</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c2ca0420-1e65-411d-b5f6-a11509b8b0ad" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.13</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_326944c6-9a95-4cc1-8cd1-e6a612441e82" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,869,946</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_85e91e23-01e9-4c64-8622-527dc7eebc6c" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">17.66</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0c8fce59-4a93-4f07-9dd9-01eae39edabf" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">599,838</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_97433d14-4eea-410b-9109-0bdcc89ffd60" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.61</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_365d50c4-a096-41cd-b697-ce1874cb5fcc" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">39,636</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c4852a30-be12-4edc-ba3f-79dcc781826e" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.56</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c6d40844-0db0-46ec-a921-b089d37f5a53" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,119,295</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_186c7d48-063e-4e0e-b407-3e010bb2e30c" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.44</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_192a5ed0-9732-43ed-84ca-cd785b6bec3c" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8.7</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_09c816c2-1e12-4899-9ecf-678b1a4962d0" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">171,636</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Exercisable at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_89602f64-2d34-40cf-9722-1ddc9969c917" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,373,507</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a49ee9f4-2f4a-4491-b702-49e05680ec76" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_e6387850-21a9-4ed0-b9ba-04e93ab12e1b" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_24230ffe-ae0b-4bb2-ad26-32083b8b57ec" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47,691</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected to vest after December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Arial;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fe0539bc-5d0e-4e16-bca5-d18ebbbf88c5" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,745,788</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9802e87b-b16a-46c7-b5ca-97ffa81f49a2" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">11.56</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_efe98daf-06cf-42fb-80d8-de37d0ecc08f" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8.9</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_07bb18eb-0554-426b-b84f-e1ce1d9e124f" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">123,945</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">27</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_247ca409-7f5d-47a8-8c48-39a833c8dcd8" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;">This represents the number of unvested options outstanding as of December 31, 2021 that are expected to vest in the future.</span></ix:footnote><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;"> </span></div></div><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><ix:footnote id="FNT_cbfa0a0e-19c5-4a4c-98d4-6e84510cdcd3" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December 31, 2021.</span></ix:footnote><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;"> </span></div></div></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the year ended December 31, 2021 the weighted average grant-date fair value of the stock options granted </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0487af77-e35b-4faf-8c04-606e24350be4" contextRef="C_24a4dfda-a75a-45db-8bd3-e0d4bcac39a6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">14.27</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The aggregate intrinsic value of stock options exercised during the year ended December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> was approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bea329c8-d720-4db1-841c-17458b9cc085" contextRef="C_24a4dfda-a75a-45db-8bd3-e0d4bcac39a6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.6</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million while the Company received $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_544e9a0e-36f1-4c17-a1da-017a2790d6cb" contextRef="C_24a4dfda-a75a-45db-8bd3-e0d4bcac39a6" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in proceeds for the exercise of these options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, there was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3b118a4a-d003-497d-8559-fe023db52b69" contextRef="C_6e65181b-d50d-473b-a928-4dbc316e780c" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">40.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_a114c795-a02b-4554-9790-d9e9143fa8a6" contextRef="C_24a4dfda-a75a-45db-8bd3-e0d4bcac39a6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.9</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Restricted stock and restricted stock units</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In 2018, the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_67ce94d1-94e6-42db-a22c-583f1ae9cb3d" contextRef="C_56d972ec-31cc-4208-aa1d-caae39e63a9b" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,150,537</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of restricted common stock. The restricted shares vested in </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3fff03ca-ac44-4e11-96a9-acabd5773455" contextRef="C_ea995c0d-ad65-44c4-b2b7-9fa84f6854c0" name="verv:NumberOfInstallmentsForRestrictedSharesVested" unitRef="U_Instalment" decimals="INF" format="ixt:numdotdecimal">48</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> equal monthly installments, commencing on January 1, 2018. The restricted shares were fully vested as of December 31, 2021.</span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_dd7076fd-599e-4f38-9420-955001da0f62" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" escape="true" continuedAt="F_dd7076fd-599e-4f38-9420-955001da0f62_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A summary of the status of and change in unvested restricted stock as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.822%;"></td>
        <td style="width:1.581%;"></td>
        <td style="width:0.716%;"></td>
        <td style="width:13.391%;"></td>
        <td style="width:0.865%;"></td>
        <td style="width:1.074%;"></td>
        <td style="width:1.591%;"></td>
        <td style="width:0.726%;"></td>
        <td style="width:13.52%;"></td>
        <td style="width:0.716%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Shares</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Weighted-<br />average grant<br />date fair<br />value per share</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unvested restricted stock as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8e0d8b09-a4c1-4c1c-bba8-2b52c68608c7" contextRef="C_59fe6e15-fa1d-432e-b68b-41815233efa2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">537,633</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1f874851-1af9-4724-9659-391e104b1975" contextRef="C_59fe6e15-fa1d-432e-b68b-41815233efa2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">0.0028</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Restricted stock vested</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4b14195d-6675-4d4f-89f9-08c067d1220c" contextRef="C_0a65eb8e-9c85-4a38-b989-299e4aceb2c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">537,633</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_43065d67-17c3-4692-936b-b1e37429e220" contextRef="C_0a65eb8e-9c85-4a38-b989-299e4aceb2c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">0.0028</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unvested restricted stock as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f3f79f13-f129-4b3f-866a-2accf5e10696" contextRef="C_9a295b66-ffd1-4f8f-9e1a-8acda5aafa35" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9ba3f93d-7924-49c6-b8ff-c0297b827790" contextRef="C_9a295b66-ffd1-4f8f-9e1a-8acda5aafa35" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, the Company granted </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8b0c168b-0361-4072-9c21-8e2095342467" contextRef="C_38d1bdab-4490-418c-9908-c0fd520a968b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> restricted stock units under the 2021 Plan. These restricted stock units vest in substantially equal installments over a </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_2206cbd7-5b12-42b5-afc4-d9ccb9f45e5d" contextRef="C_8d26e837-c809-4998-bfb7-aca676d66949" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">four-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_dd7076fd-599e-4f38-9420-955001da0f62_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A summary of the status of and change in unvested restricted stock units as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.398%;"></td>
        <td style="width:1.59%;"></td>
        <td style="width:0.726%;"></td>
        <td style="width:13.4%;"></td>
        <td style="width:0.716%;"></td>
        <td style="width:1.054%;"></td>
        <td style="width:2.256%;"></td>
        <td style="width:0.726%;"></td>
        <td style="width:13.419%;"></td>
        <td style="width:0.716%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Shares</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Weighted-<br />average grant<br />date fair<br />value per share</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unvested restricted stock units as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c87441b3-e768-4ba0-8820-ac7574ac3283" contextRef="C_900eaaf9-9f36-4773-beee-ac7b0f139194" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9d57bf28-415d-4868-a65f-75627304e514" contextRef="C_900eaaf9-9f36-4773-beee-ac7b0f139194" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Restricted stock units granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_69759b24-e073-4323-8bb6-dd278cbbd534" contextRef="C_ea995c0d-ad65-44c4-b2b7-9fa84f6854c0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_43219033-75b2-4460-b41b-1c4a1a9013fd" contextRef="C_ea995c0d-ad65-44c4-b2b7-9fa84f6854c0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">36.58</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unvested restricted stock units as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_83e60bad-8ca9-4b94-9319-e997f7a52a82" contextRef="C_86c2f76f-8f40-41c6-a1f0-570a5a905595" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b392c775-8c55-481f-87b0-15d61a289144" contextRef="C_86c2f76f-8f40-41c6-a1f0-570a5a905595" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">36.58</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">At December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, there was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e62fd7a7-f51f-4230-a9bc-6b059d6a3df4" contextRef="C_86c2f76f-8f40-41c6-a1f0-570a5a905595" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of unrecognized stock-based compensation expense related to restricted stock units that are expected to vest. These costs are expected to be recognized over a weighted-average remaining vesting period of </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_274116ac-b6c9-454a-95a9-ee113ea83652" contextRef="C_ea995c0d-ad65-44c4-b2b7-9fa84f6854c0" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.0</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">2021 Amended and Restated Employee Stock Purchase Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2021, the board of directors adopted, and the Company's stockholders approved, the 2021 Employee Stock Purchase Plan, or the ESPP, as amended and restated, which became effective on June 16, 2021. The Company has initially reserved </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c322f56d-2d65-4653-a55b-5b6f4884eabf" contextRef="C_a47c1a5e-5ed1-4aff-9633-a0341b906481" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">433,316</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock for sale under the ESPP. The aggregate number of shares reserved for sale under the ESPP will increase automatically on the first day of each fiscal year commencing on January 1, 2022 through January 1, 2031, by the number of shares equal to the least of (a) </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4ccffba4-654c-45b6-ab94-cdefd9a05466" contextRef="C_a5a771bf-09d6-4a35-b7ac-216b653bc10f" name="verv:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,083,290</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares, (b) </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f73a9d4c-592b-4e4d-a936-0c67e84d52d8" contextRef="C_dd92968d-2cf3-45c1-b345-bc554cadcd11" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the total outstanding shares of common stock on such date, and (c) a number of shares as may be determined by the board of directors in any particular year. The first offering period under the ESPP commenced on June 16, 2021 and ended on December 13, 2021. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_71d5853a-b731-4e3b-ae16-e9036af83b48" contextRef="C_27017e45-4a76-45b0-84c2-5942f0fdfb77" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,297</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares had been purchased by employees under the ESPP and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_48401614-09f1-4a30-8056-1910f35fb333" contextRef="C_27017e45-4a76-45b0-84c2-5942f0fdfb77" name="verv:StockAvailableForIssuanceUnderEmployeeStockPurchasePlan" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">385,019</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares remained available for issuance under the ESPP. On January 1, 2022, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8250da12-40b0-4359-b655-e35d70a00628" contextRef="C_f15881ae-e851-43f0-9443-9c9364fbebc0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">485,117</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock were added to the amount reserved for sale under the ESPP. The second offering period commenced on December 14, 2021 and will end on May 31, 2022.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <div><ix:nonNumeric id="F_6a616277-fd97-4d1c-9c54-f2a712f5cef1" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">12. Net loss per share attributable to common stockholders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_d1615e06-d89d-48dc-99d7-bc658619a0c5" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.457%;"></td>
        <td style="width:1.372%;"></td>
        <td style="width:1.432%;"></td>
        <td style="width:10.876%;"></td>
        <td style="width:0.855%;"></td>
        <td style="width:1.372%;"></td>
        <td style="width:1.432%;"></td>
        <td style="width:10.846%;"></td>
        <td style="width:0.855%;"></td>
        <td style="width:1.372%;"></td>
        <td style="width:1.432%;"></td>
        <td style="width:10.846%;"></td>
        <td style="width:0.855%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands, except share and per share amounts)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f37ea9e1-fc27-4fcf-ae54-a951d3c812a5" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,314</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_609abdaa-4608-4915-ae63-fdcf5340e93a" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,704</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8e06e190-8624-4d3a-bf7a-7a8be0b52fd5" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">19,297</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted average number of common shares, basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_aa16b399-b353-4598-bc91-3bf1fde1f279" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">26,872,036</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7059016c-5f4f-43a5-a6ee-dbba6bdd857b" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,250,093</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7921951d-20b9-4779-931b-e3985faca3b1" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,277,156</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss per common share attributable to common stockholders, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1023d135-8612-409f-9a54-41da3750be01" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">4.48</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_121c4c39-cec6-4323-b9b6-8c111c8a1978" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">20.31</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_70ad09f5-d1d8-4abe-8c60-00780b3e69fd" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">15.11</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#x2019;s potential dilutive securities, which include convertible preferred stock, unvested restricted stock and common stock options, have been excluded from the computation of diluted net loss per share as the effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_fce58d0c-072e-401a-98e9-0026e05dc38d" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_fce58d0c-072e-401a-98e9-0026e05dc38d_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_fce58d0c-072e-401a-98e9-0026e05dc38d_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.859%;"></td>
        <td style="width:1.382%;"></td>
        <td style="width:0.716%;"></td>
        <td style="width:11.561%;"></td>
        <td style="width:0.716%;"></td>
        <td style="width:1.382%;"></td>
        <td style="width:0.716%;"></td>
        <td style="width:11.581%;"></td>
        <td style="width:0.716%;"></td>
        <td style="width:1.382%;"></td>
        <td style="width:0.716%;"></td>
        <td style="width:11.561%;"></td>
        <td style="width:0.716%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Convertible preferred stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5c52fad8-e806-403c-92f0-5284d3a786de" contextRef="C_a8085576-61b7-454c-a519-9ae96812318a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_454ee4d7-d33b-4606-a664-6efb2a96bbc1" contextRef="C_5cba4e1e-72af-462f-b037-4423f24b01af" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">19,387,544</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_47d0a3dd-68ef-417d-8c37-a786a9cea615" contextRef="C_b94a23b8-43bb-4383-a20f-d50aa1e8c3b4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,553,367</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unvested restricted stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_dd8d2162-ff6b-4998-b7d5-e9a557ff35ab" contextRef="C_bcc73401-287e-4ac0-a87f-a7584a3ebe73" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a07401b8-cde7-4647-85f0-369c314f2d80" contextRef="C_8deec1cb-9d18-458c-80a6-69065b7fd6e1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">537,633</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_59d4d106-1557-4c77-8cf1-2da63ec02860" contextRef="C_2dcf3819-ab63-4939-86b0-10870a857990" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,075,268</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unvested restricted stock units</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d348a3de-e167-4cae-aa20-2abac1dc85d0" contextRef="C_7c5380ff-43e4-4da6-9d3d-4f142569329f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c26e616d-f170-4f2f-9b75-e1455c0e92cc" contextRef="C_f5f342f9-12eb-4269-ba58-fc8d87544ebf" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_12373f35-c7e9-419e-8cda-a7a6ca8830d2" contextRef="C_1afabfe3-8755-45d0-ac91-81a3418d2248" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Outstanding options to purchase common stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2fe1e96b-f55e-4f1b-adee-6407b07e9449" contextRef="C_e08bb552-0254-44e1-ada0-095671a76529" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,119,295</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4cddf9a8-c6ed-4c11-8ef7-e5dddffe6ba5" contextRef="C_17fbf683-2a55-4bef-952f-f0d1c18ff75d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,888,823</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_232b78c2-cc73-469d-9acf-f89e09a44bc0" contextRef="C_f7f9ed07-4a59-4247-ad5a-a6b36bcb98c2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,933,507</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4663e26b-f2eb-44a2-bedd-8ef351b30f4a" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,151,295</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_360eb3c2-e99e-4fd0-8d2e-c98b431dead6" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">23,814,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4202c421-f864-4cab-872f-0348c0251a5e" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">8,562,142</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As part of the license agreements with Harvard and Broad, the Company is required to make success payments. The Company may elect to make these payments by issuing shares of the Company's common stock. As of December 31, 2021, an aggregate of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2f1ebbf5-b40e-4eee-ad6c-5b46a2a98157" contextRef="C_1a988b86-2da6-44fb-8d8b-025bc3040bcb" name="verv:SuccessPaymentLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million was earned relating to these success payments, which the Company settled in cash in November 2021.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_b26d7591-4c66-4678-8f20-6abfd099108b" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_b26d7591-4c66-4678-8f20-6abfd099108b_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">13. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Income taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For the years ended December 31, 2021, 2020 and 2019, the Company did not record a current or deferred income tax expense or benefit due to current and historical losses incurred by the Company. The Company&#x2019;s losses before income taxes consist solely of losses from domestic operations, which totaled </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_028e5041-d564-47e0-8a9f-8006adf26baf" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">120.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a5cffae1-0b02-4464-8333-0083b8040933" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">45.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_735f3462-e4b9-4644-9e52-a8eb64d7a562" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">19.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> for the years ended December 31, 2021, 2020 and 2019, respectively</span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_86c6daa9-b1f1-4f74-9636-2a332691304d" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.103%;"></td>
        <td style="width:1.362%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:9.423%;"></td>
        <td style="width:3.141%;"></td>
        <td style="width:1.362%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:9.423%;"></td>
        <td style="width:3.141%;"></td>
        <td style="width:1.362%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:9.423%;"></td>
        <td style="width:3.141%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9835d11d-39cb-4eac-8667-1eb37dc5dde5" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3c1f5118-3011-4108-bdb5-3c3c854fbc1b" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_31db19ae-7651-4b2c-9432-7b6dca4dad3f" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e23b4ef9-e36f-406a-81ce-b2ba0f6fa988" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">31.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_48bfc8db-c7aa-4b2b-b99b-bdb9c0fb57e0" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">29.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2d628ce9-5391-4c33-903a-018173155852" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">17.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1bcd8a60-f0db-4241-ad64-325de4199652" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8814cbcb-a21d-453b-ad56-8fc3141caf24" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c7979a97-a557-48b8-909a-beb808af5eef" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Executive compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3d42fa6a-57ca-4e36-a119-75097ca9b06c" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fa94be69-f7dd-4e69-8b47-90970e26bcb8" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6c80ffe3-a577-4787-bba6-4e5288482a6a" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other permanent items</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a0c33bbd-4afb-4ecc-b197-bec1cf24dc0f" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:EffectiveIncomeTaxRateReconciliationPermanentItems" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_cb01735d-e42b-4afb-b7d1-89c04eafef3c" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="verv:EffectiveIncomeTaxRateReconciliationPermanentItems" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7e0c0195-60c6-4391-8e42-22825ee7e0b1" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="verv:EffectiveIncomeTaxRateReconciliationPermanentItems" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">5.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ba33de10-1d96-4489-9d3a-b218de31512d" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">6.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_848769ed-071d-4e63-bf6e-78570abc5740" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">6.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_dc3218cc-1be2-4957-94ee-78d942d70793" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e9677d75-9b79-4547-b53d-4803763490ab" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2b3ed054-1002-4e3a-ac13-00f5525160c1" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_92cd8719-abe3-4150-b94a-169af3276b28" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_db34497c-ec0f-4b75-9d4f-35ff6c6b6cb9" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_de1d9603-ebc9-4f08-9a99-c599e3e65a80" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6806beaf-8616-407f-b7f0-09632014c229" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">29</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#x2019;s deferred tax assets and liabilities as of December 31, 2021 and 2020 are comprised of the following</span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_62aabbff-d5ef-4a46-b2b9-ff9bf50ebe31" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_62aabbff-d5ef-4a46-b2b9-ff9bf50ebe31_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_62aabbff-d5ef-4a46-b2b9-ff9bf50ebe31_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.358%;"></td>
        <td style="width:1.601%;"></td>
        <td style="width:1.432%;"></td>
        <td style="width:12.924%;"></td>
        <td style="width:0.865%;"></td>
        <td style="width:1.601%;"></td>
        <td style="width:1.432%;"></td>
        <td style="width:12.924%;"></td>
        <td style="width:0.865%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_cf431f61-0424-457c-8440-861d12534c1d" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,409</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f17cba29-3d11-4d07-8389-e911f8c1fffa" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,973</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Capitalized costs&#x2014;net of amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ab2a5b46-696b-4736-bd30-da11ca64e7c3" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="verv:DeferredTaxAssetsCapitalizedCostsNetOfAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,395</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f2bc2320-4bf4-4eb1-9f3a-7dd77c37b478" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="verv:DeferredTaxAssetsCapitalizedCostsNetOfAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">855</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_880fd481-b0d0-4c7e-9b67-e62d93429e7d" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,098</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_93313d21-689b-4de8-aeac-95e54813697f" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">682</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Antidilution liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_59ab44d5-b03d-436c-ace7-e15b2fb4b067" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="verv:DeferredTaxAssetsAntidilultionLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,815</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_50373372-738d-4f5b-971d-2863cf759862" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="verv:DeferredTaxAssetsStockBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,117</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_87311de0-1ef7-4d1a-bd55-100f9e153264" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="verv:DeferredTaxAssetsStockBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">149</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a809f83b-2d53-4ab6-8b7d-ad4a3fcd6f0a" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_49213078-c4bf-46ca-a58b-f70cbc2a6e64" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Lease liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e86a832b-4c8d-4e3c-9ec3-b999b85444c1" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">533</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_0691f387-dd9a-4985-8c9a-0c01efabf653;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f457d8b9-af2e-4973-8d33-3107fc2e9e01" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="verv:DeferredTaxAssetAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,852</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_16fdcd14-15e0-458a-bad4-e30ed4eb6427" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="verv:DeferredTaxAssetAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">905</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a4615e23-82b9-4d90-8184-98e3262d481b" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,480</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6d82ef0e-5303-48a0-a1df-ffca60413574" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,440</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3dd3a702-53a0-4f89-80dc-c92c9b5aef79" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">899</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f5f311a6-3e73-4128-94b7-eda27a19f198" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,061</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Right of use asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d4992123-7284-4515-92df-7f5d31209fb9" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="verv:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">501</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_20d4266c-6aad-4cbb-ab46-faac5900b5d5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_884ba004-7739-4185-81cb-0a8c3ecb3fa2" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,400</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0dbbe498-6054-43b8-9233-a0adc77b7f26" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,061</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total deferred tax assets, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_cb135c47-2eb8-4512-84a8-4e183f2b58c3" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,080</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5ecce637-a07f-4819-863f-75e3ec9d2d27" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,379</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f036d32e-4ec8-4b4e-8564-b4a547867a5d" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,080</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d7ca509e-9359-4ce9-aab6-e1c31d6221ad" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,379</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_97a4254d-5370-4d62-9523-6c09a5d4ee9f" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_830ab8d3-5892-4dd4-b9c7-06c48b38d1a8" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has incurred net operating losses in each year since inception. The Company had no income tax expense due to the operating loss incurred for all years since inception. Management has evaluated the positive and negative evidence bearing upon the realizability of the Company&#x2019;s net deferred tax assets, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">which are comprised primarily of net operating loss carryforwards, tax credits, and costs capitalized for tax purposes. Management has considered the Company&#x2019;s history of cumulative net losses in the United States and estimated future tax losses and</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> has determined that it is more likely than not that the Company will not recognize the benefits of the net deferred tax assets. As a result, the Company has recorded a full valuation allowance at December 31, 2021 and 2020. The valuation allowance increased by </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_51f015b0-ade7-412f-bdd6-299c123b1cf8" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.7</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> in 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, due to the increase in deferred tax assets, primarily due to net operating loss carryforwards, tax credit carryforwards, and increase in deferred tax assets associated with current year temporary items. The valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_93392314-c12f-4e81-9ef4-4496941ea757" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.6</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in 2020, primarily due to the increase in deferred tax assets, primarily due to net operating loss carryforwards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Realization of the future tax benefits is dependent on many factors, including the Company&#x2019;s ability to generate taxable income within the net operating loss carryforward period. The Company&#x2019;s ability to utilize these federal and state net operating loss and research and development credit carryforwards may be limited in the future if the Company experiences an ownership change pursuant to Internal Revenue Code 382. </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_8f6950b5-2821-4050-831b-7eea4db80fd7" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:ChangeInOwnershipDescription"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">An ownership change occurs when the ownership percentages of 5% or greater shareholders change by more than 50% over a three-year period.</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> As of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021, the Company has not completed a study to assess whether a change of control has occurred and whether the net operating losses and credits are limited due to a change in ownership. To the extent that an assessment is completed in the future, the Company&#x2019;s ability to utilize tax attributes could be restricted on a year-by-year basis and certain attributes could expire before they are utilized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, the Company had approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4c3281b5-bff3-4d22-884d-3a479df4c60b" contextRef="C_9b37319a-0d54-4ccd-83eb-9d11fc5d438b" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">124.7</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of pre-tax federal and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ca3b7ada-49b8-40ee-a9d0-79e5dece3159" contextRef="C_38d37eaf-cd29-452c-8228-ce29419522e6" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">114.4</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of pre-tax state net operating loss carryforwards. The federal net operating losses have an indefinite life and can be utilized to offset </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7cd9f7b4-526a-4a68-8055-f8f6f24e4ade" contextRef="C_38d37eaf-cd29-452c-8228-ce29419522e6" name="verv:PercentageOfFutureTaxableIncomeUtilizedToOffset" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">80</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of future taxable income, while the state net operating losses will start to expire at various dates through </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_56e5f7eb-9a56-48ac-816e-8d436ac6ef8f" contextRef="C_e0e52d02-fa91-4a31-93c5-67e517633a88" name="verv:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2041</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Additionally, as of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, the Company had approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_645ead91-65c2-40d6-a71e-b115670480dc" contextRef="C_9b37319a-0d54-4ccd-83eb-9d11fc5d438b" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.2</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of federal and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_78070042-a050-4ac3-ab54-b6ba0c7132f8" contextRef="C_9315a78c-93a9-491d-b78a-acdccb6d99a8" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of Massachusetts tax credits that expire starting in </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_94d11eb4-c454-463f-b5c9-782453100b3a" contextRef="C_7eaf836e-97a5-4b96-901b-fbc846401d37" name="verv:TaxCreditCarryforwardExpirationYear"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2041</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_b7b1ee3d-7d56-4851-9d18-2dab6110d64f" contextRef="C_76a2ae17-640c-473b-b6d2-7f1f8e136700" name="verv:TaxCreditCarryforwardExpirationYear"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2036</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021 and 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, the Company had </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_148eaf79-9d2f-4c3d-84bc-f7ffe023efd8" contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_21b615d8-1239-4b77-ad76-6ba47310071b" contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> uncertain tax positions. The Company recognizes both interest and penalties associated with unrecognized tax benefits as a component of income tax expense. The Company has </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5e766aca-7763-4f7e-9cca-74f50c4edffd" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">t recorded any interest or penalties for unrecognized tax benefits since its inception.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Company files income tax returns in the United States, California, Connecticut, the Commonwealth of Massachusetts, and Pennsylvania. The Company is not currently under examination by the Internal Revenue Service or any other jurisdiction for these years. All tax years remain open to tax examination. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may be adjusted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">30</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_b26d7591-4c66-4678-8f20-6abfd099108b_1"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">upon </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. No federal or state tax audits are currently in process.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_8201be74-920b-4059-ba8a-af846ec31048" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">14. Related party transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the years ended December 31, 2021, 2020 and 2019, the Company made total payments o</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">f $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4b6281bd-7e40-4e85-a885-fc547a23eb51" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7cb7126a-dc37-4782-9bbd-f7167798a453" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fbd574fe-17aa-4628-bafa-c97a06057d1f" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively, to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> the five founder shareholders for scientific consulting and other expenses. These same individuals also vested in </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bdce6cad-9f6b-4370-b2cd-edd26f35c3be" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">537,633</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_20a92703-6b84-424a-a56d-3f77f6b7cc35" contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">537,635</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_020d7164-9aa8-43e9-8fb9-7f3a86222810" contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">537,635</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of restricted stock in the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021, 2020 and 2019, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">An executive officer of Beam is a board member of the Company. From February 2019 through December 2019, the Company leased office space from Beam in Cambridge, Massachusetts. Total rent payments under this sublease was less than $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0e7ffa12-716c-479c-8814-b4c7180ffe7b" contextRef="C_dc246b1a-e277-4475-a822-7b299288320b" name="us-gaap:ShortTermLeaseCommitmentAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In April 2019, the Company and Beam entered into a collaboration and license agreement. As partial consideration for the license rights granted by Beam, the Company paid a one-time, nonrefundable fee through issuing </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_97d5de4f-0156-41a7-a279-0e732e22aeb3" contextRef="C_368253bb-0ab9-4644-bcce-9c12ebebd714" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">276,075</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of its common stock with a fair value of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_515fcdb2-5253-43e9-8fa2-55ebcb701e78" contextRef="C_368253bb-0ab9-4644-bcce-9c12ebebd714" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. Refer to Note 8, License agreements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In July 2019, the Company agreed to be designated as Beam&#x2019;s collaboration partner in an NHP study connected to Beam&#x2019;s development and option agreement with Acuitas. As a result, Beam granted the Company a non-exclusive, royalty-free sublicense under Beam&#x2019;s right, title and interest in and to certain Acuitas technology, solely to the extent necessary to enable the Company to perform the NHP study activities. The Company paid to Beam a one-time payment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5e7aa45a-ee0e-4496-8116-47a798743db0" contextRef="C_1541fd57-3030-489b-9a4b-89cd76467fe9" name="verv:OutOfPocketCostsIncurred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million upon execution of the agreement and is responsible for certain out-of-pocket costs incurred by Beam in connection with the performance of the NHP study activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In October 2020, the Company and Beam entered into a materials exchange agreement wherein the parties agreed that Beam would provide certain mRNA, gRNA, and protein to the Company and that the Company would provide certain gRNAs to Beam at an agreed upon price per each material provided. For the year ended December 31, 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_eb9d9b07-958a-4fdf-9e15-91d2cf8ba096" contextRef="C_b00ab393-cfc3-45d7-90b3-dfac30d815bd" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as a reduction to research and development expense related to reimbursements received for materials sold to Beam. For the year ended December 31, 2020, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_913ed8f4-b666-42ad-b945-f21e6571c07f" contextRef="C_4a2a7d48-0ad0-4027-b312-8b11192978ef" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as research and development expense related to payments made for materials purchased from Beam and also recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ebda3630-0208-4a17-ad2b-6ae19ba6467d" contextRef="C_e5a60e47-ab5b-41f6-99da-8c71cb8625d8" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as a reduction to research and development expense related to reimbursements received for materials sold to Beam</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2021, the Company entered into a sublease agreement with Beam for laboratory and office space in Cambridge, Massachusetts. Total rent payments under this sublease were less than $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a5b26d7a-0249-43fc-85c4-2dea1d90805d" contextRef="C_f014d533-46a7-4112-9279-b10412cf8bb1" name="us-gaap:ShortTermLeaseCommitmentAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">An officer of the Company was formerly affiliated with Massachusetts General Hospital (&#x201c;MGH&#x201d;) as a physician. As of August 2021, the officer is no longer a physician at MGH. In February 2019 and November of 2019, the Company entered into an Option License Agreement and Patent License Agreement, respectively, with MGH. Upon execution of the agreements in 2019, the Company incurred $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0b7fcda0-cc5f-4b9f-bf5c-ea682996faac" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="verv:OptionAndLicenseIssueFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for option and license issue fees, which were recorded as research and development expense. For the years ended December 2021 and 2020, the Company incurred $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_133434a5-720b-4760-9a0b-6e7935a1b6bb" contextRef="C_5f4306bb-8ee0-4a9e-a1ff-c73a4446835b" name="us-gaap:ProceedsFromLicenseFeesReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_50cf490b-c0c6-4a30-bbe2-3d650ac2810f" contextRef="C_6fe755bd-39b2-4058-bb31-ac7a1399a7a0" name="us-gaap:ProceedsFromLicenseFeesReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million each year relating to the annual license fee, which was recorded as research and development expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">An executive of Broad was a board member of the Company. The board member resigned, effective May 2021. In March 2019, the Company simultaneously entered into the Harvard/Broad License Agreement and Broad License Agreement for certain base editing technologies pursuant to which the Company received exclusive, worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed products and nonexclusive, worldwide, sublicensable, royalty-bearing licenses under certain patent rights to research and develop licensed products. Additional consideration under the license agreements include antidilution rights and success payments. See Note 8, License agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_5833ca62-52e8-44a3-a505-61c0b0855bef" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:DefinedContributionPlanTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">15. Employee benefit plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has a defined-contribution plan established under Section 401(k) of the Internal Revenue Code (the &#x201c;401(k) Plan&#x201d;), which covers substantially all employees. Employees are eligible to participate in the 401(k) Plan beginning on the first day of the month following commencement of their employment. </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_6f1a9b03-1f12-47ca-9082-522a517205d1" contextRef="C_f78045b2-d23b-4e9d-b193-d192ee9bb611" name="us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" continuedAt="F_6f1a9b03-1f12-47ca-9082-522a517205d1_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The 401(k) Plan includes a salary deferral arrangement pursuant to which participants may elect to reduce their current compensation by up to the sta</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">tutorily prescribed limit, equal to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_63c009cc-f852-40de-a918-8dd0b69927c4" contextRef="C_f78045b2-d23b-4e9d-b193-d192ee9bb611" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">19,500</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> in 2021 with a catch up contribution limit equal to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f2c38330-1efe-4b51-882e-678a54ca5291" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">6,500</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> for </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">those 50 years of age or older, and have the amount of the reduction contributed to the 401(k) </span></ix:nonNumeric></span><span style=""></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">31</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_6f1a9b03-1f12-47ca-9082-522a517205d1_1"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Plan.</span></ix:continuation></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> Since January 1, 2020 the Company matches </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_200d1701-15a6-4b3b-ae23-90e3e1cc7e17" contextRef="C_d1a50b9b-5f34-479b-86a9-1686cbaaf4d7" name="verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of each participant&#x2019;s annual contribution to the 401(k) plan up to </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_47e58c33-7095-45c8-b620-1f52d0e07748" contextRef="C_f78045b2-d23b-4e9d-b193-d192ee9bb611" name="verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the participant&#x2019;s salary and then </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1ad15a16-7a06-419e-ad19-1446f850772e" contextRef="C_d1a50b9b-5f34-479b-86a9-1686cbaaf4d7" name="verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of each participant&#x2019;s contribution up to </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ef550e08-b8c3-4bbf-b2f2-4e8c5da879e7" contextRef="C_f78045b2-d23b-4e9d-b193-d192ee9bb611" name="verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">2</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the participant&#x2019;s salary. The match immediately vests </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4c7192e0-294c-450a-b2b2-1bdfa289ecfc" contextRef="C_d1a50b9b-5f34-479b-86a9-1686cbaaf4d7" name="us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%. The matching c</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ontributions by the Company to the 401(k) plan were $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_beac1807-1c87-4fb8-9770-1b939a2778d1" contextRef="C_f78045b2-d23b-4e9d-b193-d192ee9bb611" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_639b9586-fe64-4d92-b9f7-49fea3baeb26" contextRef="C_dd29659d-951a-45fc-a69a-2e59256ccd54" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_39f6a875-1663-47c3-9823-4ec1d2466731" contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">16. S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">ubsequent events</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company evaluated all subsequent events and determined there are no material recognized or unrecognized subsequent events requiring disclosure.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>verv-ex4_3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<html>
 <head>
  <title>EX-4.3</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 4.3</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">DESCRIPTION OF REGISTRANT&#x2019;S SECURITIES</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">REGISTERED PURSUANT TO SECTION 12 OF THE</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following description of the capital stock and provisions of Verve Therapeutics, Inc&#x2019;s. (the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and/or &#x201c;our&#x201d;) restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to our restated certificate of incorporation and amended and restated bylaws, each of which is filed as an exhibit to our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. For additional information, please read our restated certificate of incorporation and amended and restated bylaws and the applicable provisions of the Delaware General Corporation Law.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our authorized capital stock consists of 200,000,000 shares of our common stock, par value $0.001 per share, and 5,000,000 shares of our preferred stock, par value $0.001 per share, all of which preferred stock is undesignated. Our common stock is registered under Section 12(b) of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Common stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Each election of directors by our stockholders will be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of outstanding preferred stock that we may designate and issue in the future.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event of our liquidation or dissolution, the holders of our common stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any of our outstanding preferred stock. Holders of our common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Preferred stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the terms of our restated certificate of incorporation, our board of directors is authorized to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. There are no shares of preferred stock outstanding, and we have no present plans to issue any shares of preferred stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Delaware anti-takeover law and certain charter and bylaw provisions</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Delaware law</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to Section 203 of the Delaware General Corporation Law (the &#x201c;DGCL&#x201d;). Subject to certain exceptions, Section 203 prevents a publicly held Delaware corporation from engaging in a &#x201c;business combination&#x201d; with any &#x201c;interested stockholder&#x201d; for three years following the date that the person became an interested</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">stockholder, unless either the interested stockholder attained such status with the approval of our board of directors, the business combination is approved by our board of directors and stockholders in a prescribed manner or the interested stockholder acquired at least 85% of our outstanding voting stock in the transaction in which it became an interested stockholder. A &#x201c;business combination&#x201d; includes, among other things, a merger or consolidation involving us and the &#x201c;interested stockholder&#x201d; and the sale of more than 10% of our assets. In general, an &#x201c;interested stockholder&#x201d; is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Staggered board; removal of directors</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our restated certificate of incorporation and our amended and restated bylaws divide our board of directors into three classes with staggered three-year terms. In addition, our restated certificate of incorporation and our amended and restated bylaws provide that directors may be removed only for cause and only by the affirmative vote of the holders of at least 75% of our shares of capital stock present in person or by proxy and entitled to vote. Under our restated certificate of incorporation and our amended and restated bylaws, any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. Furthermore, our restated certificate of incorporation provides that the authorized number of directors may be changed only by the resolution of our board of directors. The classification of our board of directors and the limitations on the ability of our stockholders to remove directors, change the authorized number of directors and fill vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stockholder action; special meeting of stockholders; advance notice requirements for stockholder proposals and director nominations</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our restated certificate of incorporation and our amended and restated bylaws provide that any action required or permitted to be taken by our stockholders at an annual meeting or special meeting of stockholders may only be taken if it is properly brought before such meeting and may not be taken by written action in lieu of a meeting. Our restated certificate of incorporation and our amended and restated bylaws also provide that, except as otherwise required by law, special meetings of the stockholders can only be called by our board of directors. In addition, our amended and restated bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to our board of directors. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors, or by a stockholder of record on the record date for the meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder&#x2019;s intention to bring such business before the meeting. These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities. These provisions also could discourage a third party from making a tender offer for our common stock because even if the third party acquired a majority of our outstanding voting stock, it would be able to take action as a stockholder, such as electing new directors or approving a merger, only at a duly called stockholders meeting and not by written consent.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Super-majority voting</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#x2019;s certificate of incorporation or bylaws unless a corporation&#x2019;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our amended and restated bylaws may be amended or repealed by a majority vote of our board of directors or the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in any election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our restated certificate of incorporation described above.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Exclusive forum selection</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for the following types of proceedings: (1) any derivative action or proceeding brought on behalf of our company, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or stockholders to our company or our stockholders, (3) any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware or as to which the General Corporation Law of the State of Delaware confers jurisdiction on the Court of Chancery of the State of Delaware, or (4) any action asserting a claim arising pursuant to any provision of our restated certificate of incorporation or amended and restated bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine. These choice of forum provisions will not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;) creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any claims arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>verv-ex10_4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<html>
 <head>
  <title>EX-10.4</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Exhibit 10.4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Verve Therapeutics, Inc.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">STOCK OPTION AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Verve Therapeutics, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) hereby grants the following stock option pursuant to its 2021 Stock Incentive Plan.  The terms and conditions attached hereto are also a part hereof.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Notice of Grant</font></p>
  <table style="margin-left:0.07500000000000001in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.119%;"></td>
    <td style="width:49.881%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Name of optionee (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Participant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;):</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Grant Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Incentive Stock Option or Nonstatutory Stock Option:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Number of shares of the Company&#x2019;s Common Stock subject to this option (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;):</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Option exercise price per Share:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-5.628pt;white-space:pre-wrap;font-weight:normal;font-size:8.040000000000001pt;font-family:Times New Roman;position:relative;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Number, if any, of Shares that vest immediately on the grant date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Shares that are subject to vesting schedule:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vesting Start Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Final Exercise Date:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-5.628pt;white-space:pre-wrap;font-weight:normal;font-size:8.040000000000001pt;font-family:Times New Roman;position:relative;">&#160;2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vesting Schedule:</font></p>
  <table style="margin-left:0.07500000000000001in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:49.984%;"></td>
    <td style="width:50.016%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Vesting Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Number of Options that Vest</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:28.1pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">All vesting is dependent on the Participant remaining an Eligible Participant, as provided herein.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:86.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This must be at least 100% of the Grant Date Fair Market Value (as defined in the Plan) of the Common Stock on the date of grant of the option. For the option to qualify as an incentive stock option (an &#x201c;ISO&#x201d;) under Section 422 of the Internal Revenue Code, this must be 110% in the case of a Participant that owns more than 10% of the total combined voting power of all classes of stock of the Company or its parent or subsidiary (a &#x201c;10% Shareholder&#x201d;)).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Final Exercise Date must be no more than 10 years from the date of grant for the option.  For the option to qualify as an ISO, the Final Exercise Date must be no more than 5 years in the case of a 10% Shareholder. The correct approach to calculate the final exercise date is to use the day immediately prior to the date ten years out from the date of the stock option award grant (5 years in the case of a 10% Shareholder).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:5.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Verve Therapeutics, Inc.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Signature of Participant</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Street Address</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Name of Officer</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Title:</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">City/State/Zip Code</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Verve Therapeutics, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Stock Option Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Incorporated Terms and Conditions</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Grant of Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This agreement evidences the grant by the Company, on the grant date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Grant Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) set forth in the Notice of Grant that forms part of this agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Notice of Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), to the Participant of an option to purchase, in whole or in part, on the terms provided herein and in the Company&#x2019;s 2021 Stock Incentive Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), the number of Shares set forth in the Notice of Grant of common stock, $0.001</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">par value per share, of the Company (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Common Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), at the exercise price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">per Share set forth in the Notice of Grant.  Unless earlier terminated, this option shall expire at 5:00 p.m., Eastern time, on the Final Exercise Date set forth in the Notice of Grant (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Final Exercise Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The option evidenced by this agreement is intended to be an incentive stock option as defined in Section 422 of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to the maximum extent permitted by law, solely to the extent designated as an incentive stock option in the Notice of Grant.  Except as otherwise indicated by the context, the term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Participant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;, as used in this option, shall be deemed to include any person who acquires the right to exercise this option validly under its terms.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Vesting Schedule</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This option will become exercisable (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">vest</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) in accordance with the vesting schedule set forth in the Notice of Grant[, provided, however, that upon the Participant&#x2019;s death while the Participant is providing services to the Company as an employee or member of the Company&#x2019;s board of directors, this option will vest and become immediately exercisable]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The right of exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date or the termination of this option under Section 3 hereof or the Plan.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exercise of Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Form of Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Each election to exercise this option shall be in writing, in the form of the Stock Option Exercise Notice attached as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Annex A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, signed by the Participant, and received by the Company at its principal office, accompanied by this agreement, or in such other form (which may be electronic) as is approved by the Company, together with payment in full in the manner provided in the Plan.  The Participant may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may be for any fractional share.</font></div></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:86.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Include for employees/board members only.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Continuous Relationship with the Company Required</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Except as otherwise provided in this Section 3, this option may not be exercised unless the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee, director or officer of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive option grants under the Plan (an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Eligible Participant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Termination of Relationship with the Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If the Participant ceases to be an Eligible Participant for any reason, then, except as provided in paragraphs (d) and (e) below, the right to exercise this option shall terminate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">three months after such cessation (but in no event after the Final Exercise Date), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">that</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> this option shall be exercisable only to the extent that the Participant was entitled to exercise this option on the date of such cessation.  Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the restrictive covenants (including, without limitation, the non-competition, non-solicitation, or confidentiality provisions) of any employment contract, any non-competition, non-solicitation, confidentiality or assignment agreement to which the Participant is a party, or any other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon such violation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exercise Period Upon Death or Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If the Participant dies or becomes disabled (within the meaning of Section 22(e)(3) of the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated such relationship for &#x201c;cause&#x201d; as specified in paragraph (e) below, this option shall be exercisable, within the period of one year following the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized transferee), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">that</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> this option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or her death or disability, and further provided that this option shall not be exercisable after the Final Exercise Date.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Termination for Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If, prior to the Final Exercise Date, the Participant&#x2019;s employment or other service is terminated by the Company for Cause (as defined in below), the right to exercise this option shall terminate immediately upon the effective date of such termination of service.  If, prior to the Final Exercise Date, the Participant is given notice by the Company of the termination of his or her employment or other service by the Company for Cause, and the effective date of such termination is subsequent to the date of delivery of such notice, the right to exercise this option shall be suspended from the time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed that the Participant&#x2019;s service shall not be terminated for Cause as provided in such notice or (ii) the effective date of such termination of service (in which case the right to exercise this option shall, pursuant to the preceding sentence, terminate upon the effective date of such termination of employment).  If the Participant is subject to an individual employment, consulting or other service agreement with the Company or eligible to participate in a Company severance plan or arrangement, in any case which agreement, plan or arrangement contains a definition of &#x201c;cause&#x201d; for termination of service, &#x201c;Cause&#x201d; shall have the meaning ascribed to such term in such agreement, plan or arrangement.  Otherwise, &#x201c;Cause&#x201d; shall mean willful misconduct by the Participant or willful failure by the Participant to perform his or her responsibilities to the Company (including, without limitation, breach by the Participant of any provision of any employment, consulting, advisory, nondisclosure, non-competition or other similar agreement </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">between the Participant and the Company), as determined by the Company, which determination shall be conclusive.  The Participant&#x2019;s employment or other service shall be considered to have been terminated for Cause if the Company determines, within 30 days after the Participant&#x2019;s resignation, that termination for Cause was warranted.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Tax Matters</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Withholding</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  No Shares will be issued pursuant to the exercise of this option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this option.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Disqualifying Disposition</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If this option is an incentive stock option and the Participant disposes of Shares acquired upon exercise of this option within two years from the Grant Date or one year after such Shares were acquired pursuant to exercise of this option, the Participant shall notify the Company in writing of such disposition.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Transfer Restrictions; Clawback.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This option may not be sold, assigned, transferred, pledged, encumbered or otherwise disposed of by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In accepting this option, the Participant agrees to be bound by any clawback policy that the Company has in place or may adopt in the future.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Provisions of the Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This option is subject to the provisions of the Plan (including the provisions relating to amendments to the Plan), a copy of which is furnished to the Participant with this option.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ANNEX A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Verve Therapeutics, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Stock Option Exercise Notice</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Verve Therapeutics, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">500 Technology Square, Suite 901</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Cambridge, MA 02139</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Dear Sir or Madam:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">I, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">                           </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Participant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), hereby irrevocably exercise the right to purchase </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">             </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">shares of the Common Stock, $0.001</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">par value per share (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), of Verve Therapeutics, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) at $</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">                   </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> per share pursuant to the Company&#x2019;s 2021 Stock Incentive Plan and a stock option agreement with the Company dated </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">                 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Option Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Enclosed herewith is a payment of $</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">            </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the aggregate purchase price for the Shares.  The certificate for the Shares should be registered in my name as it appears below or, if so indicated below, jointly in my name and the name of the person designated below, with right of survivorship.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:21.33%;"></td>
    <td style="width:78.67%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Signature</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Print Name:</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Address:</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Name and address of persons in whose name the Shares are to be jointly registered (if applicable):</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>4
<FILENAME>verv-ex10_5.htm
<DESCRIPTION>EX-10.5
<TEXT>
<html>
 <head>
  <title>EX-10.5</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:3.2%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Exhibit 10.5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Verve Therapeutics, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Restricted Stock Unit Agreement</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Verve Therapeutics, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) hereby grants the following restricted stock units pursuant to its 2021 Stock Incentive Plan.  The terms and conditions attached hereto are also a part hereof.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Notice of Grant</font></p>
  <table style="margin-left:0.07500000000000001in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Name of recipient (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Participant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;):</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Grant Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Number of restricted stock units (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">RSUs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) granted:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vesting Start Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vesting Schedule:</font></p>
  <table style="margin-left:0.07500000000000001in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:49.984%;"></td>
    <td style="width:50.016%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Vesting Date:</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Number of RSUs that Vest:</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:28.1pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">All vesting is dependent on the Participant remaining an Eligible Participant, as provided herein.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.884%;"></td>
    <td style="width:3.619%;"></td>
    <td style="width:5.15%;"></td>
    <td style="width:44.347%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Verve Therapeutics, Inc.</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Signature of Participant</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Street Address</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:17.3pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:17.3pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Name of Officer</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:17.3pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:17.3pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Title:</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">City/State/Zip Code</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:17.3pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:17.3pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Verve Therapeutics, Inc.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Restricted Stock Unit Agreement</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Incorporated Terms and Conditions</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For valuable consideration, receipt of which is acknowledged, the parties hereto agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Award of Restricted Stock Units</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In consideration of services rendered and to be rendered to the Company by the Participant, the Company has granted to the Participant, subject to the terms and conditions set forth in this Restricted Stock Unit Agreement (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and in the Company&#x2019;s 2021 Stock Incentive Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), an award with respect to the number of restricted stock units (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">RSUs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) set forth in the Notice of Grant that forms part of this Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Notice of Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Each RSU represents the right to receive one share of common stock, $0.001</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">par value per share, of the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Common Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) upon vesting of the RSU, subject to the terms and conditions set forth herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Vesting</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The RSUs shall vest in accordance with the Vesting Schedule set forth in the Notice of Grant (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Vesting Schedule</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;)[, provided, however, that upon the Participant&#x2019;s death while the Participant is providing services to the Company as an employee or member of the Company&#x2019;s board of directors, the RSUs will immediately vest]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Any fractional shares resulting from the application of any percentages used in the Vesting Schedule shall be rounded down to the nearest whole number of RSUs.  Upon the vesting of the RSU, the Company will deliver to the Participant (or the Participant&#x2019;s Designated Beneficiary, if applicable), for each RSU that becomes vested, one share of Common Stock, subject to the payment of any taxes pursuant to Section 7.  The Common Stock will be delivered to the Participant (or the Participant&#x2019;s Designated Beneficiary, if applicable) as soon as practicable following each vesting date, but in any event within 30</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">days of such date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Forfeiture of Unvested RSUs Upon Cessation of Service</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In the event that the Participant ceases to be an employee, director or officer of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive awards under the Plan (an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Eligible Participant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) for any reason or no reason, with or without cause, all of the RSUs that are unvested as of the time of such cessation shall be forfeited immediately and automatically to the Company, without the payment of any consideration to the Participant, effective as of such cessation.  The Participant shall have no further rights with respect to the unvested RSUs or any Common Stock that may have been issuable with respect thereto.  If the Participant provides services to a subsidiary of the Company, any references in this Agreement to provision of services to the Company shall instead be deemed to refer to service with such subsidiary.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:66.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:8.040000000000001pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Include for employees/board members only</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Restrictions on Transfer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Participant shall not sell, assign, transfer, pledge, hypothecate, encumber or otherwise dispose of, by operation of law or otherwise (collectively &#x201c;transfer&#x201d;) any RSUs, or any interest therein. The Company shall not be required to treat as the owner of any RSUs or issue any Common Stock to any transferee to whom such RSUs have been transferred in violation of any of the provisions of this Agreement.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Rights as a Stockholder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Participant shall have no rights as a stockholder of the Company with respect to any shares of Common Stock that may be issuable with respect to the RSUs until the issuance of the shares of Common Stock to the Participant following the vesting of the RSUs.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Provisions of the Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This Agreement is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Tax Matters</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.   </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Acknowledgments; No Section 83(b) Election</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Participant acknowledges that he or she is responsible for obtaining the advice of the Participant&#x2019;s own tax advisors with respect to the award of RSUs and the Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents with respect to the tax consequences relating to the RSUs.  The Participant understands that the Participant (and not the Company) shall be responsible for the Participant&#x2019;s tax liability that may arise in connection with the acquisition, vesting and/or disposition of the RSUs.  The Participant acknowledges that no election under Section 83(b) of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), is available with respect to RSUs.   </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Withholding</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Participant acknowledges and agrees that the Company has the right to deduct from payments of any kind otherwise due to the Participant any federal, state, local or other taxes of any kind required by law to be withheld with respect to the vesting of the RSUs.  At such time as the Participant is not aware of any material nonpublic information about the Company or the Common Stock and is not prohibited from doing so by the Company&#x2019;s insider trading policy or otherwise, the Participant shall execute the instructions set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> attached hereto (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Automatic Sale Instructions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) as the means of satisfying such tax obligation.  If the Participant does not execute the Automatic Sale Instructions prior to an applicable vesting date, then the Participant agrees that if under applicable law the Participant will owe taxes at such vesting date on the portion of the award then vested the Company shall be entitled to immediate payment from the Participant of the amount of any tax required to be withheld by the Company.  The Company shall not deliver any shares of Common Stock to the Participant until it is satisfied that all required withholdings have been made.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Miscellaneous</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">No Right to Continued Service</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Participant acknowledges and agrees that, notwithstanding the fact that the vesting of the RSUs is contingent upon his or her continued service to the Company, this Agreement does not constitute an express or implied promise of continued service relationship with the Participant or confer upon the Participant any rights with respect to a continued service relationship with the Company or any affiliate of the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The RSUs awarded pursuant to this Agreement are intended to be exempt from or comply with the requirements of Section 409A of the Code and the Treasury Regulations issued thereunder (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  The delivery of shares of Common Stock on the vesting of the RSUs may not be accelerated or deferred unless permitted or required by Section 409A.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Participant&#x2019;s Acknowledgments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Participant acknowledges that he or she:  (i) has read this Agreement; (ii) has been represented in the preparation, negotiation and execution of this Agreement by legal counsel of the Participant&#x2019;s own choice or has voluntarily declined to seek such counsel; (iii) understands the terms and consequences of this Agreement; (iv) is agreeing, in accepting this award, to be bound by any clawback policy that the Company has in place or may adopt in the future; and (iv) is fully aware of the legal and binding effect of this Agreement.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  This Agreement shall be construed, interpreted and enforced in accordance with the internal laws of the State of Delaware without regard to any applicable conflicts of laws provisions.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Schedule A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Automatic Sale Instructions</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The undersigned hereby consents and agrees that any taxes due on a vesting date as a result of the vesting of RSUs on such date shall be paid through an automatic sale of shares as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Upon any vesting of RSUs pursuant to Section 2 hereof, the Company shall arrange for the sale of such number of shares of Common Stock issuable with respect to the RSUs that vest pursuant to Section 2 as is sufficient to generate net proceeds sufficient to satisfy the Company&#x2019;s minimum statutory withholding obligations with respect to the income recognized by the Participant upon the vesting of the RSUs (based on minimum statutory withholding rates for all tax purposes, including payroll and social security taxes, that are applicable to such income), and the net proceeds of such sale shall be delivered to the Company in satisfaction of such tax withholding obligations.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Participant hereby appoints the Chief Executive Officer, Chief Financial Officer and General Counsel (or, if none, the Chief Operating Officer), and any of them acting alone and with full power of substitution, to serve as his or her attorneys in fact to arrange for the sale of the Participant&#x2019;s Common Stock in accordance with this Schedule A.  The Participant </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">agrees to execute and deliver such documents, instruments and certificates as may reasonably be required in connection with the sale of the shares pursuant to this Schedule A.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Participant represents to the Company that, as of the date hereof, he or she is not aware of any material nonpublic information about the Company or the Common Stock and is not prohibited from entering into these Automatic Sale Instructions by the Company&#x2019;s insider trading policy or otherwise.  The Participant and the Company have structured this Agreement, including this Schedule A, to constitute a &#x201c;binding contract&#x201d; relating to the sale of Common Stock, consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Company shall not deliver any shares of Common Stock to the Participant until it is satisfied that all required withholdings have been made.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.991%;"></td>
    <td style="width:2.009%;"></td>
    <td style="width:60.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Participant Name:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Date:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>5
<FILENAME>verv-ex10_7.htm
<DESCRIPTION>EX-10.7
<TEXT>
<html>
 <head>
  <title>EX-10.7</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.7</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VERVE THERAPEUTICS, INC.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective as of February 12, 2022, the non-employee directors of Verve Therapeutics, Inc. (the &#x201c;Company&#x201d;) shall receive the following compensation for their service as members of the Board of Directors (the &#x201c;Board&#x201d;) of the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Director Compensation</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our goal is to provide compensation for our non-employee directors in a manner that enables us to attract and retain outstanding director candidates and reflects the substantial time commitment necessary to oversee the Company&#x2019;s affairs. We also seek to align the interests of our directors and our stockholders and we have chosen to do so by compensating our non-employee directors with a mix of cash and equity-based compensation.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Compensation</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fees that will be paid to our non-employee directors for service on the Board, and for service on each committee of the Board on which the director is then a member, and the fees that will be paid to the chairperson of the Board, if one is then appointed, and the chairperson of each committee of the Board will be as follows:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:76.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:53.869%;"></td>
    <td style="width:2.72%;"></td>
    <td style="width:2.748%;"></td>
    <td style="width:14.771%;"></td>
    <td style="width:1.438%;"></td>
    <td style="width:2.72%;"></td>
    <td style="width:2.748%;"></td>
    <td style="width:17.548%;"></td>
    <td style="width:1.438%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Member Annual<br>Fee</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;border-bottom:1.000pt solid rgba(255,255,255,0.01);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Chairperson Incremental<br>Annual Fee</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;border-bottom:1.000pt solid rgba(255,255,255,0.01);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Board of Directors</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,000</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,000</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Audit Committee</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,500</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,500</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compensation Committee</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,000</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,000</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nominating and Corporate Governance Committee</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The foregoing fees will be payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment will be prorated for any portion of such quarter that the director is not serving on the Board, on such committee or in such position.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity Compensation</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Initial Grants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Upon initial election to the Board, each non-employee director will be granted, automatically and without the need for any further action by the Board, an initial equity award of an option to purchase 31,000 shares of our common stock. The initial award shall have a term of ten years from the date of the award, and shall vest and become exercisable as to 2.7778% of the shares underlying such award at the end of each successive one-month period following the grant date until the third anniversary of the grant date, subject to the non-employee director&#x2019;s continued service to the Company through each applicable vesting date. The vesting shall accelerate as to 100% of the shares upon a change in control of the Company. The exercise price of the option shall be the closing price of our common stock on the date of grant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Annual Grants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Each non-employee director who has served as a member of the Board for at least six months prior to the date of our annual meeting of stockholders for a particular year will be granted, automatically and without the need for any further action by the Board, an option to purchase 15,500 shares of our common stock on the date of the first Board meeting held after our annual meeting of stockholders for such year. The annual award shall have a term of ten years from the date of the award, and shall vest and become exercisable in full on the one-year anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date), subject to the non-employee director&#x2019;s continued service to the Company through each applicable vesting date. The vesting shall accelerate as to 100% of the shares upon a change in control of the Company. The exercise price of the option shall be the closing price of our common stock on the date of grant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The foregoing share amounts shall be automatically adjusted in the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event effecting our common stock, or any distribution to holders of our common stock other than an ordinary cash dividend.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The initial awards and the annual awards shall be subject to the terms and conditions of our 2021 Stock Incentive Plan, or any successor plan, and the terms of the option agreements entered into with each director in connection with such awards.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expenses</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon presentation of documentation of such expenses reasonably satisfactory to the Company, each non-employee director shall be reimbursed for his or her reasonable out-of-pocket business expenses incurred in connection with attending meetings of the Board and committees thereof or in connection with other business related to the Board, and each non-employee director shall also be reimbursed for his or her reasonable out-of-pocket business expenses authorized by the Board or a committee of the Board that are incurred in connection with attendance at various conferences or meetings with management of the Company, in accordance with the Company&#x2019;s travel policy, as it may be in effect from time to time.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>6
<FILENAME>verv-ex10_14.htm
<DESCRIPTION>EX-10.14
<TEXT>
<html>
 <head>
  <title>EX-10.14</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">	Exhibit 10.14</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">FIRST AMENDMENT TO LEASE</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">THIS FIRST AMENDMENT TO LEASE (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">First Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) is made as of January </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, 2022, by and between </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARE-MA REGION NO. 87 TENANT, LLC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, a Delaware limited liability company (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Landlord</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">VERVE THERAPEUTICS, INC.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, a Delaware corporation (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="margin-left:30.373%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:34.157%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">RECITALS</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord and Tenant are parties to that certain Lease Agreement dated as of August 19, 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Pursuant to the Lease, Tenant leases approximately 104,933 rentable square feet (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), consisting of (i) the entire 2nd floor of that certain to-be-constructed 14-story building to be known as 201 Brookline Avenue, Boston, Massachusetts (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Building</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), commonly known as Suite 201, containing approximately 21,104 rentable square feet, (ii) the entire 6th floor of the Building, commonly known as Suite 601, containing approximately 41,662 rentable square feet, (iii) the entire 7th floor of the Building, commonly known as Suite 701, containing approximately 41,585 rentable square feet, (iv) a portion of the first floor of the Building, commonly known as Suite S113, containing approximately 371 rentable square feet of chemical storage space, and (v) a portion of the penthouse floor of the Building, commonly known as Suite S1509, containing approximately 211 rentable square feet of mechanical space.  The Premises are more particularly described in the Lease.  Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord and Tenant desire, subject to the terms and conditions set forth below, (i) to amend the definition of &#x201c;Premises,&#x201d; set forth in the Lease, and (ii) to modify the Work Letter attached as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Exhibit C </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">to the Lease.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">NOW, THEREFORE, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">in consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows:</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Modification of Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  As of the date hereof, the defined terms &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">,&#x201d; &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Rentable Area of Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; and &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Share of Operating Expenses of Building</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; on page 1 of the Lease shall be deleted in their entirety and replaced with the following:</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Premises:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Those portions of the Building consisting of (a) the entire 2nd floor of the Building, commonly known as Suite 201, containing approximately 21,104 rentable square feet, (b) the entire 6th floor of the Building, commonly known as Suite 601, containing approximately 41,662 rentable square feet, (c) the entire 7th floor of the Building, commonly known as Suite 701, containing approximately 41,585 rentable square feet, (d) a portion of the first floor of the Building, commonly known as Suite S113, containing approximately 371 rentable square feet of chemical storage space, and (e) mechanical space in a portion of the penthouse floor of the Building, commonly known as (i) Suite S1501, containing approximately 250 rentable square feet, and (ii) Suite S1502, containing</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">approximately 210 rentable square feet, all as determined by Landlord, all as shown on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.&#x201d;</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Rentable Area of Premises:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  105,182 sq. ft.&#x201d;</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Share of Operating Expenses of Building:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  20.51%&#x201d;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">As of the date hereof, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Exhibit A </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">to the Lease shall be deleted in its entirety and replaced with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Exhibit A </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">attached to this First Amendment.  For avoidance of doubt, notwithstanding the fact that the Rentable Area of the Premises is being amended by this First Amendment, the amount of the Security Deposit set forth on page 1 of the Lease shall remain unmodified.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Modification to Work Letter</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  As of the date hereof, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5(d)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> the Work Letter attached as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Exhibit C </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">to the Lease shall be deleted in its entirety and replaced with the following:</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;(d)  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Excess TI Costs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Landlord shall have no obligation to bear any portion of the cost of any of the Tenant Improvements except to the extent of the TI Allowance.  If at any time and from time-to-time, the remaining TI Costs under the Budget exceed the remaining unexpended TI Allowance (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Excess TI Costs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) monthly disbursements of the TI Allowance shall be made on a &#x201c;pari passu&#x201d; basis in the proportion that the remaining TI Allowance bears to the outstanding TI Costs under the Budget, and Tenant shall fund the balance of each such monthly draw.  For purposes of any litigation instituted with regard to such amounts, those amounts will be deemed Rent under the Lease.  The TI Allowance and Excess TI Costs are herein referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">TI Fund</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.&#x201d; Notwithstanding anything to the contrary set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5(d)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, Tenant shall be fully and solely liable for TI Costs and the cost of Minor Variations in excess of the TI Allowance.&#x201d;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Furthermore, any requirements in the Work Letter requiring Tenant to deposit 100% of the Excess TI Costs with Landlord as a condition precedent to Landlord&#x2019;s obligation to fund the TI Allowance shall be null and void and of no further force or effect.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">OFAC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Tenant and all beneficial owners of Tenant are currently (a) in compliance with and shall at all times during the Term of the Lease remain in compliance with the regulations of the Office of Foreign Assets Control (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">OFAC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">OFAC Rules</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), (b) not listed on, and shall not during the term of the Lease be listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List, or the Sectoral Sanctions Identification List, which are all maintained by OFAC and/or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Brokers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Broker</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) in connection with the transaction reflected in this First Amendment and that no Broker brought about this transaction, other </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">than CBRE and Newmark.  Landlord and Tenant each hereby agree to indemnify and hold the other harmless from and against any claims by any Broker, other than CBRE and Newmark, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this First Amendment.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Miscellaneous</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="margin-left:6.667%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This First Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions.  This First Amendment may be amended only by an agreement in writing, signed by the parties hereto.</font></div></div>
  <div style="margin-left:6.667%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This First Amendment is binding upon and shall inure to the benefit of the parties hereto, their respective agents, employees, representatives, officers, directors, divisions, subsidiaries, affiliates, assigns, heirs, successors in interest and shareholders.</font></div></div>
  <div style="margin-left:6.667%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This First Amendment may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.  Electronic signatures shall be deemed original signatures for purposes of this First Amendment and all matters related thereto, with such  electronic signatures having the same legal effect as original signatures.</font></div></div>
  <div style="margin-left:6.667%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as amended and/or modified by this First Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this First Amendment.  In the event of any conflict between the provisions of this First Amendment and the provisions of the Lease, the provisions of this First Amendment shall prevail.  Whether or not specifically amended by this First Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this First Amendment.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">[Signatures of following page]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the parties hereto have executed this First Amendment as of the day and year first above written.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:34.8%;"></td>
    <td style="width:5.129%;"></td>
    <td style="width:5.129%;"></td>
    <td style="width:5.118%;"></td>
    <td style="width:5.129%;"></td>
    <td style="width:5.129%;"></td>
    <td style="width:39.565%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">LANDLORD:</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARE-MA REGION NO. 87 TENANT, LLC,</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a Delaware limited liability company</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARE-MA REGION NO. 87, LLC,</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a Delaware limited liability company,</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;managing member</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARE-MA REGION NO. 87 MM, LLC,</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a Delaware limited liability company,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">managing member</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ALEXANDRIA REAL ESTATE</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">EQUITIES, L.P.,</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a Delaware limited partnership,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">managing member</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARE-QRS CORP.,</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a Maryland corporation,</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">general partner</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;/s/ Allison Grochola</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Its:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">SVP &#x2013; Real Estate Legal Affairs</font></p></td>
   </tr>
   <tr>
    <td colspan="7" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:34.943%;"></td>
    <td style="width:5.149%;"></td>
    <td style="width:34.921%;"></td>
    <td style="width:24.987%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">TENANT:</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">VERVE THERAPEUTICS, INC.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">,</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a Delaware corporation</font></p></td>
   </tr>
   <tr>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;/s/ Andrew Ashe</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Its:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;President &amp; COO</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#9746; I hereby certify that the signature, name, and title above are my signature, name and title.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>7
<FILENAME>verv-ex10_19.htm
<DESCRIPTION>EX-10.19
<TEXT>
<html>
 <head>
  <title>EX-10.19</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Exhibit 10.19</font></p>
  <p style="margin-left:33.92%;text-indent:0.0%;font-size:10.0pt;margin-top:3.95pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:27.435%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">EMPLOYMENT AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.413%;text-indent:7.386%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.509%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">THIS EMPLOYMENT AGREEMENT (the &#x201c;Agreement&#x201d;), is made as of November 26,  2021 (the &#x201c;Effective Date&#x201d;) by and between Verve Therapeutics, Inc. (the &#x201c;Company&#x201d;), and Allison Dorval (the &#x201c;Executive&#x201d;) (together, the &#x201c;Parties&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:33.893%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:27.435%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">RECITALS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.413%;text-indent:7.32%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.694%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">WHEREAS, the Company desires to employ the Executive as its Chief Financial Officer (&#x201c;CFO&#x201d;); and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.413%;text-indent:7.748%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.713%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">WHEREAS, the Executive has agreed to accept such employment on the terms and conditions set forth in this Agreement;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.413%;text-indent:7.42%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.917%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">NOW, THEREFORE, in consideration of the foregoing and of the respective covenants and agreements of the Parties herein contained, the Parties hereto agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.139%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Term of Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The Executive&#x2019;s employment shall commence on or around December 1, 2021 (the actual date on which the Executive&#x2019;s employment commences to be mutually agreed between the Parties) and shall continue until such employment relationship is terminated in accordance with Section 7 hereof (the &#x201c;Term of Employment&#x201d;).</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:2.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Position</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. During the Term of Employment, the Executive shall serve as the CFO of the Company, working out of the Company&#x2019;s office in Cambridge, Massachusetts, and travelling as reasonably required by the Executive&#x2019;s job duties.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.213%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Scope of Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. During the Term of Employment, the Executive shall be responsible for the performance of those duties consistent with the Executive&#x2019;s position as the CFO of the Company, in addition to such other duties as may from time to time be assigned to the Executive by the Company. The Executive shall report to the Chief Executive Officer of the Company and shall perform and discharge faithfully, diligently, and to the best of the Executive&#x2019;s ability, the Executive&#x2019;s duties and responsibilities hereunder. The Executive shall devote substantially all of the Executive&#x2019;s business time, loyalty, attention and efforts to the business and affairs of the Company and its affiliates. During the Term of Employment, the Executive will not engage in any other employment, occupation, consulting, or other business activity directly related to the business in which the Company is now involved or becomes involved during the Term of Employment without the prior written consent of the Chief Executive Officer of the Company, nor will the Executive engage in any other activities that conflict with the Executive&#x2019;s obligations to the Company, including pursuant to the Continuing Obligations Agreement (as defined below). The Executive agrees to abide in all material respects with the rules, regulations, instructions, personnel practices and policies of the Company and any changes therein that may be adopted from time to time by the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:2.722%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Compensation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. As full compensation for all services rendered by the Executive to the Company and any affiliate thereof, during the Term of Employment, the Company will provide to the Executive the following:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:14.065%;display:flex;margin-top:3.95pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.009%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.501483679525222%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Base Salary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The Executive shall receive a base salary at the annualized rate of</font></div></div>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.907%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">$435,000 (the &#x201c;Base Salary&#x201d;). The Executive&#x2019;s Base Salary shall be paid in equal installments in accordance with the Company&#x2019;s regularly established payroll procedures. The Executive&#x2019;s Base Salary shall be subject to increase, but not decrease, and will be reviewed on an annual or more frequent basis by the Board or a committee thereof and is subject to change in the discretion of the Board or a committee thereof.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.266%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.028%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Annual Discretionary Bonus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Following the end of each calendar year beginning with the 2021 calendar year, the Executive will be eligible to receive an annual performance bonus targeted at 40% of the Executive&#x2019;s Base Salary (the &#x201c;Target Bonus&#x201d;), based upon periodic assessments of the Executive&#x2019;s performance as well as the achievement of specific individual and corporate objectives determined by the Board or a committee thereof. No amount of annual bonus is guaranteed, and the Executive must be an employee in good standing on the payment date in order to be eligible for any annual bonus for such year, except as specifically set forth in Section 8 below, as it also serves as an incentive to remain employed by the Company. The</font></div></div>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Executive&#x2019;s bonus eligibility will be reviewed on an annual or more frequent basis by the Board or a committee thereof and is subject to increase, but not decrease, in the discretion of the Board or a committee thereof. Any bonus for the 2021 calendar year will be prorated based on the</font></p>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Executive&#x2019;s start date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.271%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.093%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Equity Awards</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Subject to the approval of the Board or a committee thereof, the Company shall grant the Executive an option to purchase 135,000 shares of common stock of the Company, at a per share price equal to the fair market value on the date of the grant of the option (the &#x201c;New Hire Option&#x201d;). The New Hire Option shall (i) be subject to the terms and conditions of the Company&#x2019;s 2021 Stock Incentive Plan (as amended from time to time, the &#x201c;Plan&#x201d;) and a standard form of stock option agreement to be entered into by the Executive and the Company following the grant and (ii) shall vest over a period of four years following the date of grant, with 25% of the New Hire Option vesting on the first anniversary of the date of grant of the New Hire Option and the remaining 75% of the New Hire Option vesting in 36 approximately equal</font></div></div>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.444%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">monthly installments thereafter, subject to the Executive&#x2019;s continued employment with the Company on the applicable vesting date. In addition, subject to the approval of the Board or a committee thereof, the Company shall grant the Executive an award of 7,500 restricted stock units (the &#x201c;New Hire RSUs&#x201d;). The New Hire RSUs shall (i) be subject to the terms and conditions of the Plan and a standard form of RSU award agreement to be entered into by the Executive and the Company following the grant and (ii) shall vest in substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Executive&#x2019;s continued employment with the Company on the applicable vesting date. Further, the Executive will be eligible to receive additional equity awards, if any, at such times and on such terms and conditions as the Board or a committee thereof shall, in its sole discretion, determine.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.302%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.481%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Vacation, Sick Leave and Holidays</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The Executive will be eligible for a maximum of twenty (20) vacation days plus one additional day per year of employment following completion of the Executive&#x2019;s first calendar year of employment, up to a maximum of thirty (30) vacation days per year. Vacation days shall accrue on a monthly pro rata basis for each month that the Executive is employed during the calendar year, subject to any requirements of the Company&#x2019;s policies. In addition, the Executive will be allowed up to seven (7) paid sick leave </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.481%;min-width:6.657%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">days and at</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:3.95pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.769%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">least ten (10) paid holidays per year. Paid holidays will be determined annually according to the Company calendar. Any unused sick leave pay will be forfeited at the end of each calendar year and upon the termination of the Executive&#x2019;s employment.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.292%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.352%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Subject to eligibility requirements and the Company&#x2019;s polices, the Executive shall have the right, on the same basis as other similarly-situated employees of the Company, to participate in, and to receive benefits under, all employee health, disability, insurance, fringe, welfare benefit and retirement plans, arrangements, practices and programs the Company provides to its senior executives in accordance with the terms thereof as in effect from time to time. The Company reserves the right to modify, amend and/or terminate any and all of its benefits plans at is discretion.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:8.045%;font-size:0;margin-top:0.05pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:9.889%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Withholdings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. All compensation payable to the Executive shall be subject to applicable taxes and withholdings.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.528%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The Executive will be reimbursed for the Executive&#x2019;s actual, necessary and reasonable business expenses pursuant to Company policy, subject to the provisions of Section 3 of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> attached hereto.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:7.074%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Continuing Obligations Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. As a condition of the Executive&#x2019;s employment, the Executive agrees to execute the At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit B </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(the &#x201c;Continuing Obligations Agreement&#x201d;).</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:8.111%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Employment Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. This Agreement and the employment of the Executive shall terminate upon the occurrence of any of the following:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.281%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.213%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Upon the death or &#x201c;Disability&#x201d; of the Executive. As used in this Agreement, the term &#x201c;Disability&#x201d; shall mean a physical or mental illness or disability that prevents the Executive from performing the duties of the Executive&#x2019;s position for a period of more than any five (5) consecutive months or for periods aggregating more than thirty-two (32) weeks in any twelve</font></div></div>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.907%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(12) month period. If any question shall arise as to whether the Executive has a Disability, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the</font></p>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.343%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Executive&#x2019;s guardian has no reasonable objection as to whether the Executive has a Disability, and such certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company&#x2019;s determination of such issue shall be binding on the Executive. Nothing in this Section shall be construed to waive the Executive&#x2019;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. &#167;2601 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">et seq. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">et seq</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.393%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:2.602%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">At the election of the Company, with or without &#x201c;Cause&#x201d; (as defined below), immediately upon written notice by the Company to the Executive. As used in this Agreement, &#x201c;Cause&#x201d; shall mean the Executive&#x2019;s:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:14.074%;display:flex;margin-top:3.95pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.833%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.759001931894886%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">continued willful failure, as determined in the reasonable good faith discretion of the Board, to perform the Executive&#x2019;s assigned duties or responsibilities as directed or assigned by the Board or the Chief Executive Officer of the Company (other than due to death or Disability) after written notice thereof from the Board describing in reasonable detail the failure to perform and providing the Executive a reasonable opportunity to address such alleged failure;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:14.074%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:6.074%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.759001931894886%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">engaging in knowing and intentional illegal conduct that was or is materially injurious to the Company or its affiliates;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:14.074%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.824%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.759001931894886%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">willful violation of a federal or state law or regulation directly or indirectly applicable to the business of the Company or its affiliates, which violation was or is reasonably likely to be injurious to the Company or its affiliates;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:14.074%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:3.139%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.759001931894886%;">(iv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">material breach of the terms of any confidentiality agreement or invention assignment agreement between the Executive and the Company (or any affiliate of the Company), including the Continuing Obligations Agreement; or</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:14.074%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:2.704%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.759001931894886%;">(v)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">being convicted of, or entering a plea of guilty or nolo contendere to, a felony or committing any act of moral turpitude, dishonesty or fraud against the Company or its affiliates.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:10.074%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">No finding of Cause shall be effective unless and until the Board votes to terminate the Executive&#x2019;s employment for Cause at a Board meeting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.287%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.287%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">At the election of the Executive, with or without &#x201c;Good Reason&#x201d; (as defined below), upon written notice by the Executive to the Company (subject, if it is with Good Reason, to the timing provisions set forth in the definition of Good Reason). As used in this Agreement, &#x201c;Good Reason&#x201d; shall mean (without the Executive&#x2019;s consent):</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:14.065%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.676%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.768662361086868%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a material diminution of the Executive&#x2019;s base compensation;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:14.065%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.676%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.768662361086868%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a material diminution in the Executive&#x2019;s duties, authority or responsibilities;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:14.074%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.796%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.759001931894886%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the Company&#x2019;s requiring the Executive to relocate the Executive&#x2019;s primary office more than thirty (30) miles from the Executive&#x2019;s then-current primary office; or</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:14.074%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:2.759%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.759001931894886%;">(iv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">any material breach by the Company or any successor thereof of this Agreement (to the extent not otherwise covered by this paragraph) or any other written agreement between the Company and the Executive;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.009%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">provided, however, that in each case, the Company shall have a period of not less than thirty (30) days to cure any act constituting Good Reason following the Executive&#x2019;s delivery to the Company of written notice within ninety (90) days of the action or omission constituting Good Reason and the Executive shall actually terminate the Executive&#x2019;s employment within thirty (30) days following the expiration of the Company&#x2019;s cure period if the Company has not cured.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.398%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.231%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4092352217014747%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Effect of Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.273%;font-size:0;margin-top:3.95pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.111%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">All Terminations Other Than by the Company Without Cause or by the Executive With Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. If the Executive&#x2019;s employment is terminated under any circumstances other than a termination by the Company without Cause or a termination by the Executive with Good Reason (including a voluntary termination by the Executive without Good Reason or a termination by the Company for Cause or due to the Executive&#x2019;s death or Disability), the Company&#x2019;s obligations under this Agreement shall immediately cease and the Executive shall only be entitled to receive (i) the Base Salary that has accrued and to which the Executive is entitled as of the effective date of such termination and to the extent consistent with general Company policy, to be paid in accordance with the Company&#x2019;s established payroll procedure and applicable law but no later than the next regularly scheduled pay period, (ii) unreimbursed business expenses for which expenses the Executive has timely submitted appropriate documentation in accordance with Section 5 hereof, and (iii) any amounts or benefits to which the Executive is then entitled under the terms of the benefit plans then-sponsored by the Company in accordance with their terms (and not accelerated to the extent acceleration does not satisfy Section 409A of the Internal Revenue Code of 1986, as amended, (the &#x201c;Code&#x201d;)) (the payments described in this sentence, the &#x201c;Accrued Obligations&#x201d;).</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.271%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.083%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Termination by the Company Without Cause or by the Executive With Good Reason More Than Three Months Prior to or More Than Twelve Months Following a Change in Control. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If the Executive&#x2019;s employment is terminated by the Company without Cause or by the Executive with Good Reason more than three (3) months prior to, or more than twelve (12) months following, a Change in Control (as defined below), the Executive shall be entitled to the Accrued Obligations. In addition, and subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and the conditions of Section 8(d), the Company shall: (i) continue to pay to the Executive, in accordance with the Company&#x2019;s regularly established payroll procedures, the Executive&#x2019;s Base Salary for a period of twelve (12) months, (ii) pay to the Executive, in a single lump sum on the Payment Date (as defined below) an amount equal to sixty-seven percent (67%) of the Executive&#x2019;s Target Bonus for the year in which termination occurs, and (iii) provided the Executive is eligible for and timely elects to continue receiving group medical insurance pursuant to the &#x201c;COBRA&#x201d; law, continue to pay for twelve (12) months following the Executive&#x2019;s termination date or until the Executive has secured other employment or is no longer eligible for coverage under COBRA, whichever occurs first, the share of the premium for health coverage that is paid by the Company for active and similarly-situated employees who receive the same type of coverage, unless the Company&#x2019;s provision of such COBRA payments will violate the nondiscrimination requirements of applicable law, in which case this benefit will not apply (collectively, the &#x201c;Severance Benefits&#x201d;).</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.446%;font-size:0;margin-top:0.05pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:3.241%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Termination by the Company Without Cause or by the Executive With Good Reason Within Three Months Prior to or Twelve Months Following a Change in Control. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If the</font></div></div>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.75%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Executive&#x2019;s employment is terminated by the Company without Cause or by the Executive with Good Reason within the period that begins three (3) months prior to and ends twelve (12) months following a Change in Control, then the Executive shall be entitled to the Accrued Obligations.</font></p>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:3.046%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In addition, and subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and the conditions of Section 8(d), the Company shall: (i) pay to the Executive, in a single lump-sum payment on the Payment Date, an amount equal to the sum of (x) twelve (12) months of the Executive&#x2019;s Base Salary, and (y) one hundred percent (100%) of the Executive&#x2019;s Target Bonus for the year in which termination occurs or, if higher,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:3.046%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the Executive&#x2019;s Target Bonus immediately prior to the Change in Control, (ii) provided the</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:3.95pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.111%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Executive is eligible for and timely elects to continue receiving group medical insurance pursuant to the &#x201c;COBRA&#x201d; law, continue to pay for twelve (12) months following the Executive&#x2019;s termination date or until the Executive has secured other employment or is no longer eligible for coverage under COBRA, whichever occurs first, the share of the premium for health coverage that is paid by the Company for active and similarly-situated employees who receive the same</font></p>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.37%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">type of coverage, unless the Company&#x2019;s provision of such COBRA payments will violate the nondiscrimination requirements of applicable law, in which case this benefit will not apply, and</font></p>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.491%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii) provide that the vesting of the Executive&#x2019;s then-unvested equity awards shall be accelerated, such that all such then-unvested equity awards immediately vest and become fully exercisable or non-forfeitable as of the later of the date of the Change in Control and the Executive&#x2019;s termination date (collectively, the &#x201c;Change in Control Severance Benefits&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.258%;font-size:0;margin-top:0.05pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:0.926%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. As a condition of the Executive&#x2019;s receipt of the Severance Benefits or the Change in Control Severance Benefits, as applicable, the Executive must execute and deliver to the Company a severance and release of claims agreement in a reasonable form to be provided by the Company (which shall include a release of all releasable claims, reaffirmation of continuing obligations, and confidentiality, cooperation, and non-disparagement obligations, but shall not expand the Executive&#x2019;s then-existing restrictive covenants or impose restrictive covenant obligations on the Executive that do not then exist) (the &#x201c;Severance Agreement&#x201d;), which Severance Agreement must become irrevocable within sixty (60) days following the date of the Executive&#x2019;s termination of employment (or such shorter period as may be directed by the Company). The Severance Benefits or the Change in Control Severance Benefits, as applicable, will be paid or commence to be paid in the first regular payroll beginning after the Severance Agreement becomes effective, provided that if the foregoing sixty (60) day period would end in a calendar year subsequent to the year in which the Executive&#x2019;s employment ends, the Severance Benefits or Change in Control Severance Benefits, as applicable, will not be paid or begin to be paid before the first payroll of the subsequent calendar year (the date the Severance Benefits or Change in Control Severance Benefits, as applicable, commence pursuant to this sentence, the &#x201c;Payment Date&#x201d;). The Executive must continue to comply with the Continuing Obligations Agreement and any similar agreement with the Company in order to be eligible to receive or continue receiving the Severance Benefits or Change in Control Severance Benefits, as applicable. For the avoidance of doubt, if the Executive&#x2019;s employment is terminated by the Company without Cause or by the Executive with Good Reason prior to a Change in Control, (i) any then-outstanding and unvested equity awards held by the Executive shall remain outstanding (but any vesting shall be suspended) for up to (but no longer than) three (3) months following the date of termination so that, if it is later determined that such termination occurred during the three-month period prior to the closing of a Change in Control and the Executive is entitled to Change in Control acceleration and/or Change in Control Severance Benefits rather than Severance Benefits, the vesting of such awards may be accelerated, in accordance with Section 8(c) immediately prior to the closing of the Change in Control and (ii) any Change in Control Severance Benefits shall be reduced by any Severance Benefits previously paid to the Executive, if it is later determined that the termination occurred during the three-month period prior to the closing of a Change in Control and that the Executive is entitled to Change in Control Severance Benefits rather than Severance Benefits.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.276%;font-size:0;margin-top:3.95pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.148%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Change in Control Definition</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. For purposes of this Agreement, &#x201c;Change in Control&#x201d; shall mean the occurrence of any of the following events, provided that such event or occurrence constitutes a change in the ownership or effective control of the Company, or a change in the ownership of a substantial portion of the assets of the Company, as defined in Treasury Regulation &#167;&#167; 1.409A-3(i)(5)(v), (vi) and (vii): (i) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934 (the &#x201c;Exchange Act&#x201d;)) (a &#x201c;Person&#x201d;) of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 under the Exchange Act) fifty percent (50%) or more of either (x) the then-outstanding shares of common stock of the Company (the &#x201c;Outstanding Company Common Stock&#x201d;) or (y) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors (the &#x201c;Outstanding Company Voting Securities&#x201d;); provided, however, that for purposes of this subsection (i), the following acquisitions shall not constitute a Change in Control: (1) any acquisition directly from the Company or (2) any acquisition by any entity pursuant to a Business Combination (as defined below) which complies with clauses (x) and (y) of subsection (iii) of this definition; or (ii) a change in the composition of the Board that results in the Continuing Directors (as defined below) no longer constituting a majority of the Board (or, if applicable, the Board of Directors of a successor corporation to the Company), where the term &#x201c;Continuing Director&#x201d; means at any date a member of the Board (x) who was a member of the Board on the Effective Date or (y) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (y) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or (iii) the consummation of a merger, consolidation, reorganization, recapitalization or share exchange involving the Company, or a sale or other disposition of all or substantially all of the assets of the Company (a &#x201c;Business Combination&#x201d;), unless, immediately following such Business Combination, each of the following two (2) conditions is satisfied: (x) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than fifty percent (50%) of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company&#x2019;s assets either directly or through one (1) or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the &#x201c;Acquiring Corporation&#x201d;) in substantially the same proportions as their ownership of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively, immediately prior to such Business Combination and</font></div></div>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.15pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.25%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(y) no Person (excluding any employee benefit plan (or related trust) maintained or sponsored by the Company or by the Acquiring Corporation) beneficially owns, directly or indirectly, fifty percent (50%) or more of the then-outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:3.95pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.87%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">corporation entitled to vote generally in the election of directors (except to the extent that such ownership existed prior to the Business Combination); or (iv) the liquidation or dissolution of the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:4.787%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Modified Section 280G Cutback</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Notwithstanding any other provision of this Agreement, except as set forth in Section 9(b), in the event that the Company undergoes a &#x201c;Change in Ownership or Control&#x201d; (as defined below), the following provisions shall apply:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.274%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.12%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Company shall not be obligated to provide to the Executive any portion of any &#x201c;Contingent Compensation Payments&#x201d; (as defined below) that the Executive would otherwise be entitled to receive to the extent necessary to eliminate any &#x201c;excess parachute payments&#x201d; (as defined in Section 280G(b)(1) of the Code) for the Executive. For purposes of this Section 9, the Contingent Compensation Payments so eliminated shall be referred to as the &#x201c;Eliminated Payments&#x201d; and the aggregate amount (determined in accordance with Treasury Regulation Section 1.280G-1, Q/A-30 or any successor provision) of the Contingent Compensation Payments so eliminated shall be referred to as the &#x201c;Eliminated Amount.&#x201d;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.393%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:2.593%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notwithstanding the provisions of Section 9(a), no such reduction in Contingent Compensation Payments shall be made if (1) the Eliminated Amount (computed without regard to this sentence) exceeds (2) one hundred percent (100%) of the aggregate present value (determined in accordance with Treasury Regulation Section 1.280G-1, Q/A-31 and Q/A-32 or any successor provisions) of the amount of any additional taxes that would be incurred by the Executive if the Eliminated Payments (determined without regard to this sentence) were paid to the Executive (including state and federal income taxes on the Eliminated Payments, the excise tax imposed by Section 4999 of the Code payable with respect to all of the Contingent Compensation Payments in excess of the Executive&#x2019;s &#x201c;base amount&#x201d; (as defined in Section 280G(b)(3) of the Code), and any withholding taxes). The override of such reduction in Contingent Compensation Payments pursuant to this Section 9(b) shall be referred to as a</font></div></div>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.083%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;Section 9(b) Override.&#x201d; For purpose of this paragraph, if any federal or state income taxes would be attributable to the receipt of any Eliminated Payment, the amount of such taxes shall be computed by multiplying the amount of the Eliminated Payment by the maximum combined federal and state income tax rate provided by law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.331%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.833%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For purposes of this Section 9 the following terms shall have the following respective meanings:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:14.744%;font-size:0;margin-top:4.5pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:2.25%;min-width:13.324%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:14.389856684630589%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;Change in Ownership or Control&#x201d; shall mean a change in the ownership or effective control of the Company or in the ownership of a substantial portion of the assets of the Company determined in accordance with Section 280G(b)(2) of the Code.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:14.771%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:2.417%;min-width:13.324%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:14.389856684630589%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;Contingent Compensation Payment&#x201d; shall mean any payment (or benefit) in the nature of compensation that is made or made available (under this Agreement or otherwise) to or for the benefit of a &#x201c;disqualified individual&#x201d; (as defined in Section 280G(c) of the Code)</font></div></div>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.25%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">and that is contingent (within the meaning of Section 280G(b)(2)(A)(i) of the Code) on a Change in Ownership or Control of the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.296%;font-size:0;margin-top:3.95pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.398%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Any payments or other benefits otherwise due to the Executive following a Change in Ownership or Control that could reasonably be characterized (as determined by the Company) as Contingent Compensation Payments (the &#x201c;Potential Payments&#x201d;) shall not be made until the dates provided for in this Section 9(d). Within thirty (30) days after each date on which the Executive first become entitled to receive (whether or not then due) a Contingent Compensation Payment relating to such Change in Ownership or Control, the Company shall determine and notify the Executive (with reasonable detail regarding the basis for its determinations) (1) which Potential Payments constitute Contingent Compensation Payments, (2) the Eliminated Amount and (3) whether the Section 9(b) Override is applicable. Within thirty (30) days after delivery of such notice to the Executive, the Executive shall deliver a response to the Company (the &#x201c;Executive Response&#x201d;) stating either (A) that the Executive agrees with the Company&#x2019;s determination pursuant to the preceding sentence or (B) that the Executive disagrees with such determination, in which case the Executive shall set forth (x) which Potential Payments should be characterized as Contingent Compensation Payments, (y) the Eliminated Amount, and (z) whether the Section 9(b) Override is applicable. In the event that the Executive fails to deliver an Executive Response on or before the required date, the Company&#x2019;s initial determination shall be final. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;">If and to the extent that any Contingent Compensation Payments are required to be treated as Eliminated Payments pursuant to this Section 9, then the payments shall be reduced or eliminated, as determined by the Company, in the following order: (i) any cash payments, (ii) any taxable benefits,</font></div></div>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.907%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;">(iii) any nontaxable benefits, and (iv) any vesting of equity awards in each case in reverse order beginning with payments or benefits that are to be paid the farthest in time from the date that triggers the applicability of the excise tax, to the extent necessary to maximize the Eliminated Payments. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If</font></p>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.444%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the Executive states in the Executive Response that the Executive agrees with the Company&#x2019;s determination, the Company shall make the Potential Payments to the Executive within three (3) business days following delivery to the Company of the Executive Response (except for any Potential Payments which are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due). If the Executive states in the Executive Response that the Executive disagrees with the Company&#x2019;s determination, then, for a period of sixty (60) days following delivery of the Executive Response, the Executive and the Company shall use good faith efforts to resolve such dispute. If such dispute is not resolved within such 60-day period, such dispute shall be settled exclusively by arbitration in Boston, Massachusetts, in accordance with the rules of the American Arbitration Association then in effect. Judgment may be entered on the arbitrator&#x2019;s award in any court having jurisdiction. The Company shall, within three (3) business days following delivery to the Company of the Executive Response, make to the Executive those Potential Payments as to which there is no dispute between the Company and the Executive regarding whether they should be made (except for any such Potential Payments which are not due to be made until after such date, which Potential Payments</font></p>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.907%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">shall be made on the date on which they are due). The balance of the Potential Payments shall be made within three (3) business days following the resolution of such dispute. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;">Subject to the limitations contained in Sections 9(a) and 9(b) hereof, the amount of any payments to be made to the Executive following the resolution of such dispute shall be increased by the amount of the accrued interest thereon computed at the prime rate announced from time to time by The Wall Street Journal, compounded monthly from the date that such payments originally were due.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.413%;text-indent:7.319%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.685%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The provisions of this Section 9 are intended to apply to any and all payments or benefits available to the Executive under this Agreement or any other agreement or plan under which the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.685%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Executive may receive Contingent Compensation Payments.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:3.95pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:4.778%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Absence of Restrictions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The Executive represents and warrants to the Company that the Executive is under no obligations or commitments, whether contractual or otherwise, that are inconsistent with the Executive&#x2019;s obligations under this Agreement. In connection with the</font></div></div>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.843%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Executive&#x2019;s employment hereunder, the Executive shall not use or disclose any trade secrets or other proprietary information or intellectual property in which the Executive or any other person or entity has any right, title or interest, and the Executive represents that the Executive&#x2019;s employment with the Company will not infringe or violate the rights of any other person or entity. The Executive represents and warrants to the Company that the Executive has returned all property and confidential information belonging to any prior employer.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.991%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Any notice delivered under this Agreement shall be deemed duly delivered three (3) business days after it is sent by registered or certified mail, return receipt requested, postage prepaid, one (1) business day after it is sent for next-business day delivery via a reputable nationwide overnight courier service, or immediately upon hand delivery, in each case to the address of the recipient set forth below.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:14.08%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To Executive:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:14.08%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.1466666666666665;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:30.944%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">At the address set forth in the Executive&#x2019;s personnel file To Company:</font></p>
  <p style="margin-left:14.08%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Verve Therapeutics, Inc.</font></p>
  <p style="margin-left:14.08%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">500 Technology Square, Suite 901</font></p>
  <p style="margin-left:14.08%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Cambridge, MA 02139</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.944%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Either Party may change the address to which notices are to be delivered by giving notice of such change to the other Party in the manner set forth in this Section 11.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:5.491%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Employment Conditions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The Executive&#x2019;s employment with the Company is contingent upon (a) the Executive providing to the Company, within three business days following the</font></div></div>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.694%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Executive&#x2019;s start date, documentation proving the Executive&#x2019;s eligibility to work in the United States, as required by the Immigration Reform and Control Act of 1986, (b) the Executive&#x2019;s compliance with the Company&#x2019;s COVID-19 vaccination policy (which requires employees to be fully vaccinated against COVID-19 in the absence of the Company&#x2019;s approval of a medical or religious exemption), and (c) the Executive&#x2019;s satisfactory completion of background and reference checks.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.824%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">13.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Applicable Law; Arbitration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts (without reference to the conflict of laws provisions thereof). All disputes arising under or relating to any provision of this Agreement, the Executive&#x2019;s employment relationship with the Company, and/or the equity referenced in this Agreement, shall be subject to arbitration in accordance with Section 11 of the Continuing Obligations Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.444%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">14.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Successors and Assigns</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. This Agreement shall be binding upon and inure to the benefit of both Parties and their respective successors and assigns, including any corporation with which or</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:3.95pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:3.352%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">into which the Company may be merged or which may succeed to its assets or business; provided, however, that the obligations of the Executive are personal and shall not be assigned by the Executive.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.426%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">15.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">At-Will Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. During the Term of Employment, the Executive will be an at-will employee of the Company, which means that, notwithstanding any provision set forth herein, the employment relationship can be terminated by either Party for any reason, at any time, with or without prior notice and with or without Cause; provided, however, that the Executive is expected to give the Company at least thirty (30) days&#x2019; prior notice in the event of resignation.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:2.62%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">16.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Acknowledgment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The Executive states and represents that the Executive has had an opportunity to fully discuss and review the terms of this Agreement with an attorney. The Executive further states and represents that the Executive has carefully read this Agreement, understands the contents herein, freely and voluntarily assents to all of the terms and conditions hereof, and signs the Executive&#x2019;s name of the Executive&#x2019;s own free act.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.907%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">17.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">No Oral Modification, Waiver, Cancellation or Discharge</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Executive. No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.981%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">18.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Captions and Pronouns</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.148%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">19.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Interpretation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The Parties agree that this Agreement will be construed without regard to any presumption or rule requiring construction or interpretation against the drafting Party. References in this Agreement to &#x201c;include&#x201d; or &#x201c;including&#x201d; should be read as though they said &#x201c;without limitation&#x201d; or equivalent forms. References in this Agreement to the &#x201c;Board&#x201d; shall include any authorized committee thereof.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:0.05pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:2.222%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">20.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Severability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Each provision of this Agreement must be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. Moreover, if a court of competent jurisdiction determines any of the provisions contained in this Agreement to be unenforceable because the provision is excessively broad in scope, whether as to duration, activity, geographic application, subject or otherwise, it will be construed, by limiting or reducing it to the extent legally permitted, so as to be enforceable to the extent compatible with then applicable law to achieve the intent of the Parties.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;margin-top:3.95pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:2.13%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">21.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Entire Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. This Agreement constitutes the entire agreement between the Parties and supersedes all prior agreements and understandings, whether written or oral, relating to the subject matter of this Agreement, including, without limitation, any offer letter previously executed by the Parties and/or sent by the Company to the Executive.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:36.64%;text-indent:0.0%;font-size:10.0pt;margin-top:7.9pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[Signatures on Page Following]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:7.507%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the day and</font></p>
  <p style="margin-left:6.667%;text-indent:0.9%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">year set forth above.</font></p>
  <p style="margin-left:6.667%;text-indent:0.9%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.9%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.9%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.9%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.9%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.9%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">VERVE THERAPEUTICS, INC.</font></p>
  <p style="margin-left:6.667%;text-indent:0.9%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.9%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">	By</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">: /s/ Andrew Ashe	</font></p>
  <p style="margin-left:6.667%;text-indent:0.9%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.9%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">	Name:  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Andrew Ashe</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:6.667%;text-indent:0.9%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Title: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">President &amp; COO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">EXECUTIVE:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">/s/  Allison Dorval		</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Allison Dorval</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">17</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:33.92%;text-indent:0.0%;font-size:10.0pt;margin-top:3.95pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:27.426%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">EXHIBIT A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:33.893%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:27.435%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Payments Subject to Section 409A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.683%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:6.0%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Subject to this Exhibit A, any severance payments that may be due under the Agreement shall begin only upon the date of the Executive&#x2019;s &#x201c;separation from service&#x201d;</font></div></div>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.509%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(determined as set forth below) which occurs on or after the termination of the Executive&#x2019;s employment. The following rules shall apply with respect to distribution of the severance payments, if any, to be provided to the Executive under the Agreement, as applicable:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:14.074%;text-indent:8.166%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:4.287%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.759001931894886%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">It is intended that each installment of the severance payments provided under the Agreement shall be treated as a separate &#x201c;payment&#x201d; for purposes of Section 409A of the Internal Revenue Code (&#x201c;Section 409A&#x201d;). Neither the Company nor the Executive shall have the right to accelerate or defer the delivery of any such payments except to the extent specifically permitted or required by Section 409A.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:14.074%;text-indent:8.088%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:3.5%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.759001931894886%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If, as of the date of the Executive&#x2019;s &#x201c;separation from service&#x201d; from the Company, the Executive is not a &#x201c;specified employee&#x201d; (within the meaning of Section 409A), then each installment of the severance payments shall be made on the dates and terms set forth in the Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:14.074%;text-indent:8.232%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:4.944%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.759001931894886%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If, as of the date of the Executive&#x2019;s &#x201c;separation from service&#x201d; from the Company, the Executive is a &#x201c;specified employee&#x201d; (within the meaning of Section 409A), then:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:19.472%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.296%;min-width:5.444%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.760381482217366%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Each installment of the severance payments due under the Agreement that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the Executive&#x2019;s separation from service occurs, be paid within the short-term deferral period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A-1(b)(4) to the maximum extent permissible under Section 409A and shall be paid on the dates and terms set forth in the Agreement; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:18.843%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.25%;min-width:6.074%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.484258905578077%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Each installment of the severance payments due under the Agreement that is not described in this Exhibit A, Section 1(c)(i) and that would, absent this subsection, be paid within the six-month period following the Executive&#x2019;s &#x201c;separation from service&#x201d; from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, the Executive&#x2019;s death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following the</font></div></div>
  <p style="margin-left:24.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.5%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Executive&#x2019;s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">18</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:24.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.5%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">installment of payments if and to the maximum extent that that such</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">19</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:24.92%;text-indent:0.0%;font-size:10.0pt;margin-top:3.95pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.88%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation Section 1.409A-1(b)(9)(iii) must be paid no later than the last day of the Executive&#x2019;s second taxable year following the taxable year in which the separation from service occurs.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.3%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.454%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The determination of whether and when the Executive&#x2019;s separation from service from the Company has occurred shall be made and in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h). Solely for purposes of</font></div></div>
  <p style="margin-left:7.413%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.75%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 2 of this Exhibit A, &#x201c;Company&#x201d; shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the Code.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.325%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.759%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">All reimbursements and in-kind benefits provided under the Agreement shall be made or provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements that (i) any reimbursement is for expenses incurred during the Executive&#x2019;s lifetime (or during a shorter period of time specified in the Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.406%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:2.75%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Company makes no representation or warranty and shall have no liability to the Executive or to any other person if any of the provisions of the Agreement (including this Exhibit A) are determined to constitute deferred compensation subject to Section 409A but that do not satisfy an exemption from, or the conditions of, that section.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.407%;text-indent:7.304%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.5%;min-width:6.657%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.18952836607519%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Agreement is intended to comply with, or be exempt from, Section 409A and shall be interpreted accordingly.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.3pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:30.88%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[Remainder of page intentionally left blank.]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">20</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>verv-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 23.1</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:Arial;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-257175) pertaining to the 2018 Equity Incentive Plan, 2021 Stock Incentive Plan, and the Amended and Restated 2021 Employee Stock Purchase Plan of Verve Therapeutics, Inc.  of our report dated March 14, 2022, with respect to the consolidated financial statements of Verve Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2021.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Boston, Massachusetts</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 14, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>verv-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">I, Sekar Kathiresan, certify that:</font></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">I have reviewed this Annual Report on Form 10-K of Verve Therapeutics, Inc.;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.4%;"></td>
    <td style="width:1.998%;"></td>
    <td style="width:5.001%;"></td>
    <td style="width:47.601%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Date:  March 14, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ Sekar Kathiresan</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Sekar Kathiresan, M.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>verv-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">I, Allison Dorval, certify that:</font></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">I have reviewed this Annual Report on Form 10-K of Verve Therapeutics, Inc.;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.997%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:4.583%;"></td>
    <td style="width:46.416%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Date:  March 14, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ Allison Dorval</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Allison Dorval</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>verv-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In connection with the Annual Report on Form 10-K of Verve Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the fiscal year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Sekar Kathiresan, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.459%;"></td>
    <td style="width:4.0%;"></td>
    <td style="width:4.083%;"></td>
    <td style="width:46.459%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Date:  March 14, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ Sekar Kathiresan</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Sekar Kathiresan, M.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>12
<FILENAME>verv-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Exhibit 32.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In connection with the Annual Report on Form 10K of Verve Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the fiscal year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Allison Dorval, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.459%;"></td>
    <td style="width:4.0%;"></td>
    <td style="width:4.083%;"></td>
    <td style="width:46.459%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Date:  March 14, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ Allison Dorval</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Allison Dorval</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(Principal Financial Officer)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img242628118_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %* GD# 2(  A$! Q$!_\0
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M/-^)O]W4?^^%_P *]HHH]KY(/K?]Q?<>+^;\3?[NH_\ ?"_X4>;\3?[NH_\
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M/G1_^OY/Y&MNL3Q!_P ?.C_]?R?R-;=4]D7+X4%%%%20%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5B7'_ ".=E_UZ2?\ H0K;K$N/^1SLO^O23_T(4XEPW?HS;HHHI$!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B>(/^/G1_P#K
M^3^1K;K$\0?\?.C_ /7\G\C6W5/9%R^%!1114D!1110 4444 %%%% !1110
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M10 57:R@>_CO2#Y\:&-3GC!Y/%6*X?2=,@\26M[J6J7EPMVMQ)& DY06H4X
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M?^/?X4;?B%_?T;_Q[_"CD\T'L?[R^\[.BN,V_$+^_HW_ (]_A1M^(7]_1O\
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M HHHH **** "BBB@#$;_ )'A/^P<?_1@K;K$;_D>$_[!Q_\ 1@K;JGT+GT]
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MJT*)U5M4M\L 1ALCGW%:L4L<\2RQ2+)&PRK*<@BAIK<3C);H?1112)"BBB@
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M444 %%%% !1110 4444 %%%% 'G_ (\GOO[6MH[5/W:6SN[<=#P:KZL@\B(
M8W:9"?KC%:GC<>7=6C#K-&T/X9'^-1>-+86QLS%T:W:V ]@01_*M*<;.]]ST
M(S3C"-K';1-YD*.1RR@T^D50B*HZ 8I:S//"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBF32K!!),^=L:ECCT S0 ^BN=TV_P!:O8(-3D^Q)83#>8?F
MWI'V.[H3CM0WB^U2W>XEM+J.'R7FA=E_URKR=OOCGFJY6:>RE>R.BI  #D
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M6MNP$MM.A1%><'&80W3(SR<<X'2M\$$ CH:331,HN.XM%%%(D**** "BBB@
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A 8$$
M@\$&EJ*YF^S6DTY4L(D9]HZG SB@#)M_#%I;2KY=S>?9D8LEH9OW2D^V,XYZ
M9Q47_"(V!A>&2>[DB,30Q(\@(A5NH3C\.<U@W>MZG(BW4L\*I)ISW");2'Y?
MF&,^XSU^M:3>)[JTN;I;N!4CBC=X8]K%I0JYR&Z$^HZBM+2.IQJ[IFK?>';6
M^F:4SW4)DC$4RPR!1,@Z!N/<],=:4^';$K*H\Q5DN([@J&X#(  ![?**QX_$
M^H"T9Y8(PTBQF"01N%+.<;,=2>>#W]J:?%&I'3HY_LT:E)I8[B78S!-G0[1S
M@]SSC%%I$\E7:YH1>#]/B1D$MR4-O);JI8?*C]0./YYI;G0#=^(--NG1!;:?
M&=K;CND;& ".F!R?QJI'XGO+C4G2UM5EMXYDA8*K%F! RX/0#G./2I->U*\M
MM4E6U+?Z-ITER$'1V)VC([XP31[UPM4O9LVKG38+J]@NI"_F0HZ+@\888.:S
M?^$2T]6A:*2>-HXQ$64J2Z@Y ;*GU[8K*G M=!>_A\07$US+9N^UI5(D.W.5
M';'M4<FKZJ\NC+-;36J/;2L7,RMYI$.1P#Z\\T)/HQQA.VC-P>%K$7@N5DG&
M)FG$88;0Y7:>V>GO4R:!:Q)IBQ2SH=/&V(JXRRXP0W'(.*YO3I9K6V\/RQ:E
M<3S:@%2>"27?N!7)<=UV]:Z/PU=2W>AQ-.Y>2-Y(BYZML<J#^0I2NNI,U.*O
M?^M36HHHJ# **** "BBB@ HHHH JZEI\.J:?-97!<12@!BAP>"#_ $K/E\,6
M,]\UW</-,Q1D".1@!A@C@ _F:VJ*:;12G):)F/!X>AA^S^9>7EQ]GD$D7G2
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M'YT +12;E_O#\Z-R_P!X?G0 M%)N7^\/SHW+_>'YT +12;E_O#\Z-R_WA^=
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MTG_G^U3_ ,"C_A78T4<\NX>WJ_S''?\ "N-)_P"?[5/_  */^%'_  KC2?\
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&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img242628118_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "? 4\# 2(  A$! Q$!_\0
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M:VMF:WLE/3CAW^I/'T%=+5/30U;Y%RK?K_D%%9UWKVEV,ACGO8Q(.J+EV'U
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=HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img242628118_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $_ HL# 2(  A$! Q$!_\0
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MTB<26T\=NA@E2)=C;&Y)))Y(/-'+'N/V<+/4Z/2];L]5MXY(I%21P6\EF&\
M$CD?A5N"]M;EW2"XBD9/O!&!(KC=/\/Z@JZ=!)I<5NUK)))+<K(N95.[Y>.>
M<\YK1\-:9?Z?>NLEKY-FL6Q1*8V<'/0,O)7Z\T.*Z,4Z<%=IG44445!@%1EI
M/M 7">5MSUYS4E0%1]N#>3SLQYN>G/2@">BBB@ HHHH **** "BBB@ K"\3F
M5(+:0&7[.LA\X1W AR,<?,2._:MVN?\ $,J^;;E(V>6W?>$>W>2-\@CL.HH
MT=&'_$KB(25 <D"6;S6QGKNR<U?K+\/1K%I"!2?F=V(\LQA26)("GD =JU*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***;)(D4;22,%11DLQP * '455@U*RN5=H;J)PGWB&''UJUU&
M13::W$I)ZH**BDN8(@2\R*%(4Y/0GH*EI6"Z"BBB@84444 %%%% !1110 57
M.W[>/];N\O\ X!U_G5BH"X^VA/.YV9\K'7GKF@">BBB@ HHHH **** "BBB@
M KF?%*B*:TNEDN_,&Y0D=T84QC))/K735D:^V+:,>;<1@L0?)MQ*3QW!!Q0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#
M=?\ 'G/_ -<V_E570O\ D!V7_7(5:NO^/.?_ *YM_*JNA?\ (#LO^N0H ODX
M!/I6%>ZEJ$^GW26]E-;W'E,\<C$8'3'/J>>/:MZLS5=4L;22WL;M3(;QA&(P
MN1@G&3Z#)H PAJEW%$UD;BXCN6N(HI))V5_+1P3N!''.,<^M*=0U5(KAEN1+
M%9SF+S<A?,P0?F]>,CCOS6Z-.TBWMYK+R($C9?,DC/<#N?RIUN-*B$-G!]G
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MH"S&-%Q\J9.T<<9 Q6C0 4444 9&J?\ (:T7_KM)_P"BVK7K(U3_ )#6B_\
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MK[CDAJGC./[^@6DO^Y<@?SH/B+Q/'_K/"+G_ '+I3_2NMHHYEV#VD?Y5^/\
MF<E_PENJI_KO"FH#_<(:C_A.2G^M\.ZTG_;OG^M=;11==@YX?R_BSDQ\0--7
M_76.IP^N^V/%*/B+X=SAYYX_]Z!O\*ZK /4"D,<;=44_447CV#FI_P K^_\
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MAUK5DI_R-DO_ %YC_P!#H UJ*** "BBB@ HHHH **** "BBB@ HHHH ****
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M[/[U_F:RLK#*L"/8TM8+>$-+)RAN8S_LSM2?\(PR?ZC5[^(>@DS_ #HY:?\
M-^ <]5;P_'_@(WZ*Y\Z+K$?^IUZ4_P#76,-1]E\3Q#Y=1LYO9H=M'LX])+\?
M\@]M);P?X?YG045S_G>*(AS:6$WTD(-']K:Y'_K="+_]<I1_6CV+Z-?>@^L1
MZI_<SH**Y_\ X22=/]?HE]'] &_E2CQ=8?\ +2"\B_WX#1["IV#ZS2ZNWX&_
M16,OBO16.&O5C/HX(JU%KFES?<OX#_P/%2Z4UNF4JU-[27WE^BH5N[9_N7$3
M?1P:E!!&00?I4V:-$T]A:***0PHHHH **** "BBB@ J N/MP3SN=F?*QUYZU
M/4)+_:Q\T>S9T_BS_A0!-1110 4444 %%%% !1110 5S7BB\M2;>QD>V5V?<
MS3!OW8P<$;?7I72US.N-=/JT0M9+C,2C='"$.[.><-0!JZ'Y8TB$1/ Z#(!@
M4A>OOS6C6?HL<D6F()5G$A9F83XW9+$]N,5H4 %%%% &1JG_ "&M%_Z[2?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV84_-Z>]) =UO&?,\S*CY\?>]Z )**** "BBB@ HHHH **** "BBB@ HHHH
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MUIO]V;_O\W^-(WAC3'4JR2E3P09FY_6@#1LO^/"W_P"N2_RJ>FHBQQJBC"J
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M1^5 &7_PDNC?\_\ '^1_PH_X271O^?\ C_(_X5J;%_NC\J-B_P!T?E0!E_\
M"2Z-_P _\?Y'_"C_ (271O\ G_C_ "/^%:FQ?[H_*C8O]T?E0!DR>)='\ML7
M\(.#C<#C\>*2'Q+I A3=J$);')0''X<5HW</G6<\:*NYXV4?4BF6%N;?3[>&
M15WI&JMCU H J?\ "2Z-_P _\?Y'_"C_ (271O\ G_C_ "/^%:FQ?[H_*C8O
M]T?E0!E_\)+HW_/_ !_D?\*/^$ET;_G_ (_R/^%:FQ?[H_*C8O\ ='Y4 9?_
M  DNC?\ /_'^1_PH_P"$ET;_ )_X_P C_A6IL7^Z/RHV+_='Y4 9?_"2Z-_S
M_P ?Y'_"D_X2?122!J$61U'/'Z5J[%_NC\JH6MF\6JZA<.J^7/Y>S_@*X- $
M7_"2Z-_S_P ?Y'_"C_A)=&_Y_P"/\C_A6IL7^Z/RHV+_ '1^5 &7_P )+HW_
M #_Q_D?\*/\ A)=&_P"?^/\ (_X5J;%_NC\J-B_W1^5 &7_PDNC?\_\ '^1_
MPH_X271O^?\ C_(_X5J;%_NC\J-B_P!T?E0!E_\ "2Z-_P _\?Y'_"D/B?11
MC.H1#/ SGG]*U=B_W1^59^I63W4ED8E7$-PLCYXX% $?_"2Z-_S_ ,?Y'_"C
M_A)=&_Y_X_R/^%:FQ?[H_*C8O]T?E0!E_P#"2Z-_S_Q_D?\ "C_A)=&_Y_X_
MR/\ A6IL7^Z/RHV+_='Y4 9?_"2Z-_S_ ,?Y'_"C_A)=&_Y_X_R/^%:FQ?[H
M_*C8O]T?E0!E_P#"2Z-_S_Q_D?\ "C_A)=&_Y_X_R/\ A6IL7^Z/RI&12I&T
M=/2@#+'B?16 *ZA$0>A&?\*7_A)=&_Y_X_R/^%3:-9O9:/:VTZKYL:!6QR,U
M>V+_ '1^5 &7_P )+HW_ #_Q_D?\*/\ A)=&_P"?^/\ (_X5J;%_NC\J-B_W
M1^5 &7_PDNC?\_\ '^1_PH_X271O^?\ C_(_X5J;%_NC\J-B_P!T?E0!E_\
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M_P"/\C_A6IL7^Z/RHV+_ '1^5 &7_P )+HW_ #_Q_D?\*/\ A)=&_P"?^/\
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ML1GF@#3L+Q;^S2X5&0-GY6[8_G5FJNG69L;)(#)YA!)SC &>P'85:H ****
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M'O@8JQ-)>SZO ER]UYT>H(?)6(^4(QT8-C^M '8T444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2%[4,@0%@ I7M@8^O>NBLHG@LH8I&W.B ,?>@">BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img242628118_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %# C@# 2(  A$! Q$!_\0
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M !1161<ZI-#XJT_2U5##<6TTK,>H*% ,?]]&@#7HHHH **** "BBB@ HHHH
M**** "BBB@"C/>V$.HK#+(@O/)9E7&6V=\?E^E9!U#PRR-<F.+;&=A?R3\IZ
M8Z4MQX?OYM9.IK?1*ZW"/''Y>?W:C!7=U&0S=N]6FT:9M(O+/S4WSW#RJW.
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MPB+RSGT KS'4OBMJMQ(PT^WAMHNQ<;V_PKF?$>N7'B/6Y;MRQ0ML@C'\*YX
M'J:UHOAMXAEL/M1C@C^7=Y3R8?'\A^==4:<8KWCU:>'I4HIU=V26_P 3O$<,
M@:22WG7NKQX_E7?>%_B!8>()%M)T^R7IZ(QRK_[I_I7E_A_P=JGB2"::R\E8
MX7V,96(RWH,"L[5-)U#0-0^S7D303KAD8'@^A4TY0A+1;FDZ%"HW!:,^D:*Y
MGP-X@;Q!X>26=LW4!\J8^I'0_B*Z:N5JSLSR)P<).+Z!1112)"BBB@ HHHH
M**** "BBB@#@E#P"YALY?-D,4C&[C1DFBP0<2 \$GL?:M"#4]3>\D59U8(&V
M(W_+2,)D.!CDD^^*EUWQYHFAR- \IN;D<&* 9Q]3T%<R?B]%YG&COL]?.&?Y
M5LHRET.V-.I-74#>EN-4%O"9[V=%W6LKR; -NX_..G2NPKE-#^(.B:U*L'F-
M:W#<".? #'V/2NKK.5UHT<]523M)6"BBBI,@ILB>9$Z9QN4C-.JO?2R0V$\D
M31K(J$J9#\H/O0-;G-1^&9+.VD:7RG5+=XPEO&=\A)R,Y/8TZ'1]20V;%87N
M7MY?M4DHXWN5].^!C\*=;^(Y%@C::5 "LH+R 89U ( (.#^%*NKZD]DUR\B1
M)OBC9O*SY895+.?S(]JT]XZ?WG4='X8F22 /<)+'"?E+Y^8>48]I7IWSGK2G
MP]>FT$:SQB17)B;>Q,(*@<'J>F<&J;>(M0+B-)(BH+^7,0%64AL <GT]/6K\
MVL7MG#/?W 4VL4YC>)4Y5<<$'N=V!^-'O"?M#H(U*QJK-N8  G&,FG5!9-.U
ME"UUM\]E!<*. :GK,YV%%%% AC11NZ.R*60Y5B.5[<4PVEN49#!&59_,(VCE
MLYS]<U-10%S.>YTRSU.&U(C2\E1WC54Y(SEN0.Y_.LQ=2\/1N]TMBRO:G:T@
ML7!CQVSMXIU[X=N[O4Y=06_\N42QM"@0%55.Q/7G+=/6K9T>0V6J0>:N;QW9
M3C[N1BKT-ER);A'J.D32P6NU5DO TZ1R0E2^.K$$=?K56*[\-PM++%;PH%.\
MRBV(#$'J#C#8/I4%UX6NKF=[C[?LD'EB)0@P%08Y/7G)Z5++H6H3:/+I,EU;
MFT\ORXRL9#D9XR<^GI1IW':'<U;<:=>RSS0PQ2,&,4DGE_>[$9QR.U6EMX49
M66) R+L4@<A?0>U5=*L9--M3:&0/!&Q\CCY@GH?4CUJ]4LREOH%%%%(D****
M "BBB@ HHHH **** "BBB@ HHHH **** .,O)=+N_%L-K:QQPW<%P)9[ID(9
MFQQ&I[Y[]@*I6D+$626,4B:XK3?:W*$-R&^\W0Y.W'X5WWEINW;%SZXI< $G
M R: .-T".W_M+2_[/A>.:.V8:B3&5RV!PQ/5M_/YTGB;4FTKQMHURMI-='[+
M.GEQ=>63G\,?K79@ 9P!SUKD=>_Y'S1?^O*Y_P#0HZ3=E<NG;F5T7/\ A*W_
M +3GM!H]Z4C5F6; VN0,@#Z]*I_V_P")+[3FEM-)@LY_,^5+N7.4QUX[UI<T
MM9>V?1'2HP70HMJ?B?[59[;?3C!M7[3\S9#?Q;?Z40>*;RQ>\;Q!9I:VD)!B
MN8265@3@ CKFKU-=%D0HZAE(P589!H59]4'+!Z-#KKQAH5I]E\S4$;[4 8=@
M+;AG&>*KGQ<LE[>6EKI5]+);JQ#LFQ)&'8$^OK2Q6=K B)%;1(J#" (/E'M4
M^:IUET0E3IKH94FI>*-3TY?(AM])N#(=WF8E.S'&.V:D%IJ_]JQ7AUR;8J@2
M6^P;&(&"0.V3S6C2U#K2>Q6BV2,A#XKM;.[_ .)I;7<YP;</ $"\\@XZY'%7
M;;QA:PRV=EK -GJ,Z F/:63<>P:K5(R(Q!9%8CD$C.*I5GU0FHRW7W:%%O%E
MSJ"WT.CZ;,9X.$DNU*1NV<''>L+Q/9ZM>>&)+K4M2D6>W@9GAM3MB<]L^N*Z
MVH+VU6]L+BT?[LT90_B*:K.ZL5#E@TTCQGPD\$?BW2VN<>7YZ]>@/;]:^A)8
MUEA>-QE'4JP!Z@U\TW=K-87LMM,"DT+E3]1WKU+P=\1H9XHM.UJ013J J7)^
MZ_IN]#[UVUHN7O(WQM&4[3CK8O?#JR>U?6BT4UN@NVC2W9LH@'ISR?4UE?%Y
MX/*TM./M&YS[[<?XUT^L^)]'\)6 CWB6=LND$9RSD\[B>V?6O%M;UJ[U[4Y+
M^\8;VX51T1>P%*G%RES$8>G*I5]J]$=Y\(9'^T:G%SY>U&_'I7JE<+\+M'DT
M_0)+V92KWK[U!'(0<#\^M=U6=5WFSEQ<E*LV@HHHK,YPHHHH **** "BBJ6I
MZO8:/;&>^N4A0#.">3]!U- TFW9%VN!^)'BN72;5-+L9"EW<+F21>L:>WN:Z
M1/%V@O:P7/\ :<"Q3DB-F.-Q'6O&/&]VUYXRU*0MD))Y:^F%&!6U*%Y:G9A*
M'-4]];&!U))R2>23WJYIFEWFL7R6=E"9)7_)1ZD]A4NCZ-=:W=F&WVI&G,L\
MAPD2^I/]*]'ALK70[&"UTVWN9HUNU2ZN+612[\=7&,A>>E=$IVT1Z-6LH:+<
MX#Q-H7_"/:E%:><9=T*R>9MV@GG./;BO0_AKXLEU"-M&OY"\\2;H)&/+(.Q]
MQ_*J&MW&FZ#HXM-24ZA<B24V]K<(-R MP6/4*.WKFN+\)W36GBW3)4XS<*AQ
MZ,<']#4-<\-3%KVU%\W3J?0]%%%<AXX4$ C!Z45%<W,5I;27$[A(HU+.Q[ 4
M /*(%Y50HYY' K#U+Q#X=5'MKK58$R1GRY2"#]5KR?Q9XYOO$%P\,$KV^G X
M2-3@N/5C_2LBVT99K2*XFO88//W&-"I9F"]3Q71&CI>3/1A@K+FJ.Q[KI&HZ
M%/"MMIMY;R@$D+YF6)/)//)-:%U9P7B(DZED5P^T,0"1R,XZC/:OG.]LFTR2
M"2.ZCD29/,BFA)&1DC\#D5Z%X#\?327,6DZQ+Y@D^6"X8\Y_NMZ^QI2I-*Z)
MJX-Q7/!W/4J***P. **** "BBH+V[CL;&>[F.(X8R[?0#- )7,OQ%XHT_P -
M6HENW+2O_JX$^\_^ ]Z\RU#XI:[<RG[&L%G'V 0.WXDURVL:K<Z[JTU]<$O)
M*V$4<[1V45->>&M:T^S%Y=Z;/%;]=Y X^N.E=<:48_%N>Q2PM.FESZMFW:_$
MSQ+!*&EG@N%[H\(&?Q&#7H7A;Q]8>(G%K*GV6^QQ&QRK_P"Z?Z5Y#9>&]:U*
MS-W9Z;/- /XU P?IGK6<K2V\X92T<T;9!Z%6%.5.$MBJF&HU$U'1^1].T5@>
M#M=/B#PY!=R8^T)^[F_WAW_'@UOUR-6=F>/*+C)Q?0****1(4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7(:]_R/FB_P#7E<_^A1UU]<AKW_(^
M:+_UY7/_ *%'4S^%E0^)&G1117*=84444""BBB@84M%+3 ****!!112TP.7\
M5^#XM>7[3;,L-^HP&/W9!Z'_ !KS"_T+5--E,=W8S)_M!2RGZ$5[O1U&#R/2
MNBGB)05MT;T\1*"MNCY_BM;J[N!%%!/-,?X0I+8KOO"OPTNKB>.[UQ/)MU.X
M6V?F?_>]!76:4UD/'EY&EO(MW]D4M(&^0KGT]>E=?73*NVM-"<1C)_#%6&HB
MQHJ(H55& !T IU%%8'G!1110 4444 %%%% !7(ZPEA=>.M-CE>0W5O;/(L10
M%"K<<GUZUUU<J7EF\;W8>P1$@M55+HJ=S9.<9Z8ZT7LF;4/B;\BW<:7I]TBI
M<65O(B'*JT8P/I7D7CO3VL/%-PVW$=P!*A['U_6O:*P_%/AN+Q'IOE9$=U%\
MT,A['T/L:FA5Y):['70J\D]=CE-(U6PU/0'TC2+:&SFA"RO%=IYB7&.#DCG.
M<?2K.OZU9>%[B\^S06[ZQ<NKD1.2D1"@;F'3=UP!7##^U_">JEMKVETJL@<K
MP0>X-9;.TCM([%W8Y9F.23ZUW*";OT.I8=.5[Z$ES<SWES)<W,K2S2'<[N<D
MFM[P+ISZCXOL55<I _GN?0+S_/%8NGZ=>:K=+;6-N\\K'&$' ^I[5[AX,\)Q
M^&-./F%9+Z?!FD'0>BCV%%2:C&P8JM&G!I;LZ>BBBN,\01B%4L>@&:\I\=^,
MUU+1FTZVM;NW$DN'>9-H=1V'K7?^*I8XO#%^9;K[*K1%?.P3M)XZ#FO._B!I
M[VWAO0RLAE2!?++G/.5R#S6E.W,KG9A(1<DWW%^%MA870U.:]MX9/+V -* 0
MH/7K6EJ>FW=GJWVJP$44(\Q$S#OC96QC:0>".>*P_ OV3_A&?$?V])7M=B>:
ML/WR/:N@U5_#"> ](^U07XTWS#]G0,1(#\WWOUK67QF]6_MG]WX%WPKH<,$.
MW5(89#L"QM/&%WMN9CM4]OF%><^-[>&P\97T5I&L*(49508"G:#D?C7I.K_V
M$=3\-&Y@O7EPGV-H\[5'RXW_ *5YW\0O^1WU#_@'_H(HIMN5RL*VZO,^J_4]
MD\-Z@VJ^'+"]?[\L*E_][H:U:P/!5N]KX.TV.0$,8@Q![9YK?KGENSS:B2FT
M@I&8*I8G  R2:6LSQ%-!!X=U![F5HH?(8,Z#)&1C@=Z%JR8J[2,RU\;6$JWC
M7-O=6B6HW-))'E67. 01P:S/&?B32[WP+=/9:A$YN@$B /+X8;@/PK9T*T@M
MO#EC:QL98!"I4R+]X'GD?C2:MH5EJ>ES6AM8%8HPB8(!L8]QCWH4XJ6QU15.
M,T[;,\7\+W-M9^);*YNUW11,6VXSN8*=H_/%>O:7KT*:4]KXAF079EDCDC*E
MMR]>@'3!%>'SPS65V\$H:.>%]I'0J0:[[P1XKMF\13W.M7"Q3S0I$DAX5F'!
M)]">*ZJL;JYW8NESKG6IZ##XDT*")(8;@)&@VJJPN !^5>5>)]&GU;Q%>7^D
MQ1R6DS!E<2*N3CG@D'K77>+_ (CV]G%)8Z+(LUT1M:X'W(_IZFO(I&,CM)(=
MSL<LQY)-*E!K4SPE&4;SVOW_ *1[%\+].OM-L]1CO(PBM(C( X;L<]#]*[ZN
M1^'.B/H_AA'F39/=MYS CD#^$?ES^-==6%1WDS@Q$N:K)A1114&(4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7(:[_ ,C[HO\ UY7/_H4==?7(
M:[_R/NB_]>5S_P"A1U,_A94/B1IT445RG4%%%% !0**6F,*6BB@04444 %+1
M13 *6DI: *.F_;_^$ONMT2_8/LR[7VC);/3/6NFKDM,BMQX\O)1=DSFT0&WV
MG@9ZYZ?_ *ZZVNI;(QK_ !?)!11108A1110 4444 %%%% !7)Z:LC^(=<N#?
MI<0M*B)$CEO**KR".QKJR< D]JXWPJUG/#J-W9QRHL][(S^:P))SU'M2E\#-
MZ.TF;]+117.60W-I;7L7E74$<R?W9%!KDO$O@W2%TLR65K:VL_G1_O))"JXW
M<CDXYKM*P?&(L_\ A'7-\9A )HB?)QNSNXZUK2DU)69=.4E)),Z:QT^TT^ 1
M6EM#"N!D1J!G_&K5,B*F%"N=NT8SZ4^M#C;N]0HHHH$<SXWN(8](M[>>S-TM
MU=1Q;-Q7&3UR/2I=<T:'6=&GTU\*K+B-O[C#H:37S?2:WHL5K.B0"5I+E-X#
M,H''!Y//I6E4S=K6.F+Y8QMZGBNG:UK'@6\O+(6\0ED8;Q,A(..A'M47B#QE
MJ/B.SBM;R.W2.*3S%\I2#G!'K[UZ]K&@Z=KMN(K^W#D?=D'#+]#7":O\,X;.
MUFNH-6$<4:[L7"\#ZL/\*Z85H2=Y;G=3K492YI*TC/@^)NM6]O#"L%F5B0(I
M,9S@#'K3-&TR^\?^*GO[N-4M]RM<NBX7 & H]SBNGT?X5:=Y<-S?7\EVKJ'V
M1#:AR,]>I'Y5Z!96-KIUJEM9P)#"GW408%.52,?@W,:F(I0O[):]R9$6-%1
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M8P*ER.,G&>F:YS^PY9E(:T@A0>5^ZW[@S*<E^G7'%:%]9R2:G'<?98[J$1[
MCOM\MMV=P_"CE7<3BNYI@@DX(XZ^U&1G&1GKUKFET.]>24RK&!(FV0 @!COS
MV'IZU971YUU>28Y:'S-\>TJ %VXV'C./Q[T^5=Q\J[FO-=VUO)$DT\<;2G$8
M9L;C[58K@/B';RRZ=I,$-NPDWD+%'\VWCH,5I>#M/\26<*_VI<J+7'RP2?-(
M/Q[?2G[)<G/<ITUR<US8TR6 ^/+R(66)A:*3<[C\PSTQT_\ U5UE<UIHO_\
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M8/'?(ZU5_=-E)*G;J:M%%%28A7(:[_R/NB_]>5S_ .A1UU]<AKO_ "/NB_\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<CKG_ "/NB_\
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MS34G<FK%QF[H*<!2 4ZI,Q:44E.%-"9(OW12T@Z"EJR HHHH **** "BBB@
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M7LD$\5S;QSPN'BD4,C#N#7@FN6GV359 )VG64"82.,,0XW<^_->D_#+4'N=
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MK5?_  .D_P :/^$!TK_GZU7_ ,#I/\:.1ASFUM/H:7!]#6)_P@.E?\_6J_\
M@=)_C44O@O0K=@LVI:A&3T#ZBXS^9HY YSH,'T- 4^AK!/@?15=4-_J09_NJ
M=0?+?3FG_P#"!:5_S]ZK_P"!\G^-'('.;F#Z&C!]#6'_ ,(%I7_/WJO_ ('2
M?XT?\(%I7_/WJO\ X'2?XT<@N<W,'T-&#Z&L/_A M*_Y^]5_\#Y/\:/^$"TK
M_G[U7_P/D_QI\@<YNX/H:,'T-87_  @6E?\ /WJO_@?)_C1_P@6E?\_>J_\
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M1#(D^\!V!]\8K3HH **** "BBB@ HHHH YSQC%?W.EM;V]HT]JT<C7&R4(V
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,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img242628118_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $L A8# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW3()+:PB@E2-&C&W]W]T@=_QI,SFE:]RW1114F84444 %%%% !1110 4444
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M*TZ[K6=N2T0X8^XKE8/A]/-XA;3/MH"+!YWG^4<=<;>O6O3JHV/F_P#"9O\
MZ:GD_8A_HN[YL[OO8].U=%*K/:YJJTXQ=F0Z#\/])T65;APUW<KRKRXPI]A7
M6445;;>YPSG*;O)W"BBBD2%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %<KKO_ "..C?\ 7"?_ -EKJJY77?\
MD<=&_P"N$_\ [+4S^%E0^)%ZEI*6N4Z@I:** "BBBF 4"BEH ****8!2T44"
M"LVR:W'CQE^SR?:#89\[=\NW?]W'K6E5*S-U_P )B0+F/[+]B_U&X;MV[[V.
MN*UI?$#^%^ATM%%%:G(%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB1L>&$H;C&>W<>E2+J]BR%UFR,@ !3DY&1@=^*@31(Q(\LDS/(^ 2JA<\8Y
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MFW=^>:U*I6XN_P#A+X2L,1M/LK;I2HWAL] >N*JE\0GL_0Z6BBBMCC"BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN8),7&3\GMZ5I2^(.C]#J:***V.0**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N6US_D<=&_ZX3_ /LM
M=37+:Y_R..C?]<)__9:F?PLJ'Q(OTHI*6N8Z@HHHI@%+110(****!A2TE+0
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MY HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%=TMU"B[MN6<#GTJ99$?&UU;(R,'.17*Q>%]%BM'MA8QO%(V]PY+;F]<T_\
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M;7/^1QT;_KA/_P"RU,MBH?$C0H%%+7.=(4444 %%%% Q:**6@04444 %%%%
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M88X=$@F,L23 Q608!&SM)XXZ&M3_ (1O0_\ H#V'_@.O^%'LP]HRC_;6D_\
M05L/_ E/\:7^VM)_Z"MC_P"!*?XU=_X1O0_^@/8?^ Z?X4?\(WH?_0'L/_ =
M/\*/9A[1E+^VM)_Z"MC_ .!*?XT?VUI/_05L/_ E/\:N_P#"-Z'_ - >P_\
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MA_\ 0'L/_ =/\*/^$;T/_H#V'_@.G^%'('.5O[:TG_H*V'_@2G^-+_;6D_\
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M_P"!*?XTO]N:/_T%K#_P)3_&J%E9^%M0G:&WTNQ+A=PW6JC>N<;EXY&:O_\
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$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img242628118_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #( ?8# 2(  A$! Q$!_\0
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M444 (0#U -+110 4F!D' R.]+10 4444 %%%% !1110 4444 %%%% !1110
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ML*P/^$<O;GF_UFX<_P!V+Y14B^#]+',@GD/J\I-&@N:H]H_B;(NK<G GC/\
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MA0":DKHC@F6>%9$((/H<\U)5*RRDUS#SM1\J-F  ?3UJ[0-.Z"BBB@84444
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M10 4444 %%%% %.8F/487.=KJ4X3//7D]JJ7^DB^U2.:8*;<0M&P/7)-:-S
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M=1QR112$(ZD\@BNZKG/&7_'A8_\ 7]#_ .A4 7-$NK9I;ZPM+1;>.QE$6%&
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M7MM8]U=PV^KV>D"TB,-VKNW P"OM0!>TW_D&6O\ UQ3^0JU2 !0   !T I:
M"BF2LZ1,R+O8#A?6J'VS4/\ GP_\?H TJ*S?MNH?] __ ,?H^VZA_P! _P#\
M?H TJ*S?MNH?] \_]]T?;=0_Z!Y_[[H TJ*S?MNH?] \_P#?=(;V_(P=//\
MWW0!IT5A:9=W3:A)"49H\\@MG9^-;M &=K\CQ>']0DC8JZV[D,.H.*Q/",EO
M"RV,-HB,+2*>2;JTC,.<FMGQ%_R+>I?]>[_RK \*?\AD_P#8-M_Y4 =E1110
M!D^)SCPOJ9'_ #[O_*O-(/[2TY/#>FW6^:SDN(Y[:?NH(Y0_2O7W19$*.H96
M&"",@UD&\5O$JZ2;:(PQVPG1BO*G=CCTH \]NCK']D^*OLPMS8_:7\TOG?\
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M]]L&.:[%W6-&=R JC))["N>\.W>D12W5O:ZK;W,MQ</,%5L$9[>] '1T444
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MT->,1:=?-9A9K**.QEU0A[H1$SQX;/Y&O:*3:N,;1CTQ0 B !% .0!UIU%%
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M7*0328=D,AXX51U)]!62\7AJ^OFE^TQO/<*6XD^\"NTG\J +9\4Z2)C']H.
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,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img242628118_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #. G,# 2(  A$! Q$!_\0
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MO^-?,>!Z"C ]!1[!=P^JQ[GTY_PE?A__ *#5A_X$+_C1_P )7X?_ .@U8?\
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ML/\ P(7_ !KYCP/048'H*?L%W']5CW/IS_A*_#__ $&K#_P(7_&C_A*_#_\
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M2K3^%D46R&ZD$UQ$'7=;X3<5SMW;NO&.E+V4>Y/U>'<]Z_X2OP__ -!JP_\
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MXFUN;3M9>74I7>&U5XR57Y&\Q1D<>A(I-L3<D<C@^A_*C!]#^5;/_"7>(?\
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MN%4[P"H!!/&#NS619ZC<V"L+=PH<ACQGD9Q_,U9AU_4(;9+?S$DA1&C5)4#
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M2C9*#O4C(*^O2E'A[4#)LVPY"!R?-&%!Q@$^IR.*;#KNH00) DP$:($4;1P
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M_P"^V_PK'9"N-RD9&1D=10J%SA5+'T S19]P^K_WC8_X0RW_ .AGTC_OMO\
M"C_A#+?_ *&?2/\ OMO\*QL"DXHY7W#ZO_>.J?PW9MX>ATX>)=*\Q+IIRV]L
M8*@8Z=:S_P#A#+?_ *&?2/\ OMO\*QL"C I<K[B6'M]HV?\ A#+?_H9](_[[
M;_"C_A#+?_H9](_[[;_"L<HRD H03T!'6E:)T8*\;*3T!7&:=GW'[#^\:_\
MPAEO_P!#/I'_ 'VW^%'_  AEO_T,^D?]]M_A67+:SP%1-;RQEON[T(S],U&R
M%&*LI5@<$$8(HL^XO8?WC8_X0RW_ .AGTC_OMO\ "C_A#+?_ *&?2/\ OMO\
M*RTL[F2!ITMIFA7AI%C)4?4]*B92K%64@CJ",46?</8?WC9_X0RW_P"AGTC_
M +[;_"K^G^&K.SL]2A?Q+I1:Z@$2$.V 0X;GCVKE\#THP/2ERON#P]_M&S_P
MAEO_ -#/I'_?;?X4?\(9;_\ 0SZ1_P!]M_A6-@>E&!Z4^5]Q_5_[QL_\(9;_
M /0SZ1_WVW^%'_"&6_\ T,^D?]]M_A6-@>E&!Z4<K[A]7_O&S_PAEO\ ]#/I
M'_?;?X4?\(9;_P#0SZ1_WVW^%8V!Z48'I1RON'U?^\;/_"&6_P#T,^D?]]M_
MA5^T\-6=OI&H6;>)=*+W)CVD.V!M))SQ[UR^!Z48'I2Y7W$\/?[1L_\ "&6_
M_0SZ1_WVW^%'_"&6_P#T,^D?]]M_A6-@>E&!Z4^5]Q_5_P"\;/\ PAEO_P!#
M/I'_ 'VW^%'_  AEO_T,^D?]]M_A6-@>E&!Z4<K[A]7_ +QL_P#"&6__ $,^
MD?\ ?;?X4?\ "&6^?^1GTC_OMO\ "L; ]*,#THY7W#ZO_>.IUOPW9ZGK%Q>1
M>)=*5)",!G;(P,>E9_\ PAEO_P!#/I'_ 'VW^%8V!Z48'I246NHEA[*W,;/_
M  AEO_T,^D?]]M_A1_PAEO\ ]#/I'_?;?X5C8'I1@>E/E?<?U?\ O&S_ ,(9
M;_\ 0SZ1_P!]M_A1_P (9;_]#/I'_?;?X5C8'I1@>E'*^X?5_P"\=-I'AFST
M[5K>[D\2Z4R1,20KMD\8]*IMX-MF=F_X2?2.23]]O\*Q<#THP/2ERON+ZOUY
MC9_X0RW_ .AGTC_OMO\ "C_A#+?_ *&?2/\ OMO\*QL#THP/2GRON/ZO_>-G
M_A#+?_H9](_[[;_"C_A#+?\ Z&?2/^^V_P *QL#THP/2CE?</J_]XV?^$,M_
M^AGTC_OMO\*O6_AJSAT6^LCXETHO<21.K!VP N[.>/>N8P/2C ]*7*^XGA[_
M &C9_P"$,M_^AGTC_OMO\*/^$,M_^AGTC_OMO\*QL#THP/2GRON/ZO\ WC9_
MX0RW_P"AGTC_ +[;_"C_ (0RW_Z&?2/^^V_PK&P/2C ]*.5]P^K_ -XV?^$,
MM_\ H9](_P"^V_PH_P"$,M_^AGTC_OMO\*QL#THP/2CE?</J_P#>-G_A#+?_
M *&?2/\ OMO\*/\ A#+?_H9](_[[;_"L; ]*,#THY7W#ZO\ WC9_X0RW_P"A
MGTC_ +[;_"C_ (0RW_Z&?2/^^V_PK&P/2C ]*.5]P^K_ -XV?^$,M_\ H9](
M_P"^V_PH_P"$,M_^AGTC_OMO\*QL#THP/2CE?</J_P#>-G_A#+?_ *&?2/\
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M81T34QUTVZ'_ &R-']C:G_T#KG_OT:=O,.56^(VH3!/XKTKYE=1#&!TP6 .
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MG_[X-%T',NY5HJU_9M__ ,^<_P#WP:/[-O\ _GSG_P"^#1=!S+N5:]E^$_\
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M?SILC-Y9Y/YTM-D_U9H K[CZFC<?4TE%44+N/J:-Q]3244 +N/J:-Q]3244
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M7.UT6A?\>+?]=#_(4I;$5-C3HHHJ# **** (KJWCN[2:VE&8Y4*-]",5SO\
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M_0+N/^^:/^$5U[_H%W'_ 'S6G+3-_9X?LC<_X6=K?_/&S_[]G_&C_A9VM_\
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M /GSG_[X-']F7_\ SYS_ /?!KT6C(SC//I1];EV#^S8?S,\Z_LR__P"?.?\
M[X-']F7_ /SYS_\ ?!KT6FM(B#+N%'N<4?6Y=@_LZ'\S///[,O\ _GSG_P"^
M#1_9E_\ \^<__?!KT3>NX+N&XC(&>33?.BVEO-3:#@G<, T?6Y=A?V=#^8\]
M_LR__P"?.?\ [X-']F7_ /SYS_\ ?!KT4$'H<T4?6Y=A_P!FP_F9YU_9E_\
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M)_=-'VI/[IJI11RH.9EO[4G]TTR2=9$V@&J]*.M'*@YF-DA$DD3EG!C.0%.
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img242628118_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #6 C4# 2(  A$! Q$!_\0
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M1SL"Y]L7^Z:='<K(X4*1FJ-2VW^O6FI.X&A1116HR&[_ ./27_=-<Y71W?\
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MQ(VV.)"6-<57$2A64+:"O9V.PK@[J>6:Z>1W;?N."3TK9F\3N21!;@#L7/\
M2L)W:21G;EF.37)BZT:EE%BDT]CK='U :A:F.1?WD8VM_M#UKFK^V^PW[Q<,
MJG('MZ59L+L6.GW,L4BBX=@JJ>H'K6=)(\LA>1BS'DD]ZBM54Z<4]Q-W2.G?
MQ%:1)&$C=OE&0O\ #[5JV\\=S DT9RC#(K@:ZO3MW_"-_NC\^Q\?7FNC#XB<
MY-2[%1DV:$=[;2S&&.=&D'50:GKA; LNH6Y4X/F#^==WWK?#UG53;1497,N[
MURVM+KR&5V(^\R]%JCXDG62*U5&)5\O[$5D:G$\.HSH_)+9SZ@TZ[OVNK2W@
M* "$8W=S7'4Q$I*4)$.6Z94W-LV;CLSG;GBNG\-RR/9RHY)5&^4G^5<O6[9:
MM;VFD/%$"MP!GD<,3WK/"R49\TGT%%V9T,\\=M"TLS!47J345GJ%M?!C ^2O
M4$8(KD9+^[NH6ADD,BD[N1R,5;T*>&UEGGFD"JJ 8[G-=4<9S5$EL7SW9H^)
ME<V<)!^0/\P_E67H 8ZO'M_NMGZ8JQJ>N1WD#V\<'R'H['D'Z5CQ2R0R"2-R
MCCH17/6J1]LIQ=T2VKW._HKDK?Q!>1.OFL)4SSN'.*ZM'62-74Y5@"#7H4J\
M:OPFBDF.J6V_UZU%4MM_KUK>.XS0HHHK<9#=_P#'I+_NFN<KH[O_ (])?]TU
MSE5$TAL%%%%46<)XZ\27%K(^D6Z!!)&#)*>I!["O/8Y'BD5XV*.IR&4X(KT3
MXC::KVEOJ2#YXV\ISZJ>1_GWKSFNJE;ET/8PG+[)6%=VD<N[%F/4DY)I***U
M.D*N:9J=UI%X+JT<+*%*\C(P:IT4FKB:35F37=W<7UR]S<RM+,YRS-4-%% T
MK:(****8!3M[;-FYMF<[<\4VB@!R?>%:NG7<]E/'-!*Z,K _*Q&:RD^\*OP]
M14LPKZHV=6?S-<O7_O3,:CCI+PEM1N">I<TZ.G$\>IL3IP16I_:L\VGR6ETS
M3+P8BQR4(/K]*RUJ5:UBDSR:[L3Q^3Y,IDW>9@>6!TSGDG\*U_#.M1:;<207
M&%AE.=^/NGW]JQ.U1'K74J:G%Q9X56M*E44X[H]7FO;:"T-U),@@QG?G(/TK
M@_$FKVVK7$)MXV C!!=A@M_]:J5S?M+I5G9!CLBW,P]23Q^E4:SH894WS/<>
M+QTJT>1+30****ZSS0HHHH **** "BBB@ !P0?3FNYT[Q?:S-%!/"\3G"[AR
MN:X:E0[75AU!!K*K1C47O'1A\3.@[PZGJ5]?6=G WVN9%5AC:3RP]A7F$C(M
MRSV^X('S'NZ@9XJUK%Q]KU6>8-D,1C\JHUGAZ/LXW[FV-Q3K3M;1#Y99)Y#)
M*[.YZLQR:O:;J=WIQ/V>4JIZJ>0:SJFCZ5I52<;'/1E)3YD]2[<7<M[<M<3L
M#(WMQ6\GB(S:=);2CRI-F$>,<' Z$=JYI:F3&X9Z5YE9(]2C4DM;[DBUJ:-J
M":=<L\B%E<8)'45F 8.*>*\VH[.Z.FFVG<[ZUO;>\7,$H;'4=Q^%6!UKA]+F
M:'4H&4XRV#[@UOZWJDUG(D$&%9ER6(SBLO;I0<I=#OA.ZNS!U%WDU"=I 0VX
MC!["NFT>Z=]*#S@KY8(W'N!WKDI)7FE,LC%G)R2:U'UN6;39;:11O("AE&..
M]>30K*%24VRDR/4M8EO_ -VHV0 _=]?K6<"0" 3@]:2BN:<Y3?-)ZBO<****
M@04444 %6(+^ZMHS'%,RH>JU7HIIM:H!R.T<BNI^92"/K75PZRLFE27AC&^,
M[2F>IKDJ7>P0IN.TG)&>*UHUI4KVZE*5A\\SW$[RR'+.<FHZ**R;OJR0HHHI
M 3VMTUJ[NJJS,A3GMGO4%%%.[M8 HHHI %=CHDPFTJ+G)3*&N.KI_#43I:2N
MP(5V&WWKKP3:J6+AN;=2VW^O6HJEMO\ 7K7KQW-30HHHK<9#=_\ 'I+_ +IK
MG*Z.[_X])?\ =-<Y51-(;!1115%G*_$&<1>&O+QS+,JC]3_2O*J]&^)1(L;
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M;#Y1(>E5:F2L["#'7VHJU G_ !+[J3'0JOZU5H:M8 J:U3S+N%/5Q_.H0,G
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MR31F5YDSAV;'Z"K51*+1S2BVTT8_C7R_.M,8\S:V?7'&*7P5/ HN8"P$[$$
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M_P"^Q1Y\'_/>+_OL5Y+11]17\P?VN_Y/Q_X!ZUY\'_/>+_OL4>?!_P ]XO\
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M;6PM;K-M86YDN]-FS"Y(&]6(& 6."0/6F+IVFW($TR"YN$MK5?))+;5*#<0
MP[\>U3[1$?6%V. HKMK>PT,FTMELUD2Z:Z7SY9"LB!,[. <9XJREO8ZB=+>;
M3H=ATR,1NARN_.#O7<#Q^F:.<;KI=#@* "3@#)]JZ'3=+MKGQ#?:3-Y 9U=8
M)%?*(XY&">H(XK?MK#1;?5-/NK/:$O+M5A_><QHF0Y/ID[3^--S2'*LH]#@
M"<X!..M( 20 ,D]!7H(N+<6-O<&PM3$-'D!(?'F.)/NGG/O^-84T-I#XNT=[
M6)(8IC:S-&K95&8J2,GMFA3N$:U[Z'.;6Y^4_+UXZ4*I9@J@DGH ,UWC'0Y6
M\31P&ZB=RJRO,Z%=IEY* #/K5JUL-)T_Q'IS01&)DN]L4JCY9(]AY)+')[@X
M%+VGD2\1;I_5CSMH94^]$Z]^5(II4@ D'!Z''6NYM-5T^_\ [7\^XU.:W2Q<
M.+B5"_WA]SC K)\0-8GPYH0T\3"$&XXF92X.Y>N *:EK:Q4:K;Y6OZL<W111
M5FQU\?\ JD_W13J;'_JD_P!T4ZO46Q^/U/C?J%%%%,@**** "G,CJ 61@#T)
M%,/0UV>IZA;R7LNG&620W CCVR,!#%T.1CFLYS<6DE<WI4E--MVM_P '_(XV
MC&.M=E%;6=O<*T5I#YDL$\?EL2 2O3@D]:A2SLYU2251+,EO$!$?FP#G)QD?
M2L_K"[&OU.6U]3DZ*ZB"TTKS;:$6RNEQ<2QEY'(9%&,=#CJ34YAM;QK(O9Q%
M?L:A'4Y7=GG<,@\?UINNET$L(WU7]?\ #G(48ST&:VK'3[>XU6\T^4Q*W(BD
M5_E4AN<'N-N:TXK73H9HI[<*HNA(R#?S&HC.1^+9IRK):6)AAI25[_U_5OO.
M2 )!(' ZT5UMQ/"EM-.;.W,9TZ'"AN'.>0<'/%8.LP0V^J2QVZA8L*RJ#D#(
M!Q3A5YG:PJM#V:O>_P#3_P BA1116ISA1110 4444 .3_6+]16]6"G^L7ZBM
MZOE.)/BI_/\ 0]O*=I_(****^9/7"BBI+>$W%Q'"IP78+GTII7=D S!XX//3
MWH((Z@BNFG6"=X3%- XM)U50AY\L\<_C69JFT_90,=7SC_?K:='E3=RFC+HK
MH9M/LQ.R30I;QK,JHX?)<'J#S4;6=F9@!#^]"L5B)VK(1C SD^_UIO#R74.4
MPJ,'&<<5O"RAVS.EI&\ZQQL8-_",2<C.?TJ3[+9D_9]RB(7+$+NSSL'RY],T
M?5Y=PY3G:*OWT,"W4"1+Y;.!O##"@Y^IK7AM[6WN866&+?O>+!) ;Y>#R?UJ
M8T')M7!(YFBKUFD6;UYX%8QQEEC)P VX#%:26UO<% R*SF&,*SGY5X.0<'(^
MM$:+DM&)(Y_!'448.,UMSPP-I43@I)<)#@)G[J[CEO<TE@T+Z5%;R!%62Y*N
MV<%@%R ?QXI^QUM?H.QBT $G ZUN?9K9<23VL<<@BD8P!\@XZ'K5;1U47$UX
MS11B%24\P_*'/2E[%\R3>XK&;@DX .?2D ). "3Z5T@7RKZ6:W42I<Q!B\$@
M5E.>=N??^=,E65!<K9S^9>%U+,2 ^S'3/3(/7%5]7MU'RG/X.,X.*4(Y&0K'
M\*V84EOGN-/NY(Q.VV16R, C@Y/T_E4QN)[BVO#8$J4EC2,(0#L (I*BGK?^
MOZ_,+'/45?U<J;I.4,WEKYQ3H7[]*H5E*/*VA,****D05K>&_P#D.V_X_P J
MR:UO#?\ R';?\?Y5K0_BQ]4-;GH-%%%?2'05-5_Y!%[_ -<)/_037S"OW1]*
M^GM5_P"0/>_]>\G_ *":^85^Z/I75A]F>KENTOD+1DDY))/K1172>F+N8G.Y
ML^N:-S YW'/3.:2B@!<D=R,=.: S#&&88Z8/2DHH  2#P<?2ER1CD\=.>E)1
M0 NXXQN./3-)D^IX]Z** %R>>3SUYZT;CQ\QXZ<]*2B@ R1W//6C)QC)Q110
M 4444 =?'_JD_P!T4ZFQ_P"J3_=%.KU%L?C]3XWZA1113("BBNKDU>P"QF$6
M_E_N]D<@8^61C/ 'U_.LYS<;65S:E3C.]Y6.82"61)&2-F6,;G('W1ZFE@@E
MNITBB4O(^=H]<#/]*Z.74[;=>QQ7Y43VNTDC*AMV=H..>/YU9CU;38Y8#]I4
MK%,&C<C+*NP@D\<<XXK-UIV^$W6&IW5Y_E_GV.4A@GN#)Y89C&N]N>@]:;+%
M+!,T<@*R(<'GI^-=&VIVH@*2W:7%P;:1&F5-H.6!5?P%.FU*PEBOD^T)&CNS
M(8UPS9 P",8(X_"G[65_A%["G;XM3FYX)K68Q3*4=<9&>F1FH\L",%@>U=2=
M;LI+J7[4XFMEDA:--@Z  -B@ZK9FX ,T EV2".Y +^63C&<CZ_3-"JSZQ!X>
MG?2?]7_K_@'-2P2VXC,BE?,3>GN/6II-.O8?LV^"0&Y&80/X@?2K^HSVU]J5
M@LMXLD:1*D\P7 ZG/%:-SK&G7@=HKFXMYHKA9H'E0$(.A"@=L 4.I/304:--
MN5Y>FWS,*;2=0@DBB>!BTIVHJL&R?3@TZ31-2CR7MB0%+$A@W Z]#VK:.I:9
M!<12EX3<2>8DLUI&54*PP&P?XL^E9EO);Z/>6TT-^+KYSYB(I"[#P<Y[FDJD
MVMOP8Y4:2>^GJM-OO^14M-+O+U$>WA+*[%5.0 2!D_I3+O3[JQ*?:(B@?[K
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M[+_GT@_[]BBBBX78?V?9?\^D'_?L4?V?9?\ /I!_W[%%%%PNP_L^R_Y](/\
MOV*/[/LO^?2#_OV***+A=A_9]E_SZ0?]^Q1_9]E_SZ0?]^Q111<+L/[/LO\
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I#_GC'_WR***+( ^S0?\ /&/_ +Y%.6&)&W+&@/J%%%%%D ^BBBF!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img242628118_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "H 38# 2(  A$! Q$!_\0
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M2/.#Q@J?0BH<6CDG2G"]T7Z***DS"BBB@ HHHH **** "BBB@ HHHH ****
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M:;#?[S@QPQR >IV8_F*71S_9QO7F)7RH8V?ZXR?U-1W,*75W'.TA4  .@Z.
M<@'\:2:!KB_,K2@6[[3+'W8KT_"A-IJW3]0:4D[]=_E;_@D^@+(NHW-S/_K!
M&&8GL7.X_IBJ,NGV?BKQ#YM[ '@0$KV.P<#\SS5@_:9KR[ME4QP7#JSS?[&
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M93&GF*"%;;R >O-"A)-.XIUZ4HM*-FR2BBBMCD"BBB@ HHHH **** "BBB@
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? HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img242628118_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $  G4# 2(  A$! Q$!_\0
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MM#KZ***@P"BBB@ HHHH **** "BBB@ HHHH *R=3UP:=?6]FEE<74\R-(%A
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MCIZ=:?+'N/V=-[/^K'6/J=C&L+/=PA9O]62XPWTJO#KVFSR7J+=(ILW"3%N
MI^M<Q<^#]3?3Q;+-;,&A<; =JQ.SECC@DKR !QTJY-X;OO/N)(UM&7[5%=1K
M)G$A5-I5N.G<'UI<L>XN2G_,=$^J6$=JER]Y"('.%<N,&E?4K)('G:ZB$2-M
M9MW /I7,Q^&;^WF2]1+&6<RRNUI)GR4WX^[QU&.>.:5-+>Y\7A50"RC19[E!
M&1&;@#:H4GKP<_A1RKN'LX=S<M/$&F7FGQWL=VBP2,44N=IR#@BK?VZT%RMM
M]HB\YQE4W#)%<@OA+4HX;4!X,P+-#L1]H=';<&SM.#V(Q^-7;;PU=66K6LUJ
M8HH4""4F0OO"KC&"O7T((XH<8]PE"GT9U5%%%08!2,H=2K %2,$'O2T4 ,CB
M2&-8XU"(HPJ@< 4^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S]7
MU5-(M8YF@EG:258DCB'S%FZ5#9^(+.Y@G>?=9O;R".6.XPI5B,CZY%)XBTA]
M:LK>V5@%2Y25_F*DJ,YP1WK"_P"$/O((XQ;RH6M[J21"TAW3(X &]B#\PZ=*
MM*+6IO"--QU>IU4NHV4)B\R[A7SO]7EQ\WTI1?VC3R0"YB,L8RR!AD"N<M/#
M=WIUS#+!#9SH85BD2X8MY6&R2AV\CVP.:AM_"UU8R2/+()HH?.DB<2?,2X/&
MW;[XZT<L>XN2'<WKGQ%I5M8SWC7D3Q0*&?RVW'!Z<"K/]IV/FQ1?:X?,F :-
M=XRP/3%<;9^%[[4-#B\R*SMC_9@MXU53EF.TY?CC&/?DUH7'AN_N9K@%+)4O
M)(I9)>3) 5"Y5..1\O'3&33Y8]RG3IK2YTT-Y;7#RI#/'(\1PZJV2IZ8/Y&L
MG3?$R:A$MP;&XM[,J6%S+@)@''K5C1=+.FQ7@<1^9/=2S;U')#,2,GUP:Y[2
M/#.H:;9/ ;"P:4PO'YQG=@V[U0\8I)1U)C&&NIU<FIV,.[S+N%=I"G+C@D9Q
M^5 U*Q/DXNX3YPS'\X^<>WK7(R:!>:7!IME''#=A+_S4>0'# J<[^O0\ _2K
MMGX4G26-[@VXS%."(QQ$TAR-F>PHY8]QNG32O<Z)-2LI%E9+J%A#_K"''R_6
MFG5; 11R&\A"2'"'>.37,6OA"X2RE@NEBF9;;[/&3.0'&0>0%&.F>_-))X8U
M9[>%O-M_M<9<),7Y1&Q\K?+A^G/ [4<L>X>SIW^(Z7^U[11<M/(L"02^46D(
M )P#Q^=/FU73X AEO($#J&4EQR#W'M6#)X=ODU![^,6EQ(+EY5AFR$8,BKGH
M<,"OY&H8_",RV\L<AMI&:PE@7*\)([,WRYZ*,@?A1:/<.2GW.JN+NWM8?.GF
M2./^\QP*AEU;3X0ADO8%#J&4EQR"<9'M6=J6DWMSIVG6\,D?^CE?-1CC?A<<
M'!QS61:>#[F*Q:&?[-(XT][9"1G:Y<L",CI@T)*VK%&$&KMG1:EKMCIB_O9E
M:3*XB5AN(8X!Q4T^HQ0:G:V#*QDN5=E(Z#:,G-<O<>%=1998HQ92),T$AFDS
MYB% H*CCIQQSWK8UBQU&35]/U#3TMY&MED5DF<KG< ." :+1#DAHD^X7?B5+
M74+FU73[R=;4*TTD*!@@(STZGBK&G:G87^H7 M%#/Y,4K3 <.K [>?P-9GV#
M7X=2O[FV2Q4WJ1AFDD8^4RK@X '/6H]-T+4]!OS]A2VN+9H(86:60JPV9R<
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M_P#)4?XT6C_-^8>QC_.OQ_R.YHKAO[ \7?\ 0X?^2H_QH_L#Q=_T.'_DJ/\
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M-"5S-#)AGQGG^O/-.R#E7<WF8*I9B !U).*6N=ETW6)XGBDN-P92#F3Y2,#
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MT9W8*JC))["EK \7QW%UHZ6-K.(I;N=(>G4$\_3BA*["$>:2B;J.LD:NARK
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M^'V>6WAD\^:(XE FR5/N.U)<>#H$8S:9=36DXZ'>2#]?:ES(I0@GH_P-6D)
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MICOK&N7&L.I%N@\JW![^I_+(_'VK17OY"E+=]$OQM8WJ***9PA1110 4444
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M&N4U+0Y89O/C9HY%QB>,=?J*UTJ*W4F$U3O&7P_E_P  [FL'Q/X5L_$UELE
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MCZMZ_EG\Q705!9VD-C:1VUNNV-!@>I]S[U/4F%22E+38****1 4444 %%%%
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MJT$R7%O'/'G9(H=<C!P1FKY'"*1QXN$J:C%K3]22BBBD<04444 %& >"***
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M^??7!W32_P!!["M, !=H  '8=**7H92J*W+%604444&84444 %%%% !1110
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M_P#@'G__  L30_2[_P"_!H_X6)H?I=_]^#7H&T>@HVCT%'M%V#]S_*_O_P"
M>?\ _"Q-#]+O_OP:/^%B:'Z7?_?@UZ!M'H*-H]!1[1=@_<_RO[_^ >?_ /"Q
M-#]+O_OP:KW'C7PO=D&XM996'0O:Y(_'%>D;1Z"C:/04>T78:=);1?W_ / /
M,H_%OA&)PZ6#AAT)M,D?I5S_ (6)H?\ T]_]^#7H.T>@HVCT%'M%V!ND]XO[
M_P#@'G__  L30_2[_P"_!H_X6)H?I=_]^#7H&T>@HVCT%'M%V%^Y_E?W_P#
M//\ _A8FA^EW_P!^#1_PL30_2[_[\&O0-H]!1M'H*/:+L'[G^5_?_P  \_\
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MKK_OP:]!VCT%&T>@JO:+L9-TGO%_?_P#S_\ X6)H?I=_]^#1_P +$T/TN_\
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M#S__ (6)H?I=_P#?@T?\+$T/TN_^_!KT#:/04;1Z"CVB[!^Y_E?W_P# //\
M_A8FA^EW_P!^#6:=?L]?\=>'6L5FQ"[[R\97J./Y5ZEM'H*,#T%'M%V*C.G!
/WC%W]?\ @"T445D8G__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img242628118_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &) <H# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ K
MUS5KFQNQ%$X1/(,BD0F0LP/0@?='O^M;]4+W2HKRX\\330R[/+9HFQN3K@T
M4&U'4+@3M;M!']F@21U(W!V9=Q .>!6JM]#_ &:E_*?+A,0E8GG:",U4DT&U
M=52-YH8_+$;I&Y D4= ?\:TE150(J@(!@#'&* ,J/Q1HLLJ1I?(7=@J@JPR3
MT'2M>L+Q2B#2X"%4'[9!T'_305NT %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &'
MXJ_Y!<'_ %^0?^C!6Y6'XJ_Y!<'_ %^0?^C!6Y0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,/Q5_R"X/\
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M%7H->?BX\M6WH>KE\^:A?I=_=<****YCN"BBB@ HHHH **** ,/Q5_R"X/\
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M4375TY$TBW!^=/[6C0=,$8]*]!/2N)U"QMYY;R2QCTIK>[M]^^6/#0JHPS
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M ->I_G79UQFK?\CU#_UZG^=&&^)^C'C/AC_B1?HHHJQ!1110!GZ9_P CX?\
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MR_Q,*XJ__P"1^D_Z]17:UQ5__P C])_UZBC#;R]&&,VA_B7ZFC1115@%%%%
M%#1O^1ZN?^O8?TKLZXS1O^1ZN?\ KV']*[.HQ/Q+T08+X)?XF%<1<?\ (]WG
M_7NO]*[>N(N/^1[O/^O=?Z48;>7H&,^Q_B7Y,TZ***L HHHH H^'O^1TU/\
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M /D?I/\ KU%=K7%7_P#R/TG_ %ZBC#;R]&&,VA_B7ZFC1115@%%%% %#1O\
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MAO8<YZ<5UE !1110 4444 %%%% !1110 4444 %%%% !1110 4F ,8 XI:*
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M3_C1_P )/%_T"]5_\!3_ (U9E\1:/!,T,NHVZ2*=I4MR#6DK!U#*<J1D'UH
MQ/\ A)XO^@7JO_@*?\:/^$GB_P"@7JO_ ("G_&MRB@##_P"$GB_Z!>J_^ I_
MQH_X2>+_ *!>J_\ @*?\:U!?6IO39>?']I"[S%GYMOKBHSJM@'G0W<.Z A91
MN^X3T!H S_\ A)XO^@7JO_@*?\:/^$GB_P"@7JO_ ("G_&MRB@##_P"$GB_Z
M!>J_^ I_QH_X2>+_ *!>J_\ @*?\:W** ,/_ (2>+_H%ZK_X"G_&C_A)XO\
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M]5_\!3_C1_PD\7_0+U7_ ,!3_C6O%<0S/(D<BNT9PX!^Z>O-2T 8?_"3Q?\
M0+U7_P !3_C1_P )/%_T"]5_\!3_ (UN'@9JM;W]I=N4M[B.5@H?"G/RGH:
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M444 %8>I_P#(TZ)])_\ T$5N5A:JRIXHT0LP48GY)Q_"* -VBH_M$'_/:/\
M[Z%'VB#_ )[1_P#?0H DHJ/[1!_SVC_[Z%'VB#_GM'_WT* .2\6)-;:O!-;H
MS?VA ;%]HZ$L""?P+52TNUE75I; H_DZ+;RI$S#AM_W2/^ UW)GMSUEB./\
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M_P! RW_[YH_X1?0_^@9;_P#?-:U% &3_ ,(OH?\ T#+?_OFC_A%]#_Z!EO\
M]\UK44 9/_"+Z'_T#+?_ +YH_P"$7T/_ *!EO_WS6M10!D_\(OH?_0,M_P#O
MFC_A%]#_ .@9;_\ ?-:U% &3_P (OH?_ $#+?_OFC_A%]#_Z!EO_ -\UK44
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M?\(OH?\ T#+?_OFM:B@#)_X1?0_^@9;_ /?-'_"+Z'_T#+?_ +YK6HH R?\
MA%]#_P"@9;_]\T?\(OH?_0,M_P#OFM:B@#)_X1?0_P#H&6__ 'S1_P (OH?_
M $#+?_OFM:B@#)_X1?0_^@9;_P#?-'_"+Z'_ - RW_[YK6HH R?^$7T/_H&6
M_P#WS1_PB^A_] RW_P"^:UJ* *=EI-AIK.UG:10,XPQ08S5RBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img242628118_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &> 6T# 2(  A$! Q$!_\0
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M#7M<O^J?_=->2>"_^03<?]?4G\ZUINT6SKP[<82:\OU'_P#".7G_ $,.I?\
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MN/\ KZD_G6L/A9U4/X<OE^IT= ZT4#K2&1_"W_CPU?\ Z_G_ *UWU<#\+?\
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M_P#U_/\ UKOJ53XF9XG^*SR;0?\ D.>(O^OY_P#T(UOU@:#_ ,ASQ%_U_/\
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MQOI\WF6I<M:1D%.1P3GH?Z4 =A1110 4444 85W_ ,CIIW_7I-_-:W:PKO\
MY'33O^O2;^:UNT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V7
M_5/_ +IKR3P7_P @FX_Z^I/YUZW+_JG_ -TUY)X+_P"03<?]?4G\ZUA\+.JA
M_#E\OU.CH'6B@=:0R/X6_P#'AJ__ %_/_6N^K@?A;_QX:O\ ]?S_ -:[ZE4^
M)F>)_BL\FT'_ )#GB+_K^?\ ]"-;]8&@_P#(<\1?]?S_ /H1K?K2>YT5?C^[
M\@JO\/\ _D9_$O\ UV6K%5_A_P#\C/XE_P"NRTOLLG_EW/T_5'H5>5I_R4?Q
M#]$_DM>J5Y6G_)1_$/T3^2U-/J9X?:7I^J-JBBB@HS_"O_)3]1_Z\A_-:]*K
MS7PK_P E/U'_ *\A_-:]*HJ;HC$_$O1'F&J?\E7O/^O-/Y"M6LK5/^2KWG_7
MFG\A6K52Z>AM/:/H@K*TG_DJ]M_UY-_(UJUE:3_R5>V_Z\F_D:(]?0(;2]&>
MGT445B<)CZ_?2:?]@F'G&#[1B<1)O)38W4#MG%8WAJ_>XO[.)()8C]GD:Z)M
MO+#ON7:2<#)QFNKO+E+.RGNG!*0H7('4@#-9>EZZ][=+:SVPBF8.0$DW@!2.
MO_?0H VJ**SKK5X[;4K:R$;2/*VUF7I'GIGZXH T:*R8M<66:(_9I%M9I#%%
M<$C#-TZ=0"0:U20.I H P[O_ )'33O\ KTF_FM;M85T0?&FG8(/^B3=/JM;M
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -E_U3_[IKR3P7_R"
M;C_KZD_G7K<O^J?_ '37DG@O_D$W'_7U)_.M8?"SJH?PY?+]3HZ!UHH'6D,C
M^%O_ !X:O_U_/_6N^K@?A;_QX:O_ -?S_P!:[ZE4^)F>)_BL\FT'_D.>(O\
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MM<K#9W5IXRLA<ZA)>%K67:70+MY7TKJJ "BBB@ HHHH **** "BBB@ HHHH
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 V7_5/_NFO)/!?_()N/\
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M(Q/Q+T1YAJG_ "5>\_Z\T_D*U:RM4_Y*O>?]>:?R%:M5+IZ&T]H^B"LK2?\
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MW%M%=*BR@D(XD7!QR.E344 4(]'LXKH7"J^0Q=4+DHK'J0O0&K]%% &%=_\
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M  K_ ,E/U'_KR'\UKTJO-?"O_)3]1_Z\A_-:]*HJ;HC$_$O1'F&J?\E7O/\
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MQ_\ ?0H%S;Y_U\?_ 'V*U-9\.::MSI8M]*@VF[42[(AC;@]?:M;_ (1G0_\
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M[&NGJ!K.U9BS6T))ZDH* *G_  D&C?\ 04L_^_R_XT?\)!HW_04L_P#O\O\
MC5O[#:?\^L/_ '[%'V&T_P"?6'_OV* *G_"0:-_T%+/_ +_+_C1_PD&C?]!2
MS_[_ "_XU;^PVG_/K#_W[%'V&T_Y]8?^_8H J?\ "0:-_P!!2S_[_+_C1_PD
M&C?]!2S_ ._R_P"-6_L-I_SZP_\ ?L4?8;3_ )]8?^_8H J?\)!HW_04L_\
MO\O^-'_"0:-_T%+/_O\ +_C5O[#:?\^L/_?L4?8;3_GUA_[]B@"I_P )!HW_
M $%+/_O\O^-'_"0:-_T%+/\ [_+_ (U;^PVG_/K#_P!^Q1]AM/\ GUA_[]B@
M"I_PD&C?]!2S_P"_R_XT?\)!HW_04L_^_P O^-6_L-I_SZP_]^Q1]AM/^?6'
M_OV* ,NZO_#5\4-U=:=,4^Z7D4XJP-?T55"KJ=F . !,O%7/L-I_SZP_]^Q1
M]AM/^?6'_OV* ,VZU3P]>Q>5=7MA*@.0'E4X-/AUK0;>%8H=0L8XU&%5)5 %
M7_L-I_SZP_\ ?L4?8;3_ )]8?^_8H J?\)!HW_04L_\ O\O^-4(+ZTOO&,3V
KES%.JV+AC&P8 [U]*VOL-I_SZP_]^Q3H[>"%BT4,:$\950* ):*** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img242628118_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %# GX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ JC
MJM^=/M&>-!+.0?+C)QN(&3GVJ]56]TZTU&/9=0))@$*67)7(P<4 9S:U<NC/
M!!&RP01S3!F()W#.%_#-:C7EO' DTLT<4;@%6D8+G//>J)T&U$:1Q-)%'Y:Q
M2(AP)%7H#_\ 6K0EM;>>-8YH8Y$7HK*"!0 075O<AC;SQ2A>OEN&Q^52UAZ7
M!%;^)-6CAC2-/*MSM08&?GK<H **** "BBB@ HHHH ***9+-%!&9)I$C0=6<
MX H!NP^BJ?\ :VG?\_\ :_\ ?U?\:/[6T[_G_M?^_J_XU7)+L1[2'=%RBHH+
MJ"Z4M;S1R@'!*,&Q^52U+5MRDT]4%%%% PHHHH **** "BBB@ HHHH ****
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M.N#N[:"#6M%,4*1DW)SM&,\5WE95J<86<>IOAZLYN2G;3MZ!1116!TA1110
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M]5^2"BBBN8[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"0LG'*Y&0/R-34 %%%% !1110 53U2].GZ=+<J@9EP &.!DG&2>PJY6=KC7
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MTFN98Y[,M<2>8V8SP<8XIUGXCU^\\2?V,KV2OY'G>88VQ],4M4=#_P"2G?\
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M5F158;<CC.2:WFQM.3@8Z^E8'A0*EK/&MIY #A@2Y8L",C)/<"N@(!&",@T
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MU;_T(UZ3J7_(+N_^N#_^@FO-O"G_ "+=K]6_]"-:1^%G51_AOU7ZFS5'0_\
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M !7\R>L[7_\ D 7W_7%JT:SM?_Y %]_UQ:JCN:0^)':>%O\ D4])_P"O2/\
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M'_T8M:]8_B8C^PY.?^6L/_HQ:V* "BBB@ HHHH **** "BBB@ HHHH ****
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M%%% !1110 4444 5=2_Y!=W_ -<'_P#037FWA3_D6[7ZM_Z$:])U+_D%W?\
MUP?_ -!->;>%/^1;M?JW_H1K2/PLZJ/\-^J_4V:HZ'_R4[_MQJ]5'0_^2G?]
MN-4MF7':7HST&\_X\;C_ *YM_*O,/!__ "+-K_P+^9KT^\_X\;C_ *YM_*O,
M/!__ "+-K_P+^9J8_"R*/\.7JOU-RJ6B_P#)3HO^P<__ *$*NU2T7_DIT7_8
M.?\ ]"%4MF7':7HST*Y_X]9?]P_RKR[PE_R %_Z[R_\ H5>HW/\ QZR_[A_E
M7EWA+_D +_UWE_\ 0JF'PLBC_#EZK]3<JAIG_)3;'_KSD_D:OU0TS_DIMC_U
MYR?R-4NI<=I>C/1Y/]4_^Z:\H\'?\B\G_75__0C7J\G^J?\ W37E'@[_ )%Y
M/^NK_P#H1J8?"R*/\.7JOU-^J&F?\E/T_P#Z\9?YBK]4-,_Y*?I__7C+_,52
MZEQVEZ,])HHHK$X@HHHH *R/$5Z;732B([2R$!0+=I0.1DX /3KS6O6/K!N(
M+ZPO%AFGMH2_FQP\L"1PV.^.?SH 3P['!';SB"1G!DW,6M#!R?8@9^M:<UNL
MS(Y9P\9RN'(&?< \CZUGZ(+AY+ZZDBEAAGFWPQ2GY@,8)QVR><5K4 8<6B73
M17 O+N.6:4AA,L15E93E>Y&!Z5?LK.2&:>XN)5DGFVABB[5"KT &3ZG\ZNT4
M <OK^B6%OISW4<<@E$T1!,SD9,B]B<5U%9'B;_D!R?\ 76'_ -&+6O0 4444
M %%%% !1110 4444 %%%% !1110 5YUXD_Y*99?]>#_SKT6O.O$G_)3++_KP
M?^=:4]V=&&^)^C+=9'BG_D6KS_='\ZUZR/%/_(M7G^Z/YU4=T;4_C7J>B:/_
M ,@2P_Z]H_\ T$5Q/BG_ )*/I_\ UX-_Z$:[;1_^0)8?]>T?_H(KB?%/_)1]
M/_Z\&_\ 0C4P^)F5'^)+T99K*\3?\BSJ/_7$_P Q6K65XF_Y%G4?^N)_F*J.
MZ-*?QKU.^T#_ )%[3O\ KW3^0KC_ !A_R/VB?]>LU=AH'_(O:=_U[I_(5Q_C
M#_D?M$_Z]9JF/Q/YF='^*_F3UG:__P @"^_ZXM6C6=K_ /R +[_KBU5'<TA\
M2.T\+?\ (IZ3_P!>D?\ Z"*Y3QA_R/\ HO\ UZR?SKJ_"W_(IZ3_ ->D?_H(
MKE/&'_(_Z+_UZR?SI1^)_,BE_%E\RQ6;XA_Y%S4?^N#5I5F^(?\ D7-1_P"N
M#4X[HN'Q([;PQ_R*^F?]>R?RK6K)\,?\BOIG_7LG\JUJREN<M3XV%%%%(@*Y
M.62]U2Y:./<8(').[.Y<G .!CD8X^M=97)R>*KF.Z#I:6YLR7)Q+^]PC!22.
M@Z]#0!U:C"@9)XZFEI%(901T(S2T %%%% &/8_\ (T:M_P!<;?\ ]GK8K'L?
M^1HU;_KC;_\ L];% !1110 4444 %%%% !1110 4444 %%%% %74O^07=_\
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M\.7JOU-RJ&F?\E-L?^O.3^1J_5#3/^2FV/\ UYR?R-4NI<=I>C/1Y/\ 5/\
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MMS3R26JW$:P6Q+[Q+*0K$#Y<E.?PKHESM&[KCF@@,,$ CWH Y"2Y6=&EN3-
MXMXVLD#MG=SG'KSCKV-='<W%[#9Q/#9?:9SC>@D"8XY.3[U<(!() )'3VI:
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MC\!6E63KNHSZ;#%)%+:H&;:1/NRQ[!0H)- ">'X6-I)?32,]S=MOD)7;C'
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M%%% !1110 4444 5=2_Y!=W_ -<'_P#037FWA3_D6[7ZM_Z$:])U+_D%W?\
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MZEQVEZ,])HHHK$X@HHHH *RM4L;V:_L[RR:WWP!QMF!Q\V.1CZ5JU3O]-BU
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M]9/YUU?A;_D4])_Z](__ $$5RGC#_D?]%_Z]9/YTH_$_F12_BR^98K-\0_\
M(N:C_P!<&K2K-\0_\BYJ/_7!J<=T7#XD=MX8_P"17TS_ *]D_E6M63X8_P"1
M7TS_ *]D_E6M64MSEJ?&PHHHI$!1110 56N[^VL0AN)=F_.T!2Q..O JS6#J
MFFWT[PLLKSA6<Y1A"Z9&  P[>M &A)K&GQ>5ON5Q(H92 2,'N2.GXU>KFUTJ
M_MX)8D@AD-S;I$Y#;5B*@CIW'.?K6Q<-=VEI$MG;"Z=<*0T@3@#KF@"G8_\
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M4J.%+6WF]7!'RY^3C\JU]4TO4-3U:#S([81+!*N\@NHRRX],-@&M'^T]1_Z
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MVH5'12?<_P JP9++5=NGK<6LX>V@FMV:. 3 C*[<9[$=_:NH_M/4?^@%<_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img242628118_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ;D$,L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ3_S0M%%%8G4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/E\JL>:3LCQ,;GE/#S=.G'F:W['O,4\4XS%*D@]48&O,OB1_R,5O_P!>B_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.^QY^58:.*Q*C4U2U8RX^'FCR6Y2!IX9<<2;]W/N#_\ 6KS74M/FTO4)K*X
M$D38)'0CL1]17N]>6?$9%3Q)$P'+VRL?KN8?TKBR_$U)5.2;N>OG> H4Z"JT
MXV:?0YBR_P"/ZW_ZZK_.O>J\%LO^/ZW_ .NJ_P Z]ZI9KO'YAPW\-3Y?J%%%
M%>2?3!7A6J_\AB^_Z^)/_0C7NM>%:K_R&+[_ *^)/_0C7JY5\4CYOB/X*?JR
MSX:_Y&;3?^OA?YU[97B?AK_D9M-_Z^%_G7ME+-/XD?0OAW^#/U_0****\L^A
M,/QC_P BGJ'^XO\ Z$*\:KV7QC_R*>H?[B_^A"O&J]W*_P"$_7]$?'<1?[S'
M_#^K/0?AC]W5/K%_[/7H%>?_  Q^[JGUB_\ 9Z] KSL?_O$OE^2/=R;_ '&'
MS_-A7 _$R!?+T^X ^8%T)]1P1_7\Z[ZN#^)DH%MI\/=G=OR ']:6!O\ 6(V_
MK0><6^I3OY?FCSJO6?A_,9?"R(3_ *J5T'_H7]:\FKU;X>1E/#)8]'G=A^0'
M]*]3,K>Q^9\[D#?UO3L_T.5^(?\ R,P_Z]T_F:Y.NL^(?_(S#_KW3^9KDZZ,
M)_ CZ'%F7^]U/5GNVE_\@BR_ZX)_Z"*MU4TO_D$67_7!/_015NOFI_$S[^E\
M$?0***\ZUWQMJVG:Y=V< M_*B?:NZ,DXQ]:TH4)UI<L#GQ>,IX2"G4V>FAZ+
M17E/_"P];]+7_OV?\:/^%AZWZ6O_ '[/^-=7]FU_(\_^W\)Y_<:GQ-E.[38N
MV)&/_CO_ ->N KH_$>HW.L:3I5_=!/,9ID.P8'!7_&N<KUL)!PHJ+Z7_ #/F
M<SJJKBI5([.WY(]>\"QA/"5JPZNSL?\ OLC^E='7.^!G#^$;,#JID!_[[8_U
MKHJ^?Q/\:?JS[; 6^JT[?RK\@J@VB:4\[SOIUJ\KL69WB5B3Z\BK]%9*36S.
MF4(R^)7(HK:W@_U,$4?^X@'\JEHHI-WW&DEH@HHHH&%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'E_Q(_P"1@MO^O5?_ $-JY"/_ %B_45U_Q(_Y&"V_
MZ]5_]#:N/4[6!]#FOIL)_ CZ'Y_F?^^5/4^@**XG_A96G_\ /C<_FO\ C2'X
ME6&/EL+DGW917A_4J_\ *?7_ -K8+_GXOQ+/Q$MH9/#Z7#@>;%*H1N^#U']?
MPKRRM[Q'XIN?$+HC1B&VC.4B!SSZD]S6#7MX.E.E249[GR.:XFGB<2YTMOS/
M4_AU.\OAV2-CD17#*OL" ?YDUQGC?_D<+[_MG_Z+6N^\#Z>]AX:B,BE7N&,Q
M![ X _0 _C7 ^-_^1POO^V?_ *+6N/"M/&3:\_S1ZN8QE'*Z*EO=?DRMX7_Y
M&?3O^NPKT;QU"9?"ER5&?+9'_P#'@/ZUYSX7_P"1GT[_ *["O8[VTCOK&>TE
M^Y,A0^V1UJ<?/DQ$)=O\RLFI>UP56FNMU^!X+7J/PXF5] FBS\T=P<CV*C']
M:\UO;2:PO9K2==LL3%6']:U_"OB(^']09Y%9[68!957J,="/<<_G7;BZ;K46
MH>IY.68A87%IU-%JGY'L=<1\2Y5&F64.?F>8N![!<?\ LPK7/C7P^(?,^WYX
M^Z(VW?3&*\X\3Z^VOZGYRJ4MXQLB0]<=R?<UYF!PU3VRE)62/H<WQ]#ZJZ<)
M)N79W,6O38K1S\*C%CG[.TOX;R_\J\]TS3YM4U&"R@'SRMC/]T=R?H*]P2TA
M2R6S"?N%C\K:?[N,8_*NO,:R@X+K>_W'FY%A74563V:Y?O/!*]%^&<RFUU"#
M/S*Z/CV((_I7$:OILNDZI/92@YC;Y6/\2]C^56?#NN2:#JBW04O$PV2H/XE]
MO<5TXF'MZ#4.NQYV K?5,6I5-+-I_D>U5R?Q#E6/PTJ$\R3J /H"?Z5<3QMX
M?> 2F^V\<HT;;A[8Q7 >+?$@U^\C6!62T@SL#=6)ZL:\K!X:I[9.2LD?39IF
M%!864823<M-'<YVO3/#5JS?#F[3',\<Y7\B/Z5YS:VTM[=16T"%Y96"J!ZFO
M<=.L8]/TRWLDP4BC"9]?4_C7;F551C&/6]_N/(R'#NI4G-[6M]YX17=_#.4"
M[U"+/S-&C#\"1_6N3UK3FTK6+FS8$"-SL)[J>0?RQ4F@:P^AZM%>*I= "LB
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M-E!UFH+1'O93"K'"Q=5MMZZ]N@4445R'I!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*4Y73+,'U$"_X5WK-8]8GBRX<G?2HON/$K:SN;V41VMO+,_]V-2Q_2NY\.^
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MO._<*X[XD?\ ( MO^OI?_0&KL:*X:-3V=13M>Q[&*H>WHRI7M<^?J]I\*?\
M(K:=_P!<OZFMC ]**Z<5C?;Q4>6WS//R[*?J51SY[W5MK?JPHHHKA/8"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \2\1_\C+J7
M_7R_\ZRZ^@<48'I7K0S3EBH\FWG_ , ^:J<.\\W+VF[[?\$^?J*^@<#THQ5?
MVK_<_'_@$?ZM_P#3W_R7_@GA=GI&HW[A;6RGESW"''XGH*]$\*>#?[)D%]?E
M7N\?(B\K'[Y[FNPHKFKYA4JQY4K([\'DE'#S523YFON^X*\!E_UK_P"\:]^H
MP/2HPF*^KWTO<US++?KO+[W+:_2^]O-=CS/X:_\ (9N_^O?_ -F%>F445EB*
MWMJG/:QT8'"?5**I7O\ @>>^*_!,KW$FH:3'O#G=+;CJ#W*^OT_*N"DBDAD,
M<J,CKP588(_"O?ZAGM+:Z %Q;Q3 =I$#?SKKH9C*G'EFKGF8S(:=:;G2ERM]
M.G_ /!*V]%\+:EK4BF.%H;<]9Y!A<>WK^%>MQ:5IT#;HK"UC;U2%0?Y5;K2I
MFC:M"-C"AP[%2O5G==E_F4-(TFUT6P2TM5^4<LYZNW<FK]%%>5*3D[O<^DA"
M,(J,59(X?Q=X,>^F?4=,4>>W,L/3>?4>_MW_ )^=3P36TIBGB>*1>JNI!'X&
MO?:BFMH+E=L\,<J^DB!A^M>AA\QG3CRR5T>)C<CIUYNI3?*WOV/ ZUM(\.:E
MK4BBVMV$1/,SC"#\>_X5Z^FD:;$VZ/3K1&]5A4'^57,8&!6U3-&U[D3EH\.I
M2O5G==DOU,O0="MM!L?L\'S2-S+*1RY_H/05J445Y4I.;<I;GTE.G&G!0@K)
M'GWC+P?-)<R:GID1DW_--"HYS_>4=\]Q7 ,K(Q5@0P."".17T!5>XT^RNVW7
M-I;S'UDC#?S%>AA\QE3CRS5SP\;D4*TW4I2Y6]UT/"[>WFNIEAMXGEE;@(@R
M36GK>@2Z%!9"Y8?:)U9W0'(3&,#W->QP6EM:J5M[>*$'J(T"_P JFJY9H^9-
M1T,H<.Q5-J4_>?6VB_$\%LO^/ZW_ .NJ_P Z]ZHP**Y<7BOK#3M:QZ.6Y=]2
M4ES<U[=+?JPHHHKD/3"O"M5_Y#%]_P!?$G_H1KW6C KKPN*^KMNU[GFYEEWU
MV,5S<MO*_P"J/GZBOH' ]*,#TKM_M7^Y^/\ P#R?]6_^GO\ Y+_P3Y^HKZ!P
M/2C ]*/[5_N?C_P _P!6_P#I[_Y+_P $Y;6O^2<'_KTA_P#9:\GKZ!HP/2N?
M#X[V*:Y;W=]SNQV3_6I1ESVLK;7_ %/GZE ). "3[5] 8'I171_:O]S\?^ <
M/^K?_3W\/^">&VNBZG>L!;6%Q)GN(R!^9XKK]$^'<A=9M8D"J.?L\;9)_P!Y
MO\/SKT.BL*N959JT=#LP^0X>D^:;YOR^X9##';PI#"BI&@VJJC  I]%%><>X
ME;1'E7Q#_P"1F'_7NG\S7)U] T8'I7J4LR]G!0Y=O/\ X!\]B<A]O6E5]I:[
MOM_P3Y^HKZ!P/2C ]*T_M7^Y^/\ P##_ %;_ .GO_DO_  3Y^KU3X=_\BT__
M %\-_):ZW ]**Y\3CO;PY.6WS_X!VX#)_JE;VO/?3M;]0HHHKSSVPKG_ !/X
M7AU^W#J1%>1C$<AZ$?W6]OY5T%%73J2IR4HO4RK485H.G45TSPS4='O])E,=
M[;21<X#8RK?0]#5&OH!E5U*L 5/4$=:IMHVENVYM-LV;U,"G^E>K#-=/>B?.
M5>'-?W<]/-'AT4,L\@CAC>20]%122?P%=OX;\!S22I=ZPGEQ+RMN3\S_ .]Z
M#VZ_2O0H;:"V7;!#'$/1$"_RJ6L:V93FN6"L=.$R"E2DIU7S>73_ ((@ 4
M  < #M2T45YI[X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !574E9]+
MNT12S-"X  R2=IJU133L[BDN9-'AO]AZO_T"K[_P'?\ PKN/AW87EDVH_:K2
M>#>(]OFQE<XW9QFNZHKOKYA*K3<&MSQ<)DM/#5HUE-NW^5@HHHKSSVPHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHIN] ^W<N[TSS0 ZBBB@ HHI-PW;<C/I0 M%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !4%Y=P6%G-=W,@CAA4N['L!4]4]4TNTUG3Y+&
M]C+P28R Q!R.0<CWH \5\2^/-4UVXD2":2TL>BPQM@L/5B.OTZ5SC6=Y]F^U
MM;3^03_KBAVD_P"]TKTZW^%*6_B&"5KI;C2E)=XWXD..BG'!&>IX^E=UK4UC
M8Z!=O>*@LTA(9"!@C& H'OT% 'B.@>--7T&X39<R3VH(WV\K%E(]L_=/T_6O
M=-.U&WU/3(+^W;]Q,@<$]O4'W'3\*^::]42ZGTCX+(3N62X#1I[*[G^:Y/XT
M 8WC#X@WNI7<MGI,[V]BA*^9&<--[YZ@>@'X^@XLPW3Q&[,<S1@X,Q4D9_WO
M6H5!9@HZDX%?2%KH]I;Z#'I#0HULL/E,F.&&.3^)R: /'_"GC[4-%NHX;Z:2
MZT]CAE<[FC'JI//'ITKVV*6.>%)HG#QNH964Y!!Y!%?-%[;FSO[BV)R896C)
M^AQ_2O:/AEJ#WWA%(I&):UE:$9_N\,/_ $+'X4 =E1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MID$B'U!&14U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYJG_ (#+_P#%4?\ #0G@K^YJG_@,O_Q5>A_\(YH?_0%T[_P%3_"C_A'-#_Z
MNG?^ J?X4 >>?\-">"O[FJ?^ R__ !5>H6ES%>V<%W"<Q3QK(A]589'\Z\>^
M/^D:;8_#VWEM-/M+>0ZC&I>&%4.-DG&0*]8T, >']-   %K%@#_<% %^BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *PO%^BW'B#P[-I]J\23.Z,#*2%
MX.>P-;M% 'C7_"I=>_Y^]-_[^/\ _$4?\*EU[_G[TW_OX_\ \17LM% 'C7_"
MI=>_Y^]-_P"_C_\ Q%>E>$M'N-!\-VVG73Q/-$7+-$25Y8D8R!ZUMT4 <?XK
M\ 67B*4WD$GV2^(^9PN5D_WAZ^_\ZX@_"C7Q+L$]@5_O^:V/_0<U[/10!Q'A
M7X<VFAW"7M]*MW>)R@"XCC/J,]3[G\J[>BB@ HHHH *YWQW_ ,B3JG_7,?\
MH0KHJYWQW_R).J?]<Q_Z$* '>!O^1*TO_KD?_0C705S_ (&_Y$K2_P#KD?\
MT(UT% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=
M\=_\B3JG_7,?^A"NBKG?'?\ R).J?]<Q_P"A"@!W@;_D2M+_ .N1_P#0C705
MS_@;_D2M+_ZY'_T(UT% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'DG[1/\ R3BV
M_P"PE%_Z!)7INB?\@'3O^O6+_P!!%>9?M$_\DXMO^PE%_P"@25Z;HG_(!T[_
M *]8O_010!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N=\=_\B3JG_7,?^A"NBKG?'?\ R).J?]<Q_P"A
M"@!W@;_D2M+_ .N1_P#0C705S_@;_D2M+_ZY'_T(UT% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'DG[1/\ R3BV_P"PE%_Z!)7INB?\@'3O^O6+_P!!%>9?M$_\
MDXMO^PE%_P"@25Z;HG_(!T[_ *]8O_010!>HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=\=_\B3JG_7,?
M^A"NBKG?'?\ R).J?]<Q_P"A"@!W@;_D2M+_ .N1_P#0C705S_@;_D2M+_ZY
M'_T(UT% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'DG[1/\ R3BV_P"PE%_Z!)7I
MNB?\@'3O^O6+_P!!%>9?M$_\DXMO^PE%_P"@25Z;HG_(!T[_ *]8O_010!>H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "N=\=_\B3JG_7,?^A"NBKG?'?\ R).J?]<Q_P"A"@!W@;_D2M+_
M .N1_P#0C705S_@;_D2M+_ZY'_T(UT% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'DG[1/\ R3BV_P"PE%_Z!)7INB?\@'3O^O6+_P!!%>9?M$_\DXMO^PE%_P"@
M25Z;HG_(!T[_ *]8O_010!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "N=\=_\B3JG_7,?^A"NBKG?'?\
MR).J?]<Q_P"A"@!W@;_D2M+_ .N1_P#0C705S_@;_D2M+_ZY'_T(UT% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'DG[1/\ R3BV_P"PE%_Z!)7INB?\@'3O^O6+
M_P!!%>9?M$_\DXMO^PE%_P"@25Z;HG_(!T[_ *]8O_010!>HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=
M\=_\B3JG_7,?^A"NBKG?'?\ R).J?]<Q_P"A"@!W@;_D2M+_ .N1_P#0C705
MS_@;_D2M+_ZY'_T(UT% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'DG[1/\ R3BV
M_P"PE%_Z!)7INB?\@'3O^O6+_P!!%>9?M$_\DXMO^PE%_P"@25Z;HG_(!T[_
M *]8O_010!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N=\=_\B3JG_7,?^A"NBKG?'?\ R).J?]<Q_P"A
M"@!W@;_D2M+_ .N1_P#0C705S_@;_D2M+_ZY'_T(UT% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'DG[1/\ R3BV_P"PE%_Z!)7INB?\@'3O^O6+_P!!%>9?M$_\
MDXMO^PE%_P"@25Z;HG_(!T[_ *]8O_010!>HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=\=_\B3JG_7,?
M^A"NBKG?'?\ R).J?]<Q_P"A"@!W@;_D2M+_ .N1_P#0C705S_@;_D2M+_ZY
M'_T(UT% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'DG[1/\ R3BV_P"PE%_Z!)7I
MNB?\@'3O^O6+_P!!%>9?M$_\DXMO^PE%_P"@25Z;HG_(!T[_ *]8O_010!>H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "N=\=_\B3JG_7,?^A"NBKG?'?\ R).J?]<Q_P"A"@!W@;_D2M+_
M .N1_P#0C705S_@;_D2M+_ZY'_T(UT% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'DG[1/\ R3BV_P"PE%_Z!)7INB?\@'3O^O6+_P!!%>9?M$_\DXMO^PE%_P"@
M25Z;HG_(!T[_ *]8O_010!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "N=\=_\B3JG_7,?^A"NBKG?'?\
MR).J?]<Q_P"A"@!W@;_D2M+_ .N1_P#0C705S_@;_D2M+_ZY'_T(UT% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'DG[1/\ R3BV_P"PE%_Z!)7INB?\@'3O^O6+
M_P!!%>9?M$_\DXMO^PE%_P"@25Z;HG_(!T[_ *]8O_010!>HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN2\5>/;#PY(;6-#=W
MV,F-6PL?IN/]/Y5Q#?%K7#+N6TL G]THY_7=0![)17%>%OB)9:]<)97<7V.\
M;A!NRDA] >Q]C^==K0 4444 %<[X[_Y$G5/^N8_]"%="S*B%W8*JC)). !7
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"HKG/#/B6\UXW(NM$N=/$(!4R$D/G/ RJ\UA2?$35DD9?^$/ON"1R[ _^BZ
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M -%UO^)O$MYH(MOLVB7.H><"6,9($>,<'"MSS^E '145YZ/B-JQ('_"'7O\
MWV__ ,;KH?$'B.\T:PL[BWT2YO7N/OQH2#%P#AL \\_H: .AHKSW_A8VK?\
M0GWO_?Q__C==#K'B.\TS0K/4(=$NKF6?;OMU)#197/S8!/'3I0!T-%>>_P#"
MQM6_Z$^]_P"_C_\ QNNAOO$=Y:>&+?5DT2ZFGEV[K,$AX\YY/!../3N.E '0
MT5Y[_P +&U;_ *$^]_[^/_\ &ZZ&3Q'>)X3361HET;ANMED[Q\V,],X[]* .
MAHKSW_A8VK?]"?>_]_'_ /C==##XCO)?"DFLG1+I;A,XLLG>W.,CC.._3L:
M.AHKSW_A8VK?]"?>_P#?Q_\ XW70Z=XCO+WPU<ZK)HEU!/#NVVA)+28 .1D
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M (<NM4ET2Z@GAW;;4DEI< 'Y<@'G..G;O0!T-%>>_P#"QM6_Z$^]_P"_C_\
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M4 =W17+^)?%=]H5]%;VV@7-^CQ[S+&Q"@Y(QPIYX_6LB'XAZK+/'&?!]\ S
M$AV)'_D,4 =_17-^)_$U[H$T$=KH=SJ"RJ6+QD@+@].%/-82_$75F8#_ (0Z
M]Y..'?/_ *+H ]!HKG?$GB2\T**U>VT2YOS.#N$9(\O&.#A6YY_2N?\ ^%C:
MMG_D3KW_ +[?_P"-T >A45SVO>([S2-,L[N#1+J\>XQOA4D&'C.&P#SVZ=JY
M[_A8VK?]"?>_]_'_ /C= 'H5%<]JOB.\T[P_::E%HEU<33[=]JI(:+(S\V 3
MQTZ?E7/?\+&U;_H3[W_OX_\ \;H ]"HKGKOQ'>6WA:#5TT2ZDN)-NZS!.],Y
MY/&<<>G<=*Y[_A8VK?\ 0GWO_?Q__C= 'H5%<\?$=X/"7]L_V)=?:/\ GRR=
M_P![&>F<8YZ5SW_"QM6_Z$^]_P"_C_\ QN@#T*BN>M?$=Y<>%9M8;1+J.XCS
MBR).]\$#(XSCGT[&N>_X6-JW_0GWO_?Q_P#XW0!Z%17/:7XCO-0\.W6IRZ)=
M6\T&[;:DDM+@9^7(!YZ=.W>N>_X6-JW_ $)][_W\?_XW0!Z%17/:'XCO-7TJ
M\O)]$NK22WSLA8DF; SA<@<]NG>N>_X6-JV?^1.O?^^W_P#C= 'H5%<[X;\2
M7FN07<ESHES8&#&T.2?-SG@95>>/UK ;XBZL&(_X0Z]X/=W_ /C= 'H-%<WX
M8\37FORW"76AW.GB)00\A)#9[<J.:Q)OB'JT<SH/!]\0K$<NP/\ Z+H [^BN
M7\->*K[7KV6WN= N=/1(]XED8E2<@8Y4<\_I69>^/]4M;Z>W3PE>R+'(4#[V
M&X ]>$/\S0!W=%<GX=\77^MZD;6X\.W5C'L+><[$J".QRHJIJ?CO4[#4[FTC
M\*WDZ0R%%E#, X'\0PAX/UH [>BN/T#QEJ&L:M'93^&[NSC<,3.S,57 SSE!
MUZ=>]1ZSXWU+2]6GLX?#%Y<QQ$!9@S /QU&$/'XT =I17&:-XWU+5-6@LYO#
M%Y;1RDAIBS$)QU.4''XT_7O&>H:/JTEE!X;N[R- I$ZLP5LC/&$/3IU[4 =A
M17$:9X[U._U.VM)/"MY DT@1I2S$(#_$<H.!]:M^(O%U_HFI"TM_#MU?1[ W
MG(Q"DGL,*: .LHKA++Q_JEU?06[^$KV-9) A?>QV@GKR@Z?45I^)?%5]H-[%
M;VV@7.H(\>\RQL0H.2,<*>>/UH ZBBN A^(>K23(A\'WP#,!D.Q/_HL5M^)_
M$UYH$UNEKH=SJ E4DO&2 N.W"GF@#I**\^7XBZL6 _X0Z]Y/9W_^-UO^)/$E
MYH<-I);:)<WYGSN$9(\O&.#A6YY_2@#HJ*\]_P"%C:MG_D3KW_OM_P#XW70Z
M[XCO-(TJSO(-$NKN2XQOA4D&'(SAL \]NG:@#H:*\]_X6-JW_0GWO_?Q_P#X
MW70ZIXCO-/\ #UIJ<6B75Q-/MW6H)#19&?FP">.G3OVH Z&BO/?^%C:M_P!"
M?>_]_'_^-UT-UXCO+?PK#K"Z)=27$F,V0)WIDD9/&<<>G<4 =#17GO\ PL;5
MO^A/O?\ OX__ ,;KH?\ A([S_A$O[9_L2Z^T?\^63O\ O8STSC'/2@#H:*X.
MS\?ZI=7L$#^$KV-9'"%][':">O*#^8KO* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMT/F\;A?J]7E6SV"BBBL#D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,/ %[I-W+=Z9 ]QI[DMMC&6A]B.I'O\ G7("\NTM6M!<SK;L<M")"$)]UZ4
M)>7!N[ZXN2,&:1I"/3)S7M'PQT][+P@DKC#74S3 'L.%'_H.?QKS[PIX$O\
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M\C:    & ****\@^7"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %07UG#J%C/9W"[H9T,;CV(Q4]% '@-]9:UX$U_='(
M\3J3Y4ZCY)D_D>V1VIOB?Q;=>*5L_M5O#$]L'&8LX;=CL>G2O>;RRM=0MVM[
MRWBGA;JDBAA^M<Q<?#3PS.Y9;66'/:.9L?KF@#A(_B9J%IH5MIMC:10-! L/
MGLV\\#&0, #\<U1\*^'+[Q;KGVFZ\Q[02>9=7#Y^<]2H/<G]!7I=K\./#-LX
M<V;SD=/.E8C\A@&NH@@AMH5A@B2*)!A410H'T H D  & , 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'FGQM;;X5TD_P#4
M8@'YK)71_#Q]W@>P']TR#_R(U<O\=6V^#]*;TUFW/_CKUT/PT?=X-A']V:0?
MKG^M;K^ _7]#LCKA'_B7Y,Z^BBBL#C"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /)?BI/I4VHQQ;9TU2!%RP0&.1#R 3G((Y[
M=ZK>'_B?=Z78Q65]:"\CB4(DBOM<*.@/!!_2N\UOP)I&OZDU_>/="9E"D1R
M# _ UG?\*J\/?\]+[_OZO_Q- %$?%W3\<Z7<_P#?:T?\+=T__H%W7_?:U>_X
M55X>_P">E]_W]7_XFC_A57A[_GI??]_5_P#B: -/PMXRMO%,MS'!:RP&!58[
MR#G.?3Z5TM8/A[PCIOAF2>2P:X)G #>:X;IGI@#UK>H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "N=\=_\B3JG_7,?^A"NBKG?
M'?\ R).J?]<Q_P"A"@# ^$S9T2_7TN ?_'1_A7H-><_"1LZ=J2^DJ']#_A7H
MU;XG^*SLQ_\ O,OZZ!1116!QA1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLL"[I)%<9! 4]1]<5V8:G!QE.:ND>IE]"E*G.K55TCI/^%M7O_0+M_\ OXU
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ME8(CW/J?85K:A?P:9I\][<MMAA0NQ_H/<]*\=TV"[^(/C(S79(MU^>0 \1Q
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M6B!_D363_P *?@_Z#,G_ (#C_P"*H_X4_!_T&9/_  ''_P 50!M_\+.\-?\
M/:X_[\FC_A9WAK_GM<?]^36)_P *?@_Z#,G_ (#C_P"*H_X4_!_T&9/_  ''
M_P 50!Z4CB2-74Y5@"/I3J9%'Y4*1YSL4+GUQ3Z "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#R3]HG_ ))Q;?\ 82B_] DK8^$[
M?\2[4X_[LZG\Q_\ 6K'_ &B?^2<6W_82B_\ 0)*T_A0W.M1^CQ'_ -#_ ,*W
MI_PI_+\SLH_[O5_[=_,](HHHK XPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*ZZT*4YMRG8]+%TL-5K.4ZEGV.RUSXA:-IMI)]BN4O+O&(TCR5SZENF/IS7
M^!-&N=;\3QW\BM]GMI?/EEQP7!R!]<\_2J.M^"M9T"W-S=0QR6X(#2PON"YZ
M9Z$?E7??#WQ9%J4/]D36\-O<0INC\E0B2+WX[-W]Z'%4J3=+6^['*$,/AI2P
MWO7W?8[6]N5LK"XNG^[#$TA^@&?Z5X'X;\F?Q7827L\<<7V@2R22N%7CYN2>
M.<?K7KOC^\^Q^#;X@X:8+"OON(S^F:\E\-^%[SQ/-/':20Q^0H9FE) Y/ X!
M]#4X1)4Y2;L1ED8QP]2<G9/2_P#7J>V_\)'H?_09T[_P*3_&C_A(]#_Z#.G?
M^!2?XUYI_P *GUG_ )_;#_OI_P#XFC_A4^L_\_MA_P!]/_\ $UG[&A_.8?5<
M'_S]/2_^$CT/_H,Z=_X%)_C6G7D]I\*M3CO('N+RR:%9%,@5FR5SSCY?2O0]
M7\2:3H4D2:E=^2TH)0>6S9 _W0:RJ4XII4W<YJ]"FI*-"7,V:M%<Q_PL/PM_
MT$__ "7E_P#B:N:9XNT/6+T6EA>^;.5+!?*=>!UY( J'2J)7<68RPU:*NX.W
MHS,^)-Y]E\'S1@X:YE2(?GN/Z+7+_":SWZEJ%Z1_JHEB!_WCG_V7]:G^+=Y\
M^FV(/0/,P_(#_P!FKC=(OO$.GV['2C>1PRG<3%$2&(XZXKOI4V\/9:7/:PU!
MRP+BG9R[_P!>1] U'//%;0/-/*D42#+.YP /<UXD=>\;/\OG:GSZ0G_"HGTK
MQCKS!;BWU.<9X^T;E4?]]8%8K!V^*2.5979WG421'XRUU?$?B)[BW#&W11#!
MQRR@GG'N2?TKT34FE\)_#!( VRZ\E81[.YRV/IEORJIX1^'1TR[CU'5WCDGC
M.Z*!.50^I/<C\J=\6),:%8Q?WKG=^2G_ !K24X3G"E#9&TZM*K5I8>GK%,Y'
MX=Z*FK>)%FF3=!9KYK ]"V?E'Y\_A7MM>=_"6%5TS49\?,\RH3[!<_\ LQKT
M2L,7-RJM=CCS.HYXAKHM IDT,=Q!)#*H:.12C*>X(P13Z*Y3SS!TSP9H6D7D
M=W9V12XCSMD,KL1D8/!..A/:K?B+2SK7A^]T]2 \T?R$]-P(*Y_$"M.BK]I)
MR4F]35UJCFIMW:[GS]H^K:AX1UQI%BVS1YBG@DXW#/(/Y<&O6M$\>:+K06/S
M_LER?^6,YQD^S=#_ #]JM>(/"6E>(EW7<12X PL\7#CV/J/K7F>M_#?6-,W2
MV8%_;CG,0Q(![KW_  S7:Y4<1\6DCUW4PN-M[1\LSVFLE/"^AI=&Z&F6YG+^
M9O*Y.[.<\^]>/:'XSUGP]*(A*TUNAPUM/D@>P[K_ )XKV;1-9M=>TN._M"=C
M<,AZHPZJ:PJT9T=;Z'%B,)6PNJ>CZK]2MXMO/L'A/4Y\X/D%%/H6^4?J:\G\
M ?9X?$HO[N58K>RA>9W?H.-H_'+=*[CXJ7GD>&X+4'YKBX&1ZJH)/Z[:\CMX
M9[J9+:WC>221@JQH,EC]*ZL+3O1?F>CEU'FPLKNW-^7]7.H\8>-KCQ#*UK;;
MH--4\)T:7W;_  KHO O@2%H8-9U0)+O426\'50#R&;U/M^?MSVN> [W0_#L.
MI2R!Y=V+B)1D1 _=Y[\\'ZCZUT?PO\1;XWT*X?YDS);$GJ/XE_K^=.HTJ/[G
M9%8AI81_57HM_P"OZT/2JY[QU(T7@O4V3.3&J\>A8 _H:Z&J&MZ<-6T2\L"0
M#/$54GH&['\\5YU-I339X5&2C4C)[)H\U^$T4;:OJ$IQYB0!5^A;G^0KUFO
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MO<Z\<^%MGY_B>2Y(^6W@8@_[3$ ?INKO/'>O_P!A^'I!$^V[NLQ0X/(_O-^
M_4BC%1YJJIQ#,(>TQ$:$.B2_KY'G_BN_F\8>,XM.LFW0QO\ 9X?3.?G?Z<?D
MHKTO4%A\.>#+F.V^5+6T98_=L8!/N2?UKDOA;H&R&;6YT^9\Q6^?3^)OSX_
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M_-;;M27&,\8P.E0^=X[_ .H__P!\2_X5["^O:/&[(^K6*LIP5-P@(/IUI/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\8-]<@2$96%/F=OP_J>*B,7)V1E"$IOEBKLUZ*\UN?BY$'(M=(=U[-+.%/Y
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M5C?Z6[9C4">,>ASAO_9:]1KQ_P"$D#MX@O;@ [$M=A/NS*1_Z":]@H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=\=_\ (DZI
M_P!<Q_Z$*Z*N=\=_\B3JG_7,?^A"@#A_A6<>(;M?6R4_JG^->M5Y%\,#M\5S
M+ZZ>/YQUZ[6^(^)>B.S&_'%_W5^04445@<84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!Y/\2/"TT%\^MVD9:WFQ]H"C_5MTW?0_S^M>>5]-,H92K %2,$'H:Y
M+4OAQH&H2M+''+9NW)^SL I/^Z00/PQ7H4,8HQY9GMX/-(P@J=7IU/$JZ3P=
MX7G\1:JFY&%A"P,\G8C^Z/<_I7H-G\+M"MY0\\EU<X_@=PJG_OD _K786MK;
MV5NEO:PI#"@PJ(N *JKC8VM#<TQ.;0Y7&COW)0 H    X %+117FG@!1110
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M*X#Q3RKXM7F_4-.L@?\ 5Q-*1_O' _\ 03^===\/[+[%X-LLC#S[IF]\GC]
M*\R\=W3:AXVO%3YO+98$'N  1_WUFO;+&U6RT^VM%^[!$L8_  ?TKMK^[0A
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MFBWYW;!G/7.*EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /)/VB?^2<6W_82B_\ 0)*N^!_W7CV[3^]IT9_\=B/]:I?M$_\
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M?U^84445QGE!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <7X_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO1'#5KNHDN5+T5@HHHK,P"BBB@ KP[QUK[>(/$!BMV+VML3% %YWG/+#ZG]
M*]"^(7B'^QM#-M ^+N\!1,'E4_B;^@^OM7EFB^&=8UR.2?3;?>L+ %S($PW7
MC)ZUZ&$IJ*]K(]O*Z,81>(J.W17_ *^1['X/T >'] BMW4?:9/WDY_VCV_ <
M5S7Q:MM^E:==8_U<S1Y_WES_ .RUSG_"%>-/[LO_ (&+_P#%52U7PGXGLM.E
MNM01S;0X9LW ?'.,XS[TX4XJJI\Z;+HT(+$*LZR;O^?S.X^%-UYGAZZMB<F&
MY)'L&4?U!KK-=O/[/T&_N\X:*!V7_>QQ^N*\Y^$MUMU+4;3/^LA63'^Z<?\
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M..2  2?QX_6HP24>:;Z&64I0YZLMDO\ @LFT30=4\5ZALB+%4 $EQ)DK&H&
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MXC]W@:<%]K7]31KP3Q?<-J?C34#'\Q,_DH/]W"?TKW6[N%M+.>Y?[D,;2-]
M,UX3X3MVU3QI8"3YBUQYS^^W+G^5/!Z<T^R'E2Y/:57T7_!_0]SAL88]+CL&
M4- L(A*GH5"XQ^5>&,+CP;XSXW%K.?(_VXS_ (J?UKWRO-/BKHV4M=9B7E?W
M$V/3JI_F/Q%1A*GON,MF99962JNG/:1W6I:E';^'KG4HG#(MLTT;#O\ +E?S
MXKQOP!9_;/&=ED96'=,WX X_7%:\7B S?":ZLW?]_#,EL/783N'Z!A^%6OA+
M9[K[4;TC_5QK$I_WCD_^@BMH0]C2G?T_K[SJITGA<-6OO>W^7YGJE&!Z5QOQ
M"T/5-<L;*+3(#*T<K,X\Q4P,<=2*\_\ ^%?^*_\ H'G_ ,"8_P#XJN>G0A.-
MW-(X:&$I5(*4JJB^W],]RP/2C ]*\-_X5_XK_P"@>?\ P)C_ /BJ/^%?^*_^
M@>?_  )C_P#BJOZM3_Y^+^OF;?V?0_Y_K\/\SW*O.?B!XU^S+)HVF2_OB-MS
M,I^X/[@/KZ^GUZ6O"NF:MX9\):P;RV=+KYI(41@Y8[,#&TGO7F4>FZS%<+.F
MGWGFJP<,;=CSG.>1S5X>A#G;;ND:8+"4O:RE*2:CMV9Z+\/_  7]C2/6=3B_
MTEAFWA8?ZL?WC_M>GI]>F;\6;S?J6GV0/^JB:4CW8X_]E_6LC^W_ !S_ ,]-
M2_\  ;_[&N>U*]U#4]0:34)));OB,[UPPQQC%;PI3=7VDVF=M'#598GV]22=
MNW0]H\ V?V/P;8@C#3!IF]]Q./TQ735Y%X5O_%K:SIEA(][%8HZJRO!A1&HZ
M9*^@Q7KA(4$D@ <DFN#$0<9W;O<\7'4I0JMR:=]=#P?Q<?M'CJ_"]3<!!^
MKWFO ]-!U[QW"_)%S?>:?]W=N/Z5[Y6V,T4(]D=>:>[&G3[+_+_(****XCR
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(OBGK<T^KQZ+$Y$$"
MJ\B*?ONW(S]!C'UKIOAYX5U#P]!<SWSQJUVJ'R%Y*8SU/3/-<5XH*V_Q7,ER
M1Y0N[=V)Z;,)_2O6/$>I#2?#M_?;@K1PML/^V>%_4B@#Q3Q5J$WB/QC<>43(
M&F%M;KGC .T8^IY_&NCUGX6OI^A/>6U\T]S!'OEB*8# #)V]^/?K6+\.M/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8\UN]O'QLA&W9[%>,?E0!I  # & **** "BBB@ HHHH **** "BBB@ HHHH
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MM0O_ (_)_C7L%;UOAAZ'9BO@IO\ N_JPHHHK XPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]%%%8'&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<9)'Z5[@R*XPZAAZ$9I5147:BA1Z 8KJ^M0OS<FIZ/\ :-+FY_9+F[_TCAO
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAXS['^E<S%\(],$VZ74KIXNRJJJ?SY_E0!F?".PE-[?ZB4(A6,0*W8L2&(_
M ?G7J]5=.TZTTJRCL[&!88$Z*O\ ,GN?>K5 !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5SOCO_ )$G5/\ KF/_ $(5T5<[X[_Y
M$G5/^N8_]"% ' S_ "6'@&3_ *:'])4KV"O'[_Y?#O@>3^[(_P#Z&O\ A7L%
M;U/X</G^9V5_X%+Y_F%%%%8'&%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGQ%;^)=(6\A&R0'9-$3DHW^'H:V:\@^$=Q(NNWUL"?+DMO,8>ZL /_0C7K]
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M !7.^._^1)U3_KF/_0A715SOCO\ Y$G5/^N8_P#0A0!P.K?+X)\(2?W9&_\
M0O\ ZU>P5X_KOR_#7PS)_=D/_LW^%>P5O4_A0^9V5O\ =J7_ &]^84445@<8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2WT^[>5(F8,3$0&R#GN#7*_\*FT'_GZU'_OXG_Q% ':_;+7_ )^8?^^Q7/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,FABN(
M7AFC22)P59'&0P]"*?10!G+X?T5!A=(L /06R?X5G:U-I?@_2+G5K72K9)0
MF((EC+$G@$@=,UT59'B;0_\ A(M$ET[[1]GWLK>9LWXP<],C^= '@FL:S>Z[
MJ#WE],9)&X '"H/11V%6=!\0'P_.;B'3K.XN,_)+<*S%/]W! 'UZUW/_  I[
M_J._^2G_ -G1_P *>_ZCO_DI_P#9T 9O_"V];_Y\M/\ ^^'_ /BJ[G3I9/&_
M@)C>)%%)>)(A\L':K!B%."2>" :YC_A3W_4=_P#)3_[.N[\-Z+_PC^A0:9]H
M^T>46/F;-F<L3TR?7UH ^>KVSGT^]FM+F,QS0L4=3V(KT.T^*GD>&UMGM)&U
M..+RTER-A(& QYSGIQW]J[?Q)X.TOQ*H>Y5HKI5PEQ%PV/0^HKC#\'Y/-P-:
M7R_4VW/Y;J /-889;JX2&)&DFD8*JCDL37T-X9T<:#X>M-/)!DC7,C#NY.3_
M #Q^%4/#7@?2_#;">/=<7F,>?+V]=H[?S]ZZ:@ HHHH *YWQW_R).J?]<Q_Z
M$*Z*N=\=_P#(DZI_US'_ *$* .-U=<_!S2CZ2(?U:O2-(;=HUBWK;QG_ ,=%
M>=ZDN?@Q8'TV'_Q\UW^@-O\ #FEMZVD1_P#'!6\OX*]6=D_]TCZO]#1HHHK
MXPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCWB'49_'_BR"VTR)S @\N(D=%S\TC>@_P'>J_P#PK;Q1_P ^"?\ ?]/\:/\
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M3)[^62S3 $1QT'0$]2![UL>#/!MSXAOHYYXFCTV-@9)&&/,_V5]?<]J /4O
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#*UWQ%IWAVT$^H3;=V?+C49>0CT
M'^17%S?%^T5OW.D3.OJ\P4_H#7,?$*>?4O'4UHI9O+\N"%">Y /\V-=KI_PK
MT2"U07KW%S/@;V#[5S[ =OK0!F_\+@C_ .@(_P#X$C_XFC_A<$?_ $!'_P#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KW=A9ZA&L
M=[:07**=P6:,. ?7!%4_^$:T'_H":;_X")_A6I10!E_\(UH/_0$TW_P$3_"C
M_A&M!_Z FF_^ B?X5J44 ,BBC@A2*&-(XD 5$08"@=  .@I)X(;F%H9XDEB;
M[R2*&!^H-244 9">%M 27S%T:Q#?]<%Q^6,5K*H50J@!0,  <"EHH **** "
MBBB@#R3]HG_DG%M_V$HO_0)*]-T3_D Z=_UZQ?\ H(KS+]HG_DG%M_V$HO\
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M\*_N_B3XDC_O;F_\?'^->@5OB/COY+\CLQW\6_=+\D%%%%8'&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!X=XXA6W^(TSW:G[/))#(
M21]Y-J@_R(_"O;T*F-2F-F!MV],>U>3?%34;.;4TL&LF%Y BLETLG56Y*E<<
MC\:Q-#^(6MZ':I:*T5S;(,(DZDE!Z @@X^N: /=J*\E'Q>O\<Z7;$^TC4?\
M"WK[_H%6_P#W\:@#UJBN/\%>,Y_%4]Y'-:1P>0JL"C$YR3Z_2NPH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=\=_\B3JG_7,
M?^A"NBKG?'?_ ").J?\ 7,?^A"@#)L5W?!XC_IPD/Y;JT/AXV[P/IX]#(/\
MR(U4]*7=\(V'KITW\FJ?X;MGP7;#TDD'_CQK=?P'Z_H=B_W1_P")?DSK:***
MP.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *Q?%NE2:UX7OK*$9F9 T8]64A@/QQC\:VJJ:IJ,.DZ7<W]Q_J
MH$+D#J?0#W)P/QH \Q^%^NVVFSWFDWT@MWF</&9#M&\<%3GH>GY&O6:^<-8U
M.?Q#K,MX;:-)9FXB@3KZ=.2??O5RWLO%L,8%O;:VB=O+CE _2@#Z#HKP+R?&
MO_/+Q!_WS-1Y/C7_ )Y>(/\ OF:@#WVBHK?=]FBWYW[!NSUSBI: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R3]HG_ ))Q;?\
M82B_] DKTW1/^0#IW_7K%_Z"*\R_:)_Y)Q;?]A*+_P! DKTW1/\ D Z=_P!>
ML7_H(H XW0_W7Q<UM/[UN3_Z+->@5Y_:?N_C-??]-+8?^BT_PKT"MZ^\?1'9
MC/B@_P"ZOR"BBBL#C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)Z, >H]0?\*[J#XOVY0?:-(E5N_ES C]0* /2Z*\Y_X6[I__ $"[K_OM:/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q#QR9-5^(LEG
MNXWPVT?L"!_5C7LNG:?;:5I\-E:1B.")=JC^I]2:\?\ B393Z9XS&H("%N%2
M:-NP90 1^@/XUZ5X9\6Z?XBL8F2:..\Q^]MBV&5N^ >H]Z .@K%\5Z-;ZWX>
MNK>9 71&DA;NC@'!_H?8UM5Q7CGQE9:7I5Q8VL\<U_.ABV(V?*!&"6QT/H*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9B=:=)^7ZL****P.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHH \D_:)_P"2<6W_ &$HO_0)*]-T3_D Z=_UZQ?^@BO,OVB?^2<6W_82B_\
M0)*]-T3_ ) .G?\ 7K%_Z"* .-^(/[OQ)X6F]+D_H\9KT"O/_B;\DV@S?W+E
MO_93_2O0*WJ?PX?/\SLK_P"[TGZ_F%%%%8'&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !17)?$35;O2/#*SV4[P3O<(@=.H&"?Z4GP[UB_U
MOP_-<:C<^?,ERT:MM"D*%4]@/4T <;\4]2676Q8-90;HHU9+GGS.>2.N"/J*
MY?2/%>MZ''Y5A?.D.<^4P#K^ .<?A7H_BCQ-8V'BR/39] LKQW$8,\P4M\Q]
MU/3ZUV']@:-_T"+#_P !D_PH \C'Q1\1@8+VI]S#_P#7H_X6CXC];3_OS_\
M7KUS^P-&_P"@18?^ R?X4?V!HW_0(L/_  &3_"@#EOA_XLU/Q)<7T>H>21"B
M,GEIMZDY[^U=U5:UTZQL2QM+.WMRW#&*)4S]<"K- !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5SOCO_D2=4_ZYC_T(5T5<[X[_
M .1)U3_KF/\ T(4 .\#?\B5I?_7(_P#H1KG_ (=?+K?B>/TN5_\ 0I*Z#P-_
MR)6E_P#7(_\ H1KG_ GR>+_%4?\ T\G])'K>G_#G\OS.RA_ JKR7YGH%%%%8
M'&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %! (((R#VHKG/'=]+I_@W4)H&*R,JQAAV#,%/Z$T <-XL^&UW!
M=27FAQ>?;.2QMP?GC/HH[C]:Y=-4\4:.OV<7.IVJKQY;EP%_ ]*[+X57^IWE
M]=Q3ZA-):01#$,C;OF)XQGD 8/3UKU*@#YZ>;Q/X@(A=M3O5/\'SLOUQTKO?
M!/P\ET^[CU365431G=#;@AMC=F8CC(["O2** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH \D_:)_Y)Q;?]A*+_ - DKTW1
M/^0#IW_7K%_Z"*\R_:)_Y)Q;?]A*+_T"2O3=$_Y .G?]>L7_ *"* .-^*PVZ
M1ITHZI<_^RD_TKT '(R*X7XK)GPQ;-_=O%_] >NTM'\RS@?^]&I_2MY_PH_,
M[*NN&I^LOT)J***P.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** .=\;:)-KWAF>UMAFX1A+$N<;B.WX@FO&--US6_#%Q-%:3RVCDXEBDC!Y'
MJK#@U]$U'+;PS?ZV&.3_ 'E!H ^<]0UR_P!4U5=2NY5>Z7;A@@ ^7IP.*W/^
M%D^*/^?Z/_OPG^%=;XE\#:CJ7BZ+4+*&U6S4QY4L%^Z>>,5WW]GV7_/G;_\
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M7Q0;0>&-0-\)C:^4?,$) <C/;/% 'AVDZ[-X:UI[O29C+%RF)DV^8GHP!X_
MUWMO\7[<H/M.D2JW?RY@P_4"JOAGPAX5\46T\]J-5B6%PA$LJ9)QGLM;G_"J
M/#__ #VO_P#OZO\ \30!4_X6[IO_ $#;O_OI?\:/^%NZ;_T#;O\ [Z7_ !JW
M_P *H\/_ //:_P#^_J__ !-'_"J/#_\ SVO_ /OZO_Q- ';QN)8DD (#*&&?
M>G4V-!'&J+T4 "G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1IG]J:?_ ,_]K_W^7_&G9E<LNQ;HJI_:FG_\_P#:_P#?Y?\ &C^U-/\ ^?\
MM?\ O\O^-'*^P<DNQ;HJ"&\M;ABL%S#*P&2$D#''X5/2L)IK<****!!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %<[X[_Y$G5/^N8_]"%=%7.^._\ D2=4_P"N8_\ 0A0
M[P-_R)6E_P#7(_\ H1KG] ^3XM:ZGK 3^L?^-=!X&_Y$K2_^N1_]"-<_I?R?
M&/5E_O6P_P#08S6]':?H=F%^&HO[OZH] HHHK XPHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M //A8_D__P 57H?_  AGAS_H#VO_ 'S1_P (9X<_Z ]K_P!\T ;,#F6WCD(
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M"O/_ !E_R/OA?_KJO_HP5Z!6]7X(>GZG9B/X5+T?YL****P.,**** "BBB@
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MIRD[R9YU2I.H^:;NPHHHJ2 HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME_\ 7(_^A&N?/R?&<?[=M_[3_P#K5O0^UZ,[,'_R\_PO]#T"BBBL#C"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:W7\%^IV1UPDO\2_)G84445@<84444 %%%% !1110 4444 >?^,O^1]\+_\
M75?_ $8*] KS_P 9?\C[X7_ZZK_Z,%>@5O5^"'I^IV8C^%2]'^;"BBBL#C"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_3_ /DLNJ?]
M>P_] CKT"O/]/_Y++JG_ %[#_P! CKT"MZ^\?1'9C-X?X8_D%%%%8'&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTD%;T-Y>C.S![S7]U_D>@4445@<84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** //]/_Y++JG_ %[#_P! CKT"O/\ 3_\ DLNJ?]>P_P#0(Z] K>OO
M'T1V8S>'^&/Y!1116!QA1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 <1XG^(8\-ZRVG?V6;C:BOY
MGG[.OMM-8W_"X1_T S_X%_\ V%4OBI<:?_:T=M#:(U^R*TUQN8D#^%0,X]^G
MI5[PW\+89+2.ZUR27S)%W"VC.W9_O'KGV&,4 )_PN$?] ,_^!?\ ]A1_PN$?
M] ,_^!?_ -A72GX;^%C'L&GL#_?$\F?_ $+%<'XT^'_]@6W]HZ=))-9@XD1\
M%HL]#D=1V]J -R+XOVQ8>;H\J+ZI.&_H*ZW0/%^D>(\I9S,EPHR8)AM?'J.Q
M'TKA/!_A3P[XIT%G=+B"]A/ES&.7J<<, 0>O\P:YS7]$O_ _B"!X;@G!\VVN
M%&,X/((]?4>A]Z /?**J:7?IJFE6E\@PMQ$LF/3(Y%6Z "BBB@ HHHH ****
M "BBB@ KSSQ;\2'T?5C8:7#;W#1<3O+D@-_=&".G?_ZU:GCWQ8/#VF_9K5Q_
M:-RI$>/^6:]W_P /?Z5XB\<QB%PZMLD=E$AZ,PP3SZ\C\Z /5/"OQ$U/7O$E
MKIMQ:VD<4V_<T8;<,(6XRQ]*])KP?X<_\CWIWTE_]%M7LGB+51HGA^]U#@O%
M'\@/0N>%_4B@#&\5>/;#PY(;6-#=WV,F-6PL?IN/]/Y5Q#?%K7#+N6TL G]T
MHY_7=7"S327,\D\SEY9&+NS=6)Y)KU:T^%UC-X93S))5U22+?YF[Y5<C(7'I
MV]: -/PM\1++7KA+*[B^QWC<(-V4D/H#V/L?SKM:^82)()B.4D1NW!!%?0/@
M_66UWPS:WDIS. 8YCZNO!/X\'\: -VBBB@ KG?'?_(DZI_US'_H0KHJYWQW_
M ,B3JG_7,?\ H0H =X&_Y$K2_P#KD?\ T(US_B'Y/BQH+^L 7]9/\:Z#P-_R
M)6E_]<C_ .A&N?\ %7R?$KPX_KM7_P ?/^-;X?XGZ,[,%_$:\G^1Z!1116!Q
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7YGH%%%%8'&%%%% !1110 4444 %%%% 'G_C+_D??"__ %U7_P!&"O0*\_\
M&7_(^^%_^NJ_^C!7H%;U?@AZ?J=F(_A4O1_FPHHHK XPHHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#P[QBZVGQ,FGN1NB2>&1AZH%0X_+BO;HI8YX4EB
M=7C=0RLIR"#T(KA?B)X/FUJ./4]/3?>0IL>(=9$SD8]QD_7\*X'1O&FO>&0;
M2-P\2$C[-=(2$/?'((^F: />ZY[QQ=V]IX.U$W!7][$8D!/WG;@8_G^%<$WQ
M<U4QX73K,/\ WB6(_+/]:YR\U/7_ !OJ44+;[F0?ZN&)<(GJ<=OJ?SH Z[X/
MJ_F:N_/EXB'U/S5-\7Y(_(TJ+(\W=(P'<+A?\_A70:;I8\#>![QE=9+J.)YY
M'Q\IDV\#Z# '_P"NO*X4UKQUX@02,\\S85Y-N$A3\. .OU/N: /8? ZNG@O2
MP_7R<_@22/TQ705#9VL5C906D"[8H8UC0>P&!4U !1110 4444 %4-8U>UT/
M3GOKTN($(!*+D\G XJ_6%XOT6YU_P[-I]H\23.R,#*2%X8$] : ,W_A9GAG;
MG[5-GT\AO\*D'Q!T232+W4(7E9;7:NUUVF1VSM4?D?I7$CX2:SCF^L,^S/\
M_$UG:_X3O_#'ATK>2P2FXNXRGD%CC:C]<@>M %"UM]3\<^*3N;,T[;I'Q\L2
M#^@' 'TKIOB;IEMH^EZ!8VB;(8A,!ZD_)DGW)YKS^">ZMB3!+-$3P3&Q7/Y4
M7%S=7&W[3/-+MSM\QRV/IF@#H_AS_P CWIWTE_\ 1;5Z%\4W9?!X Z/<H#],
M,?Z5XO#++#*)(7=)!T9"01^(KL='M[S6/ OB+S99I7MVAF3S&+?=W%L9]LT
M<A;*'NHD/1G _6OIROE]6*.K*<$'(KZ2M=6M+G18]5$JBU:'S2^>%&,G/TY_
M*@#Y\U]53Q%J:K]T7<H'TWFO3_A&['0+Y#G:MUD?4J/\!7D]Y<&[OKBY(P9I
M&D(],G->T?#'3WLO""2N,-=3-, >PX4?^@Y_&@#>\07NH:?I+W&F67VRZ#*!
M#@G()Y/%<C_PEOC7_H5/_''_ ,:]"HH \]_X2WQK_P!"I_XX_P#C67XC\1^*
MKSP_>6]_X=^S6KH!)-M8;1D>IKU:N=\=_P#(DZI_US'_ *$* #P&6;P3I988
M/EL/PW'%8/C/Y/'GA=_695_\B+_C70>!O^1*TO\ ZY'_ -"-<_X\^3Q9X5D_
MZ>1^CQUOA_XGR?Y'9@?XUO)_DST"BBBL#C"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZQ\0ZW;W6GN[1);",EUVG=N8_P!11X UZQ\/:Y/=:@[K$]LT8*+N.XLI_H:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/YT >'^%/ E_KMS'-=Q26VG#YFD<8,@]%'OZ]*]PBBC@A2&) D:*%55'  X
MI]% !1110 5SOCO_ )$G5/\ KF/_ $(5T5<[X[_Y$G5/^N8_]"% #O W_(E:
M7_UR/_H1KG_B-\NL>&9/[MRW_H4==!X&_P"1*TO_ *Y'_P!"-<_\3?EET*3^
M[<G_ -E_PK?#?Q5\_P CLP'^\1^?Y,] HHHK XPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 >?Z]_R5S0O^O8?SEKT"O/]>_Y*YH7_7L/YRUZ!6];X8>AV8KX*?\ A_5A
M1116!QA1110 4444 %%%% !1110 4444 >?Z?_R675/^O8?^@1UZ!7G^G_\
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MT^E=+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH **** "BBB@ HHHH **** "BBB@ HHHH ***@O+N&PLIKNX;;#"A=SZ #-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7*_$9W3P-?[,C)C#$>F]:ZJL[7;*VU'0KVTO)4B@EB(:5R $[ACGT.#^%
M'GWPFTFTF6]U.6-9+B)Q%%N&?+&,DCW/K[5ZE7A_A3Q&W@O7+FVNBMQ9R$+*
M;=PXR.CJ0<'@]/?VKTZ'QWX9G0,NK1+GM(K*1^8H Z*BL+_A-/#?_08M?^^J
M/^$T\-_]!BU_[ZH W:*16#*&4@@C(([TM !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!Y)^T3_R3BV_["47_ *!)7INB?\@'3O\
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M<M>@5Y_KW_)7-"_Z]A_.6O0*WK?##T.S%?!3_P /ZL****P.,**** "BBB@
MHHHH **** "BBB@#S_3_ /DLNJ?]>P_] CKT"O/]/_Y++JG_ %[#_P! CKT"
MMZ^\?1'9C-X?X8_D%%%%8'&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %5=2U"'2].GOK@.8H$WL$
M&21["K5! (((R#36^HU:^IPO_"U]"_Y]-1_[]I_\71_PM?0O^?34?^_:?_%U
MVOV6W_YX1?\ ? K'\56T"^%-5988P1;/@A1Z5O%T6TN7\3MA/#2DH\CU\_\
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M?_7(_P#H1JG\2%SX*NCZ/&?_ !\5K0_B1]3IP;_VB'JC=T-M_A_36];6(_\
MC@J_67X:;=X6TD_].<7_ * *U*B?Q,QJZ3?J%%%%20%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F^(--DU?0+S3X7
M1))X]JL^<#GOBM*D9E12S$*JC))/ % 'D'_"I-8_Y_['\W_^)H_X5)K'_/\
MV/YO_P#$UJZQ\68H;AHM)LA.BDCSIF(#?0#G'U/X5E_\+<U;_H'V7_C_ /C0
M G_"I-8_Y_['\W_^)H_X5)K'_/\ V/YO_P#$T'XN:OVL+'\G_P#BJI7WQ0\0
MWD1CB-M:9_B@C.[\V)_2@#VF!#%;QQD@E5"G'L*DJ*V8O:PLQRS("3[XJ6@
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MO)%;U1*,HNTE8RG3G3=IJS"BBBI("BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MY+XD_P#(EW/_ %TC_P#0A76UR7Q)_P"1+N?^ND?_ *$*UH?Q(^IT83_>(>J-
MKPW_ ,BOI'_7E#_Z *TZS/#?_(KZ1_UY0_\ H K3J)_$S.K\<O5A1114F844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G^O?\E<T+_KV'\Y:] K
MS_7O^2N:%_U[#^<M>@5O6^&'H=F*^"G_ (?U84445@<84444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-;M*I\;]2:ZM5EZL****@R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU96*_CS]7^84445F8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB_\ H:U+X+_Y$[2_^N/]36__ "X^?Z'9_P P?_;WZ&[1116!QA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %8_BO_D4M5_Z]7_E6Q6/
MXK_Y%+5?^O5_Y5=/XT:T?XD?5&?\//\ D1]/^LO_ *,:NHKE_AY_R(^G_67_
M -&-744ZW\27JRL5_'GZO\PHHHK,P"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQRTO9\W[R]O(K?\ ";^&O^@M#^3?X4?\)OX:_P"@M#^3?X4?\(/X:_Z!,/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\_5_F%%%%9F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN<<X[2>]+9^)?'M_:1W5KHUE)!*-R.!C(_&2NE\>?\B3J?\ N+_Z&M2^"_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKQOJ-MHZQVEK;@^9*%)4N.#@=LG/3L,UZ%XQUS^P?#D]PC8N)/W4'^\>_P"
MR?PJMX"T/^QO#D;2KBZN_P!]+GJ,_='X#]2:Z:4G2@ZBZZ(]##3EAZ4JR>KT
M7ZOY'F-OX+O)_%<^@"Y@$T";VEYVD84\<9S\PKT?PY\/M-T.9+J=S>7:\J[K
MA$/J%]?<_I6=I_\ R675/^O8?^@1UZ!5XBO4:2OND:XW&5FHQOHXIOYA4-S:
MV]Y"8;J".:)NJ2*&!_ U-17&>6FUJCB=2^&NF32?:-*GFTVX!RIC8LH/TSD?
M@:X#Q;<Z[:W"Z)J^HB[6W(D4@YSD<9. 2<>OK7NM>)?$FW>'QG<2,#MFCC=?
MIM"_S4UWX2I*<[2U/9RRO.K5Y*CO9:7W^\Y&BBBO3/H KWKP3J\FL^%K6>9B
MT\>896/<KW^I&#7@M>S_  OMWA\)%W!Q-<O(OTPJ_P U-<>.2]G<\K-XQ=!-
M[IG:4445Y)\T%%%% 'G_ ,,?^8W_ -?(_P#9J] KS_X8_P#,;_Z^1_[-7H%;
MXG^*SLQ_^\2^7Y(****P.,**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#G?'G_(DZG_N+_Z&M2^"_P#D3M+_ .N/]347CS_D2=3_ -Q?_0UJ7P7_
M ,B=I?\ UQ_J:W_Y<?/]#L_Y@_\ M[]#=HHHK XPHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_7O^2N:%_U[#^<M
M>@5Y_KW_ "5S0O\ KV'\Y:] K>M\,/0[,5\%/_#^K"BBBL#C"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "L?Q7_R*6J_]>K_RK8K'\5_\BEJO_7J_\JNG
M\:-:/\2/JC/^'G_(CZ?]9?\ T8U=17+_  \_Y$?3_K+_ .C&KJ*=;^)+U96*
M_CS]7^84445F8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+^(/ >C:]
MNE,7V6[//GPC&3_M+T/\_>NHKFM5\>>'](N&MYKPRS+]Y(%WX/H3TS[9H \Z
MN=#\5^!+AKJQE>2U!RTL'S(1_MH>GU_6NHT#XHV-Z%M]9B%I*>/-4%HF^HZK
M^H]ZO6_Q0\.3OM=KJ $XS+#D?^.DT:MX'\/^*+?[=I\D<$L@RL]K@HQ]UZ'\
M,&@!M_\ #GPYK)%Y92/;+(-P-JX,;>X'(_+ JI!\)-)1@9[^\E /1=JY_0UR
MDMAXM\ 3M- [M9YR7C^>%O\ >7L??CV-=AX?^)^FZAM@U118W!XWYS$Q^O5?
MQX]Z .PTS2;'1K06NGVR01 Y(7JQ]2>I/UJY38Y$EC62-U=&&593D$>QIU !
M1110 4444 %%%% !1110 4444 %%%4;O6=+L&*7>HVD#C^&695/Y$T 7J*KV
MFH65^I:SNX+A1U,,@<#\JL4 %%(S!5+,0% R23P*S6\1Z&DOEMK%@']#<I_C
M0!IT4U)$E17C=71AD,IR#3J "BBB@ KG?'?_ ").J?\ 7,?^A"NBKG?'?_(D
MZI_US'_H0H =X&_Y$K2_^N1_]"-=!7/^!O\ D2M+_P"N1_\ 0C704 >?^%/D
M^)'B1/7<W_CX_P :] KS_P ._)\5M?3UA+?^/)_C7H%;XCXEZ+\CLQO\1/R7
MY!1116!QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8W_U\C_V:O0*WQ/\5_UT.S'_ .\2^7Y(****P.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#G?'G_(DZG_ +B_^AK4O@O_ )$[2_\ KC_4U%X\
M_P"1)U/_ '%_]#6I?!?_ ")VE_\ 7'^IK?\ Y<?/]#L_Y@_^WOT-VBBBL#C"
MBBJFJW9L-(O;P#)@@>0#U(4FFE=V&DV[(X/QSX]FLKF32=(<+,G$]P.2I_NK
M[^IKR^:>:YE:6>5Y9&Y9W8L3^)ILCO+(TCL6=B69CU)/>FU[E*E&G&R/L,-A
MH4(<L5KW+-E?W>G7 GLKF6"4?Q1L1^?K7L'@?QI_PD,;65[M34(UW9' E7U
M['U'^1XM6AH5^^F:[8WD9(,4RD^ZYP1^()%37HQJ1?<C&82%>F]->C/HNBBB
MO$/D2CJ6CZ?K$:1ZA:1W"H<KO['VK._X0CPW_P! F#\V_P :WZ*I3DE9,TC6
MJ15HR:7J>6_$7P_I6D:=8R6%E' \D^UBI/(QTY-=G_PA'AO_ *!,'YM_C7/?
M%;_D%:=_U\G_ -!->@5T3J3]E%W[G;5K55AZ;4G]KKZ& /!/AL$$:3!QZY/]
M:W@ H    X %+17/*4I;LX9U)S^)MA1114D!1110 4444 %%%% ''?$K439^
M%C;(?WEY(L0 Z[1\Q_D!^-;^@:<-)T"QL<8:*(!_]X\M^I-<=X@_XGOQ,TK2
MA\T%BHEE'8'[YS]0$'XUZ'6]3W:<8]]3LK>Y0A3[^\_GM^!Y_KW_ "5S0O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "L;Q80/"6JY('^C/_*L7QOXU'A]1
M9605]0D7)+<B)?4CN?0?C]?(;[4KW4YS->W4L\A[R,3CZ#M^%=F'PLIVF]$>
MK@LNJ5+56[+\SVGX=D'P/8 $9!DS_P!_&KJ*^:[6\N;&836EQ+!(.C1N5/Z5
MZKX'\=OJTRZ7JI7[61^ZF P)<=B.S?S_ )UB,+)-S6I6.RZI%RK1=TVWZ'?T
M445PGD!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&?%MKI]SYQTR;S-QC.^%L(Q!_P!DY ]#7J5%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG>Q-%K*955D_N#J%]\]?;&.]36J<D&UN1BJZI4I-:M+^F>H4445X9\>%%%%
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M];X8>AV8KX*?^']6%%%%8'&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M..KW\FJ:O=WTA)::5GY[#/ _ 8%4JMZI8R:9JMU92 AH)63GN >#^(YJI7T$
M;65MC[B'+RKEV"I()Y+:XCGA8I+$P=&'8@Y!J.GPPR7$\<,2EI)&"*HZDDX
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9XP3Z!CC^>*ZJO"G'EDX]CXRM3]G4E#LPHHHJ#,**** "BBB@ HHHH ****
M"BBB@ HHHH ***S=:UVPT"R-U?S;%/"(O+.?0"FDV[(J,7)\L5=F?X\_Y$G4
M_P#<7_T-:E\%_P#(G:7_ -<?ZFO./$GQ&N-;L;C3X+&*&UF !9V+/@$'M@#I
M[T_P[\2)]'LK>PN;&.:UA78&C8JX'XY!_2NWZM4]CRVUO<];ZA7^K<EM;W_
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M.O0*\_T__DLNJ?\ 7L/_ $".O0*WK[Q]$=F,WA_AC^04445@<84444 %>?\
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M/("BBB@!DW^HD_W3_*N%^%'_ "+EW_U]G_T!:[J;_42?[I_E7"_"C_D7+O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'MY-3BW*;W04445Z1[YHZ#+9P:[927\"S6HE D1^F#QD^N.N.^*^B54*H50
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MZWPP]#LQ7P4_\/ZL****P.,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_H0K6A_$CZG1A/\ >(>J-KPW_P BOI'_ %Y0_P#H K3K,\-_\BOI'_7E#_Z
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MTY.X]PN>?^^BU=U6V(?O\JZ:'7C6E4]FMHI+_/\ $****P.,\_U[_DKFA?\
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MG+7H%>?Z]_R5S0O^O8?SEKT"MZWPP]#LQ7P4_P##^K"BBBL#C"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH S]<U:+1-&N=0FP1$ORK_ 'F/ 'XFN7^'>DRBVN?$
M%]EKS4&+*Q'(3.<_B?T JCXIE?Q7XPM/#5LY^RVS>9=LOKW_ "!Q]6KT.*)(
M8DBB4)&BA54= !T%=$OW=/EZR_([9_N*"A]J>K].GW[CZQ_%?_(I:K_UZO\
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M5Y_\0_DU[PO)Z7+?^A1UZ!6]3^'#Y_F=E?\ @4GY/\PHHHK XPHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX2[LX+F/[DT:R+]",BIJS?#R-%X:TJ-_O+9Q _78*TJ "BBB@ HHHH ****
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MLG<X,R<5AI7\OS/2****\8^4"BBB@#S_ $__ )++JG_7L/\ T".O0*\_T_\
MY++JG_7L/_0(Z] K>OO'T1V8S>'^&/Y!1116!QA1110 5Y_X"_Y&OQ5_U\_^
MSR5Z!7G_ ("_Y&OQ5_U\_P#L\E;T_P"'/Y?F=E#^!5]%^9Z!1116!QA1110
M4444 >?_  Q_YC?_ %\C_P!FKOW19$9'4,K#!4C((K@/AC_S&_\ KY'_ +-7
MH%;XG^*SLQ_^\2^7Y(\SB+_#SQ<8G+?V%J!RI/(C/_V.?Q!]J]+!# $$$'D$
M5F>(-$M_$&CS6,^ 6^:.3'*..A_SVS7,^!-;N(9)?#&JY2^L\K%N/WT';WP.
M1ZCZ4Y?O8<_5;_YE5/\ :*7M5\4=_-=_\SNJ***YSA&3?ZB3_=/\JX7X4?\
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M20[=PSC.^M?81Y>;GT^9O]4I\G/[16VV9Z517G__  @OB/\ Z'&\_P"^Y/\
MXNNVTZVFL].M[:XN7N98T"O,_5SZFLIPC%:2N<]6G3@KPGS?)EJBBBLS ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K)\2:U'H&A7%\V"ZC;$I
M_B<]!_7Z UK5YQK;'QEXZM]%B).G:>2]R1T)'WOZ+^=:T8*4M=EN=.%I*I.\
MOA6K]#5^'FBR6>E2:K=Y:]U$^86;KLZC\\D_B*[*D50JA5 "@8 ':EJ:DW.3
MDS.M5=6HYOJ%8_BO_D4M5_Z]7_E6Q6/XK_Y%+5?^O5_Y44_C04?XD?5&?\//
M^1'T_P"LO_HQJZBN7^'G_(CZ?]9?_1C5U%.M_$EZLK%?QY^K_,****S, K#\
M4^&[?Q+I36[X2X3+02X^ZWH?8]__ *U;E%5&3B[HN$Y4Y*47JCB?!7B2X>5_
M#NLYCU.URJ%SS(H[>Y []QS7;5R'C7PO)JD2:KIF8]6M,,A3@R <X^H[?E5S
MP?XHC\1Z=B7$=_!\L\73_@0'H?T-:U(J:]I'Y^1U5X1J1]O37JNS_P F='11
M16!Q!1110 45PU[K_C:*^GCM_#L+P+(1&QRVY<\'(85!_P )'X\_Z%N#_OEO
M_BZW5"3ZK[SK6#FU?F7WH] HKS.T\<^+;ZZN+6UT2UEGMFVS(JME#DC!^;U!
MJY_PD?CS_H6X/^^6_P#BZ;PTUNU]Y3P%2+LVOO1Z!17.>&M3\17\\ZZUI4=G
M&J@QNN1N.>F"371UC*+B[,Y:E-TY<K_#4****D@**** "BBB@ HHHH ****
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M^%>@5Y_\4OEMM(D_NW)_D/\ "O0*WJ?PH?,[*W^[TO\ M[\PHHHK XPHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8YXUD7VR,XHK>]&-3OH_5#Q7[R$*W?1^J_S18HHHK X@HHHH **** "BBB@
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M?^./7;6S;K6)O5 ?TK>?\*/S.RK_ +M3]9?H2T445@<84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!!-96ES_K
M[6&7/_/2,-_.L#7=6T'PA';R3Z: )V8)]FMTR,8Z\CUKIJ\T^+__ !Z:5_UT
MD_DM '<:%KEKXATT7]HDJ1%RF)0 V1]":TZXSX7_ /(FI_UWD_I79T %%%%
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M"BBBLS **** .=\>?\B3J?\ N+_Z&M2^"_\ D3M+_P"N/]347CS_ )$G4_\
M<7_T-:E\%_\ (G:7_P!<?ZFM_P#EQ\_T.S_F#_[>_0T=5T^/5=*NK&7[D\93
M/H>Q_ X-<E\--0D_LZ[T6Y^6XT^8C:>RDG(_!@WYBNYKSK5/^*8^)UIJ ^6S
MU1?+E/;<< _KL;\312]Z,J?S7R'AOWE.='YKU7^:/1:***P.(**** "BBB@
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >2?M$_\
M).+;_L)1?^@25Z;HG_(!T[_KUB_]!%>9?M$_\DXMO^PE%_Z!)7INB?\ (!T[
M_KUB_P#010!>HHHH \_^*7_'MI'_ %\G^0KT#I7G_P 4O^/;2/\ KY/\A7?2
M(LL;1N,HP*L/4&MY_P *'S.RM_N]+_M[\R@?$&B@X.KV (_Z>4_QIK>(-%V-
M_P 3>PZ?\_*?XUB'X:^&R?\ CWG'MYS4?\*U\-_\^\__ '^:BU'N_N#EPG\T
MON7^9B?#'4]/L=#NX[N^MK=VN<A9950D;5YY-=Q_PD&B_P#08T__ ,"4_P :
MPO\ A6OAO_GWG_[_ #4?\*U\-_\ /O/_ -_FJZDJ,Y.5WJ:UYX6K4=1N6ODO
M\SI[6\M;V,R6ES#<(#@M%(' /ID5/67HGA_3O#\$L6GQ,BRMN<LY8D]NM:E<
MTK7]W8X)\O,^38BFMK>XQY\$<N.F] V/SJ+^S+#_ )\K;_OTO^%6J*+L2DUL
MRK_9EA_SY6W_ 'Z7_"C^S+#_ )\K;_OTO^%6J*.9CYY=RNEA9Q.'CM($<=&6
M, BK%%%*]Q-M[A1110(**** "BBB@ HHHH **** //\ 3O\ DLNJ_P#7L/\
MT".O0*\_T[_DLNJ_]>P_] CKT"MZ^\?1'9C-X?X8_D%%%%8'&%%%% !1110
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MF,WA_AC^04445@<84444 %%%% !1110 4444 %%%% 'G_P ,?^8W_P!?(_\
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M5N_X"]?T.Q_[HO\ $_R1JT445@<84444 %%%% !1110 4444 %%%% !1110
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M+ZWXOO9(OG,]R8XO< [5_0"O;O%6M1Z%X>N[MI LNPI ,\LY&!CZ=?H*\?\
MA]IIU+QC9Y7,=L3<.?3;T_\ 'MM 'N5E:QV-A;VD0_=P1K&OT Q6;XMB2;PC
MJRR %1:NPSZJ,C]0*V:XSXDZW%IOAF2R5Q]IO?W:J#R$S\Q^F./QH X_X2NP
M\37:#[K6;$_@Z?XU['7E/PBLF-YJ-^1A%C6$'U).3_Z"/SKU:@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YWQW_R).J?]<Q_Z
M$*Z*N=\=_P#(DZI_US'_ *$* '>!O^1*TO\ ZY'_ -"-=!7/^!O^1*TO_KD?
M_0C704 <E\25SX+N#Z21G_QX5M>'6W>&-);ULX?_ $ 5D_$1<^![\^AC/_D1
M:TO"K;O">DG_ *=8Q^2BMW_ 7K^AV2_W1?XG^2->BBBL#C"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\/-5TB\:;3(9;RSW;HVB&9$]BHY./4?I7ME07=Y;6%LUQ=SQP0KU>1L 4 >
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M]O?H=#1116!QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3U#)D']:5?A<$4*FO7:J.@"8 _6O0:*OZS5[FO\ :&(_F_!?Y'G_ /PK$_\
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M2_906'735^O_   HHHKG.(**** "BBB@ K'\5_\ (I:K_P!>K_RK8K'\5_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !2_X]M(_P"OD_R%>@5O4_A0^9V5O]VI?]O?F%%%%8'&%%%% !1110 4444
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M\0_M?@@HHHK Y HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //\
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M *^6_P#0HZWPW\5?/\CLP'^\+Y_DST"BBBL#C"BBB@ HHHH \_U[_DKFA?\
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M %%%% !1110 4444 %%%% !1110 4444 %<[X[_Y$G5/^N8_]"%=%7.^._\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!X+X]&_P >ZB#W>,?^.+7O5>"^
M/&"^/-18]!(A_P#'%KT7_A:7ASUN_P#OS_\ 7H [6BN*_P"%I>'/6[_[\_\
MUZ/^%I>'/6[_ ._/_P!>@#M:\+^)2@>.+PCND9/_ 'P*[_\ X6EX<];O_OS_
M /7KS+QEJ]KKOB6>_L]_DNB ;UP>% /% 'OMJ2;.$GJ8U_E4M0VG_'E!_P!<
MU_E4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MY)^T3_R3BV_["47_ *!)7INB?\@'3O\ KUB_]!%>9?M$_P#).+;_ +"47_H$
ME>FZ)_R =._Z]8O_ $$4 7J*** //_BE_P >VD?]?)_D*] KS_XI?\>VD?\
M7R?Y"O0*WJ?PH?,[*W^[4O\ M[\PHHHK XPHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **** "BBB@ HHHH **** "BBB@!DW^HD_P!T_P JX7X4?\BY=_\
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M )%72?\ KSB_]!%;O^ O7]#L?^Z+_$_R1JT445@<84C*KJ58 J1@@C((I:*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTJD\3O9:>NU_EN>HVMM%9VD5M @2&) B*.P P*EHHKS#P&[ZL****!!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >?^!_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC#O]>M>5:]X.U;P[")[Q(FMRX02QR @DY(X.#V/:O?*XCXJ?\BI%_P!?:?\
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M0HHHJ2 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!YS\3-=U31KO31IU[);B1'+A,88@C&:X5O'/B9Q
M@ZO-^ 4?R%>[7>F6&H.C7MC;7+1YV&:)7VYZXR.*@;0-&88;2+ CT-LG^% '
M&IXT33/A]I]QJ0^WWMXDBB*3&' =@2WMC ]Z\SL=.NO$.L&WTZT19)6+"-"0
MD:]^23@"NR^*FE"RN--FMK=8K$1&%5C4*B-N+8P.F<_H:YKPAXD_X1C63>-!
MYT4D9BD4'#;20<@^N0* *FK^'=6T)]NH64D2DX63[R-]&'%/T#Q'J/AV\$]E
M,?+)_>0L?DD'N/7WZUWGB/XDZ1J6@75C:V=Q++<1E/WZ*%3/\74\CJ/>O+D1
MI)%1%+.Q 50,DGTH ]-^)]PFI^'M#U.$$0RDL,]MZ@@'WX-<1X4=8_%NDLW3
M[5&/S8"O6;_PK+>_#F#1CC[9! CIGM(!DC]2/QKQ-6FM+H,-T<T+YY&"K _S
MS0!]+W,@AM9I6( 1&8D^PKYCKTC5_B@NH^&9+**SDBOIX_*E<D;%!&&*\YYY
M^F>]<%IFG7&K:E!8VJ;IIF"CT'J3[#K0![5\-HC%X(LR<_O'D;G_ 'R/Z4WQ
MY\/M/^(%G9VVH7=S;K:R-(IM]N22,<Y!KI--L8],TRVL8O\ 5P1+&#ZX&,_C
M5J@#QC_AF[PW_P!!G5?SC_\ B:/^&;O#?_09U7\X_P#XFO9Z* /F+XH_"'2/
M GA6+5K'4+ZXE>[2 I/LVX*L<\ <_**^B_#T8A\-:5$I)"6<*@GV05YM^T3_
M ,DXMO\ L)1?^@25Z;HG_(!T[_KUB_\ 010!>HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DKM
M'"[JA=E4D(.K'TK@SX[\0 D?\(=>?E)_\17?T5I"48_%&YM2J0A?GAS?-_H>
M?/XZ\0.C+_PA]X,@CI)_\16'X5UC7O#&G2VB^&+VX$DIEW&-UQP!C[I]*]=H
MK55X)./)H_-G2L7347!4U9^;//\ _A//$'_0GWGY2?\ Q%=-X;UB]UFSEFOM
M*FTYT?:J2Y^<8ZC(!K:HK.4X-64;&%2K2E&T::3]6%%%%9'.%%%% !1110 4
M444 %%%% !1110 4444 %9'B--<?3T&@RP1W/F#>90/NX/3((ZXK7HIQ=G<J
M$N62E:_J>?\ V?XD_P#/Y9_E'_\ $U0U;P]X\URS%KJ$]I+"'#A047D CJ%]
MS7I]%;K$-.ZBON.N..E%WC"*?H>>QV?Q'BB2-+NS"(H51B/H/^ T[[/\2<_\
M?EG^4?\ \37H%%+V_P#=7W"^N/\ DC]Q%;B86L0N2AGV#S"GW2V.<>V:EHHK
M XV%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y_KW_)7-"_Z]A_
M.6O0*\_U[_DKFA?]>P_G+7H%;UOAAZ'9BO@I_P"']6%%%%8'&%%%% !7G\W_
M "6>#_KV/_HMJ] KS^;_ )+/!_U['_T6U;T/M>C.S!_\O/\ "ST"BBBL#C"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **R6\4:"C%6UBR!!P1Y
MR_XTW_A*_#__ $&;+_O\M5R2[&GL:G\K^XY?X8]=<_Z^1_[-7H%>8_#W6=,T
M\ZO]LO[>#S;@,GF2!=PYY%=M_P )7X?_ .@S9?\ ?Y:WQ$).H[(Z\=2F\1)J
M+Z?DC8HJI8ZG8:FKM8WD%R$.&\IPVWZXJW7.TUHSA::=F%%%%(04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /)/VB?^2<6W_82B_P#0)*]-
MT3_D Z=_UZQ?^@BO,OVB?^2<6W_82B_] DKTW1/^0#IW_7K%_P"@B@"]1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!Y_KW_)7-"_Z]A_.6O0*\_U[_DKFA?\ 7L/YRUZ!6];X8>AV
M8KX*?^']6%%%%8'&%<EKVB>*+[57GTO74M;4JH6$Y&TXYZ YYYKK:*J$W!W1
MI2JNG+F5OFKGG_\ PC/CC_H9H_\ OIO_ (FJA\">*CJ8U(Z[;_;0NT3;FW 8
MQC[OI7I=%;+$S6UON.E8^JMDON1Y_P#\(SXX_P"AFC_[Z;_XFM'0]#\56>K1
M3ZEKR7-HH.^(9.[CCJ!CG!_"NOHJ77DU:R^XB6,G).+2^Y!1116)RA1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBM%6J)63-HXNO%*,9.QY!J/@_3+7Q]IVB1M<?9+B'>Y+C=GY^AQ_LCM74_\
M"K?#_P#STO?^_J__ !-4M:GB_P"%NZ._FIM6WPQW# /[S@UZ'U&16]6M42C9
M]#LQ.*KQC3:D]8_JSE-,^'NB:5J,-] UTTL+;D#R C/X 5U=%%<LIRF[R=SS
MZE6=5WF[A1114F84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >2?M$
M_P#).+;_ +"47_H$E>FZ)_R =._Z]8O_ $$5YE^T3_R3BV_["47_ *!)7INB
M?\@'3O\ KUB_]!% %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA6<%L%%%%9',%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11535-
M032M,N+Z2*2584W%(QEC32N[(:3D[(MT5Y__ ,+5LO\ H%7GYK0?BM8@9.E7
M@'U6MOJU7L=?U#$_R_D>@45Y\/BM8D9&EWA'L5I?^%JV7_0*O/S6CZM5[!]0
MQ/\ +^1Z!16?HFK1ZWI4-_'!+"DF<)*,'@X_*M"L6FG9G+*+BW%[H****1(4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >2?M$_\ ).+;_L)1?^@25Z;HG_(!T[_KUB_]!%>9?M$_
M\DXMO^PE%_Z!)7INB?\ (!T[_KUB_P#010!>HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \_U[_DK
MFA?]>P_G+7H%>?Z]_P E<T+_ *]A_.6O0*WK?##T.S%?!3_P_JPHHHK XPHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@"J2:YI$DGEIJMBS]-HN$)_+->#ZUXAU+7[DS7UPS+G*1*<(GT']>M9=>A'
M:>\SVZ>3>[[\M?(^FP<C(HKPCPSXRU'P]<(OF//8Y^>W<Y 'JOH?TKW"RO(-
M0LH;NV</#,H=&]C7+6H2I/78\[%X*>&>NJ?4GHHHK XPHHHH **** "BBB@
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M?^']6%%%%8'&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$J<X_$FB:BBBI(,W76U5-*D.BQQ/>Y&U93QC//7C/UKD?M'Q)_Y\[/\ ./\
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M"BBBI("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /)/VB?^2<6W_82B_\ 0)*]-T3_ ) .G?\ 7K%_Z"*\R_:)
M_P"2<6W_ &$HO_0)*]-T3_D Z=_UZQ?^@B@"]1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -_$_P#B*/\ A5&A_P#/WJ/_ '\3_P"(KNZ*T^L5?YCH^O8G^=G"?\*HT/\
MY^]1_P"_B?\ Q%3VGPQT6SO(+I+F_9X7$BAI%P2#D9PH-=I11]8JO[0GCL0U
M9S85%=6T5Y:36LZ[H9D,;KG&5(P:EHK$YD[.Z./_ .%9^'/^>5Q_W^-'_"L_
M#G_/*X_[_&NPHK7V]7^9G1]<Q'\[^\X__A6?AS_GE<?]_C1_PK/PY_SRN/\
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M31_%;0V^_:WZ'_<0C_T*NZJ&2TMIO];;Q/\ [R T<]+^7\0]KAGO3_\ )O\
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M,6<;V_P'>O$M8\0:GKLYEO[IW&<K$#A%^B]/ZUTT,-*KKLCOPF7SQ"YKV1]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG?'?_(DZI_U
MS'_H0KHJYWQW_P B3JG_ %S'_H0H =X&_P"1*TO_ *Y'_P!"-:=[K&FZ:ZI?
M7]O;NXRJRR!21ZX-9G@;_D2M+_ZY'_T(U8U?PMH^NW"3ZC:>;*B[%82,IVYS
MC@CU-5'EO[VQ=/DYOWE[>0O_  E6@?\ 09L?^_Z_XUQ'B;6=-N?'>@74%_;R
M6\)7S)%D!5/FSR>U=+_PKOPO_P! YO\ O_)_\51_PKOPO_T#F_[_ ,G_ ,57
M1"5&#NK_ ('=1J82E+F3ELULNOS-+_A*M _Z#-C_ -_U_P :D@\1Z+<SI#!J
MMG)*YVJBS*2Q]!S63_PKOPO_ - YO^_\G_Q536O@3PY9W<5S#I^)8F#H3,Y
M(Y!P3BLVJ-M&_P #%K"6T<ON7^9T=%%%8G(%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M10 4444 %5-4^W#3+C^S!&;W9^Z\W[N:MT4T[.XT[.YY_N^)/_/.S_\ (?\
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MM*DI]V%%%%29A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'DG[1/\ R3BV_P"PE%_Z!)7INB?\@'3O^O6+_P!!
M%>9?M$_\DXMO^PE%_P"@25Z;HG_(!T[_ *]8O_010!>HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \D_:)_Y)Q;?]A*+_ - DKTW1/^0#
MIW_7K%_Z"*\R_:)_Y)Q;?]A*+_T"2O3=$_Y .G?]>L7_ *"* +U%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5SOCO\ Y$G5/^N8_P#0A715SOCO_D2=4_ZYC_T(4 .\#?\ (E:7_P!<C_Z$
M:Z"N?\#?\B5I?_7(_P#H1KH* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /)/VB?^2<6W_82B_\ 0)*]-T3_ ) .G?\ 7K%_Z"*\R_:)_P"2<6W_
M &$HO_0)*]-T3_D Z=_UZQ?^@B@"]1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %<[X[_P"1)U3_ *YC_P!"
M%=%7.^._^1)U3_KF/_0A0 [P-_R)6E_]<C_Z$:Z"N?\  W_(E:7_ -<C_P"A
M&N@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH \D_:)_Y)Q;?]A*+_P! DKTW1/\
MD Z=_P!>L7_H(KS+]HG_ ))Q;?\ 82B_] DKTW1/^0#IW_7K%_Z"* +U%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\:/^$"\,?] F+_OM_P#&@"3_ (3?PU_T%[?]?\*/^$W\-?\ 07M_U_PJ/_A
MO#'_ $"8O^^W_P :/^$"\,?] F+_ +[?_&@"3_A-_#7_ $%[?]?\*/\ A-_#
M7_07M_U_PJ/_ (0+PQ_T"8O^^W_QH_X0+PQ_T"8O^^W_ ,: )/\ A-_#7_07
MM_U_PH_X3?PU_P!!>W_7_"H_^$"\,?\ 0)B_[[?_ !H_X0+PQ_T"8O\ OM_\
M: '-XY\,JI)U># ] Q_I2KXX\,L 1J\&#ZAA_2N>\:>$=!TSPE?WEGIT<5Q&
M$V.&8D9=0>I]":L>&/!OA^^\,Z==7.FQR3RPJSN7;D_G0!M?\)OX:_Z"]O\
MK_A1_P )OX:_Z"]O^O\ A4?_  @7AC_H$Q?]]O\ XT?\(%X8_P"@3%_WV_\
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M #AXZ\,ERG]KPY'^RV/SQBG?\)OX:_Z"]O\ K_A7#V7AO2)?BGJ&E/9(;&*
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MC\\4G_"!>&/^@3%_WV_^-<7I/AO2+CXFZMI<MDC64,!:.(LV%/[OG.<]S^=
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M7_07M_U_PH_X3?PU_P!!>W_7_"H_^$"\,?\ 0)B_[[?_ !H_X0+PQ_T"8O\
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M_P!!>W_7_"H_^$"\,?\ 0)B_[[?_ !H_X0+PQ_T"8O\ OM_\: )/^$W\-?\
M07M_U_PH_P"$W\-?]!>W_7_"H_\ A O#'_0)B_[[?_&C_A O#'_0)B_[[?\
MQH D_P"$W\-?]!>W_7_"C_A-_#7_ $%[?]?\*C_X0+PQ_P! F+_OM_\ &C_A
M O#'_0)B_P"^W_QH D_X3?PU_P!!>W_7_"C_ (3?PU_T%[?]?\*C_P"$"\,?
M] F+_OM_\:/^$"\,?] F+_OM_P#&@"3_ (3?PU_T%[?]?\*:_CKPRF,ZO#SZ
M*Q_D*;_P@7AC_H$Q?]]O_C7%_$/PWI&CVVFMI]DD#2SE7*LQR,=.30!W'_";
M^&O^@O;_ *_X4?\ ";^&O^@O;_K_ (5'_P (%X8_Z!,7_?;_ .-'_"!>&/\
MH$Q?]]O_ (T 2?\ ";^&O^@O;_K_ (4?\)OX:_Z"]O\ K_A4?_"!>&/^@3%_
MWV_^-'_"!>&/^@3%_P!]O_C0!)_PF_AK_H+V_P"O^%'_  F_AK_H+V_Z_P"%
M1_\ "!>&/^@3%_WV_P#C1_P@7AC_ *!,7_?;_P"- $G_  F_AK_H+V_Z_P"%
M'_";^&O^@O;_ *_X5'_P@7AC_H$Q?]]O_C1_P@7AC_H$Q?\ ?;_XT 2?\)OX
M:_Z"]O\ K_A1_P )OX:_Z"]O^O\ A4?_  @7AC_H$Q?]]O\ XT?\(%X8_P"@
M3%_WV_\ C0!)_P )OX:_Z"]O^O\ A3%\=>&7SC5X>/56'\Q2?\(%X8_Z!,7_
M 'V_^-<7\/\ PWI&KG5_M]DD_D3A8\LPVCGC@^U '<?\)OX:_P"@O;_K_A1_
MPF_AK_H+V_Z_X5'_ ,(%X8_Z!,7_ 'V_^-'_  @7AC_H$Q?]]O\ XT 2?\)O
MX:_Z"]O^O^%'_";^&O\ H+V_Z_X5'_P@7AC_ *!,7_?;_P"-'_"!>&/^@3%_
MWV_^- $G_";^&O\ H+V_Z_X4?\)OX:_Z"]O^O^%1_P#"!>&/^@3%_P!]O_C1
M_P (%X8_Z!,7_?;_ .- $G_";^&O^@O;_K_A1_PF_AK_ *"]O^O^%1_\(%X8
M_P"@3%_WV_\ C1_P@7AC_H$Q?]]O_C0!)_PF_AK_ *"]O^O^%'_";^&O^@O;
M_K_A4?\ P@7AC_H$Q?\ ?;_XT?\ "!>&/^@3%_WV_P#C0!(GC;PV\J1)JT+.
MYPH ;D_E6_7E7CKP_I6B76B-IUFMN9;DARK$YP5QU/O7JM !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%-=Q'&SM]U02:Y%/B;X989-S.OL8&_I0!V%<5\2;#
M4]1TBTM]-AGF8S_O%BS]W:>OM]:T=*\=:)K6IQZ?92S-/("5W1$ X&3S]!72
M4 ?,=U;365U+:W";)HG*.N0<$=1Q7K/PC_Y 5_\ ]?/_ +**\X\5_P#(VZO_
M -?<G_H1KT?X1_\ ("O_ /KY_P#910!O^.M;?0O"\\T#[;F8B&)NX)ZD?0 _
MCBO!H(9+JYB@C&9)7"*/4DX%>I_%]V%CI4?\)DD)^H _Q-<#X34/XNTD'_GZ
MC/Y,#0!WVM?#+3[7PS++9O*;^WB,C.S9$N!EACMWQ7EUK=365W%=6\ACFB8.
MC#L17TO.JO!(K?=*D'Z8KYBH ]N\0^+##\/HM6M6\NXO46./'\#L/FQ],-^(
M%>*P0R75S%!&,R2N$4>I)P*Z759G;X=Z!$<[1<7&/P/_ -D:S_":A_%VD@_\
M_49_)@: .^UKX9:?:^&99;-Y3?V\1D9V;(EP,L,=N^*\NM;J:RNXKJWD,<T3
M!T8=B*^EYU5X)%;[I4@_3%?,5 'TGHVHIJ^C6FH(,">(.1Z'N/P.15ZN1^&K
MLW@BU#9PLD@'TW$_UI/'OBC7/"]G9S:'X;N-;DFD99(X$=C& ,@G:IZT =?1
M7BW_  MKQ_\ ]$OU/_OS/_\ &Z/^%M>/_P#HE^I_]^9__C= %[]HG_DG%M_V
M$HO_ $"2O3=$_P"0#IW_ %ZQ?^@BOF_XH^.O%/B3PK%9:SX,O-&M5NTD%S-'
M*JE@K +\R@9.2?PKK-/^*OCR#3+6&/X::C*D<**LBPSX<   C]WWH ]RHKQ;
M_A;7C_\ Z)?J?_?F?_XW1_PMKQ__ -$OU/\ [\S_ /QN@#VFBO%O^%M>/_\
MHE^I_P#?F?\ ^-T?\+:\?_\ 1+]3_P"_,_\ \;H ]IHKQ;_A;7C_ /Z)?J?_
M 'YG_P#C='_"VO'_ /T2_4_^_,__ ,;H ]IHKQ;_ (6UX_\ ^B7ZG_WYG_\
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M_P#T2_4_^_,__P ;H ]IHKQ;_A;7C_\ Z)?J?_?F?_XW1_PMKQ__ -$OU/\
M[\S_ /QN@#VFBO%O^%M>/_\ HE^I_P#?F?\ ^-T?\+:\?_\ 1+]3_P"_,_\
M\;H ]IHKQ;_A;7C_ /Z)?J?_ 'YG_P#C='_"VO'_ /T2_4_^_,__ ,;H ]IH
MKQ;_ (6UX_\ ^B7ZG_WYG_\ C='_  MKQ_\ ]$OU/_OS/_\ &Z /::*\6_X6
MUX__ .B7ZG_WYG_^-T?\+:\?_P#1+]3_ ._,_P#\;H ]IHKP9OCEXP76DTMO
M <JWS+N6R*R^>PP3D+MSC )Z=JT/^%M>/_\ HE^I_P#?F?\ ^-T >TT5XM_P
MMKQ__P!$OU/_ +\S_P#QNC_A;7C_ /Z)?J?_ 'YG_P#C= 'M-%>+?\+:\?\
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M6UX__P"B7ZG_ -^9_P#XW0![317BW_"VO'__ $2_4_\ OS/_ /&Z/^%M>/\
M_HE^I_\ ?F?_ .-T >TT5XM_PMKQ_P#]$OU/_OS/_P#&Z/\ A;7C_P#Z)?J?
M_?F?_P"-T >TT5XM_P +:\?_ /1+]3_[\S__ !NC_A;7C_\ Z)?J?_?F?_XW
M0![317BQ^+?C\#)^&&I#_MC/_P#&ZS])^./C#6+=YM/\!RZA&C[&DLUE=5.,
MX)"GGG]: />:*\6_X6UX_P#^B7ZG_P!^9_\ XW1_PMKQ_P#]$OU/_OS/_P#&
MZ /::*\6_P"%M>/_ /HE^I_]^9__ (W1_P +:\?_ /1+]3_[\S__ !N@#VFB
MO%O^%M>/_P#HE^I_]^9__C='_"VO'_\ T2_4_P#OS/\ _&Z /::*\6_X6UX_
M_P"B7ZG_ -^9_P#XW1_PMKQ__P!$OU/_ +\S_P#QN@#VFBO%O^%M>/\ _HE^
MI_\ ?F?_ .-T?\+:\?\ _1+]3_[\S_\ QN@#VFBO%O\ A;7C_P#Z)?J?_?F?
M_P"-UGO\<O&":TFEMX#E6^==RV167SV&"<A=N<8!/3L: />:*\6_X6UX_P#^
MB7ZG_P!^9_\ XW1_PMKQ_P#]$OU/_OS/_P#&Z /::*\6_P"%M>/_ /HE^I_]
M^9__ (W1_P +:\?_ /1+]3_[\S__ !N@#VFBO%O^%M>/_P#HE^I_]^9__C='
M_"VO'_\ T2_4_P#OS/\ _&Z /::*\6_X6UX__P"B7ZG_ -^9_P#XW1_PMKQ_
M_P!$OU/_ +\S_P#QN@#VFBO%O^%M>/\ _HE^I_\ ?F?_ .-T?\+:\?\ _1+]
M3_[\S_\ QN@#VFBO%O\ A;7C_P#Z)?J?_?F?_P"-U2U7XW>,M)M/M-_X GL(
M=P7SKM9D3)[9*CGCUH ]VHKQ.+XO>/)H4EC^&>H2(ZAE=(IRK ]"/W?2G_\
M"VO'_P#T2_4_^_,__P ;H ]IHKQ;_A;7C_\ Z)?J?_?F?_XW1_PMKQ__ -$O
MU/\ [\S_ /QN@#VFBO%O^%M>/_\ HE^I_P#?F?\ ^-T?\+:\?_\ 1+]3_P"_
M,_\ \;H ]IHKQ;_A;7C_ /Z)?J?_ 'YG_P#C='_"VO'_ /T2_4_^_,__ ,;H
M ]IHKQ;_ (6UX_\ ^B7ZG_WYG_\ C='_  MKQ_\ ]$OU/_OS/_\ &Z /::*\
M6_X6UX__ .B7ZG_WYG_^-T?\+;\?_P#1+]3_ ._,_P#\;H ]IHKP;2?CEXPU
MFW>;3_ <NH1HVUI+-9753C."0IYK0_X6UX__ .B7ZG_WYG_^-T >TT5XM_PM
MKQ__ -$OU/\ [\S_ /QNC_A;7C__ *)?J?\ WYG_ /C= 'M-%>+?\+:\?_\
M1+]3_P"_,_\ \;H_X6UX_P#^B7ZG_P!^9_\ XW0![317BW_"VO'_ /T2_4_^
M_,__ ,;H_P"%M>/_ /HE^I_]^9__ (W0![317BW_  MKQ_\ ]$OU/_OS/_\
M&Z/^%M>/_P#HE^I_]^9__C= 'M-%>+?\+:\?_P#1+]3_ ._,_P#\;H_X6UX_
M_P"B7ZG_ -^9_P#XW0![317@S_'+Q@FM1Z6W@.5;YUW+9,LOGL,$Y"[<XP">
MG8UH?\+:\?\ _1+]3_[\S_\ QN@#VFBO%O\ A;7C_P#Z)?J?_?F?_P"-T?\
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M_P +:\?_ /1+]3_[\S__ !NC_A;7C_\ Z)?J?_?F?_XW0![317BW_"VO'_\
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MKQ__ -$OU/\ [\S_ /QN@#VFBO%O^%M>/_\ HE^I_P#?F?\ ^-T?\+:\?_\
M1+]3_P"_,_\ \;H ]IHKQ;_A;7C_ /Z)?J?_ 'YG_P#C=9[_ !R\81ZU'I;>
M Y5OI%W+9,LOGN,$Y"[<XP">G8T >\T5XM_PMKQ__P!$OU/_ +\S_P#QNC_A
M;7C_ /Z)?J?_ 'YG_P#C= 'M-%>+?\+:\?\ _1+]3_[\S_\ QNC_ (6UX_\
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MMKQ__P!$OU/_ +\S_P#QNC_A;7C_ /Z)?J?_ 'YG_P#C= 'M-%>+?\+:\?\
M_1+]3_[\S_\ QNC_ (6UX_\ ^B7ZG_WYG_\ C= 'M-%>+?\ "VO'_P#T2_4_
M^_,__P ;H_X6UX__ .B7ZG_WYG_^-T >TT5X-I/QR\8:Q!)+I_@.74$1MK/9
MK*ZJ<=#A3S6A_P +:\?_ /1+]3_[\S__ !N@#VFBO%O^%M>/_P#HE^I_]^9_
M_C='_"VO'_\ T2_4_P#OS/\ _&Z /::*\6_X6UX__P"B7ZG_ -^9_P#XW1_P
MMKQ__P!$OU/_ +\S_P#QN@#VFBO%O^%M>/\ _HE^I_\ ?F?_ .-T?\+:\?\
M_1+]3_[\S_\ QN@#VFBO%O\ A;7C_P#Z)?J?_?F?_P"-T?\ "VO'_P#T2_4_
M^_,__P ;H ]IHKQ;_A;7C_\ Z)?J?_?F?_XW1_PMKQ__ -$OU/\ [\S_ /QN
M@#VFBO!I/CEXPCUJ+2W\!RI?2+N2R991.XP3D+MSC )Z=C6A_P +:\?_ /1+
M]3_[\S__ !N@#VFBO%O^%M>/_P#HE^I_]^9__C='_"VO'_\ T2_4_P#OS/\
M_&Z /::*\6_X6UX__P"B7ZG_ -^9_P#XW1_PMKQ__P!$OU/_ +\S_P#QN@#V
MFBO%O^%M>/\ _HE^I_\ ?F?_ .-T?\+:\?\ _1+]3_[\S_\ QN@#VFBO%O\
MA;7C_P#Z)?J?_?F?_P"-T?\ "VO'_P#T2_4_^_,__P ;H ]IHKQ;_A;7C_\
MZ)?J?_?F?_XW1_PMKQ__ -$OU/\ [\S_ /QN@#VFBO"M2^-OC+2;476H?#ZX
ML;?>%,MTLR)D]LE ,FO:=)O3J6C6-^R!&N;>.8H#G;N4''ZT 7**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH .E&*** .8\;>)[CPOI]M<6UO%,\TNPB0G
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MZ^(_ZT =-HO_ " =._Z]H_\ T$5>JCHO_(!T[_KVC_\ 015Z@ HHHH ****
M"BBB@ HHHH *XSPWHFHV/C?7=0N;8QVMR3Y,F]3N^;/0'(X]:[.B@ HHHH *
M*** "BBB@ HHHH **** .&^*W_(I1?\ 7VG_ *"U=AIO_(+M/^N*?^@BN/\
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M %\_^RBO(F8LQ9B23R2>]/CGFB!$<KH#U"L10![%\5=/>Y\-17:#/V68%O\
M=;C^>VO)]&O%T[6[&\;[D%PDC?0,"?TKW[2[>*^\*65O<KYD4UE&LBM_$"@S
M7C?BCP1J7A^YD>.*2YL,Y2=%SM'HP'0^_2@#V76]4@L?#=YJ/FH8Q;EHV!X<
MD?+@^Y(_.OG*K#7EY-;):-<SO I^2$N2H/LO2NW\%> +N]O(M0U:!H+.,AUB
MD7#3'MQV7Z]: +/B'0);;X5Z0Y!\RU832#'02$G]"RBN%T:\73M;L;QON07"
M2-] P)_2OHZZMH;RUEM;A \,J%'4]P:\+\4>"-2\/W,CQQ27-AG*3HN=H]&
MZ'WZ4 >RZWJD%CX;O-1\U#&+<M&P/#DCY<'W)'YU\Y58:\O)K9+1KF=X%/R0
MER5!]EZ5V_@KP!=WMY%J&K0-!9QD.L4BX:8]N.R_7K0!Z)X+T]],\(:=;R#$
MAC\Q@>H+DMC\,X_"MZBB@ HHHH \D_:)_P"2<6W_ &$HO_0)*]-T3_D Z=_U
MZQ?^@BO,OVB?^2<6W_82B_\ 0)*]-T3_ ) .G?\ 7K%_Z"* +U%%% !1110
M4444 %%%% !1110!%<_\>DW^XW\J\@_9O_Y$74_^PDW_ **CKV*1!)&Z$X#
MBN7\!^!K/P#H]QIME=SW,<UP9RTX&02JKC@=/EH ZJBBB@ HHHH **** "BB
MB@ HHHH *\6N_P#DZFP_Z\#_ .B7KVFO%KO_ ).IL/\ KP/_ *)>@#VFBBB@
M HHHH **** "BBB@ HHHH *\F_:(_P"2;P?]A&+_ - DKUFN:\<^#+3QUH*:
M3>W4]M$LZSAX0-V0",<]OFH U="_Y%[3/^O2+_T 5H5!9VRV5C;VJ,66&-8P
M3U( Q_2IZ "BBB@ HHHH **** "BBB@ J.?_ (]Y?]P_RJ2HY_\ CWE_W#_*
M@#Q[]F__ )$C5/\ L)-_Z+CKV6O&OV;_ /D2-4_["3?^BXZ]EH **** "BBB
M@ HHHH **** "BBB@#Q:^_Y.ITW_ *\#_P"B9*]IKDYO =E-\1[?QH;NX%W#
M"81  OED;&7/3/\ %764 %%%% !1110 4444 %%%% !1110!Y/\ M#?\DVB_
M["$7_H+UZ/H'_(MZ7_UZ1?\ H KSC]H;_DFT7_80B_\ 07KT?0/^1;TO_KTB
M_P#0!0!HT444 %%%% !1110 4444 %%%% #9?]4_^Z:\;_9N_P"1*U7_ +")
M_P#1:5[*PW*5]1BN5\!^!++P#I-SI]E=W%S'//Y[-.!D':%QP/:@#JZ*** "
MBBB@ HHHH **** "BBB@ KQ;4?\ DZG2?^O!O_1,M>TUXMJ/_)U.D_\ 7@W_
M *)EH ]IHHHH **** "BBB@ HHHH **** "O*/VA?^2:I_U_Q?\ H+UZO7-^
M./!MIXYT :1>7,UO$)EFWP@;LJ",<_6@#2\._P#(LZ5_UYP_^@"M*J]C:K8:
M?;6:,62")8E9NI"@#)_*K% !1110 4444 %%%% !1110 4C?</TI:1ON'Z4
M>,?LW?\ (FZM_P!A#_VFE>T5XO\ LW?\B;JW_80_]II7M% !1110 4444 %%
M%% !1110 4444 >+:G_R=3HW_7@W_HF:O::Y.X\!V5Q\1[3QHUW<"[MH3"L
M"^6059<GC/\ &?RKK* "BBB@ HHHH **** "BBB@ HHHH \J_:$_Y)H/^O\
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M28M_U^P_^S5WOA;_ )%'1?\ KP@_]%K0!K4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !574M/M]
M5TZ:QN@Q@F&'"G!QG/7\*M44 5=.T^#2M/AL;4,((5VH&.3C.>M6J** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"GJFF6VL:;-
M87:LT$N-P5L'@@CGZ@4^PL8=-L(+*W!$,*!$#')P/>K-% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 52U;2K76M.DL+Q6:"0@L
M%;!X((Y^HJ[10!!96D5A8P6< (A@01H"<G &!4]%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!0UC2+37-/:QO59H&8,0K;3D'
M(YJS:6T=E9P6L((BAC6- 3D[0,#^5344 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6?K.C6>O6'V*^5VAW!\(VTY'O6A10!';P
M):VT5O&"(XD"+DYX P*DHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** ,[6M#LO$%BMG?J[0AQ( C;3D C^IJ]%$L,*1)]U%"C/
MH.*?10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%9FN:#8^(;-+74%=HDD$@"-M.X C^IK3HH 1%"(J+T48%+110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 9>N>'[#Q%;1V^H([1
MQOO78^WG&/ZUJ444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !67K7A^PU^.!+]'80/O38^WFM2B@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ,O6/#]AKK6K7R.QMG+Q[7VX
M/'7\A6I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 P0Q+(9%C0.>K!1D_C3Z** "BBB@!@AB60R+&@<]6"C)_&GT44 %%%% !1
M110!Y1^T)#+/\.[=(8GD;^T8CA%).-DGI7I.B@C0M/!&"+:/(/\ NBKU% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>-
M7<$Q_:CL9O*D\H6)&_:=O^I?O7LM% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %1S_P#'O)_NG^5244 >/?LZ036_@K4U
MFB>-CJ+$!U(./+3UKV&BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /*OV@899_AS$D,;R-_:$1PBDG[K^E>BZ""OAW3
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M*N[\,*5\)Z,K @BQ@!![?NUK5HH **** "BBB@ HHHH **** "BBB@ HHHH
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M-C91)%)C&Y3Z^^017<?"KQ!))YVAW#EE13+;Y[#/S+^N?SH ]/HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N6\7>-$\*36L;6)N3.K-Q+LVXQ[
M'UKJ:\@^+DN=>L8O[MKN_-C_ (4 :7_"X(_^@(__ ($C_P")H_X7!'_T!'_\
M"1_\37):!X$U3Q'IQOK.:T2(2&/$SL#D8]%/K6K_ ,*FU_\ Y^M._P"_K_\
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M5^498CVZUX)KVLW&O:Q/?W!.7.$3.0B=E'^?6@#T&;XP(),0Z*S1YZO<8)_
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M/UQ7%^&_AM_;7A]=0N+UX)9P3 BJ" .@+?7V[5PUU;3:??36TP*3P2%&P>C
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MG[[0G'Z<_I0!V%%5K'4+/4[87-C<QW$)XW1MGGT/H?:K- !11T&37,ZAX_\
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MD9_B7X9A?:MU+-S@F.%L#\\5J:/XLT37'\NQOD:;_GDX*.?H#U_"@#:HHHH
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MT =-17,:?\0/#FHS+$E]Y,C=!.I0'\>GZUT_6@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHK*U?Q)I&A/$FI7JP/*"478S$@=\*#B@#5HKF5^(/A9W"KJ@
M))P!Y$G_ ,3734 %%%<_JGC70-'G:WNK]3.OWHXE+D>QP, ^Q- '045R=G\1
M_#5W*(S>/ S< S1E1^?0?C751R)+&LD;JZ,,JRG((]0: '445%<7,%I \]S,
MD,*#+/(P 'XF@"6BN1G^)?AF%]JW4LW."8X6P/SQ6IH_BS1-<?R[&^1IO^>3
M@HY^@/7\* -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKFYO'WABWG
MDADU50\;%6Q%(PR/<+@U=TGQ1HVNW#P:;>B>5%WLOENN!G&?F ]: ->BBL?5
MO%.C:%<I;ZE>B"5TWJOENV5R1GY0?0T ;%%<Q_PL/PK_ -!4?]^)?_B:/^%A
M^%?^@J/^_$O_ ,30!T]%8VD^*M%URZ:VTZ]$\RH7*^6Z_*"!GD#U%;- !167
MJ_B+2="53J-['"S?=3!9C_P$9./>L-/B;X::78;B=5S]]H3C].?TH ["BJUC
MJ%GJ=L+FQN8[B$\;HVSSZ'T/M5F@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** /F:_E:?4;F9B2TDK,<^I)->P?"F,)
MX3E<#E[MR3_P%17E&O63Z=K]_:.,&.=P/<9R#^6*]1^$UVDGAZ[M-P\R&Y+$
M?[+*,?J#0!D_&"-1=:3)_$R2J?H"O^)KE_ ,S0^-]-*D_,[(?<%2*Z#XN7:2
M:S86BG+0P%V]MQZ?^._K63\-;)[OQG;2 92V1Y7^FW:/U84 >YT444 %%%%
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M'UV_+G]* .R^$$S"XU6')VE(WQ[@L/ZUZI7FGPALG2SU.^8?)(Z1(?=02?\
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M%H;#4KJS+B0P3/%O'1MI(S^E>M_#R]GUOP;=Z?<N6,.ZW1VY^1EX'X9/X8H
M\;KWSP!&(_ ^F@#&5=C^+L:\&FB>">2&5=LD;%6![$'!KW/X<7:77@JS16!>
M!GB<>AW$C]"* .!^*L:IXN1AU>U1C]<L/Z53\ 7;VFIZDR$C_B6SGCU !'\J
MD^)EVEUXSF1#GR(DB)]\;C_Z%5SX8:6U_?ZI*>(A9M 2?[TAX_130!P=>^>
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MW;OT_.H?%W@K3?#/A%9HB\]X;A%:=SCC#9 4< ?F?>@#AM(_Y#5C_P!?$?\
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MYJO8/LM_<6X_Y92LGY'%>V?#6]:\\&0(Y)-O(\.3Z Y'Z,* .NHHHH ****
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M?!)KUG7)/)\/ZE+_ '+65OR0T ?-ZJTCJB*6=C@ <DFM3_A%O$'_ $!=0_\
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M%>%_$J3?XWNU_P">:1K_ .. _P!: ,&TT/5K^ 3V>FW=Q$20'BA9AGZ@5/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!,404GZD=: .?\"^%#X:TMFN0IO[C!E(YV#LH/\ /W^E=7110 4444 %%%%
M!1110 4444 %%%% !1110!D>*;F:S\+ZE<6\C1S1P,4=>JGU%>!ZAK&I:J(Q
M?WLUR(\[/,?.W/7'Y"OI":&*YA>&>))8G&&1U#*P]"#UK._X1K0?^@)IO_@(
MG^% 'SQ:W4]E<I<6TKQ31G*NAP17K?POU;4-5@U,W]Y-<F-HPGFMG;D-G'Y5
MUG_"-:#_ - 33?\ P$3_  JU9Z;8Z<'%E96UL'QN$$2INQTS@<T >/>.O!=Q
MH]_+J%E"7TV5BV$&?))Z@^@]#^'UYW3_ !'J^E6<MI8W\L$$N2R+CJ>XST/T
MKZ-(R,&LF7POH,\OF2:/8L^<D^0HS]>.: /!M$T*_P!?OUM;&$L2?GD(^2,>
MK'M7O^B:1!H>D6^GV_W8E^9L<NW=C]35NVM;>SA$-K!%!$.B1(%4?@*EH \H
M^(G@NX%Y+K>FPF2*7YKB)!EE;NX'<'O[\_3AM*U[5-$,ITZ\>W\T8<* 0?P(
MZ^]?2%9EUX<T6]E,MSI5G)(3DN85W$^YQS0!\_6=E?ZYJ/E6T4ES=3-N8]22
M3RS'M]37O'A/P['X:T2.S!5YV.^>0?Q,?3V'05J6EA9Z?&8[.T@MT/)6&,(#
M^56* "BBB@ HHHH **** "BBB@ HHHH *R/%-S-9^%]2N+>1HYHX&*.O53ZB
MM>F30Q7,+PSQ)+$XPR.H96'H0>M 'S?J&L:EJHC%_>S7(CSL\Q\[<]<?D*KV
MMU/97*7%M*\4T9RKH<$5]#_\(UH/_0$TW_P$3_"C_A&M!_Z FF_^ B?X4 <7
M\/;S4/$>E:U;7^I7;$A$242'?'D-DJ>W05P/B#POJ?AV[=;N%V@W82Y4?(_I
MSV/L:]\L]-L=.#BRLK:V#XW"")4W8Z9P.:L21I+&T<B*Z,,%6&01]* /G^'Q
MMXDM[3[-'JT_EXP-P5F _P!XC/ZUEVEE?:Q?>3:PRW5S*22!R2>Y)_J:]^?P
MGX?>3>VC6.[KQ"H'Y5HVEC:6$7E6=K#;Q_W8HPH_2@#%\&^&QX:T06[LKW4K
M>9.R]-V.@]A_C7FOCKP7<:/?RZA90E]-E8MA!GR2>H/H/0_A]?:Z",C!H ^<
MM/\ $>KZ59RVEC?RP02Y+(N.I[C/0_2FZ)H5_K]^MK8PEB3\\A'R1CU8]J]Y
ME\+Z#/+YDFCV+/G)/D*,_7CFM&VM;>SA$-K!%!$.B1(%4?@* *FB:1!H>D6^
MGV_W8E^9L<NW=C]36A110 4444 %%%% !1110 4444 %17+M':S.IPRHQ!]\
M5+2$!@00"#P0: /F6ZNI[ZZDN;J5Y9I#N=W.2340)4Y!(^E?1G_"-:#_ - 3
M3?\ P$3_  H_X1K0?^@)IO\ X")_A0!\Z>8_]]OSKTWX0,S2:N"Q/$/4_P"_
M7??\(UH/_0$TW_P$3_"K5GIEAIQ<V5C;6Q?&_P B)4W8Z9P.>IH \R^(G@NX
M%Y+K>FPF2*7YKB)!EE;NX'<'O[\_3AM*U[5-$,ITZ\>W\T8<* 0?P(Z^]?2%
M9EUX<T6]E,MSI5G)(3DN85W$^YQS0!\_6=E?ZYJ/E6T4ES=3-N8]223RS'M]
M37O'A/P['X:T2.S!5YV.^>0?Q,?3V'05J6EA9Z?&8[.T@MT/)6&,(#^56* /
M*/B)X+N!>2ZWIL)DBE^:XB0996[N!W![^_/TX;2M>U31#*=.O'M_-&'"@$'\
M".OO7TA69=>'-%O93+<Z59R2$Y+F%=Q/N<<T ?/UG97^N:CY5M%)<W4S;F/4
MDD\LQ[?4U[QX3\.Q^&M$CLP5>=COGD'\3'T]AT%:EI86>GQF.SM(+=#R5AC"
M _E5B@ HHHH **** "BBB@ HHHH **** (KEVCM9G4X948@^^*^:;JZGOKJ2
MYNI7EFD.YW<Y)-?31 8$$ @\$&LS_A&M!_Z FF_^ B?X4 ?.8)4Y!(^E+YC_
M -]OSKZ+_P"$:T'_ * FF_\ @(G^%'_"-:#_ - 33?\ P$3_  H \Y^%UNU_
M:Z]:FXFB\V.)1)&V&3._D'UKD_$'A?4_#MVZW<+M!NPERH^1_3GL?8U[Y9Z9
M8:<7-E8VUL7QO\B)4W8Z9P.>IJQ)&DL;1R(KHPP589!'TH ^?X?&WB2WM/LT
M>K3^7C W!68#_>(S^M9=I97VL7WDVL,MU<RDD@<DGN2?ZFO?G\)^'WDWMHUC
MNZ\0J!^5:-I8VEA%Y5G:PV\?]V*,*/TH Q?!OAL>&=$%N[*]U*WF3NO3=CH/
M8?XUQ/Q$\%W O)=;TV$R12_-<1(,LK=W [@]_?GZ>KT4 ?-^E:]JFB&4Z=>/
M;^:,.% (/X$=?>H[.RO]<U'RK:*2YNIFW,>I))Y9CV^IKZ!NO#FBWLIEN=*L
MY)"<ES"NXGW..:MVEA9Z?&8[.T@MT/)6&,(#^5 &7X3\.Q^&M$CLP5>=COGD
M'\3'T]AT%;E%% !1110 4444 %%%% !1110 5GZYIKZOHUS8QW,EL\JX$L9P
M0??V/0CTK0HH ^<=7T/4_#U[Y5[ \+@Y25?NM[JW^36A_P )[XF^Q_9O[5DV
M8V[MB[\?[V,_CG->]RPQ3Q-%-&DD;<%'4$'\#64WA/P\[[SHMCGVA4#\NE '
M@%E87NJW@M[."2XG<YPHR?J3V'N:]X\'^'O^$:T%+1V#W#L99V7IN.!@>P
MK8M;*UL8O*M+:&WC_NQ(%'Y"IZ /*/B)X+N!>2ZWIL)DBE^:XB0996[N!W![
M^_/TX;2M>U31#*=.O'M_-&'"@$'\".OO7TA69=>'-%O93+<Z59R2$Y+F%=Q/
MN<<T ?/UG97^N:CY5M%)<W4S;F/4DD\LQ[?4U[QX3\.Q^&M$CLP5>=COGD'\
M3'T]AT%:EI86>GQF.SM(+=#R5AC" _E5B@#RCXB>"[@7DNMZ;"9(I?FN(D&6
M5N[@=P>_OS].&TK7M4T0RG3KQ[?S1APH!!_ CK[U](5F77AS1;V4RW.E6<DA
M.2YA7<3[G'- 'S]9V5_KFH^5;127-U,VYCU))/+,>WU->\>$_#L?AK1([,%7
MG8[YY!_$Q]/8=!6I:6%GI\9CL[2"W0\E88P@/Y58H **** "BBB@ HHHH **
M** "BBB@"&\MS=V<UN)I(3*A3S(CADR.H/K7@'B/PMJGAZ[<7<320,QV7*C*
MO]3V/L:^A:1E5U*LH92,$$9!H \!M/'7B2RLQ:PZF_EJ,+O1791[$@FL55O-
M4OL*LUU=3-G@%W<G]37T%+X5T"9]SZ-8[LYR(%&?R%7;/3;'3E*V5G;VX/7R
MHPN?RH Y+P?X,ETKPY>0W<TD%[?KAVA;#0K@X /KR2:\P\0>%]3\.W;K=PNT
M&["7*CY'].>Q]C7T-39(TEC:.1%=&&"K#((^E 'S_#XV\26]I]FCU:?R\8&X
M*S ?[Q&?UK+M+*^UB^\FUAENKF4DD#DD]R3_ %->_/X3\/O)O;1K'=UXA4#\
MJT;2QM+"+RK.UAMX_P"[%&%'Z4 8O@WPV/#6B"W=E>ZE;S)V7INQT'L/\:\U
M\=>"[C1[^74+*$OILK%L(,^23U!]!Z'\/K[701D8- 'SEI_B/5]*LY;2QOY8
M()<ED7'4]QGH?I3=$T*_U^_6UL82Q)^>0CY(QZL>U>\R^%]!GE\R31[%GSDG
MR%&?KQS6C;6MO9PB&U@B@B'1(D"J/P% %31-(@T/2+?3[?[L2_,V.7;NQ^IK
M0HHH **** "BBB@ HHHH **** "HKFUM[R$PW4$4\1P2DJ!E/X&I:* ,S_A'
M-#_Z VG?^ J?X5Q?Q.TG3;'PS!+9Z?:6\ANU4O#"J$C8_&0.G KT>H+NQM+^
M(17EK!<QAMP2:,. ?7![\F@#YX\.Q1S>)M*BE19(WNXE9&&0P+C(([BOH.TT
MO3[!V>SL+6W9AAFAA5"1Z' J&+P_HL$R30Z181RH0RNEL@*D=""!P:T: /%/
M'7@NXT>_EU"RA+Z;*Q;"#/DD]0?0>A_#Z\[I_B/5]*LY;2QOY8()<ED7'4]Q
MGH?I7T:1D8-9,OA?09Y?,DT>Q9\Y)\A1GZ\<T >#:)H5_K]^MK8PEB3\\A'R
M1CU8]J]_T32(-#TBWT^W^[$OS-CEV[L?J:MVUK;V<(AM8(H(AT2) JC\!4M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#G?':L_@G5 O7RP?P# FO *^E]2LDU'3+J
MR<X6XB:,GTR,9KYMNK:6SNY;:="DT3E'4]B#@T ?26F,&TFS8=# A_\ '17F
M7Q?_ ./W2AW\N3^:UU7@;Q)9:CX:M87N8TNK6,12QNP!PHP&YZ@@#GZUYW\1
M];M]8\1A;20206L?E!U.0S9)8CVZ#\* (/ARI/CK3R.PE)_[]M7O%>1_";2W
MEU6[U1E/E01^4A(ZNW7'T _\>%>N4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5P/Q'\-:MK[V#Z;;K,MNK[E\Q5.3CU(]*[ZO-?&/CK7= UR
M73X;>T2+:'BE9&9F4]^N.N1T[4 <II7P\U[4-0-O<VS642C+S3#('TQ]XUH>
M(OAE=:/IDE_:7HO$A7=*ABV,%'4CDYQ70^"OB$E_YUKKUY%%<E]T,K (A7 ^
M7/0$'UZYK8\8>*],T_P_=Q1W<,]U<1-%%%&X8_,,9..@&<\T >(6EU-8W<5U
M;2&.:)@Z,.Q%>V^)KO\ M7X97%Z@V^?:QRD#MDJ2/YUX97T%I>E>=X$MM+N/
ME,M@(G_V2R?TS0!\^U]+Z8P;2;-AT,"'_P =%?-MU;2V=W+;3H4FB<HZGL0<
M&O;_  -XDLM1\-6L+W,:75K&(I8W8 X48#<]00!S]: .5^+_ /Q^Z4._ER?S
M6N>^'*D^.M/(["4G_OVU3_$?6[?6/$86TD$D%K'Y0=3D,V26(]N@_"M7X3:6
M\NJW>J,I\J"/RD)'5VZX^@'_ (\* /7**** "BBB@ HHHH **** "BBB@ HH
MHH ***K7FHV.GA#>WEO;!\A3-*J;OID\T 6:^8[K_C\F_P"NC?SKZ(_X270O
M^@WIO_@4G^-?.]R0UU,00078@COS0![9\,O^1*@_ZZR?^A5V%>??#W7M(L/"
M4-O>:E:P3"1R4DE"D GT-=A::_I%_<+;VFIVL\S D1QRAB<=>!0!X3XO5D\7
MZL&Z_:7/X$Y%>@?"%A_9>I+W$ZG_ ,=KG?BCI+V?B87X4^3>H&W=MZ@*1^0!
M_&G_  QU^VTK5KFSO)5BBO%78[G #KG )[9!/Y"@#TSQ?QX0U;/_ #[/_*OG
MBO:OB-X@L[7PS-8Q7$;W5WA%1&R0N023CM@8_&O(-+T^75=4MK" $R3R!!QT
M'<_@,G\* /8=8C?_ (5"J<[AIT&?P"9KQ.OI6\TZ*[T:?3?NQ20& >P*X%?-
M]U;2V=W+;3H4FB<HZGL0<&@#Z2TQ@VDV;#H8$/\ XZ*\R^+_ /Q^Z4._ER?S
M6NJ\#>)++4?#5K"]S&EU:QB*6-V .%& W/4$ <_6O._B/K=OK'B,+:2"2"UC
M\H.IR&;)+$>W0?A0!!\.5)\=:>1V$I/_ '[:O>*\C^$VEO+JMWJC*?*@C\I"
M1U=NN/H!_P"/"O7* "BBB@ HHHH **** "BBB@ HHHH *XCXJ?\ (H+_ -?2
M?R:NFFU_1K>9X9M6L(Y4.UD>Y0,I]"">*XSXE:QIE]X66&SU*SN)?M*-LAG5
MVQAN< T >7:1_P AJQ_Z^(__ $(5]*U\T:8ZQ:M9R.P5%G1F8G  ##FO?_\
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M7O7O-% %#1](M=#TN&PLU(BC')/5CW)]S5^BB@ HHHH **** "BBB@ HHHH
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M0!Y9X-^'%Q'=Q:CKD:HL9W1VN02S#H6QQCV_/W]3HHH **** "BBB@ HHHH
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M% !1110 4444 %<7\3K*[O\ PS!%9VLUQ(+M6*0QER!M?G [<BNTHH ^<O\
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MOZG110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF>GO7+^!?"=GXIDOENYYXA;A"ODD#.[=G.0?2@#VJQOK;4K**\LY1+;RC*.
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M8B>GFQ,H_/&!0!U-%16]S!=P+-;31S1-]UXV#*?Q%2T %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^?\ QS_R.NJ?]=1_Z"*]ZL_^/*#_ *YK_*O!?'/_ ".N
MJ?\ 74?^@BO>K/\ X\H/^N:_RH FHHKGO&'B2#PYHLLGF+]LE4K;QYY+?WL>
M@Z_IWH \5UY_M_BO46B^;SKR0)COER!7T--#;O;E;A(VA49(D *@#OS7A7@/
M2'UCQ9:DJ3#;-]HE;_=.1^;8_6NZ^*VJW%GH]I8P.R+>.WFE>ZJ!\OT)8?E0
M!)=?$'POH3R0:9:B8ELN;2)40M[GC/U -8]S\7Y2"+72$4]FEF+?H /YU1^'
M_@JRUZUFU+4B[P)(8DA5MNX@ DDCG'/2O2K3PIH%E@P:1:!AT9HPY'XMDT >
M&>(=?OO$=^E[?)$KB,(@C0J-H)/<G/)->W>#/^1.TK_KW6O+_B?=PW'BP0P%
M=MK;K"P7H&RS8_\ 'A7J'@LY\&Z5_P!<!0!YE\4-(^P>)1>HN(KU-_\ P,<-
M_0_C7IWA#5O[:\+V5VS;I0GER^N]>#^?7\:SOB-I']J>%)I$7,UF?/7Z#[P_
M+)_"O/\ PAXF_L?PUK]J9-KF'S+?GH[80D?FI_ T 4O$%S+XL\=R1V[;EEG6
MV@/4!0<9^G5OQKVN;2;>707TA04MVM_LXQU5=NT5Y;\*=(^U:W/J<BYCM$VH
M3_?;C]!G\Q7J>L:K;Z)I<VH72R&&+&X1KD\D#^9H \(O=.UOP=JX<^;;2QL?
M*N(_NN/8]"#Z'\171Z=\5]7M\+?6MO=J.K+^[<_B,C]*[SP_XNTOQ=+=6D-M
M(!$H8I<*OSJ3@\ GIQ^=)J/P_P##>HY)L!;N?X[9MF/P^[^E $.A_$31-9F2
MW9GL[ES@).  Q] PX_/%=;7S_P",?#0\+ZPMK'<&:&6,2QLPPP&2,'\NM>R>
M#KR:_P#".FW%PQ:5HMK,>IVDKD_E0!N4C_<;Z4M(_P!QOI0!X)X M4N_&VG)
M(H9$9I,'U521^H%>^5\_^!]0CTWQAI\\S!8F<Q,3T&X%0?S(KZ H PO&=LMU
MX.U5&4';;M(,]BOS?TKS;X43M'XIGBR=LMJV1[AE(/\ /\Z]!\>ZC'IW@^^W
ML ]PGD1K_>+<'],G\*X;X263R:W>WN/W<-OY>?\ :9@1^BF@#FM8!U+QY>1R
MDXEU!HC[#?M_E7T$JJB!% 55& !T KP#Q/')I'CJ^?;\R79N%]P3O'\Z]YL[
MN&_LX;NW</#,@=&'H: )Z\ \<6RV/C74HX@$!D$@V\<LH;^9KW\G R>E?/GB
M:[_M_P 9WDEI^\\^<10X_BQA%(^N!^= 'K'BO0YO%7A&%8<?:U"7$0)QN;;R
MOMD$_CBO(['5==\)7TD<+S6<O22&5.&^JG^=>S:]XHT_PE;6D=Y%</YBE8Q"
M@/W0,\DCU%2Z7?:7XRT1+M[..6%F93%<(K%2#^/;!_&@#A-.^+ERF%U+38Y!
MW>W8J?R.<_F*[O0?%FD>(@5L9R)E&6@E&UP/7'?\,UDZE\,O#]\K&WCELI3T
M:%R5S[JV?TQ7D\:W/ASQ6$CD!GLKK9N3HV&P?P/I[T >P_$;_D1-1^L7_HQ:
MY3X/_P"OU?\ W8OYO75_$;_D1-1^L7_HQ:Y3X/\ ^OU?_=B_F] 'JE%%% &5
MXG_Y%35_^O*;_P! ->6?"G_D;9?^O1__ $):]3\3_P#(J:O_ ->4W_H!KRSX
M4_\ (VR_]>C_ /H2T :WQA^_H_TF_P#9*Z/X9PK'X*MW48,LLCM[G=C^0%<Y
M\8?OZ/\ 2;_V2NG^&_\ R(UC_O2_^AM0!U=> ZT GQ#N\?\ 01)_\?S7OU>!
M:Y_R4.[_ .PA_P"ST >^UX%X3_Y'ZP_Z^C_6O?:\"\)_\C]8?]?1_K0![+XL
M_P"11U?_ *])/_037F7PF_Y&NY_Z\G_]#2O3O%2EO"6K@?\ /I*?_'37EOPJ
ME6/Q<Z,0#):NJ^YW*?Y T >TUYA\8?\ 5Z/]9O\ V2O3Z\F^+MY')J&FV:L"
M\,;R. >FXC'_ *#0!U7PS_Y$FV_ZZR?^A&N!\=>%+_2=:N=2MX9'L9Y#,LL8
MSY3$Y(..G/0_2N]^&AQX(MS@G$DG3_>-)I_Q'T?5-9M]-@@NE:=M@DE554''
M ZD\GC\: .!TOXF:_IZ)'.\5[&HQ^_7YL?[PQ^9S78Z5\5=)NV5-0MI;)SQO
M'[Q!^(Y'Y5T>H^$- U0LUSID&\]9(QY;9]<KC/XUYKXY\"VWAVRCU"PN)&@:
M01M%*02I()!!'4<4 >PPSQ7,"302))$XW(Z'(8>H->#2_P#)2G_[#!_]'5W/
MPDO)IM(OK1V)B@E5H\]MP.0/RS^-<-+_ ,E*?_L,'_T=0!Z'\5YFC\*PQKTE
MNU5OH%8_S JA\(;5!8:E=X'F-*L>?0 9_K^E:GQ1M'N?"'FH,_9[A)6^F"O_
M +,*POA'J4:MJ&F.P$C%9HP?XL<-_P"RT >I5R'Q+M4N/!=Q*5!:WDCD4]QE
M@I_1JZ^N)^*.I1VOA4V18>;>2*JKWVJ0Q/Z ?C0!S_P@F87FJ09.UHT?'N"1
M_6N4NX5N/B%/"XRLFJLA'J#+BNQ^$%HX75+PK\A*1*?4C)/\U_.N2?\ Y*4W
M_88/_HZ@#WVN;\?*&\$:F#_<4_DZUTE<[X\_Y$C5/^N:_P#H0H X;X0_\A74
MA_TP7_T*O6Z\D^$7_(6U'_K@O_H5>MT %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 <A\3/^1*N/\ KK'_ .A5YMX*
M\*0^*KB[CFNI(! JL"B@YR3Z_2O2?B9_R)5Q_P!=8_\ T*N7^$'_ !^ZK_US
MC_F: +Y^$-ECC5;C/_7)?\:S=3^$EW! TFG:@ERX&1%)'L)^AR1^>*]:HH ^
M?M \0ZEX0U=@1((U?;<VCG ;'!X[,/6O>K.[AO[*&[MWW0S('0^Q%>8_%G1X
MHI;/5XD"M*3#,0/O$#*GZX!'X"MCX4Z@USX=GLW8DVLWR^RL,@?F&H [VBN/
M\9^.8O#)6TMHEGOW7=M8_+&.Q;'7Z?Y/ IXG\<ZX6DLGO'C!Q_HMO\J^V0/Y
MF@#VZBO"W\6^,]%F47EQ=Q,>B7<'WA_P(?RKTGP3XP'BBUF2>)(;VWQO5#\K
M@_Q#//X?3UH ZNBO,/'?BCQ'X>\0F&UNU2SFC62$>2AQV(R1Z@G\17=>&M6&
MM^'K*_)!DDCQ)CLXX;]0: -6BBO)-=\>:[)XKGT_1KE5A$XMX5\I6W-]TG)'
M=LT >MT5ROBSQ:OA32X4)6YU*5 $5A@''5VQT&>PKSM/$_CG72[V3W;Q@]+6
MW 5?;('\S0![=17B*^-?&.A72I?O-GKY-Y!C</K@'\C7J7A7Q+;^)]+^U1)Y
M4T;;)HB<[6]O4&@#<HHHH **X/XC^)=5\/-IHTVX$7GB3S,QJV<;<=0?4US%
MS\3-9N=/M+*P'^G,N)IQ$"SN3T1<8Z8[4 >QT5XC<ZUX^TE/M5U)J$41P2\L
M(*#ZY&!79>"_B"-<N%T[4D2*];_5.@PLN!TQV/Z&@#O**"0 23@#O7EWB?XH
M21W,EIH*Q[4.UKIQNW'_ &!TQ[G.?2@#U&BO#DUKQY<Q?:XWU1XNN](#M(_!
M<8K1T+XH:E9W*PZTHNH,[6D"!9$_ 8!^GZT >P45%:W4-[:Q7-M(LD,JAD=>
MA!K@O&OQ"DTB\;3-)$;W*<33.,B,^@'<^O;^@!Z%17B2:O\ $&_C%S$=3>,C
M*M%;X4CVPN#4VF?$G7]+O/)U5?M4:MMDCEC"2+]" .?J* /9Z\-^)-]=3^,+
MRUEGD:W@V>5$3\J912<#UR37I^NZS=2>#6U7P_OEFE5&AV1;VP6&?EYY SGT
MKQ#6;K4+W5I[C55=;U]OF!X]AX4 ?+@8X H ^CX?]1'_ +H_E3Z\U\'ZYXOO
M?$%M;ZI%<K8E&WE[/8.%./FVCOBO2J "N%\9^!;SQ-K,5[;WD$*) L160$G(
M9CGC_>KNJ\U^(/B[6=!UZ"TTZY6*%K99"#$K98LP[CV% '>:-8OIFBV5C(ZN
M]O"L;,O0D#&:O5F:%=S7WARPO+AMT\ULDCM@#+%<G@5Y;HWQ-U:&^,FJW'VB
MV6-B(DB12[X^49 XYH ]EHKQ.;QEXQUV9WT\7"Q \1V4!8+]2 3^M0V?Q \3
MZ3=[+N=IPAP\%U'@_G@$&@#W*O._BY=21Z/86RL0DLS,P'?:./YUU=GK:ZQX
M6;5=/5M[0.R1D;BL@!^7'?D?C7B_B35O$>I1VXUV.=%0L8O,MO*Y.,XX&>U
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ](M[&TM?^/>U@A_ZYQA?Y5/0!SOC/PW_P )+H9MXV"74+>9 QZ%L8VGV/\
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M3?%7Q ]L(5ALUE(QYJQ$M]<9QG\*PM7T;6$TY==U?S ]W-M43???@G<1V'&
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M.1CGVY->GQW.F:Y92113VUY;R*5=4<."#V.*\[U;X2/O:32+]=IY$-R",?\
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M#,N.3M?GC\*]^MM:TN[MEN(-0MGB(SN$H&/KZ?C7/^*?A_8>(IVO(YFM+U@
MTBKN5\>J\<^^:Y+_ (5%J/F8_M.UV?WMC9_+_P"O0!J>/O'%BVES:3I<ZW$T
MXV2RQG*(O< ]R>G';-<O\,7"^-(03]^&0#\L_P!*[S0/AMI.D2K<7;&_N%^[
MYB 1K]%YS^)-4M,^&)TK7;?4K?62!#-YBQ_9NJYY7._N,C.* /0:\@^*^D?9
MM8M]4C7Y+I-DA']]?\5Q^5>OUQGQ/:U'@YQ/_K3,GD?[^>?_ !W=0!Y= ;OQ
M?XGLH9B3)-Y4+$=D50&;\@6KZ"CC2&)(HU"HBA54= !T%>5?"72/,O+S5Y%^
M6)?(B)_O'EC^ Q_WU7J] 'C_ ,2;K6M.\1$)J-XEE<1J\2)*RH"!AAQQU&?Q
M%=OX;\;Z5K&FPFXO(;>]5 )HIG"?-W(SU!Z\5L:WH=CX@L#9W\19,[E93AD/
MJ#7G=W\(9PY-EJL;+GA9HRI ^HSG\A0!U'B_Q1HEMX?O+=[JWNIIX6CC@C<.
M22, G'0#KD^G%<!\+K*6X\6BY0'RK:)F=NWS#:!^I_*M>S^$,YD!O=5C5.XA
MC))_$XQ^5>B:+H=AH%B+2PAV)G+,3EG/J3WH T:*** /+?C#]_1_I-_[)5;X
M=>,[72X&TC4Y/*A9R\,S?=4GJK>@SSGW-6?C#]_1_I-_[)5?0_ 5GXD\&6-Y
M%,;6^S(&DV[ED =L;A_4?K0!W^I>+M"TRS:YDU*WEPN5CAD5W?Z ']>E>-,;
MSQQXQ)5-LEW+TZB*,?X*/Q_&NGA^$-Z9<3ZI;K'GJD;,<?0XKOO#OA73?#5N
MR6:,TS_ZR>3!=O;V'L* (O%6@C5?"4^FVJ /&BFW7W3H/Q Q^->3^"O$Q\*Z
MQ*+J-S:S#RYT ^9"#P<>HYX]S7O%<CXE^'VF>()FND=K.\;[TD:Y5_=E[GWR
M* -F+Q+H<UM]H35[+RL9):=1CZ@G(/L:\P^(7C.WUSR],TYB]I$^^27H)&'
MQ[#)^OX58/PBU'S,#4[4IZE6S^7_ ->NAT'X8:;IDR7-_,;^9#D(5VQ@^XYS
M^)Q[4 /^&6ARZ;X>EN[A#'-?,'7U$8'R_P R?Q%<%_PD&M^'_%X.HWMY<_8Y
MRKQR2MAUY' /'(.1^%>Z@8&!TKF_$_@O3O$P668M!=HNU9X^N/1AW'^<T 7K
M+Q/HFH6ZSP:I:[6'W7D",/J#R*X/XG>(M)O]/@TZTFBNKE9O,:2,AA&,$8W#
MN<C@>G/:JTWPBU!7Q!JELZ>KHRG\AFM'2_A)!%,LFJ7YG4'/DPKM!^K'G\L4
M 3_"2REAT>^O'!$=Q*JQY[[0<G\SC\*XKXBJ5\=:B2.&$9'_ '[6O<[>WAM+
M>.WMXUCAC4*B*,!0*YCQ9X%M/$\R70N&M;Q5V>8%W*X[9''YYH O:+XLT75E
MM8+6^C:YE3B @A@0,D?A@_E6]7G7A_X:7&C:W:ZBVJHWD-NV+"?FX((SGC@U
MZ+0 5XU\6?\ D:[;_KR3_P!#>O9:XSQ9X"_X2C58[[^TOLVR$1;/(WYPS'.=
MP_O?I0!M>%_^1/TK_KSC_P#017CGP_\ ^1YTS_>?_P! :O;]+L/[-T>TT_S?
M,^SPK%OV[=V!C..<5QWA_P"&G]A:[;:E_:WG^06/E_9MN[*D==Q]?2@#OJXG
MXJ?\B@O_ %])_)J[:L3Q5X>_X2;1Q8?:OLV)5DW^7OZ9XQD>M ')_"'_ )!>
MI?\ 79?_ $&H_B__ ,>FE?\ 723^2UU'A#PI_P (K:W,/VW[5Y[A\^5LVX&/
M4TWQAX2_X2N&TC^V_9?L[,V?*W[LX]QCI0!2^&'_ ")D7_7:3^=8_P 7K*1[
M/3;U5S'$[QN?0L 1_P"@FNQ\,:#_ ,(WHJZ=]I^T;79_,\O9U]LFK^HZ=:ZK
M82V5Y$)8)1AE/Z$>AH \\^&_BW3K72/[(O[F.VDB=FB>5MJ,IYQD\ YS^8KI
M=>\=Z-H]E(T-Y#=W6T^7# X?)[;B. *Y2_\ A%)YS-IVIIY9Z)<(01^(Z_D*
ML:3\)8HKA9=5OA-&ISY,*E0WU8\X^@_&@#SG3)7G\16<TAW/)=HS'U)<$UZM
M\3Y-5M-*M;W3KRY@B20I.('*Y#="2.V1C\:2[^&D4_B(:I#J*P1++&Z6RVW"
MA<84'=[>E=Q<6\-W;R6]Q&LD,BE71AD,#VH \Y^'WC:T&G_V7J]YY<Z.3%-.
M_#@G."QZ$'/7UKM;OQ+HEE;M//JEH$49^64,3] .3^%<3J?PD@EF:33-1:%#
MTBF3=C_@0.<?@:SX?A%J#.!-JELBYY*(S'\CB@#DPG]O^,"+" QK=W9:- ,;
M%+9_# YKTKXM?\BO:?\ 7ZO_ * ];7AKP9IGAD&6#=/=L-K3R=<>@'85)XM\
M-?\ "4Z7%9?:_LOES"7?Y>_.%88QD?WOTH Y[X2?\B[>_P#7V?\ T!:Y/XEZ
M)+IWB1[]4/V:]PX8#@.!AA]>_P"/M7IGA'PQ_P (MITUI]L^U>;+YN[RMF.
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M^$?#/_"+:;-9_;/M7F3&7?Y6S' &,9/I704 >&?$O_D=KK_KG'_Z"*]HTO\
MY!-E_P!<$_\ 017(^)OAU_PD6MRZE_:OV?S%5?+^S[\8&.NX5VEK#]FM(8-V
M[RHU3=C&<#&: ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#DO'/BF^\+PV,UI!
M!*DSNLGF@\8 (Q@CWKRS5]?UGQIJ-M#(@=\[8;>!2%!/4\D\^Y]*]WOM.LM2
MA$5]:0W,8.0LJ!L'U&>E0Z?H>EZ4Q:PL+>W8C!9$ 8CZ]: (/#6BIH&@VVGJ
M0SHNZ5A_$YY)_I] *UJ** "BBB@ HHHH **** /+?C#]_1_I-_[)73_#?_D1
MK'_>E_\ 0VKI+FQM+S;]JM8)]N=OFQAL9],T^""&VB$4$4<48Z)&H4#\!0!)
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img242628118_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '% =,# 2(  A$! Q$!_\0
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M;I=UMC1D3FWD]\=5/KVK:H:&XVU"BBBD2%%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% %74@ATVX$EM]I38<PY W^V3TKCM+CU%9W?2]4M(L#<FF"?S@?4%CT_"
MNF\1O;+H-TEW<K;QRH4#GGD]!@<GZ5@^&([>XUEY;22S$4&]MJ0F.;Y\8!!
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M=I]ZT-)_Y ]E_P!<$_D*HZOI6GIHM\RV-L&$#D$1#@[35[2?^0/9?]<$_D*
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M+X^ZV.Q[&MNAJPG&P4444B0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3BQ<P-L\X#Y9QV<?U'K6G2>A+5G8****!!1110 4444 %%%% !1110 4444
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M)_(5BZKX6TB'2+R5+4ATA=E/F-P0#[UM:3_R![+_ *X)_(4 7**** "BBB@
MHHHH **** "BBB@ HHHH 1E5U*L RD8((X-8T-C#X:@O+F%KA['_ %@M(UW^
M6>^P=<=\5M44TRE*VG0@L[RWU"UCNK65989!E64TMW:07UI+:W42RPRJ5=&&
M016=/:?V+;W=UI%@)999!++ K[0WJ5'0''YU;TS5+75K,7-JY*YVLK##(PZJ
MP[$46ZH;5O>CL>3ZC8:I\,]>&H:>7GTF9L%3T(_NM[^AKU31=:L]>TV.^LI
MT;#YE[H>X/O5B]LK?4;.2UNXEE@D&&1AP:\CO;/5?ACKPO;(M/I$[8*GH1_=
M;T8=C6NE1>9U)K$JS^-?C_P3TV]T5GU6'5+"<6UV"%FXRL\?HP]1V/:KUI?V
MM\9EMIED:&0QR*."C#L14&C:S9Z[IL=]92!XW'([J>X/O39='@&L)JL+217
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M08:-QU4U?J7H0TT[,****!!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!')+$CI'(ZAI,A58_>]:S;"XTR/4)
M;6SM%@<LP,B0A%D9?O#(ZD5#XF6YDM8HXD<QL3O:.+S&! ^7 [<]^U)H^CRV
M5RMS,H=Y$RQ9R6C8XR .ASZ]>.<T ;M%%% !113)8Q+$\99E# C*G!'T- %3
M6O\ D!W_ /U[R?\ H)IVD_\ ('LO^N"?R%8FJ^'88M(O)!J&I-MA<X:Z8@\'
MJ*V])_Y ]E_UP3^0H N4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !63K&C-?/%>6<WV;4H/]5-U!'=6'=36M133L.,G%W15@O89+AK-IHS>1HK2
MQJ>F>X]J34M-M=7T^6RO(A)!*,$'M[CT-0:EHT.H3V]TLCV]Y;MF.>/[V.ZG
MU!]#3[75[6YU&XT\%X[J#[T<@P67^\OJ*/-%6^U$\I5M5^%WB#8VZYT>Y;CT
M8?T8?K7K>G:C:ZK8Q7EG*)8)1E6'\C[U'JVDV>MZ=+8WL0>&0?BI[$'L:\H@
MGU3X7^(?L\^^XT>X;((Z,/4>C#T[UKI47F=6F)7]]?C_ ,$]3U>+4!;";2GC
M6XC?S&B8#$X[J3V/O5G3[PW]C%<F"6!G'S12KAE/0@TMC?6VI645W:2K+!*N
MY66J&LVFH.T-]I<Y%S;Y_P!'=OW<ZGJI]#Z&L_)G*M?=>AKT5'!(9849T,;E
M06C)!*D]CBI*D@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** ,K6-2N;.2TM;&&.2[NF98_-8A%"C))QS6?H/B
M"^O;J*WU&WMU,PD,4D!.-R'#*0?YU/XHACEMK=KFPDNK5'+2O"Q$L/\ M+CD
MCKFJ^AO:7-[ =)L%&G6L;1K>/G+DGD)GD\]2: .FHHHH ***9*ADB= [(6!&
MY>H]Q0!4UK_D!W__ %[O_P"@FG:3_P @>R_ZX)_(5AZIH$T6D7CG6]2<+"YV
MM*,'@\'BMS2?^0/9?]<$_D* +E%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %4[K3+2\N;:YEC_ ']LVZ*120P]1D=1[5<HH&FUL96G:VMU
M?SZ?=0FUOHB2(F.1(G9U/<?RJ;6='L]=TV2QOH@\3C@]U/8@]C5B>UBED6;R
MXS<1AA%(RY*$BL[1]6N)[B73M2@\G4(1N)0'RY4[.I_IVJO-%_WH:6/,[6ZU
M7X8:\;6Z#7&D3MD$="/[P]&'<5ZY97MOJ-G%=VDJRP2KN5U[U7UK1;/7M-DL
M;V,-&_W6[H>Q'O7E=A?:I\,M>-A?;Y])G;(8="/[R^A]16FE1>9TM+$JZ^-?
MC_P3TS4M*N&OXM4TV417JX21')\N://W6'J.QK2ANH;AI4BE1WB;9(JG)5O0
MT6EW!?6L=U;2K+#(NY'4\$51GT93K$6IVDQMYQ\LX4?+.GHP]1V-9>3.6]])
M=#4HJI8:E:ZDDC6TFXQ.8Y%(PR,.Q':K=(EIK1A1110(**** "BBB@ HHHH
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M@8.<<5N:3_R![+_K@G\A0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU8_M?6/^A=G_ / F+_&@#;HK$_M?6/\ H79__ F+_&C^U]8_Z%V?_P "8O\
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M[7UC_H79_P#P)B_QH VZ*Q/[7UC_ *%V?_P)B_QH_M?6/^A=G_\  F+_ !H
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MIS6C6;!K5O+(T<D<]LPC,H\]-NY!U(_SFEL]9MKR=(5CFB:1=\1E3:)%]5H
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5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img242628118_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_15.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %P F\# 2(  A$! Q$!_\0
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M%CD^@'- &A16+_PE%CYQA\F]\T+N*?97SCIGI3;CQ9IUI T]S'>0PK]YWMG
M'Z4 ;E%<^/&.E, 1]J((R"+9^?TI?^$PTOTN_P#P&?\ PH'9F_16#;>+]+O5
M=K5;N8(Q1RELYVMZ'CK1<^+M,LHA+=+=PQE@H:2V< D]!TH"SO8WJ*P/^$PT
MKTN__ 9_\*/^$QTH#.+O_P !G_PH"S-^BL*V\6Z;>PB:U2\FB)(WQVSD9'7M
M3;GQAI=GY?VE;N'S&V)OMG&YO0<=: L[V-^BL#_A,-+]+O\ \!G_ ,*1O&6D
MHI9OM04#))MGX'Y4!9G045AP>*]/NH%GMXKV6)QE72U<@_I3)_&.E6TT<,XN
MHI)?N(]LX+?3B@+/8WZ*P/\ A,-*]+O_ ,!G_P *;+XUT>&)I96N4C499FMW
M  _*BP69T-%8L?B>REC62."^=' 966U<@@]#TK1LKZ._B:2..9 IQB6,H?R-
M BS1110 R2&.7;YB*VWID9J!=.LTA>%;:,1N<LN.M6J* (X88K>(10HJ(.BJ
M*S=5_P"0KHW_ %\/_P"BVK6K)U7_ )"NC?\ 7P__ *+:@#6HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ (!&#R*@M[
M.WM2Q@A2/=UVCK4]% &5XE_Y%K4?^N#?RK3C_P!4G^Z*S/$O_(M:C_UP;^5:
M<?\ JD_W10!YE:_\CAXC_P"O@?RK5K*M?^1P\1_]? _E6K6TMSNJ;_)?D9-[
M_P C;X:_Z^_Z5ZA7E][_ ,C;X:_Z^_Z5ZA4SV1E7VCZ?J>5>'O\ 7ZS_ -A&
M;^=;=8GA[_7ZS_V$9OYUMU4MS:K\;,ZV_P"2C:/_ -<)/ZUZ-<_\>LW^X?Y5
MYS;?\E&T?_KA)_6O1KG_ (]9O]P_RJ9]#&OO'T_5GEWA+_D C_KO+_Z%6Y6'
MX2_Y (_Z[R_^A5N54OB9K5^-E7P[_P E+N/^P</_ $*NTU[_ )%[4O\ KUE_
M]!-<7X=_Y*7<?]@X?^A5VFO?\B]J7_7K+_Z":F7Q(RK?Q(^B. \,_P#(MV/_
M %SK5K)\,_\ (MV/_7.M:JENS2I\;]2'P5_R.NO_ /7.+^M>@5Y_X*_Y'77_
M /KG%_6O0*BIN8XGX_DOR"BBBH, HHHH **** "BBB@"&XM+>[4+<0I( <C<
M.E2JH50J@ #@ =J6B@#'3_D<9?\ KP3_ -&-6?\ $/\ Y$;4O]P?S%:"?\CC
M+_UX)_Z,:L_XA_\ (C:E_N#^8JH?$C6A_%CZHQ[3_CRM_P#KDG\A4XZU!:?\
M>5O_ -<D_D*G'6K-GN.^&O\ QY:S_P!A&3^E2_$O_D6K?_K^A_K47PU_X\M9
M_P"PC)_2I?B7_P BU;_]?T/]:/\ EX/_ )B?F5QT'TILG^J?_=/\J<.@^E-D
M_P!4_P#NG^5 BY\-/^1/3_KXE_\ 0JK?$?[WA[_L(K_Z":L_#3_D3T_Z^)?_
M $*JWQ'^]X>_["*_^@FFOX@U_O+]6)5;4?\ D&7?_7%_Y&K-5M1_Y!EW_P!<
M7_D:2W".Z.@\!?\ (DZ9_P!<OZFL/QM_R-_A[_MI_*MSP%_R).F?]<OZFL/Q
MO_R-_A[_ +:?RH7QOYBA_'E\_P!26LKQ-_R+.H_]<6K5K*\3?\BSJ/\ UQ:G
M'=%T_C7J=]X?_P"1<TS_ *](O_016C6=X?\ ^1<TS_KTB_\ 016C63W..?Q,
M****1(4444 %9.J_\A71O^OA_P#T6U:U9.J_\A71O^OA_P#T6U &M1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!E>)?\ D6M1_P"N#?RK3C_U2?[HK,\2_P#(M:C_ -<&_E6G'_JD_P!T4 >9
M6O\ R.'B/_KX'\JU:RK7_D</$?\ U\#^5:M;2W.ZIO\ )?D9-[_R-OAK_K[_
M *5ZA7E][_R-OAK_ *^_Z5ZA4SV1E7VCZ?J>5>'O]?K/_81F_G6W6)X>_P!?
MK/\ V$9OYUMU4MS:K\;,ZV_Y*-H__7"3^M>C7/\ QZS?[A_E7G-M_P E&T?_
M *X2?UKT:Y_X]9O]P_RJ9]#&OO'T_4\N\)?\@$?]=Y?_ $*MRL/PE_R 1_UW
ME_\ 0JW*J7Q,UJ_&RKX=_P"2EW'_ &#A_P"A5VFO?\B]J7_7K+_Z":XOP[_R
M4NX_[!P_]"KM->_Y%[4O^O67_P!!-3+XD95OXD?1'G_AG_D6['_KG6M63X9_
MY%NQ_P"N=:U5+=FE3XWZD/@K_D==?_ZYQ?UKT"O/_!7_ ".NO_\ 7.+^M>@5
M%3<QQ/Q_)?D%%%%08!1110 4444 %%%% !1110!CI_R.,O\ UX)_Z,:L_P"(
M?_(C:E_N#^8K03_D<9?^O!/_ $8U9_Q#_P"1&U+_ '!_,54/B1K0_BQ]48]I
M_P >5O\ ]<D_D*G'6H+3_CRM_P#KDG\A4XZU9L]QWPU_X\M9_P"PC)_2I?B7
M_P BU;_]?T/]:B^&O_'EK/\ V$9/Z5+\2_\ D6K?_K^A_K1_R\'_ ,Q/S*XZ
M#Z4V3_5/_NG^5.'0?2FR?ZI_]T_RH$7/AI_R)Z?]?$O_ *%5;XC_ 'O#W_81
M7_T$U9^&G_(GI_U\2_\ H55OB/\ >\/?]A%?_0337\0:_P!Y?JQ*K:C_ ,@R
M[_ZXO_(U9JMJ/_(,N_\ KB_\C26X1W1T'@+_ )$G3/\ KE_4UA^-_P#D;_#W
M_;3^5;G@+_D2=,_ZY?U-8?C?_D;_  ]_VT_E0OC?S%#^/+Y_J2UE>)O^19U'
M_KBU:M97B;_D6=1_ZXM3CNBZ?QKU.^\/_P#(N:9_UZ1?^@BM&L[P_P#\BYIG
M_7I%_P"@BM&LGN<<_B84444B0HHI,C&<B@!:R=5_Y"NC?]?#_P#HMJUJR=5_
MY"NC?]?#_P#HMJ -:BBB@ HHHH **** "BBB@ HHHH **** "BBL?5-3U*P,
MTD.E">VB0N9/M"J2 ,G@TTKCC%R=D;%%9&F:EJ5\T3SZ4+>WD3>)/M"MU&1P
M*UZ&K XM.S"BBBD(**** "BBB@ HHHH **,C.,\T9S0!E>)?^1:U'_K@W\JT
MX_\ 5)_NBLSQ+_R+6H_]<&_E6G'_ *I/]T4 >96O_(X>(_\ KX'\JU:RK7_D
M</$?_7P/Y5JUM+<[JF_R7Y&3>_\ (V^&O^OO^E>H5Y?>_P#(V^&O^OO^E>H5
M,]D95]H^GZGE7A[_ %^L_P#81F_G6W6)X>_U^L_]A&;^=;=5+<VJ_&S.MO\
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MY_J2UE>)O^19U'_KBU:M97B;_D6=1_ZXM3CNBZ?QKU.^\/\ _(N:9_UZ1?\
MH(K1K.\/_P#(N:9_UZ1?^@BM&LGN<<_B84444B2O?!C87 0.7,38"?>)QV]Z
MY6U2<0,'25H-\)F\M7 VC.X$'DGIG%=E10!F:2)5L9RB-L\US;K(2/D[=>0,
MYK-GEU.36M(%]:V\*><^#'*6.?+;V%=+63JO_(5T;_KX?_T6U &M1110 444
M4 %%%% !1110 45%<7$-I \]Q*D4*#+.YP!]37.W_B2W:0-8>(=&CC"\K,VX
MD_@PII-E1@Y;'3T5QFD>*VN8;:YO==T6)'YDA'RN!SQDM_2NJLM1LM11GLKJ
M&X13AFB<, ?PIN+0YTY0W)I)8X4WRR*B^K' K,UB^LVT2^474!)MW  D']TU
M@_%!0WA':1D&YC!_.N8O/"NBQ6,\B6*AUC9E.]N#CZU48JUV;4J46E*3ZGH^
ME7UFND68-U "(4R#(/05HQRQS)OBD5U]5.17E%KX5T22RAD>Q4NT8).]N3CZ
MUT_PP 7P<BCH+B4#_OJB45:Z"K2BHN47U.SHHHK,Y@HHHH ***CGE\F!Y2I8
M(,D @?SH DJ.9I%C)A0._8,<"LNRUU=0U,V]M&'M]N?-&<@XSR,8]NM;% '-
MRLL^L2+9J\,\:N7=BW[QROW1GC ]?RJ?15Q=*84G2(6X$_FYYER/7O\ >S^%
M;M% ',^)IM6_L?44^QVWV7RF'F><=VWUQCK721_ZI/\ =%9GB7_D6M1_ZX-_
M*M./_5)_NB@#S*U_Y'#Q'_U\#^5:M95K_P CAXC_ .O@?RK5K:6YW5-_DOR,
MF]_Y&WPU_P!??]*]0KR^]_Y&WPU_U]_TKU"IGLC*OM'T_4\J\/?Z_6?^PC-_
M.MNL3P]_K]9_[",W\ZVZJ6YM5^-F=;?\E&T?_KA)_6O1KG_CUF_W#_*O.;;_
M )*-H_\ UPD_K7HUS_QZS?[A_E4SZ&-?>/I^IY=X2_Y (_Z[R_\ H5;E8?A+
M_D C_KO+_P"A5N54OB9K5^-E7P[_ ,E+N/\ L'#_ -"KM->_Y%[4O^O67_T$
MUQ?AW_DI=Q_V#A_Z%7::]_R+VI?]>LO_ *":F7Q(RK?Q(^B//_#/_(MV/_7.
MM:LGPS_R+=C_ -<ZUJJ6[-*GQOU(?!7_ ".NO_\ 7.+^M>@5Y_X*_P"1UU__
M *YQ?UKT"HJ;F.)^/Y+\@HHHJ# **** "L74]*N-1U!-S!;7;@LK;6 [@]S[
M5M5S_BSSA8Q-%<)$ _*-/Y6\]N?;TH V;.W%K:1P#'R#' //YU6U*98K:=KN
M!GME ($9)9CGI@4[1VD?2X7DF29FW-O1]PY8D 'OCI^%7J .6C1!#;/=+*]F
MWFMY<>XB-R1M7CGIG\:V+<ZA%HEOMB66\$:[EE?;SWR<5HT4 <]I\E[)XLG-
M]!%#)]B3:(I"X(WM["H/B'_R(VI?[@_F*T$_Y'&7_KP3_P!&-6?\0_\ D1M2
M_P!P?S%5#XD:T/XL?5&/:?\ 'E;_ /7)/Y"IQUJ"T_X\K?\ ZY)_(5,.M6;/
M<?\ #7_CRUG_ +",G]*E^)?_ "+5O_U_0_UJ+X:_\>6L_P#81D_I4OQ+_P"1
M:M_^OZ'^M'_+P?\ S$_,KCH/I39/]4_^Z?Y4X=!]*;)_JG_W3_*@1<^&G_(G
MI_U\2_\ H55OB/\ >\/?]A%?_035GX:?\B>G_7Q+_P"A56^(_P![P]_V$5_]
M!--?Q!K_ 'E^K$JMJ/\ R#+O_KB_\C5FJVH_\@R[_P"N+_R-);A'='0> O\
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MIC_KYB_G4%"^%"A_"7J_T ]#]*L?#'_D3U_Z^9?_ $(U7/0_2K'PQ_Y$]?\
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MZUZ-<_\ 'K-_N'^53/H8U]X^GZGEWA+_ ) (_P"N\O\ Z%6Y6'X2_P"0"/\
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M_81D_I4OQ+_Y%JW_ .OZ'^M1?#7_ (\M9_[",G]*E^)?_(M6_P#U_0_UI?\
M+PG_ )B?F5QT'TILG^J?_=/\J<.@^E-D_P!4_P#NG^5 BY\-/^1/3_KXE_\
M0JK?$?[WA[_L(K_Z":L_#3_D3T_Z^)?_ $*JWQ'^]X>_["*_^@FFOX@U_O+]
M6)5;4?\ D&7?_7%_Y&K-5M1_Y!EW_P!<7_D:2W".Z.@\!?\ (DZ9_P!<OZFL
M/QO_ ,C?X>_[:?RK<\!?\B3IG_7+^IK#\;_\C?X>_P"VG\J%\;^8H?QY?/\
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MF@ HHHH RO$O_(M:C_UP;^5:<?\ JD_W169XE_Y%K4?^N#?RK3C_ -4G^Z*
M/,K7_D</$?\ U\#^5:M95K_R.'B/_KX'\JU:VEN=U3?Y+\C)O?\ D;?#7_7W
M_2O4*\OO?^1M\-?]??\ 2O4*F>R,J^T?3]3RKP]_K]9_[",W\ZVZQ/#W^OUG
M_L(S?SK;JI;FU7XV9UM_R4;1_P#KA)_6O1KG_CUF_P!P_P J\YMO^2C:/_UP
MD_K7HUS_ ,>LW^X?Y5,^AC7WCZ?J>7>$O^0"/^N\O_H5;E8?A+_D C_KO+_Z
M%6Y52^)FM7XV5?#O_)2[C_L'#_T*NTU[_D7M2_Z]9?\ T$UQ?AW_ )*7<?\
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MT :U9.J_\A71O^OA_P#T6U7;*\6\A9]C1NCE)$;&58=1D<51U1E;5='PP/\
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MY*-J?_7E'5FJWA;_ )*-J?\ UY1U2V9:^&7I^J.M\4?\BMJ?_7L_\JXGP_\
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MAEZ?JCK?%'_(K:G_ ->S_P JXGP__P B]8?]<17;>*/^16U/_KV?^5<3X?\
M^1>L/^N(I1^$FE_"?K^AI5'X$_Y&?Q)_O0_R-25'X$_Y&?Q)_O0_R-'V6/\
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M ,BOJ'_7+^M;"_<'TI]"W\"]7^@M%%%(@P_%'_'C9_\ 7[#_ .A5N5A^*/\
MCQL_^OV'_P!"K<IO9%OX%\PHHHI$!1110 4444 %9.J_\A71O^OA_P#T6U:U
M9.J_\A71O^OA_P#T6U %^]_X\+C_ *Y-_*O,?"/_ "+%K_O/_P"AFO3KW_CP
MN/\ KDW\J\Q\(_\ (L6O^\__ *&:TC\+.JC_  WZK]3;JMX6_P"2C:G_ ->4
M=6:K>%O^2C:G_P!>4=4MF6OAEZ?JCK?%'_(K:G_U[/\ RKB?#_\ R+UA_P!<
M17;>*/\ D5M3_P"O9_Y5Q/A__D7K#_KB*4?A)I?PGZ_H:51^!/\ D9_$G^]#
M_(U)4?@3_D9_$G^]#_(T?98_^7<O3]4;7C__ )$75O\ KD/_ $(5@Z?_ ,@V
MU_ZY+_*M[Q__ ,B+JW_7(?\ H0K!T_\ Y!MK_P!<E_E1'X!4_P"%\_T19'44
MGPWZZ[_U^_TI1U%)\-^NN_\ 7[_2C[+&_P"%+Y?F3_$[_D4Q_P!?,7\Z@J?X
MG?\ (IC_ *^8OYU!0OA0H?PEZO\ 0#T/TJQ\,?\ D3U_Z^9?_0C5<]#]*L?#
M'_D3U_Z^9?\ T(T/X6$_X3]5^IV5%%%9'(%%%% !6?KCK'HEX[1"51&<J>GU
M/TZ_A6A5#6KB2UT>ZFB +JG&5W=3C.._6@#+LX;.RU32[>V6.0-#(^Y9"Q5C
M@ECZYZ9KHZY3PG-813W%K$%:<L=LWD%#(F,_A@FNKH **** ,KQ+_P BUJ/_
M %P;^5:<?^J3_=%9GB7_ )%K4?\ K@W\JTX_]4G^Z* /+HY#%XK\32"-Y"LX
M^5!DGZ5-_;/[_P G^S[WS-N_;L[9QFF6O_(X>(_^O@?RJ;_F8O\ MT_]GK=V
MN>A*U]5T7Y(JSR&7Q/X8D,;QEKO[CC!''>O5*\OO?^1M\-?]??\ 2O4*B>R,
M,1M'T_4\J\/?Z_6?^PC-_.MNL3P]_K]9_P"PC-_.MNJEN;5?C9G6W_)1M'_Z
MX2?UKT:Y_P"/6;_</\J\YMO^2C:/_P!<)/ZUZ-<_\>LW^X?Y5,^AC7WCZ?J>
M7>$O^0"/^N\O_H5;E8?A+_D C_KO+_Z%6Y52^)FM7XV5?#O_ "4NX_[!P_\
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M^2C:G_UY1U9JMX6_Y*-J?_7E'5+9EKX9>GZHZWQ1_P BMJ?_ %[/_*N)\/\
M_(O6'_7$5VWBC_D5M3_Z]G_E7$^'_P#D7K#_ *XBE'X2:7\)^OZ&E4?@3_D9
M_$G^]#_(U)4?@3_D9_$G^]#_ "-'V6/_ )=R]/U1M>/_ /D1=6_ZY#_T(5@Z
M?_R#;7_KDO\ *M[Q_P#\B+JW_7(?^A"L'3_^0;:_]<E_E1'X!4_X7S_1%D=1
M2?#?KKO_ %^_TI1U%)\-^NN_]?O]*/LL;_A2^7YD_P 3O^13'_7S%_.H*G^)
MW_(IC_KYB_G4%"^%"A_"7J_T ]#]*L?#'_D3U_Z^9?\ T(U7/0_2K'PQ_P"1
M/7_KYE_]"-#^%A/^$_5?J=E11161R!1110 4444 %,FFC@C,DC!5'4T^B@#F
MSKETFH2;MK6ZLZ@"/Y3A<C#YY)],5?TZ[NGN8X;F2*3SK<3J8UV[.1\O4YZ]
M?:K0TRS%T;CR%\PDGOC)X)QTS[TZUL+6R+FWB"%NIR3QZ>P]J ,/Q-K>G_V/
MJ-GYY\_RF3;L;K]<5T<?^J3_ '169XE _P"$:U'C_E@W\JTX_P#5)_NB@#@;
MWP;X@_M[4;_3M0LHHKN3?MD5B1^E9W_"-^*?[?\ (_M*P^T?9=^_8VW9OQCI
MUS7J-8W_ #.A_P"P</\ T96BJ,ZHXB?EMV.7M/!GB$Z[IM]J.H64L5G-YFV-
M6!/Z5Z#114RDY;F-2I*=KGDVC7$-JVM2SN$0:C*,GZU?_MS3,X^V1YJIX?&9
M]9_[",W\ZN6X']MWO _U<?;ZUJ[79VS2YG<CLG63XA:*Z'*M;R$$=QS7I%S_
M ,>LW^X?Y5YS;?\ )1M'_P"N$G]:]&N?^/6;_</\JB?0YZ^\?3]6>7>$O^0"
M/^N\O_H5;E<[X;NX;/P\KSN54W$H!"D\[O:M$:[IK$@7!)!P1Y;<?I5R3NS>
MI&3F[(G\._\ )2[C_L'#_P!"KM->_P"1>U+_ *]9?_037%>'"#\2IR.ATX?^
MA5VNO?\ (O:E_P!>LO\ Z":B7Q(PK?Q(^B. \,_\BW8_]<ZDT?\ U%S_ -?4
MO_H51^&?^1;L?^N=2:/_ *BY_P"OJ7_T*K?4WGO+U+?@K_D==?\ ^N<7]:]
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M_'A<?]<F_E7F/A'_ )%BU_WG_P#0S7IU[_QX7'_7)OY5YCX1_P"18M?]Y_\
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M5ZQ]@LL_\>D'_?L?X5C:+96K:GK0:UA(%T ,QCCY!6O/%W=CJ]O3ES2L_O\
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M **** "BBB@ HHHH *R=5_Y"NC?]?#_^BVK6K)U7_D*Z-_U\/_Z+:@"_>_\
M'A<?]<F_E7F/A'_D6+7_ 'G_ /0S7IU[_P >%Q_UR;^5>8^$?^18M?\ >?\
M]#-:1^%G51_AOU7ZFW5;PM_R4;4_^O*.K-5O"W_)1M3_ .O*.J6S+7PR]/U1
MUOBC_D5M3_Z]G_E7$^'_ /D7K#_KB*[;Q1_R*VI_]>S_ ,JXGP__ ,B]8?\
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MHHH **** "BBB@#*\2_\BUJ/_7!OY5IQ_P"J3_=%9GB7_D6M1_ZX-_*M./\
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M_P!_TJ ZW?B^6T_L=_-:,R >>O3.* -VBLG^T=4_Z S_ /?]*/[1U3_H#/\
M]_TH UJ*R?[1U3_H#/\ ]_TJ%-;OWO);5='D\V-%=AYZ]&SC^1H W**R?[1U
M3_H#/_W_ %H_M'5/^@,__?\ 2@#6HK)_M'5/^@,__?\ 2H(=<OY[B>!-'<O
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B,"@"?3()[;2[:&Z??.D85VSG)Q5NBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img242628118_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_16.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %S 8T# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#$N/^1TL?^O*7_P!"2MNL2X_Y'2Q_
MZ\I?_0DK;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH Q+C_D=+'_ *\I?_0DK;K$N/\ D=+'_KRE_P#0DK;H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **\_P#%OQ*&@ZJVFV-HMQ-%
MCS7=L*I]!CK6WX/\70^*[&1Q#Y%S"0)8LY'/0@^E6X22YC:5"I&'.UH=+111
M4&(4444 %%%% !1110 4444 8EQ_R.EC_P!>4O\ Z$E;=8EQ_P CI8_]>4O_
M *$E;= !1110 4444 %%%% !1110 4444 %%%% !17*>*?'NG^&+A;5XI+F[
M8;C$A VCW-6_"_BZP\4V\CVJO%-%CS(9.HSW'J*KDE:]M#1T9J'/;0Z"BBBI
M,PHHKSJ_\;^(AXAU'3M-TVRFCM'V[G+ X]^:J,7+8TITI5+V/1:*\.\0_$#Q
M/+<?9'>/3WB^^MMG)/U))J]X=\?^*KB%K2""VOY(AN,D^0V/P(S6GL96N=#P
M-11YKH[_ ,3^-=,\+F.*Y$DUQ(-RQ18R!ZGTJ3PSXOT[Q3%(;3?'-%S)#(,,
M!ZCU%>0^*[;7]7U)M5OM.",R+'MM\L ![9)J7PE%XBT2\;4K#3D<NACVW!*@
MCZ9!JO91Y-]39X2G[*]_>]3WFBN0\%^*=2\07>HVVHVMO!):%1B'/4YSG)/I
M77UA)-.S."<'"7*PHHKQZXL[G5_&&O1MJE[ D%P0BQ2$#!IQCS%4J2J7N[6/
M7)KF"V4-/-'$"< NP7/YU("& (((/0BOFG6_M,6J3VMQ<SS>0Y53*Y)Q6YX5
ML+O5[:??J=]!'"0J".0XK5T;*]SKE@5&',Y?@=/XZ^(.IZ=KDFEZ4ZP"WP))
M2@8LQ&<#/&.:W/A[XQN?$D%Q;7ZJ;JW ;S%& ZGV]:XG4/ LDS>;!J#R2L?G
M-QR3^-6+#P4;2//]J7,4S#YS =H-4U3Y;=324,.Z7*M^Y[-17G?PU:X35-=M
M9KJ>X6"1$0RN2>]>B5A*/*['GU:?LY<MPK#N?&'A^SN9+:XU2&.:-MKH<Y!_
M*MRO(;:PM+WQCXB^U6T4VVX&W>N<<4X13O<NC3C.[ET.]_X3GPS_ -!>W_7_
M  H_X3GPS_T%[?\ 7_"O"-<*G6;I4@CA1'**B+@ "NH\%VEGJ&GS+=6,$AB?
M"R,@R0>U;.C%*YV3P=.$.=ME7QQ;Z?>:]-J6EZG;7,5R0SH&PR-WZ]172?#R
M[T/PU9W$U_K-J+JY(S&I)"*.@)QUYJY_86D_] ZV_P"_8H&A:3G_ )!UM_W[
M%#FG'E'*K&5/V;O;Y'=:9K>FZR)#IUW'<",@.4SQFM"O//AI&D.I^(HXT"(M
MRH55& !BO0ZPFN5V1P5H*$W%!1114F04444 %%%0&\MA<BW,\8F/_+/<,_E0
M!/14*7=O).T"3QM*OWD##(J:@#$N/^1TL?\ KRE_]"2MNL2X_P"1TL?^O*7_
M -"2MN@ HHHH **** "BHYIX;>,R3RI$@_B=@!^M$,\-Q&)()4E0]&1@1^E
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M %\TX;,>'VGZ?JC;HHHH*"BBB@"K\._^1B\2_P#79?YM7HE>=_#O_D8O$O\
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MQ_R.EC_UY2_^A)6W6)<?\CI8_P#7E+_Z$E;= !7ED?\ R4/Q#]$KU.O+(_\
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M3^M>B5YW\//^1D\2?]=$_K7HE*I\1&)_B?)?D%>56'_(Z>)O^OFO5:\JL/\
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MC_Y*'XA^B5I3ZG3A]I>GZHV:***"@HHHH I^ _\ D=?$?^['_,UZ-7G/@/\
MY'7Q'_NQ_P S7HU%3XB,3_$^2_(*\KM_^1_\2?\ 71?Y"O5*\KM_^1_\2?\
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M%HYK>Y;<(E'(P3R>>E6=,T)I;J:XO["&VB<*/L:D.A8?\M/8]OIUKI0 !@#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img242628118_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_17.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %  >(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/.M6>YU5;M]CLA,=G,ZY4
MD$ A<'!!'%:%9^C?\>,G_7W<_P#HYZ #^V;7_GE??^ $_P#\11_;-K_SROO_
M   G_P#B*T** ,_^V;7_ )Y7W_@!/_\ $4?VS:_\\K[_ , )_P#XBM"B@#/_
M +9M?^>5]_X 3_\ Q%']LVO_ #ROO_ "?_XBM"B@#/\ [9M?^>5]_P" $_\
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M_@!/_P#$4?VS:_\ /*^_\ )__B*T** ,_P#MFU_YY7W_ ( 3_P#Q%']LVO\
MSROO_ "?_P"(K0HH S_[9M?^>5]_X 3_ /Q%']LVO_/*^_\  "?_ .(K0HH
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M_P"(K0HH S_[9M?^>5]_X 3_ /Q%']LVO_/*^_\  "?_ .(K0HH S_[9M?\
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MQ3Q2>8I=-K [E& 2/4<C\ZFH XJ34[EGGM9+TPA;=5CM1 &$J&');.,CGOG
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M^@"@"'1_^/UA_P!,S_,5N5AZ/_Q_-_US/\Q6Y0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6?-_R,-E_UZ7'_ *'#
M6A6?-_R,-E_UZ7'_ *'#0!H4444 %9^C?\>,G_7W<_\ HYZT*S]&_P"/&3_K
M[N?_ $<] &3XJ5'\M;E;HVPVD%(X&0-\P_Y:'.3G^7O6GX?CCBT6W6(.$^;
M=44_>/9/E_*J?BUK5-,C:Y>6,AV\MHPI(;8W&&XY&1ZY(JYH!1M'C*"0'?)O
M\P@G?O;=]WC[V>E &G1110!F:T+@PP" N$\S]X4#DXVG'"$'&<=*J6WVYKZ
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M8 @&X'WA@_<%;%9.H_ZF?_KX'_H H AT?_C^;_KF?YBJ%M]ZW_WD_F*OZ/\
M\?S?]<S_ #%4+;[UO_O)_,4 =715>6]MX9#'))AAU&":FCD26,.C;E/0T .H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SYO
M^1ALO^O2X_\ 0X:T*SYO^1ALO^O2X_\ 0X: -"BBB@ K/T;_ (\9/^ONY_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH1_4U)69B%9\W_(PV7_7I<?^APUH5GS?\C#9?]>EQ_Z'#0!H4444 %9^C?\
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M@"Q1110 4444 %%%% !1110!6OX7N+-XXP"Q((R<="#5*PL+B"[6210% /\
M%FM:B@#D_P"'\*O:K_R$&_W%_K5'^'\*O:K_ ,A!O]Q?ZT 8GB[_ )$B'_KY
M_J]97@+_ %>L_P#7M_C6KXN_Y$B'_KY_J]97@+_5ZS_U[?XUZU'_ ')^OZH^
M9Q7_ "-H^GZ,PO#'_(SZ=_UW6K7C;_D;K[_@'_H"U5\,?\C/IW_7=:M>-O\
MD;K[_@'_ * M=[_WI?X?U/&7_(O?^-?^DLU_&/\ R*_AW_K@/_0%J+P__P B
M'KOU'\A4OC'_ )%?P[_UP'_H"U%X?_Y$/7?J/Y"N.7^Z?/\ 4]K!_P#(YAZ+
M_P!)13\"_P#(UVW^Z_\ Z":R]=_Y&#4_^OJ7_P!"-:G@7_D:[;_=?_T$UEZ[
M_P C!J?_ %]2_P#H1KE7\1^A]^OXS]#H_B-_R%[/_KV'_H1I@_Y)@?\ K[_K
M3_B-_P A>S_Z]A_Z$:8/^28'_K[_ *UG'X(F,?X4/5#_ (<?\ANZ_P"O8_\
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MU=#\0_\ D9(_^O9/_0FJG\2-7_$CZ/\ 0GO_ /DEVF_]?!_]"DJ/P-]S6?\
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M %]_UK./P1,8_P *'JA_PX_Y#=U_U['_ -"6N;TC_D.V'_7U'_Z&*Z3X<?\
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M _Y$?7OP_E4GB[_D5_#?_7N/_0$J/0/^1'U[\/Y5FO@^?ZF*_@KU_4I^!?\
MD:[;_=?_ -!-96O?\A_5/^OJ;_T,UJ^!?^1KMO\ =?\ ]!-96O?\A_5/^OJ;
M_P!#-:+^)\C9?QGZ'1_$?_D.6O\ U[#_ -":FI_R2R3_ *^Q_P"ABG?$?_D.
M6O\ U[#_ -":FI_R2R3_ *^Q_P"ABLU\$?4QC_"AZH7X<?\ (?N?^O5O_0EK
MG-&_Y#NG?]?47_H8KH_AQ_R'[G_KU;_T):S=)T#5XM9L7DTVZ5$N8V9C$0
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M*_Y&T?3]&87AC_D9]._Z[K5KQM_R-U]_P#_T!:C\-6ERGB73V>WF51,N24(
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MJ/\ ]#%=)\./^0W=?]>Q_P#0EKF](_Y#MA_U]1_^ABK^U(T7QS]%^IK>._\
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M/_0%JKX;_P"1ET[_ *^$_G5KQI_R-U_]4_\ 0%K3_EY\C?\ Y??+]35\7?\
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M $(UVK^(_0]=?QGZ'1_$;_D+V?\ U[#_ -"-,'_),#_U]_UI_P 1O^0O9_\
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MVF'RUV9X//7(K-SCRM7ZF#JPY)1OK?\ 4X3PW_R,NG?]?"?SJUXT_P"1NO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_ A/\:T** ,_^WM'_P"@M8_^!"?XT?V]H_\ T%K'_P "$_QK0HH S_[>T?\
MZ"UC_P"!"?XT?V]H_P#T%K'_ ,"$_P :T** ,_\ M[1_^@M8_P#@0G^-']O:
M/_T%K'_P(3_&M"B@#/\ [>T?_H+6/_@0G^-']O:/_P!!:Q_\"$_QK0HH S_[
M>T?_ *"UC_X$)_C1_;VC_P#06L?_  (3_&M"B@#/_M[1_P#H+6/_ ($)_C1_
M;VC_ /06L?\ P(3_ !K0HH S_P"WM'_Z"UC_ .!"?XT?V]H__06L?_ A/\:T
M** ,_P#M[1_^@M8_^!"?XT?V]H__ $%K'_P(3_&M"B@#/_M[1_\ H+6/_@0G
M^-']O:/_ -!:Q_\  A/\:T** ,_^WM'_ .@M8_\ @0G^-']O:/\ ]!:Q_P#
MA/\ &M"B@#/_ +>T?_H+6/\ X$)_C1_;VC_]!:Q_\"$_QK0HH S_ .WM'_Z"
MUC_X$)_C1_;VC_\ 06L?_ A/\:T** ,_^WM'_P"@M8_^!"?XT?V]H_\ T%K'
M_P "$_QK0HH S_[>T?\ Z"UC_P"!"?XT?V]H_P#T%K'_ ,"$_P :T** ,_\
MM[1_^@M8_P#@0G^-']O:/_T%K'_P(3_&M"B@#/\ [>T?_H+6/_@0G^-']O:/
M_P!!:Q_\"$_QK0HH S_[>T?_ *"UC_X$)_C1_;VC_P#06L?_  (3_&M"B@#/
M_M[1_P#H+6/_ ($)_C1_;VC_ /06L?\ P(3_ !K0HH S_P"WM'_Z"UC_ .!"
M?XT?V]H__06L?_ A/\:T** ,_P#M[1_^@M8_^!"?XT?V]H__ $%K'_P(3_&M
M"B@#/_M[1_\ H+6/_@0G^-']O:/_ -!:Q_\  A/\:T** ,_^WM'_ .@M8_\
M@0G^-']O:/\ ]!:Q_P# A/\ &M"B@#/_ +>T?_H+6/\ X$)_C1_;VC_]!:Q_
M\"$_QK0HH S_ .WM'_Z"UC_X$)_C5>._L[WQ#:_9+N"XV6D^[RI ^W+Q8SCI
+T-;%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img242628118_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_18.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $? GT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *0$$D C(ZBL[7+E[6R62,E7,@ ?=M5>#RW!X[=.XJGH=G.EW)>7",KS
MKOR% !W'.&[Y'8'H* ->\NDLK.6YD!*QJ6('4^U946NR26N\);23/(D<<<,^
M[#-V8XX_6M:[MH[RTEMI03'(I4XK,_L'>3++=NUPH18I @&P*<CCO0!=L+U[
MDS13Q+'<0/M=5;<.>00<#BL_Q+?6A\/ZC"+F+S/)8;-XSGTQ6C8V7V02L\IE
MFF;?(Y&,^@ [ 5F>)=/LAH&HS?9(/-\EFW^6-V?7- &W%_J4_P!T4^F1?ZE/
M]T4^@ K%/_([#_L'_P#M2LKXBWEW9Z!;-9W4MM))>Q1F2)L'!SFN1_L[4_[=
M6/\ X2"_\PV^?-W_ #8W=/IWK2,+J]SII4;QYF[7N>NT5QWP[N[RZTJ]%Y=R
MW+Q731J\K9.!78U$E9V,:D.23B%%%%(@**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ JGJ\CQ:-?21L5=('96'4$*>:N
M5%<P)=6LMO)G9*A1L=<$8-"&M&>2Z/!JVHZ/:WDGB/4$>9 Q4/TK8\+2ZA;>
M-_L$^JW-Y";0R8E;(SFM-/ACH2(%62^50, "?_ZU:6B^"]+T+4#?6C7#3%"F
M99-W%;2G%W.V=>FU*SW\AVJW=QIGB;39VF;^S[H-;2(3\JR=4;\<$5S5]J>H
M7.GKJ7VJ]2WOM5$4*6O+^0H8?*,=21FNVUC2+76].>QNP_E.0<H<,"#D$'M5
M:[\.6=UIEE8!YH(K-E:%H7VLI4$#G\:F,DC&%2"2ON<OJ5T]IHEKLN]=ACEU
M%(Y7N$(FVE3D*,<CIVJ&+4-2;2]0U#3;V]N-/L9HY89+A</(!_K4Z D8]1VK
MKD\/0>7 D]W>7)@N!<(TTNXA@" .G3FK%OH]I:R7S1AO+O6W2Q$_)DC!(';/
M>GSHKVL$MKG*ZYK-U>2ZG/I]U)':6&G[]T9X:5\$?D/YU9T"\@M$-W>76M)&
M(5+OJ*[8<G'0X'-:MIX3TVRT.ZTF(2_9[DL9&+98Y]_;M4^FZ&NF2;EO[ZX7
M9L$<\NY0/88I.4;6$ZE/E<48VL:C?#7=%N;6^C.ESN56.+K*=C$ECZ<< 52M
M+W4H[+2==?4I93?W*QRVIQY81R0 HQD$<<_6NNO-,M[ZYLYY=VZTD,D84X&2
M".?P-4+;PIIUK?)<H9RD4AEBMVE)BB<]2J]CR?SH4E82J0Y;-?UJ5- GU,^*
M-:MM1NEF\M8GC1!A(PV[@?D.:I7VK:IH_B/49[J99[>/3VN(;5#M4 /@9..I
M[FNH@TV"WU.ZU!-WG7*HLF3QA<XQ^=5]1T"SU.>::X\S=-:FU;:V/D)S^>:7
M,KZB52'-=K2R,2;Q=J4"W9?1XP;6%+A_])_Y9MZ<?>Z\=/>I+SQ=<QQW]Q::
M:LUI8A1*[S;6W$ X P> #6K/X>LK@7>\R?Z5 MO)AOX5Z8]ZP=8\)W=W=3Q6
M86&VN5C65_M# ';CED P3@>OUIKE9<72;U7]:>?J2^(M3NOLNI3VT[P)96B$
M[3_RT<@_HN?SJ9?%S36)NK2S$\4MPMK9DR;3/(>"3Q\JCUK4?0+273;NQE:1
MX[MM\K$C<3Q[=.!5+4O#$#VMU]ABQ),Z2B+S3&JNO\:D [6Q0G'9DJ5-I)K^
MM"WH^K7-_=WUK=VBV\UHR*VV3>&W+G(X%:]8/AK1[K3#>SWC@S74@8KYAD*@
M# RQ R?PK>J)6OH95+<WNE;4+C[)IMU<A0QAB:3:>AP,US\7B2^6\MXYXK&2
M.549C;REBH8X'ZUOZE)+#I=W)"H:5(79%(SD@'''>L'PS';F5]LC,S*'9&L!
M" WKG'-(@ZBBBB@ K*\2_P#(M:C_ -<&K5K*\2_\BUJ/_7!J -*+_4I_NBGT
MR+_4I_NBGT <7\3/^0!8_P#81A_F:RO^9E3_ *]/_9S6K\3/^0!8_P#81A_F
M:R=Z?\)*GS+_ ,>GK_MFMH_#]YW4_P"$OF:GPV_Y!VI_]?SUVU<3\-O^0=J?
M_7\]=M45/B9SXC^*PHHHJ#$**** "BBB@ HHHH **** "BBB@ HHHH ****
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M_(M:C_UP:M165U#(P93T(.0:R_$O_(M:C_UP:@#2B_U*?[HI],B_U*?[HI]
M'%_$S_D 6/\ V$8?YFHA]X?6I?B9_P @"Q_[",/\S40^\/K6J^%'7'^%'YC_
M (;?\@[4_P#K^>NVKB?AM_R#M3_Z_GKMJFI\3,L1_%84445!B%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5-1TRTU6V%O>1"2
M,,'7G!5AT(/K5/2]%ETN^N91?S7$,X!*3@%@0,#YOIQ6O10!!>-"EG,US_J0
MA+]>GX5RL;075O+=0*JVCSQ&6WC!^6(9R6'J>,CTKL:* ,G1 I:\>!2MF\N8
M1C Z<D#TS6?XD.L_V/J(*6'V7RVYW/OV_EC-=-65XE_Y%K4?^N#4 :47^I3_
M '13Z9%_J4_W13Z .+^)G_( L?\ L(P_S-1#[P^M2_$S_D 6/_81A_F:B'WA
M]:U7PHZX_P */S'_  V_Y!VI_P#7\]=M7$_#;_D':G_U_/7;5-3XF98C^*PH
MHHJ#$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K*\2_P#(M:C_ -<&K5K*\2_\BUJ/_7!J -*+_4I_NBGTR+_4
MI_NBGT <7\3/^0!8_P#81A_F:B'WA]:E^)G_ " +'_L(P_S-1#[P^M:KX4=<
M?X4?F/\ AM_R#M3_ .OYZ[:N)^&W_(.U/_K^>NVJ:GQ,RQ'\5A14-W=0V-G-
M=7#[(84+NV,X4#)->>:QXRT*YNX)K/Q%>QJ\RB9(PP58\') V^N*48N6PJ=*
M539'I-%8'A[Q+HVJG[#IVHR7<L2;F,BMN(SU)(%;])IK1D2BXNS04444B0HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBH;JZALX#-
M,V%R ,#))/0 >M $U97B7_D6M1_ZX-5VTO(;V(O$3\K%65A@J1V(JEXE_P"1
M:U'_ *X-0!I1?ZE/]T4^F1?ZE/\ =%/H XOXF?\ ( L?^PC#_,U$/O#ZU+\3
M/^0!8_\ 81A_F:B'WA]:U7PHZX_PH_,?\-O^0=J?_7\]=M7$_#;_ )!VI_\
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M4 %%%% !1110 4444 %%%% !113'FBC(#R(I/9F H ?134=)%W(RL/53FG4
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M&%PR-*"&&.AXJKI7A"U;2+-EOKY T*':LN ,@=.*ZT@,I5@"#P0:%4*H50
M, #M1<+M:'-P>#+2UO7O(+Z_2Y=-C2";DKZ=*N_V#)_T&-3_ ._P_P *V**
M;;W,?^PI/^@QJ?\ W^'^%<YHO@^QN[2_C:ZO%C^URHRK+@-SU/'6NZ=UC1G=
M@JJ,DGH!38A%LW1!-K_-E>ASWHN"DUL<V? ]@9X)S>7YEMSNB;SN4/MQ5_\
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MZ[N-PQMG?<![CBKU%%(D**** "BBB@ HHHH *0D*,D@#U-1O<PQSQP/*BRR
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M=(UW.P49QDG% !)(D2%Y'5%'4L<"N7\2W.IP7*QLMDVCW"^6[3QL0C'^\0>
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M;.?$WV<K\HDZAU[J?6@"OHDTER&TV^@>:%8Q+&;A/F49QL?/!8$<'N!FNB
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MBWF215"M*WWGQTR>]+86?V&T6'S6E;)+.W&2?;L/:K5 !1110 4444 %%%%
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M3])EU!UN1>7!!!Q<L=EQ"XX:,^JG],5UD,201+%&H5%& !3@ !P*6@ HHHH
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H:WBM+:*WA7;%&H51Z 5+10 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img242628118_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_19.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #H FX# 2(  A$! Q$!_\0
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M0 4444 %%4-7OI+"Q\R%%::218HPYPH9CC)]A56PO;^/4Q8:A);3&2(RQRP
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M-9/A[_D'S?\ 7W/_ .C&K6K)\/?\@^;_ *^Y_P#T8U &M1110 4444 %%%%
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MO>3_ -!--T;_ ) 6G_\ 7M'_ .@BK]H^6W0V^L/V?);3L)I>L6&LVWGV,ZR
M<,O1D/HPZ@U?K#U7PQ;WUQ]NLY7T_4A]VY@XW>SKT8?6J</B.[TB5;7Q+;K"
M"=J7\()@D_WNZ'ZU'+?8QY%+6'W=?^"=1134D26-7C971AD,IR"*=4F04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6MQ]214J^+?#[=-8L_QE J%[+7&^\-(?_>@;_&H6TG4W^_9:$_UMS1[./?\
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M / 6=[17!'1_$2?ZNYUD?[U[$W_LM LO%J?=NM2_%X6_I1[%]U]Z#VM+N_\
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M_C0!KT5D?\(Y:?\ /S?_ /@4_P#C1_PCEI_S\W__ (%/_C0!KT5D?\(Y:?\
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MG_QJS9:7#82,\4MRY88(EF9Q^1-267J*** "BBB@ HHHH 1F5$+NP55&22>
M*KVE_:WRL;699-I^;'&*;JEJ][I=S;1D!Y(RJYZ9]_:JUC'<R:C)=SVWV=?)
M6(*6!+$$DGCMSQ^- &I1110 4444 %%%% !1110!5N]1M+$H+F81F3.T8))Q
MUZ4V75;&!XEEN$1I0"H.>0>Y]/QJMJ]L\LD$L<%Q(Z!@#!,$(R/?K5!['4DB
MN$>W6YDO($C9RXPC#(^;UZ]O2@#I**9"ABACC+%BJA<GO@4^@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***X>VUK57TFQ:2*78U\$:Y\Q3O7>?EQU]J .XH
MKE/^$HNUA\]HK<I+%+)$B,2T>S^_]:GE\07+WXM;1;=RTD*!F8X&]&8]/3%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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>1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>img242628118_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_20.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #D FT# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCT%[%W2ON=717$Z?K>JV480P7-Y%<W@ALVO,1R%=N23[ CBKB>,E?4/*%L#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !4<MQ#!CS9%3/3<<9J2D*JW4 _44+S$[]#
MG3XSTX:U_9^U\;MGG?P[O\/>MZ*XAGSY4BOCKM/2J!\.Z6=5_M(VP^TYSG)Q
MGUQTS6F%5>B@?05K4=-VY$S&BJR;]JUOI;L9-]<7S:S#8VD\<*M TI9H]W((
M&/UK/N=<O(E2"6:"WF2Z,$TQ7*8V[@P!]>*UKW2Y+F_CO(+Q[>5(S'\J*V03
MGO\ 2HH]!@C^SDRR.\<QG=WP3*Q!'-7&5-)7,IPK.3Y>_?II_70R6U^\%M_Q
M\P[/M0A%V(B592N<@>QXXJ1=<OS8W+Q-'<+%.D8N$B/"D<DIUXK9U#3!>I (
MYC;M!)YB,J \_0\=ZK1Z)(GG2#49Q<RLK&555>%Z#:!C%4ITFMOZ^[^NQ#IU
MU*R;M_P/7^NY-H]ZUW;2.UY!<A6P&B0J1[,#T-5;:YU;48OMML]M' 7(CA=2
M2R@XR6SP>*O:?IHL7GE:9IIIV!D=@!G P.!P*K#1&C9UM]0N8+9WWF%,<'.3
M@]0#47A=V->6IRQOY[/[OZO]X^;7;>&>1##,T43A)9U4%$8XX/.>XIHUZ W/
ME?9[C9YY@\W:-N_TZYHFT))990+J5+:=Q)+  ,.1COU&<#-/_L:+9L\U\?:O
MM/0=?3Z4?NK!^_N58/$+>4[7%E,K?:FMXU0 EB,X[]>*L-KUNDQ4PS^4CB.2
M;:-B.>QYI5T55N!)]ID*"Z-RJ;1PQSD9].:9)H222R#[5*MK++YTEN ,,W7K
MU R.E/\ =-B7UA+_ (8?::D[65]<7&,6\TBC _A6H$UXPV\/GVTLL[6_VEQ"
MHPJ$^Y["K:Z6B6-Y;!RPN6=R2.A:J]GI3M CW+,DQM/LKJ,$8'\0_*DO9ZMC
M:K:)=BR=43:CI;W$B.@=611@@C(ZFL^\U&^M-3AB\^W8RR@+;",@[">N[.,C
MK6C'I-FL$,;PI*8XUC#L.2 ,5!-HS7$ZF6^F>W642B$A>"#D#=C./:B+II_U
M_7Y!.-5KS_K^NI/IEX]W#,)@HFAF:)]O0X/!_*KU9^DVLMO#/). LL\SRLH.
M=N3P/RK0K.=N9V-J5^1<VX4445!H%%%% ',^(A8+?QO<E3+Y?"26IE4C)[CD
M5IZ"T#Z6K6T=ND18X^SYVGUX/(/L:J:YJ5[8W2"&6.& IDR20.XW9Z97I3_#
MDL9MI41I9F:1II)VA,:,S')"Y]* -NBLO6]4;3K0^3Y9N75F19#@ *,DFJKZ
MQ=>7+<QK";>W6,R+W?< 3@]L9H WJ*Q8]4NFDCN"L?V.6X^SJHSO'. WY]O2
MK][J=EIVS[7.L6_.W(//Y4 <1XKM1=>"M9!<J4U#<,="2RCGVYIOPSTXZ5/>
MVS2;S)!#-D# ^8$XQ[9I^NW4$O@K4YUD!@DU$$/[;U.?TJ;PG>VUSXBS:2K)
M$]EPR_[+D#]*V5_9M'9!R^KN/3_ACNZ***Q.,**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** ,6\UN2SUIK/['<7$?V=9!Y
M$>X@EF'/MQ6E971O+<3&":#)(V3+M;\JH:M<7=C+]I@734BV /+=2E&ZGC@'
MBF^&9GN=-EN7ECE,T\CAHBQ3!/0%@"10!HW=C;7T31W$*2!E*Y902 ?3TJL=
M$LRZ$*ZH H:-6PK[?N[AWQ6C10!172;9;S[2-^=YD$9;Y YZL!ZU>HHH \S\
M87-D?#UY8SW2133:D612><#&6QZ5#\/;"/3]8LV1B7N+27S,_P!X,O _ URW
MQ!$8\22$!]Y=]Q/W<;N,>_6I%UK4]"UZUBTR NL3D0HZ99U<+E3[X KJC']W
M9=3U:=)N@HQ>]SW>BFQDM&K,NUB 2/0TZN4\H**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** ,;5_#T>IW<5XDYBNHDV(60
M2)CW4_S&#5G1+.YT_2(+.Y:)W@7RU:/(#*.AP>AK0HH **** "BBB@#S[6[:
MVN(XA-!&[G5I5#,H) V'C\\?E7.>,K?5[?QR9M.:1$62!E93A4=E"@GZX(KI
M-38&_L8ST.KN?U4?UJ[XKMF>XU3RQ\S::LR_[T4A;^5;PE:QW4)\O+\_S.QC
MW>6N\@O@;L>M.J&SF%Q903*<B2-6S]14U8'"PHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (9[NWM=OGSQQ[NF]@
M,TC7ELDR1-<1B1_NJ6&36=KTDOE+!#8R3F8%7F2,/Y2]^,]:H3:?*J7%K%9R
M,;@1>3,0/W84#[Q[$8H Z$7=NUP;<3QF8=4W#/Y5-7.QV<XN(K8VK"6.[\]K
MO PRYSUZY(XQ6M?6][/L^QWHML9W9B#[OSZ4 >3W?B&1OB#%83HD=K;ZB3N)
MP<EAR3Z<"N]UO4]+M?$=C!>7L41N+>6%E8]FV[<_7FO,O$NF+>^()O/NL.LI
M2:81\-SU"CO75>)_ =K?R6>K+?R?9U2&*;(R63A0P/;J*ZYT^51<M+HZ:6(P
ME=J,):I6:\SLO"S,?#EG&_WX5,3?53C^E;%9&B1BUFU&S7[L5QO7Z. W]:UZ
MY9;F-3XFPHHHI$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4QXHW(+HK$="1G%%% "M&C_>13CU%5[>P@MIKB9 QDG8&1G;)..@^@]*
M** + 1 FP*NWIMQQ2E05VD @]B*** $\M#M^1?E^[QTHV+AAM'S=>.M%% !L
M3^XO7/2@QQD %%('(&*** #RTR3L7D8/'44;%W;MHW8QG'.***  (JXPH&!@
M8%.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>img242628118_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_21.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #  G8# 2(  A$! Q$!_\0
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MNG?UI2B,<LJDXQDCM5>TUV-GB-=$<5X=T;4+R'0+ZZ^Q0V]G 'B\A3YDFY,
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M%=[&UEW;X$;>06R.I%/EMH9H1%)$C1CHI' ^E2T478^5=B 6=LJ!!"@4*5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+G[TG<]/I0!T5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXZ,R@D5+5#66F339)()6C="IRHY(R.*EO;BZ@"?9K,W.?O8D"[?SH S/#=K
M]DMT8U\])IU5^^#(W%;M8OA9F;0PSKL8SS$KG.#YC<5M4 %%%1W$\5K;R3SR
M+'%&I9W8X % $A.!DU5AU&RN"1#=0N0VT[7!Y]*SM,\2:/XEBN8-.NDN&5"'
MC8%,@\=QG'N*R+7P_J:@P$>59[2@C,H++\I'#  E?KS5<O<U5.UU/1G8@@@$
M'(/((I:Y/3M'UBWN-/#2F.W@BB4J)"VW:,,IYP=WK@_A4NH:7KDNH3M:W96V
M9_D'F$':X"O]-N,CZT<J[A[-7MS'1&Z@",YF0*K;2=W0YQC\^*>[K&C.[!54
M9))P *X^X\-7TLTK$,YE)7=YYX7S]XXS_=K3ET>[ET*YL?,WM]H,D0FD+!D#
M[@K$Y."!BBR[@X1TU-5-2L9+?[0EW"T.[;O#C&?2I8KF"="\4R.@;;N5LC/I
M7,3:!<ZA?)=SVR6R&>(M!%,1\JALL2N.>0!["G_\(]=IX?MK($,(723R0[!L
MAR3\^?3M3LNXW"'<ZFBN332-:DO6:65T@>16D5)VQ@29XYR/EXXQ5,6^L3WT
M]M;2SK.!+OF>1_+8;OE&#PIV\<?6CE\P5)/J=OD;L9&>N*K1:E93W36T5U"\
MZ9W1JX+#'7BL33-'OH-5M+VY+2;8I(VS*?W>2"!@DYZ'UZ^U58M(UB%=0BC,
MJ"6:21,2H$*M)NP"!N!*Y&<]Z7*NXE"/<ZH74#2&,3(7'5=W([4])$E7<C!@
M"1D'O7&OX;U":TNHS&461MZ1&X).?,#8+9R> :M#1M5+-)YTJ,J@Q*)S@-YF
M3D9P?EXYI\J[C=./\QU55IM1LK?;YUU"F]MJ[G R?2N<T,7QUN99#<$+%())
M'=RC.7^4@'@<=A3-.TR]@43C3X;DR1&%X[@[3&P=B3R#E6SD_04<J#V:6[.D
M&J6!G> 7D'FI]Y-XROUJW7(W&DWMM->R10D6DB2M+&'#B3*8"JNT$'./RKIK
M%)(K"WCF.95C4.?4XYI-);$SBDKIEBBBBI,PHHHH **** "BBB@ HHHH ***
M* "BBB@ K";5;M]3DLI+.V7;*NPR3C)3CYL>OI6[7%W)EG\61QFSGW,X>5(I
ME90!MPS';E1\J\9[4 ;OB5@-((**^Z10 59N_8 @D_C2>'[**WM7E52)'8[C
MY;1YY_NL3^=/\0PR3Z2\<4"S.2"%;/&._!%1^&=QT@$K@&1MIP1D9Z\DT ;-
M%%9VKEA%#N,HMO,_?F+.[&..G.,XS0!HUE0?\C5>?]></_H4E2V;7BZ.C*GF
M7'.P2L1E=QVY/7.W%8\4VL_\))=$65IYGV6+*^>< ;GQSM^M '445AWEUXB2
MRG:&PM/-$;%,3DG...-O->.IJ?C?4[>]@674YD^].NTY7GH/3Z"M(4^;J=%#
M#NJF[I6/?6.U20,X&<#O7E>B_$36K_QK'I\T$?V6:<P^4$PT8SC.?;O7*RZ=
MXVDM;$M%JAC!/V<9.4.>X[?C7H.J+KFC^'9M3BTFQ&JB!1+=Q?-+V!;&WD_C
M5\BCH];F_L84O==I.6GH=Z$4$X4<]>*-J_W1Z]*\"/C/Q>^F#%[<^0)/^/A4
MYS_=W8_2ISKWCNXU.W*R:@)W0".-8R$88ZXZ?B:/8/N'U":WDCW8@'J :"JG
MJH/X5X';>(?&.@QW5R[WJ([;'>ZC+*KGN-W&>#2SZSXR\0O:7B&]<*=D3VR%
M4+ ]3CC-'L'W#ZA*_P 2L>^8 [4@50.% S[5X.+KQY=7UY;!]3:<H1-'R  .
MN.P_"J^[QIINE1@'5(+1Y,KC=G=_,"CV/F'U'^^CZ P,8P,4FQ?[H_*O"_[4
M\>C5HOGU+[5L&V,H=I7'<=*KIJWC>>PNE6?57@# RMM;<I] >H^@H]@^X?49
M?S(]S.FVK7XO61FF'*EG)"G&,@9P#CO5K:O]T>O2O!7U+QTAL TNJ@X_<#:W
MS\]_7\>U.6^\>7%U?1*^J&4H?/3:0%'?;V'X4>Q?<'@I=9H]WV+NW;1GUQ0$
M4=% _"O E\0^,-"TV*-YKRWMY'+1M/&<DCL"W./:IQ<^.[K6%O434?M4D>]=
MJ$)LQZ?=_"CV#[A]1EUDK'NX51_"/RJJNFVJWQO=C&?G!9R0N>#@$X'X5X4L
MGC74M-N$W:K-;(X:4-NSGTYY/T%3KXM\8:"UKI\LLL;1@%(9HPS.#T![FCV+
MZ,/J,MHR5SW2.VAB,I2-1YK[W]VQC/Z4YXT=2&4<C!]<5X2/%?C2_EO8(I[M
MG*DRQQQ8:(9[<96H6UKQK:Z=;JUQJ<=N7)C<JVYCZ9ZX]J/8/N'U&?62/?(8
MHX(4BB0)&@PJCH!3Z\'\GQY_:YO_ "M1^UF/S"^/EVX].GX5 NO^-4TV8BZU
M/[.9!OE96W*WH&ZBCV/F'U%O::/?Z*\&;Q1XW2YLM\U\'" Q1F(_O1ZD8^:D
M;Q?XPUL7=E#--(6!:2."+#1@=0,<CTH]@^XOJ$_YD>]45X =4\:Z=86L;3:G
M# S$PY5@6/H>^/8U9_MCQ[-JLL:R:E]I9#NB"$*!CJ!T'UH]@^X?47_,CW:B
MOGY;CQK'I4F&U86AE^8X;.[^>/TJPVI>/%OK-3)J8FV+Y*;3AA[CH??-'L/,
M?U%_S(]YHKP)+_QQ-'?JLFJLO6X&ULKSV]/P[4?\)1XQTBUM();B[A1CNB\Z
M/YG]LD9(]J/8/N'U"722/?: 0>E>#GQ!XVU?49[%);OSYT*M;JFT*N.P_A^M
M5E'C+P_IAV_VC:6TTG49SN'ZC^M'L/,/J+V<E<^@:*Y/PQ?>)KGP_9RWMG"T
MK+R\TA1R,\$C'7%=8,XYZUBU9V.*4>63CV"BL'5C<"^(0SB3:OV41[MI;/S9
MQQ^?:M2]>^4)]BB@D.?F\URN/I@4B2CX9_Y Y_Z^)_\ T8U;%<KX?DUD:61%
M;6;)Y\W+2L#GS&SV]:K^+KKQ3#X<N7LX(HY!C<]L[-(JYY(&*:5W8J$>:2CW
M.RJCK&FQZQI%UI\KE$N(RA9>H]Z\.;6O&R:;#FYU1;?S#LDVMN8^F>I%:.GW
M7CJ7Q5:/(+_SV*DK(I6+9[]@,5M[%K6YV_4I1][F6AV_@OP"WA>_GO)[T7$C
MIY:!%V@#U/O7;UYU\0HO%-UI,(MX,0K)F5;-V9F],CKCZ5Q+P^.H9[!"NJ>8
M%!MP,D >_8?C24'4]YL2HRQ"]I*:N>]T5X*FJ^.;>:_D$FI[@")RR$A.>H]/
MPJ&67QIK%A;2N=3N+='*QN <EO?N?J:?L/,?U%]9(^@**\*7Q;XVM=3:S::X
M:ZB0QM 8MQ  ZXQR>^:@B\<>+K.PE)NYS$\@'GS1[MI_N@D<?2CV$NXOJ$^C
M1[Y17A3?$3Q:]U:8EVL5&R,0?Z[WQCG/M42>,/&;_;@EQ='_ )[8B/[GGMQ\
MM'L)=P^H5.K1[U17@$A\9Z[9VEPPU"YA1RD+KD?-ZG_$U8&K^/8M4F@\W4C<
MHA5H]I*@ =0.F?>CV'F/ZB_YD>[T5X%!XP\7Z18/ON;H12O@2W498@CJ 6%2
M-K/C;5=2M;Z(WYDD ,/DQD1L!WQTY[T>P?</J$NLE8]YHKP--8\<317JK/JC
MJ.9_E;*<]O3\*:^L>-X;6R#3ZHD1),)VME^>A[GZ&CV#[A]0E_,CWZBO!UUO
MQII.KS:C<B^+QC,RS(WE;??MCZ4EWX^\5ZK9!(YI(UB?+S6L94G/0$CI1[!]
MQ?4)O9JQ[S17@QMO'5YJ=M?^5J#73('BDZ#:/T'T-1Q:]XUM[>\?[1J7EY F
M>1&/EG/8D<?A1['S']1;VDCWVBO!O^%@^+;*"UCDN&4#YE::$%I1GN2.?2FQ
MVOCF:^N[B./4EGDC+RMD@%3V';\!1[!]6+ZC)?%)(][HKY^75O&.B:6JF74+
M:UEDRK2*0=P[ GD?3O5K^UO'=QJT,RMJ/VAT!C01D(5QZ=*/8/N/ZB_YE8]W
MHKP&+Q)XSL;2ZD-SJ A9@LDDR$[#[$CBGR>,/&<HLF^TW8&/W12(@3<]^/FH
M]@^X?4)_S(][HKPC_A-?&=S=7<$<TYE*G?%'#\T0'4@8R*CA\<>+M*L$C>YF
M".Y9)KJ+<QQU +#I1["7<7U"IW1[W0:\)_X2CQM<ZLEW$]Z'==R0)$?**XZ[
M>A^M51J'C'Q)8W%NLE[=P1L'E"C!!Z8_^M1[!]6/ZA+K)'T!17@AU#QOHTEC
M9-)J$14 PQ8)# GH<=?H:]HT^76)#%]NMK:-2@+[)"6!QZ8]:B<.7J85J#I6
M=T[FG11169SA61!X;T^UNFN(?M"2/)YC8G;#-[C/-:]% &1KFE3:D8/)N5AV
MAD?<"<HV,XYZX&/QJQI-@-.MI(592AE9T5.BJ>@JIXGM[>33!-,J%H7#(&!.
M[U7CGFG^'(EBTUPI3F9V*)G$9/\ #SZ4 :]%%13B5@J1@;6.'.[! ]1[T 2U
ME0?\C5>?]></_H4E264%S;Z,L,(59U+!//R1C<<9[]*I:8+P>);W[<T#2_98
M<>0"!C=)Z]Z -ZD"@$D #/6EHH *",C!Z444 ,\F()L$:;<YV[1BG8&0<#(I
M:* (YH8KB(Q31I)&W57&0:6**."-8XD6-%X"J, 4^B@+ACF@C/6BB@ QSFD
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M)9EF\Z>9VZM-(6_3H/P% %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>img242628118_22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_22.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /N!E(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRV=U/F%7SGF=D/RGK@CA1CW"POK?4].MK^SD\RUNHDFA?:1N1@"IP>1D$=:
M/+_"UC;^#/CEKN@VL=C::;K6GQZA:P(Q#!T8J44'@9)G;:,X4#& "*V/C;_R
M2'7?^W?_ -*(ZYNS$WBC]IFZO(Y(S9^&[+R1+"A=79D*F-VSA7#32_\ ?HC&
M034WQ@U7Q!/X"U^RNO#/V;3 Z*-1^WQOE5F38WE@;OF(48[;N>E 'KU%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !6?K=IJ-]H\]MI.J?V7?/M\N\^SK/
MY>&!/R-P<@$<],Y[5H44 >7ZK\-_&6M_8O[1^(_G?8;N.]M_^)'"NR9,[6X8
M9QD\'(]JZ#1/#OC*QUB"YU;QW_:EBF[S+/\ LB&#S,J0/G4Y&"0>.N,=Z["B
M@#@_%_PSA\0>(+'Q)H^J2:%X@M7!-[#")/.4# #ID G'&2>5RI!&,4T^%4NK
MZY:ZKXV\23^)&LL?9;5K1+:!>I.^-<A\G:>V=H#;AP/2** *]_8V^IZ=<V%Y
M'YEK=1/#,FXC<C AAD<C()Z5YVGPQU_2;>[TSPQX\N](T.9W:&Q:R6=K<./F
M5)68.HSDC&",YR6RQ],HH YOP9X,L?!NEO!!))=7]R_G7^H3\RW4IR2S$DG&
M2<#)QD\DDDX?QM_Y)#KO_;O_ .E$=>@5Y_\ &W_DD.N_]N__ *41T >@4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G_QM
M_P"20Z[_ -N__I1'7H%>?_&W_DD.N_\ ;O\ ^E$= 'H%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y_P#&W_DD.N_]N_\
MZ41UZ!7G_P ;?^20Z[_V[_\ I1'0!Z!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %>?_&W_ ))#KO\ V[_^E$=>@5Y_\;?^
M20Z[_P!N_P#Z41T >@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7G_ ,;?^20Z[_V[_P#I1'7H%>?_ !M_Y)#KO_;O_P"E
M$= 'H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5Y_\;?\ DD.N_P#;O_Z41UZ!7G_QM_Y)#KO_ &[_ /I1'0!Z!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?\ QM_Y
M)#KO_;O_ .E$=>@5Y_\ &W_DD.N_]N__ *41T >@4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7G_QM_P"20Z[_ -N__I1'
M7H%>?_&W_DD.N_\ ;O\ ^E$= 'H%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5Y_P#&W_DD.N_]N_\ Z41UZ!7G_P ;?^20
MZ[_V[_\ I1'0!Z!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/
M_P##1W@__H&ZY_WXA_\ CM>P5'//#:V\MQ<2QPP1(7DDD8*J*!DDD\  <YH
M\OTGX^^%=9UFQTNWT_65GO;B.WC:2&(*&=@H)Q(3C)]#78>-?&NF^ ]&AU35
M(+N:"6X6W5;5%9@Q5FR=S*,80]_2N/\  $-]XZ\2S?$+6#(+")Y8/#MMYFT0
MQ99))'0$C>0-I)8Y.[C 3!\8=;AT_6? 5E<>7%!)KL5Y)<R2!5B6%E!SGC&)
M<YR,;??@ I_\-'>#_P#H&ZY_WXA_^.UZ1X6\26?B[PY::Y81SQVMUOV).H#C
M:[(<@$CJI[UQ<GQP\.0I#=RZ5X@329KCR(M5:PQ:O\Q&Y6W9(^5C@#=@'C(Q
M7H&E:K8ZYI=OJ>F7,=S9W";XI4Z,/Y@@Y!!Y!!!P10!<KS_XV_\ )(==_P"W
M?_THCKT"O/\ XV_\DAUW_MW_ /2B.@#T"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *\S^.^MS:/\,KB&#S ^HW$=F9$D*%%(+MTZ@K&4(XR&/T
M/IE<GXN\&S>*=9\-WJZO):0:->B\>V$1=;EE9"N?F ! 5@#@XWG\0#8\-Z)#
MX<\-:;HT'EE+.W2(ND8C$C ?,^T="S98\GDGDUC^)]+\%Z]X@T73_$26EUJB
M.SV%I)*VXY!=B8U.&0B$\N"ORX[X/65R_C?P19^-=.MHI;J>QOK*7[197UL
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7G_P ;?^20Z[_V[_\ I1'7H%>?
M_&W_ ))#KO\ V[_^E$= 'H%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5Y_\;?^20Z[_P!N_P#Z41UZ!7G_ ,;?^20Z[_V[
M_P#I1'0!Z!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MASQCH_BA6%A*ZW"+O>WF7:ZKG&>,AATY4G&1G!.*'"25[ Z4U'F:T-^BL/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7G_ ,;?^20Z[_V[_P#I1'7H%>?_ !M_Y)#KO_;O_P"E
M$= 'H%%%8OBKQ!%X:T*:^?F4_N[=-I8-*02H/3C@D\C@'OBFDV[(<8N3LA_B
M'Q+IWAFR6YOW8EVVQPQ@%Y#WP"1P.Y/'XD \;/\ &#3UNXUM]*N9+8X\R221
M4=>><*,@\?[0S[=:\JOKZYU*]EO+R9IKB5MSNW4G^@[ = *KUVQP\4O>/4IX
M*"7O:L]]T+X@Z%KUVUK%)+:S<;%NPJ>:2<84AB"<XXZG/&><=37RS7M7PV\7
M2:W9/IE_,TFH6R[E=EYDBX&2W=@3@YQD$=3DUE5H\JO$PQ&%Y%S0V.\KD_B7
M_P D_P!2_P!Z#_T<E=97)_$O_DG^I?[T'_HY*QI_&O4Y:/\ $CZHQ/!NM>&H
MOAU;66L7^FL$\YIK2X='8XF=A^[.23T(&,GC%<MH%S<Z9X7\8:SI"FVT^1X[
M:V#Y\R/=)@8(;*LB2CGG)(Y^4YZ/P/X'\.ZSX0LK^_L&FN96EWO]IE7.)74<
M*P'0"NK\3>'4OO!5[HVEP16^4#P0PHJ*65Q(% X W$8SVSFMG.*DUW>OWG6Z
MD(S<>[UOMN9GPOTF/3_!\-UY+)<7SM+(74 E02J <9V[0&'7[Y(ZU+9>"VTO
MQ]_;6F26]IIKVQ26UCC RQP-JJ  J_*C9SG<#V:L?X:^+-(M_"B:??7]K92V
MLC[?M$P3S4=BX8;L#JQ& 3C )QD5?3QMJ&J^+)K'P[90ZCIMK;NT\OW2\@5]
MH20MM"LP102#GYB,J,U,E/FD1.-7VD[?TCD?#.H6WPX\2WVFZU8,6?"17Z)F
M3RMV VW)_=D?,=N2""#N( 7KM,LO"7B/Q3%KVBZD8K^V)9X($6+S.NYWC=-Q
MW>9M+_3G(HTSQEX?\3V=Q!XDM=.L)K:?'V349%89 QN'F*HW [E(QD8YZBN/
MU.UT:Q\=Z!'X,;SI?,1Y!!=F6,_/TW@LP^4/OZ@+@XZYNSDW?1_@:-.;=TU*
MWR+%_?VNF?'&6]O9UAMH6W.[=O\ 0_U)/  Y).!3_#VJ6_CCXC"YU2XD$=H6
METVUR%4%6! /S??P Y SN*GD*H!J:WI,.N?&F33K@XAEGB+]>56W5RO!!&0I
M7.>,Y[5T/Q#T7^Q?[/\ %.BP16\^GR(DJQC8K)PJ9P1P.(R ,E7QG"U3:T75
MHIN/NQZN*_KYE?XQB4QZ*&:X2R+RB5HU+!6PFTXR 7V^9@$C/S<CFNJU>'PQ
M)X'N7:.R;1HHI'C-HL95&^89B_A$FXD#_:-5/$OB3P_/X)MK_4K6YO-+U%D7
MR8"-X;E\-AQ@J4((!ZC%<Y)X1\!:!!#KESJDM_ -SPPM-#(MT5.-JA5!?!(R
M,X_O<9K-:Q2=]#*.L(J5U9OYE_X0:JUUH%UIDC%FLY0Z$ ;0DF3@'J3O60\^
MHY[#M->U>+0=#N]3F7<MNF53)&]B<*N0#C+$#..,YKE?A/I$FG>$C<SQ(DE[
M+YB-M(<Q!0JYR.F0S#J,/GN:G^*.G27_ (->:/<393I<E%3=N7!1OH '+$^B
M_B)DDZMNA%11EB+=+F)_:?Q$_LC_ (2GS],^P>1]I^P[/^66W[V,9Z?/CS,^
MW\-;6K^++BZ^&$GB+2R]G<-L"[@KE&\X1N!D$$?>P2.F#@&FZ5XFT6#X:P/)
M<V=R;73DAEM)954O((B/**GNVQ@.#D<C(KC=.M9K?X'ZO)*OR3WT<D39'SJ)
M(4)]OF1ASZ5HHIO56U-5%2>L;6DEZFC#XD\?ZCX<37[9;2&PLH1))NV,]WLX
MD)'8 HQ(&S@X!8X-=_X8\1VWBC1UO[=&C96\N:)N?+D !(SW&""#Z'L<@9/_
M #1S_N7_ /VWKC?!'AZ]U[PC,+'7;S2I8=1DRT#-MD!BBX8*RDD8&#GC)XYX
MEJ,DWM9DRC"<6VE&S.F^*8UA?#?GV%XL.GH-E]%G#RAW15 .T\<MD9&0<<]*
MSOAL->LO#YU&>=;C0DM[AK>Q@0-/Y@D).!M&22'P-Q^\/P=K7A35M*\":^ES
MKMUK#2)#*HG+#REBDWN1N=OX>>,?=[U9\(:JVG?"%[VT5+BXLH[EC&"#L82.
MWSC(X (8C.<=,DC+T]G9:ZCT]CRQL];?U_F5X#\2M>\S4+6YM]'MY'(BL[F,
M!T4<?Q1,WXG&3D@ $5M?#WQ;)XHT:07>W[?:E5E*C'F*P^5R,8!.&! [J3P"
M!7#:?X?TGQ#H3^)_%OB:;+.\>-Z Q%2Q*?,&R2/F5%5< \ Y%:/P9,9GUXPJ
M5B(@**S!BHS+@$@ $CU &?04YQ7(_+R_JY56$?9R=MO*WX]2KHWBSQSXIL+>
MTT9X_M$ 4WEZ\<2D,[R;>#QLVA?NINRI_'=U#Q%XE\0^)[[1/"LUK:Q6'^MN
MY4)W.#M9<E& ^8D ;>?+)#8XH^#7_(HW?_7\?_145<JTTX\=:[=Z'JFG:!+'
M-)#(VH7:XF)D;>4W(>"4#$<[2>#@X#LG-I):%.,74DE%:?KW_0T_#;M+X]U3
M4O%5Y*FJ:+;EU"*?+:-$9)'QMSMPRN -N3(2!S@78/$OC3Q9<SWOAN"VMM-M
M)&"I/L+3D!3Y;YR=Q!!^7:!N(WY -3:%X;MFT#Q++:ZO9:UKFHVLBRM:O&5C
M>16.T$'C<Y/)V@[5X&*Y?P=X0\*^(]&DN;[4[BWO8?,>XC$L* 1C!\P!E)V8
M906/<&CW7=OIY?H#Y&W)]++;]#;O_%&M>)/"6M:<#:Z?JVG"4ZA&"-LUN%D6
M14!WG<" #@XZ$,-V!#\*;;7G=KBVO8$T-+IQ<VS ;W?REP1\F<<I_$.AX]9?
M#OAW19[+Q/\ \(V=4N)DLY]/1[EHO(F9P?\ 5LH /*J<DCA@>]:/P=GB?PYJ
M$2R(9%O2Y0'Y@K1I@D=0#M/Y'THDTH220JCC&G)17],[S4+V/3=-NK^97:*V
MA>9P@!8JH).,]^*\[TC5?B+X@LDUVR;2$M0'5+-E(%P5R"><D'=D#+J,J,C'
M)[S7K^VTS0KR\O+26[M8X_WT$48<LAX;*D@$ $DYXP#7F-GX1TO48+C6_"/B
ME].58"\T,DA5X.2=DDBL&1/EQR&^[NRW%94TK-LPH*/*W)?-JYT.NZY?7_PJ
MNK^[T_['?*T<<T%S:94-YR#(25<$$$$<'&<9)%<=XV&NS>#M$O+N>T&BO!;"
M*W@0(XD-N26("X'\8 4@ ;>*T&\1:EXB^$.LRZGF2:"YAC$^U5W@R1-@@8^8
M9_N@8*]3FIO&L,DOP<\.-'&[K'';,Y520H-NR@GT&6 ^I'K6T%RM+S.FDN1I
M6^T_R.A76M>\':#=WGBVZM=0=I%2R6U&&=R&)1CL50N%SG!/WNO K(_MGXB1
MZ1_PDV-,EL)8/.^R;?\ 4Q;=WF8R#T&<;V/S?=["S\6T:]\'V5W:2--;BX5\
MQX:,JR,%<G'3) !S@[^YQC'E\#> H]"?65UV[EM%4XV30!F?;N\L H/WA'\)
MP:F*C;F:W\C.FH.*E):M]OZL>FZ#J\6O:'::G"NU9TRR9)V.#AER0,X8$9QS
MC-:-<OX!T[3['PPDNF#4%M[R1K@"_"B3D!0?E&,$(".N0<]ZZBN>22DTCCJ)
M*;2"BBBI("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/.1U..!@#G/8457M)7O<KVU2]^9A1114&84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O/_C;_ ,DAUW_MW_\ 2B.O0*\_^-O_ "2'7?\ MW_]*(Z /0**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKA[_XO^!-,U&YL+S7?+NK
M65X9D^R3G:ZDAAD)@X(/2@#N**X_1/BEX-\1ZQ!I.DZS]HOI]WEQ?99DW;5+
M'ED ' )Y-=)JNJV.AZ7<:GJ=S';6=NF^65^BC^9).  .22 ,DT 7**\W3XY>
M"3>,DEQ?16/(BU%[*3R)G4(61< ON <9RHQZ\C/HD$\-U;Q7%O+'-!*@>.2-
M@RNI&001P01SF@"2O/\ XV_\DAUW_MW_ /2B.O0*\_\ C;_R2'7?^W?_ -*(
MZ /0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBHYYX;6WEN+B6.&")"\DDC!510,DDG@ #G- 'F?Q\T>XU7X:M+;O BZ?=I=R
M^=*$W(%=,*3P6RXP,\]!DX!T/!/C[P$?"6GQ6&J:5I$,,2HUA-<B(P/M#,N9
M-I?!8Y?!W')R3FI/&MMX)\>>%84U3Q/:0Z7%>J5N[6_A53,$;Y"[;ESM<G'7
MH:\[_P"%6?"#_H??_*Q:?_$4 >R0>-/"MU<16]OXET::>5PD<<=_$S.Q.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S?XW>&-4\4> 1#I$'VBX
ML[M;MH%^_(BHZD(/XF^<''?!QDX!YO3?VBM-@MVM_$F@ZE::I YBFCM45EW*
M &R'960[MPVG.,#DUZQXCU^Q\+>'[S6M2:06EJ@9_+7<S$D*J@>I8@<X'/)
MYKPR^^(=YXC\?:(FI> =*&D:K=PVUE=:QI9>>2W9U&Y9&.T_?W *"!O'7J0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.N_]N_\ Z41UZ!7G_P ;?^20Z[_V[_\ I1'0!Z!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@$X]C75_\)MXB_X:-_X13^T/^))_SZ^3'_SZ>9]_;N^_SU]NE'[1W_)/-/\
M^PK'_P"BI: /5-)LYM.T:QLKB[DO)[>WCBDN9,[IF50"YR2<DC/4]>IJY7/^
M!/\ DGGAK_L%6O\ Z*6N@H **** "BBB@ HHHH *\_\ C;_R2'7?^W?_ -*(
MZ] KS_XV_P#)(==_[=__ $HCH ] HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+:YJ.I:/<0:WI$UW<W:6+OYQBC.=J$-MDX&,)$Q&5Z<\@'G'VSXC_P#"Q_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'7?^W?\ ]*(Z] KS_P"-O_)(==_[=_\ THCH ] HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#POXN?%R^T?Q!/X2THR6*(B)?:BB;YT#A6
M_<#< "$;J2"2>-N QI^$_BU\,_!6G-9Z+H6N1>;M,\SQ1/),RC +,9?J<#"@
MDX R:^@** ,?PMXDL_%WARTURPCGCM;K?L2=0'&UV0Y )'53WK8HHH *\A^,
M'@OP_I_@+7]?M=/\O4V=)#/YTARTDR!SM+;>0S=N,\5Z]7G_ ,;?^20Z[_V[
M_P#I1'0!Z!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5BCW<[0%ST'+'.3ECT%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]P\UIX:BVO%&1A4::13B4X#''(^;J 62O2(((;6WBM[>*.&") D<<:A510,
M #@ #C%244 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*<<DCUKUZO/_ (V_\DAUW_MW_P#2B.@#T"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\_^-O\ R2'7?^W?_P!*(Z] KS_X
MV_\ )(==_P"W?_THCH ] HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHJG'JVFS:I-I<6H6CZA"F^6T693*B\<LF<@?,O)'<>M %RBBB@
M KS_ .-O_)(==_[=_P#THCKT"O/_ (V_\DAUW_MW_P#2B.@#T"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M &[_ /I1'0!Z!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>?\ QM_Y)#KO_;O_ .E$=>@5Y_\ &W_DD.N_]N__ *41T >@
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEL %E;BMD> _'L5A>6D7A2%],DNXITL9KZ#>I++(Z+ABGE!D9<$ _O <'Y@
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M9+#DD'!4US=S\</$-U874]GX<L-*6S9?M%SJ%S)<1KG \O;&BMORRYZ[<$$
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MN!48 !R<G''^'/ 7CWP]<6DVIZ&UQ8)"[R+!<QRR0/\ =#%=Q+L$0* F?E;
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M0. O6LGPOX)^(MIKTA_LBW:RF ADGO;@18\L-R0&=@6<DDA6#%B02#NK=L/
M'CB[\,W=C<6.D68N1.D4,U^^^WC<L%4[(V4@ \8(XP,#% "77QPU^WDAL_\
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M 5Y_\;?^20Z[_P!N_P#Z41UZ!7G_ ,;?^20Z[_V[_P#I1'0!Z!1110 4444
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MD:3X6T/0[F2YT[388)Y 5\P LR(2#Y:$YV1Y PBX4=@*UZ** "BBB@ HHHH
M**** ,:^\(^'=4OVO;_1+"ZN'&'>:!7\S@ %@1AB , G)4$@8!.=GI110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7D/Q@U7Q!/X"U^RNO#/V;3
MZ*-1^WQOE5F38WE@;OF(48[;N>E>O5S_ (V\,?\ "8^$+[0/MGV/[5Y?[_RO
M,V[9%?[N1G.W'7O0!T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>=W\FOV?Q2\+QWNL.]K
M?SZ@5LK?Y(4A2(>6&[R/_$2Q(#'"@ 9(!Z)1110 4444 %%%% !1110 4444
M %%%% !1110 45YQXDTN^T3P9+J5WXGU/_A)G\DP2)<.T<ET N((K=-J,KE2
M "A.&+-G!KT. RM;QFX1$F*@R)&Y=5;'(#$ D9[X'T% $E%%% !1110 4444
M %%%% !1110 445R/C"72=*GBUCQ'KVH6>E[1:PVUK+-$OG,68NS0G>Q*J
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MG=0I:1"4=L#@ LI(]B.!TH Z&BBB@ HHHH **9,95@D,"(\P4E$=RJLV. 2
M<#/?!^AKD_"]OK%IXFU:+6=4>]N9K.UN7C0D6\#L\ZE(5/10$49/+$9/)P #
MKZ*X#XKW&NV7@_5+VQU+[#:010%#;;EN'E,P5@7S\J;2O"_,3U( (;OE^X/I
M0 M%%% !1110 445QNG0:[#X\@GUC4=QO+*Z*V%M(QMK=(Y( F,@%WP[%G('
M7   H [*BL/5-&OM7UF S:E-;:/!'N^SV<SPRSS'</GD4@A%7!"J1DDYX !I
M^$VO8=0UW3V>ZN=+M;L"QO+FX\YFRH,D08_,PC?<N6)/\.<H: .HHHHH ***
M* "BO.]%DU^V^*T=AK.L/=M+H374D$7R6T3FXP B=PHX#-ECW/8:7BR33]*N
MO[8\3>(;VUTCY;:UM;-IX )""S,[0MO<G:<=%49X).: .RHKE_ 5Q<7?AZ6X
M>[2[L9+R=M.F\]YI&MBYV>8SDG<.1@G(  .""*ZB@ HHJCJD6I310Q:;<P6Q
M:7$\TB;V2+:V3&.F_.W!;*CDD'H0"]17&_"J]N]0^'.F75]=3W5P[3;IIY"[
MMB5P,D\G@ 5S?BK6-2U#6M#UG3=6FBT0ZW:Z?;BTNL1WF6;SW< #*[E" $D'
M:Q PP) /5J*** "BH+S[5]AN/L/D_:_+;R//SY>_'R[L<[<XSCG%<3X*DU6+
MQUXLTW4]8N=2-I'8[7EPJAFB)8I&ORH">P]!DD\T =[17G=Y?V$GBKQ!;W8\
M1WD]M=0?N-,N+H+;P/#%ARL;JI&\N2%RYY." 2.UT6]L-1T:TNM+NOM-D\8\
MJ4R,Y8#CYBWS%N,'=SG.>: +]%%% !17F^I#7;+XJ^&WO-9F:WU">\1;&W=D
MMTACCS'N7^-SNW,Q[X X45?\5ZQ;?\)AI>C7D^LP68MWN)?[.2;]_(Q*Q1EH
M09/NI.V!@':#SC% '<T5RG@N[MKB34TM=0O7021.=/U)9OM5B6C7*N97+%3C
M<,#&2V">W5T %%%>>_%>37[/POJ.HV&L/865M;Q[4M1MFEE:902S]54+C 7!
M)8Y.!@@'H5%4KS3X=3LXX;B2Z500^;>ZD@;./[T;*2.>F<5R6CZ<+OQS<S:=
MJ>IKI>C_ +B5'U*6X2ZN67+*V^5OEC5EXV@[B>?EQ0!W5%%% !17FWQ7_P"$
MBA\.ZCJ5MJSZ;86"1- MC,RS7$K.JL9&P-J*&.%4G).2> *Z'QQ)J,/A,W%B
M7\J"2*>^\J9HIC:H0TOE,&7#X'J,C<.N* .HHKS/PWX@TS6?'%G#X1U.ZNK&
M*UE?4A?WUQ("&*B/RTF<DN&'+!=H#=<D"O3* "BN6\=IK/\ PC]W/IFI_P!G
MV]O9W,]P\2@S.5C.Q4)!"C.26'S<#!&21EW.N:OIWP2M]9L6>XU1=+@D\R13
M*V2J[Y#ZD LV3D<9.1F@#O:*\]OFC\,OX8O]+U74]1%W<QV\ZS:D]PEQ!( O
MG$-N VNT9W(%'S[?XA7H5 !17":KH6I6GAC4=6O]>U Z_M,\)L[N2.".48\N
M&.'.QU+!4PREG+'N1B35II]<\6Z1X;N+W4-.=+!M2NUT^Y\L2,'1%3S  Y7_
M %F0 N<J>HX .WHKE/#[W>E^*M5\/7.H_:;411WNGBXG,EPL;LRNK,W+*KKQ
MG) 8 D\ 2W_APW,NIW^L>(=0CA9#Y'V2ZDLX[*( _-\KX=N22[Y' X &* .F
MHKC-!O/%>M?#G3KA9+.'6+M!FZF&52(DXF"+D,Y3:VT[1D\X VTS2M.UB\\'
M#2[37+E774;FVN-0N',ESY"32+\C=!(<*H)X4$D#(% ';45R%M;R:3X\MM/T
MZZU&XMI+!Y;Z&\NYITBPX$3JT@;#L?,&T, 0N?X1G,UO1+_2O#NN>(-5\4:@
MNIQJ\]NUO>-#:PE&)B583\OS#8K*^_))P23D@'H5%9^@W=W?^'M.N]0A\B\G
MMHY)XMA38Y4%A@\C!SP:T* "BBN.\<7EWX<:T\60W4QL;#]UJ%B)#BXB=@H9
M5.5#JQ!Z D9&X"@#L:*P?"7V^?1SJ6HW'F3ZC*;I8EG6:."-L>7&C* " @7)
M&<MN.3FMZ@ HHHH **JZE8KJ6G3V;SW-N)EV^=:S&*1#V*L.01^78Y'%<#9^
M(-6\1>3X1D2]M]7L[E8]9O(U9%$,?S>8DBF,CSB !@9P7., $@'I%% &!BB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "O*=4F\>:EXJT#6_^$"\O^R/M'[G^V(#YOFH$^]_#C&>A
MS[5ZM10!!92W$]A;S75M]EN9(E:6#>'\IR 2NX<-@Y&1UQ4]%% !1110 444
M4 %%%% !1110 4444 %07LMQ!87$UK;?:KF.)FB@WA/-< D+N/"Y.!D],U/1
M0!Y3;3>/#XDFUW4_ 7VZZ7='8)_;$"1V41ZA%YR[?Q2=2, !1Q7I]E+<3V%O
M-=VWV6YDB5I8-X?RG(!*[APV#D9'7%3T4 %%%% !1110 4444 %%%% !1110
M 5C7LVN6>K27%O9I?Z68(U^SQ3*EPD@9]S*& 5@0T?WI%P$. 3P=FB@#F_#&
MA7>F:CKFHWB0V\FIW*3"SM9S)!'B-5+C*)\[MN+''/R^E=)110 4444 %%%%
M !1110 4444 %>::Q\*@-)UM]-\0^(WN[U9YVM5O8XX;F=U/#HJ*N&. >@QQ
MP*]+HH H:-IG]CZ5!8?;KV]\K=_I%[+YLKY8GYFP,XS@>P%7Z** "BBB@ HH
MHH **** "BBB@#*UBZUJSDMYM,TV'4+<9%S!Y_E3\L@#1EOD.!O)5BN>,'UJ
M:!::Q)J=[K6LP6MG-=P6\,=E!(93"D>]OGDP S%I7'RC "CD]:Z"B@ HHHH
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M\]-^_=^F,?C75R7_ (QLV-X-$AU""YB1Q81W21SV4OEG=&7(V2)O ^;((W'
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M!>O\.,9Z'/M76RZ;>OJFG>*H]+1=56P-K=V37/S!&*OM1\%&96# 9VAMW+*
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MXR 2.U>I44 <1X7OO%,5[%::AX,>S@G9GN]2EU:&9V?;]YE51DG"J ,!1@
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M]"]_Y.W'_P <KT"B@#S_ /X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\
MQRO0** //_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<KT"B@#S_\
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MRO0** //_P#A27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\ D[<?_'*] HH \_\
M^%)?#S_H7O\ R=N/_CE'_"DOAY_T+W_D[<?_ !RO0** //\ _A27P\_Z%[_R
M=N/_ (Y1_P *2^'G_0O?^3MQ_P#'*] K@Y?B9"OQ:A\!Q:7(SLF9;QI@H5O)
M,N%3!W#;M&21R3QQR 1_\*2^'G_0O?\ D[<?_'*/^%)?#S_H7O\ R=N/_CE>
M@44 <GH_PS\(:#YW]F:1Y'G;?,_TF5LXSC[SGU-:G_"*Z+_SY?\ D5_\:V**
M ,?_ (171?\ GR_\BO\ XT?\(KHO_/E_Y%?_ !K8HH Q_P#A%=%_Y\O_ "*_
M^-'_  BNB_\ /E_Y%?\ QK8HH Q_^$5T7_GR_P#(K_XT?\(KHO\ SY?^17_Q
MK8HH Q_^$5T7_GR_\BO_ (T?\(KHO_/E_P"17_QK8HH PKGP;H%W:S6T]AOA
MF1HW7SI!E2,$9#>E<Y_PI+X>?]"]_P"3MQ_\<KT"B@#S_P#X4E\//^A>_P#)
MVX_^.4?\*2^'G_0O?^3MQ_\ '*] HH \_P#^%)?#S_H7O_)VX_\ CE'_  I+
MX>?]"]_Y.W'_ ,<KT"B@#S__ (4E\//^A>_\G;C_ ..4?\*2^'G_ $+W_D[<
M?_'*] HH \__ .%)?#S_ *%[_P G;C_XY1_PI+X>?]"]_P"3MQ_\<KT"O/\
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M7SI!E2,$9#>E,TOQMX=UKQ%>Z!I^H>=JEEO^T0>3(NS8P1OF*A3AB!P3704
M>?\ _"DOAY_T+W_D[<?_ !RC_A27P\_Z%[_R=N/_ (Y7H%% 'G__  I+X>?]
M"]_Y.W'_ ,<H_P"%)?#S_H7O_)VX_P#CE>@44 >?_P#"DOAY_P!"]_Y.W'_Q
MRC_A27P\_P"A>_\ )VX_^.5Z!10!Y_\ \*2^'G_0O?\ D[<?_'*/^%)?#S_H
M7O\ R=N/_CE>@44 8-MX,T"SM8;6WL-D,*".-?.D.% P!DMFIO\ A%=%_P"?
M+_R*_P#C6Q10!C_\(KHO_/E_Y%?_ !H_X171?^?+_P BO_C6Q10!C_\ "*Z+
M_P ^7_D5_P#&C_A%=%_Y\O\ R*_^-;%% &/_ ,(KHO\ SY?^17_QH_X171?^
M?+_R*_\ C6Q10!PEU\&_ -Y=S75QH.^:9S)(WVR<98G). ^*B_X4E\//^A>_
M\G;C_P".5Z!10!Y__P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\ XY7H
M%% 'G_\ PI+X>?\ 0O?^3MQ_\<H_X4E\//\ H7O_ "=N/_CE>@44 8P\*Z*!
MC[%_Y%?_ !I?^$5T7_GR_P#(K_XUL44 8_\ PBNB_P#/E_Y%?_&C_A%=%_Y\
MO_(K_P"-;%% &/\ \(KHO_/E_P"17_QK&U;X6>#-<NDN=1T;SYD3RU;[5,N%
MR3C"N.Y-=C10!Y__ ,*2^'G_ $+W_D[<?_'*/^%)?#S_ *%[_P G;C_XY7H%
M% 'G_P#PI+X>?]"]_P"3MQ_\<H_X4E\//^A>_P#)VX_^.5Z!10!R^D_#OPKH
M=L]MIVE^1$[^8R_:)6RV ,Y9CV K0_X171?^?+_R*_\ C6Q10!C_ /"*Z+_S
MY?\ D5_\:/\ A%=%_P"?+_R*_P#C6Q10!C_\(KHO_/E_Y%?_ !J*X\&Z!=VT
MMM/8;XI4,;KYT@RI&",AO2MVB@#S_P#X4E\//^A>_P#)VX_^.4?\*2^'G_0O
M?^3MQ_\ '*] HH \_P#^%)?#S_H7O_)VX_\ CE'_  I+X>?]"]_Y.W'_ ,<K
MT"B@#S__ (4E\//^A>_\G;C_ ..5TX\*:*  ++@?]-7_ ,:V:* ,?_A%=%_Y
M\O\ R*_^-'_"*Z+_ ,^7_D5_\:V** ,?_A%=%_Y\O_(K_P"-5=0\"^&]5L9;
M*]T[S;>7&]//D7."".0P/4"NBHH \_\ ^%)?#S_H7O\ R=N/_CE'_"DOAY_T
M+W_D[<?_ !RO0** //\ _A27P\_Z%[_R=N/_ (Y6[IW@3PUI-C'96.F^5;QY
MVIY\C8R23R6)ZDUT=% &/_PBNB_\^7_D5_\ &C_A%=%_Y\O_ "*_^-;%% &/
M_P (KHO_ #Y?^17_ ,:YVZ^#?@&]NYKJXT'?-,YD=OMDXRQ.2<!\5W5% 'G_
M /PI+X>?]"]_Y.W'_P <J]I7PJ\%Z)=M=:=HWDS,A0M]JF;Y20<89R.PKLJ*
M ,?_ (171?\ GR_\BO\ XT?\(KHO_/E_Y%?_ !K8HH X _!/X>$DGP]R?^GV
MX_\ CE)_PI+X>?\ 0O?^3MQ_\<KT"B@#S_\ X4E\//\ H7O_ "=N/_CE'_"D
MOAY_T+W_ ).W'_QRO0** //_ /A27P\_Z%[_ ,G;C_XY1_PI+X>?]"]_Y.W'
M_P <KT"B@#S_ /X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\ QRO0** ,
M&U\&>'[*TAM;>PV0PH$1?.D.% P!DMFIO^$5T7_GR_\ (K_XUL44 8__  BN
MB_\ /E_Y%?\ QK8 P,"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>img242628118_23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_23.jpg
M_]C_X  02D9)1@ ! 0$ -@ V  #_X2<J17AI9@  34T *@    @ "0 +  (
M   F   (A@$2  ,    !  $   $:  4    !   (K $;  4    !   (M $H
M  ,    !  (   $Q  (    F   (O $R  (    4   (XH=I  0    !   (
M]NH<  <   @,    >@  $9(<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M         %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P,3$N,38S.#0
M    -@    $    V     5=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 ,C R,CHP,CHQ," Q,3HS,SHQ,   ") #  (    4   1:) $
M  (    4   1?)*1  (    #.#,  )*2  (    #.#,  * !  ,    !  $
M * "  0    !   "T* #  0    !   !E>H<  <   @,   )7      <Z@
M  @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                         #(P,C(Z,#(Z,3 @,3 Z
M-3$Z,3@ ,C R,CHP,CHQ," Q,#HU,3HQ.      & 0,  P    $ !@   1H
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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MTZT +#]HCBN&?1X6+E5V1I@,IR3D'\,_7VIT%WJ$;$II*('=LA%*D@ ;2?\
M/:@#0TZ]EO5F:6W: QR% K YX[]/Y4V^FU".9!:11/$%S(7!)'T Z^N* ,N6
M749Y6:32+:4[,>8\1X']W!Y//8<5).]Q'9HBZ+'+(L!905RJNQ.5QUY[_6@!
MPU._MK?YM*(1$;B,$!<'  'N,&MF"0RV\<C#:S*&(YXR/>@"2B@ HH J7]K-
M=1HL%R8&5PVX#.?:JR:?J&V43:FS[U(7"!0I..?YT 0-IVKJT 75B1N_>9C&
M2,'^N*NZ=#>0^:+NZ$_("$+C' S^M %ZB@!&Y4@'&1UK'73-25=JZLX7)/\
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7J,\]:F5%-7IO7L92PD*B;H.[7V7O\NY])T5&N&7(Y!IU<IY8ZBBB@ HHHH
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M#C"\\+P<GFFK\%=&_P"%I1^.Y+N[GU2$N886$.R(O%Y3#>(Q*R[2<(TA4'D
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M @'!(S6+_P *A\#KS_PA^@_^"R#_ .)JUR6U-H^SM[UR?_A:G@W_ *&O1/\
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M9()P,XKWL7.C+"P49:GVF9UL//+J,*=2[73_ #1ZO3J6BO!/BPHHHH ****
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M0/$3:VLZ!63RL&(1Y+AL_)R,;>]>JW]E%&D<BAM_GQGEV(YD7MG% &G1110
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M^I\5C/\ >:O^)_F.HHHK$XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!6WTIU-D_U;?2FMQK<_//X?_\ 'QXN_P"QBOO_ $,5UU<C\/\ _CX\7?\
M8Q7W_H8KKJ^GGN?HE3XA" P((R#U%-BA2! D2+&@[* !^0I]%3>W4SN]D%%%
M% 7?0****!/S+OP*_P"3K+/_ +%F7_T>*^T?2OB[X%?\G66?_8LR_P#H\5]H
M^E>3COXB]#YS./X\?\*'4445YYX04444 %%%% ">M?#/Q"_Y.F^)7_7'3_\
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M &+]Q_Z4Q5QE?04?X4?0^WPO^[4_3]0HHHK4Z0HHHI@%%%%(#G/B+_R(>O\
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MDY. . /:J]=ZV/;C?E]XN_ K_DZRS_[%F7_T>*^T?2OB[X%?\G66?_8LR_\
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MBBB@ HHHH **** /E+]I;_DN7A[_ +%^X_\ 2F*N,KL_VEO^2Y>'O^Q?N/\
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MN]'LH]__ &2?^3>_"?\ NW/_ *4RUZ__ (5Y!^R3_P F]^$_]VY_]*9:]?\
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M/EQM?Y1P=_\ LBF6^CZM''IZSZ]+.85(N3]EB7[22N < ?)@\X&: /@[X?\
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M9H&>YNGB6$I)&" 7DRN'!SP  PV\]>O'++;]GC1(TL1->W,S11[;E@ GGMM
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MX958AU8#C((Z]Q@U>M?&GA^_MKV>VUS3KBWL@3=2Q7<;+!UR7(.%Z'KBO._
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MM&N[N6SG@LI;/4[6X2T5E\V3S(8T$JY.1F5F()Q[T ?6=%%% !1110 4444
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MVHZA:V%D,?Z1=3+''ST^9B!S]:^?_B)\(=:\8:AJUII_AF\TB+69XKB>Z37
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MFHF]B,4OFDA0 #D<C )X).!FM2+Q?H,VES:E'K6GOI\+%);M;N,Q1L.JEP<
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>img242628118_24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_24.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %Y <H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MK&O->^R7LL/V<,D)0.3(%9MW38O\5 &S161+K9CED;[,39Q2^3)-OY#=SM]!
MGKFM9F51EF 'J30 M%,$L;'"NI/H#3Z "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN(UGQ[
M<Z;X@N-)M=%>\:!58LDN."/3%4)_B5J5M \TWA>9(T&68S\ ?]\U:IR9NL-4
M:32W\T>C452T[4/M^CP:AY>SS8A)LSG'&<9JOIFM+J7AU-7$!16C9_++9/RD
MCK^%39F7(S5HKEK7QO:7GA2XUN*!MUMCS;8MAE)(QSZ'.<U)<^)KX:K=V5CH
MKW?V6.-Y'$ZI]Y=P !%/D9?L9WM;^OZ9TM%4]*U*'5],@OX PCF7(5NH]0:E
MM;N&\1W@;<J2-&W&,,IP14V,VFMR>BL*^\0RQZG)IVF:=+J%S"H:;:X1(\]
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \OUW3O$-MXXO\
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MT;+O^A=HHHJ20SFL+QA_R+%U]5_G6[6%XP_Y%BZ^J_SJH_$BZ7QQ]3TK1_\
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M-%%%4,****!D'@/_ )!EW_U\M_(5U=<IX#_Y!EW_ -?+?R%=766)_BR'@O\
M=XD-Y_QY3_\ 7-OY5Y3X)_Y%[_MO)_2O5KS_ (\I_P#KFW\J\I\$_P#(O?\
M;>3^E3#X6>K1_A2]5^IT5%%%( J&[_X\KC_KD_\ (U-4-W_QY7'_ %R?^1IH
M%N7_ (7_ /(CVW_767_T(UV-<=\+_P#D1[;_ *ZR_P#H1KL:FI\3,L1_%EZA
M1114&(4444 %%%% !1110!S/Q _Y$?4_]P?^A"N>TC_D#6/_ %P3^5=#\0/^
M1'U/_<'_ *$*Y[2/^0-8_P#7!/Y5K'X#KI_P?G^A=HHHI %87C#_ )%BZ^J_
MSK=K"\8?\BQ=?5?YU4?B1=+XX^IZ5H__ "!+#_KWC_\ 015VJ6C_ /($L/\
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M]5^IT5%%%( J&[_X\KC_ *Y/_(U-4-W_ ,>5Q_UR?^1IH%N7_A?_ ,B/;?\
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M]>Z?R%=K7%7/_(^WO_7NG\A73AMY>GZHX\9]C_$OR9HT4458!1110,I>'/\
MD;]5_P"N:_TKL:X[PY_R-^J_]<U_I78UGB?C7HOR%@OX;]7^85Y18_\ (]>)
M_P#KL*]7KRBQ_P"1Z\3_ /785G3V9ZN'VGZ?JC=HHHH*"CO11WH K_#G_D->
M)?\ KY'\VKT*O/?AS_R&O$O_ %\C^;5Z%2J?$9XG^(_E^05P6@?ZS4_^OIOZ
MUWM<%H'^LU/_ *^F_K6^'^"?R/+Q/\6G\_R-FBBBJ&%%%% R#P'_ ,@R[_Z^
M6_D*ZNN4\!_\@R[_ .OEOY"NKK+$_P 60\%_N\2&\_X\I_\ KFW\J\I\$_\
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M;?\ 767_ -"-=C7'?"__ )$>V_ZZR_\ H1KL:FI\3,L1_%EZA1114&(4444
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M0O\ KM)_Z+-;E8>L?\A_0O\ KM)_Z+-;E !7%7/_ "/M[_U[I_(5VM<5<_\
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MK'_K@G\JZ'X@?\B/J?\ N#_T(5SVD?\ (&L?^N"?RK6/P'73_@_/]"[1112
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MEOY"NKKE/ ?_ "#+O_KY;^0KJZRQ/\60\%_N\2&\_P"/*?\ ZYM_*O*?!/\
MR+W_ &WD_I7JUY_QY3_]<V_E7E/@G_D7O^V\G]*F'PL]6C_"EZK]3HJ***0!
M4-W_ ,>5Q_UR?^1J:H;O_CRN/^N3_P C30+<O_"__D1[;_KK+_Z$:[&N.^%_
M_(CVW_767_T(UV-34^)F6(_BR]0HHHJ#$**** "BBB@ HHHH YGX@?\ (CZG
M_N#_ -"%<]I'_(&L?^N"?RKH?B!_R(^I_P"X/_0A7/:1_P @:Q_ZX)_*M8_
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MQJB6_P!HN=IA+YW\]:Z6LQ[B$>(8T,J!O(*XSWSTK:%6H[ZF-3#T5;3JBO\
M\(Q;?\_5W_WW5?4- @M=/GG2YNB\:%@"_%='5+6/^0->?]<C2A6FY+4=3#4E
M!M1Z&YX9);PU8$DDF(<FM6LGPQ_R+.G_ /7$5K5PU?XDO5GHT/X4?1?D<S\0
M/^1'U/\ W!_Z$*Y[2/\ D#6/_7!/Y5T/Q _Y$?4_]P?^A"N>TC_D#6/_ %P3
M^5./P'H4_P"#\_T+M%%%( K"\8?\BQ=?5?YUNUA>,/\ D6+KZK_.JC\2+I?'
M'U/2M'_Y EA_U[Q_^@BKM4M'_P"0)8?]>\?_ *"*NUD]SBENPHHHI""BBB@
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MI_\ 7TW]:[VN"T#_ %FI_P#7TW]:WP_P3^1Y>)_BT_G^1LT4450PHHHH&0>
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MXJY_Y'V]_P"O=/Y"NUKBKG_D?;W_ *]T_D*Z<-O+T_5''C/L?XE^3-&BBBK
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M./J>E:/_ ,@2P_Z]X_\ T$5=JEH__($L/^O>/_T$5=K)[G%+=A1112$%%%%
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MFO\ A#+7_H(ZA_W^'^%'_"&6O_01U#_O\/\ "NEHHN%V<U_PAEK_ -!'4/\
MO\/\*BN/ >GW<#0W%[?R1MU5I00?TKJJ*=V',UU,&/PR(HUCCU?4U1 %51/P
M /PI_P#PCK?]!G5/^_\ _P#6K;HI"*MA9FQMS$;F>X^;.^=MS?3-6J** "BB
MB@ HHHH **** "BBB@ K*OM?M+"]^R/%<RS! Y6&(O@'@9K5K#M_^1UO?^O*
M+_T)J %_X2>V_P"?+4?_  &-'_"3VW_/EJ/_ (#&MNB@#$_X2>V_Y\M1_P#
M8T?\)/;?\^6H_P#@,:VZ* ,3_A)[;_GRU'_P&-'_  D]M_SY:C_X#&MHD 9)
MQ1D<\CB@#%_X2>V_Y\M1_P# 8T?\)/;?\^6H_P#@,:V/-CSCS%S]:?0!B?\
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M:H ;(ZQQL[?=4$GZ"L.+Q993Q++%:W[QN,JPMC@BM>\_X\;C_KFW\JH^&?\
MD6-,_P"O=/Y4 0_\)/;?\^6H_P#@,:/^$GMO^?+4?_ 8UMT4 8G_  D]M_SY
M:C_X#&C_ (2>V_Y\M1_\!C6V3@9/2D+*HR6 'J30!B_\)/;?\^6H_P#@,:/^
M$GMO^?+4?_ 8UM;EVYR,>N:&=5^\P'U- &+_ ,)/;?\ /EJ/_@,:/^$GMO\
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>+(/]FP\<]_\ &MFB@!  H  P!P*6BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>img242628118_25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_25.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %9 G,# 2(  A$! Q$!_\0
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M:I_.V?89MOFA-^Y,;2N=_7H#QCKGMBK5 !1110 4444 %%%% !1110 4444
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MUS,$EN-WEC!.=HR>G3 ]:25]@2;T1<HK.77]*;3VOUOX3:(VQI0W ;T/YBM
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MY&N[ETS79)G>&XE$3,2@%\5P.W'E\?2M:V$A#:7?\#GPF;5:U^:F[I+;SO\
MA:QN2ZUID%U]FEO[=)LX*%QP?0^E36^H6UW<W-O#)NEMF"RK@C!/2O/?$CV,
MD)^S/:;HW47:8Q.\@X)#%>1ZGUYKH=*9?^$RE,2,B3:='(R-U!&T#/OBIGAH
MJGS:WM_D72S*<Z_LW:UTM.SO^37YZ'54445Q'LA1110 4444 %%%% !1110
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M15'1]135M'M+],8FC#$#LW0C\#D5>K-JSL)IIV84444A!1110 4444 %%%%
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MZ%J;F$7!&1$7&\CZ=: )JS]._P"/W5O^OL?^B8JT*S]._P"/W5O^OL?^B8J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O.?'6JRVGBBUMI-=GTVV^R>8#!!YAWEB.>1U ]>W3FO1J\_\<ZAJT&K
M>5:7;6MK#:+.S);B0L/,VN<G^Z&!Q_C0!N^"_LTFA+<07C7Q=RK7+P^6[8/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!@3&,;P/][K5BB@ K/T[_C]U;_K['_HF*M"L_3O^/W5O^OL?^B8J -"BBB@
MHHHH **** "N*^)&F?:M&CO4'[RW;!(_NG_Z^/SKM:KW]HE_I]Q:2?=E0IGT
MST-:49\DU(RK1DX>Y\2U7JM5^)1\-:I_;'AZSO"<R,FV3_?'!_49_&M:O//A
MW>/9ZCJ.AS_*P8S(I[$?*X_E^1KT.G6AR3<39RC-*<-I*Z^84445D(**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K&;Q/IPTNXO@9";<A9;<KME1B0 I4XP
M<D<GCWK6FE2""261MJ(I9F] !DUYGH\&F:NMS/JWB&UDE9 L<INP9,\[CM=1
MA#Q\A!% '<VVH)KV@W$MJ'@=TDBQ*0#&X!')!(_$5XQ.]SI>H&UU36;MU_YZ
M6%X)<?AD?KBO4],U'2IK'_A'(]2T^2ZECDCC^PQX3;@_-@?*#CDC-85E\+KK
M3Y?-M=?1).S&P5B/H2QQ0!U_A8Q'PS8F"XGN(BA*RSC#M\QZBMBJFFVUQ::=
M#!=W9NYT!#SE-I?GT[>E&HZ?#J=H;:=I5C)!S%(4;CW'- &+/XN UJ6PL]-N
M+Q+>58KB:-@-C-V"GEL=\=*KS^/+:'5'A^PS-8170LY+T,-JR^FWJ1P>:QKO
MX;3F]G6RFMA;33)*MS*7-Q!CJ%/1L^I-6I_ M])>SVJW=N-&GOQ?.I!\X-W0
M=L<]?:@#O*S]._X_=6_Z^Q_Z)BJQ=6%G>[?M=I!<;,[?-C#[<]<9^E4]'MX;
M6?5(;>&.&(78PD:A0/W,?84 :E%%% !1110 4444 %%%% 'F?B@'PYXYM-80
M$0R,'?'<'Y7']?QKTM6#*&4@@C(([URWC[3!?>'FF"Y>V;=[[3P?Z'\*F\"Z
MF=2\,0*[9FM2;>3_ (#T_3%=-7WZ<9_)F5#12I?RNZ]):_A+F_ Z2BBBN8U"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *R;[0= N6>>]TZQ9AR\CQJ#^)_
MQK6KRO3_  1>7\)N]0:[3-S,=2A9B&N=IRAC '/.>I^E 'I-CINGZ?'BPL[>
M!&'6&,+N_$=:MUS7@*.>+PA:K-O W.8U<Y94W':#^%=+0 4444 %%%% !6?I
MW_'[JW_7V/\ T3%6A6?IW_'[JW_7V/\ T3%0!H4444 %%%% !1110 4444 1
MSPI<V\D$HS'(I1AZ@C!KSCP9.^B^,+O2)SA;C*C/_/1,X_,9_2O2Z\U\>VTN
MF:]:ZQ;##$K*#_MIC.?;&*ZL/[RE3?7]#&3Y*T)]'[K_ .WMO_)DOO9Z514-
MI=1WMG!=0G,<R"13[$9J:N4V:MH%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5P0\?:VPR/!.HD>H+_ /QNN]KR7PA)XS7P]$-%ALFLM[[3*1NSGGOZT =A
M\/+6YL_"<<5W;RV\OG2$QRH58 GT-=56;H3:LVEJ=:6%;W<=PB^[CM6E0 56
MO[Z+3K)[J9)71,9$2%VY(' ')ZU9HH X#Q*+F[N].FTW6]4MKC5942&U#E%C
M0 ;W*]1@<X]363<:]K$4USJJZE<;K75A8I9$C8T8!^\.[''7ZUZ/-I%C<:M;
MZI+!NO+=2D4F]OE!!!XSCN>U5W\,Z-)JXU5[",WH8-YF3]X=#C.,^^* +UU-
M<0[?(M3/G.<.%Q^=4]'>22?5&EA,3F[&4+!L?N8^XK4K/T[_ (_=6_Z^Q_Z)
MBH T**** "BBB@ HHHH **** "L#QEI_V_P[,57,EO\ OE_#K^F:WZ1E#J58
M J1@@]Q5TYN$E)=#*M256G*#ZG'?#K4?/T:;3G8F2RDPN>IC;E?Z_I795Y=H
M['PUX]^S.2(97-JQ/HW,9^IXKU&M,3!1J:;/4TA5=:G&J]Y+7U6DOQ3"BBBL
M!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5Y)H/BC4(M7T^^NM8M18WT\B2V>]5
M%NHZ$C^'V/MWS7K9.!D]*\>DL]"N=(DU#3O"CO&UXEM;>9<R_O\ .[)&&XY
M'XT >MVUW;7L(FM;B*>(G >)PRY^HJ:N:\!R6TOA6![6VCMD,CYA1W;8V>02
MW.:Z6@ HHHH **YV;QKI,&IO9,+DB.<6\EPL),22'^$MZTLOC31X=7.G,\VX
M3"!IQ&?*60_P%O6@#H:S]._X_=6_Z^Q_Z)BK0K/T[_C]U;_K['_HF*@#0HHH
MH **** "BBB@ HHHH **** //?B+IK">WOX@0TB^7N Y#KROXGD?A79:%J2Z
MOHEI?#&98P7 [,.&'Y@U#XET\ZCH%S"HS*J^9'CKN7GCZ\C\:YCX=:@%>]TI
MCA<BY@'^RW# >P./UKJE^\H)]8Z?U_70PH>[4J4?^WU\])?C9_,[VBBBN4W"
MBBB@ HHHH **** "BBB@ HHHH **BGF,$>\0R2G.-L8!/ZD56L]2%XV$M+E%
MW,I=U4 %201U]013MU'RNUR]1112$%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:DVI^&K9Y"?/@'D3 ]0R\<^^,'\:WJYY*SL=<XN,G%] HHHI$A1110 4444
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MM;'5HA_%$WE2'\\#\@:ZVBE[1O?4?MY/XDGZ_P">YRB>/+*!Q'JUC?:9(?\
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MZWI7_>B?_"J]E5ZPO\O\C19MA)?'*/WV_P B#_A.-'NK.0VFH00W*C(2[1E
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M_P"-T :%%9_]GW?_ $&;W_OB'_XW56Z@OH;NRB76+O;/*R-F.'H$9N/D]0*
M-JBL_P#L^[_Z#-[_ -\0_P#QNC^S[O\ Z#-[_P!\0_\ QN@#0JGI7_(*MO\
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M?WD_4\/_ ,^X_<BH?".@G_F')_WVW^-(?!V@'_F'K_W\?_&KG]GW?_09O?\
MOB'_ .-T?V?=_P#09O?^^(?_ (W1[>K_ #/[Q?4L+_S[C]R*)\&: ?\ EP_\
MC2?_ !5(?!6@'_ER(_[;/_C4NGV]]=6SR2:Q=@B>:,8CAZ+(RC^#T JU_9]W
M_P!!F]_[XA_^-T_K%7^9_>Q?4,)_SZC]R,X^"=!/_+HX_P"VK?XTT^!]"/\
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M@"CJVJVNC6)N[LOY88(JHI9F8\  =S60OC/16LIK^59XI;:3[.T,L.)U9OX
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M?O?I0!V5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>img242628118_26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_26.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %1 E4# 2(  A$! Q$!_\0
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M+GV'.>] %ZBJAN;O<0+!B-SC/FKT'W3_ ,"_3O2"YO"1FP89,>?WJ\;OO?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5=6<)/W58$F8NN7MQ:WNF)!*466;:X 'S#*_XU7\2ZG>:=<69M7(!#,Z8R&
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MX<LKV*[M].V3Q.'1_/D.".^"V*N6'AK1M+OI+VRL(X;AP07!)P#UP"<+^&*
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MT]5M4@:SD4[5B \ME/7@<8.:Q%\)>&+**;3UMHH3J *E#,=\@7YL+DYXX/%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME_UDB1A6?ZD=:L44 %9^A?\ (O:;_P!>L7_H K0K/T+_ )%[3?\ KUB_] %
M&A1110 4444 %%%% '!WUN^FZ[>P1?+N(U"V^H^^/YG_ ("*[:UN$N[6*XC^
M[(H8>WM6%XNA:&WM=6C7=)8R@N/[T;<,/Y?K4OAV987N-.#;DC(E@;^]&W(_
MF/SKKJ_O*2GU_K_@'#A?W=2=#L[KT>OX.Z^XWJ***Y#N"BBB@ HHHH ****
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M\I:^<V?PR<_F![5[%HMGXACNC+J=QIT5MAO]$LX3M+$YW%CSG.?KFM_:/04
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M0U%5:W[G5%IJZ"BBBLR@HHHH **** "BBB@ HHHH ***1T5T*.H92,$$9!H
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M]&+*WE+D$\Y!QUJU14)M;&LHQENCGO%NF7NJ6-O':(LJI*'DA+!2X]B>G?\
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M?:O-3++Z8)S[TZ7P_K?F2VZ62M!_:/VD2B502O(Z$^E>@45?UZIV7X_YF/\
M8U#^:7X?Y?\ !.,T70KZRG%I=:7:RQ+,\AO9&#$J1C '7/'>J$/A[6%T2.P.
MFJLD5ZDWF"5/G7# ]^W'YUZ%12^N3O>R_'_,K^R*/*HW>E^VSMIMY>IP$?A?
M55U". V\?E)>_:?MOF#)7CC'7MGZTMKX9U*)+-VLE$L>I><[;TR(OEP<YZ<'
MBN^HI_7:GD)9-AUK=_AY>7EZA1117&>L%%%% !1110 4444 %%%% !6?H7_(
MO:;_ ->L7_H K0K/T+_D7M-_Z]8O_0!0!H4444 %%%% !1110 4444 %%%%
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M/B1G5^!EM?N#Z4M0V[7!4B>)(\8QLDW9_05-2:LRXNZN%%%%(84444 %%%%
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M]C_WR_\ C6A10!GXU?\ OV/_ 'R_^-&-7_OV/_?+_P"-:%% &?C5_P"_8_\
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M7CK6C:7=O?6J7-K,DT$@RKH<@T 5<:O_ '['_OE_\:,:O_?L?^^7_P :T**
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M^RP-#'O\J3(^]_='&<UVNAVDUAH-A:7#9FAMT1^<\@ $5?HH **** "BBB@
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%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>img242628118_27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_27.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &D 5 # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH R+G7H[>ZEC^S2M%"ZQR2 @8+=,#.33FUM%N&7[-*;99?):X!&T/\ 3KC)
MZU2OM"N+G4I;A/(+2,C)</GS( .R@=:F;2;O+VBR1?89)_.9CG>!G)7'3KWH
M W*,U6OK&WU&V-O<H7C)!(#$=/I7/7>C6.E:UHLEG&\;/<LK?O&.1L8]S0!U
M5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B:W_ ,A;0O\
MK[;_ -%M6W6)K?\ R%M"_P"OMO\ T6U &W1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 45G:AJPT[<TEK.\2@9D0 CGCUI#K=LMUY)278)!$TVSY%
M<_PDT :58FM_\A;0O^OMO_1;5MUB:W_R%M"_Z^V_]%M0!MT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 9]_:2WEY9J<?98G\V3)Y9A]T?GS5!M,OM
MLMBJQFVDN?.,Q;D+D$C'K[UOT4 5KZR6_MC \LT0)!W0N4;\Q7.7>CQ:=K>B
M2)=7DQ:Y9<3SEP/W;= :ZRL36_\ D+:%_P!?;?\ HMJ -NBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<A?S-S GYL'@#D?+[4 =''()8ED7.U@",TZD4$* 3D@<XI: "BBB@ K$UO\
MY"VA?]?;?^BVK;K$UO\ Y"VA?]?;?^BVH VZ*** "BBB@ HHHH **** "BBB
M@ HHHH #T->2>%?O:M_U_/7K9Z&O)/"OWM6_Z_GK2'PLZJ'P2^1T-*.HI*4=
M10,K?#7_ )"'B/\ Z^A_*O0J\]^&O_(0\1_]?0_E7H5*I\1GB?XK^7Y'E5G_
M ,CSXD_Z[+_(5MUB6?\ R//B3_KLO\A6W5RW.BKNO1?D%4?!O_)0]:_Z]TJ]
M5'P;_P E#UK_ *]TH6S$O@GZ?JCTBO,=7_Y*M<_]>2?RKTZO,=7_ .2K7/\
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MZ=7F.K_\E6N?^O)/Y5-/KZ&6&WEZ&I1110496G?\E5L?^O-O_9J]/KS#3O\
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M +-7I]>8:=_R56Q_Z\V_]FKT^BIT]"<3O'T/-_%__)2='_Z]&_F:O51\7_\
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MD%JTHF:W &TN/?KCCI6K10 UXTE7;(BNOHPR*PM7MX8M7T,Q0QH3=MRJ@?\
M+-JWZQ-;_P"0MH7_ %]M_P"BVH VZ*** "BBB@ HHHH **** "BBB@ HHHH
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MEN=%7=>B_(*H^#?^2AZU_P!>Z5>JCX,Y^(>M'_I@E"V8E\$_3]4>D5YCJ_\
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MB@HRM._Y*K8_]>;?^S5Z?7F&G?\ )5;'_KS;_P!FKT^BIT]"<3O'T/-_%_\
MR4G1_P#KT;^9J]5'Q?\ \E)T?_KT;^9J]5/9&C^"/I^K"L2Z_P"1^\-?[[?S
MK;K$NO\ D?O#7^^W\Z([E4]WZ/\ (]5HHHK$X HHHH **** "BH'O;6.Y6W>
MXB69ONQEAD_A0;RV%T+8SQB<C(CW#=CZ4 3UB:W_ ,A;0O\ K[;_ -%M6W6)
MK?\ R%M"_P"OMO\ T6U &W1110 4444 %%%% !1110 4444 %%%%  >AKR3P
MK][5O^OYZ];/0UY)X5^]JW_7\]:0^%G50^"7R.AI1U%)2CJ*!E;X:_\ (0\1
M_P#7T/Y5Z%7GOPU_Y"'B/_KZ'\J]"I5/B,\3_%?R_(\JL_\ D>?$G_79?Y"M
MNL2S_P"1Y\2?]=E_D*VZN6YT5=UZ+\@JEX*_Y'_7/^N,=7:I>"O^1_US_KC'
M0MF2O@GZ?JCT>O,=7_Y*M<_]>2?RKTZO,=7_ .2K7/\ UY)_*II]?0SPV\O0
MU****"C*T[_DJMC_ ->;?^S5Z?7F&G?\E5L?^O-O_9J]/HJ=/0G$[Q]#S?Q?
M_P E)T?_ *]&_F:O51\7_P#)2='_ .O1OYFKU4]D:/X(^GZL*Q+K_D?O#7^^
MW\ZVZQ+K_D?O#7^^W\Z([E4]WZ/\CU6BBBL3@"BBB@ HHHH YO5KFVN-1_LX
M0/&"Z//<>2><'A5(')]^U0R1-^^LS;2&^>]$J2",XQD$/NZ8 [9KJJ* *U\E
MW);%;*:*&;(PTB;ACZ9%<Y>0ZM'K>B&_N[::/[2VU8H2A!\MN^3765B:W_R%
MM"_Z^V_]%M0!MT444 %%%% !1110 4444 %%%% !1110 'H:\D\*_>U;_K^>
MO6ST->2>%?O:M_U_/6D/A9U4/@E\CH:4=124HZB@96^&O_(0\1_]?0_E7H5>
M>_#7_D(>(_\ KZ'\J]"I5/B,\3_%?R_(\JL_^1Y\2?\ 79?Y"MNL2S_Y'GQ)
M_P!=E_D*VZN6YT5=UZ+\@JEX*_Y'_7/^N,=7:I>"O^1_US_KC'0MF2O@GZ?J
MCT>O,=7_ .2K7/\ UY)_*O3J\QU?_DJUS_UY)_*II]?0SPV\O0U****"C*T[
M_DJMC_UYM_[-7I]>8:=_R56Q_P"O-O\ V:O3Z*G3T)Q.\?0\W\7_ /)2='_Z
M]&_F:O51\7_\E)T?_KT;^9J]5/9&C^"/I^K"L2Z_Y'[PU_OM_.MNL2Z_Y'[P
MU_OM_.B.Y5/=^C_(]5HHHK$X HHHH **** "BBB@ K$UO_D+:%_U]M_Z+:MN
ML36_^0MH7_7VW_HMJ -NBBB@ HHHH **** "BBB@ HHHH ****  ]#7DGA7[
MVK?]?SUZV>AKR3PK][5O^OYZTA\+.JA\$OD=#2CJ*2E'44#*WPU_Y"'B/_KZ
M'\J]"KSWX:_\A#Q'_P!?0_E7H5*I\1GB?XK^7Y'E5G_R//B3_KLO\A6W6)9_
M\CSXD_Z[+_(5MU<MSHJ[KT7Y!5+P5_R/^N?]<8ZNU2\%?\C_ *Y_UQCH6S)7
MP3]/U1Z/7F.K_P#)5KG_ *\D_E7IU>8ZO_R5:Y_Z\D_E4T^OH9X;>7H:E%%%
M!1E:=_R56Q_Z\V_]FKT^O,-._P"2JV/_ %YM_P"S5Z?14Z>A.)WCZ'F_B_\
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MU>GUYAIW_)5;'_KS;_V:O3Z*G3T)Q.\?0\W\7_\ )2='_P"O1OYFKU4?%_\
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MJSS6QU*SC^(]G?/<*+5+5D:4@[0?FX_6O0?^$KT+_H)P?F:T_LMO_P \(O\
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MKO\ SZ6?_?TTS0G6.QO78X5;RX)/MO-.LO$FF7\T<44[!Y?]5YB%1)_ND]:
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MN05 P/0$G\:Q5TS5X3IHN+:Z<V22P&2SD"LRDC:03VP*Z/\ X2G1_P#G[/\
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M3HP  NL ?],V_P *:_B;1)4*27 =3U5HF(/Z4 5O")1EU)XH3%"UT=B%MP'
MZ&K6H_\ (SZ+_P!MO_0*1/$VB1($CN BCHJQ, /TJHVJ6FI^)])^R2&3RQ,7
M.PC&4]Q0!TU%%% !1110 4444 %%%% !1110 8HP/2BB@ P/2C ]*** # ]*
M,#THHH ,#THP/2BB@ P/2C ]*** # HHHH *,#THHH ,#THP/2BB@ P/2C ]
M*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/
32C ]*** # ]*,444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>img242628118_28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_28.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #, G4# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5P;>V81A7( P..._2JTW[KQ7X??_ )ZVDL?Y!350ZFE/JO)G44445)F%%%%
M!112,ZHI9V"J!DDG % "T576^LW8*MW S'@ 2 DU8H"P4444 %%%% !1110
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M+-%_#?JOU.CHHHJ3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLR+,5PK/G -<Y#I5W!"R3623)F141'SM9B,/D_CS73QES&ID4*^!N .0#3J
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MMG)/TH O>(/^1=U'_KW?^57+3_CS@_ZYK_*L7Q#JD47AV9)DF66XM6(58F8
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M\9-=2?#.GGJUR?\ MNW^-'_",Z?_ 'KD?2=O\:KVGNVL7]8]SDLBE]E\9?\
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M^-1?V!HS;U4$L@^8"X;Y?KS0!MT5S>G>'].CTRV^VN'GVA7D%RV&;V.:O?\
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MS+)N ^T@G(7_ /7Z5K:5 \,,Q>+R5DE+I%_<7 XXZ="?QJ_10 4444 %%%%
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MMA/;W:&2%8Q$K*TP8$SY.1GO^=7YM1L[>-Y);F-51/,/S?P^M-;4[1)(5,H
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M^2X+(DZRY52O"L#M'.1TZYS3;CPU!),C0,D,8"AE,>XC#;LJQ.5))Y/-;E%
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LRSQ*5. N,84+_2KM% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>img242628118_29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img242628118_29.jpg
M_]C_X  02D9)1@ ! 0$ -@ V  #_X2',17AI9@  34T *@    @ "0 +  (
M   F   (A@$2  ,    !  $   $:  4    !   (K $;  4    !   (M $H
M  ,    !  (   $Q  (    F   (O $R  (    4   (XH=I  0    !   (
M]NH<  <   @,    >@  $9(<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M         %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P,3$N,38S.#0
M    -@    $    V     5=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 ,C R,CHP,CHR,B Q-CHR.#HT.   ") #  (    4   1:) $
M  (    4   1?)*1  (    #-3$  )*2  (    #-3$  * !  ,    !  $
M * "  0    !   "T* #  0    !   !E>H<  <   @,   )7      <Z@
M  @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                         #(P,C(Z,#(Z,C(@,38Z
M,C8Z,#, ,C R,CHP,CHR,B Q-CHR-CHP,P     & 0,  P    $ !@   1H
M!0    $  !'@ 1L !0    $  !'H 2@  P    $  @   @$ !     $  !'P
M @( !     $   _3         &     !    8     '_V/_; $, " 8&!P8%
M" <'!PD)" H,% T,"PL,&1(3#Q0=&A\>'1H<'" D+B<@(BPC'!PH-RDL,#$T
M-#0?)SD].#(\+C,T,O_; $,!"0D)# L,& T-&#(A'"$R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_  !$( ' !
M  ,!(0 "$0$#$0'_Q  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_
MQ "U$  " 0,# @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q  ? 0 # 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($
M! ,$!P4$!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M<"I4M2W3TOU1;1UD170AE89!'<4ZH-D[JX44 %% !10 44 %% !10 44 %%
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MNYX6=BS%6ZYS_C^E;>V;DY-;G*L*E35--Z"II<J%#_:%RV'#'+9W8[?2H3H
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MNIA.G%U%-.SL_P!"+Q3X>NM1T=H1?33?.K!74D_^.?X5I6^EWT5O&D>HA0%
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M% !10 54DS!)+/-<[82  I'"GI0!9P?[Q_2EVG^\?TH 3:?[Q_2EVG^\?TH
MCE=88FDDD*J.I(Z40R)/&)(I2R'H10!)M/\ >/Z4FTY^\?TH 7:?[Q_2F2,L
M4;2/)M102Q..!0 V&5)U)CEW[6*L1V(ZU+M/]X_I0!$MN%G:8.^YP <GC ]O
MQJ3:?[Q_2FW<459$:0Q6Z-L"QK]X[0 /K4*RV^H0RQ17)8%>2F,@'IV]C1=W
MN+E7+RHLI&40*9'8CN<9/Y"HY[6*Y55F4.$<.NX X(Z&A-IW0."E'E9+M/\
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M7/)^X>H!P0>A!J3P-XKGUB]U?2M0N$N-1L)\12>08FN+<JA68KROWV=<J<'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!0U694CB0[MS318PI(_UB]3CBK]4=2Q
M]G7T\Z+_ -&+5S=0 ZBBB@ HI,TW=UH ?12<T9H 6BBB@ HK@O'GQ.NO KRR
M2^%]2O\ 3T:)/MUL\'EEY&"*H#2!L[F4=._IS71>%]>O=>L9)[[1;K0Y%D*+
M!=O$S,, [AY;L,9)'7.5/M6\J,XP51[/S1Q0QE&I6="+?,O)_G:QMT445@=H
M44W=1N[T .HIN\<4;ATH =1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %-W>U.K!\:1,?#=Y(=2O-,MX$:>XFL57SS$JDLJ$@[21W'/'
M&#S0!N;N].KP/X=ZI;ZYKUA%9R:_H-Y<>;+&\NN/J,<_E>6766.0LOS)*OS+
MT.<-FO?* "DS2UR?Q.UO6?#O@K4]2T*"UEO+6"6<O=N0D4:1LY? !W'*@!>/
MO9R,4 =4&]J-U>/>)/B-XCBM_,TV>SMVTWPRGB"\%U;%Q=L=W[I3N78/W;\C
M/++38OBIKM]JB:K$+>/0?[=M-#.F20'[1^]BC8S>9NZAY5PNW!5?<&@#UC4C
MBW7L/.B_]&+5@'G-?&G[4GQ2\66?Q*GT2SU&^T33;&.-H5M)F@-P64,9"RD%
MADX'.!L['->D_LX_'#^W/!OV#Q)J\-QKT%RT-LMS,L<US#M0@[F(#,"7'7.%
M&<GD^[5R>O2P<,7=-2Z=4?'8?B?!U\SJ98TXRAU>S9]#T53GOI8[=)(K5YY&
MQF)74%>.>2<?E3[JZDA:(1V[SASAF5E 0>IR?Y5X1]A=/4ES^=<EXB^+7A+P
MGJ4EAJVM06-Y&%+12!L@,,CH*Z>2XE2XBC2V>2-OO2AE 3Z@G-<!\;Y9%\&^
M7]G;R_[1TX^?N7&?ML/&,Y_2NG#QA4JJ$^O;^F>?CZM6AAIUJ+5XIO779>J.
MN\,^,-(\96+WFC7R7UK'(8FDC! #  D<CT(_.MC/:JEK*_GM$;9DB505F++A
MNG  .>_>I+>XEFEE62V:%4.%=F4AQSR,'CIWK"5KOEV.RGS\BYW=];%JBJMO
M=3312-):R0,I(5&926X[8-$=U,]FTK6DB2@'$!9=Q_'./UJ34X;XZ#_BW,__
M %_Z?_Z6P5WJK^[&>>*\]^.$TC?#&>1H&C?[=IY\HD9!^VP\9SBNZDNIH;2*
M2.TDF<@9C5E!7CODXKKE_N\?\4ORB>73_P!^J?X8?G,NTM5KFXE@:();/.&.
M&964!!ZG)_E2S7$J7$<:VSR1M]Z564!/J,YKD/4)<?-[5YC\8+CQ7X;TRXUS
M1_$<=G:1R6\(L7T]).9)DC+;RV?X\XQVKT?SI/M8B^SOY.W/G;EVY],9S^E>
M=?'C4EA\ 7\4Z_9X_M=ELFDD4!_]*A) &<\#/Y&NS!_QX*U[M+:_7S/)S6WU
M*I)R:LFTTVM;>31V/A73=8TW3W36=976KEGWI,MJ+<*N!\NT$YY!.?>MO'O5
M33[XWBD^2R1#'ER[E99!ZC!/Z^M.M[J6:.1I+5X64_*K,I+<=L&N:;<I-O\
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M2T4 )BC%+10 FVC;2T4 )MHQ2T4 )BC;2T4 )MHQ2T4 )BC;2T4 )MHVTM%
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M?%.MZ?JGA^SF$PL[>-R]WM.560,-JJ3C(!;(R.^:^P_%7C32/!NEW=[J=Y%
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MI]S-=!C!'#<HS2A<[BH!^8#!SCTK.4J[WN=,LR]I9.K?YKT.%\"_L[Z#\/\
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MMH^]!KMJ=4/>I2CVL_T_4]9HHHK$Y0HHHH **** //OCK_R3F?\ Z_\ 3_\
MTMAKOHO]6OT%<!\=/^2=3_\ 7_I__I;!7?1M^[3UP*ZY?[O#U?Y1/+I_[]4_
MPP_.9)1117(>H%%%% !1110 S/?M28W CMWIVWUI=M CS'P__P 6Z^(5QX?;
MY="U]I+[3"3\L-S]ZX@]@W^L7ZR>E>E_05S'Q$\(_P#"9>&IK6"46NI0.MU8
M77>"X0Y1_IG@^H)'>G?#WQ:/&7AF"^>/[+?1LUO>VA/-O<(=LB'Z,./4$'O7
M74_>P57KL_T?S_,\K#?[+6EA7\+UC^J^3V\GY'4T4F[IGBDW>U<AZPZBBB@
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M$>2X2Y,T=J9FMW^SK<.F](#+C:)"I!QGN!U.*Y?XK?"V^\<:E]JL;71Y99+
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MG!TY.+-L/6CB*2J1Z_AW0^BBBLSI"BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO_7:+_T8M6Z "BBB@#R7QY_Q3'QN^'WB#[EOJB7?AVZ<],N@N(/_ !Z!P/\
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MK*8]VQI  /G(+>] &QJ,TQC4&#$?GQ?/O'3S%YQ6G534O^/=?^NT7_HQ:MT
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M[K5?JCR,1_LM=8E?#+27Z/Y;>C\CU"BO+=2^*OBG3_$5GHQ\#,]U?+-):_\
M$TBQ(D17<W3C[Z\'UKT?3;JXNM/MI;NV^QW,D:M+;^8'\IB!E=PX.#QD=<5G
M4HSI)2E;7S3_ ".JAC*6)E*%.]X[W37YHMT4E%8':+129]*;O]J 'T4W?2T
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M_%WAWQE>Z19Z1HNIV$$YA_M*WCN&BP#@$9(9L=R!SCY=U=SY,U^P/BOQ7\5
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MG%=S\-?A_K_AGXI:KJ,NE_9=(N/M1>XNS!)*Y>4.@26,[W!Y.)5&T* ":**
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:***D8?A1FBBF%@YI<>U%% @S29HHH)N?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>43
<FILENAME>verv-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-11T19:57:56.2227+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.vervetx.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:verv="http://www.vervetx.com/20211231" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="verv-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="verv-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="verv-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="verv-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1" id="StatementConsolidatedBalanceSheets1">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails2" id="DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails2">
        <link:definition>100020 - Disclosure - Income Taxes - Schedule of Deferred Taxes (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2" id="DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2">
        <link:definition>100030 - Disclosure - Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100040 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100080 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentation" id="DisclosureNatureOfTheBusinessAndBasisOfPresentation">
        <link:definition>100090 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecurities" id="Role_DisclosureMarketableSecurities">
        <link:definition>100110 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100120 - Disclosure - Property and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" id="Role_DisclosureFairValueOfFinancialInstruments">
        <link:definition>100130 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100140 - Disclosure - Accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100150 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreements" id="Role_DisclosureLicenseAgreements">
        <link:definition>100160 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosurePreferredStockTrancheLiability1" id="DisclosurePreferredStockTrancheLiability1">
        <link:definition>100170 - Disclosure - Preferred Stock Tranche Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStock" id="Role_DisclosurePreferredAndCommonStock">
        <link:definition>100180 - Disclosure - Preferred and Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100190 - Disclosure - Stock-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholders">
        <link:definition>100200 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100210 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100220 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlans1" id="DisclosureEmployeeBenefitPlans1">
        <link:definition>100230 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>100240 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100260 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables" id="DisclosureMarketableSecuritiesTables">
        <link:definition>100270 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTable" id="Role_DisclosurePropertyAndEquipmentNetTable">
        <link:definition>100280 - Disclosure - Property and equipment, net (Table)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" id="Role_DisclosureFairValueOfFinancialInstrumentsTables">
        <link:definition>100290 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100300 - Disclosure - Accrued expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100310 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100320 - Disclosure - Stock-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>100330 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100340 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>100360 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails">
        <link:definition>100380 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" id="Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails">
        <link:definition>100390 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" id="Role_DisclosureMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Marketable securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails">
        <link:definition>100410 - Disclosure - Property and equipment, net - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Property and equipment, net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails" id="Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails">
        <link:definition>100430 - Disclosure - Fair Value of Financial Instruments - Summary of Financial Instruments within Fair value hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" id="Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" id="Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails">
        <link:definition>100450 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" id="Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails">
        <link:definition>100460 - Disclosure - Fair Value of Financial Insruments - Schedule of Reconciliation of Changes in Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
        <link:definition>100470 - Disclosure - Accrued expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails" id="Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails">
        <link:definition>100490 - Disclosure - Leases - Summary of Components of Operating Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" id="Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails">
        <link:definition>100500 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails" id="Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails">
        <link:definition>100510 - Disclosure - Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails" id="Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Preferred Stock Tranche Liability - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" id="Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Preferred and Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Stock-based compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100560 - Disclosure - Stock-based compensation - Summary of Stock Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails" id="Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails">
        <link:definition>100570 - Disclosure - Stock-based compensation - Schedule of Assumptions Used for Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails">
        <link:definition>100580 - Disclosure - Stock-based compensation - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails" id="DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails">
        <link:definition>100590 - Disclosure - Stock-based compensation - Schedule of Status and Change in Unvested Restricted Stock and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>100600 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100610 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails">
        <link:definition>100620 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>100630 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails" id="DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails">
        <link:definition>100640 - Disclosure - Income Taxes - Schedule of Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100650 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100660 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" id="DisclosureEmployeeBenefitPlansAdditionalInformationDetails">
        <link:definition>100670 - Disclosure - Employee Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100680 - Disclosure - Subsequent Events (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_LicenseAgreementAbstract" name="LicenseAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_PreferredStockAbstract" name="PreferredStockAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_AccruedExternalResearchAndDevelopmentExpenses" name="AccruedExternalResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_AdditionalLesseeOperatingLeaseArea" name="AdditionalLesseeOperatingLeaseArea" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="verv_AdditionalTenantImprovementsAllowance" name="AdditionalTenantImprovementsAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_AmortizationOfPremiumOnMarketableSecurities" name="AmortizationOfPremiumOnMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_AntidilutionRightsLiability" name="AntidilutionRightsLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_ChangeInFairValueOfAntidilutionRights" name="ChangeInFairValueOfAntidilutionRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" name="ChangeInFairValueOfPreferredStockTrancheLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_ChangeInFairValueOfSuccessPaymentsLiabilities" name="ChangeInFairValueOfSuccessPaymentsLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_ChangeInOwnershipDescription" name="ChangeInOwnershipDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_ClinicalAndRegulatoryMilestone" name="ClinicalAndRegulatoryMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_CommonStockIssuedDuringPeriodValueNewIssues" name="CommonStockIssuedDuringPeriodValueNewIssues" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing" name="CommonStockIssuedForFullySatisfyingPreferredStockFinancing" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing" name="CommonStockIssuedForPartlySatisfyingPreferredStockFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_CumulativeProbabilityOfTriggeringEvent" name="CumulativeProbabilityOfTriggeringEvent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_DebtBorrowedAmount" name="DebtBorrowedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_DeferredTaxAssetAccruedExpenses" name="DeferredTaxAssetAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_DeferredTaxAssetsAntidilultionLiability" name="DeferredTaxAssetsAntidilultionLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization" name="DeferredTaxAssetsCapitalizedCostsNetOfAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_DeferredTaxAssetsStockBasedCompensation" name="DeferredTaxAssetsStockBasedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary" name="DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" name="DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary" name="DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_DevelopedBaseMilestonePayments" name="DevelopedBaseMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_DevelopedBaseMilestonePaymentsForStatedPeriod" name="DevelopedBaseMilestonePaymentsForStatedPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent" name="EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_EffectiveIncomeTaxRateReconciliationPermanentItems" name="EffectiveIncomeTaxRateReconciliationPermanentItems" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_FairValueAssumptionOfEquityVolatilityRate" name="FairValueAssumptionOfEquityVolatilityRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_FairValueAssumptionsExpectedTerm1" name="FairValueAssumptionsExpectedTerm1" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_FairValueInputsProbabilityOfTermination" name="FairValueInputsProbabilityOfTermination" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_FairValueOfCommonStockPerShare" name="FairValueOfCommonStockPerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset" name="IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" name="IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="verv_InterestRateForAdditionalImprovementsAllowance" name="InterestRateForAdditionalImprovementsAllowance" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_IssuanceCostsOfCommonStockFromInitialPublicOffering" name="IssuanceCostsOfCommonStockFromInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock" name="IssuanceCostsOfSeriesA2ConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_IssuanceCostsOfSeriesAConvertiblePreferredStock" name="IssuanceCostsOfSeriesAConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_IssuanceCostsOfSeriesBConvertiblePreferredStock" name="IssuanceCostsOfSeriesBConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_IssuanceOfAdditionalCommonStock" name="IssuanceOfAdditionalCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="verv_IssuanceOfPreferredStockTrancheLiability" name="IssuanceOfPreferredStockTrancheLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability" name="IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_LeaseCommencementDate" name="LeaseCommencementDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_LeaseNoncancelableTerm" name="LeaseNoncancelableTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_LesseeOperatingLeaseArea" name="LesseeOperatingLeaseArea" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="verv_LesseeOperatingLeaseIncrementalBorrowingRate" name="LesseeOperatingLeaseIncrementalBorrowingRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_MaturitiesOfMarketableSecurities" name="MaturitiesOfMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_MilestoneRelatedExpenses" name="MilestoneRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_NonRefundableUpfrontLicenseFee" name="NonRefundableUpfrontLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_NonRefundableUpfrontLicenseFees" name="NonRefundableUpfrontLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_NonRefundableUpfrontLicenseFeesPaid" name="NonRefundableUpfrontLicenseFeesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_NonRefundableUpfrontPayment" name="NonRefundableUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_NumberOfInstallmentsForRestrictedSharesVested" name="NumberOfInstallmentsForRestrictedSharesVested" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_OperatingLeaseRelatedExpensesPriorToCommencement" name="OperatingLeaseRelatedExpensesPriorToCommencement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_OptionAndLicenseIssueFees" name="OptionAndLicenseIssueFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_OutOfPocketCostsIncurred" name="OutOfPocketCostsIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_PaymentOfMilestoneDevelopment" name="PaymentOfMilestoneDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_PaymentOfSalesBasedMilestone" name="PaymentOfSalesBasedMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" name="PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset" name="PercentageOfFutureTaxableIncomeUtilizedToOffset" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="verv_PercentageOfTaxBenefitRealized" name="PercentageOfTaxBenefitRealized" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="verv_PercentageSharesOfDevelopmentExpense" name="PercentageSharesOfDevelopmentExpense" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_PreferredStockFinancingFullySatisfied" name="PreferredStockFinancingFullySatisfied" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_PreferredStockFinancingPartiallySatisfied" name="PreferredStockFinancingPartiallySatisfied" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_ProceedFromShareholderLoan" name="ProceedFromShareholderLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross" name="ProceedsFromIssuanceOfCommonStockUnderIPOGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses" name="ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_ProductCollaborationTerminationNoticePeriod" name="ProductCollaborationTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses" name="PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_PublicPrice" name="PublicPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="verv_ReductionInResearchAndDevelopmentExpense" name="ReductionInResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm" name="RemainingContractualMaturitiesOfMarketableSecuritiesTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability" name="ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_SalesBasedMilestone" name="SalesBasedMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock" name="SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_SettlementOfTrancheRightLliability" name="SettlementOfTrancheRightLliability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_ShortTermBorrowingsReducedValue" name="ShortTermBorrowingsReducedValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan" name="StockAvailableForIssuanceUnderEmployeeStockPurchasePlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions" name="StockIssuedDuringPeriodAdditionalShareLicensorInstitutions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" name="StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_StockIssuedDuringPeriodShareLicensorInstitutions" name="StockIssuedDuringPeriodShareLicensorInstitutions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock" name="StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" name="StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee" name="StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock" name="StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_StockIssuedDuringPeriodValueLicensorInstitutions" name="StockIssuedDuringPeriodValueLicensorInstitutions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock" name="StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" name="StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee" name="StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock" name="StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_SuccessLiabilityPayment" name="SuccessLiabilityPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_SuccessOfPaymentLiability" name="SuccessOfPaymentLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_SuccessPaymentLiability" name="SuccessPaymentLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_SuccessPaymentLiabilityCurrent" name="SuccessPaymentLiabilityCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" name="TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_TenantImprovementsAllowance" name="TenantImprovementsAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_AcuitasAgreementsMember" name="AcuitasAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_AntidilutionRightsLiabilityMember" name="AntidilutionRightsLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_AntidilutionRightsMember" name="AntidilutionRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_BeamLicenseAgreementMember" name="BeamLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_BeamMember" name="BeamMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_BroadLicenseAgreementMember" name="BroadLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_CambridgeLeaseMember" name="CambridgeLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_CollaborationAndLicenseAgreementMember" name="CollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_DeliveryTechnologyProductMember" name="DeliveryTechnologyProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_FirstAmendmentMember" name="FirstAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_FourZeroOneKPlanMember" name="FourZeroOneKPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_HarvardAndBoardMember" name="HarvardAndBoardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_HarvardAndBroadLicenseAgreementMember" name="HarvardAndBroadLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_HarvardAndBroadMember" name="HarvardAndBroadMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember" name="HarvardLicenseAgreementAndBroadLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_HarvardLicenseAgreementMember" name="HarvardLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_MassachusettsTaxAuthorityMember" name="MassachusettsTaxAuthorityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_MaterialsExchangeAgreementMember" name="MaterialsExchangeAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_NewAmendmentMember" name="NewAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_OfficeFurnitureMember" name="OfficeFurnitureMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember" name="OptionLicenseAgreementAndPatentLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_OutstandingOptionsToPurchaseCommonStockMember" name="OutstandingOptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_PreferredStockTrancheLiabilityMember" name="PreferredStockTrancheLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_PremisesMember" name="PremisesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_SecondAmendmentMember" name="SecondAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_SecondTrancheMember" name="SecondTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_SeriesA2PreferredStocksMember" name="SeriesA2PreferredStocksMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_SuccessPaymentLiabilityMember" name="SuccessPaymentLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_ThirdTrancheMember" name="ThirdTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_TwentyEighteenMember" name="TwentyEighteenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember" name="TwentyTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_TwoThousandAndTwentyOneStockIncentivePlanMember" name="TwoThousandAndTwentyOneStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_UnvestedRestrictedStockMember" name="UnvestedRestrictedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_UnvestedRestrictedStockUnitsMember" name="UnvestedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_USAgencySecuritiesMember" name="USAgencySecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_USTreasuryBillsAndNotesMember" name="USTreasuryBillsAndNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_VerilyLicenseAgreementMember" name="VerilyLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" name="ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_ConvertiblePreferredStockPolicyTextBlock" name="ConvertiblePreferredStockPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock" name="FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_IndemnificationAgreementsPolicyTextBlock" name="IndemnificationAgreementsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_LicenseAgreementDisclosureTextBlock" name="LicenseAgreementDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_PreferredAndCommonStockTextBlock" name="PreferredAndCommonStockTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_PreferredStockTrancheLiabilityTextBlock" name="PreferredStockTrancheLiabilityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_RentExpensePolicyTextBlock" name="RentExpensePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" name="ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" name="ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_SegmentAndGeographicInformationPolicyTextBlock" name="SegmentAndGeographicInformationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>44
<FILENAME>verv-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-11T19:57:59.5085+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:href="verv-20211231.xsd#StatementConsolidatedBalanceSheets1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails2" xlink:href="verv-20211231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2" xlink:href="verv-20211231.xsd#DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="verv-20211231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="verv-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="verv-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:href="verv-20211231.xsd#Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="verv-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="verv-20211231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails" xlink:href="verv-20211231.xsd#Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails" xlink:href="verv-20211231.xsd#Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails" xlink:href="verv-20211231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="verv_SuccessPaymentLiability" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="verv_AntidilutionRightsLiability" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessPaymentLiability" xlink:label="verv_SuccessPaymentLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AntidilutionRightsLiability" xlink:label="verv_AntidilutionRightsLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="verv_ChangeInFairValueOfAntidilutionRights" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="verv_ChangeInFairValueOfSuccessPaymentsLiabilities" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" xlink:label="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ChangeInFairValueOfAntidilutionRights" xlink:label="verv_ChangeInFairValueOfAntidilutionRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ChangeInFairValueOfSuccessPaymentsLiabilities" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="verv_ProceedFromShareholderLoan" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="verv_MaturitiesOfMarketableSecurities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForLeaseLosses" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="verv_AmortizationOfPremiumOnMarketableSecurities" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromContributedCapital" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="verv_ChangeInFairValueOfAntidilutionRights" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="verv_ChangeInFairValueOfSuccessPaymentsLiabilities" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="verv_SuccessOfPaymentLiability" order="12" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="13" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherDeferredLiability" order="14" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ProceedFromShareholderLoan" xlink:label="verv_ProceedFromShareholderLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_MaturitiesOfMarketableSecurities" xlink:label="verv_MaturitiesOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLeaseLosses" xlink:label="us-gaap_ProvisionForLeaseLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AmortizationOfPremiumOnMarketableSecurities" xlink:label="verv_AmortizationOfPremiumOnMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" xlink:label="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ChangeInFairValueOfAntidilutionRights" xlink:label="verv_ChangeInFairValueOfAntidilutionRights"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ChangeInFairValueOfSuccessPaymentsLiabilities" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessOfPaymentLiability" xlink:label="verv_SuccessOfPaymentLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:label="us-gaap_IncreaseDecreaseInOtherDeferredLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="verv_AccruedExternalResearchAndDevelopmentExpenses" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AccruedExternalResearchAndDevelopmentExpenses" xlink:label="verv_AccruedExternalResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="verv_EffectiveIncomeTaxRateReconciliationPermanentItems" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="verv_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="verv_DeferredTaxAssetsAntidilultionLiability" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="verv_DeferredTaxAssetAccruedExpenses" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization" xlink:label="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DeferredTaxAssetsAntidilultionLiability" xlink:label="verv_DeferredTaxAssetsAntidilultionLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DeferredTaxAssetAccruedExpenses" xlink:label="verv_DeferredTaxAssetAccruedExpenses"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>45
<FILENAME>verv-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-11T19:57:58.6376+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="us-gaap_RepaymentsOfSeniorDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ThirdTrancheMember" xlink:label="verv_ThirdTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PreferredStockFinancingPartiallySatisfied" xlink:label="verv_PreferredStockFinancingPartiallySatisfied"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_NewAmendmentMember" xlink:label="verv_NewAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IssuanceOfPreferredStockTrancheLiability" xlink:label="verv_IssuanceOfPreferredStockTrancheLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OperatingLeaseRelatedExpensesPriorToCommencement" xlink:label="verv_OperatingLeaseRelatedExpensesPriorToCommencement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PreferredAndCommonStockTextBlock" xlink:label="verv_PreferredAndCommonStockTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ReductionInResearchAndDevelopmentExpense" xlink:label="verv_ReductionInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_MassachusettsTaxAuthorityMember" xlink:label="verv_MassachusettsTaxAuthorityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ShortTermBorrowingsReducedValue" xlink:label="verv_ShortTermBorrowingsReducedValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FourZeroOneKPlanMember" xlink:label="verv_FourZeroOneKPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LicenseAgreementAbstract" xlink:label="verv_LicenseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross" xlink:label="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing" xlink:label="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SettlementOfTrancheRightLliability" xlink:label="verv_SettlementOfTrancheRightLliability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardLicenseAgreementMember" xlink:label="verv_HarvardLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_USTreasuryBillsAndNotesMember" xlink:label="verv_USTreasuryBillsAndNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TwentyEighteenMember" xlink:label="verv_TwentyEighteenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SeriesA2PreferredStocksMember" xlink:label="verv_SeriesA2PreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardAndBoardMember" xlink:label="verv_HarvardAndBoardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_NumberOfInstallmentsForRestrictedSharesVested" xlink:label="verv_NumberOfInstallmentsForRestrictedSharesVested"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:label="us-gaap_IncreaseDecreaseInOtherDeferredLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IssuanceCostsOfSeriesAConvertiblePreferredStock" xlink:label="verv_IssuanceCostsOfSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PaymentOfSalesBasedMilestone" xlink:label="verv_PaymentOfSalesBasedMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_USAgencySecuritiesMember" xlink:label="verv_USAgencySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AmortizationOfPremiumOnMarketableSecurities" xlink:label="verv_AmortizationOfPremiumOnMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OptionLicenseAgreementAndPatentLicenseAgreementMember" xlink:label="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:label="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ProceedFromShareholderLoan" xlink:label="verv_ProceedFromShareholderLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_BroadLicenseAgreementMember" xlink:label="verv_BroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SalesBasedMilestone" xlink:label="verv_SalesBasedMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_BeamMember" xlink:label="verv_BeamMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AdditionalLesseeOperatingLeaseArea" xlink:label="verv_AdditionalLesseeOperatingLeaseArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_RentExpensePolicyTextBlock" xlink:label="verv_RentExpensePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PublicPrice" xlink:label="verv_PublicPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ChangeInOwnershipDescription" xlink:label="verv_ChangeInOwnershipDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SecondTrancheMember" xlink:label="verv_SecondTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FairValueAssumptionsExpectedTerm1" xlink:label="verv_FairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LeaseNoncancelableTerm" xlink:label="verv_LeaseNoncancelableTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" xlink:label="verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ChangeInFairValueOfAntidilutionRights" xlink:label="verv_ChangeInFairValueOfAntidilutionRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IssuanceCostsOfCommonStockFromInitialPublicOffering" xlink:label="verv_IssuanceCostsOfCommonStockFromInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LicenseAgreementDisclosureTextBlock" xlink:label="verv_LicenseAgreementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_UnvestedRestrictedStockMember" xlink:label="verv_UnvestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan" xlink:label="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TwentyTwentyOneEmployeeStockPurchasePlanMember" xlink:label="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ClinicalAndRegulatoryMilestone" xlink:label="verv_ClinicalAndRegulatoryMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AntidilutionRightsMember" xlink:label="verv_AntidilutionRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLeaseLosses" xlink:label="us-gaap_ProvisionForLeaseLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent" xlink:label="verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ChangeInFairValueOfSuccessPaymentsLiabilities" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_InterestRateForAdditionalImprovementsAllowance" xlink:label="verv_InterestRateForAdditionalImprovementsAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCommitmentAmount" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability" xlink:label="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DeferredTaxAssetAccruedExpenses" xlink:label="verv_DeferredTaxAssetAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock" xlink:label="verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodShareLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodShareLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PercentageSharesOfDevelopmentExpense" xlink:label="verv_PercentageSharesOfDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardAndBroadLicenseAgreementMember" xlink:label="verv_HarvardAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_MaterialsExchangeAgreementMember" xlink:label="verv_MaterialsExchangeAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PreferredStockTrancheLiabilityTextBlock" xlink:label="verv_PreferredStockTrancheLiabilityTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodValueLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodValueLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AdditionalTenantImprovementsAllowance" xlink:label="verv_AdditionalTenantImprovementsAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardAndBroadMember" xlink:label="verv_HarvardAndBroadMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_MilestoneRelatedExpenses" xlink:label="verv_MilestoneRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ProductCollaborationTerminationNoticePeriod" xlink:label="verv_ProductCollaborationTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DevelopedBaseMilestonePaymentsForStatedPeriod" xlink:label="verv_DevelopedBaseMilestonePaymentsForStatedPeriod"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CollaborationAndLicenseAgreementMember" xlink:label="verv_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OperatingLossCarryforwardsExpirationYear" xlink:label="verv_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LeaseCommencementDate" xlink:label="verv_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AntidilutionRightsLiability" xlink:label="verv_AntidilutionRightsLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SegmentAndGeographicInformationPolicyTextBlock" xlink:label="verv_SegmentAndGeographicInformationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock" xlink:label="verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset" xlink:label="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TenantImprovementsAllowance" xlink:label="verv_TenantImprovementsAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_VerilyLicenseAgreementMember" xlink:label="verv_VerilyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ConvertiblePreferredStockPolicyTextBlock" xlink:label="verv_ConvertiblePreferredStockPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FirstAmendmentMember" xlink:label="verv_FirstAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingGainsLossesAbstract" xlink:label="us-gaap_NonoperatingGainsLossesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm" xlink:label="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="verv_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IssuanceCostsOfSeriesBConvertiblePreferredStock" xlink:label="verv_IssuanceCostsOfSeriesBConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessPaymentLiability" xlink:label="verv_SuccessPaymentLiability"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:label="verv_LesseeOperatingLeaseIncrementalBorrowingRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PreferredStockAbstract" xlink:label="verv_PreferredStockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DeferredTaxAssetsAntidilultionLiability" xlink:label="verv_DeferredTaxAssetsAntidilultionLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses" xlink:label="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_UnvestedRestrictedStockUnitsMember" xlink:label="verv_UnvestedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DeferredTaxAssetsStockBasedCompensation" xlink:label="verv_DeferredTaxAssetsStockBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember" xlink:label="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DevelopedBaseMilestonePayments" xlink:label="verv_DevelopedBaseMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OptionAndLicenseIssueFees" xlink:label="verv_OptionAndLicenseIssueFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_NonRefundableUpfrontLicenseFees" xlink:label="verv_NonRefundableUpfrontLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing" xlink:label="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DeferredOfferingCostsPolicyTextBlock" xlink:label="verv_DeferredOfferingCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PreferredStockTrancheLiabilityMember" xlink:label="verv_PreferredStockTrancheLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AntidilutionRightsLiabilityMember" xlink:label="verv_AntidilutionRightsLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure" xlink:label="us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OutOfPocketCostsIncurred" xlink:label="verv_OutOfPocketCostsIncurred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PercentageOfFutureTaxableIncomeUtilizedToOffset" xlink:label="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CommonStockIssuedDuringPeriodValueNewIssues" xlink:label="verv_CommonStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessPaymentLiabilityCurrent" xlink:label="verv_SuccessPaymentLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CambridgeLeaseMember" xlink:label="verv_CambridgeLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization" xlink:label="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" xlink:label="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PreferredStockFinancingFullySatisfied" xlink:label="verv_PreferredStockFinancingFullySatisfied"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PercentageOfTaxBenefitRealized" xlink:label="verv_PercentageOfTaxBenefitRealized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SummaryOfSignificantAccountingPoliciesTable" xlink:label="verv_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IssuanceOfAdditionalCommonStock" xlink:label="verv_IssuanceOfAdditionalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract" xlink:label="verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_BeamLicenseAgreementMember" xlink:label="verv_BeamLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" xlink:label="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsDate" xlink:label="us-gaap_SubsequentEventsDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OfficeFurnitureMember" xlink:label="verv_OfficeFurnitureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_NonRefundableUpfrontPayment" xlink:label="verv_NonRefundableUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DebtBorrowedAmount" xlink:label="verv_DebtBorrowedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CumulativeProbabilityOfTriggeringEvent" xlink:label="verv_CumulativeProbabilityOfTriggeringEvent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_NonRefundableUpfrontLicenseFee" xlink:label="verv_NonRefundableUpfrontLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LaboratoryEquipmentMember" xlink:label="verv_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AccruedExternalResearchAndDevelopmentExpenses" xlink:label="verv_AccruedExternalResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability" xlink:label="verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock" xlink:label="verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ComputerEquipmentAndSoftwareMember" xlink:label="verv_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LesseeOperatingLeaseArea" xlink:label="verv_LesseeOperatingLeaseArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="verv_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TaxCreditCarryforwardExpirationYear" xlink:label="verv_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="verv_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FairValueOfCommonStockPerShare" xlink:label="verv_FairValueOfCommonStockPerShare"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OutstandingOptionsToPurchaseCommonStockMember" xlink:label="verv_OutstandingOptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FairValueInputsProbabilityOfTermination" xlink:label="verv_FairValueInputsProbabilityOfTermination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DeliveryTechnologyProductMember" xlink:label="verv_DeliveryTechnologyProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_MilestonePayments" xlink:label="verv_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessPaymentLiabilityMember" xlink:label="verv_SuccessPaymentLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SecondAmendmentMember" xlink:label="verv_SecondAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_NonRefundableUpfrontLicenseFeesPaid" xlink:label="verv_NonRefundableUpfrontLicenseFeesPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PremisesMember" xlink:label="verv_PremisesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PaymentOfMilestoneDevelopment" xlink:label="verv_PaymentOfMilestoneDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessLiabilityPayment" xlink:label="verv_SuccessLiabilityPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_MaturitiesOfMarketableSecurities" xlink:label="verv_MaturitiesOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="verv_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AcuitasAgreementsMember" xlink:label="verv_AcuitasAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessOfPaymentLiability" xlink:label="verv_SuccessOfPaymentLiability"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IndemnificationAgreementsPolicyTextBlock" xlink:label="verv_IndemnificationAgreementsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FairValueAssumptionOfEquityVolatilityRate" xlink:label="verv_FairValueAssumptionOfEquityVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets Held For Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfSeniorDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayments of Senior Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfSeniorDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Senior Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfSeniorDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayments of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ThirdTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Third Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ThirdTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third tranche.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ThirdTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ThirdTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third tranche</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forecast</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockFinancingPartiallySatisfied_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock financing partially satisfied</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockFinancingPartiallySatisfied_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Financing Partially Satisfied</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockFinancingPartiallySatisfied_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock financing partially satisfied</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NewAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NewAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NewAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfPreferredStockTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of preferred stock tranche liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfPreferredStockTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Preferred Stock Tranche Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfPreferredStockTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of preferred stock tranche liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OperatingLeaseRelatedExpensesPriorToCommencement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease related expenses prior to commencement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OperatingLeaseRelatedExpensesPriorToCommencement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Related Expenses Prior To Commencement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OperatingLeaseRelatedExpensesPriorToCommencement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease space build out cost prior to commencement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, maximum annual contributions per employee, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from purchase of shares through employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Ownership Plan (ESOP), Cash Contributions to ESOP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredAndCommonStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred and common stock disclosure text block.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredAndCommonStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred And Common Stock [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredAndCommonStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred and Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in common stock capital shares, reserved for future issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in common stock capital shares, reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ReductionInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction In Research And Development Expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ReductionInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reduction In Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ReductionInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction In Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MassachusettsTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Massachusetts Tax Authority [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MassachusettsTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Massachusetts Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MassachusettsTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Massachusetts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ShortTermBorrowingsReducedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short term borrowings reduced value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ShortTermBorrowingsReducedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Borrowings Reduced Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ShortTermBorrowingsReducedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit reduced value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FourZeroOneKPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FourZeroOneKPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Four Zero One (K) Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FourZeroOneKPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">401(k) Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 200,000,000 and 255,000,000 shares authorized, 48,511,735 and 3,123,424 shares issued at December 31, 2021 and 2020, respectively; 48,511,735 and 2,585,789 shares outstanding at December 31, 2021 and 2020, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LicenseAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LicenseAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds From Issuance Of Common Stock Under IPO, Gross.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Under I P O Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from common stock, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Future Minimum Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Commitments under Non-Cancellable Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issued for partly satisfying preferred stock financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued For Partly Satisfying Preferred Stock Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued for partly satisfying preferred stock financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SettlementOfTrancheRightLliability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Settlement of tranche right liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SettlementOfTrancheRightLliability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Settlement Of Tranche Right Lliability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SettlementOfTrancheRightLliability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of tranche right liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Terms [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued upon conversion of preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Harward.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Harvard License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Harvard</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares used in net loss per share attributable to common stockholders, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer Contribution amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation and related benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual life (in years), Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_USTreasuryBillsAndNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. treasury bills and notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_USTreasuryBillsAndNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Bills And Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_USTreasuryBillsAndNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Bills and Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Borrowings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used for Options Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Repurchase Of Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of initial public offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, net of valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net of valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional issuances of common stock to licensor institutions (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Additional Share Licensor Institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of additional common stock to licensor institutions (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S. Treasury Bills and Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Treasury Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (See Note 7 and 8)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TwentyEighteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty eighteen</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TwentyEighteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Eighteen [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TwentyEighteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Twenty Eighteen</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, convertible, conversion ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from initial public offering, net of issuance costs of (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock under ESPP(shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash&#8212;end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash&#8212;beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Immaterial Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SeriesA2PreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-2 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SeriesA2PreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-2 Preferred Stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SeriesA2PreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A2 Preferred Stocks [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock upon closing of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardAndBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Harvard and Board.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardAndBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Harvard And Board [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardAndBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Harvard And Board</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding stock, reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NumberOfInstallmentsForRestrictedSharesVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Installments for Restricted Shares Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NumberOfInstallmentsForRestrictedSharesVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of installments for restricted shares vested.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial Liabilities Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherDeferredLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Deferred Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherDeferredLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Costs of Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Costs Of Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs of series A convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Lease Not Yet Commenced Existence Of Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to extend true/false, lease not yet commenced</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PaymentOfSalesBasedMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of sales based milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PaymentOfSalesBasedMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Sales Based Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PaymentOfSalesBasedMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of sales based milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Price Volatility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_USAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. agency securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_USAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Agency Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_USAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Agency Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AmortizationOfPremiumOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of premium on marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AmortizationOfPremiumOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Premium On Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AmortizationOfPremiumOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of premium on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option License Agreement and Patent License Agreement [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option License Agreement And Patent License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option License Agreement And Patent License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A-2 convertible preferred stock, net of issuance costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Series A2 Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Series A-2 convertible preferred stock, net of issuance costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Regulatory Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProceedFromShareholderLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholder loan given</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProceedFromShareholderLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceed from Shareholder Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProceedFromShareholderLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceed from shareholder loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease obligations, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_BroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Broad License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_BroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Broad License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_BroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Broad License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SalesBasedMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales based milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SalesBasedMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Based Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SalesBasedMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Based Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_BeamMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Beam [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_BeamMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Beam [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_BeamMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beam</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Us [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-US</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AdditionalLesseeOperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Lease Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AdditionalLesseeOperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Lessee Operating Lease Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AdditionalLesseeOperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional Lessee Operating Lease Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Financial Instruments, Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_RentExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policy of rent expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_RentExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rent Expense Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_RentExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PublicPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PublicPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PublicPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, convertible terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInOwnershipDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in ownership, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInOwnershipDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in ownership description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInOwnershipDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Ownership Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SecondTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Second Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SecondTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SecondTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second Tranche Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assumptions expected term 1.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Expected Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LeaseNoncancelableTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease noncancelable term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LeaseNoncancelableTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Noncancelable Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LeaseNoncancelableTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease Noncancelable Term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, Conversion of convertible preferred stock to common stock upon closing of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock upon closing of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S. Agency Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Agencies Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Government Agencies Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets In Process Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfAntidilutionRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of antidilution rights.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfAntidilutionRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Antidilution Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfAntidilutionRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of antidilution rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfAntidilutionRights_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of antidilution rights liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfCommonStockFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Costs Of Common Stock from Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfCommonStockFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Costs Of Common Stock From Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfCommonStockFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs of common stock from initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LicenseAgreementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LicenseAgreementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LicenseAgreementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and oustanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock (See Note 10)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of shareholder loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_UnvestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested Restricted Stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_UnvestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_UnvestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock available for issuance under ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Available For Issuance Under Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Available For Issuance Under Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Liability Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty twenty one employee stock purchase plan member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Twenty One Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer matching contribution, percent of match upto 3% of employee's salary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match Upto Three Percent Of Employee Salary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan, employer matching contribution, percent of match upto 3% of employee's salary.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ClinicalAndRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical and regulatory milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ClinicalAndRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical And Regulatory Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ClinicalAndRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical And Regulatory Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual life (in years), Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense (benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of noncash investing and finnacing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic and Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share attributable to common stockholders, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AntidilutionRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Antidilution rights.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AntidilutionRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilution Rights [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AntidilutionRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilution Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested RSUs, ending balance, Unvested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested RSUs, beginning balance, Unvested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProvisionForLeaseLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Provision For Lease Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProvisionForLeaseLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executive compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Executive compensation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation, Executive compensation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of success payments liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Success Payments Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of success payments liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of success payment liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_InterestRateForAdditionalImprovementsAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest rate for additional improvements allowance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_InterestRateForAdditionalImprovementsAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Rate For Additional Improvements Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_InterestRateForAdditionalImprovementsAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Improvement allowance interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Rent Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term Lease Commitment, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and development expense of antidilution rights liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense of antidilution rights liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross unrealized losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Asset Accrued Expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A-2 convertible preferred stock, net of issuance costs of $112</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Series A2 Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Series A-2 convertible preferred stock, net of issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance costs of series A2 convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Costs Of Series A2 Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs of series A2 convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross unrealized gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodShareLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuances of common stock to licensor institutions (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodShareLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock to licensor institutions (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodShareLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Share Licensor Institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance of Series A Preferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan employer matching contribution percent of match upto two percent of employee salary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent of Match Upto Two Percent of Employee Salary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan employer matching contribution percent of match upto two percent of employee salary.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PercentageSharesOfDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage Shares of Development Expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PercentageSharesOfDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Shares Of Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PercentageSharesOfDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage Shares of Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive (loss) income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of stock options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of options, Outstanding, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of options, Outstanding, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardAndBroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Harvard and Broad license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardAndBroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Harvard And Broad License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardAndBroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Harvard and Board</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MaterialsExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Materials Exchange Agreement [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MaterialsExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Materials Exchange Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MaterialsExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Materials Exchange Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockTrancheLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock tranche liability disclosure text block.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockTrancheLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Tranche Liability [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockTrancheLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Tranche Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuances of common stock to licensor institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Period Value Licensor Institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Licensor Institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering, net of underwriting discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AdditionalTenantImprovementsAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional tenant improvements allowance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AdditionalTenantImprovementsAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Tenant Improvements Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AdditionalTenantImprovementsAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional tenant improvements allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardAndBroadMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Harvard And Broad.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardAndBroadMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Harvard And Broad [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardAndBroadMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments received on shareholder loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Contributed Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due after year four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MilestoneRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone related expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MilestoneRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Related Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MilestoneRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Operating Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive (loss) income:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProductCollaborationTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Product collaboration termination notice period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProductCollaborationTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Collaboration Termination Notice Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProductCollaborationTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product collaboration termination notice period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DevelopedBaseMilestonePaymentsForStatedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Developed base milestone payments for quarterly period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DevelopedBaseMilestonePaymentsForStatedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Developed Base Milestone Payments For Stated Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DevelopedBaseMilestonePaymentsForStatedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Developed base milestone payments for quarterly period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration And License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration And License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A Preferred Stock in payment of licensing fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Series A Preferred Stock In Payment Of Licensing Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Period Value Series A Preferred Stock In Payment Of Licensing Fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease Commencement Date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Expected Term [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AntidilutionRightsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilution rights liability (See Notes 5, 8 and 15)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AntidilutionRightsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Antidilution rights liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AntidilutionRightsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilution Rights Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201602 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASC 842</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, Expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SegmentAndGeographicInformationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policy related to segment and geographic information.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SegmentAndGeographicInformationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment And Geographic Information Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SegmentAndGeographicInformationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment and Geographic Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows related to operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Settlement of Antidilution Rights Liability By Issuing Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Settlement Of Antidilution Rights Liability By Issuing Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of derivative liability by issuing common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase Decrease In Operating Lease Right Of Use Of Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Of Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in Right-Of-Use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TenantImprovementsAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvements allowance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TenantImprovementsAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TenantImprovementsAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvements allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_VerilyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Verily License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_VerilyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Verily License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_VerilyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Verily License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FirstAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First Amendment Member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FirstAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FirstAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Success payment liability, payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Fair Value, Gross Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Fair Value Of Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success payment liability, payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Success payment liability, payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingGainsLossesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingGainsLossesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Gains (Losses) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining contractual maturities of marketable securities term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Contractual Maturities Of Marketable Securities Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining contractual maturities of marketable securities term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Lease Not Yet Commenced Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to extend, lease not yet commenced</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand And Twenty One Stock Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Stock Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Stock Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets valuation allowance increase (decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from initial public offering, net of issuance costs of $25,098</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfSeriesBConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Costs Of Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfSeriesBConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Costs Of Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfSeriesBConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs of series B convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Basic [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reconciliation of cash, cash equivalents and restricted cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation Of Cash Cash Equivalents And Restricted Cash Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value Liabilities Measured on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success payment liability (See Notes 5, 8 and 15)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success payment liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Payment Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LesseeOperatingLeaseIncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease incremental borrowing rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LesseeOperatingLeaseIncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Incremental Borrowing Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LesseeOperatingLeaseIncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease incremental borrowing rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock abstract.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsAntidilultionLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Antidilultion Liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsAntidilultionLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Antidilultion Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsAntidilultionLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilultion liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of preferred stock tranche liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Preferred Stock And Preference Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Preferred Stock, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Preferred Stock, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Preferred Stock after Deducting Underwriting Discounts and Offering Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from Issuance of Preferred Stock after Deducting Underwriting Discounts and Offering Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value Per Share, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, convertible preferred stock, and stockholders&#8217; equity (deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsStockBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsStockBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsStockBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets, Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Harvard/Broad License Agreement and Broad License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Harvard License Agreement And Broad License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Harvard License Agreement And Broad License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Series B convertible preferred stock, net of issuance costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B convertible preferred stock, net of issuance costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DevelopedBaseMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Developed base milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DevelopedBaseMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Developed Base Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DevelopedBaseMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Developed base milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OptionAndLicenseIssueFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option And License Issue Fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OptionAndLicenseIssueFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option And License Issue Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OptionAndLicenseIssueFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option And License Issue Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, convertible, conversion price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Conversion Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Refundable Upfront License Fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront License Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Refundable Upfront License Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Status and Change in Unvested Restricted Stock and Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property, Plant and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issued for fully satisfying preferred stock financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued For Fully Satisfying Preferred Stock Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued for fully satisfying preferred stock financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of property and equipment estimated useful life.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property And Equipment Estimated Useful Life Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment Estimated Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Series B convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B convertible preferred stock, net of issuance costs of $241</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other expense, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockTrancheLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock tranche liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockTrancheLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Tranche Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockTrancheLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Tranche Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Increase Accrued Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and unpaid interest paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant-Date Fair Value, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AntidilutionRightsLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Antidilution rights liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AntidilutionRightsLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilution Rights Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AntidilutionRightsLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilution Rights Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Mandatorily Redeemable Preferred Stock Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic By Common Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Earnings Per Share Basic By Common Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OutOfPocketCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">out-of-pocket costs incurred.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OutOfPocketCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Out Of Pocket Costs Incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OutOfPocketCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Out-of-pocket costs incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of future taxable income utilized to offset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of future taxable income utilized to offset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Lease Not Yet Commenced Variable Lease Payment Terms And Conditions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease payment term, lease not yet commenced, terms and conditions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Officer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Changes in Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success Payment Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Payment Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success payment, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A Preferred Stock in payment of licensing fee (shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Series A Preferred Stock In Payment of Licensing Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Period Shares Series A Preferred Stock In Payment of Licensing Fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash research and development license expense in operating activity in cash flow</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CambridgeLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cambridge lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CambridgeLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cambridge Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CambridgeLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cambridge Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Capitalized Costs Net Of Amortization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Costs Net Of Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized costs&#8212;net of amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer matching contribution, percent of match after 3% and before 5% of employee's salary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match After Three Percent And Before Five Percent Of Employee Salary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan, employer matching contribution, percent of match after 3% and before 5% of employee's salary.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and equipment additions included in accounts payable and accrued expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property And Equipment Additions Included In Accounts Payable And Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment additions included in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual life (in years), Expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Purchase Commitment By Category Of Item Purchased [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Category of Item Purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment received for license agreement reimbursement of costs incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Received For License Agreement Reimbursement Of Costs Incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursement received related to reduction to research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockFinancingFullySatisfied_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock financing fully satisfied</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockFinancingFullySatisfied_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Financing Fully Satisfied</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockFinancingFullySatisfied_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock financing were fully satisfied</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PercentageOfTaxBenefitRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of tax benefit realized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PercentageOfTaxBenefitRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of tax benefit realized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of RSUs, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Purchase Commitment Category Of Item Purchased [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Purchase Commitment, Category of Item Purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A convertible preferred stock and settlement of tranche right liability, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares series a convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value of stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfAdditionalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Additional Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfAdditionalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of additional common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for amounts included in the measurements of lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Amounts Included In The Measurements Of Lease Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_BeamLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Beam license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_BeamLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Beam License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_BeamLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beam License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of preferred stock tranche liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Preferred Stock Tranche Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of preferred stock tranche liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of preferred stock tranche liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent event, date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event, Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OfficeFurnitureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office furniture.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OfficeFurnitureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Furniture [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OfficeFurnitureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Furniture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cumulative dividends payable per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Payable Amount Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non refundable upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average period over which unrecognized compensation is expected to be recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DebtBorrowedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt borrowed amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DebtBorrowedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Borrowed Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DebtBorrowedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowed amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CumulativeProbabilityOfTriggeringEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative probability of triggering event.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CumulativeProbabilityOfTriggeringEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Probability Of Triggering Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CumulativeProbabilityOfTriggeringEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative probability of triggering event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs on issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non refundable upfront license fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront License Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Refundable Upfront License Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AccruedExternalResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued external research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AccruedExternalResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued External Research And Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AccruedExternalResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued external research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A convertible preferred stock and settlement of tranche right liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Series A Convertible Preferred Stock and Settlement of Tranche Right Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Series A convertible preferred stock and settlement of tranche right liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Grant Date Fair Value Per Share, ending balance, Unvested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Grant Date Fair Value Per Share, beginning balance, Unvested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A convertible preferred stock and settlement of tranche right liability, net of issuance costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Series A convertible preferred stock, net of issuance costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Freestanding financial instruments and derivatives.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Freestanding Financial Instruments And Derivatives Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Freestanding Financial Instruments and Derivatives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional issuances of common stock to licensor institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Additional Shares Value Licensor Institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of additional shares issued to licensor institutuons.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer equipment and software.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment And Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment and Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LesseeOperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease area.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LesseeOperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LesseeOperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From License Fees Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax liabilities, Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax liabilities, Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other permanent items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation Permanent Items.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter Of Credit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueOfCommonStockPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of common stock per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueOfCommonStockPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Common Stock Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueOfCommonStockPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock (per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OutstandingOptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding Options to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OutstandingOptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding Options To Purchase Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OutstandingOptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options To Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueInputsProbabilityOfTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value inputs probability of termination.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueInputsProbabilityOfTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Probability Of Termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueInputsProbabilityOfTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value inputs probability of termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeliveryTechnologyProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Delivery Technology Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeliveryTechnologyProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Delivery Technology Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeliveryTechnologyProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Delivery Technology Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employers matching contribution, annual vesting percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success payment liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Payment Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success Payment Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Servicing Liability at Fair Value, Other Changes in Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unvested Restricted stock vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Due to Related Parties, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Current And Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount due as a result of termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second Amendment Member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontLicenseFeesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable upfront license fees paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontLicenseFeesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront License Fees Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontLicenseFeesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable upfront license fees paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equtiy (deficit):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PremisesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Premises.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PremisesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Premises [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PremisesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Premises</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of the Business and Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Or Sale Of Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance or sale of preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PaymentOfMilestoneDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of milestone development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PaymentOfMilestoneDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Milestone Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PaymentOfMilestoneDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of milestone development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Computation of Basic and Diluted net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessLiabilityPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Liability Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessLiabilityPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success Liability Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MaturitiesOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maturities of marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MaturitiesOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturities Of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MaturitiesOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success payment liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Success payment liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock, price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, convertible preferred stock, and stockholders' equity (deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental cash flow information related to operating leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Supplemental Cash Flow Information Related To Operating Leases Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Cash Flow Information Related to Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock under ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted and Issued Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Lease Not Yet Commenced Existence Of Option To Terminate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to terminate, lease not yet commenced</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease not yet commenced, lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AcuitasAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acuitas agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AcuitasAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acuitas Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AcuitasAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acuitas Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized (loss) gain on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessOfPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success of payment liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessOfPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success of payment liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IndemnificationAgreementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Indemnification agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IndemnificationAgreementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indemnification Agreements Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IndemnificationAgreementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indemnification Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueAssumptionOfEquityVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assumption of equity volatility rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueAssumptionOfEquityVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumption Of Equity Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueAssumptionOfEquityVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure - Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfSeniorDebt" xlink:to="us-gaap_RepaymentsOfSeniorDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ThirdTrancheMember" xlink:to="verv_ThirdTrancheMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PreferredStockFinancingPartiallySatisfied" xlink:to="verv_PreferredStockFinancingPartiallySatisfied_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_NewAmendmentMember" xlink:to="verv_NewAmendmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IssuanceOfPreferredStockTrancheLiability" xlink:to="verv_IssuanceOfPreferredStockTrancheLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_OperatingLeaseRelatedExpensesPriorToCommencement" xlink:to="verv_OperatingLeaseRelatedExpensesPriorToCommencement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PreferredAndCommonStockTextBlock" xlink:to="verv_PreferredAndCommonStockTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:to="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ReductionInResearchAndDevelopmentExpense" xlink:to="verv_ReductionInResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_MassachusettsTaxAuthorityMember" xlink:to="verv_MassachusettsTaxAuthorityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ShortTermBorrowingsReducedValue" xlink:to="verv_ShortTermBorrowingsReducedValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_FourZeroOneKPlanMember" xlink:to="verv_FourZeroOneKPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_LicenseAgreementAbstract" xlink:to="verv_LicenseAgreementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross" xlink:to="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing" xlink:to="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SettlementOfTrancheRightLliability" xlink:to="verv_SettlementOfTrancheRightLliability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_HarvardLicenseAgreementMember" xlink:to="verv_HarvardLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_USTreasuryBillsAndNotesMember" xlink:to="verv_USTreasuryBillsAndNotesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions" xlink:to="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_TwentyEighteenMember" xlink:to="verv_TwentyEighteenMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SeriesA2PreferredStocksMember" xlink:to="verv_SeriesA2PreferredStocksMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_HarvardAndBoardMember" xlink:to="verv_HarvardAndBoardMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_NumberOfInstallmentsForRestrictedSharesVested" xlink:to="verv_NumberOfInstallmentsForRestrictedSharesVested_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:to="us-gaap_IncreaseDecreaseInOtherDeferredLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IssuanceCostsOfSeriesAConvertiblePreferredStock" xlink:to="verv_IssuanceCostsOfSeriesAConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PaymentOfSalesBasedMilestone" xlink:to="verv_PaymentOfSalesBasedMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_USAgencySecuritiesMember" xlink:to="verv_USAgencySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AmortizationOfPremiumOnMarketableSecurities" xlink:to="verv_AmortizationOfPremiumOnMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember" xlink:to="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:to="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenseMember" xlink:to="us-gaap_OtherExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ProceedFromShareholderLoan" xlink:to="verv_ProceedFromShareholderLoan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_BroadLicenseAgreementMember" xlink:to="verv_BroadLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SalesBasedMilestone" xlink:to="verv_SalesBasedMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_BeamMember" xlink:to="verv_BeamMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AdditionalLesseeOperatingLeaseArea" xlink:to="verv_AdditionalLesseeOperatingLeaseArea_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_RentExpensePolicyTextBlock" xlink:to="verv_RentExpensePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PublicPrice" xlink:to="verv_PublicPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ChangeInOwnershipDescription" xlink:to="verv_ChangeInOwnershipDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SecondTrancheMember" xlink:to="verv_SecondTrancheMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_FairValueAssumptionsExpectedTerm1" xlink:to="verv_FairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_LeaseNoncancelableTerm" xlink:to="verv_LeaseNoncancelableTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" xlink:to="verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ChangeInFairValueOfAntidilutionRights" xlink:to="verv_ChangeInFairValueOfAntidilutionRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IssuanceCostsOfCommonStockFromInitialPublicOffering" xlink:to="verv_IssuanceCostsOfCommonStockFromInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_LicenseAgreementDisclosureTextBlock" xlink:to="verv_LicenseAgreementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_UnvestedRestrictedStockMember" xlink:to="verv_UnvestedRestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan" xlink:to="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember" xlink:to="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" xlink:to="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ClinicalAndRegulatoryMilestone" xlink:to="verv_ClinicalAndRegulatoryMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AntidilutionRightsMember" xlink:to="verv_AntidilutionRightsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForLeaseLosses" xlink:to="us-gaap_ProvisionForLeaseLosses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent" xlink:to="verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ChangeInFairValueOfSuccessPaymentsLiabilities" xlink:to="verv_ChangeInFairValueOfSuccessPaymentsLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_InterestRateForAdditionalImprovementsAllowance" xlink:to="verv_InterestRateForAdditionalImprovementsAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCommitmentAmount" xlink:to="us-gaap_ShortTermLeaseCommitmentAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability" xlink:to="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DeferredTaxAssetAccruedExpenses" xlink:to="verv_DeferredTaxAssetAccruedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock" xlink:to="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock" xlink:to="verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodShareLicensorInstitutions" xlink:to="verv_StockIssuedDuringPeriodShareLicensorInstitutions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary" xlink:to="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PercentageSharesOfDevelopmentExpense" xlink:to="verv_PercentageSharesOfDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_HarvardAndBroadLicenseAgreementMember" xlink:to="verv_HarvardAndBroadLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="us-gaap_EarningsPerShareReconciliationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_MaterialsExchangeAgreementMember" xlink:to="verv_MaterialsExchangeAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PreferredStockTrancheLiabilityTextBlock" xlink:to="verv_PreferredStockTrancheLiabilityTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodValueLicensorInstitutions" xlink:to="verv_StockIssuedDuringPeriodValueLicensorInstitutions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AdditionalTenantImprovementsAllowance" xlink:to="verv_AdditionalTenantImprovementsAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_HarvardAndBroadMember" xlink:to="verv_HarvardAndBroadMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributedCapital" xlink:to="us-gaap_ProceedsFromContributedCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_MilestoneRelatedExpenses" xlink:to="verv_MilestoneRelatedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ProductCollaborationTerminationNoticePeriod" xlink:to="verv_ProductCollaborationTerminationNoticePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DevelopedBaseMilestonePaymentsForStatedPeriod" xlink:to="verv_DevelopedBaseMilestonePaymentsForStatedPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CollaborationAndLicenseAgreementMember" xlink:to="verv_CollaborationAndLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_OperatingLossCarryforwardsExpirationYear" xlink:to="verv_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee" xlink:to="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_LeaseCommencementDate" xlink:to="verv_LeaseCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AntidilutionRightsLiability" xlink:to="verv_AntidilutionRightsLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SegmentAndGeographicInformationPolicyTextBlock" xlink:to="verv_SegmentAndGeographicInformationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock" xlink:to="verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset" xlink:to="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_TenantImprovementsAllowance" xlink:to="verv_TenantImprovementsAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_VerilyLicenseAgreementMember" xlink:to="verv_VerilyLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ConvertiblePreferredStockPolicyTextBlock" xlink:to="verv_ConvertiblePreferredStockPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_FirstAmendmentMember" xlink:to="verv_FirstAmendmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingGainsLossesAbstract" xlink:to="us-gaap_NonoperatingGainsLossesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm" xlink:to="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:to="verv_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IssuanceCostsOfSeriesBConvertiblePreferredStock" xlink:to="verv_IssuanceCostsOfSeriesBConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SuccessPaymentLiability" xlink:to="verv_SuccessPaymentLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:to="verv_LesseeOperatingLeaseIncrementalBorrowingRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PreferredStockAbstract" xlink:to="verv_PreferredStockAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DeferredTaxAssetsAntidilultionLiability" xlink:to="verv_DeferredTaxAssetsAntidilultionLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses" xlink:to="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_UnvestedRestrictedStockUnitsMember" xlink:to="verv_UnvestedRestrictedStockUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DeferredTaxAssetsStockBasedCompensation" xlink:to="verv_DeferredTaxAssetsStockBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember" xlink:to="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DevelopedBaseMilestonePayments" xlink:to="verv_DevelopedBaseMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_OptionAndLicenseIssueFees" xlink:to="verv_OptionAndLicenseIssueFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_NonRefundableUpfrontLicenseFees" xlink:to="verv_NonRefundableUpfrontLicenseFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing" xlink:to="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock" xlink:to="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DeferredOfferingCostsPolicyTextBlock" xlink:to="verv_DeferredOfferingCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PreferredStockTrancheLiabilityMember" xlink:to="verv_PreferredStockTrancheLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AntidilutionRightsLiabilityMember" xlink:to="verv_AntidilutionRightsLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure" xlink:to="us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_OutOfPocketCostsIncurred" xlink:to="verv_OutOfPocketCostsIncurred_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset" xlink:to="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CommonStockIssuedDuringPeriodValueNewIssues" xlink:to="verv_CommonStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SuccessPaymentLiabilityCurrent" xlink:to="verv_SuccessPaymentLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CambridgeLeaseMember" xlink:to="verv_CambridgeLeaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization" xlink:to="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary" xlink:to="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" xlink:to="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PreferredStockFinancingFullySatisfied" xlink:to="verv_PreferredStockFinancingFullySatisfied_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PercentageOfTaxBenefitRealized" xlink:to="verv_PercentageOfTaxBenefitRealized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SummaryOfSignificantAccountingPoliciesTable" xlink:to="verv_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" xlink:to="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IssuanceOfAdditionalCommonStock" xlink:to="verv_IssuanceOfAdditionalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract" xlink:to="verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_BeamLicenseAgreementMember" xlink:to="verv_BeamLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" xlink:to="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsDate" xlink:to="us-gaap_SubsequentEventsDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_OfficeFurnitureMember" xlink:to="verv_OfficeFurnitureMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableAmountPerShare" xlink:to="us-gaap_DividendsPayableAmountPerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_NonRefundableUpfrontPayment" xlink:to="verv_NonRefundableUpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DebtBorrowedAmount" xlink:to="verv_DebtBorrowedAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CumulativeProbabilityOfTriggeringEvent" xlink:to="verv_CumulativeProbabilityOfTriggeringEvent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_NonRefundableUpfrontLicenseFee" xlink:to="verv_NonRefundableUpfrontLicenseFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_LaboratoryEquipmentMember" xlink:to="verv_LaboratoryEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AccruedExternalResearchAndDevelopmentExpenses" xlink:to="verv_AccruedExternalResearchAndDevelopmentExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability" xlink:to="verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock" xlink:to="verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" xlink:to="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ComputerEquipmentAndSoftwareMember" xlink:to="verv_ComputerEquipmentAndSoftwareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_LesseeOperatingLeaseArea" xlink:to="verv_LesseeOperatingLeaseArea_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="verv_DeferredTaxLiabilitiesRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_TaxCreditCarryforwardExpirationYear" xlink:to="verv_TaxCreditCarryforwardExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="verv_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_FairValueOfCommonStockPerShare" xlink:to="verv_FairValueOfCommonStockPerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_OutstandingOptionsToPurchaseCommonStockMember" xlink:to="verv_OutstandingOptionsToPurchaseCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_FairValueInputsProbabilityOfTermination" xlink:to="verv_FairValueInputsProbabilityOfTermination_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DeliveryTechnologyProductMember" xlink:to="verv_DeliveryTechnologyProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_MilestonePayments" xlink:to="verv_MilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SuccessPaymentLiabilityMember" xlink:to="verv_SuccessPaymentLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:to="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SecondAmendmentMember" xlink:to="verv_SecondAmendmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_NonRefundableUpfrontLicenseFeesPaid" xlink:to="verv_NonRefundableUpfrontLicenseFeesPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PremisesMember" xlink:to="verv_PremisesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PaymentOfMilestoneDevelopment" xlink:to="verv_PaymentOfMilestoneDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SuccessLiabilityPayment" xlink:to="verv_SuccessLiabilityPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_MaturitiesOfMarketableSecurities" xlink:to="verv_MaturitiesOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="verv_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AcuitasAgreementsMember" xlink:to="verv_AcuitasAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SuccessOfPaymentLiability" xlink:to="verv_SuccessOfPaymentLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IndemnificationAgreementsPolicyTextBlock" xlink:to="verv_IndemnificationAgreementsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_FairValueAssumptionOfEquityVolatilityRate" xlink:to="verv_FairValueAssumptionOfEquityVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>46
<FILENAME>verv-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-11T19:57:59.3169+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:href="verv-20211231.xsd#StatementConsolidatedBalanceSheets1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="verv-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:href="verv-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:href="verv-20211231.xsd#Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="verv-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails" xlink:href="verv-20211231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="verv-20211231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" xlink:href="verv-20211231.xsd#Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="verv-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails" xlink:href="verv-20211231.xsd#DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="verv-20211231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:href="verv-20211231.xsd#DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessPaymentLiability" xlink:label="verv_SuccessPaymentLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AntidilutionRightsLiability" xlink:label="verv_AntidilutionRightsLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="verv_SuccessPaymentLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="verv_AntidilutionRightsLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodValueLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodValueLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodShareLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodShareLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueLicensorInstitutions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodShareLicensorInstitutions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="verv_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SummaryOfSignificantAccountingPoliciesTable" xlink:label="verv_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardAndBroadLicenseAgreementMember" xlink:label="verv_HarvardAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PercentageOfTaxBenefitRealized" xlink:label="verv_PercentageOfTaxBenefitRealized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IssuanceOfAdditionalCommonStock" xlink:label="verv_IssuanceOfAdditionalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessLiabilityPayment" xlink:label="verv_SuccessLiabilityPayment"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="verv_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="verv_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardAndBroadLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="verv_PercentageOfTaxBenefitRealized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="verv_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="verv_IssuanceOfAdditionalCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="verv_SuccessLiabilityPayment" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ComputerEquipmentAndSoftwareMember" xlink:label="verv_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OfficeFurnitureMember" xlink:label="verv_OfficeFurnitureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LaboratoryEquipmentMember" xlink:label="verv_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_ComputerEquipmentAndSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_OfficeFurnitureMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_LaboratoryEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm" xlink:label="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessPaymentLiabilityMember" xlink:label="verv_SuccessPaymentLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AntidilutionRightsLiabilityMember" xlink:label="verv_AntidilutionRightsLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_USTreasuryBillsAndNotesMember" xlink:label="verv_USTreasuryBillsAndNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_USAgencySecuritiesMember" xlink:label="verv_USAgencySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_SuccessPaymentLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_AntidilutionRightsLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="verv_USTreasuryBillsAndNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="verv_USAgencySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AntidilutionRightsLiabilityMember" xlink:label="verv_AntidilutionRightsLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardAndBroadLicenseAgreementMember" xlink:label="verv_HarvardAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PreferredStockTrancheLiabilityMember" xlink:label="verv_PreferredStockTrancheLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardLicenseAgreementMember" xlink:label="verv_HarvardLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_BroadLicenseAgreementMember" xlink:label="verv_BroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability" xlink:label="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessPaymentLiabilityCurrent" xlink:label="verv_SuccessPaymentLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FairValueInputsProbabilityOfTermination" xlink:label="verv_FairValueInputsProbabilityOfTermination"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_AntidilutionRightsLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardAndBroadLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_PreferredStockTrancheLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_BroadLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_SuccessPaymentLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_FairValueInputsProbabilityOfTermination" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FairValueOfCommonStockPerShare" xlink:label="verv_FairValueOfCommonStockPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FairValueAssumptionOfEquityVolatilityRate" xlink:label="verv_FairValueAssumptionOfEquityVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CumulativeProbabilityOfTriggeringEvent" xlink:label="verv_CumulativeProbabilityOfTriggeringEvent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FairValueAssumptionsExpectedTerm1" xlink:label="verv_FairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_FairValueOfCommonStockPerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_FairValueAssumptionOfEquityVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_CumulativeProbabilityOfTriggeringEvent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_FairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PreferredStockTrancheLiabilityMember" xlink:label="verv_PreferredStockTrancheLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AntidilutionRightsLiabilityMember" xlink:label="verv_AntidilutionRightsLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CommonStockIssuedDuringPeriodValueNewIssues" xlink:label="verv_CommonStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessPaymentLiabilityMember" xlink:label="verv_SuccessPaymentLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_PreferredStockTrancheLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_AntidilutionRightsLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="verv_CommonStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_SuccessPaymentLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CambridgeLeaseMember" xlink:label="verv_CambridgeLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FirstAmendmentMember" xlink:label="verv_FirstAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LesseeOperatingLeaseArea" xlink:label="verv_LesseeOperatingLeaseArea"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AdditionalLesseeOperatingLeaseArea" xlink:label="verv_AdditionalLesseeOperatingLeaseArea"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SecondAmendmentMember" xlink:label="verv_SecondAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PremisesMember" xlink:label="verv_PremisesMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_NewAmendmentMember" xlink:label="verv_NewAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LeaseCommencementDate" xlink:label="verv_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LeaseNoncancelableTerm" xlink:label="verv_LeaseNoncancelableTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset" xlink:label="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:label="verv_LesseeOperatingLeaseIncrementalBorrowingRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TenantImprovementsAllowance" xlink:label="verv_TenantImprovementsAllowance"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AdditionalTenantImprovementsAllowance" xlink:label="verv_AdditionalTenantImprovementsAllowance"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_InterestRateForAdditionalImprovementsAllowance" xlink:label="verv_InterestRateForAdditionalImprovementsAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ShortTermBorrowingsReducedValue" xlink:label="verv_ShortTermBorrowingsReducedValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OperatingLeaseRelatedExpensesPriorToCommencement" xlink:label="verv_OperatingLeaseRelatedExpensesPriorToCommencement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_CambridgeLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="verv_FirstAmendmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_LesseeOperatingLeaseArea" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_AdditionalLesseeOperatingLeaseArea" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="verv_SecondAmendmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_PremisesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="verv_NewAmendmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_LeaseCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_LeaseNoncancelableTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_LesseeOperatingLeaseIncrementalBorrowingRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_TenantImprovementsAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_AdditionalTenantImprovementsAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_InterestRateForAdditionalImprovementsAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_ShortTermBorrowingsReducedValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PrepaidRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_OperatingLeaseRelatedExpensesPriorToCommencement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_BroadLicenseAgreementMember" xlink:label="verv_BroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DeliveryTechnologyProductMember" xlink:label="verv_DeliveryTechnologyProductMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_NonRefundableUpfrontLicenseFeesPaid" xlink:label="verv_NonRefundableUpfrontLicenseFeesPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AntidilutionRightsMember" xlink:label="verv_AntidilutionRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardAndBroadLicenseAgreementMember" xlink:label="verv_HarvardAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_VerilyLicenseAgreementMember" xlink:label="verv_VerilyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_BeamLicenseAgreementMember" xlink:label="verv_BeamLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PreferredStockFinancingPartiallySatisfied" xlink:label="verv_PreferredStockFinancingPartiallySatisfied"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AcuitasAgreementsMember" xlink:label="verv_AcuitasAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PreferredStockFinancingFullySatisfied" xlink:label="verv_PreferredStockFinancingFullySatisfied"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing" xlink:label="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing" xlink:label="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PaymentOfMilestoneDevelopment" xlink:label="verv_PaymentOfMilestoneDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PaymentOfSalesBasedMilestone" xlink:label="verv_PaymentOfSalesBasedMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure" xlink:label="us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DevelopedBaseMilestonePayments" xlink:label="verv_DevelopedBaseMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DevelopedBaseMilestonePaymentsForStatedPeriod" xlink:label="verv_DevelopedBaseMilestonePaymentsForStatedPeriod"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_MilestonePayments" xlink:label="verv_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PercentageSharesOfDevelopmentExpense" xlink:label="verv_PercentageSharesOfDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ProductCollaborationTerminationNoticePeriod" xlink:label="verv_ProductCollaborationTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_MilestoneRelatedExpenses" xlink:label="verv_MilestoneRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" xlink:label="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_NonRefundableUpfrontLicenseFee" xlink:label="verv_NonRefundableUpfrontLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ClinicalAndRegulatoryMilestone" xlink:label="verv_ClinicalAndRegulatoryMilestone"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SalesBasedMilestone" xlink:label="verv_SalesBasedMilestone"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_NonRefundableUpfrontPayment" xlink:label="verv_NonRefundableUpfrontPayment"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_BroadLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="verv_DeliveryTechnologyProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_NonRefundableUpfrontLicenseFeesPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="verv_AntidilutionRightsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardAndBroadLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_VerilyLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_BeamLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PreferredStockFinancingPartiallySatisfied" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_AcuitasAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PreferredStockFinancingFullySatisfied" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PaymentOfMilestoneDevelopment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PaymentOfSalesBasedMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_DevelopedBaseMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_DevelopedBaseMilestonePaymentsForStatedPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_MilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PercentageSharesOfDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_ProductCollaborationTerminationNoticePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_MilestoneRelatedExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_NonRefundableUpfrontLicenseFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_ClinicalAndRegulatoryMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_SalesBasedMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_NonRefundableUpfrontPayment" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SecondTrancheMember" xlink:label="verv_SecondTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ThirdTrancheMember" xlink:label="verv_ThirdTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="verv_SecondTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="verv_ThirdTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardAndBoardMember" xlink:label="verv_HarvardAndBoardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_VerilyLicenseAgreementMember" xlink:label="verv_VerilyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardAndBroadMember" xlink:label="verv_HarvardAndBroadMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SeriesA2PreferredStocksMember" xlink:label="verv_SeriesA2PreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses" xlink:label="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PublicPrice" xlink:label="verv_PublicPrice"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross" xlink:label="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="verv_HarvardAndBoardMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_VerilyLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="verv_HarvardAndBroadMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="verv_SeriesA2PreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="verv_PublicPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DividendsPayableAmountPerShare" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TwentyEighteenMember" xlink:label="verv_TwentyEighteenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="verv_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TwentyTwentyOneEmployeeStockPurchasePlanMember" xlink:label="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan" xlink:label="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_NumberOfInstallmentsForRestrictedSharesVested" xlink:label="verv_NumberOfInstallmentsForRestrictedSharesVested"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="verv_TwentyEighteenMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="verv_TwoThousandAndTwentyOneStockIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="verv_NumberOfInstallmentsForRestrictedSharesVested" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="verv_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="verv_TwoThousandAndTwentyOneStockIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_UnvestedRestrictedStockMember" xlink:label="verv_UnvestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_UnvestedRestrictedStockUnitsMember" xlink:label="verv_UnvestedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OutstandingOptionsToPurchaseCommonStockMember" xlink:label="verv_OutstandingOptionsToPurchaseCommonStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="verv_UnvestedRestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="verv_UnvestedRestrictedStockUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="verv_OutstandingOptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardAndBoardMember" xlink:label="verv_HarvardAndBoardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessPaymentLiability" xlink:label="verv_SuccessPaymentLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="verv_HarvardAndBoardMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="verv_SuccessPaymentLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PercentageOfFutureTaxableIncomeUtilizedToOffset" xlink:label="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_MassachusettsTaxAuthorityMember" xlink:label="verv_MassachusettsTaxAuthorityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ChangeInOwnershipDescription" xlink:label="verv_ChangeInOwnershipDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OperatingLossCarryforwardsExpirationYear" xlink:label="verv_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TaxCreditCarryforwardExpirationYear" xlink:label="verv_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="verv_MassachusettsTaxAuthorityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="verv_ChangeInOwnershipDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="verv_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="verv_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SecondTrancheMember" xlink:label="verv_SecondTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_BeamMember" xlink:label="verv_BeamMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CollaborationAndLicenseAgreementMember" xlink:label="verv_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ThirdTrancheMember" xlink:label="verv_ThirdTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_MaterialsExchangeAgreementMember" xlink:label="verv_MaterialsExchangeAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OptionLicenseAgreementAndPatentLicenseAgreementMember" xlink:label="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember" xlink:label="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OutOfPocketCostsIncurred" xlink:label="verv_OutOfPocketCostsIncurred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ReductionInResearchAndDevelopmentExpense" xlink:label="verv_ReductionInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OptionAndLicenseIssueFees" xlink:label="verv_OptionAndLicenseIssueFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_NonRefundableUpfrontLicenseFees" xlink:label="verv_NonRefundableUpfrontLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCommitmentAmount" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DebtBorrowedAmount" xlink:label="verv_DebtBorrowedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="verv_SecondTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="verv_BeamMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_CollaborationAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_OfficerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="verv_ThirdTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_MaterialsExchangeAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsForRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_OutOfPocketCostsIncurred" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_ReductionInResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_OptionAndLicenseIssueFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_NonRefundableUpfrontLicenseFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermLeaseCommitmentAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_DebtBorrowedAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfSeniorDebt" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FourZeroOneKPlanMember" xlink:label="verv_FourZeroOneKPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="verv_FourZeroOneKPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RetirementPlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>47
<FILENAME>verv-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-11T19:57:59.1599+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="verv-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:href="verv-20211231.xsd#StatementConsolidatedBalanceSheets1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="verv-20211231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="verv-20211231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="verv-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="verv-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="verv-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentation" xlink:href="verv-20211231.xsd#DisclosureNatureOfTheBusinessAndBasisOfPresentation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="verv-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecurities" xlink:href="verv-20211231.xsd#Role_DisclosureMarketableSecurities" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="verv-20211231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" xlink:href="verv-20211231.xsd#Role_DisclosureFairValueOfFinancialInstruments" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:href="verv-20211231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeases" xlink:href="verv-20211231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreements" xlink:href="verv-20211231.xsd#Role_DisclosureLicenseAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosurePreferredStockTrancheLiability1" xlink:href="verv-20211231.xsd#DisclosurePreferredStockTrancheLiability1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStock" xlink:href="verv-20211231.xsd#Role_DisclosurePreferredAndCommonStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="verv-20211231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:href="verv-20211231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="verv-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="verv-20211231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlans1" xlink:href="verv-20211231.xsd#DisclosureEmployeeBenefitPlans1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="verv-20211231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="verv-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="verv-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:href="verv-20211231.xsd#DisclosureMarketableSecuritiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTable" xlink:href="verv-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetTable" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:href="verv-20211231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:href="verv-20211231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="verv-20211231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="verv-20211231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:href="verv-20211231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="verv-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="verv-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:href="verv-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:href="verv-20211231.xsd#Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="verv-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails" xlink:href="verv-20211231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="verv-20211231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" xlink:href="verv-20211231.xsd#Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="verv-20211231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails" xlink:href="verv-20211231.xsd#Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" xlink:href="verv-20211231.xsd#Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails" xlink:href="verv-20211231.xsd#Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="verv-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails" xlink:href="verv-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xlink:href="verv-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails" xlink:href="verv-20211231.xsd#DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="verv-20211231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="verv-20211231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails" xlink:href="verv-20211231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="verv-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:href="verv-20211231.xsd#DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="verv-20211231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessPaymentLiability" xlink:label="verv_SuccessPaymentLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AntidilutionRightsLiability" xlink:label="verv_AntidilutionRightsLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_7"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="verv_SuccessPaymentLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="verv_AntidilutionRightsLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingGainsLossesAbstract" xlink:label="us-gaap_NonoperatingGainsLossesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" xlink:label="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ChangeInFairValueOfAntidilutionRights" xlink:label="verv_ChangeInFairValueOfAntidilutionRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ChangeInFairValueOfSuccessPaymentsLiabilities" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingGainsLossesAbstract" xlink:to="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingGainsLossesAbstract" xlink:to="verv_ChangeInFairValueOfAntidilutionRights" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingGainsLossesAbstract" xlink:to="verv_ChangeInFairValueOfSuccessPaymentsLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingGainsLossesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingGainsLossesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingGainsLossesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodValueLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodValueLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockIssuedDuringPeriodShareLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodShareLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_28"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_29"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueLicensorInstitutions" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodShareLicensorInstitutions" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_28" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_29" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability" xlink:label="verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IssuanceCostsOfSeriesAConvertiblePreferredStock" xlink:label="verv_IssuanceCostsOfSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock" xlink:label="verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IssuanceCostsOfSeriesBConvertiblePreferredStock" xlink:label="verv_IssuanceCostsOfSeriesBConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IssuanceCostsOfCommonStockFromInitialPublicOffering" xlink:label="verv_IssuanceCostsOfCommonStockFromInitialPublicOffering"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="verv_IssuanceCostsOfSeriesAConvertiblePreferredStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="verv_IssuanceCostsOfSeriesBConvertiblePreferredStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="verv_IssuanceCostsOfCommonStockFromInitialPublicOffering" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IssuanceOfPreferredStockTrancheLiability" xlink:label="verv_IssuanceOfPreferredStockTrancheLiability"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ProceedFromShareholderLoan" xlink:label="verv_ProceedFromShareholderLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_MaturitiesOfMarketableSecurities" xlink:label="verv_MaturitiesOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLeaseLosses" xlink:label="us-gaap_ProvisionForLeaseLosses"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SettlementOfTrancheRightLliability" xlink:label="verv_SettlementOfTrancheRightLliability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessOfPaymentLiability" xlink:label="verv_SuccessOfPaymentLiability"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AmortizationOfPremiumOnMarketableSecurities" xlink:label="verv_AmortizationOfPremiumOnMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" xlink:label="verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock" xlink:label="verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" xlink:label="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:label="us-gaap_IncreaseDecreaseInOtherDeferredLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ChangeInFairValueOfAntidilutionRights" xlink:label="verv_ChangeInFairValueOfAntidilutionRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ChangeInFairValueOfSuccessPaymentsLiabilities" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="verv_IssuanceOfPreferredStockTrancheLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="verv_ProceedFromShareholderLoan" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="verv_MaturitiesOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForLeaseLosses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="verv_SettlementOfTrancheRightLliability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="verv_SuccessOfPaymentLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="verv_AmortizationOfPremiumOnMarketableSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherDeferredLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromContributedCapital" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="verv_ChangeInFairValueOfAntidilutionRights" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="verv_ChangeInFairValueOfSuccessPaymentsLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LicenseAgreementAbstract" xlink:label="verv_LicenseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LicenseAgreementDisclosureTextBlock" xlink:label="verv_LicenseAgreementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_LicenseAgreementAbstract" xlink:to="verv_LicenseAgreementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/DisclosurePreferredStockTrancheLiability1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PreferredStockTrancheLiabilityTextBlock" xlink:label="verv_PreferredStockTrancheLiabilityTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="verv_PreferredStockTrancheLiabilityTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PreferredStockAbstract" xlink:label="verv_PreferredStockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PreferredAndCommonStockTextBlock" xlink:label="verv_PreferredAndCommonStockTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_PreferredStockAbstract" xlink:to="verv_PreferredAndCommonStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlans1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DeferredOfferingCostsPolicyTextBlock" xlink:label="verv_DeferredOfferingCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IndemnificationAgreementsPolicyTextBlock" xlink:label="verv_IndemnificationAgreementsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock" xlink:label="verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ConvertiblePreferredStockPolicyTextBlock" xlink:label="verv_ConvertiblePreferredStockPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_RentExpensePolicyTextBlock" xlink:label="verv_RentExpensePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SegmentAndGeographicInformationPolicyTextBlock" xlink:label="verv_SegmentAndGeographicInformationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="verv_DeferredOfferingCostsPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="verv_IndemnificationAgreementsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="verv_ConvertiblePreferredStockPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="verv_RentExpensePolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="verv_SegmentAndGeographicInformationPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTable" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SummaryOfSignificantAccountingPoliciesTable" xlink:label="verv_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="verv_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardAndBroadLicenseAgreementMember" xlink:label="verv_HarvardAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PercentageOfTaxBenefitRealized" xlink:label="verv_PercentageOfTaxBenefitRealized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IssuanceOfAdditionalCommonStock" xlink:label="verv_IssuanceOfAdditionalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessLiabilityPayment" xlink:label="verv_SuccessLiabilityPayment"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="verv_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardAndBroadLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="verv_PercentageOfTaxBenefitRealized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesTable" xlink:to="verv_SummaryOfSignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="verv_IssuanceOfAdditionalCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="verv_SuccessLiabilityPayment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ComputerEquipmentAndSoftwareMember" xlink:label="verv_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OfficeFurnitureMember" xlink:label="verv_OfficeFurnitureMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LaboratoryEquipmentMember" xlink:label="verv_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_ComputerEquipmentAndSoftwareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_OfficeFurnitureMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_LaboratoryEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm" xlink:label="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessPaymentLiabilityMember" xlink:label="verv_SuccessPaymentLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AntidilutionRightsLiabilityMember" xlink:label="verv_AntidilutionRightsLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_USTreasuryBillsAndNotesMember" xlink:label="verv_USTreasuryBillsAndNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_USAgencySecuritiesMember" xlink:label="verv_USAgencySecuritiesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_SuccessPaymentLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_AntidilutionRightsLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="verv_USTreasuryBillsAndNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="verv_USAgencySecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AntidilutionRightsLiabilityMember" xlink:label="verv_AntidilutionRightsLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardAndBroadLicenseAgreementMember" xlink:label="verv_HarvardAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardLicenseAgreementMember" xlink:label="verv_HarvardLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PreferredStockTrancheLiabilityMember" xlink:label="verv_PreferredStockTrancheLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_BroadLicenseAgreementMember" xlink:label="verv_BroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability" xlink:label="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessPaymentLiabilityCurrent" xlink:label="verv_SuccessPaymentLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FairValueInputsProbabilityOfTermination" xlink:label="verv_FairValueInputsProbabilityOfTermination"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_AntidilutionRightsLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardAndBroadLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_PreferredStockTrancheLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_BroadLicenseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CommonStockValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_SuccessPaymentLiabilityCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_FairValueInputsProbabilityOfTermination" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FairValueOfCommonStockPerShare" xlink:label="verv_FairValueOfCommonStockPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FairValueAssumptionOfEquityVolatilityRate" xlink:label="verv_FairValueAssumptionOfEquityVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CumulativeProbabilityOfTriggeringEvent" xlink:label="verv_CumulativeProbabilityOfTriggeringEvent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FairValueAssumptionsExpectedTerm1" xlink:label="verv_FairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_FairValueOfCommonStockPerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_FairValueAssumptionOfEquityVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_CumulativeProbabilityOfTriggeringEvent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_FairValueAssumptionsExpectedTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PreferredStockTrancheLiabilityMember" xlink:label="verv_PreferredStockTrancheLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AntidilutionRightsLiabilityMember" xlink:label="verv_AntidilutionRightsLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessPaymentLiabilityMember" xlink:label="verv_SuccessPaymentLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CommonStockIssuedDuringPeriodValueNewIssues" xlink:label="verv_CommonStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_5"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_PreferredStockTrancheLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_AntidilutionRightsLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_SuccessPaymentLiabilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="verv_CommonStockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AccruedExternalResearchAndDevelopmentExpenses" xlink:label="verv_AccruedExternalResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="verv_AccruedExternalResearchAndDevelopmentExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LesseeOperatingLeaseArea" xlink:label="verv_LesseeOperatingLeaseArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FirstAmendmentMember" xlink:label="verv_FirstAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CambridgeLeaseMember" xlink:label="verv_CambridgeLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AdditionalLesseeOperatingLeaseArea" xlink:label="verv_AdditionalLesseeOperatingLeaseArea"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PremisesMember" xlink:label="verv_PremisesMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SecondAmendmentMember" xlink:label="verv_SecondAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_NewAmendmentMember" xlink:label="verv_NewAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LeaseCommencementDate" xlink:label="verv_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LeaseNoncancelableTerm" xlink:label="verv_LeaseNoncancelableTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset" xlink:label="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:label="verv_LesseeOperatingLeaseIncrementalBorrowingRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TenantImprovementsAllowance" xlink:label="verv_TenantImprovementsAllowance"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AdditionalTenantImprovementsAllowance" xlink:label="verv_AdditionalTenantImprovementsAllowance"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_InterestRateForAdditionalImprovementsAllowance" xlink:label="verv_InterestRateForAdditionalImprovementsAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ShortTermBorrowingsReducedValue" xlink:label="verv_ShortTermBorrowingsReducedValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OperatingLeaseRelatedExpensesPriorToCommencement" xlink:label="verv_OperatingLeaseRelatedExpensesPriorToCommencement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_LesseeOperatingLeaseArea" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="verv_FirstAmendmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_CambridgeLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_AdditionalLesseeOperatingLeaseArea" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_PremisesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="verv_SecondAmendmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="verv_NewAmendmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_LeaseCommencementDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_LeaseNoncancelableTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_LesseeOperatingLeaseIncrementalBorrowingRate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_TenantImprovementsAllowance" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_AdditionalTenantImprovementsAllowance" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_InterestRateForAdditionalImprovementsAllowance" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_ShortTermBorrowingsReducedValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PrepaidRent" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_OperatingLeaseRelatedExpensesPriorToCommencement" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract" xlink:label="verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_NonRefundableUpfrontLicenseFeesPaid" xlink:label="verv_NonRefundableUpfrontLicenseFeesPaid"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DeliveryTechnologyProductMember" xlink:label="verv_DeliveryTechnologyProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_LicenseAgreementAbstract" xlink:label="verv_LicenseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_BroadLicenseAgreementMember" xlink:label="verv_BroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardAndBroadLicenseAgreementMember" xlink:label="verv_HarvardAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AntidilutionRightsMember" xlink:label="verv_AntidilutionRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_VerilyLicenseAgreementMember" xlink:label="verv_VerilyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_BeamLicenseAgreementMember" xlink:label="verv_BeamLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PreferredStockFinancingPartiallySatisfied" xlink:label="verv_PreferredStockFinancingPartiallySatisfied"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PreferredStockFinancingFullySatisfied" xlink:label="verv_PreferredStockFinancingFullySatisfied"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_AcuitasAgreementsMember" xlink:label="verv_AcuitasAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing" xlink:label="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing" xlink:label="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PaymentOfMilestoneDevelopment" xlink:label="verv_PaymentOfMilestoneDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PaymentOfSalesBasedMilestone" xlink:label="verv_PaymentOfSalesBasedMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure" xlink:label="us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DevelopedBaseMilestonePayments" xlink:label="verv_DevelopedBaseMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DevelopedBaseMilestonePaymentsForStatedPeriod" xlink:label="verv_DevelopedBaseMilestonePaymentsForStatedPeriod"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_MilestonePayments" xlink:label="verv_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PercentageSharesOfDevelopmentExpense" xlink:label="verv_PercentageSharesOfDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ProductCollaborationTerminationNoticePeriod" xlink:label="verv_ProductCollaborationTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_MilestoneRelatedExpenses" xlink:label="verv_MilestoneRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" xlink:label="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_NonRefundableUpfrontLicenseFee" xlink:label="verv_NonRefundableUpfrontLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ClinicalAndRegulatoryMilestone" xlink:label="verv_ClinicalAndRegulatoryMilestone"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SalesBasedMilestone" xlink:label="verv_SalesBasedMilestone"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_NonRefundableUpfrontPayment" xlink:label="verv_NonRefundableUpfrontPayment"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_NonRefundableUpfrontLicenseFeesPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="verv_DeliveryTechnologyProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_LicenseAgreementAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_BroadLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardAndBroadLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="verv_AntidilutionRightsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_VerilyLicenseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_BeamLicenseAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PreferredStockFinancingPartiallySatisfied" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PreferredStockFinancingFullySatisfied" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_AcuitasAgreementsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_StatementGeographicalAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PaymentOfMilestoneDevelopment" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PaymentOfSalesBasedMilestone" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_DevelopedBaseMilestonePayments" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_DevelopedBaseMilestonePaymentsForStatedPeriod" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_MilestonePayments" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PercentageSharesOfDevelopmentExpense" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_ProductCollaborationTerminationNoticePeriod" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_MilestoneRelatedExpenses" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_NonRefundableUpfrontLicenseFee" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_ClinicalAndRegulatoryMilestone" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_SalesBasedMilestone" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_NonRefundableUpfrontPayment" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SecondTrancheMember" xlink:label="verv_SecondTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ThirdTrancheMember" xlink:label="verv_ThirdTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="verv_SecondTrancheMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="verv_ThirdTrancheMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardAndBroadMember" xlink:label="verv_HarvardAndBroadMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_VerilyLicenseAgreementMember" xlink:label="verv_VerilyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PreferredStockAbstract" xlink:label="verv_PreferredStockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardAndBoardMember" xlink:label="verv_HarvardAndBoardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SeriesA2PreferredStocksMember" xlink:label="verv_SeriesA2PreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses" xlink:label="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PublicPrice" xlink:label="verv_PublicPrice"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross" xlink:label="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="verv_HarvardAndBroadMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_VerilyLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_PreferredStockAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="verv_HarvardAndBoardMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="verv_SeriesA2PreferredStocksMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_TitleOfIndividualAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="verv_PublicPrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DividendsPayableAmountPerShare" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TwentyEighteenMember" xlink:label="verv_TwentyEighteenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="verv_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TwentyTwentyOneEmployeeStockPurchasePlanMember" xlink:label="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan" xlink:label="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_NumberOfInstallmentsForRestrictedSharesVested" xlink:label="verv_NumberOfInstallmentsForRestrictedSharesVested"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="verv_TwentyEighteenMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="verv_TwoThousandAndTwentyOneStockIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="verv_NumberOfInstallmentsForRestrictedSharesVested" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="verv_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="verv_TwoThousandAndTwentyOneStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareReconciliationAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_UnvestedRestrictedStockMember" xlink:label="verv_UnvestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_UnvestedRestrictedStockUnitsMember" xlink:label="verv_UnvestedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OutstandingOptionsToPurchaseCommonStockMember" xlink:label="verv_OutstandingOptionsToPurchaseCommonStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="verv_UnvestedRestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="verv_UnvestedRestrictedStockUnitsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="verv_OutstandingOptionsToPurchaseCommonStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardAndBoardMember" xlink:label="verv_HarvardAndBoardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SuccessPaymentLiability" xlink:label="verv_SuccessPaymentLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="verv_HarvardAndBoardMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="verv_SuccessPaymentLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent" xlink:label="verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="verv_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="verv_EffectiveIncomeTaxRateReconciliationPermanentItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="verv_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization" xlink:label="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DeferredTaxAssetsAntidilultionLiability" xlink:label="verv_DeferredTaxAssetsAntidilultionLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DeferredTaxAssetsStockBasedCompensation" xlink:label="verv_DeferredTaxAssetsStockBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:label="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DeferredTaxAssetAccruedExpenses" xlink:label="verv_DeferredTaxAssetAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="verv_DeferredTaxLiabilitiesRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="verv_DeferredTaxAssetsAntidilultionLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="verv_DeferredTaxAssetsStockBasedCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="verv_DeferredTaxAssetAccruedExpenses" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_PercentageOfFutureTaxableIncomeUtilizedToOffset" xlink:label="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_MassachusettsTaxAuthorityMember" xlink:label="verv_MassachusettsTaxAuthorityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ChangeInOwnershipDescription" xlink:label="verv_ChangeInOwnershipDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OperatingLossCarryforwardsExpirationYear" xlink:label="verv_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_TaxCreditCarryforwardExpirationYear" xlink:label="verv_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="verv_MassachusettsTaxAuthorityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="verv_ChangeInOwnershipDescription" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="verv_OperatingLossCarryforwardsExpirationYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="verv_TaxCreditCarryforwardExpirationYear" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_CollaborationAndLicenseAgreementMember" xlink:label="verv_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_BeamMember" xlink:label="verv_BeamMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_SecondTrancheMember" xlink:label="verv_SecondTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ThirdTrancheMember" xlink:label="verv_ThirdTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_MaterialsExchangeAgreementMember" xlink:label="verv_MaterialsExchangeAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OptionLicenseAgreementAndPatentLicenseAgreementMember" xlink:label="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember" xlink:label="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OutOfPocketCostsIncurred" xlink:label="verv_OutOfPocketCostsIncurred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_ReductionInResearchAndDevelopmentExpense" xlink:label="verv_ReductionInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_OptionAndLicenseIssueFees" xlink:label="verv_OptionAndLicenseIssueFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_NonRefundableUpfrontLicenseFees" xlink:label="verv_NonRefundableUpfrontLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCommitmentAmount" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DebtBorrowedAmount" xlink:label="verv_DebtBorrowedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_CollaborationAndLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="verv_BeamMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="verv_SecondTrancheMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_OfficerMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="verv_ThirdTrancheMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_VestingAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_MaterialsExchangeAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsForRent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_OutOfPocketCostsIncurred" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_ReductionInResearchAndDevelopmentExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_OptionAndLicenseIssueFees" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_NonRefundableUpfrontLicenseFees" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermLeaseCommitmentAmount" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_DebtBorrowedAmount" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfSeniorDebt" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_FourZeroOneKPlanMember" xlink:label="verv_FourZeroOneKPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary"/>
    <link:loc xlink:type="locator" xlink:href="verv-20211231.xsd#verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="verv_FourZeroOneKPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsDate" xlink:label="us-gaap_SubsequentEventsDate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146681873048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 09, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VERVE THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001840574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VERV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,576,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4800132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 Technology Square, Suite 901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">603-0070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Portions of the registrant&#8217;s definitive proxy statement that will be filed for the 2022 Annual Meeting of Stockholders </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">which the registrant intends to file with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2021, are incorporated by reference in Part III of this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146682070120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 64,330<span></span>
</td>
<td class="nump">$ 8,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">296,112<span></span>
</td>
<td class="nump">63,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,686<span></span>
</td>
<td class="nump">1,854<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">367,128<span></span>
</td>
<td class="nump">73,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,224<span></span>
</td>
<td class="nump">3,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">5,237<span></span>
</td>
<td class="nump">463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,839<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long term assets</a></td>
<td class="nump">2,696<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">384,124<span></span>
</td>
<td class="nump">78,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,077<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">12,992<span></span>
</td>
<td class="nump">7,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligations, current portion</a></td>
<td class="nump">1,955<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent, current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,024<span></span>
</td>
<td class="nump">7,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_SuccessPaymentLiability', window );">Success payment liability (See Notes 5, 8 and 15)</a></td>
<td class="nump">4,371<span></span>
</td>
<td class="nump">2,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_AntidilutionRightsLiability', window );">Antidilution rights liability (See Notes 5, 8 and 15)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">377<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">26,772<span></span>
</td>
<td class="nump">17,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See Note 7 and 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock (See Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equtiy (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and oustanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 and 255,000,000 shares authorized, 48,511,735 and 3,123,424 shares issued at December 31, 2021 and 2020, respectively; 48,511,735 and 2,585,789 shares outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">544,381<span></span>
</td>
<td class="nump">2,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(228)<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(186,850)<span></span>
</td>
<td class="num">(66,536)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">357,352<span></span>
</td>
<td class="num">(63,909)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock, and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">384,124<span></span>
</td>
<td class="nump">78,413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock (See Note 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">125,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equtiy (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and oustanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 125,160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_AntidilutionRightsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Antidilution rights liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_AntidilutionRightsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SuccessPaymentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Success payment liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SuccessPaymentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146682532216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">255,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">48,511,735<span></span>
</td>
<td class="nump">3,123,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">48,511,735<span></span>
</td>
<td class="nump">2,585,789<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146682110776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 68,202<span></span>
</td>
<td class="nump">$ 35,371<span></span>
</td>
<td class="nump">$ 11,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">18,865<span></span>
</td>
<td class="nump">5,256<span></span>
</td>
<td class="nump">2,498<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">87,067<span></span>
</td>
<td class="nump">40,627<span></span>
</td>
<td class="nump">13,642<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(87,067)<span></span>
</td>
<td class="num">(40,627)<span></span>
</td>
<td class="num">(13,642)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingGainsLossesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_ChangeInFairValueOfPreferredStockTrancheLiabilities', window );">Change in fair value of preferred stock tranche liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,507<span></span>
</td>
<td class="num">(4,883)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_ChangeInFairValueOfAntidilutionRights', window );">Change in fair value of antidilution rights liability</a></td>
<td class="num">(25,574)<span></span>
</td>
<td class="num">(5,359)<span></span>
</td>
<td class="num">(982)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_ChangeInFairValueOfSuccessPaymentsLiabilities', window );">Change in fair value of success payment liability</a></td>
<td class="num">(7,815)<span></span>
</td>
<td class="num">(2,387)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(33,247)<span></span>
</td>
<td class="num">(5,077)<span></span>
</td>
<td class="num">(5,655)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (120,314)<span></span>
</td>
<td class="num">$ (45,704)<span></span>
</td>
<td class="num">$ (19,297)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share attributable to common stockholders, basic and diluted</a></td>
<td class="num">$ (4.48)<span></span>
</td>
<td class="num">$ (20.31)<span></span>
</td>
<td class="num">$ (15.11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares used in net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="nump">26,872,036<span></span>
</td>
<td class="nump">2,250,093<span></span>
</td>
<td class="nump">1,277,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Comprehensive Loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (120,314)<span></span>
</td>
<td class="num">$ (45,704)<span></span>
</td>
<td class="num">$ (19,297)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(236)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (120,550)<span></span>
</td>
<td class="num">$ (45,705)<span></span>
</td>
<td class="num">$ (19,288)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingGainsLossesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingGainsLossesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ChangeInFairValueOfAntidilutionRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of antidilution rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ChangeInFairValueOfAntidilutionRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ChangeInFairValueOfPreferredStockTrancheLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of preferred stock tranche liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ChangeInFairValueOfPreferredStockTrancheLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ChangeInFairValueOfSuccessPaymentsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of success payments liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ChangeInFairValueOfSuccessPaymentsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146680940984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Preferred Stock</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">$ (1,484)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,535)<span></span>
</td>
<td class="nump">$ 6,905<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,565,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock', window );">Issuance of Series A convertible preferred stock and settlement of tranche right liability, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock', window );">Issuance of Series A convertible preferred stock and settlement of tranche right liability, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,183,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee', window );">Issuance of Series A Preferred Stock in payment of licensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee', window );">Issuance of Series A Preferred Stock in payment of licensing fee (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,672,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodValueLicensorInstitutions', window );">Issuances of common stock to licensor institutions</a></td>
<td class="nump">748<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodShareLicensorInstitutions', window );">Issuances of common stock to licensor institutions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="nump">537,635<span></span>
</td>
<td class="nump">643,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities', window );">Repayment of shareholder loan</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,297)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,297)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="num">(19,553)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,268<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(20,832)<span></span>
</td>
<td class="nump">$ 25,480<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,854,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,421,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock', window );">Issuance of Series A convertible preferred stock and settlement of tranche right liability, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock', window );">Issuance of Series A convertible preferred stock and settlement of tranche right liability, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,749,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock', window );">Issuance of Series A-2 convertible preferred stock, net of issuance costs of $112</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock', window );">Issuance of Series A-2 convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,348,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions', window );">Additional issuances of common stock to licensor institutions</a></td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions', window );">Additional issuances of common stock to licensor institutions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="nump">537,635<span></span>
</td>
<td class="nump">537,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(45,704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="num">$ (63,909)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">2,616<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(66,536)<span></span>
</td>
<td class="nump">$ 125,160<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">2,585,789<span></span>
</td>
<td class="nump">2,585,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,519,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock', window );">Issuance of Series B convertible preferred stock, net of issuance costs of $241</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock', window );">Issuance of Series B convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,163,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock upon closing of initial public offering</a></td>
<td class="nump">$ 218,919<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">218,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (218,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,720,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(256,682,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs of $25,098</a></td>
<td class="nump">281,584<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">281,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs of (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,141,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodValueLicensorInstitutions', window );">Issuances of common stock to licensor institutions</a></td>
<td class="nump">$ 32,490<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">32,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodShareLicensorInstitutions', window );">Issuances of common stock to licensor institutions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="nump">537,633<span></span>
</td>
<td class="nump">537,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 966<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">599,838<span></span>
</td>
<td class="nump">599,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under ESPP</a></td>
<td class="nump">$ 780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">780<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under ESPP(shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(236)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,072<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(120,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 357,352<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 544,381<span></span>
</td>
<td class="num">$ (228)<span></span>
</td>
<td class="num">$ (186,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">48,511,735<span></span>
</td>
<td class="nump">48,511,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of additional common stock to licensor institutions (in shares)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of additional shares issued to licensor institutuons.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodShareLicensorInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to licensor institutions (in shares)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodShareLicensorInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series A-2 convertible preferred stock, net of issuance costs (in shares)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series A convertible preferred stock, net of issuance costs (in shares)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Series A Preferred Stock In Payment of Licensing Fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series B convertible preferred stock, net of issuance costs (in shares)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodValueLicensorInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Licensor Institutions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodValueLicensorInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series A-2 convertible preferred stock, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares series a convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Series A Preferred Stock In Payment Of Licensing Fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series B convertible preferred stock, net of issuance costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146682078856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement Of Stockholders Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability', window );">Issuance of Series A convertible preferred stock and settlement of tranche right liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_IssuanceCostsOfSeriesAConvertiblePreferredStock', window );">Issuance costs of series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock', window );">Issuance costs of series A2 convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_IssuanceCostsOfSeriesBConvertiblePreferredStock', window );">Issuance costs of series B convertible preferred stock</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_IssuanceCostsOfCommonStockFromInitialPublicOffering', window );">Issuance costs of common stock from initial public offering</a></td>
<td class="nump">$ 25,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IssuanceCostsOfCommonStockFromInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Costs Of Common Stock from Initial Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IssuanceCostsOfCommonStockFromInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance costs of series A2 convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IssuanceCostsOfSeriesAConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Costs of Series A Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IssuanceCostsOfSeriesAConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IssuanceCostsOfSeriesBConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Costs Of Series B Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IssuanceCostsOfSeriesBConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series A convertible preferred stock and settlement of tranche right liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146681030184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (120,314)<span></span>
</td>
<td class="num">$ (45,704)<span></span>
</td>
<td class="num">$ (19,297)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">1,535<span></span>
</td>
<td class="nump">1,328<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Non-cash research and development license expense in operating activity in cash flow</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForLeaseLosses', window );">Non-cash lease expense</a></td>
<td class="nump">1,842<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_AmortizationOfPremiumOnMarketableSecurities', window );">Amortization of premium on marketable securities</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7,072<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="nump">446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_ChangeInFairValueOfPreferredStockTrancheLiabilities', window );">Change in fair value of preferred stock tranche liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,507)<span></span>
</td>
<td class="nump">4,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_ChangeInFairValueOfAntidilutionRights', window );">Change in fair value of antidilution rights</a></td>
<td class="nump">25,574<span></span>
</td>
<td class="nump">5,359<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_ChangeInFairValueOfSuccessPaymentsLiabilities', window );">Change in fair value of success payments liabilities</a></td>
<td class="nump">7,815<span></span>
</td>
<td class="nump">2,387<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(7,528)<span></span>
</td>
<td class="num">(1,582)<span></span>
</td>
<td class="num">(182)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">6,829<span></span>
</td>
<td class="num">(1,898)<span></span>
</td>
<td class="nump">1,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">5,977<span></span>
</td>
<td class="nump">6,071<span></span>
</td>
<td class="nump">945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_SuccessOfPaymentLiability', window );">Success of payment liability</a></td>
<td class="num">(6,250)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,940)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherDeferredLiability', window );">Deferred rent liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(77,880)<span></span>
</td>
<td class="num">(35,265)<span></span>
</td>
<td class="num">(7,442)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(4,359)<span></span>
</td>
<td class="num">(3,424)<span></span>
</td>
<td class="num">(1,857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(371,494)<span></span>
</td>
<td class="num">(98,484)<span></span>
</td>
<td class="num">(22,001)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_MaturitiesOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">136,755<span></span>
</td>
<td class="nump">50,781<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(239,098)<span></span>
</td>
<td class="num">(51,127)<span></span>
</td>
<td class="num">(12,758)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Preferred Stock, net</a></td>
<td class="nump">93,759<span></span>
</td>
<td class="nump">92,616<span></span>
</td>
<td class="nump">18,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting discount</a></td>
<td class="nump">285,214<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_ProceedFromShareholderLoan', window );">Shareholder loan given</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering', window );">Payment of initial public offering costs</a></td>
<td class="num">(3,630)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">966<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Payments received on shareholder loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP', window );">Proceeds from purchase of shares through employee stock purchase plan</a></td>
<td class="nump">780<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">377,089<span></span>
</td>
<td class="nump">92,627<span></span>
</td>
<td class="nump">17,954<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">60,111<span></span>
</td>
<td class="nump">6,235<span></span>
</td>
<td class="num">(2,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash&#8212;beginning of period</a></td>
<td class="nump">9,456<span></span>
</td>
<td class="nump">3,221<span></span>
</td>
<td class="nump">5,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash&#8212;end of period</a></td>
<td class="nump">69,567<span></span>
</td>
<td class="nump">9,456<span></span>
</td>
<td class="nump">3,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and finnacing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses', window );">Property and equipment additions included in accounts payable and accrued expenses</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_IssuanceOfPreferredStockTrancheLiability', window );">Issuance of preferred stock tranche liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_SettlementOfTrancheRightLliability', window );">Settlement of tranche right liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,064<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering', window );">Conversion of convertible preferred stock to common stock upon closing of initial public offering</a></td>
<td class="nump">218,919<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock', window );">Settlement of derivative liability by issuing common stock</a></td>
<td class="nump">32,490<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 809<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the amount of cash contributions during the period made by the entity to the Employee Stock Ownership Plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherDeferredLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherDeferredLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForLeaseLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to estimated loss to be realized from lease transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.11)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForLeaseLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_AmortizationOfPremiumOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of premium on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_AmortizationOfPremiumOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ChangeInFairValueOfAntidilutionRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of antidilution rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ChangeInFairValueOfAntidilutionRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ChangeInFairValueOfPreferredStockTrancheLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of preferred stock tranche liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ChangeInFairValueOfPreferredStockTrancheLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ChangeInFairValueOfSuccessPaymentsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of success payments liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ChangeInFairValueOfSuccessPaymentsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IssuanceOfPreferredStockTrancheLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of preferred stock tranche liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IssuanceOfPreferredStockTrancheLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_MaturitiesOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maturities of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_MaturitiesOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ProceedFromShareholderLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceed from shareholder loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ProceedFromShareholderLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property and equipment additions included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement of Antidilution Rights Liability By Issuing Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SettlementOfTrancheRightLliability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement of tranche right liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SettlementOfTrancheRightLliability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SuccessOfPaymentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Success of payment liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SuccessOfPaymentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, Conversion of convertible preferred stock to common stock upon closing of initial public offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146685143288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">1. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Nature of the business and basis of presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Organization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Verve Therapeutics, Inc. (the &#8220;Company&#8221; or &#8220;Verve&#8221;) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The Company was incorporated on March 9, 2018 as Endcadia, Inc., a Delaware corporation, and began operations shortly thereafter. In January 2019, the Company amended its certificate of incorporation to change its name to Verve Therapeutics, Inc. The Company&#8217;s principal offices are located in Cambridge, Massachusetts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Liquidity and capital resources</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On June 21, 2021, the Company completed its initial public offering, or IPO, in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,141,157</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of its common stock, including </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,105,368</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">306.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. The Company received approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">281.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in net proceeds after deducting underwriting discounts and offering expenses payable by the Company. In connection with the IPO, all outstanding shares of convertible preferred stock converted into </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">27,720,923</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company&#8217;s common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In connection with the Company's IPO, the Company effected a </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">one-for-9.2595</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> reverse stock split of the Company&#8217;s issued and outstanding common stock. Accordingly, all shares of common stock and per share amounts, as well as the conversion ratio of the Company&#8217;s outstanding convertible preferred stock, for all periods presented in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split, including reclassification of par and additional paid-in capital amounts as a result of the reverse stock split.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Basis of presentation and liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred losses since its inception, including losses of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">120.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">45.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> for the years ended December 31, 2021, 2020 and 2019, respectively. As of December 31, 2021, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">186.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. To date, the Company has funded its operations primarily through equity offerings. Through December 31, 2021, the Company had raised an aggregate $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">523.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in gross proceeds from the sales of its preferred stock in private placements and common stock in its IPO. The Company expects to generate operating losses and negative operating cash flows for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company expects that its cash, cash equivalents and marketable securities as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> will </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">be sufficient to fund its operations for at least the next twelve months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">strategy. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed could have a negative impact on the Company&#8217;s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146685370024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">2. S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">ummary of significant accounting policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Principles of consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The accompanying consolidated financial statements include the accounts of Verve and its wholly owned subsidiary, Verve Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair values of common stock (prior to completion of the IPO), convertible preferred stock, preferred stock tranche liability, stock-based compensation, and the liabilities for antidilution rights and success payments. Actual results could differ from these estimates.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Cash and cash equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cash and cash equivalents consist of standard checking accounts and money market account funds that invest primarily in U.S. government-backed securities and treasuries. The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at cost, which is substantially equivalent to fair value.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Restricted cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Restricted cash represents collateral provided for a letter of credit issued as a security deposit in connection with the Company&#8217;s leases of its corporate facilities. </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:</span></span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.402%;"/>
          <td style="width:1.6%;"/>
          <td style="width:1.441%;"/>
          <td style="width:13.052%;"/>
          <td style="width:0.716%;"/>
          <td style="width:1.6%;"/>
          <td style="width:1.441%;"/>
          <td style="width:13.032%;"/>
          <td style="width:0.716%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31,</span></p></td>
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">64,330</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,993</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,237</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">463</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">69,567</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9,456</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
        </table></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Marketable securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are maintained by the Company&#8217;s investment managers and consist of U.S. treasury bills and U.S agency securities. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income (loss) as a component of stockholders&#8217; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense).</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Company reviews marketable securities for other-than-temporary impairment whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security&#8217;s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if the Company has experienced a credit loss, has the intent to sell the marketable security, or if it is more likely than not that the Company will be required to sell the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">marketable </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">security before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company&#8217;s investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period. The Company evaluated its securities for other-than-temporary impairment and considered the decline in market value for the securities to be primarily attributable to current economic and market conditions. It is not more likely than not that the Company will be required to sell the securities, and the Company does not intend to do so prior to the recovery of the amortized cost basis. Based on this analysis, these marketable securities were not considered to be other-than-temporarily impaired as of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span></p></div><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Concentrations of credit risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and restricted cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Deferred offering costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company capitalized incremental legal, professional accounting and other third-party fees that were directly associated with the IPO as other non-current assets until the IPO was consummated. After consummation of the IPO, these costs were recorded in stockholders&#8217; equity (deficit) as a reduction of additional paid-in-capital generated as a result of the offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></div><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Indemnification agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Fair value of financial instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ASC Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Fair Value Measurement </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Level 1&#8212;Quoted market prices in active markets for identical assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Level 2&#8212;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Level 3&#8212;Unobservable inputs for the asset or liability (i.e. supported by little or no market activity). Level 3 inputs include management&#8217;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There have been no changes to the valuation methods utilized by the Company during the years ended December 31, 2021, 2020 and 2019. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Property and equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment are stated at cost less accumulated depreciation. </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.968%;"/>
          <td style="width:2.064%;"/>
          <td style="width:48.968%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Asset category</span></p></td>
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Office furniture</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Shorter of useful life or remaining lease term</span></span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Impairment of long-lived assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> impairment losses recognized during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021, 2020 and 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Freestanding financial instruments and derivatives</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has identified the following financial instruments, which are recorded as liabilities in the balance sheet and separately accounted for at fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Preferred Stock Tranche Liabilities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;The Company has determined that its obligation to issue, and the Company&#8217;s investors&#8217; right to purchase, additional shares of convertible Series A Preferred Stock (&#8220;Series A Preferred&#8221;) pursuant to subsequent closings represent a freestanding financial instrument. The freestanding preferred stock tranche liability (the &#8220;tranche liability&#8221;) was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss. The tranche liabilities were remeasured at each reporting period and upon the exercise or expiration of the obligation. As of December 31, 2020, all Series A Preferred closings occurred, and all preferred stock tranche liabilities have been settled. Refer to Note 9, Preferred Stock tranche liability, for additional discussion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pursuant to license agreements with (i) the President and Fellows of Harvard College (&#8220;Harvard&#8221;) and The Broad Institute, Inc. (&#8220;Broad&#8221;) (&#8220;Harvard/Broad License Agreement&#8221;) and (ii) Broad (&#8220;Broad License Agreement&#8221;) (see Note 8, License agreements), the following financial instruments were issued by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Antidilution Rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;The antidilution rights represent the obligation to issue additional shares of common stock to Harvard and Broad following the completion of additional financings, including the Company&#8217;s initial public offering. These antidilution rights were accounted for under ASC 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Derivatives and Hedging ("ASC 815"),</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and were initially recorded at fair value with a corresponding charge to research and development expense. The liability was remeasured at each reporting period, with changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss while this instrument was outstanding. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The obligation was satisfied in full upon the issuance of an aggregate of an additional </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">878,098</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock upon the closing of the Company's IPO in June 2021. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Refer to Note 5, Fair value of financial instruments, for additional discussion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Success Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;The Company is obligated to pay to Harvard and Broad tiered success payments in the event the Company&#8217;s average market capitalization exceeds specified thresholds ascending from a high nine digit dollar amount to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control of the Company or a sale of the Company, the Company is required to pay in cash within a specified period following such event. Otherwise, the payments may be settled at the Company&#8217;s option in either cash or shares of the Company&#8217;s common stock. The success payments are accounted for under ASC 815 and were initially recorded at fair value with a corresponding charge to research and development expense. The liability is remeasured at each reporting period with all changes in value recognized in other income (expense) in the statement of operations and other comprehensive loss. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the year ended December 31, 2021, certain success payment obligations were triggered, and amounts paid to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> These amounts were settled in cash in November 2021. The Company will continue to adjust the liability for changes in fair value until the earlier of the achievement or expiration of the remaining success payment obligation. Refer to Note 5, Fair value of financial instruments, for additional discussion</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Research and development costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, third-party license fees related to technology with no alternative</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">future </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">use, laboratory supplies, depreciation, manufacturing expenses, preclinical expenses, consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s stock-based compensation program allows for grants of stock options and restricted stock awards. Grants are awarded to employees and non-employees, including directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Compensation-Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> (&#8216;&#8216;ASC 718&#8217;&#8217;). ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#8216;&#8216;Black-Scholes&#8217;&#8217;) for stock option grants to both employees and non-employees. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s stock-based compensation awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized over the implied service period when achievement of the performance-based milestones is deemed probable. The Company uses judgement to determine whether and, if so, how many awards are deemed probable of vesting at each reporting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The estimation of fair value for stock-based compensation requires management to make estimates and judgments about, among other things, the estimated life of options and volatility of the Company&#8217;s common stock. The judgments directly affect the amount of compensation expense that will be recognized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to the Company's IPO in June 2021, there was no public market for its common stock. As a result, prior to the IPO, the estimated fair value of the Company's common stock was determined by its board of directors as of the date of each option grant, with input from management, considering the Company's most recently available third-party valuations of common stock and its board of directors' assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of grant. Following the Company's IPO, the fair value of its common stock is determined based on the closing price of the Company's common stock as reported on the Nasdaq Global Select Market</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Rent expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s real estate operating leases provide for scheduled annual rent increases throughout the lease term. The Company recognizes the effects of the scheduled rent increases on a straight-line basis over the full term of the lease. Prior to the adoption of ASU 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, or ASC 842, tenant improvement allowances, if any, provided by the landlord are recorded as deferred rent and amortized as reduction to rent expense over the lease term. Subsequent to the adoption of ASC 842, tenant improvement allowances, if any, provided by a landlord are recorded as a reduction of the right-of-use, or ROU, asset related to that lease.</span></p></div><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Income taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Comprehensive loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2021, 2020 and 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, the Company&#8217;s only element of other comprehensive income (loss) was unrealized gains (losses) on marketable securities.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Net loss per share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2021, 2020 and 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Segment and geographic information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#8217;s Chief Executive Officer. The Company views its operations as and manages its business in </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> operating segment operating exclusively in the United States.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Subsequent events</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company performs an evaluation of all subsequent events after the balance sheet date through the date of issuance of the consolidated financial statements to ensure appropriate disclosure of events both recognized in the consolidated financial statements and events which occurred subsequently but were not recognized in the consolidated financial statements.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Recently adopted accounting pronouncements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), as subsequently amended, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors), and replaces the existing guidance in ASC 840. The FASB has issued several updates to the standard which: (i) clarify how to apply certain aspects of the new standard; (ii) provide an additional transition method for adoption of the new standard; (iii) provide a practical expedient for certain lessor accounting; and (iv) amend certain narrow aspects of the guidance. The new standard requires the identification and classification of arrangements that are or contain a lease and requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine the recognition pattern of lease expense over the term of the lease. In addition, a lessee is required to record (i) a right-of-use asset and a lease liability on its balance sheet for all leases with accounting lease terms of more than 12 months regardless of whether it is an operating or finance lease and (ii) lease expense in its consolidated statement of operations for operating leases and amortization and interest expense in its consolidated statement of operations for financing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">leases. Leases with a term of 12 months or less may be accounted for similar to existing guidance for operating leases under ASC 840. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842), which added an optional transition method that allows companies to adopt the standard as of the beginning of the year of adoption as opposed to the earliest comparative period presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to January 1, 2021, the Company accounted for leases pursuant to ASC 840, Leases. At lease inception, the Company determined if an arrangement was an operating or capital lease. For operating leases, the Company recognized rent expense, inclusive of rent escalations, holidays and lease incentives, on a straight-line basis over the lease term. The difference between rent expense recorded and the amount paid was recorded as deferred rent. The Company presented lease incentives as deferred rent and amortized the incentives as a reduction to rent expense on a straight-line basis over the lease term. The Company classified deferred rent as current and noncurrent liabilities based on the portion of the deferred rent that was scheduled to mature within the next twelve months.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adopted </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Topic 842 during the quarter ended September 30, 2021, with an effective adoption date of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, using the modified retrospective transition approach which uses the effective date, or January 1, 2021, as the date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. At contract inception, the Company determines if an arrangement is or contains a lease. A lease conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If an arrangement is determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on which the leased asset is made available for use by the Company, based on the economic characteristics of the lease. The Company has elected to apply the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or the capitalization of initial direct costs for any existing leases. As a result of the adoption of ASC 842, the Company recorded (i) an operating lease liability of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million determined using an incremental borrowing rate as of the effective adoption date and (ii) an operating lease right-of-use asset of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, net of the unamortized balance of prepaid/accrued rent as of the transition date. There was </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> impact to the Company&#8217;s results of operations and cash flows from operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has elected the short-term lease exemption, which allows the Company to not recognize lease liabilities and right-of-use assets arising from lease arrangements with lease terms of twelve months or less. For each lease with a term greater than twelve months, the Company records a right-of-use asset and lease liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A right-of-use asset represents the economic benefit conveyed to the Company by the right to use the underlying asset over the lease term. A lease liability represents the Company&#8217;s obligation to make lease payments under the arrangement. The Company measures its lease liabilities at lease commencement as the present value of the future lease payments in the contract using the rate implicit in the contract, when available. As an implicit rate has not historically been readily determinable, the Company uses an incremental borrowing rate measured as the rate at which the Company could borrow, on a fully collateralized basis, a commensurate loan in the same currency over a period consistent with the lease term at the commencement date. The incremental borrowing rate is determined based on the Company's synthetic secured rating using the ordered logit model as of the measurement date. The Company measures its right-of-use assets as the lease liability plus initial direct costs and prepaid lease payments, less lease incentives granted by the lessor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Components of a lease are split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) are allocated, based on the respective relative fair values, to the lease components and non-lease components. The Company has elected to account for lease and associated non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company remeasures right-of-use assets and lease liabilities when a lease is modified, and the modification is not accounted for as a separate contract. A modification is accounted for as a separate contract if the modification grants the Company an additional right of use not included in the original lease arrangement and the increase in lease payments is commensurate with the additional right of use. The Company assesses its right-of-use assets for impairment in a manner consistent with its assessment for long-lived assets held and used in operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s operating leases are presented in the consolidated balance sheet as operating lease right-of-use assets, classified as noncurrent assets, and operating lease liabilities, classified as current and noncurrent liabilities. Operating lease expense is recognized on a straight-line basis over the lease term. Variable costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">associated with a lease, such as maintenance and utilities, are not included in the measurement of the lease liabilities and right-of-use assets but rather are expensed when the events determining the amount of variable consideration to be paid have occurred.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Recently issued accounting pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company ("EGC") to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. As an EGC, the Company has elected to take advantage of this extended transition period for certain new accounting standards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></div><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Financial Instruments&#8212;Credit Losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The new standard will be effective for the Company on January 1, 2023. The Company is currently evaluating the potential impact that this standard may have on its consolidated financial position and results of operations.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146685371112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">3. Marketable securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Marketable securities by security type consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.07%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.432%;"/>
        <td style="width:9.414%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.441%;"/>
        <td style="width:9.414%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.441%;"/>
        <td style="width:9.285%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.432%;"/>
        <td style="width:9.365%;"/>
        <td style="width:0.706%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31, 2021</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Amortized<br/>cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Gross<br/>unrealized<br/>gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Gross<br/>unrealized<br/>losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Fair<br/>value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">277,559</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">218</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">277,341</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18,781</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18,771</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">296,340</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">228</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">296,112</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.12%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.432%;"/>
        <td style="width:9.414%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.441%;"/>
        <td style="width:9.414%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.441%;"/>
        <td style="width:9.414%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.432%;"/>
        <td style="width:9.335%;"/>
        <td style="width:0.706%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31, 2020</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Amortized<br/>cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Gross<br/>unrealized<br/>gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Gross<br/>unrealized<br/>losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Fair<br/>value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,221</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,224</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">30,890</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">30,895</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">63,111</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">63,119</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The remaining contractual maturities of all marketable securities were less than </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">one year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146682697032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">4. P</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">roperty and equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment, net, consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.359%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1.441%;"/>
        <td style="width:12.92%;"/>
        <td style="width:0.865%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1.441%;"/>
        <td style="width:12.91%;"/>
        <td style="width:0.865%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Lab equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,567</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,937</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">266</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">259</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">566</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">481</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Computer equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">158</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">105</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9,557</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,782</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,333</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">798</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,224</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,984</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Depreciation expense for the years ended December 31, 2021, 2020 and 2019 w</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">as $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146685301992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Disclosure - Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">5. f</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">air value of financial instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s financial instruments consist of money market funds, marketable securities, the preferred stock tranche liability, the antidilution right liability, and success payment liability pursuant to the Harvard/ Broad License Agreement and the Broad License Agreement. The preferred stock tranche liability was fully settled in the year ended December 31, 2020, and the antidilution right liability was fully settled in the year ended December 31, 2021. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The liabilities are carried at fair value. </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following tables set forth the fair value of the Company&#8217;s financial instruments by level within the fair value hierarchy: </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.289%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.431%;"/>
        <td style="width:9.373%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.431%;"/>
        <td style="width:9.343%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.431%;"/>
        <td style="width:9.373%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.431%;"/>
        <td style="width:9.303%;"/>
        <td style="width:0.706%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">As of December 31, 2021</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Fair<br/>value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">58,127</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">58,127</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">277,341</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">277,341</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">354,239</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">58,127</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">296,112</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Success payment liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,371</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,371</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.359%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.432%;"/>
        <td style="width:9.345%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.432%;"/>
        <td style="width:9.315%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.432%;"/>
        <td style="width:9.345%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.432%;"/>
        <td style="width:9.315%;"/>
        <td style="width:0.706%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">As of December 31, 2020</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Fair<br/>value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,724</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,724</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,224</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,224</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">30,895</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">30,895</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">69,843</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,724</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">63,119</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Success payment liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,806</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,806</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Antidilution rights liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,916</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,916</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9,722</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9,722</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Cash Equivalents</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;Cash equivalents of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">58.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> as of December 31, 2021 and 2020, respectively, consisted of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Marketable Securities&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company measures its marketable securities at fair value on a recurring basis and classifies those instruments within Level 2 of the fair value hierarchy. Marketable securities are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Preferred Stock Tranche Liability</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;The preferred stock tranche liability is stated at fair value and is considered Level 3 within the fair value hierarchy because its fair value measurement is based, in part, on significant inputs not observed in the market. The tranche liability was valued using a probability-adjusted scenario-based method that considered the probability of triggering the tranche rights through achievement of certain non-scientific and scientific milestones as well as the pu</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">rchase price of Series A preferred stock. Subsequent Series A Preferred Stock closings occurred in both 2019 and 2020 and the preferred stock tranche liability was fully settled as of December 31, 2020 (refer to Note 9, Preferred stock tranche liability). Prior to settlement, the Company remeasured the liability with a corresponding increase of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million to other expense for the year ended December 31, 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Antidilution Rights Liability</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212; The antidilution rights liability represents the obligation to issue additional shares of common stock to Harvard and Broad following the completion of (1) a defined aggregate level of preferred stock financing and (2) either a sale of the Company&#8217;s preferred stock, an initial public offering, or a company sale meeting a certain value threshold. The antidilution rights liability was stated at fair value and was considered Level 3 in the fair value hierarchy because its fair value measurement was based, in part, on significant inputs not</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">observed in the market. The antidilution rights liability related to meeting a defined aggregate level of preferred stock financing was valued using a probability-weighted present value model that considered the probability of meeting the defined aggregate level of preferred stock financing, as well as the fair value of the Company&#8217;s common stock. The antidilution rights liability related to the achievement of a specified valuation through either a sale of the Company&#8217;s preferred stock, an initial public offering, or a company sale was valued using a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the fair value of the Company&#8217;s common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">At issuance in 2019, the estimated fair value of the antidilution rights liability was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, which was recorded as research and development expense. The Company remeasured the liability at fair value with corresponding charges of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million recorded to other expense for the years ended December 31, 2020 and 2019, respectively. The antidilution rights associated with the Company achieving a defined aggregate level of preferred stock financing were partially satisfied in 2019 and fully satisfied in 2020, which settlement amounts totaled $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively, and which amounts were settled through issuances of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">121,411</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">187,867</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company common stock, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2021, upon completion of its IPO, the Company settled the antidilution rights liability in full through the issuance of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">878,098</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company's common stock for a settlement amount of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. Prior to settlement, the Company remeasured the liability with a corresponding increase of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">25.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million to other expense for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Success Payment Liability</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212; The Company is obligated to pay to Harvard and Broad tiered success payments in the event its average market capitalization exceeds specified thresholds for a specified period of time ascending from a high nine-digit dollar amount to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control or a sale of the Company, the Company is required to pay success payments in cash within a specified period following such event. Otherwise, the success payments may be settled at the Company&#8217;s option in either cash or shares of its common stock, or a combination of cash and shares of its common stock. The maximum aggregate success payments that could be payable by the Company is $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">31.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million (after termination of the Broad License Agreement).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The success payments liability is stated at fair value and is considered Level 3 because its fair value measurement is based, in part, on significant inputs not observed in the market. The Company used a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the value of the Company&#8217;s common stock. The Company also estimated the likelihood that it would maintain both the Harvard/Broad License Agreement and the Broad License Agreement based on its on-going research efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company remeasured the liability at fair value with incre</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ases of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.4</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> recorded to other expense </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">for the years ended December 31, 2021, 2020 and 2019, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In September 2021, multiple success payments were triggered and amounts due to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. These amounts were settled in cash in November 2021. The Company will continue to adjust the remaining success payment liability for changes in fair value until the earlier of the achievement or expiration of the obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The primary inputs used in valuing (i) the success payments liability and (ii) the antidilution rights liability associated with the Company&#8217;s realization of a certain valuation threshold through either a sale of the Company&#8217;s preferred stock, an initial public offering, or a company sale at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 (only applicable to success payments liability), 2020 and 2019, were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.375%;"/>
        <td style="width:1.352%;"/>
        <td style="width:1.432%;"/>
        <td style="width:12.138%;"/>
        <td style="width:2.287%;"/>
        <td style="width:1.352%;"/>
        <td style="width:1.432%;"/>
        <td style="width:12.138%;"/>
        <td style="width:2.287%;"/>
        <td style="width:1.352%;"/>
        <td style="width:1.432%;"/>
        <td style="width:12.138%;"/>
        <td style="width:2.287%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">At<br/>December 31,<br/>2021</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">At<br/>December 31,<br/>2020</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">At<br/>December 31,<br/>2019</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fair value of common stock (per share)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">36.87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8.24</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.59</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Equity volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">77</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">105</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">100</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cumulative probability of triggering event</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">n/a</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">n/a</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.50</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.89</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">At </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2020 and 2019, the fair value of the Company's common stock was determined by management with the assistance of an independent third-party valuation specialist using methods consistent with the AICPA Valuation Guide. The computation of equity volatility was estimated using available information about the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">historical </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">volatility of stocks of similar publicly traded companies for a period matching the expected term assumption. In addition, the Company incorporated the timing and probability of future events in the calculation of liabilities. The Company also estimated the likelihood that it would maintain both the Harvard/Broad License Agreement and the Broad License Agreement based on its on-going research efforts. The Company applied a </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% probability of termination of the Broad License Agreement at December 31, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In February 2021, the Company provided written notice to Broad of its election to terminate the Broad License Agreement, which termination became effective in June 2021.</span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.244%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.431%;"/>
        <td style="width:10.556%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.441%;"/>
        <td style="width:10.635%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.431%;"/>
        <td style="width:10.536%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.431%;"/>
        <td style="width:9.144%;"/>
        <td style="width:0.855%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Preferred<br/>stock<br/>tranche<br/>liability</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Antidilution<br/>rights<br/>liability</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Success<br/>payment<br/>liability</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Balance at December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9,571</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,044</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">419</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12,034</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of Series A Preferred</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,064</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,064</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">487</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">487</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,507</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,359</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,387</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,239</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,916</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,806</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9,722</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of common stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,490</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,490</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Success payment liability earned and paid</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_170610ab-9c1b-4510-8f28-c508389451c8;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_716c6897-a6df-4fdf-9e99-b336dfd3b30f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">25,574</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,815</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">33,389</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146685341032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">6. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Accrued expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued expenses consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.395%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1.441%;"/>
        <td style="width:13.05%;"/>
        <td style="width:0.716%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1.441%;"/>
        <td style="width:13.04%;"/>
        <td style="width:0.716%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Employee compensation and related benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,050</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,636</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued external research and development expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,041</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,827</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,109</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">303</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">792</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">423</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12,992</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,189</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146685274680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">7. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s operating lease activity is comprised of non-cancelable facility leases for office and laboratory space in Cambridge, Massachusetts. In March 2020, the Company entered into an operating lease agreement for </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,843</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> square feet of space located at 500 Technology Square, Cambridge, Massachusetts (the &#8220;Cambridge Lease&#8221;), with the Company acting as subtenant. The term of the Cambridge Lease commenced in August 2020 and is scheduled to expire </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> from the commencement date. The lease provides for annual rent escalations. The Company pays for its proportionate share of building operating costs such as maintenance, utilities, and insurance. In June 2020, the Company entered into the First Amendment to the Cambridge Lease adding </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,980</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> square feet of additional space. In January 2021, the Company entered into the Second Amendment to the Cambridge Lease adding </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,980</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> square feet of additional space at a commensurate rent increase which was treated as a new contract. In July, 2021, the Company entered into an amendment for its office space at 500 Technology Square and corresponding parking lot to extend the lease term through </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">November 30, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. The renewal operates under the same terms and conditions as the original lease. As a result of the renewal, the right-of-use asset and lease liability were remeasured at the present value of the lease payments not yet paid, discounted by the incremental borrowing rate (IBR) at the remeasurement date. This resulted in a net increase to the lease liability and right-of-use asset of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. There was no impact on the consolidated statement of operations and comprehensive loss or the consolidated statement of cash flows as a result of the lease renewal.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has also entered into multiple contract research and contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. The embedded leases are</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">considered short term leases, as the contractual terms are twelve months or less. Accordingly, no lease liability or right of use asset has been recorded, and the Company has recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of short term lease costs associated with the embedded leases during the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The components of operating lease cost were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.863%;"/>
        <td style="width:1.938%;"/>
        <td style="width:1.441%;"/>
        <td style="width:16.032%;"/>
        <td style="width:0.726%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31, 2021</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,923</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Variable lease costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">747</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Short term lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,278</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,948</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Supplemental cash flow information related to operating leases was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.863%;"/>
        <td style="width:1.938%;"/>
        <td style="width:1.441%;"/>
        <td style="width:16.032%;"/>
        <td style="width:0.726%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31, 2021</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cash paid for amounts included in the measurements of lease liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating cash flows related to operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021, the Company&#8217;s operating leases were measured using a weighted-average incremental borrowing rate </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.57</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> over a weighted-average remaining lease ter</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">m of 0</span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.9 </span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On August 19, 2021, the Company entered into a lease agreement with ARE-MA Region No. 87 Tenant, LLC, a Delaware limited liability company (the &#8220;Landlord&#8221;), pursuant to which the Company will lease approximately </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">104,933</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> square feet of office and laboratory space located at 201 Brookline Avenue, Boston, Massachusetts (the &#8220;Boston Lease&#8221;), further amended in January 2022 to include an additional </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">211</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> square feet, for a total of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">105,144</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> square feet. The Boston Lease premises have not been made available to the Company as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 and is therefore excluded from the table below, as the Lease has not commenced.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The term of the Lease will commence on the earlier of (1) the date the Landlord </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delivers the premises under the Boston Lease to the Company, which the parties expect to be on or prior to August 1, 2022, or (2) the date the Landlord could have delivered the premises but for any delays attributable to the Company (the &#8220;Commencement Date&#8221;). </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s obligation for the payment of base rent for the Boston Lease begins 90 days after the Commencement Date (the &#8220;Rent Commencement Date&#8221;) and will initially be $0.8 million per month, which will increase by approximately 3% per annum.</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> The Boston Lease has a term of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> years, measured from the Rent Commencement Date. The Company has the </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">option to extend</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> the term of the Lease for a period of an additional </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">five years</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Under the terms of the Lease, the Landlord has agreed to make up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in certain tenant improvements to the premises to suit the Company&#8217;s use (the &#8220;Tenant Improvement Allowance&#8221;), which amount is included in the base rent set forth in the Boston Lease. In addition to the Tenant Improvement Allowance, the Company may receive up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for additional improvements to the premises, which amount is subject to an </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% annual interest charge and may be paid in equal monthly installments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In connection with its entry into the Boston Lease and as a security deposit, the Company has provided the Landlord a letter of credit in the amount of approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, which may be reduced to approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million on the expiration of the 36-month anniversary of the Rent Commencement Date so long as there are, and have been, no defaults by the Company under the terms of the Boston Lease. The Company also paid a deposit in the amount of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, which is equal to the first month of base rent.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Landlord has the right to terminate the Boston Lease upon customary events of default. The Company </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">may also termina</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">te</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> the Boston Lease if the premises are not ready for occupancy within a specified time period after August 1, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Boston Lease requires the Landlord to perform a scope of work to build-out the base building prior to the construction of the premises. The Company concluded the accounting commencement date will occur when the Landlord completes the build-out of the base building and control passes to the Company. The Company will assess the classification of the Boston Lease at the accounting commencement date, measure the right-of-use asset and lease liability. Payments made by the Company prior to commencement will be treated as prepaid rent which will increase the right-of-use asset. As of December 31, 2021, the Company has incurr</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ed $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million re</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">lated to the build out of the lease space prior to the Commencement Date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In October 2021, the Company entered into a sublease for </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11,931</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> square feet of office and laboratory space in Cambridge, Massachusetts. The sublease commenced in </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and has an initial noncancelable term of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">twelve months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has the option to extend the sublease for one extension term of three months by written notice not less than six months prior to the expiration of the sublease term, which the Company is not reasonably certain of exercising.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> Therefore, this sublease is treated as a short term lease. The total fixed lease payments over the sublease term is approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and the Company is also required to pay its proportional share of operating expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Future minimum commitments under non-cancellable leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.833%;"/>
        <td style="width:1.938%;"/>
        <td style="width:1.441%;"/>
        <td style="width:15.923%;"/>
        <td style="width:0.865%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Years ending December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Amount</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12,951</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9,958</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10,257</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10,565</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10,882</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">54,158</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">108,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less: interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">108,758</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Accounting under ASC 840</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to the adoption of ASC 842, the Company recorded rent expense on a straight-line basis over the term of the lease, including any rent-free periods. In addition, the Company recorded deferred rent for certain lease incentives received, which were amortized as a reduction of rent expense over the life of the lease. Rent expense was presented as part of continuing operations in the consolidated statement of operations and comprehensive loss; deferred rent was recorded on the consolidated balance sheet.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Rent expense for the years ended December 31, 2020 and 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146685176680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_LicenseAgreementDisclosureTextBlock', window );">License Agreement</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">8.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> License agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Harvard/Broad license agreement and Broad license agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In March 2019, the Company simultaneously entered into the Harvard/Broad License Agreement and Broad License Agreement (the &#8220;license agreements&#8221;) for certain base editing technologies pursuant to which the Company received exclusive, worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed products and nonexclusive, worldwide, sublicensable, royalty-bearing licenses under certain patent rights to research and develop licensed products. The Company agreed to use commercially reasonable efforts to develop licensed products in accordance with the development plans, to introduce any licensed products that gain regulatory approval into the commercial market, to market licensed products that have gained regulatory approval following such introduction into the market, and to make licensed products that have gained regulatory approval reasonably available to the public. The term of the agreements will continue until the expiration of the last to expire valid claim. The Company may terminate either of the license agreements without cause upon four months&#8217; prior written notice to Harvard and Broad, unless terminated earlier. In February 2021, the Company provided written notice to Broad of its intent to terminate the Broad License Agreement, which termination was effective in June 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As partial consideration for the rights granted under the Harvard/ Broad License Agreement and Broad License Agreement, the Company paid $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in non-refundable upfront license fees and also issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">276,075</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of its common stock with a fair value of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. Additional consideration under the license agreements is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Antidilution Rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;The initial shares of common stock issued to Harvard and Broad are subject to antidilution provisions as further described in Note 5, Fair value of financial instruments. The antidilution rights associated with the Company achieving a defined aggregate level of preferred stock financing were partially satisfied in 2019 and fully satisfied in 2020, which settlement amounts totaled $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively, and which amounts were settled through issuances of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">121,411</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">187,867</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">of common stock, respectively. The remaining antidilution rights obligation was fully satisfied in June 2021 upon the Company&#8217;s IPO. The settlement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">amount </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">totaled $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and was settled through issuance of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">878,098</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company's common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Success Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;The Company is required to make success payments under the license agreements as further described in Note 5, Fair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">value of financial instruments. For the years ended December 31, 2020 and 2019, no success payments were paid or due. In September 2021, certain success payments were triggered and amounts due to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. These amounts were settled in cash in November 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Other Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;The Company agreed to pay an annual license maintenance fee ranging from low-to-mid five figures to low six figures,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">depending on the particular calendar year, for each of the license agreements. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Harvard and Broad related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">46.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">108</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in development and sales-based milestones, respectively. If the Company undergoes a change of control during the term of the license agreements, then certain of the milestone payments would be increased by a mid-double-digit percentage. The milestones have not been achieved and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> expense has been recorded for these milestones as of December 31, 2021. To the extent there are sales of a licensed product, the Company is required to pay low single digit royalties on net sales, for each of the license agreements. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company concluded that the assets acquired from Harvard and Broad did not meet the accounting definition of a business as inputs, but no processes or outputs were acquired with the licenses. As the inputs that were acquired along with the licenses do not constitute a &#8220;business,&#8221; the transaction has been accounted for as an asset acquisition. As of the date of the license agreements, the assets acquired had no alternative future use and the assets had not reached a stage of technological feasibility. As a result, all share-based and cash payment obligations have been recorded as research and development expense in the statement of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">At the inception of the license agreements in March 2019, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as research and development expense, which includes the non-refundable upfront license fees payable in cash and the fair value of the common stock issued, along with the initial fair values of the antidilution rights liability and success payment liability. As further disclosed in Note 5, the antidilution rights liability and success payment liability are remeasured at fair value each reporting period with subsequent changes recognized in other income (expense).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Verily agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In March 2019, the Company and Verily Life Sciences LLC (&#8220;Verily&#8221;) entered into a collaboration agreement. Pursuant to the agreement, the Company and Verily intend to collaborate to utilize Verily&#8217;s nanoparticle platform to screen, develop and characterize improved nanoparticles for the delivery of the Company&#8217;s gene editing tools to enable development and commercialization of nanoparticle-based drug products. As part of the agreement, Verily granted the Company an exclusive, perpetual, worldwide, sublicensable, fully paid right and license to Verily&#8217;s solely owned and developed intellectual property to research, develop, make, offer for sale, sell and import products targeting the Company&#8217;s gene targets for the treatment or prevention of atherosclerotic cardiovascular disease. The term of the agreement continues until the earlier of (i) completion of all activities related to the collaboration or (ii) the three-year anniversary of the agreement date, unless terminated earlier. At any time during the term, the Company has the right to terminate the agreement in its entirety for any reason by delivering a 90-day termination notice to Verily.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As partial consideration for the license rights granted by Verily, at inception of the arrangement, the Company paid a one-time, nonrefundable fee through the issuance of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,672,240</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred with a fair value of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. To the extent achieved, the Company was obligated to make one-time payments to Verily of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in development-based milestones. The Company paid a milestone payment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in 2020 related to a study in wild type mice that demonstrated a certain gene editing percentage level. In addition, as consideration for Verily&#8217;s activities under the agreement, the Company was obligated to pay a $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million quarterly development payment for a period of ten quarters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company concluded the assets acquired from Verily did not meet the accounting definition of a business as inputs, but no processes or outputs were acquired with the licenses. As the inputs that were acquired along with the licenses do not constitute a &#8220;business,&#8221; the transaction has been accounted for as an asset acquisition. As of the date of the collaboration agreement, the assets acquired had no alternative future use and the assets had not reached a stage of technological feasibility. As a result, at the inception of the agreement in 2019, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">as research and development expense, which includes the one-time, nonrefundable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">license </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">fee settled through issuing </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,672,240</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred. In addition, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in quarterly development payments to Verily as research and development expense in 2019. In 2020, the Company recognized the milestone payment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million described above as research and development expense upon achievement of the related development-based milestone. Further, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in quarterly development payments to Verily as research and development expense in 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company elected to terminate the agreement with Verily effective June 26, 2020 and has </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> outstanding amounts due or payable to Verily as of December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Beam license agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In April 2019, the Company and Beam Therapeutics, Inc. (&#8220;Beam&#8221;) entered into a collaboration and license agreement. Pursuant to the agreement, the Company received an exclusive, worldwide, sublicensable license under certain of Beam&#8217;s base editing technology, gene editing, and delivery technologies to develop, make, use, offer for sale, sell and import base editing products and nuclease products using Beam&#8217;s CRISPR associated protein 12b, or Cas12b technology, in each case, directed to any of four gene targets, including the PCSK9 and ANGPTL3 genes, that are associated with an increased risk of coronary diseases. In addition, the Company granted Beam an exclusive, worldwide, sublicensable license under certain of its delivery technology to develop, manufacture, sell and import product candidates and products, except for base editor products licensed to Verve.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Both parties may conduct certain activities in accordance with an agreed-upon research and/or development plan. Following the final dosing of a patient in a Phase 1 clinical trial of a given licensed product, Beam has the right to opt in to share </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">33</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share profits and expenses of commercializing such licensed product in the United States on a 50/50 basis. If Beam exercises its opt-in right for a given licensed product, which we refer to following such opt-in as a collaboration product, it will be obligated to pay for a specified percentage of the development and commercialization costs of such collaboration product and will have the right to receive a specified percentage of the profits from any sales of such collaboration product. The term of the agreement continues until the last to expire of any royalty term for any product. The Company has the right to terminate the agreement as to any licensed product, but not for any collaboration product, by delivering a 90-day termination notice to Beam, provided that Beam has elected not to exercise its opt-in right or the period to exercise such opt-in right has expired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company is responsible for all costs and expenses incurred in the conduct of activities under the research plan, any development plan and any costs and expenses for the development of a licensed product for which Beam has not elected to opt-in.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As partial consideration for the license rights granted by Beam, the Company paid a one-time, nonrefundable fee through issuing </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">276,075</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of its common stock with a fair value of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. To the extent achieved, for each licensed product, the Company is also obligated to pay up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in development and regulatory-based milestones and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in sales-based milestones. To the extent there are sales of a licensed product, the Company is required to pay low-to-mid single digit royalties on net sales. To the extent achieved, for each collaboration product outside of the United States, the Company is obligated to pay up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in development and regulatory-based milestones and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in sales-based milestones. To the extent there are ex-U.S. sales of a collaboration product, the Company is required to pay low-to-mid single digit royalties on net sales. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The milestones have not been achieved and no expense has been recorded for these milestones as of December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The parties have also promised that in further consideration for the licenses granted under the parties&#8217; respective delivery technologies, each party will pay to the other party development-based milestone payments up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for each delivery technology product of such paying party to achieve the corresponding milestone event. The triggering of these milestone payments was not considered probable as of the transaction date, and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> expense has been recorded for these milestones as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021. To the extent there are sales of a delivery technology product, each party will pay the other party low-to-mid single digit royalties based on the annual aggregate worldwide net sales resulting from the sale of each delivery technology product of such paying party; provided, however, that such royalty payments will not apply to net sales of the collaboration products or licensed products. The Company concluded the receipt of any milestone or royalty payments under the agreement was not probable as of December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Company further concluded the assets acquired from Beam did not meet the accounting definition of a business as inputs, but no processes or outputs were acquired with the licenses. As the inputs that were acquired along with the licenses do not constitute a &#8220;business,&#8221; the transaction has been accounted for as an asset</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">acquisition. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of the date of the license agreement, the assets acquired had no alternative future use and the assets had not reached a stage of technological feasibility. As a result, at the inception of the agreement in 2019, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as research and development expense, which includes the one-time, nonrefundable license fee settled through the issuance of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">276,075</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Beam materials exchange letter agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In October 2020, the Company and Beam entered into a materials exchange agreement wherein the parties agreed that Beam would provide certain mRNA, gRNA, and protein to the Company and that the Company would provide certain gRNAs to Beam at an agreed upon price per each material provided.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For the year ended December 31, 2021, the Company did </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">t purchase any materials from Beam. For the year ended December 31, 2020, the Company purchased $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as a charge to research and development expense related to materials purchased from Beam.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For the year ended December 31, 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as a reduction to research and development expense related to reimbursements received for materials sold to Beam. During the year ended December 31, 2020, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as a reduction to research and development expense related to reimbursements received for materials sold to Beam.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Acuitas agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Development and option agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2019, the Company and Acuitas Therapeutics, Inc. ("Acuitas") entered into a development and collaboration agreement, which agreement was amended and restated in October 2020. The Company agreed to reimburse Acuitas on a quarterly basis for its services performed related to the program activities based on an agreed upon number of fulltime employees committed to work on the program at an annual rate per employee, including reimbursement of reasonable external costs. These services commenced during 2020 and the Company recognized research and development expense of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for the years ended December 31, 2021 and 2020, respectively, related to the reimbursement of research and development services provided by Acuitas and technology maintenance fees. In 2020 upon the one-year anniversary of the agreement the Company had exercised one of its options to enter into a non-exclusive license agreement, as further described below.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">License agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In October 2020, the Company paid Acuitas a non-refundable, upfront license fee of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million (less a previously paid target reservation fee) to exercise an option with respect to a licensed product and a licensed genome target and entered into a non-exclusive, worldwide license with Acuitas, with a right to sub-license through multiple tiers, under the licensed LNP technology to research, develop and commercialize the licensed products using the LNP technology in connection with the PCSK9 gene target for all human therapeutic or prophylactic uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To the extent achieved, the Company is also obligated to pay up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in clinical and regulatory milestones and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in sales-based milestones. The milestones have not been achieved and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> expense has been recorded for these milestones as of December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Third-party license agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In October 2021, the Company entered into a license agreement with a third party to obtain a non-exclusive license to certain technology the Company is using for research and development. As consideration for the license and rights granted under the agreement, the Company made a one-time, non-refundable, upfront payment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million during the three months ended December 31, 2021. The license agreement provides for specified development milestones relating to the licensed technology and requires the Company to make payments upon achievement of each milestone up to an aggregate amount of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Abstract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_LicenseAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_LicenseAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146685339912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock Tranche Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_PreferredStockTrancheLiabilityTextBlock', window );">Preferred Stock Tranche Liability</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">9. Preferred stock tranche liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Included in the terms of the Series A Preferred Stock purchase agreement were certain tranche rights whereupon the Company was obligated to issue, and the Series A Preferred investors had the obligation to purchase, additional shares of Series A Preferred Stock, as follows:</span></p><div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">29,347,825</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred Stock at $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.598</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share upon the Company achieving certain scientific and non-scientific milestones ("second tranche"); and</span></div></div><div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#8226;</span><div style="display:inline;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">49,749,167</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred Stock at $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.598</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share upon the Company achieving additional scientific and non-scientific milestones ("third tranche").</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The second tranche and third tranche represent freestanding financial instruments accounted for as liabilities under ASC 480, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Distinguishing Liabilities From Equity, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">because these tranche rights (i) embody an obligation to repurchase the Company's equity shares and (ii) may require the Company to settle the obligation by transferring assets. As a result, upon issuance, the respective tranche rights were initially recorded at fair value and subsequently re-measured at fair value in each reporting period (and at settlement, as applicable). Changes in fair value were recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. The second tranche and third tranche were settled in 2019 and 2020, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Second tranche</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In April 2019, the board of directors agreed to amend certain scientific milestones and subsequently determined the second tranche milestones, as modified, were achieved and the Company settled the second tranche by issuing </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_91ee41f9-52b7-4c98-a858-be106bcef7e4;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">29,347,825</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred Stock at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.598</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Third tranche</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In March 2020, the board of directors agreed to waive the final remaining milestones and determined the third tranche milestones, as modified, were achieved. In March 2020, the Company settled the third tranche by issuing </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">49,749,167</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred Stock at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.598</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">29.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PreferredStockTrancheLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock tranche liability disclosure text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PreferredStockTrancheLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146685281848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_PreferredStockAbstract', window );"><strong>Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_PreferredAndCommonStockTextBlock', window );">Preferred and Common Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">10. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Preferred and common stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has issued and sold Series A Preferred, Series A-2 Preferred, Series B Preferred and common stock, as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During 2018, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19,565,217</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.598</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. The Company incurred issuance costs in connection with these transactions of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. These issuances included the tranche rights for the second tranche and third tranche, as previously described in Note 9, Preferred Stock tranche liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In March 2019, the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,672,240</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred in exchange for in-licensing certain technologies from Verily. See Note 8, License agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In August 2019, the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">29,347,825</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.598</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. This issuance represented the settlement of the second tranche. See Note 9, Preferred Stock tranche liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In October 2019, the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">836,122</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.598</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. This issuance included tranche rights for the third tranche.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In March 2020, the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">49,749,167</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A Preferred at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.598</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">29.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. This issuance represented the settlement of the third tranche.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Between April and June 2020, the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">78,348,461</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series A-2 Preferred at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.8041</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">63.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. The Company incurred issuance costs in connection with this transaction of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In January 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">77,163,022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series B Preferred Stock at a price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.2182</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">94.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. The Company incurred issuance costs in connection with this transaction of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2021, the Company amended and restated its certificate of incorporation to authorize </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of preferred stock, which shares of preferred stock are currently undesignated, and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">200,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock, $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> par value per share.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2021, the Company completed its IPO, pursuant to which the Company issued and sold </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,141,157</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of its common stock, including </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,105,368</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">306.7</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company received approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">281.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in net proceeds, after deducting underwriting discounts and offering expenses payable by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Upon the closing of the IPO, all outstanding shares of the Company's preferred stock automatically converted into </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">27,720,923</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company's common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">878,098</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of its common stock to Harvard and Broad as final settlement of its antidilution rights obligation.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The holders of common stock are entitled to one vote for each share of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following is a summary of the rights and preferences of the Series A Preferred, Series A-2 Preferred and Series B Preferred, prior to the completion of the Company's IPO:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Conversion</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Each share of Series A Preferred, Series A-2 Preferred and Series B Preferred may be converted at any time, at the option of the holder, into shares of common stock, subject to the applicable conversion rate as determined by dividing the original issue price by the conversion price. The initial conversion price for each of the Series A Preferred, Series A-2 Preferred and Series B Preferred (each as may be adjusted for certain dilutive events) was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.598</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.8041</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.2182</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, respectively. Each series of Series A Preferred, Series A-2 Preferred and Series B Preferred automatically converted into shares of common stock on a </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_b2d78b98-0d63-4d03-af96-185a21d44c07;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1:1</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> conversion ratio (as may be adjusted for certain dilutive events) at the earlier of the closing of an initial public offering of the Company&#8217;s common stock with gross proceeds to the Company of at least $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and a purchase price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">22.34</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, or at the election of the holders of at least two-thirds of the then-outstanding shares of Preferred Stock.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Dividends</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;Holders were entitled to non-cumulative dividends of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.05</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share with respect to Series A Preferred and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.06</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share with respect to the Series A-2 Preferred, and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share with respect to Series B Preferred when, as, and if declared by the board of directors. No dividends have been declared through December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Voting Rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;Series A Preferred, Series A-2 Preferred, Series B Preferred and common stock generally voting together as one class on an as-converted basis; however, common stock voting rights on certain matters were subject to the powers, preferences, and rights of the Series A Preferred, Series A-2 Preferred and Series B Preferred. The holders of Series A Preferred, Series A-2 Preferred and Series B Preferred, voting together as a single class, were entitled to elect three directors to the Company&#8217;s board of directors and the holders of common stock, voting as a single class, were entitled to elect two directors to the Company&#8217;s board of directors. Certain actions, such as mergers, consolidation, sale of substantially all assets, liquidation, dissolution, wind up of business, or any other deemed liquidation events, must be approved by the holders of at least two-thirds of the then-outstanding shares of Series A Preferred, Series A-2 Preferred and Series B Preferred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Liquidation Preference</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;Upon liquidation, dissolution, or winding up of business, the holders of the Series A Preferred, Series A-2 Preferred and Series B Preferred were entitled to receive a liquidation preference in priority over the holders of common stock, at an amount per share equal to the greater of i) the original Series A Preferred, Series A-2 Preferred and Series B Preferred issue price plus any declared but unpaid dividends, or ii) the amount per share payable had all shares of Series A Preferred, Series A-2 Preferred and Series B Preferred been converted to common stock immediately prior to such liquidation. If assets available for distribution are insufficient to satisfy the liquidation payment to holders in full, assets available for distribution would have been allocated among holders based on their pro rata shareholdings. When holders are satisfied in full, any excess assets available for distribution would have been allocated ratably among the holders of common stock based on their pro rata holdings. Upon a deemed liquidation event, as defined, holders had the option to redeem their outstanding shares at a price equal to the liquidation payment amounts summarized above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Redemption</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;Aside from upon the occurrence of a deemed liquidation event, the Series A Preferred, Series A-2 Preferred and Series B Preferred were not redeemable.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PreferredAndCommonStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred and common stock disclosure text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PreferredAndCommonStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146682696472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">11. Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2018 Equity Incentive Plan, or the 2018 Plan, adopted by the board of directors in August 2018 provided for the grant of qualified incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock and restricted stock units to the Company&#8217;s employees, officers, directors, advisors, and outside consultants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the issuance or purchase of shares of the Company&#8217;s common stock. The maximum number of shares of common stock that were authorized for issuance under the 2018 Plan was </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,885,653</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2021, the Company's board of directors adopted, and the Company's stockholders approved, the 2021 Stock Incentive Plan, or the 2021 Plan, which became effective on June 16, 2021. The 2021 Plan provides for grant of qualified and nonqualified stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, and other share-based awards to the Company's employees, directors, advisors and outside consultants. Under the 2021 Plan, the number of shares of common stock that was initially reserved for issuance under the 2021 Plan was the sum of: (1) </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,466,530</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">; plus (2) the number of shares as is equal to the sum of (x) the number of shares of common stock reserved for issuance under the 2018 Plan that remained available for grant under the 2018 Plan on June 16, 2021 and (y) the number of shares of common stock subject to outstanding awards granted under the 2018 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an annual increase, to be added on the first day of each fiscal year, commencing on January 1, 2022 and continuing until, and including, January 1, 2031, equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the number of shares of common stock outstanding on such date</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and (ii) the number of shares of common stock determined by the Company's board of directors. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 the Company had reserved</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,632,042</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company's common stock for issuance of stock options and restricted stock, of which </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,489,589</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> remained outstanding for future grant under the 2021 Plan. On January 1, 2022, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,425,587</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company's common stock were added to the amount reserved for issuance under the 2021 Plan in accordance with the 2021 Plan described above. Upon effectiveness of the 2021 Plan, the Company ceased granting additional awards under the 2018 Plan.</span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Stock-based compensation expense recorded in the consolidated statements of operations and comprehensive loss is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.764%;"/>
        <td style="width:1.382%;"/>
        <td style="width:1.431%;"/>
        <td style="width:10.903%;"/>
        <td style="width:0.716%;"/>
        <td style="width:1.382%;"/>
        <td style="width:1.431%;"/>
        <td style="width:10.874%;"/>
        <td style="width:0.716%;"/>
        <td style="width:1.382%;"/>
        <td style="width:1.431%;"/>
        <td style="width:10.874%;"/>
        <td style="width:0.716%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended<br/>December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,830</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">336</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,242</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">356</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">110</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,072</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">850</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">446</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Stock options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The assumptions used in Black-Scholes for stock options granted were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.355%;"/>
        <td style="width:1.371%;"/>
        <td style="width:0.715%;"/>
        <td style="width:10.166%;"/>
        <td style="width:2.296%;"/>
        <td style="width:1.371%;"/>
        <td style="width:0.715%;"/>
        <td style="width:10.166%;"/>
        <td style="width:2.296%;"/>
        <td style="width:1.371%;"/>
        <td style="width:0.715%;"/>
        <td style="width:10.166%;"/>
        <td style="width:2.296%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended<br/>December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">77.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">84.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">76.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted-average risk-free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.9</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.0</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.0</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.9</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table provides a summary of stock option activity during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.065%;"/>
        <td style="width:1.193%;"/>
        <td style="width:0.706%;"/>
        <td style="width:9.89%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.431%;"/>
        <td style="width:10.764%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.193%;"/>
        <td style="width:0.726%;"/>
        <td style="width:11.42%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.431%;"/>
        <td style="width:10.824%;"/>
        <td style="width:0.706%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Number of<br/>options</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Weighted<br/>average<br/>exercise<br/>price per<br/>share</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Weighted<br/>average<br/>remaining<br/>contractual<br/>life (in years)</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Aggregate<br/>intrinsic<br/>value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Arial;position:relative;">(2)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"><br/>(in thousands)</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,888,823</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.13</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,869,946</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17.66</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">599,838</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.61</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">39,636</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.56</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,119,295</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9.44</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8.7</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">171,636</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Exercisable at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,373,507</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.15</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8.0</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">47,691</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected to vest after December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Arial;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,745,788</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11.56</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8.9</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">123,945</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;">This represents the number of unvested options outstanding as of December 31, 2021 that are expected to vest in the future.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;"> </span></div></div><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December 31, 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;"> </span></div></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the year ended December 31, 2021 the weighted average grant-date fair value of the stock options granted </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">14.27</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The aggregate intrinsic value of stock options exercised during the year ended December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> was approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million while the Company received $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in proceeds for the exercise of these options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, there was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">40.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.9</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Restricted stock and restricted stock units</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In 2018, the Company issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,150,537</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of restricted common stock. The restricted shares vested in </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">48</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> equal monthly installments, commencing on January 1, 2018. The restricted shares were fully vested as of December 31, 2021.</span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A summary of the status of and change in unvested restricted stock as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.822%;"/>
        <td style="width:1.581%;"/>
        <td style="width:0.716%;"/>
        <td style="width:13.391%;"/>
        <td style="width:0.865%;"/>
        <td style="width:1.074%;"/>
        <td style="width:1.591%;"/>
        <td style="width:0.726%;"/>
        <td style="width:13.52%;"/>
        <td style="width:0.716%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Shares</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Weighted-<br/>average grant<br/>date fair<br/>value per share</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unvested restricted stock as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">537,633</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0028</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Restricted stock vested</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">537,633</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0028</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unvested restricted stock as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, the Company granted </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> restricted stock units under the 2021 Plan. These restricted stock units vest in substantially equal installments over a </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">four-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A summary of the status of and change in unvested restricted stock units as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.398%;"/>
        <td style="width:1.59%;"/>
        <td style="width:0.726%;"/>
        <td style="width:13.4%;"/>
        <td style="width:0.716%;"/>
        <td style="width:1.054%;"/>
        <td style="width:2.256%;"/>
        <td style="width:0.726%;"/>
        <td style="width:13.419%;"/>
        <td style="width:0.716%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Shares</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Weighted-<br/>average grant<br/>date fair<br/>value per share</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unvested restricted stock units as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Restricted stock units granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">36.58</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unvested restricted stock units as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">36.58</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">At December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, there was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of unrecognized stock-based compensation expense related to restricted stock units that are expected to vest. These costs are expected to be recognized over a weighted-average remaining vesting period of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.0</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">2021 Amended and Restated Employee Stock Purchase Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2021, the board of directors adopted, and the Company's stockholders approved, the 2021 Employee Stock Purchase Plan, or the ESPP, as amended and restated, which became effective on June 16, 2021. The Company has initially reserved </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">433,316</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock for sale under the ESPP. The aggregate number of shares reserved for sale under the ESPP will increase automatically on the first day of each fiscal year commencing on January 1, 2022 through January 1, 2031, by the number of shares equal to the least of (a) </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,083,290</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares, (b) </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the total outstanding shares of common stock on such date, and (c) a number of shares as may be determined by the board of directors in any particular year. The first offering period under the ESPP commenced on June 16, 2021 and ended on December 13, 2021. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">48,297</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares had been purchased by employees under the ESPP and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">385,019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares remained available for issuance under the ESPP. On January 1, 2022, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">485,117</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock were added to the amount reserved for sale under the ESPP. The second offering period commenced on December 14, 2021 and will end on May 31, 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146685319576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">12. Net loss per share attributable to common stockholders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.457%;"/>
        <td style="width:1.372%;"/>
        <td style="width:1.432%;"/>
        <td style="width:10.876%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.372%;"/>
        <td style="width:1.432%;"/>
        <td style="width:10.846%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.372%;"/>
        <td style="width:1.432%;"/>
        <td style="width:10.846%;"/>
        <td style="width:0.855%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands, except share and per share amounts)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">120,314</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">45,704</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19,297</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted average number of common shares, basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">26,872,036</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,250,093</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,277,156</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss per common share attributable to common stockholders, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">20.31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">15.11</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s potential dilutive securities, which include convertible preferred stock, unvested restricted stock and common stock options, have been excluded from the computation of diluted net loss per share as the effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.859%;"/>
        <td style="width:1.382%;"/>
        <td style="width:0.716%;"/>
        <td style="width:11.561%;"/>
        <td style="width:0.716%;"/>
        <td style="width:1.382%;"/>
        <td style="width:0.716%;"/>
        <td style="width:11.581%;"/>
        <td style="width:0.716%;"/>
        <td style="width:1.382%;"/>
        <td style="width:0.716%;"/>
        <td style="width:11.561%;"/>
        <td style="width:0.716%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Convertible preferred stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19,387,544</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,553,367</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unvested restricted stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">537,633</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,075,268</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unvested restricted stock units</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Outstanding options to purchase common stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,119,295</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,888,823</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,933,507</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,151,295</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">23,814,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,562,142</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As part of the license agreements with Harvard and Broad, the Company is required to make success payments. The Company may elect to make these payments by issuing shares of the Company's common stock. As of December 31, 2021, an aggregate of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million was earned relating to these success payments, which the Company settled in cash in November 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146685188776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">13. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">Income taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For the years ended December 31, 2021, 2020 and 2019, the Company did not record a current or deferred income tax expense or benefit due to current and historical losses incurred by the Company. The Company&#8217;s losses before income taxes consist solely of losses from domestic operations, which totaled </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">120.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">45.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> for the years ended December 31, 2021, 2020 and 2019, respectively</span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.103%;"/>
        <td style="width:1.362%;"/>
        <td style="width:0.706%;"/>
        <td style="width:9.423%;"/>
        <td style="width:3.141%;"/>
        <td style="width:1.362%;"/>
        <td style="width:0.706%;"/>
        <td style="width:9.423%;"/>
        <td style="width:3.141%;"/>
        <td style="width:1.362%;"/>
        <td style="width:0.706%;"/>
        <td style="width:9.423%;"/>
        <td style="width:3.141%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">31.3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">29.6</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17.9</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Executive compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other permanent items</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#8217;s deferred tax assets and liabilities as of December 31, 2021 and 2020 are comprised of the following</span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.358%;"/>
        <td style="width:1.601%;"/>
        <td style="width:1.432%;"/>
        <td style="width:12.924%;"/>
        <td style="width:0.865%;"/>
        <td style="width:1.601%;"/>
        <td style="width:1.432%;"/>
        <td style="width:12.924%;"/>
        <td style="width:0.865%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">33,409</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12,973</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Capitalized costs&#8212;net of amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12,395</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">855</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,098</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">682</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Antidilution liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,815</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,117</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">149</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">61</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Lease liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">533</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_0691f387-dd9a-4985-8c9a-0c01efabf653;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,852</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">905</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">56,480</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18,440</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">899</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,061</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Right of use asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">501</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_20d4266c-6aad-4cbb-ab46-faac5900b5d5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,400</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,061</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total deferred tax assets, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">55,080</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17,379</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">55,080</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17,379</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has incurred net operating losses in each year since inception. The Company had no income tax expense due to the operating loss incurred for all years since inception. Management has evaluated the positive and negative evidence bearing upon the realizability of the Company&#8217;s net deferred tax assets, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">which are comprised primarily of net operating loss carryforwards, tax credits, and costs capitalized for tax purposes. Management has considered the Company&#8217;s history of cumulative net losses in the United States and estimated future tax losses and</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> has determined that it is more likely than not that the Company will not recognize the benefits of the net deferred tax assets. As a result, the Company has recorded a full valuation allowance at December 31, 2021 and 2020. The valuation allowance increased by </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">37.7</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> in 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, due to the increase in deferred tax assets, primarily due to net operating loss carryforwards, tax credit carryforwards, and increase in deferred tax assets associated with current year temporary items. The valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in 2020, primarily due to the increase in deferred tax assets, primarily due to net operating loss carryforwards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Realization of the future tax benefits is dependent on many factors, including the Company&#8217;s ability to generate taxable income within the net operating loss carryforward period. The Company&#8217;s ability to utilize these federal and state net operating loss and research and development credit carryforwards may be limited in the future if the Company experiences an ownership change pursuant to Internal Revenue Code 382. </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">An ownership change occurs when the ownership percentages of 5% or greater shareholders change by more than 50% over a three-year period.</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> As of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021, the Company has not completed a study to assess whether a change of control has occurred and whether the net operating losses and credits are limited due to a change in ownership. To the extent that an assessment is completed in the future, the Company&#8217;s ability to utilize tax attributes could be restricted on a year-by-year basis and certain attributes could expire before they are utilized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, the Company had approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">124.7</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of pre-tax federal and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">114.4</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of pre-tax state net operating loss carryforwards. The federal net operating losses have an indefinite life and can be utilized to offset </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">80</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of future taxable income, while the state net operating losses will start to expire at various dates through </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2041</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Additionally, as of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, the Company had approximately $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of federal and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of Massachusetts tax credits that expire starting in </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2041</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2036</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021 and 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, the Company had </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> uncertain tax positions. The Company recognizes both interest and penalties associated with unrecognized tax benefits as a component of income tax expense. The Company has </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">t recorded any interest or penalties for unrecognized tax benefits since its inception.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Company files income tax returns in the United States, California, Connecticut, the Commonwealth of Massachusetts, and Pennsylvania. The Company is not currently under examination by the Internal Revenue Service or any other jurisdiction for these years. All tax years remain open to tax examination. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may be adjusted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">upon </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. No federal or state tax audits are currently in process.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146685325688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">14. Related party transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the years ended December 31, 2021, 2020 and 2019, the Company made total payments o</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">f $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively, to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> the five founder shareholders for scientific consulting and other expenses. These same individuals also vested in </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">537,633</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">537,635</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">537,635</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of restricted stock in the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021, 2020 and 2019, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">An executive officer of Beam is a board member of the Company. From February 2019 through December 2019, the Company leased office space from Beam in Cambridge, Massachusetts. Total rent payments under this sublease was less than $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In April 2019, the Company and Beam entered into a collaboration and license agreement. As partial consideration for the license rights granted by Beam, the Company paid a one-time, nonrefundable fee through issuing </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">276,075</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of its common stock with a fair value of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. Refer to Note 8, License agreements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In July 2019, the Company agreed to be designated as Beam&#8217;s collaboration partner in an NHP study connected to Beam&#8217;s development and option agreement with Acuitas. As a result, Beam granted the Company a non-exclusive, royalty-free sublicense under Beam&#8217;s right, title and interest in and to certain Acuitas technology, solely to the extent necessary to enable the Company to perform the NHP study activities. The Company paid to Beam a one-time payment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million upon execution of the agreement and is responsible for certain out-of-pocket costs incurred by Beam in connection with the performance of the NHP study activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In October 2020, the Company and Beam entered into a materials exchange agreement wherein the parties agreed that Beam would provide certain mRNA, gRNA, and protein to the Company and that the Company would provide certain gRNAs to Beam at an agreed upon price per each material provided. For the year ended December 31, 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as a reduction to research and development expense related to reimbursements received for materials sold to Beam. For the year ended December 31, 2020, the Company recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as research and development expense related to payments made for materials purchased from Beam and also recognized $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as a reduction to research and development expense related to reimbursements received for materials sold to Beam</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2021, the Company entered into a sublease agreement with Beam for laboratory and office space in Cambridge, Massachusetts. Total rent payments under this sublease were less than $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">An officer of the Company was formerly affiliated with Massachusetts General Hospital (&#8220;MGH&#8221;) as a physician. As of August 2021, the officer is no longer a physician at MGH. In February 2019 and November of 2019, the Company entered into an Option License Agreement and Patent License Agreement, respectively, with MGH. Upon execution of the agreements in 2019, the Company incurred $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for option and license issue fees, which were recorded as research and development expense. For the years ended December 2021 and 2020, the Company incurred $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million each year relating to the annual license fee, which was recorded as research and development expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">An executive of Broad was a board member of the Company. The board member resigned, effective May 2021. In March 2019, the Company simultaneously entered into the Harvard/Broad License Agreement and Broad License Agreement for certain base editing technologies pursuant to which the Company received exclusive, worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed products and nonexclusive, worldwide, sublicensable, royalty-bearing licenses under certain patent rights to research and develop licensed products. Additional consideration under the license agreements include antidilution rights and success payments. See Note 8, License agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146682697592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">15. Employee benefit plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has a defined-contribution plan established under Section 401(k) of the Internal Revenue Code (the &#8220;401(k) Plan&#8221;), which covers substantially all employees. Employees are eligible to participate in the 401(k) Plan beginning on the first day of the month following commencement of their employment. </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The 401(k) Plan includes a salary deferral arrangement pursuant to which participants may elect to reduce their current compensation by up to the sta</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">tutorily prescribed limit, equal to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19,500</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> in 2021 with a catch up contribution limit equal to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,500</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> for </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">those 50 years of age or older, and have the amount of the reduction contributed to the 401(k) </span></span><span style=""/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Plan.</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> Since January 1, 2020 the Company matches </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">100</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of each participant&#8217;s annual contribution to the 401(k) plan up to </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the participant&#8217;s salary and then </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">50</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of each participant&#8217;s contribution up to </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the participant&#8217;s salary. The match immediately vests </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">100</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%. The matching c</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ontributions by the Company to the 401(k) plan were $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146685365656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">16. S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;">ubsequent events</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company evaluated all subsequent events and determined there are no material recognized or unrecognized subsequent events requiring disclosure.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146681029912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Principles of consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The accompanying consolidated financial statements include the accounts of Verve and its wholly owned subsidiary, Verve Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair values of common stock (prior to completion of the IPO), convertible preferred stock, preferred stock tranche liability, stock-based compensation, and the liabilities for antidilution rights and success payments. Actual results could differ from these estimates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Cash and cash equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cash and cash equivalents consist of standard checking accounts and money market account funds that invest primarily in U.S. government-backed securities and treasuries. The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at cost, which is substantially equivalent to fair value.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Restricted cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Restricted cash represents collateral provided for a letter of credit issued as a security deposit in connection with the Company&#8217;s leases of its corporate facilities. </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:</span></span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.402%;"/>
          <td style="width:1.6%;"/>
          <td style="width:1.441%;"/>
          <td style="width:13.052%;"/>
          <td style="width:0.716%;"/>
          <td style="width:1.6%;"/>
          <td style="width:1.441%;"/>
          <td style="width:13.032%;"/>
          <td style="width:0.716%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31,</span></p></td>
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">64,330</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,993</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,237</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">463</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">69,567</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9,456</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Marketable securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are maintained by the Company&#8217;s investment managers and consist of U.S. treasury bills and U.S agency securities. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income (loss) as a component of stockholders&#8217; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense).</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Company reviews marketable securities for other-than-temporary impairment whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security&#8217;s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if the Company has experienced a credit loss, has the intent to sell the marketable security, or if it is more likely than not that the Company will be required to sell the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">marketable </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">security before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company&#8217;s investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period. The Company evaluated its securities for other-than-temporary impairment and considered the decline in market value for the securities to be primarily attributable to current economic and market conditions. It is not more likely than not that the Company will be required to sell the securities, and the Company does not intend to do so prior to the recovery of the amortized cost basis. Based on this analysis, these marketable securities were not considered to be other-than-temporarily impaired as of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Concentrations of credit risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and restricted cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_DeferredOfferingCostsPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Deferred offering costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company capitalized incremental legal, professional accounting and other third-party fees that were directly associated with the IPO as other non-current assets until the IPO was consummated. After consummation of the IPO, these costs were recorded in stockholders&#8217; equity (deficit) as a reduction of additional paid-in-capital generated as a result of the offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_IndemnificationAgreementsPolicyTextBlock', window );">Indemnification Agreements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Indemnification agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Fair value of financial instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ASC Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Fair Value Measurement </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Level 1&#8212;Quoted market prices in active markets for identical assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Level 2&#8212;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Level 3&#8212;Unobservable inputs for the asset or liability (i.e. supported by little or no market activity). Level 3 inputs include management&#8217;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There have been no changes to the valuation methods utilized by the Company during the years ended December 31, 2021, 2020 and 2019. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Property and equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment are stated at cost less accumulated depreciation. </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.968%;"/>
          <td style="width:2.064%;"/>
          <td style="width:48.968%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Asset category</span></p></td>
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Office furniture</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Shorter of useful life or remaining lease term</span></span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Impairment of long-lived assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> impairment losses recognized during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021, 2020 and 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock', window );">Freestanding Financial Instruments and Derivatives</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Freestanding financial instruments and derivatives</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has identified the following financial instruments, which are recorded as liabilities in the balance sheet and separately accounted for at fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Preferred Stock Tranche Liabilities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;The Company has determined that its obligation to issue, and the Company&#8217;s investors&#8217; right to purchase, additional shares of convertible Series A Preferred Stock (&#8220;Series A Preferred&#8221;) pursuant to subsequent closings represent a freestanding financial instrument. The freestanding preferred stock tranche liability (the &#8220;tranche liability&#8221;) was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss. The tranche liabilities were remeasured at each reporting period and upon the exercise or expiration of the obligation. As of December 31, 2020, all Series A Preferred closings occurred, and all preferred stock tranche liabilities have been settled. Refer to Note 9, Preferred Stock tranche liability, for additional discussion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pursuant to license agreements with (i) the President and Fellows of Harvard College (&#8220;Harvard&#8221;) and The Broad Institute, Inc. (&#8220;Broad&#8221;) (&#8220;Harvard/Broad License Agreement&#8221;) and (ii) Broad (&#8220;Broad License Agreement&#8221;) (see Note 8, License agreements), the following financial instruments were issued by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Antidilution Rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;The antidilution rights represent the obligation to issue additional shares of common stock to Harvard and Broad following the completion of additional financings, including the Company&#8217;s initial public offering. These antidilution rights were accounted for under ASC 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Derivatives and Hedging ("ASC 815"),</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and were initially recorded at fair value with a corresponding charge to research and development expense. The liability was remeasured at each reporting period, with changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss while this instrument was outstanding. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The obligation was satisfied in full upon the issuance of an aggregate of an additional </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">878,098</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock upon the closing of the Company's IPO in June 2021. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Refer to Note 5, Fair value of financial instruments, for additional discussion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Success Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;The Company is obligated to pay to Harvard and Broad tiered success payments in the event the Company&#8217;s average market capitalization exceeds specified thresholds ascending from a high nine digit dollar amount to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control of the Company or a sale of the Company, the Company is required to pay in cash within a specified period following such event. Otherwise, the payments may be settled at the Company&#8217;s option in either cash or shares of the Company&#8217;s common stock. The success payments are accounted for under ASC 815 and were initially recorded at fair value with a corresponding charge to research and development expense. The liability is remeasured at each reporting period with all changes in value recognized in other income (expense) in the statement of operations and other comprehensive loss. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the year ended December 31, 2021, certain success payment obligations were triggered, and amounts paid to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> These amounts were settled in cash in November 2021. The Company will continue to adjust the liability for changes in fair value until the earlier of the achievement or expiration of the remaining success payment obligation. Refer to Note 5, Fair value of financial instruments, for additional discussion</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Research and development costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, third-party license fees related to technology with no alternative</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">future </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">use, laboratory supplies, depreciation, manufacturing expenses, preclinical expenses, consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s stock-based compensation program allows for grants of stock options and restricted stock awards. Grants are awarded to employees and non-employees, including directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Compensation-Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> (&#8216;&#8216;ASC 718&#8217;&#8217;). ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#8216;&#8216;Black-Scholes&#8217;&#8217;) for stock option grants to both employees and non-employees. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s stock-based compensation awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized over the implied service period when achievement of the performance-based milestones is deemed probable. The Company uses judgement to determine whether and, if so, how many awards are deemed probable of vesting at each reporting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The estimation of fair value for stock-based compensation requires management to make estimates and judgments about, among other things, the estimated life of options and volatility of the Company&#8217;s common stock. The judgments directly affect the amount of compensation expense that will be recognized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to the Company's IPO in June 2021, there was no public market for its common stock. As a result, prior to the IPO, the estimated fair value of the Company's common stock was determined by its board of directors as of the date of each option grant, with input from management, considering the Company's most recently available third-party valuations of common stock and its board of directors' assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of grant. Following the Company's IPO, the fair value of its common stock is determined based on the closing price of the Company's common stock as reported on the Nasdaq Global Select Market</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_RentExpensePolicyTextBlock', window );">Rent Expense</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Rent expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s real estate operating leases provide for scheduled annual rent increases throughout the lease term. The Company recognizes the effects of the scheduled rent increases on a straight-line basis over the full term of the lease. Prior to the adoption of ASU 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, or ASC 842, tenant improvement allowances, if any, provided by the landlord are recorded as deferred rent and amortized as reduction to rent expense over the lease term. Subsequent to the adoption of ASC 842, tenant improvement allowances, if any, provided by a landlord are recorded as a reduction of the right-of-use, or ROU, asset related to that lease.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Income taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Comprehensive loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2021, 2020 and 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, the Company&#8217;s only element of other comprehensive income (loss) was unrealized gains (losses) on marketable securities.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Net loss per share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2021, 2020 and 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_SegmentAndGeographicInformationPolicyTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Segment and geographic information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#8217;s Chief Executive Officer. The Company views its operations as and manages its business in </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> operating segment operating exclusively in the United States.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Subsequent events</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company performs an evaluation of all subsequent events after the balance sheet date through the date of issuance of the consolidated financial statements to ensure appropriate disclosure of events both recognized in the consolidated financial statements and events which occurred subsequently but were not recognized in the consolidated financial statements.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Recently adopted accounting pronouncements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), as subsequently amended, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors), and replaces the existing guidance in ASC 840. The FASB has issued several updates to the standard which: (i) clarify how to apply certain aspects of the new standard; (ii) provide an additional transition method for adoption of the new standard; (iii) provide a practical expedient for certain lessor accounting; and (iv) amend certain narrow aspects of the guidance. The new standard requires the identification and classification of arrangements that are or contain a lease and requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine the recognition pattern of lease expense over the term of the lease. In addition, a lessee is required to record (i) a right-of-use asset and a lease liability on its balance sheet for all leases with accounting lease terms of more than 12 months regardless of whether it is an operating or finance lease and (ii) lease expense in its consolidated statement of operations for operating leases and amortization and interest expense in its consolidated statement of operations for financing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">leases. Leases with a term of 12 months or less may be accounted for similar to existing guidance for operating leases under ASC 840. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842), which added an optional transition method that allows companies to adopt the standard as of the beginning of the year of adoption as opposed to the earliest comparative period presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to January 1, 2021, the Company accounted for leases pursuant to ASC 840, Leases. At lease inception, the Company determined if an arrangement was an operating or capital lease. For operating leases, the Company recognized rent expense, inclusive of rent escalations, holidays and lease incentives, on a straight-line basis over the lease term. The difference between rent expense recorded and the amount paid was recorded as deferred rent. The Company presented lease incentives as deferred rent and amortized the incentives as a reduction to rent expense on a straight-line basis over the lease term. The Company classified deferred rent as current and noncurrent liabilities based on the portion of the deferred rent that was scheduled to mature within the next twelve months.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adopted </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Topic 842 during the quarter ended September 30, 2021, with an effective adoption date of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, using the modified retrospective transition approach which uses the effective date, or January 1, 2021, as the date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. At contract inception, the Company determines if an arrangement is or contains a lease. A lease conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If an arrangement is determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on which the leased asset is made available for use by the Company, based on the economic characteristics of the lease. The Company has elected to apply the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or the capitalization of initial direct costs for any existing leases. As a result of the adoption of ASC 842, the Company recorded (i) an operating lease liability of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million determined using an incremental borrowing rate as of the effective adoption date and (ii) an operating lease right-of-use asset of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, net of the unamortized balance of prepaid/accrued rent as of the transition date. There was </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> impact to the Company&#8217;s results of operations and cash flows from operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has elected the short-term lease exemption, which allows the Company to not recognize lease liabilities and right-of-use assets arising from lease arrangements with lease terms of twelve months or less. For each lease with a term greater than twelve months, the Company records a right-of-use asset and lease liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A right-of-use asset represents the economic benefit conveyed to the Company by the right to use the underlying asset over the lease term. A lease liability represents the Company&#8217;s obligation to make lease payments under the arrangement. The Company measures its lease liabilities at lease commencement as the present value of the future lease payments in the contract using the rate implicit in the contract, when available. As an implicit rate has not historically been readily determinable, the Company uses an incremental borrowing rate measured as the rate at which the Company could borrow, on a fully collateralized basis, a commensurate loan in the same currency over a period consistent with the lease term at the commencement date. The incremental borrowing rate is determined based on the Company's synthetic secured rating using the ordered logit model as of the measurement date. The Company measures its right-of-use assets as the lease liability plus initial direct costs and prepaid lease payments, less lease incentives granted by the lessor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Components of a lease are split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) are allocated, based on the respective relative fair values, to the lease components and non-lease components. The Company has elected to account for lease and associated non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company remeasures right-of-use assets and lease liabilities when a lease is modified, and the modification is not accounted for as a separate contract. A modification is accounted for as a separate contract if the modification grants the Company an additional right of use not included in the original lease arrangement and the increase in lease payments is commensurate with the additional right of use. The Company assesses its right-of-use assets for impairment in a manner consistent with its assessment for long-lived assets held and used in operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s operating leases are presented in the consolidated balance sheet as operating lease right-of-use assets, classified as noncurrent assets, and operating lease liabilities, classified as current and noncurrent liabilities. Operating lease expense is recognized on a straight-line basis over the lease term. Variable costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">associated with a lease, such as maintenance and utilities, are not included in the measurement of the lease liabilities and right-of-use assets but rather are expensed when the events determining the amount of variable consideration to be paid have occurred.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Recently issued accounting pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company ("EGC") to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. As an EGC, the Company has elected to take advantage of this extended transition period for certain new accounting standards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Financial Instruments&#8212;Credit Losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The new standard will be effective for the Company on January 1, 2023. The Company is currently evaluating the potential impact that this standard may have on its consolidated financial position and results of operations.</span></span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Freestanding financial instruments and derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IndemnificationAgreementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indemnification agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IndemnificationAgreementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_RentExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting policy of rent expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_RentExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SegmentAndGeographicInformationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting policy related to segment and geographic information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SegmentAndGeographicInformationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146685293928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.402%;"/>
          <td style="width:1.6%;"/>
          <td style="width:1.441%;"/>
          <td style="width:13.052%;"/>
          <td style="width:0.716%;"/>
          <td style="width:1.6%;"/>
          <td style="width:1.441%;"/>
          <td style="width:13.032%;"/>
          <td style="width:0.716%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31,</span></p></td>
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">64,330</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,993</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,237</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">463</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">69,567</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9,456</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Schedule of Property and Equipment Estimated Useful Life</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.968%;"/>
          <td style="width:2.064%;"/>
          <td style="width:48.968%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Asset category</span></p></td>
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Office furniture</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Shorter of useful life or remaining lease term</span></span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of cash, cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of property and equipment estimated useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146685347816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Marketable securities by security type consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.07%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.432%;"/>
        <td style="width:9.414%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.441%;"/>
        <td style="width:9.414%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.441%;"/>
        <td style="width:9.285%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.432%;"/>
        <td style="width:9.365%;"/>
        <td style="width:0.706%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31, 2021</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Amortized<br/>cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Gross<br/>unrealized<br/>gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Gross<br/>unrealized<br/>losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Fair<br/>value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">277,559</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">218</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">277,341</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18,781</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18,771</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">296,340</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">228</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">296,112</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.12%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.432%;"/>
        <td style="width:9.414%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.441%;"/>
        <td style="width:9.414%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.441%;"/>
        <td style="width:9.414%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.432%;"/>
        <td style="width:9.335%;"/>
        <td style="width:0.706%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31, 2020</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Amortized<br/>cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Gross<br/>unrealized<br/>gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Gross<br/>unrealized<br/>losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Fair<br/>value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,221</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,224</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">30,890</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">30,895</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">63,111</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">63,119</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146682674408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Table)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment, net, consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.359%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1.441%;"/>
        <td style="width:12.92%;"/>
        <td style="width:0.865%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1.441%;"/>
        <td style="width:12.91%;"/>
        <td style="width:0.865%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Lab equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,567</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,937</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">266</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">259</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">566</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">481</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Computer equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">158</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">105</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9,557</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,782</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,333</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">798</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,224</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,984</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146763510504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value of Financial Instruments, Assets and Liabilities</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following tables set forth the fair value of the Company&#8217;s financial instruments by level within the fair value hierarchy: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.289%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.431%;"/>
        <td style="width:9.373%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.431%;"/>
        <td style="width:9.343%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.431%;"/>
        <td style="width:9.373%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.431%;"/>
        <td style="width:9.303%;"/>
        <td style="width:0.706%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">As of December 31, 2021</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Fair<br/>value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">58,127</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">58,127</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">277,341</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">277,341</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">354,239</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">58,127</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">296,112</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Success payment liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,371</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,371</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.359%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.432%;"/>
        <td style="width:9.345%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.432%;"/>
        <td style="width:9.315%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.432%;"/>
        <td style="width:9.345%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.432%;"/>
        <td style="width:9.315%;"/>
        <td style="width:0.706%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">As of December 31, 2020</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Fair<br/>value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,724</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,724</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,224</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,224</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">30,895</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">30,895</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">69,843</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,724</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">63,119</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Success payment liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,806</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,806</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Antidilution rights liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,916</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,916</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9,722</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9,722</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Liabilities Measured on Recurring Basis</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The primary inputs used in valuing (i) the success payments liability and (ii) the antidilution rights liability associated with the Company&#8217;s realization of a certain valuation threshold through either a sale of the Company&#8217;s preferred stock, an initial public offering, or a company sale at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 (only applicable to success payments liability), 2020 and 2019, were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.375%;"/>
        <td style="width:1.352%;"/>
        <td style="width:1.432%;"/>
        <td style="width:12.138%;"/>
        <td style="width:2.287%;"/>
        <td style="width:1.352%;"/>
        <td style="width:1.432%;"/>
        <td style="width:12.138%;"/>
        <td style="width:2.287%;"/>
        <td style="width:1.352%;"/>
        <td style="width:1.432%;"/>
        <td style="width:12.138%;"/>
        <td style="width:2.287%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">At<br/>December 31,<br/>2021</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">At<br/>December 31,<br/>2020</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">At<br/>December 31,<br/>2019</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fair value of common stock (per share)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">36.87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8.24</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.59</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Equity volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">77</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">105</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">100</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cumulative probability of triggering event</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">n/a</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">n/a</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.50</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.89</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Reconciliation of Changes in Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.244%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.431%;"/>
        <td style="width:10.556%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.441%;"/>
        <td style="width:10.635%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.431%;"/>
        <td style="width:10.536%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.431%;"/>
        <td style="width:9.144%;"/>
        <td style="width:0.855%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Preferred<br/>stock<br/>tranche<br/>liability</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Antidilution<br/>rights<br/>liability</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Success<br/>payment<br/>liability</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Balance at December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9,571</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,044</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">419</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12,034</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of Series A Preferred</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,064</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,064</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">487</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">487</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,507</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,359</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,387</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,239</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,916</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,806</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9,722</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of common stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,490</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,490</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Success payment liability earned and paid</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_170610ab-9c1b-4510-8f28-c508389451c8;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_716c6897-a6df-4fdf-9e99-b336dfd3b30f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">25,574</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,815</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">33,389</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146685296904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued expenses consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.395%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1.441%;"/>
        <td style="width:13.05%;"/>
        <td style="width:0.716%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1.441%;"/>
        <td style="width:13.04%;"/>
        <td style="width:0.716%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Employee compensation and related benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,050</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,636</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued external research and development expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,041</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,827</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,109</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">303</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">792</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">423</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12,992</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,189</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146686883640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Operating Lease Cost</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The components of operating lease cost were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.863%;"/>
        <td style="width:1.938%;"/>
        <td style="width:1.441%;"/>
        <td style="width:16.032%;"/>
        <td style="width:0.726%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31, 2021</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,923</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Variable lease costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">747</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Short term lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,278</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,948</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock', window );">Supplemental Cash Flow Information Related to Operating Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Supplemental cash flow information related to operating leases was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.863%;"/>
        <td style="width:1.938%;"/>
        <td style="width:1.441%;"/>
        <td style="width:16.032%;"/>
        <td style="width:0.726%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31, 2021</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cash paid for amounts included in the measurements of lease liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating cash flows related to operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Lease Commitments under Non-Cancellable Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Future minimum commitments under non-cancellable leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.833%;"/>
        <td style="width:1.938%;"/>
        <td style="width:1.441%;"/>
        <td style="width:15.923%;"/>
        <td style="width:0.865%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Years ending December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Amount</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12,951</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9,958</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10,257</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10,565</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10,882</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">54,158</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">108,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less: interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">108,758</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental cash flow information related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146679751032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Stock-based compensation expense recorded in the consolidated statements of operations and comprehensive loss is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.764%;"/>
        <td style="width:1.382%;"/>
        <td style="width:1.431%;"/>
        <td style="width:10.903%;"/>
        <td style="width:0.716%;"/>
        <td style="width:1.382%;"/>
        <td style="width:1.431%;"/>
        <td style="width:10.874%;"/>
        <td style="width:0.716%;"/>
        <td style="width:1.382%;"/>
        <td style="width:1.431%;"/>
        <td style="width:10.874%;"/>
        <td style="width:0.716%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended<br/>December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,830</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">336</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,242</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">356</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">110</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,072</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">850</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">446</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used for Options Granted</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The assumptions used in Black-Scholes for stock options granted were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.355%;"/>
        <td style="width:1.371%;"/>
        <td style="width:0.715%;"/>
        <td style="width:10.166%;"/>
        <td style="width:2.296%;"/>
        <td style="width:1.371%;"/>
        <td style="width:0.715%;"/>
        <td style="width:10.166%;"/>
        <td style="width:2.296%;"/>
        <td style="width:1.371%;"/>
        <td style="width:0.715%;"/>
        <td style="width:10.166%;"/>
        <td style="width:2.296%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended<br/>December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">77.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">84.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">76.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted-average risk-free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.9</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.0</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.0</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.9</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table provides a summary of stock option activity during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.065%;"/>
        <td style="width:1.193%;"/>
        <td style="width:0.706%;"/>
        <td style="width:9.89%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.431%;"/>
        <td style="width:10.764%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.193%;"/>
        <td style="width:0.726%;"/>
        <td style="width:11.42%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.431%;"/>
        <td style="width:10.824%;"/>
        <td style="width:0.706%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Number of<br/>options</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Weighted<br/>average<br/>exercise<br/>price per<br/>share</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Weighted<br/>average<br/>remaining<br/>contractual<br/>life (in years)</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Aggregate<br/>intrinsic<br/>value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Arial;position:relative;">(2)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"><br/>(in thousands)</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,888,823</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.13</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,869,946</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17.66</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">599,838</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.61</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">39,636</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.56</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,119,295</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9.44</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8.7</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">171,636</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Exercisable at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,373,507</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.15</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8.0</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">47,691</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected to vest after December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Arial;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,745,788</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11.56</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8.9</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">123,945</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;">This represents the number of unvested options outstanding as of December 31, 2021 that are expected to vest in the future.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;"> </span></div></div><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December 31, 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;"> </span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Status and Change in Unvested Restricted Stock and Restricted Stock Units</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A summary of the status of and change in unvested restricted stock as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.822%;"/>
        <td style="width:1.581%;"/>
        <td style="width:0.716%;"/>
        <td style="width:13.391%;"/>
        <td style="width:0.865%;"/>
        <td style="width:1.074%;"/>
        <td style="width:1.591%;"/>
        <td style="width:0.726%;"/>
        <td style="width:13.52%;"/>
        <td style="width:0.716%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Shares</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Weighted-<br/>average grant<br/>date fair<br/>value per share</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unvested restricted stock as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">537,633</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0028</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Restricted stock vested</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">537,633</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0028</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unvested restricted stock as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A summary of the status of and change in unvested restricted stock units as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.398%;"/>
        <td style="width:1.59%;"/>
        <td style="width:0.726%;"/>
        <td style="width:13.4%;"/>
        <td style="width:0.716%;"/>
        <td style="width:1.054%;"/>
        <td style="width:2.256%;"/>
        <td style="width:0.726%;"/>
        <td style="width:13.419%;"/>
        <td style="width:0.716%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Shares</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Weighted-<br/>average grant<br/>date fair<br/>value per share</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unvested restricted stock units as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Restricted stock units granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">36.58</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unvested restricted stock units as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">36.58</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146682705416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.457%;"/>
        <td style="width:1.372%;"/>
        <td style="width:1.432%;"/>
        <td style="width:10.876%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.372%;"/>
        <td style="width:1.432%;"/>
        <td style="width:10.846%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.372%;"/>
        <td style="width:1.432%;"/>
        <td style="width:10.846%;"/>
        <td style="width:0.855%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands, except share and per share amounts)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">120,314</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">45,704</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19,297</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted average number of common shares, basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">26,872,036</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,250,093</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,277,156</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss per common share attributable to common stockholders, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">20.31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">15.11</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.859%;"/>
        <td style="width:1.382%;"/>
        <td style="width:0.716%;"/>
        <td style="width:11.561%;"/>
        <td style="width:0.716%;"/>
        <td style="width:1.382%;"/>
        <td style="width:0.716%;"/>
        <td style="width:11.581%;"/>
        <td style="width:0.716%;"/>
        <td style="width:1.382%;"/>
        <td style="width:0.716%;"/>
        <td style="width:11.561%;"/>
        <td style="width:0.716%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Convertible preferred stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19,387,544</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,553,367</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unvested restricted stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">537,633</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,075,268</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unvested restricted stock units</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Outstanding options to purchase common stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,119,295</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,888,823</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,933,507</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,151,295</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">23,814,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,562,142</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146681870456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.103%;"/>
        <td style="width:1.362%;"/>
        <td style="width:0.706%;"/>
        <td style="width:9.423%;"/>
        <td style="width:3.141%;"/>
        <td style="width:1.362%;"/>
        <td style="width:0.706%;"/>
        <td style="width:9.423%;"/>
        <td style="width:3.141%;"/>
        <td style="width:1.362%;"/>
        <td style="width:0.706%;"/>
        <td style="width:9.423%;"/>
        <td style="width:3.141%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year ended December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">31.3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">29.6</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17.9</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Executive compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other permanent items</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Taxes</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.358%;"/>
        <td style="width:1.601%;"/>
        <td style="width:1.432%;"/>
        <td style="width:12.924%;"/>
        <td style="width:0.865%;"/>
        <td style="width:1.601%;"/>
        <td style="width:1.432%;"/>
        <td style="width:12.924%;"/>
        <td style="width:0.865%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">33,409</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12,973</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Capitalized costs&#8212;net of amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12,395</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">855</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,098</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">682</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Antidilution liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,815</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,117</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">149</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">61</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Lease liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">533</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_0691f387-dd9a-4985-8c9a-0c01efabf653;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,852</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">905</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">56,480</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18,440</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">899</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,061</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Right of use asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">501</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_20d4266c-6aad-4cbb-ab46-faac5900b5d5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,400</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,061</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total deferred tax assets, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">55,080</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17,379</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">55,080</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17,379</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146679972296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 21, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (120,314)<span></span>
</td>
<td class="num">$ (45,704)<span></span>
</td>
<td class="num">$ (19,297)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (186,850)<span></span>
</td>
<td class="num">(66,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,214<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds From Issuance Of Preferred Stock And Preference Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,759<span></span>
</td>
<td class="nump">$ 92,616<span></span>
</td>
<td class="nump">$ 18,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="nump">2,105,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="nump">16,141,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting discount</a></td>
<td class="nump">$ 306,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="nump">$ 281,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion of preferred stock</a></td>
<td class="nump">27,720,923<span></span>
</td>
<td class="nump">27,720,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-9.2595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds From Issuance Of Preferred Stock And Preference Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 523,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146682015176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 64,330<span></span>
</td>
<td class="nump">$ 8,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">5,237<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 69,567<span></span>
</td>
<td class="nump">$ 9,456<span></span>
</td>
<td class="nump">$ 3,221<span></span>
</td>
<td class="nump">$ 5,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146681040216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_PercentageOfTaxBenefitRealized', window );">Percentage of tax benefit realized</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability, payable</a></td>
<td class="nump">$ 6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 108,758,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 1,839,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_HarvardAndBroadLicenseAgreementMember', window );">Harvard and Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability, payable</a></td>
<td class="nump">$ 10,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_IssuanceOfAdditionalCommonStock', window );">Issuance of Additional Common Stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_SuccessLiabilityPayment', window );">Success Liability Payment</a></td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 33: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IssuanceOfAdditionalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of additional common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IssuanceOfAdditionalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PercentageOfTaxBenefitRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of tax benefit realized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PercentageOfTaxBenefitRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SuccessLiabilityPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Success Liability Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SuccessLiabilityPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_HarvardAndBroadLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_HarvardAndBroadLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146679806872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_OfficeFurnitureMember', window );">Office Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment estimated useful life</a></td>
<td class="text">Shorter of useful life or remaining lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_OfficeFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_OfficeFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146676048504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 296,340<span></span>
</td>
<td class="nump">$ 63,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">296,112<span></span>
</td>
<td class="nump">63,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Bills and Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">277,559<span></span>
</td>
<td class="nump">32,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(218)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">277,341<span></span>
</td>
<td class="nump">32,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">18,781<span></span>
</td>
<td class="nump">30,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 18,771<span></span>
</td>
<td class="nump">$ 30,895<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146685178264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable securities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm', window );">Remaining contractual maturities of marketable securities term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining contractual maturities of marketable securities term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146675094008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and equipment, net - Schedule of Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 9,557<span></span>
</td>
<td class="nump">$ 4,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(2,333)<span></span>
</td>
<td class="num">(798)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,224<span></span>
</td>
<td class="nump">3,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">8,567<span></span>
</td>
<td class="nump">3,937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">566<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146763587576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146676653608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Summary of Financial Instruments within Fair value hierarchy (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 354,239<span></span>
</td>
<td class="nump">$ 69,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">4,371<span></span>
</td>
<td class="nump">9,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">58,127<span></span>
</td>
<td class="nump">6,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=verv_USTreasuryBillsAndNotesMember', window );">U S Treasury Bills And Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">277,341<span></span>
</td>
<td class="nump">32,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=verv_USAgencySecuritiesMember', window );">U S Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">18,771<span></span>
</td>
<td class="nump">30,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=verv_SuccessPaymentLiabilityMember', window );">Success Payment Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">4,371<span></span>
</td>
<td class="nump">2,806<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=verv_AntidilutionRightsLiabilityMember', window );">Antidilution Rights Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">58,127<span></span>
</td>
<td class="nump">6,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">58,127<span></span>
</td>
<td class="nump">6,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U S Treasury Bills And Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U S Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Success Payment Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Antidilution Rights Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">296,112<span></span>
</td>
<td class="nump">63,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U S Treasury Bills And Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">277,341<span></span>
</td>
<td class="nump">32,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U S Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">18,771<span></span>
</td>
<td class="nump">30,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Success Payment Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Antidilution Rights Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">4,371<span></span>
</td>
<td class="nump">9,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U S Treasury Bills And Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U S Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Success Payment Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 4,371<span></span>
</td>
<td class="nump">2,806<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Antidilution Rights Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,916<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=verv_USTreasuryBillsAndNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=verv_USTreasuryBillsAndNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=verv_USAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=verv_USAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=verv_SuccessPaymentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=verv_SuccessPaymentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=verv_AntidilutionRightsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=verv_AntidilutionRightsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146676402472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 58,100<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="nump">48,511,735<span></span>
</td>
<td class="nump">3,123,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Issuance of common stock, value</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability, payable</a></td>
<td class="nump">6,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue', window );">Servicing Liability at Fair Value, Other Changes in Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability', window );">Research and development expense of antidilution rights liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_HarvardAndBroadLicenseAgreementMember', window );">Harvard and Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability, payable</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Success payment liability</a></td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_SuccessPaymentLiabilityCurrent', window );">Success payment, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_BroadLicenseAgreementMember', window );">Broad License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="nump">276,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_FairValueInputsProbabilityOfTermination', window );">Fair value inputs probability of termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Harvard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability, payable</a></td>
<td class="nump">$ 31,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember', window );">Other Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Success payment liability</a></td>
<td class="nump">7,800<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=verv_AntidilutionRightsLiabilityMember', window );">Antidilution Rights Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,867<span></span>
</td>
<td class="nump">121,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Issuance of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability, payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=verv_AntidilutionRightsLiabilityMember', window );">Antidilution Rights Liability | Other Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Increase in liabilities</a></td>
<td class="nump">25,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=verv_PreferredStockTrancheLiabilityMember', window );">Preferred Stock Tranche Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Increase in liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability, payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from changes in fair value classified as other for a contract to service financial assets under which the estimated future revenues from contractually specified servicing fees, late charges, and other ancillary revenues are not expected to adequately compensate the servicer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(4)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=125521744&amp;loc=d3e122625-111746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_FairValueInputsProbabilityOfTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value inputs probability of termination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_FairValueInputsProbabilityOfTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense of antidilution rights liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SuccessPaymentLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Success Payment Liability Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SuccessPaymentLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_HarvardAndBroadLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_HarvardAndBroadLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_BroadLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_BroadLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_HarvardLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_HarvardLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=verv_AntidilutionRightsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=verv_AntidilutionRightsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=verv_PreferredStockTrancheLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=verv_PreferredStockTrancheLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146681010888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_FairValueOfCommonStockPerShare', window );">Fair value of common stock (per share)</a></td>
<td class="nump">$ 36.87<span></span>
</td>
<td class="nump">$ 8.24<span></span>
</td>
<td class="nump">$ 2.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_CumulativeProbabilityOfTriggeringEvent', window );">Cumulative probability of triggering event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_FairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 20 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Equity Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_FairValueAssumptionOfEquityVolatilityRate', window );">Equity volatility</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_FairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_CumulativeProbabilityOfTriggeringEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative probability of triggering event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_CumulativeProbabilityOfTriggeringEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_FairValueAssumptionOfEquityVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assumption of equity volatility rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_FairValueAssumptionOfEquityVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_FairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assumptions expected term 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_FairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_FairValueOfCommonStockPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_FairValueOfCommonStockPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146679388600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Insruments - Schedule of Reconciliation of Changes in Fair Value of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Beginning balance</a></td>
<td class="nump">$ 9,722<span></span>
</td>
<td class="nump">$ 12,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,064)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_CommonStockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="num">(32,490)<span></span>
</td>
<td class="num">(487)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability, payable</a></td>
<td class="num">(6,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="nump">33,389<span></span>
</td>
<td class="nump">5,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Ending balance</a></td>
<td class="nump">4,371<span></span>
</td>
<td class="nump">9,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=verv_PreferredStockTrancheLiabilityMember', window );">Preferred Stock Tranche Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,064)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_CommonStockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability, payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,507)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=verv_AntidilutionRightsLiabilityMember', window );">Antidilution Rights Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Beginning balance</a></td>
<td class="nump">6,916<span></span>
</td>
<td class="nump">2,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_CommonStockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="num">(32,490)<span></span>
</td>
<td class="num">(487)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability, payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="nump">25,574<span></span>
</td>
<td class="nump">5,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=verv_SuccessPaymentLiabilityMember', window );">Success Payment Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Beginning balance</a></td>
<td class="nump">2,806<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_CommonStockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability, payable</a></td>
<td class="num">(6,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="nump">7,815<span></span>
</td>
<td class="nump">2,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Ending balance</a></td>
<td class="nump">$ 4,371<span></span>
</td>
<td class="nump">$ 2,806<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_CommonStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issued During Period Value New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_CommonStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=verv_PreferredStockTrancheLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=verv_PreferredStockTrancheLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=verv_AntidilutionRightsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=verv_AntidilutionRightsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=verv_SuccessPaymentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=verv_SuccessPaymentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146679947592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation and related benefits</a></td>
<td class="nump">$ 6,050<span></span>
</td>
<td class="nump">$ 1,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_AccruedExternalResearchAndDevelopmentExpenses', window );">Accrued external research and development expenses</a></td>
<td class="nump">5,041<span></span>
</td>
<td class="nump">4,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">792<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 12,992<span></span>
</td>
<td class="nump">$ 7,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_AccruedExternalResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued external research and development expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_AccruedExternalResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146674596680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 19, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 30, 2022 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_LeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_LeaseNoncancelableTerm', window );">Lease noncancelable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has the option to extend the sublease for one extension term of three months by written notice not less than six months prior to the expiration of the sublease term, which the Company is not reasonably certain of exercising.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Increase in operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,940)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,839<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_LesseeOperatingLeaseIncrementalBorrowingRate', window );">Operating lease incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=verv_NewAmendmentMember', window );">New Amendment | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_LesseeOperatingLeaseArea', window );">Lease area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_AdditionalLesseeOperatingLeaseArea', window );">Additional Lease Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_CambridgeLeaseMember', window );">Cambridge Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_LesseeOperatingLeaseArea', window );">Lease area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset', window );">Increase in Right-Of-Use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Increase in operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_CambridgeLeaseMember', window );">Cambridge Lease | First Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_LesseeOperatingLeaseArea', window );">Lease area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_CambridgeLeaseMember', window );">Cambridge Lease | Second Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_LesseeOperatingLeaseArea', window );">Lease area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_PremisesMember', window );">Premises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_LesseeOperatingLeaseArea', window );">Lease area | ft&#178;</a></td>
<td class="nump">104,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease not yet commenced, lease term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend', window );">Option to extend, lease not yet commenced</a></td>
<td class="text">five years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend', window );">Option to extend true/false, lease not yet commenced</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions', window );">Operating lease payment term, lease not yet commenced, terms and conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company&#8217;s obligation for the payment of base rent for the Boston Lease begins 90 days after the Commencement Date (the &#8220;Rent Commencement Date&#8221;) and will initially be $0.8 million per month, which will increase by approximately 3% per annum.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate', window );">Option to terminate, lease not yet commenced</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_TenantImprovementsAllowance', window );">Tenant improvements allowance</a></td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_AdditionalTenantImprovementsAllowance', window );">Additional tenant improvements allowance</a></td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_InterestRateForAdditionalImprovementsAllowance', window );">Improvement allowance interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_OperatingLeaseRelatedExpensesPriorToCommencement', window );">Lease space build out cost prior to commencement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_PremisesMember', window );">Premises | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Letter of credit issued</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_ShortTermBorrowingsReducedValue', window );">Letter of credit reduced value</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to terminate operating lease not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease that has not yet commenced. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of basis, terms, and conditions on which variable lease payment for lessee's operating lease that has not yet commenced is determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_AdditionalLesseeOperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Lessee Operating Lease Area</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_AdditionalLesseeOperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_AdditionalTenantImprovementsAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional tenant improvements allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_AdditionalTenantImprovementsAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Operating Lease Right Of Use Of Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_InterestRateForAdditionalImprovementsAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate for additional improvements allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_InterestRateForAdditionalImprovementsAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_LeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Commencement Date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_LeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_LeaseNoncancelableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Noncancelable Term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_LeaseNoncancelableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_LesseeOperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease area.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_LesseeOperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_LesseeOperatingLeaseIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease incremental borrowing rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_LesseeOperatingLeaseIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_OperatingLeaseRelatedExpensesPriorToCommencement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease related expenses prior to commencement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_OperatingLeaseRelatedExpensesPriorToCommencement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ShortTermBorrowingsReducedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short term borrowings reduced value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ShortTermBorrowingsReducedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_TenantImprovementsAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant improvements allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_TenantImprovementsAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=verv_NewAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=verv_NewAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_CambridgeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_CambridgeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=verv_FirstAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=verv_FirstAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=verv_SecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=verv_SecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_PremisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_PremisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146679750872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Components of Operating Lease Cost (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 1,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease costs</a></td>
<td class="nump">2,278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">$ 4,948<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146685377768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract', window );"><strong>Cash Paid For Amounts Included In The Measurements Of Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows related to operating leases</a></td>
<td class="nump">$ 2,021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurements of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146675817992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 12,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">9,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">10,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">10,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">10,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">54,158<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">108,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 108,758<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146674036152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,511,735<span></span>
</td>
<td class="nump">3,123,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281,584,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Issuance of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,202,000<span></span>
</td>
<td class="nump">$ 35,371,000<span></span>
</td>
<td class="nump">$ 11,144,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_BroadLicenseAgreementMember', window );">Broad License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_PreferredStockFinancingPartiallySatisfied', window );">Preferred stock financing partially satisfied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_PreferredStockFinancingFullySatisfied', window );">Preferred stock financing were fully satisfied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing', window );">Common stock issued for partly satisfying preferred stock financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing', window );">Common stock issued for fully satisfying preferred stock financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_PaymentOfMilestoneDevelopment', window );">Payment of milestone development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_PaymentOfSalesBasedMilestone', window );">Payment of sales based milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_MilestoneRelatedExpenses', window );">Milestone related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_HarvardAndBroadLicenseAgreementMember', window );">Harvard and Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Success payment liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_VerilyLicenseAgreementMember', window );">Verily License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_NonRefundableUpfrontLicenseFeesPaid', window );">Non-refundable upfront license fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_DevelopedBaseMilestonePayments', window );">Developed base milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_DevelopedBaseMilestonePaymentsForStatedPeriod', window );">Developed base milestone payments for quarterly period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Amount due as a result of termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_VerilyLicenseAgreementMember', window );">Verily License Agreement | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,672,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,672,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_BeamLicenseAgreementMember', window );">Beam License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Issuance of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_PaymentOfMilestoneDevelopment', window );">Payment of milestone development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_PaymentOfSalesBasedMilestone', window );">Payment of sales based milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_PercentageSharesOfDevelopmentExpense', window );">Percentage Shares of Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_MilestoneRelatedExpenses', window );">Milestone related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred', window );">Reimbursement received related to reduction to research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_BeamLicenseAgreementMember', window );">Beam License Agreement | Delivery Technology Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_PaymentOfMilestoneDevelopment', window );">Payment of milestone development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_BeamLicenseAgreementMember', window );">Beam License Agreement | Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_PaymentOfMilestoneDevelopment', window );">Payment of milestone development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_PaymentOfSalesBasedMilestone', window );">Payment of sales based milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_AcuitasAgreementsMember', window );">Acuitas Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_MilestoneRelatedExpenses', window );">Milestone related expenses</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_NonRefundableUpfrontLicenseFee', window );">Non Refundable Upfront License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_ClinicalAndRegulatoryMilestone', window );">Clinical And Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_SalesBasedMilestone', window );">Sales Based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_NonRefundableUpfrontPayment', window );">Non Refundable Upfront Payment</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement | Broad License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_NonRefundableUpfrontLicenseFeesPaid', window );">Non-refundable upfront license fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=verv_AntidilutionRightsMember', window );">Antidilution Rights | Broad License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Issuance of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ClinicalAndRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical and regulatory milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ClinicalAndRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for fully satisfying preferred stock financing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for partly satisfying preferred stock financing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DevelopedBaseMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Developed base milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DevelopedBaseMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DevelopedBaseMilestonePaymentsForStatedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Developed base milestone payments for quarterly period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DevelopedBaseMilestonePaymentsForStatedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_MilestoneRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone related expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_MilestoneRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_NonRefundableUpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non refundable upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_NonRefundableUpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_NonRefundableUpfrontLicenseFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable upfront license fees paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_NonRefundableUpfrontLicenseFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_NonRefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non refundable upfront payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_NonRefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PaymentOfMilestoneDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of milestone development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PaymentOfMilestoneDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PaymentOfSalesBasedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of sales based milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PaymentOfSalesBasedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment received for license agreement reimbursement of costs incurred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PercentageSharesOfDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Shares of Development Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PercentageSharesOfDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PreferredStockFinancingFullySatisfied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock financing fully satisfied</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PreferredStockFinancingFullySatisfied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PreferredStockFinancingPartiallySatisfied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock financing partially satisfied</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PreferredStockFinancingPartiallySatisfied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SalesBasedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales based milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SalesBasedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_BroadLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_BroadLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_HarvardAndBroadLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_HarvardAndBroadLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_VerilyLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_VerilyLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_BeamLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_BeamLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=verv_DeliveryTechnologyProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=verv_DeliveryTechnologyProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_AcuitasAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_AcuitasAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=verv_AntidilutionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=verv_AntidilutionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146676660344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock Tranche Liability - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,347,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.598<span></span>
</td>
<td class="nump">$ 0.598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,347,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance or sale of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Third Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,749,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, value per share</a></td>
<td class="nump">$ 0.598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">49,749,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance or sale of preferred stock</a></td>
<td class="nump">$ 29.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=verv_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=verv_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=verv_ThirdTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=verv_ThirdTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146672867144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stock - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 21, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Preferred Stock, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,759<span></span>
</td>
<td class="nump">$ 92,616<span></span>
</td>
<td class="nump">$ 18,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">255,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,511,735<span></span>
</td>
<td class="nump">3,123,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred stock, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Preferred stock, convertible terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of Series A Preferred, Series A-2 Preferred and Series B Preferred may be converted at any time, at the option of the holder, into shares of common stock, subject to the applicable conversion rate as determined by dividing the original issue price by the conversion price. The initial conversion price for each of the Series A Preferred, Series A-2 Preferred and Series B Preferred (each as may be adjusted for certain dilutive events) was $0.598, $0.8041 and $1.2182 per share, respectively. Each series of Series A Preferred, Series A-2 Preferred and Series B Preferred automatically converted into shares of common stock on a 1:1 conversion ratio (as may be adjusted for certain dilutive events) at the earlier of the closing of an initial public offering of the Company&#8217;s common stock with gross proceeds to the Company of at least $50.0 million and a purchase price of $22.34 per share, or at the election of the holders of at least two-thirds of the then-outstanding shares of Preferred Stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting discount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,214<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Preferred Stock, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 523,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses', window );">Proceeds from issuance of Preferred Stock, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,105,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_PublicPrice', window );">Public Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross', window );">Proceeds from common stock, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion of preferred stock | shares</a></td>
<td class="nump">27,720,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,720,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting discount | $</a></td>
<td class="nump">$ 306,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share | $ / shares</a></td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock, convertible, conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Non-cumulative dividends payable per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Verily License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,672,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,672,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=verv_SeriesA2PreferredStocksMember', window );">Series A-2 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock, convertible, conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Non-cumulative dividends payable per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock, convertible, conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Non-cumulative dividends payable per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=verv_HarvardAndBoardMember', window );">Harvard And Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,749,167<span></span>
</td>
<td class="nump">836,122<span></span>
</td>
<td class="nump">29,347,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,565,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.598<span></span>
</td>
<td class="nump">$ 0.598<span></span>
</td>
<td class="nump">$ 0.598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Preferred Stock, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,800<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Transaction costs on issuance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series A Preferred Stock | Verily License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,672,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series A-2 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,348,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Preferred Stock, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Transaction costs on issuance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,163,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Preferred Stock, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Transaction costs on issuance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting discount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,141,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of conversion terms for preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock Under IPO, Gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Preferred Stock after Deducting Underwriting Discounts and Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PublicPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Public price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PublicPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_VerilyLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_VerilyLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=verv_SeriesA2PreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=verv_SeriesA2PreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=verv_HarvardAndBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=verv_HarvardAndBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146673025000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Instalment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 16, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,632,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 966<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under ESPP(shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_NumberOfInstallmentsForRestrictedSharesVested', window );">Number of Installments for Restricted Shares Vested | Instalment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=verv_TwentyEighteenMember', window );">Twenty Eighteen | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,885,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=verv_TwoThousandAndTwentyOneStockIncentivePlanMember', window );">2021 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,466,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-based Compensation Arrangement by Share-based Payment Award, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">an annual increase, to be added on the first day of each fiscal year, commencing on January 1, 2022 and continuing until, and including, January 1, 2031, equal to the lesser of (i) 5% of the number of shares of common stock outstanding on such date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,489,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=verv_TwoThousandAndTwentyOneStockIncentivePlanMember', window );">2021 Stock Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=verv_TwoThousandAndTwentyOneStockIncentivePlanMember', window );">2021 Stock Incentive Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">2,425,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=verv_TwoThousandAndTwentyOneStockIncentivePlanMember', window );">2021 Stock Incentive Plan | Common Stock | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding stock, reserved for issuance</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=verv_TwentyTwentyOneEmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">433,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under ESPP(shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan', window );">Stock available for issuance under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=verv_TwentyTwentyOneEmployeeStockPurchasePlanMember', window );">ESPP | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">485,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=verv_TwentyTwentyOneEmployeeStockPurchasePlanMember', window );">ESPP | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding stock, reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance', window );">Increase in common stock capital shares, reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,083,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in common stock capital shares, reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_NumberOfInstallmentsForRestrictedSharesVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of installments for restricted shares vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_NumberOfInstallmentsForRestrictedSharesVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Available For Issuance Under Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=verv_TwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=verv_TwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=verv_TwoThousandAndTwentyOneStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=verv_TwoThousandAndTwentyOneStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=verv_TwentyTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=verv_TwentyTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146762764184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Summary of Stock Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 7,072<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
<td class="nump">$ 446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,830<span></span>
</td>
<td class="nump">494<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,242<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146681146584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Schedule of Assumptions Used for Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">77.70%<span></span>
</td>
<td class="nump">84.80%<span></span>
</td>
<td class="nump">76.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted-average risk-free interest rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146675102792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Schedule of Stock Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding, Beginning balance | shares</a></td>
<td class="nump">3,888,823<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted | shares</a></td>
<td class="nump">2,869,946<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, Exercised | shares</a></td>
<td class="num">(599,838)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of options, Forfeited | shares</a></td>
<td class="num">(39,636)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding, Ending balance | shares</a></td>
<td class="nump">6,119,295<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Exercisable | shares</a></td>
<td class="nump">1,373,507<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of options, Expected to vest | shares</a></td>
<td class="nump">4,745,788<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning balance | $ / shares</a></td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted | $ / shares</a></td>
<td class="nump">17.66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised | $ / shares</a></td>
<td class="nump">1.61<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited | $ / shares</a></td>
<td class="nump">2.56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending balance | $ / shares</a></td>
<td class="nump">9.44<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable | $ / shares</a></td>
<td class="nump">2.15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Expected to vest | $ / shares</a></td>
<td class="nump">$ 11.56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), Outstanding</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (in years), Exercisable</a></td>
<td class="text">8 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (in years), Expected to vest</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value, Outstanding | $</a></td>
<td class="nump">$ 171,636<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable | $</a></td>
<td class="nump">47,691<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, Expected to vest | $</a></td>
<td class="nump">$ 123,945<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;">This represents the number of unvested options outstanding as of December 31, 2021 that are expected to vest in the future.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December 31, 2021.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146676459128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Schedule of Status and Change in Unvested Restricted Stock and Restricted Stock Units (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=verv_TwoThousandAndTwentyOneStockIncentivePlanMember', window );">2021 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested RSUs, beginning balance, Unvested | shares</a></td>
<td class="nump">537,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Unvested Restricted stock vested | shares</a></td>
<td class="num">(537,633)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested RSUs, ending balance, Unvested | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value Per Share, beginning balance, Unvested | $ / shares</a></td>
<td class="nump">$ 0.0028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value Per Share, Vested | $ / shares</a></td>
<td class="nump">0.0028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value Per Share, ending balance, Unvested | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested RSUs, beginning balance, Unvested | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs, Granted | shares</a></td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested RSUs, ending balance, Unvested | shares</a></td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value Per Share, beginning balance, Unvested | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant-Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">36.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value Per Share, ending balance, Unvested | $ / shares</a></td>
<td class="nump">$ 36.58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=verv_TwoThousandAndTwentyOneStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=verv_TwoThousandAndTwentyOneStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146681949528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (120,314)<span></span>
</td>
<td class="num">$ (45,704)<span></span>
</td>
<td class="num">$ (19,297)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares used in net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="nump">26,872,036<span></span>
</td>
<td class="nump">2,250,093<span></span>
</td>
<td class="nump">1,277,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share attributable to common stockholders, basic and diluted</a></td>
<td class="num">$ (4.48)<span></span>
</td>
<td class="num">$ (20.31)<span></span>
</td>
<td class="num">$ (15.11)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146679769896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">6,151,295<span></span>
</td>
<td class="nump">23,814,000<span></span>
</td>
<td class="nump">8,562,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,387,544<span></span>
</td>
<td class="nump">5,553,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=verv_UnvestedRestrictedStockMember', window );">Unvested Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">537,633<span></span>
</td>
<td class="nump">1,075,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=verv_UnvestedRestrictedStockUnitsMember', window );">Unvested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=verv_OutstandingOptionsToPurchaseCommonStockMember', window );">Outstanding Options To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">6,119,295<span></span>
</td>
<td class="nump">3,888,823<span></span>
</td>
<td class="nump">1,933,507<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=verv_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=verv_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=verv_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=verv_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=verv_OutstandingOptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=verv_OutstandingOptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146681111752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_SuccessPaymentLiability', window );">Success payment liability (See Notes 5, 8 and 15)</a></td>
<td class="nump">$ 4,371<span></span>
</td>
<td class="nump">$ 2,806<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=verv_HarvardAndBoardMember', window );">Harvard And Board | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_SuccessPaymentLiability', window );">Success payment liability (See Notes 5, 8 and 15)</a></td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SuccessPaymentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Success payment liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SuccessPaymentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=verv_HarvardAndBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=verv_HarvardAndBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146676042280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(31.30%)<span></span>
</td>
<td class="num">(29.60%)<span></span>
</td>
<td class="num">(17.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock-based compensation</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent', window );">Executive compensation</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Other permanent items</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="num">(5.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Executive compensation, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Permanent Items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146679778984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 33,409<span></span>
</td>
<td class="nump">$ 12,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization', window );">Capitalized costs&#8212;net of amortization</a></td>
<td class="nump">12,395<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="nump">6,098<span></span>
</td>
<td class="nump">682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_DeferredTaxAssetsAntidilultionLiability', window );">Antidilultion liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_DeferredTaxAssetsStockBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities', window );">Lease liability</a></td>
<td class="nump">533<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_DeferredTaxAssetAccruedExpenses', window );">Accrued expenses</a></td>
<td class="nump">2,852<span></span>
</td>
<td class="nump">905<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">56,480<span></span>
</td>
<td class="nump">18,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(899)<span></span>
</td>
<td class="num">(1,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(501)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(1,400)<span></span>
</td>
<td class="num">(1,061)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total deferred tax assets, net</a></td>
<td class="nump">55,080<span></span>
</td>
<td class="nump">17,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(55,080)<span></span>
</td>
<td class="num">(17,379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences derived regulatory assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DeferredTaxAssetAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset Accrued Expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DeferredTaxAssetAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DeferredTaxAssetsAntidilultionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Antidilultion Liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DeferredTaxAssetsAntidilultionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Capitalized Costs Net Of Amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DeferredTaxAssetsStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Stock-based compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DeferredTaxAssetsStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax liabilities, Right of use asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146676354232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Income (Loss) from Continuing Operations before Income Taxes, Domestic</a></td>
<td class="nump">$ 120,300,000<span></span>
</td>
<td class="nump">$ 45,700,000<span></span>
</td>
<td class="nump">$ 19,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax assets valuation allowance increase (decrease)</a></td>
<td class="nump">$ 37,700,000<span></span>
</td>
<td class="nump">13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_ChangeInOwnershipDescription', window );">Change in ownership, description</a></td>
<td class="text">An ownership change occurs when the ownership percentages of 5% or greater shareholders change by more than 50% over a three-year period.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">124,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit amount</a></td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward expiration year</a></td>
<td class="text">2041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_PercentageOfFutureTaxableIncomeUtilizedToOffset', window );">Percentage of future taxable income utilized to offset</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 114,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=verv_MassachusettsTaxAuthorityMember', window );">Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit amount</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward expiration year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ChangeInOwnershipDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in ownership description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ChangeInOwnershipDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PercentageOfFutureTaxableIncomeUtilizedToOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future taxable income utilized to offset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PercentageOfFutureTaxableIncomeUtilizedToOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=verv_MassachusettsTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=verv_MassachusettsTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146674529928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537,633<span></span>
</td>
<td class="nump">537,635<span></span>
</td>
<td class="nump">537,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,511,735<span></span>
</td>
<td class="nump">3,123,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs of $25,098</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,202<span></span>
</td>
<td class="nump">35,371<span></span>
</td>
<td class="nump">$ 11,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_OptionAndLicenseIssueFees', window );">Option And License Issue Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCommitmentAmount', window );">Lease Rent Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=verv_BeamMember', window );">Beam | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=verv_BeamMember', window );">Beam | Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_OutOfPocketCostsIncurred', window );">Out-of-pocket costs incurred</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=verv_BeamMember', window );">Beam | Materials Exchange Agreement | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_OfficerMember', window );">Officer [Member] | Option License Agreement And Patent License Agreement | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Annual license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918705-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_OptionAndLicenseIssueFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option And License Issue Fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_OptionAndLicenseIssueFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_OutOfPocketCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>out-of-pocket costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_OutOfPocketCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=verv_BeamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=verv_BeamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_MaterialsExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_MaterialsExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_OptionLicenseAgreementAndPatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_OptionLicenseAgreementAndPatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140146680901832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Defined contribution plan, maximum annual contributions per employee, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=verv_FourZeroOneKPlanMember', window );">401(k) Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary', window );">Defined contribution plan employer matching contribution percent of match upto two percent of employee salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Defined contribution plan, maximum annual contributions per employee, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary', window );">Defined contribution plan, employer matching contribution, percent of match upto 3% of employee's salary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary', window );">Defined contribution plan, employer matching contribution, percent of match after 3% and before 5% of employee's salary</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage', window );">Defined contribution plan, employers matching contribution, annual vesting percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans', window );">Defined contribution plan, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 401(k) Plan includes a salary deferral arrangement pursuant to which participants may elect to reduce their current compensation by up to the statutorily prescribed limit, equal to $19,500 in 2021 with a catch up contribution limit equal to $6,500 for those 50 years of age or older, and have the amount of the reduction contributed to the 401(k) Plan.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer Contribution amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of defined contribution pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan, employer matching contribution, percent of match after 3% and before 5% of employee's salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan, employer matching contribution, percent of match upto 3% of employee's salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan employer matching contribution percent of match upto two percent of employee salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=verv_FourZeroOneKPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=verv_FourZeroOneKPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>verv-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:verv="http://www.vervetx.com/20211231"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="verv-20211231.xsd" xlink:type="simple"/>
    <context id="C_758d254a-8812-49dd-a35c-9b632827b258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_a6d1a849-b7f6-4b32-8b52-0bd344744eb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_3d70dec1-7c1e-48b3-b61d-3e6ca572b452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_dd29659d-951a-45fc-a69a-2e59256ccd54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">verv:FourZeroOneKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1541fd57-3030-489b-9a4b-89cd76467fe9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">verv:BeamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_2b6cf2c2-5ffb-41c1-b814-6954698f90f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_ccde73cb-e336-419a-a1be-6bc267e8d5ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_89a10d74-f017-4e8e-9761-a6d46cf3afb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:OfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6d2ce482-3934-425f-b2d1-f6ee23bbabef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_47adbab3-b838-4d39-aa2e-17b98510b0b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_88ca2b88-300c-48c8-815f-cc259e125c7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_46b3a3b3-5e47-4d6e-bbdd-cf18cb6fea59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_9a01908a-58f3-4cbb-a2c9-d102afa07909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3c6e9331-d8d3-43e7-8098-fbde994f4649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:CambridgeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-31</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="C_d04521c5-cb77-4e26-9e7d-c596e315d733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0a65eb8e-9c85-4a38-b989-299e4aceb2c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b374bc60-e066-42aa-99b0-3e124c675fda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_8128aaac-e7e6-4fa6-bac7-a3ac19d8ff0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_140060dd-8e0c-44a2-9769-d8ce6de4ed4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_bae1dfa2-41b7-46c1-9e1e-5fae784a1de3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9b218daf-9568-4fb9-ba54-24937e994d44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d971946d-306c-459c-8b3a-e96fc64334f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_7dd626b0-6fc1-4783-8c59-97a950918aed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a4af95d5-0d99-42f7-b5a7-c6ec697551f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">verv:DeliveryTechnologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_335ebba5-72b4-421b-898b-d3de7d54c1a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_4d5e8986-339e-4a27-a33a-2ddab2c8cf2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_66e16c0c-c5f1-4264-b019-a5f4059f00f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_3585e227-4c98-4454-befd-78b3ac98ed4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VerilyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_d25de583-668f-4235-b7a0-421690a06540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_1ff558da-6b5f-4d32-9a66-1203371d1d23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="C_7d6fc6e3-0bd2-4c41-a389-d8c78306592d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:PreferredStockTrancheLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_492a51ac-c738-417e-89a8-b0263437fb8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_d4248d0a-06a2-4040-a853-becbd34bcc18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_30c56851-0530-4749-a9d8-9d1a01a7d426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d44651b4-0a1c-4a0d-ae7f-725d09d63521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4fb1ec91-4db7-4fda-877e-5282a568c8a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_ea995c0d-ad65-44c4-b2b7-9fa84f6854c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6147ead1-a934-40a0-954e-50f7ab4904e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_3c269b18-dd31-496d-b16c-e1c0dd1e2c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3d0c6332-d1dd-4a36-9324-fb3b21711262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VerilyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_dee7f513-4115-4cdf-b302-37edddf7187e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_456b2896-d611-45e2-8641-7467961b8168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_470eef76-a3e4-47c1-9135-bcd76e05752b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3282e3cf-7f95-478d-ade5-6727746ef749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_94dd9299-01a2-4f67-9f44-7bbd116cd6f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_7eaf2c5f-f4cf-4ef5-8686-522ecb024096">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="C_7c5380ff-43e4-4da6-9d3d-4f142569329f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6318768f-6910-4cea-8012-84a1cded066e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cef2ca29-eb4f-4af7-8d4a-cda3d18e4727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:SeriesA2PreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_556c543d-6999-40a3-9b90-5c280daba957">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_02e26f3d-99d2-4166-a4b7-b128f163b312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7e66db40-4afb-4ea5-b66c-0674f32df2e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <instant>2022-03-09</instant>
        </period>
    </context>
    <context id="C_8c90a925-ca54-4ef3-abb8-1d5e67ef2449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f78045b2-d23b-4e9d-b193-d192ee9bb611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">verv:FourZeroOneKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5e0553e9-7c8d-4aae-b19e-97a94012299f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_dc246b1a-e277-4475-a822-7b299288320b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_bc02f4c1-1fb9-4d8b-93c6-bd1442840b62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_29a82fc7-8d8b-4988-8c6b-cb6aaeac3cf1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_dae0176e-5286-4cb9-be3e-28858705d8a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ea3f7d23-8c4f-4c06-944b-9769311160d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9a295b66-ffd1-4f8f-9e1a-8acda5aafa35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_db7855c5-c342-42e3-a442-d44d2061ccbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_9b37319a-0d54-4ccd-83eb-9d11fc5d438b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b587c055-bdab-476a-b3ab-de00dcd68ee5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">verv:SecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_dc4de63a-1a13-435a-91bf-1d42b2503336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_69242d4b-64e4-4e88-8436-10a5845fd9c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5026dda8-28ac-4046-b30f-f4c2af3df266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:CambridgeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_1fa28ee7-1e59-47ad-b9b0-95bb75660ed2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_597ac98d-16ac-4d83-be6a-8276c0ed1129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9315a78c-93a9-491d-b78a-acdccb6d99a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">verv:MassachusettsTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0199df91-6706-46b0-a6e5-0c3d2416dcec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0e74774f-4077-4438-a31c-22d5b9e9bf39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_1afabfe3-8755-45d0-ac91-81a3418d2248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_e08bb552-0254-44e1-ada0-095671a76529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5f4306bb-8ee0-4a9e-a1ff-c73a4446835b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:OptionLicenseAgreementAndPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_dc4c7421-4413-4b48-9fbf-b319860463d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c27b92cd-9d6c-4111-bd60-2b3bb8205544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_13793679-16f2-4f46-aa19-c85c5a12a0ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_d11db810-1bfc-445d-b0c0-43624d7bd52d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_bcc73401-287e-4ac0-a87f-a7584a3ebe73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ea8434d0-a39e-4a6a-bb26-7799962446b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_2b400acd-8cd9-40ff-8255-a68985c37814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">verv:FirstAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:CambridgeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_40e00f19-0436-48b3-a978-909a38c95f51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7349e083-8b38-4939-84b9-b52dd9e2c764">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_75ebca27-b89c-4f74-8d07-a6fdfe31387c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8020214a-330a-4afc-8e4e-cfbc08b56cfc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:AcuitasAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a9ae8471-e3e2-4484-84b2-6eaafd17e730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:PreferredStockTrancheLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ace78012-0407-4c33-9333-78a05d5e4482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_c286c886-b8bc-4074-85c6-6c1d797c88f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1a988b86-2da6-44fb-8d8b-025bc3040bcb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">verv:HarvardAndBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2da1fcc5-d34b-4f3a-ae28-f14234789060">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f014d533-46a7-4112-9279-b10412cf8bb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b046bc96-323a-433d-9185-6710e68adfba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:AcuitasAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e2eab36f-a537-4eda-9a0f-fecf0f2bddb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_79857874-5e87-4b53-b5bf-f51a27d64b5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_25716468-76d3-40f2-8351-b9e832a0d2ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1407fd53-32a3-4a0c-83d7-8d75bcc6c92f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0ea046e2-86bb-4bd2-985f-27d259b832a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:CambridgeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ea754504-c0d8-4221-a285-32e891462575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_96a9ec98-0425-4b68-a1ef-a3660007003a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-19</instant>
        </period>
    </context>
    <context id="C_f97bfb71-9b79-4c00-862c-5692b411f52b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:SeriesA2PreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_84c106c3-aeb7-42d5-ab70-a059d1961a3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8deec1cb-9d18-458c-80a6-69065b7fd6e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1f16c804-a208-4c37-b6c5-31908dac33d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">verv:SecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:CambridgeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_a0a301cf-8d3e-495c-a4ea-93524f1c444e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_d1a50b9b-5f34-479b-86a9-1686cbaaf4d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">verv:FourZeroOneKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="C_38d1bdab-4490-418c-9908-c0fd520a968b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ac6b8994-377a-4736-97a7-37eee958602b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e7d3e278-0275-4b6b-8cfb-0c4d84c235a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_3965b88b-aada-4b0f-bb79-9e1564c8b01f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="C_892a0591-a196-401b-abe3-20fff82d78ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_c9dfcbc2-a577-4626-9277-24561a8feca3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_314775f6-60d3-4cdd-a7e4-d2d47b4bb14b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VerilyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_bf52cb0e-645b-4c9d-abcc-988c1ab77568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c20382c9-9ff7-450f-8cd6-93193f146b1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ef58d5a4-7912-466b-bc19-b009959eba29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">verv:HarvardAndBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_371af29c-852e-4e21-b3b0-7a743ce9c595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="C_cace6097-6c52-4518-b31c-14d8a4a9ede2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_671bfcc0-ebf7-4194-8895-80b3fa98b658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e1981d33-fdc8-48c3-99e8-ac5c58411837">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_5d8591bc-11a9-40ab-b3a4-bc7e3800e026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20e318f5-772b-42ae-8de4-e92d6afce885">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_82be291d-e5c6-4821-b8c8-65d4e399c80f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VerilyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_900eaaf9-9f36-4773-beee-ac7b0f139194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0c8d563c-b4ce-43e3-aa5e-0284d836e33c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_24a4dfda-a75a-45db-8bd3-e0d4bcac39a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6111bf12-8023-40ef-949d-f9fc8eb769e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-21</instant>
        </period>
    </context>
    <context id="C_1ad41b74-8200-44de-a163-b3c17e30b9e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_fec04bb0-37db-4624-a7d4-cd02343359c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_86c2f76f-8f40-41c6-a1f0-570a5a905595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1349c1bd-0a8c-4898-8535-2e458967423b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_fcb68bae-6468-4eef-9487-908de3c3ac46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5d453b81-de24-40a9-aeeb-d32cb8afa2fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_45b88831-c3cd-4f43-a393-141647d5c8ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_dd92968d-2cf3-45c1-b345-bc554cadcd11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwentyTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_55860b8b-baa2-4e63-b435-ce9e60ae5e06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4a2a7d48-0ad0-4027-b312-8b11192978ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">verv:BeamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:MaterialsExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a9ee4883-4610-4244-845a-4be4346c5921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_91c2bb60-3204-485e-91bc-fcd6e061eaf0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_25c1a637-7cb1-4291-89c3-54a541318110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="C_1bcde1fb-0fd0-4aef-8c8e-7bc374f704bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_5cba4e1e-72af-462f-b037-4423f24b01af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_adefa849-4678-4e94-b863-2d12ecdad8f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f9897674-e8be-4c3a-a297-cb53a9538487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:SeriesA2PreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a8085576-61b7-454c-a519-9ae96812318a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7230ac96-5876-4bec-b9a0-17578497db18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e544b1d4-8651-4bbd-86e5-229213fc8bef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f64ad974-2e0f-4ca6-b8b0-bd9dc4283255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">verv:ThirdTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_b94a23b8-43bb-4383-a20f-d50aa1e8c3b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_6306fa6b-7c2e-44e2-9da5-5dfd36995ad7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">verv:ThirdTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_f674fccd-11fb-4942-800b-db52e4338c03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_7db4cc42-112c-43d0-8092-a99672ba28cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_3a46f484-c7b1-4249-a6d6-d259c573d801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">verv:AntidilutionRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_37648f64-a03f-4b57-83e1-dcf5c52767e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_894ba0d1-0497-4bb2-8773-85db59da1dac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_01810b2e-60ca-470b-a8e4-f620cad1af9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VerilyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a01d169a-8516-477d-a424-137cbc7bf6ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_e36ace04-7d0f-46f4-a4fc-05e0cddb3357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5758acaf-19d3-46c4-a26d-234bb9c7e3a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b5c31764-a8fd-4905-a067-8962ee2846e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4871c68a-70f7-4ee7-b7ae-3986b18102dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_56d972ec-31cc-4208-aa1d-caae39e63a9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_8bbab493-1d5c-406a-b732-8bf3f0c4c8aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_27017e45-4a76-45b0-84c2-5942f0fdfb77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwentyTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_70bdd4a9-53a3-4196-bff4-9fe631ab414d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:PreferredStockTrancheLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c672a00b-7f2c-4ee3-878b-42ff6ea68467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_428c5b12-83cd-4341-b4bb-932e3b77cd04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:PreferredStockTrancheLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1a692e9d-fc22-429a-866a-28850d71edcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_38d37eaf-cd29-452c-8228-ce29419522e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9d0f6183-f1e6-4aa0-b41e-2e38deb97369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_577f8c7c-690b-48eb-85f5-78944ac5fb74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_ae35d2d7-335e-4000-8d8b-98d22cdc0bcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0d594e36-72b4-4236-bd90-bc5bab9f7a9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4303f47d-2279-40f2-a160-e7a91300902b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_46b68a29-4a56-4a0e-b6e7-327c4a2472e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_cc8e1463-c758-4dfb-9de6-62be2741f27c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_b5b793ed-2405-4df6-a73b-f8234a21676c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0bc5b84f-e1f5-4d52-92d2-4a44875d520e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f9dffce0-4bc6-41d0-9e68-e6fdba07b1d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_676f07bf-c94c-4783-88ad-393a30ab16eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwentyEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_368253bb-0ab9-4644-bcce-9c12ebebd714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">verv:BeamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="C_2c8ab043-9f70-4b7c-b82d-c140cdb7038c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c6bcfa12-5656-4390-89e7-006e60b45be7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f7f9ed07-4a59-4247-ad5a-a6b36bcb98c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_6fe755bd-39b2-4058-bb31-ac7a1399a7a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:OptionLicenseAgreementAndPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1d25d519-2490-4618-87e0-211daed76d06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">verv:SecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="C_b00ab393-cfc3-45d7-90b3-dfac30d815bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">verv:BeamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:MaterialsExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_62daab16-1f95-4011-9dfa-cdc86ccb527d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_f5f342f9-12eb-4269-ba58-fc8d87544ebf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9bb47951-6b36-400c-bc9e-6e6219af2c06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">verv:ThirdTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8943ede3-21ba-4dd5-a69f-6510b3c9441e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_81529f1c-4f4b-492c-a430-5a7eaa203e49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_765b171f-952c-4b00-b1af-1c4809294e61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ac0671b9-90e0-41a4-b113-3a0ff36d64e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-19</instant>
        </period>
    </context>
    <context id="C_8ce3a7dc-9959-4295-a7ff-97a898ccd354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f357484d-ef7a-4007-9dd8-60b4ae94c728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_07b567cb-3946-416a-a923-420f97322263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5489e665-131f-4276-8480-9cbe40f275d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dc3057b9-a834-4bce-9400-bb870b34a39e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VerilyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a807f8cc-a5fc-49a8-8923-6ff09f00f06a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0c4a09a2-209e-467e-bf15-7eedabe54a49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e5a60e47-ab5b-41f6-99da-8c71cb8625d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">verv:BeamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5fed7261-bc42-45e4-aa7b-b1860010cd80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e8b5087a-c8c5-42b6-b02a-2126a65898d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e1a13442-1d67-4846-9344-f2e64eb45cf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7d62c74e-40c7-4d44-95f2-9153b525923e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_0e18a72a-d76f-4344-ab19-24bc729bb1a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_25e7d82a-63d5-46e3-ace4-4ed5f2668166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d8897390-cbaa-48a9-b558-fd628bd36c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:PreferredStockTrancheLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0904d4b8-89c7-4202-8393-1c301fba7ae3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8d26e837-c809-4998-bfb7-aca676d66949">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a47c1a5e-5ed1-4aff-9633-a0341b906481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwentyTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_48f8ab70-75b9-4435-b737-aadd04d499cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_dd01459a-975e-48f9-9d4f-b18bb361be4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4862c09a-79bf-4f14-8cca-db22dcbb94b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c0b06ae8-891a-4456-9a30-d851caa260c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2dcf3819-ab63-4939-86b0-10870a857990">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_cb1b7494-a0dd-49fc-8914-d1f55848827c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-19</startDate>
            <endDate>2021-08-19</endDate>
        </period>
    </context>
    <context id="C_f15881ae-e851-43f0-9443-9c9364fbebc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwentyTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a5a771bf-09d6-4a35-b7ac-216b653bc10f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwentyTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5a7068fa-0013-401d-b7c4-675485fce3a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_ac07bf25-eb1b-41db-9a17-637a6b3c0cf0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e665d618-f742-42d3-8066-c2f5fa033034">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_238fca8e-6dc3-4ea3-aa6d-7d316fa8ad10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_d9143aa7-990d-4ec9-968a-0a9605086b21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6ad6efa1-92e1-4627-b9eb-e717d27461ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2e418dc0-e214-4a34-8796-62a40cabca50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_17fbf683-2a55-4bef-952f-f0d1c18ff75d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_8b41bdfb-bbc2-43d8-bf32-532fc3b99db4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_249fda00-bd80-4288-a41d-c1199d73ce90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_76a2ae17-640c-473b-b6d2-7f1f8e136700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">verv:MassachusettsTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6e65181b-d50d-473b-a928-4dbc316e780c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_078a5bfc-2f82-4f5d-a355-1da428971361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5703a3c6-815c-4560-9f18-f134cd85e185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f480ce79-c162-4b52-8c8e-1412a8a69e68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_604919a2-0184-407a-a67d-53f3e9d796d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_256a0140-df8b-4d59-a0a5-3457018ea09f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VerilyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_a810db97-eb14-448b-9d1b-137166449fdd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">verv:NewAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-30</instant>
        </period>
    </context>
    <context id="C_7a75dc28-f9fd-42c4-8bd8-5f9dfd827ae8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_983ffc57-7b63-4e06-ab2d-e82bf6082b61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="C_53ef7791-90d1-4f91-a9c9-7449eead72a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_03a67782-22aa-4a91-8ef4-d8c7202b8a6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_b3c87878-bc9c-48e0-848d-9e7ea4f29412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_235eb2e2-4747-444d-b7ee-6cc0e5a83ec6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_67f0fbbf-3525-49ad-8377-5e53391e7282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bb24676f-df61-4c43-a65c-58adb308cd98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">verv:SecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5c294a1f-8a23-47e3-aa6b-63b180777613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_db73ec29-59ce-4649-9f8f-424cfebeac57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_898d61f8-6a19-4832-b357-ffe134d84eaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_7eaf836e-97a5-4b96-901b-fbc846401d37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_38e0bdc6-ddc8-4961-80a7-3305ab5afc10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2a3189e2-c048-4d31-976f-cb3b47d3233e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ec36089a-8e3c-4348-a1b7-6a7b4ec227a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e5482ed2-d888-4dd2-a7a7-cb1d249e3b82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_aa339973-30be-44d3-9b51-80410c37ae10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e0e52d02-fa91-4a31-93c5-67e517633a88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_59fe6e15-fa1d-432e-b68b-41815233efa2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_af6a2a40-edbe-4dd3-98a2-c59fe2070928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VerilyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Segment">
        <measure>verv:Segment</measure>
    </unit>
    <unit id="U_Instalment">
        <measure>verv:Instalment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-2"
      id="F_b2d78b98-0d63-4d03-af96-185a21d44c07"
      unitRef="U_pure">100</us-gaap:PreferredStockConvertibleConversionRatio>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_4711663b-eb09-4c14-bccc-f40f8ee10977">--12-31</dei:CurrentFiscalYearEndDate>
    <verv:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      id="F_7b568b03-6f3e-45ce-a87c-1ec473c7ffe5"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      id="F_49633ab7-17ec-409d-b405-fd6cdad7c037"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      id="F_efbe0182-38f2-4c14-aa56-5eaf21133d27"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      id="F_c08a69ad-f5e0-4908-9918-b4f986751489"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_5d453b81-de24-40a9-aeeb-d32cb8afa2fc"
      id="F_24f0c297-5b40-4261-8880-ccb299caf8c9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_69242d4b-64e4-4e88-8436-10a5845fd9c6"
      id="F_99459b3b-1a2c-459f-b816-892c31fc08bc"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      id="F_de72a9fd-4a77-4d2f-ba45-5844e0d16589"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      id="F_6343e105-a44a-4f4c-ad0d-c287a92b1cc7"
      unitRef="U_USD"
      xsi:nil="true"/>
    <verv:SettlementOfTrancheRightLliability
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      id="F_d49f3879-e87a-4c1e-a6e0-035761dfab62"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_69242d4b-64e4-4e88-8436-10a5845fd9c6"
      id="F_7ab3c223-66e6-4171-bde7-910ed8108a8e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:EmployeeStockOwnershipPlanESOPCashContributionsToESOP
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      id="F_4473dfb8-6ba4-4ff4-a96b-2aef947716c9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:EmployeeStockOwnershipPlanESOPCashContributionsToESOP
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      id="F_f3bdee0c-b5f4-4a77-95ee-e42be9f8c8f6"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_668b85ea-2c1e-4621-b400-bb2f4a0c0f4d">FY</dei:DocumentFiscalPeriodFocus>
    <verv:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      id="F_20d4266c-6aad-4cbb-ab46-faac5900b5d5"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      id="F_a3f44760-a4cb-49fc-bd74-735d8b6dacf1"
      unitRef="U_USD"
      xsi:nil="true"/>
    <verv:ProceedFromShareholderLoan
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      id="F_02e069bd-fd82-4cb6-b6b3-51bdba9b5b35"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      id="F_932e1120-c25b-42f9-8bd9-be59fe4ca8b0"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ProvisionForLeaseLosses
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      id="F_13b5ecec-3028-4049-b33c-b897063f625f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_1d25d519-2490-4618-87e0-211daed76d06"
      decimals="INF"
      id="F_91ee41f9-52b7-4c98-a858-be106bcef7e4"
      unitRef="U_shares">29347825</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      id="F_d1baddea-0268-4ef8-92ff-2fd1d349837d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      id="F_d83fbab4-b113-4b4d-a221-03e745689d8d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_d4248d0a-06a2-4040-a853-becbd34bcc18"
      id="F_716c6897-a6df-4fdf-9e99-b336dfd3b30f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      id="F_d90eb3d0-a3a5-4e78-a456-79d0199bcd53"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5d453b81-de24-40a9-aeeb-d32cb8afa2fc"
      id="F_8f855dc4-4041-400d-9c4c-39e7f19cdb67"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_d8897390-cbaa-48a9-b558-fd628bd36c53"
      id="F_170610ab-9c1b-4510-8f28-c508389451c8"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      id="F_daa77256-f925-4e80-9690-a788d67f31a1"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_5d453b81-de24-40a9-aeeb-d32cb8afa2fc"
      id="F_6a658ad5-652c-475a-ae7d-c2c5d9b56b54"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:AmendmentFlag
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_d4188ab7-710e-403e-8205-b3322f211365">false</dei:AmendmentFlag>
    <us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      id="F_0691f387-dd9a-4985-8c9a-0c01efabf653"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_42dc52cc-b872-424a-896a-7d468cadf04e">0001840574</dei:EntityCentralIndexKey>
    <verv:IssuanceOfPreferredStockTrancheLiability
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      id="F_0b5612a3-b12a-43fc-ba6b-c3bd38e949ff"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      id="F_290ed904-ef2e-4b0f-8479-82d256b9d6b1"
      unitRef="U_USD"
      xsi:nil="true"/>
    <verv:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      id="F_a0e3a388-511c-4ae3-a547-38055910ae18"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_285bdbbe-45f7-4aee-88f8-e9d1fa448eb3">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_92192fba-312a-4fcb-838e-d3961ddee1f2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_ce149dbb-8f7b-4b36-a8e9-04d6c83d6025">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_44d5b546-3627-4775-9f04-2f43ee62ab0c">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_19e00e2f-1d2e-459a-b99c-766e00a8ac99">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_9ea9bdea-30bf-474c-b6f9-0c2c1bf31e82">001-40489</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_fdd01a10-9a2e-45a9-af28-00fbdc8b3e53">VERVE THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_3216b3fc-f18f-48c0-92ad-d72cb405dce2">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_cccdc195-2cf0-49a2-b4be-8bd9fbf4145e">82-4800132</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_700637c5-ae33-429c-8d7c-d5bf6b6fe62f">500 Technology Square, Suite 901</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_c5e7870b-8927-441c-a0d9-708f58282cdc">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_42e17c88-9325-41bb-9d81-447e955528f7">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_26d07b84-0302-4a47-9ff5-dbcf68e10f1d">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_e68143ef-5976-4dc0-8b1d-83da464c8ecc">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_00f5d761-5303-41a5-84d9-d0220688f2dc">603-0070</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_dc569aa9-a03f-49c3-a684-e2a04f5ad7de">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_c466fd87-d4fa-462e-960f-0affa9b3c4db">VERV</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_da81291c-f7a2-4fec-a932-97915d3dc774">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_e2c8cc31-c1b5-48e4-9a4f-acb774f60dbf">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_aedb6d95-1571-4cf9-8c30-5bde1d3c5a68">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_efc90f84-d578-4373-b7ee-9045d294a5e0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_6e67d064-7883-403a-9ca9-294e6ac9391b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_6a5e12db-0697-4c64-8e2c-9960ffa80753">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_cde85b49-1d1d-47f2-86b0-78e53c51dd30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_7d450487-c31d-4942-9b27-b689e3977fea">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_e29f4a85-a50d-4ca9-80b5-0c60027b95b9">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_4e197b63-3d10-4035-9b55-fcdd6b59a585">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_8f222858-513c-463f-ab41-61af5ba8c488">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_c9dfcbc2-a577-4626-9277-24561a8feca3"
      decimals="-6"
      id="F_3e6c9ee3-1b9e-40cc-8491-cda83012f869"
      unitRef="U_USD">2185000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_7e66db40-4afb-4ea5-b66c-0674f32df2e3"
      decimals="INF"
      id="F_d0102689-ad51-444b-a3b9-37877862b018"
      unitRef="U_shares">48576595</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_4c9ede53-7831-4416-a5d0-24ba894a28d5">&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Portions of the registrant&#x2019;s definitive proxy statement that will be filed for the 2022 Annual Meeting of Stockholders &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;which the registrant intends to file with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year ended December 31, 2021, are incorporated by reference in Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_cf784487-7054-4eee-b4d3-aeed5800ed03">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_c797f504-8cf1-4a3a-8004-8264eba8105d">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_5a49f3af-9a2c-417c-85a0-50232bc6f82b">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_a51fae52-5078-49d4-b720-8a47ed05f1f9"
      unitRef="U_USD">64330000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_1ceb684a-e429-4d0b-961b-3fdd1028de54"
      unitRef="U_USD">8993000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_b9091609-e59b-4a03-91c4-c6dafe8fe39e"
      unitRef="U_USD">296112000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_2667a7c4-705e-4899-ab7c-13eab4f4508b"
      unitRef="U_USD">63119000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_88199754-54a6-4b66-a425-bfcfa8a2c1e5"
      unitRef="U_USD">6686000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_92d1600b-14d6-4960-80b7-b882c7f7fd2d"
      unitRef="U_USD">1854000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_8628350c-7d28-4152-a7fb-448cf7ddf0db"
      unitRef="U_USD">367128000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_672c3d50-4942-47d2-9ed3-941abf945227"
      unitRef="U_USD">73966000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_c14da6c5-b71e-4e6e-9dfb-519e887ccabc"
      unitRef="U_USD">7224000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_24637723-830b-4a13-b271-44423d63c753"
      unitRef="U_USD">3984000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_ab9a0b62-574b-4e4a-b5b2-a5b420713e98"
      unitRef="U_USD">5237000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_f2f55cee-3f7b-45de-b858-4249314d33f0"
      unitRef="U_USD">463000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_75b27076-f915-41fa-aa36-4839571c1b72"
      unitRef="U_USD">1839000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_64ac9484-eb3b-4bca-b98e-0135f5b9319b"
      unitRef="U_USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_b1c97340-0b35-4ce6-8952-24173373c03b"
      unitRef="U_USD">2696000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_d98febaa-4eda-4755-a064-a684d3838efe"
      unitRef="U_USD">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_6335638c-2e23-4268-8bdd-693a488786b5"
      unitRef="U_USD">384124000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_25bd7310-847a-4fa9-9d26-3c5a0484a4de"
      unitRef="U_USD">78413000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_a85f864a-aca5-4528-b009-14c0b6d0ec6c"
      unitRef="U_USD">7077000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_a934d6ba-6fdd-40c0-9ed9-0f86f1189f26"
      unitRef="U_USD">36000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_1e477143-f6df-4679-ab01-9a33f3db6218"
      unitRef="U_USD">12992000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_5e792990-8c0b-433f-8b8a-b28e2cad617c"
      unitRef="U_USD">7189000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_ab6de889-2dfd-4cc5-904d-4964550b06a6"
      unitRef="U_USD">1955000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_b00a4ec0-778a-4d69-8166-eb5fd1c9c29b"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_8fc883a9-92db-48a7-a895-7a7a72f401e2"
      unitRef="U_USD">0</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_911188ef-0b7d-4419-876c-32a4aa3cc611"
      unitRef="U_USD">90000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_021e3a73-61cd-4e06-8aea-2c49249dcfce"
      unitRef="U_USD">22024000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_6b32b4b8-c4c1-4434-bfd3-4eb34d07e854"
      unitRef="U_USD">7315000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_6a13dff3-0c68-4082-a47a-2b72be08f8be"
      unitRef="U_USD">0</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_67175970-d0a6-4319-a512-bbd20bead636"
      unitRef="U_USD">125000</us-gaap:DeferredRentCreditNoncurrent>
    <verv:SuccessPaymentLiability
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_58274360-c9d2-42cf-a8d2-ca681fe7250e"
      unitRef="U_USD">4371000</verv:SuccessPaymentLiability>
    <verv:SuccessPaymentLiability
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_9739dee4-00b4-4064-ac86-a3e32f86ec4c"
      unitRef="U_USD">2806000</verv:SuccessPaymentLiability>
    <verv:AntidilutionRightsLiability
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_b82279ed-e492-4826-b9a1-f0a66a82a843"
      unitRef="U_USD">0</verv:AntidilutionRightsLiability>
    <verv:AntidilutionRightsLiability
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_05870e75-b964-4b35-a977-69648b9fc564"
      unitRef="U_USD">6916000</verv:AntidilutionRightsLiability>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_ae9a2c2b-476b-460c-84ed-0f8adf6f7c65"
      unitRef="U_USD">377000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_8af1377b-859e-447a-b0b3-371d1f26cb84"
      unitRef="U_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_ab8a86fc-2653-4362-bb3e-603926413d4c"
      unitRef="U_USD">26772000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_0b5bbf8f-6684-42a9-9186-bfb0ebb0d780"
      unitRef="U_USD">17162000</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="C_37648f64-a03f-4b57-83e1-dcf5c52767e2"
      decimals="-3"
      id="F_747ebff7-8b2b-4198-a3b4-d8d41165402e"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_2c8ab043-9f70-4b7c-b82d-c140cdb7038c"
      decimals="-3"
      id="F_de0ed0df-f492-4697-9669-d22ace666b44"
      unitRef="U_USD">125160000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="INF"
      id="F_93f5ba50-4f92-4b4c-b5f3-9b8de738e0d1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="INF"
      id="F_5c988436-9af9-4118-b6fe-31c181084a6b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="INF"
      id="F_47209971-e492-4e4c-a2bc-23c25d5cff48"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="INF"
      id="F_9a0f7e94-520a-4e38-936c-60420cf15837"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="INF"
      id="F_57ba3643-4f7b-49da-8803-de116c0d5116"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="INF"
      id="F_2e1126db-a646-4d88-92f2-03fbc55829a8"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="INF"
      id="F_d30475fd-a943-48fe-8907-90e0357fd8aa"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="INF"
      id="F_05b15d10-fe88-4488-a7f5-8f913fb161a4"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="INF"
      id="F_088613a8-51b7-4c59-aa11-2ef0b4ceb220"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="INF"
      id="F_b199e1f2-95bd-497c-9787-db3c3997faa6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="INF"
      id="F_81d7b26f-47ee-4b2f-9c8d-4fb970a2afdd"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="INF"
      id="F_4cd3867e-130c-40fe-b545-0737cfbf237c"
      unitRef="U_shares">255000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="INF"
      id="F_cc674b35-13dc-4619-a562-13c30ddb9e6b"
      unitRef="U_shares">48511735</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="INF"
      id="F_6057a13a-4fda-4fc6-8573-7dc75201dafc"
      unitRef="U_shares">3123424</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="INF"
      id="F_6b3663f2-893c-4038-a01c-439724b08a56"
      unitRef="U_shares">48511735</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="INF"
      id="F_2d372f37-858a-496f-852e-724c08503745"
      unitRef="U_shares">2585789</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_86987cf8-ea18-412c-bb54-27c1512248f4"
      unitRef="U_USD">49000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_23f86597-32d7-4271-8509-7dbefc40a240"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_c7c38810-4532-47fd-a298-92a157db5121"
      unitRef="U_USD">544381000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_6a3ff5c3-b329-4e81-bc06-84c75e53a8bc"
      unitRef="U_USD">2616000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_caf9e20c-6474-41ef-8e8b-dca862afdd11"
      unitRef="U_USD">-228000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_582c52fa-0edc-4a31-b86f-20ed848eff0f"
      unitRef="U_USD">8000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_778f7081-4af2-4d17-a272-078468b56894"
      unitRef="U_USD">-186850000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_aa44b87a-6c1e-4845-b4ee-10d7d934c8b6"
      unitRef="U_USD">-66536000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_203d2411-2f98-40f4-870d-e76a11a4ce89"
      unitRef="U_USD">357352000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_be5e39c7-ea1b-4feb-bf88-ed52056251c5"
      unitRef="U_USD">-63909000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_f0e61c9a-bf65-4afb-b2d3-b39508116738"
      unitRef="U_USD">384124000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_17645dd7-ec01-4f85-a534-93e70738163f"
      unitRef="U_USD">78413000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_e17c4a3f-15f4-42f5-b6e6-c81f9931331e"
      unitRef="U_USD">68202000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_303f04a6-9f4d-46eb-be33-cd6f0e0b2eea"
      unitRef="U_USD">35371000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_e711f529-6af0-47c2-be63-a3b2aa746483"
      unitRef="U_USD">11144000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_485d0c56-6ae6-4841-9c27-56eafee9a817"
      unitRef="U_USD">18865000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_08bb3bee-d47c-4e0b-a455-7720469e2345"
      unitRef="U_USD">5256000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_821e015b-7d97-4169-b428-a0ce51a7d6fc"
      unitRef="U_USD">2498000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_5911d009-aae6-4419-a9d6-24390fea6437"
      unitRef="U_USD">87067000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_f64e2a9f-91fe-4c75-9cdc-76529d5a3508"
      unitRef="U_USD">40627000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_81e3033b-b828-4e15-8e9c-a00243ddc211"
      unitRef="U_USD">13642000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_1ea0a570-f55a-47a3-9649-1bc1dbfcaa4d"
      unitRef="U_USD">-87067000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_844be838-228b-4d9a-9730-c79af6392eca"
      unitRef="U_USD">-40627000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_d29ec4bf-c4f5-4d24-806f-3c143758c4ad"
      unitRef="U_USD">-13642000</us-gaap:OperatingIncomeLoss>
    <verv:ChangeInFairValueOfPreferredStockTrancheLiabilities
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_a935956f-84a0-429e-92f5-ee7f012afdf7"
      unitRef="U_USD">0</verv:ChangeInFairValueOfPreferredStockTrancheLiabilities>
    <verv:ChangeInFairValueOfPreferredStockTrancheLiabilities
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_ca192b77-9b02-49b5-be83-e0cc9c8cf971"
      unitRef="U_USD">2507000</verv:ChangeInFairValueOfPreferredStockTrancheLiabilities>
    <verv:ChangeInFairValueOfPreferredStockTrancheLiabilities
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_bed13db2-1b85-4a65-a2c0-647d726ed54c"
      unitRef="U_USD">-4883000</verv:ChangeInFairValueOfPreferredStockTrancheLiabilities>
    <verv:ChangeInFairValueOfAntidilutionRights
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_6a0e3ae6-4d9a-458d-a7da-f9b59ddf55bf"
      unitRef="U_USD">25574000</verv:ChangeInFairValueOfAntidilutionRights>
    <verv:ChangeInFairValueOfAntidilutionRights
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_a8a84390-d402-4dc0-b28a-a4bcbffbd2d1"
      unitRef="U_USD">5359000</verv:ChangeInFairValueOfAntidilutionRights>
    <verv:ChangeInFairValueOfAntidilutionRights
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_cf75a017-b407-4ea1-9448-d169d5c20d1b"
      unitRef="U_USD">982000</verv:ChangeInFairValueOfAntidilutionRights>
    <verv:ChangeInFairValueOfSuccessPaymentsLiabilities
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_f400d4fc-0a61-4097-b4f8-e1ce2039e6c8"
      unitRef="U_USD">7815000</verv:ChangeInFairValueOfSuccessPaymentsLiabilities>
    <verv:ChangeInFairValueOfSuccessPaymentsLiabilities
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_52f57b29-8ea7-474c-9724-c0372f96e58b"
      unitRef="U_USD">2387000</verv:ChangeInFairValueOfSuccessPaymentsLiabilities>
    <verv:ChangeInFairValueOfSuccessPaymentsLiabilities
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_761acd68-42d8-4562-94af-da36048b8ca1"
      unitRef="U_USD">68000</verv:ChangeInFairValueOfSuccessPaymentsLiabilities>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_43f21d05-c1c8-4fce-86c2-1b344d6ecb83"
      unitRef="U_USD">142000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_f6b6265d-7d3b-45bd-a385-c96914399ee9"
      unitRef="U_USD">162000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_c3525023-b061-48df-ba2a-6d55f8126751"
      unitRef="U_USD">278000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_7050b25a-a5af-40d3-8ac8-e846d292977d"
      unitRef="U_USD">-33247000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_61b6a7ee-dab0-4dcc-b097-2eaefb3ba057"
      unitRef="U_USD">-5077000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_cd0aa2b9-7bfa-4805-b989-2e236fc27c54"
      unitRef="U_USD">-5655000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_3012f02e-33c2-4f9d-b6e8-9a4a7b446900"
      unitRef="U_USD">-120314000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_b0e32c01-1b26-4224-ac49-073b1dbbbb69"
      unitRef="U_USD">-45704000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_068f75c0-0655-4232-8c1a-6846c6743a5f"
      unitRef="U_USD">-19297000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="2"
      id="F_129f19f7-f831-424f-a8fa-b8409db068ed"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-4.48</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="2"
      id="F_848431d1-530e-477f-b184-0d80e80daaec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-20.31</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="2"
      id="F_d5c17042-53f5-4585-ade3-c0cd3b9c650b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-15.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="0"
      id="F_203d5814-98c8-4579-96d1-13799b8815b4"
      unitRef="U_shares">26872036</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="0"
      id="F_20020b40-e83b-4de5-8d46-4dd4f0510dc4"
      unitRef="U_shares">2250093</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="0"
      id="F_7b714ba1-37b6-426e-baa3-3af92689e40b"
      unitRef="U_shares">1277156</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_e901f7cd-3579-4134-8c38-b3a9e15abab2"
      unitRef="U_USD">-120314000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_c5f4c4de-cedb-4808-8b44-6ce0e56109a4"
      unitRef="U_USD">-45704000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_5695fa66-c320-4a6c-9f8f-6e7a40c8d95d"
      unitRef="U_USD">-19297000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_b231ab16-4fad-41ed-93fc-cd71e940edcf"
      unitRef="U_USD">-236000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_222c5736-be92-4bf8-9955-8659758c2e6f"
      unitRef="U_USD">-1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_21f43725-58f4-48d5-9fd2-2684df391c3c"
      unitRef="U_USD">9000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_8f30ae09-8909-4f5e-87ba-dd7a15ce038d"
      unitRef="U_USD">-120550000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_49d47ab4-c453-4bde-baac-2683698791ed"
      unitRef="U_USD">-45705000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_0ca5cfef-c41f-4476-863a-471a6f64efe9"
      unitRef="U_USD">-19288000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_758d254a-8812-49dd-a35c-9b632827b258"
      decimals="INF"
      id="F_3a3f7bbc-2e93-4745-a7d2-465820c0934d"
      unitRef="U_shares">19565217</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_758d254a-8812-49dd-a35c-9b632827b258"
      decimals="-3"
      id="F_4f8b82b7-93bc-499f-a446-ddd5d01ade07"
      unitRef="U_USD">6905000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_48f8ab70-75b9-4435-b737-aadd04d499cd"
      decimals="INF"
      id="F_9a3cded9-a893-482a-907f-ef6557517168"
      unitRef="U_shares">537635</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_48f8ab70-75b9-4435-b737-aadd04d499cd"
      decimals="-3"
      id="F_4dcff5b8-5904-452a-874a-aeb62c3003bd"
      unitRef="U_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e1981d33-fdc8-48c3-99e8-ac5c58411837"
      decimals="-3"
      id="F_1379a97e-e0a0-45b0-9596-2a2928050442"
      unitRef="U_USD">51000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_492a51ac-c738-417e-89a8-b0263437fb8f"
      decimals="-3"
      id="F_1a01c320-ba7b-417c-a0c3-ecc644fc0ad1"
      unitRef="U_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_13793679-16f2-4f46-aa19-c85c5a12a0ab"
      decimals="-3"
      id="F_f53c3b4f-41a3-4276-a3ae-8a4d4691cc13"
      unitRef="U_USD">-1535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ace78012-0407-4c33-9333-78a05d5e4482"
      decimals="-3"
      id="F_fd3ea7e6-5a14-40c1-9f7a-aa4b0adce5fc"
      unitRef="U_USD">-1484000</us-gaap:StockholdersEquity>
    <verv:IssuanceCostsOfSeriesAConvertiblePreferredStock
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_0ac22d1e-08ea-46d4-bc5f-52419c5e25ad"
      unitRef="U_USD">10000</verv:IssuanceCostsOfSeriesAConvertiblePreferredStock>
    <verv:IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_32a1b76c-2bef-4537-b0c6-a042ff04eee1"
      unitRef="U_USD">84000</verv:IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability>
    <verv:StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock
      contextRef="C_62daab16-1f95-4011-9dfa-cdc86ccb527d"
      decimals="INF"
      id="F_c2339faf-104d-4cff-aa10-25c6a7bf639c"
      unitRef="U_shares">30183947</verv:StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock>
    <verv:StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock
      contextRef="C_62daab16-1f95-4011-9dfa-cdc86ccb527d"
      decimals="-3"
      id="F_eb4050f7-44c0-4673-9588-ec8ce4e50af3"
      unitRef="U_USD">17956000</verv:StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock>
    <verv:StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee
      contextRef="C_62daab16-1f95-4011-9dfa-cdc86ccb527d"
      decimals="INF"
      id="F_9b3fcbbb-bdf4-48f7-b332-f1a8b3d4ec7a"
      unitRef="U_shares">1672240</verv:StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee>
    <verv:StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee
      contextRef="C_62daab16-1f95-4011-9dfa-cdc86ccb527d"
      decimals="-3"
      id="F_5f31fd36-590f-4599-bdb3-c61a01ae8028"
      unitRef="U_USD">619000</verv:StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee>
    <verv:StockIssuedDuringPeriodShareLicensorInstitutions
      contextRef="C_3282e3cf-7f95-478d-ade5-6727746ef749"
      decimals="INF"
      id="F_6cb6d6c6-be40-4bc9-8ebb-ba0258cf298d"
      unitRef="U_shares">673562</verv:StockIssuedDuringPeriodShareLicensorInstitutions>
    <verv:StockIssuedDuringPeriodValueLicensorInstitutions
      contextRef="C_3282e3cf-7f95-478d-ade5-6727746ef749"
      decimals="-3"
      id="F_094e169d-cc9d-4270-862e-346231440bc1"
      unitRef="U_USD">1000</verv:StockIssuedDuringPeriodValueLicensorInstitutions>
    <verv:StockIssuedDuringPeriodValueLicensorInstitutions
      contextRef="C_a807f8cc-a5fc-49a8-8923-6ff09f00f06a"
      decimals="-3"
      id="F_e5d5767c-c13e-43e9-9d44-8eed02d47c4c"
      unitRef="U_USD">747000</verv:StockIssuedDuringPeriodValueLicensorInstitutions>
    <verv:StockIssuedDuringPeriodValueLicensorInstitutions
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_d48c5fc4-d2d0-42e5-a89e-6eeaf4932ed2"
      unitRef="U_USD">748000</verv:StockIssuedDuringPeriodValueLicensorInstitutions>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_3282e3cf-7f95-478d-ade5-6727746ef749"
      decimals="INF"
      id="F_b2ae96c4-b090-46c1-b102-f01d817af5db"
      unitRef="U_shares">643241</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_3282e3cf-7f95-478d-ade5-6727746ef749"
      decimals="-3"
      id="F_7f50ecd4-2d24-42bb-9d68-7b73caf5027e"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_b337cd10-7d4f-40ba-89ed-a4c7530557ae"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="C_a807f8cc-a5fc-49a8-8923-6ff09f00f06a"
      decimals="-3"
      id="F_5a525a2a-cce0-41b6-bd61-7eade266a016"
      unitRef="U_USD">24000</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_57cd3b75-c207-41d1-89be-3c62e169829b"
      unitRef="U_USD">24000</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_e2eab36f-a537-4eda-9a0f-fecf0f2bddb9"
      decimals="-3"
      id="F_b0d7d634-d5a9-49e9-b3a0-e5e98a56e304"
      unitRef="U_USD">9000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_358a9c22-1e3f-4acb-bf60-e1cd780cab5c"
      unitRef="U_USD">9000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a807f8cc-a5fc-49a8-8923-6ff09f00f06a"
      decimals="-3"
      id="F_7d76be0a-4187-4bec-adc7-01d25611a7f7"
      unitRef="U_USD">446000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_67fa5a65-ca20-49a7-822b-e11534b3be0a"
      unitRef="U_USD">446000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_2b6cf2c2-5ffb-41c1-b814-6954698f90f6"
      decimals="-3"
      id="F_8a69c29f-5ead-4816-a6a6-32e66f4680ec"
      unitRef="U_USD">-19297000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_0acac921-456b-43ee-b76d-90c6d45006c2"
      unitRef="U_USD">-19297000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e7d3e278-0275-4b6b-8cfb-0c4d84c235a4"
      decimals="INF"
      id="F_6d9cb3a6-6917-4b8f-8d05-d00f42aea45d"
      unitRef="U_shares">51421404</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e7d3e278-0275-4b6b-8cfb-0c4d84c235a4"
      decimals="-3"
      id="F_ecc6c0cc-1b22-4b58-98b9-ba712e2b36c1"
      unitRef="U_USD">25480000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4fb1ec91-4db7-4fda-877e-5282a568c8a6"
      decimals="INF"
      id="F_25c7daef-d095-43bd-89b8-5623b6cb8cd6"
      unitRef="U_shares">1854438</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_4fb1ec91-4db7-4fda-877e-5282a568c8a6"
      decimals="-3"
      id="F_3d1c00f2-be79-48d2-931a-41007f6dd30f"
      unitRef="U_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_45b88831-c3cd-4f43-a393-141647d5c8ee"
      decimals="-3"
      id="F_b6add65a-7957-4455-8ca7-eb9d709e5c13"
      unitRef="U_USD">1268000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a01d169a-8516-477d-a424-137cbc7bf6ac"
      decimals="-3"
      id="F_e06926e2-17f8-4b85-bfe0-5a4906f1efcb"
      unitRef="U_USD">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a0a301cf-8d3e-495c-a4ea-93524f1c444e"
      decimals="-3"
      id="F_6dd0256f-3d23-4e92-baed-4a938de24879"
      unitRef="U_USD">-20832000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9d0f6183-f1e6-4aa0-b41e-2e38deb97369"
      decimals="-3"
      id="F_8d4dcdb5-8f6b-46a0-853a-c65a7399d3e9"
      unitRef="U_USD">-19553000</us-gaap:StockholdersEquity>
    <verv:IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-5"
      id="F_c2f4f7c7-4bee-404e-8eed-fb93f8909f11"
      unitRef="U_USD">7000000.0</verv:IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability>
    <verv:IssuanceCostsOfSeriesAConvertiblePreferredStock
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_c31d047c-7545-47b8-acd9-d72aaea91bda"
      unitRef="U_USD">22000</verv:IssuanceCostsOfSeriesAConvertiblePreferredStock>
    <verv:StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock
      contextRef="C_f480ce79-c162-4b52-8c8e-1412a8a69e68"
      decimals="INF"
      id="F_289be1cd-953b-4d4b-b8d0-2ada30bda344"
      unitRef="U_shares">49749167</verv:StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock>
    <verv:StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock
      contextRef="C_f480ce79-c162-4b52-8c8e-1412a8a69e68"
      decimals="-3"
      id="F_308947a1-2d31-41e7-9c62-46e1237e97e3"
      unitRef="U_USD">36792000</verv:StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock>
    <verv:IssuanceCostsOfSeriesA2ConvertiblePreferredStock
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_111c0078-af39-41c0-b3b0-a998441b00b0"
      unitRef="U_USD">112000</verv:IssuanceCostsOfSeriesA2ConvertiblePreferredStock>
    <verv:StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock
      contextRef="C_f480ce79-c162-4b52-8c8e-1412a8a69e68"
      decimals="INF"
      id="F_ba159799-06b4-4d16-8562-1374578e12bc"
      unitRef="U_shares">78348461</verv:StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock>
    <verv:StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock
      contextRef="C_f480ce79-c162-4b52-8c8e-1412a8a69e68"
      decimals="-3"
      id="F_f6b27704-0a42-48df-a41f-8538f8c01601"
      unitRef="U_USD">62888000</verv:StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock>
    <verv:StockIssuedDuringPeriodAdditionalShareLicensorInstitutions
      contextRef="C_d9143aa7-990d-4ec9-968a-0a9605086b21"
      decimals="INF"
      id="F_bb464bfb-1f30-41db-b1f1-fa70dec0b43c"
      unitRef="U_shares">187867</verv:StockIssuedDuringPeriodAdditionalShareLicensorInstitutions>
    <verv:StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions
      contextRef="C_66e16c0c-c5f1-4264-b019-a5f4059f00f4"
      decimals="-3"
      id="F_0f36b1a4-d278-482a-a5e9-bf7fc0e987c2"
      unitRef="U_USD">487000</verv:StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions>
    <verv:StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_bd618cf9-216f-4d94-8d44-9807610465ac"
      unitRef="U_USD">487000</verv:StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_d9143aa7-990d-4ec9-968a-0a9605086b21"
      decimals="INF"
      id="F_9bfe9d1f-3914-4093-ac73-64250684d1b8"
      unitRef="U_shares">537635</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_d9143aa7-990d-4ec9-968a-0a9605086b21"
      decimals="-3"
      id="F_9b574ad1-7975-4039-bde5-0c318259d4d4"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_f9bfd702-6bcb-4aac-84fe-99bab49c576f"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_c6bcfa12-5656-4390-89e7-006e60b45be7"
      decimals="-3"
      id="F_7e9900f3-49f5-4da5-b3b4-049a82109d78"
      unitRef="U_USD">-1000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_5ed58e9b-1f62-4449-bba3-65814ae945af"
      unitRef="U_USD">-1000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_66e16c0c-c5f1-4264-b019-a5f4059f00f4"
      decimals="-3"
      id="F_6c373337-26b1-4360-b66e-4059fe1484a3"
      unitRef="U_USD">850000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_79e4154c-7e8f-4cb3-bd16-dab194d8403f"
      unitRef="U_USD">850000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_d9143aa7-990d-4ec9-968a-0a9605086b21"
      decimals="INF"
      id="F_5dad2389-401b-4a7c-b005-e2ac2f477d2c"
      unitRef="U_shares">5849</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_66e16c0c-c5f1-4264-b019-a5f4059f00f4"
      decimals="-3"
      id="F_74f01467-f981-4810-aae6-ed557eb7bda5"
      unitRef="U_USD">11000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_086f0077-5560-4d18-b5c7-4fa9b76bcd78"
      unitRef="U_USD">11000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="C_ea3f7d23-8c4f-4c06-944b-9769311160d9"
      decimals="-3"
      id="F_f20e66c9-d5a4-404a-a5eb-0893778e772e"
      unitRef="U_USD">-45704000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_43342c5e-b38a-41bb-85e5-1db03dc55f11"
      unitRef="U_USD">-45704000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_8bbab493-1d5c-406a-b732-8bf3f0c4c8aa"
      decimals="INF"
      id="F_063123ba-4fed-4063-ab3a-9f080ee961e7"
      unitRef="U_shares">179519032</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_8bbab493-1d5c-406a-b732-8bf3f0c4c8aa"
      decimals="-3"
      id="F_8e3fd0ba-2647-4f25-9e51-2e8e80d40a37"
      unitRef="U_USD">125160000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_5e0553e9-7c8d-4aae-b19e-97a94012299f"
      decimals="INF"
      id="F_ebe2289d-7302-418b-91bf-d3f3f62016a8"
      unitRef="U_shares">2585789</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_5e0553e9-7c8d-4aae-b19e-97a94012299f"
      decimals="-3"
      id="F_bfebbc35-8512-4f9f-a60a-59bdd32fc459"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_40e00f19-0436-48b3-a978-909a38c95f51"
      decimals="-3"
      id="F_379095d0-3bb3-4bb6-a2c3-9895e1efa53b"
      unitRef="U_USD">2616000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e665d618-f742-42d3-8066-c2f5fa033034"
      decimals="-3"
      id="F_95f55839-e05d-40b2-b6bf-8ed7708f496d"
      unitRef="U_USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5c294a1f-8a23-47e3-aa6b-63b180777613"
      decimals="-3"
      id="F_12db51c9-8243-477c-92ee-d72a8e638c46"
      unitRef="U_USD">-66536000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_5694afe2-bd4a-4b33-8825-9bba3fd78038"
      unitRef="U_USD">-63909000</us-gaap:StockholdersEquity>
    <verv:IssuanceCostsOfSeriesBConvertiblePreferredStock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_15d24441-2cfe-4988-9516-6f7e572cb820"
      unitRef="U_USD">241000</verv:IssuanceCostsOfSeriesBConvertiblePreferredStock>
    <verv:StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock
      contextRef="C_0199df91-6706-46b0-a6e5-0c3d2416dcec"
      decimals="INF"
      id="F_df3e87f9-57d5-4239-b754-47549f58e4bd"
      unitRef="U_shares">77163022</verv:StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock>
    <verv:StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock
      contextRef="C_0199df91-6706-46b0-a6e5-0c3d2416dcec"
      decimals="-3"
      id="F_cdd13871-726d-4b7b-9c38-66b2439b3a3c"
      unitRef="U_USD">93759000</verv:StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0199df91-6706-46b0-a6e5-0c3d2416dcec"
      decimals="INF"
      id="F_017ad52a-bfce-4af0-aade-62735862db1f"
      unitRef="U_shares">-256682054</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0199df91-6706-46b0-a6e5-0c3d2416dcec"
      decimals="-3"
      id="F_b2c49252-b190-4ad6-a2af-4ce7c0f05952"
      unitRef="U_USD">-218919000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4"
      decimals="INF"
      id="F_432742d6-295f-4f12-9ffb-6cde037bd112"
      unitRef="U_shares">27720923</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4"
      decimals="-3"
      id="F_d14f81f8-03cf-473e-afe6-0e1c36f364d8"
      unitRef="U_USD">28000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0c4a09a2-209e-467e-bf15-7eedabe54a49"
      decimals="-3"
      id="F_9be50ca4-105c-4cba-aaf1-26c4a7155687"
      unitRef="U_USD">218891000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_f2189005-c708-47cb-a9f4-2011f4bbf41b"
      unitRef="U_USD">218919000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <verv:IssuanceCostsOfCommonStockFromInitialPublicOffering
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_53442a00-27bc-4571-8d27-bbc12a0db1e6"
      unitRef="U_USD">25098000</verv:IssuanceCostsOfCommonStockFromInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4"
      decimals="INF"
      id="F_b0106072-3856-4d9b-9091-467200586093"
      unitRef="U_shares">16141157</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4"
      decimals="-3"
      id="F_48274c5a-d678-482a-9c22-e334d5675c24"
      unitRef="U_USD">16000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0c4a09a2-209e-467e-bf15-7eedabe54a49"
      decimals="-3"
      id="F_f6caf6fc-63ef-4226-85ab-5e1ba98afc46"
      unitRef="U_USD">281568000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_7e6058e9-f638-43d0-94d6-3675d56eeb61"
      unitRef="U_USD">281584000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <verv:StockIssuedDuringPeriodShareLicensorInstitutions
      contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4"
      decimals="INF"
      id="F_2681e1e2-dd5b-4ac8-9dc9-f269117d2af4"
      unitRef="U_shares">878098</verv:StockIssuedDuringPeriodShareLicensorInstitutions>
    <verv:StockIssuedDuringPeriodValueLicensorInstitutions
      contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4"
      decimals="-3"
      id="F_7f682017-bd83-44bd-9c45-08987d474fa7"
      unitRef="U_USD">1000</verv:StockIssuedDuringPeriodValueLicensorInstitutions>
    <verv:StockIssuedDuringPeriodValueLicensorInstitutions
      contextRef="C_0c4a09a2-209e-467e-bf15-7eedabe54a49"
      decimals="-3"
      id="F_d01fabcf-e4c1-4ea0-95e6-3587718d12d0"
      unitRef="U_USD">32489000</verv:StockIssuedDuringPeriodValueLicensorInstitutions>
    <verv:StockIssuedDuringPeriodValueLicensorInstitutions
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_dc1401fd-61f5-4d8c-9c16-cd8393515340"
      unitRef="U_USD">32490000</verv:StockIssuedDuringPeriodValueLicensorInstitutions>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4"
      decimals="INF"
      id="F_3114d981-73eb-49ff-9889-66ed8d678960"
      unitRef="U_shares">537633</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4"
      decimals="INF"
      id="F_43937e9f-20b8-4687-af8e-33a39bb53b75"
      unitRef="U_shares">599838</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4"
      decimals="-3"
      id="F_58839a2b-4c81-4bfd-94c1-8a20f5fa0185"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0c4a09a2-209e-467e-bf15-7eedabe54a49"
      decimals="-3"
      id="F_861ace3e-05ee-464b-8962-2328be6f6bbd"
      unitRef="U_USD">965000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_230675dd-3d24-4455-a63a-1027a9fcb5b0"
      unitRef="U_USD">966000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4"
      decimals="INF"
      id="F_77130e95-3648-4674-bcf9-0e130e30522c"
      unitRef="U_shares">48297</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0c4a09a2-209e-467e-bf15-7eedabe54a49"
      decimals="-3"
      id="F_278e4139-a880-4c8d-9e7e-c94f20f2c2a8"
      unitRef="U_USD">780000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_4f3d9e06-cd71-4268-b622-ff2c7d01e1d8"
      unitRef="U_USD">780000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_69242d4b-64e4-4e88-8436-10a5845fd9c6"
      decimals="-3"
      id="F_dc5bda91-5f3e-4302-9f17-ec27a9c68604"
      unitRef="U_USD">-236000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_f32b4d9b-4f45-4632-a6a1-8e7108cb8b8f"
      unitRef="U_USD">-236000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0c4a09a2-209e-467e-bf15-7eedabe54a49"
      decimals="-3"
      id="F_a5f3df76-dd86-41c5-926e-55eeb3fc649a"
      unitRef="U_USD">7072000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_bf9ceb07-8a49-4c8b-990d-0d891ba02f6e"
      unitRef="U_USD">7072000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_5d453b81-de24-40a9-aeeb-d32cb8afa2fc"
      decimals="-3"
      id="F_2d52ea39-20b8-4b9a-bc92-59c1dcac197e"
      unitRef="U_USD">-120314000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_bca1d83a-284a-4522-8cd1-a11195b34bb9"
      unitRef="U_USD">-120314000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_cace6097-6c52-4518-b31c-14d8a4a9ede2"
      decimals="INF"
      id="F_8012dc6e-d486-4e32-a895-6ec135f1b027"
      unitRef="U_shares">48511735</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_cace6097-6c52-4518-b31c-14d8a4a9ede2"
      decimals="-3"
      id="F_e3a401ee-1682-4cef-a9e4-9d2921641a64"
      unitRef="U_USD">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_67f0fbbf-3525-49ad-8377-5e53391e7282"
      decimals="-3"
      id="F_9f630540-f071-4063-8703-4a866772f066"
      unitRef="U_USD">544381000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_07b567cb-3946-416a-a923-420f97322263"
      decimals="-3"
      id="F_8e66921c-d46d-4014-9103-24ab02981c3b"
      unitRef="U_USD">-228000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3c269b18-dd31-496d-b16c-e1c0dd1e2c99"
      decimals="-3"
      id="F_cf696ab4-21c3-4b3d-9c78-09bd3222bd51"
      unitRef="U_USD">-186850000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_696eef82-7e56-40c3-b77f-b8736f20248f"
      unitRef="U_USD">357352000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_72242b1b-caa6-4588-b19c-69bb568f26e1"
      unitRef="U_USD">-120314000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_6585c1cc-fa84-402f-a65d-088084adcba6"
      unitRef="U_USD">-45704000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_ddfe237e-b41b-4af2-ac91-26662d81f388"
      unitRef="U_USD">-19297000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_e071ffb0-549a-43a6-816b-2f8badd8b0a9"
      unitRef="U_USD">1535000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_654e956b-c4e1-4287-8542-eca4c79419f1"
      unitRef="U_USD">1328000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_57500eb6-bb98-4b99-a419-8c9d4ff745be"
      unitRef="U_USD">106000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_3af3057a-aafb-4135-aae8-8b1c1f7495a0"
      unitRef="U_USD">0</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_4bbd495a-58ad-4896-bcb5-b2dc0aeef6f7"
      unitRef="U_USD">0</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_9a42ad40-f061-400a-aa0f-1fecc51536a4"
      unitRef="U_USD">2781000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:ProvisionForLeaseLosses
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_494b0cbf-70d7-4f36-ae39-75df83a224ea"
      unitRef="U_USD">1842000</us-gaap:ProvisionForLeaseLosses>
    <us-gaap:ProvisionForLeaseLosses
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_81bf6ad3-ceaa-4b65-95e7-0703067ea43c"
      unitRef="U_USD">0</us-gaap:ProvisionForLeaseLosses>
    <verv:AmortizationOfPremiumOnMarketableSecurities
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_a077f254-1ca9-4ce6-bf3e-eca2f24d118c"
      unitRef="U_USD">1508000</verv:AmortizationOfPremiumOnMarketableSecurities>
    <verv:AmortizationOfPremiumOnMarketableSecurities
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_48dc9ae1-71d2-42b3-97dd-3a91f0a0e7b4"
      unitRef="U_USD">380000</verv:AmortizationOfPremiumOnMarketableSecurities>
    <verv:AmortizationOfPremiumOnMarketableSecurities
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_f349312d-3fc6-42b9-8e29-f989374f3dc9"
      unitRef="U_USD">-72000</verv:AmortizationOfPremiumOnMarketableSecurities>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_0f4f4228-1221-4457-831f-c5cf8d054489"
      unitRef="U_USD">7072000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_aecc6746-a067-4431-b531-a59420d4bdc3"
      unitRef="U_USD">850000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_da913716-f06d-4cad-876b-15f476383510"
      unitRef="U_USD">446000</us-gaap:ShareBasedCompensation>
    <verv:ChangeInFairValueOfPreferredStockTrancheLiabilities
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_d285f6bd-1be9-457c-ae20-9c006a88c407"
      unitRef="U_USD">0</verv:ChangeInFairValueOfPreferredStockTrancheLiabilities>
    <verv:ChangeInFairValueOfPreferredStockTrancheLiabilities
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_8b07fcf0-3610-4dc3-8c80-4040284f0c52"
      unitRef="U_USD">2507000</verv:ChangeInFairValueOfPreferredStockTrancheLiabilities>
    <verv:ChangeInFairValueOfPreferredStockTrancheLiabilities
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_9502d78d-8f67-4478-8e0e-9ddbafcaa784"
      unitRef="U_USD">-4883000</verv:ChangeInFairValueOfPreferredStockTrancheLiabilities>
    <verv:ChangeInFairValueOfAntidilutionRights
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_117952f0-fd37-473a-a12e-85c0903ec992"
      unitRef="U_USD">25574000</verv:ChangeInFairValueOfAntidilutionRights>
    <verv:ChangeInFairValueOfAntidilutionRights
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_eb0df781-7700-4dad-8de8-542476be8b4c"
      unitRef="U_USD">5359000</verv:ChangeInFairValueOfAntidilutionRights>
    <verv:ChangeInFairValueOfAntidilutionRights
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_7fa36348-d8b5-4116-8aaf-22a5bf90845f"
      unitRef="U_USD">982000</verv:ChangeInFairValueOfAntidilutionRights>
    <verv:ChangeInFairValueOfSuccessPaymentsLiabilities
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_2784cb7d-d315-449f-b25d-83eb83a3e70e"
      unitRef="U_USD">7815000</verv:ChangeInFairValueOfSuccessPaymentsLiabilities>
    <verv:ChangeInFairValueOfSuccessPaymentsLiabilities
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_2c7ff87e-5c70-4350-a77b-9fc782fc8841"
      unitRef="U_USD">2387000</verv:ChangeInFairValueOfSuccessPaymentsLiabilities>
    <verv:ChangeInFairValueOfSuccessPaymentsLiabilities
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_a6376081-9c64-4308-919e-7859b46507ef"
      unitRef="U_USD">68000</verv:ChangeInFairValueOfSuccessPaymentsLiabilities>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_566afad4-f233-4b8a-85c4-511b4c7455a0"
      unitRef="U_USD">7528000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_ab308196-7e08-4c21-b1e6-06e8f0911ca2"
      unitRef="U_USD">1582000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_c1bf943b-f0ac-4e19-8452-0bffa0473420"
      unitRef="U_USD">182000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_12967d40-b13a-486b-8a76-8acb952743bb"
      unitRef="U_USD">6829000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_899d04ff-788f-45f9-b0fc-b2a8cc064e01"
      unitRef="U_USD">-1898000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_fe0a526f-4867-47a5-a92e-3234fbd07192"
      unitRef="U_USD">1735000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_40c555f6-15a3-45c4-8907-289696f354cb"
      unitRef="U_USD">5977000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_d09262bc-e2b1-41cf-8cd9-57445f69b753"
      unitRef="U_USD">6071000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_17c9e9ca-f58a-4d69-966f-033d15e0e61c"
      unitRef="U_USD">945000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <verv:SuccessOfPaymentLiability
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_9345770d-f811-4c82-90f7-559225ace066"
      unitRef="U_USD">-6250000</verv:SuccessOfPaymentLiability>
    <verv:SuccessOfPaymentLiability
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_df87b555-a8fd-4888-920c-0dbf12e05c6e"
      unitRef="U_USD">0</verv:SuccessOfPaymentLiability>
    <verv:SuccessOfPaymentLiability
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_c6bb8fa5-8579-45ff-afbe-3c24c92c4107"
      unitRef="U_USD">0</verv:SuccessOfPaymentLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_77118c09-6cfc-4809-8b1f-224c03891c39"
      unitRef="U_USD">-1940000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_299ac9cc-51c0-4875-835b-31815e27fb07"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherDeferredLiability
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_ad8ffba9-2e26-42ab-92c7-75267dc0a44d"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOtherDeferredLiability>
    <us-gaap:IncreaseDecreaseInOtherDeferredLiability
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_475831e5-eb3a-4d42-a857-95edff0a6534"
      unitRef="U_USD">51000</us-gaap:IncreaseDecreaseInOtherDeferredLiability>
    <us-gaap:IncreaseDecreaseInOtherDeferredLiability
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_aa1352be-cda4-4d64-8f55-6bd35f7fc6bb"
      unitRef="U_USD">163000</us-gaap:IncreaseDecreaseInOtherDeferredLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_0af904a7-4ccf-4781-b2f2-007fbea0dbb8"
      unitRef="U_USD">-77880000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_395342a9-783a-4123-90c4-84cc41e89b0a"
      unitRef="U_USD">-35265000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_a0f9a615-3576-4140-8dc2-2f95bcced577"
      unitRef="U_USD">-7442000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_c1a92001-49c0-4ff2-950b-ee3ea7b8c5e7"
      unitRef="U_USD">4359000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_543653f2-112e-476c-811e-f010a62b3428"
      unitRef="U_USD">3424000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_787bbc21-ce5a-4b59-b0ed-fb5e36caf599"
      unitRef="U_USD">1857000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_2201ca3d-ab9a-47c6-abba-c0cdc1901b4f"
      unitRef="U_USD">371494000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_dd7596ce-75aa-46f9-956f-68ea9851e71a"
      unitRef="U_USD">98484000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_447c7a42-879d-4bcb-a699-78e096fd2ca0"
      unitRef="U_USD">22001000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <verv:MaturitiesOfMarketableSecurities
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_e0afd937-29dd-411e-a301-acda5e30a67d"
      unitRef="U_USD">136755000</verv:MaturitiesOfMarketableSecurities>
    <verv:MaturitiesOfMarketableSecurities
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_657dcc2b-65ca-441a-9549-83a3893b75f1"
      unitRef="U_USD">50781000</verv:MaturitiesOfMarketableSecurities>
    <verv:MaturitiesOfMarketableSecurities
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_7f57d877-1c64-4673-a5ad-eb315ef64afb"
      unitRef="U_USD">11100000</verv:MaturitiesOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_dbf986bd-c69c-4f17-af9c-0efa4c671493"
      unitRef="U_USD">-239098000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_518ee430-b462-4c20-819d-b3dec360d98a"
      unitRef="U_USD">-51127000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_54b405c9-4053-430b-bd05-2dec4b359c3c"
      unitRef="U_USD">-12758000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_643bf729-ba6f-4807-a93d-11fafb665cd3"
      unitRef="U_USD">93759000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_62fc96b3-e575-4e68-85da-7a82578a6831"
      unitRef="U_USD">92616000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_43df18e4-db89-45e1-af12-454114d2e913"
      unitRef="U_USD">18040000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_960c2583-3520-4918-98ce-c6608762037c"
      unitRef="U_USD">285214000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_1cfd9018-0f1f-4ea0-ae7d-4b366161360d"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <verv:ProceedFromShareholderLoan
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_8717d460-6332-416b-ae33-6633ea62d241"
      unitRef="U_USD">0</verv:ProceedFromShareholderLoan>
    <verv:ProceedFromShareholderLoan
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_48d3f077-8c1c-4fbe-8e12-5d12e9f57e11"
      unitRef="U_USD">-110000</verv:ProceedFromShareholderLoan>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_2a4d6d67-14d3-43a9-80d3-b266e87ef9b0"
      unitRef="U_USD">3630000</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_b2b81c5c-1bac-4e90-b911-5b8d3e4e9eb7"
      unitRef="U_USD">966000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_5dc28582-a9e8-48a3-a549-6ca1db167a58"
      unitRef="U_USD">11000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_6b1b0f05-bddd-4876-8612-5f672b7cbf15"
      unitRef="U_USD">0</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_1f938ed0-4fc4-475f-bdec-c61defde13bd"
      unitRef="U_USD">24000</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:EmployeeStockOwnershipPlanESOPCashContributionsToESOP
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_697cdbe8-83c0-4d01-9377-f2580edc6a33"
      unitRef="U_USD">780000</us-gaap:EmployeeStockOwnershipPlanESOPCashContributionsToESOP>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_bf394e6b-9baa-4cd1-884c-ee46ea21a0e5"
      unitRef="U_USD">377089000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_2c3b6c59-6255-407c-b0ac-5286d278c314"
      unitRef="U_USD">92627000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_8656330e-da47-433c-8089-35d3ece8363a"
      unitRef="U_USD">17954000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_2dfe2bc4-9897-4428-8d11-c6aa90717f86"
      unitRef="U_USD">60111000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_87bbc9fd-d302-4eb1-bb88-cde0c27bb667"
      unitRef="U_USD">6235000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_fce92172-f40d-4e97-93a6-a65b4cf78472"
      unitRef="U_USD">-2246000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_f9dfbd10-ff13-4dd3-af8f-9b3704f28b49"
      unitRef="U_USD">9456000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_9d0f6183-f1e6-4aa0-b41e-2e38deb97369"
      decimals="-3"
      id="F_1bce4bf2-08aa-4384-99c6-d55d7abc7dfc"
      unitRef="U_USD">3221000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_ace78012-0407-4c33-9333-78a05d5e4482"
      decimals="-3"
      id="F_438bf6e0-8f77-4ec5-8281-021c97c3246b"
      unitRef="U_USD">5467000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_51e7f618-a97c-4090-9272-effe13f42159"
      unitRef="U_USD">69567000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_3a3b89eb-ad6c-4968-8d7c-6c9e286a2503"
      unitRef="U_USD">9456000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_9d0f6183-f1e6-4aa0-b41e-2e38deb97369"
      decimals="-3"
      id="F_47043e1d-154b-4471-a323-cdc4148c5543"
      unitRef="U_USD">3221000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <verv:PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_6d8ff399-2768-4243-9b5a-850dc2d8caf2"
      unitRef="U_USD">503000</verv:PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses>
    <verv:PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_b9ac7ceb-f9e3-4a83-aeab-d7a518bf79c1"
      unitRef="U_USD">86000</verv:PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses>
    <verv:PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_731dcab6-aac7-4bb4-a1d1-e58e5364ac99"
      unitRef="U_USD">556000</verv:PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses>
    <verv:SettlementOfTrancheRightLliability
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_e3457fdd-4edc-41c0-9176-3120d144815f"
      unitRef="U_USD">0</verv:SettlementOfTrancheRightLliability>
    <verv:IssuanceOfPreferredStockTrancheLiability
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_0e34cd30-4705-41a8-b30c-6845070e7473"
      unitRef="U_USD">84000</verv:IssuanceOfPreferredStockTrancheLiability>
    <verv:SettlementOfTrancheRightLliability
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_ceb1185c-3a41-499a-9161-a77ef5610672"
      unitRef="U_USD">0</verv:SettlementOfTrancheRightLliability>
    <verv:SettlementOfTrancheRightLliability
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_9fd6ed98-1fbe-4e0d-9fde-bd3e9e0222c0"
      unitRef="U_USD">7064000</verv:SettlementOfTrancheRightLliability>
    <verv:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_56fcdf28-7cf5-4362-89a3-080bde2d8357"
      unitRef="U_USD">218919000</verv:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering>
    <verv:SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_3ba00fe1-ae58-4b22-ae9b-8e5b9e40abe6"
      unitRef="U_USD">32490000</verv:SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock>
    <verv:SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_8c6d0ef4-57bb-4873-b94f-6b1821816e2a"
      unitRef="U_USD">487000</verv:SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock>
    <verv:SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_ab0d91dd-1367-4160-b3ca-9321414e5736"
      unitRef="U_USD">135000</verv:SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_837f4a32-2847-4fad-a035-d0ab69d072c8"
      unitRef="U_USD">809000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_5245fd97-6ac7-49d2-8f6c-dd4d573b7ec4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;1. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;Nature of the business and basis of presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Organization&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Verve Therapeutics, Inc. (the &#x201c;Company&#x201d; or &#x201c;Verve&#x201d;) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The Company was incorporated on March 9, 2018 as Endcadia, Inc., a Delaware corporation, and began operations shortly thereafter. In January 2019, the Company amended its certificate of incorporation to change its name to Verve Therapeutics, Inc. The Company&#x2019;s principal offices are located in Cambridge, Massachusetts.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Liquidity and capital resources&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;On June 21, 2021, the Company completed its initial public offering, or IPO, in which the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16,141,157&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of its common stock, including &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,105,368&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;19.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share, for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;306.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. The Company received approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;281.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in net proceeds after deducting underwriting discounts and offering expenses payable by the Company. In connection with the IPO, all outstanding shares of convertible preferred stock converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;27,720,923&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In connection with the Company's IPO, the Company effected a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;one-for-9.2595&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; reverse stock split of the Company&#x2019;s issued and outstanding common stock. Accordingly, all shares of common stock and per share amounts, as well as the conversion ratio of the Company&#x2019;s outstanding convertible preferred stock, for all periods presented in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split, including reclassification of par and additional paid-in capital amounts as a result of the reverse stock split.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Basis of presentation and liquidity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred losses since its inception, including losses of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;120.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;45.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;19.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; for the years ended December 31, 2021, 2020 and 2019, respectively. As of December 31, 2021, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;186.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. To date, the Company has funded its operations primarily through equity offerings. Through December 31, 2021, the Company had raised an aggregate $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;523.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in gross proceeds from the sales of its preferred stock in private placements and common stock in its IPO. The Company expects to generate operating losses and negative operating cash flows for the foreseeable future.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company expects that its cash, cash equivalents and marketable securities as of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; will &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;be sufficient to fund its operations for at least the next twelve months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;strategy. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed could have a negative impact on the Company&#x2019;s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_1ff558da-6b5f-4d32-9a66-1203371d1d23"
      decimals="INF"
      id="F_fc2e5b00-b68e-4f82-8850-014ee61b0e3b"
      unitRef="U_shares">16141157</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_3965b88b-aada-4b0f-bb79-9e1564c8b01f"
      decimals="INF"
      id="F_322be980-a8b2-47bc-bece-b71f258e9730"
      unitRef="U_shares">2105368</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_6111bf12-8023-40ef-949d-f9fc8eb769e3"
      decimals="2"
      id="F_4c7d2d44-e656-4abf-a968-e0b7e331daa0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_1ff558da-6b5f-4d32-9a66-1203371d1d23"
      decimals="-5"
      id="F_57e28610-3af9-4f8a-808d-24a0e465f9e0"
      unitRef="U_USD">306700000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_1ff558da-6b5f-4d32-9a66-1203371d1d23"
      decimals="-5"
      id="F_d542cb88-f34d-4103-b2be-11b0d32369e6"
      unitRef="U_USD">281600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_6111bf12-8023-40ef-949d-f9fc8eb769e3"
      decimals="INF"
      id="F_5ccd6123-3ca5-4e80-bbc2-1e6cd745a2c5"
      unitRef="U_shares">27720923</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_6318768f-6910-4cea-8012-84a1cded066e"
      id="F_8ce1c6e7-ec61-4125-b9c7-679170c396d9">one-for-9.2595</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:NetIncomeLoss
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-5"
      id="F_37040f59-8db6-43d9-b26f-4a4481824c6d"
      unitRef="U_USD">-120300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-5"
      id="F_0a0e7447-8e95-4184-8b96-4b29a5ea9a31"
      unitRef="U_USD">-45700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-5"
      id="F_f9c2b4b1-8fec-4c33-98a5-2c0d0c6cb05e"
      unitRef="U_USD">-19300000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-5"
      id="F_40d45dd1-ee44-4d4b-8fae-9638e53ea890"
      unitRef="U_USD">-186900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_6318768f-6910-4cea-8012-84a1cded066e"
      decimals="-5"
      id="F_41de67f1-71e1-41ac-bdb4-4c79baca1fdb"
      unitRef="U_USD">523200000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_583ca74f-38d2-43b3-bb08-49e7a5321b97">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;2. S&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;ummary of significant accounting policies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Principles of consolidation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The accompanying consolidated financial statements include the accounts of Verve and its wholly owned subsidiary, Verve Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Use of estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair values of common stock (prior to completion of the IPO), convertible preferred stock, preferred stock tranche liability, stock-based compensation, and the liabilities for antidilution rights and success payments. Actual results could differ from these estimates.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Cash and cash equivalents consist of standard checking accounts and money market account funds that invest primarily in U.S. government-backed securities and treasuries. The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at cost, which is substantially equivalent to fair value.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Restricted cash represents collateral provided for a letter of credit issued as a security deposit in connection with the Company&#x2019;s leases of its corporate facilities. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.402%;"/&gt;
          &lt;td style="width:1.6%;"/&gt;
          &lt;td style="width:1.441%;"/&gt;
          &lt;td style="width:13.052%;"/&gt;
          &lt;td style="width:0.716%;"/&gt;
          &lt;td style="width:1.6%;"/&gt;
          &lt;td style="width:1.441%;"/&gt;
          &lt;td style="width:13.032%;"/&gt;
          &lt;td style="width:0.716%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;64,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;69,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Marketable securities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are maintained by the Company&#x2019;s investment managers and consist of U.S. treasury bills and U.S agency securities. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income (loss) as a component of stockholders&#x2019; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Company reviews marketable securities for other-than-temporary impairment whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security&#x2019;s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if the Company has experienced a credit loss, has the intent to sell the marketable security, or if it is more likely than not that the Company will be required to sell the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;marketable &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;security before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company&#x2019;s investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period. The Company evaluated its securities for other-than-temporary impairment and considered the decline in market value for the securities to be primarily attributable to current economic and market conditions. It is not more likely than not that the Company will be required to sell the securities, and the Company does not intend to do so prior to the recovery of the amortized cost basis. Based on this analysis, these marketable securities were not considered to be other-than-temporarily impaired as of December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Concentrations of credit risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and restricted cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Deferred offering costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company capitalized incremental legal, professional accounting and other third-party fees that were directly associated with the IPO as other non-current assets until the IPO was consummated. After consummation of the IPO, these costs were recorded in stockholders&#x2019; equity (deficit) as a reduction of additional paid-in-capital generated as a result of the offering.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Indemnification agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Fair value of financial instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;ASC Topic 820, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Fair Value Measurement &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Level 1&#x2014;Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Level 2&#x2014;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Level 3&#x2014;Unobservable inputs for the asset or liability (i.e. supported by little or no market activity). Level 3 inputs include management&#x2019;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;There have been no changes to the valuation methods utilized by the Company during the years ended December 31, 2021, 2020 and 2019. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the years ended December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Property and equipment, net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Property and equipment are stated at cost less accumulated depreciation. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.968%;"/&gt;
          &lt;td style="width:2.064%;"/&gt;
          &lt;td style="width:48.968%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Asset category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Office furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; impairment losses recognized during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021, 2020 and 2019&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Freestanding financial instruments and derivatives&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company has identified the following financial instruments, which are recorded as liabilities in the balance sheet and separately accounted for at fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Preferred Stock Tranche Liabilities&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;The Company has determined that its obligation to issue, and the Company&#x2019;s investors&#x2019; right to purchase, additional shares of convertible Series A Preferred Stock (&#x201c;Series A Preferred&#x201d;) pursuant to subsequent closings represent a freestanding financial instrument. The freestanding preferred stock tranche liability (the &#x201c;tranche liability&#x201d;) was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss. The tranche liabilities were remeasured at each reporting period and upon the exercise or expiration of the obligation. As of December 31, 2020, all Series A Preferred closings occurred, and all preferred stock tranche liabilities have been settled. Refer to Note 9, Preferred Stock tranche liability, for additional discussion.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Pursuant to license agreements with (i) the President and Fellows of Harvard College (&#x201c;Harvard&#x201d;) and The Broad Institute, Inc. (&#x201c;Broad&#x201d;) (&#x201c;Harvard/Broad License Agreement&#x201d;) and (ii) Broad (&#x201c;Broad License Agreement&#x201d;) (see Note 8, License agreements), the following financial instruments were issued by the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Antidilution Rights&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;The antidilution rights represent the obligation to issue additional shares of common stock to Harvard and Broad following the completion of additional financings, including the Company&#x2019;s initial public offering. These antidilution rights were accounted for under ASC 815, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Derivatives and Hedging ("ASC 815"),&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and were initially recorded at fair value with a corresponding charge to research and development expense. The liability was remeasured at each reporting period, with changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss while this instrument was outstanding. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The obligation was satisfied in full upon the issuance of an aggregate of an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;878,098&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of common stock upon the closing of the Company's IPO in June 2021. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Refer to Note 5, Fair value of financial instruments, for additional discussion.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Success Payments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;The Company is obligated to pay to Harvard and Broad tiered success payments in the event the Company&#x2019;s average market capitalization exceeds specified thresholds ascending from a high nine digit dollar amount to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control of the Company or a sale of the Company, the Company is required to pay in cash within a specified period following such event. Otherwise, the payments may be settled at the Company&#x2019;s option in either cash or shares of the Company&#x2019;s common stock. The success payments are accounted for under ASC 815 and were initially recorded at fair value with a corresponding charge to research and development expense. The liability is remeasured at each reporting period with all changes in value recognized in other income (expense) in the statement of operations and other comprehensive loss. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;During the year ended December 31, 2021, certain success payment obligations were triggered, and amounts paid to Harvard and Broad totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; These amounts were settled in cash in November 2021. The Company will continue to adjust the liability for changes in fair value until the earlier of the achievement or expiration of the remaining success payment obligation. Refer to Note 5, Fair value of financial instruments, for additional discussion&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Research and development costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Research &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, third-party license fees related to technology with no alternative&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;future &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;use, laboratory supplies, depreciation, manufacturing expenses, preclinical expenses, consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Stock-based compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s stock-based compensation program allows for grants of stock options and restricted stock awards. Grants are awarded to employees and non-employees, including directors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; (&#x2018;&#x2018;ASC 718&#x2019;&#x2019;). ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#x2018;&#x2018;Black-Scholes&#x2019;&#x2019;) for stock option grants to both employees and non-employees. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock awards.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s stock-based compensation awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized over the implied service period when achievement of the performance-based milestones is deemed probable. The Company uses judgement to determine whether and, if so, how many awards are deemed probable of vesting at each reporting period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The estimation of fair value for stock-based compensation requires management to make estimates and judgments about, among other things, the estimated life of options and volatility of the Company&#x2019;s common stock. The judgments directly affect the amount of compensation expense that will be recognized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Prior to the Company's IPO in June 2021, there was no public market for its common stock. As a result, prior to the IPO, the estimated fair value of the Company's common stock was determined by its board of directors as of the date of each option grant, with input from management, considering the Company's most recently available third-party valuations of common stock and its board of directors' assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of grant. Following the Company's IPO, the fair value of its common stock is determined based on the closing price of the Company's common stock as reported on the Nasdaq Global Select Market&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Rent expense&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s real estate operating leases provide for scheduled annual rent increases throughout the lease term. The Company recognizes the effects of the scheduled rent increases on a straight-line basis over the full term of the lease. Prior to the adoption of ASU 2016-02, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, or ASC 842, tenant improvement allowances, if any, provided by the landlord are recorded as deferred rent and amortized as reduction to rent expense over the lease term. Subsequent to the adoption of ASC 842, tenant improvement allowances, if any, provided by a landlord are recorded as a reduction of the right-of-use, or ROU, asset related to that lease.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Income taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Comprehensive loss&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2021, 2020 and 2019&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, the Company&#x2019;s only element of other comprehensive income (loss) was unrealized gains (losses) on marketable securities.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Net loss per share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2021, 2020 and 2019&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Segment and geographic information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;), or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#x2019;s Chief Executive Officer. The Company views its operations as and manages its business in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; operating segment operating exclusively in the United States.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Subsequent events&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company performs an evaluation of all subsequent events after the balance sheet date through the date of issuance of the consolidated financial statements to ensure appropriate disclosure of events both recognized in the consolidated financial statements and events which occurred subsequently but were not recognized in the consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), as subsequently amended, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors), and replaces the existing guidance in ASC 840. The FASB has issued several updates to the standard which: (i) clarify how to apply certain aspects of the new standard; (ii) provide an additional transition method for adoption of the new standard; (iii) provide a practical expedient for certain lessor accounting; and (iv) amend certain narrow aspects of the guidance. The new standard requires the identification and classification of arrangements that are or contain a lease and requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine the recognition pattern of lease expense over the term of the lease. In addition, a lessee is required to record (i) a right-of-use asset and a lease liability on its balance sheet for all leases with accounting lease terms of more than 12 months regardless of whether it is an operating or finance lease and (ii) lease expense in its consolidated statement of operations for operating leases and amortization and interest expense in its consolidated statement of operations for financing&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;leases. Leases with a term of 12 months or less may be accounted for similar to existing guidance for operating leases under ASC 840. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842), which added an optional transition method that allows companies to adopt the standard as of the beginning of the year of adoption as opposed to the earliest comparative period presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Prior to January 1, 2021, the Company accounted for leases pursuant to ASC 840, Leases. At lease inception, the Company determined if an arrangement was an operating or capital lease. For operating leases, the Company recognized rent expense, inclusive of rent escalations, holidays and lease incentives, on a straight-line basis over the lease term. The difference between rent expense recorded and the amount paid was recorded as deferred rent. The Company presented lease incentives as deferred rent and amortized the incentives as a reduction to rent expense on a straight-line basis over the lease term. The Company classified deferred rent as current and noncurrent liabilities based on the portion of the deferred rent that was scheduled to mature within the next twelve months.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;adopted &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Topic 842 during the quarter ended September 30, 2021, with an effective adoption date of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, using the modified retrospective transition approach which uses the effective date, or January 1, 2021, as the date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. At contract inception, the Company determines if an arrangement is or contains a lease. A lease conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If an arrangement is determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on which the leased asset is made available for use by the Company, based on the economic characteristics of the lease. The Company has elected to apply the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or the capitalization of initial direct costs for any existing leases. As a result of the adoption of ASC 842, the Company recorded (i) an operating lease liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million determined using an incremental borrowing rate as of the effective adoption date and (ii) an operating lease right-of-use asset of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, net of the unamortized balance of prepaid/accrued rent as of the transition date. There was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; impact to the Company&#x2019;s results of operations and cash flows from operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company has elected the short-term lease exemption, which allows the Company to not recognize lease liabilities and right-of-use assets arising from lease arrangements with lease terms of twelve months or less. For each lease with a term greater than twelve months, the Company records a right-of-use asset and lease liability.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;A right-of-use asset represents the economic benefit conveyed to the Company by the right to use the underlying asset over the lease term. A lease liability represents the Company&#x2019;s obligation to make lease payments under the arrangement. The Company measures its lease liabilities at lease commencement as the present value of the future lease payments in the contract using the rate implicit in the contract, when available. As an implicit rate has not historically been readily determinable, the Company uses an incremental borrowing rate measured as the rate at which the Company could borrow, on a fully collateralized basis, a commensurate loan in the same currency over a period consistent with the lease term at the commencement date. The incremental borrowing rate is determined based on the Company's synthetic secured rating using the ordered logit model as of the measurement date. The Company measures its right-of-use assets as the lease liability plus initial direct costs and prepaid lease payments, less lease incentives granted by the lessor.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Components of a lease are split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) are allocated, based on the respective relative fair values, to the lease components and non-lease components. The Company has elected to account for lease and associated non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company remeasures right-of-use assets and lease liabilities when a lease is modified, and the modification is not accounted for as a separate contract. A modification is accounted for as a separate contract if the modification grants the Company an additional right of use not included in the original lease arrangement and the increase in lease payments is commensurate with the additional right of use. The Company assesses its right-of-use assets for impairment in a manner consistent with its assessment for long-lived assets held and used in operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s operating leases are presented in the consolidated balance sheet as operating lease right-of-use assets, classified as noncurrent assets, and operating lease liabilities, classified as current and noncurrent liabilities. Operating lease expense is recognized on a straight-line basis over the lease term. Variable costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;associated with a lease, such as maintenance and utilities, are not included in the measurement of the lease liabilities and right-of-use assets but rather are expensed when the events determining the amount of variable consideration to be paid have occurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company ("EGC") to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. As an EGC, the Company has elected to take advantage of this extended transition period for certain new accounting standards.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The new standard will be effective for the Company on January 1, 2023. The Company is currently evaluating the potential impact that this standard may have on its consolidated financial position and results of operations.&lt;/span&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_aed9b359-a27e-4559-913d-ed12255a5f35">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Principles of consolidation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The accompanying consolidated financial statements include the accounts of Verve and its wholly owned subsidiary, Verve Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_916cba5c-4f50-467b-a62e-c3157bd17aad">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Use of estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair values of common stock (prior to completion of the IPO), convertible preferred stock, preferred stock tranche liability, stock-based compensation, and the liabilities for antidilution rights and success payments. Actual results could differ from these estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_87f1bbf8-d595-4188-a033-52bc19df12a6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Cash and cash equivalents consist of standard checking accounts and money market account funds that invest primarily in U.S. government-backed securities and treasuries. The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at cost, which is substantially equivalent to fair value.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_7617d36e-b1a0-4d61-a874-12343010908b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Restricted cash represents collateral provided for a letter of credit issued as a security deposit in connection with the Company&#x2019;s leases of its corporate facilities. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.402%;"/&gt;
          &lt;td style="width:1.6%;"/&gt;
          &lt;td style="width:1.441%;"/&gt;
          &lt;td style="width:13.052%;"/&gt;
          &lt;td style="width:0.716%;"/&gt;
          &lt;td style="width:1.6%;"/&gt;
          &lt;td style="width:1.441%;"/&gt;
          &lt;td style="width:13.032%;"/&gt;
          &lt;td style="width:0.716%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;64,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;69,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <verv:ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_1f4622e3-61f2-497f-a7ab-7c1f8cce355f">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.402%;"/&gt;
          &lt;td style="width:1.6%;"/&gt;
          &lt;td style="width:1.441%;"/&gt;
          &lt;td style="width:13.052%;"/&gt;
          &lt;td style="width:0.716%;"/&gt;
          &lt;td style="width:1.6%;"/&gt;
          &lt;td style="width:1.441%;"/&gt;
          &lt;td style="width:13.032%;"/&gt;
          &lt;td style="width:0.716%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;64,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;69,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</verv:ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_bec5d017-a50a-41bd-9d60-54f0c77ab38d"
      unitRef="U_USD">64330000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_e404bc04-a3ea-435b-acc4-baaed1fe268c"
      unitRef="U_USD">8993000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_841c9165-e360-4b58-b18f-5f60b355d37c"
      unitRef="U_USD">5237000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_02fe5c17-91bf-4511-b318-431689661b19"
      unitRef="U_USD">463000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_d7fa0568-c3a5-4c6e-91b7-d8e0b276c12c"
      unitRef="U_USD">69567000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_ab9ee428-4c6a-4d21-92da-dabd575a8603"
      unitRef="U_USD">9456000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_0b3f3954-9d7e-4b69-bd5b-122be6e825f1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Marketable securities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are maintained by the Company&#x2019;s investment managers and consist of U.S. treasury bills and U.S agency securities. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income (loss) as a component of stockholders&#x2019; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense).&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Company reviews marketable securities for other-than-temporary impairment whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security&#x2019;s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if the Company has experienced a credit loss, has the intent to sell the marketable security, or if it is more likely than not that the Company will be required to sell the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;marketable &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;security before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company&#x2019;s investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period. The Company evaluated its securities for other-than-temporary impairment and considered the decline in market value for the securities to be primarily attributable to current economic and market conditions. It is not more likely than not that the Company will be required to sell the securities, and the Company does not intend to do so prior to the recovery of the amortized cost basis. Based on this analysis, these marketable securities were not considered to be other-than-temporarily impaired as of December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_bc347694-a55d-4383-881d-551a04cc8c46">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Concentrations of credit risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and restricted cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.&lt;/span&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <verv:DeferredOfferingCostsPolicyTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_1ff4b253-5d0b-4f67-ac90-ada5a08700c3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Deferred offering costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company capitalized incremental legal, professional accounting and other third-party fees that were directly associated with the IPO as other non-current assets until the IPO was consummated. After consummation of the IPO, these costs were recorded in stockholders&#x2019; equity (deficit) as a reduction of additional paid-in-capital generated as a result of the offering.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;</verv:DeferredOfferingCostsPolicyTextBlock>
    <verv:IndemnificationAgreementsPolicyTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_af4fc85a-30e2-4e7b-98a7-66d0d85f0089">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Indemnification agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.&lt;/span&gt;</verv:IndemnificationAgreementsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_64f4134f-1198-46a9-ad0c-f1b05182355c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Fair value of financial instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;ASC Topic 820, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Fair Value Measurement &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Level 1&#x2014;Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Level 2&#x2014;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Level 3&#x2014;Unobservable inputs for the asset or liability (i.e. supported by little or no market activity). Level 3 inputs include management&#x2019;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;There have been no changes to the valuation methods utilized by the Company during the years ended December 31, 2021, 2020 and 2019. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the years ended December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.&lt;/span&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_ea20810d-169b-4e69-a3aa-ebe4e6568c16">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Property and equipment, net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Property and equipment are stated at cost less accumulated depreciation. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.968%;"/&gt;
          &lt;td style="width:2.064%;"/&gt;
          &lt;td style="width:48.968%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Asset category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Office furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <verv:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_3f265e3d-d76b-433c-9646-0e1b46b67911">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.968%;"/&gt;
          &lt;td style="width:2.064%;"/&gt;
          &lt;td style="width:48.968%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Asset category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Office furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</verv:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_47adbab3-b838-4d39-aa2e-17b98510b0b2"
      id="F_bc086466-58f7-468f-b1fb-0b14febc9b25">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_89a10d74-f017-4e8e-9761-a6d46cf3afb2"
      id="F_7d8fcb95-df90-42f0-bb82-a69c5a5d388d">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_25e7d82a-63d5-46e3-ace4-4ed5f2668166"
      id="F_a41e78fe-94cf-4a47-a9b3-109fd8cab670">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_bf52cb0e-645b-4c9d-abcc-988c1ab77568"
      id="F_48cd622b-82c5-40dc-9f3f-2ecdb9a1578e">Shorter of useful life or remaining lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_8765d91d-f860-4b16-b2c1-bb8727a01263">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; impairment losses recognized during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021, 2020 and 2019&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.&lt;/span&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="INF"
      id="F_1f575086-efce-4204-8c38-897e9d401bbb"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="INF"
      id="F_df6852ac-fc37-4177-95b6-060848a9b27e"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="INF"
      id="F_97f25cd1-10d8-4e2f-a588-315cf6916989"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <verv:FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_977783b8-9784-465f-a09b-4b6269d58006">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Freestanding financial instruments and derivatives&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company has identified the following financial instruments, which are recorded as liabilities in the balance sheet and separately accounted for at fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Preferred Stock Tranche Liabilities&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;The Company has determined that its obligation to issue, and the Company&#x2019;s investors&#x2019; right to purchase, additional shares of convertible Series A Preferred Stock (&#x201c;Series A Preferred&#x201d;) pursuant to subsequent closings represent a freestanding financial instrument. The freestanding preferred stock tranche liability (the &#x201c;tranche liability&#x201d;) was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss. The tranche liabilities were remeasured at each reporting period and upon the exercise or expiration of the obligation. As of December 31, 2020, all Series A Preferred closings occurred, and all preferred stock tranche liabilities have been settled. Refer to Note 9, Preferred Stock tranche liability, for additional discussion.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Pursuant to license agreements with (i) the President and Fellows of Harvard College (&#x201c;Harvard&#x201d;) and The Broad Institute, Inc. (&#x201c;Broad&#x201d;) (&#x201c;Harvard/Broad License Agreement&#x201d;) and (ii) Broad (&#x201c;Broad License Agreement&#x201d;) (see Note 8, License agreements), the following financial instruments were issued by the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Antidilution Rights&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;The antidilution rights represent the obligation to issue additional shares of common stock to Harvard and Broad following the completion of additional financings, including the Company&#x2019;s initial public offering. These antidilution rights were accounted for under ASC 815, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Derivatives and Hedging ("ASC 815"),&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and were initially recorded at fair value with a corresponding charge to research and development expense. The liability was remeasured at each reporting period, with changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss while this instrument was outstanding. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The obligation was satisfied in full upon the issuance of an aggregate of an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;878,098&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of common stock upon the closing of the Company's IPO in June 2021. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Refer to Note 5, Fair value of financial instruments, for additional discussion.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Success Payments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;The Company is obligated to pay to Harvard and Broad tiered success payments in the event the Company&#x2019;s average market capitalization exceeds specified thresholds ascending from a high nine digit dollar amount to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control of the Company or a sale of the Company, the Company is required to pay in cash within a specified period following such event. Otherwise, the payments may be settled at the Company&#x2019;s option in either cash or shares of the Company&#x2019;s common stock. The success payments are accounted for under ASC 815 and were initially recorded at fair value with a corresponding charge to research and development expense. The liability is remeasured at each reporting period with all changes in value recognized in other income (expense) in the statement of operations and other comprehensive loss. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;During the year ended December 31, 2021, certain success payment obligations were triggered, and amounts paid to Harvard and Broad totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; These amounts were settled in cash in November 2021. The Company will continue to adjust the liability for changes in fair value until the earlier of the achievement or expiration of the remaining success payment obligation. Refer to Note 5, Fair value of financial instruments, for additional discussion&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.&lt;/span&gt;</verv:FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock>
    <verv:IssuanceOfAdditionalCommonStock
      contextRef="C_db7855c5-c342-42e3-a442-d44d2061ccbe"
      decimals="0"
      id="F_dfc0dfbe-c007-4308-9b38-2f9888467c2f"
      unitRef="U_shares">878098</verv:IssuanceOfAdditionalCommonStock>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_e8b5087a-c8c5-42b6-b02a-2126a65898d5"
      decimals="-8"
      id="F_00e74a8d-9abd-450e-b5b1-8554944ca6f0"
      unitRef="U_USD">10000000000.0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <verv:SuccessLiabilityPayment
      contextRef="C_30c56851-0530-4749-a9d8-9d1a01a7d426"
      decimals="-5"
      id="F_5aded431-cd1c-4291-b3da-3f4a88bda714"
      unitRef="U_USD">6300000</verv:SuccessLiabilityPayment>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_fcf3f601-a6d6-4909-9e24-a5ddb9d5f50a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Research and development costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Research &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, third-party license fees related to technology with no alternative&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;future &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;use, laboratory supplies, depreciation, manufacturing expenses, preclinical expenses, consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_f666bfc5-78c3-4122-a562-60265c68bb10">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Stock-based compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s stock-based compensation program allows for grants of stock options and restricted stock awards. Grants are awarded to employees and non-employees, including directors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; (&#x2018;&#x2018;ASC 718&#x2019;&#x2019;). ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#x2018;&#x2018;Black-Scholes&#x2019;&#x2019;) for stock option grants to both employees and non-employees. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock awards.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s stock-based compensation awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized over the implied service period when achievement of the performance-based milestones is deemed probable. The Company uses judgement to determine whether and, if so, how many awards are deemed probable of vesting at each reporting period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The estimation of fair value for stock-based compensation requires management to make estimates and judgments about, among other things, the estimated life of options and volatility of the Company&#x2019;s common stock. The judgments directly affect the amount of compensation expense that will be recognized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Prior to the Company's IPO in June 2021, there was no public market for its common stock. As a result, prior to the IPO, the estimated fair value of the Company's common stock was determined by its board of directors as of the date of each option grant, with input from management, considering the Company's most recently available third-party valuations of common stock and its board of directors' assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of grant. Following the Company's IPO, the fair value of its common stock is determined based on the closing price of the Company's common stock as reported on the Nasdaq Global Select Market&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <verv:RentExpensePolicyTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_186dd7ed-e017-4813-b895-72996897bab3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Rent expense&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s real estate operating leases provide for scheduled annual rent increases throughout the lease term. The Company recognizes the effects of the scheduled rent increases on a straight-line basis over the full term of the lease. Prior to the adoption of ASU 2016-02, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, or ASC 842, tenant improvement allowances, if any, provided by the landlord are recorded as deferred rent and amortized as reduction to rent expense over the lease term. Subsequent to the adoption of ASC 842, tenant improvement allowances, if any, provided by a landlord are recorded as a reduction of the right-of-use, or ROU, asset related to that lease.&lt;/span&gt;&lt;/p&gt;</verv:RentExpensePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_17b5eee7-2816-4393-8489-cf31fe2927fb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Income taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.&lt;/span&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <verv:PercentageOfTaxBenefitRealized
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="2"
      id="F_fac67e05-e0f5-40fc-9023-eeb56def41e8"
      unitRef="U_pure">0.50</verv:PercentageOfTaxBenefitRealized>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_44bf6855-6531-4ce8-9d24-da4ce6952b1e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Comprehensive loss&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2021, 2020 and 2019&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, the Company&#x2019;s only element of other comprehensive income (loss) was unrealized gains (losses) on marketable securities.&lt;/span&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_7a39b202-b8fe-400c-8ef8-6010933a177d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Net loss per share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2021, 2020 and 2019&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.&lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <verv:SegmentAndGeographicInformationPolicyTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_44e8e985-6119-4d77-8d4c-5870f84f2fcd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Segment and geographic information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;), or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#x2019;s Chief Executive Officer. The Company views its operations as and manages its business in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; operating segment operating exclusively in the United States.&lt;/span&gt;</verv:SegmentAndGeographicInformationPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="INF"
      id="F_a1d2bc75-f64f-4af8-b463-0a438cc91ea7"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_90d868c1-a716-413d-a0b3-65cae5a28847">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Subsequent events&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company performs an evaluation of all subsequent events after the balance sheet date through the date of issuance of the consolidated financial statements to ensure appropriate disclosure of events both recognized in the consolidated financial statements and events which occurred subsequently but were not recognized in the consolidated financial statements.&lt;/span&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_d8d49096-5159-42ed-91f6-c48a662a04e5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), as subsequently amended, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors), and replaces the existing guidance in ASC 840. The FASB has issued several updates to the standard which: (i) clarify how to apply certain aspects of the new standard; (ii) provide an additional transition method for adoption of the new standard; (iii) provide a practical expedient for certain lessor accounting; and (iv) amend certain narrow aspects of the guidance. The new standard requires the identification and classification of arrangements that are or contain a lease and requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine the recognition pattern of lease expense over the term of the lease. In addition, a lessee is required to record (i) a right-of-use asset and a lease liability on its balance sheet for all leases with accounting lease terms of more than 12 months regardless of whether it is an operating or finance lease and (ii) lease expense in its consolidated statement of operations for operating leases and amortization and interest expense in its consolidated statement of operations for financing&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;leases. Leases with a term of 12 months or less may be accounted for similar to existing guidance for operating leases under ASC 840. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842), which added an optional transition method that allows companies to adopt the standard as of the beginning of the year of adoption as opposed to the earliest comparative period presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Prior to January 1, 2021, the Company accounted for leases pursuant to ASC 840, Leases. At lease inception, the Company determined if an arrangement was an operating or capital lease. For operating leases, the Company recognized rent expense, inclusive of rent escalations, holidays and lease incentives, on a straight-line basis over the lease term. The difference between rent expense recorded and the amount paid was recorded as deferred rent. The Company presented lease incentives as deferred rent and amortized the incentives as a reduction to rent expense on a straight-line basis over the lease term. The Company classified deferred rent as current and noncurrent liabilities based on the portion of the deferred rent that was scheduled to mature within the next twelve months.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;adopted &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Topic 842 during the quarter ended September 30, 2021, with an effective adoption date of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, using the modified retrospective transition approach which uses the effective date, or January 1, 2021, as the date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. At contract inception, the Company determines if an arrangement is or contains a lease. A lease conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If an arrangement is determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on which the leased asset is made available for use by the Company, based on the economic characteristics of the lease. The Company has elected to apply the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or the capitalization of initial direct costs for any existing leases. As a result of the adoption of ASC 842, the Company recorded (i) an operating lease liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million determined using an incremental borrowing rate as of the effective adoption date and (ii) an operating lease right-of-use asset of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, net of the unamortized balance of prepaid/accrued rent as of the transition date. There was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; impact to the Company&#x2019;s results of operations and cash flows from operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company has elected the short-term lease exemption, which allows the Company to not recognize lease liabilities and right-of-use assets arising from lease arrangements with lease terms of twelve months or less. For each lease with a term greater than twelve months, the Company records a right-of-use asset and lease liability.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;A right-of-use asset represents the economic benefit conveyed to the Company by the right to use the underlying asset over the lease term. A lease liability represents the Company&#x2019;s obligation to make lease payments under the arrangement. The Company measures its lease liabilities at lease commencement as the present value of the future lease payments in the contract using the rate implicit in the contract, when available. As an implicit rate has not historically been readily determinable, the Company uses an incremental borrowing rate measured as the rate at which the Company could borrow, on a fully collateralized basis, a commensurate loan in the same currency over a period consistent with the lease term at the commencement date. The incremental borrowing rate is determined based on the Company's synthetic secured rating using the ordered logit model as of the measurement date. The Company measures its right-of-use assets as the lease liability plus initial direct costs and prepaid lease payments, less lease incentives granted by the lessor.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Components of a lease are split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) are allocated, based on the respective relative fair values, to the lease components and non-lease components. The Company has elected to account for lease and associated non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company remeasures right-of-use assets and lease liabilities when a lease is modified, and the modification is not accounted for as a separate contract. A modification is accounted for as a separate contract if the modification grants the Company an additional right of use not included in the original lease arrangement and the increase in lease payments is commensurate with the additional right of use. The Company assesses its right-of-use assets for impairment in a manner consistent with its assessment for long-lived assets held and used in operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s operating leases are presented in the consolidated balance sheet as operating lease right-of-use assets, classified as noncurrent assets, and operating lease liabilities, classified as current and noncurrent liabilities. Operating lease expense is recognized on a straight-line basis over the lease term. Variable costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;associated with a lease, such as maintenance and utilities, are not included in the measurement of the lease liabilities and right-of-use assets but rather are expensed when the events determining the amount of variable consideration to be paid have occurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company ("EGC") to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. As an EGC, the Company has elected to take advantage of this extended transition period for certain new accounting standards.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The new standard will be effective for the Company on January 1, 2023. The Company is currently evaluating the potential impact that this standard may have on its consolidated financial position and results of operations.&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"/&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_88ca2b88-300c-48c8-815f-cc259e125c7f"
      id="F_f5aa6f95-8bea-43f3-a617-fa4df3bf91f3">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_88ca2b88-300c-48c8-815f-cc259e125c7f"
      id="F_069ae8d5-049a-4c2b-9d3e-66c62ce24ad2">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_88ca2b88-300c-48c8-815f-cc259e125c7f"
      decimals="-5"
      id="F_f3f5849f-a7d5-47ed-b9e1-095092b256de"
      unitRef="U_USD">2600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_88ca2b88-300c-48c8-815f-cc259e125c7f"
      decimals="-5"
      id="F_ec6d73ad-818f-4a34-8505-10cafd092b23"
      unitRef="U_USD">2400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_88ca2b88-300c-48c8-815f-cc259e125c7f"
      id="F_916b20b7-88e1-48af-8ccf-e6abe50a20b0">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_0b89be4e-4c85-426d-8553-dcfb69a899a8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;3. Marketable securities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Marketable securities by security type consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.07%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:9.414%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:9.414%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:9.285%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:9.365%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;U.S. treasury bills and notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;277,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;277,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;U.S. agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;18,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;18,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;296,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;296,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.12%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:9.414%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:9.414%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:9.414%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:9.335%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;U.S. treasury bills and notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;U.S. agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;30,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;30,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;63,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;63,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The remaining contractual maturities of all marketable securities were less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_2569f2c8-c555-498e-9657-6fe2fbdf0f5c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Marketable securities by security type consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.07%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:9.414%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:9.414%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:9.285%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:9.365%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;U.S. treasury bills and notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;277,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;277,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;U.S. agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;18,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;18,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;296,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;296,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.12%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:9.414%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:9.414%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:9.414%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:9.335%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;U.S. treasury bills and notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;U.S. agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;30,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;30,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;63,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;63,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c0b06ae8-891a-4456-9a30-d851caa260c4"
      decimals="-3"
      id="F_8a827730-32bc-48f0-a2dd-3993a375a2ad"
      unitRef="U_USD">277559000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_c0b06ae8-891a-4456-9a30-d851caa260c4"
      decimals="-3"
      id="F_52623e9f-ca4a-4498-91f5-2649a7ed24b1"
      unitRef="U_USD">218000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c0b06ae8-891a-4456-9a30-d851caa260c4"
      decimals="-3"
      id="F_d263ff55-a10b-4577-a162-38c44dcebd15"
      unitRef="U_USD">277341000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_dee7f513-4115-4cdf-b302-37edddf7187e"
      decimals="-3"
      id="F_a9b326d3-9bdd-42e1-a8c3-25ed8a394f74"
      unitRef="U_USD">18781000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_dee7f513-4115-4cdf-b302-37edddf7187e"
      decimals="-3"
      id="F_54b9eec5-6dfa-4beb-8b5f-c0c734350590"
      unitRef="U_USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_dee7f513-4115-4cdf-b302-37edddf7187e"
      decimals="-3"
      id="F_9dcbf029-4f0b-49d1-a7b8-52af5ed0231c"
      unitRef="U_USD">18771000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_6e89a28e-efb0-43cb-90bd-4cbc5e333e0f"
      unitRef="U_USD">296340000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_89d713eb-3082-40ac-84cf-4483a414f05b"
      unitRef="U_USD">228000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_c02d674e-2e65-4361-a31d-cf027ee04910"
      unitRef="U_USD">296112000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_dae0176e-5286-4cb9-be3e-28858705d8a5"
      decimals="-3"
      id="F_fb18e436-7197-4b69-b1e1-21c46de350ff"
      unitRef="U_USD">32221000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_dae0176e-5286-4cb9-be3e-28858705d8a5"
      decimals="-3"
      id="F_29a129d1-32e5-459c-a70c-2798f0d2bf5c"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_dae0176e-5286-4cb9-be3e-28858705d8a5"
      decimals="-3"
      id="F_ef04fb35-9d8d-4319-813b-f56c3d41fca1"
      unitRef="U_USD">32224000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6d2ce482-3934-425f-b2d1-f6ee23bbabef"
      decimals="-3"
      id="F_85a70808-d14c-4f3d-aff3-a4a5a5128804"
      unitRef="U_USD">30890000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_6d2ce482-3934-425f-b2d1-f6ee23bbabef"
      decimals="-3"
      id="F_7b33745c-6825-46c3-91a4-7d30932f65f1"
      unitRef="U_USD">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6d2ce482-3934-425f-b2d1-f6ee23bbabef"
      decimals="-3"
      id="F_90408028-cc57-41bf-a017-63abf3d15ea0"
      unitRef="U_USD">30895000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_39b90851-086e-455a-a800-c878e28c4434"
      unitRef="U_USD">63111000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_3c25243b-b25f-4289-99c1-6f2de8970323"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_ee207300-ab76-4e18-a32c-6e8714d5683b"
      unitRef="U_USD">63119000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <verv:RemainingContractualMaturitiesOfMarketableSecuritiesTerm
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_1aabd6b6-2385-4bea-ac98-22e15af74ad5">P1Y</verv:RemainingContractualMaturitiesOfMarketableSecuritiesTerm>
    <verv:RemainingContractualMaturitiesOfMarketableSecuritiesTerm
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      id="F_fbfdc4ce-941c-4b43-9e55-09fb75d304f2">P1Y</verv:RemainingContractualMaturitiesOfMarketableSecuritiesTerm>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_602e56ff-f245-4ee0-bfe3-034021e77526">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;4. P&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;roperty and equipment, net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Property and equipment, net, consist of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.359%;"/&gt;
        &lt;td style="width:1.6%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:12.92%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
        &lt;td style="width:1.6%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:12.91%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,782&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Depreciation expense for the years ended December 31, 2021, 2020 and 2019 w&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;as $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_4d86f1df-32aa-4023-9575-2d874c901033">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Property and equipment, net, consist of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.359%;"/&gt;
        &lt;td style="width:1.6%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:12.92%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
        &lt;td style="width:1.6%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:12.91%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,782&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0bc5b84f-e1f5-4d52-92d2-4a44875d520e"
      decimals="-3"
      id="F_268fb89f-e4b5-486f-9f8e-a4447082679b"
      unitRef="U_USD">8567000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ac6b8994-377a-4736-97a7-37eee958602b"
      decimals="-3"
      id="F_0da12667-acd9-4688-b693-d83176b64d34"
      unitRef="U_USD">3937000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5489e665-131f-4276-8480-9cbe40f275d4"
      decimals="-3"
      id="F_95003466-6917-40d1-9489-92bb809504ce"
      unitRef="U_USD">266000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20e318f5-772b-42ae-8de4-e92d6afce885"
      decimals="-3"
      id="F_ac9bb1d7-14cf-4d38-8076-146156075c93"
      unitRef="U_USD">259000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_078a5bfc-2f82-4f5d-a355-1da428971361"
      decimals="-3"
      id="F_177a4538-c33e-4862-9cc6-0500d8b08c71"
      unitRef="U_USD">566000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_597ac98d-16ac-4d83-be6a-8276c0ed1129"
      decimals="-3"
      id="F_86e3124a-33e5-47b9-a179-6f1374038c00"
      unitRef="U_USD">481000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b5b793ed-2405-4df6-a73b-f8234a21676c"
      decimals="-3"
      id="F_78bc303f-e6a9-4a56-8bba-5db8f818794c"
      unitRef="U_USD">158000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f357484d-ef7a-4007-9dd8-60b4ae94c728"
      decimals="-3"
      id="F_a3af4f5a-6915-4625-b934-0ed3407830f7"
      unitRef="U_USD">105000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_4f61622d-bb99-4984-a7f5-97e58fe19bd8"
      unitRef="U_USD">9557000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_f40b04bb-9c70-4983-ba0b-a2d4f79112f1"
      unitRef="U_USD">4782000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_5fbb0d1f-ee0d-493b-a0bf-1d1b70a8b9fb"
      unitRef="U_USD">2333000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_fa00dfff-68c2-4045-90f1-4716901fd3b2"
      unitRef="U_USD">798000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_764fdc20-3921-4ebe-8a3a-6f04c2889883"
      unitRef="U_USD">7224000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_08b8facd-47e8-4966-985b-1aeccc9dfb89"
      unitRef="U_USD">3984000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-5"
      id="F_acbb6c3c-00dc-4230-814c-83dbbd8177df"
      unitRef="U_USD">1500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-5"
      id="F_9a39e5cf-332c-48c2-84e0-e31728b62a95"
      unitRef="U_USD">1300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-5"
      id="F_fd711dfc-adf9-4721-97a4-e4f53d0021d1"
      unitRef="U_USD">100000</us-gaap:Depreciation>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_e9424503-4914-4f4b-b0a4-ee75786113b7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;5. f&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;air value of financial instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s financial instruments consist of money market funds, marketable securities, the preferred stock tranche liability, the antidilution right liability, and success payment liability pursuant to the Harvard/ Broad License Agreement and the Broad License Agreement. The preferred stock tranche liability was fully settled in the year ended December 31, 2020, and the antidilution right liability was fully settled in the year ended December 31, 2021. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The liabilities are carried at fair value. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following tables set forth the fair value of the Company&#x2019;s financial instruments by level within the fair value hierarchy: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.289%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:9.373%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:9.343%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:9.373%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:9.303%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;58,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;58,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;U.S. treasury bills and notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;277,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;277,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;U.S. agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;18,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;18,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;354,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;58,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;296,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Success payment liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.359%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:9.345%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:9.315%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:9.345%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:9.315%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;As of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;U.S. treasury bills and notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;U.S. agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;30,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;30,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;69,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;63,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Success payment liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Antidilution rights liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;Cash equivalents of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;58.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; as of December 31, 2021 and 2020, respectively, consisted of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Marketable Securities&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company measures its marketable securities at fair value on a recurring basis and classifies those instruments within Level 2 of the fair value hierarchy. Marketable securities are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Preferred Stock Tranche Liability&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;The preferred stock tranche liability is stated at fair value and is considered Level 3 within the fair value hierarchy because its fair value measurement is based, in part, on significant inputs not observed in the market. The tranche liability was valued using a probability-adjusted scenario-based method that considered the probability of triggering the tranche rights through achievement of certain non-scientific and scientific milestones as well as the pu&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;rchase price of Series A preferred stock. Subsequent Series A Preferred Stock closings occurred in both 2019 and 2020 and the preferred stock tranche liability was fully settled as of December 31, 2020 (refer to Note 9, Preferred stock tranche liability). Prior to settlement, the Company remeasured the liability with a corresponding increase of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million to other expense for the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Antidilution Rights Liability&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014; The antidilution rights liability represents the obligation to issue additional shares of common stock to Harvard and Broad following the completion of (1) a defined aggregate level of preferred stock financing and (2) either a sale of the Company&#x2019;s preferred stock, an initial public offering, or a company sale meeting a certain value threshold. The antidilution rights liability was stated at fair value and was considered Level 3 in the fair value hierarchy because its fair value measurement was based, in part, on significant inputs not&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;observed in the market. The antidilution rights liability related to meeting a defined aggregate level of preferred stock financing was valued using a probability-weighted present value model that considered the probability of meeting the defined aggregate level of preferred stock financing, as well as the fair value of the Company&#x2019;s common stock. The antidilution rights liability related to the achievement of a specified valuation through either a sale of the Company&#x2019;s preferred stock, an initial public offering, or a company sale was valued using a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the fair value of the Company&#x2019;s common stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;At issuance in 2019, the estimated fair value of the antidilution rights liability was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, which was recorded as research and development expense. The Company remeasured the liability at fair value with corresponding charges of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million recorded to other expense for the years ended December 31, 2020 and 2019, respectively. The antidilution rights associated with the Company achieving a defined aggregate level of preferred stock financing were partially satisfied in 2019 and fully satisfied in 2020, which settlement amounts totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively, and which amounts were settled through issuances of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;121,411&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;187,867&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of the Company common stock, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In June 2021, upon completion of its IPO, the Company settled the antidilution rights liability in full through the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;878,098&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of the Company's common stock for a settlement amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. Prior to settlement, the Company remeasured the liability with a corresponding increase of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;25.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million to other expense for the year ended December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Success Payment Liability&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014; The Company is obligated to pay to Harvard and Broad tiered success payments in the event its average market capitalization exceeds specified thresholds for a specified period of time ascending from a high nine-digit dollar amount to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control or a sale of the Company, the Company is required to pay success payments in cash within a specified period following such event. Otherwise, the success payments may be settled at the Company&#x2019;s option in either cash or shares of its common stock, or a combination of cash and shares of its common stock. The maximum aggregate success payments that could be payable by the Company is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;31.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million (after termination of the Broad License Agreement).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The success payments liability is stated at fair value and is considered Level 3 because its fair value measurement is based, in part, on significant inputs not observed in the market. The Company used a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the value of the Company&#x2019;s common stock. The Company also estimated the likelihood that it would maintain both the Harvard/Broad License Agreement and the Broad License Agreement based on its on-going research efforts.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company remeasured the liability at fair value with incre&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;ases of &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7.8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; recorded to other expense &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In September 2021, multiple success payments were triggered and amounts due to Harvard and Broad totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. These amounts were settled in cash in November 2021. The Company will continue to adjust the remaining success payment liability for changes in fair value until the earlier of the achievement or expiration of the obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The primary inputs used in valuing (i) the success payments liability and (ii) the antidilution rights liability associated with the Company&#x2019;s realization of a certain valuation threshold through either a sale of the Company&#x2019;s preferred stock, an initial public offering, or a company sale at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021 (only applicable to success payments liability), 2020 and 2019, were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.375%;"/&gt;
        &lt;td style="width:1.352%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:12.138%;"/&gt;
        &lt;td style="width:2.287%;"/&gt;
        &lt;td style="width:1.352%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:12.138%;"/&gt;
        &lt;td style="width:2.287%;"/&gt;
        &lt;td style="width:1.352%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:12.138%;"/&gt;
        &lt;td style="width:2.287%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;At&lt;br/&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;At&lt;br/&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;At&lt;br/&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Fair value of common stock (per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;36.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Equity volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Cumulative probability of triggering event&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;n/a&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;n/a&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.89&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;At &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2020 and 2019, the fair value of the Company's common stock was determined by management with the assistance of an independent third-party valuation specialist using methods consistent with the AICPA Valuation Guide. The computation of equity volatility was estimated using available information about the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;historical &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;volatility of stocks of similar publicly traded companies for a period matching the expected term assumption. In addition, the Company incorporated the timing and probability of future events in the calculation of liabilities. The Company also estimated the likelihood that it would maintain both the Harvard/Broad License Agreement and the Broad License Agreement based on its on-going research efforts. The Company applied a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;90&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% probability of termination of the Broad License Agreement at December 31, 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In February 2021, the Company provided written notice to Broad of its election to terminate the Broad License Agreement, which termination became effective in June 2021.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.244%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:10.556%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:10.635%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:10.536%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:9.144%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Preferred&lt;br/&gt;stock&lt;br/&gt;tranche&lt;br/&gt;liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Antidilution&lt;br/&gt;rights&lt;br/&gt;liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Success&lt;br/&gt;payment&lt;br/&gt;liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9,571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Issuance of Series A Preferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Issuance of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Issuance of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Success payment liability earned and paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_170610ab-9c1b-4510-8f28-c508389451c8;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_716c6897-a6df-4fdf-9e99-b336dfd3b30f;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;25,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;33,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_bcd9a29d-674c-4f45-8387-045745de323e">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following tables set forth the fair value of the Company&#x2019;s financial instruments by level within the fair value hierarchy: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.289%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:9.373%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:9.343%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:9.373%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:9.303%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;58,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;58,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;U.S. treasury bills and notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;277,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;277,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;U.S. agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;18,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;18,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;354,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;58,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;296,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Success payment liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.359%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:9.345%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:9.315%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:9.345%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:9.315%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;As of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;U.S. treasury bills and notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;U.S. agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;30,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;30,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;69,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;63,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Success payment liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Antidilution rights liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_aa339973-30be-44d3-9b51-80410c37ae10"
      decimals="-3"
      id="F_59a9ec8d-48b9-4dd8-9750-bd59fbecb6cc"
      unitRef="U_USD">58127000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8ce3a7dc-9959-4295-a7ff-97a898ccd354"
      decimals="-3"
      id="F_a2537bc9-2b2a-4fab-9fd1-62b05beb72bf"
      unitRef="U_USD">58127000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e1a13442-1d67-4846-9344-f2e64eb45cf4"
      decimals="-3"
      id="F_1aac1561-3e0a-416a-af6d-96c3588208d5"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_25716468-76d3-40f2-8351-b9e832a0d2ec"
      decimals="-3"
      id="F_1d21d31d-202f-45a8-a97e-abcb2975386d"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_894ba0d1-0497-4bb2-8773-85db59da1dac"
      decimals="-3"
      id="F_5ec0dc35-0b16-4387-8719-15917499f296"
      unitRef="U_USD">277341000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ec36089a-8e3c-4348-a1b7-6a7b4ec227a5"
      decimals="-3"
      id="F_62b41829-65f4-4116-aec1-233a358b121b"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7a75dc28-f9fd-42c4-8bd8-5f9dfd827ae8"
      decimals="-3"
      id="F_aeaef4e6-9f99-46a9-9669-95541d024cd5"
      unitRef="U_USD">277341000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_765b171f-952c-4b00-b1af-1c4809294e61"
      decimals="-3"
      id="F_ad850c03-8049-477a-8fc1-dc34f5a984ef"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5703a3c6-815c-4560-9f18-f134cd85e185"
      decimals="-3"
      id="F_138a8ded-97dc-48a5-a080-6b6539676d57"
      unitRef="U_USD">18771000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d44651b4-0a1c-4a0d-ae7f-725d09d63521"
      decimals="-3"
      id="F_84b736a4-4527-4787-b2d3-cba01d5536b5"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1407fd53-32a3-4a0c-83d7-8d75bcc6c92f"
      decimals="-3"
      id="F_e9c45200-4193-4469-9bfb-9a82321deaec"
      unitRef="U_USD">18771000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4862c09a-79bf-4f14-8cca-db22dcbb94b8"
      decimals="-3"
      id="F_a64882f6-c9b2-4fab-95f0-aa868724e02c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_0c10cfb2-0a2d-4747-a5a8-fd90d9895160"
      unitRef="U_USD">354239000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7230ac96-5876-4bec-b9a0-17578497db18"
      decimals="-3"
      id="F_0eea3d80-a182-4990-9f9e-eb27ebc7c361"
      unitRef="U_USD">58127000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8c90a925-ca54-4ef3-abb8-1d5e67ef2449"
      decimals="-3"
      id="F_826f6c7c-3588-4383-8f8f-fe0d70747ff0"
      unitRef="U_USD">296112000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_470eef76-a3e4-47c1-9135-bcd76e05752b"
      decimals="-3"
      id="F_e9136b00-0c65-413e-ae52-e51922290f65"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_7349e083-8b38-4939-84b9-b52dd9e2c764"
      decimals="-3"
      id="F_5165db28-f71f-4360-96a0-09c3e8a3e71d"
      unitRef="U_USD">4371000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_75ebca27-b89c-4f74-8d07-a6fdfe31387c"
      decimals="-3"
      id="F_912a226c-9130-48a6-9dc3-a61c9f5d16a8"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_79857874-5e87-4b53-b5bf-f51a27d64b5e"
      decimals="-3"
      id="F_3a8dc576-86e5-4609-8721-0f18f7bfe6e0"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_604919a2-0184-407a-a67d-53f3e9d796d4"
      decimals="-3"
      id="F_66acce79-31ae-40e6-95dc-38f2b30ebab8"
      unitRef="U_USD">4371000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_71072021-752f-42f8-bcf1-7cb9b7d99e2a"
      unitRef="U_USD">4371000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_7230ac96-5876-4bec-b9a0-17578497db18"
      decimals="-3"
      id="F_732640ce-d4a9-4c0a-93f8-d5ea2097d987"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_8c90a925-ca54-4ef3-abb8-1d5e67ef2449"
      decimals="-3"
      id="F_3791ad8f-d84f-42fa-84a0-578380bcacc8"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_470eef76-a3e4-47c1-9135-bcd76e05752b"
      decimals="-3"
      id="F_a025c259-a341-460c-aa4a-0cabff3c6cdb"
      unitRef="U_USD">4371000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_55860b8b-baa2-4e63-b435-ce9e60ae5e06"
      decimals="-3"
      id="F_8f1cc944-94cf-4f44-bb14-1ea58b870fa4"
      unitRef="U_USD">6724000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5d8591bc-11a9-40ab-b3a4-bc7e3800e026"
      decimals="-3"
      id="F_f7228270-3c68-4502-b88f-ba56fa8a6ac7"
      unitRef="U_USD">6724000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c20382c9-9ff7-450f-8cd6-93193f146b1d"
      decimals="-3"
      id="F_9f22e028-db08-441f-b3d6-79146c53a05a"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_adefa849-4678-4e94-b863-2d12ecdad8f9"
      decimals="-3"
      id="F_1040b145-a0b2-44b5-992f-65d883cc8a77"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_dd01459a-975e-48f9-9d4f-b18bb361be4f"
      decimals="-3"
      id="F_d00614ae-22b1-4f13-8cda-ce846723dc6a"
      unitRef="U_USD">32224000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3d70dec1-7c1e-48b3-b61d-3e6ca572b452"
      decimals="-3"
      id="F_4728c1f9-fc3c-4f1b-a5fa-b2353293a4b1"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b3c87878-bc9c-48e0-848d-9e7ea4f29412"
      decimals="-3"
      id="F_e1e9248b-35ea-4021-b0d9-e0a9d79c3290"
      unitRef="U_USD">32224000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7dd626b0-6fc1-4783-8c59-97a950918aed"
      decimals="-3"
      id="F_8a1d0030-7151-46dd-bc57-6382428585ba"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_235eb2e2-4747-444d-b7ee-6cc0e5a83ec6"
      decimals="-3"
      id="F_b8cebfad-2551-4a40-8f00-4b2a89a5a278"
      unitRef="U_USD">30895000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_dc4c7421-4413-4b48-9fbf-b319860463d2"
      decimals="-3"
      id="F_04079d02-93c1-4305-952d-d42f9a852632"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f9dffce0-4bc6-41d0-9e68-e6fdba07b1d5"
      decimals="-3"
      id="F_edaf6119-d57a-4dff-8e60-d5ed2d00d915"
      unitRef="U_USD">30895000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fec04bb0-37db-4624-a7d4-cd02343359c8"
      decimals="-3"
      id="F_63f8233e-199c-4401-8e11-3e0217d36e1c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_12bd5615-45e0-4b97-a674-3a71be67404a"
      unitRef="U_USD">69843000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9b218daf-9568-4fb9-ba54-24937e994d44"
      decimals="-3"
      id="F_e1af820d-2f66-44f9-a179-bd7a513cdba7"
      unitRef="U_USD">6724000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d971946d-306c-459c-8b3a-e96fc64334f7"
      decimals="-3"
      id="F_aef1854f-9af7-4a18-b92d-51debcfadbe5"
      unitRef="U_USD">63119000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fcb68bae-6468-4eef-9487-908de3c3ac46"
      decimals="-3"
      id="F_87412c66-0d57-40d5-bee4-7f85abe8c753"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_ea8434d0-a39e-4a6a-bb26-7799962446b9"
      decimals="-3"
      id="F_650bfcaa-5e8c-4c6c-bb92-6078b5863583"
      unitRef="U_USD">2806000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_2e418dc0-e214-4a34-8796-62a40cabca50"
      decimals="-3"
      id="F_19afaae9-71a0-488a-9214-16ec5e6e868c"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_c27b92cd-9d6c-4111-bd60-2b3bb8205544"
      decimals="-3"
      id="F_0a0a4dc1-788d-4331-9bc6-9f4e32e4b2c0"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_2da1fcc5-d34b-4f3a-ae28-f14234789060"
      decimals="-3"
      id="F_de2d689e-8d58-4876-9055-7f301b72a007"
      unitRef="U_USD">2806000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_0e18a72a-d76f-4344-ab19-24bc729bb1a1"
      decimals="-3"
      id="F_2673090f-55ec-463e-82ea-e98ea67d67e8"
      unitRef="U_USD">6916000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_bae1dfa2-41b7-46c1-9e1e-5fae784a1de3"
      decimals="-3"
      id="F_046dda2f-f641-4888-a22d-5316ba99c97e"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_2a3189e2-c048-4d31-976f-cb3b47d3233e"
      decimals="-3"
      id="F_4e225368-9ba4-47ab-a01d-4d20d80351c9"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_1a692e9d-fc22-429a-866a-28850d71edcd"
      decimals="-3"
      id="F_c0dae9fe-ff81-41c0-841b-3ace6881d4f7"
      unitRef="U_USD">6916000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_a716a00a-91d7-45d1-b16d-0588d013e7d6"
      unitRef="U_USD">9722000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_9b218daf-9568-4fb9-ba54-24937e994d44"
      decimals="-3"
      id="F_efcfb617-310e-4677-bc17-426d3011f6fd"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_d971946d-306c-459c-8b3a-e96fc64334f7"
      decimals="-3"
      id="F_0ea0bd6d-642b-48b0-9575-6e39fbbe21e0"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_fcb68bae-6468-4eef-9487-908de3c3ac46"
      decimals="-3"
      id="F_4b9f1df4-4978-4740-a9a8-a278c04c9174"
      unitRef="U_USD">9722000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-5"
      id="F_928addd6-1b7b-450d-a683-6ddeed5cb4f6"
      unitRef="U_USD">58100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-5"
      id="F_d57a39df-1c3c-4298-bf08-1f2aff6bf696"
      unitRef="U_USD">6700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="C_70bdd4a9-53a3-4196-bff4-9fe631ab414d"
      decimals="-5"
      id="F_f2baeb7b-5428-424d-b430-f7a21c1a26c4"
      unitRef="U_USD">2500000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <verv:ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability
      contextRef="C_9d0f6183-f1e6-4aa0-b41e-2e38deb97369"
      decimals="-5"
      id="F_9eba4e63-cf69-417b-8ebb-902716c2c659"
      unitRef="U_USD">1200000</verv:ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability>
    <us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-5"
      id="F_1e142230-07bb-4c69-acac-6577f72c2a43"
      unitRef="U_USD">5400000</us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue>
    <us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-5"
      id="F_9398b980-f4f1-4c9c-8e44-1c661bc81aa6"
      unitRef="U_USD">1000000.0</us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue>
    <us-gaap:CommonStockValue
      contextRef="C_0e18a72a-d76f-4344-ab19-24bc729bb1a1"
      decimals="-5"
      id="F_6698ec8c-9694-4589-8d77-924854a0e302"
      unitRef="U_USD">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_d11db810-1bfc-445d-b0c0-43624d7bd52d"
      decimals="-5"
      id="F_2e58c0a7-deb1-4595-8bbe-3d745f3d6801"
      unitRef="U_USD">500000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_d11db810-1bfc-445d-b0c0-43624d7bd52d"
      decimals="INF"
      id="F_88a57ce1-322e-41ef-b1e3-71e305818f5b"
      unitRef="U_shares">121411</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0e18a72a-d76f-4344-ab19-24bc729bb1a1"
      decimals="0"
      id="F_17e2c68d-c11d-488e-9d14-5418ec2609a0"
      unitRef="U_shares">187867</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4303f47d-2279-40f2-a160-e7a91300902b"
      decimals="INF"
      id="F_99705fed-3d84-43d8-9af2-ccc7aa0d1b1a"
      unitRef="U_shares">878098</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_4303f47d-2279-40f2-a160-e7a91300902b"
      decimals="-5"
      id="F_c43d1af5-db55-4b92-86fe-d86f8af274c7"
      unitRef="U_USD">32500000</us-gaap:CommonStockValue>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="C_84c106c3-aeb7-42d5-ab70-a059d1961a3b"
      decimals="-5"
      id="F_59acd1fc-7b40-447d-a3f0-3f84f97be906"
      unitRef="U_USD">25600000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_e8b5087a-c8c5-42b6-b02a-2126a65898d5"
      decimals="-8"
      id="F_36a20210-e688-43fc-8e4d-17bd636d8101"
      unitRef="U_USD">10000000000.0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_c286c886-b8bc-4074-85c6-6c1d797c88f0"
      decimals="-5"
      id="F_fd60e236-c77d-420c-ae9b-3f07695d31d0"
      unitRef="U_USD">31300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilities
      contextRef="C_dc4de63a-1a13-435a-91bf-1d42b2503336"
      decimals="-5"
      id="F_3b2127c3-dbab-4359-b572-fdd069fd7220"
      unitRef="U_USD">7800000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="C_d04521c5-cb77-4e26-9e7d-c596e315d733"
      decimals="-5"
      id="F_01d8b8f3-5ad3-40f4-9013-44f68ccceb54"
      unitRef="U_USD">2400000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="C_556c543d-6999-40a3-9b90-5c280daba957"
      decimals="-5"
      id="F_ed35125d-387d-4aa8-9f3c-a78c04c820cb"
      unitRef="U_USD">100000</us-gaap:DerivativeLiabilities>
    <verv:SuccessPaymentLiabilityCurrent
      contextRef="C_ea754504-c0d8-4221-a285-32e891462575"
      decimals="-5"
      id="F_dc625304-9ad4-4237-bb91-c688f6b285f8"
      unitRef="U_USD">6300000</verv:SuccessPaymentLiabilityCurrent>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_4aff1eeb-6402-45b2-921f-00a65231210e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The primary inputs used in valuing (i) the success payments liability and (ii) the antidilution rights liability associated with the Company&#x2019;s realization of a certain valuation threshold through either a sale of the Company&#x2019;s preferred stock, an initial public offering, or a company sale at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021 (only applicable to success payments liability), 2020 and 2019, were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.375%;"/&gt;
        &lt;td style="width:1.352%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:12.138%;"/&gt;
        &lt;td style="width:2.287%;"/&gt;
        &lt;td style="width:1.352%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:12.138%;"/&gt;
        &lt;td style="width:2.287%;"/&gt;
        &lt;td style="width:1.352%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:12.138%;"/&gt;
        &lt;td style="width:2.287%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;At&lt;br/&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;At&lt;br/&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;At&lt;br/&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Fair value of common stock (per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;36.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Equity volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Cumulative probability of triggering event&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;n/a&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;n/a&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.89&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <verv:FairValueOfCommonStockPerShare
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="2"
      id="F_961f204a-4515-4b04-84f8-5c0cb2ac5269"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">36.87</verv:FairValueOfCommonStockPerShare>
    <verv:FairValueOfCommonStockPerShare
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="2"
      id="F_55b30178-001a-4dc0-ae5b-0064632b8cb1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.24</verv:FairValueOfCommonStockPerShare>
    <verv:FairValueOfCommonStockPerShare
      contextRef="C_9d0f6183-f1e6-4aa0-b41e-2e38deb97369"
      decimals="2"
      id="F_8e3f2d6d-af49-43c0-bff8-4590d89e195b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.59</verv:FairValueOfCommonStockPerShare>
    <verv:FairValueAssumptionOfEquityVolatilityRate
      contextRef="C_bc02f4c1-1fb9-4d8b-93c6-bd1442840b62"
      decimals="2"
      id="F_6c406168-9348-45b8-8e1f-1f3708beaee6"
      unitRef="U_pure">0.77</verv:FairValueAssumptionOfEquityVolatilityRate>
    <verv:FairValueAssumptionOfEquityVolatilityRate
      contextRef="C_46b68a29-4a56-4a0e-b6e7-327c4a2472e7"
      decimals="2"
      id="F_9f93ef32-d55c-48c3-8942-c82d50d704ae"
      unitRef="U_pure">1.05</verv:FairValueAssumptionOfEquityVolatilityRate>
    <verv:FairValueAssumptionOfEquityVolatilityRate
      contextRef="C_0e74774f-4077-4438-a31c-22d5b9e9bf39"
      decimals="2"
      id="F_f50a8f18-00ab-4e14-9ba0-0f8bb32d9a40"
      unitRef="U_pure">1</verv:FairValueAssumptionOfEquityVolatilityRate>
    <verv:CumulativeProbabilityOfTriggeringEvent
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="2"
      id="F_7b4cb2c1-e05f-43c6-b416-59bad49d4761"
      unitRef="U_pure">0.70</verv:CumulativeProbabilityOfTriggeringEvent>
    <verv:CumulativeProbabilityOfTriggeringEvent
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="2"
      id="F_bb8a4160-253d-4ce1-87c5-b8e92442fcc4"
      unitRef="U_pure">0.11</verv:CumulativeProbabilityOfTriggeringEvent>
    <verv:FairValueAssumptionsExpectedTerm1
      contextRef="C_456b2896-d611-45e2-8641-7467961b8168"
      id="F_45336371-7440-411b-b0c4-b1d32c08bab7">P0Y6M</verv:FairValueAssumptionsExpectedTerm1>
    <verv:FairValueAssumptionsExpectedTerm1
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      id="F_11c69e3d-d6ec-46dd-9ca6-cb6ffab30229">P2Y10M20D</verv:FairValueAssumptionsExpectedTerm1>
    <verv:FairValueInputsProbabilityOfTermination
      contextRef="C_671bfcc0-ebf7-4194-8895-80b3fa98b658"
      decimals="2"
      id="F_be178b54-aed5-463f-ab18-baaef524fae9"
      unitRef="U_pure">0.90</verv:FairValueInputsProbabilityOfTermination>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_0a19e1c8-a172-4d01-97c9-184e242281bb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.244%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:10.556%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:10.635%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:10.536%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:9.144%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Preferred&lt;br/&gt;stock&lt;br/&gt;tranche&lt;br/&gt;liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Antidilution&lt;br/&gt;rights&lt;br/&gt;liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Success&lt;br/&gt;payment&lt;br/&gt;liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9,571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Issuance of Series A Preferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Issuance of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Issuance of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Success payment liability earned and paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_170610ab-9c1b-4510-8f28-c508389451c8;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_716c6897-a6df-4fdf-9e99-b336dfd3b30f;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;25,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;33,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_7d6fc6e3-0bd2-4c41-a389-d8c78306592d"
      decimals="-3"
      id="F_83bdef29-aa3f-4072-816b-c5cf62eb59c8"
      unitRef="U_USD">9571000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_d11db810-1bfc-445d-b0c0-43624d7bd52d"
      decimals="-3"
      id="F_51537789-acf0-4ffa-aaf2-730bd5e53d4f"
      unitRef="U_USD">2044000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_cc8e1463-c758-4dfb-9de6-62be2741f27c"
      decimals="-3"
      id="F_abe51183-9e8d-4fe8-87a1-949cc3a80851"
      unitRef="U_USD">419000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_9d0f6183-f1e6-4aa0-b41e-2e38deb97369"
      decimals="-3"
      id="F_9d0a4f71-155c-4e0f-8d78-a1b731925b92"
      unitRef="U_USD">12034000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_70bdd4a9-53a3-4196-bff4-9fe631ab414d"
      decimals="-3"
      id="F_8cbd6174-acb5-4d49-ad91-36a591df2c81"
      unitRef="U_USD">7064000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_a6d1a849-b7f6-4b32-8b52-0bd344744eb9"
      decimals="-3"
      id="F_877bab3f-45a2-4a8e-b480-4f257d3e1a91"
      unitRef="U_USD">0</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_b374bc60-e066-42aa-99b0-3e124c675fda"
      decimals="-3"
      id="F_33fdf371-28d1-474c-868f-d9b168a28dfd"
      unitRef="U_USD">0</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_ab997002-95b7-4731-9352-bf69cbfe008d"
      unitRef="U_USD">7064000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <verv:CommonStockIssuedDuringPeriodValueNewIssues
      contextRef="C_70bdd4a9-53a3-4196-bff4-9fe631ab414d"
      decimals="-3"
      id="F_516a9bd8-9e7b-4138-a389-13c0fe042dac"
      unitRef="U_USD">0</verv:CommonStockIssuedDuringPeriodValueNewIssues>
    <verv:CommonStockIssuedDuringPeriodValueNewIssues
      contextRef="C_a6d1a849-b7f6-4b32-8b52-0bd344744eb9"
      decimals="-3"
      id="F_4e68e4b9-fa4b-4c74-8c18-fd723ced7c2d"
      unitRef="U_USD">-487000</verv:CommonStockIssuedDuringPeriodValueNewIssues>
    <verv:CommonStockIssuedDuringPeriodValueNewIssues
      contextRef="C_b374bc60-e066-42aa-99b0-3e124c675fda"
      decimals="-3"
      id="F_68e9b49b-355f-4005-8d00-5631883b675c"
      unitRef="U_USD">0</verv:CommonStockIssuedDuringPeriodValueNewIssues>
    <verv:CommonStockIssuedDuringPeriodValueNewIssues
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_550621d4-ca11-4305-8785-086e3854162d"
      unitRef="U_USD">-487000</verv:CommonStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="C_70bdd4a9-53a3-4196-bff4-9fe631ab414d"
      decimals="-3"
      id="F_a7bc52f8-3857-4a31-8d22-5a27a340b9f8"
      unitRef="U_USD">-2507000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="C_a6d1a849-b7f6-4b32-8b52-0bd344744eb9"
      decimals="-3"
      id="F_56701c1c-a478-4151-adda-dddac65a7ed3"
      unitRef="U_USD">5359000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="C_b374bc60-e066-42aa-99b0-3e124c675fda"
      decimals="-3"
      id="F_9cfa8121-caaf-40e3-aea8-a1e49852b40d"
      unitRef="U_USD">2387000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_722eb242-52cf-4fdc-88c4-78faf7d2c524"
      unitRef="U_USD">5239000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_a9ae8471-e3e2-4484-84b2-6eaafd17e730"
      decimals="-3"
      id="F_b3d88014-9004-46ad-9946-2efb7d361f51"
      unitRef="U_USD">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_0e18a72a-d76f-4344-ab19-24bc729bb1a1"
      decimals="-3"
      id="F_820a2af1-b709-47cd-a15e-50e27c3b920f"
      unitRef="U_USD">6916000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_ea8434d0-a39e-4a6a-bb26-7799962446b9"
      decimals="-3"
      id="F_53b38a61-90de-4240-8fe9-65c2a45780d5"
      unitRef="U_USD">2806000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_7399c03b-b50e-4931-8f33-67794d5bc35a"
      unitRef="U_USD">9722000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <verv:CommonStockIssuedDuringPeriodValueNewIssues
      contextRef="C_428c5b12-83cd-4341-b4bb-932e3b77cd04"
      decimals="-3"
      id="F_75e12c86-32ba-4d74-8114-e5c131a78b59"
      unitRef="U_USD">0</verv:CommonStockIssuedDuringPeriodValueNewIssues>
    <verv:CommonStockIssuedDuringPeriodValueNewIssues
      contextRef="C_ccde73cb-e336-419a-a1be-6bc267e8d5ae"
      decimals="-3"
      id="F_a95b2f42-359e-4c0e-bc36-dca1ee8da839"
      unitRef="U_USD">-32490000</verv:CommonStockIssuedDuringPeriodValueNewIssues>
    <verv:CommonStockIssuedDuringPeriodValueNewIssues
      contextRef="C_02e26f3d-99d2-4166-a4b7-b128f163b312"
      decimals="-3"
      id="F_9d6069ea-e067-44cc-80c0-30b0970d42b6"
      unitRef="U_USD">0</verv:CommonStockIssuedDuringPeriodValueNewIssues>
    <verv:CommonStockIssuedDuringPeriodValueNewIssues
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_224135ad-4d8a-4902-b65b-d14e1268e1fe"
      unitRef="U_USD">-32490000</verv:CommonStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_7349e083-8b38-4939-84b9-b52dd9e2c764"
      decimals="-3"
      id="F_9bd5c2af-897e-4f55-a318-751f7d337d0e"
      unitRef="U_USD">6250000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_c02a509b-8ce8-4301-8f17-3212655b3a24"
      unitRef="U_USD">6250000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="C_428c5b12-83cd-4341-b4bb-932e3b77cd04"
      decimals="-3"
      id="F_984f39ca-45a8-4013-bdcf-991b052e9cb2"
      unitRef="U_USD">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="C_ccde73cb-e336-419a-a1be-6bc267e8d5ae"
      decimals="-3"
      id="F_f923abc7-7cf5-45ed-a844-3ff72965540f"
      unitRef="U_USD">25574000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="C_02e26f3d-99d2-4166-a4b7-b128f163b312"
      decimals="-3"
      id="F_d3c73700-86e5-419b-9f1c-91317f8e7950"
      unitRef="U_USD">7815000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_696e8fdc-03cb-4f8f-bdac-db102b735ee4"
      unitRef="U_USD">33389000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_d8897390-cbaa-48a9-b558-fd628bd36c53"
      decimals="-3"
      id="F_68f6d087-757f-40d2-a77c-b018bb0f253f"
      unitRef="U_USD">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_d4248d0a-06a2-4040-a853-becbd34bcc18"
      decimals="-3"
      id="F_3ce8e30c-5963-4546-9419-cc60bac51309"
      unitRef="U_USD">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_7349e083-8b38-4939-84b9-b52dd9e2c764"
      decimals="-3"
      id="F_fe3630f4-3971-4bc3-89bf-f89b15b5c7e8"
      unitRef="U_USD">4371000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_e2e239f7-26e2-4e3e-9be7-63a97025c916"
      unitRef="U_USD">4371000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_c9ac1cda-cca0-4872-b187-c0b859e59c84">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;6. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;Accrued expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.395%;"/&gt;
        &lt;td style="width:1.6%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:13.05%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:1.6%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:13.04%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Employee compensation and related benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Accrued external research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_cdb0d812-ce68-451c-aa7b-9de5beef4b0c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.395%;"/&gt;
        &lt;td style="width:1.6%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:13.05%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:1.6%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:13.04%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Employee compensation and related benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Accrued external research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_7e99517b-fa90-4918-98a0-a8bf0c86f780"
      unitRef="U_USD">6050000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_1e7bfe61-e769-436d-8483-76b25c60c049"
      unitRef="U_USD">1636000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <verv:AccruedExternalResearchAndDevelopmentExpenses
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_21036f38-c3ca-463a-9b22-5fa8453732a7"
      unitRef="U_USD">5041000</verv:AccruedExternalResearchAndDevelopmentExpenses>
    <verv:AccruedExternalResearchAndDevelopmentExpenses
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_ecf1e015-aec3-4018-bb84-a5be40d8c173"
      unitRef="U_USD">4827000</verv:AccruedExternalResearchAndDevelopmentExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_c323b9f4-adb3-4a92-9183-a318346e43f4"
      unitRef="U_USD">1109000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_0c899048-85b9-4e34-a901-7d0e674bf281"
      unitRef="U_USD">303000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_726af2b9-7126-4e7b-8c61-dbf3b6b3c133"
      unitRef="U_USD">792000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_f149f819-e7c2-4287-aaf7-75faab95399c"
      unitRef="U_USD">423000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_bc8bb8c9-c66e-4515-93ca-42ae2208e583"
      unitRef="U_USD">12992000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_2b5dc6a5-2a70-4f0a-af64-4d7d2e0e436e"
      unitRef="U_USD">7189000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_ec76d4e7-beb1-4586-b86e-ae1f314d2f1e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;7. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s operating lease activity is comprised of non-cancelable facility leases for office and laboratory space in Cambridge, Massachusetts. In March 2020, the Company entered into an operating lease agreement for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16,843&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; square feet of space located at 500 Technology Square, Cambridge, Massachusetts (the &#x201c;Cambridge Lease&#x201d;), with the Company acting as subtenant. The term of the Cambridge Lease commenced in August 2020 and is scheduled to expire &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; from the commencement date. The lease provides for annual rent escalations. The Company pays for its proportionate share of building operating costs such as maintenance, utilities, and insurance. In June 2020, the Company entered into the First Amendment to the Cambridge Lease adding &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,980&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; square feet of additional space. In January 2021, the Company entered into the Second Amendment to the Cambridge Lease adding &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,980&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; square feet of additional space at a commensurate rent increase which was treated as a new contract. In July, 2021, the Company entered into an amendment for its office space at 500 Technology Square and corresponding parking lot to extend the lease term through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;November 30, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. The renewal operates under the same terms and conditions as the original lease. As a result of the renewal, the right-of-use asset and lease liability were remeasured at the present value of the lease payments not yet paid, discounted by the incremental borrowing rate (IBR) at the remeasurement date. This resulted in a net increase to the lease liability and right-of-use asset of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. There was no impact on the consolidated statement of operations and comprehensive loss or the consolidated statement of cash flows as a result of the lease renewal.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company has also entered into multiple contract research and contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. The embedded leases are&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;considered short term leases, as the contractual terms are twelve months or less. Accordingly, no lease liability or right of use asset has been recorded, and the Company has recognized &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; of short term lease costs associated with the embedded leases during the year ended December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The components of operating lease cost were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.863%;"/&gt;
        &lt;td style="width:1.938%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:16.032%;"/&gt;
        &lt;td style="width:0.726%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Variable lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Short term lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Supplemental cash flow information related to operating leases was as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.863%;"/&gt;
        &lt;td style="width:1.938%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:16.032%;"/&gt;
        &lt;td style="width:0.726%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Cash paid for amounts included in the measurements of lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating cash flows related to operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As of December 31, 2021, the Company&#x2019;s operating leases were measured using a weighted-average incremental borrowing rate &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.57&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; over a weighted-average remaining lease ter&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;m of 0&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.9 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;On August 19, 2021, the Company entered into a lease agreement with ARE-MA Region No. 87 Tenant, LLC, a Delaware limited liability company (the &#x201c;Landlord&#x201d;), pursuant to which the Company will lease approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;104,933&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; square feet of office and laboratory space located at 201 Brookline Avenue, Boston, Massachusetts (the &#x201c;Boston Lease&#x201d;), further amended in January 2022 to include an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;211&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; square feet, for a total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;105,144&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; square feet. The Boston Lease premises have not been made available to the Company as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021 and is therefore excluded from the table below, as the Lease has not commenced.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The term of the Lease will commence on the earlier of (1) the date the Landlord &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;delivers the premises under the Boston Lease to the Company, which the parties expect to be on or prior to August 1, 2022, or (2) the date the Landlord could have delivered the premises but for any delays attributable to the Company (the &#x201c;Commencement Date&#x201d;). &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s obligation for the payment of base rent for the Boston Lease begins 90 days after the Commencement Date (the &#x201c;Rent Commencement Date&#x201d;) and will initially be $0.8 million per month, which will increase by approximately 3% per annum.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; The Boston Lease has a term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; years, measured from the Rent Commencement Date. The Company has the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;option to extend&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; the term of the Lease for a period of an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. Under the terms of the Lease, the Landlord has agreed to make up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;21.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in certain tenant improvements to the premises to suit the Company&#x2019;s use (the &#x201c;Tenant Improvement Allowance&#x201d;), which amount is included in the base rent set forth in the Boston Lease. In addition to the Tenant Improvement Allowance, the Company may receive up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5.2&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million for additional improvements to the premises, which amount is subject to an &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% annual interest charge and may be paid in equal monthly installments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In connection with its entry into the Boston Lease and as a security deposit, the Company has provided the Landlord a letter of credit in the amount of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4.8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, which may be reduced to approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million on the expiration of the 36-month anniversary of the Rent Commencement Date so long as there are, and have been, no defaults by the Company under the terms of the Boston Lease. The Company also paid a deposit in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, which is equal to the first month of base rent.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Landlord has the right to terminate the Boston Lease upon customary events of default. The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;may also termina&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;te&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; the Boston Lease if the premises are not ready for occupancy within a specified time period after August 1, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Boston Lease requires the Landlord to perform a scope of work to build-out the base building prior to the construction of the premises. The Company concluded the accounting commencement date will occur when the Landlord completes the build-out of the base building and control passes to the Company. The Company will assess the classification of the Boston Lease at the accounting commencement date, measure the right-of-use asset and lease liability. Payments made by the Company prior to commencement will be treated as prepaid rent which will increase the right-of-use asset. As of December 31, 2021, the Company has incurr&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;ed $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million re&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;lated to the build out of the lease space prior to the Commencement Date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In October 2021, the Company entered into a sublease for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;11,931&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; square feet of office and laboratory space in Cambridge, Massachusetts. The sublease commenced in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and has an initial noncancelable term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;twelve months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company has the option to extend the sublease for one extension term of three months by written notice not less than six months prior to the expiration of the sublease term, which the Company is not reasonably certain of exercising.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; Therefore, this sublease is treated as a short term lease. The total fixed lease payments over the sublease term is approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and the Company is also required to pay its proportional share of operating expenses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Future minimum commitments under non-cancellable leases as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021 were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.833%;"/&gt;
        &lt;td style="width:1.938%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:15.923%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Years ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;54,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;108,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Less: interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;108,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Accounting under ASC 840&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Prior to the adoption of ASC 842, the Company recorded rent expense on a straight-line basis over the term of the lease, including any rent-free periods. In addition, the Company recorded deferred rent for certain lease incentives received, which were amortized as a reduction of rent expense over the life of the lease. Rent expense was presented as part of continuing operations in the consolidated statement of operations and comprehensive loss; deferred rent was recorded on the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Rent expense for the years ended December 31, 2020 and 2019&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <verv:LesseeOperatingLeaseArea
      contextRef="C_5026dda8-28ac-4046-b30f-f4c2af3df266"
      decimals="INF"
      id="F_dfd8ee05-13ab-4254-8441-95f12a1ff452"
      unitRef="U_sqft">16843</verv:LesseeOperatingLeaseArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_5026dda8-28ac-4046-b30f-f4c2af3df266"
      id="F_42e9ee53-50e0-4a73-b7e7-11f3408d3bb5">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <verv:LesseeOperatingLeaseArea
      contextRef="C_2b400acd-8cd9-40ff-8255-a68985c37814"
      decimals="INF"
      id="F_5d5eb654-3df1-4724-81d1-f8c79ddeb9b3"
      unitRef="U_sqft">2980</verv:LesseeOperatingLeaseArea>
    <verv:LesseeOperatingLeaseArea
      contextRef="C_1f16c804-a208-4c37-b6c5-31908dac33d8"
      decimals="INF"
      id="F_d901e511-82d8-4328-a5fc-fd6408a236ac"
      unitRef="U_sqft">2980</verv:LesseeOperatingLeaseArea>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0ea046e2-86bb-4bd2-985f-27d259b832a4"
      id="F_dc1df3fa-7900-4cee-8404-778a4a582e3e">2022-11-30</us-gaap:LeaseExpirationDate1>
    <verv:IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset
      contextRef="C_3c6e9331-d8d3-43e7-8098-fbde994f4649"
      decimals="-5"
      id="F_d49e1867-03d7-4b4b-8bbd-7fb02982bbf7"
      unitRef="U_USD">800000</verv:IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_3c6e9331-d8d3-43e7-8098-fbde994f4649"
      decimals="-5"
      id="F_9d407fff-5153-431a-956c-ced452ab5225"
      unitRef="U_USD">800000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_0d594e36-72b4-4236-bd90-bc5bab9f7a9e"
      decimals="-5"
      id="F_77b1c8e4-5bf6-4056-ab14-2e93a3cbf0ca"
      unitRef="U_USD">2300000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_88fce536-a431-4513-8762-d0967b079f69">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The components of operating lease cost were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.863%;"/&gt;
        &lt;td style="width:1.938%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:16.032%;"/&gt;
        &lt;td style="width:0.726%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Variable lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Short term lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_5df73ae8-7efa-4ad9-b6c9-ad8f05d5504f"
      unitRef="U_USD">1923000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_6032bcb4-bd36-4cb8-b5c7-0a761188b440"
      unitRef="U_USD">747000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_37b6e701-80a5-4795-a0bb-12da16b85cf0"
      unitRef="U_USD">2278000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_a7062af5-80c6-45ab-9db2-1a23966108c5"
      unitRef="U_USD">4948000</us-gaap:LeaseCost>
    <verv:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_0c43ad9c-3a38-4ebf-99a8-e0eb14d2a7dd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Supplemental cash flow information related to operating leases was as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.863%;"/&gt;
        &lt;td style="width:1.938%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:16.032%;"/&gt;
        &lt;td style="width:0.726%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Cash paid for amounts included in the measurements of lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating cash flows related to operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</verv:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_7d0e1eb1-ada3-450f-a000-2f5e328fd9cf"
      unitRef="U_USD">2021000</us-gaap:OperatingLeasePayments>
    <verv:LesseeOperatingLeaseIncrementalBorrowingRate
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="4"
      id="F_2a892a8c-f160-4d74-9f8f-5f63f8ad3a00"
      unitRef="U_pure">0.0157</verv:LesseeOperatingLeaseIncrementalBorrowingRate>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      id="F_18c751ed-902e-456b-8d93-8ce25e1f9226">P0Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <verv:LesseeOperatingLeaseArea
      contextRef="C_ac0671b9-90e0-41a4-b113-3a0ff36d64e8"
      decimals="INF"
      id="F_1a9c73c3-c0e2-4753-92d4-a010ffc299c6"
      unitRef="U_sqft">104933</verv:LesseeOperatingLeaseArea>
    <verv:AdditionalLesseeOperatingLeaseArea
      contextRef="C_a810db97-eb14-448b-9d1b-137166449fdd"
      decimals="0"
      id="F_0b456726-6972-4719-a9e5-2cc651b8a176"
      unitRef="U_sqft">211</verv:AdditionalLesseeOperatingLeaseArea>
    <verv:LesseeOperatingLeaseArea
      contextRef="C_a810db97-eb14-448b-9d1b-137166449fdd"
      decimals="0"
      id="F_62f3c73e-bd7f-4a35-98dc-d1c33eebe3d5"
      unitRef="U_sqft">105144</verv:LesseeOperatingLeaseArea>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions
      contextRef="C_e544b1d4-8651-4bbd-86e5-229213fc8bef"
      id="F_30ee5534-441d-44a5-86cb-334102c93680">The Company&#x2019;s obligation for the payment of base rent for the Boston Lease begins 90 days after the Commencement Date (the &#x201c;Rent Commencement Date&#x201d;) and will initially be $0.8 million per month, which will increase by approximately 3% per annum.</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="C_ac0671b9-90e0-41a4-b113-3a0ff36d64e8"
      id="F_9136bb54-a38e-4eeb-ac1a-52d36cb01150">P10Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend
      contextRef="C_cb1b7494-a0dd-49fc-8914-d1f55848827c"
      id="F_a174abc4-deb0-4f6f-a373-38042ddea732">true</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend
      contextRef="C_cb1b7494-a0dd-49fc-8914-d1f55848827c"
      id="F_0c6f3856-46ea-4fe4-a594-010cc4b83548">five years</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend>
    <verv:TenantImprovementsAllowance
      contextRef="C_ac0671b9-90e0-41a4-b113-3a0ff36d64e8"
      decimals="-5"
      id="F_a73f030a-9454-4f42-abe9-9f4979200c44"
      unitRef="U_USD">21000000.0</verv:TenantImprovementsAllowance>
    <verv:AdditionalTenantImprovementsAllowance
      contextRef="C_ac0671b9-90e0-41a4-b113-3a0ff36d64e8"
      decimals="-5"
      id="F_1ec5ff8b-9008-4751-9569-8671c2979eac"
      unitRef="U_USD">5200000</verv:AdditionalTenantImprovementsAllowance>
    <verv:InterestRateForAdditionalImprovementsAllowance
      contextRef="C_cb1b7494-a0dd-49fc-8914-d1f55848827c"
      decimals="2"
      id="F_d4a3c486-1e05-4b8a-acfd-8d71fd62c306"
      unitRef="U_pure">0.08</verv:InterestRateForAdditionalImprovementsAllowance>
    <us-gaap:ShortTermBorrowings
      contextRef="C_96a9ec98-0425-4b68-a1ef-a3660007003a"
      decimals="-5"
      id="F_8a3cb0a6-190c-408e-a980-05db5c2e351f"
      unitRef="U_USD">4800000</us-gaap:ShortTermBorrowings>
    <verv:ShortTermBorrowingsReducedValue
      contextRef="C_96a9ec98-0425-4b68-a1ef-a3660007003a"
      decimals="-5"
      id="F_557a0b1b-39fa-4607-924e-74836514082d"
      unitRef="U_USD">3500000</verv:ShortTermBorrowingsReducedValue>
    <us-gaap:PrepaidRent
      contextRef="C_ac07bf25-eb1b-41db-9a17-637a6b3c0cf0"
      decimals="-5"
      id="F_d9810f7a-9c08-4d90-a618-dc33eaef3413"
      unitRef="U_USD">800000</us-gaap:PrepaidRent>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate
      contextRef="C_cb1b7494-a0dd-49fc-8914-d1f55848827c"
      id="F_9331ff94-4e22-427d-8ee5-8546fc694267">true</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate>
    <verv:OperatingLeaseRelatedExpensesPriorToCommencement
      contextRef="C_e544b1d4-8651-4bbd-86e5-229213fc8bef"
      decimals="-5"
      id="F_05017be7-2dde-46ca-bf0c-08fb0bffa74e"
      unitRef="U_USD">1500000</verv:OperatingLeaseRelatedExpensesPriorToCommencement>
    <verv:LesseeOperatingLeaseArea
      contextRef="C_7eaf2c5f-f4cf-4ef5-8686-522ecb024096"
      decimals="INF"
      id="F_f8faea77-4eea-4fd2-b02f-62734b13181c"
      unitRef="U_sqft">11931</verv:LesseeOperatingLeaseArea>
    <verv:LeaseCommencementDate
      contextRef="C_4d5e8986-339e-4a27-a33a-2ddab2c8cf2a"
      id="F_e9576d66-bc51-4319-a155-2735da202c36">2021-12</verv:LeaseCommencementDate>
    <verv:LeaseNoncancelableTerm
      contextRef="C_4d5e8986-339e-4a27-a33a-2ddab2c8cf2a"
      id="F_d63d3e53-3c3d-4929-9925-fb028b4c8f31">P12M</verv:LeaseNoncancelableTerm>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_4d5e8986-339e-4a27-a33a-2ddab2c8cf2a"
      id="F_df85c665-1298-40a1-85ed-0206d0efaabe">The Company has the option to extend the sublease for one extension term of three months by written notice not less than six months prior to the expiration of the sublease term, which the Company is not reasonably certain of exercising.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:OperatingLeasePayments
      contextRef="C_7d62c74e-40c7-4d44-95f2-9153b525923e"
      decimals="-5"
      id="F_1107bbb2-c9ec-4381-8a28-f3c275f6ce6b"
      unitRef="U_USD">1400000</us-gaap:OperatingLeasePayments>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_3bc16061-4f01-428c-925d-3fc5367e040e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Future minimum commitments under non-cancellable leases as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021 were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.833%;"/&gt;
        &lt;td style="width:1.938%;"/&gt;
        &lt;td style="width:1.441%;"/&gt;
        &lt;td style="width:15.923%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Years ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;54,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;108,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Less: interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;108,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_985f04be-f325-4c26-86a4-3840501351fb"
      unitRef="U_USD">12951000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_1bb89759-c9a0-4224-a5a7-060a4ef0a067"
      unitRef="U_USD">9958000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_3efad5fc-bceb-4c08-943a-ee193b0c293f"
      unitRef="U_USD">10257000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_53fa8207-bb87-4957-a179-509f7b344bb6"
      unitRef="U_USD">10565000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_6c878b17-2c59-44c4-adf7-34ffedd938db"
      unitRef="U_USD">10882000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <verv:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_90660f4a-cb3e-4579-b4c1-5503ca526b95"
      unitRef="U_USD">54158000</verv:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_87930dee-9edd-4737-a1ce-5d65cc32b410"
      unitRef="U_USD">108771000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_4b7cc866-6238-4226-adb6-ebce83f76392"
      unitRef="U_USD">13000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_4e7a03cb-a50b-4a39-a154-7df1e7f1c587"
      unitRef="U_USD">108758000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-5"
      id="F_f7fe94af-f283-4a93-822a-75b9de1acd89"
      unitRef="U_USD">1300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-5"
      id="F_0035d75a-9517-4e49-ab56-ed1ec884a42c"
      unitRef="U_USD">200000</us-gaap:OperatingLeaseExpense>
    <verv:LicenseAgreementDisclosureTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_97edbfe1-f1ca-4bd4-bf1c-3a7f56ad76fe">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;8.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt; License agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Harvard/Broad license agreement and Broad license agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In March 2019, the Company simultaneously entered into the Harvard/Broad License Agreement and Broad License Agreement (the &#x201c;license agreements&#x201d;) for certain base editing technologies pursuant to which the Company received exclusive, worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed products and nonexclusive, worldwide, sublicensable, royalty-bearing licenses under certain patent rights to research and develop licensed products. The Company agreed to use commercially reasonable efforts to develop licensed products in accordance with the development plans, to introduce any licensed products that gain regulatory approval into the commercial market, to market licensed products that have gained regulatory approval following such introduction into the market, and to make licensed products that have gained regulatory approval reasonably available to the public. The term of the agreements will continue until the expiration of the last to expire valid claim. The Company may terminate either of the license agreements without cause upon four months&#x2019; prior written notice to Harvard and Broad, unless terminated earlier. In February 2021, the Company provided written notice to Broad of its intent to terminate the Broad License Agreement, which termination was effective in June 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As partial consideration for the rights granted under the Harvard/ Broad License Agreement and Broad License Agreement, the Company paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in non-refundable upfront license fees and also issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;276,075&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of its common stock with a fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. Additional consideration under the license agreements is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Antidilution Rights&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;The initial shares of common stock issued to Harvard and Broad are subject to antidilution provisions as further described in Note 5, Fair value of financial instruments. The antidilution rights associated with the Company achieving a defined aggregate level of preferred stock financing were partially satisfied in 2019 and fully satisfied in 2020, which settlement amounts totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively, and which amounts were settled through issuances of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;121,411&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;187,867&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;of common stock, respectively. The remaining antidilution rights obligation was fully satisfied in June 2021 upon the Company&#x2019;s IPO. The settlement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;amount &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and was settled through issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;878,098&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of the Company's common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Success Payments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;The Company is required to make success payments under the license agreements as further described in Note 5, Fair&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;value of financial instruments. For the years ended December 31, 2020 and 2019, no success payments were paid or due. In September 2021, certain success payments were triggered and amounts due to Harvard and Broad totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. These amounts were settled in cash in November 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Other Payments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;The Company agreed to pay an annual license maintenance fee ranging from low-to-mid five figures to low six figures,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;depending on the particular calendar year, for each of the license agreements. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Harvard and Broad related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;46.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;108&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in development and sales-based milestones, respectively. If the Company undergoes a change of control during the term of the license agreements, then certain of the milestone payments would be increased by a mid-double-digit percentage. The milestones have not been achieved and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; expense has been recorded for these milestones as of December 31, 2021. To the extent there are sales of a licensed product, the Company is required to pay low single digit royalties on net sales, for each of the license agreements. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company concluded that the assets acquired from Harvard and Broad did not meet the accounting definition of a business as inputs, but no processes or outputs were acquired with the licenses. As the inputs that were acquired along with the licenses do not constitute a &#x201c;business,&#x201d; the transaction has been accounted for as an asset acquisition. As of the date of the license agreements, the assets acquired had no alternative future use and the assets had not reached a stage of technological feasibility. As a result, all share-based and cash payment obligations have been recorded as research and development expense in the statement of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;At the inception of the license agreements in March 2019, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million as research and development expense, which includes the non-refundable upfront license fees payable in cash and the fair value of the common stock issued, along with the initial fair values of the antidilution rights liability and success payment liability. As further disclosed in Note 5, the antidilution rights liability and success payment liability are remeasured at fair value each reporting period with subsequent changes recognized in other income (expense).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Verily agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In March 2019, the Company and Verily Life Sciences LLC (&#x201c;Verily&#x201d;) entered into a collaboration agreement. Pursuant to the agreement, the Company and Verily intend to collaborate to utilize Verily&#x2019;s nanoparticle platform to screen, develop and characterize improved nanoparticles for the delivery of the Company&#x2019;s gene editing tools to enable development and commercialization of nanoparticle-based drug products. As part of the agreement, Verily granted the Company an exclusive, perpetual, worldwide, sublicensable, fully paid right and license to Verily&#x2019;s solely owned and developed intellectual property to research, develop, make, offer for sale, sell and import products targeting the Company&#x2019;s gene targets for the treatment or prevention of atherosclerotic cardiovascular disease. The term of the agreement continues until the earlier of (i) completion of all activities related to the collaboration or (ii) the three-year anniversary of the agreement date, unless terminated earlier. At any time during the term, the Company has the right to terminate the agreement in its entirety for any reason by delivering a 90-day termination notice to Verily.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As partial consideration for the license rights granted by Verily, at inception of the arrangement, the Company paid a one-time, nonrefundable fee through the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,672,240&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of Series A Preferred with a fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. To the extent achieved, the Company was obligated to make one-time payments to Verily of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in development-based milestones. The Company paid a milestone payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in 2020 related to a study in wild type mice that demonstrated a certain gene editing percentage level. In addition, as consideration for Verily&#x2019;s activities under the agreement, the Company was obligated to pay a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million quarterly development payment for a period of ten quarters.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company concluded the assets acquired from Verily did not meet the accounting definition of a business as inputs, but no processes or outputs were acquired with the licenses. As the inputs that were acquired along with the licenses do not constitute a &#x201c;business,&#x201d; the transaction has been accounted for as an asset acquisition. As of the date of the collaboration agreement, the assets acquired had no alternative future use and the assets had not reached a stage of technological feasibility. As a result, at the inception of the agreement in 2019, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;as research and development expense, which includes the one-time, nonrefundable&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;license &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;fee settled through issuing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,672,240&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of Series A Preferred. In addition, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in quarterly development payments to Verily as research and development expense in 2019. In 2020, the Company recognized the milestone payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million described above as research and development expense upon achievement of the related development-based milestone. Further, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in quarterly development payments to Verily as research and development expense in 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company elected to terminate the agreement with Verily effective June 26, 2020 and has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; outstanding amounts due or payable to Verily as of December 31, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Beam license agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In April 2019, the Company and Beam Therapeutics, Inc. (&#x201c;Beam&#x201d;) entered into a collaboration and license agreement. Pursuant to the agreement, the Company received an exclusive, worldwide, sublicensable license under certain of Beam&#x2019;s base editing technology, gene editing, and delivery technologies to develop, make, use, offer for sale, sell and import base editing products and nuclease products using Beam&#x2019;s CRISPR associated protein 12b, or Cas12b technology, in each case, directed to any of four gene targets, including the PCSK9 and ANGPTL3 genes, that are associated with an increased risk of coronary diseases. In addition, the Company granted Beam an exclusive, worldwide, sublicensable license under certain of its delivery technology to develop, manufacture, sell and import product candidates and products, except for base editor products licensed to Verve.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Both parties may conduct certain activities in accordance with an agreed-upon research and/or development plan. Following the final dosing of a patient in a Phase 1 clinical trial of a given licensed product, Beam has the right to opt in to share &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;33&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share profits and expenses of commercializing such licensed product in the United States on a 50/50 basis. If Beam exercises its opt-in right for a given licensed product, which we refer to following such opt-in as a collaboration product, it will be obligated to pay for a specified percentage of the development and commercialization costs of such collaboration product and will have the right to receive a specified percentage of the profits from any sales of such collaboration product. The term of the agreement continues until the last to expire of any royalty term for any product. The Company has the right to terminate the agreement as to any licensed product, but not for any collaboration product, by delivering a 90-day termination notice to Beam, provided that Beam has elected not to exercise its opt-in right or the period to exercise such opt-in right has expired.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company is responsible for all costs and expenses incurred in the conduct of activities under the research plan, any development plan and any costs and expenses for the development of a licensed product for which Beam has not elected to opt-in.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As partial consideration for the license rights granted by Beam, the Company paid a one-time, nonrefundable fee through issuing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;276,075&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of its common stock with a fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. To the extent achieved, for each licensed product, the Company is also obligated to pay up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;11.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in development and regulatory-based milestones and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in sales-based milestones. To the extent there are sales of a licensed product, the Company is required to pay low-to-mid single digit royalties on net sales. To the extent achieved, for each collaboration product outside of the United States, the Company is obligated to pay up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in development and regulatory-based milestones and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in sales-based milestones. To the extent there are ex-U.S. sales of a collaboration product, the Company is required to pay low-to-mid single digit royalties on net sales. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The milestones have not been achieved and no expense has been recorded for these milestones as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The parties have also promised that in further consideration for the licenses granted under the parties&#x2019; respective delivery technologies, each party will pay to the other party development-based milestone payments up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million for each delivery technology product of such paying party to achieve the corresponding milestone event. The triggering of these milestone payments was not considered probable as of the transaction date, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; expense has been recorded for these milestones as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021. To the extent there are sales of a delivery technology product, each party will pay the other party low-to-mid single digit royalties based on the annual aggregate worldwide net sales resulting from the sale of each delivery technology product of such paying party; provided, however, that such royalty payments will not apply to net sales of the collaboration products or licensed products. The Company concluded the receipt of any milestone or royalty payments under the agreement was not probable as of December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Company further concluded the assets acquired from Beam did not meet the accounting definition of a business as inputs, but no processes or outputs were acquired with the licenses. As the inputs that were acquired along with the licenses do not constitute a &#x201c;business,&#x201d; the transaction has been accounted for as an asset&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;acquisition. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As of the date of the license agreement, the assets acquired had no alternative future use and the assets had not reached a stage of technological feasibility. As a result, at the inception of the agreement in 2019, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million as research and development expense, which includes the one-time, nonrefundable license fee settled through the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;276,075&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of common stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Beam materials exchange letter agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In October 2020, the Company and Beam entered into a materials exchange agreement wherein the parties agreed that Beam would provide certain mRNA, gRNA, and protein to the Company and that the Company would provide certain gRNAs to Beam at an agreed upon price per each material provided.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;For the year ended December 31, 2021, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;t purchase any materials from Beam. For the year ended December 31, 2020, the Company purchased $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million as a charge to research and development expense related to materials purchased from Beam.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;For the year ended December 31, 2021, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million as a reduction to research and development expense related to reimbursements received for materials sold to Beam. During the year ended December 31, 2020, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million as a reduction to research and development expense related to reimbursements received for materials sold to Beam.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Acuitas agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Development and option agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In December 2019, the Company and Acuitas Therapeutics, Inc. ("Acuitas") entered into a development and collaboration agreement, which agreement was amended and restated in October 2020. The Company agreed to reimburse Acuitas on a quarterly basis for its services performed related to the program activities based on an agreed upon number of fulltime employees committed to work on the program at an annual rate per employee, including reimbursement of reasonable external costs. These services commenced during 2020 and the Company recognized research and development expense of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million for the years ended December 31, 2021 and 2020, respectively, related to the reimbursement of research and development services provided by Acuitas and technology maintenance fees. In 2020 upon the one-year anniversary of the agreement the Company had exercised one of its options to enter into a non-exclusive license agreement, as further described below.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;License agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In October 2020, the Company paid Acuitas a non-refundable, upfront license fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million (less a previously paid target reservation fee) to exercise an option with respect to a licensed product and a licensed genome target and entered into a non-exclusive, worldwide license with Acuitas, with a right to sub-license through multiple tiers, under the licensed LNP technology to research, develop and commercialize the licensed products using the LNP technology in connection with the PCSK9 gene target for all human therapeutic or prophylactic uses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;To the extent achieved, the Company is also obligated to pay up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in clinical and regulatory milestones and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in sales-based milestones. The milestones have not been achieved and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; expense has been recorded for these milestones as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Third-party license agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In October 2021, the Company entered into a license agreement with a third party to obtain a non-exclusive license to certain technology the Company is using for research and development. As consideration for the license and rights granted under the agreement, the Company made a one-time, non-refundable, upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million during the three months ended December 31, 2021. The license agreement provides for specified development milestones relating to the licensed technology and requires the Company to make payments upon achievement of each milestone up to an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million.&lt;/span&gt;&lt;/p&gt;</verv:LicenseAgreementDisclosureTextBlock>
    <verv:NonRefundableUpfrontLicenseFeesPaid
      contextRef="C_e5482ed2-d888-4dd2-a7a7-cb1d249e3b82"
      decimals="-5"
      id="F_6795cd6e-54f6-4285-ad52-ea28307cfe32"
      unitRef="U_USD">300000</verv:NonRefundableUpfrontLicenseFeesPaid>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_6ad6efa1-92e1-4627-b9eb-e717d27461ed"
      decimals="INF"
      id="F_e9f611f2-cf5b-471a-b81c-3a01812c8182"
      unitRef="U_shares">276075</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_e36ace04-7d0f-46f4-a4fc-05e0cddb3357"
      decimals="-5"
      id="F_9c2a0740-31ae-46be-8c4d-b156a5a344cf"
      unitRef="U_USD">300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <verv:PreferredStockFinancingPartiallySatisfied
      contextRef="C_29a82fc7-8d8b-4988-8c6b-cb6aaeac3cf1"
      decimals="-5"
      id="F_2890fa5d-def1-46c4-85e8-2b2f5b013fab"
      unitRef="U_USD">100000</verv:PreferredStockFinancingPartiallySatisfied>
    <verv:PreferredStockFinancingFullySatisfied
      contextRef="C_671bfcc0-ebf7-4194-8895-80b3fa98b658"
      decimals="-5"
      id="F_069af261-c399-42e2-8a66-f5ce7321027d"
      unitRef="U_USD">500000</verv:PreferredStockFinancingFullySatisfied>
    <verv:CommonStockIssuedForPartlySatisfyingPreferredStockFinancing
      contextRef="C_29a82fc7-8d8b-4988-8c6b-cb6aaeac3cf1"
      decimals="INF"
      id="F_329968ff-e5d7-4706-b7ff-868a5db33b76"
      unitRef="U_USD">121411</verv:CommonStockIssuedForPartlySatisfyingPreferredStockFinancing>
    <verv:CommonStockIssuedForFullySatisfyingPreferredStockFinancing
      contextRef="C_671bfcc0-ebf7-4194-8895-80b3fa98b658"
      decimals="INF"
      id="F_605000ec-a24f-4ce5-ab82-14e4ed42e6ed"
      unitRef="U_shares">187867</verv:CommonStockIssuedForFullySatisfyingPreferredStockFinancing>
    <us-gaap:CommonStockValue
      contextRef="C_3a46f484-c7b1-4249-a6d6-d259c573d801"
      decimals="-5"
      id="F_668ab4ee-e0b1-4955-8296-e726af209b16"
      unitRef="U_USD">32500000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_3a46f484-c7b1-4249-a6d6-d259c573d801"
      decimals="INF"
      id="F_1e7ea8da-f256-4b3c-beea-69c4bdbd72b5"
      unitRef="U_shares">878098</us-gaap:CommonStockSharesIssued>
    <us-gaap:DerivativeLiabilities
      contextRef="C_ea754504-c0d8-4221-a285-32e891462575"
      decimals="-5"
      id="F_9a41cd7e-3df4-4740-96c4-373eaf95e7a4"
      unitRef="U_USD">6300000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="C_e8b5087a-c8c5-42b6-b02a-2126a65898d5"
      decimals="-5"
      id="F_999288cd-f895-49b2-9c49-ed10963dd03f"
      unitRef="U_USD">6300000</us-gaap:DerivativeLiabilities>
    <verv:PaymentOfMilestoneDevelopment
      contextRef="C_e36ace04-7d0f-46f4-a4fc-05e0cddb3357"
      decimals="-5"
      id="F_fb895f56-5710-41f1-8ec7-ebe86aee56eb"
      unitRef="U_USD">46200000</verv:PaymentOfMilestoneDevelopment>
    <verv:PaymentOfSalesBasedMilestone
      contextRef="C_e36ace04-7d0f-46f4-a4fc-05e0cddb3357"
      decimals="-6"
      id="F_c15d6dd1-55d8-4f35-8438-134b670cf8d6"
      unitRef="U_USD">108000000</verv:PaymentOfSalesBasedMilestone>
    <verv:MilestoneRelatedExpenses
      contextRef="C_e36ace04-7d0f-46f4-a4fc-05e0cddb3357"
      decimals="-3"
      id="F_0fc1964f-996d-46fa-9152-83aa021a2fa9"
      unitRef="U_USD">0</verv:MilestoneRelatedExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_898d61f8-6a19-4832-b357-ffe134d84eaf"
      decimals="-5"
      id="F_3dd87235-77e2-44c5-af6a-c1c0376b6c85"
      unitRef="U_USD">2100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_314775f6-60d3-4cdd-a7e4-d2d47b4bb14b"
      decimals="INF"
      id="F_b9751dca-a20b-4456-a030-ba27239f3710"
      unitRef="U_shares">1672240</us-gaap:CommonStockSharesIssued>
    <verv:NonRefundableUpfrontLicenseFeesPaid
      contextRef="C_3585e227-4c98-4454-befd-78b3ac98ed4a"
      decimals="-5"
      id="F_3704656d-b9c9-49aa-baf3-785349d2c0e8"
      unitRef="U_USD">600000</verv:NonRefundableUpfrontLicenseFeesPaid>
    <verv:DevelopedBaseMilestonePayments
      contextRef="C_3585e227-4c98-4454-befd-78b3ac98ed4a"
      decimals="-5"
      id="F_85a169e2-ddce-4358-8b69-8afd1580ed8a"
      unitRef="U_USD">5500000</verv:DevelopedBaseMilestonePayments>
    <verv:MilestonePayments
      contextRef="C_3585e227-4c98-4454-befd-78b3ac98ed4a"
      decimals="-5"
      id="F_d2a17364-8630-4204-9950-e2618eba742c"
      unitRef="U_USD">1000000.0</verv:MilestonePayments>
    <verv:DevelopedBaseMilestonePaymentsForStatedPeriod
      contextRef="C_3585e227-4c98-4454-befd-78b3ac98ed4a"
      decimals="-5"
      id="F_4636333c-4d1c-49b5-a1cb-d49b2d3af351"
      unitRef="U_USD">300000</verv:DevelopedBaseMilestonePaymentsForStatedPeriod>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_3d0c6332-d1dd-4a36-9324-fb3b21711262"
      decimals="-5"
      id="F_9691044a-1985-4d48-9c11-a2db342192ec"
      unitRef="U_USD">600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_af6a2a40-edbe-4dd3-98a2-c59fe2070928"
      decimals="INF"
      id="F_175d8201-412a-4260-8474-ddc6e5210c3b"
      unitRef="U_shares">1672240</us-gaap:CommonStockSharesIssued>
    <verv:DevelopedBaseMilestonePaymentsForStatedPeriod
      contextRef="C_3d0c6332-d1dd-4a36-9324-fb3b21711262"
      decimals="-5"
      id="F_934d5a0d-d421-4ca2-9a6d-d95e3235c79a"
      unitRef="U_USD">800000</verv:DevelopedBaseMilestonePaymentsForStatedPeriod>
    <verv:MilestonePayments
      contextRef="C_dc3057b9-a834-4bce-9400-bb870b34a39e"
      decimals="-5"
      id="F_936a6a1b-14e5-44c5-81f7-9002dcf81f62"
      unitRef="U_USD">1000000.0</verv:MilestonePayments>
    <verv:DevelopedBaseMilestonePaymentsForStatedPeriod
      contextRef="C_dc3057b9-a834-4bce-9400-bb870b34a39e"
      decimals="-5"
      id="F_2d698e39-d654-46fd-929b-620db3b3d161"
      unitRef="U_USD">500000</verv:DevelopedBaseMilestonePaymentsForStatedPeriod>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="C_01810b2e-60ca-470b-a8e4-f620cad1af9d"
      decimals="-3"
      id="F_1085f00a-b6b3-4bf2-9abd-3123707e9667"
      unitRef="U_USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="C_82be291d-e5c6-4821-b8c8-65d4e399c80f"
      decimals="-3"
      id="F_5d17a45c-b471-4236-a377-bbb3481fda27"
      unitRef="U_USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <verv:PercentageSharesOfDevelopmentExpense
      contextRef="C_81529f1c-4f4b-492c-a430-5a7eaa203e49"
      decimals="2"
      id="F_6f83b1f0-cd77-49e2-b2f9-b732711279ed"
      unitRef="U_pure">0.33</verv:PercentageSharesOfDevelopmentExpense>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_983ffc57-7b63-4e06-ab2d-e82bf6082b61"
      decimals="INF"
      id="F_e7d2fcfd-2132-4019-9244-d31241628c2a"
      unitRef="U_shares">276075</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_983ffc57-7b63-4e06-ab2d-e82bf6082b61"
      decimals="-5"
      id="F_bf06edf3-ea61-4dc3-9c83-96b3577990b7"
      unitRef="U_USD">300000</us-gaap:CommonStockValue>
    <verv:PaymentOfMilestoneDevelopment
      contextRef="C_81529f1c-4f4b-492c-a430-5a7eaa203e49"
      decimals="-5"
      id="F_79653bbd-b9c3-489c-a94c-0b747ebf023f"
      unitRef="U_USD">11300000</verv:PaymentOfMilestoneDevelopment>
    <verv:PaymentOfSalesBasedMilestone
      contextRef="C_81529f1c-4f4b-492c-a430-5a7eaa203e49"
      decimals="-5"
      id="F_24b79e9c-1299-40b7-ab4e-251d608e035e"
      unitRef="U_USD">15000000.0</verv:PaymentOfSalesBasedMilestone>
    <verv:PaymentOfMilestoneDevelopment
      contextRef="C_1ad41b74-8200-44de-a163-b3c17e30b9e5"
      decimals="-5"
      id="F_b7b11378-fa16-46f4-9914-ccc125b86433"
      unitRef="U_USD">5600000</verv:PaymentOfMilestoneDevelopment>
    <verv:PaymentOfSalesBasedMilestone
      contextRef="C_1ad41b74-8200-44de-a163-b3c17e30b9e5"
      decimals="-5"
      id="F_dcdfa498-5f5d-4bb7-bf08-1de333185777"
      unitRef="U_USD">7500000</verv:PaymentOfSalesBasedMilestone>
    <verv:PaymentOfMilestoneDevelopment
      contextRef="C_a4af95d5-0d99-42f7-b5a7-c6ec697551f5"
      decimals="-5"
      id="F_246a66dc-ebad-48d2-bd5f-dabc7839df42"
      unitRef="U_USD">6000000.0</verv:PaymentOfMilestoneDevelopment>
    <verv:MilestoneRelatedExpenses
      contextRef="C_38e0bdc6-ddc8-4961-80a7-3305ab5afc10"
      decimals="-3"
      id="F_f9a2871b-e430-4628-bd56-3021cdf3a00a"
      unitRef="U_USD">0</verv:MilestoneRelatedExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_81529f1c-4f4b-492c-a430-5a7eaa203e49"
      decimals="-5"
      id="F_c28f907e-388a-438f-9be4-90370cc8d1bd"
      unitRef="U_USD">300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_983ffc57-7b63-4e06-ab2d-e82bf6082b61"
      decimals="INF"
      id="F_d131cf84-7337-4aa6-92c0-21c1e05ab02a"
      unitRef="U_shares">276075</us-gaap:CommonStockSharesIssued>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_38e0bdc6-ddc8-4961-80a7-3305ab5afc10"
      decimals="-6"
      id="F_9ee0b004-5adc-41b4-9740-f5558f32f9fc"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_8943ede3-21ba-4dd5-a69f-6510b3c9441e"
      decimals="-5"
      id="F_fa249b10-0162-4939-a37a-52edec776478"
      unitRef="U_USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <verv:PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred
      contextRef="C_577f8c7c-690b-48eb-85f5-78944ac5fb74"
      decimals="-5"
      id="F_eaec161c-a9d8-4423-92fd-57cd2d0589b6"
      unitRef="U_USD">200000</verv:PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred>
    <verv:PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred
      contextRef="C_db73ec29-59ce-4649-9f8f-424cfebeac57"
      decimals="-5"
      id="F_e4dd2c0f-ea64-438d-a432-ace9ccce2829"
      unitRef="U_USD">300000</verv:PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_8020214a-330a-4afc-8e4e-cfbc08b56cfc"
      decimals="-5"
      id="F_f540a9b6-f95e-41aa-88c8-10562f2453f1"
      unitRef="U_USD">1000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_b046bc96-323a-433d-9185-6710e68adfba"
      decimals="-5"
      id="F_c0895d1e-1002-42e6-bbb0-1423eeed94e1"
      unitRef="U_USD">2000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <verv:NonRefundableUpfrontLicenseFee
      contextRef="C_1bcde1fb-0fd0-4aef-8c8e-7bc374f704bf"
      decimals="-5"
      id="F_03e65150-7079-4ae5-b055-6c073d065f53"
      unitRef="U_USD">2000000.0</verv:NonRefundableUpfrontLicenseFee>
    <verv:ClinicalAndRegulatoryMilestone
      contextRef="C_ae35d2d7-335e-4000-8d8b-98d22cdc0bcd"
      decimals="-5"
      id="F_7a2102cf-a42e-46e7-9b6e-328295d5ecbc"
      unitRef="U_USD">9800000</verv:ClinicalAndRegulatoryMilestone>
    <verv:SalesBasedMilestone
      contextRef="C_ae35d2d7-335e-4000-8d8b-98d22cdc0bcd"
      decimals="-5"
      id="F_bd6044d9-b393-4b48-9af5-d19d52af4af3"
      unitRef="U_USD">9500000</verv:SalesBasedMilestone>
    <verv:MilestoneRelatedExpenses
      contextRef="C_ae35d2d7-335e-4000-8d8b-98d22cdc0bcd"
      decimals="-6"
      id="F_7656141a-63e7-486c-ae38-4e64e2d9a8fe"
      unitRef="U_USD">0</verv:MilestoneRelatedExpenses>
    <verv:NonRefundableUpfrontPayment
      contextRef="C_1349c1bd-0a8c-4898-8535-2e458967423b"
      decimals="-5"
      id="F_907fcb1e-6e01-425c-baee-8995104f884a"
      unitRef="U_USD">800000</verv:NonRefundableUpfrontPayment>
    <verv:MilestoneRelatedExpenses
      contextRef="C_1349c1bd-0a8c-4898-8535-2e458967423b"
      decimals="-5"
      id="F_50316d06-37cc-4db2-9bf2-7150c9700285"
      unitRef="U_USD">10000000.0</verv:MilestoneRelatedExpenses>
    <verv:PreferredStockTrancheLiabilityTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_78489430-1a5a-48dc-93b8-9572d5a2e402">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;9. Preferred stock tranche liability&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Included in the terms of the Series A Preferred Stock purchase agreement were certain tranche rights whereupon the Company was obligated to issue, and the Series A Preferred investors had the obligation to purchase, additional shares of Series A Preferred Stock, as follows:&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;29,347,825&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of Series A Preferred Stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.598&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share upon the Company achieving certain scientific and non-scientific milestones ("second tranche"); and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;49,749,167&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of Series A Preferred Stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.598&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share upon the Company achieving additional scientific and non-scientific milestones ("third tranche").&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The second tranche and third tranche represent freestanding financial instruments accounted for as liabilities under ASC 480, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Distinguishing Liabilities From Equity, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;because these tranche rights (i) embody an obligation to repurchase the Company's equity shares and (ii) may require the Company to settle the obligation by transferring assets. As a result, upon issuance, the respective tranche rights were initially recorded at fair value and subsequently re-measured at fair value in each reporting period (and at settlement, as applicable). Changes in fair value were recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. The second tranche and third tranche were settled in 2019 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Second tranche&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In April 2019, the board of directors agreed to amend certain scientific milestones and subsequently determined the second tranche milestones, as modified, were achieved and the Company settled the second tranche by issuing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_91ee41f9-52b7-4c98-a858-be106bcef7e4;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;29,347,825&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of Series A Preferred Stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.598&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Third tranche&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In March 2020, the board of directors agreed to waive the final remaining milestones and determined the third tranche milestones, as modified, were achieved. In March 2020, the Company settled the third tranche by issuing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;49,749,167&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of Series A Preferred Stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.598&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;29.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;</verv:PreferredStockTrancheLiabilityTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_bb24676f-df61-4c43-a65c-58adb308cd98"
      decimals="INF"
      id="F_3ebb689e-5b11-4009-b5bb-5176d5df023c"
      unitRef="U_shares">29347825</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_bb24676f-df61-4c43-a65c-58adb308cd98"
      decimals="3"
      id="F_fba91369-4397-404e-a659-ba927f505087"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.598</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_9bb47951-6b36-400c-bc9e-6e6219af2c06"
      decimals="0"
      id="F_294beff0-341f-43a8-97ec-2940923d0a65"
      unitRef="U_shares">49749167</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_9bb47951-6b36-400c-bc9e-6e6219af2c06"
      decimals="3"
      id="F_9ac58b83-429d-4567-a5d9-3066784851ad"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.598</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_1d25d519-2490-4618-87e0-211daed76d06"
      decimals="3"
      id="F_5ae6d810-6f77-409a-b9df-44109acab18f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.598</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_b587c055-bdab-476a-b3ab-de00dcd68ee5"
      decimals="-5"
      id="F_e55318ce-56f0-4e44-8e99-d467be7a34e3"
      unitRef="U_USD">17500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_f64ad974-2e0f-4ca6-b8b0-bd9dc4283255"
      decimals="INF"
      id="F_d6c13514-d2db-4ec1-ab68-124a255fcab1"
      unitRef="U_shares">49749167</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_f64ad974-2e0f-4ca6-b8b0-bd9dc4283255"
      decimals="3"
      id="F_27f24d05-f75f-48fa-be62-7656c5b6c7f7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.598</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_6306fa6b-7c2e-44e2-9da5-5dfd36995ad7"
      decimals="-5"
      id="F_089d237f-342c-4c76-8137-205a3254c3c4"
      unitRef="U_USD">29800000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <verv:PreferredAndCommonStockTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_bdca0d67-c220-4b62-9b84-6d044bcbbbdb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;10. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;Preferred and common stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company has issued and sold Series A Preferred, Series A-2 Preferred, Series B Preferred and common stock, as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;During 2018, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;19,565,217&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of Series A Preferred at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.598&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;11.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. The Company incurred issuance costs in connection with these transactions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. These issuances included the tranche rights for the second tranche and third tranche, as previously described in Note 9, Preferred Stock tranche liability.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In March 2019, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,672,240&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of Series A Preferred in exchange for in-licensing certain technologies from Verily. See Note 8, License agreements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In August 2019, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;29,347,825&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of Series A Preferred at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.598&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. This issuance represented the settlement of the second tranche. See Note 9, Preferred Stock tranche liability.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In October 2019, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;836,122&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of Series A Preferred at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.598&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. This issuance included tranche rights for the third tranche.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In March 2020, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;49,749,167&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of Series A Preferred at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.598&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;29.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. This issuance represented the settlement of the third tranche.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Between April and June 2020, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;78,348,461&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of Series A-2 Preferred at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.8041&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;63.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. The Company incurred issuance costs in connection with this transaction of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In January 2021, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;77,163,022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of Series B Preferred Stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.2182&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;94.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. The Company incurred issuance costs in connection with this transaction of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In June 2021, the Company amended and restated its certificate of incorporation to authorize &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of preferred stock, which shares of preferred stock are currently undesignated, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;200,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of common stock, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; par value per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In June 2021, the Company completed its IPO, pursuant to which the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16,141,157&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of its common stock, including &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,105,368&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;19.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share, for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;306.7&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company received approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;281.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in net proceeds, after deducting underwriting discounts and offering expenses payable by the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Upon the closing of the IPO, all outstanding shares of the Company's preferred stock automatically converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;27,720,923&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of the Company's common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In June 2021, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;878,098&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of its common stock to Harvard and Broad as final settlement of its antidilution rights obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The holders of common stock are entitled to one vote for each share of common stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following is a summary of the rights and preferences of the Series A Preferred, Series A-2 Preferred and Series B Preferred, prior to the completion of the Company's IPO:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Conversion&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Each share of Series A Preferred, Series A-2 Preferred and Series B Preferred may be converted at any time, at the option of the holder, into shares of common stock, subject to the applicable conversion rate as determined by dividing the original issue price by the conversion price. The initial conversion price for each of the Series A Preferred, Series A-2 Preferred and Series B Preferred (each as may be adjusted for certain dilutive events) was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.598&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.8041&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.2182&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share, respectively. Each series of Series A Preferred, Series A-2 Preferred and Series B Preferred automatically converted into shares of common stock on a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_b2d78b98-0d63-4d03-af96-185a21d44c07;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1:1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; conversion ratio (as may be adjusted for certain dilutive events) at the earlier of the closing of an initial public offering of the Company&#x2019;s common stock with gross proceeds to the Company of at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and a purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;22.34&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share, or at the election of the holders of at least two-thirds of the then-outstanding shares of Preferred Stock.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Dividends&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;Holders were entitled to non-cumulative dividends of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.05&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share with respect to Series A Preferred and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.06&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share with respect to the Series A-2 Preferred, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share with respect to Series B Preferred when, as, and if declared by the board of directors. No dividends have been declared through December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Voting Rights&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;Series A Preferred, Series A-2 Preferred, Series B Preferred and common stock generally voting together as one class on an as-converted basis; however, common stock voting rights on certain matters were subject to the powers, preferences, and rights of the Series A Preferred, Series A-2 Preferred and Series B Preferred. The holders of Series A Preferred, Series A-2 Preferred and Series B Preferred, voting together as a single class, were entitled to elect three directors to the Company&#x2019;s board of directors and the holders of common stock, voting as a single class, were entitled to elect two directors to the Company&#x2019;s board of directors. Certain actions, such as mergers, consolidation, sale of substantially all assets, liquidation, dissolution, wind up of business, or any other deemed liquidation events, must be approved by the holders of at least two-thirds of the then-outstanding shares of Series A Preferred, Series A-2 Preferred and Series B Preferred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Liquidation Preference&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;Upon liquidation, dissolution, or winding up of business, the holders of the Series A Preferred, Series A-2 Preferred and Series B Preferred were entitled to receive a liquidation preference in priority over the holders of common stock, at an amount per share equal to the greater of i) the original Series A Preferred, Series A-2 Preferred and Series B Preferred issue price plus any declared but unpaid dividends, or ii) the amount per share payable had all shares of Series A Preferred, Series A-2 Preferred and Series B Preferred been converted to common stock immediately prior to such liquidation. If assets available for distribution are insufficient to satisfy the liquidation payment to holders in full, assets available for distribution would have been allocated among holders based on their pro rata shareholdings. When holders are satisfied in full, any excess assets available for distribution would have been allocated ratably among the holders of common stock based on their pro rata holdings. Upon a deemed liquidation event, as defined, holders had the option to redeem their outstanding shares at a price equal to the liquidation payment amounts summarized above.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Redemption&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;Aside from upon the occurrence of a deemed liquidation event, the Series A Preferred, Series A-2 Preferred and Series B Preferred were not redeemable.&lt;/span&gt;</verv:PreferredAndCommonStockTextBlock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_8b41bdfb-bbc2-43d8-bf32-532fc3b99db4"
      decimals="INF"
      id="F_b783a066-012a-4f6d-a676-064720b76912"
      unitRef="U_shares">19565217</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_8b41bdfb-bbc2-43d8-bf32-532fc3b99db4"
      decimals="3"
      id="F_9b150e91-2b78-429f-8492-957bb19f1397"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.598</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_335ebba5-72b4-421b-898b-d3de7d54c1a3"
      decimals="-5"
      id="F_4c710f44-1ea5-4ea0-af90-380d8169862d"
      unitRef="U_USD">11700000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_335ebba5-72b4-421b-898b-d3de7d54c1a3"
      decimals="-5"
      id="F_17b05281-3305-40d9-9981-972ac5c20b9a"
      unitRef="U_USD">200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_256a0140-df8b-4d59-a0a5-3457018ea09f"
      decimals="INF"
      id="F_1464bb17-0dd4-4797-bc87-ea9672effa98"
      unitRef="U_shares">1672240</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_25c1a637-7cb1-4291-89c3-54a541318110"
      decimals="INF"
      id="F_a0b18463-e345-432d-96f9-509105315b96"
      unitRef="U_shares">29347825</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_25c1a637-7cb1-4291-89c3-54a541318110"
      decimals="3"
      id="F_13d017c2-9573-47b7-a2a4-c0ecb0336eb4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.598</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_6147ead1-a934-40a0-954e-50f7ab4904e4"
      decimals="-5"
      id="F_a95b5160-241b-44e4-9a27-b49228b790a8"
      unitRef="U_USD">17500000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_03a67782-22aa-4a91-8ef4-d8c7202b8a6a"
      decimals="INF"
      id="F_ca2de50e-c691-4d97-8801-bd3ac4183664"
      unitRef="U_shares">836122</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_03a67782-22aa-4a91-8ef4-d8c7202b8a6a"
      decimals="3"
      id="F_7ad6dd3c-e15c-4013-b28f-4c456671b220"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.598</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_1fa28ee7-1e59-47ad-b9b0-95bb75660ed2"
      decimals="-5"
      id="F_79651330-728e-4e66-ad65-e635550fce25"
      unitRef="U_USD">500000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_4871c68a-70f7-4ee7-b7ae-3986b18102dc"
      decimals="INF"
      id="F_156b3ba1-46e6-4661-b561-e821c56f8653"
      unitRef="U_shares">49749167</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_4871c68a-70f7-4ee7-b7ae-3986b18102dc"
      decimals="3"
      id="F_d299181f-2145-47ca-8456-79cf6020eceb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.598</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_8128aaac-e7e6-4fa6-bac7-a3ac19d8ff0f"
      decimals="-5"
      id="F_d652697a-ddaf-432b-a5b9-63ab62affd9e"
      unitRef="U_USD">29800000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_f97bfb71-9b79-4c00-862c-5692b411f52b"
      decimals="INF"
      id="F_a26ce785-6808-42bf-be8e-856c9b9f09e9"
      unitRef="U_shares">78348461</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_f97bfb71-9b79-4c00-862c-5692b411f52b"
      decimals="4"
      id="F_87e21bf6-03bc-4593-a46d-fa94c4e1f276"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.8041</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_cef2ca29-eb4f-4af7-8d4a-cda3d18e4727"
      decimals="-5"
      id="F_6e31882e-aa25-4bb5-b523-c04db9cd011b"
      unitRef="U_USD">63000000.0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_cef2ca29-eb4f-4af7-8d4a-cda3d18e4727"
      decimals="-5"
      id="F_cbd60be1-f42d-4188-82e6-98c4562487ec"
      unitRef="U_USD">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_7db4cc42-112c-43d0-8092-a99672ba28cd"
      decimals="INF"
      id="F_1084915f-21d4-4b6b-8042-6ed9d2d7245a"
      unitRef="U_shares">77163022</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_7db4cc42-112c-43d0-8092-a99672ba28cd"
      decimals="4"
      id="F_3c956fca-130b-4a59-b69d-9742b6d9b986"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.2182</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_238fca8e-6dc3-4ea3-aa6d-7d316fa8ad10"
      decimals="-5"
      id="F_0ec0db8e-67d3-4591-bf39-23d5a1215f37"
      unitRef="U_USD">94000000.0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_238fca8e-6dc3-4ea3-aa6d-7d316fa8ad10"
      decimals="-5"
      id="F_3dfbc269-1613-46d3-b64d-bea0360a2ec8"
      unitRef="U_USD">200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_140060dd-8e0c-44a2-9769-d8ce6de4ed4b"
      decimals="INF"
      id="F_6ba87b7b-9bf3-4346-8c8d-9faac914bf50"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_d25de583-668f-4235-b7a0-421690a06540"
      decimals="INF"
      id="F_d045bdeb-8ae2-4e91-a81a-0b13aa7a435b"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_d25de583-668f-4235-b7a0-421690a06540"
      decimals="3"
      id="F_57e79717-89fc-42b2-b46d-222c8e483a9a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_892a0591-a196-401b-abe3-20fff82d78ec"
      decimals="INF"
      id="F_99c1bafb-bb91-4781-bee7-cb4a46db6ff3"
      unitRef="U_shares">16141157</us-gaap:CommonStockSharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_91c2bb60-3204-485e-91bc-fcd6e061eaf0"
      decimals="INF"
      id="F_658222b5-6fea-4e9c-9b75-908029eba4ea"
      unitRef="U_shares">2105368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <verv:PublicPrice
      contextRef="C_94dd9299-01a2-4f67-9f44-7bbd116cd6f9"
      decimals="INF"
      id="F_2edbaf6f-8bde-47bb-adcc-538189e19496"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.00</verv:PublicPrice>
    <verv:ProceedsFromIssuanceOfCommonStockUnderIPOGross
      contextRef="C_91c2bb60-3204-485e-91bc-fcd6e061eaf0"
      decimals="-5"
      id="F_18bed447-d711-484d-bf1c-8133d30d50d6"
      unitRef="U_USD">306700000</verv:ProceedsFromIssuanceOfCommonStockUnderIPOGross>
    <verv:ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses
      contextRef="C_6318768f-6910-4cea-8012-84a1cded066e"
      decimals="-5"
      id="F_079a43e8-dc12-43f2-a39d-94d29e019016"
      unitRef="U_USD">281600000</verv:ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_5758acaf-19d3-46c4-a26d-234bb9c7e3a1"
      decimals="INF"
      id="F_f36bd0b2-11b1-4941-9972-1831166690ba"
      unitRef="U_shares">27720923</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_ef58d5a4-7912-466b-bc19-b009959eba29"
      decimals="INF"
      id="F_d08efe5f-0899-4aa6-91d6-02a91f29906f"
      unitRef="U_shares">878098</us-gaap:CommonStockSharesIssued>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_5d3d7d34-c7cc-4c96-b25a-f8a25257ef0e">Each share of Series A Preferred, Series A-2 Preferred and Series B Preferred may be converted at any time, at the option of the holder, into shares of common stock, subject to the applicable conversion rate as determined by dividing the original issue price by the conversion price. The initial conversion price for each of the Series A Preferred, Series A-2 Preferred and Series B Preferred (each as may be adjusted for certain dilutive events) was $0.598, $0.8041 and $1.2182 per share, respectively. Each series of Series A Preferred, Series A-2 Preferred and Series B Preferred automatically converted into shares of common stock on a 1:1 conversion ratio (as may be adjusted for certain dilutive events) at the earlier of the closing of an initial public offering of the Company&#x2019;s common stock with gross proceeds to the Company of at least $50.0 million and a purchase price of $22.34 per share, or at the election of the holders of at least two-thirds of the then-outstanding shares of Preferred Stock.</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="C_249fda00-bd80-4288-a41d-c1199d73ce90"
      decimals="3"
      id="F_71bcb644-3869-4989-a2f5-0dfe72ee64dd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.598</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="C_f9897674-e8be-4c3a-a297-cb53a9538487"
      decimals="4"
      id="F_f2a80fdf-280e-413a-b6c7-ffb216e11bca"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.8041</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="C_a9ee4883-4610-4244-845a-4be4346c5921"
      decimals="4"
      id="F_cde30a73-17b2-4602-a89b-17b3e10eff39"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.2182</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_53ef7791-90d1-4f91-a9c9-7449eead72a4"
      decimals="-5"
      id="F_47a81eec-25fc-4db2-8391-06d12f204526"
      unitRef="U_USD">50000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="2"
      id="F_3822b655-c693-424a-a759-694a713de5a2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.34</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="C_249fda00-bd80-4288-a41d-c1199d73ce90"
      decimals="2"
      id="F_5e10f418-cad0-4ad1-86b5-83845c15659f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.05</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="C_f9897674-e8be-4c3a-a297-cb53a9538487"
      decimals="2"
      id="F_bba0b59a-8467-41af-a623-28db8773e736"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.06</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="C_a9ee4883-4610-4244-845a-4be4346c5921"
      decimals="2"
      id="F_85bc7696-3653-479d-b33c-055d159ee8d3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.10</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_f4703c94-e43f-49b9-a8a6-80ba7c39c6c6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;11. Stock-based compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2018 Equity Incentive Plan, or the 2018 Plan, adopted by the board of directors in August 2018 provided for the grant of qualified incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock and restricted stock units to the Company&#x2019;s employees, officers, directors, advisors, and outside consultants&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;for &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;the issuance or purchase of shares of the Company&#x2019;s common stock. The maximum number of shares of common stock that were authorized for issuance under the 2018 Plan was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,885,653&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In June 2021, the Company's board of directors adopted, and the Company's stockholders approved, the 2021 Stock Incentive Plan, or the 2021 Plan, which became effective on June 16, 2021. The 2021 Plan provides for grant of qualified and nonqualified stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, and other share-based awards to the Company's employees, directors, advisors and outside consultants. Under the 2021 Plan, the number of shares of common stock that was initially reserved for issuance under the 2021 Plan was the sum of: (1) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,466,530&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;; plus (2) the number of shares as is equal to the sum of (x) the number of shares of common stock reserved for issuance under the 2018 Plan that remained available for grant under the 2018 Plan on June 16, 2021 and (y) the number of shares of common stock subject to outstanding awards granted under the 2018 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;an annual increase, to be added on the first day of each fiscal year, commencing on January 1, 2022 and continuing until, and including, January 1, 2031, equal to the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% of the number of shares of common stock outstanding on such date&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and (ii) the number of shares of common stock determined by the Company's board of directors. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021 the Company had reserved&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,632,042&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of the Company's common stock for issuance of stock options and restricted stock, of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,489,589&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; remained outstanding for future grant under the 2021 Plan. On January 1, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,425,587&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of the Company's common stock were added to the amount reserved for issuance under the 2021 Plan in accordance with the 2021 Plan described above. Upon effectiveness of the 2021 Plan, the Company ceased granting additional awards under the 2018 Plan.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Stock-based compensation expense recorded in the consolidated statements of operations and comprehensive loss is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.764%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:10.903%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:10.874%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:10.874%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Year ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Stock options&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The assumptions used in Black-Scholes for stock options granted were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.355%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:0.715%;"/&gt;
        &lt;td style="width:10.166%;"/&gt;
        &lt;td style="width:2.296%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:0.715%;"/&gt;
        &lt;td style="width:10.166%;"/&gt;
        &lt;td style="width:2.296%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:0.715%;"/&gt;
        &lt;td style="width:10.166%;"/&gt;
        &lt;td style="width:2.296%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Year ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;77.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;84.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;76.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Weighted-average risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following table provides a summary of stock option activity during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.065%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:9.89%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:10.764%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:0.726%;"/&gt;
        &lt;td style="width:11.42%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:10.824%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Number of&lt;br/&gt;options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price per&lt;br/&gt;share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Arial;position:relative;"&gt;(2)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,888,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,869,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;599,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;39,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,119,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;171,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,373,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;47,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Expected to vest after December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Arial;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,745,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;11.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;123,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;"&gt;This represents the number of unvested options outstanding as of December 31, 2021 that are expected to vest in the future.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;"&gt;(2)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December 31, 2021.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;During the year ended December 31, 2021 the weighted average grant-date fair value of the stock options granted &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;14.27&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The aggregate intrinsic value of stock options exercised during the year ended December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;11.6&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million while the Company received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in proceeds for the exercise of these options.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, there was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;40.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Restricted stock and restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In 2018, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,150,537&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of restricted common stock. The restricted shares vested in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;48&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; equal monthly installments, commencing on January 1, 2018. The restricted shares were fully vested as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;A summary of the status of and change in unvested restricted stock as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021 was as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.822%;"/&gt;
        &lt;td style="width:1.581%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:13.391%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
        &lt;td style="width:1.074%;"/&gt;
        &lt;td style="width:1.591%;"/&gt;
        &lt;td style="width:0.726%;"/&gt;
        &lt;td style="width:13.52%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Weighted-&lt;br/&gt;average grant&lt;br/&gt;date fair&lt;br/&gt;value per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Unvested restricted stock as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;537,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Restricted stock vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;537,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Unvested restricted stock as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;During the year ended December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, the Company granted &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; restricted stock units under the 2021 Plan. These restricted stock units vest in substantially equal installments over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;A summary of the status of and change in unvested restricted stock units as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021 was as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.398%;"/&gt;
        &lt;td style="width:1.59%;"/&gt;
        &lt;td style="width:0.726%;"/&gt;
        &lt;td style="width:13.4%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:1.054%;"/&gt;
        &lt;td style="width:2.256%;"/&gt;
        &lt;td style="width:0.726%;"/&gt;
        &lt;td style="width:13.419%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Weighted-&lt;br/&gt;average grant&lt;br/&gt;date fair&lt;br/&gt;value per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Unvested restricted stock units as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Restricted stock units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;36.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Unvested restricted stock units as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;36.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;At December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, there was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million of unrecognized stock-based compensation expense related to restricted stock units that are expected to vest. These costs are expected to be recognized over a weighted-average remaining vesting period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4.0&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;2021 Amended and Restated Employee Stock Purchase Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In June 2021, the board of directors adopted, and the Company's stockholders approved, the 2021 Employee Stock Purchase Plan, or the ESPP, as amended and restated, which became effective on June 16, 2021. The Company has initially reserved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;433,316&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of common stock for sale under the ESPP. The aggregate number of shares reserved for sale under the ESPP will increase automatically on the first day of each fiscal year commencing on January 1, 2022 through January 1, 2031, by the number of shares equal to the least of (a) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,083,290&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares, (b) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% of the total outstanding shares of common stock on such date, and (c) a number of shares as may be determined by the board of directors in any particular year. The first offering period under the ESPP commenced on June 16, 2021 and ended on December 13, 2021. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;48,297&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares had been purchased by employees under the ESPP and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;385,019&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares remained available for issuance under the ESPP. On January 1, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;485,117&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of common stock were added to the amount reserved for sale under the ESPP. The second offering period commenced on December 14, 2021 and will end on May 31, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_676f07bf-c94c-4783-88ad-393a30ab16eb"
      decimals="INF"
      id="F_ba56e261-27d6-4c16-97e3-5c6306860efb"
      unitRef="U_shares">6885653</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_371af29c-852e-4e21-b3b0-7a743ce9c595"
      decimals="INF"
      id="F_3a4ac815-d0c9-4207-a1ad-a293f97880fb"
      unitRef="U_shares">3466530</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_0a65eb8e-9c85-4a38-b989-299e4aceb2c2"
      id="F_b2e7184e-696b-4327-b998-4968ee01cc0d">an annual increase, to be added on the first day of each fiscal year, commencing on January 1, 2022 and continuing until, and including, January 1, 2031, equal to the lesser of (i) 5% of the number of shares of common stock outstanding on such date</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_46b3a3b3-5e47-4d6e-bbdd-cf18cb6fea59"
      decimals="2"
      id="F_1ae185e7-d6fb-4948-954d-aa69e90987f4"
      unitRef="U_pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="0"
      id="F_9a7571b3-0496-453b-9638-e47e4148616e"
      unitRef="U_shares">4632042</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_9a295b66-ffd1-4f8f-9e1a-8acda5aafa35"
      decimals="INF"
      id="F_b2db3e81-3572-4fa8-811a-e149e962c681"
      unitRef="U_shares">3489589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f674fccd-11fb-4942-800b-db52e4338c03"
      decimals="0"
      id="F_75a96bcb-c0d3-4b16-9891-03f39d618419"
      unitRef="U_shares">2425587</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_3ef679e6-9294-4840-a01c-5639b6e38086">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Stock-based compensation expense recorded in the consolidated statements of operations and comprehensive loss is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.764%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:10.903%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:10.874%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:10.874%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Year ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c672a00b-7f2c-4ee3-878b-42ff6ea68467"
      decimals="-3"
      id="F_adcbad96-11a4-43f4-8806-f65ba2c646a0"
      unitRef="U_USD">3830000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b5c31764-a8fd-4905-a067-8962ee2846e9"
      decimals="-3"
      id="F_b5fdb866-2c1f-4b03-b990-a162c704d70c"
      unitRef="U_USD">494000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5a7068fa-0013-401d-b7c4-675485fce3a2"
      decimals="-3"
      id="F_1d44e08a-1f35-4b14-b7cc-5fb2551a5c94"
      unitRef="U_USD">336000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9a01908a-58f3-4cbb-a2c9-d102afa07909"
      decimals="-3"
      id="F_43ab446d-ebf3-4957-bbba-6d5a41506f66"
      unitRef="U_USD">3242000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5fed7261-bc42-45e4-aa7b-b1860010cd80"
      decimals="-3"
      id="F_ac3c5e6d-635a-4143-a5cf-40b794799753"
      unitRef="U_USD">356000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0c8d563c-b4ce-43e3-aa5e-0284d836e33c"
      decimals="-3"
      id="F_fd0be8aa-3b32-42cc-9309-ffea10d8c579"
      unitRef="U_USD">110000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_b86ac30c-a7e0-493e-9bff-41f6edc50e22"
      unitRef="U_USD">7072000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_a32f90eb-489e-4070-b36f-00f8edc46c5d"
      unitRef="U_USD">850000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_a9228411-d465-4136-beb0-12af45951877"
      unitRef="U_USD">446000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_e8bb2a2c-fbde-4b33-a534-01d405e7bfd0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The assumptions used in Black-Scholes for stock options granted were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.355%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:0.715%;"/&gt;
        &lt;td style="width:10.166%;"/&gt;
        &lt;td style="width:2.296%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:0.715%;"/&gt;
        &lt;td style="width:10.166%;"/&gt;
        &lt;td style="width:2.296%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:0.715%;"/&gt;
        &lt;td style="width:10.166%;"/&gt;
        &lt;td style="width:2.296%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Year ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;77.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;84.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;76.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Weighted-average risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="3"
      id="F_a10c39a6-c39a-4ce6-8ef4-0bb8d954988b"
      unitRef="U_pure">0.777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="3"
      id="F_ebf164b6-35b6-4392-8ab9-1d11532bee4e"
      unitRef="U_pure">0.848</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="3"
      id="F_9b3caba3-9966-4b6a-9b5f-5878ddc9406f"
      unitRef="U_pure">0.761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="3"
      id="F_a3e0c520-401f-4c0f-89fa-9a2ac8dae0a7"
      unitRef="U_pure">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="3"
      id="F_84126fe0-6eac-419a-839b-3988eade2d00"
      unitRef="U_pure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="3"
      id="F_6a16f510-8b91-4310-a833-d69e5aaeb8a8"
      unitRef="U_pure">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="2"
      id="F_239d6154-5337-467d-8a84-993b7de8d071"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_b358f697-4f34-4f90-a294-d045fc51169c">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      id="F_dc98141a-6906-44e0-852c-c3b1b71f8799">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      id="F_8c7bed02-c541-4897-8ce2-dc403a873684">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_bc6910a5-0098-49fc-bf8c-2266e58b7440">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following table provides a summary of stock option activity during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.065%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:9.89%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:10.764%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:0.726%;"/&gt;
        &lt;td style="width:11.42%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.431%;"/&gt;
        &lt;td style="width:10.824%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Number of&lt;br/&gt;options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price per&lt;br/&gt;share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Arial;position:relative;"&gt;(2)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,888,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,869,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;599,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;39,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,119,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;171,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,373,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;47,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Expected to vest after December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Arial;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,745,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;11.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;123,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;"&gt;This represents the number of unvested options outstanding as of December 31, 2021 that are expected to vest in the future.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;"&gt;(2)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December 31, 2021.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="INF"
      id="F_36c52a92-fe3f-4e31-a7f4-eaf8aadd3c6b"
      unitRef="U_shares">3888823</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="2"
      id="F_c2ca0420-1e65-411d-b5f6-a11509b8b0ad"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="INF"
      id="F_326944c6-9a95-4cc1-8cd1-e6a612441e82"
      unitRef="U_shares">2869946</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="2"
      id="F_85e91e23-01e9-4c64-8622-527dc7eebc6c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="INF"
      id="F_0c8fce59-4a93-4f07-9dd9-01eae39edabf"
      unitRef="U_shares">599838</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="2"
      id="F_97433d14-4eea-410b-9109-0bdcc89ffd60"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="INF"
      id="F_365d50c4-a096-41cd-b697-ce1874cb5fcc"
      unitRef="U_shares">39636</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="2"
      id="F_c4852a30-be12-4edc-ba3f-79dcc781826e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="INF"
      id="F_c6d40844-0db0-46ec-a921-b089d37f5a53"
      unitRef="U_shares">6119295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="2"
      id="F_186c7d48-063e-4e0e-b407-3e010bb2e30c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_192a5ed0-9732-43ed-84ca-cd785b6bec3c">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_09c816c2-1e12-4899-9ecf-678b1a4962d0"
      unitRef="U_USD">171636000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="INF"
      id="F_89602f64-2d34-40cf-9722-1ddc9969c917"
      unitRef="U_shares">1373507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="2"
      id="F_a49ee9f4-2f4a-4491-b702-49e05680ec76"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_e6387850-21a9-4ed0-b9ba-04e93ab12e1b">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_24230ffe-ae0b-4bb2-ad26-32083b8b57ec"
      unitRef="U_USD">47691000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="INF"
      id="F_fe0539bc-5d0e-4e16-bca5-d18ebbbf88c5"
      unitRef="U_shares">4745788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="2"
      id="F_9802e87b-b16a-46c7-b5ca-97ffa81f49a2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_efe98daf-06cf-42fb-80d8-de37d0ecc08f">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_07bb18eb-0554-426b-b84f-e1ce1d9e124f"
      unitRef="U_USD">123945000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_24a4dfda-a75a-45db-8bd3-e0d4bcac39a6"
      decimals="2"
      id="F_0487af77-e35b-4faf-8c04-606e24350be4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_24a4dfda-a75a-45db-8bd3-e0d4bcac39a6"
      decimals="-5"
      id="F_bea329c8-d720-4db1-841c-17458b9cc085"
      unitRef="U_USD">11600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_24a4dfda-a75a-45db-8bd3-e0d4bcac39a6"
      decimals="-5"
      id="F_544e9a0e-36f1-4c17-a1da-017a2790d6cb"
      unitRef="U_USD">1000000.0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_6e65181b-d50d-473b-a928-4dbc316e780c"
      decimals="-5"
      id="F_3b118a4a-d003-497d-8559-fe023db52b69"
      unitRef="U_USD">40200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_24a4dfda-a75a-45db-8bd3-e0d4bcac39a6"
      id="F_a114c795-a02b-4554-9790-d9e9143fa8a6">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_56d972ec-31cc-4208-aa1d-caae39e63a9b"
      decimals="INF"
      id="F_67ce94d1-94e6-42db-a22c-583f1ae9cb3d"
      unitRef="U_shares">2150537</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <verv:NumberOfInstallmentsForRestrictedSharesVested
      contextRef="C_ea995c0d-ad65-44c4-b2b7-9fa84f6854c0"
      decimals="INF"
      id="F_3fff03ca-ac44-4e11-96a9-acabd5773455"
      unitRef="U_Instalment">48</verv:NumberOfInstallmentsForRestrictedSharesVested>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_dd7076fd-599e-4f38-9420-955001da0f62">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;A summary of the status of and change in unvested restricted stock as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021 was as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.822%;"/&gt;
        &lt;td style="width:1.581%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:13.391%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
        &lt;td style="width:1.074%;"/&gt;
        &lt;td style="width:1.591%;"/&gt;
        &lt;td style="width:0.726%;"/&gt;
        &lt;td style="width:13.52%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Weighted-&lt;br/&gt;average grant&lt;br/&gt;date fair&lt;br/&gt;value per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Unvested restricted stock as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;537,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Restricted stock vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;537,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Unvested restricted stock as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;A summary of the status of and change in unvested restricted stock units as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021 was as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.398%;"/&gt;
        &lt;td style="width:1.59%;"/&gt;
        &lt;td style="width:0.726%;"/&gt;
        &lt;td style="width:13.4%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:1.054%;"/&gt;
        &lt;td style="width:2.256%;"/&gt;
        &lt;td style="width:0.726%;"/&gt;
        &lt;td style="width:13.419%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Weighted-&lt;br/&gt;average grant&lt;br/&gt;date fair&lt;br/&gt;value per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Unvested restricted stock units as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Restricted stock units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;36.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Unvested restricted stock units as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;36.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_59fe6e15-fa1d-432e-b68b-41815233efa2"
      decimals="INF"
      id="F_8e0d8b09-a4c1-4c1c-bba8-2b52c68608c7"
      unitRef="U_shares">537633</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_59fe6e15-fa1d-432e-b68b-41815233efa2"
      decimals="4"
      id="F_1f874851-1af9-4724-9659-391e104b1975"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0a65eb8e-9c85-4a38-b989-299e4aceb2c2"
      decimals="INF"
      id="F_4b14195d-6675-4d4f-89f9-08c067d1220c"
      unitRef="U_shares">537633</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0a65eb8e-9c85-4a38-b989-299e4aceb2c2"
      decimals="4"
      id="F_43065d67-17c3-4692-936b-b1e37429e220"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_9a295b66-ffd1-4f8f-9e1a-8acda5aafa35"
      decimals="INF"
      id="F_f3f79f13-f129-4b3f-866a-2accf5e10696"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_9a295b66-ffd1-4f8f-9e1a-8acda5aafa35"
      decimals="0"
      id="F_9ba3f93d-7924-49c6-b8ff-c0297b827790"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_38d1bdab-4490-418c-9908-c0fd520a968b"
      decimals="INF"
      id="F_8b0c168b-0361-4072-9c21-8e2095342467"
      unitRef="U_shares">32000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_8d26e837-c809-4998-bfb7-aca676d66949"
      id="F_2206cbd7-5b12-42b5-afc4-d9ccb9f45e5d">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_900eaaf9-9f36-4773-beee-ac7b0f139194"
      decimals="INF"
      id="F_c87441b3-e768-4ba0-8820-ac7574ac3283"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_900eaaf9-9f36-4773-beee-ac7b0f139194"
      decimals="0"
      id="F_9d57bf28-415d-4868-a65f-75627304e514"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_ea995c0d-ad65-44c4-b2b7-9fa84f6854c0"
      decimals="INF"
      id="F_69759b24-e073-4323-8bb6-dd278cbbd534"
      unitRef="U_shares">32000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_ea995c0d-ad65-44c4-b2b7-9fa84f6854c0"
      decimals="2"
      id="F_43219033-75b2-4460-b41b-1c4a1a9013fd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">36.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_86c2f76f-8f40-41c6-a1f0-570a5a905595"
      decimals="INF"
      id="F_83e60bad-8ca9-4b94-9319-e997f7a52a82"
      unitRef="U_shares">32000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_86c2f76f-8f40-41c6-a1f0-570a5a905595"
      decimals="2"
      id="F_b392c775-8c55-481f-87b0-15d61a289144"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">36.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_86c2f76f-8f40-41c6-a1f0-570a5a905595"
      decimals="-5"
      id="F_e62fd7a7-f51f-4230-a9bc-6b059d6a3df4"
      unitRef="U_USD">1100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_ea995c0d-ad65-44c4-b2b7-9fa84f6854c0"
      id="F_274116ac-b6c9-454a-95a9-ee113ea83652">P4Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a47c1a5e-5ed1-4aff-9633-a0341b906481"
      decimals="0"
      id="F_c322f56d-2d65-4653-a55b-5b6f4884eabf"
      unitRef="U_shares">433316</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <verv:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a5a771bf-09d6-4a35-b7ac-216b653bc10f"
      decimals="0"
      id="F_4ccffba4-654c-45b6-ab94-cdefd9a05466"
      unitRef="U_shares">1083290</verv:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_dd92968d-2cf3-45c1-b345-bc554cadcd11"
      decimals="2"
      id="F_f73a9d4c-592b-4e4d-a936-0c67e84d52d8"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_27017e45-4a76-45b0-84c2-5942f0fdfb77"
      decimals="INF"
      id="F_71d5853a-b731-4e3b-ae16-e9036af83b48"
      unitRef="U_shares">48297</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <verv:StockAvailableForIssuanceUnderEmployeeStockPurchasePlan
      contextRef="C_27017e45-4a76-45b0-84c2-5942f0fdfb77"
      decimals="0"
      id="F_48401614-09f1-4a30-8056-1910f35fb333"
      unitRef="U_shares">385019</verv:StockAvailableForIssuanceUnderEmployeeStockPurchasePlan>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f15881ae-e851-43f0-9443-9c9364fbebc0"
      decimals="INF"
      id="F_8250da12-40b0-4359-b655-e35d70a00628"
      unitRef="U_shares">485117</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_6a616277-fd97-4d1c-9c54-f2a712f5cef1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;12. Net loss per share attributable to common stockholders&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.457%;"/&gt;
        &lt;td style="width:1.372%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:10.876%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.372%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:10.846%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.372%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:10.846%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands, except share and per share amounts)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;120,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;45,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;19,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Weighted average number of common shares, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;26,872,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,250,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,277,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Net loss per common share attributable to common stockholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;20.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;15.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s potential dilutive securities, which include convertible preferred stock, unvested restricted stock and common stock options, have been excluded from the computation of diluted net loss per share as the effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.859%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:11.561%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:11.581%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:11.561%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;19,387,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,553,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;537,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,075,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Outstanding options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,119,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,888,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,933,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,151,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;23,814,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,562,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As part of the license agreements with Harvard and Broad, the Company is required to make success payments. The Company may elect to make these payments by issuing shares of the Company's common stock. As of December 31, 2021, an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million was earned relating to these success payments, which the Company settled in cash in November 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_d1615e06-d89d-48dc-99d7-bc658619a0c5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.457%;"/&gt;
        &lt;td style="width:1.372%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:10.876%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.372%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:10.846%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.372%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:10.846%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands, except share and per share amounts)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;120,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;45,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;19,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Weighted average number of common shares, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;26,872,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,250,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,277,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Net loss per common share attributable to common stockholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;20.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;15.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-3"
      id="F_f37ea9e1-fc27-4fcf-ae54-a951d3c812a5"
      unitRef="U_USD">-120314000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-3"
      id="F_609abdaa-4608-4915-ae63-fdcf5340e93a"
      unitRef="U_USD">-45704000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-3"
      id="F_8e06e190-8624-4d3a-bf7a-7a8be0b52fd5"
      unitRef="U_USD">-19297000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="INF"
      id="F_aa16b399-b353-4598-bc91-3bf1fde1f279"
      unitRef="U_shares">26872036</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="INF"
      id="F_7059016c-5f4f-43a5-a6ee-dbba6bdd857b"
      unitRef="U_shares">2250093</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="INF"
      id="F_7921951d-20b9-4779-931b-e3985faca3b1"
      unitRef="U_shares">1277156</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="2"
      id="F_1023d135-8612-409f-9a54-41da3750be01"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-4.48</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="2"
      id="F_121c4c39-cec6-4323-b9b6-8c111c8a1978"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-20.31</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="2"
      id="F_70ad09f5-d1d8-4abe-8c60-00780b3e69fd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-15.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_fce58d0c-072e-401a-98e9-0026e05dc38d">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.859%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:11.561%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:11.581%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:11.561%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;19,387,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,553,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;537,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,075,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Outstanding options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,119,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,888,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,933,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,151,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;23,814,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,562,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a8085576-61b7-454c-a519-9ae96812318a"
      decimals="INF"
      id="F_5c52fad8-e806-403c-92f0-5284d3a786de"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5cba4e1e-72af-462f-b037-4423f24b01af"
      decimals="INF"
      id="F_454ee4d7-d33b-4606-a664-6efb2a96bbc1"
      unitRef="U_shares">19387544</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b94a23b8-43bb-4383-a20f-d50aa1e8c3b4"
      decimals="0"
      id="F_47d0a3dd-68ef-417d-8c37-a786a9cea615"
      unitRef="U_shares">5553367</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bcc73401-287e-4ac0-a87f-a7584a3ebe73"
      decimals="INF"
      id="F_dd8d2162-ff6b-4998-b7d5-e9a557ff35ab"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8deec1cb-9d18-458c-80a6-69065b7fd6e1"
      decimals="INF"
      id="F_a07401b8-cde7-4647-85f0-369c314f2d80"
      unitRef="U_shares">537633</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2dcf3819-ab63-4939-86b0-10870a857990"
      decimals="0"
      id="F_59d4d106-1557-4c77-8cf1-2da63ec02860"
      unitRef="U_shares">1075268</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7c5380ff-43e4-4da6-9d3d-4f142569329f"
      decimals="INF"
      id="F_d348a3de-e167-4cae-aa20-2abac1dc85d0"
      unitRef="U_shares">32000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f5f342f9-12eb-4269-ba58-fc8d87544ebf"
      decimals="INF"
      id="F_c26e616d-f170-4f2f-9b75-e1455c0e92cc"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1afabfe3-8755-45d0-ac91-81a3418d2248"
      decimals="0"
      id="F_12373f35-c7e9-419e-8cda-a7a6ca8830d2"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e08bb552-0254-44e1-ada0-095671a76529"
      decimals="INF"
      id="F_2fe1e96b-f55e-4f1b-adee-6407b07e9449"
      unitRef="U_shares">6119295</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_17fbf683-2a55-4bef-952f-f0d1c18ff75d"
      decimals="INF"
      id="F_4cddf9a8-c6ed-4c11-8ef7-e5dddffe6ba5"
      unitRef="U_shares">3888823</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f7f9ed07-4a59-4247-ad5a-a6b36bcb98c2"
      decimals="0"
      id="F_232b78c2-cc73-469d-9acf-f89e09a44bc0"
      unitRef="U_shares">1933507</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="0"
      id="F_4663e26b-f2eb-44a2-bedd-8ef351b30f4a"
      unitRef="U_shares">6151295</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="0"
      id="F_360eb3c2-e99e-4fd0-8d2e-c98b431dead6"
      unitRef="U_shares">23814000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="0"
      id="F_4202c421-f864-4cab-872f-0348c0251a5e"
      unitRef="U_shares">8562142</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <verv:SuccessPaymentLiability
      contextRef="C_1a988b86-2da6-44fb-8d8b-025bc3040bcb"
      decimals="-5"
      id="F_2f1ebbf5-b40e-4eee-ad6c-5b46a2a98157"
      unitRef="U_USD">6300000</verv:SuccessPaymentLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_b26d7591-4c66-4678-8f20-6abfd099108b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;13. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;For the years ended December 31, 2021, 2020 and 2019, the Company did not record a current or deferred income tax expense or benefit due to current and historical losses incurred by the Company. The Company&#x2019;s losses before income taxes consist solely of losses from domestic operations, which totaled &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;120.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;45.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;19.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; for the years ended December 31, 2021, 2020 and 2019, respectively&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.103%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:9.423%;"/&gt;
        &lt;td style="width:3.141%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:9.423%;"/&gt;
        &lt;td style="width:3.141%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:9.423%;"/&gt;
        &lt;td style="width:3.141%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;31.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;29.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Executive compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Other permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#x2019;s deferred tax assets and liabilities as of December 31, 2021 and 2020 are comprised of the following&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.358%;"/&gt;
        &lt;td style="width:1.601%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:12.924%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
        &lt;td style="width:1.601%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:12.924%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;33,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Capitalized costs&#x2014;net of amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Antidilution liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_0691f387-dd9a-4985-8c9a-0c01efabf653;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;56,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;18,440&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_20d4266c-6aad-4cbb-ab46-faac5900b5d5;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total deferred tax assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;55,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;55,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company has incurred net operating losses in each year since inception. The Company had no income tax expense due to the operating loss incurred for all years since inception. Management has evaluated the positive and negative evidence bearing upon the realizability of the Company&#x2019;s net deferred tax assets, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;which are comprised primarily of net operating loss carryforwards, tax credits, and costs capitalized for tax purposes. Management has considered the Company&#x2019;s history of cumulative net losses in the United States and estimated future tax losses and&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; has determined that it is more likely than not that the Company will not recognize the benefits of the net deferred tax assets. As a result, the Company has recorded a full valuation allowance at December 31, 2021 and 2020. The valuation allowance increased by &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;37.7&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; in 2021&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, due to the increase in deferred tax assets, primarily due to net operating loss carryforwards, tax credit carryforwards, and increase in deferred tax assets associated with current year temporary items. The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;13.6&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in 2020, primarily due to the increase in deferred tax assets, primarily due to net operating loss carryforwards.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Realization of the future tax benefits is dependent on many factors, including the Company&#x2019;s ability to generate taxable income within the net operating loss carryforward period. The Company&#x2019;s ability to utilize these federal and state net operating loss and research and development credit carryforwards may be limited in the future if the Company experiences an ownership change pursuant to Internal Revenue Code 382. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;An ownership change occurs when the ownership percentages of 5% or greater shareholders change by more than 50% over a three-year period.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; As of &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021, the Company has not completed a study to assess whether a change of control has occurred and whether the net operating losses and credits are limited due to a change in ownership. To the extent that an assessment is completed in the future, the Company&#x2019;s ability to utilize tax attributes could be restricted on a year-by-year basis and certain attributes could expire before they are utilized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, the Company had approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;124.7&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million of pre-tax federal and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;114.4&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million of pre-tax state net operating loss carryforwards. The federal net operating losses have an indefinite life and can be utilized to offset &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;80&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% of future taxable income, while the state net operating losses will start to expire at various dates through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2041&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. Additionally, as of &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, the Company had approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4.2&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million of federal and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million of Massachusetts tax credits that expire starting in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2041&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As of December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; uncertain tax positions. The Company recognizes both interest and penalties associated with unrecognized tax benefits as a component of income tax expense. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;t recorded any interest or penalties for unrecognized tax benefits since its inception.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Company files income tax returns in the United States, California, Connecticut, the Commonwealth of Massachusetts, and Pennsylvania. The Company is not currently under examination by the Internal Revenue Service or any other jurisdiction for these years. All tax years remain open to tax examination. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may be adjusted&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;upon &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. No federal or state tax audits are currently in process.&lt;/span&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-5"
      id="F_028e5041-d564-47e0-8a9f-8006adf26baf"
      unitRef="U_USD">120300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-5"
      id="F_a5cffae1-0b02-4464-8333-0083b8040933"
      unitRef="U_USD">45700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-5"
      id="F_735f3462-e4b9-4644-9e52-a8eb64d7a562"
      unitRef="U_USD">19300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_86c6daa9-b1f1-4f74-9636-2a332691304d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.103%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:9.423%;"/&gt;
        &lt;td style="width:3.141%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:9.423%;"/&gt;
        &lt;td style="width:3.141%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:9.423%;"/&gt;
        &lt;td style="width:3.141%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;31.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;29.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Executive compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Other permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="3"
      id="F_9835d11d-39cb-4eac-8667-1eb37dc5dde5"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="3"
      id="F_3c1f5118-3011-4108-bdb5-3c3c854fbc1b"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="3"
      id="F_31db19ae-7651-4b2c-9432-7b6dca4dad3f"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="3"
      id="F_e23b4ef9-e36f-406a-81ce-b2ba0f6fa988"
      unitRef="U_pure">-0.313</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="3"
      id="F_48bfc8db-c7aa-4b2b-b99b-bdb9c0fb57e0"
      unitRef="U_pure">-0.296</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="3"
      id="F_2d628ce9-5391-4c33-903a-018173155852"
      unitRef="U_pure">-0.179</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="3"
      id="F_1bcd8a60-f0db-4241-ad64-325de4199652"
      unitRef="U_pure">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="3"
      id="F_8814cbcb-a21d-453b-ad56-8fc3141caf24"
      unitRef="U_pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="3"
      id="F_c7979a97-a557-48b8-909a-beb808af5eef"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <verv:EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="3"
      id="F_3d42fa6a-57ca-4e36-a119-75097ca9b06c"
      unitRef="U_pure">-0.011</verv:EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent>
    <verv:EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="3"
      id="F_fa94be69-f7dd-4e69-8b47-90970e26bcb8"
      unitRef="U_pure">0.000</verv:EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent>
    <verv:EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="3"
      id="F_6c80ffe3-a577-4787-bba6-4e5288482a6a"
      unitRef="U_pure">0.000</verv:EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent>
    <verv:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="3"
      id="F_a0c33bbd-4afb-4ecc-b197-bec1cf24dc0f"
      unitRef="U_pure">-0.001</verv:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <verv:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="3"
      id="F_cb01735d-e42b-4afb-b7d1-89c04eafef3c"
      unitRef="U_pure">0.011</verv:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <verv:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="3"
      id="F_7e0c0195-60c6-4391-8e42-22825ee7e0b1"
      unitRef="U_pure">-0.058</verv:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="3"
      id="F_ba33de10-1d96-4489-9d3a-b218de31512d"
      unitRef="U_pure">0.061</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="3"
      id="F_848769ed-071d-4e63-bf6e-78570abc5740"
      unitRef="U_pure">0.068</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="3"
      id="F_dc3218cc-1be2-4957-94ee-78d942d70793"
      unitRef="U_pure">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="3"
      id="F_e9677d75-9b79-4547-b53d-4803763490ab"
      unitRef="U_pure">0.045</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="3"
      id="F_2b3ed054-1002-4e3a-ac13-00f5525160c1"
      unitRef="U_pure">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="3"
      id="F_92cd8719-abe3-4150-b94a-169af3276b28"
      unitRef="U_pure">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="2"
      id="F_db34497c-ec0f-4b75-9d4f-35ff6c6b6cb9"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="2"
      id="F_de1d9603-ebc9-4f08-9a99-c599e3e65a80"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="2"
      id="F_6806beaf-8616-407f-b7f0-09632014c229"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_62aabbff-d5ef-4a46-b2b9-ff9bf50ebe31">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.358%;"/&gt;
        &lt;td style="width:1.601%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:12.924%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
        &lt;td style="width:1.601%;"/&gt;
        &lt;td style="width:1.432%;"/&gt;
        &lt;td style="width:12.924%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.250pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;33,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Capitalized costs&#x2014;net of amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Antidilution liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_0691f387-dd9a-4985-8c9a-0c01efabf653;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;56,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;18,440&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_20d4266c-6aad-4cbb-ab46-faac5900b5d5;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total deferred tax assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;55,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;55,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_cf431f61-0424-457c-8440-861d12534c1d"
      unitRef="U_USD">33409000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_f17cba29-3d11-4d07-8389-e911f8c1fffa"
      unitRef="U_USD">12973000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <verv:DeferredTaxAssetsCapitalizedCostsNetOfAmortization
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_ab2a5b46-696b-4736-bd30-da11ca64e7c3"
      unitRef="U_USD">12395000</verv:DeferredTaxAssetsCapitalizedCostsNetOfAmortization>
    <verv:DeferredTaxAssetsCapitalizedCostsNetOfAmortization
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_f2bc2320-4bf4-4eb1-9f3a-7dd77c37b478"
      unitRef="U_USD">855000</verv:DeferredTaxAssetsCapitalizedCostsNetOfAmortization>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_880fd481-b0d0-4c7e-9b67-e62d93429e7d"
      unitRef="U_USD">6098000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_93313d21-689b-4de8-aeac-95e54813697f"
      unitRef="U_USD">682000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <verv:DeferredTaxAssetsAntidilultionLiability
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_59ab44d5-b03d-436c-ace7-e15b2fb4b067"
      unitRef="U_USD">2815000</verv:DeferredTaxAssetsAntidilultionLiability>
    <verv:DeferredTaxAssetsStockBasedCompensation
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_50373372-738d-4f5b-971d-2863cf759862"
      unitRef="U_USD">1117000</verv:DeferredTaxAssetsStockBasedCompensation>
    <verv:DeferredTaxAssetsStockBasedCompensation
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_87311de0-1ef7-4d1a-bd55-100f9e153264"
      unitRef="U_USD">149000</verv:DeferredTaxAssetsStockBasedCompensation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_a809f83b-2d53-4ab6-8b7d-ad4a3fcd6f0a"
      unitRef="U_USD">76000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_49213078-c4bf-46ca-a58b-f70cbc2a6e64"
      unitRef="U_USD">61000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_e86a832b-4c8d-4e3c-9ec3-b999b85444c1"
      unitRef="U_USD">533000</us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities>
    <verv:DeferredTaxAssetAccruedExpenses
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_f457d8b9-af2e-4973-8d33-3107fc2e9e01"
      unitRef="U_USD">2852000</verv:DeferredTaxAssetAccruedExpenses>
    <verv:DeferredTaxAssetAccruedExpenses
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_16fdcd14-15e0-458a-bad4-e30ed4eb6427"
      unitRef="U_USD">905000</verv:DeferredTaxAssetAccruedExpenses>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_a4615e23-82b9-4d90-8184-98e3262d481b"
      unitRef="U_USD">56480000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_6d82ef0e-5303-48a0-a1df-ffca60413574"
      unitRef="U_USD">18440000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_3dd3a702-53a0-4f89-80dc-c92c9b5aef79"
      unitRef="U_USD">899000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_f5f311a6-3e73-4128-94b7-eda27a19f198"
      unitRef="U_USD">1061000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <verv:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_d4992123-7284-4515-92df-7f5d31209fb9"
      unitRef="U_USD">-501000</verv:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_884ba004-7739-4185-81cb-0a8c3ecb3fa2"
      unitRef="U_USD">1400000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_0dbbe498-6054-43b8-9233-a0adc77b7f26"
      unitRef="U_USD">1061000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_cb135c47-2eb8-4512-84a8-4e183f2b58c3"
      unitRef="U_USD">55080000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_5ecce637-a07f-4819-863f-75e3ec9d2d27"
      unitRef="U_USD">17379000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_f036d32e-4ec8-4b4e-8564-b4a547867a5d"
      unitRef="U_USD">55080000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_d7ca509e-9359-4ce9-aab6-e1c31d6221ad"
      unitRef="U_USD">17379000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_97a4254d-5370-4d62-9523-6c09a5d4ee9f"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_830ab8d3-5892-4dd4-b9c7-06c48b38d1a8"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-5"
      id="F_51f015b0-ade7-412f-bdd6-299c123b1cf8"
      unitRef="U_USD">37700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-5"
      id="F_93392314-c12f-4e81-9ef4-4496941ea757"
      unitRef="U_USD">13600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <verv:ChangeInOwnershipDescription
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_8f6950b5-2821-4050-831b-7eea4db80fd7">An ownership change occurs when the ownership percentages of 5% or greater shareholders change by more than 50% over a three-year period.</verv:ChangeInOwnershipDescription>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_9b37319a-0d54-4ccd-83eb-9d11fc5d438b"
      decimals="-5"
      id="F_4c3281b5-bff3-4d22-884d-3a479df4c60b"
      unitRef="U_USD">124700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_38d37eaf-cd29-452c-8228-ce29419522e6"
      decimals="-5"
      id="F_ca3b7ada-49b8-40ee-a9d0-79e5dece3159"
      unitRef="U_USD">114400000</us-gaap:OperatingLossCarryforwards>
    <verv:PercentageOfFutureTaxableIncomeUtilizedToOffset
      contextRef="C_38d37eaf-cd29-452c-8228-ce29419522e6"
      decimals="2"
      id="F_7cd9f7b4-526a-4a68-8055-f8f6f24e4ade"
      unitRef="U_pure">0.80</verv:PercentageOfFutureTaxableIncomeUtilizedToOffset>
    <verv:OperatingLossCarryforwardsExpirationYear
      contextRef="C_e0e52d02-fa91-4a31-93c5-67e517633a88"
      id="F_56e5f7eb-9a56-48ac-816e-8d436ac6ef8f">2041</verv:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_9b37319a-0d54-4ccd-83eb-9d11fc5d438b"
      decimals="-5"
      id="F_645ead91-65c2-40d6-a71e-b115670480dc"
      unitRef="U_USD">4200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_9315a78c-93a9-491d-b78a-acdccb6d99a8"
      decimals="-5"
      id="F_78070042-a050-4ac3-ab54-b6ba0c7132f8"
      unitRef="U_USD">2300000</us-gaap:TaxCreditCarryforwardAmount>
    <verv:TaxCreditCarryforwardExpirationYear
      contextRef="C_7eaf836e-97a5-4b96-901b-fbc846401d37"
      id="F_94d11eb4-c454-463f-b5c9-782453100b3a">2041</verv:TaxCreditCarryforwardExpirationYear>
    <verv:TaxCreditCarryforwardExpirationYear
      contextRef="C_76a2ae17-640c-473b-b6d2-7f1f8e136700"
      id="F_b7b1ee3d-7d56-4851-9d18-2dab6110d64f">2036</verv:TaxCreditCarryforwardExpirationYear>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_d2f43730-89bf-4b2b-adfb-57c25314c5a9"
      decimals="-3"
      id="F_148eaf79-9d2f-4c3d-84bc-f7ffe023efd8"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d"
      decimals="-3"
      id="F_21b615d8-1239-4b77-ad76-6ba47310071b"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="0"
      id="F_5e766aca-7763-4f7e-9cca-74f50c4edffd"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_8201be74-920b-4059-ba8a-af846ec31048">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;14. Related party transactions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In the years ended December 31, 2021, 2020 and 2019, the Company made total payments o&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;f $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively, to&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; the five founder shareholders for scientific consulting and other expenses. These same individuals also vested in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;537,633&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;537,635&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;537,635&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of restricted stock in the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;An executive officer of Beam is a board member of the Company. From February 2019 through December 2019, the Company leased office space from Beam in Cambridge, Massachusetts. Total rent payments under this sublease was less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In April 2019, the Company and Beam entered into a collaboration and license agreement. As partial consideration for the license rights granted by Beam, the Company paid a one-time, nonrefundable fee through issuing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;276,075&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of its common stock with a fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. Refer to Note 8, License agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In July 2019, the Company agreed to be designated as Beam&#x2019;s collaboration partner in an NHP study connected to Beam&#x2019;s development and option agreement with Acuitas. As a result, Beam granted the Company a non-exclusive, royalty-free sublicense under Beam&#x2019;s right, title and interest in and to certain Acuitas technology, solely to the extent necessary to enable the Company to perform the NHP study activities. The Company paid to Beam a one-time payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million upon execution of the agreement and is responsible for certain out-of-pocket costs incurred by Beam in connection with the performance of the NHP study activities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In October 2020, the Company and Beam entered into a materials exchange agreement wherein the parties agreed that Beam would provide certain mRNA, gRNA, and protein to the Company and that the Company would provide certain gRNAs to Beam at an agreed upon price per each material provided. For the year ended December 31, 2021, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million as a reduction to research and development expense related to reimbursements received for materials sold to Beam. For the year ended December 31, 2020, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million as research and development expense related to payments made for materials purchased from Beam and also recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million as a reduction to research and development expense related to reimbursements received for materials sold to Beam&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In December 2021, the Company entered into a sublease agreement with Beam for laboratory and office space in Cambridge, Massachusetts. Total rent payments under this sublease were less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million for the year ended December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;An officer of the Company was formerly affiliated with Massachusetts General Hospital (&#x201c;MGH&#x201d;) as a physician. As of August 2021, the officer is no longer a physician at MGH. In February 2019 and November of 2019, the Company entered into an Option License Agreement and Patent License Agreement, respectively, with MGH. Upon execution of the agreements in 2019, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million for option and license issue fees, which were recorded as research and development expense. For the years ended December 2021 and 2020, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million each year relating to the annual license fee, which was recorded as research and development expense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;An executive of Broad was a board member of the Company. The board member resigned, effective May 2021. In March 2019, the Company simultaneously entered into the Harvard/Broad License Agreement and Broad License Agreement for certain base editing technologies pursuant to which the Company received exclusive, worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed products and nonexclusive, worldwide, sublicensable, royalty-bearing licenses under certain patent rights to research and develop licensed products. Additional consideration under the license agreements include antidilution rights and success payments. See Note 8, License agreements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-5"
      id="F_4b6281bd-7e40-4e85-a885-fc547a23eb51"
      unitRef="U_USD">300000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="-5"
      id="F_7cb7126a-dc37-4782-9bbd-f7167798a453"
      unitRef="U_USD">400000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="-5"
      id="F_fbd574fe-17aa-4628-bafa-c97a06057d1f"
      unitRef="U_USD">400000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="INF"
      id="F_bdce6cad-9f6b-4370-b2cd-edd26f35c3be"
      unitRef="U_shares">537633</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f"
      decimals="INF"
      id="F_20a92703-6b84-424a-a56d-3f77f6b7cc35"
      unitRef="U_shares">537635</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_fcc3e9c4-cb19-488f-9877-80cf81fb5bee"
      decimals="INF"
      id="F_020d7164-9aa8-43e9-8fb9-7f3a86222810"
      unitRef="U_shares">537635</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="C_dc246b1a-e277-4475-a822-7b299288320b"
      decimals="-5"
      id="F_0e7ffa12-716c-479c-8814-b4c7180ffe7b"
      unitRef="U_USD">100000</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_368253bb-0ab9-4644-bcce-9c12ebebd714"
      decimals="INF"
      id="F_97d5de4f-0156-41a7-a279-0e732e22aeb3"
      unitRef="U_shares">276075</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_368253bb-0ab9-4644-bcce-9c12ebebd714"
      decimals="-5"
      id="F_515fcdb2-5253-43e9-8fa2-55ebcb701e78"
      unitRef="U_USD">300000</us-gaap:CommonStockValue>
    <verv:OutOfPocketCostsIncurred
      contextRef="C_1541fd57-3030-489b-9a4b-89cd76467fe9"
      decimals="-5"
      id="F_5e7aa45a-ee0e-4496-8116-47a798743db0"
      unitRef="U_USD">100000</verv:OutOfPocketCostsIncurred>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_b00ab393-cfc3-45d7-90b3-dfac30d815bd"
      decimals="-5"
      id="F_eb9d9b07-958a-4fdf-9e15-91d2cf8ba096"
      unitRef="U_USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_4a2a7d48-0ad0-4027-b312-8b11192978ef"
      decimals="-5"
      id="F_913ed8f4-b666-42ad-b945-f21e6571c07f"
      unitRef="U_USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e5a60e47-ab5b-41f6-99da-8c71cb8625d8"
      decimals="-5"
      id="F_ebda3630-0208-4a17-ad2b-6ae19ba6467d"
      unitRef="U_USD">300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="C_f014d533-46a7-4112-9279-b10412cf8bb1"
      decimals="-5"
      id="F_a5b26d7a-0249-43fc-85c4-2dea1d90805d"
      unitRef="U_USD">100000</us-gaap:ShortTermLeaseCommitmentAmount>
    <verv:OptionAndLicenseIssueFees
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="-5"
      id="F_0b7fcda0-cc5f-4b9f-bf5c-ea682996faac"
      unitRef="U_USD">200000</verv:OptionAndLicenseIssueFees>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="C_5f4306bb-8ee0-4a9e-a1ff-c73a4446835b"
      decimals="-5"
      id="F_133434a5-720b-4760-9a0b-6e7935a1b6bb"
      unitRef="U_USD">100000</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="C_6fe755bd-39b2-4058-bb31-ac7a1399a7a0"
      decimals="-5"
      id="F_50cf490b-c0c6-4a30-bbe2-3d650ac2810f"
      unitRef="U_USD">100000</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_5833ca62-52e8-44a3-a505-61c0b0855bef">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;15. Employee benefit plans&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company has a defined-contribution plan established under Section 401(k) of the Internal Revenue Code (the &#x201c;401(k) Plan&#x201d;), which covers substantially all employees. Employees are eligible to participate in the 401(k) Plan beginning on the first day of the month following commencement of their employment. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The 401(k) Plan includes a salary deferral arrangement pursuant to which participants may elect to reduce their current compensation by up to the sta&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;tutorily prescribed limit, equal to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;19,500&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; in 2021 with a catch up contribution limit equal to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,500&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; for &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;those 50 years of age or older, and have the amount of the reduction contributed to the 401(k) &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Plan.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; Since January 1, 2020 the Company matches &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% of each participant&#x2019;s annual contribution to the 401(k) plan up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% of the participant&#x2019;s salary and then &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% of each participant&#x2019;s contribution up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% of the participant&#x2019;s salary. The match immediately vests &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%. The matching c&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;ontributions by the Company to the 401(k) plan were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
      contextRef="C_f78045b2-d23b-4e9d-b193-d192ee9bb611"
      id="F_6f1a9b03-1f12-47ca-9082-522a517205d1">The 401(k) Plan includes a salary deferral arrangement pursuant to which participants may elect to reduce their current compensation by up to the statutorily prescribed limit, equal to $19,500 in 2021 with a catch up contribution limit equal to $6,500 for those 50 years of age or older, and have the amount of the reduction contributed to the 401(k) Plan.</us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="C_f78045b2-d23b-4e9d-b193-d192ee9bb611"
      decimals="0"
      id="F_63c009cc-f852-40de-a918-8dd0b69927c4"
      unitRef="U_USD">19500</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      decimals="0"
      id="F_f2c38330-1efe-4b51-882e-678a54ca5291"
      unitRef="U_USD">6500</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary
      contextRef="C_d1a50b9b-5f34-479b-86a9-1686cbaaf4d7"
      decimals="INF"
      id="F_200d1701-15a6-4b3b-ae23-90e3e1cc7e17"
      unitRef="U_pure">1</verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary>
    <verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary
      contextRef="C_f78045b2-d23b-4e9d-b193-d192ee9bb611"
      decimals="2"
      id="F_47e58c33-7095-45c8-b620-1f52d0e07748"
      unitRef="U_pure">0.03</verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary>
    <verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary
      contextRef="C_d1a50b9b-5f34-479b-86a9-1686cbaaf4d7"
      decimals="2"
      id="F_1ad15a16-7a06-419e-ad19-1446f850772e"
      unitRef="U_pure">0.50</verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary>
    <verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary
      contextRef="C_f78045b2-d23b-4e9d-b193-d192ee9bb611"
      decimals="2"
      id="F_ef550e08-b8c3-4bbf-b2f2-4e8c5da879e7"
      unitRef="U_pure">0.02</verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary>
    <us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
      contextRef="C_d1a50b9b-5f34-479b-86a9-1686cbaaf4d7"
      decimals="INF"
      id="F_4c7192e0-294c-450a-b2b2-1bdfa289ecfc"
      unitRef="U_pure">1</us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_f78045b2-d23b-4e9d-b193-d192ee9bb611"
      decimals="-5"
      id="F_beac1807-1c87-4fb8-9770-1b939a2778d1"
      unitRef="U_USD">400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_dd29659d-951a-45fc-a69a-2e59256ccd54"
      decimals="-5"
      id="F_639b9586-fe64-4d92-b9f7-49fea3baeb26"
      unitRef="U_USD">100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_0904d4b8-89c7-4202-8393-1c301fba7ae3"
      id="F_39f6a875-1663-47c3-9823-4ec1d2466731">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;16. S&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt;ubsequent events&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company evaluated all subsequent events and determined there are no material recognized or unrecognized subsequent events requiring disclosure.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_fe0539bc-5d0e-4e16-bca5-d18ebbbf88c5"
          xlink:label="F_fe0539bc-5d0e-4e16-bca5-d18ebbbf88c5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9802e87b-b16a-46c7-b5ca-97ffa81f49a2"
          xlink:label="F_9802e87b-b16a-46c7-b5ca-97ffa81f49a2"
          xlink:type="locator"/>
        <link:footnote id="FNT_247ca409-7f5d-47a8-8c48-39a833c8dcd8" xlink:label="FNT_247ca409-7f5d-47a8-8c48-39a833c8dcd8" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;">This represents the number of unvested options outstanding as of December 31, 2021 that are expected to vest in the future.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_fe0539bc-5d0e-4e16-bca5-d18ebbbf88c5"
          xlink:to="FNT_247ca409-7f5d-47a8-8c48-39a833c8dcd8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9802e87b-b16a-46c7-b5ca-97ffa81f49a2"
          xlink:to="FNT_247ca409-7f5d-47a8-8c48-39a833c8dcd8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_07bb18eb-0554-426b-b84f-e1ce1d9e124f"
          xlink:label="F_07bb18eb-0554-426b-b84f-e1ce1d9e124f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_09c816c2-1e12-4899-9ecf-678b1a4962d0"
          xlink:label="F_09c816c2-1e12-4899-9ecf-678b1a4962d0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_24230ffe-ae0b-4bb2-ad26-32083b8b57ec"
          xlink:label="F_24230ffe-ae0b-4bb2-ad26-32083b8b57ec"
          xlink:type="locator"/>
        <link:footnote id="FNT_cbfa0a0e-19c5-4a4c-98d4-6e84510cdcd3" xlink:label="FNT_cbfa0a0e-19c5-4a4c-98d4-6e84510cdcd3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Arial;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December 31, 2021.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_07bb18eb-0554-426b-b84f-e1ce1d9e124f"
          xlink:to="FNT_cbfa0a0e-19c5-4a4c-98d4-6e84510cdcd3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_09c816c2-1e12-4899-9ecf-678b1a4962d0"
          xlink:to="FNT_cbfa0a0e-19c5-4a4c-98d4-6e84510cdcd3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_24230ffe-ae0b-4bb2-ad26-32083b8b57ec"
          xlink:to="FNT_cbfa0a0e-19c5-4a4c-98d4-6e84510cdcd3"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>115
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M#@@3H.\O.5=O"[.;ME]/D[]02P,$%     @ A3AN5,9>ATL;!0  &A,  !@
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M^W')$[G.-@;R^J(LQ=.7YGW;W3OBY_\!4$L#!!0    ( (4X;E0D''U&!0,
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M:,(!PY&]A6[V]OEH@W+N/ @J7RW=_5^18D*;"Z83D34<:5?HIEU/M&U[<U,
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ML.,[>@#W2PLRE'[0 <,_A*[_ U!+ P04    " "%.&Y4_X@K4U,F  #I?P
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MK$2*6Z@P92O"WM+7+!;-T)<Q\/-1,>$7Q(3SB;GD55/C92Q,@!3+.OJ8]^;
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M1<GI*)2'+'/CB=)=F.@O=-CAS!TH45[.K[P\28Z+ L<G^XVL<@#?:UGU40F
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MJ)&'P U'G*C'<C=X2@HXE6RY3S:.KMRR<]1CV'*YL5:Y#91 \FVD_<K.:7P
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M+$Y<@J=EI!<.R)0.N:N( VF7.MNDFN:X#_:QV T'W,&Q.652]GV5]5K5I"1
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MTY"BTP]O-OREQ<)X5*9\N4;YJ"PMP/.E,3[]H /:3V_>_0=02P,$%     @
MA3AN5'BA"2#,$P  G4@  !D   !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M[5SKD]NXD?]74'.YG+=*HY$TGH?7CZJQ]WSKG'=WRI/-?;C*!XB$),0DP07
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MSRT *MIIU6QWI#&,)J3+);C[T^62GEU>7\VN+Z\F--U=S0E<"RQ%2( CHE<
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MQ!U;\%C^"!M!793[TQQB.+J97O5SNQ2]V2>T:XPU;M+.T0F%?&>%SVX/<!.
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M0KYWQ;RG7Q#7,U>"'GM'?XA\W1E;-/X<B+LYLBJ,I+RG@5.K&_C@F=]Q$*C
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M\TS]+$W.1KGB]3Y<NRAH0B9XGPLW=(:GCYWL'?W#,AT1Y*FM^^P*"1]*Y7Z
M@(X7N*2XN@W\W_^:I$GZDOVP9]T3]<$J>\]FHH4?RE.$W6+S=TE+2H4,#RKZ
MF$0>::<JH*EF?Z UU(8B#9'X+CNRG4F:,AL(R5'S-)9KB$?NY'(C72HXT0B'
MPX_#82@8(<%:G-Q]'UU9(EM!</AT!XWG"27[SC&#^L&'//\#\S4>D*!Z8O<
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MD#!=)5T5=<FW\+4IW<:B)F-Q>PT;EN@%6$C)L!1D7^/_&+!9RXUS9DC>?5*
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MEVLEX0@MP/.EM:'^00J:+U>W_P-02P,$%     @ A3AN5)VCT2EC!P  8!0
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MY>U<)"^JBA;HBU:WE!!(ZRYEJNQX\MNTHCW1N'5*\]P619T454G8SCLNZ_B
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M3STK02PJTJU=I-2[H<?A4.>JD;/ X0"C^;8((Z0(3NL?HCUXM!1'LKBA:Z9
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M51?W;H[OI*S&(D%QNC^[4<JP2;,D>OHPQ.QTX7ST+_AA+&$O+\$JP@0\ 5B
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MV'1P=L%E]NU3U&[(U7'\;QSQ8Q*7);_>Z$6!Y85S=-@(0/=_8/$_4$L#!!0
M   ( (4X;E0% 0'0X (  'T&   9    >&PO=V]R:W-H965T<R]S:&5E=#(V
M+GAM;*U536_;, R]]U<0WC"T0!#;2M*D71(@7?=U&% L^S@,.\@VDPBUI4RB
MFV6_?I3L>NG6]+2+35%\CX^T1$]WQMZZ#2+!SZK4;A9MB+:7<>SR#5;2]<T6
M->^LC*TD\=*N8[>U*(L JLI8),EY7$FEH_DT^&[L?&IJ*I7&&PNNKBII]U=8
MFMTL2J-[QT>UWI!WQ//I5JYQB?1Y>V-Y%7<LA:I0.V4T6%S-HD5Z>37T\2'@
MB\*=.[#!5Y(9<^L7[XM9E'A!6&).GD'RZPY?85EZ(I;QH^6,NI0>>&C?L[\)
MM7,MF73XRI1?54&;632)H,"5K$OZ:';OL*UGY/ER4[KPA%T3.THBR&M'IFK!
MK*!2NGG+GVT?#@"38P#1 D30W20**J\ER?G4FAU8'\ULW@BE!C2+4]I_E"59
MWE6,H_D':6^19%8B+#&OK2*%#DX_>8\[F\;$.7QDG+=\5PV?.,*7"OA@-&T<
MO-8%%@\)8A;7*13W"J_$DXS7F/=AD/9 )")]@F_053P(?(,C?._U'3KB<T4.
MKC$C6.@"7O^H%>T/6_!MD3FR?&B^/Y%SV.4<AIS#(SF7?)>*FGML5O!HQQ]K
M]).4_K)>NJW,<1;Q;71H[S Z_)KN3RG9_GZU!]IO$7+#E\H1%EX/;1!6IN3;
MJ?3Z\H3;C56&MFOYR:G2'&1J)W7ASF!1&4OJ%X/?6N-<^WPCE3WYW%_V@7@V
MN-KN(5-EZ8!!H VQC.<@QN/>:'3!UHMG$Y&*EVR=@D@G<-;N#H9IP\(#0>?[
MPRK226\\23OD*:0)P[QWG)Y\,B1+SW%QSAS)WQE$FX%WTU3\4V/R'VL<B)X0
MJ3<>B CNX;':!DEO<I' J ,$QZ@KZWS NCWIY %I<%_ 8P<T/A@)%=IU&'R.
MOWRMJ9D.G;>;K8MFI/P);P8S'ZJUT@Y*7#$TZ8]'$=AFV#4+,MLP8#)#/*Z"
MN>'_ UH?P/LKP[UI%SY!]\>9_P902P,$%     @ A3AN5/VABN/% @  X04
M !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULA53;;MLP#'W/5Q!&'UK
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MFR7-8-3.@<[72MG]PA$<IOKL+U!+ P04    " "%.&Y4+"$LP:@%  "@#P
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MO4G6]\%ZH$5I[V!+H?%&9U\SO$)3:1;@][7 4THS, K:2_GUOU!+ P04
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MK&F::S-QN@H-;:4=M<<P+.E[!(T_0/MKK=U^XAVT7SB+_P%02P,$%     @
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M)(#?"RG-YH4,=%??RW\!4$L#!!0    ( (4X;E3C!XAO300  $L*   9
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M%5H ]M><J]>)?LLU_QV8_@U02P,$%     @ A3AN5-V]-8F: @  1 <  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S4N>&ULC55=3]LP%/TK5L0#2*Q)\U$H
M:B-!VVE[F%11V!ZF/;C.36/AV,5V6OCWLYV0!=*ROB3^..?<<^]-[,E>R"=5
M &CT4C*NIEZA]?;&]Q4IH,1J(+; S4XN9(FUF<J-K[82<.9()?/#(!CY):;<
M2R=N;2G3B:@THQR6$JFJ++%\O0,F]E-OZ+TMW---H>V"GTZV> ,KT(_;I30S
MOU7): E<4<&1A'SJW0YO%HG%.\!/"GO5&2.;R5J()SOYGDV]P!H"!D1;!6Q>
M.Y@!8U;(V'AN-+TVI"5VQV_J7UWN)I<U5C 3[!?-=#'UKCV408XKIN_%_ALT
M^3B#1##EGFC?8 ,/D4II439DXZ"DO'[CEZ8.'<(P/D((&T)X*B%J"-&IA+@A
MQ*<2DH;@4O?KW%WAYECC="+%'DF+-FIVX*KOV*9>E-OO9*6EV:6&I]-5_7T@
MD:,5W7":4X*Y1K>$B(IKRC=H*1@E%!3Z@NZ!"$XHH]@UV7!F6!67[HD6SQ7=
M809<*X1Y9L!*2THT9/7^^1PTIDQ=&*''U1R=GUV@,T0Y>BA$I0Q#37QM,K*^
M?-*XOZO=AT?<SX$,4#2\1&$0#@_09Z?3@P/T^<GTX?@ ?7$Z_?H]W3==;%L9
MMJT,G5YT1.]0SW[?KDT7S-_XYY, 41L@<@'B(P%<&VUKB1W OWX?:EPME3@I
M>UCMTE$<1:;*NVY_^JCK\3AJ0>]LQJW-^%.;G0_/&CUDKA88=<(F873UP5L?
M%(^.6$M::\FGUAZ$QLRYNNP5T556_M][TB_L.!E]--]'C>-D]!XT[X.BT/Y'
M7="B#TKB3KBZ#G[G!++WRP\L-Y0KQ" WM&!P9?BR/K/KB19;=RBMA39'G!L6
MYIH#:0%F/Q="OTWL.==>G.E?4$L#!!0    ( (4X;E3 <K%.100    0   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;+U76V_;-A1^[GX%(6Q "R01
M*=_DP#;@2XJZZ,6HT>UAV ,M4381B=1(*DZ&_?B2DBPYMD2G'58]V"+%\YWO
M'/)\)$=[+N[ECA %'I.8R;&S4RJ]=5T9[$B"Y0U/"=-?(BX2K'13;%V9"H+#
MW"B)70_"OIM@RIS)*.];B<F(9RJFC*P$D%F28/$T(S'?CQWD'#J^T.U.F0YW
M,DKQEJR)^IJNA&ZY%4I($\(DY0P($HV=*;J]\W*#?,3OE.SET3LPH6PXOS>-
M93AVH&%$8A(H X'UWP.9DS@V2)K'WR6H4_DTAL?O!_2W>? ZF V69,[C/VBH
M=F/'=T!((IS%Z@O?OR-E0#V#%_!8YK]@7XP=#!T09%+QI#36#!+*BG_\6";B
MR,#S6PR\TL [-4 M!IW2H/-2@VYIT#TU@"T&O=(@#]TM8L\3M\ *3T:"[X$P
MHS6:><FSGUOK?%%F%LI:"?V5:CLU61<+!/ (K.F6T8@&F"DP#0*>,479%JQX
M3 -*)+@&TS"D9GIQ#):L6*1FLE\OB,(TEF]&KM*4#+ ;E.YGA7NOQ3WRP$?.
MU$Z".Q:2\#F JV.I O(. <T\*^*"!#>@@ZZ !SWT=;T KW]]LR9;O;95 [WY
MR\%@"=: LG@Q"AJVH]S94=YG3*/ (C"YPX)(2[HZU?QW<M3.A?G_?'G^__R@
M;<%2D43^9?'<K3QW<\_=%L_+),54F'D!,9?R-)IBK@N(7@YA-.]A D?NP_$$
M7ARQL(UXQKQ7,>]9F:^("#1MK:.F;!1^!!O"2$255DX<TW].UW$1BAVS!V\@
M_,V2UGY%KF\%6F=!0*0$*7XJ<DOQAL94/5V9+KR)21.Y_EF.^EX/ZJ<Y4X.*
MS,!*YE.6;(@P6=([F\#Y>I)%,8)_07M9S@K8_A$?U,S$KYCX5B:?*_\QT?M*
MG98F[_Y9-A#T!SV_-1_#BL7PNU@(LXU=\^@ZTPVLBT U5L'PG(_?&1ZS*6KA
M?%P+7P3K[0%:&4_7<^!W/<O"1$=;#?K)6H.\VK=GC6.^PTS7*S5'D\I=*B@+
M:!J3J^->J3 +L0@ER-(0*_,QY*EJKNH+;I7(B(U_+=.H\S_S-SNU:39&87?^
M'NNM!UW]\NJ5V7ML\=3BC^SJ_UWUB,XEW.O#=GE"M9(CN^S^8$&6J,\(=6V$
M:O5&=OG^3_-,=7TI(J@^GY$HTD?Q1NYV I=6;"W]R*[][[!XT.R )@EF7+_9
M4&L91_[/UI!:O)%=O7]L:T4-Z@VKIWF]>+4^>W9]7DJ981;D)Y&CX_F<)XFN
M][7BP;W>:9N.B^69$Y[MM/[ AT._A5@M]AYZ4;(^')($5D7:FG)48CT[?W2:
M\N,>W702(K;Y%5."?/*+.T+56UUCI_GE[:1_AFX7Q66TABGNQA^QV%(FM2!$
M&A+>##0K45PWBX;B:7Z?VG"E;V?YZTY?T8DP _3WB'-U:!@'U:5_\@U02P,$
M%     @ A3AN5'#3S;?< @  H@D  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S<N>&ULM59-;]LP#/TKA$\;L-6QDS1MD01H^H$5:+&@0;?#L(-BT[%067(E
M>6G__2@Y45*@<4^YV)),/CX^&B+':Z6?38EHX;42TDRBTMKZ(HY-5F+%S(FJ
M4=*70NF*6=KJ56QJC2SW3I6(TU[O-*X8E]%T[,_F>CI6C15<XER#::J*Z;<9
M"K6>1$FT/7CDJ]*Z@W@ZKMD*%VB?ZKFF71Q0<EZA-%Q)T%A,HLOD8I8,G(.W
M^,5Q;?;6X%)9*O7L-G?Y).HY1B@PLPZ"T>L?7J$0#HEXO&Q HQ#3.>ZOM^BW
M/GE*9LD,7BGQF^>VG$1G$>18L$;81[7^@9N$A@XO4\+X)ZPWMKT(LL9856V<
MB4'%9?MFKQLA]AP&HP,.Z<8A];S;0)[E-;-L.M9J#=I9$YI;^%2]-Y'CTE5E
M835]Y>1GIXNV&J *6/"5Y 7/F+1PF66JD9;+%<R5X!E' ]]A0?]$W@ATUG--
M?X:V;\!D#C<O#:^I5A9NC.6D%>;P9+!H!-SS N'+-5K&A?DZCBV1=J'C;$-P
MUA),#Q!,4GA0TI8&;F2.^7N F+(-*:?;E&=I)^(U9B?03[Y!VDN3#KQ^D+#O
M\08'\*Y453<6]9X*3I.%*NR::>R(, @1!CY"_T"$H/5<^.*\4_S//5G#G<7*
M_.V(-0RQAIW9O*LKAB@8ZMJT=154UX^JV8W>AS=DVG3P/ T\3SN1?A;TJR+<
M-EIRVW3*/ J0HZ/+?!9BG1U5YF[TP:<RGP>>YYU(]VRI-+.*KHB@10=LTMO=
M.[VCBYWLW7+)4>7^!'[XJ=Y)NJ.:=BN.U&1*)7*XJVJM_J%CV@F]NZB2_O$U
MWUU:R>"XFG?#+TJEW:U+O6@/")2F8<&-(ZYW":<ED%7U44;Q7MNL4*_\<&#
M=[ZV@X;3,(!<MFUW9]Y.+P],K[@T%+ @U][)B*Y!W0X$[<:JVC?AI;+4TOVR
MI"$*M3.@[X52=KMQ <)8-OT/4$L#!!0    ( (4X;E2'I%KX0P,  #,,   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;+576V_:,!3^*U:TAT[:2)QP
M"14@M52[2-M4E79[F/9@P@&L.C&S'5CWZW<<TG#)I4-M7XCMG.]\YQXSV$AU
MKY< AOR)1:*'SM*8U;GKZF@),=,MN8($W\REBIG!K5JX>J6 S3)0+%S?\[IN
MS'CBC ;9V;4:#61J!$_@6A&=QC%3#Y<@Y&;H4.?QX(8OEL8>N*/!BBU@ N9N
M=:UPYQ9:9CR&1'.9$ 7SH7-!S\<TM(!,XCN'C=Y;$^O*5,I[N_D\&SJ>M0@$
M1,:J8/A8PQB$L)K0CM^Y4J?@M,#]]:/V#YGSZ,R4:1A+\8//S'+HA Z9P9RE
MPMS(S2?('>I8?9$4.OLEFUS6<TB4:B/C'(P6Q#S9/MF?/!![ -JN ?@YP/]?
M0) #@LS1K6696U?,L-% R0U15AJUV446FPR-WO#$IG%B%+[EB#.CKTS=@V%3
M 60"4:JXX:#)>S+!>IFE>"KGI%KF[ K/N-!O4?IN<D7.WKPE;PA/R.U2IIHE
M,SUP#5IH>=PHM^9R:XU?8\T51"T2T'?$]WQ: 1__/]P[A+L8ER(X?A$</],7
MG!2<GU]0C'PV$.M?#21!01)D).T:DHM8*L/_PHQ$4INJF&WQG0QOVW(]\OO=
MH(T>KO=C4Q;K!I320NK NG9A7;O1NH]*:DW2!$>$R(Q<X&BHRNQXJZ>[1Q]6
M4W<*ZLYIU +W4%E5G1+W>]^OH>\6]-U&^@^,*[)F(H4JQFZ)$7-"J7^4D[*8
MS4F_VK)>85FOT;*[UJ1%;C$L.E4/Y)(+H0GV&_DFC2W/KQ!/03659E@0A:]7
M__V"I/_,^N^78]WK=3K]HUB7Q0+?]VOJGWJ[ >F]4 ?DB@XLJ&'?&\_TI9H@
MUW38!;2F"^AN!E+_&7V0@X^2$[3I47(JY&QVVC76[88G;9Z>62]<+"")'@YJ
M].DFH+L12-NOUP9T-^YH\[Q[NA%H><[1L!>68ET6"[RP[]7$>C<0:?-$/*$3
MRG.O4\.^&WJT>>J=T@F]<B?0.O=WPY"&SVF$L/3YQ=ST2KDIB]G<'$?'W;O1
MV>LTEN "8TT$S!'GM7JH0&UOJ-N-D:OLDC>5!J^,V7*)MWI05@#?SR5^'/*-
MO3<6_Q-&_P!02P,$%     @ A3AN5$;\/((Q @  8 4  !D   !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&ULE53;CM,P$/T5*T\@07/K%K1*(_4"HA(K5:V
M!\2#FTP;J[X$VR&[?\_82;-EU19XB3WVG'/FDG'6*GTT%8 ECX)+,PTJ:^O[
M,#1%!8*:D:I!XLU>:4$MFOH0FEH#+3U(\#")HDDH*)-!GOFSM<XSU5C.)*PU
M,8T05#_-@:MV&L3!Z6###I5U!V&>U?0 6[!?ZK5&*QQ82B9 &J8DT;"?!K/X
M?C%V_M[A*X/6G.V)RV2GU-$9JW(:1"X@X%!8QT!Q^04+X-P181@_>\Y@D'3
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M4D:C=W<!T=T\=X95M1^)G;(X8'Y;X1,(VCG@_5XI>S*<P/"HYK\!4$L#!!0
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MN85/IF=3^%RZLM]93;><>#:?:^H@;5^ R0KP<<U;JJD] 4D=]QFF5<5=>9B
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M%LK28_3+FN8K:@>@^Z52=KMQ!H:)G?\!4$L#!!0    ( (4X;E3%7F5NR04
M +(E   9    >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;*V:VVZC2!! ?Z5E
MS<.,M!O3=WOD6,I%T8XT647C9/9AM0_$[L0H&+)T.YY(^_$+F%!@H$W2O"3&
MKJY4E>%P LQV<?*DUTH9]&L31OITM#;F^>MXK)=KM?'U2?RLHO23ASC9^";=
M3!['^CE1_BI?M G'Q//$>.,'T6@^R]^[2>:S>&O"(%(W"=+;S<9/7L]5&.].
M1WCT]L:/X'%MLC?&\]FS_Z@6RMP]WR3IUKC,L@HV*M)!'*%$/9R.SO#7BXF7
M+<@C?@9JIRNO4=;*?1P_91O?5J<C+ZM(A6IILA1^^NM%7:@PS#*E=?Q;)!V5
M?S-;6'W]EOTJ;SYMYM[7ZB(._PI69GTZFHS02CWXV]#\B'=_J*(AGN5;QJ'.
M?Z)=$>N-T'*K3;PI%J<5;()H_]O_50RBL@"SC@6D6$#Z+J#% IHWNJ\L;^O2
M-_Y\EL0[E&31:;;L13Z;?'7:31!E7^/").FG0;K.S*_\($$__7"K4/R KH+(
MCY:!'Z)OD3;)-OV^C$:_H\7^2^X.V05F'40HS_:29UL'*O&3Y?H5?;Y4Q@]"
M_25-=+>X1)\_?4&?4!I]NXZWVH]6>C8V:2M90>-E4?;YOFS24?:E6IX@BG]#
MQ".X9?E%_^5>??DX'6 Y15).D>3Y:$>^,ZV5T99$M$Q$\T2L(]%M;-+)^BWI
M]E/9K^;YZNP(?9E3S@B=SL8OU>Z;86(Z8;2,JM7&RMJ8M<GO@7\?A($)E*U3
M7F;C/3H-NW+NV]VG$)4^&)7XH-EFT%02TMZK**L3UNJNXTB]HFL_>4I)>K5M
M[*.UI+),*MWVDDF9:.*TETP:$^$33.3!W)I10A+6/K=I6=G46MD=6J#;]'2B
MMRDMSH,PU.@L6J$_8Z,T^OM:;>Y5\H]E M@#;GENP\05!&*G<1;+JY,B4E)V
MN".VQ%%"ND:* 2Z8'!WJV:.*EJ]HH9;;)#]<>DT3L(.IXS2!$IBY39,UIH0G
MLG%4MX11;S+E'<,$[& [=Q;;Y5)IC6[\U^S4A=ZH]FIK'K"!Q0",Q$ ,+-TI
M6>0X@LF6*#+Q1,<\ 478SJ*SR 2K(-SF4I9;H.XW4T *G@XP4P+D()[S3"^*
M'#4Z3G''M B@AMA1\UV]J!!A6Q\5YW"4#@*'/W'3CF+YL3-*2UCW*84 4<@0
MXD$  60 ]2!-K? .V[6%U&L#@!"[>!0["/H/O4M!"!"%.$H(@4.?N&D(Z><A
M+6&6O0:P0>PJ I-TE1(*:*&.4D*!%-1-2FA3-@[W3VM(O2R #K6[2'VJ'[(2
M6OEGR-%**#"$NED);>I&8YRVD'I9@")J1Q&,\R->0@$K= @OH4 1.H"7T*9Q
M-&9J"ZG7!EBB=BS!3#_J)A0@0X=P$P8 80.X"6NZ2<?0&."&]1$38FL"&,$<
MQ80! 9B;F+"F<9"IP)@<[&<M<8)B/.T86^62R!!JPH ';  U8<?5Q!I2KPT8
MPOJH"7FOFC" "G-4$P8,8&YJPIK.T1BA+:1>%N""]7$2,H"3<$ *=W02#I#@
M;D[">UXH:8FS7"CA ![>1TZ(BYQP0!-WE!,.%.%N<L+[73)I";-<,N&5*[5]
M)(5\4%(X (8/(2D<>,('D!1^7%*L(?7: %"\CZ00!TGA0!T^A*0(((H80%)$
M;TD1P!_11U*HK0E@A7"4% $D$&Z2(IKR<;B+64/J90%5Q!!N(@ #8@ W$;UN
MV;1$6>[95&[:]#$4^EY#$4 4X6@H @ @W Q%'#<4:TB]+&"%Z&,H= !#D< 3
MZ6@H$@@AW0Q%'K]J8@VIEP6PD7W$A+J(B00<24<QD8 0Z28F\OA5$VM(O2P@
MD>PC)/2#0B*!)W(((9&5^[\#"$F1@]L)*M]S-T<"E60?+:$.6B(!-7((+9D
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M*),OJP5X_^X#> >B%'P.62Y(&HC+OE0@]4?U_0K0K 2$.@!!!.Y8*D,!KM.
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ME&L#]7[-F'R]T1]0_\(R^0]02P,$%     @ A3AN5$JX"XA1 P  ,@L  !D
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M9L5O$5I_@<]+8VB_\ &&URW["U!+ P04    " "%.&Y4/E;]#[X"  "X!P
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MSFYX$U<[B5:U2P&B?9"36E?VH$-8CD)%9\B;N;T>+7#J))1J3A@J9'7Z[X%
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M7](<795UT>L/]BZ8HEDN]]$+-$)R1@63*"O179DI.82'</U^QBM)RU0>C12
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M-(5@ $7-H)W.A-2=]5+/):.@>I-,)F"E%6EH9I>5259.M<$["@[%$C5'#Q!
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MFB]BF3"_L"MC'0NBC9 L+\$J@SREQ3]Y+@M1 [C=(P"O!'A-0' $X)< _Z.
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MS4<H8C$M4O6%[_]@E4.>MA?R5)K_:%_5G8Q06$C%LZHQ$&1)7O[2'U4@7M*
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MA4'1%>![S+DZON@.ZMO4Y?]02P,$%     @ A3AN5/S"3LF0 P  H@T  !D
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M=ZA]+(H+0=%0?&L/X2NN])'>?L;Z$H7"#-#_UYRKYX:9H+J63?\%4$L#!!0
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MF3L6;QI]*$F/=9_&[R9IW'%4TE'[J.PP#(;XY[=^IFU#+,E!Y%U66O>DSRU
M;NU]09'$])F'UJN9;>XD4]N)7\S/S%W%]L]'FL-%YSN36X[;((<-4GHW Q14
M'NX.AX$6.]M-KX7&WMR^9GC? FD,\/M&8&-<#\P"S0UN\C]02P,$%     @
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M\H L[<_AH4Q_T3JW-3K(2:3B40X&!E$09__T/4_$%@#\U -(#B#[ +L!8.8
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M3Z'LF[FRLGKY8/7E8]NCGU!+ P04    " "%.&Y4'M^97AP"   ])P  &@
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M _4. KT#]0X"O0/U#@*] _4. KUC\K&20.] O8- [T"]@T#O0+V#0.] O8-
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M4$L! A0#%     @ A3AN5"N2-Q'4 @  20D  !@              ("!*A8
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( (4X;E3&7H=+
M&P4  !H3   8              " @309  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " "%.&Y4?2)11) (   O+@  &
M@(&%'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ A3AN
M5"0<?48% P  M0@  !@              ("!2R<  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( (4X;E0\;XL-*@D  !DJ   8
M      " @88J  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" "%.&Y4B$]X3HL*   <&@  &               @('F,P  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ A3AN5/^(*U-3)@  Z7\  !@
M             ("!ISX  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( (4X;E3];!E8"@,  /X&   9              " @3!E  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ A3AN5.QO_'KI @
M708  !D              ("!<6@  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " "%.&Y4GGI0YT$-  !?+   &0              @(&1
M:P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( (4X;E28
M0KS.F0(  '<%   9              " @0EY  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ A3AN5$XV0;'5#   AB,  !D
M     ("!V7L  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (4X;E29#:31_ 0  %8,   9              "
M@1RW  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ A3AN
M5#FC(V+6"0  Q1H  !D              ("!3[P  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " "%.&Y4G:/1*6,'  !@%   &0
M        @(%<Q@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( (4X;E3]%LN_! 0   $)   9              " @?;-  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ A3AN5"D5+[4J @  Z@0
M !D              ("!,=(  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " "%.&Y4YX(:K# H   CBP  &0              @(&2U
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( (4X;E0)S?,.
MFP,  !L(   9              " @?G\  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ A3AN5 4! =#@ @  ?08  !D
M ("!RP ! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "%
M.&Y4_:&*X\4"  #A!0  &0              @('B P$ >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( (4X;E0L(2S!J 4  * /   9
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M970S,BYX;6Q02P$"% ,4    " "%.&Y4(-Y^36($   R"@  &0
M    @('3'0$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M (4X;E0!6Z<"D00  "D0   9              " @6PB 0!X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ A3AN5-V]-8F: @  1 <  !D
M             ("!-"<! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " "%.&Y4P'*Q3D4$    $   &0              @($%*@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( (4X;E1PT\VWW (
M *()   9              " @8$N 0!X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ A3AN5(>D6OA# P  ,PP  !D              ("!
ME#$! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "%.&Y4
M1OP\@C$"  !@!0  &0              @($.-0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( (4X;E3-@'.K)0,  +L+   9
M      " @78W 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ A3AN5"7F7HU8 @  O04  !D              ("!TCH! 'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "%.&Y4Q5YE;LD%  "R)0
M&0              @(%A/0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( (4X;E0N6>7IB04  &T9   9              " @6%# 0!X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ A3AN5$JX"XA1
M P  ,@L  !D              ("!(4D! 'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " "%.&Y4'UU F>P$  #5%@  &0
M@(&I3 $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( (4X
M;E0RQ&AJJ@(  !@'   9              " @<Q1 0!X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ A3AN5&4%U$8,"   P"0  !D
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M=#4Q+GAM;%!+ 0(4 Q0    ( (4X;E1<KP*0IP,  !P.   9
M  " @7MM 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
MA3AN5 H@YOK&"0  '38  !D              ("!67$! 'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    " "%.&Y4T5J/-P@'  #&(0  &0
M            @(%6>P$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    ( (4X;E0[5_=:]0(  )X)   9              " @96" 0!X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ A3AN5+3$/&;S @
MV @  !D              ("!P84! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX
M;6Q02P$"% ,4    " "%.&Y4]CZ$'VX%  !9%0  &0              @('K
MB $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( (4X;E3\
MPD[)D ,  *(-   9              " @9". 0!X;"]W;W)K<VAE971S+W-H
M965T-3@N>&UL4$L! A0#%     @ A3AN5*?:IEL5 P  I@@  !D
M     ("!5Y(! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (4X;E3OZFR"@ 0  !80   9              "
M@2BD 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ A3AN
M5))-DL7L!   R1,  !D              ("!WZ@! 'AL+W=O<FMS:&5E=',O
M<VAE970V-2YX;6Q02P$"% ,4    " "%.&Y4*?5)SN8#   6#0  &0
M        @($"K@$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0
M   ( (4X;E3D:\;7.0,  !84   -              "  1^R 0!X;"]S='EL
M97,N>&UL4$L! A0#%     @ A3AN5)>*NQS     $P(   L
M ( !@[4! %]R96QS+RYR96QS4$L! A0#%     @ A3AN5'0*I=8C!0  \"L
M  \              ( !;+8! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M (4X;E0>WYE>' (  #TG   :              "  ;R[ 0!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( (4X;E2E?PYQ[@$  ) F   3
M              "  1"^ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !*
- $H /10  "_  0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>262</ContextCount>
  <ElementCount>489</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>77</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpenses</Role>
      <ShortName>Accrued expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Preferred Stock Tranche Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/DisclosurePreferredStockTrancheLiability1</Role>
      <ShortName>Preferred Stock Tranche Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Preferred and Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStock</Role>
      <ShortName>Preferred and Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Stock-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlans1</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecurities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Property and equipment, net (Table)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTable</Role>
      <ShortName>Property and equipment, net (Table)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Accrued expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Stock-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Marketable securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Property and equipment, net - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property and equipment, net - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Property and equipment, net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and equipment, net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Fair Value of Financial Instruments - Summary of Financial Instruments within Fair value hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Summary of Financial Instruments within Fair value hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Fair Value of Financial Insruments - Schedule of Reconciliation of Changes in Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Insruments - Schedule of Reconciliation of Changes in Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Accrued expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Leases - Summary of Components of Operating Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails</Role>
      <ShortName>Leases - Summary of Components of Operating Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails</Role>
      <ShortName>Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails</Role>
      <ShortName>Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100520 - Disclosure - License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Preferred Stock Tranche Liability - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails</Role>
      <ShortName>Preferred Stock Tranche Liability - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Preferred and Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails</Role>
      <ShortName>Preferred and Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Stock-based compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Stock-based compensation - Summary of Stock Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based compensation - Summary of Stock Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Stock-based compensation - Schedule of Assumptions Used for Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails</Role>
      <ShortName>Stock-based compensation - Schedule of Assumptions Used for Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Stock-based compensation - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Stock-based compensation - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Stock-based compensation - Schedule of Status and Change in Unvested Restricted Stock and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-based compensation - Schedule of Status and Change in Unvested Restricted Stock and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Income Taxes - Schedule of Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="verv-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Employee Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="verv-20211231.htm">verv-20211231.htm</File>
    <File>verv-20211231.xsd</File>
    <File>verv-20211231_cal.xml</File>
    <File>verv-20211231_def.xml</File>
    <File>verv-20211231_lab.xml</File>
    <File>verv-20211231_pre.xml</File>
    <File>verv-ex10_14.htm</File>
    <File>verv-ex10_19.htm</File>
    <File>verv-ex10_4.htm</File>
    <File>verv-ex10_5.htm</File>
    <File>verv-ex10_7.htm</File>
    <File>verv-ex23_1.htm</File>
    <File>verv-ex31_1.htm</File>
    <File>verv-ex31_2.htm</File>
    <File>verv-ex32_1.htm</File>
    <File>verv-ex32_2.htm</File>
    <File>verv-ex4_3.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img242628118_0.jpg</File>
    <File>img242628118_1.jpg</File>
    <File>img242628118_10.jpg</File>
    <File>img242628118_11.jpg</File>
    <File>img242628118_12.jpg</File>
    <File>img242628118_13.jpg</File>
    <File>img242628118_14.jpg</File>
    <File>img242628118_15.jpg</File>
    <File>img242628118_16.jpg</File>
    <File>img242628118_17.jpg</File>
    <File>img242628118_18.jpg</File>
    <File>img242628118_19.jpg</File>
    <File>img242628118_2.jpg</File>
    <File>img242628118_20.jpg</File>
    <File>img242628118_21.jpg</File>
    <File>img242628118_22.jpg</File>
    <File>img242628118_23.jpg</File>
    <File>img242628118_24.jpg</File>
    <File>img242628118_25.jpg</File>
    <File>img242628118_26.jpg</File>
    <File>img242628118_27.jpg</File>
    <File>img242628118_28.jpg</File>
    <File>img242628118_29.jpg</File>
    <File>img242628118_3.jpg</File>
    <File>img242628118_4.jpg</File>
    <File>img242628118_5.jpg</File>
    <File>img242628118_6.jpg</File>
    <File>img242628118_7.jpg</File>
    <File>img242628118_8.jpg</File>
    <File>img242628118_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="743">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>121
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "verv-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 28,
   "contextCount": 262,
   "dts": {
    "calculationLink": {
     "local": [
      "verv-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "verv-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "verv-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "verv-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "verv-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "verv-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 637,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 25,
    "http://www.vervetx.com/20211231": 6,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 35
   },
   "keyCustom": 106,
   "keyStandard": 383,
   "memberCustom": 37,
   "memberStandard": 38,
   "nsprefix": "verv",
   "nsuri": "http://www.vervetx.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Marketable Securities",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Property and equipment, net",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Accrued expenses",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpenses",
     "shortName": "Accrued expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Leases",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:LicenseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - License Agreements",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:LicenseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:PreferredStockTrancheLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Preferred Stock Tranche Liability",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/DisclosurePreferredStockTrancheLiability1",
     "shortName": "Preferred Stock Tranche Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:PreferredStockTrancheLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:PreferredAndCommonStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Preferred and Common Stock",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStock",
     "shortName": "Preferred and Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:PreferredAndCommonStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Stock-based compensation",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "shortName": "Stock-based compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Income Taxes",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Related Party Transactions",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Employee Benefit Plans",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlans1",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Subsequent Events",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Marketable Securities (Tables)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Property and equipment, net (Table)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTable",
     "shortName": "Property and equipment, net (Table)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Accrued expenses (Tables)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesTables",
     "shortName": "Accrued expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Leases (Tables)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Stock-based compensation (Tables)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "shortName": "Stock-based compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
     "shortName": "Nature of the Business and Basis of Presentation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_3965b88b-aada-4b0f-bb79-9e1564c8b01f",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_47adbab3-b838-4d39-aa2e-17b98510b0b2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_47adbab3-b838-4d39-aa2e-17b98510b0b2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails",
     "shortName": "Marketable Securities - Schedule of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:RemainingContractualMaturitiesOfMarketableSecuritiesTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Marketable securities - Additional Information (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
     "shortName": "Marketable securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:RemainingContractualMaturitiesOfMarketableSecuritiesTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Property and equipment, net - Schedule of Property, Plant and Equipment (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails",
     "shortName": "Property and equipment, net - Schedule of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Property and equipment, net - Additional Information (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and equipment, net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Fair Value of Financial Instruments - Summary of Financial Instruments within Fair value hierarchy (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails",
     "shortName": "Fair Value of Financial Instruments - Summary of Financial Instruments within Fair value hierarchy (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
     "shortName": "Fair Value of Financial Instruments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "verv:FairValueOfCommonStockPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails",
     "shortName": "Fair Value of Financial Instruments - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "verv:FairValueOfCommonStockPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Fair Value of Financial Insruments - Schedule of Reconciliation of Changes in Fair Value of Financial Instruments (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails",
     "shortName": "Fair Value of Financial Insruments - Schedule of Reconciliation of Changes in Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_9d0f6183-f1e6-4aa0-b41e-2e38deb97369",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Accrued expenses - Schedule of Accrued Expenses (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
     "shortName": "Accrued expenses - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_4d5e8986-339e-4a27-a33a-2ddab2c8cf2a",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:LeaseCommencementDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_4d5e8986-339e-4a27-a33a-2ddab2c8cf2a",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:LeaseCommencementDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Leases - Summary of Components of Operating Lease Cost (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails",
     "shortName": "Leases - Summary of Components of Operating Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "verv:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails",
     "shortName": "Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_ace78012-0407-4c33-9333-78a05d5e4482",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_ace78012-0407-4c33-9333-78a05d5e4482",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails",
     "shortName": "Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - License Agreements - Additional Information (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
     "shortName": "License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "verv:LicenseAgreementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_e36ace04-7d0f-46f4-a4fc-05e0cddb3357",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Preferred Stock Tranche Liability - Additional Information (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
     "shortName": "Preferred Stock Tranche Liability - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "verv:PreferredStockTrancheLiabilityTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_bb24676f-df61-4c43-a65c-58adb308cd98",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Preferred and Common Stock - Additional Information (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
     "shortName": "Preferred and Common Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "verv:PreferredAndCommonStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ConvertiblePreferredStockTermsOfConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Stock-based compensation - Additional Information (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-based compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Stock-based compensation - Summary of Stock Based Compensation Expense (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails",
     "shortName": "Stock-based compensation - Summary of Stock Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Stock-based compensation - Schedule of Assumptions Used for Options Granted (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails",
     "shortName": "Stock-based compensation - Schedule of Assumptions Used for Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Stock-based compensation - Schedule of Stock Option Activity (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
     "shortName": "Stock-based compensation - Schedule of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_3ed655b7-1d1d-4339-89cd-79f9bc66bf3d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_59fe6e15-fa1d-432e-b68b-41815233efa2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Stock-based compensation - Schedule of Status and Change in Unvested Restricted Stock and Restricted Stock Units (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
     "shortName": "Stock-based compensation - Schedule of Status and Change in Unvested Restricted Stock and Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_59fe6e15-fa1d-432e-b68b-41815233efa2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted net Loss Per Share (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "verv:IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_8f1e4854-0726-4ea5-9fbf-d0c624f1496f",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "verv:IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "verv:SuccessPaymentLiability",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_1a988b86-2da6-44fb-8d8b-025bc3040bcb",
      "decimals": "-5",
      "lang": null,
      "name": "verv:SuccessPaymentLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Income Taxes - Schedule of Deferred Taxes (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_d2f43730-89bf-4b2b-adfb-57c25314c5a9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Employee Benefit Plans - Additional Information (Details)",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
     "shortName": "Employee Benefit Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Nature of the Business and Basis of Presentation",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20211231.htm",
      "contextRef": "C_0904d4b8-89c7-4202-8393-1c301fba7ae3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 77,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r55",
      "r57",
      "r109",
      "r110",
      "r245",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r244",
      "r258",
      "r344",
      "r350",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r571",
      "r620",
      "r623",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r244",
      "r258",
      "r344",
      "r350",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r571",
      "r620",
      "r623",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficerMember": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer [Member]"
       }
      }
     },
     "localname": "OfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r168",
      "r274",
      "r275",
      "r573",
      "r619",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r168",
      "r274",
      "r275",
      "r573",
      "r619",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r244",
      "r258",
      "r298",
      "r344",
      "r350",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r571",
      "r620",
      "r623",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r244",
      "r258",
      "r298",
      "r344",
      "r350",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r571",
      "r620",
      "r623",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r56",
      "r57",
      "r109",
      "r110",
      "r245",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r123",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r123",
      "r128",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r169",
      "r170",
      "r274",
      "r276",
      "r622",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r274",
      "r276",
      "r622",
      "r637",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r123",
      "r128",
      "r229",
      "r349",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r171",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update201602 [Member]",
        "terseLabel": "ASC 842"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r39",
      "r534"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r43"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits Current",
        "terseLabel": "Employee compensation and related benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r43"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r37",
      "r221"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r62",
      "r63",
      "r64",
      "r610",
      "r631",
      "r635"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r61",
      "r64",
      "r72",
      "r73",
      "r74",
      "r112",
      "r113",
      "r114",
      "r449",
      "r626",
      "r627",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r390",
      "r391",
      "r392",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r116",
      "r117",
      "r118",
      "r119",
      "r128",
      "r173",
      "r174",
      "r192",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r230",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r426",
      "r427",
      "r428",
      "r429",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r522",
      "r575",
      "r576",
      "r577",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r351",
      "r353",
      "r396",
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r353",
      "r382",
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r103",
      "r160",
      "r162",
      "r166",
      "r188",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r443",
      "r450",
      "r481",
      "r532",
      "r534",
      "r593",
      "r608"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r11",
      "r51",
      "r103",
      "r188",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r443",
      "r450",
      "r481",
      "r532",
      "r534"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "terseLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r178",
      "r204"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r176",
      "r179",
      "r204",
      "r596"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Fair value",
        "totalLabel": "Debt Securities, Available-for-sale, Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r354",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r34",
      "r95"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash And Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r16",
      "r96",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r88",
      "r95",
      "r98"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash\u2014end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash\u2014beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r88",
      "r491"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents At Carrying Value",
        "terseLabel": "Cash equivalents",
        "totalLabel": "Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and finnacing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r112",
      "r113",
      "r115",
      "r173",
      "r174",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r230",
      "r386",
      "r387",
      "r388",
      "r426",
      "r456",
      "r458",
      "r459",
      "r482",
      "r484",
      "r485",
      "r486",
      "r489",
      "r490",
      "r502",
      "r522",
      "r575",
      "r576",
      "r624",
      "r625",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Adopted",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r112",
      "r113",
      "r122",
      "r173",
      "r174",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r230",
      "r386",
      "r387",
      "r388",
      "r426",
      "r456",
      "r458",
      "r459",
      "r460",
      "r463",
      "r482",
      "r484",
      "r485",
      "r486",
      "r489",
      "r490",
      "r502",
      "r522",
      "r575",
      "r576",
      "r624",
      "r625",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change In Accounting Principle Accounting Standards Update Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r116",
      "r127",
      "r175",
      "r196",
      "r393",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r101",
      "r103",
      "r131",
      "r132",
      "r133",
      "r136",
      "r138",
      "r145",
      "r146",
      "r147",
      "r188",
      "r231",
      "r236",
      "r237",
      "r238",
      "r242",
      "r243",
      "r255",
      "r256",
      "r260",
      "r261",
      "r481",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r46",
      "r228",
      "r598",
      "r614"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (See Note 7 and 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Shares of common stock reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r112",
      "r113",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common Stock, Shares Issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "verboseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r25",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r25",
      "r534"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 and 255,000,000 shares authorized, 48,511,735 and 3,123,424 shares issued at December 31, 2021 and 2020, respectively; 48,511,735 and 2,585,789 shares outstanding at December 31, 2021 and 2020, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "verboseLabel": "Issuance of common stock, value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r67",
      "r69",
      "r70",
      "r76",
      "r600",
      "r617"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r151",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r100",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r255",
      "r256",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r23",
      "r24",
      "r262",
      "r265",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Shares issued upon conversion of preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "auth_ref": [
      "r23",
      "r24",
      "r265",
      "r269",
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of conversion terms for preferred stock.",
        "label": "Preferred Stock, Convertible, Terms",
        "terseLabel": "Preferred stock, convertible terms"
       }
      }
     },
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.",
        "label": "Debt Instrument Increase Accrued Interest",
        "terseLabel": "Accrued and unpaid interest paid"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r21",
      "r499",
      "r521"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as current.",
        "label": "Deferred Rent Credit Current",
        "terseLabel": "Deferred rent, current portion"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r22",
      "r499",
      "r521"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.",
        "label": "Deferred Rent Credit Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r423",
      "r424"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets In Process Research And Development",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "totalLabel": "Total deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "terseLabel": "Deferred tax assets, net of valuation allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r423",
      "r424"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r423",
      "r424"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities": {
     "auth_ref": [
      "r423",
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences derived regulatory assets and liabilities.",
        "label": "Deferred Tax Assets, Regulatory Assets and Liabilities",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsRegulatoryAssetsAndLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r407",
      "r418"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r423",
      "r424"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities Property Plant And Equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, employer Contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.",
        "label": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage",
        "terseLabel": "Defined contribution plan, employers matching contribution, annual vesting percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount",
        "terseLabel": "Defined contribution plan, maximum annual contributions per employee, amount"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlans1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r93",
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r93",
      "r219"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation And Amortization",
        "terseLabel": "Depreciation",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r52",
      "r57",
      "r58",
      "r454",
      "r552"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Fair Value Of Derivative Liability",
        "negatedLabel": "Success payment liability, payable",
        "terseLabel": "Success payment liability, payable",
        "totalLabel": "Derivative Liability, Fair Value, Gross Liability, Total",
        "verboseLabel": "Success payment liability, payable"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r53",
      "r54",
      "r57",
      "r480"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liabilities",
        "terseLabel": "Success payment liability",
        "totalLabel": "Derivative Liability, Total",
        "verboseLabel": "Success payment liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of defined contribution pension and other postretirement plans.",
        "label": "Defined Contribution Plan, Description",
        "terseLabel": "Defined contribution plan, description"
       }
      }
     },
     "localname": "DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.",
        "label": "Dividends Payable Amount Per Share",
        "terseLabel": "Non-cumulative dividends payable per share"
       }
      }
     },
     "localname": "DividendsPayableAmountPerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r107",
      "r234",
      "r236",
      "r237",
      "r241",
      "r242",
      "r243",
      "r526",
      "r597",
      "r615"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due To Related Parties Current And Noncurrent",
        "terseLabel": "Amount due as a result of termination",
        "totalLabel": "Due to Related Parties, Total"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per common share attributable to common stockholders, basic and diluted",
        "totalLabel": "Earnings Per Share, Basic and Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share Basic [Line Items]",
        "terseLabel": "Earnings Per Share Basic [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r139",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r105",
      "r409",
      "r434"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r409",
      "r434"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r409",
      "r434"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r399",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r409",
      "r434"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Weighted average period over which unrecognized compensation is expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Unrecognized stock-based compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized stock-based compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the amount of cash contributions during the period made by the entity to the Employee Stock Ownership Plan (ESOP).",
        "label": "Employee Stock Ownership Plan (ESOP), Cash Contributions to ESOP",
        "terseLabel": "Proceeds from purchase of shares through employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPCashContributionsToESOP",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r72",
      "r73",
      "r74",
      "r112",
      "r113",
      "r114",
      "r117",
      "r124",
      "r126",
      "r144",
      "r195",
      "r264",
      "r272",
      "r390",
      "r391",
      "r392",
      "r428",
      "r429",
      "r466",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r626",
      "r627",
      "r628",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r246",
      "r249",
      "r250",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r338",
      "r470",
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r475",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Fair Value By Liability Class [Axis]",
        "terseLabel": "Liability Class"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Disclosure - Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r246",
      "r299",
      "r300",
      "r305",
      "r338",
      "r470",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r246",
      "r249",
      "r250",
      "r299",
      "r300",
      "r305",
      "r338",
      "r470",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r246",
      "r249",
      "r250",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r338",
      "r470",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value Liabilities Measured On Recurring Basis [Text Block]",
        "terseLabel": "Schedule of Fair Value Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r473",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r473",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]",
        "terseLabel": "Schedule of Reconciliation of Changes in Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r246",
      "r249",
      "r250",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r338",
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": {
     "auth_ref": [
      "r474",
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings",
        "terseLabel": "Changes in fair value"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": {
     "auth_ref": [
      "r469",
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value Of Financial Instruments Policy",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r182",
      "r183",
      "r185",
      "r186",
      "r187",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r248",
      "r263",
      "r457",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Total liabilities",
        "totalLabel": "Financial Liabilities Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r211",
      "r212",
      "r214",
      "r215",
      "r574",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r211",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "Initial Public Offering",
        "verboseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r93",
      "r218",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment Of Long Lived Assets Held For Use",
        "terseLabel": "Impairment losses",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r216",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r104",
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r224",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority Name [Axis]",
        "terseLabel": "Income Tax Authority, Name"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority Name [Domain]",
        "terseLabel": "Income Tax Authority, Name"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r105",
      "r410",
      "r414",
      "r420",
      "r431",
      "r435",
      "r437",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r106",
      "r125",
      "r126",
      "r159",
      "r408",
      "r432",
      "r436",
      "r618"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "terseLabel": "Income tax expense (benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r71",
      "r405",
      "r406",
      "r414",
      "r415",
      "r419",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r92",
      "r513"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase Decrease In Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Increase in operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase Decrease In Other Current Liabilities",
        "terseLabel": "Increase in liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherDeferredLiability": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred obligations classified as other.",
        "label": "Increase Decrease In Other Deferred Liability",
        "terseLabel": "Deferred rent liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherDeferredLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Debt And Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r184",
      "r591",
      "r605",
      "r636",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r516",
      "r519"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Cost [Abstract]"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease Cost Table [Text Block]",
        "terseLabel": "Components of Operating Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee Lease Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee Lease Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease not yet commenced.",
        "label": "Lessee Operating Lease Lease Not Yet Commenced Existence Of Option To Extend",
        "terseLabel": "Option to extend true/false, lease not yet commenced"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to terminate operating lease not yet commenced.",
        "label": "Lessee Operating Lease Lease Not Yet Commenced Existence Of Option To Terminate",
        "terseLabel": "Option to terminate, lease not yet commenced"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease that has not yet commenced. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Operating Lease Lease Not Yet Commenced Option To Extend",
        "terseLabel": "Option to extend, lease not yet commenced"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Lease not yet commenced, lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of basis, terms, and conditions on which variable lease payment for lessee's operating lease that has not yet commenced is determined.",
        "label": "Lessee Operating Lease Lease Not Yet Commenced Variable Lease Payment Terms And Conditions",
        "terseLabel": "Operating lease payment term, lease not yet commenced, terms and conditions"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lessee, operating lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter Of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r41",
      "r103",
      "r163",
      "r188",
      "r231",
      "r232",
      "r233",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r444",
      "r450",
      "r451",
      "r481",
      "r532",
      "r533"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r31",
      "r103",
      "r188",
      "r481",
      "r534",
      "r595",
      "r612"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities, convertible preferred stock, and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities, convertible preferred stock, and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r44",
      "r103",
      "r188",
      "r231",
      "r232",
      "r233",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r444",
      "r450",
      "r451",
      "r481",
      "r532",
      "r533",
      "r534"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of items purchased under a long-term purchase commitment.",
        "label": "Long Term Purchase Commitment By Category Of Item Purchased [Axis]",
        "terseLabel": "Category of Item Purchased"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.",
        "label": "Long Term Purchase Commitment Category Of Item Purchased [Domain]",
        "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of shares that an entity is required to redeem for cash or other assets at a fixed or determinable date or upon the occurrence of an event.",
        "label": "Mandatorily Redeemable Preferred Stock Fair Value Disclosure",
        "terseLabel": "Preferred stock, fair value"
       }
      }
     },
     "localname": "MandatorilyRedeemablePreferredStockFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r7",
      "r42"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities Current",
        "terseLabel": "Marketable securities",
        "totalLabel": "Marketable Securities, Current, Total"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities Policy",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]",
        "terseLabel": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Text Block]",
        "terseLabel": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input Expected Term [Member]",
        "terseLabel": "Expected Term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input Price Volatility [Member]",
        "terseLabel": "Equity Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r148",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature Of Operations",
        "terseLabel": "Nature of the Business and Basis of Presentation"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r88",
      "r91",
      "r94"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r65",
      "r68",
      "r74",
      "r75",
      "r94",
      "r103",
      "r116",
      "r120",
      "r121",
      "r122",
      "r123",
      "r125",
      "r126",
      "r134",
      "r160",
      "r161",
      "r164",
      "r165",
      "r167",
      "r188",
      "r231",
      "r232",
      "r233",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r468",
      "r481",
      "r599",
      "r616"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "negatedLabel": "Net Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r123",
      "r129",
      "r130",
      "r135",
      "r138",
      "r160",
      "r161",
      "r164",
      "r165",
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income Loss Available To Common Stockholders Basic",
        "terseLabel": "Net loss attributable to common stockholders",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss Available To Common Stockholders Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non Us [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingGainsLossesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Gains (Losses) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingGainsLossesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity Table [Text Block]",
        "terseLabel": "Schedule of Status and Change in Unvested Restricted Stock and Restricted Stock Units"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r160",
      "r161",
      "r164",
      "r165",
      "r167"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r510",
      "r519"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r505"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease, rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Payments Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r504"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Operating lease liability",
        "totalLabel": "Operating Lease, Liability, Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r504"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease obligations, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r506",
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Operating cash flows related to operating leases",
        "verboseLabel": "Operating lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r515",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r421"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r43"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other long term assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r59",
      "r60",
      "r62"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax",
        "terseLabel": "Unrealized (loss) gain on marketable securities",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Comprehensive Loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r66",
      "r69",
      "r441",
      "r442",
      "r448"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]",
        "terseLabel": "Other comprehensive (loss) income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherExpenseMember": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other expense.",
        "label": "Other Expense [Member]",
        "terseLabel": "Other Expense"
       }
      }
     },
     "localname": "OtherExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long term liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Interest and other income, net",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Other Research and Development Expense",
        "terseLabel": "Non-cash research and development license expense in operating activity in cash flow"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Payments For Rent",
        "terseLabel": "Rent paid"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.",
        "label": "Payments For Repurchase Of Initial Public Offering",
        "negatedLabel": "Payment of initial public offering costs"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments Of Stock Issuance Costs",
        "terseLabel": "Transaction costs on issuance"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments To Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities",
        "totalLabel": "Payments to Acquire Marketable Securities, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r354",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share conversion price of preferred stock.",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "terseLabel": "Preferred stock, convertible, conversion price"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.",
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "terseLabel": "Preferred stock, convertible, conversion ratio"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionRatio",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, value per share",
        "verboseLabel": "Preferred stock, value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r24",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "verboseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred Stock, Shares Outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r24",
      "r534"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Convertible preferred stock (See Note 10)",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "verboseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and oustanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r9",
      "r32",
      "r33"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRent": {
     "auth_ref": [
      "r8",
      "r10",
      "r209",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Rent",
        "terseLabel": "Prepaid rent"
       }
      }
     },
     "localname": "PrepaidRent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromContributedCapital": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period.",
        "label": "Proceeds from Contributed Capital",
        "terseLabel": "Payments received on shareholder loan"
       }
      }
     },
     "localname": "ProceedsFromContributedCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds From Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering, net of underwriting discount"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds From Issuance Of Preferred Stock And Preference Stock",
        "terseLabel": "Proceeds from issuance of Preferred Stock, net",
        "verboseLabel": "Issuance of preferred stock tranche liability"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds From Issuance Or Sale Of Equity",
        "terseLabel": "Proceeds from issuance or sale of preferred stock",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds From License Fees Received",
        "terseLabel": "Annual license fee"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r82",
      "r385"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r65",
      "r68",
      "r74",
      "r87",
      "r103",
      "r116",
      "r125",
      "r126",
      "r160",
      "r161",
      "r164",
      "r165",
      "r167",
      "r188",
      "r231",
      "r232",
      "r233",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r441",
      "r446",
      "r447",
      "r452",
      "r453",
      "r468",
      "r481",
      "r602"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r37",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r226",
      "r639",
      "r640",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property Plant And Equipment Estimated Useful Lives",
        "terseLabel": "Property and equipment estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r36",
      "r220"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Total property and equipment",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r222",
      "r534",
      "r606",
      "r613"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r35",
      "r222",
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property and equipment estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForLeaseLosses": {
     "auth_ref": [
      "r601"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to estimated loss to be realized from lease transactions.",
        "label": "Provision For Lease Losses",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "ProvisionForLeaseLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r323",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction Expenses From Transactions With Related Party",
        "terseLabel": "Related Party Transaction, Expenses from Transactions with Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r323",
      "r525",
      "r529",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r523",
      "r524",
      "r526",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.",
        "label": "Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security",
        "terseLabel": "Repayment of shareholder loan",
        "totalLabel": "Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security, Total"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments Of Senior Debt",
        "terseLabel": "Repayments of Debt",
        "totalLabel": "Repayments of Senior Debt, Total"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research And Development Arrangement Contract To Perform For Others By Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research And Development Arrangement Contract To Perform For Others [Line Items]",
        "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.",
        "label": "Research And Development Arrangement [Member]",
        "terseLabel": "Research and Development Arrangement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r401",
      "r572",
      "r653"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r16",
      "r95",
      "r98"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash and Cash Equivalents, Current, Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r12",
      "r19",
      "r98",
      "r638"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r27",
      "r272",
      "r393",
      "r534",
      "r611",
      "r630",
      "r635"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated Deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r112",
      "r113",
      "r114",
      "r117",
      "r124",
      "r126",
      "r195",
      "r390",
      "r391",
      "r392",
      "r428",
      "r429",
      "r466",
      "r626",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanNameAxis": {
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Axis]"
       }
      }
     },
     "localname": "RetirementPlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanNameDomain": {
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Domain]"
       }
      }
     },
     "localname": "RetirementPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r514",
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of Stock, Consideration Received on Transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of Stock, Number of Shares Issued in Transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "terseLabel": "Sale of stock, price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Deferred Taxes"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r131",
      "r132",
      "r136",
      "r138",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule Of Earnings Per Share Basic By Common Class [Table]",
        "terseLabel": "Schedule Of Earnings Per Share Basic By Common Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r353",
      "r381",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Stock Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Instruments, Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Commitments under Non-Cancellable Leases",
        "verboseLabel": "Schedule of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r37",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r527",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions By Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]",
        "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r354",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r360",
      "r369",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Assumptions Used for Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r47",
      "r101",
      "r145",
      "r146",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock",
        "verboseLabel": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue": {
     "auth_ref": [
      "r559"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from changes in fair value classified as other for a contract to service financial assets under which the estimated future revenues from contractually specified servicing fees, late charges, and other ancillary revenues are not expected to adequately compensate the servicer.",
        "label": "Servicing Liability at Fair Value, Other Changes in Fair Value"
       }
      }
     },
     "localname": "ServicingLiabilityAtFairValueOtherChangesInFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r352",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Description",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of RSUs, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant-Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Unvested RSUs, ending balance, Unvested",
        "periodStartLabel": "Unvested RSUs, beginning balance, Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value Per Share, ending balance, Unvested",
        "periodStartLabel": "Weighted-Average Grant Date Fair Value Per Share, beginning balance, Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Unvested Restricted stock vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value Per Share, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Weighted-average risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Shares available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Number of options, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period",
        "negatedLabel": "Number of options, Forfeited",
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r362",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of options, Outstanding, Ending balance",
        "periodStartLabel": "Number of options, Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Ending balance",
        "periodStartLabel": "Weighted average exercise price, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number",
        "terseLabel": "Number of options, Expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum",
        "terseLabel": "Percentage of outstanding stock, reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r352",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r354",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding",
        "terseLabel": "Aggregate intrinsic value, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r376",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate intrinsic value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted average remaining contractual life (in years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted average remaining contractual life (in years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted average remaining contractual life (in years), Expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r20",
      "r534",
      "r594",
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short Term Borrowings",
        "terseLabel": "Letter of credit issued",
        "totalLabel": "Short-term Debt, Total"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermLeaseCommitmentAmount": {
     "auth_ref": [
      "r518"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease commitment.",
        "label": "Short-term Lease Commitment, Amount",
        "terseLabel": "Lease Rent Payment"
       }
      }
     },
     "localname": "ShortTermLeaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r511",
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short term lease costs"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r99",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r101",
      "r103",
      "r131",
      "r132",
      "r133",
      "r136",
      "r138",
      "r145",
      "r146",
      "r147",
      "r188",
      "r231",
      "r236",
      "r237",
      "r238",
      "r242",
      "r243",
      "r255",
      "r256",
      "r260",
      "r261",
      "r264",
      "r481",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r50",
      "r72",
      "r73",
      "r74",
      "r112",
      "r113",
      "r114",
      "r117",
      "r124",
      "r126",
      "r144",
      "r195",
      "r264",
      "r272",
      "r390",
      "r391",
      "r392",
      "r428",
      "r429",
      "r466",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r626",
      "r627",
      "r628",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r144",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r49",
      "r247",
      "r264",
      "r265",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period Shares Conversion Of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r24",
      "r25",
      "r264",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "terseLabel": "Purchase of common stock under ESPP(shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r264",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock from initial public offering, net of issuance costs of (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r264",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period Shares Restricted Stock Award Gross",
        "terseLabel": "Vesting of restricted common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r25",
      "r264",
      "r272",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of options, Exercised",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r50",
      "r264",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period Value Conversion Of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon closing of initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r24",
      "r25",
      "r264",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Purchase of common stock under ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r264",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock from initial public offering, net of issuance costs of $25,098",
        "verboseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r24",
      "r25",
      "r264",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period Value Restricted Stock Award Gross",
        "terseLabel": "Vesting of restricted common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r50",
      "r264",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r25",
      "r29",
      "r30",
      "r103",
      "r172",
      "r188",
      "r481",
      "r534"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equtiy (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Stockholders' Equity, Reverse Stock Split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r498",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r498",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r498",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsDate": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the event occurred after the balance sheet date but before financial statements are issues or available to be issued, in YYYY-MM-DD format.",
        "label": "Subsequent Event, Date",
        "terseLabel": "Subsequent event, date"
       }
      }
     },
     "localname": "SubsequentEventsDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events Policy Policy [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r535",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]",
        "terseLabel": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary Sale Of Stock [Line Items]",
        "terseLabel": "Subsidiary Sale Of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r421"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "Tax credit amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Value New Issues",
        "negatedLabel": "Issuance of Series A Preferred"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r182",
      "r183",
      "r185",
      "r186",
      "r187",
      "r248",
      "r263",
      "r457",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r116",
      "r117",
      "r118",
      "r119",
      "r128",
      "r173",
      "r174",
      "r192",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r230",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r426",
      "r427",
      "r428",
      "r429",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r522",
      "r575",
      "r576",
      "r577",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r108",
      "r299",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "U S Government Agencies Debt Securities [Member]",
        "terseLabel": "US Government Agencies Debt Securities",
        "verboseLabel": "U.S. Agency Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r108",
      "r299",
      "r338",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "U S Treasury Securities [Member]",
        "terseLabel": "US Treasury Securities",
        "verboseLabel": "U.S. Treasury Bills and Notes [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r404",
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r149",
      "r150",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Deferred tax assets valuation allowance increase (decrease)"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r512",
      "r519"
     ],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average common shares used in net loss per share attributable to common stockholders, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_AccruedExternalResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued external research and development expenses",
        "label": "Accrued External Research And Development Expenses",
        "terseLabel": "Accrued external research and development expenses"
       }
      }
     },
     "localname": "AccruedExternalResearchAndDevelopmentExpenses",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_AcuitasAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acuitas agreements.",
        "label": "Acuitas Agreements [Member]",
        "terseLabel": "Acuitas Agreements"
       }
      }
     },
     "localname": "AcuitasAgreementsMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_AdditionalLesseeOperatingLeaseArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Lessee Operating Lease Area",
        "label": "Additional Lessee Operating Lease Area",
        "terseLabel": "Additional Lease Area"
       }
      }
     },
     "localname": "AdditionalLesseeOperatingLeaseArea",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "verv_AdditionalTenantImprovementsAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional tenant improvements allowance.",
        "label": "Additional Tenant Improvements Allowance",
        "terseLabel": "Additional tenant improvements allowance"
       }
      }
     },
     "localname": "AdditionalTenantImprovementsAllowance",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_AmortizationOfPremiumOnMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of premium on marketable securities.",
        "label": "Amortization Of Premium On Marketable Securities",
        "terseLabel": "Amortization of premium on marketable securities"
       }
      }
     },
     "localname": "AmortizationOfPremiumOnMarketableSecurities",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_AntidilutionRightsLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antidilution rights liability.",
        "label": "Antidilution Rights Liability",
        "terseLabel": "Antidilution rights liability (See Notes 5, 8 and 15)"
       }
      }
     },
     "localname": "AntidilutionRightsLiability",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_AntidilutionRightsLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antidilution rights liability.",
        "label": "Antidilution Rights Liability [Member]",
        "terseLabel": "Antidilution Rights Liability"
       }
      }
     },
     "localname": "AntidilutionRightsLiabilityMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_AntidilutionRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antidilution rights.",
        "label": "Antidilution Rights [Member]",
        "terseLabel": "Antidilution Rights"
       }
      }
     },
     "localname": "AntidilutionRightsMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_BeamLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beam license agreement.",
        "label": "Beam License Agreement [Member]",
        "terseLabel": "Beam License Agreement"
       }
      }
     },
     "localname": "BeamLicenseAgreementMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_BeamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beam [Member].",
        "label": "Beam [Member]",
        "terseLabel": "Beam"
       }
      }
     },
     "localname": "BeamMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_BroadLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Broad License Agreement [Member]",
        "label": "Broad License Agreement [Member]",
        "terseLabel": "Broad License Agreement"
       }
      }
     },
     "localname": "BroadLicenseAgreementMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_CambridgeLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cambridge lease.",
        "label": "Cambridge Lease [Member]",
        "terseLabel": "Cambridge Lease"
       }
      }
     },
     "localname": "CambridgeLeaseMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurements of lease liabilities.",
        "label": "Cash Paid For Amounts Included In The Measurements Of Lease Liabilities [Abstract]"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.vervetx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "verv_ChangeInFairValueOfAntidilutionRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of antidilution rights.",
        "label": "Change In Fair Value Of Antidilution Rights",
        "negatedLabel": "Change in fair value of antidilution rights liability",
        "terseLabel": "Change in fair value of antidilution rights"
       }
      }
     },
     "localname": "ChangeInFairValueOfAntidilutionRights",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ChangeInFairValueOfPreferredStockTrancheLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of preferred stock tranche liabilities.",
        "label": "Change In Fair Value Of Preferred Stock Tranche Liabilities",
        "negatedLabel": "Change in fair value of preferred stock tranche liabilities",
        "terseLabel": "Change in fair value of preferred stock tranche liability"
       }
      }
     },
     "localname": "ChangeInFairValueOfPreferredStockTrancheLiabilities",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ChangeInFairValueOfSuccessPaymentsLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of success payments liabilities.",
        "label": "Change In Fair Value Of Success Payments Liabilities",
        "negatedLabel": "Change in fair value of success payment liability",
        "terseLabel": "Change in fair value of success payments liabilities"
       }
      }
     },
     "localname": "ChangeInFairValueOfSuccessPaymentsLiabilities",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ChangeInOwnershipDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in ownership description.",
        "label": "Change In Ownership Description",
        "terseLabel": "Change in ownership, description"
       }
      }
     },
     "localname": "ChangeInOwnershipDescription",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "verv_ClinicalAndRegulatoryMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical and regulatory milestone.",
        "label": "Clinical And Regulatory Milestone",
        "terseLabel": "Clinical And Regulatory Milestone"
       }
      }
     },
     "localname": "ClinicalAndRegulatoryMilestone",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And License Agreement [Member]",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration And License Agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_CommonStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Issued During Period Value New Issues",
        "label": "Common Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "CommonStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued for fully satisfying preferred stock financing",
        "label": "Common Stock Issued For Fully Satisfying Preferred Stock Financing",
        "terseLabel": "Common stock issued for fully satisfying preferred stock financing"
       }
      }
     },
     "localname": "CommonStockIssuedForFullySatisfyingPreferredStockFinancing",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued for partly satisfying preferred stock financing",
        "label": "Common Stock Issued For Partly Satisfying Preferred Stock Financing",
        "terseLabel": "Common stock issued for partly satisfying preferred stock financing"
       }
      }
     },
     "localname": "CommonStockIssuedForPartlySatisfyingPreferredStockFinancing",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer Equipment and Software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_ConvertiblePreferredStockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock.",
        "label": "Convertible Preferred Stock Policy [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockPolicyTextBlock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_CumulativeProbabilityOfTriggeringEvent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative probability of triggering event.",
        "label": "Cumulative Probability Of Triggering Event",
        "terseLabel": "Cumulative probability of triggering event"
       }
      }
     },
     "localname": "CumulativeProbabilityOfTriggeringEvent",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_DebtBorrowedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt borrowed amount.",
        "label": "Debt Borrowed Amount",
        "terseLabel": "Borrowed amount"
       }
      }
     },
     "localname": "DebtBorrowedAmount",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_DeferredOfferingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs.",
        "label": "Deferred Offering Costs Policy [Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_DeferredTaxAssetAccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset Accrued Expenses.",
        "label": "Deferred Tax Asset Accrued Expenses",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetAccruedExpenses",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_DeferredTaxAssetsAntidilultionLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Antidilultion Liability.",
        "label": "Deferred Tax Assets Antidilultion Liability",
        "terseLabel": "Antidilultion liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsAntidilultionLiability",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Capitalized Costs Net Of Amortization.",
        "label": "Deferred Tax Assets Capitalized Costs Net Of Amortization",
        "terseLabel": "Capitalized costs\u2014net of amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedCostsNetOfAmortization",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_DeferredTaxAssetsStockBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Stock-based compensation",
        "label": "Deferred Tax Assets, Stock-based compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsStockBasedCompensation",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax liabilities, Right of use asset",
        "label": "Deferred Tax liabilities, Right of use asset",
        "terseLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan, employer matching contribution, percent of match after 3% and before 5% of employee's salary.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent Of Match After Three Percent And Before Five Percent Of Employee Salary",
        "terseLabel": "Defined contribution plan, employer matching contribution, percent of match after 3% and before 5% of employee's salary"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan, employer matching contribution, percent of match upto 3% of employee's salary.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent Of Match Upto Three Percent Of Employee Salary",
        "terseLabel": "Defined contribution plan, employer matching contribution, percent of match upto 3% of employee's salary"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan employer matching contribution percent of match upto two percent of employee salary.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent of Match Upto Two Percent of Employee Salary",
        "terseLabel": "Defined contribution plan employer matching contribution percent of match upto two percent of employee salary"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_DeliveryTechnologyProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Delivery Technology Product [Member]",
        "label": "Delivery Technology Product [Member]",
        "terseLabel": "Delivery Technology Product"
       }
      }
     },
     "localname": "DeliveryTechnologyProductMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_DevelopedBaseMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed base milestone payments.",
        "label": "Developed Base Milestone Payments",
        "terseLabel": "Developed base milestone payments"
       }
      }
     },
     "localname": "DevelopedBaseMilestonePayments",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_DevelopedBaseMilestonePaymentsForStatedPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed base milestone payments for quarterly period.",
        "label": "Developed Base Milestone Payments For Stated Period",
        "terseLabel": "Developed base milestone payments for quarterly period"
       }
      }
     },
     "localname": "DevelopedBaseMilestonePaymentsForStatedPeriod",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Executive compensation, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Executive compensation, Percent",
        "terseLabel": "Executive compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_EffectiveIncomeTaxRateReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Permanent Items.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Items",
        "terseLabel": "Other permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_FairValueAssumptionOfEquityVolatilityRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value assumption of equity volatility rate.",
        "label": "Fair Value Assumption Of Equity Volatility Rate",
        "terseLabel": "Equity volatility"
       }
      }
     },
     "localname": "FairValueAssumptionOfEquityVolatilityRate",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_FairValueAssumptionsExpectedTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value assumptions expected term 1.",
        "label": "Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "FairValueAssumptionsExpectedTerm1",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "verv_FairValueInputsProbabilityOfTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value inputs probability of termination.",
        "label": "Fair Value Inputs Probability Of Termination",
        "terseLabel": "Fair value inputs probability of termination"
       }
      }
     },
     "localname": "FairValueInputsProbabilityOfTermination",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_FairValueOfCommonStockPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of common stock per share.",
        "label": "Fair Value Of Common Stock Per Share",
        "terseLabel": "Fair value of common stock (per share)"
       }
      }
     },
     "localname": "FairValueOfCommonStockPerShare",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "verv_FirstAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Amendment Member.",
        "label": "First Amendment [Member]",
        "terseLabel": "First Amendment"
       }
      }
     },
     "localname": "FirstAmendmentMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_FourZeroOneKPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "401(k) Plan [Member]",
        "label": "Four Zero One (K) Plan [Member]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "FourZeroOneKPlanMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Freestanding financial instruments and derivatives.",
        "label": "Freestanding Financial Instruments And Derivatives Policy [Text Block]",
        "terseLabel": "Freestanding Financial Instruments and Derivatives"
       }
      }
     },
     "localname": "FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_HarvardAndBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harvard and Board.",
        "label": "Harvard And Board [Member]",
        "terseLabel": "Harvard And Board"
       }
      }
     },
     "localname": "HarvardAndBoardMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_HarvardAndBroadLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harvard and Broad license agreement.",
        "label": "Harvard And Broad License Agreement [Member]",
        "terseLabel": "Harvard and Board"
       }
      }
     },
     "localname": "HarvardAndBroadLicenseAgreementMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_HarvardAndBroadMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harvard And Broad.",
        "label": "Harvard And Broad [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "HarvardAndBroadMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harvard/Broad License Agreement and Broad License Agreement [Member]",
        "label": "Harvard License Agreement And Broad License Agreement [Member]",
        "terseLabel": "Harvard License Agreement And Broad License Agreement"
       }
      }
     },
     "localname": "HarvardLicenseAgreementAndBroadLicenseAgreementMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_HarvardLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harward.",
        "label": "Harvard License Agreement [Member]",
        "terseLabel": "Harvard"
       }
      }
     },
     "localname": "HarvardLicenseAgreementMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Operating Lease Right Of Use Of Asset",
        "label": "Increase Decrease In Operating Lease Right Of Use Of Asset",
        "terseLabel": "Increase in Right-Of-Use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in common stock capital shares, reserved for future issuance.",
        "label": "Increase In Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Increase in common stock capital shares, reserved for future issuance"
       }
      }
     },
     "localname": "IncreaseInCommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_IndemnificationAgreementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification agreements.",
        "label": "Indemnification Agreements Policy [Text Block]",
        "terseLabel": "Indemnification Agreements"
       }
      }
     },
     "localname": "IndemnificationAgreementsPolicyTextBlock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_InterestRateForAdditionalImprovementsAllowance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate for additional improvements allowance.",
        "label": "Interest Rate For Additional Improvements Allowance",
        "terseLabel": "Improvement allowance interest rate"
       }
      }
     },
     "localname": "InterestRateForAdditionalImprovementsAllowance",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_IssuanceCostsOfCommonStockFromInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Costs Of Common Stock from Initial Public Offering",
        "label": "Issuance Costs Of Common Stock From Initial Public Offering",
        "terseLabel": "Issuance costs of common stock from initial public offering"
       }
      }
     },
     "localname": "IssuanceCostsOfCommonStockFromInitialPublicOffering",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance costs of series A2 convertible preferred stock.",
        "label": "Issuance Costs Of Series A2 Convertible Preferred Stock",
        "terseLabel": "Issuance costs of series A2 convertible preferred stock"
       }
      }
     },
     "localname": "IssuanceCostsOfSeriesA2ConvertiblePreferredStock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_IssuanceCostsOfSeriesAConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Costs of Series A Convertible Preferred Stock",
        "label": "Issuance Costs Of Series A Convertible Preferred Stock",
        "terseLabel": "Issuance costs of series A convertible preferred stock"
       }
      }
     },
     "localname": "IssuanceCostsOfSeriesAConvertiblePreferredStock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_IssuanceCostsOfSeriesBConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Costs Of Series B Convertible Preferred Stock",
        "label": "Issuance Costs Of Series B Convertible Preferred Stock",
        "terseLabel": "Issuance costs of series B convertible preferred stock"
       }
      }
     },
     "localname": "IssuanceCostsOfSeriesBConvertiblePreferredStock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_IssuanceOfAdditionalCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of additional common stock.",
        "label": "Issuance of Additional Common Stock"
       }
      }
     },
     "localname": "IssuanceOfAdditionalCommonStock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_IssuanceOfPreferredStockTrancheLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of preferred stock tranche liability.",
        "label": "Issuance of Preferred Stock Tranche Liability",
        "terseLabel": "Issuance of preferred stock tranche liability"
       }
      }
     },
     "localname": "IssuanceOfPreferredStockTrancheLiability",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series A convertible preferred stock and settlement of tranche right liability.",
        "label": "Issuance of Series A Convertible Preferred Stock and Settlement of Tranche Right Liability",
        "terseLabel": "Issuance of Series A convertible preferred stock and settlement of tranche right liability"
       }
      }
     },
     "localname": "IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_LeaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Commencement Date.",
        "label": "Lease Commencement Date",
        "terseLabel": "Lease commencement date"
       }
      }
     },
     "localname": "LeaseCommencementDate",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "verv_LeaseNoncancelableTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Noncancelable Term.",
        "label": "Lease Noncancelable Term",
        "terseLabel": "Lease noncancelable term"
       }
      }
     },
     "localname": "LeaseNoncancelableTerm",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "verv_LesseeOperatingLeaseArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease area.",
        "label": "Lessee Operating Lease Area",
        "terseLabel": "Lease area"
       }
      }
     },
     "localname": "LesseeOperatingLeaseArea",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "verv_LesseeOperatingLeaseIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease incremental borrowing rate.",
        "label": "Lessee Operating Lease Incremental Borrowing Rate",
        "terseLabel": "Operating lease incremental borrowing rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseIncrementalBorrowingRate",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after year four.",
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_LicenseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement Abstract",
        "label": "License Agreement [Abstract]"
       }
      }
     },
     "localname": "LicenseAgreementAbstract",
     "nsuri": "http://www.vervetx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "verv_LicenseAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement",
        "label": "License Agreement Disclosure [Text Block]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDisclosureTextBlock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_MassachusettsTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Massachusetts Tax Authority [Member].",
        "label": "Massachusetts Tax Authority [Member]",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "localname": "MassachusettsTaxAuthorityMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_MaterialsExchangeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Materials Exchange Agreement [Member].",
        "label": "Materials Exchange Agreement [Member]",
        "terseLabel": "Materials Exchange Agreement"
       }
      }
     },
     "localname": "MaterialsExchangeAgreementMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_MaturitiesOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturities of marketable securities.",
        "label": "Maturities Of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "MaturitiesOfMarketableSecurities",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_MilestoneRelatedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone related expenses.",
        "label": "Milestone Related Expenses",
        "terseLabel": "Milestone related expenses"
       }
      }
     },
     "localname": "MilestoneRelatedExpenses",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_NewAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Amendment [Member]",
        "label": "New Amendment [Member]",
        "terseLabel": "New Amendment"
       }
      }
     },
     "localname": "NewAmendmentMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_NonRefundableUpfrontLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non refundable upfront license fee.",
        "label": "Non Refundable Upfront License Fee",
        "terseLabel": "Non Refundable Upfront License Fee"
       }
      }
     },
     "localname": "NonRefundableUpfrontLicenseFee",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_NonRefundableUpfrontLicenseFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Refundable Upfront License Fees.",
        "label": "Non Refundable Upfront License Fees",
        "terseLabel": "Non Refundable Upfront License Fees"
       }
      }
     },
     "localname": "NonRefundableUpfrontLicenseFees",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_NonRefundableUpfrontLicenseFeesPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable upfront license fees paid",
        "label": "Non Refundable Upfront License Fees Paid",
        "terseLabel": "Non-refundable upfront license fees paid"
       }
      }
     },
     "localname": "NonRefundableUpfrontLicenseFeesPaid",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_NonRefundableUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non refundable upfront payment",
        "label": "Non Refundable Upfront Payment"
       }
      }
     },
     "localname": "NonRefundableUpfrontPayment",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_NumberOfInstallmentsForRestrictedSharesVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of installments for restricted shares vested.",
        "label": "Number of Installments for Restricted Shares Vested"
       }
      }
     },
     "localname": "NumberOfInstallmentsForRestrictedSharesVested",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "verv_OfficeFurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office furniture.",
        "label": "Office Furniture [Member]",
        "terseLabel": "Office Furniture"
       }
      }
     },
     "localname": "OfficeFurnitureMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_OperatingLeaseRelatedExpensesPriorToCommencement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease related expenses prior to commencement.",
        "label": "Operating Lease Related Expenses Prior To Commencement",
        "terseLabel": "Lease space build out cost prior to commencement"
       }
      }
     },
     "localname": "OperatingLeaseRelatedExpensesPriorToCommencement",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "verv_OptionAndLicenseIssueFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option And License Issue Fees.",
        "label": "Option And License Issue Fees",
        "terseLabel": "Option And License Issue Fees"
       }
      }
     },
     "localname": "OptionAndLicenseIssueFees",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_OptionLicenseAgreementAndPatentLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option License Agreement and Patent License Agreement [Member].",
        "label": "Option License Agreement And Patent License Agreement [Member]",
        "terseLabel": "Option License Agreement And Patent License Agreement"
       }
      }
     },
     "localname": "OptionLicenseAgreementAndPatentLicenseAgreementMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_OutOfPocketCostsIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "out-of-pocket costs incurred.",
        "label": "Out Of Pocket Costs Incurred",
        "terseLabel": "Out-of-pocket costs incurred"
       }
      }
     },
     "localname": "OutOfPocketCostsIncurred",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_OutstandingOptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding Options to Purchase Common Stock",
        "label": "Outstanding Options To Purchase Common Stock [Member]",
        "terseLabel": "Outstanding Options To Purchase Common Stock"
       }
      }
     },
     "localname": "OutstandingOptionsToPurchaseCommonStockMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_PaymentOfMilestoneDevelopment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of milestone development.",
        "label": "Payment Of Milestone Development",
        "terseLabel": "Payment of milestone development"
       }
      }
     },
     "localname": "PaymentOfMilestoneDevelopment",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_PaymentOfSalesBasedMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of sales based milestone.",
        "label": "Payment Of Sales Based Milestone",
        "terseLabel": "Payment of sales based milestone"
       }
      }
     },
     "localname": "PaymentOfSalesBasedMilestone",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment received for license agreement reimbursement of costs incurred",
        "label": "Payment Received For License Agreement Reimbursement Of Costs Incurred",
        "terseLabel": "Reimbursement received related to reduction to research and development expense"
       }
      }
     },
     "localname": "PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_PercentageOfFutureTaxableIncomeUtilizedToOffset": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of future taxable income utilized to offset",
        "label": "Percentage of future taxable income utilized to offset"
       }
      }
     },
     "localname": "PercentageOfFutureTaxableIncomeUtilizedToOffset",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_PercentageOfTaxBenefitRealized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of tax benefit realized",
        "label": "Percentage of tax benefit realized"
       }
      }
     },
     "localname": "PercentageOfTaxBenefitRealized",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_PercentageSharesOfDevelopmentExpense": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Shares of Development Expense.",
        "label": "Percentage Shares Of Development Expense",
        "terseLabel": "Percentage Shares of Development Expense"
       }
      }
     },
     "localname": "PercentageSharesOfDevelopmentExpense",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_PreferredAndCommonStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred and common stock disclosure text block.",
        "label": "Preferred And Common Stock [Text Block]",
        "terseLabel": "Preferred and Common Stock"
       }
      }
     },
     "localname": "PreferredAndCommonStockTextBlock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_PreferredStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock abstract.",
        "label": "Preferred Stock [Abstract]"
       }
      }
     },
     "localname": "PreferredStockAbstract",
     "nsuri": "http://www.vervetx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "verv_PreferredStockFinancingFullySatisfied": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock financing fully satisfied",
        "label": "Preferred Stock Financing Fully Satisfied",
        "terseLabel": "Preferred stock financing were fully satisfied"
       }
      }
     },
     "localname": "PreferredStockFinancingFullySatisfied",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_PreferredStockFinancingPartiallySatisfied": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock financing partially satisfied",
        "label": "Preferred Stock Financing Partially Satisfied",
        "terseLabel": "Preferred stock financing partially satisfied"
       }
      }
     },
     "localname": "PreferredStockFinancingPartiallySatisfied",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_PreferredStockTrancheLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock tranche liability.",
        "label": "Preferred Stock Tranche Liability [Member]",
        "terseLabel": "Preferred Stock Tranche Liability"
       }
      }
     },
     "localname": "PreferredStockTrancheLiabilityMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_PreferredStockTrancheLiabilityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock tranche liability disclosure text block.",
        "label": "Preferred Stock Tranche Liability [Text Block]",
        "terseLabel": "Preferred Stock Tranche Liability"
       }
      }
     },
     "localname": "PreferredStockTrancheLiabilityTextBlock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosurePreferredStockTrancheLiability1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_PremisesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premises.",
        "label": "Premises [Member]",
        "terseLabel": "Premises"
       }
      }
     },
     "localname": "PremisesMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_ProceedFromShareholderLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceed from shareholder loan.",
        "label": "Proceed from Shareholder Loan",
        "terseLabel": "Shareholder loan given"
       }
      }
     },
     "localname": "ProceedFromShareholderLoan",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance Of Common Stock Under IPO, Gross.",
        "label": "Proceeds From Issuance Of Common Stock Under I P O Gross",
        "terseLabel": "Proceeds from common stock, gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockUnderIPOGross",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance of Preferred Stock after Deducting Underwriting Discounts and Offering Expenses",
        "label": "Proceeds from Issuance of Preferred Stock after Deducting Underwriting Discounts and Offering Expenses",
        "terseLabel": "Proceeds from issuance of Preferred Stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ProductCollaborationTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product collaboration termination notice period.",
        "label": "Product Collaboration Termination Notice Period",
        "terseLabel": "Product collaboration termination notice period"
       }
      }
     },
     "localname": "ProductCollaborationTerminationNoticePeriod",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property and equipment additions included in accounts payable and accrued expenses.",
        "label": "Property And Equipment Additions Included In Accounts Payable And Accrued Expenses",
        "terseLabel": "Property and equipment additions included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_PublicPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public price.",
        "label": "Public Price",
        "terseLabel": "Public price"
       }
      }
     },
     "localname": "PublicPrice",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation of cash, cash equivalents and restricted cash.",
        "label": "Reconciliation Of Cash Cash Equivalents And Restricted Cash Table [Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_ReductionInResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction In Research And Development Expense.",
        "label": "Reduction In Research And Development Expense",
        "terseLabel": "Reduction In Research And Development Expense"
       }
      }
     },
     "localname": "ReductionInResearchAndDevelopmentExpense",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining contractual maturities of marketable securities term.",
        "label": "Remaining Contractual Maturities Of Marketable Securities Term",
        "terseLabel": "Remaining contractual maturities of marketable securities term"
       }
      }
     },
     "localname": "RemainingContractualMaturitiesOfMarketableSecuritiesTerm",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "verv_RentExpensePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policy of rent expense.",
        "label": "Rent Expense Policy [Text Block]",
        "terseLabel": "Rent Expense"
       }
      }
     },
     "localname": "RentExpensePolicyTextBlock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense of antidilution rights liability",
        "label": "Research and development expense of antidilution rights liability"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_SalesBasedMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales based milestone",
        "label": "Sales Based Milestone",
        "terseLabel": "Sales Based Milestone"
       }
      }
     },
     "localname": "SalesBasedMilestone",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of property and equipment estimated useful life.",
        "label": "Schedule Of Property And Equipment Estimated Useful Life Table [Text Block]",
        "terseLabel": "Schedule of Property and Equipment Estimated Useful Life"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental cash flow information related to operating leases.",
        "label": "Schedule Of Supplemental Cash Flow Information Related To Operating Leases Table [Text Block]",
        "terseLabel": "Supplemental Cash Flow Information Related to Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_SecondAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Amendment Member.",
        "label": "Second Amendment [Member]",
        "terseLabel": "Second Amendment"
       }
      }
     },
     "localname": "SecondAmendmentMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_SecondTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Tranche Member",
        "label": "Second Tranche [Member]",
        "verboseLabel": "Second Tranche [Member]"
       }
      }
     },
     "localname": "SecondTrancheMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_SegmentAndGeographicInformationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policy related to segment and geographic information.",
        "label": "Segment And Geographic Information Policy [Text Block]",
        "terseLabel": "Segment and Geographic Information"
       }
      }
     },
     "localname": "SegmentAndGeographicInformationPolicyTextBlock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_SeriesA2PreferredStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-2 Preferred Stock.",
        "label": "Series A2 Preferred Stocks [Member]",
        "terseLabel": "Series A-2 Preferred Stock"
       }
      }
     },
     "localname": "SeriesA2PreferredStocksMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of Antidilution Rights Liability By Issuing Common Stock",
        "label": "Settlement Of Antidilution Rights Liability By Issuing Common Stock",
        "terseLabel": "Settlement of derivative liability by issuing common stock"
       }
      }
     },
     "localname": "SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_SettlementOfTrancheRightLliability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of tranche right liability.",
        "label": "Settlement Of Tranche Right Lliability",
        "terseLabel": "Settlement of tranche right liability"
       }
      }
     },
     "localname": "SettlementOfTrancheRightLliability",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ShortTermBorrowingsReducedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term borrowings reduced value.",
        "label": "Short Term Borrowings Reduced Value",
        "terseLabel": "Letter of credit reduced value"
       }
      }
     },
     "localname": "ShortTermBorrowingsReducedValue",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Available For Issuance Under Employee Stock Purchase Plan",
        "label": "Stock Available For Issuance Under Employee Stock Purchase Plan",
        "terseLabel": "Stock available for issuance under ESPP"
       }
      }
     },
     "localname": "StockAvailableForIssuanceUnderEmployeeStockPurchasePlan",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of additional common stock to licensor institutions (in shares)",
        "label": "Stock Issued During Period Additional Share Licensor Institutions",
        "terseLabel": "Additional issuances of common stock to licensor institutions (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodAdditionalShareLicensorInstitutions",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of additional shares issued to licensor institutuons.",
        "label": "Stock Issued During Period Additional Shares Value Licensor Institutions",
        "terseLabel": "Additional issuances of common stock to licensor institutions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_StockIssuedDuringPeriodShareLicensorInstitutions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock to licensor institutions (in shares)",
        "label": "Stock Issued During Period Share Licensor Institutions",
        "terseLabel": "Issuances of common stock to licensor institutions (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShareLicensorInstitutions",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series A-2 convertible preferred stock, net of issuance costs (in shares)",
        "label": "Stock Issued During Period Shares Series A2 Convertible Preferred Stock",
        "terseLabel": "Issuance of Series A-2 convertible preferred stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series A convertible preferred stock, net of issuance costs (in shares)",
        "label": "Stock Issued During Period Shares Series A Convertible Preferred Stock",
        "terseLabel": "Issuance of Series A convertible preferred stock and settlement of tranche right liability, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares Series A Preferred Stock In Payment of Licensing Fee.",
        "label": "Stock Issued During Period Shares Series A Preferred Stock In Payment of Licensing Fee",
        "terseLabel": "Issuance of Series A Preferred Stock in payment of licensing fee (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series B convertible preferred stock, net of issuance costs (in shares)",
        "label": "Stock Issued During Period Shares Series B Convertible Preferred Stock",
        "terseLabel": "Issuance of Series B convertible preferred stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_StockIssuedDuringPeriodValueLicensorInstitutions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value Licensor Institutions",
        "label": "Stock Issued During Period Value Licensor Institutions",
        "terseLabel": "Issuances of common stock to licensor institutions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueLicensorInstitutions",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series A-2 convertible preferred stock, net of issuance costs.",
        "label": "Stock Issued During Period Value Series A2 Convertible Preferred Stock",
        "terseLabel": "Issuance of Series A-2 convertible preferred stock, net of issuance costs of $112"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares series a convertible preferred stock.",
        "label": "Stock Issued During Period Value Series A Convertible Preferred Stock",
        "terseLabel": "Issuance of Series A convertible preferred stock and settlement of tranche right liability, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value Series A Preferred Stock In Payment Of Licensing Fee.",
        "label": "Stock Issued During Period Value Series A Preferred Stock In Payment Of Licensing Fee",
        "terseLabel": "Issuance of Series A Preferred Stock in payment of licensing fee"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series B convertible preferred stock, net of issuance costs",
        "label": "Stock Issued During Period Value Series B Convertible Preferred Stock",
        "terseLabel": "Issuance of Series B convertible preferred stock, net of issuance costs of $241"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_SuccessLiabilityPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success Liability Payment",
        "label": "Success Liability Payment"
       }
      }
     },
     "localname": "SuccessLiabilityPayment",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_SuccessOfPaymentLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success of payment liability",
        "label": "Success of payment liability"
       }
      }
     },
     "localname": "SuccessOfPaymentLiability",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_SuccessPaymentLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success payment liability.",
        "label": "Success Payment Liability",
        "terseLabel": "Success payment liability (See Notes 5, 8 and 15)"
       }
      }
     },
     "localname": "SuccessPaymentLiability",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_SuccessPaymentLiabilityCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success Payment Liability Current",
        "label": "Success Payment Liability Current",
        "terseLabel": "Success payment, current portion"
       }
      }
     },
     "localname": "SuccessPaymentLiabilityCurrent",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_SuccessPaymentLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success payment liability.",
        "label": "Success Payment Liability [Member]",
        "terseLabel": "Success Payment Liability"
       }
      }
     },
     "localname": "SuccessPaymentLiabilityMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInsrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "verv_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "verv_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carryforward expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, Conversion of convertible preferred stock to common stock upon closing of initial public offering",
        "label": "Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon closing of initial public offering"
       }
      }
     },
     "localname": "TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_TenantImprovementsAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvements allowance.",
        "label": "Tenant Improvements Allowance",
        "terseLabel": "Tenant improvements allowance"
       }
      }
     },
     "localname": "TenantImprovementsAllowance",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ThirdTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third tranche.",
        "label": "Third Tranche [Member]",
        "terseLabel": "Third tranche",
        "verboseLabel": "Third Tranche [Member]"
       }
      }
     },
     "localname": "ThirdTrancheMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_TwentyEighteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty eighteen",
        "label": "Twenty Eighteen [Member]",
        "terseLabel": "Twenty Eighteen"
       }
      }
     },
     "localname": "TwentyEighteenMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_TwentyTwentyOneEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty twenty one employee stock purchase plan member",
        "label": "Twenty Twenty One Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "TwentyTwentyOneEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_TwoThousandAndTwentyOneStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Twenty One Stock Incentive Plan [Member]",
        "label": "Two Thousand And Twenty One Stock Incentive Plan [Member]",
        "terseLabel": "2021 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneStockIncentivePlanMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_USAgencySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. agency securities.",
        "label": "U S Agency Securities [Member]",
        "terseLabel": "U.S. Agency Securities [Member]"
       }
      }
     },
     "localname": "USAgencySecuritiesMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_USTreasuryBillsAndNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. treasury bills and notes.",
        "label": "U S Treasury Bills And Notes [Member]",
        "terseLabel": "U.S. Treasury Bills and Notes [Member]"
       }
      }
     },
     "localname": "USTreasuryBillsAndNotesMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_UnvestedRestrictedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Restricted Stock.",
        "label": "Unvested Restricted Stock [Member]",
        "terseLabel": "Unvested Restricted Stock"
       }
      }
     },
     "localname": "UnvestedRestrictedStockMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_UnvestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Restricted Stock Units [Member]",
        "label": "Unvested Restricted Stock Units [Member]",
        "terseLabel": "Unvested Restricted Stock Units"
       }
      }
     },
     "localname": "UnvestedRestrictedStockUnitsMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_VerilyLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verily License Agreement [Member]",
        "label": "Verily License Agreement [Member]",
        "terseLabel": "Verily License Agreement"
       }
      }
     },
     "localname": "VerilyLicenseAgreementMember",
     "nsuri": "http://www.vervetx.com/20211231",
     "presentation": [
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20211231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e21216-110875"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235116"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918705-209980"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.11)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r654": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r655": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r656": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r657": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r658": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r659": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r660": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r661": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r662": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r663": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r664": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r665": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r666": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r667": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r668": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r669": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r670": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r671": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r672": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>122
<FILENAME>0000950170-22-003499-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-003499-xbrl.zip
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M9*=8V7^0YZ_S")9YT.LFY@EP$AB69L(07GSA*RGUXO0[J=]%;E^_,O7!]A,
MU=D)U25N8G'0BJQ+3O U$94:7"1Y(AG(@?CJZU'-#PRSV3'$YKW^U7#9P:A
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M#KE@IFGR'3V0[T=_@]5DKHH0-4P:*O1EI"-XXPFP^F+*\2XQ8YJXR[J*QW;
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M,2\PQ2U+B@M+VA. [H;$40%$]:<S_"+',^"H59%]4N]S_>=9;&[(<1[;>Y\
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M:07%3+'$FJ5JVBYW..A91\D,/5 *,;VZ]^3G4UIJS&]D=4B^J7$YK&GERC
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M>;G\C-3EGBF,[M&[5NX>6615XO<=G3!<A\%Z#_>V(;L?QV6<Z3>/TR+']$\
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ML&WOI8T,JAG5!<.1'/5-O#D1G _)M!6!OTNEM)0_EW2;". A^YJ<F>**RDA
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M"USMVO!;< !9,)P;,#T>?EDS,N,@[!='6=T0]89.C1HYMB'-?#AQ9-;Z;)!
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MU4V'M:3:S[IF2H$4VCXP=$ASQ/"DQYZ(00-XT?&KJIE7-7? K>R>/C["-UG
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M\&@"EOC2*Y+XM#':L"G1$@R0YHD!CH\89O2'!VK>.'B9VI3WEE!P>#.]L^"
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MO@48I;X;E[A>_S669[V/A+W>@#FC3#,(9TIJ#NG>88"500P@8!SA.CR!BAR
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M!A7U!%VMODTQK'TW@ UYI1;%CP'("']YF=>IJN@ZF%@?"]C"0@/>1)!KZI[
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M.U..7"?PA%W(RI]T(!;0U4]VX!WE[:>X0;AZ0_4%L\\$)WR>DF%+<AR&J,0
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M \:C'P'S6 "M4/]#9-@:Y[->Z.R#$]+Z&MZ3>5+NG2&9.HE'?X4TSA(X!P9
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M?V15ELHEY>OS_JT/I41>RL+P:T_.*\^APW='7-%OUX]0-E%U@0*P?R+@\=[
M7)VLF&(C;B![A_8^\G;<]*4*!U?&^&A9?IOG)+(WJ!DV8AHQP(UJ/0R I7[0
MC0$()$QWSO7#-D B$Z'_JL% @DR0?UEHB3$Y6\6-V(X37Z/%+<N2P0!H &-S
M"B\2;[GF@!#V->I :1K<#I-\#!"8@W)P \O1?_:]AJE!8J_50M/>\ZHV_<-2
MY'2F6$&@3]=8?27V)<VJ=;*NRT#G_XG\_\3W+;V[*_XRA^\&QM<)XJ#"9(T?
M.9^+H%3M!\"-B^Z'KM)/(/D<[ ,)6_L\1_R%ML05@I;MLF2OW&&<V H.3^A[
MQPZ;O5\&%G-@NNQ:Q/IE! RPN_C;U&5L$D1=9QA0S)NP+EX=,!'?1@O"ZM0I
MC[%W35%XT!D#F'.QD/7V&NGQ:QO^]4/Y\R10@_=GS<Z*XC^WQ2'[W:#0T],L
MCP[OQ3J[#&R;?HEAK[_J))VO.6[8\I'_5OA5%LLKQW6B5[K.Z/W]M(XPVS@&
M)X>GC? QM!V49\*H1S577]KVE=;8S;BM"Q=E)CAMWA #UB#I^/5'"J?%00HI
M&@0D0FG#UJCK P.65MI5;E#!_AF<G.C/V)=4'V>/O"PKC]0E9"!TWTIY'"@
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MYX+#W8U3?\BQ0;AD=I9U/!C\N%*N@5NL;6H;C/93P #^A*;%8,4BF8D!/H<
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MLYP,0-Q.PZZ.HK3H<C^&#)_$#?-H=C=D-E$(*'Z'(7-X6WN>O+11UY[580!
M&4]/$P6Z11>RC4=_@^*%>>4)U,= NKE, J)LMIF1>-R['1XI<&F'^EK"%[Z
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M^&JIB:9OTE]ST/T1%B:R0;SXJ!:"?M<'0M39[ I>"96!E.=_34*:Y)?14O?
ML ]T1+M;9V"=6#!X8PN"XI8TI1SD:]>(3\ZBQA!T(0>$ZK&DU,X11'H.[*,J
MZ()*Q:"1!28JIZ/._(C.QP#3PHN,)!@@TA,*+P3A1[[)]*^PX^J1 3GL!1\H
MAH,;MT QI()1ZUAH2[?N]X[5AT K:3=;XHS3FJ]LHED5TI2[Z_1=O2P]4FY0
M/GWX[M YTSW^C??7X4.*4H.)>;7ZF^VS*"N<:J?()*O0^6Q ?WLKYM 3F<^3
MY$BSRWOK0ZZSEUZ/A8>WU>V2:UEPQT9/J+4&*PO],B.*Z[XO[69DIF0H!;EE
M!3W \=+XG2OCT64E<OH+N:+"1OK547 UCSFZUP+5[YT:L<^8=5#G58XOV'4U
M5#\MGG_-G*4&.+ZB+\/)<4%HX/K\Q R,<P.+JR*S/PW:7A4R?> ABT^*:.L0
M0^A%C"-E,8"LG2,2#,SA_032<;1M!ZBC"#T/BP 7VI*W'OF-88YH_W+8;)D>
MTW9SOCWK[I5"DM6%/8@("@.(!ST0]B^2>G'XBN8V;D-CQ!.+8C?)FXX92+)W
M1*S%6S4P/5F&WE*K8ILRU0+)'77>42U?)Y,VYR@/"]W8M8FO5;>?=+G-O*Z9
MET:._CR04>%<FHGV(R^MW.[$H9R:%7.;EEWR42A\HU"M\,/7,+TSFY=5]1B&
M.BV?3'Z#ALD=$EN<6*YB@ F]8\HY>[3"R4V+TBH;\0&'E=Z8,_(B/K!XDG20
M#R5?1#>K[Y;,U(DU\A>H.ME+V+[9JO%>#?%!(T?C?GZ^JRT'>W;_8!C'=2W'
MTF-JMQ_0,H]YN[V0HJ?G_=J;K5KOK40?P8V>ZP^$GQ:5I**R"426[,%P</\.
M_]A,98QUS3<?^4=YROP5FQA @$$;?9U6 >7#MG<Z!"1_@;&*(\O:FTT_6>:[
ML[5(.Y5U'R8,D%95@\:!'<#%J\BC5-*S:;6>9<T:^<B/4(0<0L_#^@U!;,!J
M01STVAHN!PIA@(LW,E'EGY&3;HG=N_RA;FV6T8\9-$-B S=*>-.KK?7NOXN5
MI74:B5!.J:5+++;=2+-Q+-XC\I-K96A3*/"(,!MZ]+E4>LR>+5:PYF.[M>8#
MVZ3$<H5T3>.#)%.FAO*:.O1PM9F(<+3CYWI+J]$R5U7'5EK'P(W]U.I):#+6
MZ2/#%=NA9R\\T/2/+I>0* QY[,@^=5[R(ZY29%+9"E2YS)AXI+?*X]*%62/T
MFB;G'.D< S194'N'LB77)HXJU:X:=OF:_2Y_@I@1;>Z5]<@5(7VQ.\U,S4,;
MFRU5/'&]86:.GRM"0^>++>"T8X%"Q3X=*B?VE:FV00M[DJ'VDY/DK)-O7K%.
M1TZ8&+^S#1S#Q?.D%.[LZ^[ SBW!WUPV; H7BD7,DG66A\I.J\F!1"104M8B
MM\_UL,MJ]V7U+ M-9DR8=K2; DS.1=Q@!S\[:\(,9C/)-G')P V5*N$L&%X5
M4V3GPS18=<+#MU$]Z)US)1J<<0U!#KM2S1V-Z">%+I7U#7X#9+GVA2R!8Z&+
M$;+:8UB>+L5F"K2JWHZ!"P;ZY]U-Y:YDSA'[?%"K;3BY5W','S>Y8"&:&>/W
M?;KD^L(YD/.VXB;%6X?)Y9X[18D^?4F6C^!&M$_$GS&KUYAT."4]^$S9[35X
MN5!"8 ,$';^ZOG4;GBV0HP>-CKS<#*>Y&S9.>G=J3,'8*C *J[@B,5L]4G*Z
M7["<3_U5.#XL&7"3N8.EHF%H?,/5AGYTUS-2 %D,U^X_Y9;X4A'(,-H:E!/(
MVS_#[Y;]D"LT^F4Z!DM?"X05DUG40Q@*=RS10QLMUV!6" .AE>T7%RHCWO<6
M0#_X%!Z(V(:_ *F=!'K*]D"S'P,LY,(FP[0^?Z=?LHT8(((N K$T^ZGQ \AI
M=[DGP/BA);Y4_1<7\B-^)W=3!89\R%<K+>OT(.D[7UBE(G?JRJA0_B##NT[Q
M-[9[]J]=BE=8']*K"_T5K;LX<P$</S:(_)ZP?<[73[B#H1_B"E"JGWYT+H6_
M.8A$"Y [.L-8_D8=%:)1VAB@WNZ3) /H6W=A8_JG.06OQM2U5-20J>:7K6.J
M:'1]"_J9[0\T=^T[S86J@QW3P%X7_IWGX<WNL/$2'+3."&Z=^[ZSV[;#T(0:
MR;AA@VU\<_FBO)F%*_6EAKO5!>%OOO&ON@CG,VL0<(6]M4JR:A:4(;,>'9J\
MP9["P7*Y'#<._T&HUV&Q>.OV=,_B2&+50+3U^_37P/)PI-&C[PL:.>=XC'7J
M"\TQP$"(X<'?U?<!75E7*U2!O:Q9M:=1($YR_$&AJ]SZ%%S3%$BGI)0_8(T,
M!II.:9R.SZP5*HV%\V;WD^R7Z5B!R];09-,B?[R#]LIRX[<Y@Y3==);T]-Z'
M#'UW).[["J^ E(4SQ,SP\E%8S+.LX^O77]!(;DSK%UY9ZUU;UO$S"<PG>OHL
MQ9RI]*'^V(RO<-XI,^]M5 *%)M"%;H0<CV6,)7M$HY7OQ:$\H'O%')N]H=!6
M%(U#&5+[E.$LGV0>C[99>N2BY0K[OBGL%82O3*2V-ZG?'  5[PPX-U/PCQ7F
MVE1RD)@HG/KX=R E,JF. ,,5%5+$(?@N2]%ZE(M6ECZ-%(A/(ZO73VY]BMBY
MO-(E' ,*B=(5@IB#O2XV_+1S#1DB'H%R@G;K*CRR49\WS?5.@W4VY<+&ZF&7
MC&&AT 4?,*X>M5T7(CVFJMQ"?%-?X(K8>8&,F&!#>?5H0X*0W2L8@ +Y$2X!
M$I*7>-]03K8#11LPM S5[$%;069=EC2K6PHE2&34P?F7*H(A'YEQ+M@M;  &
M'U5?-C%[WK*@/0B##T)1N/H<\Z3'D'TSQ$'T\6!$*]I2"\W=?"^X9X<4&9(0
M@7IH.U@T>QZ,Z^K &'$,/Y=AX.%1Y*2'!5K.6Q#=%'VL5V5Y]$/E'D^O82H=
MJ(*16,8YI40UX@O;DZSIR@J',2?7V\M)G-XM3P:OP<-V&"H'[:YHVU#%4EQ7
M.E07ZIP.>.S2406XZKE%?C;BYK=R4'G2P<86K<>1G\KC?/6A:%&QD6'PZ*A<
M50I^_26_  ?RIU%&JZLRM/OZDL*/NP*S8J>_G'-TI!]T,#Y^'O"0Q(,>8CB:
MJEU9616\M*9)Y&QA ],2# :R?][X&"\BICV<P0"MXI6CY45EQQK$74-0*<?O
M:/=7Y7^BZ_\KT;5U1/K4F<OAPG1JEKU#?J*BRRDQA08^S/QAE!:77A&52!8Y
M3-=:X&Z+I1%%D-P^3O!?.W^LP:O<2+;YEOJ+,[[G4GT]"&93WS3Z#H/8W/6T
M))?DF<C0G125:EBBO1)G 4,NGJKLP,X:D8KK<,CKO$DEIZ0[=PX^@AI48>5]
MF!O+]OQ+ O,U^86+_OT+%_C'=M/._DR5;Z.OL)R0J,$6BZ (?KN[OSYMLU=Z
M ?;Q%AB_E!*@75>JEDU9026(![V,*2D2KORX(I-X!RIO5!0!(DQGE2=Z!>U:
M:L (AE^1MGNH >1:9KU([DZI]H 0[!C[-FRL$H8@+&%K@^YJ[H/BW79$$8[9
M9X)W7OB ;CK=@)-SD@;OC8HX=1'^H%_-@5P4R$0J>0GTW/-(1,LE*Z!K4Y>X
M],H;54'XZP7O,%;?H]"<IM4^&LN?M8;L\MG,'FRF=NI#3N&A4AUQD-! C(.6
MVY! -PT=GYU'@I#(<A@$#KY"IV,.)B@.;8,)>/6.@6B)Y0UV9EAI]R<XY6W:
MD 8QY/X"=<;TOSH>D^^G(O:_@^@GCP]H!105NLD2_2AS!QI/WA+"%W^WX@EH
M,LQ+I^.DK2R\U@K=Y;6%'KS+[WAD#(+=##4H)C/0)99:HG6+#:1_KJJXQ.:V
MOP]FSY+1A[@L39D9VU)1Q@X9<15QJNYAT>&_6ZE=DW.CZ)4.R?>\8!,D7'/X
M*(J*5^<X7<6!:S75"UB)VXS(EI,JHM)\E<#JRN0?"1_-UJ"080#:> "KYA!S
MIK!;K)Q,,@6+LIK]YTFA869OVZ_RJYSF!GTE-0OOP+K^,C?XJ^0DA2O?,=XT
MN&B@N?>K>M8\ARX852%JT,_L!G]Y11')O9:)O ;"P?W?H_%27092M+([JG;D
M;R! ]^=&0K?DGQL)^R=__?EKY!^,YN=8O$&GTNR88P V+G:ZF:M3?>^4>?27
MP.9'S;Z1[I;R;L<A?:G0#5U@6_V\*0S04=2R"5DT-?G*=PSPH=SC0'SX$PJF
M?MP+:-$1ZCOFJ(8>++/M"JOD?Q^U)W0$>I+3F/EN=I>/#>4*@MI8X5^&ZCF0
MWQ'1)\\F=5?[U"AVXHZ#?^L4 4-Y="';_H995X+9B]28OJ?T(\A,$TV$,E@J
MR\^3GW-[12*O!DB)[QD>1!31!?(5\5'2Y%8_:TFDEWS#^G!\*QPF#JB3=."Z
M[06R6N&K=AOVO_MXR&0%-W0Q*NH.-_C0[ESKC._]5C*BV&K%[^M"<WT4AWF
M9\T'\MPE'&HVAG+/-CL-?'K#RT-R#_EXYV-M%,T%6G5C7BT^CGRZJK]>M!!@
ML\E[V8 MT?IN2-7U4AE\]7SDV@8Y5A<<<?EY<](WS0ZF5ZIDN-T+EIU-06VN
M%/_ O'ZY)?H#\2F5*Q7?84.^ZN)#;,.6#;6GDZD=@Q "TW\RG].#7^K($/W4
MS8AE78:!*FB85TK0/T.6!GL(6B86<K !0?MQ!8'WOO(&L9WNMU1)? QD3F4@
MUHZK=7:7>PUZT J"O&'5#WP()%J#(-%2.Y$!5_.Q&FBSC]#7086DAG6B,F!C
M12/C?PE&.="+Q_$#:*[CZ%&W%M"IG=M"S(UD&H!D'^G+UP(/T55P47RBN"')
M VIT2C0(4Y&G]*U.'>P6 X */5:4VEO?<@[6F9L%5K).P52[';(+76DY@+/M
M98,<JS,;:?"DBR)Q#G),)0Q!?!G)-FB^!([111.T%F(UB8RO.RS5VQW(8(05
MZC';;K'MQQ\KGXR2JJ1%R#7EF+'KQ"R;1G@-1;]1,SFKK6\:)^$\#9<718P9
M&">E<-:%KX@;&B4*&">IG$RQX+&&^Y?>D&$P#&6G80O/B8U4O(?[B$7H>X[T
M[X]MC!<]AAS3"CLBYATQ0,5HVR\/Q^@.MRQ0N8.W@=8M*[PT _J72(>QM5D$
M6:G2+R\5LVQ7%$1LSX( D)"9?@H &*"&MDGG$?288_9P_G>[=X3.M\^CZVIV
M2Z]NPY A(BW;?$MV0UM_\:FMQ0^L(C8$9!7B?"<$4/0SSHV?=R7_%N%=KP,#
M.0/8%/138\-[LUW #+'%AWYNFOG7.< _S=_YN_D_@,%[U1=L43\E_GZ+D@86
M_FH?T;24#0$J]*.Q5QX2:+G34X^EOU'XWV'PY^3>]XYS5S' P3S?'L7?P"J!
M/:-,U.\T[5QQ(*5H4TAWGLZ3B4^B8I(BW0#A=UO5U89X8C-^_%A9L%=,K,/A
M%1;E<W=W3T?6.)/$<S%G%?+>;JP:5AE.+$UX.E#2>T8JE6N&TH\D_&=G,_^^
M_*L8Z-II#%0N>1H#C7R/@9K^)P;Z+XR!Z&P';N3WW(^<**H0VQ/&PH*R2YV=
MWT(GPQM+>*T/XENS%VK5RQMP[[W&XBYF8X ^X[. RS DH 9Z/>#&FS5"NTJV
M-61%E*W-.]Q97.>EC5\M;Y<$N50ZP,.MF:Z^ R*\@ 76.H.![#I!F;D9D7*9
MC>2I9<;&^5(+$X:>MG41)TD1,YND>:\SV!;A:NI-QDP7S@"10Q.QOF(H2KMX
MI&RAU$CIYZS=+XQFKR$1J4G!*_]#4OX[DI1I=?64);O'A4JC=(7>DRHEB_<<
MTB+>ZL58PNM#$0_XE<BK\VBJ(Z77R];)V5G[L3U\*$6BS%19I'HF'5_&3(8^
M!!A\L2L=>#<VL!.#]*YVG&NH*THE::R1WT4;A7@V]Z\!OM47K=L)[Q *U\K+
MDRH#2PJ!5E%&.6'I_#$1ZUU3#O8-B<?S@U5%O+S28RY6+LR?MI^9,Y=,!?11
M'U +L]BX<>^654<(Y'2\;=?+JJKPZS$PU[I&7R%(R7H2+4-_V%*R6B/^>$+.
MJ=Y"4IG*9HW5S';-CN6GL[LKOSSR^"-9,0TQ=9U3/^:(-3OX@@%Z*W,;Q*_.
M7MR_5_\G7SE-1Z4>4Y9"IR&]!1*9MC#: ZF+"B ^7'Z!>@R^IP7//0&A[C+D
M-(^&?YIV<YN (I]R0^$3IS" ,Q_2-M3H:N[.K2UYO3.?/]U!Y3N ^37)Q\5G
M&IB"<5^DU:G[9SL.!A?TC.L+Y,D,;#9:1[CT@N&L=4WLF\GIXZAV79<S[7:*
M[?J&#.>SA5G7O9J?@AI["(;[IJO(YT[HJV O)Z=[K@:%;_IES4A7O_@1UMSR
MWR^!GA(0Z]0#N+ 5B&^]7O]OA%0TU"ES$L78GWGNMR[.+-['3>-KN.RUR2!=
M]7E,T/XK2JMWER.MJ;SUNIS&Z$94R;MP10=U<JS!O(DT*U'J'AX<41JXW+]Q
ME.)_D.B_ Q(5:[4?VIU(=%VIF06<JN\X[5E$1F3;CDB@1'ADF&*- @^M&&_U
M,/K42O;C$5\0RQQVO>'">N5K5FC]=4+=8P_XU.BTUM!^H;U@[U6:^)Q+R=DQ
MR>'X!%=*?MM?4 AJ62  1_T" \CSV(W^7/UE4@[K)U!HHFR$MX+SX6Z!O\,
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M91%Z;3!6A1B;XX+8I7+]Z$T<7Z-5&5KH/RJ6'NS0X<5+Z1Z;*/1M:OJ:W-'
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MXNI5HH EUF[/Y867SI^E"@QX#"=UAFGABB#\5BD6DQ<4C!MC549_>VBG_<^
MZ&,"C]F)9O?=%6B"V_D/'\_;KZ(/8?0C$LE<6M'JU@O7*O#]Q$Q4%H[]U&0P
M@.]A2<@_Z^Q3U)CV+N\BJ8?FYMO=D69S?((IQA:45YQ"=8N)'LUFE".'_>)-
M&\^'V?UYCD]P#"$3UV;W\4\5I P#@/K[(Y1H8*^UP!]M(1!F*+Q"Y;*<QW!X
MXM5''],5ER\(-@;* )#KZEZ?T[#++3% 9#D$L>^(.EM52(MR9!J[U%A3_CBO
ME9@.UU6+Q 5Y4P-7FK6J<5@U.Y2R4(AH20G9/O%<08YM"@-POHOJTIW,+6XK
M^KJ1EC"=((K[-K1DRJJ, 568][/Z_'T5)^&%>G-5795598HP);_\DP;S:]TT
MY21>KI!DN[4$GVQOSUR'7:JNF+[799[!!?IA;^<3FE"Y>2""G5U&8P"Y[UCY
M<UT#7\CPVB'/5X';2OF3E1+GG^GQ5RN95^X32.4G/'_^?I;UT/!!ER"KRJ(2
MK=(9G#+HNPA-H]1?XY/Y9QO]-W945-?TMG@:][H#"\1JII$6PXSQ&^K;AW&>
M]H59 5>")V:FTZ>V [N30JUP-U='JV&5!Q $UNEZKK0<%4!_J@'=(A4J<R$&
M&4,S[.F17=&T!;N$,_3.K<O94(V*X?LCEE$<)8-\TI<UZ;ZZD>TE]/\+ <8/
M6PYS%[.J)(:,D'VX6L/!1%PK@<>S)K+19MI2,;SY1:50$0,,HH?.!WXBH=!5
MG/(N5T+:::ETU<4;FI%\6G_!::@89);;H_5WH-=M2T45V\\>:[229%0:FR&;
M*NA&YU[R^+&^6=[R"25<ZDE 'VI/9V9S4XE287N]:/6;059@#()AN*MK6FWI
MDP?5C5IBU@=I\1D@?5T#^@=A"\2G7PS8.3U34:)K+\U6,V1O_M)\_CG9BW0
M1\_ZO_(_H_WO*CB8S_\?4$L#!!0    ( (8X;E2X8=P81R<# $4G!0 3
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M[ZB85!-R*G]0\T@:[#,_?SU*P\+[8)$/\R>T?T3V?R^PX/^MR/[/P/X]KBD
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M:+W$7;>A&FW$?_9),N$\/8)P30E&"+0E I#]A <1W[-N 1)>1/QZ@EPV/5A
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M45]YGJWP0>:X10$TLAITFT3@ Z"M65!:A6[3\#_7PF/X]WDVW/]7JM]P>52
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M*:<L^=KK=7N+P&S0._@C#$L*'IXS,R7 ;6,U2@0@Y("+9Y,-39BX.]P6N*&
M:DKY5([!P/)6ZWV]&W#;_9?],F$BCQ1+JH#/V5!Q555R&@9EA13<7U#&"WO,
M=]_;U2!H77A=?GRTZYIK. +]K.\>33:'[&X91M_M5*.+;-&TFX@W@4N=)0O5
M%=M3@21430G\1$"YE7IW[!';+0G1Q;3*-LV;=H1G9&>HE"WY_*:A8JGM/">/
ML(=!Z+C@AM<X)75PEG8O=Y=W7)X(J*J0=SI02@#\U:=O(F]?*L/.PW74]:0M
MF5#;=6:AY6)K%2S:&"[!FWHRI1"D)#Q1.PNZ,%1KK@;Z/1H:/HW@.;Y4WS6I
M7Z[C-9%AIGO#^'YM :ZO?Q7/T[XU&4 FD-0V6J38+5R,.\1#>W]KBYM0W)>]
M=5*1_6..7X?&]UD3K<O=6XEY?#=1W%E(%2LVM$&IQNBLL[L]6ZH-1MN8*\E$
MR0%1O209CN%\R&WR6P6[:XN'PA&8H0BWEW91*S-:\9]D1]^!(DFLWY25(UU:
M-.C_2C--V)$\-^Y[X&5W^U]^"<7#?'9^YVOR,1LE1BN?W;[F>_U39S<X^#>L
M^QB)][1>AQQK0!%!SQ>1X87]QS0DIYFT&8P0-B;)ILY3?( 6$9##<6J^7PXF
MJ+'.'V/X":'0B;Y60:!,!^PRR,1L'X6+F7+#!X@=PE_"J<;<=#.++2!4N';:
M=R>.[-TO44Y$P%4IDNU@0IX2 41 97GEF7.M0P;SD5R591"03EN_5%CZ C1R
M)"\\#%IT0.(OI1#^C#MY &L;A&$OB^'_G&U#0]!L\:LX_6V8RS-8]CYLY0U!
MG)0M])X2 >ZPH]L0*4C+DD5\[1G+TKKKO#35RG3&,I^N< ]TM)^Y6,N7-'+1
MG5SO^A5DRK'C%]R_MX4C4MJX^6KW]Q&L]P?YLZO=/E&RS:)X_5!/YF_4C!2Z
M)/]6CGA!J.V/:3?.]-46;R("WOJ906S"\T)#A73NPL^K:_C)^0M\B("8VH^3
M4EWW_QM[[Q45Q;:_BQ:B$D10HF05% 0!D9Q!) L-2I",(I(D@V0:1$"0(""@
M*#1!)'=+SB!!DN342,XY-+F!IOL6NO8^:^WKNN,\W/_9:XS#P^>+U56S9LTO
M_":S9@DNN]&TAH:'+4&ENH@_&&Y481$4^G=>#/PH-=/^+KS-UCNHPVOXD($A
M4])]S?U'M37)/>\PYJ#L-8#<7D1@%<O\1?2IO[E%/6GD;%,J$V1)U9[I+&IZ
M? R>YOBNT"_?-V(G7-0''[.'T(![=91':R)5.U;\"=CEIEA+NCV8M#;(L/*@
M5!LM8MH=70:\9,&[?@=%ED/Y#!(\'D(F%+I0?#Q[Y8DY>S9_GAQO7_5AJ2KZ
M= MJENVND66[M?&1!/H<].J >!RP36Q\>-S]@\BPFV>O%.]#*;T-Q>=/)T7#
M)D GV!;=JG*M%86GYHZ.20]@-1%EKB($EP[ O/V7)Y>#FBMV.>)%D)PZQ7JC
M4'+-U^DCF1X+B3SY#I?MBP0#4G,K\?9AH^PM!7RP-EC7Q^ZD'V&D)A4PG%5V
MAP.P/138%(]<2AQ0F+U/<>3W<NNP4W  (^&4[D9]NI3P:5$9]S=2:>WI_54X
M4]72;@_GX8W<Z[3A3]C'P]Q\4A])OL]0-;<OC;K>E,?X:O=JQ29&H?!^:$D5
M=JNQ \7Q,EG82[ $E&]@O9I^B7A72,]3J)-^/TM"<X*Y.6*@(AZ5(*11UH-(
MK2SRSD]>[PZR]\[NMI&\NNCX]7P?7SVWI)D628W?\5O)W$($&GU.+\K-D]\^
M?:MU1KXP9WH\2^RLV5US1RK-)]%=Q!NO.\FM[#)'(389HPJ44057B1X"GU"\
M'YUS8>3HV2(5\_S>:3>;\6!6']JFSP0RF.4P^$?2B[4BFGH%KX7;IO4T H@L
MRE,K4=H5.58>$R6E5>XV/===M36V&:8E%!%R<*')W? !O6?Q+[\7J^0\(\B0
M&=^0:M8Q,[(55'>)?]'-M/N .*_N6[]-";RJ_ READ'0I_^MG9A.\#\*][_,
M^XM6^Z7B]U2)BD04?$[^[@G*UE=)*%6DIT=/]BH7E ?-UMFGTR7,]-9$NV:H
M9@0#G6#  4OC1Q(XH 4ZD7C.SLSE>:W-ZN?W$19=)9OPSOI$_(1YE5S#T_:9
MS24=NCA@;)MIU"=F85M;P(DC6CLDKS^PF;TG*D;)27_&%P  $^+_7'[^I3MD
MKFY*XN5(KC<II@E_IU49)I"S7G1XX"JN4X<#-OD6QW<&=8HT0FY,Y4F.*6L7
M!<292*81D%J/CEO[Y,Q6ZD_RYB:5%W+$-?-VGI)9\#XBVV<R=C=U2>]X5%$2
M14M@;F"^N&RT=2^6?4XUJC'J!I9&7<XZL*DC9-9J8;9IIB_O]FZD5SZ&=D+
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ML'5H3;9#727$NR>[96]N$DZ&S;S9UKROA#GS'$N/8NA1CO.H<W?@X;2%M.&
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M;6Y8Q;-H2QR@-PWW]IL@:^HIM=)^W*8;S/HQRK-'IT8M/IV*TCN!F#?U#&&
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ML+V/IL1>7Q(\LWDAWU<!^C9T+N,A6J@A%KF[U3ZU7'8U7,[\3H?L<6@,MZX
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M0PM^UI(G]&\>':=!Q$\CV49+!>PH-S_)&OFKA.(B+I!%<6E@ 87@/\X>!*?
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M<3Q;J@=]P\.PJ"V2:$[4T>PD:FPP-@05A%>8=NMA9> [?^909FI-&4*"84+
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M*%?$D./]8C=+=D4J%TQMDB2(<I-$$OU(H.'\U3.TC,LB UP[<57^^ZP$\[8
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M)E,!]%I6=<V03)-=6KMP$)EW.\!GH"W!4%6L%%'F54I:M3-Y+#??_.86JF?
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M>!4\*<RC."9?$GV,_!!Z"UERZ TX!/=7J(:YVG(]CC4AMW<BM8\S.?)]"BP
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MS/4LQ.BOAO3NW<]YNF7\S>IV 3$[D\$A+HCK\%&KQ1[OSD!''&25FX+*#[
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M DIRWJMH9%HU"MGO1-E#%HS_WZN/=@>U1]Y1OG&RYQ(55Y4(M" $350I+[U
M82JV8D_'V#]P-E,P76<(JN%16NGTRU8<[:*KM)F'EA43JEYEW 41Z?Q\09W.
M\"9ED50HG#%G8F<<SKDC2;_BCI+)_;7^[MT=?,GD$,SV!2C3@QC:>D"XJ';2
MX^P8N>Q*F(6Y!& JIO5FYV;T,QOR.8C8^;+#?#ESUTS +QQ?J5B3Z-!*7+
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M^[U("GW.J*$J(,A66QNO<D>=^OY':C$JO0,-YZ:*TD'+CBN+YD<,:5#PVN8
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M/*C>(3]'>%QMM(#WQ,$GN_B8:ZI36"3[%T0"^37?7;NS6,N3O8[=:9M::DQ
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MGN.GMW8IU%/;4Y7G4I1((!/,2O+5S?+EN8QC4]JM@FRD9]/\RO^W1\WR'<8
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M<QMNKF/!"=YZ.F:U?.H%#06^D[M:-?.;?^=\WE.A18JJ2V 9:-W*WU6!1'"
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MB':T5V8;(IYXH1F)&7B?R_BQH-M=]E);"UYQBR*2Y[1*F.H.GYJ9YEBVK5W
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MY^0?*OBIO=I(A?F^SK7QF,NUT4]L/EG,=OP9H7E*K^ROUIQXN[P)_@C!SW#
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M51"PHK C?,6GU-?.:D).BU7+_8R+ZXO.'K*_[\C5SQ"P9]$$/@#?!\[>+H2
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MS]ZO]4G[F,&N^BQT3>SDWQ\1WU(]@>[CC""8)(-U'VS68_9?^1ZY-ST(&Z!
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M2"X6R1'3F"&T.1D(XWH/R;-9-Z551"J^:*8^&>,C"CCQ&'T=JLL?GE,=5'V
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MDO^C?Q=1E<CPJ+E1XE*6:UR99[C0U[WA@'-)SDWRNB3@!;C>=.MX,!'GL%[
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M,XK-"R5\<=C02.*QONL<04+U?1YA-SFT,^83RB.VWTYO.C6L?:R(3Y_+V9@
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M#"WVMU!X'5=^R\?M^D4/N#:4PIV5=F@@>UL!1$+H> )L U6]O//&=!H*Q5/
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M<3.?)L719NJ3GZB!)JS+Y)>EJJ%GTCK3T<^TNI6XQ]G<+>RG=^=23GK*NY.
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M=GA"@Y\IB;!+KUCT<=?PG_<A\RT0A9^0^V2%.H@$-(Q,!I7F<IB7:%.#Y>I
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MZ==W\/&7JK\JF<8-PR'+V=,3<;G?D#Q89)[2I1RK;#XP+P]^EJ.PX?G>(=S
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M:1\H=^-/5)MW^ZBZ='=.@H+M+WR4RYTWK-73;/> 8!=VI#B::JX ^0PW@:?
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MT?F%V"=123N*^-AML"ZLPGZYZD9*-Z)>O&X_G'/)SZZU\IL%/XX!>Y@':Q_
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M++Y#GSJ"7[$\]LZ.M.KAJ&_.CKCG<5#\QST''L^ZDY(@S:*+>&YCZ+;IKZ@
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MPMEQJSCWP6(EG@NG38.T"R8+.O#;NLLIA78;:POO$^*CCME@KOU=7A5[@YG
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M/-V'AKBX3H=0G<B*/IU$$9Y&[VD._6/NZG^HLY4+NP167V:@;=E^4AE6<(/
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M<<O]V99.752WA94YB=0S$2 ?R+/25.[A)97Q_=3:F,MIUEHA)9-YV1N>Z\>
M E0<-I400 $_V.,\ E ;3#$@7&R-#0*&BQ6+=T)/A,^\F5OQ.V7*+1!<A>]]
M^.'ANY#W>?9:SEKJLN9._Z*.6#F,Q8I:(<+]M5*GS5V19V,C_4ZP%R#UN/7,
MW)6>1L/VQK#'&G%Q_'@A>-,L+P-/.ZH0&F/5AA)9E4IL>:X;9R+/V70$N'PK
M^83P+N^!;8P0DYSG=Q\QZ/-@S-OT</=(O00)N^3H]_,7/"_JZIR5LEKKX1=,
M/9U!]<8 $MO.\;?&@1 NPK@@T"2HL]PD +AURXCHYL:((>9R N@U7X3S3VW&
MS%5<35)01LT")IG-& #TZ'M"YJ2&'#^,#2S>=G'')[$%^6("^R%0FUE,(I4:
MNO13W/1;4OD,^-W1E^_H(8%UFIB\K"%EIS[9P^<N:I_2@=;JXSSH+3G)UI \
M[WOE%0BVLC>C5ZMX![!W7GI:$JM!*_3$2IN)=5FE^2(C\K'M/'.:A@!&DKCO
M<5(B@URC(B/J-(#L5 "5]&.6FP"LDG8[V>&5/F+J4F"K%#/.C/4>?&A#+K71
MU8Y2,A#/6?&_&[/5=VVY(-D,IYN-!=9#T[HK/V?3K3_Q7;WP@G6/LPK"MP!'
MK9%\]SI!QMX!.\".#&LT/TV;\.M/<#734-%ZFAL%'B8Z\ID?C"M_5&QM48(8
MS6GZFHUDY$"\>=CM)\Q%7920N2XL.>;A=P+[6-=)?<A;7CG.@@^G06M1$; G
M34 4]_I-/M9AYP.O=A6S)*$(GT*!8!ZO@3 5'$A+0G?S&ODDQC<'/_#T^ CN
MZE_)MQ-X(.V<Q]DX[/#]GVF65!)_ ,AN$'/O)3R7=V_G],9P'?'J_G)J_]OA
M)V?<7K!@W?EFAMVG%J;O_?AC[9N^[ DM^'*BOZ!/[<($73EH"M^U)Z=],[FN
M*N&XYX.$4SRTL]'IQQ2N23[6TKXT9.3[:'><)W"@EM/:T[_K'(;/E(V)[-DT
M</:;V59;C>MJP_L[[Z2OG'3+]QAZSYP6SEW,K>Z:F<M+HZYV/ 3^'Z%H(>-!
M,Q(>Q/?MS1$-O<4&:T:0->(D5,\>(^DMO.6((9QC^Q!+C/7\^K7TQ%>ZBL1/
M$R$6,09UW_E,^M<@&R%XU2VYO'^6 N8T,,1EA.CL I>J3OHDU[D!)+]A0(&<
M*&*E K!23EN^O_H=6&IR\69 90#A D3B4-ET\@C08HLFX27K2[?V[CA$//'
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MLFSVDT)(-M64;.]"#:S\;M\%O9^J,J)^K-I0@?A%]6%G#X0TT_G_;6_\$!U
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M<1#EZHL);PYH/!M"L0LR<P0 1EGZN.,(/D(";"96&S8@STLX++\]2DV\+>I
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M!:O.5V=Z4OB2^)Q>ULMO!:#C^I)O,_G6\<!4-XCAYI*Q"X'7&FX]OSTP$1*
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M+7*#4RW3IGLUR[]D;BSLVXHZ77TJ266O6PI1&O--5M&I3PVVO9!]66&G9#-
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M@R\Z_/(J6U^,1" A^$S TWB[3%KB -(PXP3#9D F];#:Q->P/19](E?IU?8
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MI+(!,W%4^3A\6\/BC3@'+%.,87TK1G/5S2I)*R%+0 ^[\_"\?</?&RA:E>4
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MEY*2*E+<71PJ2H2#[(]7(N[URQ5&JA9#GH[PYS_' 4"$*G2R570#RWK9!.W
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M^Z7@G"5@.*;#7-X)!X"72N-]&YE"X%Y7&I;6*A (*^_ G I[$S=VMVQZ0%;
M3I.:FC,#S&-EH&L5ZQD/UB?;=4+\M?04A?0&%QVP3+ZY^_C-4UD$ZG5&LHMW
M#1B/ N'YX$W@?W1GWBH;/9)2956/.3Y6%Z#KD$T_!KC?J8LT1$;GF_7V/&MN
MGP%R/2 )W^W(6@S:2=T:19H&%@3$B#8V'9J\:NR,;&F@C30><_46&RM,I:4Z
MM6WA!/>V<";+[KP!_^HI?:]$,*"G-?%K_<?ZF7&5RBU$GET2;$>;8,E#1V*?
M)V>^K6X,W>DN$C/,S:_S?>G<9#&RT?4>$Y#Z&RE3(1_OWT@2R[('=J[7B2R:
M(15?5(%W>!,:Q2]4J-$XS=-+3\C+TZQUJZEMPWETHI5<E#:I?V&<U*B9$,YC
MPN1IE7V"+'I&L?9(Y*L4?6I@K.@TZD@*M'YN@4JD&"\4AO&'YW/I0EMHL8JZ
M\IYG/NI&,=P9UJ!8U1E.UM2/Z=A9Q'%:6V8 32KK4O3K%NR9.3I//:_/Q]"K
M%)P]9L:<MCFT+G( "]HSQ1]1PZA=I=;MX.U<-\@@* 7<#%RN5TR8OZ9HFX4T
M?WX%!VAX@'6%F;(/[0KS.WCSQCWMO;OT_-X:0?\NY@ 9M-7\\%[D2:155HQ6
MEEK:R8C;NB7^D*VS3((&3>G&KFO!CZ%"_:%2#U/EJJY7D5*!>4Y/=9/>9_.U
M+@ D[M2_G%_4B[O]X;)W0N=NB-W:MBL/*]."_=%)H?1S?R6ER?U2>67-H!Q>
MGT(OLG-2.'C^:B!6ND[>DRBK&YQ&#%RD0+@VHKV0A8H=<KR-1S^-6?H3IL'^
MTHYY@V RW0/5\_0.#G ,;O4VJ\XUF+TPLRJ!'M3$I"%8)O8V]&(![J=JX+U8
M:F_R83,/7[4SG>#3<_^5^I?$D<72#!B)@B<6A65R^(#9%=%\4S=Q ,@\^9S<
MUH'5:7;:YIBDW8'<$?'>HA)*!&OU3=-8&$CS1FQ)Q7M]H,Y6<7W,2_#3'/T7
MGXD2!5\6(NS;T1H:T-0+%:)/1C\@"/>0';0(50O#U;T5X_3'\+2SOIV=N;H$
M/<3+ROR\C-7#CS>V2,$\%H5W);$2N9*%::(%N<;S_4H15OP0N4D_ @)XKNNF
M9DM[_)BM+\MU K4/VK;[NPXVLH(3PN8,AO,2 >+7>@XR9>YZ^=$5&<)C0_CK
M5!TZ=>1\K_5^@;%!]@2SL;J+(BFIMA'KTWT%Z,?^U]\W@:EP@&MH!>NBP- G
MM?SR(4TC!9>'RR"IZ^F$=PF9_#N%RY=9N7Z-"TW!RV:LHK%2&_%*VF_J5"3H
M*:$/I*"KZ,(D"9U8/M5LC23/?3G\&OC\=,\Q,^M^45N7["ZS\B6^--,C4&_X
M-JBD(?XN\&W%"E!7&F31I#Q/N2D=[U.C;O9H/8@W#@X.7D2(Y'$$?9]_*,3W
M -YRUK.#SLLLY/[Q8[]SWW8XFEM<U>!;:A#/T^8_NIAY/_4-YB_=B/EB?&GU
M\5!@Q\BM?,V';I,V9;LA>TC%0S,4P0;>AR:%+AJ+M9+=;Q[1@*-F]&<>ELS>
M_:)(E>T4M;#@,CJ^%^3C:;FX09;.?9RW(!$B2@L\@115[A<)CJ/-<K8F1$=^
M>G+9&]?Q,CSC7AY-/*3Y^3%#MTMUVPM)*GM+6]>LI7"O\WC@5T]3CJ>%,.9E
M1C\OS+H9\_,"T7Z1U% #SRQ?'DNQ+8127.C!W9Y='3B8%)1E:#(S/ZWH:L?3
M0^CO+)E\)9]G)$]]21Q![43-G&NV=R<U+=[#/M7&*OI6J*>5&S'1DEWXF"R'
M]?A3\Q(JVQOT3?H*-X![+(UO11*YN\'$=S,>9H"L>9.BK6R]=F/3[FR=X2U=
MYT/GCO6T2..7.  S$KK+LSYN/[O*!,&0 +\4D DM%D;:8OW2^&I"?TA8<$^G
M8X@X$7?*CC4@'8(1DK)%RE!$UKYA8^/SI(Y6E0*%EQ7P<8C(;)+TE,Z"]PYS
M?1<-'1SR&?WX$3(8=/>!YYDP)_ C40_RP 137T;[)5]TL(-498A=XYO?Q8RT
M&2X<@,P(87Y4-8(EU#KX^95!T5^8G]%.[D7)4^ J'F%*68U:O4->,#K4-%#6
MBJR+ZY&,S-X3<Z.)+O!P49E8N@I^Q3QJ?EN[?&(=G+)46J>TJ)+DM<^].%[X
M2I=]TB*$*BO"I87<$W/I.?XL5S;@ "FY!UBD(Q[=?'A6(. -5'BC&2 <A2GB
M/;02*D *C*@B7L:EM[A*/?)2,&CB@XI*O;8;? ,DL*YARI/6*&_KWB_I?T0C
MV_(-M2PRT-A\NA)].[+5G>*6[X2U$N^A%#('O&@T#QX<.S<=8CC #1,:'@4G
ME6D_TMV"3P%/N+P=35BR\!I"+6&!MX=,>6X'K>+)T\+FPC(L]M:+]2O<+WH&
MQ+1,C9EPZ<F[(G\6L7:JWSU6)Y9NI^SWTX(I#+R:S6@,;@H4Z5)9D#&2#\^"
MMY?S^< ZORZP=J2@Y;UH:#0*Q/,X4]X4Z]H4ZNS6RFC"BI%;!H,K^M+JJ9W^
MXF>/"0 XP'86_%9-'V?KM&P%H+@A= 6XWQ4VP0J_/K!J&*$0J3#4&;3><DG_
M!6MSM8S1XOCG[$C^$ID/F$=R)R[8/?4>&N/1K)K2_9E=$5B++C*6=[?<S/V4
MV94&9F:)F,"CQ^4YR_/8&2/?@B]%'_*BW:.GR.A,=<ZIHR=W1APNM%R]8$FT
M%0)IU5A7GOB8UQGW#.9@ZQCG"8Z!V<G+V[LZ>A+WV4N[//[)(DI*L<1CV+1J
M4T '@D[A %U6H\"M2?!ZU:;9-9^G)2,OO>U%*;WO)PH'%-/)=B ;8^M?:WH,
M: 2W"=DMD5BX\+RR/J[H?48NT?\ZK=YML&6T+,$H;?S'0IYS7[E=6P:2!2'O
MY,>$##;/[X^)#<<$;?1?YX]R6:>PV ;C?8B8-ZM$-NQ]>0H9],ZCYRW!_][J
M9!V7 9HR"N%]/B>VV7[8!<4<X<LK4:!DVWF:5SNKUF4]HC6 Y;[P"FX4Z0NL
M>/Z98[#[+;GC IX[D,;HFUI Z8F'S6.VQU)I,4N6C/O)6?(OK&5OC_C(.[PH
MCCH- GJ2A$CZ*F95%7@U:SJY63$M<JG$*)^W$GW\"XT'C>&69G$Q?6U=Y5OP
MB($N."Y?JI'5PW:$;?.6'FL+L1 ,T0XTK&K6FF)X&*J$ON>X\J;L3>%ELR ]
M9PF(VK"C _2[N#'6*%1ACAW1D)GQRD>\8KV%/NF).*I8$Z4'!4%-9-0"WN67
M)Z5M#DO/FXRNC(O4UI[2044?:K#T#"FN!O7G.-BOEM7$3+_AYE/3'#UF6QC5
MW9'GB% <E^-JX]JFL5)O2% =Y=^SGZ%J7IR89VX(S-#+^D/[FZ\+%T;C&6I&
M[>_D#V38KQD%>V2I5]\B,DNAS^'M7RA'!F?\8+K;9>5.K4QSG;N) / B %@
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M8%QN14RH4S.CO-'8D+(3N7_U^ Q8?W5-R/9Z,^A1WYH):Z4C%SB99]=AN]=
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M:RG\*"GB7Z^,OG4LX4,XZ"NA\A.)6'ES3A>_?B+1F*6O;%HZJ03Z++<[27%
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M!G]=UV:WP$IUR^_7P-:S8+D8F&03JIPZ_ZKK^RA]IW"E/^97[+3DD/A4[M3
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MV*=N&R$<9<![)D#FD%C8:JH>@9'D[40',G2M!FH9?O9TZ?R2C-[]W<COE;9
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M4] ^.UF#</E]Y&76NJ56>_[F"FODI_X\&J(FLM$_#^6W8JI&,6?136 =^YI
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M>Q^8N279%N4B4"IQD[A&U7WL: U#O;YXR\5DL:O%KN^W.^YGEM4-PA-(YJL
MBP8;\8_/Y;8,4YKZ6L&]& ^<3>>S].Z"NG=S"V9]<;[W.^&\^1-!3(Y^!N^G
M#IPVC*8\RCL[*\@V$W!Z O3D&&=+,.*5?,)L:@F@P#RLD-G:JF!G+[2U#@$I
M<N-N9I.@HG<[_+Z9*PZ,E-_P<>]\AY$+;PZIJ8T^F,&:8)DG.1[6<^0)CAO%
MTW(_H:[.D/7W)=F)7?YV'::3C?#G1&O)+NP=R5MD:EOMP5([?[RW"HULYLG0
MF[ ==<KO"ONQ;U5P91.7=XG;>O&BZ4OY 9HWQU)$K#O9?J#G;JI@B?:XU0CA
M.Q2T+;TEBLVAE$)R?WQU*#.Z2"X42#Y_RNRBT )'GOT66"'N=%;32W'=(?47
M\<EH7Z!QV;.LO$K;F_-ENP=V/LPH(_/;A/D=QT?*W?N!N(LL\<))7Y@PI:C8
MOV]*WRJSN@XN!5X&\"-(^U_:*6>I^COHIM_ND3,E4V?IM$. 39"^:T=.ZVF7
MD:9'U*O06Y5%!XV/Q+!]98;=MG?IQXT<4 "%XZ1GGTPV:.?)-> V:8!.&"$<
MW"EE_\:6ZB4)N&F4:O];*<53ELRALRLN_'CYCF;DC"J[I$X'UQ'L43.JP9$I
MIEK*[ >W)(COL\AA,"G@>XAF6V"]!G+N?[X&@O<QU <LMRN2'\.S,AQ%G9B*
M:<SIK(HXRO'\CLVZ$Q&6V@VU1IZ,$A4DK^\:'M\.],$+JMHBVF7CS250!?YQ
MT$*'\,/_?V@0^^!K:>K6C'IL'Y8M/A<LVY =SF%90UC*[OHU3;84#Q>:V;EG
MIQ"RB3(#I]3C:'6$]FEU[E6: ^>K?=--5@1')FA)*BAH0@P6=@U48!A>^I6.
M^S0TQ(K?>! GNZ.VXH?1QVF;A?:,0P[C-RT?&PYX70,().WEZOG4V'N<M@!-
MA'*]5HR?[?N,^\[O/S)K#R2>K(YDJ0;&^CI'?%Y 1>C2&/!\?41CYQZF@N0Z
M*M4&SU<MQGK>"-I[5,Y]0@Q@?,L:EO'KWP4^V00+^:P2C@#:2' *X)K% 7<N
M6 Z+-FWA,>*0-C#28)7XW$LG5@=?['JR??')3W8\K.3 ])5I_$41Z)$_9;>L
MZZ%%Z&K#TP:X15Z)\!,AGFS%//"68^MJXDKB\]CH^MO]:L^X<;<OX"Z,J"R7
MV[O"'&[0'-,Z]=LLC%@=FG<-\"!+[?396VNDDEZ/&AU:/MOM.89E_Q=?!#'3
M[M2FN@:>;6?_/JUX=K&OWBO3 U9<U!L)DDL9VY6JJH[*URXT%V>/<J/RM/FM
M5B>VM/123@2AQN4Y,?<I>SD6V@I:EZ?KO(W#NG0B5[4%_FNHEE7S-0"SO,I\
M&=_I)+RH-B[:<.MII\YO .0E/<MQF3QH\==G;=CQ#Z_\KH&]77F6-@L!A(D6
MAC\66F?_[AJ(%\)4[5,O0RGR%E?]JZZ!+ >&:V U&.NY@+;*$:0C"N_4SVF^
M4SF!A=LX/"A'_QJ O_,)Q0371V!P:U"&-LO#+-L+#/#,_ \AIL5-0T=LF=\^
MVL0D+])M\8Q;TN%DG,T(D5-.W!=N#>(1N="Y@188J2*%Z+?4-9?75E_UQI+\
M>C^?VM<-G:>>0?V)3^2B8 X8UHK+IV]GQYFD!#ONG+ U7@/_G13\U/_*W(#_
MQ0=G$TK>R"C^5;7\:U?S.B5E9^Y&HIHJ2QZ9T)S-:&.'UH0G,QFBH+PV:>8U
ML3BPO:6P>@S+VY4[4QSUI!6V<*C^T>O7T'DK*- >=[/ _\KER?T%S_F]_2&"
M#9L3ZGT+?/AG^&3JH!O5XIQ5OYHTH2WA^>45;T[%:.65*+F-C8M38LBSR'N0
M)U(3]?_RQC]O=X#WTOSC,;ULO=#AYLH/:78/O-_];HJPV;885 $"=O-1!::_
MK 6G7PIWT:*/6:7B<ZSDT3R9^\C3\L#-^4'^P9_+"C+)6P FI#FD'KX0Y7LG
M:57C1Y)2GSOQVI66EFVN0[J[<\78OM,TW(0[10,M/PBX0LD:F5WSTB:JN-$-
M'RF?"W[?$)/5..$:^WXQ%L3N(^[T*-9&ZUU@/R=7E-H@6UR,K#J336U/OM]=
M*ISC%QG?=J285[5M7.]6+E&]PAD;">W9U/)NF42R[6^:+PS-+3F_@"A8*BYL
MF3S^LJ$Y*#[I"S+T>>,R7*IIF^]P8<_6W;TPRX[7=?M)4)YG#AFTM9E*CF'T
M=YEBQF4,O?JFU5[.-0"!YGO^:6[B_S.+A>5>7?IP^T5*5V,LTZ_6+F:_(B3U
MDE]X>='++T)0?['>>&F9GJ$Y9,\:[_;-S]$;M.$^24:?K!/'A;^?L")+#E&J
ME>"+&PXM**+L96Q.F\QKV[JET8PVZJFZE47@&9:B!2:J2 U('RTN:+G9V+?[
MEF;6D7X*>CH);1?#OMP(I=8UT*I\#1!7V7V=WF[K2DFI^A[@?%NYJ(%9Y,T@
MX',6UTCKFKOXL]!8T5(KY9TU04"27^B6+&@9N>F!9=2=BZ>?JE,ECMKPZOC>
MQ174#BN=P'+5>]M*/@8(Y P+?.2,?S;\*7F->W@JSAZWK5*+^!JP;#$UI=.D
M"/(E.F=G*?$W;-E*5V9@270IF+V:3MMXY;8_'S\^T>!HZB^I+/Y=!4_IB_(;
M_: ;^3D@;E344L,;W_LU7]N?1UNFKW#0VSH?$+[VOSP^6:XL]=?_15+PN-$?
M*FK='JR )MH]M%0WL)V*$#7]_:A&ZNFG),JD#>HY[;H>49QC9&8*IJ[PW."7
MAKNGB+/->)(V7T_-^%2CCW9'.<I1.6Z VG?Z,$L!_2A0-D+!)#65QB_@A;2T
M.O_(D0%=.^[YT[_)??8N"1%CE.63VIK$W'1)NES84[DO5=O)2M0# B0(CG+)
MCK^D[);"KCQ88H>A._];9-?5WA2;S-XQ6-I]"ISP[;1&[[=9?E<EC.K7I^+/
M;=0G$#2[">@*1W01C:<-S\60EQ)B@M-=,#>X4#J$M/#38QT$2TJIJ>6.X2MU
M90WEB !?TJ2"&@4S4*2,0!'*:W_R@-9>POJ^?D#\]K#-GN,BW\DLLZ1D145U
M-2BVG2A%PN;KZP?%%*I)W;]ZH[<Z\(V>DY_D@+*7$351_/MR@RRED+08TC9C
M+$?XQ&"JTAQL TLL?<6___1TO\?QIH^KCNLB_6P3GAVQH+6?:W2PV\E#N&XB
MGBJ>2NYKX/5]MN=J.I<8\A#H@KN$]X17*CCOP3QY?9,K3N;C0J>AL;ZPOTVL
MTWJBWK8<T*?*/^?7UZUT:DQ+4'6U8"H'^HC\2%76Z!3FF]9^07)TGF1_RG?>
M)Z<8<^6S4>E4ZK2W?'NFC8J<+(H"7Q=%#!1]<;AM[Z?2G.UR]LSR8_G/&B^(
MGLF?ZE+%;9^Y9*B I+ 3'*!?^98 [S:1S&U[W W3XJ+#LKRZ^I3U=*6Z^2$-
ML=MW'RNP;UNJ_OMJ@BPSC$"W;GZ]!I;8H&% P/8&Y&SV&*:%DA\8?;E4+J,T
M?@VTF)_],[[%!GZVX9_,?AO-FM)V7P-L=[6FMS^1^:4#QP*16;=J:9-V_5YQ
MJN>?E[$II!H<+'D3MK1 'C,^G*K2NMWOL=M3<ZS*Q(T';HUK1IZ$O3#W<5=I
M>O_3/=^X[\Z#^];FG9>?W.7!$./?EKOI\2E.5&D2>N(;LAH<1P/^@5K^/6_1
MTN#P2O6]-L/,N/,U<&?/V+0'=9&#M5U!M\V/RI!YT%WK&%9(BM%__2*,7I^1
M-LY\3*\;*8>"I3N7%337)VWL&*8ZD&UZ/^"8&E/^O[!T%/FWU31DE?( +SY?
MX,,UL.@RU(P53&\=L9XHAS,#:VRB_OJBXK_%%SC.#IO<ASK"3#*BOAS;1"DG
M5M.+M"0$.B8C",.0$++Y^OGV?8*]N_WQB5</]@)C_=>S/EH7T(H;B$]V(5IZ
MH_2\I.QPL[Z6:#!H,JIA+1 )M76"VFBP'#2B>X&CIO)2U*\28R$H@?\"]VI%
MY&+2/#\%2Y!K,QW\$P-Y280<66O9.XZ+V>U!8%^)ZEB;!MCM0G"*_8S1C)'*
MNO%,APOX[%D,]Q4W+FU;,R,+_2_\AHJF\=*-Q[MC7E(@:XQ8)UH9;M[:F&8Z
M9BVL(C#H2D%24>.-6RM[=7[AUX2EQ: 4V,OT.^^WI^)=-F(D=8@@;Y@#=Z2E
M>:_<=8]*OV#C^6*NIX@CRSC>I0B6X]SXX,M"OVW=:,E:PJ<TP;*5P*$'Q5[_
M'BX= LL_)EG='V>QU7UMAN6:3?>XW_W17TO1_5KA[%26Z*24F!MWD]E2:1PM
MZ[]NT0JO?:!A>%!37W/^U^SZFX=1S3VG+OO&XC;.^^]:P(<VD#AWBS,^(6U*
M%5$'#J<V-1T%-*FMQ%NTS&'C5O6#TS!Y=+T.8;"QD<5.3<C"T,W[7.Z?N/LN
MDJ?]T\_B"5'^V 3!YV<.G9.FM[/=KEVR\@> TG>FO*9TC<6:]DZKF#UUJB#%
M@O]:%7$4_U^G5?SQ<)L+_^#\I\D5ASO"G[6%V<,?Q>5<3 7[Q+?/%$24S9EW
MCLH/>)D5]K>,G\IU-X?EV1H^*?G\/N:VJD(."*<2,17%5])5(I5Q_E*PX9?Y
M>W^*FR5/30>?7!+_,#=_]'N)UIL+*79"U4P]PADXC&6D(3=6W>S>I[.RXCV/
MGU0;>)TN(8]R;V7W!S\0($0)F_-VI"7,#W+0UNQ&V)N2$B\MX>[V<39V=++0
MCJ.EO7:];U4R?D_CD5,[V2P_%3L1$U<?-9IY0&Y.9U5,$B+W'N<8+2>.N-M4
M\#MWHN (\::65Q!\2)X]6;'/!ZMZ=\@Y2>]<9LN1\(#CC.,:T+- 8RCAEWU-
ME8[,\S[8Q"M6'>T>;1?@&9ID]+D&&JBLU;;EZ9I)X=/PR4C^^92#?!=A+XN,
M\A%_$ (FAI@*.1#U/_>\Q:VY75'^BG4X25LGD/ S6JYY2H&>#ILWJ=DKLI8/
M?Z2.=F.,6-/N)KJ.G]%O!;V?IU1LF3J<G.RFZ,S.4I13[REFF3@41EDJ9%D*
M:[%T93_@ZM7-AC%-QE:5-GUB8S1B"[GSBTW^&P1'GEI4BXT4I%XSMH_9TSP6
M?^!UT+/CJ/B'":Z%94Y.AW<$YQ6H$$P423FVD#=%]CDDPR@U4<@%KL,BBCA[
MV<RR<Y]+JQP^0/%[^S3UB+'J";R]4'T:_9SL$_&)7\A!]RCF#O5Z":U0^!R%
M?4=PX&O_(ZQ-B2?K8EK@'/V20J.^<'#WN75":VTO>RTL9U^T2:[M]]X>O]/O
M</K/83J)6Z]YZ!HA7]J$M<@2K9D*E7CS*V[D>;"^:2ME !#:S#[W5]5:TG0J
MWC9G\-*TDYQS( E'_, =NT/;&/:)D^('3GPNZR$WW8QIF;5=LR*P1)Z8&&K\
M'V,T0AAJ_P?5 ?TE&BDJR[:H77-9+C PO3[; "XJ]IJL/GT=Z605312A''6C
M$(VO*<^BBZ!L\[YQ9.ZB];:/JD6L4UVX?WZ.;.GL;'.[P\'DM.@+_>-,GU.,
M?4<8$(HBGUIH3BCY"2.SKZGXZ.Q1_("#Z^X ;VVV.U9";^[^N0O[8'68#7PR
MBOD#SW'YHDPHZL.%/UE(%3\?WPEJP,LKP?3S6HG06\*CXC_[2^K!TJ8U3L9"
MMBSVD"?Z) 5P,34,^2 ($SSCC;E1@#+(Q%I0,&5EIGA/AZ"F7<&,::_SA&8'
M\6=V&T2"U&O>(1EI*G>?C(?1^L;L_K4IB>%*-U99XU::(QK**ULB57P=\0>L
M:_#2!9? 9BSH]&+:B!,C3HW/HWSL*42V'M7R^G%O;TN*XF@_A5?%;B1ZVEE3
MF7C\^+HH/G-7T7_Y.X'^&?7RS-?8;SY^)W?7*-K8JFU2W*LB#TIXMW;B_'V<
MOPB9*3&59Q6QA1/"17&6A'T6.Y-^9QA.% B15\(_1UX#_HPM)I_S[.O#ZWRJ
MJVGV>9./)> Y2)MIPT9H^]WE_<MKH/R5^S5@9@A.>SA>4QTR2D[=*-1Q>RNQ
M4 =;"U0RLE^Z<NQ3+SS4H*G"AS$N-GV0S6K>?AG/I898%HRY8C_%Q:L24R*1
MM>1QL,(6% 2K&E%5)04"U@M0\8:C)>N5Y2VI1'?[GIMYRG;[@?,EE$=@R$MD
M5?G;<J[-A/@DH9V>*O^!9MH1N[2!9+5RNR&-(RJ[W1ZQ7"='%SNB\$FBG$@/
M]02>^%8=?"U*]5"E4?Z32V@#!7HPSKRA_")]Y#]Q?-]F@%<)YN;$#>11&QKW
MAF,K[W;@PSXQ9N&=OB&:%<Z8[$<Q+YJ=ZJM3APY,'4;R?CU0TYL.#94':SC$
M,&K\L!YIC;@&F*DW+&FO@=6SA\SH.DCZU-,E%PKCEW(,56$'-IK%1IU/NO=P
MVF,(-@M9R8*J-J'DR(9 FTYK)PX*!4?P>^;'2N(:SV3K0>W!K"BW/-2N-OOW
M]]F7IQ.'U&O0FY4U:4\;)NBU4_""GE!(-7CVC(#0/H9E__K E1FH$TKZ<N9R
M6B[#^0=_??/Z,?7CQ[+J)V47C5/=<E)3'J1NYG*,_LKO['WRG[]XH;=8)K7F
ML2_/]#4%?FPQ+H;KXOYJ4I?[YZ!@+_A1X*H)"QO*UC-W.\ERQN)=9YCWPW#^
M&"I/]N1/ADI+L$@-Z*;)[E2BBINEA_!WHK#7<F8G>&"+NM)X.A_8HS$TQ)O*
M^_6PIRNE"I5NK<TQR?/5'/IA49P5FC0]H_DN3Z<[<?8?I 3W5/Q=HLJN@:H@
M>C.+G-G-F9Y[N-4/DR"9/K:!^/G;%MYO^"L;XM__M&*#GFIRG0P" 9>6FMO_
M#,*QTT1EM;?;[..PO[Z2G=7)Q'!Z#>#Z)/W4A4^4"+@SF)MTLZ5*6)%164G(
M*@#NR!PRPY5K !VTK=22QG5LLMG,5"0G-=:[=Y<+<U6EC0";UDS*J-*,*G#0
ME)\KC*^)/$]EG\U!\QHNBZ<>[=3XY=X[RHGO5U0S=*Z]P+D&XHD!9/_?#E3\
M-I4>&Y=U>V'!=):P5T_T6T;S1YD1_/3SN%T,A/,:*(M%[V[%HS0\!"Y(MUM0
M5-FKEM)S"5-ZMQ7PIT.DC^59?L-_8I0+(;LEV1?47M2;BR#/?;:.=IW9A9<&
MWQ]QN#W14$RX>2(V;>)XH7+5/COSTNO'0&LBDULX%[,/%<ZRG("!-NU.6_U5
M_O#28Q4_PG8:\&^_I#/*HK\V63-1N7E-V5%A*+VUA1RG^9I"8K4U'+3#-4#B
M>>G$:U#WHS'E633"T*:NE:RNE:M: 9*0 WJ$@++<GOAQ#<@-HXLWHT]AD0NL
M/ZK@ Y-"9JIGACXJRJ\2ZO"2XZ;IT(Z]6#(S-]2O_AY,R7&$Q^3!/+PD#"4&
M3IF?25P#88I%0\L%"MFMG(Z=N]NF@U*\30R!$@==' 0X>\1+AH-G!J._YW\Z
M25&E<W'O^-]^;8^[S2\4ZB#^2HKN-K;@OC3^_&<$=QI)5S3YU3H,OC<-.'@Z
MTD4;S0=+Z@;/(?%PAB<;#U?D:EQ*?&+X\T+4^6V.0HMZ7_3QJ=4HH'3PP&3Z
MV<P.:UX4R== T$S32F/\WV&,[/_SJD@D"AM+MI!K8&H4REF6[@15K?FXG&'P
M/4Y?VIAE'??>"6L6;PPJI<0A;8'&Z!625SHJ:#2V@GYBEL[Y-2G@ZY5X#=PI
M!E^@XJ\!1>J3TH!?7Z6ZBHU[]ZAI/%X\>PV0/(!!L6X-UG$-G#!\Q[KJ78PH
M3KF%TJHV@4^H#H+_(-?19G.VOU\_[]TG?-S/#_8MBIR@3H4SE1>! Q*W^B-4
MYQJ:;H+#?#ES$1*=B7.#3FLS)GV4[ZW**?1#0\^B,/K (.YR:L$W=LW"!V.Y
MA,0PEDV7#O8;/P),EXI;;M'EB_ /YA6\'*!U()W"<X]#;9;#=. UL:+[=@\C
M]@V_=P1%TCQ/":&QGHAX!K*0,A1 0#HG:5,%M\7U>EQ9WVOR=BOQ!!/ARC7^
M=9(&!39*4T-H9?"2DW:&W$PK-Y DA$N*C028&3#LAV(=3G7K13ADA3<>OOYC
M'I7V*$0HU1'K5P$Z"BBKXU@0[[: YY?9ET)%G+_Z^^)ZIS?AK$$>.+UH02L9
MN]NR2PF@_J;F9D]X<TD]5Q0?;&TXA7'E$=3SS1,HX(XRK+=$)6M^_[7X1")!
M@TCKU][K1Q'?63:"96Z9;)J/$VV??H2<L%N4PS^JP_/;9$E7L9@$W/59JQ =
MDRES&^J*.A,[7+@YNJ@.STQI_&;P0H\O..:VT2;A' FV=4O]L>QY'FQ&3RZ8
M1GWBT+WC;?-;OD]L-4@ %>%><IYJ8NWOB-L!4?O@?P%R&1X-EK*D"U +;]6P
M_E(_Z'EFL>26> 5IA"H<6N@R&9JD;*E/:KXK6LSY*5)>Y/%34L"%AC=CZ]7R
MSMC#FZVGN$F.DS*R13ZT':^=?HP_<YA^IAE%_JYF-8[P>PZIP V4-M;DB2UL
M$F!6"<R8WN)^"45?85*Z_WW 1TK0UCDO:5UG9G9T?\H4$+TQ349%;S3_5PVX
M# 7"6,!.]?(G.VZVV51E@(!5 #T=<T$">, P'76H$<C551.M'UG&-*?L?WLN
MNW<MB'HB@!>!7UHI(:4RWD<ID^5Q=PCW.= AUXA[/D*HB1# *&? +K;!F+>\
M'?HTGKKCGXB1+M%^R.+M[PXTQWG)C5\T%,6]N F!RR3HPV49<'XS;"6#\75>
M=\5-6\DEMB-WY#9JA'"D\H]C"XSK#^KLEO>%8##-5X0OOY&DV7S".6< &MS=
M\3,;TVB%\W2ZA0\V >(C$#U:,=E00W2?U\. :SU)K^.1K&P:$I)O[9/1-1,1
M528B[6L0[<Y< 4X)'"XZPSP%1U0.LIU"18PG<G]4ZPU84;)?"1+A+I[D$-=S
MAD%7;B$KRR/+=PZ"]FS&T\^N0&HU(Y61HI>OWD>Z]127KR4CQ4*_HG+;_%32
M9Z8M3=N(3_6#M(LD^^0VJD]:;F^;C"=Q9OJDD=+AMQ?1$>YPX[Y'Q2^7FEKZ
M$XXY3=K6&,XU/ROJZREB2>ETL 2)[2OIB)^)#]I2Q#2.D;PYZ5D0FT#U])@<
MO"G3+.APL4]T E&5Q ST^R-[S.(RO[G@!RAJ7@-24Q:-T;Q)EY]3@I5YWQQM
MYK!>( <!]X6_4QN4#IYBL7.&!J-T&U&AN62=AC6HCBZ_%]G+E[6Y#>'^Q9'I
MW%]B.\ ?;+B8@2%?&'$.R!*!7#PMZ,C@/6%4'B8I(7Q5M'HLMF[BB#_!3W="
M^1E+@&'^C^JI_@=[[QD55==M#1Y$*$2@B)(I%1 EBN18&,@/67)2 0&1G&,1
M)&<0$%1 @J"$$B5)*G*0# 5%SI)3$0LHJKJ\MWO<>_M[WSNZO]&W[]>CGQ_S
M!Q3C<,[>:\\UYZYU]JJ9IW@Q\BNG,C":V;!IGYCH+,XP MM].?86=W,(A&18
MRJ'' RO.D./MG/X2I"B4SGZJ*9;A=&I1B4SVV)O<ZK4;E;]MHP\BKLJG"D$_
M.V=:O140M23_-9\9JZFUK, .:M7G:3]UG##^!CV=,JQ O<=RC\RQLL[J*M[4
M;+W[73I\)>>S"B0$KO*/SP3X"8UB8< #4:)W!2HQXZJZOZUY!QA_3[4AD 9"
M[4*TF+"V\[?7K%R23;1NZ#046M6RW>\!(2&=Q1C6K@.QH_&L2_1S85+F@N:G
M3ILNDJ!$)[EUXK?( ,HE=L'AW7+^:Q'"&78KAE-R*B#)8JS04FPBA:7O\$.*
M82@MW\T9Y1_+G&?^AM6O<)PC'F7BZN]+:MG)/U:41-@'!N]9RM"E: KO*'!L
M+=5/>#I'2M14.]<QYQK3GW8N)@5VDHDMBNW@*$=9]A9+#22NAM?%Z#-#/,W?
M@XX'ERWX/!T%/LY4CWY2S7-+**H D0;+IXPRB:>^;/L4 L9)\_4U"1%F9_>M
MS)D;3*R\I'F.ZSLR0,SA^DQGAD%%5&'\!'$X$^6@M@+;I<, CG/+Z[PKJG5*
MA2MT''I7^D/$ZY1V?P](./!P_[<J>CQ;^?D]Z.E.B</2TC?4:PA&HQJ$%,8#
M-)H8C<*&NK*YXE\!Q9P'2<ECT^7RP;#EUFK<_ZJ\]X\3S;WO(&')^-"?>E51
MW: J'Z?"901#&7)\U/(=!\_=#3:UVIL+AW%#I'MQ 93P5SC>1L2/Z@1U7R]'
M*]XOB_0<UXY):QTM'R*/[HVSJXWEVC(_3OHU_T@2;K]?%+LMUL\+$=^4W!N^
MTD\?1Y_.;N07ADI(ZPW0155.U[,&/IBR6_NIVH"RZW[.!,19>TMM[!SE$B^>
MQI_VDX8'T@M'G#G^CKYR!5;7[)JZM75,$/B6E=EXH.T\O/ ;J>^"SQ!=2(KP
M> .X3;O7=2E04-*]85;I(?NWYE0,4=8)@GG++S+R2&OG^G6?E],WC0.&5+1]
M0*$R"T&B1"ON&+KV\8.KCG<,>IJ%O]=B6Y;1Y7F0-Q*4UAR.!I*[,6N]1MYW
MY=__.%_Z8H^@]]0KG6XJ&+Y..9$E^0)8B+.VY0D+0U7Y^6%2G_A#J^(-!GLZ
MO7WSSSP':TR LT/=T7*/CTK^URLG906J@M<#R4XX21L-%S4K!.;2/#_W=31U
M_QJFFV25#;I*<'1! N.W40$:WC#@-NDMJ^X6WEP*G.3@LCF\];KM[-=9FH,7
MDBW'LJF74&G@T+3#NO$CZQY_'%6@N\7P?F/(OO4SKVP%F+"%PW(C]U'.C;E[
MNK=KW5UIMA^[P3B3,8;Z^_#V&]5#,QN,>EQ_'?@.94A2)A%3G.^#UQ38A=H1
M9[1.B*V"/]7FE-K&8\JZ+GQC3?>VQN&?6PI,!U(T#Z*YR28G<MF(=U4O^=[L
M!Z6?(V)>.[:FLG1SOUT.CNT91!4M*T >#?^C<PQOH<'M;G;2+&VOU68MG.+9
M8%?BG* 6"A"SD_*F6N>H.;8QV<<<'T0G;NA=2VJRUN_T6OYR(DJT*G\C4BW#
M+$;CU<:M'[&G<<RJAV3K#<28"_(C9R8,0@'9P VSM2TN^-']E>;*_0%V+==U
MOEB"$W!<2CS;U[K Y2P_K=(BV:H3"YN;-^%WN05\2S--<9$D#;Z_^.Q'9_L"
MZ=6<SJ;(T0"=O,U32YMO"-75*=,7)52@(,6 [:B!S9@'?2Z@1K_$X 9(V7HV
MIT16>%X'**FG5JVLAY/MBAUQ)-KONP_"@!*U(PB[XL8W)$_]#=>+S*C]J(63
M,=OK8.?>QOXEU)ISYYC8::=101=Z$[RLA;&"3]N;5/5_7"FA-XRI9Q\ / >(
MY+Y?PX8#?K:QF/V(LIRS$]AO2UG#J@ E-,E'>,3+BI@EB;KZ5EY.Z_!NK@]>
MS5W+%@\+-PXVZPJKW@"9/$DWEW-W842I&&W0MRT:!):70=.;4IH"1R1BP6.I
M-F<_;+X^NH'PNG?S/OB9X94FY_]/[#^ 8@)4T&Q9Y=7GKVW21SI^.>*P81%6
M1^M0B,DH)K 8XZ!0D7)PH1/M>3WQ[1>E.Z*@(LU+K<6G57L )N&BG25^MC%%
M5,2LY[9P)NG3"LY0!RB.H28&NM8"W3N'Q0,::(C1Z'&9TWB@]&_;:(%0$1).
MD#N;FUR'4%N@E=9P5<F7*M:T4(F:B=+F#Q^;ET-VS.;@^99VW@AKY&T:C6_R
M0XNU\LL;FL-' LJ6M2F4XD2BR9]/2,9<1!)6_ C";2HHW_[K9-ELW)8HA0H5
M$9",*O.UC)=E7J)\W%Y3%U^6F./,=T\W1="%GNK-6I6WQ?41>*4EN:*--VV7
M1QFG(S\318J2"EP>&70'DR*36=;P7MWXMEO<C=MJ22Y!:.BO8.;<@ ?(XR?V
MGB!ICV>+^LLS.QCK9P;.L0$,WHM6])]M?E:^W3$.W;E5MY#@.L]V(K;)<0/]
M^6/IAO;EUQ,FY^$K?2G?'O5)?]M^N-6E]AO'@\EJ/>ADO_/+9Y>+-MK&I]M&
MFPBP1>6,!$M!B;=HUW'W?MB\N%6;]/#!"6\7@ .1UH%C8]K,O\$6Q2<@VEU8
M15<<6[4_@G8C2>E!OSMD@?B*U@JEGW-'(/=NI:FCDAC7E)2Q\"0K&^XJ>"!8
M"A)! 8I; C70$IT9UJ &FAC',IZ@N=.PF0?Y :J)N]]XM1:H8.2G!#U':^_%
M(K.I='#MUK4ZN81K22?$,T.@$ >SK;H0=OE1'MP;AW%YNGL<]+4\GQK<H'MO
MX&SI2EFV:0/&$Q7RJXT7+=*F&QQTWVO2U/I^V231A%YG6[@("2$LDH?_5>\E
M_HV_\7_ C#$AX.K43*3NJ+C B3#7DP6-A$BY]S5R@26-><'RKK7[NU4.]Q(<
M>8^-V&!?7H"'0L(P!N6Q"^S>AA^?I*<8FZZM9BVJ+?C?6\$#0GZG67>O1"06
MF*S[F8G?>/5$)T%UL^NG_"K\'_36_1^Z8/5C$*T&N+O?@/LQ)]0!F8E:IZ83
MN)S! L)=^",#6)<H'UBQ3=FTQTBK7F&F3BS>P"S]6!X1D\JQ]O.<;G*M>OX"
MEA9X3Q'PA;P)8K/0\&78K6%,=F2FJ-XY79'[+@.&BVV]U5%@^Z=/VULN*U-F
M\LOJO5JC 0BR:11V=/,9CN'(DYYH84HHV'/6PI/61-7&.2?+(9PO9+LH%=NX
M-549>!OU>&3QVP_=VW%N6@9R/:=B0?]) =V@/)_1G,7D1HYU579@BFK]K[CJ
M!Z0B,4?2=XE7][;9K7 AAO,8*CRPJ'Q"58$'%-[O84&P?7B!72[X/>*;9^+Y
MU7G8@@A!-7A"P:(?E5"=XJ-F]J?:[;1_-21]#SG(7C&LU%%@MK@UY!B@6-!C
MY7ZPMIJ@\, JJ-TP9A,'0E5&3[*TFKX+.7M9H[O9ADI07K;  XI P)K]XD>W
M<QWVIC2O]E.[&/A2%V!8BN%LWEKLD*@I3=E\(#A<DQ;M'[(9J+5XO+V>>Z56
MB USK>HG5>'GUZ;;+U2BF]^S4_E+./E=&/H3+K?LNCC[:ER/;4I_\YLD'M!M
MAWPB!NV7F3,V2^_"I:,%N+[7#/:+M:8UG^CUX"R.]T2U22@A*E5#1[6O^9%1
M^6RI8XEN@?V6_V00]YT9[*8*YOC&N&(U&GSF%B>-G[T@XRF6+(7]RP!*_.L
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MWJD<+=^]?2%-B588$$GM5"B!7:\L4VHS;DPY:-V<9)FWL_]D?767C2*&0-
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M*N2QX]PR5>N^.JW."N%=@M8M3QS=/(>T&RH7!1B.[>S7C%>?OI+^CML97'H
M5=N3A2[M"'6,S)H\=KQ)<_=%!CE".C6LF:<(\O%._CX>:/-+4/UV8Q>6,%EM
MM7^!* 0>?\(^&1;+3)G-W-XU6^!: +J&[B\?=GA6'>*!N !16:%2@5)O4CN;
M.'76^VU$*?=A@E7;V50-683!D';L:+N1EC?5Y_>QH%SKMP+KVS_>4%T%#[@V
MO25:R :JU!&L]CVW(YZ\3 6-/4T^#[$XLX1B(-J)&NB('-F^&W?<Z>B&G$@>
M8KOAN7>)KW=Z]7HN[.@S/YQV&J$XX3N$J1TZA]-5!MW+YO_X?:I:N=;F)AZ
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M1TLUV"RS>]D&RIKQ*Z#9WY*$7JI<Q551YK2#Z38D_ 77[%O99!EU%G ^5UF
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M)X[UWPL\9P(#[Q(WE?,L%6%C"*[&4A6;5?^J'6T8B5B\,]P1.=74'VV@@;/
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MK,,&;"3!4S-V:FEH2BQ-@["D&!&?ZG;400B^:1\^>(X)P,7TT]#^JXG4\4*
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M*.7B>%?ZX[TD3D$O<5<1.$: C/XE%Y7 ;C'ZCF/CLE>B:]A=$WPTR6>;V[G
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MVS!L)6D4D1Q.ZAV&T$ ?-;/Z"LJ-5!1;;B>B-*<V4=V;Y,T2XM)$O'9\4;Z
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MXV!LED>(,XP/ RC_D__Q^PLAHG,2(X7RL MQJF6/9?^#/>:[Q?\'4$L#!!0
M   ( (8X;E01+.*4@%0  *UT   3    :6UG,C0R-C(X,3$X7S$U+FIP9^R\
M!U@4VY8V7 0!)4D6)"B@) %%LF"+"@B(Y)R4*" YBD(K"$C.H(BTY P2F@RM
MDG,&!03).4IL.OR%=\XYX-$[<V?F^\/\ T\]3U=7=??>>ZWUKG>%7=C/V&_
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M)\%POPJ!>@=6S[>;&=T;][# BSJ%K2HL\,$""YRZ=.VJ5^!<6(BS2SRG@G[
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MC45I(-%@@G\?"$.N\6-\]6+\CYZH[KW.,PJ)>7H-"US@F\)\K,,"-_/[#+%
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MZDB<JF7  DVQQ5C@ 3TD36&#'R.= T5B_)']1J30J3;PI]X'PWK3]N+ +QY
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MPZ>P(V)+H@B4. F>0P(@8_[[#';J;5'WJ*R1 V<-(>!2TH'JD@^R@9LT/F!
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MS^W&9V=MB1+."FCT>]']4!E9FC0=+\:(M&Y>@P^$) 14YC>,<9H>/2.U^J\
M])GWT#]P5_I/W(TEWR< )6((JH)49HG1/MXP=.B*KK.X85=_]W\*C4_^_Q6-
M.P;S+F7 *<?O/O!CC-P' '=)Z%L&VZ34445V7<]V_O/[KRD0^BH%9QJ#[$TI
M*9Z'77KVI;F)([1\2;W$X+I,A?72N.!77"_SB#.G;S#190"J[./L@)PH7HVZ
M@6K#1*19Y<LF^KI2=YH+RP2SC>XTI24117@+$8&?@A3[:44[&[_8]ESVD[M%
M9[8HM1+1#>4&YL\E\KS2U#;58;,-SF M/LK(LVVN#S[,R[\+JXR<U(P&I+XD
M>.%OZ*A],1BQUKVE;Z7ZE>OU!RUI9?+8T8T;3+R@"SE328?R7&+91HXW:PX8
MSQMM[.9"AY:@Y_749RI<KK-Q-+!L\EA!MY>Q0&LY[#!PJ'D BD':=8P37#@]
M-7#A+# :]7M0C/02.7*2YPZ*0YI_ F+4W9N).H+9D2GK'*A@##L6\&"9?GAP
M";JY:@C+%JZ&@G+E U5/WQ_S@H=0"=0!FP*TH]&,WMAOH3T9 F1A >(Y)&OS
M(M?UL]M#T*5=I.H1\LUB!H9*IXSXVV&3;JA $TRM,<;EA-+&-8ST%1 %KT#%
MO7W7DV[M*0Q@GGFPI&GOF1QFR$"=:$<@*;+GDI :87Z038X"]-/#^)V!Y=,G
MZ">OG.UKW)S)16(_$"#B%7>L,< 8^41U@,FP5P]]<7*8TEN.&J<:E1'Q<><=
MF=--O;0A"K-',[I:ZNH4^=_$SLR)Y3=6V+#4[9;JYKH)C"RL-X;QL!1'59$0
MT*V&$O"DOS9U?VT<+C.70M,).068?)5B^J17G5DL'JO.$4FHIEA:"Z_FX\V0
MD_=<R1#-#0JA12K>4-HI'[V^OFQ<Q\GU#*=+J:Y&IR_/5G-1S,+WP>D18GN:
MYV..8E-EC)X/<0X#4-9!D"_KG]W73( N1J%[0'J9RP\IW 8I*]Q\LSK=CJ--
MWZ1/M,,YXG^Y_'\[E]?1'<M%:I<2G6-VBN&7>$-A?_4S,SQ'FYE=COV-DIZY
M:;4 )'HD1OTI0EB.L P.6%ON$JPV<GU),IYB_]00_OUS?'%O\9:"CTO*2*O.
MEY?GXAKE\'WZ0I-AGA9.;HP13:ZLLH!)6Z?87/FBZ+L3XGG>(Q=:JH):'#6,
MW/!#R2#<I;E,M[A.W&EFJW':B7=-NO^^V21P(N5J9@AP@V;\7'""*]I:YNS)
MJ9YW10KI?MH]ZJV!Y$HW'N)6_MH/9?3E991NF"XX/+[0=Y;]_-N;X2)EC&K5
ME@]<LO;N(3L[V2YM<A(]FY(8N#4I$ZVKP3KNE."/D0+5:J@<"W1;,=%A;NS
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M?WS)"VV%/&6&AW6F>Q)D*>F,.0R?F?;692^JW6+,2KG>I-QVL#W_^/]JZSJ
MFEZV_C]!JK10O!"#1(J4 %*E*!!::!<"" 0"*!A*D$Y4D*(!+JA  H2N")$6
M4$*37C1($Q!$I$A GDH5"2)-!?$^?-\WW[OO?F]FS\SN[,S9W;/G[/[.G-TY
M5+Z["+E]\\,KB:KQ)_"/[9*_U*E\EQ$\6VY/ZQHH2[$2/?:I=<*5'VA0<@7J
M9EW1(3JB P'VKH9,/=H!Z%>S3/+?U<,>%TS4XD$6?@N_"6PJX805%@IXBO[-
M?.<7\[\._*B),(L6UAJN;/8,%6D)3+L@#Q[^92]'P*JHP^T  #; \U_^D+E5
M7\>45X"_=&VA=EO0P(EY(HPW=7FJF0[XNS%-+F]U(!,TD\P'1FS0[DV)%6_Y
MSJ_9[-[QS.;-;V%0M#\S?@H7&EJMXH'BC'Q[:S6>DDK]1YP.4P[6J!2;+*VA
M8#:JM/]WXLLO.!H=",1B37RXDP6-?_-;6,Z1*1H?WQF))-@56E>N71S)X9J*
M<1C^66<NB?CI)[&!**&"TU/C!:("ZTO5&BBJCA=*)_EI=/IP<W;YH.NT,TJ!
MM*3?ZR)OV*,V1CQ3Q9*J:R S =.P5'DY+7W/R!"[EI: %,N. >F$$X[UL9LT
MZLW=1S>(/.1(AP]S%MY'2I.=:J.AUO?RZ'#_\J"*3AO/R\S:=I)7_5U4@J)?
M]"7>I#/GXXO(&D@)7C4907->'%>R*&%%88?T?MAX:6_0K%4\\J)G;MH<+YB[
M_WAK5W_4]'^F$" WV".YXPK>^4T2@16@['^Q(Y%I&I*SD;"LY*M*Z)M=+G/N
MF P,++18S+M^^]X@?\N((9V0]NCRF38:4VQ(P=]*T_6$=0]Z:#%CHO7G=2K_
MR"_&5&L+RJY;(^=PMJC8<JI*V(]AIY8II:"W\QJ5&>*.->5+3('7^K&(HMH)
M+3$MEV,A>IB6\%RU)V>2UE[A*OHOAD0!:_A#:*/(%?@^?NE#9)>0K5$XVIV7
MIX10/5W<$3J2%/0!SLW@9;#D9J3I./Q>]G94@ZK-\G,5\\^3@6PP8OAYR:[^
M32I_6[*">'RE+QQ0MV0AC]IAF29X6<'X<]-0YX&7+_I/U>](7-,(DL%>J9@*
M=!6$\:IO1GV5IN&<SNE7S)YY()L26^P6^\0[)"Q-3=\$UQ1EQVGS=Y1B@=0W
M4Q8![F'$F&H?D[&_Y*I &4PW';/HLH_*1/)?Y4^EE?!"D\<F$0@7UH,CYE"6
MG6UDE0W:S2W%)\TV.Z\60SBA_3VZ=L;HY\F/Z(VW![V,EL:\LV6M)QS'#A5"
M1^#GZ.%"^%;E*ZJ#O1KBRN_OHDID1L&SR-PS8UWP4[IV)4!8EYAF;4^M"<Q"
M]?8#S H'XOY$8T@C-6G0]7>>H>7..@[CU%:'PNE/F'.Z%>[_F-9I<Q\XNK;%
M^26M^VE-)Q#XR@S3T=E<>VNX-0N5WV<#*"^68G8IV!'N9*,D8#ZY@)<7H_QH
M-2WBU(P_S0V?GV/>R'2W &?IWU@^U;B-^+@CH:B[CG/*$TJU6W1)2$W#(:&.
M]D[5-:RJCJ<-+^H^>SXJ.G^@OP(*7GO?21+RM"I-D7HWGQZNV!L.+:<3"(JS
MV"'-4%1ISR4F,@LFJ5WXF^B8?T3(S?(N@LR%\\];?5B%!=$1(J#@_TA]86P<
M;PGP6^H_3)Q8>(S?]/ W4I%1C'D2&1P:]FF.*#W1B*J'F 1G6!(T1(RD669P
MX2U):I6-'+IV2N8W 8[7 2<!F&06&6= %>[:[K4LPV?,%378QGQ[DZ.ATU4
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M/[MJ2%.*:\[AB]MGOD4%5D:_^X9"4(/W+0SE>ZI)?%UI&(LA)U/W4QK;\/?
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MVS>(:G5&I;[ \/,]C+TFQ#;1FR2IB%D2?[?S$(O*TIS(S\\HN]_]-/=$CSL
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M<:6),J?4RJM-J\C60WJ&VYF2ME]KS_;M4X.]FOLT'YSDX8VHOW/3?NR!3X=
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MJ_A\WU3<US_][4B/0 9*?.1*N-JI9"EY^8K5ZB8:YPL9;5?V?1OS*%LS;$E
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ME$O-ZY^-TXTB,P+"AMXMG.3V+< :7'MD,'#F12751'B(J!2+VOY9280#6;W
M26I*A[3)XL<OZDU?:'=+.(C?UCAA9$^F<>+J3X?I=["K[18)L'P"PW'(9O^P
M*4.6_?LI.#E\8#<)L J XQ30:E7;'MC-1\3F-7#;I__0O8,X.'WJ\9UT+GGY
M_)P(P3BNKM,6R8GFH'2]8OV"PO16> U?L%^>=-GG5N;!FS?3CYY#'7W6R59<
MD''*%ZE4S+[ Y@_8IXF7CUG39$B+B$_?[KB$:0=TK[80&Q:(#0P$,F?G^PR8
M$3BF'UP\HLIT3>,$\*\<1J'(K;.CX$A^)S&*WO&'+<#Q]Q-^8+G^,L(IHI(=
M":ALS"1P;).YASP5L_TN?B:>KU=.$9!>ZE%1..[X/NE\@YRF0:++J?>;&K*/
M&1LFV,S<7NX=SEL3'NU=H;.%?ZE8W-ACMW.T33LGNM+JUEC'PO>H+EY;( 9H
M@A;@D'^YK=BRVNF;!7)B;8^5(N5O'CV/\S$LKW[^U#Y"L=562_N(N/HMV]%J
M.M_UD8WR$D&RBH<\*7YTA46\/*\]DFQK7S"J56;(7[N]2^5J="676 #BL# <
MD$7C"V()UB3@M[[OS/4FP7 \*$?P@7\R^@:<N*;Q+QO,F7+XV'-6F"4O$I#=
M9O;CIBK['Z?\M:2N_IL\ ]AABZ_A:^K-<UW/)>K+LU&$MA'-.% +>R'#F5%S
M\6(LDS9'F>;?^6G  W?TGFR5A(NY7!_@=7F2*L7YMC96Z'2MW$F(@+GJ>2H<
MJ4YIQ68E<FYY?*<1"-^9W W<'UU29?>%3+!W49MN R+>Z$GOWJ-X%%?(<9J:
MK5.GV&UGOCFBZXG0&=0$K>W)A(\HKM%)[##F!#!"=WV%6\Y&4\,.2<WRW>.F
M^2H%OR;U!-=\K8C -1)@ ">$,A" JY3G_S++UHM0[8%'8CZ1 ,GKJPOI;RDG
M?O/N3O_0J900#"S_+"?_L\8_GMOS9XN_U0W8!B[$'^/;>[;C=[A=%=DY13%5
MA@W6>GXQ4BOLV\/$3D?1QE[:(^_D.W5TS77WKV_<J,WGSWGG_?3Z.]ND])?*
M\9)?RIR,7IDN+=%)[RW5/_\T-\__0"#^_"-55D?(@L+BY2.%IM7M 0A%)OD)
MKTP4;1'OT,.)')H+]U[82%&C%'0)D@.<WXTKQ+(:HCN5+O,<TSP9C N^KEUH
MIG7^4^+,('"VDX("F"OPZ@CNIXJZ&6,2J;K-)OLH=&9U_B;-H>FPF3L_B0>B
M!VX>?%K"@@Q&$E!$F\J_7B.Q9@QBOQO?#OCY&@9YN,TD=O(]M1Z\F9:F<-RD
M+=?=H+^?HNC_VA7KVS2[XV9G>J)DXMNS+&GAN+CN"R,XPY[SAG<N,/&41G_^
M*FHT#WSEFSZ- BUK#-K5SZ4^>]ASS?,(K]J7[%/FZ\);6IA.LZK\BYM87_ZR
M1M2X0&H/DR;%<4_R.FZ*=WW6JB=6:B;57#YJO*FIO21N(BSCG2KQ6*(^D.WJ
M688F7\..I8\E;65CSQ&UG6R@^&G%;(OG)B_EE]LC>#FCLBH^1/"FS9YRQ'=_
MN_1(?F(%Z)N[)%[^:991R5Z_,?(0&^\(L[E!7?V;VT:#%Q "8D(M5S6/#MRY
MTWO>T$2F..?-P^C4$[Y/HD0_&"D_UZ+@16YGT<=T#X*#?5#&HB !JLQ%BZ^%
MC-BH:^R0/)T>4D7O6"D2L-!J;_^=JVTV"*)XY0;!19[R]I =Y7,3T;NI8GB3
M3H&Q$F?X%N/S9?@VXV4X_HZ;2B5^D4*_ SO%1O;0_A/(XI.^'V+XH?V+G4GJ
MFF;OH(9MPH6&BO;B%IF/[%%TG13<5ZG&_B7=RK]N690?_D]W,+B'RAY/M >/
MO1T^_-2HK<AHYE4;N?1W6"5*8]PQ51?^0<[#MR(O:#S"GEIYD&S/"!:;SO^B
M/I'J84CXACR5N=/*!6J1QOBC7C&9K;L??=R4:.^;Y-D?IZ9L7@B_ @#)M._F
M**^2.<U\G771UM@>Z'&3= AX]O4<!9V;J*I20M<PP3.BIC/&7K^'+OG3IA:?
M-,VHYPWR:\;BFGVS I'*+HV<!P*QTWRTMPZUUTGP4C]$S;@7Q)#NL.ZUU"M(
M8?/:#X:1)@$C[R!OJ9Q59@NMR1J/2XF<OZR]]A;[Z7,%/S6/-*%E796Y^G];
M_5HWW]%5>RFQ]ZXZ*2VQ^V#-ZE6MG,ML:N*)*]P)DUS(.,#XSTA(!?<.C859
M[0W5;Q=7" 3IOK]9*\\(^PT,3MFNSZ#)D6.<59K>TTK/W"TB+W^"#UJ&8SIQ
MLNJ0KH)M@ @"O6-[?@^=08<X+X_=F';LY@BA,MCN_,7^3\D/'_,?];2!XPT!
M@S=OTBU^H]P"."/(NCIE_</40@++(REM-@_93&> YUW3E%[KK+E?9;%!+B>
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ME\P1WD,PT# ? 5'J_8@I^'"^VW'6-CW<HO;T^AZK$G0K2Q*PSSL,OPM'N0Y
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M7S$X+FIP9]UZ951=6[+N@HTD0"!HD$WPX 1W)S@$=TAP=Y<0( 0-;"Q <+?
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M 0M#')D#3MBL,#<(V?>9Y=#2#KV?6T//?2S\3$_@/>Y6A&<+C)_:S<V%7]W
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M )K;;ND-0X&5#_)+J]&=4[8<1%MC>PX&QO&DX+,M6(70TO.JH=O/'!@W=P\
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M 4\="OBE/AU8NXJ;W0]IV%>\<7B,OE+C!R"]\S%R?8(NU3MP0#;[C\&NW_,
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MX]EV ]T65N=^5EQK]>WZY-"3P0=OPY<54W'ID:,I95Q1/TYF%/:UAH(#^A<
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M_S9'VON)5>;"7B@80T3KNB38T*+8IF-ZBJI^%WN_KR(K&0%$Y6W9%&N6;SE
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M@)H#G@'XN+AXN#CX>'AX! 3XA,04),1$1,0T=^^143#0,C$RT-+3/V#CYWS
MPLM*3\\E\9!74$A45)2)4U+VD; ,OXBH\!^38! 0$! 3$5.3D% +,],S"__=
M#?4=(,<'MC"=L3!8 $QR#"QR#%07P(2V$P?CGQKPSPT#$PL;!Q</GX"0"#T
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MX ::X0"=L$AK+DW0N;S3M4H=58LS+^[NYJ,>R=)[;QT(HOM%^F0N5]*/?O4
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MXON]5U_E,X541C]/LI#,72%KQ8K+Y3IV]%.)KKN:Y +[(P?O4^NQ?R*J&4-
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M1;;5V1T3L]--8YHBN$I$_N&O9R>PBR4=VG>1=-8_Q_DYT.'%DS<Z=@/,O8<
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M4'KLV4Y1L7!$T@QN?RV?D[>;*6B>6IB, @Y,!)&*$'"'[':I@S5R#@4@BE'
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M7\FYZ_K[[[NO9]6:-6NJJW?5KJ[ZJG;!I^!+ )Z"C+P,@(0, $B(#P"?!:0
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M:VI;V]H[.KNZ>WI'1L?&)R:GIF>65U;7UC<VM[9WCD].S\XO+J^N;_[0"PE
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MZOXS$F]NA;O?+U,U?Z:G?-\>=I_O5H-XL7H;[6KDIM>K?):IY]="3S#VA*'
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MUT&4L-;@TX/%R^.FSF@8OAV]VV$9Y=G@U\55"0K>?T\,43@<P.B,A@/B^W
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M -,/I7*&2;?*:!VJ$^ U3&\XH ^Z)J]% U!2\W2[[CXX0'8_P@%ZB<<ZD*Z
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MZ^?',1D,F,OGKHL@6)W".!T<\%J\>U*4%MSUTWD49M2^-KG"A'C1.,2GR>"
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M(^RG'Z!;"P?"A1!0-1'"EO\#THW3!ZMY! P5Z"41+,W^XN![&*=#^&&#7YW
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M:II?I2\BR!26Z#_ZW>T?PH')?&'?XHO;7#KB$;JB=VN4YI24X\MV@-,*:9L
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MUA2? P+(Y('W3KXM<)X@WN3\Q;7N:\Z?M5=T#4JC@TD=U^XV7NEZ6?F<=2&
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MG81(0&V<!<\/2XI92R_V+04!XL6(M,D9IFL6>YA3>P_\DN;IKG)2PEZ!#Y4
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M!IRE-T<#!;?*VR':]J(_+R7UF]TL96.7@#S&M-*K;U,IG .VF(V->@.1\^?
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MR&K)DOJ#5HH9+O-,S.6CHG<?.@67I,A0R5NU]^Q4RU0Y$OB/!Z2\L$*&T #
MM2SQ'R4TXJ\J50G(#(I;F\A5"&"9_J,,=AN^_$;*U]J,?-8>3ZI=YQU")UL.
M>AFR.*4#XSP!L)\(#,;"6:':TI-I,H>;U"-VGHT=!THED-2&JSL7,1P6C8,;
MMJUMB=N\9LA#R':_*?_#8J2#T/ZS_LCG-1 11H45G$[(=V:G$P!%J65@-"D(
M^]F464 JA0*@VC0L<=SD[\;9$UW[4M4U!8\2_OU[)TI5,4.1HY1(8<#K1&U/
MA[7HW8U%R9_*\!YG$-+)-\"DMMFP7Z&"6.F]T;Z$%)S-.W1RAI/3K#%&C,$(
M68UY;GS\-V"M)RZ4+Y;)?@1)5VKML9ZHHS&?S0^?O39)?T0'I"(E.J#R&"'-
M_;H8C]M%4S56YJ67513$W9,1^H%':=8N!\/)@=ZTGNEE<_13/"]OC21LW1TF
MMO'C@3L$][GVS"G47(JA+U!).C1EXY*SY 9B_2$%)8N26:C.T%;5%AV9X,#L
M6-X T5:= WOPV737@/9C\/<STX "P%*J\GWRYB"^/"6U-7O3 1WFVL.,THGD
M HYS>NQT"-T"2%!<<J^R:%SKR<CG,4F'"@,]).<X.Q2*M^AQ?4MI\?TJ@G\R
MM10CCR/;WN1KR7DV+M;?ES#</OZD\7-C?<1T\T=!1LX05'<H%M3I#1<7YP:7
M3@YC(+I1E#K:\[3; 2;9>!A=S:N'AVL53@D_K:*3:JU!,'N&=&>J59&H]0 4
MG0053PZSH(7MO#C2YL3LU]VGC.2977T<G(]17T\_B:1>^Y3P[/&;OYV-[4*2
M!5E:IW%"AGC]^/31#9(9^/D,D)S+P\+BD4D[I#(GH+SBL2WR=!^F'U'B[$O6
M)Z"]&]&O(S"NBVE3JO4R%7:ZD1__B?S!TCW1@/.C4&O8FX$L%L#*W0_WC=X\
M]#3-B"UQ/E;[_IR+&@3BMHDY8T=F-NPE:>TG.T/Y%&4&47E=.0,K2,HU[%'4
MZ6,\9?R4<)GPC'#D;Y3'[1^F%&E\I\ST##98A[2KWS%+@E=T6R'&SY)^,SH&
MH(T%!R]*UGMHUB9?#69';.]'XC>/2#%Z4%Y-D-4I;@1-XOL3"(L<=6-7#]O%
MV !J^Z.PB%G4:'YZOE2]( ^<U4(^0YT,MT)%]R_F;1"ZALNXL-XA^0X- _[_
M3V5O%_+=^YVT2]:6^'8M^:S#POW[QQXA<V]J5<#U1!?WWB;4>59FZ(-MV4]3
M\Y *8OR)-FDWJ0,GHV ;^8TD[D[ER"LCYO'RL?;264?#GWY]NK]2%@:*1K"G
M^FG:+J+MZ%+;>OWJI8?K3$MASZ)>G:*5=+FITN,[#G!"X08L[[/87] +,WYW
M]CGD20/VBBO$+^(O96OYJS!4HCZP,:ED2_[\4? 6YE<+YG2HR.J"U2I[6F0R
M<#^0FXPAZ]Q]1B5+W/>ES,;F$(E#[D':PER9G#+5#N]L[?2UCB&N\:9*_:*;
M>\44OM$/:G4Y<T7!TF@_OL[LA["(58NI W/E[Y;Q/.ERGLE/ANFYO>AJBD26
M8GJ*WANW71LY';R_=?YZQOM^@+U1TM)EK$,)V-FJ\)"9<,,N2[=H\WS)9>][
M2,!;\'#/K&305?M_^MT"T*)FF0O:*I>7EG.Z_P<E!RW("I\2&R]T85M7,#WK
M49PF(YME7,V^PE-BR<9&>L346=98..>DI$T,>T9[1A_!@B1>)^8O>^E_0,4R
MW?2JSG?><_=^'+O[Q&ATDMU+!A!IHM.^CF !CL88]XSE\*AD*4C<]_/<>3ZY
M1+!D _05W-FFIJ9:Q7_;(?Z; D+,_ =02P,$%     @ ACAN5#:C+PW9+@
M\3(  !,   !I;6<R-#(V,C@Q,3A?,C$N:G!GM;EE6)S!NB7:2/"@#<&U(7A"
MT[A#\.#N!'=W@DN@ XU#<'<+T%B0X"[!G1 :Z*#!(4$RR=YSSLS<.W-FSYQ[
MZWO6CWJJZJM:JZK>>M^JW\N_MP"$2G**<@ 45   Y<\'^+T&D %@86!@8CS!
MPL3$Q,;&PL$#/L7#Q<6C("8A -)0TM'24%)3TX.XG],S<C)14[,*L'&^Y(%
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M[K=2!VNSU?7K%'6/]LMX5YFP)+C\2DTJN6DL2*>0:1H@3*1H"/?<;'YK0JX
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MKN6)YSR2VJK.IJCYOF%23&I6)DELGQ)>C +F*HI18<U$&MH[ 35DI2HT9(&
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M')_>/'Q$!C>\VAL@.#*-WQUIM>-;*\*292+.DK.M:ZKP&R#F*#RLX\?'5'P
M9NO H6631[42&IYI$PU4QUCX5X^4_PA@_>(L%J@V 54<^.,(8Y.W\CO8"=;6
M)PZW':=(2WN*W>PU4H]'CLQ:"B<DX126E048FR:AH0"'4B?R%V2H#_BUG+I3
M)3^+454I7V,:HX7CA>QBX<+66P+N/3(V".B\!A]?3$ZJMU8)P%H$_4^#(_Z3
MN&_,*L)ZP#TV64A_ %QRW/,T#Z5'XI3IT"3-G7<].Y]D#?>]58--/N;DYNL.
M^;% AN?D-"H +W&&M*U94X5R'H424GJ2ME_FP2%1M'0H7C<Z;?ZA:>T>BK3K
M\\$@/6<1.YY4GV5+.^6FE"_<%&Y!%ZJGR]JSG06%E$(4-#ZD#&%((9O1F]&"
MIP$P1S\7$JO38?:(W+K"Z!#*Y*1>5NF667E,&E848D@LJAPT1A"G&*#+:]CK
MOVTT<L*$7[2( ;AFV*&/6*TU4/'( H\VGY1K]J-'V?83S9]IPT=/N$65WRZ1
MQ3MM+Q(2Y?#+[0MMAPI4_!O].D8:AW.1ZAC3JSIKKG,XF$.N> (-W7F,FMH<
M*3I_ZE=VS>.,UR #F5+=>PKGV=2SNZ&;USGGM966?R/KN3H<LSOK&L?E8!4G
MUT1&L2V:B#P0O#_D/C1=( GTC\78NDMK[_>7"C45VV?E9YU)F3^VJPOFTM)P
M9OD->%EL:B17JF05O1[6E*"1-9*MW:5OI<*KZSAH1UJ2V9?//(X2%M9+GT>@
M!*1ZHMC46M1.5.FPN$I;RJ$PNUZL8)E:P3-$$A<4,%<G:B"JYR$#)'Q=J""/
M[Z8/\#R$V>V\.;*Z%A[C2&\_$ULH79,^->HH_C#!BIQT>F7F1OY=89 Y(Z;>
MU=7)@VN[-5E7WGGEZWDXX%(T2X@\D,(0J2/K/EVC1A##1WA#++&R=J.[;:TN
MMXYP 8?@O'LD?BKM^#[BZ02W#UG"F$BQ)@-GH-6%6E+"LL+Q]SHY"2*S"('4
MC],MO&PVEJTH>@QN(GMUAGY0HUP+*NE$]E&.X=T?X@Y/I%>8OLSN6'A9P:#0
M':L%V_33VKVB:S)GSAZE#CV\2/:R;2P*"M< V[43+9-8*DW_;Q^&DA@52$^U
M?GRX/N=-F=<8Z5]N:BAJNA1I=X4;&67&@(6M8ZA)YO@*-2]Y':9Z_]^O0_\
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M,#$P2;"P2#B?4CSE_'=?#^T 'BK"$;(R APM (\'AX ']] -4#]^3B2XOUW
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M9EC _Y-E_VS8_[!K#L!$@'L</ 0\0!2XO&;(\4/_5RGSA2S1/P ?A3J?S#T
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MV4)MUDT7/>,(__C%&8+ -&.\B8TI5?/3XNXNO* -G=&98Z8$6/)C)O0 *#\
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MY02B/3\[16[^.-=<'@").UDP( !:>7<K_$T;MK[&WCC)"L*;(TZ6K^U31=+
MQ1FZA"+$<C44;3#Z?;#T>".X#?G"O1\8:I)!>^>N6J_.U(%H_$)G.W*[UDD4
M]US_0/_@ 2#<J9"T%<FD!163S)2D,9HAVO%'^G&JGJ2QO+.4G,Q)C6FF*F.Z
MODJ\YPA[X\%@VB!'>QJFQ<-,5)&JP GGW6H*1R?*1Y>R5^OFQ4'O?Z2;6V5-
MQI#G-I0#427?(HV O4H-0[C+507+K2GBC*RD6MZ]GMHZDYO0?-+O%[7:Z,5+
M85#T$A6EL,<QWDVZ70L1=S]9,*\>BC6"R<+-R?+S7=0W(G$O?$ZNF&/[E"%+
MPO1SSNB*\,3)U*OD>]P/I<Y9NA;Q'*;5GP1QD4?CC5>H\HXU<41R,[IJIFO=
M:BBQC]]]<65I,GD'LC6T*X[%YNS&7(_<:M3_>/TJQ?5CU(\36EE/ML]1-2$<
M2.B-?;NQ/P0C13Q3,M>BTY\] (%ZYI<$)H(ZGU06&^V46OU0F!5S[FF-$XIM
M/JHH)=$NLAKZ6MR^NN][C* %(^,B'1O>!0="HIM)R]\CS0I&8KA$EKNTM=HB
M6%E;26376)B_IW=9830P?;+EEUHQQI5>ZJ#[B@WW=5?O^4\#F"5"OZ.9@[73
M1K"VK(DJ&TUH#$/1T3P)-K8T'6W#HN"4I:__=4M\>;_PN<.K66K!L*<OO5N-
MWX_DF^>D3FJ_4R6B+[&V>+9GWK6F2+TG0B'O,VO]M*+JH^SSP\A+3_[8N!GX
M2!ER?GZD:"S7>Y(3ROIP;N>V>JFHQ);&'!NO1@ Q\I*$)G#'D\(_X0'@=KS?
M? #NZLOX.JBHOD^WT+%73MMR%[V?,!X4&ZH3,XP(1A^0)2$16*>/=DO*!2U-
M&0^PIVE;2/W8;7T1]=Z+;WM&CUG0 ROYIQD.@ZOD6^SQ7I:XN%C[D=?#,"N>
M?3:<="GWJ?67<I[!]97^"(I;:&C\Y%*R3Z%\U"VB*)9ZA),UY?"6NXYEBY98
MM!*,88,X+PP3/.,:YV'NZ]2NWS6AP=_F7#N??*]1:6BHBMZ,- BL_!B]S-^W
M D\2N4W)*3,X/CMK67A^ :ZLGEJ>ODI<$<6O/>9Z6]M8__-PPX&VNC$219+"
ME_#-<AA$00; T];'\=*F#^>V0%I:KI]+U'P=Z1[>M>G X:= @BM4!(9'LIOS
M#3G/Q-U17/,EAJ585;>X+?EUJU2^.$/NI]M24=5!:!<@RH4:0\RF(QG5:&D8
M2CK"(P?]9 !\83'2<\)MHK[;EK;B1#6\"P>7^8'E&.6RJ+41"MC7SJ5Q*;?[
MG\ [=X^3[CRNEE0WL-7<DZ.O!T6WKLXX>&[)W2+TK3_!3#RE)6K4^S:;+UWY
MA30=E/RNP@#K[4$0+W_NRO1M.)_OKUO?<Q75@9KQ&$K+>@^JH@)S_%[NV+ZY
MH+DU0V/K3;ZG*Y\PI85D5U96A.AYX[4(UY\HRTI:7%_>88EB-<NM+[Y3/E'=
M*/IF7K<Y09O)DOO*..ZD7LAN8 6KD1,?A?^)P0E;%%C34?@X>*6N;MP:9% D
MTCD>2WAEFY;>C>NCFV5#YR/&PQNTVFPZ"I9C*2LW*;5,B2J)8-)J,3%R)XH>
M%5]W3.B?PYY<,6ST17&3Z&RE^YG7V#IQQ'+\_HQJC8.9 =$(Y0?<I_3/)D@Q
M=N:7NO.[F]<(&];]YU7SY[S'MTJE;@F=6E-I6&69Q1:=[PJE4.=Y&C2))<5<
MT]O]L+$%<;M<$$71K6NW71KJOOMS<S?9.UJUV[J>)B-Z?>E]<2N1O3ZECPUS
ME<P8['X H%'IRFO&U9F*THWF+6%?.AX M0$ _"TMGM_ <RJF8W;-%_L#'G.H
ML?;8)MQ50(U%@/3CW+VB?@T:^QC_LG"=S$%)?UQHZ.6%,)]\4]L7W9RZH"T[
M/V+&K(3(R[668YE)'UI80#_/_/,Q_ D4E6H3&AVB/OJT6%=CS*;(PKY>^I;I
M\L.:(?33T],Q[6:-];MS/"F**BIR1AE$0%9@'9C^/ N3EILP:)BZI5M+'D\T
M8./FE%%=V4B/ERDA)=CL?=IZ=%!/E,A=,L^>E3NPD#Q4G([=7*:O?\O8U-8\
M?M_K54KA*.YHD8BU3=,GJXZ(*TY!848*4J=<?U\VM'*(?WKD*9[30MS)Y(9+
M%X;5^"P4P__6 (D&KCY\U!;O@QXM3*)DL&A+-JLQF$-D4G>EG\# /^:SV4V6
M0?F[E%1(13];QP@VMWUSB?T\5Z+RRT"; ;1S4@.1/(^I49U2-JZO\1L6VH>B
M?3OJ6M,ME%F+2VYU>]-O7>*4^ZVE2!>"GY$<J&($#=LI+NVWE\0<9H;&[5)#
M$XS>)'5J@(^K'M.T=\2+2Z:<..)IMD9GWDN=(STUELLHL[IS,N/:$4%>O<&1
MQ71(#O;C(, QL*T1PK$)Y?/+'<W4U'4YTI9\%Y4@1III<\P,'WCYT1>MHR@\
MJC%EN6\X)3#\4U+IQ7V)ATU@<4^YN4M*&E.MV9LJX_1H;%('L6$2O#3'R*DH
MAWNX\9H;:DQ0D\$$\=*I5 /\+4-"+"'U)R-$&KHR\1&//:8,V1?<T8)A+VH"
MPAF*:/XY'_G-OQNFD7O>!Z#_Z;3OX?(#\)JN7.S/!7X_8?B6MG6**M0:M\"*
MJ!138Y0 J78TJESZ,YX]HNY;A=&\R1;^>I>38D6#(29\F(C:<B9EV*JB\*?U
MT5W)?.[95K+7/._,0GY*$NUDS*AK0J<TZ4X6 W*K2B(8&U#@0I)Z42:,$7[!
M-PJ>VWZ\)DPF*VE:J"RJKU,+?\XVDB(V#!P09K0MD8R8?QL+;(RFE55.'#'X
MEO(UV:QD=VQ&OVM;6Z[>P]9D&/7]0*R'O]I..8\0%:VU4,[7Y/S9G3DG-6+<
M*]Z?-C.ILY7Q&J?=&7F330S9S8'6S=6IDUY(JT.&FV4VW"<4!QT9,I2YRV<V
M0@%I^ L!,XN!$[BHXV/<E&SB]>R[24K:Q=X7.LD^LN2?-U-)^?OY#[6X505D
MBWG?%?&6+(4(E[K1B4T?&3=]KZ8]>C5C%JXF14*"Y><2+ZQ!Y>> S.A-WZF%
M';HF+RH7() 8P3SR!:0322&$WVY4P;]QG3*7$^VN-8UC(>2P+$%WCQ=%?8]/
M?7A<17T(WAX^T[])%3ERN5L25(M:+.&;<IS3^0JCC\J)XY3:?!_ *4!!EA*N
M;J6@[-(\TU</A<189P_F])HKI+]XEA6O'HN9!M6(;SGK( %'NY=8V@:+$->U
M>F96]#,P1\8.<G%;U,\+&'B&, O9\9=UAG]PT'VM:EIN^@O=N%+:'J.+VP*D
M_$):^JWJ)Z@X2F'!3V53!_Q;3FC-7,1B[2=_4AG>72[0^[#A%3A$#P/*AD-=
MK(NH@CU!\;$R:Y49(M73MY_;T<7?\L;YH5(*,_XB4G#PK%J4;=8]>'<_6'4/
MN>\[]1WU&;FP9;)_ -3K;1:VA?F''97,YXA35V^D:\<.?^"V!*N]HQ/1\.-*
M ITK7:E%$99=/.$NM8Q,8CAZZF8:!0J79-C90Z_*0*7Y131DT89S*YIG6;$W
MQ7LFR<WQ2>;'CSZT/I8SD^H *:X8JS-=2<(7/#GO20=>Y%T*2$#7.PN4M9</
M:C'1C'#C6KZ" CB_0)!1YT1T\%'!1I8*HTZ+ST^OCR#S QG7BIRK+1#KPR2!
M#A"V9I-1J?E/^6%%%SYE!S7K+W.L@5]A'D.'W,VVM"BQ?8-;7)L5R [=&>&B
MC*<OGE;]//J%!O;-_N Z[:!SVQ2)+]CS7/THL/$)"2G)-@J);D.Y3<XW(@KM
MMG>OG1>T;;6O]B\S1+-W<9?=UJ4GP%PY>TVJ'V6WANP]@N*F48YL0)0#+AL<
M-[. =?\1#UM(*^FD,W)KXWC?EXVS9Z>;3IK8J!L(_OV+<0$R&Z>.$TJOOO4W
ME\*[A?4OFBN-.7F+OJPD]K"NZD!>VQ1GUHQ1E@4EC#IX (+H[=18MT)4;;;%
M$H@5+?AH:DM\W=H=?59&="@4+S!.HSG2?M6H%/5;_9B4_3KG^;_]\@>7;OF@
M^;_F%D22*MFM/@5(19%80WB+X*0E3E<VG#>VBW."Z"D_YPI(K+IP;D*/$EC]
MN'FKE;[ZY?9)F>QT^/<)#*_&.\9[;/-PI_!FLH9RN[.HGI^@=SXU5, 3PQAV
MC/,/3 O@2IO<>^'(OIWLF#[J19#GYK0G9U[5CYWMS_P$21<^:IEA'?2^[RKL
M>>$#T%D.34X;HQ244GN;C3710.G@V S><.9?,<!VG%%2/7SFN5!NK7RY]5Z2
M4(7T=PWH/Z3^0PBWE<$$TZ4<E/7,(@HW-76M<>FD$I3N'7 0I!+8RS)L" /#
MK7T^>AI4$R8WV&RAB??)P/C(P*YUEDZX>(>1R6TZ336ZT(A14MNQ%RP*+7[;
MU+!<QC=SF$PW&"YIH;%BA&@BMKUP$NF8\JN9G-R:=X!)B%^-W"WY ^TYPG7&
MQJ_G)4J:PWD%C8E:X]_N5G+"5^^9/KS;O<>:Q;#6;@X*4$9#,9UR0,;Q_BRP
M$B#MH13#)9-BYQ@?OO>H@CHM5C-K[U)O7+I\1KA<,\ M9B3+EZZ^U6GK:8:U
M1V6')=896T=K3&X$Y/E?.ADW5HPS4$#HZZRW./F:,'A/=^YYA"()@Q_37DSN
MJWPV9]J(K*L+_M'8*$3#6"I[OO!'2H-?F//#)R,8$#"X38!>@\C # ><B9TB
MB#Z.)_DW]L0T:FVJ(/NU8^PY70EKD6KCJC?-TY=9A;K9_J84##0!?'AI)RES
MY<PU4*DPE,Y^'E(6->VM\91?9@M[JBUU3H -!'D%=6=>G&Z\"&;+' ]#>6-!
MF1;# V>4QCBPE[L# -CMRFFTB>L[\EIOE;8B9F?VBHGG>Y8H6UHM^7E2Z=,X
ML_2YX>CXQ#Y"M^L'%'!04C;NV?=*+5?GK7GX3$]?'O$&E%*X@:A6CLQ'J$(R
M($O-T''Y!N@WBSG)%MRE3I7\'PO@[Y]E5N5PQ>D1(H-VD!DBZ8PW+E&50Q@_
M+6WY1GE)^N9[2?VDD9<\+"$R</_4H#'04A*M#\:K<;WY+H7#,[/;RC+J[+G+
M7.(L\ZQ1BI$@<3ERVU1LB1UM8,,H8ZUEL/?:4<_M^.4XVQ&92\K4V)+[SY=<
M25\FT[!?)L3;]Q&Q]5 *#G8U!4=XY\[.SRS ,7\)>*;*0B[5]]J_)E;V<,1C
M.IY325?^[M/S;*I2JE+'8HLZ5]JY_;<U 8ZDGR29!THKX.4,TE:0C#*-=E7/
M'P"\G;D\O@3-/78YHB^TJY?6*@CT+@HB>M@D7@4H*.%GU&%J(YXGY'+5T:[^
M9=99]6=/8*_B^TG[^OJZ**+7HW\9]:90UD4A)ZPN(B\)O9H\:O,XI*MT58X@
M,07%^_4W4ZSX20O\8%2RL"SFBD+E(?+6W"%>8H4>;IYI=I3,@E<3X:^RT$B;
M$.E#A%N5[=S 4U%'V29?.Y^WM=37AJ4:N&^J*"^D&6>T4 \TZ%/#M%^.WZ(Y
MLV0D6B).;>'&0SY[/5$12BTVYAA><]\N'#*$+:M9VZ[RAA2^UMST3-3\,L&Z
MBR^@.HQ"PIP7G4:U^(+Q@YJE=1 97GJ:K>F!A\P):[#S\_&VVH/6F1+<;M.W
M<O'J!MM)?1U*?>MT<;&P9 FR^-WEN2E]*U,&6H(73SLP*LZZC%=>;)SY=_2F
M>XE#(8FKY1@6^!9OR3T+6:<XG$K#M#=<%GYP)#2*H\#L(2A$5)6KWHPX07B6
M4BC)[Y(8;/*:DM3,S+ZL+S=G?GX?"FQ39.3%3_)SIU^2Y<KFC7OL>$Q4]=IB
M#'&'42@5N;H:$*DXR-)GE438/G%S.;TJ69FRRK ;\/<:18Q<A"?HREA^P0^F
MLASV<BQ:'EJQ19L).W7&4$FR>):,M*@,MC7EA^C;LRR*]_4X40E",\+,5BR+
MF)V:F=P//UK%%ZHX(# 8Z)QN%('Q9?GW9O**2@6:PMZ&UW,MSI\+>2Z^')3_
M*._K;FM)P-M^-E"8W\C?+^PFFJ@T#GZ7;8D,JIBT-DG2.?C8.JO E;E81UXI
M+.@XUM*LGZHZ#29?]5;3MHQ8%)S5T.LNVVA^-2_7M[*!K.*;2OU<&W1$Q/*U
M=L5;7[VB.<P6S.,)D*0,&<K(;=C)8'(,>OWXAK[M2D+T.KQ2#K/1YMC;Y;[,
M Y+_36/GPMJU<%'2&EAWBHKJ15R55N-' 8S35 2EON?O3VU9<UXP!>FW%L?N
M]B,XI'%NHY B\'3J:96'BW#(%NP)&5>.E7X,LVE/3-B4Z!OFU'JK:$CW5OS;
M$DOUV.V3]1@<2S7>$ZU>IH9&2<5%6JS"'X7?L?M)3B8*'[4;8XJ+KB;C1]U<
M7_?B*ZHHD?J\N2$P'UG^)\[V["U95CPM'GZ@@M[/E4U?:5^^:OH\2FII;6U<
MN3:%W.I+N@E))+R[K?AI/,Y+9"EIGDV//^2]EUW\P#T=2TL5L$.9S%^#*:",
M\Y91G\#MP] ]@T6*\$>\.:VE+L)D]E<0[CBBQ72[[YR5V,@B!H_+E,^ H.78
M)K.P,('-H<[YG:C^&(_V%^OS.X6I+?-&X_"WO204D<[4[*049M%9X96>A9H6
M%6'EQRR'AJ8S5.ZJA/7TI/3E**?EW"<*(05NMA ]/&^JA=F:RP_QGS=L/Z.$
M"67L_<"YK*?8YE'L<7U1=*L8/_*N8H*''$L$M]BLH/OH@)0H@H)]_DR&LZNL
MF^3X95YZRHQ2%T2>_SN+KS#.FS$OZ5Q+/U_3/7:%&SF20.M8!GY0=A=<FC-E
M;^D']?!]:K90[B']+CW,:2M07?)00\R!(OY@0(,J1@,#(P4%7/K"UO=O.7F$
M5C_3/[PFMBSJ=VONJ2<37BR+R9V]J]9N[I(F>,%0E-"_82:DW0# RP*.<="I
M2[6&*2\YZV+](6>>FKX0I_PX'7!V'8)?5N(.L,-?=G.0M&QU8S:[=J.>O.E^
M@WSW97AQT3[#7@>G:^2* OP8"/7;;M0\"FL/YN2N&^WMG8SC#Z\RPB0)U>@9
M_NH-?/]9^'?O]GT/:Q87 4$W(6E1^ JO^Q'C65\*IOW:X^3,B_:/0<E>R$FQ
M%LJ&*+!PNQLKP_;DD<"@)<I@VJF<A<7F^T/KBRNOV&Y;2C?0.@S+8@'&>*P(
MTW7.GI6JU_IT*LW=3&WN>H:;1DQCP.@_+^3H)^^!1)3[[9K.-=153=;2,?5^
M\/L#$&1Y%[?Q !3X&MVE#BR(3KD+N6SS[T,<PUW]:P:'J#LN>/F@5WP<7^1Z
M&[7)\TPIBNBR*?=S<K*':HWXE!H:+ET%8JA@+OKX,$,Y[?=->Z2(T&R#[!EX
M]'AOU51* 8@,:9GT6WTJ6+F<(K:N!8<6R<5=W:D#HN/ZUALCND+2V>8T,X.^
M<M6<;SP4JB4J3 U,6A?S?6>VN# YC<Q>*NKFZ@#+9B:&0[JD/8O1MJ--YA^S
M-)40-!H'>?D3Z2ZMWE#?:M$JJZB1^(22SXF/"\7GFVZSHXS$':=WJL8IWL&5
M^,J1S53N:R-8EF3)W?+D*M55G+/:=ZE#R4.2LU6FIBNQBHA4<*6*H7KX"3UD
MW*;CMO.'<MSBT>">]V?/'?T4" ,\"RG@Y9W/E2]BI&=>MR1$Z.*P3^2=C$0P
M@Z!WPX&61@.IQ444H<,D@E8TF4=^+E=I&2Z3;4_<6'^U4N^F8$?87A19FV$_
M ()?UY3EC\_J25V'N2!N*^HY2HISM9:TK17C.D6@6O[E,,'G^64PGZGY-[5\
M!-)N554H*IT']FF5",7H\D8O)\I\"#MR):S;E.3D-'X(37CU_4PB#YN'C"_7
MNCBI?(L"->.1C<FR#F_#K>$@ZUGJ8Y]'"=-%\<B+S+'%U6V&1EA"J+/Z.\Z?
M27E+V92*1K>\*Q#Q%PVAJ7T6J[N0W$F=)D@H%-H^?V;-26W@5JZ44Z1JF:W4
MS=.D^.T4?''6N02"7N^^@^D=VM!5U)WF5R2IRVS')K$\'UJ5??YRAIGWD(0^
MWWCOVBP,['615)]!%OC:',2A^T%!W*B&(@@%\QUS-Z I2[=%\OR[83B16FU=
MKD88BU7YPMD#0+0C.)6Z9GQB%KRJN7T:KJM-V>M#&-7CBK4.YZ,TO*$,!UHK
MK4M=$R5SRWPSY6PM>L,F-[Z!+V%S&":'$.^ND];TW!7IRKY> '2M2IBH;EV+
M7S966SNWG>';R5/BV[EZOW"#=_]CN?F0ZH/O2-U(<_JR9W1B=I&Y5F)OCRZ=
M9OB\2[KM!Z,DZSW>NME@WFW[F_U1U[+A<.'<6V9Z/?V@:"Z(!W'^-UA,Y[0:
M[Y(5L;J/2=>QZNGTC[#J '$PG=/(ZZ(U7^S])!_FD!XJDF"!HW1P<:J9=_:]
M;G.TKK@.TCH=$N'*6?1U.)%420#/)F&R[<39ONRMY5JZF6)#QL]S%BJTCP>I
M??&Z>284QAR(@1VJ.O@*!ZS>R.&,)DSGM(Y;LYH4OJ$\HA0=Q?W$0=E:BH;A
MV:8IDL\E(A-B..S@^"%"9N"3?O,I43QN83F5UMI1:SW=U_J\[YGC$M46#D_7
MWON?933N,$V;%ZM:E1I;D-U6;BKI3__(SE4L7-@E/MV;LK3P40G+EL:$0XP,
M0%OQP^:T3S->*_\I:?Q#N[GA<35#_:O+FO\9^#>59O_J!AN_^2>80MI@;2OR
M7$J-%2W37LW%FGJD"0<)Z65YP:1H@0$XKX$CAC+15[#\E66\?5P+087JBXC=
M2W=[[R3CQ5HY*DV  MZ=9^Q#4VET2/["!X_T'RY3+KNMFOHY,5NR_ "V+ UF
M@M@3AG(^Q6@]-+[(>!U]2:.^""7/%^"P])?$DNUL#2BD Y$>IUP[L8I8DRWJ
MQ*>]W/A9;AM1@4Q%I(AX'8B.*4#\GS?JGZ,_KJ3_<]N-'831OWK2_U>&:>!6
MMLQ+XD2JJ,C-M;.),(4G3>'B=%_+WSPBYE@"(O9, _GM-F;!!GCZFWKBWMPQ
M1,,Y=:>F#6UG?'?7GG9N$/2-= W3A>,.ME&&(WY.")?,UZX]I'<ZVR*WOJBN
M5AOB0N<D-$T'T]RP:PD:&7",] R87LD,!0MOUP?=TRQK2E75]GS/?=7):W_Y
MJL&[]*<$90B-]X*]FNCJ4]CV _#2-.0!\$U^U*@,#\#'D/7,.[04ZKM[_7N9
M+*P1-+=4"!06P(8%Z^IRX*KB2R[5*+)T1>?G- IBJ8Q1%3 A1W;4"U,Y_\+V
M]6>)R>33:"SQPW7+PEP!E4^%2[D)[5;1!7L?-@&BE0< 6X3&S;=C&>?\S-79
MN]BR:2F;>WQVCJBA\4S."C% G#P@^RK,E%6F;UAXS'VUMCYI;4UC-0#$!HIG
M5Y5$ ,6[ =B..@] (%AX51Y#SMWK&5)6=;/WH7#+EOT+G?+KSA\RB'B1*Y2+
M_5GH/GBP]%5;,NL(^=;3\FC?49OV:-NU'4X):'ZK\@S),%,F+$=?_T3Z(Q@W
MH=W:F:FN:<* BU.H Q6KYE!@KETV,EKS":+U\ZI[M@[LN'5J),N45THQN+)%
M'XFAA<%RO^[F8L^< *S*U>KN@@H>^FC?-;F3F_:YS9$12U>"W9,\KX;8Y#>Q
M=KQ;JP+#;C:"Q@B3]&,E-DX63JYUD1:GVJEJ]3$;2GBZS<@+UN1NZR2'>OI0
M3O>:\Q/%C\^2Y#Z.UO+*E)&&8I8,-ZAL&RP2\,*!^WP*IIGZ[K$ZQ]V*UZ@J
MT:)U1<XTC.L;HB5-8HL'>DF$>?M"A+&/N(8 C\W_M7"[(4H"5KH8@;.\%KT@
MKD>>?G5C=9%J'=T?NR'BP;OPHA<4HP7\VONK#[3\5^1Q3!E@,=T^\"?1"6L-
MF,EZE)Z.1O8%$:7A9]0<_HSBP+H%9E;F8B((GFNDXV2P1TT=[T,&#30O*8,R
MO<-_O?H3=W@O(^+P*MIL8]63K?E(!NL!N.-/ZG&WAB?/:ZL[F]B"?LD<AH3:
M\+(<X,?*+.+&6$7$XW[A?'TJ1AF&W-9%*=$])]J]C.M&KC.5-T534W^CXDI0
M+13XN6ZE$@1?A5E.@]>QIX$PRYA16B21:SX]E]_9-ZJIW6]/"X$S+,P/):4Q
M0YA0'=BZ]<WB"P>CE.R<,$>!+S:S7IDHGV;CD&TV %6% KV(IX*C*'&SL)"U
M!Z#[^[0'>D>.N;J(,1JOD@I<<_H&J9P#@9<!5I=?'@7:"<J:;]?-H'8FU6Z;
MY1AK/E[UMZY6,$)Z%-H<R;:0_K$5#5X_2M=RY+5HD)> T6H,WN[TE&L29VU-
MO*25/YYK9HHDN::F@P10TFM!S]RMBA,J2D #RR^PN">$ED5YLRP.S;C<O%&R
MN1)O?T,\/Q%_I?LMCZ*8%Q")"'"S*5UKJ$\2R$I$Z 59D>K*]-%$H]*E320F
MKY;R6I-W-DDEV_VLN5![.]_W,UZEBD992HR_[YRH2 QO!)%/[71^09)B]'40
M*%H2LRS/(  '$0_"-'C82NW6UN%ZRN;G7,KCI'D$:O!F4PT+A_P(ST(C?/*^
MEZ*,M\S5.&'OTUN45)C1*J30N<]+>KW4\<95K7YK:E&*I93ZZ[D.H!$DT5F&
MK4"R&J*T3HUBX<,_^@!4.=L*O]=4,]_POVBQX>3D1 434P1.3R,Z$;Y%^=*[
MRA9F.F"-KT^IQ9I!@/<APECK*KB]51O3+_>8FITC@8;BK-?B_WI$BOSWZ8R_
M6]PS>[WQK8U6$[M'W8/.]T./,2U('?;@I'9'D6(;P2LOKF/X3_1[%OEZ,K%6
MH4G)V8ME12Y)H]QO.XO@.:MX9U0U/T<-$*DC!!X&GHL4?YO9\="%%!0M]%J;
MV:1N)EXSW!LG^ $;\4 _S[I+&X4/A<8>UQZO#TEK?6NF:[HC5E"3[//UQGKV
M!'H0O./$*$J*#FRK5_E$O>MJ3KN!^PY^"8(1QSY0W+TR2,N8$*NJGF9\2&''
M-'Z.Y2H#\[^18"TND*.;LR 3(!YG55&8G>M)_(2+,D=A- DWC,U0!<N%3G<G
M5YF_6+6L%:%IB%[:2&6@(Q!J)<HS2;!_FNIR) ..MISBQL&VH"(>FY;_:654
M4X.M;QC?\_D7\P]9HU'CA':$+$*X(@T?CE2M.JA+L6C(*S.UZ,6,!;#)J33]
M!S]7D85#$IJZA9.4A1)?8@E;^Y5%!_+!\BJM_H(%T#259L* !#FR=VY2>W_[
M?CAPU@9OF4$$RUTM-CY1+8MR7I./,6$<H9"SYRQD:65U]:\-&SCL0J$!F,:X
M%;%V6BGJ3[FM6<=ZT&D%@FE*:92"EA9U(C,T$OI_E:..M9D54SK*U4^<CU!(
M.YK9I:XE<B^1^"XO!&"+H\2*HR"JBA+>HE5#8T)8?PT^ $2*STK+AG:1DS#2
MAPO9,=N=WR_YB23G5-WR4$:*$(W1CFW%>PLS9VMK&I.8A=+,]/KWZU %[C I
M_^F(Z+], ?9'_YQV9N&(Y?S5343_RQ']?Y*V8E1F)V?2#9,^9#5UQ_"LF2[)
M#E=C'Q?\==GSH-JL[%PCX@E^3F""]6,X:C2+$XT/*6IQF!R,/!^G:>D0#C$'
MO_ F=Q@E=RPX."A\4"2;=Z/OS2 *XE$DF)/([_'(MSFT757E0K2-;;;1.72P
MG\XN%WH @C2A@?<AR[<E6KXGA' 'L6[CG?7J>-KSL&2I%'<=D'VO+P%7)3\
MS((R.+035Z^?=-D&)8D\'6?C/B:[R[G&:,BO#[E1F[SM)^I0G7M"#X+S[R^W
MRX)OT5_;OF5^ $35[GM/15<)[D=L10=.7=T]<5+;?EQ=&KDNK-LL>,V6FY>T
MX7_0LHE;+7W] &AH+"L&+_XX:5!^IF-D2N+74UV#,!$K-(HRG('V^$D?G0(U
M*.:6-O,4\6Y[MFU]Y-Z#]_A7)M_RXO25VN9(T#V?&Z1S6W*Z[)#E_"J6._,#
M;X=.<3$2,I$9"@U55^"(D6@PV/V$3;/"!>KKSVW.K;$85>7^G*0SV88H,K1,
M'*NA<'\"<VK[%B1*\0#LO'D,L<>G#\"I).#1$Q35^J5 6T.S=W-NKCNV,S5L
M+AQ02NAO1RC5^.;Q)GG<?(IS+[87.>OBI'9"*>W;:Q5;I?X57NEWOW@<?OOC
MWSO?_B_M'PW#@5-AWW81 .K:E?23YU!1.5 V\]T3O(7*948=DI.@TW4Z<KR0
M'WD.GNMX#T 7/TST/D!K^^X!>,RFH]3A3I([6]G'[J>+]ZXOY[GE2E7O>TTN
M^O,>'2$RDPXH_HAHYS:,0M3V *!7/RKC.YRV*XU'7;7&  ]I@ZZW^Z(_JKQ;
M)7?'-:$8NK<1_=%/_,]HMR07T,L';ZK3**9;U,-@MBO'X7DGK*G%;H,]\?I?
MD^V2B2ORN^N1/E/.+#*0(V^^6:%LQX/ E5MEP3>VA1(3"R9W'?HL*^-[QVK*
M<M58-GZ"\!7#-;KB#F"C >N(*].R2O\G,<N L(T3+$K.O8SFIB",HC5>MB&G
M;F3-$U],K&[J@DT:C&K*3U<HC,SI*0HS/T9Y $;Y'A/U-MP'X&1N&ZQTPK9:
M%O5-.#IFA85< [<95 \_AYH#,KK3/)UI&%Y-@X-(K3B^@['U/@#87O(E9<E%
M;CA28V;I8T)2Q/8+S&-<2*CVN(P.4F@D^_'LG'!'24^F'H?,VM>,_G'(\.4Q
M#A^'#$D!AXXFNM;P3\/[NZ7%WR$%Q=+>O%'>Q,G<=A]P;&GG!FD&\O(5(& J
M!(-S40GUQVR3\GR.YUQ+YV='H7!+A"5S(&-\HA )U TK</0."W!O35T5#;M6
M]]=6K#]1S=T?*OHRM#EQ;-=F>AIP9=!/CNL:N4ZR/P)2%85)MPH\SL7M[ =@
M.?$!V/#H/0&W/;FERQXJWKL7'%VKCPE2#<(8V,ZAN1%EMO.EE07P62VTS'IU
M%>7J6WWQ=^N>.RU?>#:[3:E0UB/Y^=D/<\6E45#XP57F[>B3OI^R,ID$:^8J
M%N1W6SL3VC.8A;(OY5XBQ#=22D^H?U,?>0"@<;?OH-O=I2AB)[S?@>K6YE"T
ML3$NK %B\CA-PP62;3/Q@/9XPN#R+ :@3'2MX"+FEO$!>'0:DP>@MW<6^P%H
MOB^@&[Y9\"U>/MX=9JK(\0.WK7@MD<>TIWC7I3H:SK7$@9,+<[@;K5XO[Q/)
M&A8WHP_-!/JGJ8D>8CW&R^5;VI.[@C\.3(4,11RTJB=O7[E['8^,;*S[*O =
M7I9@O5LM]VNQ7$^-$NVDHKMAF4Y\MCBA-K6V-L;QN1VOP@3A^4N[?+\-K\_
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M&YC >*<Y$^P"O"&83]WD7BUH\C9*Y/61&+-NUFS.40S@ "4$.@!:>C* 62]
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ML_.>1?!CD'/Z1:[NH9U)8<,RUW[K+V!E]70JCT7LG&W))'PZ'(E),\P"E:.
MR'&10M9+T#>A5V.&V1>-@@NX)@UE307+%<-Z&V$ME[?"E_29)^(R5EWQJR^
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M3>PYQS7@XG0:;62!7):E&O]Y])'DL7U":."3"M47[V..7\BV5#9'!TY%)=F
M#?<$&CH]!0N4H0?U7LA7W_ !H6F$3[], *('Q],G2#$3IL64OI]\69+=<2!*
M1QP)"42!<YST>A8+0#W,7T$FE'XGDAC2;(W!E =_6(W(%BJ OS]OC[68)F!!
M!_0G1"U9(:AZ"S,"Z17IW<='5R/%A!866Q9J4IDTT!$UI5A3E9$6;0*+V3T
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M"KKZI4S6$9J<M_#1CA8R@!NEY.%O\BLP=0_%;&;2:AI;2Q0I%=6S:[D+[GR
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M.YY[V]KJ<SIJ.$;&9*9-UUZ#$X\Q!+A_^(<Z9B,;IAHKT,ZDSWDU3-X+^\F
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M//DW;,=W9R-E F;1+(CQ=1X@RR)5EV*;S16AJ(2_"' BWM0:-G9>?^>=M*1
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M&</LS**!W^>D:LL^ 'E<L.C'+<G#GK5SP6Y!>X_Y,?G2YR">Q^T0SX .QQ^
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MI_( \(VGFM]EH?)U2*BP()7^D?0W!E AZ8ZFS!4_'/!$^%\5D$_YHB7"HX;
MZ#MYX*=#VS1]^ Q:RK.3I3Z* U:B[4C*)X8HP".L?]3 @C_2JIW_YC^5IC\Q
M>B:KWGS2#4WA"QL#%MSY\0)7A<)JW*C*[XK_B:A+_:V[&")"2/B/:!DEXV)?
M#[!A..GADG^>:<6KL&F?;1DU*HP7'?.?"E"L.-OGX(2ZOYS(^#]@&.PHM*"Z
M6Y.N1YP>5!33&4_&M>XTQL-&A?M;SUY[\O]OI,OUE^I #^9WSVF'$IO 5RIP
M<ZX51OMF8$HWP83MY7_(=D7O]K6CK#<VSRTY16OPM/_?P5D7F^=_IA])G4O
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M:0 $ @&\3R_@<96.4<H3; 4 BHH (P  "  B@ 1 /5FT3P>A($P ^LD&/;T
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M"1T7'0,+&P<'!QD-#Q\7&Q\3&P?[KW5TH)_*P, BPL(B8J,@H6#_;^NO=71
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M[E!B%4Z_>02,C)W/27J[['Q\1J.2O>EB+4Y1B[VL+2Y=:=:$#[Y6IK=5,9L
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MHASE#-6^/21'$]!D78!S^:$BUVN[E2*<Q263KCI=RNI5O#B;TQQQM=8;5OK
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MC+3?,%X<=R#,:;((8)H@=UGLA1.;3@2:.H)!*W63+E9(EM\EC1;6R,51*A&
M+#1>6'=Z&&/>T^'-9Z*XK&(H[G<2QPWAE[#<54J0Z"2OG_#X*TRQ"ANZ7))B
MGXP4ER+2QLSH-WRV,8M96IM#=L43#D;NSUB/0Z-M[:T?KW:L[G;EB4[)PJR/
ML0[AH_=O"Y(6=[C>7RK7YX9C9QFRQ+;OLC#Q1F5LR1>9\KNT/<6F+">TOVT1
M@XG%N#:\$UW4W8?N]A-J"-8^)8ZJ*LU@B%20Z^A-QQ]=MH1V[J6C2[LRRD!-
M(APE$LIIK/I\$T">=#Q:@$T]WGBDK67D9^+"A#BB[F&-8SO-@;F5=0_ES30L
MRG%O\^WZU>?=M*3NQ-OW>+,<WZO$)<*Q&QW-)$8DI>6P 8FS,&HGN^:)X[;J
MZ@7]*IB9+VLT*7WU@!SI"NH,$(<P@HI(NI7P/E$C<VA 8Q.?H2:7;5P*!\[T
M[\_Q?RL9N9]"K_PNZ$*L"7=PU/MY_,:^M'1#MO(RX17U2!63->3=(CI'.Y48
M'VFDD?%Z>23>$M*I1J/8I=G/ZIG3)5W\*RQF66J[;/]YC4BFF/PI0F#7ZMHU
MSU8/-?:+[=@G27#R+HP+O*?+2\;D[WR^V2L)$8IV'?9LH2;CU4+3$^2!E93U
M=7AQ0Q_>FL43;R8F]W="3V8X&VEEX0D;KGD)"Z#D)WU)+50NTK<?&MY01IZI
M0ZN5@JG%[B$2=FSO$>BL]H].:\UU)S[I@/'PSO.VP)#R$D)BTJ6YTXV_)@!N
M\'M<Y%1[4,6%?O*MRN^V A\ZF8J2SX[7VK@BG2J*%/+J.7KQ^25O> ,0VP6V
M\TW CT#5EZ0"SPB%FL887XH:CL*R>%<;ZG"\_B1D\>2>GQ/)9&SX/6AZ'6*$
M/ N&M@]"/IX\#,=E+&H_J3X.VP%W"&G*++-$P>S\ L28/B9W;.]_U9[2A;JU
M:*[@CGHY)'!32I!+FR""/B"#=F14AP$G0?B#1R 7W'BAG18T9WO)7OHC6+E^
M<G(P;-B%5BT; M?^ AE58I2$24;Y^K7;<CC$\^NRNH(.<84/DL+;R!$XD4!+
M2L48O$)1G3>!$&>C:"G JZ7@NQ?%J:1W1F.ELCEJE6@%SN?JS@_)>-%Q_6WP
MR!V!\P@]0D$""V)ST]7#H@IV++[VWYE5]2OG.)/#:3#QMRE5)N#:U;"SVT<X
MY<IM<P*$7S^,V/_.9%8.DXFGYG,RL*^8-[2JUW^_$,Z>;R$UXH)O86+-8^L8
M4,=D1U U6UKBCGMG9J"(^Q%9F:0+3/2UQX*:'8,!>:2W4  ?^D=A-O(HZB[9
M2>RUO\+$_;+8@5:%/N+;P^4*J*,>):ZH=3J<@O\TO-'^=+V_SINZ8NBTZX&K
MC:<N8YN2@+\1CA"=D8U1_(V35^:GBI+(=;ED.>MU](G&._%9VE9?>00U.YU#
MV?K*.\G:!=UTW^KTV0$7_:>>%2T?L'WJY']4D=(^#-L+'KH] H<8N=':#!OI
MW]/O2YOJ N^%*J(7?68M>(BT$@;Q5%*YJLGCK$4_CNJ=W_F_1W-<0]@67(S]
MW/LU&NPV4P?WR@V+*&JA4J-NM,[!=1EGV=;_]"CKUSS;;_QJ$/=XR5@C/VK4
MBR0J\COMWF0QY'NU5K3KV)PE,-ZQW:HBDMK8/:]PRMM6A53JA'>OR#@P\JO-
M'7RBMBE;NR 2A%Q\4@0\6V2H#YP*Z\K"/W>*32K![/NUI%+]&:-@!M_ WN1\
MZAL0(Q_:1Y,,PKU<@0X^G!\73C6V:E$9.#-9LSN>+3-9:V)XUS(=\X99]]0N
MMF]%J2<M?8:5OY=:U3J'Y1LNO+:ED:3:,G/BBXJ/5U%8,<:Y5N_TOHI0EYVJ
M<22^]N\1FS<RP*6EGF:)8(99D(Z,+H=)M6^*V7B3$, T+PQ_VFZWA'$*UU0.
M/MGIE*HT?+DU\/.(.I/_M3T%<Y4$HC 5+$.#3K%I?1'5[UQAFL93!ZKI-]TY
M2N<\(Y\883E>LA((^JXC8L+N5\=\B-B]K%$'2QY?7H?0P2I/Z]\WZIQBK9+X
MK);'W+.>%821(ZWJ3#S<R9S<V1;S;*2X*#L3F?&^4&CB,^_[5;9]&3#YBPS]
M'=_LRBEJ"%T8X=Z2ZVJ3(9Y\<Z8.C4T>PBP]'ZP3 7L70.2,3VX^SNT?A=M*
M/?ZY=>)BU\(G\N;-2J@7.FX,UMU-)(43QLMO,)A(;PB(>MB9_<''2,HK1,98
MKVEM\LY6(4QJE8R+Z<;5_5!-.%KT 4%*G'ZJR3>2YU.)B0WNT@Y?*-6C;GAB
M;S(]B@V&/4K!K519WXTHIRX:FJG$/DP,5^O>[SA"4YB862Z&,]8NLP>T-9%G
M:!D0LE_[KAV_3^'+Q#G%_;R&AC:?)WB4;YG[TXC<^& KG"I&4TM+Y0B$X!PG
MMTW;^FV"S;^&NTFH+J1TWE--'<EE/%GE*:+,T/R94WG;J:?386[@2&K(HW_5
M=I-TN(&'T4VO9;A'A)JO8V$-0RIQ68Q=7=/C)?%/=R_KA9^?)^PJ3L9EXX_F
MOB 6/3\339OJ_@@@6*7[>*U%$O5$-Z<ZE)GHW"?Q]ZAN-+Z!DAW(0&4:X39D
MZTHQKHI^!$((.[LQ]QG,+2IVKXQP($M"9BE.*1HI@W!J\/S4&10BX>5YS5RG
MWH[HGN-N1=R>A]6#_>[XW'<[1Y']3'.O*3[*88A3P=;A4*13>'60JYX<KTW/
M1@MK?@7SI1FV)ESZBQRN>[&*C@L[CYB=\_8[A&E_%J+VS9\BQC*"%*LQZ1R:
M+]_V4'(T!55N^C]=M?[B:2SZ.]I3J>'9;MURO[FOUSD3RXI3;BQ:R\JXEU?2
M/ZIWPL+8K3"9/@_B,NY'0>NFC7ZX5[06ZSS&703/7Z84[:4T]I06U:;GU.:+
MA'^BU*&$L+%\DY0C]F>'I_<V:^F5^)W;3+>&%(E?NC:=@]=F]7\Q]]91<70)
MNV\A 8*&X.YNP25H"!X@(<$U."&X:P,AN+L%$B2$8,$=@KN[NUOC#33=I]]O
MOIG[SKQSYGYKG7O6NG_4'\7JKMI=>^_G^3U;"MY!R1SZK_K1'6A<48_<%5[[
M)$O\^N" "W6;@%KD?1!>8$JZL26LO9XQM7Q'XC+T;5P>BPA)5S><3*8^F4*Q
M\)B#RP!4K%->8OJVN>CXKMC;*RV;/F%3%VRKNN'';.?07J7?N64S<\>U>ITY
M@KRVI/_U]XN!K>^_T=[A1^T.-N/.SAB10$1!?NN@IX)MGV9L[?1Z5(EWAY4L
M:BTBS,.^\@5;<#0@+>Y815RK\ER'@8]74DL-#-%B[*CW2QU,Z][3=QQ[,95@
M#KD'3!#B? KXNAU&RM( 5H\P.6O[['KLOK*@KV\+@>[E9N'</WZNU,[ )"V"
MNBFA:C$JYE05DRKJ5_!*G#Q+H&T/#LC[9A9!7D% [:THPMG8L[MG5-^;B(N?
MZNT+DYBI3<84,,*TS+1>QBE$]TGZ/L$C);JJS6CT"*^^Y]*\G"CEM&$TA0UU
M.P8\<R2CDJ7#1FH'@I .]3,5ON96%.E.+6V7A[L=NUEY0#YS$6J+=OU]#%ZH
MU>SA6^F5% Y4Z;-K4A)>6(8.N*OR1;.L8Q6K[MQ=&'-].QSX;MJ:58;7U48L
ML(H-^<E%O=%SO?YZ@6OE&W*/295M40:%6R(WQ:X;P[96S[M:)+2Z/!8R0XXO
M:;H#1-QY()[#D=Z1'.QC*$,>U.N,ZC,$'$70OB$4TD/U8NF+II,#9@=7CH@F
M+H!"-@)UEG/*P8911'^87"\H*S#+MVY4#\N=MFNKJ9[3,3(23N7SR]B.(<$N
M&6KF?1A#L2DO*_/GL8GS?67\J#2I\@"5SJMUTI8\NL\X;,4B&=S\)6QN=*;$
MUIBLF6!]6.-"=4I<SL+*QZ9>%37XY 6^0132%$>QB4M4=D#\\E5$CB6/YAUU
MW2P'\ZW)R<3%O.#BR&X_><U,P29>8"O_C-O>*VU)TLE+1)^FJ8XJ-I#U(3#L
M\XF;JT,O7!(\A@/H4!DSB_7[-"C7^W6RR]KDD?)B3PVWJJ ^5%+WZ$\DC@VB
M?:3(+6JS&QXAY;[R AR&,MP.0\ZO5I3Y7X9%1&WU1S<_-NOK9_#><GDGX!!E
M1#-=@U;ED:H:E^_<>=W][B)^TPN%%34.U=K@!,6:0404170Z:6-S<.>]1O.!
M3.^\KL,M*/Y\NRU"P!@BYR^TYX]_]C*C]9N7N+!09>2FBY>/?2W8KTS.OF3Q
M9>?V&C4  $([]6!Q8A ^'*BHZ0;?=.J6EN35V EM+>@9?D!^#.UC>!]U(A<Y
MA"EC"K"(HA_@84!.7Y[-+F;*U]O6?UQF2'%@BU<1XXQ ,A'&B8F.;\?-)\C8
MJPW 6 #N-#R#OV2!2L6;/W-Z<-BTES;>>7E1R]T__Y!->=;;+H6Q*,,54[U@
MF6IKY48RR#._<\^7U].9)31CP3 6OS1;]I.=%?-9\6^4 +9UZ3U>%8.WJ>(-
ML=REZC;"3+GOY9BM=V>^=NFQL7Y]E)LY6B#VOUF1GO\5.27]2(YJ[\D=&QM_
M-PK5G^'\W<[DQY-RVJ:,&3+[]UJ*A0FT$_*ET>TZ40&.?.@&V)?%2:_1N&*#
M!;AX'.8N#84FS7>V?3-?JE;&R<29.,Z9"KNU,XA/.7O2=";,#UK>H:786;Y3
MHA-R.G)[T8U$VHZI&W;)N%E4>L"*\O2PO?'157/M#3EUIOC3M*%X)1L*CK39
MC^9!H@MY*!+H*!'3(:3'ZXJY<A&L4^ST )$T*8 T9E:C^N<U_G\]B-3?PH%8
M!&^5C8/VNHN39=]=N,O5627ORGV97\[A]7[]J*<'Q\LA0%P0W*EIVP-.WDXI
MV&ZV=*N886S _W$A7A_V])>.0CHS_>]8QKAF[:)G:[,C8GB_062=ZX>DW"?5
MQ1S#/(JUX^NQZBU9I5 ;%\*)\(+S^#QMQ5<FK*:YVJ*B[7O?D[]LFU4&148E
MYG#WEMJT84#9\O<:9Q(?!9=:E.@_)%S9\UAE*+V?ZV.XH)J?1FYZA"EMD&5:
M";4#.W3HK8269!; !NZ54@[L9(^Q4=5FBC^>4PU7XS$1*:YAF[]O_7!ATXH,
ME;[7:RD/UQC/5*FO]!K)XRQ%<LL9C %,E[YAQ_-D&"14F']?PSA&=,B0N^6<
M]GLX@+NBKV-[][FKG%[WPVSWL2F:=%^N9BT9AK0;\A,D4E)2!H43@<WG7_@>
MEI(V]8ZF(,;@A=[.:SS?QN/9\/>M=<@3MIFA*2(FCJ1ANLMS#- 2YUT1 \='
MEIZ1UZ[@DP+;0MD\%9?U2?-Q(J&W0TW!C@(8SI4<Z#HCR^N!(A1U ' H2;RW
MT!8"1<FU(9\2<ERUF:G0331SON@Y)&='7QKOD1$96:)T[3\T=.=@T7+*M,FJ
M[-*,5F#MR\NS*52:^%B2L>,S:8?\PMX^T[?R^+5PDUF*2+]$OZ#W%SE39XD7
M$:SY_VC 2BJ*JZYCZ*G6=WB=$MH]>EW>AE<%HV'-_>0G"Z,Z<8/V*Q\$NDUU
M0<YZBI-#<R1.I!^W(O:;I<"KG2ND,V5N=F+#&RWUVK*,J7P##/)^)_$<%3IQ
M;4.:R$$^CAP#YA"&38K#8@@<J!98)A:QOVI:%G[[*UNAB<_8J^/96D_0LZ#7
M71R2>H*T42B:FQ":S; K/]SK1<VZR821:Z7HW ,7 QDKE&K]O'#S4-?\X/A/
MQ+%H&A@6:]?GA=6CV@E/M:YK):@/U]&#JI?)XN:C)2=F)F;H1)OB,.BK^"0:
MF-)BE].I*N='_.U^ Z*K02 <5R[JYW9OY<]\6SDG2C?/N1ABP$L++];=R0BX
M[XW?L[^(^\J+)/^!!X#RG*E_]J?RC%6>*JPXPRWV(U7DNHK\WEB9W"5#MOW0
M\>OI,\[!4):FITIE.6NKP8)MC_>\T\\(W4&+WM'WJX9+NH;59Z,,]-SK::;G
MOS$(:=&19#B[$M^R"9)QV\:+)42QT-CX^9_'1K0"$%OCB>V@'E$!V\+486&A
M\_Y4YKWE9XZ4!.FZ:4]DN3<( Q0E<CXU"_FRK#=Q,1Z09*3784M.^[$E: \2
MMYLJT5I9][, R.IOFU0,SHO8.(2<!FJ4>A,T&A'2];7KSVNM[!S]&2#:!9#4
M[O%#$I*;7[SW',LV8"72H./2 AN[C->O6S7D&>TLT $A:>2FQELXL%'8R>70
ME4,@R'&/A^/W4[]8E9WK>9>\OAML( $K,S2]QT#YL1)!L ;--UK,A82;NHKI
M$.W$FP:U!QB>WHKM@F4AJ.S@+KS2QVN(! =W,#+L78F+4BUM>P-C,'OP16WB
M.PC+MP\+!0^7=<*#@L?+W4N!AL^H;9FJ3235@@10K1B%O!@B+E1!,I!NP=9:
M+FXWQO@R)1G*VI*JV&KEMWT/EW:$+VC8]%W0E_A0?+L;1U'FH*\0Y!O/M!K&
M;.TJ7Z,Q<Q:67X?:CG'>&8Z2JNN[H3\ ?+KYI:GMGI\\-5+WN-N%O?BEF75;
MU4A! :3V;D/"'7W<03W> TN_9Y9 [SCZ)=.U@T&)<M3+3$51S*9WN(/=-*BN
MI2Y==?XLM0T-DU EQA>L/&8]])HABK4F@/*SI!0RU.07F,FH)KZ\8,G2;U#=
M,^(:EM"03P5&NFF9-[^$,T72,X>THDZ2GEF:3OYP8[$F'?81/7VCD=]0QU\>
M5D16K'Q';0=664_Y!JZ3;9QT$,3RJ:=^:6U:5QLAQ?.!_:DAOO#NAX<U10!G
MB-<H.4)/;S<I:WF^5R/_Y_"(_J_<"/974:5F76+:H29*-8;RDVKABZ9*'F)=
M)7,C2*9\CF):ZE N=30X,#:;"P?6.FA@[#6";=C[U"QU*GYFKZJFZ>17*HST
M2P9*@_A0D)':&00CX0!FZ._#42C='1X,BQ;1'C[,,M4(Q5;5M3B#('K9.'#@
M6_E+.- >+ 75I '7B%/  5FC<#CP"0,$^0F=>,B59%7ZX:LQ77U,(3]1C<,B
M.V5>5UM7,TFKY?$Y'3N!*OUCG-KD>6!@U%;.+Y %,7BU!_29UY9\]).XI*"^
M2A&G/7.L2J"6NZ;64Z2Z(-D Z4W:393 ?:W?]^3*U;5631$#_D6A(?0."G?9
MJ[9G#!UU=6_T%R&IBMD;VOB]A!YG_,\) KZB]3."@;(T(7G;Q"J(_MHA5KV]
M73-;;KL+5CA]AH0DD:N),^F3!D0(H^(H[J7B&$KE@*CGI++,(2S^7=Q?[#*I
M)GY#5>A&:[S,3N!!RX[X7!K5X_I,@:'# UE1ERAI"UD4O51 L%C0=LMAH?.Z
M<::5$%(IA>FI-3-[//X[<7EEA2Z.^;0QK %%I)UQ]P?@46XEA05UFX01G]3!
M@:#2YW @_G W=B'R^G5KRYA@+,V*Y\*F[G3UHBQ3Q^I<)TW.4UQ"4DW 1*3_
M;?:6:0LGH_6]YK&%VX7$45DVCJG953ISDVW;DC?H*/%>Q0CJ.GFE*F50'31K
M.(EJ?ZX75&'P<AXI@'$MZ)F\HS-&+ZT?D3$/E/ A[@H4?$U"(F;<I;\LK#&%
M_V@J1<RMZAM6PD_Q2Y=VL[X>S[XU[4*>3CPJ!"-\;BE%-)YB-3BPY3V(3\Z=
MY[IM<<';^[9C$)\E-.,-0C3B#Y(T]16WZFI"V"QMT]\@-X\@I]*:5 # 8XF0
M1WIE!#W_LTV /_0\-Y/-;(C,373?Q3U&(:/U0&&X^/KX1YE/IZ3(N+BA8)>W
MZLU"]B/M]]MB]O)]VAH#PD7LCH-Q3C.-Y BU:P#A0U],^'+]E"U<\2O3+XP\
M?HJEHLORY*6^=<*+@&,-9SX_/!-5P.V?X:<,!"/6"A97?0BVK"<QMB8V75L4
MJ1.F$+ZE-["[$+JHDUSV+/OTYR]\Q3* $2;=L2(U7RB=1O@1 @/&RF[_?C'
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MZQLY+_2AOY/V8ZCFQ<UQ-!R@7PV2.K+\! >43FSW:#;*<]H^.MP20_'A@)D
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MJ7,'?P(XX(Y($<H6Y<9P /,<;YX%IGK: 3I9@@/[KVH0Y5LWE@J#<3ZH1_2
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M[8NCW_#P/FC5>KC/9!S-[/7%+U@NL-P_PT1WNMB*NK@L^RCG.1/Q9L\+<F3
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M\\[2KY]+''S[%$2-R]*:O( 0K.U1?<HF??FK0;N1QE]KZPF?6[Q#'GFR7++
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M^X0I:1W1]P<F5/<Q_ 2[=,E:X>EP8V9"'YZY J,:84:]1B1"[>5SEH'2BRX
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M'/&9K.SVB#;]I!@S()AS,M[/RAZ(7N'3:N[[TO2Y+?S('4UD\L5@A,1RQV-
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M^UI[LH;5,!,Z?T#)9=F6U4LO3R4X?C3/D_/OY)#Q?EMH8IW(XVE4 95V@.)
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MW,3B@ %3*MWRX%LW.H=\/7IE.W7Z2C7]'/[REYQ =;I8Y;\+_PM02P,$%
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M&GO#+<_0/#5@@I')?[S](0Q[!D&P+>NB)S% 3X!C$O-Z4VRVWK+^VVB+4)'
M9NJHD:JZ9RS@%=#OY(>$VF)OH:T,+>AR#D1>ZDA@D-VE&[T?UI!T5JG!T;>$
M<_G.0%L+7;>-%_1+ F;(]VEY:W-0RVD;K$O>3MMBW+(8(/)"T*%7"P9(#J[2
M*(;N8^M X=50)&%.2<S7Z;AO("5*_9 K8-5N]I5%-&&"YD%^*PEY2E9F,F%8
M7M5=#BO6JZ=P _"G]@:*527.>!YW1YT3,PD\)VT(0GP<A&$E]+QAWHG9#;NY
M)61:!/T.I+'NHE6O-,T]:E5IG$O'W:Y\[12T=2(;O$$('?MEZ!$LS).O58=O
MJDY[/\!#.@(58<0!9O6?:HRJ4UO0L@6GP0M-=/N'D_)9K)&^F6.@3W-RKDDS
M+V+7-<#VR1[%HVME-VVVN#8G@B (A@V^0^^(^<%%C6QOF4=_\X5Z*Y85(0@2
MZ;!BN.JH1X#L5$;7OD8.[4']H6P=C1B %M:-N 9:.26 6E6B]01$\]5/X+?C
M-$J7' ^]1L78O8> H2O*$ 67UI51(1,[X\I+1GD>&."L.BCM-;3FG#@12$Q>
MZ-&V0RZ3]:+!--0ESX*!Q<S48 D:L@F4AP$4SH&6>7<,<((]ESLP  D&F)4M
M!=7_@ $69:H89FKI,$!KA!T&,#0'013F)B0D?M'\5VC[&9;R@Z8)4,^0L(,G
M&$"*IMN:!8$/AHY\(E2.#HK $#*) @^O4JO*8;^O-L$ K$WP0>@;^R&Z4,BL
M3B6R8#,[HC$D?:-E8"N/!2T1Q[*]QH+VYUI5ZP7E) *O-]H Y63-'U)V#M8'
M4_-+A)R9]K,Z#^9C._!N6]P4F3PUOMTJ>^%[GC/I)F#B+QVJ(.YV*[*^5CTT
M4H)C*_G4T+^9@Y?GP/99'* K8Y#(_*'CD\1KB*U#U9;0 Y9IXQA!<!'?@Z9X
M_*):& .P^>9@  ,X4MO,P/U$[BVJW%Q#-\M#MSZ1@_IT#&-&!4:J9N!]\.<8
M8.5][M*W;FWRXD.(AGVO-#4UM7MJ^!:6\50W*K!:$0,8L^V7>-)XK)U H*8X
MFZCR!DL'@O@8U>Z47\8YM,@ ;U$ZM/6&U$.BYJ:A(<H+^XQ@4:("%K[)]\_B
M@-YK/G'H78:@&81?FH3LXQN" G6 [F1H_AS-$^2/ =R?DRV@/)1!C4;WM5_L
M<:"EUPX<.+8*M,#R).(2*/!K*!<"A@N"I08#V,VB8Z_LZ2[WHJEKM)==-%2E
MSQ$'KJ%%\R$KH$79U#6N0S?FG,!GP?89K&CG,$  !D"PC4+ANM M-L,PIXD_
MPC !=EJ@$4IKE")-K7'FR$WP?AM,W8WD^Y3;D%T"]%/NI#[(+!EH08/3^]JW
M-G#0MWV4#^LQ0 KQ0G'$/HX.J!(N6C/7%R<?MNX+37$#:WXL':,KH)^8KBS7
M=979DC2S('@,?;3W!V6GI?OV9I8]M2) 9U0D1^Z"_R5IW+*L0#EQWX/N^ @#
M;%%JVW)4-%W^HBI-_107^XJGMBCZ7'!+MYQ+2 SNU3.A45P!EQ.=NK/R \O?
ME1Y8%#F:%$,_Y$VLL=I.9B)P.KXA-]<DF.UB9[5WG QO5=U_<NY*_=E&S>#
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M]GH1"6 6+NP*VJ73AQ^<T.?0O)39I)*%'966WM7$V['F41HF!?NW5<1NUL&
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M*<D=T\CN@(^W+6MRN<[NLS8<V5Z\&\O(S=GG927 QER%\SL<DRNF-[Y4]4C
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M.@K:/ESN ^W-FD.#G4K)PR6PJ+P%Z)KLAG\;A;K].9D(ZYR>H9XTQJO 0^>
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MV7KMNI /[\EML.B/8*CF\ENJCT2'7IL3]OQ75R=VOZ.F@8VVK%YH( 'E%4A
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M8UA0W?DXK\!MDD,JA$WYB]!JF#'I)U'I>]/TZM$IO4KJC.81K60]S'?;+4V
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MFF>4I+AP>E*Y?;(48I?&(5-#^+AV\*B6>:$KUKS]^-[2T+U+]U6+BEG1$Z
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M%;TGYQ;7W6"P<.FF8.21F.+]^DVT7R3[QP0+_*<D^R[8#[E& "I""&@\0EH
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M)@8=IH(*4E+3JC6#HJ/"Y"E<_#X4LO+/>WYXB>UQ%@Y=<LB=7$U<G)&8P46
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MC0URN< 6\J#YD*-87[7"6QW',V".CAK9>]/Z0>!FI]1Z,JS39^7 @2'F@]U
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M!<YV]<X 123FXQQ]:,G#^Q(O%O"SNUUMTT]U&'KZS,Q:^A);X."O;+)O%@I
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MGZ*N;=D-2#TV2,2R\'G@#*_ST%^V]D'&NG-FSJBB-8SJV=SP# 5V;)X&ZW)
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MB^V*(1GX[]\EX*M<J!G*Z?6H,B>Q:0LS'-AN:W9,]RY71G#W;"ARTY]1'C#
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M_M=RL3*SLO(RL_*RLI*Q</*R<O.R<]_['1%P?WHIF&81\/_4/:(B?^MP'"P
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M?19Y(8<7]5+Z^88H(%EY![C<?DZ4]3JXH8%Q2MTC'8DGIU>H#*<:DY=^&H8
M<.(K.E+Q..\8%(D;\(XUR)V%;PIA,M1J0-[NU7U#I [!L.[*^DVPG%%0?0U&
M4]V8ANUJ<=D!,(I?E4]#G_1CJU'ZZDH9DI$D-X4^<ZZM4V.BI<\R?O(R\F?8
M.CXH(F^]*FA5Q41^D8AW%U@(^_@!XBRTD$VB*OV/@K5;/GU3@:U$&X)(RPHB
M4".4W!5%6&WJ+Q>QH]!/\M\)JS($W]Z7',\2- ?*9AR]6;Z4A_F=,T;%$56.
MF0F"'6N91BIO([[N*X2[D09'/A%-/N'SC'PBGL+VNS^%BK& \(H\7#G- ("?
MR0[T&H093=$6,@JWGA"_- SC-L3L*@CDA1GQ(8[<$A,O!O!)*L/R7[!*%/2T
M(TCTL,-(+1F/^J&Z<T82?])'.>2U]P&U9XN3%(UV[#P.G3C1]H_D]+-[Q#:(
M 4I/HQ=D4%B)-^!\)C'5SD;=QWVRIU#R]9SR>'H<QK[#E6*9^PX0.$]#?COF
M-4S;-J$F0414T>U/9!I]OE0L:@V/$**0@0M5-@2M4_E0]IQD]9RD(?SC@)11
M7>/?WXU%CNDGE&\G8 ;TG& ;N04!K *B:KBJ0:T?,'<?UQ(Y#]I?' FIET5"
M:>[O(\3?30%W.P#][^] [,VL;<C8&)D![E>2,O"4O^>83\:(0Z;"@7+X31_D
M+]OGK[SN%EDVS!P<;'B9F*SL&?6-K V,&0VM+9E<]&V86!B9F0!^D(N-OJ&%
ML0.9@;$IV$J >J^AA9H,;"1 K<8APRQC(V)L!I9PLS-6<I-5-G2S,.0QH@8)
M/D;A=^%UL;2Q-';0)W.Q?&=ES^LB\.+WTWGO]5^7F5X(\ML9F? JOA;[(\7]
MF<"+/\KB[.S,Z,S&:&UGRL3"P\/#Q,S*Q,K*<)^"P=[5RD'?A<'*GOR/![PV
MMC>T ]LX@*VMR'Z=ZQM8.SH(O'!T!!OQFNB;<!@8&7$P&.BS&3&PL!CI,^@;
ML;$P&+&Q&7%QL'"SFK 8O/BS@)8V_\3_;57<\^[3\(K8&>L[6-LI6UN_$_PO
M?>?$S_2?V?[U'./7]T'PU](/ S,K RNK\I]+/XP<+,S_EO$?Z?B9_L/@/Z[<
MU^&]]L\:OZ]^LO\&>8 \0!X@#Y 'R /D ?( >8 \0!X@#Y 'R /D ?( >8 \
M0!X@#Y 'R /D ?( >8 \0!X@#Y 'R /D ?( >8 \0!X@#Y 'R /D ?( >8 \
M0!X@#Y 'R /D ?+_3O[U5QO&5D8"U,[4(,'?.SW P<+^^KD7^/L?!*1?>R8@
MH" B/D)"0T%#0T5!17V,CO7D,3HF.BKJ$]PGF$^Q<7!PT#">X>%BXV%AXV#_
MWND![CX// (R @(R]F/4Q]C_P_)[IP<8;MCO<# O'G9Z^/_!3@\W2AE!-,"?
M(<L$PB:M8FU\N&0HA./X6(5!C;)L1V/+-4][,:,J(G^SUK]G>>QJ]-A=P9.]
M)AJ %JER\/NXIQ:K<CI?CL_.1&[%);RS_6Z@;KGL4PK8QX6&V<FYY75=;IOR
MV'$831]2Z^A:J*K4!4DX$SUN]_.JRJ8JLS UI9P=Z' Z/<AWCA6'48:)DMP&
M>@L2:'MM+9Q-W=GT/%,,GR6SDH$?C;^+2$/S<X?YH=:?BEO9I'NUI#.76*K[
M6*RK3V+7(52 ->)UYEJ8J\)'BD@]..?O_F\*;&S5\-P'.!T6,PGFGY9?>V*\
M:[C);D2 'Q6WS)^!%N,Z$W.VN<<L= ]'HJ2>]-BA\Q3.$9S?+%CCZ(A;@DO$
M$5;\51A*E]TUB&(=85[[VDE^.L=?,&FTD-XOOAFC_8$<Q?[)X'65?&26>0&.
MF' /##::[V'&^U%J4 <)AG.Y--T52[Y&VMMJKB">'A18D.%JG-"LD!-Y;,_T
M5'O%U9 <]-AIU=O-VS^\.%9HII0<DGQ=N,;T(16+B1^F")Q 4N@QV8PS9O54
M=G2W!'D6[."B#@-RX^07"U+O2G?^2M6< ([BAHB_+<N;44\!3HJHT96&BD5'
M+ K<L8:UCSR$]F?<5&)S(+M)]8Z'_-4U8IO\^9&864ZJ@TC*8@;B0EFG169>
MO!X"M15U#0%=]6C5$],>%W$*@5GN8<]L9WVC1^(JHC=>92OLX#HKJ[%E7K_9
MSPW$[=E,(1\YP:CNV]?RC#WDX=_$=*YG1.Y'( S<"C./K3J(_G9+')\V=JV5
ML7E$'XX<!KVE^<D;@6^CE4=AY)09I5;U?DJYA8FN;FI88]0E0.:]*&]'W,1F
M5J#@Z.E$S&M!U=GILW5"VT$W@PJ.\,"Y9_NGT<8%YLUDHPZSG%?64U:EC",T
M:S.L#?B!CR.$EVO8Z[2FL-*IRWFEZ*B..C5E/B2\<R8(+6(U5T0JBLF1M]+.
M?TM^>P;'[U0L,V,2$\_ 40NER8CPRTQ0((B2I97JFK0*P=T6[@1$; ND.;HC
MWX52I+R_&#.85J$E0@J_XKNX5;\Q:_Q4&8XR(Q&^.CB\NK(A_ YMO1KFABZU
M40]=?;K75K^DG_)8CU_"L2YGICV-9B1B_M5C"R1[IO-'BI]W+PS=B8E+\NF5
M7+E8*EE-\:SN )&YY%*7?O']IJ^I*F//RV6*VK_KU_GYR2(J^6!(.0<S6#'Q
M\WF\DRI)B^";YF-<*$?@L^,+60ZZ,!5V;WFB4YV^'AR<ZV"8+S5G6 $+]^(*
M8\Z'N2Y,O@@&F#AW8\X_ ,6=E'4&=RAG6KV.N6QJWBVZ1!;D/-?(C7TN,'4X
M;2AY^M+I?9,2_O3-NMY@/0C]?$CTP+@N57+L>:,0S',MM+I!UMS())+,*I<7
MYYS;WPY=:^9!WP\?*40AT;HYPB@EG<B[35"EF]IGS8E[:'?:PG[PNYS]@('1
M\PRQM._5ZZ1=5()F.!:J!DK_K$N.([G+$_Z>Y3+D8N7&HF5O<2=/_00ZOW.]
MY;,#E:J)U#P#!JN.TE22ML1AGY=D2GVP&+/OF+O);'4V2QFS>12C/X0[^9LM
MO<QOO\7SQ,& 9+1'OM!'Q]LE\O2DN9*R@6.4Z%FO$HVO87>/5E#IW*9BHTXD
MC45'M<(C6BZ=#)*K^596&)^)T@T3'$+:E4JWS00F64V@1=K33PQ<%><>ZOMV
ML"5[]<;+-*[)X[NIE9@WK:H[1@*##JLF34:DL.BOS0?^&X*R(SN#U<_"<:+A
MBR#A-+12= E".98P$JZW\Y\&O?5&FH5N"@1Q/<3&FLF2#44F*48<I*N#)G"T
M>G_P;\OM=Q6''/=VDV_J:?9C7ZI,:VN5[,_P>W[QEKL#=$0*YC4L</?%V23-
M?PP1K7N('E6]?VLX26Q1^EA#(95-352LZ1V?H\V.O6MA:>V:MVDXXOG[5E*T
M=^PM3P?6MY!V1Z5,6/=Z%W;Y4P0L(LX_O#LI#<:*B\5;J*B4V#6AAP6RO^P9
M?NLZ2DKA#-H29/)0;MP'^8\JCKQ37)3YKGKVC$OPK999T@[KA]=.3HKB_34)
M!WH8FB+YG)F&A7+TX>QA<4I&R,X5>UA$[X\"UA'Y?0CS-<U/J-:.ZV8#0K*I
M%:V76N;'CCVI7P4L<04:U3GY-K)E\6EI7-A("$ZOB3S%C[+[]E(<_I%HSW3[
M8F")GZ7XFX-H"P(C)^>),UZ[],A2AA#A]U:MVH=>BU"85L3T1UG[7$'K$TR.
MGG3RM=*A8FT>HM01!A;!=GFJ!HVE\Z;:^:W?N(F"A@XFHA%2LJV+U(=N4EV,
MU9KBF:@46&G]D=XJK=:]Y8RUC4@SI$ 3*U'U?C$[*XH/-LX]67,9"F77J]*"
M3EA@1VGK:$KD_>A1Z?CT4952!\_GM2GAN'W2[H9@XKGA$G*CSOY>.Z2I^]I#
M]Z<H?2/,T6?"6H2R0?>$B^BN^A]5 <J-6(U*FA I:%F73DBX3YI/R3<L>5-#
M1KF!&C^OQ'.MQ<U&ROLG) CTP"X-MN%E=\U8(W'9%626N*,4I&(,W1*-/KUF
M2MTLW?"8S_7@.&"HOWZU?],5[N0@AP)VZR AFH:+=#[='Z$)7%XW^X&W7]<:
M3>10$'OI'7@MLM_>SHO]Y#Q61G-(=9BH.7/1M$H:01)'PY>E-*$L-3Z8!'8E
M"<MBXPZ /[_TQC6?HZUH&*$<'@QVBETTB3&*4C;#DE^A>K4"FH4_"%E802,-
MN ,(ICN'9P;RP*C9T\DDQ%Z#$E9OUK1X4'<841A[ 2&IT/8U4I;6XILJN=5M
MRY.$RV:5[%2Y+=UJ?LVCQ>X@=D]0M]LUQ"N]R&52Y$ TK,S\=$(,SY'/)1+S
M-4JPG^:S>"+&Y3HQUX(*%[T.K\<'I'XG+_4GBZP9'5#KJJ1WR-MW"C ][1WB
ML%YOEOD=:D6Q?8#+=H^-OA)WD5.M#7J.6VA%V451.YJE<E&<L"8X$_>)*(\H
MN98,B\VZO86 _0[ !\NY9ZK+<'N*"7".FSCH5?*)E3?X97\<"XT/Y[G ,R3'
MOBE6:92Z[**TX/96K;E^&G0^;.V^Q/01TG8>\,K36JZ^)O+X,4AZQ)JR_J-3
MS6<QJPQ\%&5N4E:?TK /:'8),BL1,^=P'5RW6 <DF=E@+X+:_>M+=[/HBXFS
MCWSVM:][\+*"2$#,CY/>?BU],]P"9D(SU\6,UDK]+E?1R*PC:M6F'+0D)!'P
MG4_-!L"2!69@>)::GK6Y'7O1[4_$%657QI;-3W?;$[%Y%XDZHL&Y$6%&3F<;
M#]&:CWP:A"JW=\?:3#4WB_?NNUC)P;;O.U:1HIP'RQ^H?C@=*-#3V'RF9H&0
M5Y.$I/A:,5XU$B>&A])U$,'3U]"%J6BA5CF6(X$C@F+XRZPP?OM+X#T4@[Q)
M_?#RZ2"OXDX1K<II;#T/"UY 8$74Y.WC;@51'-\N'/\E/+38@3"78DBI(V(R
M/F+2CT=B+6_G:/9#5[,4Z>UTM=CU$[E5R5N6];"N03?!CDVD2QE6DV\"1!-0
MZS1V4$1HRWJ4/5>BVQUUQT\+;@K%(T-0U]JZ&0B]12"9 8I!Q*^@QYHSA)^&
M,2-B?L):=6'H+7',!G1*?3#&&<N;[!B6Y78]S <S5*EZGEX\X]<H$5U,?6Q.
M$%).;S"')5\-@#'Z@GOAZ#N%>J%NDP$N)*@RSR2CH*:A:V%46NJ4!IJF*A?R
M .L4^=<A#HRN9&_M<7Y1P61'II^5A6;ZC=752I_CUL@:0RO,6DD[SJ]J5:DJ
M^;D\3_G46LIC8G<)70GPKINV>%,33>;25L5?(?$,..IO<K=)[NZ<D7($=8AE
M2TR;U9R5;HE4C3BH7X.LG8OUQ,[4:AZOU4.FR\L+X?O>S4VAJ/$8'JZ6^:HW
MTU:5C[.[6VI"N'!KP U&P55!-7F",[=5,YHZ4UL0J<%BG/'D-M:G(87H*@'D
MN0JZSDOD)%&3$_T.:ZU!E?)-'=&N4FF[EB-88O9GPA#.<"6I#TD%[D/*=P!Z
MIT$F@8/BQS*+=:]UGOUU14_$KDMZ\-,+DR4M9*,9*>:WG;9'!>'Q=EZJAM&Q
M,T*E:?PRI<*+J1CFFE63U^X:6HU[85FT4;9[G1YWP/Z>G*5S-P%=48CAU>N:
MPZX>V#SY5MM#UNBZKT+&;X5[>A[KB<V\B:T^?+/P.52:<YS>AF<!7?(4)Y9J
M,C=7KFU[$G' ?,)ITFLH1ON"8+PJ''E#EZ5LDGVZB>-:8?$J6:)J):]-JP-M
M%!MEQY^.-HF(-"XMZP"A-(A?P+;01?:YO<!$^.)TI+X[Z67O-D5M-3?>+;MH
M)/?M1I?%)BK&)TWCL_>.(*RJIO'BL)1)5 IG3,NX,WJ5KUGK%/G?N/E/<S?O
M ,S*_E FI::QI;A7O-IMJ#]+3ZU\@S(9I=A>(AB)1,CISDSFGEPFS0P&N=WR
M>B5X#$7?=J;W9)194E5ZR>[,[C076C;))5R+%YU[+;>GL(Y<TV5KMF<.&!N^
MD+-@_X@?-/NZ09=3"#Z->T:8&L%^P$F0\IR3'[0_V:V94V::E3E@NJX)AKQC
M.'7G(0_M3D@,0)_^* &7ZW9*" K2?=(<MM!:!"EOQ8\57<&1;T47)A9Y@@1%
M92(*J5Y?^AB1@ *-$+=W?3=@@Z/*4/+Z^??0@"Z 1DR6A\PY+Y:UT1)/R4+'
MNF&ZM&<.7Q9%2K%8D]6*4U62LJA*$K1'(IX!;<8_USC0DK:H*_8 Y<HLJA]\
M0 HEEU4_)HKV\T9YKYPJ:AU*0EKW(TVMGK<=]7R"YV,.46:AQ&#'VB2"[*-G
M>*W=.-MQ+=B-#+F;EGG:\QE=#;XJK[;QE=G"/Q/%P%N1^\X$01>GV,%D,@T^
MW/I^? N3_&6RB>M)Q! +3](%9Z5^?4W!KE"SVBXI2<J":X>F!EQ$86E):=V7
MI_K_70Z9*$[PTA >6!!IF&K<,3&[HB+0T4IC&GY;8?R+CPO)1Q^.+'^]O &5
M:.E/X727:FPE'CK[ZP&9Y>Z])66V9C4[*YJ27)%6,\C&/W,-UD-2+HXYC 7)
MP4?G"998<T-*C2GXF7Y:B1;441!.!XU'FT*01Y.*7I4PWMK[*<E+,EAW@,28
M9>=@JB><UA"R0?IPG 7:^\CN]-+/' -P2N<B^5H;D&G>*?'R4<F)QB1AN_@7
MW!1=6#RL*BI""C4#D3]36@PN>AO CD-O3)M$\L"J]55%U375!SK34BB-2F3&
M;\60R"8JU_LSQXD=Z*[8%REW[P#-S%6Y&LK.3O^Q4SUP;8VPK06_D%2ZNE]1
M5F0KGFW20>5!!,T!8G#VU9/&EL;;H3*^[NF2(=1*W+X\Z#3.3T;)YW@P,:VG
MJ'? 5-RW22PYRM#BTX]':%RG*M<_R.X M6$X2[@G&0MHAOOD(NW>%>OW?IPC
MSA@O<V/CI_?BMGD#E*/IC\E?*I%S(K%)]JRO%=]D<;4L./.+TNGTMD3= 6R]
MS9C7W(WG_D7@^K5\0\IP?X?ISV/OBG?A'C4WZ*HN"K>JCS<;.:*ND9/9.!T<
M[R)*B7X02U=;A4LCSI^6=9L4D*RK&"S6&+>0IBSK (,0/=@RH)-N,070MMU=
M]?7DG$FF; T*,3%58]>@*/Y*W52'=U=9016+=X"_(-Y^(V^(IE.2OO1Y\Q!W
MU)*&MQTJ)I:UX6H7:C,F<Z;M-YS)X2#=$2V=R!US 9[X]<ON;W< "C1!IO.S
MDYU&_ OUY927*R;^L>,[AHYH'5AE$NWP3]PBY#B>M:>^/SA'V97^Q)&XH^.'
M71T$U2#ADV]][<>\NPWG:F:C[B-B"!-8^IIN4SJHU$)05VM#K:9@N6<U?=7K
MQ4T*/U?^YD0L1")1V-W4_T/LJ/0G7!"?>36%:@];CW,AX@8J9J?S'-Z/\(_7
MH-Q-D\LM10L)W*>N[M3Q[#_Q9G9FP_.+W]9F6KXID)4:<<;>4L['P>?+8L!6
MD#? 5A %?@6Q_:)D49%3O*/D*O,@8.&6T@7^O%2NNKZ<#K<L)RYV4 3:CE;'
M_Y*;E).UMJ>U%*6BMG'$$9_^-</CD;ZRZE3!E41W9K3>I"3,%BOIQY'6!FSO
M3UPUNPX0W[-;XXBN0NL]N-Y;D)EJ\WY4S+5 %X<_/BE]]9%2V&XH9\"J98!$
MD X6*CD84S4KD#J4*>A6=O"D[$JXNK+^HR0>?S^1=)2Z7]UZH6MA%V\/+Y9M
MO+>G?:&VL/EP9=3LBWZ$Y/J;#,G!3B^A+O$] RNG79F?SS\'G6&?$R[F[:XD
M>\UDB,T,>U;K^-=DKI>XL.1ZV!YSC+A8?[ND_I!^>%PL2*?@D_T9:P7--Y:'
M&DC)J3<-RCEI\%*MNG7F!B_0F7U6]MB=;<*)'+QFVD=+P:ZI'^/ 2-5JIEOG
M/+Q5-@<DSI[&01#GK+^L1]GJ-'4\MK6D![,)[6:KFGVC_Q#>" ?+*M!*,BXX
MQY.NAK,ZED];L1Z[WB#V@4;IU';ZP,LTY><U:="\Y)A#0^H3Z.2EXW6T-/]3
MSV1G]@PYYM7GBJPC5ENMHEV/A%LPV@E)S\5/&#C73@]/=<36^!H:-K][.8Q0
MQS[CDZ>!,1#]IO#M9*U!H+*V\+)3O/@[+MQC'"O=V L2G25K/Z>$C]'VN,F>
M[%QVA$7LTQHLMO;$'7U"NO'!9H,V>"L<&ONI;77OV EW0)I-6D.\<])X!!"*
M0*WI'FEF^8)GMO2LK6)[#,CX.!N+9E-J)P7-0U/STO-#>\P:NK@<396&IA:N
MGMVA+@$+*#<I;=/M-4MM@W.2E%I:@9FQW%E&H7 %Y:QW (Q!EMT("UH=SRFJ
M.H3;4(/4(RB-S3>TFRC)*=]I9">_,#!?DY;-N:R9$$X$F6<PJ(:CB1TWB*;$
M\ <*38;/?TM8%:38N*P);"3WS#';!Q_IZ+8SE$7+QR^KJTK$H^8KVZE;;?JV
M\E^>.,Q6PBQ!SGQN7[@$B]_/S#_L'YHY31RTNIJB9]J$NU;X%#-%1N(#6 4P
M/"!.VM7U-AG9K6YYBR?"F> >#CRF>84JU\ZY#E&UFI]VB5I6J+ P\JSQ.%O3
MGINPRTV PIBEOGI,AP3%T1*?7\@=4*1[DJ[" 3H_T[O<>78;HEDCA("M\/^I
M@,VA$4/^"7UG@%V]+0HTP:041GNC,%9VZGA\E'$'# >K<<G#Y64$ 319 US.
MFH G=M+PKPU'[U\(G=_!>L=6*6QCN?2BI]0=("?V27#VW;ZK\<K;H#1VWXJZ
MSPY[FP,.NL\F2QVW\*F;AZTJ>7!?!2-,=WQO!W9)M+YV21+;QPB.-^8-,JN0
M# T0R7<IY&O\"/;H[[UU*JL1Q59%-%.0F17;/0:@+QNZL:V(:6#&_A@/_[>%
MV;DQ:.M!UAL/+M?G8Z7L_2Z8N;4)G6I#++11?1_>5T;.V'?C\?]XM+9[#-T'
M!;AE-]>5JHN:4K6DS6F[EG<=;H7G=8-B5N,T#"/*KWMIK_M_K#]...L#7K))
M:Z=V[%AK[._Y50E(O_*;T.I7ITQJFHZ(%(NLB/N&:-OG\RR\*2E$'E&9$!(Z
MOCQ'<1ZZQ%U\/<#ISN<TZL&:0M;X3+6S<YIXOEZIS@ECMH6<OWS4X#R_9-[\
M4T$'P_(/[QI+=K8<29BK^V$X-&3.9#=]59MQ!D?/Q@QN@H,\V'&;?Z/EV&#<
MQW7  WREZ*%X8)S:D7\L+2!V]7KTG6%HNI9D IR-A@@^ZDN$C[*(W(1\1)-9
MMX,@(E -/^$I!I;Y_HS%#^U*SGY[UFZ.[WSR[^L"T;[%$=O[X_>N7%79N1U_
MM>F<Y6!,5CCXZ47=.OD=:AS*W4>L.Y J,JR\WAS+YQ!%IY8BUF6@)J\6YDI-
M&B,(A4IH/B=N&"1:C-<0$H;:><>XB/_4$9"TOYBD7&(*UL7:3\FF_%A<+&SH
MBJ<X+$%(QMRS09<;M:1<&\1>[4INW41C#".8EC0)<]"L\:RU66]JNO]V>#0\
MM<XVM;J]BRUUI-[FP%^JX.G6]*5I:GBAZD<"Q[PJEYR326-H6$.[(/,(O['!
M60+'H9YF]_-/62%/X !DHO!7(-Z?0^;Y%G07.YC51I^4<;Z4+];; #Q[<UDU
MM;%@8PV&!!P1?R?CY]W\(22\SD64%LTZ87T>U\')LR=EYD&%UH[LPQ(CFKUP
M+Y\KQ$M:\;T=)AX;,AFIROI$@_@$5Z?[8!"D&:WT\7P#M#0S= ?H77K?QK;J
M0$MWNUR7&L^6/XQPM>.OF!%P73FE>&2("5^]XS?E+H%*YZ=7!DGL4,3WX(=J
M".ORK2S5K][ND1Y('WY:';T#O/)O\;SL&4?&+1(_O37ST^)?#,./^0Q/DDM]
MH3A@2ZLM3C#-'UDS%Z,A))<W:!%Q@FQ[Y*[VY?IM[8'>Q^/^4'OQ R(GI\A>
M:Z0R3P&*-<DHUNE^T_.C$*=2\:.L*_7@[;V5G:'D.J?U4?RA35W'@V5%=0\8
M;^RM4Y?;2>-R,(4\Z0TMEA#^$!PHLN0[Z<%"L7ME=8L>6^^ Y0EME)UY;^6H
MA98KNY,@SJAC*)><PX1CS$2)QEE6OSE#6PEB?^73%&&>L^)&]W$9P?.YEX+2
M%"(DV@TQL<)09KFM+=F:^EBS%3"#+J[282%KU(Q3:PFXYB7G'=!S3-/%DI/Y
MS''+NZ-.5"4,:E(!UAQY_1DN$)5Q^7R=M)A<YWNU@3Z87*9[EXMQM[FN>TO^
MG59&@;;. $Z]1*R=#+DA"QT-73</Q5*JHST]PY.PJ76TGR:J\D_<DE)7A7!I
M"@YGI(F_*Q17]!)Z;JI\AK\,60NOE#YM?3:5VC>="K+;&<JY;V,^] HJF74Q
M)2N?BE.X/QN;T-=:)0'H[F<9<U"-['C=J45E;C4312+[GM;E7#>@0E2EIC[!
M+ O,8.3[.2+O>U8-\5>S^Z)7_BZZZ9\-!*@25;:HB_W^AH$"7'O3M3H[.<E]
M8U;;D$#G$$F_DG#?B53O.Y&=9">@E5$XJ]V/^IJ\VK6=\\]WKL#043;3^>_O
MW RV$T=O!^OFJ^BIZ6'U^M!,@_UFR/IQ5MB::D,45;7+DD+,/]NY#_VP2O%N
M=H)&S$[*OS?UK+^6''8<1Y4O/V$XVT(22R%)2,.9M)O[!DRP:USQ%%62P ID
M6^?L>/++GAI1Y;\IO2!T3?U^!*@8Q/_ZO2B-[(0'U/>K.E=K8_F^9&J91G%>
MC132()_@#Y":Q>WX,56 8FH$O5:G4]^8@K(!]8Q"<?O[Z<I3+7Y;FK[O&C:S
MW #1V9YHTUB%-&M315N>3<GW+.[UR/?=LL<P)G_?,0?,?G?,03+ZAO#EI/OY
MH'E0WJ0]PY<OFA*CME>A_0VE);:7P[;.[*J;+S1ZV4-#.HK22HE6HH/N#5*K
MKXO%#11_=_3Q'1L=#9* K-QAAM8GP[H@CM]C$VVY3ZI"T@^$(-H6".75V^#M
MH57+H=0_^I D\?=B9PJ9=P<=F70LQNT."X#]?!.@D5&H-2O-7D$WS4\;@++=
M)Q+FBL?OL"?YEY+_0"B@+7)6XLB4FHBBR.3V*=\%A=E>CG#,])M0X4:QSW@M
MV^UN;?VRQRHH_V]*[SG^_6OE*S[3)#;]/T?>7]79;TOOS")6/41A>9:M*O\4
MRI8@.,PT#:]GXDUGY7'37R/X9=!;"B@35?V[5A/LGF\2:WP_-Y)?U(F7L!TB
M1PQ+WH =P%&=@X(S(K.JHAXIOLK\W7\S_M)B?K4CA9(U+1;FRLB<Y3/".&<]
M[>63C*5=L^*1UQ518$+\3_>#'D\O-?:]0:5_[:RO:["Z[;$MWAV*S;NIW/].
MR.1)0\56\?YK9XWBB]?<E4B86OXDIFK0_W'S&[#>\JM3JMX/,F 3M6H7%72<
MJ<\!1(?,+IMS47\I>1JJLC)N');V*P)U@MFC<(:?3R^?*OWXRTJ&!F3G[-0J
M(&_.51(TM;,2UQ?I5[BCZ!3E BS868C5@0(AC.G%&RRM.9!.5YN*HA3MR<.I
MDMDB9*8G%"=766_7(3[\#0N<5=E0@OVZT6[?[>PQAI"1J0V;OKC\']N6W0#L
M(R' "$VM>?*3Q_/]_I_W'L $ WTWD2)YK_&21;+PV JZH6W-M$#AM!E0I(?C
M(O[F(.>+PXTF3TX%0UWF1Z@ZE[%41!>GHC":L**-)]W]9',QZYQNX:)XARSN
M3:Q+L4IFB(RGS4J7[9>?E1\J/3 BRQL=MC3M/+CV5U*H2,@L.63S2LH1CTC[
MY_++]/IGO];JPEGV;%OD9/CPGRU-MGEC7$L.ZSCR(:V,J? G6BQ(22,;^CB_
MQ >2=GA(QL/WY:2'/<#[3&U?]38FK+$T4=T+>1C&,F:ZNGC"1GCC%7H%)"E.
M2M^,!5S>SUDFS>Z 8X/)! \BTOWP\_XE<7]D2OH3VX)IT]QH%S]%Q*_Q5G0E
M' 6\VDF#P^-TVS1O]X_\)>LM$J4;S"<@-QO#UA_DTKGB%TDQS06)(,S55FN[
M0YNK$K+SYW ,U->47MS[]9$E+B8"3E.N7',DT4SA[JY(UE>K"4WDEE3S;GKJ
MGUL"/S<Y7YWQ#^6]0C]WY79E:%YW/%-?:>0Z$&D7I*Z]HDS)BH2BMH//]-/J
ME&;PDAXM;ZKKD519$(.^]<5QV4Q7)H3ZBL8*-?C-MGT7<UN E4O#+VGH\$+^
MT:AO13;A4*@C^6SWXH".U3T?BE&[ULQZDRM(!$W!.7!0G.[,TW&Q3;]O_4M@
M*U6X'YUUO>1)3Y#WMFVW5M7-\1JU#7+[+1T/CP3U H_0G#3BE)/R"^)&H-!)
MZ$1+_!E"\IA:[-<!N**O]Q-XS'(\S%9XY9.C^>V6I9?\=(LN_&Q+SG4CCOCK
MKI4_.? @SRGHL7="$_U$K/C$05Q2ET^XEG55F=#WQ[-ESR0WKE*E8PQC]3_X
MN]M5QTPJ7[&<9V(GYLUJFY:XW@'=UA?4]O?OZ3;Y#LC^.NE)L,9QJ89P,'DK
M^?T..+D#<N^ S7<<\^*WQ5XQDTQG+F[]_W!8O M_.2S$U:&5B06$A1OO+%=K
M:R/)_"B9***8553@**+< +HXSW"97E&=**OI.P!:&M!B(:.YKGT>3"[L,%DO
M$"+]KA2) ?[IH=&KG]-K#CV] C!=+'H2,H7F\W@4%I[HKL=ZB/G3G%_?&W?>
M 073ZY_#)W1SS[V;Q#N]T3>;\<]%&).SISI-C:WM#<B#.+Z1;MK:[[I'N5(U
M!] 5$[7@X _82VY:36YYW8JWVN(2:*SI*2:_M&L3/.,ZTLK0:;Q=1CQ]':XJ
MYX\$":Z <,SD=/#TJHO!P/VPQO#57:PI=@T+PF@O#8P",QR:Z5*8U)=17'^=
M@XE//T4'N62.208=[XRO&:[O6/25:\KIM5Q7"[ZGR#WQP&8NM^Q+6'4^W-J8
M*.QQHIF6%K4AV4\TNS\"5#2=#-C W^@0EM]7_JISC@P+(0>Q_+U>':+XZ\I?
M]=#*2GE8@]]7_JI;9F+_NO)ONN+P7R=0.#%+#C71[6[ELX.GU:%@F@27,!+V
MG\ZLJ?)L%ZK%)N=!&U-FO,EMD.")H D-A/P[(+;C.1_&9.ZR$*G -9*6F==S
M$?,CK-B)48;H]AR&#(D]G(K^IY%T3WIR6 U1:VP-'GLRZ/%X8$XN)W:K$IB#
MO?#*52KKHCB&#;\,X#G6Q-E;V<%*X-N<\TS5!%UR_G-Q@>U$F#H.=Z2!?^/,
MM/2R<U/7LK3TFAQ4J>9_@AF)^(D],?F%;ON@;_,PNN<I86I?$Y?2'1#N2'H,
M8;K!JUKSKC0@!K6Z>0>1HQGO=Q6""Y.;/+*C^Y,\^>,IB_,]M)L&DSBK>-PW
MSW;.4\I$Q8G2QW">?_811BSF)^A8(WC$-F!#2OC9N^V1W,WKRKT;!K^&ZV6.
ME7D2?LNT*1<K&:IEC;( ):T=09/*J$55%6%'U%A:6=O*IZG""=NM78H=K_H+
M^$,@62\7S(\:J%)7W*@:%D.9.C5%-B^K0KA.[6AFL0M3;%L1\\C+B((60U.#
M!?&N)QALETD?,UW7]7V#<A;>MJ>>0$'U/ZV2:J1V/0260JD[<:G6)<8L'?F,
MO%]F5\4;J;R%@4@(V(B3+%6Y#)@4]"4O4CI.W0&:!-*/I9]DJGXN9HP*/RDX
M-*'V]P!GG@]^F]WD"K;)FZ8,CXE]1H3M &+]2IZ.7]RRJFT:=$N@L07QF6"?
MCJ_$>)*QR"%-_^@MBW\,1C^MC:#J-5)1(2CP[!:S/ESV8+;(S>D0B]ANDJK-
M_B<+?]O<4'<F08LQ0<*PV^G6'8!X^<,_*#_ XTN5]1Y#:JEU__>JOQ]9UEN(
MJ"6;"?OZ^E1*CW>RB-9O.-%CRI8Q G&],&JJ?/6C%2>L!:49&"<?67SLYKZ%
MAF4/ 5[ /$6N&&;0Q.%UAO'.YG"72M)L'#V()R&%XD L<>&&2D=:I5Y+6OU\
M9HHRL;P@3"/\+:N,36PS\?@MK8ZX]U(@Q2@_>Q%%U?X6D4 7CUI#=S-20-JR
MDQSL'?"1']$UWWS8);KSL#O/@B4)HM$A637JNX,'<KTQ(J=.^[;4A&@IQVX&
MEM-PWMF\-2ZP[Q8T[QN[%&\Y;^G?P\>I%R;H)BBRS?NF@@<XE7*?EZ6[]'?&
M*FU<"N2$WR223_<Q,C&N2CJ+TTJ(C8=^1/_NN*<;7WDY7%V6K3*2D!<#X6/A
M-ELRJV>H>M;4X,1_IKI?7;?L#3^K;E&F#G;[KEATZ=B5RO>&+ 8PR^[/2&[U
M[8&+N9P8:A]ZYMUFN%A;LAZ\71_34%5\DZN$T$9<DOKF$,-&>$]'C$77= GM
MFO?<W[(TMS=]:X\X-@>XT*^[^BKK">==:+A'FFV-[.Y2[^FL5W"1A*-_\K*K
MWCF\G6GX.B4EO.?X\F6**7#*GEZA+5[-&_3K'SO\KPIO1OYPR:C,!@ &[,\F
M/KA!;X;K[^-_2U572FJNV9RZZ#Z:#C[C#<NG96=&5<(STXGQZW$NST?YN<Q3
M$ELW1.3RY5Q<Q%+),Z@;+7B-X>1'C9I2A I1B/6FCPN%(3D/0**WG]@^1S/J
MH6]H[YYC ?%XG,OO]AG2E4F\-/,&Y1VF3T<:HNL"3!@S[V3F^?(2O-=C2\$)
M8L8S[?&31[86N3]I&!<!QFU)&!5G1LG;_1*F1>LP#^%E/;QYJ;.OO>GP,1/C
MWY\OB]F>V@5ENEZPU?6S/NU[JMK,))YS![2)ILUH;_%.!'M:&^?),E:&,V%.
MOR#_/F*M:/LY5(PW>D>(6,Y7\+GHLMX.H2O[], SU5$=Q2/99GF*<)>9$*3%
M&!]NP:YZR$&XCS,FE/=C4]Y,?RFQ*G1B4.FFB8)QS[Q-U>\U2]["ZB'&&Y13
M-R#;N5@=?(BT6VJYDT5NHY&M3.&VD)*Z*'XZ[E./VW7Z4YL3"!C462<GA^-9
M,3PJ05U:_[#CH62;IE[MBYY)E>Y.7+66-B%-/JV1YTKDVF!/L@3[/G69>ZWV
M:N_Q/+@%-^5(=H21L<1D?"<^=NOUIV+#BB?=A)+$<_@1><)5(B_A,;^NL\/L
MU$?> >)_K,/F+@UA""^UH)I?,ORX \3&&"BKHL,7'6B]193,<0]IZ1+S-3PV
M6IQ>6=X!ZHV>,[=5F=4)3LXO!543^,\6<)M @<V8+N;N%7? 4U1W[Z^ZL*[/
M<+??QH'VN2%-*(VIB]372BU/FBG/U5<-PQ7#M:J'K@\;0M@6W) S4F\O2]6U
M+U5C5')N[X#&:4SL LYJMYO+0#>W<8W*1.G\QM[B]/BA TD\P\N@6M5H2Y/D
M*G'ZC.RL2(2F)$Z+<KQ,?[;DLC0XP4;EV<UILTYJY[P120WD3952]BM/L0EI
MBSS#VIH8J4:[/&-C 6'$O$(M,,JH3+$_33X=NP?EE0R8RPOU(&K#B547XF*<
MH97(Q\9755_&[>D3'<)\E>F;PI)PAC'U[$U=_;[.1%-!*P4D>:!=!#W=26,M
M:@H'-L^D%X+'_&TY:,<+!*ZN245?L0AVR35J^3J]1O;.JL%?JS2/@M1 U VG
MN,CI=+\3B]Y6+(V6ILTW[!'=9IE&:G5__H_5B@:9LZH6OM3DU6N!$^W3:B:(
M+J>,>,9:_37]ML2S:O"WD^Q.O-(O(+%?7>X1Z40%O^3B-!..F1I$-OU9HJGS
M4Y$79ZW$PMOB\NZ8FO[VTM5)6L$RF-QB6=I4)?&MUPP'"+.#J>Z+-R8B5"WI
M$@Q61E8UF)%?[D=\WQSD.\",>4?GYQ#_9*+'F^KH-K?.@'#ZX21UIJDJLQ]8
MQF6&4><GGYJ]<P[FFM A4+Y"ES7_"8DL>>B&'1YFA/!Q24*OU+AAQ?5EBA.Z
MG?_^N"#-NZONS!O2!'H%49P^-]__Z=]J&YP7=D),W[,3WABJUDEKT=&0+*D:
M#H[C<Q,/?87:ZO%?<]\T>= MSQ-#SIT\<<]$@R[U$9)/.O*@@UY+/9F[N!L\
M5A*#B!Q-O#CFHGV8]>+&1"3DF,C*V8_&G 73LH;6%=IM<=H0/XU/7O4)X^#<
MM&O]G)&J92!Z]XUYF<RDK+J:AW[/P')^'7MG;OQ0[H.W>>DS"Q)23^& @),Z
MPO8S2%%OMN:,&'M^ND_/)_MF,;22=NN^OOG!)IT6LR92R3%^OFSHJ5JD+K3%
M,&"')<L"=LBF0$&9WT]<9\"OIZ3 #AF>8".6)$NGV+[>A>!X-J$E?9M=+>3G
M[;@@]GU>[Y)6XX+^',B0)6PO-DO?:'SV841!EK_O[#@1W?*YC%S&[2@)Z01'
M(@/'L:6[;*RG9*6K<5.%<M#$$4(L,A[/1;R8L$X[O%'(4N[/,1VT.:Q&:Q>V
M2<^7R#AKM\_.]]+/<[ME%B6*]HI.GF*/OII\18E5)(MY*QK1B]\/"Q\83Q0R
M&>?2?1IVP!3@17X>)UI.0'RYZ19:G%S]_M0]?(=N)98[/IY" P6VV=#QC;XK
M>3'WCZ3DXGSE?<<"R4X&N1RSTL?[=T"G-:E+H?KXB0RY\*@C!@KX\ONE<)GX
MRSS6]ACW2/+:<,+NRZ:&LGF.7A?KTX0#W.Q%.=SY6;G%\8G*8G3/-V9,%LZ6
M[J;\AH+*97WB2>_/D_%=R0R3QNGYYSJ+$$S=&5J4-O>_'06QG:L-G*96KF4O
MD:*Y='=H<E3Y=R6FH](9:1C$?7?->;FFTXPN6EX8E?;2!&F@%F7[%O[:('')
M^ X(JBQ,+&933A5.02 H"0J+C8N4\H^)U$GR0ZE/_>(G)KR6HTR-5WWY5 E!
M,\F8AZ'F&C1 TBJ*K<;3]D]WO==#8IARDA]$H+5Y9,XV/4/9QE"\-\7X)"3T
M0,)ECLT'ST>8_$4]9'"2D9'^6.?5TK!*27I-Y*)BT4*MHMIS8>H(7GLA(NJ/
M)0GC#@,@\7W<7+-3X0RM'<O%$*&0J8@+WQ5GBJ1%,;PSXNK;%^>H[2GLHZK6
MF!09<ZT4$4-H>\CJ/8]$#3Y@99'U[%6JX>^'=[J=!7)HZ>TDFVK'@AE"HL%G
M*<17V)B]OA%4TX,8<-0)QQC$+IR3W;K$]:.,)"[QD==Q'Y?47]6]2JN)[:_S
MLE)>(141PO%@TE^<Y>IX5KYI'S?&H27!>,I6!CO^K#]0# /E/8,/7YE@S*1:
MJ@OIHK8N\N3;INKZ*(FN&.*0?(Z."I8(9H.%GF[S?>9,P*G3[3' 7F(V+9OA
M0VON?;#;<O)[0F"5#Y6Y#?OCQ,Z'/ZY3^@Y &MI!6)C5-M+:NO2<".![ZKO6
M'?P%1,30<VTQ0==W/W"=$TPN+KD$49C6[7=E6A3GZ>V*TAP%W%R Q9=UT^'[
MV24IC/C?P:#EDH4K:,G-?3 ^Y"UP'UMDBIN] ]!E1+%5J6D41+&!^P"S/D_L
MO9+TY_<'[3K'>M#)#3K?\WNOF6+-^_(.N)]C'U<3[&7< :HMPCIV=X!S0%$+
M38H.Z S:LABPSG*L(&I'DO;GXW2A4XS%*Q^5-0PCI5B9>\CVA4FECH8^.F.Y
MB*NW[!.OA/0;M(!'C#RB&:(Y84TGJ"X$$S'<CA,6;FG-N.(2/%.:,L6,)BOQ
M'\\664PL(G5\]22V0[P2EC.'9E+L26F!6H_O /+^KE?RU;0I^]>&XUZ% \0G
M.#&+J9@:YX6ORL:+*(XL&9<T#*T"X!W(RXB1MD7!'P?LV9<@GAAB3T,E\D5G
M6<841%^T_4]T$S$$S[/W06UZN)57M2<#5!.68EIBE0%*+'3:6G!1V7C'D._J
M[I/]\^C>"REQ;J"P8FL/I>+-R]R [;6GJ'PN,TUSHS$:<(\+LI;)<'MZ]A*N
M,#IUV4?X";-GYZ#.D4*Q^Y4[)(MKK#Y>T!.*9;BY1NE6[VK&F"5K7.$L* '=
M)FZ<HJN\;E./#?+F&N-PY=.9I^$3347$] X;@^HN-3@MUW )N;@*O:M$.%)0
MQIQ/UK=. MUMS9C#C3C9C(GIX&J(BE\%=TUEH%ABN)+OS$1V9_VL5N]3+%Q1
M&HDM/Y8W96,,532O)RHZ[9$IK#^]1PN;PKX*]K5$B_IZ0:[83=+.L=QL<9%,
M,AKO+CW_??G^Y?@3B"7O%YW#4#=8DFV&9U]L;UCQY[SRK[&<;D"S/5P6*(Q*
M/37</[Y</PV"0CKH3A-1NVK"U/WX)_PX_+]<: WU/T%PMER)@&G%=;@#(&RB
M]672T\7D:J-D*5V6KX9+%D,\2[@C&@+[>L06TI)8<&;^K]Z^.BS*YN]W%0$E
M!6DDI"0$I)L5E!97&I=8%:13.A=4NEMI2>E:6+J[NW,1D&;)!1;VX//\PO=<
MYWVO]UPG_I@_[GMV[IGYSN?;,[.SJ"/9ZAB0[XF*GMXV*M[L26X*A;,V()3M
M(TBJPB#:GRUD0LB!0-KA5?::?-4E>DBL\BK>4X HS_['4+[%6<*1JBWO+*L9
M.9*P59^S3#&AOR]C+<UAU:<5'M&<@KNK_LKFA' ?(8>4H3=VO7P=*/]@#UK0
M&BY]"@VI=(I"K;8=<8^H6H*<*J/>)1>-,G!,KVC5+,<TX\;(181+ O,&+ ES
MX+GS XY4+0]%V ?8]?<X;YW[M Q*<8DIURUNO*S@-3?>6EIO(*)L;JIH_'RC
M(]II3/+>Y5O<\)Q)]KAS? +IBW=!/%22(7ZA G3-=/T==:3/R&=<H<V)4'^T
M#$+5</;-6O54<69MS9O@6'G%:,;[@+NTKQ]$NSW>U+FA'[E9;7&N?>Z;K7@7
ML%]U_V3I/',/%2[U!USFF,72$U P6#YB=5>D5>2>_56F%V5B#"<6GMV:UIP8
MP:+>LE&RFL4$K9+P+LKF@QY_!&>>=D[$0L/%DMQ9\G%:!3R %<F]]T.(\#T7
M5]WZ!.O(]WJ^F:NRV,^B>%@!/0MMOG7)QGBYCW=&,K8HSH(*4)_;:7[&F#O\
M.M"WH.23C(\_8M>Y^\+(X3[N -M1EUA1$B1\D;[&]KY\GM-IV(/7(:^J?3)P
M3:(_^!F#DK!%X/J? )*..)8,8>+RV0BL7)EW>5*YLXD=0K8W-G>&Y!;1:V$7
MIQO8S$6%3BX.D556#/>*[=)FTUPT $&C[:H'(@H1ZK6-8R?<&G*)&PH!\C&7
MPL8^5"O6(RJM]DP$/X NEO<U@Z<.B-L\&  8@/D0X=I>0;Y%S).SVOCT;M.4
M.%E&"7(M+4T N>:M$Y8I(:/+9YOP43D,@)3;A+V8-7%QT-2?.\'AA3Y59! 1
MU==IPCF9+K!-PJ6L^>QG80R V-+9GB<C44/5_N$C[;4LW=.'RB#L<E"ZE+O:
M$VFV 4$'J.T["QZ(=>;5$_<.\LX;W^X#W'?F3JUV=A[QH[T<#RHLEOLY(@(5
M_!&HNZSAXCHJ-W;4[&2"^0\P,,G2B73@P7)8=_-]MU.A+DZ'4,W9D937[>IY
M:J.A):RU/"-RY-^&_U+-0ZC>UM8CF>HT#<ML6!FA*P9@E*B8=4X>H<F8*G X
M):-K*%@V[L1+L$5QH9U-%.6)%.ZK01R1B-ZX80]==I.7AW%CT P3@F_JU<S>
MC9X82&]M<?G>JITR;I1E)N$C\.N^4Y@O\].)ND0&U62?-XL6FV0;V6.!-X89
M?8BFSO1K/<]K(E64S=%PZ7=WOG/@V;9L$I#>@CBI'O/4R#8T5##I8TW]EDG+
M ,.JX+<UNAS7QJ(%4(N5:**R<W6W4K'''Z@WP,>*F%QMP(@]H##C^V\L6HY#
M@X6]9"5>TP^'<;D.1,#P25J=^PN6E(0TK;H6B3]I(O7W+U/UJOJ7#^U3%PC=
M!VYFW&R ^W)T3Z@'-F#1I0&/YM(,IE61ASL%6-:K*]/&.RM@V6%)0\085Z?_
M.D%YV[\ K]Y>T<7F348GE>]UF8=+P8G&7Z$\#*!X!/JKH\#Q5@)"BFBI/95A
MW#&IK';R8E;%/&'"0#EM>(KR4FI;A ;>"B1FW1S,S'TQJ[5L%/] 3^+9^1D;
M/Y3$,.RDA!VEG]F61B;-ZFJ&CNQQPVDR*QK/'O?XT%6:2$V,)EZLBFC J;-P
M>KZ8S7Y:<074F#3+"&Y?^V<04O)RM00=\PT#N-'3( Q@=-JR,>0*?(5MQT '
M_)D"^M=V@&/K2]A)<W$-M*YMXEI-LA:Z/P%L(QXTCOU3:P/ZSW:5PIK#;YQ(
M+W/G8>9^3R &0+&-(.\*F%L;KCR-OGS)@BZ=O]H.E/H,+804IL9M0F7TN]I!
M=S& U@\K>45O8\%;K\47= U</JT0J5U_6[[XI.#NTK9$$4'M:H*_$;$#'ZG0
M6YQ],-#02E?^Z.+IZOA]CRD#T&*+UG;%%</0D62AR"6W^3M(ZTG$5B/(]O%/
M)T%UF\U4#A$/G4?;1'\>:_T_+%C12'@;B!AUT;O.K:-255,=CP-7Z?0E.,@;
MQ!.[$TJJN)MX,(3MW1F4@2K'W[74#= <+3(^TAZP/C!E7'OA$RW\>=PA\<+#
MFM9K>[1M7;206TP]6T)>+PT8UOT1W5K/1Y6H$WO#\Y^7UDU_U1*EK,R1F&9/
MZYE/ID<_J@PR>IF:BP<8T&WP*^9F"WI%/1)K6L94N)LU9^@BT'"1NL'BYD8Z
MC/0B7L;.B3D8]1+IAMN2]V4.Y";-\+#&L[K=SYNIV^-@,;6(R#:V@-SQ5/,H
M ;_D<1PSQYY,<2S:4*(EKOA"E$W^=,>YBJY'M'5%@7FIOM%AT9>AY+!$5LS_
MD5)/'7S^P,)8E+I5<-PJTQHV-WP^!KI*1<O190^$5FSV9-5759>:_TS!4_A8
M+DR].A]22DX2O1P3+6?3=L!Y.*5I.><T]@Z*4J;458C@;!U_0=FW(GVZD]+D
MDEJYVW%O7WYL6TNRBT3#696'H7E$2?X)$AC0=-=39:6)UMR]ZD8/#6 GZ]AU
M3XY6\[L54[]Y/TTJ_96S25VO0E+KX#D$B9-;@/(5^K$R1:OI?]$ZQ6FM];:U
ME<7V23?1D,"C5_,URT=IMC.#,MDS@P[JR)/DJYR$RJI-C_CR)PQEIT1H>..^
M!_CL6)(2?)7F)+').,YMR\WM)#>959L2]Y6U(V8^J-W*><.]O(!H9DAR/9[A
MLS??F!,^O@HA>'+I>>E$^'>R,@,0V6CST3V63XKC;M;H9P*FHEAX5*N+SI>C
M;M PX.Y#!5YFEQ?0 A2]MV.B;?\A!N#?A'V\CZ<WM[@57[;@^HDKY%O\BFF\
M8B:I\D\R>0FUJJ=W\L,=IHK>03SID032=!./RA->>6Q*JL]>U0X\":$.&23E
M%+NK:"/6S+S8 .]+5YB2L@063\4N*$DT">1>,MRCX0PU,HZ#+5E"!E(E5FWO
MH):Z+FYO7F3G!N0$OW#R ,'TL?U?R;XLQ\8NO8>-Y]L%/A["-Q?X94@[)KA=
MD%8U#YY3((!+.)\7YM^R<NZA1EM";"1&JLKS E,4V06CP2F"3\E^:#F-V:B"
M=YS(U/2[LO[2%#$(1Z5ZH0*6JO5#-M@W\+P 1ZR5V,L?+*:Y@%1WFLD2*=1$
MQI;XC:5G55@H6%/Y@_:U;PD,]5@7[/&AQWA>EX"4L@%@GX8].?5Z A:TGX74
MV!(6)K8U-2W2I5HN?5XJ[M;*0BK232;@A)4N)0(T8WB@_^N",#O8U1D#T*VH
MMV=).!5P@[R-?JS$]'%1S_>(8,U?6B,Q8;F_D6T$AG(D-&J%UWZ(J],7:CCI
MV!&XB^ 7D".970O"D_V)/ P>0Q4=[.NA?!(=P:;!;,/<;WE/"UQ'9>'OJI;%
MPE]8$= +#*X^>YB[LV#[J&S<9@/?KI/6PZR$4AO>@,-R)-Q)0:Y&O]">,L,"
MK_3X8 ?!]Z9M:JOSF+XW^N;Q3"5L5ZIH/FXAAAE6/.JUQ^^Z,5DW"UA#*R'Q
MVMK$8>+&\>YQ5SN1M&E<JN4>T65[<S6?L'P3PR%!LP^E60Q(?E:KQ @ZYYC
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MZ (_I.G\G*>WE6@U<\_>9H::3H9.ACX@\2%+9O^D[TX^.V<XSU#)\X_1/[;
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M@ROCX?-G:]/G*TB^9#+U1OCNUHFTK72O47C?ED:)V$!E3O&9GAD,32R$>G!
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M=@@P(@ X$A@$$MA;-P#_?9Y08'\-P#\&&#@$)-0':!A8N(_O%]0@ L#!("#
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MR3-]X/X[H\*6GS&NG".H%2=)I:#)_IU-COG]@QR"=G)BSZ3CB>CK(R'+4+8
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M'_E-\U'G8@U8HOPR94A<L%10)(*B%.]OAW7V'-Y(]^(*>@/LR\]] P4TO0&
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MYM-RJMGKP$19Y6M3[,W3TA%0Y[8,J_-./.I4:WC0G2['H*_TD%YCT2QJ.$K
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M^1>E3, CA)@O3^X!=2W]87J;%/>V*C4FWSYN4UD]20WJDY^]RE[4D!"O?'
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M(1$Q9D'9.0 ;"P<'&Q<'#P\7%_/6$_,>P"7'HV#FDSUS7L,0G\41Q.\;E4[
M*E=43PGMVV03,'+R(R2BND!-0WOQ$CL')Y>@T#5A$5$Q^>L0!44E917-VUK:
M.G=T8<8FIF;F%I96SBYP5[<'#]W]'P<$!@6'(**?/HN)?1X7GY"1^2(K.R?W
M95YQ26E9>45EU9N&QO=-S2VM;>VH_H'!H0_#(Z-3TS.S<_,+BTO+6Y^_;'_=
MV=W;/SC1"PO P?KY_+=ZD6/TPL;%Q<'%/]$+"]OM9 $Y+AXSWQD*60U\0\?S
M+/R^!""YJ/2B>D)6 >@FI9%3'Q$5F^#4Q:T3U;YK]K]3S.__I-F?BOVEURA
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MNR5PJSI^&N5H;2="01Y/]W&TZM6>\M>/ IW'0V\F5MZ] 1,^ %:&<&Z]K7S
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MV<<TA![6F R]+??'*QMW"LFR2#=[<-_X<W-74M3*P$R_D.N&>LD N?9G%'&
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MARBW301@P'3D_W'ZB(,>^7]02P,$%     @ ACAN5"<U98I'+   52\  !(
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MG\3^@Q<$0 %!O1@/A F( ]=W#'F!2"\@..N++CLJ&W'.R;#>4YRDPD7YAB=
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M>GF]6]:VA,[Y0K-E[<P6O>F?A@L-,QM:N@6?PI/S'4:'BER(\GP=[,=;H!7
M ^KH,![]HK;S;^I,+#-E?^E6R<K9$2;CU&&4"=)<51EOO.D,]DUTG*-IE?O
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M /7_,I 2N 0F?[Y<?R:$!U%WL.( :C+_,]1AM6C"@*P"M/IZ52@9:JZ\%"L
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M:&]^"\4?Z%T;L]?73ZY-TX2K,-FV-T<06AZM*G84W_AWOT[Q9LVG'H/!I:<
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M.I8@-?IO5,W_3Y _+_PO4$L#!!0    ( (8X;E1QY#?X?T$  #-4   2
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MMJ3UW+4V&A&!%;X:2!6O^-7[*)D&\L[CLF@R?TOW/56J9/N2ZK[5"<-H?K+
M&'_OT,G,\.)*[:BM9V[*YH$R$^;./5_DX9UJ^R4Y7Q Z.!=X@VQ[2=H4'D80
MM03E:2)X1#A8'[HM$(V$1]-?+.%[C=S!SJ<K%6(WZR[%&[:R<O*M4,(K6A\2
M^"X@@K;V-(+8[L.LE-:%0FM]0UJMIU]@#G-"Q?HW0J(]'XT?=O44EAY9S-7Z
MKQ)&LP]@*M/K! E!;'N*,A(E1P(E&&V2X"QP@3300^I!Y&=%V&*A@LE(=_>
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M3H;YCB^U3 >_=8<7'_I<S%FG?< 0T!9,)D'W]>A=V32TIA.*ZP56GF^?U:&
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MK>S3L2DA8Y#B(_G,-ZPWEG$LMG;L>PMV,Q@VY[Z93(N'7E06[>9]^=%&D(U
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M1D)T@??OD7CT=PS\A:D/BC0*G\ZX+'.K9F1&2#"8D^!:<1R !X%B?BAJ^'\
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ME5?8G&F.&LM7_E=3;Q9KVB;=U1U(* SZ&J8XBCB_?](V$S]Y"LX79TRR@$U
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MO.SW6"RZBF7JX^Z9J1CM*%]1<3ZTT3=L:(*Q4M%1 ;R)S>5E_RW['U]JVJA
MJR^ABJ=<()O1^.O8N3OO<4V.FNNS$D61!$JDEQUYJ/[]?\_K-_\&?+D),B;(
M60T2Q/_R<4V9IN+):8E$B?1EO(1;=LV-&OZ&D8_AZQ]H/H*JRZGI,?(XF!3
M)O%-@$9MA/J!?X?NL!R8A-&%@E +XT[OH*M$,!OMM=:GN!RH#78S;SVV1_P[
M-*CB4);+X\12)#SM)-9,Q,8.43D7$7F.SY?BKM"U^[*/J(6W@ZXM@\1T2ZHE
MDZU@.I*<R<9H^1$W [K5Z1-!N&P#?N!.44DY5V]50QYM!LPJQ(3QTJ5 ->QK
MCIIX4-@1_Y.VPRORKCL7IVW(D]>#.,HJGLH>PU6K*?@MZ3UHL5FW7\L?F'^C
M;%<\+2&="6K"'Y2\6FD/NM1.R&% ;11VW#J.GD_+L[9_U'8/WX#2>^+.%;_"
MSDS49;U3;K5*4OLYS9GH[-J-^IX%@=VS4=H@UJBK,5R.;/&%^UZT9ILGQ;6W
M[%?7AQ>?9R?X@FYLSBCF5TG#Y>77!1G7C@?<SK83X!*E3WG'^N#IWX?O+=SW
M'+ .R-TDG?$*>#":&^U=,O$%K#^ZK)2D-DMV4WS);V1:[861$7$]!3XKZ^B]
M\OH$4>S5IJ"1M9O,>/!ICYF:?"1P-3UHUV3#XU4>6*?,S]')[,N/75HH2L+[
M7UV[X+-2W=E5Y"SW8&FJ=6%ABK_7"-=7=OOIQ=+0)WVXE]%HXVGC>(1>,HX
M&-197+-O*-6S-YF[&JA\4(N_9 \$LRQF$H2^@098:;NO"?J-TCMSET/&YBE7
MM4CMO1Z#/'A2X4(( *LW0,73S2MQC?E&^'M0^>WGG==;K ZL\X:&E<^=S=RN
M<,8)CM/S,[:L53CTGN_^WO/C!4:6YL/9\E7TX_9J'%[N*K64](O6(_Y[9D$"
M?7Y3#*#1G(D]HXF5Z.H5>L#W,\FH;=[&=G7?O"ROIJ@,V==LLH-@7+>I],;$
M=W+> 1&]6&,5-5X=@0=!LH]-NFK,-1)M*H) GA5$AAX1^%%9K8V]!Q(A7M-V
MHB>V"$"?A-CUNM*,0VT%:%Y(&4K(T?OQR+ ^36)1TBZ@79J!@H8&58LDPR[R
M#*,.EUA] \721-@:UBTM^TF!A*S@(;J"N^-Y'(_DY7P@6NC9XP24\7V_[9]8
MPT?L(D_-XZCEXR4@>OEO,C=G0F<-.C6M3?)Y5*44M"L];Q?42/9XH(\TUJDL
M7+;D<UTN--X[V-FXFNWHX"ND6]ZZ=%A.!&&^$#@_QAMD&8UC'T.O,PC)+$GK
M(+$[?H27(_I*'/)H6]/.HG"/KLO8CG4<$P$0WN1Q#^?#J[0^%9E@)4R(]M6J
M3W2=Y$KV-.]J5X9=8<]9WR" X0DI(P5<1W"NI,,99CI' ^YDNL[75"^Y!6F4
M6[N?U=P%0Y?J#EVWBD_Q;VQO=[)(]AD;I6=CBE)]"J(_<<>:&\XRRT]@@ %M
M4#JUW:]W$KT-K ?-':YUE#(F_Y$V'H9N)/P?!A*G+SHWN(%]0_%+ CGW"B^M
M6V=?). 6+2Q$#HA^^4EJYDWK3Y%S*U-S\E8X\N*3"10U D[2L/(+([!R! &H
M;-\6&%FE%KK754DQ_\B!&3QT9&H-H)H#/'XF[#?VF5/L:SN^BA_*$_6RK(YZ
M0AOP>>!E<;1W7C:S()J)FW9EY8GX=-/IWOZ5FV;1?O^J 37YVM.Q8C;CUMC6
M _@!3LBA-6OJ&:-:5/GCS,@@BV0L=\JK /C>+P6*:W.)T;IS<BO:G]D5#;&M
MFT.!]R0+4Y-GT$";+R$.CEC/HB+,+)Z75]/A'M;%W^&Q-HKU[4DV!P#[0Y-?
M7V2^?H<N>.2;@M0_1J#SW-CT2'-8LU7YB_81 MCU5[^5^-RS.JT#2,NNKY^N
MUKQ[HK/![HY.@QF  .+ALA6.8X(;ZG'$<:]%6E_4@/#Y;? U3J"G#\'6GL!:
M.W(9&R1>0Y;M6_D:/=I/GPTPWZ)@7,&L_:B<OA1U740$;BL4#7J/U%093W;E
MSTO6:(TV;V+3QSS9-5*9'+#-K:JXV\J:A@J?M4Q^;S P^<'0:'K+&P7F&&+%
M?^UP.?@PKMH5I:_-_U*+,\G.R6FY!M2Y#,KQ7CP*PF08LZ"A9$< K'DK3+@E
MLO*#XV9BM47+^RJ;-&"/"(S/#/)5?;G#0+XDX$$%ELF8R3JH<'*T8,VJ"!>[
M[W*ML4@7DC'%Z7^/9X;B@%O]4G8F>W+2:<5/"92W=CVE%L=!=47+H>.V&NTP
MON>>>SM N"^Q'7$G5,(7H,3^\=FS3OW=T48Y",489]<=-W3=OH_!%[:T_WAV
M"/U7I6U"UC[];= U,-ADB0 ,Y8[SWPC>:%QN_Q0XX?=IN[7WV!QSN<.UZG8]
M\%7@GVSZ?$>VXS5TR38!EX]<">+"* <D6*OR2[V*YN!):Z LSA*G<R_D1.XC
M?<>MD17=VYS<2_R.6$Z?C^B[5WK/:2=VWIQU6CC+K2>\,B&@M&+<D</?D:!;
M0Z!(ABC>6JZ+N:7LE*^B?XJ,\ 4">"?+;CMS8I!LV=,W^3,E,$TI:.YSDHQC
M=11PQT9GW:2W^.NCX_5.?3'$W&%S>M*QP.E<66L'QX0]$*1211!W:/ VHG %
M/D1Q575%)4Y13;A=7W'![65^1 &/,6[E[GI<F]7"]+#<;;'J.VUB9>*B^(GY
M*7_$"F]%.P'+<HSIM1:APXWFW2OW5A8?C#M'=W%693CH&P)P+GA7U0'V2T7B
M>,\AT#'_DGV$URS3*G2,!\II/Z!E13J _ZOB_FV^L_=8S5>ON 9=I7H$P*O4
M]A%78Q/NJ8  4B?0UG'>$>^RE90;4,A=4$"Y857I<[X%&E4?@_.<];?8[.J-
MY&C(^C/0&Y?6S!;S;,^?506"!,(+E]0'M&J"!URHS0M*]2:/C&\#HN!U6!F9
M,91%>6[O&3$>?^]IZ-S,7(TQ@DR5<E3=#I<LR-+YLC)1K#7:[)X/W"]@B#A6
M.F')]RC[ZF@6C*?;?&<_F/_:=5:9YE2IFGQJ1#*_OG0PR@V^88!*[8VCZ7/Y
M_4[<\R0X+4?3"->+-E#F\_JRMN^]_9H0WX?XH[7V\M]O<LWA-WZ&RP .WH?O
M_8UO7]"Y_F!  .'Q"*#8_'J"K7H!-PT!9.L@(7&(K>=7R?J KD46Y.9@X[:4
M]&9NOMV-(LC231/K7!/5^E3EEU=*DZ&ZH4$6!SG4JD)ZWW8HQ7A;M\3ONF3<
M$%5I4[-J#:Z'M?56!HA3/I& /49[)ZHE[H<2I2'+\%%M:46_?@^6\"(U'/LA
M<%;<2X  K&/ZPEK[H;AT#M*R$FT@4)+5(F[-%/":4."DZ"DN(3\FACGHC$1)
M,ZAG_(!LHN;=VTE"X]J@$XNFC[,CE7VZKT\3;&0:HGJ&7DQZ)!+VE;PG1M>V
MF@N]SY8Z>G^!=>EN?E(KVN^MG <&>"%LL-Y2F4FEN^"5^M3:\9FVXV!: 6<]
M/E'K&_U^#')69;>SKL]A'%I?8G\6OMS_-='>M!0#E4$ 4_FSAN6&.P1MCSVH
M-T&*<\E+O;]J8ITSF<U3BNUYV];@C_/?,+<F-\)C"O-F,^EO'E7E4^7.R)GG
MRQ'[!%O; ZIB=FS=RI_R-15:2RVOW8M\]1YQ-ICEU%+<XMF%?>[D%PW=8BY0
M!BL4!U.6D=8-%CPZTY3((HUW(+U\@Q.B9M\3%,^TS\AV[:*YYT\E<NN[Q$QT
M-=ZG.'H%E]X1D45Z\3M(W3#)998"53M0/!!DH&UNZ E::5);*=6H7MJ=3/]S
MBKV1<_V-M&LH<)=NO97@V\6N]2+_/LDTE!\ADU02\+>NT,J;@CL<WS@?\A2?
MYQDB70A K\!3VY R]L/K[O6'.UJ_HB5]EDT(# .D8V-'^JV4/&/5)R8D'^<I
M+50\T]2N6+<?/NHIXG=X]!CVDS3@*3%[I/!MIK68CYONDP_.4L 9#=N2(2F8
MC;X@;Z^-/HV4U%077"BBGSLM5*3IQ) ON.M$U%6)9FOYXXLVZ[GK!Y>Q8)@_
M>-QJC%_'<7^%2/'K/1[,05E\Q?/:_=2 9V TFYQ@5C_E3[VCTS^Q;<S%\]^K
MG?<9HAU]63R:/S*NF+=+: ]O<2KWRO1X>#HWOEHPM-FIM>AN85-^CV>Y1*C$
MC32V=7D>V_-C5Z&?[.%@HEN.KM':OE9XOZ\A2L[^]T]EO0@ +Q!659SF9H[>
M-;,>N:  $P /J<BO%F_!J>LGSC3*63ARF74S8QG\POJ*?*A)A_7:'WT@AG&/
M$#BCJRZ)W=GZ6 \/ZEQ8I0?38+=2.G[<%=7?: #\>5.,:FE82T**SARDV_9(
M*;T'4('C%SJ6+H- <:9Z/G'2P2"3GN*[D9TAEE_H#7V<18\[+6ZH9)U%DI>,
M6)))ZJI&W4_CU'3-IA^H25'I''6?ENA\(D]5>_2% 6W]HX'%J)*]@Q N_W<U
M@H5H(CVWQ9\QW&\/M/5X!?2.:(I#8;4\\]T-&2$^UT3[1DZ,)2Y\D=UNC,&Z
M/[(;WW90<5F%8-)@OG31B1/''^.TB(7\[& ,J8UVQ!A6SV$B"E%DT>F?-!<.
M"SB]V=(P(VGSFWZ=;T1H1;EG1YYK\2K,B*U<6+/F7.[<!J?TU5RXU_6$H4B;
MA_"K'CXK[:^\@59=6ZP3S]-'!IBKQV0E0MXV"8^1GSRK]G7I9'E+(HK%:<*.
MMB<%(("'189*;5K727,&?2X\W("IB]_5>()3X*O7/1]',+S>-[^1&*T\+ST7
MC1M?><UZ9ZNIH#-2'Y)5F<S8N1D2;3T..]YR4*IJ=SC^SEUA/OY!L$2K4 2*
MK2OC>?&4L3QN4/,HU/LT*[ P+\=ES;F\A+GV5$@5-\U!I[:3D()\\VYVJ*+&
MOF_:1"HVHKGXNJM-ZQF9FC*5_-QP=J<HLY@+I"2 [[)8S8;64U=%4KLXK*CM
M:Z4+,H)IKL,\1AK@& *K[3IG,<]?!000X[_PR">KYG!R<7A%1B1J7PNM5(#'
MESRO&WWUE(EP7I\Q$G^5(2'+9Z5!?T%FOXBOAU-*Q%D.I)?@F9L9M66K__1;
M%@MGR2_! =<9!W=K/V?%=-0PPPS^Q/U0^Q&G6P';7#MLSV/YL,[EVC:S1)\5
M!^%S=4Y:,J?OYJ*@UF+R;L8H[H+8B>@LYCE?+*,',^=4J=Q-_11GG6R)1ZB\
M]E.)TV7X?BF*^WPI^%*9!M^'YP<>6<YJ'H6-IC?^RD[QX56JMUGWF-_0%[K=
M99[*H1STI6A\P62[DJ$R6\+]ELF>J3@8)U>C=Z-98F%?A[1Z=.YRJ8\*\GW2
M4553%)DX'3SZ8A) _V(?C,6[Q?HM02RS/MV.O6@S=PTCK+<\!.JM?"9L_=&1
M> U4/GRG<C[:VRO;X%M6RQ:Z'S&L'4^"8Q@70)TK)E^B$TF>#2A1UM+$6Y4=
MW#ZU]O%V?)S@T"B:U0PY+6C3#N ;X^TRM=.V[9RE?4M<:A[1//2X'A]K7F]N
M!UP,LB_?#Q/CL7>$WM\N1]G@&TYY.5=Q-1F;E*EO6]U*/M7?PM'8/&BO.!VO
M0BHG3H6BE01FT9?^49)1G4J3$:$E4_FVK71?Y]GD12P9_:R^=-_/C+@'^N1B
M(1Z5=8*[!K@-.F=,TIP&?;)NM(]]/B4(G@O,3+QQQ.Y\5Y64R<N9@\IN)4T5
M+N(SY31N$APF(Y\+<\TM."4OMFT]V!#6CN/ONLBN7:!BWM& 091D!(0::"@/
MYC0"9C0Z0R*7CPPY4(LXW$8S*!5R/V@AD>?#.571X<J7(KD&I$;V3R$U-RPU
M_M2?6\Q#UZ=LY37U#YDE( 83SC"'WNM2E[H.I@*YO"Z<B-K[DEQR$*7\#JYQ
M1YHU2[5-M- 'Q</OY1GOR<F$1F>BCJ.>%29CNE:Y'%,71W%5C1/+8NI_;D9F
M2CYC)UD3A6?WOQ27,+Y@08'@20ZX4VF8;Q@)NXQ^0"&G(]BR@Q<<N#ZCKM=9
M?\U OU.VIR:%)C!:Y F;&=ASS7S5,@5B'J*OE\QO),9/S4HSA;[9F\,S9#?=
M>C.7^HS0\O&+O6X$(,::]%U 3^QX?HA(U"F\PZO3/F>VH<:!JM%E@$-[8B'2
M2;/T2L5-W?Y.>KS[$:9=BN#F3_XO3JCS@^$YB^9^AF=\]"R]Z?X[Z. 73T3K
MOGU<<7LXOS [R_\C[55Y\?SCD:3%K_D>E.PMHZOK\>:0)H;<#G<^]UVM7SV5
MZX>FQ]^*VFN$J[.9RF7IV=$<XR_X:3.R%F10C0SE:6;>FPCM&MKEY[;F@J2D
M@."'#T[YGS[(3.&=" K_>79?]S65;#R!,T9?%T2SLL$+1SMQ+5QVF-995MG]
MSXP2-Y;-C2:V+MHI!W+6"-'<PXA2"Y6A(A\GU"\5+*X/!S*P -KW:I/1+#[,
MQ_.Y!73_[5N)< XFQF4'_KZ[_#GX.Q,$T%0 YQ^V-SY&;4( )6^0:%?Y;7>J
M [5'49[ZSQ?[K:9W^=ZS78W_0<WG^Q\CE^-IHTV\M7ZT]>]>?X [-5\T5>E#
MA_I!%V?0SK!_JM^)4$>#\17% N-]I: "RSY+LT5-FS_Q;ZZ;UN3^J1IA^FW+
M8F31MO6+IS8E_A([W-=:.CG!N+LS/LKXIUJ"UGR:@3H:9OH3]-)XX)+VXKS
MZ>K*'PXON1P-^KLZY;?L#?';EBL]P<]]^O,6_]V-9LWM;0L"@&K?VB[952.
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M+NR6ZZX4Q.8T>,)1ZO$.3I3=C=_ [SK3:%2T/;SF>?!!DXG%<5+L#+[:9P@
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M'UMAS'D/M6H^(8!U$:=+!,#:4^3T=Q)6A+_:-8'KZ(U+##&6?TW";WR%9H0
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M*W_4LIFS9DAEYY%^+W(AJZ.E.H+24CEUPT_S%EW80;%5IR1J'Y-2I.)1B/-
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M$MS=G> VN 4(W#QOW;NW:G<_O+NGZU_]X9SJZE^?ZM-=W<\+SQL 0HB\DCP
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MX\[:7X-4'^*]P+7:V%IJ_E99SN)4O=+3/R%2>MO,DEDLE0IU+&>][4>OY94
M%D3JTQ.>#43H&PE+<Y(6H5E:)FZ610_')*5 UWYX^]X[C!)1>W+M]PK3;VC-
MX\WENNWJBMM*6J8Q1IY.HT86&PTZUWNF;XFLNBWK/7P4%02A<+\-V9W%Z3K3
M!X5!=\8SGP$:L0=Z%?VZGGJ1W0TA%RE\"L<ASX"^UFG]L\(&_";!6@-E=U %
M1+$U'.G4)#%-%>Y,N?06"25$?TR*A6Q[WNN^<2X_WC R+H 9>$JW7#N!?57%
M!U_2H1-5:;!C\6L/L0.'AEC9N3WL1C!6N&?!I ILM?W(4Z\>K)LH,WH*WSS-
MB?ZQ[[6]E? 1KU_0]MOB7Q@S?088$![?;Y9I$E)!JE#I,<$'?+1!%,)[Q^<2
MEZCQZ$S;SDMN;HI7)12*C=\,@%Q?AQKX!T8B0Z+K'PL4;M48,CT(E[N=\V6(
MY0E '%N"S.8E//ENMZ($M8>Z0C6&*D6U5)742O.NVE9(T$_[BJ,N^WW;=G&]
M7C0* OK10:)C8K2W6V0Y<EIV%RTK]D)_+TYU;&RY$8#_K*UVH'V\71JNB1:1
M^"C/SXL^6E:ZU^"CQ+/ 2(^#$]6TST;LTH-AH1;]WRDI=]MDM*:/X6!)99@T
M6?)*= _]P@D8SP<]90O'A<#^G5!*OG1]V;+>0,_0$,%M,T$AIS:]KS.G^T2W
M@=:*EO/DZC/ YK"!.WV@=2W@>-KI_<-.8%\:#ZM#M[5Y SOUXRB2^+N)#]]7
M#YN7N*J[#ARW&%]<S,1Z2F3_U/B0DDQ^WDVSE!\#I6OEB]>[CU<[,A'7F35:
M-3[@?-]@%GW19AQTK^V3:YKG35,]!K:K:L?'PY%G:8JK(><,>VS*4R)\!N 4
M,S4QD!PD-^,8'*:9/0B.IU$,RW3'/.HJX[:)5KCWQ(/H05.5+EIMP:[> ^_2
MFJ-%R#[M:I=EI1VLJ\3,L?#B.G>C)1*#L4@/AR)[FB5NE9SH+@0J7/,P,,X/
M#. 3^5DC&YFB;QZ&.N5(M0G)ANU3? O+H4+I-LYS-X?+5IEW Q69&6REM2I9
MUYDJVA7TH^/2T6UE!K!$STG8#)V:^\JL_C(KF;F=?6GPJ=$%C&A5E8--DU79
MQN\# 1N5-OA@<GG%?FZHRY =<HU' ^R#\>/+"6T;=8(TRT[Q*I7H2/ED%C)N
M2FRF/= ]FNJ3V?.!X>9_EJMNG\@?[9BWAYL-5IFRBGPJ[_P4&UM>F[#-1_<H
MYJU+4&]+\&W"Y /)#6C&>8Y7($21/2VA?B4H0+*635[:]P?09X"UFAEN3?/C
MDR\A]CW9N)2Z_7IW"XQ$7<D#4Z"WH2.H7GA$7UY!>QQR_?)<O0#F<2*[SBT*
M@9H47U&SY<;MA)!JZ0IC.3AP]S1=;$HC8E_SVR(;<)3,,.HA\D&(IK[N6(VL
M0&SY&01J@+EJ?,6US$Z5([F$#>FQI(YA;BF>ZF1E_"B+;NHGVA<8E$?9D$3C
M9:K'("A1^I//*4T'APX.OSU'8T>=[6+O##,APOH2'>E*@.9!+IQ96#ULY1?M
MP,O^A4G36BX-]3\5R^.$L%Q>D:M8[]7?FMR(/*ZHAI=)4;\&H!?9@1#DD:R(
M,15WM62%&)J0I'CMD&#:7V$#CQSZ'LHBJR3C"M:),I]?1%2/8TSG%%E+ZBXT
MR<F1C9#4EKU3>"$3BOT3(7FM0V<^Y3=;%U4=ESI#ZPJ!G012<_'HO,^M,>SQ
M=4L_WZT_PL 20VS;4 )GW!4E%&QN"C_F;V!%T9O%;O,3_!JE+?.//W:85%\R
MEO-SH!OA_K9M/*1"&KZ0^/$-JB5];FM>;P#QQ*,HTR'QJ.NY"NN@=2-:K*:P
M)]D1V=A=1]?1)DR2+=F%Q9NRSEE> ?SFQ^>RT;-K4=8?-8>F=NW@I_F&![+D
M+*<3LM?:XZD75S2O:;/+[=Z8^1$/>GBXUC=1Q>MT#RC,Y_Y!@Y(+)Z\3P ?C
M99\FVA;(1FS,90E$J X=RNO:6L^#"U8P@7",/+=BA<K;]*L*1VU.20^OA=,=
MC3MBC1,EYW8MMU4CH^9.]C\#C0&*UX]VQM!034R)8/&I0_)Z*(F]Y26K67ID
M:LQ;NS]8^X \Q(L3TX:(*;G@U[+.CY9(\_1)7;-U5B9/%PRD"T<ZM#+N6!'>
M<XK+I54#I3726E<"LW$IY0)+D_%;,(V0BL4%NZ7"1$VTX.F15:X(T3&80UEV
M3[-V:X!E2M7&,\"C@6% FVH.9P!7F*@L+FN$(X,:/18W?6Y2[UZ<G*&<*"'2
MOTTE_V V2MMP-4#*9Z;?B[8:5%W%ML&?K6Y'O5G[N5,+[2?*1PQ["R._N;69
MS1N#%%#V6JFRX.O+O0*%4'=]B)=@M+@SN\6+(BRG'"CI)9?C5M1Y_UP\[&9.
MTX@)@^U5L'>A,N\I4[RR4XI&C+FSCO>X<5'3J49U0>6^6%>/ M  5J'G[/K6
MI<7M;7NC! -4B;GW&1!*=)(?;3#JIL?S-O#+!ZD"O10%PQ;MIJELOC_7D9X
MR>+ ST])HP[TX/!RG@_*1Q@9IKT"$9T$.X=X']1S=T#E#AZRJ^-.?A4=\U=1
MJ\J&4ZTN9<MR[DX\V9P,'.(AKAM[W\V"UMM\WX<^"MO]^H%>7V\=E]F@!+RV
M,!(."6#HAX*S*I:"QZWBN&R+983$T*\Z*S4K(7GO<56-WFZ6JZ9/_#TP!K:P
MRXL-!7?3/1S+R K#\U"O4*.TT]BH/;U$FSZT08PE%WG\HQ9+EEX,\DC4M#WL
MEBS<N5TXT.BF##18A:(N4G]5U*1,?@8XP#U)M=U?J3F ZD17>=\TU<QP%WQ=
M]O$\8$*/5O01IMUI.YCR#I!QF\[KB4^?=@4MQY/VZ3)D?B#5&.E%,/ME9-"3
M-^&_G9)]\_*$"L0G#\J"N4_E)W3KLDT)<-MWKKD"DY2T]&D88Z'&<J3N? ]V
MM!Y%7RI&5ZIV!2,XPU:,Q!CXZBO/'K0B?QD6ZG^NE?5?F*4IP94)'1.'+C4O
ML>V9(?+=:[U];9H;^03XNKE'W(/S<(6*40-2BS?/KN<7$ BZ<@VG;4WF<$4O
MP,O!V[W+T0\S_\S,TLS6E[;9<GG7TCS.!S*@-O(J2P%28)=_J*[L(H!#&#^Y
M]U8E0[',C=*\N91MUPQAY;DX^-Y;WF&!Q]+P<\2%80+/-08:_DK.]4&O[>*=
M+XY#>N3P1^MO*Q+GT=NE>T7#TY+737*T(W3Z@@ZIS6AU]<T"?&,%(/,I?H9?
M*[W5=S:D.DEDO)HT+8T:<J28EZ=D_A()NK/;,XZ5P"^CG4G,FJXP><[TJO/A
M.^>9 P./,A<7DI=VVZQ^]3ZF8C T/W9 ,(&,B4?)(U^M< I%B0_'TN-4'9(;
M3!%C"AZ58%0K7CP?E<)MG-PWEE#0=\/^PZ31TN,RR6@;(.\E7/*DC4NR8J][
M,>B<8^E**H[/&'OP9VN>;/=TB\[<.D9*RBDW2;L>YP*-#J/--VGT)C/_@-/!
M"4K9YL' ;M8!I>):5U5QG>L6\_.7"I]D%NGPTP>W@#2"S.N$XT^3K>QD-9"]
M!*(P1![MSAJS)BN8W^#W<?S,0B<HUYOFENPU]1!/ EK*=M'<Z58$E 5FZDXC
MVI<!,="G:$?<>(+?!^S;GXXYD^3V6Z('Q=M7Y8A<U/=EV*E0O0I_.X/M1<S]
M1B77QJBPT3Z.<E:J\WL6WT\-S%.0UT\N2R[*=61S^N$#'E74E)/FYAFJ#V2Y
M[!IXP?V)CNMVAH%UC4^WN<\ ,?W<^)L=J[JOG\BJ,BEJB7T9?IIGMN"8-.-K
M1ZE649%"NE^\&B2-6_7QB@=-)#4H$*4&/93!8!AM7#IGAPTI^%\<X*UNTG\F
MFY[@/"EL+>W-P9M\Z6']J0P/#A<-=]-*JWHJ^9GW3&V9B56=;G/;@R!-?B/#
MZH$X-<98F4\Z=0DNI09T0NXMPU3AXW@-U?118M25I-VOY_Q;#J0-JS MW:,J
MSZKO/PB.>Y_J.O%JPU/D,Q3V<A)'B5!)IF./[G1FV(:<]'T$V$W<=DY++9L[
MPD_]J4J5S) 57/5<G+9#]G)^[L,<.(:[";9\BF;+*H!P_K<!D[@?Z_LEXHL:
M!?XP0-(WL4<%$9,Q-Q,</K_X0>\R4$[XYMJ W0%T]6=KJ3>*=/G63A>*J_H_
M)J,LY"6J5R+@28)%_3,->0=QMDLJ;9^Y]%\8M\3J@$=-<B/&W4>=&CQ)->20
M_^W_%DQ4TXN_O6BX/U9.Y"!O3FUO/U>8X3;!PM:1B<222>G28)V#_NCO%%0R
M4>ZLOVM\)4=)-29Z70[4*+\6*S$O4KV=N<@,W"2II>.GT?;.,:T9,D27;G,%
MOS)^FY:58K:Q#Z* ]CF;C5@MHPU[B#PZ<&K=&>.=5#+/MOT.7=/E.4\<U/3=
MF'^UE8V_KF]_CN-G5U"E1\SI5JK'AD)Y(YJ_/Y4^[4?W\D/1,&:+!QA%(<CB
M[+KWHHI)RUI3S D%.:$[^92[8*0'Y:),9I]":F0^TUZM8C^+<+J,Q:Y\H]$'
MQ!F/2?5+K:B"PQBC9ZD]\Y?*NP&N\[SO2M]LAJU%I K,JSSMBG)YU!-S6+).
MK\7'<?NF!?8J!N(E8?PS[0Q1%2509U5<C<1'LH7 $%=)O'.6<J<2%1<2P9]I
M6#06N)E#^24,L9=ET<)&L[GSFRT1NS;-\2ZI[K>#$L'@ QDT9H>VB$Q1R#OC
M8U_CMM68V,V&VJ:6",;E).UO^#2[[V?B].FYSCF\ WM-%WIJ(#F6B20A@Y3]
MFYQ)Y_0A9;%$JUAE>VE*VUPQQ7HBDJ$M.)6AE_9I =D"#5ER]X9E7C2A&PL'
M=W/5W9K!1DO7S$-$]F[)AR-[K18E1MY9PVJS&PU?#7+K-!EI6IM>C06T_=#]
MN4:B\EZVB;JW-M*"4:AG1X^6KA<62[9VY_7Z4W<S1*]K5U59O.IAQ'<.;GMH
M-TR2[/U#8;'3;C+U7C[2+&<)EM:%1$V2+#IH<:ABJR%GN3HFO^SUSP,#XW_S
MRO7O"+D-$5*8YVS:VA#C'2MN:101+@ 3XP8?$P^AU4%#PQB7 NHT5(_]QQV2
MZBKQ;.]!E3S9EE\'MM N]+:F01E:D[8&6L)]-V#)51ZE\6^$-I(=!FRYQ\YN
MSHBTOSN 23J"[3OR_U $SXO_!U!+ P04    " "&.&Y4;T7T>_16   49
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MTQ_N?CO*\:O=01- K[Y XX^(?YRW"X'[\Z5\7_>:%_IR%76XKY'"VG=?B?F
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MQ 5;4?,MCM:!0DT50STW"H&M;]&(XS/Y;SN66A@GF]KI'_3H<XM1>UKC =1
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MHK4?$THQAGK>6FZ,SJ\9=;.C4%*Q=A!?_#:/^H+*1+JQ%>64F56PYVD_6;K
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M^'XVV/WNE<HKLS>:I8'F[D58MM(9+=%KS@_4M$XH!DCBHJ1Y@7=5>+1X;,D
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MZ05SSKWX6JYY-K_HY=?0#M/@Y-KR:W<EIU2_F']X[M+IE9>J^:73LY<.SKW
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M37#]MS=_OQLBYS2A>=>1:(_X1<: 7DZ0FF3OHW*4!I7.(_)71U ;K?FQDAO
MY(*&O/C. I)6JN#<Q/ I0KCR]HD8EUV(6H<L4E_,Y45&(=(4%7P,",8RLEDR
MDABAD@TZ^9C936"L:(L2::C.<E$.5+N *#/9@J"#)D$'010+*7B'$BK.D^IH
M51W"+$AD;SQ$+_N/\64-]YC+<((#8QS!)%=('YZ1%T)R) #B+I#1HX-XD3[%
MH1O,P=;&*!5!1UK *"+G+9/5F @*(GIN@G*+&%7B*H1 ?K/.4"VRYBI?P6J?
M!\6#1<PPAPJ(CR\OXU$IP@ D0SHHCOLFH[/HE2MT7Q GZ1 A&Y W1U4Z]IK,
M[>S%E;#$48>@3>'H&*$B1+_(&D0AZ/0E#\GH1,];STEWL[.1E+?OWMP80.'N
M)R'-3Y:KNR(C%GQ*J)PIUT@XR.BP\9P)S\@T0CHK3+IYQ5=B]'N'C!X"[JQ
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MB9,R=(V+!&-,TU0M/J\F3::"HV'GN5/H5I*<$R,REP8;@,C#^IB\\CY[4:V
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MD1,:T2'6(I(@(SICHDRI] H(Y;:,?M$@1+4'!'?*4OP+C- 0#5'9;:3]P6B
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MNYA?.A8\N@H-SBCY-DT^'"3<0-2'FMXV6&DUR2P%%5F:1#@W9=1!YJ6[*26
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M"F*M3T0XX07U@6FH%G!6UF;R=<&S "L3!1/:<E5J,9',I2&)+!/5(A 7&8<
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M^N^^_>S;,EWCD3K/+FAP&?-,R#+?(FE#I$4_W>'O)'/0$H)4,5?K]%55?K.
ML%\U3&*2YM'(TLHA(I,DY ^G,B>.*1$45^B\5.MSUA DOX#5&+T[5NMK1C,%
M9KU!O9N,SJ7I%]K6T"5!AFBX"X'5VS2ZYK+]/CMA*C#)(HFT2&@I-0CB(V(@
M"0F%36O+=+5)(W>7LC_FA4_C]G"!X>P*G*-DK3.EZ"4&[]&P>D>"*OE<J$MM
M2$)'56WLN\8N>PNJ"W<4S5DH ;ABV?#FQ);$8!8%93EXXV'A5%H-?K:):[#"
M((ZGCDCG+ DYH.\?O38Z:>WJC=WTVO_Z[CIQ<6/Y5E,E>FDB\PJ(@L2(].5
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MJV L)YR7:G*/)+20)4DV&GQ20 ]XU5L&?E>H[%Q?CP>-LA+1&OQ?F2\2B;1
M2]/61!P8\#)S)UFU>:%KJ_Q8H0<N% 0.G$@C#6)W6;*' 8B.D8+R5D"LMK5(
M51'-7N>:9YI#R$0HKDH7V$2L,(8H4$(X!H;;:B6WMF:8B\&R(7!9IL^3E#7B
MIB@%\5I%HJQ/05 ;DZO6XUF0W;OS\Y<X*;+7HZ"(%M2S3*PO?>L-=/G%@6@1
MF*7&&,VJ[>)S1R'=AJD?C""]]NT(*;8R^C,%@V:+.Z)<+,V$I2,NV]*X7L8,
M 3QZH;629OF>YK<?!E'7TX"FTOI3LVR)]HB(I16<!*$,R1F8D,E*\-7&N*^N
M5CI#T$U<:NOC='?\'MH\;O??C-NNV&)RY42""_3>A79_P06_\]#PG:=RB9X<
M6?1*LA4:RBB?DN;I-'&4!9)#M"C#E"51K=3>E%ET?,TKO (M7]P<SY !GF9*
MD4 O,Z2H24K1(G)%<&2I-T0(JGQ0/L=ZBVXJT[S+(2#W@EF'[F"DLF2""8;B
MB#@W!A&D28*+>ONY5M7T]SOI3 I1:&J=)Q9$+,UC+?$L&#3<)DC$8!QU>;7\
MLNI!II69QP9*6@Z)DV1MT2KXDS=H%F)@B4L'(M0;T.B[!.L[ I++:B;IA7#.
M("ZE =T_-&+$!560B&0T"N.A7A#RE'O% P7%$^4DET,JZ0NV$%$1;4 QHX7P
MMMJ@V5T ?A=50>*5+A;#_YBU@TD:Q,6DH%<@9<IET, 44K-+V.1 @BX9::S,
MQT:8F.MM.U)7_]W%(#.?2Z6.I 12T8*I:$'K$=@7PG%JJ*MW!FH%>8*5'0I_
M.U?,1H,Y2WSX>#!K3YVW_0[<PF]']\ ?CV]P_,GQ[^4.5]QM\L\\O72WV;1]
M63ZX[[WV? N3:]YM_N$][UA:=A?:(#F1C!O[N$?1OQH/A[Z=[)0;GCPL#3XC
MSYZ]Q3OT!;I!!!??9S 92\X,^@:O;GJ=2]\O?WP%H_$^>AQ7W/:NRSQWBQ?G
MW_[FW=B9,]ZE#3XZ?ND^O.<&%Z?)#Z^_Z^GG]Z7<SJM+=[SCQO_VR^#KR[9,
M:2N5U'N#@V8X&/UC>SP\K\'*%YZ/VT\O.*7B18L?ORC7/6L0;K<W7WQTQ8N,
MN)OD\7@Z0J?P63,=;T.>_/KLS;O=CUR:B'K7$5-JN*0I,SPC^L7">2M$M"DF
M^ZS)[7C_Z#L?G:4<;#?.3'LB=30DJ%CZ.N?L+<O2>=Z\^9B!*N%")"I1U.C
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MEN/UW:7XI?(61_<IC5,GW4MT+^DGT\;1)OG#R?.^86N.CF8K25+&$BF,(,$
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M^ HI^C^OF"WYZF0AG4.P,?+#P\F@<P3>G$R.W!R/TGR@;+D&S<5L..TNV3J
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M22_K^.@,-90/BR3G@6>;()()X!8NSI'@:5;4ZY99PBA,JO"M/-W2>=_QA7#
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M(&I<23JQMEVA/2D\QN$KBR"QGBS*>H85L8^R+M,J\%#VC62*C!P=^(U9,_W
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MBCI]+8G5;U8IWT@31ZV8VMDCN-,)]Z(6.F$AZE )6G[2J.%G,&!C#0W\)*,
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MV7]]1S^</#AY>/+H^/C1;P^/?E\OOL-@R.$_6#0#-TW2G]8?G^C*3NZ?T3\
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MIJDY1*^U/ *(\1BVX"H'Q:?+-A7)HFH;]=T[/!M@:'?2X"]SDL&'-UHZ.;3
MFH?<L5R^UN *B"NAA3B\5]DY\9<'.>\'IB!'.3G8GB*L'&)?59MHI<YP<XV
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M"_CFY10*YV"H+7<+&6N[&M^?94.@HP;$ H<S5;;H.;4REI#ZH\?\89B!,(P
M*0G5*<'+ 0=7WNOP;)X[YL9.I/Z'W9HQ:C-&#T;X:0 _?33"3T?XZ0@_'>&G
M9Z<[X:>G@\0) ?ST]/$UI7B?F]N\PVR4GY,R_/T:>X5=P<!JN4..V==6?+\F
ME[#GLQI @KR^8!"71/+HT<NM I^*+#;)PV5@VDC\3FW?*.4(EDF!3_E\HT43
MHIPFH@%!E$.B?T RD!MQ42ZY.94/%4_^W__GX]G)Z;TG?".+\H;CAH_4#2+S
MB,*X7H>AEP.*W4 ?!YX-0#(0M^GM/J,UXT*IU38(,E]L9U4^GZ3)1NH< ;B\
M+J S$*9!0 ;1$DYN%,VDV!FOV?]^/1?K^]F*MN,DS:N4W, ?)(D80N#:PMQ5
M6?2(<4(@W,5 !&DX$OJ]#PK]<)>-Y+]&4!R$*??GO>H.97RV4QF?#2GC1T%=
M_/W3'\=:D$\ K&LO0$NC"D!-Y+V&ACB"X\-+W'$"@MH8B,LJ:SBU5^7UA_JG
MD%<0_9PT)(QH!'^E62)IB%VF'I+R[/4Y!ZAV2MJ=TA&/<?*'7\"0=?RP[8Z'
MC4+HCAF&;X9*E-;MJLDW"B:OOWRCGV\G*/+C&!2Y>YKTD':0\OS.4:U7;B"-
M?6$'5_,+R)H&UU:D#9!)]2EUY %H?HXGOY97&;<57)(1+3:R +D_TB_EA+-9
MBJM(-^3<G893*>?OGO[/LS[TL8;#X7XI!7Y%ML@;8=8*VN%RD\4)&>(9]V02
M/'6'LTW,<0&++XUK/63\?WQRA&X[^^LI8?TOD"X1*'H)<O,5F.DY?>IL=F8Z
M/^(R&7N!H?I&0?Z=A-VVDN!9GH)"V@W7D]/IY-X)Z^&')_P"KEJL1TA/^EO2
M1;.<2>_=+>Y/)_<?\CT>/9#23O=3QY"O[8T?G]S [PF['5D%J&>H=^.ZU+X'
MNHG4];&YD!4*NR6=/?[.-4"B(=][Z/Z\_W Z>7#/_?GH ;_$ __[QR>[.&<T
MZ[5<HMF %A)L:)M@[WA%9 UF0MN'ALW\>LQQKUZCY\"/&CKQP_=5 49T&4'!
ME?<(>2B'VACF&F?@WDYGX-YUSL#9CW?/&1CUU%^II_R9=L>9XS=,N@.8BAX@
M+XH_9%M2%0#@)TLYWE(^";W6XY5B+VE0OQW\:3S0E,*!6).'YA)Y)<_5I'63
M;49BX4-8U%O*(PZR@'B+C9^<)4Z5+5&+#6Z]' ZCD%Z)C0/9].+9^>0R3_C?
M+U^_?_[V_.E[DC.H:<WKM9!M9"LNTZ81OGS]C+[,&M=TR6Y!)M;_;5?;R=G)
MV:EGZ,!8A@>@QK8$BKD>D80=O701_CYIFPN.NRL#,M]37@Q6,@WF*"N0@T#K
M4Z6SC7("/!+I^"-)"7@ : Q%-G/=SM9Y75LLY^G[<S:AK=![:#A+8#0MO%_@
M^1;QTBD0F##L>!KK:L&6X\G9V53M*L$VZ@M88;F9]^KPL(^ EXB]DE^S%[^.
ML:9#/X/OVMF_=:_-\SIM>7N9%=#@1PI:E44=V%L"6M<=:TUC="N0';%1ZC]M
MV0L'J*JQ"D<<Z)Q.WES 33CUVTJ>&GF-5_EJ!7J:.--SGURY.6CR^ALO++*(
MOT4?GF>OWD[6;:-4@NP^\PFA+QQA-)P/^M>RQ%A J8B179 PV&SY9+LWMFFB
M&>33#IJ0358<K1(RMFSRN$! JF]\WV)VA#4VD-1IQGR>0@Z1EA?<4TPE%BY
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M8OEO! [9C<(Z?_W+F_>O[F&'+JMD_:=9MM?CP$8=>K.Z3)6/D>^KJP=M(FI
MX 7,&%4H0W1;,5"9#["M.M\DIIBUK[C"#RZY4\1LD:$K.D0FDVH@R9@O5UNR
M"_,Y0IQ-0NM.IK$4?*E@5^--0JINI&*"K[9.6_LH,#WGUQ*:5>J^$B6]BU7R
MZ13=*YQVT)?X@VY+[_X.%8TD+M]Y.KLR+&GMU@5<^=&R\)<B@$'S4PO<.N=&
M.,#@'%[E8,Q.Z@OHCUFVQ5KA;6)=AN>'&"&Q#*#B$#TO,@1I?=3<:8U_8JZ"
M*:]]K]%1TMZ%#.#C,0,X1E8_9P?]L6I4 O;3<$-R">*$S>P9VH-FBW8EBJ%$
M0A]9E;S^P")8?9-:@AF7-.4)8^PT;V4"5ILR!>[6718\W\:>^7U(7]43;JG*
MMH%9 .C.4&YH@^7_%4^Z1BB^YW5$BIP]CK;)T56"]LXOR>KU>7JT+N=2Z_;J
M]1OR/])D4YM'1/.R9CQ1D99S_>#\Y^=*2+#$5X)JM-KRT%CQH2[5R=* :5/E
M9'M46\D8^+JLMI*X6L&6AK]$1BGX5X7E:C6='2BDV=G5K=M<.V*[' 3 JG$<
M /H]\(W_5#T?FE;B4G-^Q%LH*=T@GX-B4DRK8+$D." QPN$0X>Y W5U*JQQ:
M$L&V,(M7V=UC#N$ UO2V'7TBO^DBJ3D@)3&6=4:K.I<5+N@]<=3HV*US =X+
M3IL#1<#> +M.WAG#8;)UGDB%?B"D$2Z:R,FE@X\;KYA](_N8KEKPK01BFT$*
M>!X(S%CV<:"'0:%HU'<\>=DP3P8'1#ML&<DG.7B(5Y7M\H)G D0^)C\8E,%]
MAUCD2N-N$3 54@? $^9IIOVYRZOP@5/^()9[S/Z(GP4QM472(.:4YO-:YFW-
M20FC0B]C'S>83*8Q<N3B O @0T9_0/_FOHVTY;1G4ZG"L*T6B0!"I/'A)8H7
M5DY87F1)U4PG]0>:?CI9DW5;I]K6:)'XQH!55F_0LTD3.K(^,/CG .UPX)"6
MKTH4>Q*^<30GQ[U7PTY4(R\K% 3$P*:E4 V+7IEMN13%LE<\K'F920!:.JCC
MC3EF3>J>AEM+ QPCJ,Y]]QG+[?C;T=WEAQ+QM&?7\O#12#QT\?:K%0^%QWD:
MX.[0,*SE5 (Z%]53YDNMI.$][Z6A4[\JZQK,4NYP6C+$'9Y(I&HS(OJ*)JLB
MF;K:\NGWW9&BDQ#&TP$N.9IS:= V.M:1@*%C]ROOQ\D[%R%WLJO[0@U3$G&S
MM:+T3-3)'!V=^-BO.$U;>,XD![&+;$0R]_SD<$F0O;7-R_'D15OA>>NRTIZG
ME_F\I4/M$K-Z*9-YO?[E_1N;,S>U/- %T@B,NDS+BHQ*I,]PWQ(BB6:$UI:,
M1R[Y\OD+6EKW:SRNE5@_K-XU#,?-Q9:G[NE[DG(I4FEA$1,303$9L)0$R,8B
MT;">T3R1A+Y"*9L(F$ZF;D![1*^>5-56:K\4$,K;AY^UX42#S2,I45J&IE(V
MJZ21M @0IR7S=_9F7)4K*'\YH[0D'4)RS1"NG,";W+O_'6^N^Z??:<8)_O*4
M1;E<"#\\G(QP^+A)V4H!F3W>[?_CR5,D9=Q-E-'(&L]6)6"(<ZC-$O6$!DID
M5SVT)@,H*^<,LQ83&M@;L:$AN2?V0MCU_UO$#[\-"?V;U6&$"^W[+ 9>LVT0
M=I39)O"N+PIV*DN!1IPV/N1MQBLV'1T8%DQHU0ROTA+L R[-\>3Y95XD*6F2
MF>0/UN>S@6%I#[RZ8ZY(<QLQ;>6P>>D>&X4[''!$V@$%89M0DOWW@L1F%@QN
M\ :1$$DF]Q]_YX\'PQ'=<)+)@Y/.EQVSE8'M9_>U\4<H(4C\IMFL/)[\;&$*
M#Y&<AH/4]@?2;UJ+O!1+PTBBP<1)_[7&@WWH!QO;5?:6*XR0LX %#3:$.S*Q
MMN/8KD21+J6A*P>#%P/=E+B!#LSR(X[L#2!AXOU390MD_@'"8342V%)0)F0#
MMOQ$'#L3(>ODW\"EL7I.$ZYQY+I'JX.,WXD!"=%  5=1D<,'+)M[_^7!P^^&
MSU)0:#G5PLF\N$2_W&6BP36N)1F2DCO$83P3H=<>'G6H5%A&,!H\$.BRI>U5
MDI%8L#N9D()&U3KY=;0)RZ(E6XQ,L;F)\NW0J"#UKH"5 BZ&S=0<L5$-Y0V]
M")M]YU557ET@DDL2D/9@RGH"YLCWYV]_/Z+?WOLAC%4^7^635_EJ=;?;T]]=
M0?$ERS7S;(0F'\*:?D))G[%YH)#![#SD3H*6Q@8KG%SF],(PF"QXO\<" $(,
M]V ?")B*X.B[!P55XYQ_00Z(710N%O=[C*LXE)Y5<R))DTEIFF(Z8:JX@C/I
M1&@N,4,RK8;JIX,0-N2KV;-I_*1-MC\M5MG'&^S"?[<U*)B/X/1B-^,R*-6J
M><)[[8A&O:Y_0BH*UP[NS#5](+558&YZ_-VA;M7N*;.IR@N>%IZQ6]U@S^3U
MY@08@8_(/SF4P,"BR4@.9;YLMW5@0TF4J=1$J=?BM.P"/$(B$D0Q9-#((0.0
MF$0!4K;)ANL!T/Q,LI$2'0GK'S4R:Z6+/NZB<7% CY&VV.#'H'YOV:%"5%Y.
MLH1QD9]TL8755O$#/!X6-P-0:/' R.5XXL\9+9;^_WC>QO/VYYXW.E[E M%F
M>D]FQ&9]95UWA#V?.:Q\_L3*M@,U&WA7.%P/R=&_@ML3EPY/)X\?A!$ ]-$-
M+/>']SM?=L(##=OV$AR06($+<3IE/IZB\11]#:W55L8D_27.3^(/1A0O>_SP
MNWZ".?H%S:.TBL1IH?]H<410AC]P9,*&,N.Q&8_-UU<^7&\Z@$$#3?RZG LM
M!<>?C>>PNZO9<HM"09%7J(CT >.2T7 >N18"1(]<O^K0=HR/[HYS-&*\]VZ$
M>R<CQOMZC/<HC#]%&%_F=2ZZ^:>+G-S#OUP\WSFQ'!<-/2:S_/OB?R,"3G;"
MXT?V5V2J"\:K@['JYOP%;J=7L0,M20H2QD665"A0.CE9+_\Y?V4 *D[G%5T*
MV<B)X "^;=SCVXC?3^4#O[LQUL^)3S_+Z[04.AE:QB"QK9PS8Q#] !;X-J><
M%NT(_#\<EG8X_3@25D^ K4(Q\VJ5%4MCG>[# +A6G).9J!7W#!/2/!PEEFUF
M]UXD5A0QSQ9Y2K=*'2Z7@90,T2H7\%_F%0VDEF?08R_*S<6VSKG\0.1)NVF2
M#YDC/G(@7O<"6GR#:LX+H&\;3?X:&)=+=^8ER>V$0<D8P5$ O**'7C%#=A%U
M]YQM-XGT5),Q7S&#VBSKY6V323]<6<I@)6Q95A_J8#0NS&A4MDJ),&8:#_U
M696-=)YDRL!YX+O<(I2-9M<SP*[3LMJ4E6;7==L<6R6.7%%/9KGL*=YY-8VE
M1'# 83EM0]4,1SQ_]\N;M],^#-[#GBQBG147#*MVHH$V,Z?3ZTA(',LM<=24
M:UYQT!X@I=V@&1R1@,L2==6EA-I!C=PVH$Z@$]@:USWS#R)PGVIS+A54=MR[
MQSR.V(_'Y8X<EY"@M,],J@D6*S-#PK=H\BKCB( HCB;0&VZC\SYGH7STSR/-
MT:"*HIIG5= $0D1UR,"Q(R+@O'XY?5W*4,;ZYJFE<+OR'W]'!W92VN;E!)5R
MBLZ'6ZCK;G9OPI5L07:89F9HE"J(M)+?H; Y-R7*]BI?S8^:[2:;R@/^/WV
M,>T$C[Q##9C^BJ+J.]1&Z/Y.LM+[ V2E]Q\\]F2E]QX]O'-DI0<@T0!+052
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MD7#?<PCJ ]W].-\CD(,.*W%?TW/T,8G&*-Y[8 $XPA(-</9#'JQQH\VFKD;
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M^(F2Y?@NSD6;KKB%:D]?R A$A)WVJD$&M:MTM8U$W2ATKMU/SR_S(AGVHKR
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M<W6P_!XY#V@IH]%8K[G*KDE;.$T$?%\"4^"R7%UFBO[^.%EE2R[?B9'J7-N
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M)BJYD9:PH>BS:R-J=;&+G-;2$5AY2AT769B!'EB?6= C.!9J5;X=NG(N<>8
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M8:'V;>Q'VQ,2"<KF,6IE&/LXB",U#N8Z; +9W^=LYGBGB@T<%XA9,5>] D^
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M6AZY)^"NOR5U34J%5'U#5_F#3$?U?1#YIC'\]O*]A)AY*3_MB9C=MV7Z(5L
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M-?S.0$\8E)J@/578$<#)CF'4\LZHS&)*(YU ?K7IQ N11*:PAODK,&5#=P5
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MD!>-U=EUA&^^_C+1J> Y6&"$I *:"\]-WV^I/% SHZVPK]@+&68LV#4 ?O
M6(BF][;MJ'?VCF:=IW?3V].XM@SMZE8<T! Y""O/D3N0=U0.MG/MO]@N*KT
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M_O]X-,:C\><>C9@1CZM8PA"(&+#I+[^]":!,4U=" =-4O6/E6N:/(F9X-K4
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M*1PCIHL+(8<"RN^@T[OOV <FZ@\YO-("5<743)84:.LF O=K.5ZO,F"7HN_
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M88!=E9O5X:!^=G6IS.EMPTK& BQN>&Z2LAX.!:T,&-Z(&4"5-1U+E+J-TOK
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ML#>NF)O0ADZ0/B49U0<G@+M,2#8#@V)!*-<0:\Y;IE[U@O/G9Z>SEX/)X?*
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MDW'4O\XC.'),? AB[(4_;+[[G[,CY>3]C:26!<:)C?M5!4;% )?LIS+6P=+
MH^YQ%LM754YZ3H.2J2;]ER8#AOW-5#<14E.0@U4OA%0)[%A6=)[XF&6_R\AX
MF?:/DN71*^BW-#X%#< J!K!X[&"M3B2RJ89$/Q,>9:):S1^9[\R;1*BDR6SG
M;6JL)3 6@LL7(HMMQ544O \IQ2CB-QO-*#LU\/_H %KE)2D!L+\.(UG.*]4A
M$YHF5<1*_. T7 ^6D9'M-C P<?4M]SDT+3-02^3!83"^$-](]'-IF'1V"L!H
M3H]A[JDH1(IH;6Q[L 8-+BZG>$'.\S0K*XD<K<EO(]E3!QN,;"AA<U&&?"BK
M>VT-01]UE[<WS>'-M&?+I,#!T9K/4T&]7PZAN:Z:&R)53RM_ X8YPF35EU4A
M<0"GM_1R R8:IC29Q .09SJ)*B';I1 _8G*[R1DV:+K3884W;<>;[CQ89I3$
MPLV??O/-USR<BERRRA?4D(@IIY \X8G4P 5?Z?\+#_W_.^\LBP 4DXV"(5H4
M\N6EQ7:42/L-[T\IX58E30VXS]70/FKF: !91D9><@Y108>Y22[T6!"_!C3=
MORXRB_2L5(GKX6%@5'4(4LT42<')L\;54 &)7,9JIF3RJOP&UNFR#AN)O<64
MMDV7&VG]E;4LM,GYG-T^G[PBIR8T@?LRCA=!*CTU%50);<,UV7@34>I-P&,'
M9A;0E>"9%4 =$SPL;B:A6AR00Z[Z%IY".#HJ.=;@C9NZE0GG&H#(;CWU/N@)
MAD.*Y!*[8FN43S+/.I('W-AR/&<<=D9SB+$_*5$O%HD[85%VC0,I1_%$+FF0
MW\HH.9#7@KQP11UMS1P1-0WZ8:>J"8.:%0,'BY+QFK/S-_\S\[UMX5LL;XI"
M0 MF3QP6B7><JDZYXI%Y84!()WYXKE8&M8/W&Q7<T(2&SV!$6\6Y#,*+<O#?
MR6&E)XA\_R0R' 2SZ-(0I5+;1GQ&S)7-FR5*([:1'=7;L,=AJC6@C'UOS.FI
M)VER?Z2%_" XKEEI@<16";.?0F3%U6S@C%8[:?/EDQW#"*X#&VB=&AVL)&XJ
MT3CAFA=P+'Q_8=4C#]L@Y]O(IDK-KW NZ'$Q(5<B!1NVDS2F#!::32 ML8_8
MJ'TZ*)>G1Y3+$>7R(2LHC"Y\O1$R9SHIJI.;IJV6$QEFT\QINNV)6)"N0%?(
M\R1WPUG<O Y+4'0O&RW9^*PX?R(F9W%(P \<@CFVJ3F.YY9J>Q;Y6N 5X4-K
MLH0YF"^793!IO8$H?1'.\7K77(+4PTC:N9BDH<CL/.+TQIP.>TL_HV+M/''?
MVL!M$#]/#'5+!3"5+QBX#T)L$&:VUE[S!OXSQ+S>X1M:+CN6=^[A \))TIC<
M99I4.G:WJ(JI''[9&2XW&];>9(G&KA2KM):L>*'U<'(;2)>-QL <]80W$M%>
M7DR&1A4FV '4&VT%:57*0AB7*E#^RR95VRT)0[L4]1(7-=+:DT!V$@).X_5W
M=7<RY\&J-US:]*2]Y76S#?]_ 0G.SP?^QJ/NL5:6I"[NP"28Z+#J3EB=%UW+
M8\(7$>$9MAI/]20/N7E1XF'/N52)AZ1AHO;)1XJIT<&(.:-DIL%MTO<VA2/.
M*%<E(&_JL[+"$I3ABO5DM2=$NS?TTC)=2E02;@LV$2S3-L2C):IY"OA61YFS
M"C+V5+1)(YEE;-^0)O$K;?R04C2 4PQP$]R&Q.:\MS0@H8P<)5(CZ)Q!$EB8
MO+*)G7W83Z/D_:>SER$"CYG]M #+A\%D<FPB$==76VUW9=&J!24K;//?TK15
M:(<: K[@SP>?/D^$#M.99/$^.23+B,ZW=4:79\@#B&R":[Z0K-X[#3#3 H9K
MK/DU+.1%[ @X&O][&/]18&S5"S8]5\P]S/1]_V(PI!)TQX[U"2AA=%^TI, L
M.*D.BWTH:?+_F1LWS.KP^+2##_PZ$=4WKF$\*DXO3V,]/0H82MY![_28>IRY
MV*'G2EBO)W94:27C=/8]I]2R\79-G#0RW$K7(P'I$%7FF,(81N@>/)O=Y*!I
M8ZE3,M9Y+_Q,J8*'GVP=Y7/V/R/-@MC\F*7AT^:+\;$P9%G6#")[EE.4")HN
M2!1<G^NII6<MJSZUUT5X<TA-2B=\Y^4N_+/P]>(2$[!#IERWG2[+^-+] R:X
M"D"Z@$IGW$4I)$@>4!%=\76Q"$N][,+8N#RFB D!).5DBF#ET #/Y;8T[RR>
MOR#35J4Q6D_A471%D' .9%]:4335N4\VEZ.&\E(ECG'$Q1ZPEXP&0]%N8OZ#
MQY6\N8R9Q$P99)$23 T9BR*HA8Z;<#MN2W(+><"W+I<;5&\BOUN5E^LN&[*6
MZ53H<AJ!@%WX@$OKT7,\ .Y\ ,2&OI>$Q:)I?F54"+,S>M>\ U U"T\! T0*
MLCF]\MG9IBTKB% -DJ8B%S=+@T8J>JS#-)7_4LJ$B' DOTE0/K2>*,4J6O,F
M*B@8]<]C+[]7C\:BC"Q^/S?H%\G(Q8C 2":+2)*#%O$>X4,? A]Z^9Y$@^D(
MB5A+6)LC'=8#>+._!7Y \81Z?EPHE%?L\P-AXQ%6#(2F(J!."57?*_P]H1%^
M;L-3Z9H8 03C"1>)H#P)@ O-E9@F;;9AE..$/XEC:C $I2E-!'BL$DZ7E1Y@
M.;I?_?CB='9N S/2'.AM*S</NMOB;1Q_#M6]PF5VTLSCR*C:@@$0!2LHP@M8
M%2?4"DQ,7>.J2"J X=T/U\[;U^MB.RB3:'[#+G>Z;[ L=-Q%_WH]UZ#KD$))
MZ@Z[^5^!3T<04-9OSNF')=*:ZA, CX C7^MFT=. 'R(.E0*9+C%+@D'/%Y'O
M)288O/>M1%QNY7KRCF21^/C7,3;LSW]9E_>[NKG!HJ-Z/[LM253Z$=:-/@VK
M=S:EZCU->,>"5N)L^PA$8X<IBZ?M_]Y>" 94_6ZZML5(WE"8X1WK37(?D&X3
M5+:"^5!93VC[)51> \:"#*01%5/+.G>*6HR<:"B,20D C4@E3US\8:SQ97FM
M]PX!X:;*=]^NJN+]'18TL9J5J]V)L-[@:\&/R-OM<RS;DS#J=?<MQ6#TW<E%
MO@Z_N"F7VRLXBM_\]T-=]<,-JU-5UI@6S-B]+G!@\D9S0@7)]\1Y9R7)B9?&
M(WDH\[7?L_SNEBUW.@O_F]H9?[;!"P$2 Z)WYAU,F@^S8!/=C4J<=%^O1N20
MA97:.3B>U<T250; $+HVKE7-A&(J1GW)R)#5CMZ2KPN5:\29++A;3W8L4]>[
M[^&MEYNFA&S=-;!UI<FI,;!DT!/>%<6[I,-IX.WNF^C!Z2,L;'(8 -5C.#],
M&*-UD.<4UL9X/MA[BU\6C+HJ#4LME?-@0G4?X>]095NMN!<(X-DM&@G#PA2V
M?04^+=JFZTZH$%,&_\@S\N&,2AVA:*_#II?_'NWVT6[_T7;[8D#=]!!--!T=
M9U-*J5WJ1PZ<.NG"A"'NG"5.3"W#,26UR]2+UA>=V#YO+;7^[OO5QRTQN#$C
M4I9E?EDW:(1I-=M- P!KLZA>L"N=2'"H,:7$\(@!+,9OP^>>8OYTU59B5MAP
MFTJXYM,G1OU%B7)MI3B:J:.9>D!FZFPB/'NP+N4+\D&(/G<HU*OY'O4TRW8
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ME_'5\I*WNKGU*VS<R[67Z5+3/^0AK#SY1_Z>Z-/.8EZ1A0FZ..SX91K4!B@
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M*RS"ZUQ$Q3OPL04GC3RC(\#R ;SP>_9I22W,;?_X<O&VDS<\$];/G1"'SBB
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M\_BEK@ L,JHOL:64/-Y2X3I"RN>.JLBHR/P7]/\R:26XFM2,N+P*> E2(Z8
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M(_)/2_EF9%JY6AS-6#!@P0?-=T-F)I=HE'Z&J[):ML$$&BDR-],6-<1$?(L
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M>3/R]YBQ6];POK<5_=E@FL+$M[L3R5YP1P^I1EMO(E4*PO=<$7%)-(5EQPV
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MP9T_SF"%M5O4EUNMJ7%O'^7.P]8'$DJ<C!0"SNX2 M<%)4G;ZR*L9LZ32K_
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M>?]=LX'PTYUNF,D*-'65/5-V+"@]^#/_9X%3A86BH-9AX,F6AK72H>R#?#T
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MEIX(3>MK@H1=U8\Z\/DTS,$>6>J]Q>Y9M[@JZ*FO*25'D##-@BB#L+4%[$)
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MUHRW+G9PB2LG.0SRNHR+_ET!RD$*@NU1D/>IF_KDE].WITQI"@J]@; (GM]
ME+"G^@_?;QTI4JC5#5WA%F):F]ES0\#I4K\PA/6%CNIM3]JK=<$3Q/-B)-K&
MOIG7/2T ;A\2[[/+HIBY(C85WL7(^*Z/1'$"96 ZA<HV[CF*"3P-9K+_[WR]
M>6Y&>_967C&F_?SUVTP)9G[XX6V62#@Z;D2;]N@P)@HZP2/N^;#AIL"PXV&"
M=X-LW2/P[?(UU4E8-B 7H.</7^EH/38;\HR#3X)_;9JP:O@??#*$S=ELA)/G
ML>"AB384?/--MZ%HJ\L2=I\;XOLA55SF57"(8H8;$H%CA;2+&ZU;O6LL76J)
M@NLD61/.OX075@273RBA2,CI639008K>5/KRXZM,)U[I^N\V[]8!N.R-)-D(
M/8@_(WD+E+8I.XE-:C0R,HL W9NC%ZVI\U\E_<@O@Q9QN2*>B##*\"LT/?#G
M\K"?PJWE'<J_.E[+W3:Y+5ZC78F_OBZ7-T3">HP7'GJ\8,T2X!3AF, Q(!7#
M)%[*8Y&J$PT_2VYT9[IDA%:E4D -']#Q55(UH*@,^+7U5,&#CPF=9[/NJTO8
M,VE;'GLYPUZB2.ATMUT[-I>I]9N.MF-J PZ!9AI\#6#8+N/F'>Q3H)M*W@!/
MR*60X0A6.9UI[L;=PX#LP<>GC+-*D.$<]A&NG*=/JV-(-7!CI)!=&R ]F2Q"
M! +[D'()KB5-RR>G-*[ 5R#[+I,W()"FZC-/+5A:6609]2#R#_E]B_>ZO>J[
MF-YG(+6ME?\ Y,\?8W[^9*VI!S@C#S@/WA:TZ?Z#<M^?1EO/F66R0P!26P,!
MPAT7PNEIR9FQ$#7>H$0'N8ENZQN#M'KGFW3J'J6_V /D<GP4;S4=Q53.J:SR
M<-%5F%=R*KM9*BNU<>C8]*0)5_V(C>JG _KZRQ'T=>2@^I 5-"^;/?7[C O]
MAWM9F<.$DB'.51[2;F3>85?LD"/F19^9$2$Y6REHJ:ENG=/C.[X/[OIUW@9G
M/(1G3[+Q7))P\R7!AHQLESYR<7%VKIG"Z1RPI(.ZX1O<V\F1UFSW=$4EY8Q.
M46P51485LX3J[>+!R$>?0&5$)CE$'(QSD4<)48<](/K/S_I+(FX-D_*4)^6[
M?GE9;%G&.JS0,^Y:X+]//;_FU$V;!\VHB %1FJ+'1'$MA#,ZQ<0C\3?(\KPM
M2'*2%:FWVP* K1?%"DSD;_2[86!Y]ZY8<O!MM26F;M\27PX-8"E?LUNB:D6,
M1'3Z_]?3TV?4:\'$KIIO97\@/-SGX9]A<5Y>0<\\PS1%JG:(^T00W66#/!U-
M0T%!>5M>7A;1V="7U-0Q&9#W8:/D6ZA2Z/# =G(]C.7C._\9H#Q]S[+.PIN]
M9'KKPD]NN)8E3I,H/@;IRG-+DNR;H@7A/:6F!83G^&IG-Y)B;)0R(QB?L^ G
M53Q56D28B39U6>OG_@][[[H<QW%LC;[*Q(Z](^R( 2Q2DBU9<78$15$R]V=)
M_$A:BG/^[.B9K@':[.D>]P7@^.E/Y<K,JJR^#$%2$@"A?]@"@9F^9F7E9>5:
M\2%^^NA\]<([R%[D>E#FK9NZRJZ*QF>S3ZC-\]*5A=MQ6>V9PMU>:0:NQ7I\
M]<G+9Z]BD\WP[9O'K2KDX4G@,VVGB#!^5''!@.<62O5ZW8S,R]&P5&_Q^/'Y
MZEM*Y?4)/'X</O\_?>6D<)JM'OV7.>&V[P)=1W@^ZU@^ MGIX__"Y_@QBOUX
M6]MU3&KA5D_V-,/MG>CK["V37O C,\OR\?2R9 A</FT5:G8I.B6%D4H?C,YB
ML6Z$S*SSL(",X6*=,.T+_=^T%<K MLB [<B180VJM:,^P^,D.OF4R.^$M^C_
MD#1W;7T*O]SUXB'TCVB49&JG 1,MLUPR]#$-N3M),QC&1<9$@_*0=@UL=2O5
M0YGP5HG[\5P+R/$"T9]T3I>]_GWX)E$8HVW.ZKC+9MZE">4ZH+F!?T7[?!VT
M(46BT1"<T*=U(V.SS*(3;MS!23[J?RPSU61H+4FS-_*)L0*_Q+&L^1"R"E5Q
MS4 O6!C.G0>9M=>HF>*\.(%R*[8LN)LV\_:47ZM;X<)VUI#-KHAM;D_U6*7G
M&8X=K,=*QV@;/?HRX2'R^_>6L;F//F,!9'*.J !\4\@ !$NK_)-"#0UL?ZAQ
MA"I^R%_":_^$6LCCY)&7;_PLAFR0'.H0Y0)I3+>&VMS?#'P? X0R3,2GUB%E
M>=2?'.ZX%^)K/1G%!N$E$538\&C*2UQ+(5O]^M@&^!*Y%L+J+]+V.U_AA>)Y
MO>H/1/$AC\N_CR;G][L%-J+R#^U*'O4G]*@??\)]/?\7[$R/_K*6>"8OVGW1
MLF^GYR(J:<!Z[XI*BB%*? @:\V*W:U=YC:(TDYZ0'*6TM\-ZD%BW"MPCF9W3
MP%V>K_[N'?A%1#&:+1M;Q>"!1'Y1792R;_:5?QQ4W,?KHR,%,MF@N7&/"S8/
MPS>3<;]N^OTAD3T WW_KP\2Z?J. F2MG/2L2I7W!M"F8AAXJX:7K.()C& ('
M>(26"TG13C5JDLET&;H^$#%>4+*)DI!LI$3EFA4DY)X30&[->%NZ[+V.@ &^
M%2X47FMTL3)<SHXA]0NLQ,B**R)"J'$ZT" AU&#52EKP.EAA$&7K >F%HGP'
M3+!K;N -P!W#,:$ZEC0$\.&S4N]G_/>HW/OX"W4UE_4UN=CUZH5HR'2KK^D_
M1-]3OX$' L2EB8$G#4H1-(QF89Z%E_\CT(3:4FN@PS!Z@Q)U,H^A"*D92@WE
MO,$#Y8&KL/D%[:MLRW('M4V^0UC 1PZ6B#<CG+100>/:<^.=84>JM(R?PQ'/
M5_\0R_$N%W>S'M\ O1N^.^[!^O7%U*_NKX/+CRL@RIL(=L_5WK@4S4T'B'Q+
MPBMM%T3L)-(!3/_WZ8\_/?_FC!Y)I+D,>&N8?*.K(>!RM(UM#)?C=\!*0Q6$
MHMAP_3*N-Z+!(D7?A-GJJ]E'0(<0H/WS,!?Y/;K0''8%ODPEZHXHLAC2#(]/
MJ"U,+=9X*X3/HBP$'(&D'AS3CN&=,\PJ/9H\@XP:M+F98+0/Q6#/!6>R3<3\
MF!X9::K%I#_0C>9CVG@OAA5>\F$/_'F^[\9M2/1.$<DP 2OMYZBSH)P@<R(P
M?_:IB.)H1K5'(C5=X1ZU_[1V(9*-B).W23I65("_@(A?MR#()86=A?>>!&F7
M%$^U FR8!<5MV] U=P3G@.><KL%L&(-#OB31HQ_374H/<BV$WHH+8N]+\#\=
MB+0T(7;+-F,SZE8YE($'2D? AV_+.O0!5!XE8LHK[&[.T9MLVOHZA@^71V5S
MWE=*4GX:7L74L&T V#$!:TB:V#1BU& E0[=U<ZB9#A E2S/0H56EJ1D/S#,0
M='D/'UPB=DBI&S/.E@&J=2H6[7_G@SH9#6<%HQBL^7<0'R1QB:V^CH4W^DJX
M-T57G6D4#$#B\-5(X92>7ZMD+ ?:>X+JA$X) TZ;Y5<9IJ;CM'3,U352>\2!
M&CV;C*5G3<P6)GW-7%<F=PXYL@-)LA)2OCD:,4X.N4SJ__A+#0>??O\J!GCF
M23,?@C=F?S/=^>IGBEWH<RSW*G4,OCHZ!):B% $*B<!(LY06%YCA#R%3,"8A
M0%/81?(>1B]I8B@>X.TKQ9MO&0$^$32Z*R@ENK,-BJ=TV/N<ACX<W,!?%MS
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M?.4.'?OT\!;U"=(0#Z)_FB/%(XP7/Y'KZX;ZQAVU#2F=09HYIJ]G2M7]9N8
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M94WP!:$]YD[XUAV"%>"+56U@I:JCC<&AK'0)<+;FD^A1=9Z4J %;YWC0AL,
MQIT?O9E=@2WJLG#@PEA1KUV!ZCL:S@$-T"_G;!9EB]\F*7XUMBA!*EX1'NFJ
M!F%,OX%4F(1[9:D16W1*$0^&*$M@2<R&,0DT3&<G7! Y:SO_.YE<.+$@8E+
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M55\),TD54HTU0I1B2P@[R'71'J"'7NOF$.^KK]Y45*C86:([.LN0,G) >DF
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M$\'+23S=N;F)T\BY/-4X5$&=I4E]%VSQ/;.K""ABI:3$!*?TM@225E<7M5:
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M!Q"Y[9QXZR*]NJR"VUX%_HV"PK:.0?,'R94L&B6+3=\5FPY5D8^3FS+85R/
MM\S<+Y9]9RQ[#H>]S,N_OV*#83X*LQ$S[*TZD/$>?%XT0)E1>\^1G;;]'MT(
M1OI3A2J9+J?3HD3 46;VQI\6E(4B<DY8%">CJ&YJHCYE$?37G=%NK@BNP+D?
M0?E3A SD N.<>&RO#"8DS(!_Y .@*0YYH!:Q/O<\F3L?,\TRU)G,BNIEV(H@
MGXJ'C.WPK7 )Q*)BG'#V7R(^W$("GM;[#;IWS):8F8*30PQV9J)Q(!M(IAAX
MD^&AZ$!.:NAR_0/_)_,D+HCX.^\3GL#7?N,7$N:U/WVT7OF]X]&:B4+]&L_:
MRS7^?T5+RJ^:4+[C!86:!Z%K9/JZEJGEMYC?]M;SGY_^^9/SSRCY+#&L\[/S
M=EH*YV:F$U,%NY7W/ATLU_$@"Q-UTJB*-7A_U(1B68'_AN,Z'0+PP7^]FC+<
MZ7?U^///U_J_1[_!&_.OY[.;7]UO9TGGJ[_5U\PUJR2S&S!Y@%E5!_KA3%J_
M.3#O363@AD\4HM7KIM9&=OHB:9@0G]Y>@GP5D0'[?!0XS+R&&9I2UF]_\)Z<
M7_R2F8+-';8<+DJ'V1 =H&KKNC)T O'8,FK&.^9HFA93AQ,38/9P,B!YGUWE
MPQGQ?[R,^/]:(_X/9+]-"Z?D$&CX$KN43"^BU4M#-;PWFC1>26^*Q@>\1__4
MSG+2+C 8(ZYPS2H:F":''62TN"4W Q7B053OJCC.U#">^:S&'BY0-%UE18G=
M>7):E)!)Z)*0(A;% 1E%_KB/DF/\F*@4/O,35YOWC8&\NM73'W]Z_LW9HR]7
M_DWG;N_S1*';N2CK#>WU/J:M]\>PHX1050AZ>+Y:!U>#I@0B7))W:)ED'-Q5
M3$D33G29M;*9@/-\'4B%TC :6Q3]V<Y%^VR\Z0]Z(W*ML8@C_$ R,:MHY(2[
M'"F4;%?Z]GD?$E*AH%1QD5%$GII#6?BP)U>&,:&D'XT/(Z0SM7[9'$%]5LP.
M$T]\ Y/1(3UATJ]6!HEA#XF!T&8=4B1<&VVH\>F51YTKY@D%6MDL6M;&1S]4
M?)IBJ)B=:[=Z:C.CR3)BCUP'"T1C )N (@J(+1(*3G;UY D'0 ]:&M7*G]F'
MRXUPNR%FB)/)UWK"W+4%-R#M PUT<R49BFE2TE'VY+W,L=+E2G?MO;&_#1^,
MU[&)[X_=5X-V)\]OAV'K=]]9R,<Q5,ZZ!,.;PF.CH_5-V]_D/2YSV/=I%Q37
M[=>$7]H0>FAE^:2+G!@'$Z>-B;V6PN[6EKRI8,7JA4QIQH4@6R+7_(\($!E:
M7FP#62+9$U7'NWK[AO='*F\MBCOWCS3II<13$SL0]F6\_[PH>Y&ZQ.O'>[_T
M9P7JVEM/UQ2R2QK[@5.TJB#&14;W1U^R?<+5I+-?&)'N@J&]SZK\AX\J2L86
M4Y7;B.L(AY&_U,CY9SA@ OOK6.QIP%?#[DRK$-ZJJ"AKE=>]F]H098H$+F2,
M1/Q".JTDJTRT29LNUFBAB6:Q2CY:(I59=^%#5Q]V%W0V6U]#S3Z9'@A;/]94
M ]4;%,H0\"2$--ZKQY QAI'4@&\T.6@A)63[\L*Y,ALVZLU;MD^];[#F4*I4
M4"R">X_%P?5H9:,S]NC+K]#@IT7>1M9.<@A4E%>U.@ELE#W8U!S)B_!<AI,0
M>C"2QW0Q#H]6$J2)9&SRPL2+H+!EMR3^W/GJ"31/[2M6<BQ_1HHWY<F$/W.7
M0,.ZM5S\55U>)7A,UI"2FZ)Y=_]U_VM0]@A+KSK%B42$^C<KVI)IVT9"RJ8F
M,'PP+S4#GTQWL0X$\8F5X>@^[^HPY_*&"\.CJBV,?5MBW),29NK&Y'"V_LF#
M?C0]%H?B6TJ')"LB][;Q+QTB?_=XHW\8[I>)JT9N@JFIU$G<Q-M!2>\]G1U/
M96&\EBL&;IR<FF#@*BM[I$?S4<%:K5 985LBE-US])'R=D\'$)'F*K"RI'F?
M:0N:?(V+X/,L8+./-OK<P1X3'5_ZQ$9L82>2_.NIQ/EFO&%3G)1UL["$+1G%
M+Q4D_XA:F3="LN30C+KTCH/FE6F9[6D#+#I3.J0*C]WA 2R'6Q#PPF!&(I0D
MR7Q4X-'4'R-S&6E(+,*?=\:PWI-3%?ZHVD9+HKRRJ%8^_/LB2$)+U>]XQC6_
M 'KZ,4U'U52XV4K"R&JEM-\T%UDE6IFDQ-/YT%,#(CG@.EH=NI#8#[4=$:K*
M4<4SW</\UXL;(HK6$C[/$6*$L!<0H9QZ"V^&R*.VZ_."RJQ/?, ^IW#!TAH=
MQ?12  \?J9O!X40I(]&ND."_:*"(@=%N'SGW+!1RZ2_25LJ[U='1MN.#= XS
M1OK-@8&5"Y;<809%9PJ=6L^#E%H[WPW2STF9V 0AQ 5QHX\J^S)/@ILHACM!
M/BRN5UQ ]59TF96[M616(U'B<'61:3:"L.#RHEY*,(.QF.QS;KN0)$.4(_%/
MN$0-?X<HOREHF:PEL9YJ.UG&W E+":F=/GEP.E+FSE(B7 ,4>N*I[T]AW.28
M%P5BQ:F#F]&?\]53;QH^H %68"V=-721L'Z3_0%;B ]=^\XZ^[!+--'OV\ N
M:X.\"OWL;^D8FQ#<G2$83[8J_9-RS<3V!9,(_]BE"#>S]H>-0OH=53M6Q$%K
M" KN=8#S,+:AD_',@'&ZH$T%?:*=:-D?BIR +U1"4!OP'U_MR:YI,_&9@2OS
M]4Q<9,.@=#L1SNJ\]\Y4Z958+<BL!W^U@+)[U\#;H=Z'6C MB,K<E6QUN)*6
MYY804>E0U+O66ML#S3AH/AJ9)&Z>"@YM2SU-UQ@]I7#GD'5IU!D8%P>UD?%V
M#RF3:OR\\71#!B?U-Q%8D5H5G]TNY'4:8^)JJ1?KFON\6A\.[NC3!7>TX(X^
MJGAF\>Q9F[H#?V'7L9P5O5A/8T/>H;A(V!][8UQ?L^YMS<%0I-5#_49F_5$?
M8APF1_G\LZ UHP]5%+H/J*M6^KD^!H5REX_T! 25!;^.NEPVC]#8U5MNU<6O
M^,R&(0X4[!P.=:,;A<;/,;K%=27P>BL'R/5M<ZF+,[V7M1V3L2$;\;^JJ&07
M@HBR;A4^/FMH7?96!1FV/M\Z^J5SG34YUWYWN]8?4.(,_TG87U$Q^UU#OY&^
M$FPL1!R:[B#(D>&-I>CSBUC<;PW;U[)!DFMM^SW4Y_SOC8E1UWA;'+A0:.1(
MQV(F-B*5 RCNCQTW[(S-[BO_>RFV2]!('C@(_8G,9CA9'+1*K36F^[1:N@*0
MT;D5@SK"#S_^G7]X[Z4#K/[)\92=\[FS]]C^'(-5Y[_VGX\>?W;^%YT\T2J8
MOZ693S_ZS,RIW&-/_I"6U7.%7)1KH:9XY:2Z\ND7C_'./_WB4TU>GU>"1'@I
M/;>G=8XXX-&77_P9<5&V)^W./"A%T@?64OMHO $?ZDK9&*^*ED%!.S&K,KM>
M(\QH#DJ%@?6+Z[JHL;I7W.G??N6#']>TE\5!9EG6_(?\*[T?5%]V17479WU(
MSXL0"A<D@:F#+)]_0MDY)5"4Q'*P)G,Z?_ 9+B7][H_DGXJN#<W$\!1(<5-V
MNZ0L1M3[J%DVSIW1A"B=I*@)>]S:K=)LD52)HW/8;5T<%?V:[EZNBUS31^_J
M8"*4 \YL[6G56 JK]!!1:SR:/H^Z8V!I*+P<VDG+QQ'VECP$J/BM+2K,?%M%
MHS-A@$?$'[[VCF]) #,8NR*H$]<U[.<#Q,4<[@]Q/F%#NT;7%KD+XE=-7?YQ
M,)Y%@L_2"!M AA@XE345-I[TN:^'=7B-ZG[I5\]8L/2=CZ,X&[VA9H5S4X4=
M1^? +RM;S+[1E /ZW^S-@F=9-J2[GF*_5D%YO,J,.TC8 '*= @D<U[).(D2J
M[5O,R8O[(F.7QD@(GSB%-CDY"0LBSTY&:&%<W +PZUI8;BS('U;:5Q'J/TI0
MQ))I 912".7.6TMC!MNFV%#1TB^4:UKHNJ,]-;Z"OIE=*[\Q=]0*:I30R@IH
M.:#P_'.7W\R.+85"!2W1"<1WW#OIN;WV)W_:2S?Q?^I-NWIBI)_IK_AWW.QI
M[^&]OJG]8RF:WG^E\#O,2YI3%@_T#"-$Q9;B"P("'L-1GSYY^>P5_TL ='GP
M@_[1_N/\U7F(4^G!-(83P*V:GKIK%[3-5?+ZANY&L3PI+E[&H8:>SD3DL(3X
M<@=^*G'I/'XEU6,U*T-[D'5*V@#M=)S.:OU%$!%9;;:B4=\&O6"JKL0AF^!U
MV9CI<?A# WZU(&/N>/7D/_[[)?H*1K(S:",--\_?O$BQ;%4?J3--P F\2:=M
M/UJO-AX2W%P@94E0$+$-7E17-.Q_(:Q4/CR[7N5-?P%?^?R';\[6S-> .7CI
MM&,O8*C$C*I6O9N>2QV/\PN8OH@2=* %8'*9C:/=DZ?^WSGS&@#^TW!)J\*K
M\L$1=SB!&P2Q!/M] :O>& 7"-?.R4U*-].KGQQ=M9&\'3[DP[T^5U\Q',-4@
MQ*-C/RYS6+\D3<'#+C_^IIBS&Z]MF!G6-=HF FB:S9#T6XI#JZOX67M$"ZXQ
MWS_W89KP:*P)+F,F<2.8"U''Y-<EN Q[$.=6)A8*)4Q=&Y$Y*3!!2BE4G ;,
M'JDUP$S1<9A9'ZL1>^E\N,@,20;22=VA!%4VLYXQ]-@CD+WQ3+(=\6=&+%SN
M&):F-Y\'?/EX^"C)#";(M@A?),Y.$<V#R5N.]0(QCQS]/@=R#\,I/&44*BN.
M#5C<V);_40%6\ZKCK2NIM0F"GW8529V^_>8);]&TPX<T35!BF*9"-D!#ZA>5
M\ +5O';[EK->&;#@8\44P23-6=]=UDWLR\+>J0O L4,Y/MSTE_5OK4[=80=/
M'H->*7D!+$2!";ZX])>^>C3\M+_UGYZ]_.G9V:-/'A&HMAO%1_LL=_9R_-/<
M%^FEALNQN,3D:CAV8%;F^%O#AV3>$?/-F2>R+,J[OBA?ZT)J)FS_@I:K-(G3
M&>0(+(Z3.U-PUM'PLBCJR,GHS("GM:B1%W4C!Y]Q%'8G0CS)6R"1D@9<7=&T
MW<C!;-RQ%AZ68.7^Y6':?DS.-0W]U2ZEV:$BUMH<^,0Z54?7$CD,13WECOY.
MS*GGJV=4^@">RFJL,$!1^SMN=4&CG^0%E9BG=3,N9QV]Y-3+-;Y)V,B*%L.9
MX6[A3/B%%2Y@U"UM77Q94Q!S;-S2H\!W#[6@:R1VT:DLCI[D!29^1@IHX;@^
M $*3IZ4A3K?%\&PTB0^VT9&9P;CNL?-Z."C%SQ:4XH)2_&BZ_JJIR]+"LX<;
M2(U> H4WC$2D=JGF5:$GT,Z2-9ZON%-#V64D&55"8H5Y,8";58)EAQEX5"LA
MC)P:;AW8R08NWZCZZB]UTWG6T^23OSX?9B]@D[MOF$^G,O093<T!U17B%-T-
M[9Z7C!>9>L%726B0CEVIF5.1D,J!?E-=_;/WQIH'1&ZT.I.;:;?IV?=/OAIH
MN1,$E@HPA(K=%B)S@;JA#S;<5\)#(<A8&2K$(V"A %M6C!<JU1\L-3OI.O^X
M)KFT;:T%#<+([VIOE %O95E?^W_]]4XLID4H81%*^!7W2<J7>*F8FJ,$V>*=
M)L+K9,W4;XLMSUV%OVZ*.F'#L(.0_O$5>S0"'"'^O:NH?6B?\R[,'R.--'P(
MN:%CJGO9/Q>MG&6AW 90$2 2RMV?__!-JV/8&5.A4"L0934;R#%?$^TE(9VV
ML>AT8:&UA".#OYQ0WUZ$[)<E<NM+Q&P@)O62:6^SGXSJ,G$O8:BBQ)I*9188
M^%??U76^>JI??]'0>-56A@.^>_J"YL;L)_^N-+G'^%F9BTBXLTV4G!3"4(S3
MM3U=95N6VK+4;F&I<<WUR@5V6IBJF4 ?[AW8C&1&T2=BNX*'#PASG>V<YFJZ
MQP6(9)90K5,IXVSC_[HK.D;PE0']1PA,0" /]0&32(L(\[(X;F=QH,ER$!V7
M$0N.C/W&>MSBV!?;O?7G%=(,50P/6$5+A*AP/_ 5\<R[0.HQ=1F()<^8DLG0
M/8E20,SC4:MCZ85AAKVV=;JTQ(>!=SGELD*6%7+;*X00<8@\,C!\Y6X'90D$
M,Q74LW0=T1 T?;YKLMS1MB _4M>^<9W!"4WSROD?.IX'9?A#V#/<6Y^\M,3R
M<%PR]&7MW.FU8_QZF?45#6C>L/G$7'11;U2'2\NZ$O'SE#"9-R,LJ&6C6(S]
M-HS=8$ME:%]25V$';=T\.'IL_:%$M?>67^<L946M#!!V@@P)(KHYDU_$I;(Y
MTMY#0E6"W0*]G6"U^TK[I#9N.V3'9=DLR^:V&QU4M?7)\\"=DPT3E>"2 "P&
M>BL&:B)^>.' 9I3;6B67-;W'K4MOK@)&E2(G-9V/H8!Y8_Q- (:$8A(#5Y95
ML*R"6RX4,;@K61>7+BN[RVW6L I/0U0Z*.GG[E_@S&U<L=^0E@2.L-&PXWS.
MGA=4WPGR*$NABSXHYI=7DAWM:50X"$"IKCBA7%8"P-D3&*")*K9&3_STY"TJ
M#OY09EHQX=V^B2+O*-J5H4:<?C"XFTSWOGN<>4KTI)X$*X:995N/_XBAY?4=
MGUK^78P/W =*@N\,M7P":J4!O/A[&A>JO*,L+9$XBYFUD9Q #+<$"QD,#01F
M&P<S\C&'C3$ ;*.:X&7OGZ4$SJXGCG.??3*D%2:>;2]Y%68@]7S#L+HPD)P@
M6>4:X[%:67Y(.*M Q<6#MZ7+P*\Q'JU=^#_OA&5_P !^F*BOK*I"9,UGYIZ1
MJH*56V$'3X;MGP=93.F?!GE6-2,V3KM$4B'29)I,5,/R.%:J>T*X$N2/<6*.
MY]_@<Y_\\-V+UW__5&?UTV%72-&81>?].J;#*DB1@'XCN\Z:$,1/0>8$X$"[
M@8;^_ASP #AZX!L!RMW(LJWZH"&8/ @Z9N%?3);*L E$'9KD4"]T$!+<LMRX
M0"\ ,'=96\3Q./,.)W;+,.$\_2X+'JGV5DS2-8X(XJI,T/XB:'"^>C7))G"J
M^F4G#73$<^=8*+U@'L5P/4R_1=*-WH3\85P) I*#WZUI=\8DCFBU;P5I+/J.
M\@# 7#9Q%=S%:4%T?.D2]\ES@MQTF3^"SN>0G.H&BO19ZP^'X 1F.FW?1[Y_
M=9TCZ??=A%(%1AK3<=(!P[>(+I"5DO$R204'A(6_JOM-6O4P_.^/8X4/$7/"
MRJ#A$AC(*0X/-9_)I;S&ZB&]%%UH1ZDW!YJWL 02K#%,B<;Y@PT'.L_<K[6<
MX_*RDQ1CXP\F,DW*>!"I4GA3\ LH4XJ_2/ GQ!X7%*>;V+I(=J+T]DR@0M=T
MCXW\X8S??KZ,WR[CMQ_5: YD"[)]B\A:$K=@HSR2")'P$: N$@H4.D'1N"2Q
MXN;$&M)T++[1!#9)AJ-:MT8XU^ D&9RA* _] SFT0]_X+?A\]81)0ZW##I.V
MD\Q100)V)\>=";F-%!-7=2;I28V@+*A;B 3[<)K&B:)61'_,ED=U)>8BGB2[
MN<?>]V$LG%><6+#&'UL4[<9S5H45<IFUHBKC(HF93QJ8+0BLJKECI6,FVZ3"
M%E4DB3 UXUX?1MQM.'R^^MY_I 91&3.WQD!"2Q'S*8EV"E'UH,D^%HH?EUTF
MB5DF.%FT-A@$EIDP.TF_GI3^7 2/- QPNQHC)42'7IOY?9#N0Y^^(OR\JA+Z
M15FT(%5RS16F1<!#JQ[ NZ*,#CR?%K,P1TNU1@WV:%U6XH VI;!9ZH&G")OB
MN4F"463JD,GVC"!H;W@*>,YI7GL4E)2PCH#[<O*B65W7S9M(0L :<2NF\%&<
M_Q@=ES4L]:KT-?XXSJ?5]1&7J(1<()K!O8(#9TM(/(ID+7=Z4;5=T?7"<?XZ
MO/G3:J]X'(%_F6KL^M[55.QQC4ZXBD0A#N,\5JH9*]#F&,GVJ<-$!CT1T0R1
M<EV9*G5Y%"YD-F>(EX=2OS?<ZCCN#O V$:7*);?OE.4^3M*CLA"1)/Q%D8@)
M],FRW\@.&D1:I>"]GB3##M,EM)BB6# 3,=9XD<N6<N>WE&],N&+4=I6U&_'7
M,"E%US!X2TO8MZIZ".CX;S1#$F<Z7I1H," K=>PG%W&,]N+I&+7+].X[OZE1
ML@EZ%4<E_!F*04!Y#X&6:O!Y)DQAFG(S UA44 /%-WSPE#6!#X)O,W"G9P#.
M"]=?)O1C[#/\LM69Q9.W2B+63BG#<$9RWUWI;T$I\/F_GWTU(LKFX';BV(&Y
M?J<-1W-+RRJ]ZZOT23!%BOT.O=_'MS8!X$V2S8#*CEGLZN/7TC)"F)+7(6F@
MX#'I%7GCX Z2:3Q!)-%EG2B74R?*1U#^OZZ[%*@BB=16T1"U@LM%^3IQ'NN!
M_((WP[+G.O@E!W;^0Y70N,A:;WFQ-T&NK*@F.*T;P5@>DT)8T1JT)2']+X^M
M/TRF.Y6 +R/=J&RT\ACH(_Y*:Y",@B=3GH0//UZ$0ZT%3[$"H$+"QT:K<@ET
MDS;O>M=1*XZ<&<W_HRGN7PI>AZ:WZS1TQ)'TW/Y#8;8Y$5'F:#HZ(Q((T4*]
M\6;]P4=BI*)3MYT>VCM@Q/7QIFSD(N\%<2FK3(6OQ,L?/;B:W#,'..E#5(S@
M.JE!0BY([T8^=*07V-7*[/<6^;PY+KG?8[P$"L5(V1RO_-" IU$O=!V:G]O+
MNFZYC81O,E!71LOEO'X+Z!OZ>:VR*OJ* _/7.E3Z U@LDBZ*MH7N;<'.S$,U
M:?JNMB='OI(HJ;(B6,L)O8I\1*$Y9>U<DQ#\!2DT\XNF.+#H.B<&I,/JK (2
MZ!PK=\':@"._LAZO<2*@L,$@*2MIZ,=\C)!K*BI8<^DNBK;,]"8N=/87L!=!
M.OM;J/*H0,(!*M*1H>C(/#GT)' E8$9 L>VWQ3G\2")<XYU>X:Y<JD%RCNTC
M/K>4"4#2Z "Z<KF]%28M11T*3-S3ES!;P6'2@X3._#E0!^"F:PM)@57#7&<O
MPI,GJ*ZHQ&C:[*J,:33-&_&>I"Z+K0P+!L91_BKKU*4R.C#%0!>+5])3=<I^
MXQI=ATL71&2D&1=DB=AAK^4)GJ^^UGZF)+)A["JP<<T[6G&NB4>1TP=H?\BC
MXLY'5R_)+J8D21N8?NX[[-.2F<)5WN<XZ8'">ZCIGN0NG-$4$JSXU5$> \S!
M_]9I(8HL(R^Y419@%=KP?Z=2P; CSU^=:2@SD_>I K$2,F^<K>#!O+5690%L
M@-B1.J+(&@Z*:BA+;-\-WUL00'? ^-^+V)OU,=8!>F/5->9,,S&RL9V>KWX4
MOE'M4.#(M)<1@ V@H)R"G#>NFE\7I]K:<M)_%]660HL+*FKWV])'4+1#N,J_
M!0=[W_LX)?Q%P]:*=.(D":+R!>VK9V7Q1FM9=7(T6FBJ(E(1_)9%+A$FN$D&
M3 SM3ND!#<$C$NEUQU\+//(N!Q&VKHT+@1GT\SII[ ^K^AIT#JX@G)FK(.YM
M1I'W>O6M?Q6K_X]V[DB]1-9^6,DN^WW6MCYZ\A;7>3M[+K50E'A>&V?GC_G]
M\]<<C7_MD\Q\S40#K2/"-$+PKE>OLGWOLXA7)*.[\>G&Q!F?UF6_W_A,]Q\5
M02%:BA&)VP,U*6H:]) GQ0T&^3 9]9/"$\S'!U$L;MB$\LH_^WV *K3GH73R
M.GX<[[WP 3F#MO8^E;U2Y:6\V*$8U1&)VS;6TOS1 )>@(BQ;C: J]ER[@1I?
MR)U7W_SP9,5RI])I"'_QMPJ!%LEUZ-@H5+.4#."A>>U#>>]7Z ZA/$@]>5R)
M/ZP/LURVIX<  O[]*1"@Z/P1_/7IR^>O7KSD47>ZI8#IRE;[7J05Z=+D+*JG
MZK/T-R1 ZX]?@DD901V_!SD KNF[GK:QE_1%&J1I62IQ=$[_BFN_TT$1QCZB
M ,;E1!'ZCRP>CF<?#TZ-',J+Z7$CLUZ"NGN .?GS@CE9,"<?Q8E&CH[EMB@-
MIV;7('H@Q^#_!J?-PLS4I-2]?N);M,-OZP,#GEWX>'1)XOC) U)5M(#4G]\6
M,RFF7;+GO<]IY<,PGB>FKP6<9,6%%5,EIQR1YSPDG.)^,W-<F,&2-4PP!%7/
MT:SQ4<QK4X:G7V_/=0L.08VW31_!)\J5!,-DQK(@&144:'3'_M/3K/WRC)'B
M2?0X"FIC&3)4FC$J"/EP[*9D^]WEL:$@>97MCV5=Y'5;2 _\4)?'RE$'+?,?
M.E\9N,J[P"IA:B  _$_@5>X]/(7BSRF(RB_5Z5\OK?[;CJ/N0W%,,. !BVDG
M$FS)@%2OIF030B-F<KKBN5IRD.C$(%H\31#V5A5(AI-;FVZIBB6U!]30@]8F
M_5MU-I=*U5VPQ/>5H#-R'<ET+8]*<&J:-21[VA_$2YE>D!KD.EBC4$F;MM"I
M@2D<3K;O88^:P(*CEHRMDB3*L6U'[EYBO5 !XWZ/448@0X[S7&$N?U[@FC2L
M1PK6LQQRK$H;3A^ND-;7+BO*9!&?6K@I$Z2]7"Z%&80/-SD'9^:)%"YVR7YM
M%ST]*+T.%-J,4-N)J^()[)/7+2=K+XG[DOJU+-O9[.FL5 V3+:\=:/U..8_;
M71^3WL5?]%71-?7=NUQ_<3SMP]U06"C)<_@X+7=&% 2(5=UPZ#716]PS-)3:
M%] WV"7H#0E2:$*.PJ7!:8R:7S@V%W2Y9.U?/C4ZFZ(%N"7@(O;9&X$;3(BG
M[P5<D94\&1U(4M?>CLV@-"%N*RHT,\9%M1O')>3['!@]C-WH.<.&0NB--GW+
MBM<A2-D@/=IRK=;.R%F7/]4+#!T$###747<\9=+XS>+TU<O1)F'W!@-"LNM"
M841MOR' !IPPLA=:*?9J(.T.1@-_,?Z2MZ*BC(V(^E%):"GH;OX<W63BXOGJ
MZFFB$%K-AO4#&"^97QA$F>8IHS?2=B)J1/0J9T#Y[VG;O\<+]8%F,!1'/OWQ
MI^??G#WZ<G6@7@>-# #[%N>F;-2HXKU&=\0- C79K:+6L'Q),)/3$@IK*E4T
M_2%%]T0\-=%\Q)TI7=OM<'$+1EG7[P +UET6;;Q7&N\Q:$K@;+R/(K%AO[=2
M6[!NROS:+^^T\Q]Q6N^XF/5OD/$O:==OEW:-EPN9T#8CH("!2-;,FL>-2?^W
M-:LB#J"#A?;:?-B?T3 G=RJ!:J44SU]Q%KI]X81*5/^OW@=H=!Y$ATU&P%%_
M"(BM,B:-WX7#\$[=$!"NW38^,JR.!ANFI^8Z?3@+?< @]N(% JH *""#*F7K
MI:;@99:C5QFQ-+RBUCQ%F?L=<-L)/PG_8TWK1=>*P!(D"W6,EJY]0-A0O-LP
M)(?]P!8#%/E7RK7O@]6BDC]JZ9/\"7W$$/G+ J3-D/Q1_'C;MV 8R+^2$LU>
M$)^A,'E1*U& SI"M.:KV%QFPF#I=QI)_1") 'R,+:0\^UF7I[=+9XPLNX<31
M^=7R87996;IEXN!>N K9ZA"(,:9XM)2Q%+PON-E.)B5 L4C&ULF,##D<2KP&
MDA)6")9!&D^__['5^K9\Q43@HT^__!'VZY=)9*3@1I^N(1W@5EU:Q;B3GPB'
M/J.!<F>7GL ;W%NW)9!+2[7+R4#"5GG\C0D1$M=EMD[7N1$%_-C(!>O?'+7@
M*2=^H" 'C=-4Y+0XW,92/H5MC-&,:6<M*K@+F>KOG4RUR:Y#6I[NC"N@*\6!
M#'S#P:^WG9)( %9'2XW0C2]_> +?M,</0">2)]T6>6O'J\KB0+^9.84_(CZP
M\GEWS6,SI=!:_OV'%PO[]K)4[O!2,575&Q-L+Q:]6/0M6'0956)'ILSMP5$$
MMO"^+]9Z6ZHV:+R9^!ZFNALTHXDG%;-0&-&CFF#'(G^-,W6*C4/A![V$Z@),
MV 80DN4YY81(1>J*^R5I;KA0Q7\@B:]DQ)2ZXA^4\<9Y[E'2.*!_D*1]$CV
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MS,?O_IZ]8V#0F0&CQ6*<>DO^PJB^TO (1YNL!FL?_A@'JCZ(>E BLR>:=WE
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M93YZ(MQALD',A3B19SQ*B"?[-@<+H3D2*UY,P$4'=4 I1JYTY,9XT0/CX=1
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MB=&W2B?L!)9JV!)OWG<VO*,_1BF1.5,T]&:;I#-&!4SI1RO7V31%V VEOVY
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M &?J9C583A&VNK:B' ;_,C$;I>A6O<1$I4HZM<MB6A;3+2RF*>$DNVRT]Q1
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M%-PIR* $Q767JF!5['UJD;$LQSIBDKPO7L\]&F57OE 9C/&]RV.2N\3JQ\Y
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M1'D,6P*+KX501BP$4B2^'7\!$N",0XDPR/[NA$'F5D984RC3-OUA1.Z7/NB
MX(VNS!"NZ>VG_G#*^I()1!*?X]J?S(PL._OOWQ]*H8SW\9.+6FQ.Y J9/R[
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M1B.1*0$<G+>[?5Z,O8O4'  ONS<),[_5O=C5[X<L@MHBG#Y(9^.8GT\1/[A
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M&RU#Q@(KA@!>4[UC/PL3REU!==]X6%1D4/8IZ>'$Y/8[DH9&5ZROF/&C.X[
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M#;QLT!NS*]AL&'I(J!+ EEF;/;,.FP;^3:-VT>+DOF]:[-2)UW;:.DW$!&T
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M<\ZI>@X1ULSFYYZ;GSMBR"8]8]WW(2.G!"!_,(UQ53B#5?.L_>,D%BX"WQ"
MXQB3P//.*(DKL^S1;)S4P.VV#>92L).=VP@'"#*UB%GP9K!Y.?96,SW28W0%
M&XP[Z9S@P]' AAHKMD,?!D=YK0%KD;:TG=&C&,.+Y78#CN@X_1L!" -2\21Z
M$&R%TN.=A!*&!2+GE*TLJW6[?/5-+BBFT!K11GX(?%%>MVWY/'.6F8FQC"3M
MB"OP/"[RX\(B*8L]H?(#5Z!%C2=6)(_)2_^WUN2)0BX3%"4MVM">32<3:34%
MU"VOJK#PA^NK;LPF-4C>$/=,J?A0H+7$I&K18ELMHPX'PCTT)O7X3K8.A=N=
MQ<:_5W,1!3@S!OZ!8N O%[%0;<93"A9^<S4@/TP]<DQ<%1GX2&O-O=N#GCCL
M.;_BFW[/%>>8DY,K3_XO?DNU872ZI8="%V<._=].\F(&=?]FH7..^M[,.FD9
M90QM%Y8UJ%J;J[YBM&2SQ)JE%0/?9R)V0\!NI2[2IR^2:,"R^BAL[:+UH4S-
M9\GL85[X0N1'[*'TB[=%LN3*.QB=GJ%M7A)G7SIIA1O1]OTS1P)YH1T7TX^,
M%HE8V VU^@G.>72!QM(Y8TW3(6<0ZI&[1E[9.6KZ;D#W3@]G$Y)$0=4!SV#,
M_,%^(T#_5S2NE1@?TTPYS#/C0%09'8.?X0RS)J*AD* 6/?%Y=;3>,XNKS^FG
M@:LS:XAP[!DE0K:&:?;[@=P@?%Y:(6N_7FYJQ&>@6!_>"O(#A+0)E\#WB72.
M1CQ0::&)*X(U;6N.5DZ.:9@B"?P=P9"G#7_=1$05O#7NT#3XX5W7?N<BCL,O
M>[]OR]+/"6SULA2WK2G:MRVC(99^(B$A7U0CU"\A,>RD1#@ AK-8XX7^-:80
M*5M/;0E8C#&;.-%$'P5&"(. @72-<+KQW/!^U+,:@OFFZP'",[<0W/^3\VM)
MKV"F&53#C*A8>CN9/'1NRS2AT5HWZE_OQ?M?%[=R;XC'ROSXUTWIWEWPLG_I
M_6[='*^ Y0@6#7S-^VE^:WV%K_3*CWK7_A4 3O#=Y +PAO?J4*R[[5^?73_[
MXO/_<U]7Q' QRU05%4X+SMB=+G!B\D9S F"&=] NH7"&Q$NCD=R7^9+5UED2
M<3Z4A [3,!.,5<<6JJM-![,X5X3(^RJL8C\5_-]Y-<^K^==?S>+)2Q215N<%
M9P+3LT0,/JV_65M-2\P=YLHM9\Z2\)GH-)G<!_<FS7-/T7)_F=%RY]%RLS&=
MC>FO[!KTRV#50FTM> %1T$NI#(%O0$G/9IBB/.CL(,QK^A.L:5BAF@!-I.K&
MSNY!^$EO"V*W]Y]O-T?.0B2O-:_M>6U_(GL=U7+12EO$Q8!X^&U5'ZZ@R892
M@,JGW2G5_LJ[69*%[:FG)^TE+X_#,G6U1IYEQCM#/@\&\A7^9MX>\_;X)-MC
MDFN&_!H72V)\U-#M<21DHSQ\7#CC$U9+>UP5*P/*_8+Z1TIO)A?9 />.N=54
M$[:^Q>:^0*8[*!(A&K9=N7U7,+)I!X9PS]"[D-[BKEAL:NDM6E48Y(?I,+\7
M@A^A)5A*4:^LBM^!=="6H,-S*PV#45HNKA=AO45Z.BXJ&2'&!TPY-N2F;H>E
M$"T.!4&6I'^D-S<Y<U?0%S87L=%]_/K4]W7CH&*; 6Q*09?8UY*>(I&?BYGP
MI0@%,[;;YT4SQ'[%*KE<US5Y'XL?&:+OH(*U[\XU9P1L5WD\P=6*>TMZ@,Y"
MRBXC";S#:_G]LXH^#GO]8Y^")SP<F;!)^W<21!6)BMU=4^PCW#0CI,DIP:_W
MN\NO)0_V!EBQ9JKBV:A<Y@1&M.TH_*G<[8,6,40W^26 ,O;QL9QB=S?8#NO,
M(1*=@%* /2%JEHBM??RET#C:N%VMK:._!E4Z8('& Y!FZM9:!C* .O;U!!%Z
MV@@ **W]Y,3GT4Q@$\28"?VWL">_>W/RJ%'?R8Z4$]TY%W7#7 (EITAH$$YF
M,>9;.]6AD_EC,K3,F.S?#),=$A3D 9_V_[+0]G:J0PR^CM9P<V3I:CIB4C$;
M8[^AS8! !FB-40YNKXG5$0YW7^PQR;E@W54X@?1X$3V0\#!OO1L:8RDM21,^
M.8:DCB6^S76LB0_/.E)U"<!7I09GRO"_N7Q'C_D<J*USU1;:YVUGP:%(=4)I
MBK:K5V^!H1J;@]E=$#X3L09&"@1:W%8$C8X?/(EB;J/<23%I2(:QO*&T>,#G
MR>/8VO^3-T4-V.WHI;* H",AR.!KV-P*G!C<],A& =%N9\D$:)G"&J6.];S5
M;T0-^ -J##^(M6-^/7*/WX,ZAF1"8;&?X'_APRI0Q=035\N(W[X\JG6IZ0&(
MH&#U%>BEP:&WK!OZU?HK MFW#I0@01QR1YH#=(Q^]F>D*GIQO0"$R^=?+9Y]
M_O0/[H]_>/I'F0SZ!F]$GEV!;5&5-A1GM<.CIG82,#K??OT\N*T;(L!K>@UU
MKQ?_J _NE@G\RYB=M,P/XDJW(NA]ZDDE^O9;"-W=A'V1/&K1AOQT1N\AS(TW
M\-Y@H?(X]G>^_.%KF,6_??<<H&=MO]P!_^#Z>O'WXI:UL?LJ$.=Y=U>'T,&J
MCY#VRZ &RUF4#OHK;OBGHN%LNA(6%3$+GAA=I#3$H?A9@:%M,..C85\J1H*/
M0D\1/9EM[#U)4U00C11TF<_V];[;UY=4ZPB!./24*Z71!DO)5II6:V_4C+MO
M"M>A(J/A(=H,F]I.&#_LM1%+FI."["&8N'%[OX;F4OW&@9G;I9O@HVS=L-ZB
MG\=%NS[Q>6R.J\9=1LEPPJ1$.+*X(Y54NN@@7NB@AWU09CA75Q@,+GX$$2H8
MN%*'RDA,GLAKTAW0 >9:$[:]_\(J /#Y;;$D BMT$ZD5$#[V@ W&X\'[?C[C
M?6=VS ]"]FF&1C*&Z)Z.6H:]'?HO+7 #^QAF!]'CKUK\?L2_D9_C)$R1IIRG
M)+P3]>#L\MSWQ?=MW\ ;!T>6WWW@@\=^%"Q=DJ.#. $*68Z!K1N8E/PZM$2,
ME!G9PU'J!]E3 AU645YA*FE9U%&]0?\ 7\M7^=KMBA6TYOM%UW/FFZ$R5.S#
M[&9/IV0C>2:FZ\$/.?W(J7$.X0<;'Y^J5&L<".]KG %.O\;!9DCELZO0J*.2
M8+X<Q=>(_*!P/&/BP;(^#%P.BII!2&U'.(_ ^R/M\7]SU-PM?3]^,?K=W:.$
MC +%6@G\I^0TE1V<D#5^UC)I"9]@(R4'!XC?;QP5AS'!$)-9N0I?,_5!3T7H
MD26!\,IUVWI-3=)ULR9I.J[\GHCR80XW!85_P8U$'[U?<X=5,NL^8C%,.W:<
MP[/Q=PH.XU;$3&C)KB(6%LGN131AC,W:*35;)M, +[$'VZU-8(9C\J0+FL@$
M2B@<4KKM(-29*!1.[9\AB163[V('O# \G*IQP"TEN$_?HXCD$N2S:U>"W.%Q
M/#@[B93[XGF49T?3@8QU9+282"QFEN0/^&G?,)08+<L%-%X1HA 5*"VOW4?1
MON5%9_0,"!6GBC%C5A7_9@;<!I:<\L07=96/WB9AOPSUY9CS4SX2*/!^:Y[1
MJ13GB')T ME"^26#5;D3F>C'@;)\("%I1!='Q%)B5(6H-)JPCTM .CMCYP5_
ME!P)V./Y!0=H&IN>M(/4$=%(Z?"#=#HZS:5J%MMO MO9QLAF%H49LL@(PB/<
M!M>@F%X4U,T2GU(01]^*.HKH]48\-OEP>RLV3J\51&UXZX%U#J=.HO_#M/$-
M(B*4#FZ%1&@?;:/HZ$Z-4*]O!F?U85G]"):]7XB;!B(C.# H:8Z5-F5 LS4X
MW"-)<[CV-K/.1O>$T=:;#4.:ST+JD.TQB_S795FOWB9 0UAXT(3DC7^$.7Z[
M[R9CU+9@FEZY?DPND&:B3[JVLLF >G;K_UT>HY(BU!$Y2C.1!59!_(GK%V[1
M M1-(SI:[> ":E$+^#4[)P1FR5IWB'G.$PJJD?3/C*Q='?%WWN(UU:/%)HAV
M:I1:%,WCIUU#E)<#QP+ \;TQ6_>.4Q\%<)/^VWN%JWP/,!5LL.C]$<I>,K2?
M.5-/.T]8YR]$>W%,"Q5&BL_L9V'E8(!4C5C:<0<RW+Z"NBUSAQ$GNN5##R:"
M^>U4[&N9*A6\SPL"<Q\,WT'"1!_;&NT)$*W;4_$$#&[C4%2A%M++6__&A,I=
ME#=2QC)J/F!',CQBJ)U<//8F=$P0-P<3_YU#2L,ZTE.%@(E^^I?^G4-OC5D%
M0D FR00VN4GEBH_>!3$!,,Q^/PC#1V+^I\.HJ=5_B?W_.*M_4+2$+!V$#D$O
MA0KJJ#.CUA/'2QJB P*<+)GO85)LB>U1Z$ZIN1DTAILJ+A:J&71(L4?-;N96
M3!%(V\X$-QN7$Y8 $ ;T#;3O4?T1E!>+TU[=^]<R[]PR-:AGOC_@.):ZF8W#
M?3<.<3A97,PX33%+JNW@(S"^&H@#=2S"3L"O#72Z>#?$3/NXNPFT'SR= %0@
MKG[^)N;T8EN@7^<B1<!1"CG6J/DA9G?%U#)0<K+8@:NX.)>$5G\,RMJD9L ]
MHJS-&"0W(B@U@26T9<#CJ1.JY#P)_MEAMS/BK0C(Q:>19OBD2T>0&L&\_KH\
MNI^,1)?;>_WYF%$FI\Q%Z@PQ))RXQI)>[&PVB8AC(%"12&GCKD#09#UJ0W_(
M]O_QH%.^F-$IOQ8ZY9'V,+V9S#J6WG"TJWP/+B^,%\IQ4/8:5PNM.01JFP <
M\%:>\T[K8^6'LI*BNJT54I6.Q.J]B;Z)Q.Y;*D63ZQ\*?0R\)J>@:$/.04I_
MH2Y[6]2BN(Z)GE-!#R7=ZKY;<8'/LIPO#;A9T??,U) %ZQWNK&HXP3$3J[PN
M6O1-HN8;M.W<GSIW:MV'G75G"H,0-'(*R[];B).])[$?>%("1)6?V?V)N0LP
M?J9B3Y;TH3,I.&(=ST&<.P%Y1R(LK0>,T<VP%6&=^M5_<GN=V%UGTA #\#11
MV5@HCS$OV0)+VN13LZ<(^6KXI+4QL1EJ61>@ !\3675]:'PDHU-)T7H\-\PL
M09W=F'_ .;U>?*T98NI>QA0#U]Z&&U=BCB[':@QQ_?O HP5028R8"N;24)-%
M]65\XJ(UD)VS5MI_VH'&FXC]0J-"V;]3O6!RHB$19,S8AA,N_N;PO:-_-'XO
M,:HK@0#SN[^'.$&8C_Q?_9+T8="_*> *>#/.D ,QT@(RXC?"U"T,^188<0$
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M*WJ/E9@6\"F/M#57Q3X?^'J]5M(".A9P(+?2A7_<.]D$_K6@GZ[03?*2BV8
MWEY$Y4DZCQ$C<\A)(EC<[/=J'$#DK]_O32^]$+?,;7^W]V!='H2%)#L96I/N
MH*<(O"-]14^$)SJ_1"P+A= QPK4/:SRFFMN!QQ%H^.G)L&]\-)W3_=NA.R(U
MF?YS$(3! WM' D,:7"$PM=(5(_.KCWCV%$!1=$0!A4K$X#31?3*Q%V31#_!
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M,I>"A")'=<)!!=N,VY@?1J0)S4>"3#L-G%)3FO&2;;K-UXL6*LH/NDOKD68
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MV91[FUA:)<6D@KZ 5$&<+VC,!E7@7_HUG_C^^Y$+'[6&<_KLY$-P$@Z0W@@
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MK1 W*Y-PFTY!$7)PZ\)125 P98 MY[3LO&$_R8:- I#08%\##D[!JEP&/+F
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M\4WKMV.!Y=N@*Y=7=+_!& :WIRWSVF_BG>N:XMWBN^]>F"Q/T8FR/7CS)0/
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M^^'\JZ=\<CT/FV.SS-S+$^G'[IAMCG0) &52&=(R'PQ9<%50$W)$^,N^(=O
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MS4B^JGIP9PC565YQJ*B[U/3 S"V?5I=_-Q1N+JHTHZT_1TY^FUA(R4XRJTO
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MY)'Y(M8)ZPX-:FEA-C4%'<)839UG@9J[=64IVUR(FMP-K^>&5\+J<"H(1\_
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M ?0OV;6;TN5D:PXU]+$LTGTZK9A3\I%R:&W -#!4X\ID\?*VK3=%P"'R%_T
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M+ G&02-E$'"DE4)'I"21+(7G4[;HSS3Q\P]MPHTMX1W%F!SX,4F)LIM'3I)
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MM 2J_">)#T28 3BQ.EGT_30?O"G)L4/;#?D*T2E1.)1"K-/VPC31T$9&1U@
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M^J9NKC#<<*O8)A>^3%>2V_V)43#T5Q[CN\-@J.VF$ D;O8 9R1'X'7OIF'"
MA]>Q*(E23S!S9G#WN$F29]W<!]</$$5'/4LKF_I Z0#U0%6"8U//B=4) M[1
M=!.JC#IDV$TXPFW1NK@3S\%<$Q?J(1F(]+3?').9!27#))/#EB-08*9)!^,)
M&=,4?)J0/;E<_> V35\$7H((U(\V*LZ<7;L#Q%.L,6?"\L;^3NGT7%3Z@V#R
M1!^*HC2"M332QB 9'K&_3]DM>AYV\ /XQ=N /1!MEW:T ,/FB L19V=(Y4G.
M^7ARTD<FG,;:,#"?.DBIEC1W4,.S#Z>RM)27YXCC,*=Y;#3FJ$+Z'!,0.O2K
MW?X<U&Z/=0/].>)'AE#H^%GISNEC2@P3F\]X?YRY6YS(&3\)N0F%637+[OAU
MHL!PG6B@ ?VW(A.JE56:E")"RP61$W>P3>U'OP-C]E5B.H58CF9%9CQ;[3D4
M"X0F1%I^Q3G'X9NPI1MJ$?"_4!(=.KTT:>M#:WV<4UV7W#M"## N=(0'GD?M
M#S@4(E)55,'-\BLK>%F<&HJVDDQ.C6X@=^KX(OX-MJM]<>64 2$.,#_6S#++
M!;X!6E^J6D&Y_&S:EICAD$6^HG\7*BMFINW]M%QU*+0[;.[$BD^#R>NK@H+A
M*&X;/ _ML"^&NKG("#04/M?5B/O)Q]9%"U8H [B;&4K\;FP+XS0UP8I[0?W:
M?3MTAV:V;MQI;UGO?'*(NB9D;Z$/0OZ;K Q,3'?P.ZIOPR;#X0ZVG8Y/<4:/
MR2VD7TUN$','>MCS\4DM<0%N +4! '/Y7$_TY(4RZ6T\T$2G(485P=;H&:S'
MO4&QE;&-2TO W(4FC)5D'DJV48J>"VX94T$! CFE*9XPSW+08CP!N+?L"W1F
M'V5#ZWGJF[9W%IJL;S#@5F5_/^4#_1GASGZSX,X6W-E/FEOX!S.F*KW;28E-
MAX>!(0;:Y*>([0*6P#0+1A]MR$"GX)=(B6XO)(B(F,S-(NP',0R4=<4WDR;"
MD-6+!B[MS) L^%"L?DGJ/()%>R\$1#M:DV",@ @Z%DJRAM61LP@9.?^D&!*=
M\Q2VH,=XNR%]5@6UF_ZU85,KSGQJ[X' !;40S225+ W7CIK3VRF>&#W2M15.
M>3Y-YF"B4D/4\PP:&/K^8Q[(T2Z\7'VH)27#[H/?R92V(:=?DJYA:PF7NG5.
MXGX7)AI_7V?2/,UD'BWZ0=PFWV;6]O@YL>8E[21#8H1?5(,4;NPAFTK@KK[I
M0]NRQC+6"[.,T#9\,\MHE+9"=BHQ0'E@*H!#RJQ:9B+M#$9.,77V0L-0>=8W
M(4S6>>A#&?0]H%/COE/QX9:+6H6N"729N.I;"FRZX90D[*)VHQH4VROP+1G_
M5!Y6]J;8;%?F9WE^A.UQJ+%=I,QY#GYN _^K<&:?@AOR+5N:?///OF!:-KQ?
M"5<HP"VYEMM.'.V)P&7((DTPQ6D@/B:+6WR"Q[""[EGH(6N$%=,DK<2Z'"#6
MKJF@(G(2=BR->)Q<74#+.DI4_5C[,'\%49_&M5-89NT!7?LHWUL\[7N.64I_
MOWX?$I;NDS]V4[8="?WE&>+ ^6Y$1UQ !8Z/;Z;3-D\T=Z TCI-\2"RZRNT*
M9&KY/MRJZ0\H<[MB(@61IEZ] [YO)']WM#46>:9!3YX>A^2MDPK7ZA]#9S[D
M\(9>_<U,>M:1.4/J)K2XUS/.48)$S2?>.EY4M#PQ@<1G$:[+D'%M,N<)EM[4
MHA'WDU)=/-L8C*L..1,ZI?(8$=*.=F*G8-'-QX.W'90CHP%D(HFECRI,G6&4
M6>@^EGQ\4+_ 0-ISY9J]8'-_)#W5'9^JA@6)/0+F*KVF[J&-F\*R)D99R.#_
M\"B.6.^*Z+T)?.5?UA]VI?MT!V,H,W)!OB495?J9M\9^8_\1)N^B(*_T#^N\
M109OTD >_1^NBVUW^,/+RY>_^^V_/5:+.33V.E5%A6G!C-WK C=,WFA.*$?S
MZ>57+U^&+,W$2^.1/);YTM6VY0P^^Y_6^Z>J#Z*8>J,&P13GK4,2=<.PC8V-
M48.*/$A@(?IC7.'^[O+_EY6^K/2?=Z5OZIKTM@([P&Q92'#?RS)=END#+%.2
M!*QTC:;5^]!E)+YT\$"7I;HLU8>PJ$($ DF%R*C2JG)K&3J)1PAVC6'F<R'*
M7$\^Q42CG?GALOJ7U?\0JQ]1?Z(I.^J%"0XP ;1NM^.,^$2>M]GGE2!2EO6]
MK.\'6-\H(3K&XA4VW:?U+\4%94.:".(%WZ"P10IE,4ZDC-.I*=!^/#3B$2!5
M^N>FW$X/SE5_SX1M[M:;+KMEV2T/L%MB=SU \%&Y4!"S(U._=D1W/-P&0W[V
MDHC=B>*>&S#!@+"C/+%(H:!W/TMY]9A9T,B_TLSU8/3L\D\):5%L]V!])_/9
MLH^6??0 ^ZBO+*3@NJ%+U[L=UZP.?D'0RJ1ENZS.974^@)4/PO*AD43X4R9J
M2E-V/V&JXE]R.* M6ELK$JARK%+,=8,26AA#4K*]G-L;2Z5]_LV^36E?I: A
MC1Q!Z5";_B#;T/X_]MZ$N6TCVQ_]*J@\YSVG"N*(U&[?.U6.G60\-XGSMS,S
M=>O5JQ1(-$6,08#!(IGSZ=_9>@$(2J0LB:#45?=.9 E+H_OLR^_81"]/A>G"
MQUE$I0M1LGGM!_?;,):X!GEP4]ZNF+0)68TSYHZ!"1O/8M26IIAMFP0\^7)F
MD_46]XS2J0P53=T$$8.4D6W?]8V4O+4H*#RXA[$PN.HL5N,JE/*W2[1IG,6$
MV H#-*T!631,$R,Q,OR]Q=ZG)BB^(M3%A&ZA[(U%,U1K]J U,[[,ZA$[Z4WS
M2F-ZNFV9,A69U/HD@":,7NY$+<V8>D?:YQIRFDT2VQX4D@M+K(J,S2 F9H !
M=BU,9DB9NF&1YZ ; ]R"F:R=6^M BCK0)ZV2V97Z81KJB]J'"FVP23)#YKQJ
M3I9WP"4:R=V.NI"(2F9(@>G&6>=)V!:77%XZ6U5+/2SUYCZA$K1GU))SYEMR
M?$O.O;*@ Z(?-GIK</Y#*=.C01B9N$K8#0A%PO.:AM098*:(HX7M.I5F3;YH
M>U\3>S^4-#HY"?7_#Q\/ L5BG]0+*CBZ6=MC\ P,\J*V$&&DAAT M689HV#I
M<N4(->7J0?5V6C=!G%&@CN&0E>Y6R$ILS04U..59[FU%:3U!' :/M9*Z,8/L
M]([H'T6]%T6B*ER,,_/2?K8=&=5\'7P+P<A9L LN[.5^6K%SPE;6=B.S)\Z#
M,F?[A,P=@F'+&/_1X(>0R^*T)X?&- H;.Y3P1R97NK^84V@$6SKE^M!U&SKP
M3+0E$[U3.$E/Z5GQ[AQDW&QMN\Y5A"6\9>C./;O-M)9F(S&M>99@EVD=WD!;
MQ.)7=8J^IQ1L,TI@H >*:B.8#%,T<FLLN[Y*BIJ\0/.;&2:5N!T-TT18DCW)
M8R!^@Z0&S\H+&KXX)8<=;&4". >J@<TZR*<'@BZ"K>KP- 0JS!<SK R?D.7,
ME648]*I8 KB_.$ HP9PQ=2?\_>""RYA>^N6$9 G<0SEEL.\179'@#6AE23D'
M21.Y/(F3AZAQ; J?5.&%*>(*SNO,S,M!= V4(05QO,0W&FRMW0+MUQNPQBBS
M0[TPMK%$="--$;(%#ASZ*D)AD&>7N8R!I17"4ZMK'+WXL0;W@7V??WS&IBZ-
MIZ^<2@\+?@B4"51D)DVN#HW_H4;Q" NVDV\(%N)2\>!'JN_&<<.V?4(CK44K
MH(MZ=BZ_;>Z%RM;36)%2#C2%( <+'7%.2YH)I@CUHK+)LL%&FF@9@(5T@1FX
M*:"9]F&$1NI,48\52*%J$#078-#D:8 >H?(K@WY%4-W%?%KC= !P7 A2!_1V
M/N>?;V#^#O8E,P([>%.E9>@TH<Y4J@I)<;@#D( R?1Y,<2!>,ZZBYOD@^E4T
M^5V2BLP?U+.C\6):.M/J2>HQ=Y% FL,6VQO4Q-RG7<+SH.'@B"XY7TBGQ\$<
M8QM@0-5DH'!0T0Q,)8GL* 1"UM)&D-@T"(>2T=DBQ%"A)LD"$_RF<:;5X6-#
ME#S:>KG@?*H10[PC90.GI_4,6[D@80SJ(1:%YM05:*1S?!%9&>V7Z EC.%T2
M*+=$J'>22209S?2!,N"J.$W@-$'=69<S_9=GJ*51G4UF>JHDCD(#FKIDM#9I
MYKE&>'@<ZZG$"N)>4]> U(,<D?T7I?31E 3G5/ @3:8I 9LO*/)%)4:*A\DI
MI#X@%Y[\J'5.U2A$HD,&C0[+MD/:'9E++4:7.-^].=3BLHZ #BHET,4$U*M/
M0&/>(0!5Q@J^TN-21!++P1)$56,N2F@ 7FRQ" ]"XX"5 [.LPV_[',Y]3DKD
M]UPZO2H"*51-X&<3!I7Y\V+8$!0@"<60N5)D',]$;01B"51[J_AJ5UPUT,W\
M-ESJP"A<S]C^D#D2D8G\$DIT$<48BP5E5C532\:]8UNXT]6Q-SAAXT'P(R%D
M1RCR>(RX?F-S*C;[O"1<A#W:4[/;.T,]@@;8S85YT/AKTC3!:'>VK9ZZ*IW1
ML-QESQ@'-(N#\BYZ] YI9UB;[AD5$$J0R?E$6]5K< 0LR$&F4!?C!J(.JI,T
M%BCPTCBB,NS;<5I(]C9,W&:HP $RUY%]!SO 8@*8TV@,6++).'8S".3<@1;/
MBU83J.O;Z%*W4@PH):)N0@DR.DH^YJ)QY&B(L*^T+IC0377>H;XWL47:#I60
M*TU61!%05B$-S580R2F&C6,,I338C=CHH3>MR(V9A=,5P7'_Z'C;YM=$4[D9
MTRM$2 8>\3O0"G(C?-4$UDG-O=.FJ,K7TI3#2)R)=@*\EF.<.@N*!Q,'VG$9
M$LE5'2/\"-A&</6IR<N*JHF=?W6E2OV"T PM)CA$,$5TYX$ *9AQJW:. 7O>
MVF>=,B#G)JB@:]%MS+-)TN+HW#=-AUK05GBJ5^B 4@*Y"!V9#*9-NSE1]A9P
MJ.FV9E.)2!5A44@X=X8F*!K"<"3.L7>%&MV3[/H[GDI4Q&9@M"YR(2_#*7YI
M9NWM27!<1Z62(G!GLDQ53!.C8&?_0N452*BR/Z!*["AA,P=!V['PBP#11T&9
M<?Q 4Q&_!,12+,A@>5%HIV'"RS&^'"4BFC=:'\Z9%=R>L"&ET0CJ68F&LA%0
M(R_6;G=WNMC54!87V69 -&>UZ)SL QK%P6 VNH!US#7?VP^X#+L*+L+N<@N1
M'#1+I?3ZYRZ R!T';!I.B-D1+@(L&+2EX\:QJH3DF'BJ!.OMS #+S5\8+8/L
M-T5A"4(OY_Z5]NAXDP!@B?B8U+,".RON*/F+A2RQ@>]AEV]FL G<B07G&IL\
M1JHZ,7W)#I,G\QX64@:%+P>:73H3WCCN8_U4*@DTL5@@KS'.$&4,#;NO!L/+
MCAAR1^0UU(">-HY8M2@S)HI77MB!<_ S7V-EF)9%NN;#K1 S)DG77)IU)'8_
MO/R,2B[.?<G%0Y5<[&]%ZU>,#,JO,Q!$LV1A[<3YG."N\\EG$\A @ZD6OE[4
M8#U.=.&RW_FO*DCLFM,1)VA(YH4!9D0(;R<*JV>\368YIE%14Q#\)^>U)/K)
MT5,RT.Q @58 9IK6'#E+4S,Q"JQ4&YAO5)5/V?6CN(XOC^D#\6U;R+YF%L2M
M]"9E&I>7Z*!A&)X+RR=<F842!+P1<,@(<0S']VCH>*26+\F\BUCZ81C#U\ 7
MC$X'HV]1_FV^T,<[N%693(;=WZ.LQAC*T3 ,L&FF$1G0,@*]3I>%=4AIG>0@
ML<(VGQM/=?)F6XN0%7PW5XPTIB=U@*H*6O!J!!M-47)Y-Q"'$IY=LW"R35-I
MS\#RZP8S-.>(8,E+<<G/S,H\Q2"-#MY%*1>TI%+F;::Z8A%$FFKMRAB,/MW4
M=W'Y.\Y_@5-&-Z"P43IC+&F0ZGFT]'" K6:^TPO?X-AN<,0]V>,&1PH_8]W+
ME'-S)I6NRQJXS0U98A\:Q#V%/CD*13D-"GW6B<V>1T7<4.Z4X_)TZNET-Y*T
M*4([C<J0"IMT+41K]BKX V,-69ED5WEZI3MC*,+,4\)=HYL!G<L$T:COM0O\
MF;8I_8;U<J6 0DO8K%CDU"F"<!0TL2>?U%S_AC*(LWSOX/2QA)32BNR8S&7$
MH@MZ9$-QC W B3S)[%KGN\N_"@-,Y':,<C3TIFLWQ\L.\.U<1D<JKL"9ZX$F
MW)I=M=PC9[BM%;D^-M0'ZMY&)JU2<Z$H11X'$YSQ3-EQQ?7"FLYU(00YM7.N
MW)4)$WSG>$DI;9Z:4F*#%-!'N HK;^5?@P-,?4K;OFPQ!XN\%6&'LA0+6H-I
M=)53E\B:RBOZ9.:O%6Z8XTXZV2\]:RC"Q<^3>JY'9":%Q+\H15=*/2WO*',Y
M55.;F8R8Q]=).ZXZR<WKQIQ<I&7F6$?=+&[E69X<;.N(V%-TI%!C&O^ML;>I
MLI9F!\B+.VYLI47-8%=,N:Z83]@P!@]?X":/4Z5C.C@TPKQOW=QK&B!D@CAV
MGZA+OJ@9^:)!(-GR*X66\_(Q5@=^IJ1NU9:4M+-K'MSZG-4M&01O:#RK 5[)
M+LO5K_2Q @^&]-3!D% !C-.DG&%T(,41O#2+JT.*4*$9FZP93?Z50=*%4GPG
MR[B&V*%8+:(A8>G64D7%/L0;/)4_.2K'XO-KSHO9FLCF:$5+MUP?Q*9,S,0.
MB@AKT]/FD+>.0(6G;D_=.P"TTY:J].P;([EA(&$EFMA;EMAY)HRG9D_-N]ZO
M#HLDOJ)R2:SYIE9:0F'D*$W+_*=.A;S$MB<R4:3J,B+K YW?AM<)#@)-9N.X
M2);/)3Q7&N0LSPR>&?K #$+S*W$3TU=+8X['NNX:PSH8I(EKK.W&B09Q%]TS
MODR1SY(QCN6U8 DKWCK\#N%[L6$=@S2PTYX1/"/LS,:YGN4<,*0._PZ![JG3
M4^<N_$OM5:X+P6+[;EG6&%W$JHQ"RV5J>,OKEFPW!7=N3]A8,5H%=0+#KE8U
M-E,'W/ Y>;W(DQ(,G462IORK^+7T[]#=UWGQF9 9DK06L"A>0*.D/+(H?@8C
M0L"OB[!19:B!.)K#(L7ZHG)F[M(!Q<&?PS@;ZXPK#P;O.7?'!I9JU(_BOPU"
M^S3@QEHPM<Y.OM5_OLHK/5J;:D;;MI/3L@7<FBH!W"D)WH2R< *<H! $8Z$F
M''IULBP2:-HLOY??F-KS>/)W((Y?\H**.FR&36:/VYUGT'A=*1#J"QA0Q^*=
M-0_UDU0PCPZ/-#&96H.?&(TM>.L<[<_1=:BA(=[]]/9GK1BT"4^-/E1A3182
MB'1*E*HO!&@%;Q@RU1+R0%UAL3-E5H&"":6-% %%@C"[2RW=A92MX#^H*;N6
M8G!\49+'-O:/87U8 #:Q:>P/I;_*!<TP02G:#UZM&:RP[6H1NBL5;'])2=LU
M2ZE-:34/P3%@AG52)&,52YQLGPN[GVDISYN,QS(1:1%52*I\*H@:C>8+#=GE
MMOX*P -2"_40$Z",BGT=3!](8]L>J<9IC]4EK$[31<YU&+]&91S]&?R4YF,0
MJI\H(1G\PC0#E_R]SE0P/*.NG.$@^ DH*[.=V2HVCT-P0P2.6%_%00+'&:01
MW4:J4A>R#9$BI))][DVD'^>(HK3^L0G]U0O ?>@BO_!=Y+Z+_&M(R @00LR3
MRM1F*557G5:)O7YNP9R)5MQ4KB95=G(+V:WL(?46/6(?#)_W!C&5L;.B=(D@
M? *N1UW^Y8Q,8(+IDU_(W&VPT"<S<38)X \+]N26>5(B9!1<B367T03>(25]
M=6;*,>U#HC&>?WNZC.[JU _-L/48590"=[JV ">&RD*GL%* ]L7&3^NY:EPJ
MX:]8(;ZA\G9:'RAY6SBC38QU1$J6!G:<@1=J"\Z2'B-<$0%+,6Z,%:A4H&SQ
MA0QO:&)DDJU+#;IG!T/<@M!C((7,(U> A!C_LK: 01D<5?-R,$N3S+VV/7UM
M]<61AA=:?;E@_]I*:8-#- C>I"B=+V<&CS<?L]C7SS#74A\V5? 57%>K\<'T
MN\S;&YP>Y]?9)6&>LE98Q]VN?+F33 D%! H_M>05NO>E+%P*0LI762Q+L,_1
M2("$TFDES0UB!2WKU0TIW2TAP6K.T1%E!KXPQ99VC/-8%"='/3;4K [AX"5U
MH7$);1DWKW&M@"1C_IX%XI.PX?=!E__>)LB&')Q%)>=-KF@<=*I,4] T11Q;
MY*0&8L%:Z$![$4&1JK+3TO,:M0_TM&WDPY4/AF)HZD(9I,EG3-&1J&I@WFF*
M8AA\'2,CX03T(G- #"2J([;*.=:2@'Q.\@5B><)GU#R B!M[T"85O8TN152P
M_K%XWS'"Z6+MEEX#@_)3KA!U!Q:8T"?4F0-W10-(S%Q0^('@,F7FJ/,RLX@5
MQ-4*D2'L*\..MJ'5<0..W]/$<B'\1 9;=/N"T/"-DKB[OVC5.>H,4Q)6H\"<
MQ-SX@H"">LZ,Z8;R/2D^)_O4<[(53N&XU%E,@Q#: &=F>5,H WI?5L ? BO=
M1L)?#]F\.CG6&(YD@IIJB 8PMZ\R\GRQBRHCP=AU\-#!">"TLMLPZXQ UTVP
M'=,>))^;+=>SAZ=S3^<[ M$K:Y[&1:WD%H)?AR16:95"&C1":N;4G'D*]A2\
M$]P8QU"A\AELP*>Y 'ES3 73,1LB>I)-XB6OI]L=54,:,P$(DN=-M(WN[O&=
M>CY-G8'-[>G7T^_NY2Z/N<'1P0(.6E U(XZB1*"2QEPD*LZ/Y6_.*+>U,[?<
MR4@%KM.3O"?YG01+*$4Z*>JDXFFX&";!V*C,=OJ,T4FJMLW47L!]>AI]DC2:
MHFA&@L2D0%:JQER+&Z,05-6B(WI=$SP]57NJWIGDM?%IG-D@ U2IT:Z<<.^(
MD&RHNQUX>N$!6!_(!\8%##N#&JY3&,K0\))?V(Z+F&F QJG4F3QSB\L] I+O
MWM&.C'N'U//8CD/>,@*S<.;(QX+-Q#U.L US]D*)[6P=F+!FV"!ZN)B(J>1J
MR&;]T'C956/I*=]3_@XH_RK" ;TNS.L*:>N6P(X_3)W"#"XI+*CICK)!L92#
ME F\,2IH6*PG<T_F.VE-B%)EK!G;RK4$B@QEKN=-,]<H$I-DJ!@:@"!<04HQ
M'$_9GK)W0=F.D<)H&P56;W)09J:BM)I-2"A'2[),2K UE/=E/;'NA%BE2-',
M9C9DVRKWI $M26X\0[*8?4F4I]L=T:VN609/#F$<)Z%M"N*J^199AQSOB!@X
M(@$3>6*&7K_]\,_W[PZ&%R"2LUC!P_04\YL?Z<&+//7O, +)>4HI%,>Q00)Q
M0O([*0T^&,Z2UI<9@+"2@6@\.- =-O^]*,BHK,)@FB/"N'0I)'E,+HW3ZM#L
M!#/-/Y$>C,(G<O&Z=")0H1N-(H3] X'2@4<FEXQRTVJ?,,AP<1!=1O@OP</E
MUPR"-]D2QQF5=4*U2-PY)*!%$?548#\15BR!_Z3;O>?P3?"1V*=@VXNBK-'-
M]^\ZOJ2!0L&_%/<U\ABK"78K4E-%5:5*O[M$V>K>7JEB7O+R2$*;#F)X/RQ>
MK70WB=U,&^UV.L71/+KD^-X4 WVA_$9#^Q9J45<:,:L7S12]Z9WK*?[%T:''
MO_#X%_=1.*]=<A$%^71*3<XD+$R3\Z) *3O!]JU/*(D<88L2C40;]^G6C.N9
M36I=+N0*(DZZ4:/N%+'^2*R!&$_F>I [+,H==V1U  Y0RLS0+IP\41>TH!_K
M M^#'<JA%9'4:CV!:S/8XHDR8K&5H)RIJ.!!1_-<>K;=,J<BF6,><*)4K/>D
M44[% ICZ^B('X($P076O_JUSJ[S W;=FY7\)EL"XR*.8LMJ%TGA^>.2UTSP5
ME8S20#\@L.95E)J9BKK1$F^ &^<NG*SO0>X#F6S;@^Q,:J,6Y#44XE1:;D8I
M+&F03DAF3N$C>? ?J'8V9P7V!OSW0H^/<RLQN&58))S*9H*LH0+$JU@S4 ];
M=77CE  5NV/P<OJ,I8!"\))</.2V>6IS<M)Z+V:X(T,Q;5T08HFH)RM+FU@8
MK&U68"P:&1,+",'*A08W$AQGL^2CN\1J$/RF&&23^Y?A?01K,:>!ACCRL/'A
M!*<ILV;D/ 1MCA_- *ES95!1$!BCY-WW*F#O5,";H(2E$O P5MWEA<O*55YA
M@8:#TRI88>A1*OC&1+KJ,>$,BT!;(W>-!9$2&5@G,C6S"6AAJ?\VZX*8H,@7
M[G(1'@.1R@GPQL6R21#.AM!ME0--YO7/GNB?3SIO'#6,;CO3;?W459/:8+.9
MJ<K@*U.1Q,+57T)V),C:L.!!"ENG5E^+!G46&S )C86GM03)R,T&O?Y&M=LE
M 3M?(VS4"H(%W)P7VJ=Y_]N'!NH'7G2'/2(\)"X-E/?C=X1<NA@S GF4\6?2
M7LF7AHTW17/L!]KF$"H'+&P]GS\0(MQ6"L4SZU:A4CNL&$'LH\3HCYOK.]"6
M:1![!!>E"54!<I2R,;J146?0F54$KH_V"_V3M<['&E31\'!\<C ,%FF4E8(Q
M1DWS"'.CA<H-PH-@TK&,D !JX+^#X!\T+3Y:>7P(OP.C^+/27XEF(,*G(39=
M4=81&Y:+J(CFJL*O,[//+'+\RO[8[:&R2+L?[@@1:H*F+Z?IR5KE\JIT6'?*
MT01Y'G(Q?]Q=WSH(WJSL@0:WT:,)J*RXH(%KG*0H*;B;%)-ZCG*#PAP?[ILN
M3#QZ7%/W%@EE39)1:LX;K!@,5Y-D7_D2VE-"^T'3AOR/#*PAM.Y+,8BT21_"
MGS,1;4E&J$649]ECV_=Y2"H[\:&AY;<V,4@0<5\@J<1_2^^W'?/AYJ0)J(-[
M VJI8B:<P\N$!JPG]%@@+1V($VS&!C0OFP , J*:?TJRM<_B"4'LZ-%+!: *
M&.1*.0'"!F!<H&-"Q%9X6TR@6UVO0&_V1SB X-/!.7\G7H7B,C5S5NP^-JUY
M61M9/1J;BZ<HU21Q27W ME5+[JG/2GXYBW9*C#4!WAD?0CG6&7WSUFNGJ(:5
M'J/P8G@8GAT>WT01]#4X1F2NZ"/H@S;Y#D2IC[(:&TV']!FC0?")WZ,7!/O/
M3^*([ZW?(HBGTT)AZ$*\LE5S+*@7-$<#-=5$->A88"@))5^C;W*81\[)R&,@
M;XP?4(-*46#\G2@O1 %?3!*)'BZ$$W3'2@I;=E O@N@2ULBDJM4Z*3."!<DR
M45M&XH/UN\\R]IG&%_XEZ>?,%"LH/8<&EGE=S9I9\I@K;NSH,XU.R.# >)M<
M'S9N8.9 UXNCE&E>8K"O,5:V2<3=R] H8^M>F\A0AWGT6:W* 9I:$U55H8=#
MY!)ARST49S](>1N^WYAT+2F"3OWAI[<AZJ=830F>683OW^OY@HJ4R #^7D>J
M/N&OZD49O.%:-7C,R(0K_O[A^T_X!U+*7* QC[@Z ]X":J%*4K;HLYAO'IW"
MNS52- .W:WF_-CPN>-O@8*F4/!,P;P^LB*?932HN@Q=GAX<!;%!*N<M2]QB2
M$CXZ!)TSS?4P6W*A&#I>PU5'68;-7K!Q)>JV*Y75K$Q?# >'9\%8GJLAFNDK
MT6PIL3(5QU!1S)K'KAFTYK'2>\'K>:<FB@RXHZ%!O;9,CT^Q%2QK'\6+9EMD
M+I^4P3+M&J>T1:"C,,E+(=!8C>'XKLA3I,E9!_@RJ1<:H'(&30R*#Q5EB8]O
MG*29++9 [ZFJ9,J;M60*5.4YCM%2<]:F[,UI=WN=Q#/=04W1QV:?F ,=O43H
M_L"R&..T5.YKQ0;U2*6^ /.I%V R<#!/V9!)=@+P!<Q(5BG)ESI&1%$JZRBE
M]JS!@SI12J$$-U-'=1E9Q#,'BCQE^>'V^XGIX<OO/?WWDOY10SNTS@I$QP1C
M\/MLI/,W5C9OV6 "HX;0Q/#A'S _CHL+OJ?9P>#BPG]XH AV;Q.L*3(9L :X
MN$5N"CPI=@.*S63Q'7ZT]5;,1DXPV''NG?"=#)@PCS!>A65(&UI9RY&]<0W[
M6NXY].6>MY=[>KGNY?I#XD"NA$ER$,Z7$NJS\M=F:=S(I6^)\I2[(\IMN[\<
M]'-L;2R$SE/6\NBCCY-,5/Y54J(A@6/=Q9'N(.UVYK$Q-![-EDO\-8U"B2:S
MNE*V487KX]15DM=ENC00U;[YZBOB;ABEV2X0W(BZ<8YW-#X8.0F43[;KZH<O
MW#*@0V_#BZ-CBMQ).MN$X=P+G?#:-<_ $=QG-XZT-GJ\[,IML)&9$OHY>X;_
MIP;.5070T4<V7G5^9WAX\'_,#$XPA\LJ^).OE? ?IH\L\ O&<,(;0]F<RKQ1
M(=BNVL@)0#$#6J.ZI.'+\!!K+H/M'G$P'XUKF0J4FR%W90*.!*=+UW!CPSK'
M"&>&-;K7N4RE1YY$2[WQ4IL3X^B:A!V+E7W\'^F$F^0%PG?G)"C2I=D,37:_
M=+1PO(.-JKDN -?UAL"D$EK1CV8E;W4.F*[Y:"N8/Y@*9D.X=N<I/CG!;@^2
M)W$"Y'4]4]+((:D$GA8('QW?GH+@:*8.()KZ'#='VXCP<7$8UFW8UVWVILA.
M9])3L[4O*-=N/MP]DA>ZD[#D8122-<.N>A&'],)\P_(P-ZDAP>Y2A]W1?\>D
M&NCJ**NPJ9.4+LX6X^HBH)NL9([BN'H['('C.0GY#90]AM!MC('*E\&J;><
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M<'9"@:J*DRDU)!)0Z0*M6)Y(L[3BSWDN^2,(7K3?C:G/0]<YD,0ZK>\JBY+
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M#,=_U!F7=ZOX#S 6I],_,.*!9O<.//OS]3%5+ X9?C\ BU\O%ZW^*091YTW
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MN8/\<KFZVW%N24#A5>X(IC$+^N&ITH)B&B4ICS%K74!?5*@]IOAG5 1VX8O
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MY_"YO<@D>"J^L>V,!E)$1;H,%F9<70.AY$;33TB<RBY U!CH9&Z5R*<'\']
M#HCT8VQ2TU.%)2;@(X(IR]B]+,\T9DF T(%89!F ^+]4U6NN.D",SF89RU)A
M@^MEG2%:T>2SMIDM/$I&>*/D1!Z,EP?R(^,,>!KM.XVNS86V!!E&[!%E6KHM
M3*? /(]5V@"?U!W]:ZG:(F5BAV +J9(:9VZ C)5&!RW;F_"W#)38KC"BNB 7
MD+HK+B(-+DU@2A=4ZB8D1VXFP:XJV02J@S+A&+,3#9@]VB*.<%H\/^9XVABS
M&1&!0+90W9P7W;K1KC.JM683/&E=N#1L+V6,O?JSI,0N0=Q!A@+A3B[9(5-+
MQ;BC;@>//G@')+19W\U5VTNKLO5\8FK+<L)/O.SK63[7;UNM 8--F_Q9)Z4=
M2Y0O.LK/Z:)"\: 8 TJF<W*K9^U%6L]%VIN*R]NQ)3H4$$+49$C".>*$+!U0
MBB+XG.777$\9X9&'&A>,J^Q+V_6EN9?-2 $!TQIV*;BG7&!9S9H-O W,U68T
M-MR@ C,,9)+VFAK*W I!-BJ=@LJN*0@=,K)<Z<'&)R7TEUC:U>X-EJT9&S.C
ME'QMC(]-//78A ,\*.8***.2)_)L(C!\--@3\,X)&+3 6)#.P<9=J!NIUYCG
MU)\\P?Y^]%\)0]C3L*?A'="P'JC4 L$NUUAS&UIR:VPK3^.>QG=K:&!V(DFU
MR2'(X)*V2+(K=(8N93X!#4N,BYK&,( ?[4 @O?_U'?] D.8%QV3R E:6-2Z6
M""3:]&9BG.:0[F3Y#>UAGGD\\^R(>1P?FJ?3<7!+907XJW:2"BL) ?1I$;:G
M7D^].Z!>0DH5^&<7GS['4.B5'8=-#:LTQKTEEHW)SK-I92A(A#!_L2@4!.@2
M8%,&1X('FQ'D46/^!(:*#B2%R>#4J>FKI10ZYD=E'"TL<H$1,!ZPL1:P0V*^
M8G]Y-O-LMGLV:W2D"V6&&P1V8\9B;W?JVP%:X;J@K<Z2<2Z(RA5B8X51=&F5
MJ3RO>%[9/:_0A#JN&R3V^*R6Z].8SHPZ3[N>=G=6_[J:W**NBV8," V6&VL%
M. PJ<R<+)_LLM0F-&6.>XCW%[UY:.W,XW3;NSOX@@;ZQ+16((HJ&BFV>X/&<
M.N;3C@4U,?2:O1DT&O &'"$VK6YH@/9LX]GF@4.N.&R1K7H3?$6=8.;;Y-;=
M=D5]Z")7<8VZ,U*R73*Q[BVVFLHI>E:%HH8^SQ6>*_JF3,0]7C/26G#%I7K/
M\:'5%^"&$@LAEC=BR]F1VN)53)647G:_4>K_.,D7)?/U!IB'TK@%2F/HH30\
ME(:7O#V2O(V@HD$3)9N:QA1@%%);T-@7QW-CHE3@/PEUP 6TM%.NO9_J";P'
M!&X]4]/"$;N)*,Y9X4RD5!7Z/LE@@0LZ69KLU/I":5.L;.+XOM'9T_\.'<[;
M1M/X_N.[M)#HH7,$7;B4S07G'&=;H"R1D!>.^Q$,;Z=#@]J1,1Q<K&\CDN&F
MSJ@+3/OQ2TW N=&+<I48D75[&)J'FK;?2GUJ-%@>KBXXY2@().2',:1I-PAX
M9R:^E8CO<6^4AS=> QS\$R&><V%K% .U)66%!MZ5\@#'?3KC;3AB@S,U$,>+
M(IES@S@6\:^ [XD<ZD3>VP1P+R3A81M<!>V(1UTF.+AO#0*LZ3!>;=)M?I'!
MYQL$FWPWM>EJN(]47:)X4[HG5:; =0>'.#-1X-3/"L5>51&2*]J,L$XI(U=2
MEP%F)^(Y4-(BJC$?B#]5T1=Y#&&FT7X*]$1H(4.,\"\B^/10)I]V ),(YLAR
M!2K103JQ,]#IJ3T6T9YYS8!.()Q)LHBHDU3:Z2\WH.UFLW83O(0JE+B0S\ZG
MW #&9*6WO37$D+N\[2.[,^5C16:,GG5,)>39<K4Q'?,8;<X)F4W#AFF"J8_H
MBR%\ ^#2?K'V"?D5\T6:$(?1WWZ-RCCZDY[U"<118=%[?O@BIMC;?#Y/B+FI
M]/W3#V]#/9]1YG<P8^;<#<5#*(M55F9(("RUERME(UCJ8+V6Y\Z]-)\^D) %
M,L:9S2^%$[_;'XO)V\5K=N^M<0"G48)##=-:]SE.%<&PDLF#2CJ;X"AV[9[M
MS]D_89;>1OS=^:2U#5TVC6A4#322F33I)2@?0FA(\[+L4%"L:.PDR\82*-<O
MK]6YR=;]:!M\PJGT9? &YR/(DC_AD@W"V"W?<1V5H$&K*F7(,7CQ.S51U.-[
M- R#T>'HT%0J:XPH^M'"8"!B2D&RL/'Y/59H7O)M*?G0*HV3M.89IDR-7NKU
MZ=3O0^K=>,I6XGVMG+OY-5U";G5X'O]-CWY!^22S7*0O0O[R%Y[]HJ?GOM'W
MAQVWK+FTQV+,DS./X%Q#4P7BOY9(H'B\=E@UN:YE62NW6KN<105C-&*N' ='
ML\+,5XG,201RN-YM VUKW&F",+%PK1N802\2RY?,WS06+6IC;@/"$%HY3> Y
M]8+G0@838"\I^$.F>/_;AT'PII)>.LQTRA*(QYPQDU5#X>O.H:X=P]=;V-+*
M%0\FVT!PT"ZVZ6T8=%QA(,:"$1ST?!5-,)&"D0F"7P=;)F_)#/,FC!YV.ERX
M=:F2;2BKHF8!0="9=556$34N>C;>5S9NVJH$ A@U.01(8W0XO"!"0X.5*0X-
M6_<2Y"O\[]_K3.%EPYLXR]([2@J-F!!EKL@X/SL/#R_.'=%!&4!'? R\,?H
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M6I[:\T\]?5S.>9QOWC7;?+PMWA1<JT(%+T[/!R,LYTZ3/ NF>1%4,Q4LX=9
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MA+>/59V&%^<GGMSW)/CDP8@>A@T^=(Z8\X!$CZ8,/(R AQ'P>^R%A!<2SX"
M_1Y[(>&%A"=@O\<[+USPK50/[ELR6#2.M)Y&21'03'F<Y@L/GJJB4'AL^>0S
MC:R>S%20)A&/IO51F7T,0OJM]/'<7=8>GASZPH:]I':_E7XK^[>57@9O+8-?
M'H?GYT>>W'MS((\YG++O9[%'HL=OI9?BNQ,:9^'1Q6..XNS3@>Q]880/<?4B
MQ!5E51(G:5TE>180EY=?&][R*9'^A.C]AOJ<QZY%S\N3\.CDCO-EGS#I[_I8
M[NAR/>$3V3MAY#?42_==BY&7%^=W[!!ZPH2_ZT/QLGWO19'?4"_;=RU&7AZ'
M1V=WS%4_8=+?];%T2G=?A;;OQ[HN1%?6DXDJRV 1+7%*GJ\^ZXTV\EOI<V;[
MIM)'X=&Y+S_KSX'XRH>]%#U^*[T4WZ$4/[TC>NF3I/5=GX87X7LI=_Q6>A&^
M6T-\>,>L^),D]UT?R -'U7SYVRX/]ST*)556-"TO=Z"$PB!3E8]P]T+U>&C]
MI[WUWDK8'H'U]/&+*SPO[0$O^:WW6__\MMYKD.WA!L[\H"//2W[K_=;[K?<:
MY$Z1RN'0S^S>W]#7+JH%_;"]!S]6&;9'H4Q!0_?)A'W,G3T=2?<D-]T;#'=I
M^#V\:]O ,V>A71_=8Y:R/)U3>Y*"SV^ZUS9[HFU.3QYS/M;38:%='YW7-E[P
M^4WWVF:/M,W)7=-IGG_V!YMPX[CETSF?7?/5KZH*TKPL?:*A5RSFMWXON.=%
MC\_.&QEWP%TY"<\.CWM\J'TZPCXRY.,#<#V=L_-Z[-FRC==C3TN/#2_"T<7C
M XAYAO1Z;/=GY_78LV4;K\>>EAX;G8;'=QW:Z!FR!R=X8Q$L_#<:IXI^[-S%
MT6!T>O;MC=LX''7LXW O]G&<I_$FN\B7X#I>)14L<0*+^ZA*%163&?75Q^I*
MI?F"0"JE)-7$<]V/>/15!L[IKSUD>.#-1WSZM2=\N@^<\OM,!=,\3?/K)+L,
MB#&"LI[#E\"-99#715#<=NCP@"*HX$%+N*X,%&QP'+Q3$S4?JR(X&H;!Z'!T
M2+>/#H<7K^Z-2+;YT#91R*>N%J%'=95K48SOAGUY=?B:+C](HV5>5Z^FR1<5
MO[Y.XFH&KR1*DAO@,])H4:I7I5I$150I31.DZ/C9W[236%=)F3#$ZRM]?T<J
MBU]W>CHX.C_Y%LFH2R?)F@:GMUYQ?#R\[9HCT RW7',X.!O>_J[=K>9..4,^
M2I0!H E.UNG@9U1>_Z 2W+*F]H/6V5O^7![+Y82-P[_\]S>GW^QN][V/\V <
M][^@J%E/_]>X"/[R5U=9W^KV>$*X3T+H=Z7,,R]CVBV7ODPR,*OSN@3+N?3%
ML_W4D*-O=GH >RCQ=LM4Z(KVDI7V\"2?9)5TGW;=B[3]8(1=B[1'119^TB?9
M;W/\KH7K?=KV/D;!?Y@OTGRIU$&ATJA2\4H^PT,%[VN50]\W=->D__BU"WNH
M%79]2+#7%X]?']ZG8_&RR&_H_FWHKN6&%^Y[(-Q'X>GAX\.^]^E8]J^#>#O'
MV;M@MY_:Q^@ZF(/OA?\,)GE9E50P!(M610:_,L5&45GFDX2\M.NDFL%-63V-
M)E5=8 43_)!<)56BRA!'OJ1U3'5-LP2.:1$5U3)X^\N'.[IUOH9@MS%<OY5^
M@ML.H4#"T_,[^F">VKW@\%OIM]++X*^=CW5'/\F3ND]5/1$_Z8=;'2)XQ01V
M ?<5%@T.$%RS4,447@*7C)=!7E=E$BOPLK*R3BMTD$I57"63&YRFCW=UFGR(
MPH=+G^R&>A6^O0H?AA<[Z*WMT[D\"=+W&^HWM-\;ZH7S]L(Y/!YZV;Q?CI9/
M1=TW%_P<C8.R7BQ2])SJ$IRF)%O?!6\S3CXVL8]A.+^5/J*YR^*/P[M6]GEJ
M]X+#;Z7?2B^#O]KK&5X\9D]HGPYD__P=GUAZ&"[X,9H0!I7I@>(BO)<V(10K
M3"TE497DV>,CQ?;]_/8N/N8WU <<=RUT1N')L:]]WWO*]QOJ-[3?&^IE\]:R
M^<BGZ??,-?*IH'M/!243++*CI _\0955GJE@$2TQ]>,3/KM6"'XK?;!QW[1J
M>''TF#.%^W0@>T[M?BO]5O9O*[T,WEH&'X>GPR-/[7OBU?B$S\-PP8=JIFZ8
M[D+I'Q\ Z(5B\$/%GO;6>QU^AZ*-B[MV WMN>MK<Y+?>;_WSVWJO0^Z@0PX/
M[^@'>F[JO=^X?3;LZ9S,KCGK][R*TMLGA_9R:D'?SW:/8I-/9]-WS5!W1/)]
MX%/S-L?V^;^3\.ALV,O3[-/9><'G-_WY;OJNA937-D]$VPR'X?#X,?N+GPX/
M/J1S"_^-QJFB']=MPK=;[\'PL??@?/,MZ/N7[II1/][F*@?7JE#!BZ.3P3%6
MHJ9)G@73O BJF0J69IQWX$[R#G#6:1A,\ODB*N!O51Z\&,+F;7'_\&(0_ Y7
M)-D$.+]403X-7HR.!R/SC.NH#!9% EL.GQ/$M<+7X$.G>9KFUTEV^4J3@;O?
M#[ZA08OXXN1*OSM.RD4:+5]-4_7%I;33;DK[=UU6R70)= $Z!R@6;SLHJZBH
M7A,]'<"JY^6K,6P/WMM)?7/XQ7425S.<F7YZ\6U?R;'-27JKDHRVA79LJP?<
ML'DK>X)BXPO0[,@(CHY#XY7T9;\TM<%*#(LDV093*[I 6E]:/HHR^"D]P+\L
MN1+CNWO!< V)@>%#3C0#O[:, KLM_^L9QC/,HS),L6[ZRQKV$0U)$U_@NBL@
MC#@B+LCKHC429E'DP!4E:;N:7X<7=7$@/FM:PWW 6/IO%:ZI)+XY&9P9MEG#
M-7>S<8:C>S=RK(?4IV,?'I^T]/+,9'D6T:5B-^,@FL+:7T7I=;0L7W\3_*7W
MYN,].@M>]GK9^ZBR%^R*,L\RE;:0/U#B'5N)%\1%<J4R-#Y:#YBI*)[ YU1X
MBY)1RB7\Y2I/KS9&3_2&B&>&W3-#ZF)_(@<<#BXL!UCO5M^#U'VERHJ(>3-"
MQ\O0,_<$[PE^]P0_W0[VB>@ZI\Z!*$WS"=TR3\J)2M,H4WE=6J.=8D5.J.B^
MV0>N\1SD.6C7')1OT$?35B7A:LRT;945^12\5K@6?-"I$N?4"?=,V<8B;947
M9'MYI;1K$O$L=3>6P@@E_ 3<D$^GI:K(RP!2=2)$MR1(@JBJBF1<5YSH2&\$
M[A!V/+N!':?J&KB:'T.1U"+*2N07X$#-+,%+?#RROYKFA8(UQO4$WE\OI@5\
MI'.W?O%W@W7\9:(;0OY(U7BP)T="[)L&/-9PX1[DR\9Y&F]"+GP)KN-54L$2
M)["XGU2F"I"4>"!1#*R1E'!B(-W42K'I5Z>AOF:=/BWEQ>KCB=4-N$+RRB>#
MHZ])*X]L0NG.6>7!^9JDLI;L6#*QFEWV!HOGK-WZ $R]AX9ZW9AJ:!QLQW,V
MO%<"(<W)F"_R^?JP*M"\L?+K(H#OOJYFWO_UM-\/VC]T2I(PA*HN1>4T?%@I
M3R"_M</>MK[KJN>+&B6JXZ0*@RKZTG:$==V#-ZT?QF1EG! XGWRN@I<BN[[K
MI37=>=+'@Y,C?]*;;.?;691=2E0X*;"JHB8.AQ=-58&V'KC1D\_D"T_ "$N3
M:$RZK=_$\$Q.?JO^3#B]R9K31O/ZUA/OKOML63!HZ=LGYF-]K_Q*/]3$9\I@
MK%"BSQ5(>K;PN=H-KRY55:6*0CX;+Q+6\ L%C2A:@WHC*<L:KJ(/_:0*C'R^
M"7XS#_J$#QIXJ?(84B7*JB1.TAI#:@%U3Y1>HO3JU.]3HMQXVK<X_%$P@QO
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M(<% LO ,&X[ (5CAPAHL(E4?F&?>@&G\A)I%O16 4;/HUL:JG(:D;.I[!9&
M39$L8F&Z-))*=+ADE2BT4?9-+6T:JV?&[H2.C.ZT!5@,]\2O$K"!'XR,L"LQ
M4>PL24T0>O_%RAM6)N)1/Y<%J&PPDM),EDBLIK@>C9IOQY4=+B%\5^ 8S:%T
M4MSVLRSXU%#YW-!14_ZI*>MU,45#__^0[=!W4;XN\MA"M:() QA=%<[ + ++
M(2NPU@@\%M!]23^&% U8:WE/5L<]H+X4 N]'R=EB7M3SY/"Q6.QKO!67ZQ-V
M5RSFYVGVC2=O95V=:0A J2\ ZB9L5O'SBL\8!@GK5Q9"5-[[U>J<\9NLRJ1H
M/:^___;^M''Y.-<[<UT7Z_C6CM139SJS?>O):QS;?.H:XRRPG2<N@FN\?1[(
M.((#O6C:O*0PY#PL(C0>F&]X0OOC=JHN6RE9BX^'IE@27O8UNQ< AW_YZ95I
MO#H<^&ER[,Y8[G^:WIW_%Y7@4G?CC4].DR5"V"8A'-.2E:,;$GQ8+GV=Y=I\
M7"PJ\'.J-T_R)2'P$"K2>G50! Q0XAV6J3"JUTM6&B F:7D$B31BA#Z(-*.7
MK#1 3))((Y%&C- #D6:&O62E 6*RWQ&&EVS:Q66N?0)['].H(@.^D,,".S6=
M[4C O2]&[CO&!K<\O.\ /30+O'#-W7=@9(#:X=!(>NW[HR!XH?]"S+,SO+PP
MWGS$&"']<&0D3OIA"/K!=D>6YQ+S] POI!](/QPYB9-^&()^\$>.8Q'O] PM
M:]7#H>J2*%[XS'BAG+2QC7CAB\+Q?<?5@)*$!,JM@9*4\_.5LV6'V#-)!-\;
ME.RSCK3ON!B0\"%0DAP_H!QWS9%I^43OO<$(B?%!RAX")8GQ XIQTQKY+EGC
M_<'(CL-D5%RWPV#9K"QNLD1NL, !/WE,!78]5"[? 5"JL!\ Z,D.>+;XLGU_
M9 0O++ G?CIN?B+0$^A/#_2D19ZM14)KY+TT)DCL=-SL1* GT)\>Z$F)/'\(
MN#\*7:?'..T3!O?%3CNHT^N"SG3$/3:.1KX,6=U9L^J)?<3?H1GP-SYOE_J^
MKG=VO7EBLP@NYRJS&%=2X-][V:I_BIQ+0.\YN[VPIV#'6"/#Y=F(]."69C\G
MR?4)=R3X".BG"_1#"RG2-L>B;4:6_<(>Z!-G09)[!/33 /JA910IFR-1-J^M
MD;6TF[$_V.P3[OK(@X_6D\*_N%WK9%>1K0T-6V>6Y_]E-33<!S#T;:?BYT>&
M2';/O?>#T7;%S07$+VJ9^UVS 6C=LG'<L!P_-4!4NV65]H/OGX7U.O*1%A=Y
ME<G) >UR=K4I%6^**^7E@F?+.+.;->:84F#B DQ K".J!S* KCNJ_V?N 7HB
M2:+6M7= 4E5<Y47JY:V97$KY@]4"!U?1<UR&/96[:&]YR;49 WW()@)(*=P%
M:\GG2PLP\R+7!2KB,<NO>76N?L!CI"PKM1LV68BEV>N6R>*9JD4<\TJLN16[
M9U?/:-OM0OD1( "@%&=,W$6MR)48.W/;J\2Z6SUB2!ZXG1RNDM_ *_TSL[VR
M.?]$ &_YCL$R!4P+@,;_-3>"@TRSQ11.F:]?9;]ZKE/?F+ME06 \2Q#8;LO0
MSQ $CGOFK\B!_O)_G1[5V'Q>9M%"$N2\:*D<'C:M6=]MWZNJ"N0I@.%M-A]+
M%F^9M^5H_ .<,N5ER1--+94N61[#Y^UBZ+Y*$K]%Y:."Q-Y0D!BM]/P. 6%T
MQ1M#<$TF^*]4.$WN^WEBW;LG<[[;!-K_9N%#2KI]L^[3\LX,GV?X=,EJ<[LG
M[%(_O&$\%K=['ON6C[+ODP)$"MZNW=;<'!=FLQ(.A62?\!L^*6:*UV/!P5U.
MMCH*_'7[WJO2#H'P7ZR\867RH_9S6;!$^Z3N=G%=<B[NC\][X&]O1EN75&;7
M1'E"!CEKS-072@W_24MEQ35U[6>ZIL,U7K[' _SXR+PR<DV/QR)=<DW[:R8^
M,D5/Z@[+#KL"J*,]4'PO0/Z";!%"XV&SQO;-KH4)\F;IB[,291+(>OP+EN])
M,2XE?T=SM6*[Y!,AL\&<G;"H_4ZMII;,3:6E6K4%^FK*YIT#/N*QV5ZK.,A^
M.@*^7.<I/DS]KOG=Q!\&+Z1]^\"T[QI$^L=$^FN=AH=)W^R8S"\D?<LZ,UY$
M^F;7X-^$]/$66Y?]'=XG(WBKMN8OC\P@(2/X:"3.DA'\U P:%9KUET+R_36<
MEP4BP@'?%%XRYCRIM+0LIN+3K*H6\*XB!'#)2WS1G[4O3=CC4H0]A)U@=^7M
M^IM5;,+K6 VX_],B5W$3Y=M__/)9"M[ /;.Z$K1[(_Z-EW&FA+#\>C'#($(=
M;UB6V=T7J,:LA._-QP#^:QDMX=/9I+CC7-VIEO#:;,)$5(+-X.G?0(+/.8C?
M'XQNW'6==*[#(/!5?!L5PU%^Q)I8YG<Q*NBX;7-J6[G3)UXU'7\%8..F76[&
MKKDL?]%9"F<_9Y-;=E>]?:7]./3ZB^=4[Y&XWZIOM9FX#SOI">T[1.K%6I%J
MA2L)N\WOIUMK[^AUL^3D$PV>9)=\HLU(U@PZ"O*A9,K+"??4"P.^RZV DR J
M2O0,2Y&0(;>B#TA]#M-^7LI1-?8?BN]T 9X[AW_NHUD#PU1<'*L 09/VJA91
M-<?DF[ P15(=V1;NOA#U$"RYD3P)SYT5Y3PM@+-5?.*Z9-.*Y'S?2>82T)ZE
M6*P]N1M)KZ0FFUL0U)T4:"H3HT@$Y[U :Y+=U,].L@J<IKOS=,*_;8##_UV
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M)^,V*MUZ9'H58Y=\791^713""EZD#&/1L@H,>_IBC&&#'(__\]<ON#IRUD[
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MVH.>\#42(M 6(EU02J=^?JEV?HGR!&5<*YY0"]FR,I$S<Y%3E1(3(@G5-^8
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MDMTT4F,&=J<V+5>_5+R\R80;*%?]MJ=2WC)^(!([2I@T*R*Z4D6D>&0$J!:
M(E*C+68%)J$R;'XKT</.\:89BJPO=8=X I:KN$Y^6PYPJF=S@]$G9W(W#>4R
M^"I/W0[]+CI38Z5_B-FBMCIY13JW6K@>-*)N6=\18[J+F7!& 36)L!73I1.2
M'38 ?I.Q'HS5",X3\47</W6_95\JQJ4>YJ@A%.E.B!$'3695T:-46/P;PV0J
M4APHH1NI'YLZDQG+[FV*K=:L5_':E;UB;H*848"\I<86U)X#&A#@=%R+%[H_
MW."!V0;"9>MHUGL'8MW[CEH/914.\(4U9Y/<PI8&GOQ@N9UQ^\\XJ;1GVG!2
MB[+U\[+J4%.;<%\WBJ(.F"<<HS[HYPFY(SA\[<!<((M*F1L//%@=JXN&SKE5
MBA_MP*6GJ6AW_;05S[,[):E.HC>O4RVM%N^DN==M(VZ_=:9=8O2LV<_3$8!"
M<*\Y9!'+F+V,<BF;$B,-ZL54F+Z.&4ZR/_DD&V/!)NX:$D]KL+'Z/-0L(IGP
MJ+T'1NE"!E77,*S:T[YH,!LK8L7"9GQ1(>F5;E6GETB2<<3.R(^*<TT4#YKQ
MVY^5TI6_.V]KXI2H7)I<TMQ!7IO("E)A@P:#L4'O ;9_YWZ1/3I K;R#\HW-
MU?(V:OY6 Q'6@P#[ %+K&B4''.1V/JXK7*40 [!/.(I!;"$3T7KU5T3S8G=Q
MDX>/.WRK:]\EG1<HH#6^'LTB,??A/]]U)S/]=3&=B<INH?MK*:Q=XD>+6:5=
MQ$)5@IRUQ-?_^OGG2_QPU [:F,!_A79-Y$8\8;'7H9HX1E4A7)XY4!E8'VCS
MS;.)5 <BW\PJ-6BMO004L S"@!-S@UZ ? 694Q<N&/_&ZQ)0I%X994XZU+M4
MB=MY8?4"PJ$!8%2M$8-^6ZY*!] ]01=H?ENHTCVT&\&I>4@"HLK#9/YU)C(7
MHE^X_J.:KJC)T;Z3NKZ\2%->BE1&(;80C@3NZO=J-R!UWD2"1(XE19L/#U24
M4A&&;ROU^IH8)J0RJL*U+";P EABV!Z]A13XEIA6$S>_Y"+MISF&\SIZ4Z\4
MNV1EQ( P],_?)ORN)0K#6G=F&8SJG+G.:42*2&1% =[XBX3$.R5I+EIR^8PY
M7J1_[><"[=PV"#5%(I%F&KX^O%(YU<I"(DX6*4R0AC&G+(LSDZR*)T6%IDAK
MV\"AXP46]@C:@BN5>=')A Q9JYV2U%NJ9UUB<L4KM1.2(\>+@AF1ZQ;3XN?L
M6EC:@H[G<N$9<#!0CJ '\#<RL*U3D?P'9U,4&(O(4 Z $V[#C2@<6"?J,+R3
MJ7!)):AK,BENJ_H@=:[LGOBLP)8>,.V=4$%L2 6QQU@0NV\)]HB=M&H:K::O
M'S.5ZE <GS0KWA855PTUVQ9V4L:*YR59*@J=YIBUE^6SFMI_A+%RJ?1EQ=/*
MF9N7AD.S<I+AX-&T#0:#T?DZ>Z-B&=JD $U=/F+QXI%?9_B%%*T$A@>92'<G
M*^%=BIA%&.>>H4DPKY_T"&2:P+<*<-2*YDR[:&LY1YOYS-TR#W'>ILZCA8:*
ML" JGL(#'"TOL/Q4Q6GD@+RE3L95;)!],PSI\ ^N*N$PG:O%$U9569KQ1)8V
M"E.BPS9Y4A-RFF%;M]SD*B]832)[8"]/0,)@4CR37U*%+U@(M7YMNBPRK+0Q
MGP@['H<"(W]-,L'A_)M<X/J#;Q@K*6PDP;\N<J[9!A ]B(*Z4!F]0)P.DLKV
M4%$HFF/ %V!?54TK4;UJW=<B=5^L",/;H/.%Q=/M"W<"Z;&H'I"M!8_(BGMI
M]AJ,*&&S6# GWEF(59'<6'M[Q(9\$:Q6Y/)\HA+Z![,]=RK =J^<5/AHV$%?
M<JX+O$G!0YPZ&$Y%W23+E)O@]H.AM5$;PJYP4TF62]7R=0$$85J1;G4B%Y=M
MK_*';ZJ#0'GB9F@[(D'!ID)SB8@"?J=[X:C#ZW6'S!+M/A("%%."\UP%!U1)
M)0J8B5H\CE+BOQ>L!$,75-77)@SQ"P!/,PW]OX7FE]\IJ[GV3WFM#"-8UIEV
MF0$@F2@G6<^@HO+RH1,B4(3<J.- '9>_DP3IC&;)NY7/=4BERD#32M'Z0'A@
M*4^"DO;Y0:*\%F[E/2C];21A&Q<EMJT4N>QH:MZJ)JA?FSZ0-O3S'MYX457U
MP2YR-KFK,G&D7YJCO,-;-H?_JAI*X9+/3=M+0Y(M"(<L?0X:W=]N\>/#@?)W
M*!?$G,V./0C&9UQ7GU1P;K'L%TSR_UTDU[O=\GW,$?W]!1=$Z&BZAM.394YG
M'4Y',=P*GGB)V\N6VQ]H<MO(;1FUU1I"XL)[@NLB]18379BBVE#(L3_.+L]4
M5[MHY10%Y*MN2P9/F$U4+92Z71.$EQ6':V6I?"=9\]C*JJ8]OE)3/$3Y2-.^
M-VK)7VVU7ADEP82+I.+N*)]YF^]&Z:X:6L#8K2<?R9#STF00X:]V-%#:S?2K
M\E69O&_G)V4;PE_./4&U+:+835\BP L(9EZ40A#@<<H,JPA&FFH?+)NVFDXU
MP0T#\Q+[N$12I6X^K$OEZ_$J3'0[L*I0XU$:FR3.RG@QQ1" F PEH=:0F204
M5)CB+W#H3$8 5#M0!Q4B+"_NR,I2A!V$ ]*!^3V -74EZ$/#Z1*LVP5;G8G
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MS ,S%8'^I:#?7L[_>2@", \T@;!=X_%A:_MBD<"]$NV7+&=Y#)]IEW.P7Z8
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M7U:(5?3,=,$F ==X*XWBK0#\ O+O8_Y.2K^.E;(5 \5UG)$=K"N[(:$P;*%
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M(5Z'$B];-2LI*Q)9*%(B1O+9.++1RM2DBPE;]BA>NPO!+].N8U<3@1UZ80?
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MJ'NZ _  _KR A\!#X+&9 #R !_"0#\@'-A. !_  'O(!^<!FFM1F O  _KR
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M;%F5H6<*HP:LKG4\NHV:L$J-9> 26+)" #?M@AVMVY]AN@!,>S7OUGK+"P_
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M:-/!VIS=PAC58V5UHQZ!93)S4]$-$^IKA?5;NY09/?[A\WBYF@L=%6:][ES
M)& %RL7V]*1>&H,<U1/2-;6H=/4O'XC2#JNGW[_;A?=0O]^V0S#NSZ\+J<J-
MRQRFI=\W,P-0A%_@AG$$T+.<@%J_D3@GBML69VL'=E82<!;3G 2)\ D-LH!D
MF9L0FLJ8A8'O96E\B#CJIY[ ??;!QW*.*EW].SS[Q[FR=$=X6JWN),5EL^]@
M_^E9&*Y[TIQVPTGY%\ZGZ>%PK6YN,%L#N.JH#G^0W6/VT+$!N+8CV3TP49A)
MD69!F!+FQY+0$/Y*O4 0*3S?#T,6YL%&1OYC3N.;+GD'^*DZA7?[GL%]AOB$
M,WBZJM53$@H_]BEJNAZE7YWI)3QN%3*37&YUR,S^9</^N_ONX2DIO(_(P-.I
M:;++SFZQ2S3 5JM&?;XN,76R_(SM0.M55A>B )X[,Y=]ZGU9;WKHK@OG<CY7
M*-A5BY;6]$5N+5#B7&NR?2:@1!2>18O,-=KH?=KTVJ)M=5)_7[WJ(,P]]2*>
ML9 3FH<NH5&<$1;YDO# "^-,>#%C!TE9^Z.6'_*W=:.*.M<A2M?9^3Z#.GF5
MZKOSRS]T9JEL%\$R\<,S\;UW[M28N,Z&[KP%.S@W'E2%'-G<Z91WE4AN0*GJ
M-=3(&_:G['>;+F>IZ]7-LO54H-6NJMM,5C5ZI]%_/<"S4JG5LXT<ZK;F=M9E
M76-Q[KRL#3RN7IDKA?O59V>/GJ*?C_!>&B:M'X)2X%4]T=A(SQC&V!3ZW,Y)
M ?6NB[HI*X7[A<.L"I6^KWP.[)85<^6Y4%57"^>6P6M6M8/IXHB\9B(Z();F
M:.(K1T^F$L[K4GM25$6R+J8J*KZZP3(ICGA< UOVGO&9LJ2N/FJ?[A"MQ-:H
M=5C?M8%<AQ%%5E0PG_EJ2W78RR' &>))F5UFRJ!_F-U?Y+4>2D69SJ_[#N!W
M,_T#P142&LIN40_ 0YOK4;MP'92!'2**^4J-1;5(TM0R$&58S6W<6I>\66E0
MQ]5<A4[08R0*=*1UH9MZL-//7F=(XMS+LCPA(M29MPFV#0Y(Z&?<2T7N^6P#
MPN!1!B&KKR\7 O]YVX<U'V89[C-6JTH\5&KCDAC$TW',V>H4A]<I]M["4](I
M=NX0)6] 1"KOF:GS<H";\S]50($/(#9 @,@[D\'0_F+"!EI0@LRHFT%B&<BT
M/RX^70RP1 G2 07'(/<!!0)*5/AB';::&Z246A457\.LX:FZS-.\S40D4/=!
M/&H0' 4&,VX0F5_'5S $([O8/DB:N<+H;T81_@[S2POX=2)=.&\VDCD0/K-1
M0AJ>Q<NZ:>O3-'0MTA)QA6# _6TJ4-0)YHD+INW")HZ\6 21))G'0*,6D4=8
M$E/B^0$%T0%R)=G(@CN<L/D-EAS& E2_3QB=5<>-[\ZN>QJK<S ]$3)%83$5
M/K^V>&A"Z3+Y6H>3&ZGZT57E;8'A5J5Y T=L,.2+9D*%C00Z+ J$,C"L^@Y!
MILL:?[P7,Z6/RF*.U1 'U/0>0..J0RT^+(2*E]/(]V5 (B_W"4WCG !OR4C,
MO3P!,R((P_PIO FDV.VKWR16)<,,%*O^D",'6N-"P)?&C.IWM!7W59'WF<7D
M](M+A,T8T*4U)[>G0LX,]/;&7M4>!]Q3+72[=@\[];64C58SP'INJ^B;LE$M
M'4RZ[TT'=8+M*#XOVGKNSG;6;3BZ[-NBUD7W<_STZBO ,H\UU[9HD'NO\ FG
M6VUV'=VOTZK^WW^:%%G]*C,Z',4KMFK*MF,OOARTU%?N:W4YF;.[<M6\RHLO
M4KS^7(CF&JBCR&5N4"QP6<M7M?:NR7;BRN&@G_VB'P4,HTN+NRWJ0GLW7K5/
M&5TZ[%"L7QU%%]3U_XITZ]H8[[C4NXCVO(Y2;[\K@PLWW._E[D7L[?OZ;S',
MX&G#;#L4;RY9N_GU=MZU6&9KX,'Q+_S0W='Z^2L,]B']IJ?4C'S;R?ZFVEVO
MR[6G?WG?VMO5^:9IKIMT!_+A[ZINZ&AKL']']JT9X)-9/R56IF3OO?C[L,CD
M*UO!+O^W6/YO=WZ?+ F/L8)36J^I>6=>_/VELF#*50WV4OW#GN?5+N/QI*;_
MXJC+<(+\\+@';%AF.<%C=8+K^8U/FF5RELF=WJ$X.I-S)WRL3G ]3TV)]]UX
MYE-WYH>^VEO[K".0<U(+,<5PVU<3;QYSW!ZS6-9Y]9S)>NQC\)<CK<L)2HX]
MZ'GLU=P.?Y5)'@K7BPD+74:HEPF2BL@E(<U='L<L"Y*-RI3'P,]M3^RY;-ZP
MJL*2IO_%U*F=:%?!".TJN!?M*J*S(-C=&M#R&,NZ+5E/E*S'YJ%6(IZ_1)34
MI1EW*6&!!(D8A"#=.*<D8TP*+Y=^E/"-KL]21&&8Q02[1,(]08J)9X+$:9YF
M/(JR/!#'DXC)+$UW0S);%G/2/H"'>7&L]?_@9-OO[F*;^OK84( EO747G[**
MDU"/IUX4$AF J4^S,"&9E^0DS",W"\)0!/&&BO,XS/G[ZWJ^A;(3SOQ@=[N7
M"6[\*6WS9\9S+.DMZ9\?Z:VD_7Z2UO5S&7(O)JF'4C/T/)(%7D)HX$5)&D5>
MYFVT_WZ,,^$8DI9&AW4J6(YS4HZ'-1_0D*0>5<_;VR/QN$4<UH^9-TYQ78_-
MF'Y7U93W-*^H#N?O>()?T![D(\=^SF<!CGWBCA4ELBK@%%5 $>?,#:.$\("%
MA/)(HC(8$Y%(-_/CB'O^09PM6Q +-K3"\1>#*P^3>9'.PNBPOA?+SZQ L0OP
M[!?@V)S=2G0KT0<8\EDJ)?43%.:,4.%[)/4%(X)E(HQ#ED1N<*@,D>-*]'1&
MP\@*]-.1)V-7#WQ"!)VM4(0*"O"0L)W;2'<:^$2'P>MULR /TI"25&!GB2Q*
M";"#C'B^G\E()GZ8>X> 4/REZS7:MV?8"I"XCD"VSP!M^Y8'0AC^LJWSZ_3
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M!YYYN;8IP/AJM?9T<$,L1[A?[?N?U<VR;K!1VX=5Y?S80FU]PJ]6R]JYU+C
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MMEB>&S[5@Q)NJAYL4P\.M>#.P653[7?!?MMY>]-%ZR:QK:?L^\V:[-5>)V&
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M+MAO1Y-F?CI=M&X2V^]J%G^O6?-+!1LK"O9K<97HU%_\K/G^KQ]+C*JWJVN
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MXE$3Y <*.M!"4IZ#5S0"3RHXJ9D7DM4,CXH!59Q5G(<ISLI0NV.H1)-E2#+
M97(@"*/@2;20B+-1VX L16XSE.?!:/P?^&"1U4PB8(2)8)-.3F1F!7UNAJIN
MU.'#0!5G%6=_Q5E):G<D91R-A' "FDH*0D6<I2 U*&Z88$8:Z3=B?3I&Q90G
MH#+Z4D*;$A^4%JQV5A)+C4OU+-A+P8!G3Y2O6Y*[WY)T'](D7%S+IZ^Y*[VB
MU2<(M3:3'8CXJQ6T.RO(FY!\=A&8+%:0$^AV9T) >.:,==(Q;6Y;00S=>L\2
M0P-(:!!"H [HE$"%0))TAJ>PX[(OG!P9*[=H"%68.7R8J>*OXG^YXJ\DNSN2
M)8)H&PD#RTO8@!,)5K((4;!LG9%,<;:15A1$T(+14J6&(QT+ S;[4J^&6J.(
M4#P.>L>V8LSA8TP5?Q7_RQ5_9=@=[CA'EQ6E%J+4#D3,&4Q2!']-D45"HJ7R
M-L-FBY>%5'S=H$#02, F92"I'+TCVM,HJQM;8::*OXJ_BK^GXJ\DNSN253P;
MQGD":DN*EB 42992X(DPJB-7B88-DDV!".\)<!T]",4$.!T%!'2'N>!<VF"J
M&ULQ9I_'?9G9SM[ZZCE]G*%] \K[Z=R-&_?$UO0U/67_*6J'@UK[7A.[KL);
MC:H^&E64^2@5E2!D%XJP&IS2 KC3U"?\B8B--$2>HI+2:Z"11D KRH*Q(8*V
MV?J@E,_\N=,0;_==L4=&\'UG(AX.-E52J()_68+?-SI7-JYL7$ZNN6P8B<"R
M4B!$MN"HMN"C=I+R$+W;J)YO/:,FN@Q6ELYIV=O2-$T $Y;K9*V(0KS +FB'
M TV5$ZK@7Y;@]PW.E8PK&;_]ITN9&BF06%WIO.:H 6]9!$EC\B&[Z-/&IGZT
MFEJA(G"B OK4-H#QW$&R*@>%KK+(>L=DS(\HM96-*RE4P5?!5S:N;#Q,-C9:
M4!;0*R91(AOCO^!3$J"SD<XG$[3D&[O_P2OC70(EBFN<$G*Y,!HL,3'QP%T0
MSWU2K'_GY0\'F(:S[U];T#T<*OQT')??BZMJ.G-EC9S@-Z19>9N'S>^O(^='
MXWJ OC9_Z _S#C(3LLJY D8%C*K(5<X]DW.?I%H!HRIRE7//Y=PGJ5; J(I<
MY=S'0-77111?:HCJ:Z+9[Q8AI+9MSMW%&<JE&:]"4Q?U'$I/L.@@Q;EOM=_U
MIMT 66&P6W%*$I^#<R"3"2"""N"]9:"(-EX:Q:79V(I+S@@N(@'';0+AE,-[
MF *MK;6*":&\O;T5]W8T<9. ([D6SG^N-!EV9(C:]]9<GU2V8G05Y[#$N6^P
MK)1WN)1'K<O.)0N:.@+"& >640%4I2"32D:9C=H3+ EJ8B"0RI7"<0%&6P6*
M.4&"\\%)LE/*ZU\N2I\4MB)T%>>PQ+EOJ*R$=[B$1QQQ(I:.K<9T9_PIE+/]
M8+-(')G-L[#10R\PC6Y@B&!C.?Q *04?%0'FN?>&$2DW3R)6PNL5I%2$KN+L
MKSCW#965\ Z7\&)B41F;P$1IT,/3R'7(6* S)]1KY@C9.'K/HJ,Y! F1"P\B
M<P<N,0.9"L:%-I:HW7IX-:C9'XRNIPB& NMO)O-1'(T7'1ITJ-9N8YNV)NOT
M*W&D'GP:B/BKV;,[LX<IS8DE&:1,Z+,KC@802Z5@@4E.Z:ATVFC 1Q(U#BTB
MB%IE$%P(<)Y:8,('S:SWU-%]FCWJR-)MFCT5<PX?<ZKXJ_A?KO@KX^XPLBY4
MC(YER$K0LI5LP+%25HA3Y9VUP>ITFW&]2S1FQT!0KY&E P6;: *97=)&.!H3
M/YS(>D6<PT><*OXJ_I<K_LJWN^-;D1B37!FPW@D0VGEPI-2MCXQ$0[BDP6X$
M]AVGQB8&@0B#5Y;=[^+K!L^]T)&7-D25;ROB# =QJOBK^%^N^"O?[HYO XDN
MV9P@9X/^+0T$#+JMP/$[E3$T=B5P;_(M=<JR9"/DP-#)9=:!4<H!,T:2J&F*
M8:.C3(TH5\S9]:GHZV+\VK9]CYNXE5QK@[_/:\2RP=]X&V7_'I7D4E=E+;,\
M\"54RRQ7Z^WM/YVFRA'BP-*H0<A(P5,5@4AC(J$\Z:BVT0]PE]:;/=*,[3L-
M\G" JC)$%?S+$OR^H;I2<Z7FM_],.62OJ 9.20*AM 8?\%?!5.2$TJQRW$9S
MP.%N9+QPF*K\4 7_L@2_;Z"NQ%R)^>T_27+$1W22E6 >A/$$Z59+4(G;['UB
M-&V<E7],H\!*S .%J<H/5? O2_#[!NI*S)68W_Y3>)MIS *$U>C]:D' 65?R
M[;4)1 1+M=A&S\ :S!XL4.TB"0%_=GZ<_MK-6M&VT63A5M,61Q_OE] W7RT@
MNFL!J0WYW/[.NR35YQ=^MIZ&#]*J']$$;W[^UV+T$9%A,K_,8^@3N:X=A&ZL
MZ6JLS30W?1SOO]TUJ,&2FF7&Q1@54*_1VY0D@E.&@XHQI2B#%WECAS:R++CF
M!(SU&81'-]7%[$'JP"2G(DBW47V[S.XU17PS_]'-9A>CR8>.U>[E,G6#R^1G
MN4R:8WHOE?5)@QK\;8R#Z^78W"369??\]:&D=MS&##3P4%)4#?A,#-#,7,[*
M9V6WDABQ@V6GCG5==4]>=1W=_91".O-IUG!ZU##":+<:\0=RU,Q2>YY0NA_3
M^.*H:$8[:N<IEMO.II-TT:!Q\D>:-QE?HNWN<[/4A+%KVU$>X86?1O/3T:3Y
M->$3&EKNFY^F)J-CT7PLRM"<CM+,S<+I1>-3<(LVE0LNNL=T%\1FT:+F-/]:
M3,L7K[[O?#8*:"3ADUTWNM7?V^.[Y/S\@GRZ7:A>@%WXMVZ.BAO1O$MA,>M\
MS*M(;?\6R'M4U1^G9S@B5/3DBO^+.H=&XMG5F[27;]*X^77%1M1UN'[PTUG1
M7^]PZ70KY')UM*CJ4U3XT:2=SQ9GG?EY8[VPSZV7X^9O=X_B,POPLP^\7(!E
M<94ACR;GB_GR@5.\:89WXMRL%N)]*_"HP2D(I]U=:=3=%D<HAOGXHIG.\/JK
MWWR;9A^[X2^!J QLELZGZ*WCMT<W3T>=P*X-%D48TSS-SG"A1+P!E>/#:7=C
M&7B'2C&-V_)-RR&7VSH_%2<0I1U193Z@E"I.]!@G?I^EG&8SG.!W\VGXHWD_
M<Y. 4_SK[7IV?<**-8X5S#B_?(&V>X'YZ@4N"_(5/6[GKJRCFZ!1U!T_ZX@V
MIO*$Y<+EZW7\Q<5;X.G:!2O8ZMJVX8,1A5(\*JOVW,WF1P6D6E0"A(K@RA7+
M%3^9SE>K$P>P^M+E\CYNROMMOL\G7,$WZ-JA$*9^]3$Z:O__HK,;VI F;C::
M0C>0U9HLN#*__L[S3H:7MW?8,!M]^) Z))U?&\&JTN$:"%Q @7Q<OBW>%-)L
M[G#\:"1"&T;XU_*BG9"O_8K3F'">)@4[$8#3>%S^VXUA\7!-8U(>K?]/=Z!O
M..ENA=4=\+U#X> ;O+FM?,?-NP5.Y;\612:7%]U>8B6ZB[)%X R%L);3CHAQ
MBG8@M9<&8??#_$$:7C0B+\:(\VV:S\=%T^^T-DGS;?>L9CYM_H[,TMBC:Z.[
MY^G?'>,UHVEWT_+Q9<J/NJ&M";LH?:?[RQ%?&QFN)-3/,)T5ZW:*A-1Q79@E
MM^20[3I]NU:,NUV_S+Q+)=@B!3/H^HD(7G "63M& W5,A8UM!$U\C,)9D-QQ
M$-0J=!>S )N3XM1Y0<6&Z_?+2HXXS=U_?YG\5GCXQZ)4D_FUO86M>('L6#[!
M"]SUS*Q]P:*U2^LD_7F>)JATN:@R*NE%<OA'- 7BYCHYKL;#0X1\HQ#N/Y;T
M, C#H6-6][DROL4X1LCJ_(2B+5./<[ T;E&C1FU;#(@81^4O;MRTIZ[X*X4'
MIV=GA>F78#IM_L.AW3V+'9K_,)LZ-+&GX_'TTYI=\?KS<>H>C'=_2[]#N(PI
M=S:W^_!AEO!;$5$[RP0ON$T&>;F56*P _()OV7=K1\ U+2[QM:F_ NKE^]O7
M[>WG%.,?<1E?!U_F?($O&_#6W!D!1\7"=]U "]9WCSU+:;XT/=:\OS2!T#A(
M[2DJT/$#1%QHZU[+K'QXAVGV1+.L//7!=MG^_1:$V_1G&"]B>BP,4;9U'+I*
M0^C3TGX+?00<JJ]-YW)[]R^GER?,S]V'M-Q"!Y=1IB=N_,E=M*]?-=_W>\]S
MJ[O@3U?RX7+MU^C2Y[S$+W'9N$-9I*,KX'X4R7S!]UR^51>QZKASC< E4/00
MSW,]NO+18\9W=-NKO!XCO(<)KQ/V5PJS/.^6&XRT>XX6<Q<.O(J'K7WFG7#S
M'7/TM^)K-#^ZV1A]N-'98KP*TY5Y60<15]&\,J(; KMZ\V4<H<@*7WB&@_DC
M7>"UJ)X>O?K"J&45EV^\-:UX>9'.TMV=A(3.X^BL7'?G9T^<POVS=@6QS[@,
M\\YXQN5:8O%=Q&,92D@MZD2WL#8G_,MFY&'M'=ODG4"_'T)6%@35'DSR'BQA
MFJK @I(;)0AM)%E1PR'3I$ X1\ +FH E;F+R5G-UF;*!J_?CR3\0H8O=_&82
M?RK .CTO&/;STDO^+5_W[9:NW:5GMY5P CV^/RNQ3PJ[#B2L8;)HVRR%DM#8
MA=EF*S%V3DN\$N0ZWK"DE"\&RFXZ0%W8[&;0+*"'^6'I8AZ6LM-$!6.< -&H
MXB*@QKO@ BBI==8L,"?X;64WJ.3"2('W,%3VY"38[#-$$A03F0JK\NUHV3M4
M^FZO[5*/W\PODVZ7@;-3-T$1_S*Y_/-VLI:.Q: TO=/DP](QRZWQUA#(J!RH
M8^7T5!(":%"*^F"H<QO).#D$GFP0$$JO$F%,!FNT!D-"-C1[Z=-&3=>]Z1@]
M)L/2L4L(_6Q\MKTO0+O:)2G&P_6TF?OM=]>VTS#J[(L.7*_O7BQ-^*=X1>C/
M=,$D?,FR"8/6==MY "L+9[FSOKCCLY+WL^25JZV5QIWA!)6X8RE2E@YM+2IE
M30HF@%56@)#&@HFXKBPKB.Y(XH1MHX/0CYU3T&VY;6^=D8$EH!X@EK,D32!.
M UJUM)R$E6"\3\"C%C+SJ RA&_G,E$9O* 'J<P A9 1/ D%-0G,A:A\EVTRL
M?![]><HFVCZLWIM9B5UD?IESM *I#OO6V\[K.,?:Q;LWQ7^PVF>,DSHD"IRQ
MA*Y9RN!IXJ#Q'R(--5GZ+6O?NVYOZ9>RY11O*.%RT^FZ]OWR][>?-Q,8/1)T
M(!!V7Y[Z8'6'ZH2NN\$QT9+>;4P"&ZD *2@R(E/$NHUS_T]DOJ_0'?)YS3'Z
MR*B!Y(%?[<9>-_.N1PEOF8TU>O<PR?XR:?YS,4E=YOI1LSA'<=[<ORY;K[_\
M_MO-[* K=OA2* ]MXF(FWT@VO0P7'AJ56*N)S"FBY6+0$,9_P;K,((2@G2.1
MXMJ^#0>"$YZ%CL"81J>4X.6.*@)).TLY(98POQLJ,=H<$6L&# C_Y^;&0>=X
MNDT_[/ B;@%UC;HL(7HI07C+P*B<(.*_!C50B[!1<?^)BK<]"YH_+0]M]R;T
M@-(G]ZV8TKH0*=K(V@LTCXNZ.9X)\&Q$MMHG2S;"=$8$2E3@4%(N0; HT4#2
M!!R1:%Q911W?4,P=)T[*X_M[0?118Q^5,TGKQFN/,S7?+0)ZXVWSN[OHJ&TX
M69IKC!RUZQS,9=#XW%W<G5Z)Z[:+T:[>^'SYQNTZ:V:9;U#L5%>2&#ZL\VB:
MX,Y'<YR__UGF1J0_0TJQO9;.<9G;V*Y-A<N/SA-"?'=2<XZ:TKAR]*+#ZCR;
MGN&5IRB#9E(T+(X^C.9-G(['N))6!@:^QF'A.%>N( ):!\H8M&QSM]T2@6H?
M%5?1T,T073)>$J,=!!/0*&%>@2?H]S+*E%/26!/E;1S_"<7^T14?[FJ3)5_]
M\<L;UO8&C)O/>\!D*'LL?AV[0RV](]&HT]YU'M92V4=+?6]7)O*TO9;)VQXW
MOUQ?.EV24^BVL9;YSI/Y;#I>YB'=\6TW+9U1V3#_UV(TNUK$=RW44"J%K$YA
MW;'.KC*H\>;3Y;B.FX[#/XW:M/S*C>>>N9(B?'5$9GYW,M'T_%(DRVRM;C!%
ME)=.1$&/F]&$=1:6'TW<VA?N[NO./]U[XW*_ZLS].3I;G%W;<]H8^RIW;C&.
MY17PS]U13G]Q6[B'A2,Y*I(85Q TFH*"D8!6GO5H#Q*MK(R<QHV 66!&!6,0
M/8P/Z*AH 48&!2K0J*W&CS+9.HY\E0-#C_DP<&1M#G[;)2<WRZ/ E^I=-&_)
MN+^.0F<EOD'U[;R;[ZHMV.LPWON[X/$I!V9W>2!VC7:+DHPZ[-36KTU,ODQ8
M&+?3:PF3RU?Y(XU'I]/U"5\T,C]U=''F1I/N@$YWPK1<NC*9O[]G\5Z>.[WO
M\TM9E=F>3N##M+SO91Y<R@A^M3K( "#@,4F)7?"IO\<^436_LJS<KD=XB >>
MN4<O30<.$:$1_3UIP4O-(,=(E,U1,[99T#R(F!1W0!WEY9[20LQGH!%]/R8)
MYWRC;NJF2;:M&)T^?LI.QKX.-_=WA$=U!>YT!1(:C3>9@W21E^T9 9:4=26R
M,@$M/2\W2@Y$(B2C04+P6H-(3(%-Z&<%:57B5$;-^>Y6('M2EG1=@4\L\U@7
MX18:;D4N*9,1N"GA"N<,V,P#N&7U<,-(V,@-DU(%*7@$96W95W4<K+<$9&"&
M1.>=E1M]/9YO$3XMO;4NPHT1WI_FWL>(ST-2[[^0@%^]OCY[?;],FG?I?+Z<
MT.5DGBW&\]'Y^(Z 4)?9NZH%EI8[;.NDWUA*?=RY^7:01Q9B4$QR@C:5BP($
MXQJ\MQ2",B8KSXS,9F,_RVDI)-X32"Q%H!@%AQ<"9\E8*O"!6MXXC[G:HEWM
MT%[&G%=)"5LJY#NLR',7]4*LO#/7?+U-A/_]^_3CE4K?#)5]PB<UJQX*G<XN
MR^.MZE^6X-AJ&^FZ[E\+@71[9<LS6UUVXE4X!$<T&B_WQ=QL/,)O7Y]6OEX1
MH /\T>Q&U/RJEE /X#*./G[%^KQ<(7]?G*$5$M:-4US.-"4/2A &0GH&EM$,
MA#@E&:>,DK21V6R)B,*;4N*Z).[@C89;7NIE$YJ]TRYMN!^7VS/7#)^_K6)7
MOTW^L2X ^T.I__H>O^J'\33\\:I)N%;."R/,%NDS#48J0RSC@N<SA(O9Q3H@
MWP7:5Q6>RF+Y=O3=W1NLUP*'I1;5:'7=YU-^/W,P[RH4/DM7B1G+_>=K5:<N
M2VPL]ZMW6VS#S7MIR6W6&?]V.AFCM,_/\8VZS>.2CWCO#'ZW8>5UV%OJ3'9[
M[^W)_I&KSP62MB.)AS3+68MD75CI_+*+T*I:]7) JW<H8SUQB_ETW9*I# =5
M^X2\[BZ'L;N8+N8G>?1GBJ\_C>+\%&78"75U0RBI2^=M.FG3N4->2VOQ="M[
M^>Q75VV-YI?%KCZ.VM%2N4[6S[AVX?7&4\NO%>:8:_E-D>Q]':I6XSOFDCWH
M.L$?=!T[IMP\X$)VS(RN ]SZ *_WPKJN0>OUNER!=^O.2DO+2L>'2W)/F[':
MVVQ;H/7P'-1-I+J_]5R=Q7[4YKL]/RCF\NF_OV*OAC!7 VR>N>>*OO._^%GS
M_0W[<?F78D0^J&MD58=MJL-..A+7*1O,E%4 ?L$ 3.IJ/JS57*=L<%-6 ?CE
M C"U=34?S&I^4I3I[NP2HH^8($=,LDXI'S*#*,A>34$?]Z3>WB@(?:-FQ[?G
M:74P[[L'+<VMS=MJY?5]ZG9BO;PTH>Y[/?S;7F9E@-0QV(0CJVAF1#@0DI8*
M/42 $=F #"1XYH)D:J, ?&19<,T)&.LSWL,\N)@]2!V8Y%0$Z6X6@+]VUO5:
MI9[?TZRK$G4SX0A_3/%=.138_I;?=*D?[J>NB$&[NGJ5CD2NIR.Q5W_EZMC<
M7S6NPDK%ZBK4P0EUWZ!9"?#0"5!*SPG5!@BAR((Q$'!)>OQ5"<69-\%O5)#A
M*2J\3P.-I;PJY[:D%D;0-EL?E/*9Q]T3H#EF]Q]LJJA2H;H*=7!"W3=F5OX[
M=/XSB6<65027A44N0_[S&1U (2V)QB9J-\O,?W4'L)WP'SN6MO+?/J%Z^X'N
MK]NDJ"'N+\_@S_]:E,,0'Z>E?-'UNIQ?OT(>M8/4]_G9GQE3Q;E_<5;+8W>6
MAPJ"**H,6"Z*O5$.Z"6:@6:NB?')I;11@]L'PK((%"_R:*U$X_'NH,!'*@0S
M@GC%[K8\WK3MXJPKN/E;7F+@?U]"X#_0V+AAA)POKMD9P&X:&I^M[K/-"/1!
M L*^=?&;.A]#!N@JSLIW ^4[FRU/F3.(4@80)G P5C (AD5)HB;";1Q=%\HK
MXQA2G9/%TR8)O$H:.--!."8T2WJ??$?)_2U2*B)4PNOA? P,H:LX*^$-E/"R
M),YD6K962['61 58[PB0;+SG+%HG[NA"J876(I=Z^AJ$X 8<IP$8<J2WR?K,
M[PDM[XKP[F_-41&AWX17\["',H4_+I;E]3^FVU7P5U7B2G6@KNA]W=_IP\'\
MN@&\]R4S^=[5O?J'357-5!D:YE2A#DBH T2$P;I8VHO@6:"0B,PE>T>53!P%
M$AVM*&P46FUDKZ)+EH21 HAF"MTR)\%FGR&2H)C(5%B5;[A85];8[U?&V&_Y
M_:4I]O/'VW5C'[^!MDWWZH"18=_J^(2HX@'/RB#QN@JUDN"@2=![XY#T"##)
M(XB0*!@=)'B3+!."Y1 V6M+@WWBR04#PU((P)H,U6H,A(1N:O?0I[8T$Z?V]
M,2HR#($$^Y (>SAU)O<]S3__6;J.E-8J:7;6?#N:+-N6/*$.Q*/B_H<SH?V(
M3S[S) S0 MCW0GM2#+-.9W\,YXIO5?!5\"\;?;[&H;O5XT=RKKBFH(4@("CU
MX FZ:IY&S@(QZ'WIC41)6;IC605140I")@9&B?((I:VBWE!EOI0WTJX-O?=H
MY]$;'AJT*9S$Q:P8?CTCS:(VEWI[0YR[3DRI.-)['*F"KX)_68)_4<Q):5 V
M\8@LF ((%2/8X!0$KW)VGA/&-JJY?74D]&"8DQT;6YES&#AR/:**/Y<.8G=,
M6AQ]['>WMB^(YR%MV#;EU.<7WO<:?S.,KHG7^Q^6YI'Y1B'B:^TD_T][LRSQ
M)]<V,97 -$YD;/Q%@Q/E/BQ[PEZVN71M.VKG;A*ZQW5])V,Z3YVFX 4C1*IS
M-RME(2Z[7)9.VSA6O*U9M"7=]BS-3Z>Q?/VD/.S&\]_\\N/O;YK_OKSY_RY&
M,2W;XY8>EHOY94/-=+O\1/<&J9V/SKK.G,OO<A_=:-PU%1Q-EEQ2;G=^NNCZ
MZ>Z_(R0"3_HSC!<Q/7;Y4;;U]7=EW_1)U=]"'Q<@-=>F<\DK?SF]W*<[QQ6T
MY&YP&65ZXL:?W$7[^E7S?;_A=JOT^W0E?QD<<XIP."UEJL:]Y)IK6(L W-%&
MV_TTPLO<;-5[>'S1S&<NIKCJ.CQ*;=>2W#7G:%Q-(_+*/)P6<.X:D=_8$G67
MCL!Q\POB=(RC\LO1=>)") _3V?ETUL%\^0 AO\-Z)+Y;ASSR8KZ8I>4!CZX9
M>KD<Q1NZ#(PED8RO^G+?[,/NQNWT&J&46\>C/])X=#J=EE_=O!DA=4T7X_).
MHTG7W1G5;<ED_^%F']TL?O_#;.IB\^L(,;5%?OLP2TM*+:,MU]WWN7>EAW5)
M3<&13R?P85K><99:='_":9,RRG1^>\2E53+>Y>Y4G^&FY22JC9<"7(H2G5&>
MP7EJP#N7LF0BN[3AC"I-/3JD!)+/&@2U HRQ$IU1S[.SQBMY3QCWEZZ%^,W<
MG,XJZC1F.WDY]O[DU#XM^&\V#DU="6)M3MZKW_-FPS8]WK^]]3CZ42^"?A!Q
MWR8_6[C91=> _2;LHBI\'!58_S0;S=%J;R;3.<YZ:<J^U %4B()5:9R6BQ<_
M6.M+^IRJ'#7X%@AIUY7+IX!+LZ!<>=C'8KXW_[F8I&Y<Q]<G%#WUIX>[B*,V
MT6# 4<U 1$+!ZF"!&I&88,Q0OU&[DE@BHBBUIFQ A,&!@>&6 PV<T.R==HFO
M$6;1P@?GSJ] YM<KTOE;<BWB2/QM\H\4%K.2 ?B#0\?HOR93WR(R%>^EPR3\
M>#H)>%<GHO<XDA_&2,&OD*.".R\J/5NDSX1UJHJ_^FMAR]D-.7;]>4[=Y$.Z
M-!!N^LP9=7)2/%C\N$41GW6VQ"4]_XK&Q;CA^&&AC>93FA4O&<%_/)Y^:D^&
MBGB[,;BW(XF'!+LV.WFO8X!="' ]H-4[E+&>N,5\N@ZHEN'@PCPAK[O+8>PN
MIHOY21[]F>+K50=YT@EU=4,HA6;/VW32IG-73-6U>+I _?+9K^[*[/PX:D=+
MPCU9/^.>_,[EUPIYS(1X2(?[8VKX@ZX3G#[D.G(LI7K A>382+G= 8H'#E#Q
MAWSQ,PSPP1+D>Y+@@P9HC^F#5.ON\3TI=[G'#0G[OG.RWV:4WW8D.EVTZ. ^
M,+.YSG4_PG2U;^PAY$D_?*G^/DLYS=#U6#:+[0)ZRQ_G,S1Y3]/REW6 [&$%
MOJN"#"[SND[98*:L0O)A0_*;R7P41^-%B4PLT;<;9%N1>-]Z49&X3EE%XI>#
MQ.\6(:1V!;SG[J*$?2L*[ULG*@K7*:LH_')0^/UT[L9UT1[,HJV5DX>R4_Z#
M&W=IWIMY/-0^_E#+ =<0&F1UL;X+==^KH+8MWMY1PWW/Y3UMB[F/*3,+SO&N
M600#0Y6'($-6+'EI@[F=^J6CRD$E#L1'!B(("HX;"]$$;3A1TK)X;^K7W]/\
MIS0;?>Q*P+UIVS1?)X-=W)<*]O^-YJ<;Z6#MS6['[WZZS$3EUQ-1@7\^$_5(
MZEHDK@)\%>H!"77?2%M9\]!94U+)M4;*<R$3$#D[Y,_,0'.D1)DDCR+?9LU(
M:?2&$B@G,T (&4LU'KR;*R:BQOL&PYKLB A16;,"?!7JX0AUWTA;6?/06=/Y
M)"DU'&PR$5DS&3#:4;#"AL"=(49N--D(P20J%(>@I0$1LP<;DP+%?&):T,QT
M& AKBA(YK)Q9X;T*]5"$NF^<K9QYZ)QI(W$B:PJT:W:?2 83=3FIZS6GEDEO
MV6W.Q'NR*CR;:2K-[ATIS:P2L,1-3-YJKNQ .).BJ\FKJ[E7A'_&)AS7Q4A%
M]YQ'[6!?/[>Z>DX?9VC?$/-+VR[6Q<O>X2+']WG37!V#J>VW^V$P57'N7YP#
MM''VC2[?'E35)1-\5%0+<,%+$%%8<-%2X,I)2V-FP6P$*S3Q,0IG07+'2]4E
M!3YG 38GQ:E#(TQLA/C?I[-2S&MV\7-7T?%=.858<#K%GQ;%POJ]JQJV,LT^
M=9]LQ[321T1MT[(Z2-3:MV[NNC=6W^=C8"Q2Q?G227FX_*>U=[[DA$G'0#B3
MP M3-KN9U)$GZNP&_SD5J3/(E%YG!<)S!L9+5O+$N!!:B.0W @^[X[__2;-I
M=.UI4=X_&:'B=66_@X*'*LXJSOZ*LY+7[LB+\QQSZ7S&3*2 S!/ *),A6D^5
M<?C7'&^3E^=:^* ()**0O)AS8*TG@%3'1%!:YN@J>55XJ.*LXGQQXAP@>>V;
MF0XK'.J\M9H0!E9ZC8S**5B.KIW/R@:?$R%F@U%-IDD8*8!HAHR:G 2;/;(P
M"8J)3(55N89#AX1:^];->\.ASWZPNNY4[VVG^GJ?KIKXT2M;H@JU7T(=H)DV
M6(M(4N6LCP9LTAX$Y69Y"IKR0- >$BRZ\)0-XJXMSX\=]@TUKE#AH5_P4(5:
MA3H,H0Z0R/;-4H<5;Q!)F22\Q:L%LFO0 DR@!G+4C(<4=6 ;\8:OV7Y^/G9M
M44/PI\\?!3.ZTNP0_- GY%\=\*P,DE*J4"M/#YH2D1"M%]8#E[*4ZB(23"0$
M)+J.QG"OM-QP.+]F4[LZG'W1VX.!ARK4*M1A"'6 1+9OECHLAU-*HAB- H*C
M% 0O[*J-!&)4XD8*JC8=SJ_9X*X.YR# :]_*N<,=[LN7JGO;.YWB'Z_:;5^U
MVJZ))CVQ(1XESMI1M?>"KP;>"S?PG/9!LFP K3D-PG$*)C(&TC'MN"#>YLU*
MYX\XT/V42CJ;573P\^DDX$VNO,K_=:/)K].V_642QHN8XB^3G]UL@G=OV5QD
M1Y)LTV!\X:"Z[P6QZU/DAS-S!TN'5?#5#CGX'1.I-*&!!G!"&Z1O2<'%Z"#B
M/T%)IU/DVSC#WG?*_PS3RR,NMUF6ML+68<)6%7P5_,L2?"7JW1&U#=D9RB@$
MYTIJ0^+@DBM5;I.P1C(OR%;.ZP^8J-D1W^H>3H6MPX2M*O@J^)<E^$K4NR-J
MS5CR3#"0+"!1YQC F"! F^RRCBQ()K91!F# 1"V/&*\>=>]AJ[9B'\KNQ?VM
MV!FI.4R]8OHJU'X)M9I&NS.-/(_&$"K $B) *!?!6J& I>QUY(KFS>YVSKID
MA*:0>&(@A!%@A&>@DG,Y4ITT)WWMU%,/<KP@(*E"K4(=AE KY>V.\@PCCKE,
MP6MB0>@0P5&90)+$=.#>,K+1!ITD:IQF#J)6&007 IRG%ICP03/K/76TKY1W
MR]-71Y:J2GH'"R55J%6HPQ!J);T=)I5QSXU3%/V\F$#@C(')R8*2@3DAM2%1
MWB:]Y PR723@N,5[G'+@/5.@M;56,2'4=I/*GI'TV)$AE?0.%TJJ4*M0AR'4
M2GH[W/?EU@;"/7CT[4#8<G@J<PX*&4Q$Z0.7[C;I\125+-7B::01/3UNP5AT
M$;7-U@>E?.9;/3SUC*1GCS1CE?0.:[_V<DW5\^\#K^W^J!2)E[J0JCB'(,YJ
MW.S0N)&)LF 4<.8=B%AJS5(J(,E .77:>&EO&S>"F2 ]96!X*,:-H."%]V Y
M2]QK'2(1!U18KT+"_B&ABK.*L[_B'"!A[9N-#JR^BI6>9<& RQ+C#B2!#UQ!
M#(ZF9*(S?(-%0XA)\^ A<;Q24.O 49] ^<"4QIND2_THH,?9D;"D,FJ_7<M=
M%SKI^WP,C$.J.%\Z)0^6_6Q41-GDRFED#4*$ (8$ IQX8C6)@GFUD0K%$E.9
MESSAR)#]E (GO 9T*TVFBGM.6?4A^Z.Q!P )59Q5G/T5YP ):]]L=%@^)&."
M<NDBB&@<H,/%P"OI(5*1*%,FT9PV6-02$84W97,9F9>1$I.U'&C@A&;OM$N\
M^I##P:Q]:V;M,?Y")OK=(H34MLVYNSA#N33C=8))D]QLDF+C)A$_',6:Y]$K
MTZ(*M5]"':#5]C 3Y?H=T*8 HS_A=!3Q54[>_I-JHBAQ'FR@'H2D)0V<&0B2
M&&XL_B&8OB'>E5._4I.;_ZDK<> KL0JU"G480GV9G*&I"LI8#4[%KGI6!INL
M!<\Y_B%RSTFNG%%78A5J%6H5Z@%PQK[!^["BP];'<L8V U)H0OJ4$ARG!K2D
M64?.=20;T6'-A4WHD8'QW)2#2[946$+*E2Q&FUC02MP^A'1U\.CR.-)O^>J/
MEP>1ME1$@LEMQH0/&+7VK95/R"XZX%D9))=4H5:"[@.D'!9!!\*<)-:#"<F4
M'MKEE##5P!EEY2@P=YO5H2/+@FM.D-0]^L2>>7 Q>Y Z,,FI"-)ME,:H!+W_
MY30H@JZ'AP]EBI?-LVOO[%[:#H\29RU5WWO!#]"P&ZP-98W(W 8'0CJTH0CE
MX&/(8"WU1+)D@V=/.8P\Q X;_4M+KZ#5>]"J@J^"?UF"KS2].YK.EG'G@P8=
MLD2N3A&<$0)XSII9):78+'W]-:>=ATC3MRN%RB.I167JBEM5\%7P5?"5J??"
MU)$'S34A8%22A771+\XT@*6<ZFR2MI(\Y63V 3"U/C)45J*NL%4%7P5?!5^)
M>B]$K:Q*IG24)L5'%MED\-$%B)X2YC67*6UD#WS-X>\#(&K.C[BIS:5[CUO]
M:2Y].'.U;]#Z3!MJNI=LH,.9VD%F.QZ.^/>]LOZMY_-7C< =&H$FJTB,!BUU
M!D$B Z=U $^H\9YD)OG&ODHTQFIN"03O' CCRO$.:2!'Q8R/7 6Y52/P)731
M/AQTJ^12Q?]RQ;]OE*_<7KE]S>T\)),X"2"MXB"D4& %M1""(CAB23G9J! ?
M!1,F$@=$.8;V@"#@C.3@4T!F%SX$:BJWOU1TJ^12Q?]RQ;]OE*_<7KG],A\R
M<<5)%L"MIH"\S)<'.C/^2Z6702>SC=H,?>'V6QLSXHAK6MF]TDL5?Q5_9??*
M[H?%[HDEQFW6P%1"+SSQ!-8G#8H[JPF3P=*-[C:/*>Q0V?WEX-LN<B_PYZ(*
M?UW/W=\79ZA5 7^/HX_W_!5OO5=PWWRUW.BNY:8VQ';[.^\08'EG?/<[<(I]
M"2E6PEM7@+$NT! =A. ("*,9>&HT!.*-M$G:8+:2P_4F!%Q4\_9W=U$F^,TD
MXE]FBQ37,#%*[4^C-HRG!2O>XY?],)Z&/UXU"9?_>9E8O/@S*^3S$[V2RG//
M]$,JC\QG;M(6Z#I9G)^G67!M>AQ)^.DXOG[0Q*OCYJZJ1<_!7 \?U&KZF_3G
M>9JTJ;UKA,\\A.8Z(MV]FK[(N[=64_0D&LH@)&5*C?D SFD/-B;I4\K"D["-
MU?0NG*:X&*??\N8J>E_6U[87D.K#^GEV6^JV3I:90D-EWDQS,S]-:'&,Q]-/
M:+^<;$U;OV9X-_3U!3+>TE0KZGU7#2:WF$_7UE;YZC)-Y'5W.8S=Q70Q/\FC
M/U-\_6D4YZ<HFTY8JQMP[L;NO$TG;3IW,S=/Z]?NW(+ELU_=E2#Z<=2.EF;N
MR?H9]Z2)+K]6J6-NY3=%8O>9H*OQ':L'724$?<AU' W"!UQ'CC5]V/=N>W3B
MT:-[4N[N<OK+TF#'3-YGFK^@8E1;X=PO8]AZ?7_.%:MSL\L 'PJO?/KOK]2K
M_<W 04>3=F%PWZ\"UW/@'Q0)J9._S<D?SLF59YZ[/LW4KIR0AZ_2;T<3=#6F
MB]9-8ON$^N4O?!)WPY3LU5XG88 HN-_%];237W4V^[/A7.&MPEL/%\3>X8WT
M=DD-<#:'8[(_]K!YGZ:@CQL"/Y^=CZ<7*2$FGI4M@:YD1-=F?);&;IYBX],D
MY=&\W4MN0=^G;Y ):7T7ZK[7Q'[2S 9('X--'M/)6DFUQZLM 6&I 6M<.<?E
M,PE&96TV"O ])GELM=VZ!MD?5E#ZXV(VPXG<4B\@4GL!5;"N0CTDH>X;-2L#
M'CH#TJ1]3HI"TLJ"X"J"$8:#5I[)H$@@8N/@,T^QM,S30",M/5W*X2@;(FB;
MK0]*^<SC'AB0'BFN*@/V)<%Y'UMTU=/_FM0_1-:)&Z.#WR8W"Z>=MQ_3QS2>
MGI^AQ#825FL3NR'N!51Q;E6<U3C9G7'"*.$J<P.!EZYSBCNPGC&0V1DAT0EG
M3C_%/<<9_GAIF:S@\!\K-'PSB3]=8>'/*RC<BJ$BCXC8YIFM"@O[AX4JSBK.
M_HJSDM;N2"N%3!.A$EP*O'1)->"]$>"D3X)$$ZCF3_&H]T1:XL@P74GK4/SJ
MNH_^/)CP^VR:4]OBVD#/.J>G.,\U_E0W"PY>J-4RV9UE$CCCWF8T1:)'R\19
M!I8:#H[COT(EP?-&!80G['9?A\*WB(3;C?53LLUF,Q46^@4+5:A5J,,0:B6P
MW1$8"<9:(@P8Z6VI]8549@D%'4E26OC,#-WB9O5S$A@GO-+78;G4=:MZVRCP
MV_PTS6J(J2<D64^B':;@JP6SPX1SIEQF:+QHRA1:,-J#"8I"1#/$*\\#Y1N;
M X]QP3ODW*R8MDT+1ENV[^V "BZ]!Y<J^"KXER7X2J>[H]-,A<V&6DC(A2"8
MT>!<+ATZLW/>2F[M1A72QP0$=D"G@FTS(%#!92!!@UN1F^O"I*)[VC/W4[]>
M6'3UC7V<T7WCS_OIW(UK6?U>KLHJ_D$LH=JUI1IN:\/-!^.]"1;0X$JE?+P$
MV^7X,Y<8(R9)LY4XR//:;)0=V:U&02I.59JHXG_1XM\W7E>6KBQ]>?[.RQB4
MD\"<)B R<>"R$B"BCBR1)+A*6\RW>*Z-BB-J>I(K>#@P55ND]:IAS'9:I*6@
M511)@T^>HE5N%'B#]KE+-*.!C08XW5COCVGJ]&MJVY1^.T\S-Q]-/OR:7)O:
M]ZEV0MM>QR_=QTYHRXG>=_^SVA?L,V'.T]3\.#W#$5W\[__U)R/4OFZ;Z7JA
M-N,R@4UAT(^C^44S:KMRH;-1FV+I'(:  L%-0AIWK:NR"UV_J.5M;>%HO"J/
M0NI*C>!%4WSN=';1=*-O1I/F1W?F9Z/X(1TU?W-MZ\+IHDWS>7O<_#+!OY0J
M):7V[U'7I&PUT*8S W$$H\E\BD_>'.^'64I=19,R@KO4;[ 66LS1I$0D4.X\
MHJ\48(2@8&6FS-&<A62W$5L2IF)T!IAQ 001B/*<9,@B,(?6669*W3AL>A=<
MOT%3YX9UUOXKSZ\;9;_\_>WG8R?JR(C[M[SZM"B:]E\+-TOE.%_7(&^IK4A5
M75U<-V_0C&O>IW ZP9%\N&C>=9<?W:O,S;=%>Y?K*[R^O*KI!+O\<WS]W5'S
M:30_O:'H14:HU:YMVH6?IXF;S(^;LF11_\_6K?MN/:^L4-3]T*V/YLWBPZ*=
M=VNH6X.X@MM5A\78X.I)?YZ/\$T?N4;N,2L$2S8ER4&2A&Z$TQR\1BN#HE4A
MB(G<>_D4)?V<6?$>)?-;_A&?733LAD9"F\))7,R*O=ZF2<^0>/YIVEPD-[LZ
M0'K;W.WA0LFSZ5FGA&NEZU WXCI9ZND2C\]GTX^CN"($-YDLNB)4I>!4\>ZZ
MRM/M\OJUXI^[B^75(UP]>/OY=%:NPN<V[6E9FJC[?C$:Q[(\KN _3-MY62NE
MME7;G#DDB+)H B[(Q7SE:1XMU\&D7<S*)QW1_.=BDK[$,^6#MZ,9+J8W^)*Q
M>]'5GV^O0!>[<1T4\<@HDU=(-[@4T570#(D'/7[()F@;8_+6;P3PF1>$N!#!
MA&AQ3><,ADD)3AEK9.#:4/'\Q,..K+F_4&ZOEM,MWBEZ-%^>+.^^8:FK#M</
MFE"EX\L7U/5=POF(+U-?HR4T24I1XZ(!P9D!)W. '!52D&-<N8U,(9JI"H8(
M<(S@/:B@X%60P*E%UG*!\VBJOCY<7XNIY%;44. 6T;N#_=$DS#K%P]$@5']"
MK)[C'SKCJL4[)NA1A16#K_!Y?''T)8U'N;A+35]SQ\K]N!S.G99;QPAA.INE
M]AP73%D+YV[V1^=03.=+,PF))';?O:2TS@";GZ+P/YQNV7J*@<;,LP-M"5I/
M(24T\5$IM39..&E8XIM!F>308DH,C/+H%OC( !$V ].12>L-9TYL6D_X(C\7
M^Z]CX)]0_O2F8A8>/\/O.8WNHI@FO;.9_C[]N&K\2#KU8 .RG98&#\HT?<+U
MLK1AT$3"\>#[%$5K<;8Z/6M7^CE9KJZV+))RP70V^C JBZU3R>/F35D[J,.+
M\65;[]7CEZNFVZN :89%P7Q$KOG2+>\4>KR*Q5\TGW!)X8UG^.?%;.GOE+O/
M2]E07%D?W7B1UL]?V7?NHBRZMIG@:KG QYZ[43QJXJ@-*-^NE\A%=WFW\,NE
M.&B/ZZWK.-YTP/#M+S_\X[OU=UU^^PUS$GV7Y=LM79N"$]>P9,5MM]^FZVBR
M^>(X_G\[++X3-E&C-! >-2* \&"\CZ"S)\P:YGW>*)W(@TJ6<PH1?3+D2'31
M#+$&LH_)6I&%$C=+)_ZR$O9/:?G?7R8WN>\?Y65^R__5IM_RFR+G>_=SU(W]
M'/E90KS[A6T41&<T*2659?#4@94J #J^0C+G)6,;3N;7O/ :)K_TSNM-K(NM
MO"LY-G=0_Q!L ?QMC(/K8 T!I)#Z9-J,D*@#+K?)RDN<='M?'=6W\T(O98'C
M8ESY<!VZ=6!WAB,Z1;-A]+%$7EID\MD7'A%<>]KD\?13N[0B;B+A$A=6>'B\
MM9#T5XFH!T%I-;"@='-:YG+<3F_:>F<XLZ/S<;HT$V\6M;[\*PI@D?&'Q:P0
M38L8U@6CU_'A=AUR&\UB,?E*?&!EE)9'.&298E^@>QO7,>URPVBIS<ANYQT3
MOGGW8V,$6S+Z[1O0;-J_MB& I#_#>!%3CW;7KM(Y^J1\;Z&/\$KMS?W?LEM^
M>GD<X=Q]2,N4!' 997KBQI_<1?OZ5?/]8^>[%[OC7Y=5\'0E?QGP6BAT%#LP
M;4^GL_G2F5W"U=':N5A#:(G5KIP09/7YIS1&0NZ<PHZ2QZEMT?,(Z#T7O[FX
MZ<CZMXUPO+"SP0M87MG@!=I]2A/$[G)[BLO0[/P6^I=//TSPG>+.=K@?E3]W
M$&Z$UIX&DP1(GQ4((A4X3P4PM)L=#Z5+FML(/D1I1>(*-/,"!,.??+0$?)#>
M>9NUL^FV5?VN*%[9J^ELZ!^G[79<!78\D!W&E;7<R[&5'<];N+#:6<%U.PVC
MSO2^W*N\;>_$I:U5/BHQ([3;RH?H/:TB-709R.N!"7YW"M571NN,R2%)5'F'
M+F@YV,#!:,4@$JNT)]IFM=%/Z7$I5*MU\KZD6FP[=^IE$-_[Y4;E^732V?Y7
M;N=EYDA1\V4 S)7]QW'Q)D\V+*_F+UV>XETG*MUB/EUG?991XZ-/R.ON<AB[
MB^EB?I)'?Z;X^M,HSD]QL-W4K&Y  8S=>9M.VH3.""ZSM9 [\EP^^]5=QU$_
MCMK1DFI/UL^XYU#J\FNU/3:*?U/FY[Y4V-7XCBTW#[I."/J0ZU!/.'O A>18
M,[5QW9..XRYE7+2='3-Y7QYN/5Z]HX7[\.;OWW;^]G31HG78?O>@/.X>S_4
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M&?)6[)JOR '[&L.&'3%]UR&*7NMWG[1YV*;0Y>JII=5[:E0]L;3Z"\_%&5A
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MF77#N%#:@K5>]4T7ORL<8[UYQ>=^SOR/YX:FC-'*>\])L"D "#&@ !PW)(O
M*Y5U2-KWH"EF6U82]CY%EMLH);$J<V*9$EYQ9;E(#V2YO5\@ZDPX&[H0E&M5
MQ]8^+4=M[0E $_1WMR7=#B3O!@2YR0BNWR# 16R[IKM,;93O! (_C](O4O@
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M(M8(U_<K] 1^+8>%_\!9!1-<?G.\D]$EZ[NKT:OVK+1GQ3?F^@!4G=1X2MD
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MC^*7"7YFCEGCB8$!/^9Z79SGQ5*5G(F.9*XTD5X$XE-R1-L@??2QXK['1OM
M^7K$@S)3F3&UQ^L^3TK&-K'@+?#W+[M'9B^Z+.GN)P*_KP*2QHQ^W:-#/:7U
MWCX.Z&+G$RQ1^^_59)$VF6)U^RT=M>N'3ZWN$O9_KHSP.S@4I[1 'SL<^>%>
MQ6[CT6S>7\OVK&,21_"PN$HE:>WW=+-LGM)DK75)G(?O7H*+^;IDWY:,C39
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M<,=VBW)P$$UO$AQ$X2K:T24M5/O(,+KE*FF/:.C7'&_'WWK?LM^IJ\N(0!P
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M+WKZGUMW#Q9[L-CKHP[!LZ7)$VEL(I)6E'BA,Z$T&[#84@?5:R!F,DO2*$G
M,FHBDU/$9I^QH:#F,C-I=7Y&BVW4B93,78[&&@S&,/TO=_J?6W,/]GJPUVM[
M;3DWDC$2I5;@5PM-?/*4,.ZR5%8Q4U6]/C0AB&2#),$S"X8>.RK!9<30D VX
MV,JG])RE??)$2AHN1V,]Q4D*_!T[1?REW\PQ3MZ^O&X;+Z[QS%WIO)I+<!Q?
M8SNK2?BF;433=<1[M,XP#QG13J>81VFME(SWW/% LH_@67F!260"G"86)56I
M\CGVZ$@>UEKI<(N[,M>_-%/]#S==-0V6ZGIUW?SL#]S%?Z2AG](G'"]B<['-
M3(Y6==,ZZ=LI#(S PLRGJ2[MQG9;0';=S9M694./I.?3VI?3(TDH=;<./]5=
M.O=@0YX[/8]>,7V7UD+\BML[MB :!GB/ 0X]DH8>22]C;88>2><=<AEZ) W"
M<(:IGD^W=IW2.YF5VPC3B=K((8EZ8-0_%XWWW(SZ0S^D<[!?S[X6IS3S@WH[
MGPWQ[.IMZ(<TJ+=!O0WJ[3+5V] /Z1S4V] /Z5Q.;C%_*> 1[-OYU"W+2=O
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M04,?\^-]S!^E^;4/VC(*8)U2:XBT.1"?S?]C[UV;VTB.M-'OYU=TZ'C..XY
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M\7HA93UI[Y\6>?CCR69D:D7:7M&F6J\0.&/U;Q'??HDO?;CX>I<LMC@B8KQ
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MD)Q26QB6Y2EKOQBZ^5!=-*=3D^N04;YHY7)DCZ-Y9 40UZ FU2# :84DIQ:
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MIAG\!SAOOOJH339NYB*KZ7F&);C]J87G 6I.\OCW_(A0I=GTK)J?YH>=G2\
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M&L:MRL6W*SC]*Z#I3YM@>N64R._O7Z\/B;#-,R+HZ\VN&!MQ; Y]3J1/?%N
MNI!S6.0\-&(6O7>\>B\1Y9VE!K% ".(!*Z29-B@:0I+V)*5DK^L]%H,4PBD$
MJC$@SIC)5?P!*9.,\U*ZQ,*A]1ZA(Z-8T7N' >HR]>JX-,!/]KR>P_+R02H_
M;>;-Z@#R) <$4F7/ID#F?[?G0TK8N%<642%JOXA:C)O]&3?642L<ET@:Z1!7
M3"(7P%\/EA!O)8_*;XT(O8]3#SO\:=NRV0#+GS)6_AKG;].K#83<E8'#3$^&
M4?6)@X\&* I1"U&'0=2BTO;HKU/G*:,8-%/BB$='D$G,(A6" FVF'%=;@QON
MXZ\?4J5I4?39D;GM)5%_C&.J2RRL)"V.C)S%AMF?#:,U3H%K@AP.8,AX%9%Q
M4J$H:3",4Q/5T^3:WTS>S:8^-LT=QDL]U(B1(VQTR3L<%3@4<A9R]I><177M
M3W49Q@@+E" )>@CQ$#6RT7ID1!2@T9@T*CU)NGPOJDO3HKB.Q?,N"?-#HL>K
MR;P.]7C10L>J<>=%"6;U2ML6HO:+J ,T9 Z-,Y># (H0'(<0%*(6H@Z#J .$
MZ\'ZG<)8QWD0R&&6?4CI$3Q-H4B$H\EQAZ7:?=IW9<6.\TI6_=4O=N)KTI$F
M)=M[9#YGR?8>!C/>SZ?^G\C9IBW//CN/D^:1I=@E>'/XN&XA9PF3#]5<P4PQ
MIBA23(/ID81#1H$10K5D/BEAM*2[+[QN8?#'C((_;8#@;JJM1X2H$AP_*D H
MY"SD["\YB[K:8T&28H2$B!&)22$>B$4N"($(QLF B\VHY+OWKI]27?'2\N-H
MO.J2R3TD8KR=G\99B4OU2J$6HO:+J,56V>.99HU-TLPA&@1#W#J)M%,!?&5N
M6?)!)KS5L&4WC<HR$.[$.E&R!/Z/%@L*40M1AT'4HK7VI[6XH81AI9'G60-)
M;Y$5VJ&DL'>>6AD?YV'O06M)4K36<3G6)5U]&(CX:[1-W$55= E,'3Y.7<A9
MPOX#-4JBEE8S<(:YSUGJR#PRT3/DC#%."\ZY)T_B2O\6/R[&=CZ=7:SJ[,*J
MNJZ.N^E_*EAI?EJ0X<#(,# *]XF>A6%[JLJN?0,UT:/Z"SJM [S*RU_^@:4A
MB6F%0C 6<:,%TAY^PAZ3F*Q+4K"^&>1;IXBN_J=(W[#\VI(P/NC17^]GBQBJ
M^"77=,1'M-DJ0:)^!8SO/C2ZD/^@Y#].R^/0P'9+0U(N5-#.()MH!'M',:0#
M8X@1K)*GT43\*"?ZQMJY)<;^O(3879U($[OL?U* YFB!A@HQ6OT/WJ#L0Q&#
M9TW^HF_WIV^)3,$'PA$1$2,NM$7.!HXBPS'PZ"2GNS\)_A3ZUN">G/\N,-.3
MU#O5NPE.+._3QQTZ-*9\F,[M&&2T$^^V&[AM4U EV-<3A5W(>7AR%GMFC_7L
M7((E0QG2U!G$@\%($\V1T9%127.?</<D2?B_S*;-CG+M<L0U+NGVH\* 0LY"
MSOZ2LVBH_6DH&32-"4<D&&:(:XN1)2&AE+R5F!,FU-/4KN].0Q$]XKQHJ*-Q
MGQ\2[;CN,?=Q!PX- *\W'>/Q94GFRY+$W[?.!!+F3__S!7U13H#UP4XI=.X]
MG?M$U0(8A9$+G?MH/)9CCX<Q+M_-IN= R(MV)FO\UZ)N)S<5'ZPG<%7(>7AR
M#A#W#XTJWZ^VZ"AB;2P$9A6F2#"+$4_:((V#1]Y0;YRP,2FSXVS0QLG+%4*_
M&]O)_-4D_+P"Z=V,MS>E*6//5?0?RWX,67T4<A9M7+3Q#L]VB,0(L1*QJ!CB
MA&IDN%,H!DN5)281HW><^=J;-B8CO-..3D<)6(=FRUOU<3DT>UP;_5O^1C5-
MU:*)745J":#WRH H]?7'3_YB[SUS>R]P8RBA#"FJ.>*""&1H2$@E$1BAV"3W
MJ.C+];-%&\9>JP#>IM^;V-8^W=W$:X WX*>O%^CBGO3N/!XH/#0#/R)24TX&
M/R.=5LA?3(J]]P"C.' JI4?2VH"X=Z 3'9=P$^N%P=B)(/H&J+ON 5:D>_A%
M(>5 [B$.Y&[4'9=P9$^492'GX<DY0%OBT.AR7.$)K;FS&'.D%#.(D]Q:E7B'
ML-6>1>]8LH^:*OWU=-2.LDX<EW-8/=?)I0IDT'JBD+.HW:)V=Z=V<7 N<J.1
MQ((CSIQ&AC*&++;!*^54HO+IJD!*L<>S5[OE_/10MO#6]F*C:E)*.GIF#12B
M]HNH S2T!FO3>$>8\%PA&L&<X8)0I+F%GR+1+%$GM&=/TG5LP[+Y]3YE#E^K
M;A CO-/V8P48^@4,A:B%J,,@:E%A^U-A(GH?)5/@ARM01YJ BRU90DI$%KT)
M-#RN$?@^51A1(Z9V>3JR $.I*7BV7OA?8].\K#[9\<*V>&''X^EG._&Q!+QZ
MHF(?1,Y2%M5[P@_0_CDT6!U7KB1A)@/+@]"BUX@['I$6DB/'K>!*2V5%>)*X
MPO^LT/[5"NS[&5MXYLAW:*[==VE#.3 Q'.55"%^LAF(U'.3<I?)68!.18<(@
M[J-!UCJ)(O&,!$DIL5M6PTY".4]D->P\G//,D>_07#N RHRRV4_2 W^C>B-W
MY]AI3*F<$!MJFN=XR']H8?M#S_=O@*;I8*U HRRG@@<DF,*(@]V'C* ,28^-
M%8'':-*3Q(X>G,7[=YQ-@VU.-T\/]R&%=SSX5-1#(?_S)?^A<;IHYZ*=UX=/
M&;9.!X:$-A2T<^#(&:\0EIYKQW0@=M>]4(MV[A$W'ZH4!WZV;AS_W.Y=9J]Z
MTKG@\)=0?[J=0M_=FT!DWP22]Z!/GU_S%A'92&V1?1R^.8W53],S6-=%=6J;
MJI[X11O(:8,WYW$&;#/Y6(VG "OYTRI:?UI=1#NK&K@VYB_$\\Q:)]75>\$M
MIOG3Z5ELHT+QRWF<-+$*"_A]6LWAXJOWOWPV %*.%;6/:;:?\S<[L1]C;NK<
M+CEV :8<?()[GD^;>EY_BNW G$G\:-M?XJ<:]AYNX^"6^8&+<P#I?#T S[C^
M=U><>)'#5?/+M^@@T/S0M-2X\83232F%0^LBN!GLD9U%T"QGY[.Z@37#?X!'
MX:K\BMM[6WD[FUT W3_;68#7RJ_HX5WK_(Z9DG[:S/-5Y_4\TVNY2?FR\\4,
M:!Z;K7T!W&F ZK/EQFS1]+1NYM-9NR"_.%N,NYW*:[ODMOS%WT&-P3W>SV&/
MFVX.4C.'M\E_3(OY8M;QU_)+\/G=]V3?TM;2)40PNLX 73)=[+RJX?^;ZFP*
M[S&N_QEAB^#/$Y">>??Y!O&JSS6(1?YD%OWTXP0>UW[LXB0FV*L5_]["KB?5
M*R 0?+=9C.>C*S?."\OW!"T;X)*T@.?<$+BM8#VOHX]G+LXJ1D85Q92T>P(_
MX X";OH:2"\(6F9$=W$/F=GW_OQAIQG"?:_^EI)ODC 1#B,;HLK]^!-R(4A$
MC?&$,D=\VK)!L<$\<*>SY0G?@;U%FAF&B&>8)&>5C>RZ#;J=%KQNE?X$;/TQ
MOIF\.@-*W6Z?RBOVJ?AJTI"I$W6K@=H__JK@MS$LL<<K!-#-,MW?%8XV+8@5
MKN1EWZB?+_7>\EOWT7W7/\DX]XTGYO],?=TJI\_U_+1J31K0B*W)-(]GY].9
M!:4'!#EK[HB7QXA*!OQ:R@A'/@,2CYH@$Q-'G!MI.(E6B:V#*#J1R+7@""LJ
MX3M6()-<0@%[27DB\-74"U0B[$0.$)66LH]OD)JGD;63FVCR]*_[> ]1/B,/
M\;?.06IE=VE>;EC=:\NSSH8M>'B9@!5<>I:MR@2\/YT!:P#OC!<A<\&-KL#*
M_0*>^0@W!(9I[YYC&"L7,H/ITB'X!EM5\%$]#5?\T1L?M9C7XZ4%#5R=(O@J
M=MR"?)-]C9N>DS\$\QFP/'M8\$N(G^)XVDX8NE%I !TN@$A@V9^U7LSR%984
MK*^XFZV+/*NSGYJ?5$T_ RF:T_J\\BU&95>K65AX$BS^30[=3F"]O\$*)HM\
MDQ KING)C?;U?:#ZU\49+,.O8IA)&H&=0%13@C@6&&Q!XI"*T?+@-$YA"ZGO
M8S^V_?U7(/QV]<JO8^-G=>OP]U(J7MVP/5,/RKZI/I_&;I,O+X!MS;%V\(Y;
M%TU\5X'S_!'0%/:P:D[!53^=CH']FM6M0.NW#F'K"0H,UP.9P"^;G\YB1*TM
ML>3R-9A=V;L^:YM7+0WZN\ M_W;;4\X>>(ZMC..\=9>;^2*TD))58=.R 'PE
M;]B*-5(K(;/IN/U^RRE9?68(65U\,[0M0Q[+8$P;U5EAR5++KA]2;_ DH%^G
MM4$H,S:UD02@=+? %J[J9N,=KN#2Z)LHO8;.K/[G\UGM%CDXXZ>+<<AP!Q@)
M?_3YSMFN;:U?Y"XZSG6VJ9=O%6=S"X_>N@4@83W+<8W424&\:-]\^=@-KB\J
M_"Y@U4K<%E_W5P2O2QP(ROGY;/JEC?J-C],CXIY134#/NI08XH&"SM0\(&:Y
M,B%Q+[&[KF>-8XH18Q$.N<N>]P'T;'3(!$*2%X$S[:Y[1&]7\/)70)>?-FV5
MW?@^E \R)),E)-\L(]JF*7B,K.8M<\H&B[C)C8PPF!36!(R4B0(V,C(BMD8V
M,1V8BC8A'ZA!7%"/-*4:^4C!7S>"TBCWS6J$G_"!L]JMGL951[GU959L>:.1
M<&K;G%>5]5^J<\H$[(34I<$\_-U=:L^LP*<I@=/^4%>A'_2\F;F5#R8IQY&@
M$CC<2O!"L! H@2.3*(_<AO@8YF[]E7=K@_YM^J6UF3YT[NJ;UEO]?4GI#].W
M+9VOL#MX<7'-[XAN,CS]^BSXV\_4]H_9O\M<?ADHV'#E1V#QUN,N<74;^P-#
MMZDN^'S6NKM+@Q",V$\6_)Y%4X4V'0@.T73Q\73'/J^04225%:D5$G%M@1^(
MC$B#1I76RPC,=)V'(HZ"!O!TDS7@)UM&D&%>(*FB($HR9K6^PD.WH^//^67;
MB,O?P5[NI4E),2>#<SU/JE<!O"B@JQV/+T:5'9HGVM^E/D>+77(1;0!AE\)3
M,*."1%:1B!PA0BK,-0Y^%Q8[J):?6O=_$R1VF*[@)W1 BF73BCIV0UUIK##F
M%-D<=N76,V0=\(V3SF*O"*/;N7L#UKM5VH/VL6#+&!*04]HBZX/W3@9CK-XW
MA]$3-E .^YMM&NM/%V#$S9O-LJ@NHK8T2UHS)=LN]63'EHCA  P1K%G/,U[D
M7GU.>(.4IEPP@K%C]CH'9$M6,S!7C+("<6<D,I@XE)S77'),P-B]8HG<N/W%
M"'DB[LI@M5LF<<J1&%E *K3FJB!9GVA$@W62$%!,?,M<5=)2&XE"P! ><<4<
MH$J@2"62="0,%!@^$B9A<G!,,LH1]//H<TGD^*+DR8<;9%\71_:9V:[;[D=H
M2A&N02TJ \B8"XX\H*7FSJ.D4HJ8LIC"EBGUD(.ROT_6I;FYQ.C'97W$@T[C
MY!G!V93*YV*:.+GMU2@!E!=!(T+SB#NG%"Q3201&(N ZV B*;&4.'G+*Z$E?
M;3*]P4(<CLFXF*QRF6U-?'L(83IIKAZ*6).OJ0#?3L%:G,><*6TQXCQ.[#CW
M1]XJ(5QLT/UJT8W-Y=PYB3N=M&4WZ88#%]?/933'*-TB*BFMMT@IR1!/"HQ?
MGW_E26#/8TAIJQG20XJ<;Q&!+NH+?WBWVL17D_!FN;L_=_NP+2:7PH$?(!M]
M%87YQCD"8+@UCT]G&RR>#X_<SM;+$S_S9N/43S&!^F\"9:#I+V.N(##5X_9P
MT1HH9W&^F$UN/F\TJGX"J@.[3FH+/T\GDVR4^\7E\9FSZ>1S!+8^W0H7= 7C
M  F3YF+\R<(=KF)QO2PDZBK$QQ<@$0$LQ_@%UCWI"B[=1?N8K6*_]^"1U2 C
M^: <W&G:%A#][V)6-Z'N<+$]GM46-K:GZ$ZJ5^-Q^[;=H;I9/,O*:GJ>:]6F
M2WVQ?NYV]=!5#7*E[&>K?OXT;CP('M*=1\M_OOS.9[C+JM0SK(HD;?C?10._
M'U[6 6WCEURR&A\J]X3N7/ OC^M_6[CV=]KP%]3',Y ,;VQG=RKZ/T[7K>;.
M[<?8G3Q'-@%-7]KQ9WO1_/"B^E._#PWO]/#X)I-O14;R,7&@6Z^UWIT-QLTC
M\*N8&95!B9RI!6\'<:G #DP4(VE="M@8@K7[!^FEFFW/+O=7S]Y3?W4E *U&
M6<Q/I[-V1LSJS,E2_ZPK5W*MZ*JJ8%7F_^MTG0>Z=KMUQ>REBH4;G,^F/C;-
ME<KI:ST2#JQ^LMR!_-W YO2>M?L4$Q<51X9BEVOW#7(VYX*2YC)Z1C#?R=G/
MW^(XZ_%W=C:_^#"SDZ;S4IK7=>/'TR:7Q\ #?AQ/_3]?5+'Q]CP#RFP1O]*L
M8^_J=5_-A-QT''ZXTYX2?E(M25N=9]I6\PWB[HQ-[[Z@@?M#^S,_WG2N1&<"
MYT-183LRW/Z+E_%A8JY&8<]LR,7]>3+NN;W(]?I-->TOYJ>C3+]S)W-)=D J
M<IP/J0ID-?R3O.#*4A:=($\(G\O 4?/+;'JVB:K_MYZ?;GYE)REZ/,@4_>@H
M^4YYITBN7@V> 0\I39%QP(9)$:F4T9:+K4&S#SD<W0^^&V0)][%6'"47A.(I
M(J*L!;>(:K 8DT7>*(LE%BJ0K5*"Y#V+QG/D'3&(:YV0T4HAC7W2@'G"Q5A8
M;W>0MUD: %;#/<R"_1E W6G"W- I3;NPYI5CKCDZV?@:S)HZ@;>26T4MQFT%
M51:L+IRYS%]U.;0F5@TP4#[>4'^JPP+VMX+_3:M/L5F>7SRJZ1XN^"B]#0#B
M$CRWW-S941]0#('*Q(1G;NL4PT-,C_=S\,G>-,TBAM>+W!GM7>M5O\^;U?RV
M/L797O8J!WC_,ILV5U.^[<8VFW+WYM=?OCX@C*F19(^Q-_:W/3>W>!LL7U%L
M#568(>DT!Q[A%EDA V))*> T!5 N=F%:')"OQ"#XZC%E@(=>^\VL!<YL  .5
M(V.M!LB*!NGD#%*)62TI!5<*[\)T**SU+=;J7B_G(S?.X3>9'JL<YV9@HH^O
M\.U@2:F/'$PP[-4$;+GH%VU_SVD"@P\V%ICSQVC/<A+<5FZ:^_:<=5M^M0?K
M295]@>J7Z&:+W#@M[_[ZU-^:3;8#:..N?5KWN*I]DRKE.W5/G50_V3,WJ\/'
M.+J:M<^Y[QQV:[NVK6-OG0T[/X7E-@O7WKS-88]SNX^V2\MNO<&#@WE4*5E"
M$2!Z+@\W'FE-\DQ:KXC&*46U55,8/.72$8LB!0CG7.5P&85;.&H,U9I1O'6V
MZ?WI=#;_$&=G?\TDS>44]3Q3?(>'3_ )&09L+QV\@3<WV6N0_=7YK![?(/U9
M3[2"WI9,M/YAUREG.AY;-YTM^RW"56. A]R6VGZ<Q;9W<=LD-V=;X"'K'L9V
MLZ9F_9UV6$%3?9S9R;QKU9B?>74EY[;.'8*FL!7S.A]^!C:<Q01$:X]$IQC7
M:%:#39-=X*,"$J."")$GA$D^FT*L0I8J@P!@&(V4VNBV8IE,:BJ8<PA;L!^Y
MY( [WN>23D*CBP[,3'X=2+I*K-;HZRS!SD)\I-E'E1QA-3BS+^>]?4N0I=G7
MUA';*MEZUO8;;3M2'9?&$D0D'QQ% GAGY7Y8^%5$YYW")*KM61N/8[3<7/3V
MX:?[R[X<0$=5O^4.H+E,X]?I/%9Z5/WU.I V19'=79']]V)\<9,>R\1L&[:X
M"-S4P!NTU0!@>695<]F;[:IBR^IK MN3RV4FU:__]6[9H<YW]:O=':_>8+.1
M91N#/>]4Y&HW.PAYY1?UW%YO)-]JVI46O++\K.U06V36@/$/7MOTPH[G%RC!
M75M#>LDTG7E]=46M=@5RU/-Q7+9>7I:2UYWJAG=8';I8KJN:1W\Z@>WZ>#'*
MPV':9OI7*HG@]<%BSXY$;BHR:77PYHKAK^=QEB6U_?,EZ;)0?FIKDZX6\;;Z
M?4G-#3V_\AR.$&>CLI8+L/(CCFV_9J0) =6NK#):<1;<5IB'"$Y2$ HQS##B
MVN3.*MRU1XZ4Y%*E:*[V1EG,WZ9W +%Q_E.>//%F.1KD63H$W;"2I0M]V87W
M4C1;X6C:D$BV5UN[$DS5E7!,%W,T3>B\)>=RDL=ZULK2:,TRM42'_(A6V-MQ
M*ITPM$W)E\^]429*!*;G"N:MGT^[2$EN\'T77REW;LG?;X#UEAU&-[3!*5RZ
M#":VSE(^M[945KDQ0GO#SVTOS_/9-$_?6;/CV6^_OAI5']M_VX-O,[ @ZLD*
MJ#>7M3W_Y,8[YGLUER#<-3KM%M.*#CB)OF7E;GK1ZL56]PDGU2]+SZ[M3WIK
MO=;F2C;.+AT7OD=G@G%8(2.T13R%A$PD AD2J$_:66SD=7QW& SHG&KTR8/M
M+0)\&SN&0K*>X:")<%NG27];MM%^-0FO+VV/6P_+/0CG']/7Y@ X;SNC*BRZ
M_0"&OK77^&J:UFQ9'MI>6Y^YQ:SIC._,H!%LKFY0TZ4L@U6TME?NQ/?XF?"]
M(2P&G7)SG7P@@-J G.$")4JB%(IXK+8J7[BE5@6NP7\,8-=@JI!CA"+M""&&
M&J7C#457A>^W^?X^C+X.RK=%LE?9^WP!-VDC_Y?!_GS+ME;D:'DWNF"9!-,:
MQ%4C;DGN $ =DC82XVRVL+>./T=A)8Y<Y8Y2#H%]+I$QP2+M@=>=EE2$K3Y1
M^^#=805"]H[9Q>2]L\F[D1V\;KU=,W77*;UKX8X6/O)>+&,K>5QA&QS9S"KN
M)I<8<V/_(TTF6M&>MK, 3]P@SI)'6GB.:(B6!(,U%EOPE##A03"P)J7-8^M
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MS<16%=.[?*0\AO;8RI+),W__MC3G=\+GMV1CL$_<P"MY[&7N.H^1<Y$B%J3
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MVN7]KC+>)=B[5<I*@_F2+BC_VLO)@N\X/PO?06-<)]2)%_DQ\N[UAF,**;9
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M_[+X$^SP,!MV #_S2&H*^P[$_*YJ23P$H(W A@"D]*'.+AKL6GE(@F@%N-?
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M9]\RGB$4T2$,D7_3+$33\Q[KLY]UQGCS;8LNHM4"G?<HGB]\U!OL#,1&W$&
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MTP?RGT3^$8H*+2X.'P],K)1TE@2-^YZ2:IU;G!/- 8$DVY%.B:544]WW2).
MFW3]XCB>5BFG29]KU!8![8X]Z/*SS6Z'P8><W<^VCT#)@(/.HQ7&=$?LF[.=
M=%-1M"Z90-=,AFG>_KBH:D,:\*8_YL#<V>7+"4>U#7%N>8-)QAMR?UEA2W-
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M9%I;,V=M]0=$?N3E5SEP, \CR/K0&AN&N!Z4+6\C5_H&V]#R CW.KS<]O;%
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M<$\;T0EPB?(0QVRWV+;'U(>&,J=/:5SD]P]/)G/;ZF-91]KNA\;Y-2EQ.">
MJG:6T0C^K<X)PO1\"&9H/!V715Z0,R1.9]66"][B1;FPO6IU/ND?D!LWAK7S
MPDL0)]0,2"Z.GTC?PC:(JL_Y!V E4.2,_/PF):LDSJ)?$3-<1".R&\F"83]>
M!@6Z#F+,?&ULX]J1"F_AOGHCNS'.T9;7QZR@KR#D>$[S..P38ZU/@TAO51-X
MMU2+TX.J^KF7]\G-%H>(/W]W6>4#6FDN.9N3^N_4V?HN*_Z!BGL49K.4.FC5
M^53I#KU^^_B@K78&.=;7?Z+M/@V-,9\(_\X\]H]UE<R*)Q&45C]Q?*MR-U+5
M:5S,$7Z<!ZFK0T!%CS65@JC3&)$/W:2'FAX.'L[A(\XZ^ 9%ER7>+O2*7J&*
M)'[BZ3::O>(/[$VI)D%O$&9>IT(*>-/9=2C_CM)-O C1X\LJ)JNUY9H2M.UC
MUO3SUA;+1N^BGPZ2A'V;78Q;@P9;M[^P$XRW1,P&\#'9IC6WI88KGCV_'^\R
MAV@Y^&RBM$1N-4"Y5B88DGK>M)GFH .3[RXEX.WXNS7<?AON03"1TLO'Q7-T
MXG$*>U4H$DQU8];C]%%RAZMM^!#?%0HHMZ<DE!:RE?2>[&?X;((25Z=V%+_
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MSOCY*(TNT0M*LB6E;GW,J!*7*'NZ2WJ6L-'K.@SG&!5PIMG9&7,_H13A("'
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M/8@F!E]A/0BI P10WK4FWMPEHEGE>O_9'CP:LMA%VW <002CV#5C>S?6'2:
M\JE,0[GG7K%-2%IW<@#*G2+5Z+Z;QH:YEJL$4/:T3C*I.T6C2HVI\P)05#1J
M_71ST]A%0&GZ20 %R"!L7^HQL1]G*?1, (J$;B2EPN.B>==I^#5X"T<7??E@
MEPAOH[?E(@+'5\);3N4V IYK!DQ6AU><&^8&F* <($8UO5V\8\^6P*!VO_$6
MFDX6U([^.S#S,0Q_9IAHXS Q&V#/=?2K\A8OZQNQYOT ,P/(<!NO90B!"<<
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M4VU7/88>9==W"ZY=E@SY0RB,^$$%?-H1F.2O5+MV8GY$W49<!:W^-?B+N5V
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M<5>7 I"UNZX\<KSPI.:/H>C\TB[BS[C.U%N$]^#68'RJPCO&U#]!]1+&;UU
MTQC]\=ZL_QSZ*]\%9<1UX8X#@Q-"05R$5G]"MX<GX$N1F:)@6>]T+^?9+O>;
MAG=]&*U!=+IS4-7XL7$>>55!C]RO)_ NJGVG(G]+7#WP38G;*O.C[NG@,L)D
M"@:(.%JJ@AXM@T</Y%Y%[)YNMLQ]X:]AL;H.?:@0N-L^\?-AL>)S+KO$#B(Q
MG;=T2SO8@ME0<_Z[S'UXL65I6=;<\WPT941RGO"F1 RR;_Q$I$-6^O4.IS;:
MJ\CTIBQ&T:C^-3PPGK?O!53SZU"[2_GRN_XFH-F/'L O!!5?CQN/7S9S+]K4
M^YCZ4!PUX<!/5+@2; P^21JZ]>'QIB?,U<6]<?J[2[2$:$-V5>6X$;UVNGVC
M>8$S/^\]W(*U#KN.CT] KYCSU^Z!E]1_U2*5E^]NL/6H!UD!8 AO$[ST%ZM+
MAX$-"^4Q>*!UURV,,1HW=EH^XD4LX):^X:]J3;QN#X_G3](2\QX</6H-U;[9
MO^H\2UT?'R>)3-6SMB60Y<9-(;4I-98[IV-W?'B:7U&N+N5.JK#@:C[HLVJ@
M-MX]#;4U_#^(8+SR#X7?OO>4OQ/?Y>H#_(+?Q?D?:"/K;O)>-$=$(<@,_\;,
MA(J!1Z5N7J\A2L>X$7;)S:_:+]<(:8/I#>#JG9_FE9D&+VSS U,[;_!<S/0Q
M2'E,U;36VZX?S9%K>]++KE-=3WGT!)36UES#N"[9L)NSLB_]H_;=W[1D-IKE
M83I=AG,[B_C_6]-D"@-'>V6W-($;&1/JN2%TMGN,H<3]FI\<"!:$H'1-A]$>
M!(XO*9D?K"XD6C[SKU++[Q%Q1P'>8#H?N0M+<R@M,H$)'().$&3^6Z6M"4T6
M@*.JD67V(S#53(S#<C F4,+9;&W5G: =GYY0B2<67RI__ %@"M6/3R\MKSX8
MT?C(%.K,])S4]G*SW&CCD$\ P85P<6@2U*;15AUH^Y(8$9.,ZS^T !,"?]Q&
MR5_YG2P!E;S+=WYN42RK$D'4972)Z)5U#IS>=$>/[65X-E WM2<$CO;(9+RA
M>2?F?!WQK?@OT"SB!/79CE[15C+CP_X(B#"(PRQ67)%$';]&NN9G!DGBD(NY
MNWQWT7ERZZRKDCDJAPWJB;X'MK5PB_IOQ]-IMBSTH<")7VY7_CO\K3D:W/#
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M@]M/?MI2;VOU".]%PERIIR@0T@*E]4U;.CQ@MCQ'ASM0NB6V#ZX%XJRMRSF
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M5FTV>DP 3!7U:8.^+(R;7CRHJ4=/RT-CHF RM!&B%3?<,*T9VMU68V]U?&A
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M#6T(X8)4+N1&)#L!%%^1/:@[(H$I0:ZV+LRYY_EP5#E!%6S;G%&GGYVLJ,L
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M"])!:GX-+8QC!_LYQ'VZ;N38YV(M>$]J_Q:QE 1B*?F'K+7G$)B_(=^X-$[
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MN*#B_QK4.'HT\!I8K!YCRJ\'T/UZ*@6*'U$,\Q#KPFV#3.&BY&SQO@3&Q[H
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MQ=-WE3M]RZM"')@62>=%](F1=&;H(U)S4ZXQ>PZBJ:QFR<ETG*N:PL_0!.(
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M!1H \>5Q55EU6J#2)IA .@[_V54.F$-6S8CB^"R_E$% =26A^J@C*K)$A^)
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M=6+IRU?5^A:I!\D64T5K2+GX=&0V39=LP1,]5-7V'*N/(W$3&QFI^)@] QV
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MBAY5%G+W(=**]FI"W^6JQ?4%:[FMKSPU"T].H];JRA,QBC(/ZVF"!5O$<1I
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M8_(D[PC!"[T,*I_\K<MHR?%9J=T)1[[-%#5([OP,JIGE,H4%GLT @D*CN"P
MI>8M)D.+'^C52.1X5:8.>ZD#'LS+!_78J(XK'TR\%,;J+"E'#B[Y887_Y6OA
M:VL!-< >TCQWF=K4VU.5'\E_E?FLV,G(>;]L9#7=B\@]1EW\DY*-'8($Z.$X
M3<O<P*BB*HA#T)OW["T!7A-P(7?L?1)D8+>\)?S?]XDR:-[X^X@J(@-M1G(
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MC>@.-2XUU^9N3\\=+Z'WD(+7DMZ?_,[\+8D!=/DU5]^G2$_LR!;R[]&88Z&
M=Y_[B"/$W%*I[4<3+Z9VR%,_6G#,5F^,_4/@9G!X#B/+8])'7JIG(DP0.14*
M21*E&7B)3$R;6R)/OPH82/-<#W;.32S86R.QP92F]3;*0DBR#+:$![CI<[<T
M09HP,WL')/'IWJ6W% G\O&C/V=YJ#G<:/&H22--ZH>F-,#?'DX1 94J6$.SH
MY>%G!97O8JK.%5&^B4C8VC.]>V*R!_EE$M[#LO?;33 GK.IG;^KK*PZG,A&W
MV.C;$8DY!M;" ?P>4FX#U%DP_(SY%>IY$@*=4X 1Y$_TULG6J4Q>@'W3^AJG
M$D"^MV[))DI VD@X2A1=?HB+^NI_1KMRMTB2$N3VZD> JY(* $_[,5UTPZG.
MY?677Z[K6K<V1F:BP\QS?:@,/6"L,[%U0G?\3<RNO6= W^+9:3R8R[(WS8WG
MLN6J&)O.S58U0YYX1YG7>NU0H[[:MS,RDS4\S=6WA&20C@J7VMW+Z@F  VKW
MV3J%/YL8/HO0+.1$@%ZHBD$I2Z-=/+1T0!6R$KG-3JYKU9:[SJ>%N03/!$"^
MZ-ZZ3V!^M!N :MR2#Q*G+ A:O&(M?OMVQ&3N*WV0_&!;TD>JR'54<(L*<*0]
MHLC,\]SO=B1[IW?ASUGZK=B*VCA-\;FC*?[3P-'9*Y="ER#5T1QS4[W0+5%
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M[+=T!GM+],<!5C;;I]SJR3SM-R!B9E3#"8GYM>CL@GU/=A3F5@4;V,THHN)
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M=5E1XIV:^9'3JM!')E-]A/_S]]4WH"+T'__C?\B_T'_ V_8?_Q]02P,$%
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M_1_3Y6JY Y 038HHZ3S9[B#8@#A%'.XF2=-.^Z@^O*G%H[^C8;+P.0)W:(4
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M!T)Q5+->[AK7W><31KSC^ZR]_\BC^]3K66Z745E+W=5<Q6[0'\KF>!V#)\!
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MXQ2IP/R%Q.MX?A<5J%H&1=?3E2CP-5E3I^.^B K$)+2C.NYZV(&XQ'3E:D8
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M/[WP:UZX6G9@+#V-%8KB.+R#JFG*432.@ZW;+,:,S7 <QU'UX&'0+)+YHX7
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MX8V-C4N-? ]%TKB)65@N/1@CM?VP.H%\RVINKC)-:T:B\\]N;_IDB[:B$37
M7K7CI[%PKW[T7J=FR]Q/G!T_>N0RP^YALMA:>U)BUQ].%].G3F);6A&0G.4[
M?O9*B>#.@TCC1AIXBD"J>V9/XR"R5B$XC<)NYDI9,F8F?T)51C!]8&6WKQ&,
MKX*0:X?XL,@JUO ,Q& 59MC[*)V8%;:NH)!PWRR$+=.ZX!RKC&!.]T7[$V/=
MZQ#ZB7=+J-R*NID^O!VVKUF*1P2+NX?W(7].P>\Y&O?R97I^<>W9"PXIL[FY
M<)?6C(01+LSVIL^@:"L:(2WL5;MVTCK%G<WQ9^;J2-<#*\FTF.^@4EV,+>0)
MIXJ\3+-PBV145I1KJY'1ZMWXA:F5+UL.?JF^EBWM*,,,=?I**Y8<TA@0M  ^
M[C(Y'4RR!Q^!681)WX?I;^?H$@HS_&]L[L#LH>U]NDJ5566#):\K_.,CWT_;
M+*_1];0M;CTBF.R]VR1F*MW7?&@#/>"$2^IR?>V+OI+CT-+=S9F?MSNT R0S
M$$3"VBY)O6BYNDEP$9P7$!3QD'*+[324MB-VA8Y%FGDQCN*D41*I? C1E9"A
MR<B<NWX#:EL7,S>^Q!*D^QHTM7+J4G(9ATQ/<\HM-0%TD6\;3?B:7(R(;(C%
MD+O,+B-IH[W[-J)<:N.T-O^Z)LG"6,T-BEU;I/QN$*AHDXOI%7.3U= DNUOC
M;R"W+E$O;4?@ :R)1WH<_ R2-?1VF]"_CE<)W$KHR5U&L,8@IT)F<GW-Y;X"
MWVH6%YC$Z%_]NA MMTKE84Q;)M72[? -0&.8)R<#5=O$Y'A1744ZDC-I.5Y?
M3P=FLK8RQZM>J4')L[8Y7LM"F=^S+7J.ITJ70TK!PNAXNF,%O.1MG6.DU[4>
M,T4C:HG9GV?,E*RS)6R?9]@ZVWPK&?>T-0 =MN8*R=-6%Q2MVQ5HL[X@;3>O
M()OU@LXV^0K"T]88A(\!%4RGK2Z('QTJG$Y;35!_VZAPFU4%J2>3"J[3UA(Z
MO=]4T,V:@L*;4&7*/6W5H/MK4X7?H J!];[?CR0KY>SY+;\(IMM&43TK+(OB
M4.H\'E5V). +W#MZCZKO5=[?@""/2 G:X[3UU<-<\)2"51[=A"L@7E[?(:?!
MH[31Q_P<G&@BG%$>C\V$V-&>XJ;(Y4^B?@UULP0>,?P^I@]QOTHR CP<#]=C
ME(,AIW=:A_>4:L)TCD>PY]#JK?]R.@=6\'X\Q6O7F=HO!Q%Q/[_BD161:JV*
MPA?@X0D'R_@>WSC8V814Y.4J+\-\PWPLF<R<9<OG*(TUB:4_Q<ESBG@$WK7K
M>)=G39U.)S+2GS)]<ZC6(])\*AW7B#M7>U([R(Y[4@^)HCQ/&,/UVIY26U,4
M?1PIN'5@L<<UHQ2E&N$ IH^V8EDM%6@<5UW*&D<3/*83JZ>%YH&]UZ5.'JOU
M &\X#_EN%Y$'4B_";PU74?*M]D9?)IM\3-I%L13>=/1\P@(^>I5GV+ >QN$V
MW]Z3]509Y*\2J(*0WK%-<U^9PFH,\G=<<&<C,\PQ=%R"%Q.:IL/JN)!.+R\S
M12%@+C)#O:FJY,@/B#1"']#=KQ<1F0QQ0\#JZCH._XF6 Q#%%VN4O[UT?\\"
M"(^JQ"R^>;"(CRC\UE-L&R@6EJ;YMOB;XJVOY2-6@57?\/HZ%GX6ON#B=ET!
M4AS87+Z+A+Q\@YH/#YDN68D:#)V&,GU'ZZ_I-"!;<US\''(O]/!'QP76<39
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MD0L0-4S9"^XRDKD=KCWN%+']]P!/JO N>]A%3#XOT].JLTD4Q=IV%,(+^@-
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M<$7Y_N8>G)469/GT#Z1#HSZY/H/:4 E!8'[M16<)A,DW] ,K*ZM2?TLVX%>
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M%:AC-Z Z*Y+"UW'H)#Q=I2"K(WV2D+$U.1GO+\>C(!6I3%'T&@(\.T2J+C=
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MXSE>N].@\,H8 [GI*#5W28;=E[RH_ GW28ENN8P7VR3'>N3AY"ZRNTJ%^Q5
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M^]+!6.$F-"OR;:#W,/QJ?30I"3<95A]S+\]85XK7G!VHMS ]32["S3;&IKJ
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M.ZAI951=#ZGI[@-K X[&:\AJ 'N@69+YR>'#CB%C(>EN>@P9O8&/T7 9!^Q
MJ(-"TC3I\@!V%[9N-X).]<CQ4 ;5DZNR(>X&(QD75+C:K...^2;![Z@J.^YW
M/0B7[J9%.^Y^W!?I_HJXXZ[)@Y*R4*D?P\W4S /J0_Z<@M]S[('V0D*$G'D\
M/5H9_UV!V=Q<^M?6C"Z\C)FXG=;4])$5;4##G8BZUC%L%\QC5_Z _^_92\%_
M_']02P,$%     @ ACAN5/3A[R!]%0  H%L! !    !V97)V+65X,3!?,30N
M:'1M[5WK;]LXMO]\]Z\@.NB@!1S7=EZMTRW@INZ,%XG3=3SM A?W R71-K>2
MJ"4IIYZ__IY#2K+LV'E-UY$28G<:/R@^?N=]>$B_G^DH_/ W\G[&: !_R7O-
M=<@^]/^UUVXUVP?OW]CWT.)-UN2])X*%:9H0I1<A^_L+S7[H/1X'+-;=5K/U
M\F0B8KVG^)^L"[VT$GT243GE\9X62==^$/*8[<T8G\YTM]UL']I')C3BX:([
MYA%39,BNR$A$-,Z?]H36(LHZ,&/2D$_C;L@F^N3%A_?813ZEJQG7;$\EU&?=
M1+*]*TF3Z].Z:= 7'W[]I7W4.GG_!EM]>/\F><Q%MSOKJY;8S?JR/>I_GTJ1
MQL&>+T(ANW+JT5>MAOG?ZY-KG[5?GVQ'ZLK.U!-A4%Y<YP[0_4__QXQ[7).,
MBZH)H0\#,UE5##\/1I=CTCOO#S_!?V,ROB!G_=YE_RYH'C6/CHYWCN>_4Z7Y
M9+$+0&,A(QK>%]+Q[X-+L@U7\DK/N"*__O*CTVK[A=Q7DC6X5)KT(A8'\)_>
MU50?!KH%-#AY30#=B :,4$7$A/R#QBF5"[+CV1M^#9@O)-5<Q%T8@TD4@_NN
MZZ#:L#=(I]7I-(BW(#0.B,?T%6/QSM!^"%OW1OV]\QX9]7\;7 S)\*))WAZ3
M<7_8&XX;Y.SLM.J 4_*)A?2*2D9"'L$@ ?RE'@^Y7A!?1 F-%^15'13,&; ,
M#!54&_%"LS0,BU<9T*_]T=<^&?_>'_6^]/\8#TXO&V0P/&U6&^ 5E@:-F61*
MLQY,/&8QK8UQ;&YSZS*G"X.<[GZKN7^\__+D41SG[$,3=W3W#Z"/XY?U\:9'
M_=/!N'=VN09SP.=W\I];=T T<W]AG0 $=#()V8\]I:G46P"%3ZYXH&?Y<'_9
ME38=:$EC-0%N[*9)PJ1/%=L5S"M\>1)PE81TT>6Q@0KAN%]W-P&ZCMV+#[00
MH1)15^=0W<@D-[C&D%G%15#I)K!8#FVU('I&-?&9U)3'Y(P!64EO*AG#"( $
M%+T-ZUCWTBD 1]KOC O8QKB&U2*L,8NJB[XFY$LJ58J$,L1AEB:-G'HAOE.$
M)HD4/W@$] D7I-TZ:+S;WR<2:$:]D!'UGQ3)/&%,UX=.7R2+."RN)J1J@.L2
M*PZZ))ZB?+SBKPV]@ 8<L.^ Q$U"(21^MR)D6NQY#+6/TC+U4<#:!Z!_! 2M
M7LK# /L#VGN,?(_%58SB!R.2CU*([ZAN2&_.XA18XJ. I^(&.:=*47^6*J:U
MJ@^]/V:+K1&]HTC$(&\%72Y3&!.I8Y@!J8O$6Q7.3KL!\KE1-AO -*M<<Z1G
M9:YA) =I^^A'-XY^T&X<'76VC[XZ_/']AS^^;?C#MX=;AY^_AE  W'_C_6=#
M3DP6ZIZSN&RW]V^8QOYQ>[-RA '\&:@=GX8$19!.X7MD(1O[O=HTP00ZF@F0
MMOM/\K#U[D9.V3[+B/DS&MMYXOS 4(QAT%QG&JL>B=RT^VE()?08,.5+[H&*
M0;V3&Q-X]I0F7(-/^"=\!>YUI BL)R S)AFTO.*X0##_; +S-&M7,QJ&9$;G
MS/03,8H+4+8)/ F>(5&I/\MZ6QFN<([!@\K^=4[RDW*2O:?F)(/@@#YL $M[
M_V9^X8M9YL9V@$M@)$,1,+O(_J Z/1:*JX;U! 2AF$@WCY7D"$0YM\VY[#9R
M$U/JJ2P_F2KBMM=(!$ 7\^TW(;]#$PVS(E1K< &LLUYEHY_OX)WN.D%_SWF6
MG>]M"NQY[I$]A.K#BV\-DZ;L?[X8]1L5IST(GW'M Y;E)7//!.SK5*#='C$?
MS:=J$)@"&#VTOCS.4YE+0^JAH'(%5GT"'\3H5ACKF>H4##G8_LQXKRJ4S$$H
MNK$* "VL@*<EF0IAE=6<AJEQ%E:F:\>0S&<\T::=2B<3[G.8P +7LIPS]H\[
M.3YZ*B$+IBQHD$WZ,&^(F0%4,1,1@JI3W>UYKUS[&]/SEPRXX? ]H'2DNAZ(
MH[$F.[+J.Y*0'9OK=C7,M<'IIVV<GJ-A! <YE]AZI!/ %^^I7,%@NLV(FI@T
MEHY#X:+7(:BO!^I+EZL.F([RF+ G&:T/:Q<8HQVI \[6UMF9OCN!J'V&-A+P
MODB,:07#W_\!T3^:;/BT7ODK EHQP?1&.]<V-MEO WL/=4W(=)$IX#++"6E;
MZ"$9& <?OL;<0.8-H0L Z^_>YAZ7]QK;^\W]_<?::ZQ345D=!";70]UJBP"F
MR@2P>I;'4^L9N_5$/KTID7^71-]?20A[CYD/]A\S&QQ4/1G,7E]+PZ*V_!D)
M8DP9+9/$-W+/86L+@$66:-E1I]S1)B'=I116HU[[<>O\9S(? FWQG@<.W?<]
M.@'_ODO#*[I0\&"5P-EX'. V=.YFWFXZ!>$\A@<(V+J5V:HGP-^CN'.#4:4)
M+[U%D?0IOE8S5$VBVJ6]>3:Y5VT'I)D[X8[?GYF'O#5TK[S+W&X=-MIO.Z Z
MFF2B'0<_5PY^8%*D\OS=:34/VR_OP];E/07'U3><M]F<SZXRDQ=^1,5W)LN[
MTALS=URKF_)VC@8_P<W.*RT,,;@B:\<FFX1\AJ"?S@4/:.P;71F(U //.Q8:
MR: T4,94>6*&@V)Y"=:'XKMK_H(N%WG!8!XS*0$<S#KNFZ9@-X]H!'#IO)-+
MYJ<23XQ]8HE0@/.RV.3&S#",C46K:6P*3S@+UH^4N#W?6NSY=I[\GB_(8ZDB
MJMI*9/NV;UW/+8-^,50X?!6\KC;VKG:NXEZ*VUW<6>2)FRX5YWF?*47& W(J
ME*YXQ0-H]:)XKE0P'PLB/."+PDQYC(+6B1?K&T<^+!%?XU?91UG]W2!*I)B;
M0WD@.H!)4M0D ]>QI9L'0/50<M#SA.D,H#-M^M,P6UM'*$5DW@'S[^'?O%XP
MRO:;<JR)L079UE4P!7<1!V;!6O,T9AC_HSM:'KP>A[EKQ5[+*T\B:#?#\QU<
M>:E4&5]L8(&E^C57I C<K<SIDE#)P?%7*BUJ1,#5YL7A#>"XG#^+^&2%2Y:C
M($.KG"%%JHL(9RLO-<K5I7:2DS0KE_=HF =.# RS/5=2+%G2JRS$2E()H8S-
M.R&+AUSG0L9C4, ZU;E)D6Q*I0G93&<V-%+(^5@8D+V%IKFI D0#$XR5)IZ?
MG1FO8XPK66.DHKH6L#3%O](&C.!AU.5X'BSE,TRBVB)1Y*7)<"VV!H: T-@>
MI;2Z-=82+P9:.V3!=^?S/5^7N[$JZ2!BDS0,K>^G1(C[E7BE36AJ[$M"E"F$
MW"Z><QB>? 6]16TA#U"06<';9/Y<<O?G4_)S*O$, AXU;!BE*]E_4G#DK07*
M+$<YN++?&UM@60#D,<A24.U6ZV5.N74%:M3V\B@",,/RB 28)@;1 K.]Y8V6
M>Q2KWE9A5S8;QCC%#6\\32&X/?, ,XKQ,;-2Y$BT19*PR00$SJ6_:IG^VG^*
MZ:^+S[V*WUZ&[E)V[0@(EI6XF.%A)!H2<14S:51WZ6H2/Y58M@(6 >LPS5&L
M* 'C@#)K=(*Q&49X,;*!/]J,&J0R3ZF/03^MIK*S)/:&WJQ3.TU#NE(:>H$'
MIHP'"HXF !"3G@+'08%R C="A/6(;JK/'\N0)@/^C^9E$[<H0(RC+*P=2Z!A
M*JVW@"8'A!Q=^P;8?N:GFL]1/8,(-5!++XD)+T.[08UZG($E> 4K"]%IFH/'
MT:B-)XYD)*,TK,N!C]>VC#D6&KPZA3&8R,XP6KG%+TKBJJ^)J\?*#YK=JX2A
MR@AQ^TJ!.)I#ED-#9AI:1_%C*/SO\.D7T"DHR6?00Z,0WTL0>2OA_3E$PC+_
M7LA\=PP+?L-2NP'Z%\O=!=M\>702%X)*)3NIZ2V((1/,Y V6_,8VB6,\",4!
M,"K-FC8]4SK8.6<R1KZ'F= 4@E.S8Y>4;@3"7K-O_D0 [R@+676P;ZE"26)
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MSB:*O^*@49:6OLL9;43&/O*Z=V(UCWWO4G:=7T62"'>9@?&4)NQF36-Q)8.
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M 5;3'@WZ2J]=*O/+TO-_*WRNM6,K3X>]85@Z39FOI*\7"ZNTZLZ) UF881Z
MI4*O19X0 ?;!0OHJV6EW#A9*(TI=TBY%1%W:;0[E=D\;&+]O8'RV9\?1Z&38
M.HX>[3B2+\MQ]+,,Y<)/#]X_9,7$[;2O@INB%)4H^2FP.K_HF6 ?RU*H,E*Z
M)UWM\D\$%M&3BP6!]0G#(/%A?EAE %-/,\K!TIF.92=)EP+KB'WG^FM.<C0H
M'3H2,%>T=PA3HTM5MB9S<BE%D"X1Y2,QD!U^F&0Q9HAVG07Z<>"_&QDL,/BN
MQE*X':FBB0.G$J$'1!QCS0"1J5N&'XBCRUBLDH*$4?6VA(! $0,9(ER$U+3;
M6IG!$0J3/$?/26HY4(V4L]=/OS*6*A?3[ 4^MXH\N*==#K?C?'_$!#F-".B8
M,F-&&<&I&JK2VE'JP1;FP8X6]N]!\FK:ZX]/=LFK^Y8RWBJP9KWI=-8*K$<+
MK,7+$EA_ *<![1G5XH,76F=E+ 50S(4*!]>)HF)@WPHZI^):<>N-M?R6E1TR
MILN@=X*E7 UA5\^+Z3)Y69@NY]=XI>7!\Y_ZH&HL_=4\B]%GH*L-ZG#B"!JZ
MZX2@K":4N,>JI4(9M<#*I*)& 8?+*)*H>M]4$G)(OTQTFI(NT!GA'WLF*MU/
M3[H1=P-X3;HX'<A[DEOWY#L[[%.!T'K"Q>IH;D70"I%#%B*GO?YI<[(_GU>(
MG+XL(7(;2N%ALQ$""Q-Y&N*=?,1E!TR.LLB.!?;#G*7'?Z"HL@'!@%@+'UD0
M@B]^"*E2EI--/H17"BGTC.!:^7EJ0Q@#.U8]7G+LQQ+[0Q=%TR7.S_M>P3WG
M66H9N?O8M_T9&B&8IKW!8- *)A),TY<EF"S X(L\"'C8+ 9M';N1G(D%V#WI
M%K5.E]R9;&*?".D<QU)ADU,=@.X1]DQ(D]]/OOQPNN=Z8.J?T'J1'^E%;C X
MWJNW_]07VY,B76*-C-9&WIOHFM8[*FR"-%W*L*BTJ^R:D->N 9G-K"2683GK
MY4V"&"4$20%#8-E3$) ?!3[)@WV<R TTN-(%=!;CHDB: HPQ99J,V[\#8$:W
M2^!<^KSRDY QX'6,UK[ %QR==!@27D.[ 'F7-$/\,?\4NX "(5"!@RGD@W"N
M^W&ZB9RCT;#C;*3\FF@L^'0C@ZM]X*8\>4)2T\#ZC@9 >ZX)X/WJ.1]8EOV5
M80F;J906L9]PSZ+(V2RI$7OIN%''5^>]%8@N ?\(U8%"91@1R$I2;G"D:]"2
M;+[RTW)*$YB2,DX)OX?F!N?%\C5Z,A5^0#WJU0WRX:2!KBJINK((S<,+P5AS
M89;LZCQPG)1RRLZX.;U_:H%3$#'*P[W",Q1&]IXJD"K5O^7N9X]:I& Q9/'
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MVE8V?!>R8=K*AF\A&[9ETCY*.*A4VL:<O3;L\SV$?9JD7@U[H^8X_4&[:FY
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MS@!Q+L^.1V!#'9UTCJXZ8$Y=D3[KX3_\SFL#MB-<L* 27Y?R" 1P@0OC>YD
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M)Y/)=#P9]4^FS [\)K.#>P9 K-JU1U66<>;54]23.;MMPK(%,"Q8 $_>N^T
MN-4^5!=D5_MM$3T$,^?T%GZEQC_4RW9(+.ME\*S=YG<MT\+HC,B!PU02:D<S
M([",LECA[5HC:NQD\HEA1BC^5UP)/R!3[D@71MJQ:E.*@<&9CFK_ID,A.OF5
M6)Y>#] ?>^QP3#\O7KB3<\,M>C::Z4$H93D?^'U^]=9 RV"I5'X8;RDLSD71
MT5GGR"\%RS!-W=DMC9\I[^JI@S=;MJ]- V[3@ _N)@\&;1KP<Z7PS/:-.3.:
MM9@SWS7>\ZNW9[F>9Y4$SPWLI$F:\;*:')[Z=J6UHIC$OTL.?@->3/!^8!S'
MP@5^ 7/VE.IF#-42$"T&?6Z-)170(WZ+4D8DKN2Q=(I)2Z2IYCU*L%H^R?WV
M"VV&%T)37J>G^QC#_\2(&3O2H+T,+4)%NPP'68L$JP!7%19P75;2T68I:4\(
M^U^!$<-F( K#+:3@0C%R3ZH(]^X]JNF1F>^% G#&.U*.HZHXID&DAM^ PJ]B
MLCJZ,A>)S_TG\5SI81EBM4.Q<R9/=<-LO(W;-K]+@?/Z*#RA78SP/5+5IDNG
M-JB%6JJ-H;I[BQ6D]XV%+I#Z;O6RE+'!-7T9$)Q*:+%T3Y8P*,H0.?KGG]7C
MUG%.>;,UBLQ9;3(<8=8F%<#:/&I<V)I*\Z UGDM58L<Q=JJ!^+GV7< $[=<Q
M#(4]?+5'2I5">?HR V9L.23)4@</BPSE#ARC:X!O*H=&]5[]UP-.S8?:W&KK
MYL,=H59.Y@B$3G5['2XFL2":5=<9C]A*MWX/-=Q$<2]-%!0L8_%-NZ8/[A H
M^+#@3,-JO0Z71=\B!1 -PI"*09A30K>@(U&75[(]!\%JO+VNI/]H\%="$M&C
M*O"N+7+,)-[G\I/ HE\;_&.X#4OSKFZ.2YN*:V*Q6D!WF^B_Z/=F_4/1,^]R
M$AFQ!,D?PG/E'5# P5>= J@THGD5&_V$K P0G_.Q>13<>0+-]F1L8=D3I[0U
M,J.+\=F/"P#Y=(A 1UTB# P>*H2Y,1!3"IH=60]0_A(A.R@\H+B4'UAX.GD.
M4W=7)C0E/P#EMB5$?4NN<J<N[8MG[+/U'( &XW%S8HVE%K><#&. OVJ$VZ/U
MDSJ5=26^\O&LT1(J%HSQ0&I ][DN]"RUWC!J7DD]*Z??Y8O3%:<+E399,QV%
MH!)+4NV5B54T1BR(0A;X.S0@.R%5Y2Q6;(\;>AT:$*"BE.?^D TK*7EWW#/X
M7Z*+!BI'Y7EKVQ-;Q:Z?6%FYUC4*Q9.!$%V7V(L ="^8JER@7IFPM95$V.62
MZ0RV.Q@;1!_[ VY'F>J'/=.O!9^9](_S7B'=XN_R#@,R)?N.D#X2PF8AF+-X
M[J<Y4L_/49(BF7X5P';=98:_2FJA[TD?S((<>?%L!>]W09,\LX8\2Y+(]76
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MDAH,,4#@ :H_3FS\^6\,U&_7648;Q.;KYEGLA?J4,@(11DHYX4>W +1AA5E
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M0%"_49C>A_>D9UAZX'DIJ7@9J:1@*QUJJ_?Q;,?<G1=[F)JWP5@ '$_@U%)
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MQD^5?'/?R<J]/,:C%>Y>HW3FF$*D>39.8U(CY4E&>/V*KAD%?U_9P%F;&$6
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M^3(\W%F)]LP99WT>:./6=]3LY=TS#_1T?Q)ZRP]_.]V?Q7/_P_\#4$L#!!0
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MN.JCW(>>N(;]YYWALP-:[<%#6P+TLEO'Z/:\2'+[K=K-.."SXA]2R0\?L07
MMG;/_FM'$%\;.K7&!K[8W]-M9@3/(*KI]W?$$MJ$>R#K %@ +'C7;4<\>-=/
M\:[]X%UWA*P?+L?QF?)<(;OQV;;Q<95(AW_]Y/\89(O2F]N)_-<.NP)46[A)
M-PRX6H1U"+4^ ?[]SMZFD5:+3*!-@ =F#E %J((3W2ZL@Q,-3K1%@&]SHB*\
MC+&=)+[\-2V?FK4(6<A6;>X V [OV_#(*(1@1^%]C,#5 ;  V&X UAY>#<XU
M.-?@7'>&J\/K&-\NE9_I0BK_1<7XY9TGVI0:OXZ2_8K?J:RXBD5X66-']GF
M:B>W<'C.]$W'8<\WC\-:9 )M CPP<X J0!6<Z'9A'9QH<*(M OSKI3'@)Y9@
M"-7H/K)VB39BJC$10'5!%B5!9E3_ LL]&3!A7_DIQ7HFXF_\CAKXQP#;Y#.X
M;AW/<_P6&]M4,LFY=2SALWD9D%J\T]2<2GP%$I3E!:R%0TE;@22,3)6>YIH8
MRDSXDBA<S5BI#;V6T32HNUYTN%P#16GGZZA@2::5*BOPB9HO%2@Q.$>OA+8R
ME%YJ@6$_3&FC"976"L67VHMSO3UHY$3$N.4!I!&, 1P#\_G8C7.J)-6/^]5P
MH*5U8+>'AGOL]Q+82-8J"ZR$AP175V2J^8IH=&TMJ3E53G&R5)"I C YQ15
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M&1PS6=Y&_IEW[I\8WT[K/C@[KX/];O32ZO_8ZA,YAPM9&B //),^(]"ED;0
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MBR6[S8VY7)6N2(9>+)%<>B0U?_1#4LS)0IE$>S-U-U)S0[5WV9]02P,$%
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ML/Y01N'HB]<J3+<P3%N[%Z8?T,61B<1T3NXR,>,0C<%ST2I=F$8"I_],:&)
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MS=]#?(-7+N-JSY'B&<D]8^$(ME4>9@N\4MGNH]_.7T?MM[,76?\%4$L#!!0
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M,^+1],VO-7%QK'D8O3)6I<H3)9P51,+#K#P02B93O$8\IC]T)<;:8"S($"I
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M'Q?((<S=LPY-:%OL$:N")8&_J!OX_&4FWZO[9#\_/N\9D$>G$(T6Y1W8^$S
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M,"YJ<&=02P$"% ,4    " "&.&Y401)!]88C  !O)@  $@
M@ '=.   :6UG,C0R-C(X,3$X7S$N:G!G4$L! A0#%     @ ACAN5,-/Q+6P
M-   :4L  !,              ( !DUP  &EM9S(T,C8R.#$Q.%\Q,"YJ<&=0
M2P$"% ,4    " "&.&Y45.H$I?TA  #6-@  $P              @ %TD0
M:6UG,C0R-C(X,3$X7S$Q+FIP9U!+ 0(4 Q0    ( (8X;E1@> 72:SH  -Y1
M   3              "  :*S  !I;6<R-#(V,C@Q,3A?,3(N:G!G4$L! A0#
M%     @ ACAN5+AAW!A')P, 12<% !,              ( !/NX  &EM9S(T
M,C8R.#$Q.%\Q,RYJ<&=02P$"% ,4    " "&.&Y4848YY.@N   S/   $P
M            @ &V%00 :6UG,C0R-C(X,3$X7S$T+FIP9U!+ 0(4 Q0    (
M (8X;E01+.*4@%0  *UT   3              "  <]$! !I;6<R-#(V,C@Q
M,3A?,34N:G!G4$L! A0#%     @ ACAN5%N)U%5&'P  *#,  !,
M     ( !@)D$ &EM9S(T,C8R.#$Q.%\Q-BYJ<&=02P$"% ,4    " "&.&Y4
M<<$M780O   $0P  $P              @ 'WN 0 :6UG,C0R-C(X,3$X7S$W
M+FIP9U!+ 0(4 Q0    ( (8X;E1([-67&RT  %HW   3              "
M :SH! !I;6<R-#(V,C@Q,3A?,3@N:G!G4$L! A0#%     @ ACAN5,T4$-$2
M*   "C(  !,              ( !^!4% &EM9S(T,C8R.#$Q.%\Q.2YJ<&=0
M2P$"% ,4    " "&.&Y4+\!LQ-,_  #92P  $@              @ $[/@4
M:6UG,C0R-C(X,3$X7S(N:G!G4$L! A0#%     @ ACAN5":V$"'Y*@  ,#(
M !,              ( !/GX% &EM9S(T,C8R.#$Q.%\R,"YJ<&=02P$"% ,4
M    " "&.&Y4-J,O#=DN  #Q,@  $P              @ %HJ04 :6UG,C0R
M-C(X,3$X7S(Q+FIP9U!+ 0(4 Q0    ( (8X;E3/F2I2&KT  * F 0 3
M          "  7+8!0!I;6<R-#(V,C@Q,3A?,C(N:G!G4$L! A0#%     @
MACAN5%O:V@:7J0  D_4  !,              ( !O94& &EM9S(T,C8R.#$Q
M.%\R,RYJ<&=02P$"% ,4    " "&.&Y4CP^MZO8K  "I1P  $P
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M;6<R-#(V,C@Q,3A?,C@N:G!G4$L! A0#%     @ ACAN5.##F9DS=@  O\,
M !,              ( !*U(( &EM9S(T,C8R.#$Q.%\R.2YJ<&=02P$"% ,4
M    " "&.&Y4P0;.+"%,  #74@  $@              @ &/R @ :6UG,C0R
M-C(X,3$X7S,N:G!G4$L! A0#%     @ ACAN5';K_Z#3'@  )BD  !(
M         ( !X!0) &EM9S(T,C8R.#$Q.%\T+FIP9U!+ 0(4 Q0    ( (8X
M;E0G-66*1RP  %4O   2              "  >,S"0!I;6<R-#(V,C@Q,3A?
M-2YJ<&=02P$"% ,4    " "&.&Y4<>0W^']!   S5   $@
M@ %:8 D :6UG,C0R-C(X,3$X7S8N:G!G4$L! A0#%     @ ACAN5+A,[JJH
M.0  4D   !(              ( !":() &EM9S(T,C8R.#$Q.%\W+FIP9U!+
M 0(4 Q0    ( (8X;E1D&OZS5Q\  /X@   2              "  >';"0!I
M;6<R-#(V,C@Q,3A?."YJ<&=02P$"% ,4    " "&.&Y4;T7T>_16   49
M$@              @ %H^PD :6UG,C0R-C(X,3$X7SDN:G!G4$L! A0#%
M  @ ACAN5+5D OE2N 4 ?B=" !$              ( !C%(* '9E<G8M,C R
M,3$R,S$N:'1M4$L! A0#%     @ ACAN5/ YO-@U&0  !S$! !$
M     ( !#0L0 '9E<G8M,C R,3$R,S$N>'-D4$L! A0#%     @ ACAN5"0M
M2K.L#P   ]T  !4              ( !<200 '9E<G8M,C R,3$R,S%?8V%L
M+GAM;%!+ 0(4 Q0    ( (8X;E15CPT3)SH  /M)!  5              "
M 5 T$ !V97)V+3(P,C$Q,C,Q7V1E9BYX;6Q02P$"% ,4    " "&.&Y4WE7M
MPB32  ")E0D %0              @ &J;A  =F5R=BTR,#(Q,3(S,5]L86(N
M>&UL4$L! A0#%     @ ACAN5%=%GI5K6P  OAH' !4              ( !
M 4$1 '9E<G8M,C R,3$R,S%?<')E+GAM;%!+ 0(4 Q0    ( (8X;E3TX>\@
M?14  *!; 0 0              "  9^<$0!V97)V+65X,3!?,30N:'1M4$L!
M A0#%     @ ACAN5.RI1Y@80P  XVD" !               ( !2K(1 '9E
M<G8M97@Q,%\Q.2YH=&U02P$"% ,4    " "&.&Y4.>^]>CL8  #O,0$ #P
M            @ &0]1$ =F5R=BUE>#$P7S0N:'1M4$L! A0#%     @ ACAN
M5 ?,GFB?%@  GA4!  \              ( !^ T2 '9E<G8M97@Q,%\U+FAT
M;5!+ 0(4 Q0    ( (8X;E0W:_-/<0L  +J2   /              "  <0D
M$@!V97)V+65X,3!?-RYH=&U02P$"% ,4    " "&.&Y42Y!9X]D"  #2#@
M#P              @ %B,!( =F5R=BUE>#(S7S$N:'1M4$L! A0#%     @
MACAN5"*3:E11"   ,T4   \              ( !:#,2 '9E<G8M97@S,5\Q
M+FAT;5!+ 0(4 Q0    ( (8X;E2@U=K32 @  "I%   /              "
M >8[$@!V97)V+65X,S%?,BYH=&U02P$"% ,4    " "&.&Y4F:B7'D$%   #
M*@  #P              @ %;1!( =F5R=BUE>#,R7S$N:'1M4$L! A0#%
M  @ ACAN5!JM)>0Y!0  SRH   \              ( !R4D2 '9E<G8M97@S
M,E\R+FAT;5!+ 0(4 Q0    ( (8X;E1#L9O&)1   /98   .
L  "  2]/$@!V97)V+65X-%\S+FAT;5!+!08     +P O +X+  " 7Q(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
